PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chambraud, B; Belabes, H; Fontaine-Lenoir, V; Fellous, A; Baulieu, EE				Chambraud, Beatrice; Belabes, Hamida; Fontaine-Lenoir, Virginie; Fellous, Arlette; Baulieu, Etienne Emile			The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation	FASEB JOURNAL			English	Article						cytoskeleton; neurite differentiation; microtubule dynamics; FK506 binding protein	HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; FK506-BINDING PROTEIN; STEROID-RECEPTOR; HSP90-BINDING IMMUNOPHILINS; DYNEIN INTERACTION; COMPONENT; HSP90; CALMODULIN; TRANSPORT	The FK506 binding protein FKBP52 belongs to the large family of immunophilins and is known as a steroid receptor- associated protein. Previous data suggest that FKBP52 is associated with the motor protein dynein and with the cytoskeleton during mitosis. Here we demonstrate a specific and direct interaction between FKBP52 and tubulin. The region of FKBP52 located between aa 267 and 400, which includes the tetratricopeptide repeat domain, is required for tubulin binding. We provide evidence that FKBP52 prevents tubulin polymerization and that an 84 residue sequence located in the C- terminal part of the molecule ( aa 375 - 458) is necessary and sufficient for its microtubule depolymerization activity. In colocalization experiments in PC12 cells, FKBP52 is associated with tubulin in motile cellular compartments. Furthermore, we suggest that, by using siRNA, a decrease of FKBP52 expression in PC12 cells may lead to differentiated cell phenotype characterized by neurite extensions. Collectively, our data define an unexpected property of FKBP52 as a novel regulator of microtubule dynamics. The possible role of microtubule formation and tubulin binding of other immunophilins such as FKBP12 and FKBP51 is discussed.	Univ Paris 11, INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; Univ Bicetre, Ctr Hosp, MAPREG Co, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Baulieu, EE (corresponding author), Univ Paris 11, INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	baulieu@kb.inserm.fr						Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bareille O, 1998, MEC IND MATER, V51, P52; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Castoldi M, 2003, PROTEIN EXPRES PURIF, V32, P83, DOI 10.1016/S1046-5928(03)00218-3; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Clement MJ, 2005, BIOCHEMISTRY-US, V44, P14616, DOI 10.1021/bi0512492; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; Davies TH, 2005, INT J BIOCHEM CELL B, V37, P42, DOI 10.1016/j.biocel.2004.03.013; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Galat A, 2004, COMPUT BIOL CHEM, V28, P129, DOI 10.1016/j.compbiolchem.2004.01.004; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Gold BG, 2003, CURR TOP MED CHEM, V3, P1368, DOI 10.2174/1568026033451880; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Klettner A, 2003, CNS NEUROL DISORD-DR, V2, P153, DOI 10.2174/1568007033482878; Krebs A, 2005, EMBO REP, V6, P227, DOI 10.1038/sj.embor.7400360; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LEE YC, 1982, J BIOL CHEM, V257, P6306; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Mattson MP, 1999, J NEUROSCI RES, V57, P577, DOI 10.1002/(SICI)1097-4547(19990901)57:5<577::AID-JNR1>3.0.CO;2-H; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RICHTERLANDSBERG C, 1984, DEV NEUROSCI-BASEL, V6, P32; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Sosa I, 2005, EXP NEUROL, V195, P7, DOI 10.1016/j.expneurol.2005.04.016; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Wu BL, 2004, P NATL ACAD SCI USA, V101, P8348, DOI 10.1073/pnas.0305969101; Zhao WH, 2006, VIROLOGY, V353, P283, DOI 10.1016/j.virol.2006.04.042	56	73	75	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2787	2797		10.1096/fj.06-7667com	http://dx.doi.org/10.1096/fj.06-7667com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435176				2022-12-25	WOS:000249237500020
J	Wang, Y; Kreisberg, JI; Bedolla, RG; Mikhailova, M; White, RWD; Ghosh, PM				Wang, Y.; Kreisberg, J. I.; Bedolla, R. G.; Mikhailova, M.; White, R. W. deVere; Ghosh, P. M.			A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells	ONCOGENE			English	Article						proliferation; prostate cancer; androgen receptor; Akt; bicalutamide	ACTIN-BINDING PROTEIN; C-TERMINAL REGION; PHOSPHORYLATION SITE; MEMBRANE ANTIGEN; CROSS-LINKING; AKT; PROLIFERATION; BICALUTAMIDE; PROGRESSION; EXPRESSION	Prostate tumors are initially dependent on androgens for growth, but the majority of patients treated with antiandrogen therapy progress to androgen- independence characterized by resistance to such treatment. This study investigates a novel role for. lamin A ( FlnA), a 280 kDa cytoskeletal protein ( consisting of an actin- binding domain ( ABD) followed by 24 sequential repeats), in androgen- independent ( AI) growth. Full- length FlnA is cleaved to 170 kDa ( ABD+FlnA1 - 15) and 110 kDa fragments ( FlnA16 - 24); the latter is further cleaved to a 90 kDa fragment ( repeats 16 - 23) capable of nuclear translocation and androgen receptor ( AR) binding. Here, we demonstrate that in androgen- dependent LNCaP prostate cancer cells, the cleaved 90 kDa fragment is localized to the nucleus, whereas in its AI subline C4 - 2, FlnA failed to cleave and remained cytoplasmic. Transfection of FlnA16 - 24 cDNA in C4 - 2 cells restored expression and nuclear localization of 90 kDa FlnA. Unlike LNCaP, C4 - 2 cells proliferate in androgen-reduced medium and in the presence of the AR- antagonist Casodex. They also exhibit increased Akt phosphorylation compared to LNCaP, which may contribute to their AI phenotype. Nuclear expression of 90 kDa FlnA in C4 - 2 cells decreased Akt phosphorylation, prevented proliferation in androgen- reduced medium and restored Casodex sensitivity. This effect was inhibited by constitutive activation of Akt indicating that FlnA restored Casodex sensitivity in C4 - 2 cells by decreasing Akt phosphorylation. In addition, FlnA-specific siRNA which depleted FlnA levels, but not control siRNA, induced resistance to Casodex in LNCaP cells. Our results demonstrate that expression of nuclear FlnA is necessary for androgen dependence in these cells.	VA No California Hlth Care Syst, Res Serv, Mather, CA 95655 USA; Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio	Ghosh, PM (corresponding author), VA No California Hlth Care Syst, Res Serv, 10535 Hosp Way, Mather, CA 95655 USA.	paramita.ghosh@ucdmc.ucdavis.edu	WANG, YU/E-4655-2013		NCI NIH HHS [CA109057, R21 CA109057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA109057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anilkumar G, 2003, CANCER RES, V63, P2645; BARRY CP, 1993, J BIOL CHEM, V268, P25577; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ghosh A, 2005, CANCER RES, V65, P727; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Ghosh PM, 2002, CANCER RES, V62, P2630; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hara T, 2003, CANCER RES, V63, P149; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HSIEH JT, 1993, CANCER RES, V53, P2852; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jay D, 2000, ARCH BIOCHEM BIOPHYS, V377, P80, DOI 10.1006/abbi.2000.1762; Jay D, 2004, MOL CELL BIOCHEM, V260, P49, DOI 10.1023/B:MCBI.0000026052.76418.55; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Murray JT, 2004, BIOCHEM J, V384, P489, DOI 10.1042/BJ20041058; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Tepper CG, 2002, CANCER RES, V62, P6606; Thomas P, 1996, NEUROLOGY, V46, P1165, DOI 10.1212/WNL.46.4.1165; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wen Y, 2000, CANCER RES, V60, P6841; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	37	65	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6061	6070		10.1038/sj.onc.1210435	http://dx.doi.org/10.1038/sj.onc.1210435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420725				2022-12-25	WOS:000249277200009
J	Quaranta, MG; Napolitano, A; Sanchez, M; Giordani, L; Mattioli, B; Viora, M				Quaranta, Maria Giovanna; Napolitano, Alfonso; Sanchez, Massimo; Giordani, Luciana; Mattioli, Benedetta; Viora, Marina			HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets	FASEB JOURNAL			English	Article						AIDS; innate immunity; immune evasion	NATURAL-KILLER-CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS; DISTINCT FUNCTIONAL-RESPONSES; INTERFERON-GAMMA PRODUCTION; CHEMOKINE RECEPTOR CX3CR1; HUMAN DENDRITIC CELLS; CD8(+) T-CELLS; IFN-ALPHA-BETA; SIGNALING PATHWAY; INFECTED CELLS	Dendritic cells ( DCs) and natural killer ( NK) cells are essential components of the innate immunity and play a critical role in the first phase of host defense against infection. Interactions between DCs and NK cells have been demonstrated in a variety of settings, with evidence emerging of complex bidirectional crosstalk between the two cell types. The accessory HIV-1 Nef protein is a crucial determinant for viral replication and pathogenesis. We previously demonstrated that Nef, hijacking DC functional activity, subverts the DC arm of immune response to escape the adaptive immune attack. Here, we monitor the effect of Nef on the outcome of the innate immune response, focusing on the impact of Nef on DC/NK crosstalk. We demonstrate that Nef up-regulates the ability of DCs to stimulate the immunoregulatory NK cells ( CD56(bright)) as assessed by the activated phenotype, up-regulation of their proliferative response and INF-gamma release. On the other hand, Nef-pulsed DCs inhibit cytotoxic NK cells ( CD56(dim)), as assessed by the reduced HLA-DR surface expression, reduced proliferation and cytotoxic activity. Moreover, in the presence of Nef-pulsed DCs, we found a significant up-regulation of TNF-alpha secretion and a significant reduction of IL-10, GM-CSF, MIP-1 alpha and RANTES secretion. Our findings suggest that the Nef-induced dysregulation in the DC/NK cell crosstalk may represent a potential mechanism through which HIV escapes innate immune surveillance.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it	Sanchez, Massimo/AAD-1746-2021	Sanchez, Massimo/0000-0003-3696-7582; Quaranta, Maria Giovanna/0000-0002-1077-1488				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Alter G, 2006, CURR MOL MED, V6, P621, DOI 10.2174/156652406778195035; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barlic J, 2003, BLOOD, V102, P3494, DOI 10.1182/blood-2003-03-0946; Bonaparte MI, 2003, AIDS, V17, P487, DOI 10.1097/00002030-200303070-00003; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Carson WE, 1997, EUR J IMMUNOL, V27, P354, DOI 10.1002/eji.1830270203; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Chen N, 2006, EUR J IMMUNOL, V36, P278, DOI 10.1002/eji.200535487; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cooper GJS, 2001, AUST J DAIRY TECHNOL, V56, P97; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, EUR J IMMUNOL, V31, P792, DOI 10.1002/1521-4141(200103)31:3<792::AID-IMMU792>3.0.CO;2-U; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; FONTANA L, 1986, IMMUNOBIOLOGY, V171, P425, DOI 10.1016/S0171-2985(86)80074-2; Fortis C, 2005, IMMUNOL RES, V33, P1, DOI 10.1385/IR:33:1:001; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Goodier MR, 2003, CLIN EXP IMMUNOL, V134, P470, DOI 10.1111/j.1365-2249.2003.02329.x; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Gupta N, 2005, VIROLOGY, V332, P491, DOI 10.1016/j.virol.2004.12.018; Hanna J, 2004, J IMMUNOL, V173, P6547, DOI 10.4049/jimmunol.173.11.6547; Jacobs R, 2001, EUR J IMMUNOL, V31, P3121, DOI 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4; JEWETT A, 1993, CELL IMMUNOL, V151, P257, DOI 10.1006/cimm.1993.1236; Kinter A, 1996, IMMUNOL RES, V15, P1, DOI 10.1007/BF02918280; Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222; Kottilil S, 2006, J IMMUNOL, V176, P1107, DOI 10.4049/jimmunol.176.2.1107; Lande R, 2003, J IMMUNOL, V170, P1174, DOI 10.4049/jimmunol.170.3.1174; Lazdins JK, 1997, J EXP MED, V185, P81, DOI 10.1084/jem.185.1.81; Lieberman J, 2002, CURR OPIN IMMUNOL, V14, P478, DOI 10.1016/S0952-7915(02)00366-7; Loza MJ, 2004, J IMMUNOL, V172, P88, DOI 10.4049/jimmunol.172.1.88; MACCARIO R, 1987, INFECTION, V15, P99, DOI 10.1007/BF01650205; Mavilio D, 2006, J EXP MED, V203, P2339, DOI 10.1084/jem.20060894; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Nguyen KB, 2002, J IMMUNOL, V169, P4279, DOI 10.4049/jimmunol.169.8.4279; Parato KG, 2002, AIDS, V16, P1251, DOI 10.1097/00002030-200206140-00007; Poggi A, 2002, J IMMUNOL, V168, P95, DOI 10.4049/jimmunol.168.1.95; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; Portales P, 2003, AIDS, V17, P495, DOI 10.1097/00002030-200303070-00004; Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302; Quaranta MG, 2006, FASEB J, V20, P2198, DOI 10.1096/fj.06-6260rev; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2004, FASEB J, V18, P1459, DOI 10.1096/fj.04-1633fje; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; Schierloh P, 2005, J IMMUNOL, V175, P6852, DOI 10.4049/jimmunol.175.10.6852; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SCOTTALGARA D, 1992, CLIN EXP IMMUNOL, V90, P181; Sechler JM, 2004, CELL IMMUNOL, V230, P99, DOI 10.1016/j.cellimm.2004.10.001; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; Suzuki S, 2000, MICROBIOL IMMUNOL, V44, P111, DOI 10.1111/j.1348-0421.2000.tb01254.x; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Trotta R, 2005, BLOOD, V105, P3011, DOI 10.1182/blood-2004-10-4072; TYLER DS, 1990, J IMMUNOL, V144, P3375; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vitale M, 2003, BRIT J HAEMATOL, V120, P337, DOI 10.1046/j.1365-2141.2003.04053.x	68	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2323	2334		10.1096/fj.06-7883com	http://dx.doi.org/10.1096/fj.06-7883com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17431094				2022-12-25	WOS:000248454400007
J	Abbott, RJM; Spendlove, I; Roversi, P; Fitzgibbon, H; Knott, V; Teriete, P; McDonnell, JM; Handford, PA; Lea, SM				Abbott, Rachel J. M.; Spendlove, Ian; Roversi, Pietro; Fitzgibbon, Hannah; Knott, Vroni; Teriete, Peter; McDonnell, James M.; Handford, Penny A.; Lea, Susan M.			Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; 7-SPAN TRANSMEMBRANE MOLECULE; ACTIVATION ANTIGEN CD97; EGF-TM7 RECEPTOR; LIGAND CD55; MAXIMUM-LIKELIHOOD; EXPRESSION; DOMAIN; EMR2; REFINEMENT	CD97, the archetypal member of the EGF-TM7 protein family, is constitutively expressed on granulocytes and monocytes and rapidly up-regulated on T and B cells following activation. The key isoform of CD97 expressed on leukocytes binds the complement regulatory protein CD55 (also termed decay-accelerating factor). CD97 has been shown recently to mediate co-stimulation of T cells via CD55. Here, we demonstrate that blocking the interaction between CD55 on monocytes and CD97 on T cells leads to inhibition of proliferation and interferon-gamma secretion. This implies that bidirectional interactions between CD97 and CD55 are involved in T cell regulation. Structural studies presented here reveal the molecular basis for this activity. We have solved the structure of EMR2, a very close homolog of CD97, using x-ray crystallography. NMR-based chemical shift mapping of the EMR2-CD55 interaction has allowed us to generate a model for the CD97-CD55 complex. The structure of the complex reveals that the T cell and complement regulatory activities of CD55 occur on opposite faces of the molecule. This suggests that CD55 might simultaneously regulate both the innate and adaptive immune responses, and we have shown that CD55 can still regulate complement when bound to CD97.	Univ Nottingham, City Hosp, Sch Mol Med Sci, Acad Clin Oncol, Nottingham NG5 1PB, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Oxford; University of Oxford	Lea, SM (corresponding author), Univ Nottingham, City Hosp, Sch Mol Med Sci, Acad Clin Oncol, Hucknall Rd, Nottingham NG5 1PB, England.	susan.lea@path.ox.ac.uk	Roversi, Pietro/F-8925-2011; Teriete, Peter/N-3331-2014; Roversi, Pietro/AAK-4241-2021; Lea, Susan M/B-7678-2009	Roversi, Pietro/0000-0001-9280-9437; Teriete, Peter/0000-0003-3692-9308; Roversi, Pietro/0000-0001-9280-9437; Lea, Susan M/0000-0001-9287-8053; McDonnell, James/0000-0001-9037-2980; Abbott, Rachel/0000-0003-1902-1429; Spendlove, Ian/0000-0002-7480-3768	Medical Research Council [G0400775] Funding Source: Medline; Medical Research Council [G0400503B] Funding Source: researchfish; MRC [G0400775] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott RJM, 2004, ACTA CRYSTALLOGR D, V60, P936, DOI 10.1107/S0907444904005098; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aust G, 2002, AM J CLIN PATHOL, V118, P699; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Capasso M, 2006, J IMMUNOL, V177, P1070, DOI 10.4049/jimmunol.177.2.1070; Chang GW, 2007, BIOCHEM BIOPH RES CO, V353, P133, DOI 10.1016/j.bbrc.2006.11.148; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Eichler W, 1997, TISSUE ANTIGENS, V50, P429, DOI 10.1111/j.1399-0039.1997.tb02897.x; Freedman SJ, 1996, BIOCHEMISTRY-US, V35, P13733, DOI 10.1021/bi9610257; Gray JX, 1996, J IMMUNOL, V157, P5438; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Hamann J, 1999, ARTHRITIS RHEUM-US, V42, P650, DOI 10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hamann J, 1996, GENOMICS, V32, P144, DOI 10.1006/geno.1996.0092; Hubbard S. J., 1993, NACCESS; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Jaspars LH, 2001, TISSUE ANTIGENS, V57, P325, DOI 10.1034/j.1399-0039.2001.057004325.x; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Kwakkenbos MJ, 2005, J LEUKOCYTE BIOL, V77, P112, DOI 10.1189/jlb.0704402; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lesk A.M., 2004, INTRO PROTEIN SCI AR, V2; Li L, 2001, BRIT J CANCER, V84, P80, DOI 10.1054/bjoc.2000.1570; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POST TW, 1990, J IMMUNOL, V144, P740; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Steinert M, 2002, AM J PATHOL, V161, P1657, DOI 10.1016/S0002-9440(10)64443-4; Visser L, 2002, J NEUROIMMUNOL, V132, P156, DOI 10.1016/S0165-5728(02)00306-5; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604	42	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22023	22032		10.1074/jbc.M702588200	http://dx.doi.org/10.1074/jbc.M702588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17449467	hybrid			2022-12-25	WOS:000248196800049
J	Free, RB; Hazelwood, LA; Cabrera, DM; Spalding, HN; Namkung, Y; Rankin, ML; Sibley, DR				Free, R. Benjamin; Hazelwood, Lisa A.; Cabrera, David M.; Spalding, Heather N.; Namkung, Yoon; Rankin, Michele L.; Sibley, David R.			D-1 and D-2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; COUPLED RECEPTORS; DRUG DISCOVERY; ASSOCIATION; TRAFFICKING; DESENSITIZATION; D1	As for all proteins, G protein-coupled receptors (GPCRs) undergo synthesis and maturation within the endoplasmic reticulum (ER). The mechanisms involved in the biogenesis and trafficking of GPCRs from the ER to the cell surface are poorly understood, but they may involve interactions with other proteins. We have now identified the ER chaperone protein calnexin as an interacting protein for both D-1 and D-2 dopamine receptors. These protein-protein interactions were confirmed using Western blot analysis and co-immunoprecipitation experiments. To determine the influence of calnexin on receptor expression, we conducted assays in HEK293T cells using a variety of calnexin-modifying conditions. Inhibition of glycosylation either through receptor mutations or treatments with glycosylation inhibitors partially blocks the interactions with calnexin with a resulting decrease in cell surface receptor expression. Confocal fluorescence microscopy reveals the accumulation of D-1-green fluorescent protein and D-2-yellow fluorescent protein receptors within internal stores following treatment with calnexin inhibitors. Overexpression of calnexin also results in a marked decrease in both D-1 and D-2 receptor expression. This is likely because of an increase in ER retention because confocal microscopy revealed intracellular clustering of dopamine receptors that were co-localized with an ER marker protein. Additionally, we show that calnexin interacts with the receptors via two distinct mechanisms, glycan-dependent and glycan-independent, which may underlie the multiple effects (ER retention and surface trafficking) of calnexin on receptor expression. Our data suggest that optimal receptor-calnexin interactions critically regulate D-1 and D-2 receptor trafficking and expression at the cell surface, a mechanism likely to be of importance for many GPCRs.	NINDS, Mol Neuropharmacol Sect, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sibley, DR (corresponding author), NINDS, Mol Neuropharmacol Sect, Natl Inst Hlth, 5625 Fishers Ln,Rm 4S-04,MSC 9405, Bethesda, MD 20892 USA.	sibley@helix.nih.gov	Sibley, David/AAC-3591-2019; Cabrera, David/I-1013-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003028, Z01NS003028] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bai J, 2004, BIOL PSYCHIAT, V56, P427, DOI 10.1016/j.biopsych.2004.06.022; Bergson C, 2003, TRENDS PHARMACOL SCI, V24, P486, DOI 10.1016/S0165-6147(03)00232-3; Bermak J C, 2001, Mol Interv, V1, P282; Bermak JC, 2002, EUR J CELL BIOL, V81, P77, DOI 10.1078/0171-9335-00222; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ermonval M, 2000, GLYCOBIOLOGY, V10, P77, DOI 10.1093/glycob/10.1.77; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Karpa KD, 1999, MOL PHARMACOL, V56, P1071, DOI 10.1124/mol.56.5.1071; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; Laurin N, 2005, MOL PSYCHIATR, V10, P1117, DOI 10.1038/sj.mp.4001737; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lundstrom K, 2005, IDRUGS, V8, P909; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; Meissner JD, 1999, BIOCHEM J, V338, P561, DOI 10.1042/0264-6021:3380561; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Namkung Y, 2004, J BIOL CHEM, V279, P49533, DOI 10.1074/jbc.M408319200; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Qi YP, 1997, J NEUROSCI, V17, P1217; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Tan CM, 2004, ANNU REV PHARMACOL, V44, P559, DOI 10.1146/annurev.pharmtox.44.101802.121558; Van Craenenbroeck K, 2005, J BIOL CHEM, V280, P19350, DOI 10.1074/jbc.M414043200; Wanamaker CP, 2005, J BIOL CHEM, V280, P33800, DOI 10.1074/jbc.M501813200; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	48	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21285	21300		10.1074/jbc.M701555200	http://dx.doi.org/10.1074/jbc.M701555200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17395585	hybrid			2022-12-25	WOS:000248047500057
J	Fujimori, K; Aritake, K; Urade, Y				Fujimori, Ko; Aritake, Kosuke; Urade, Yoshihiro			Novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVATION; OBESITY; ACID; ATHEROSCLEROSIS; IDENTIFICATION; ADIPOGENESIS; MECHANISM	Lipocalin-type prostaglandin (PG) D synthase (L-PGDS) is expressed in adipocytes and is proposed to be involved in the regulation of glucose tolerance and atherosclerosis in type 2 diabetes, because L-PGDS gene knock-out mice show abnormalities in these functions. However, the role of L-PGDS and the regulation mechanism governing its gene expression in adipocytes remain unclear. Here, we applied small interference RNA of L-PGDS to mouse 3T3-L1 cells and found that it suppressed differentiation of these cells into adipocytes. Reporter analysis of the mouse L-PGDS promoter demonstrated that a responsive element for liver receptor homolog-1 (LRH-1) at -233 plays a critical role in preadipocytic 3T3-L1 cells. Moreover, we identified two sterol regulatory elements (SREs) at -194 to be cis-elements for activation of L-PGDS gene expression in adipocytic 3T3-L1 cells. L-PGDS mRNA was induced in response to synthetic liver X receptor agonist, T0901317, through activation of the expression of SRE-binding protein-1c (SREBP-1c) in the adipocytic 3T3-L1 cells. The results of electrophoretic mobility shift assay and chromatin immunoprecipitation assay revealed that LRH-1 and SREBP-1c bound to their respective binding elements in the promoter of L-PGDS gene. Small interference RNA-mediated suppression of LRH-1 or SREBP-1c decreased L-PGDS gene expression in preadipocytic or adipocytic 3T3-L1 cells, respectively. These results indicate that L-PGDS gene expression is activated by LRH-1 in preadipocytes and by SREBP-1c in adipocytes. Liver X receptor-mediated up-regulation of L-PGDS through activation of SREBP-1c is a novel pathway to enhance adipocyte differentiation.	Osaka Biosci Inst, Dept Mol Behav Biol, Suita, Osaka 565, Japan		Urade, Y (corresponding author), Osaka Univ Pharmaceut Sci, Lab Biodef & Regulat, Takatsuki, Osaka 569, Japan.	uradey@obi.or.jp	Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769				Aritake K, 2006, J BIOL CHEM, V281, P15277, DOI 10.1074/jbc.M506431200; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Beuckmann CT, 1999, BIOCHEMISTRY-US, V38, P8006, DOI 10.1021/bi990261p; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Fujimori K, 2003, J BIOL CHEM, V278, P6018, DOI 10.1074/jbc.M208288200; Fujimori K, 2002, J BIOCHEM, V131, P383, DOI 10.1093/oxfordjournals.jbchem.a003113; Fujimori K, 2000, J BIOL CHEM, V275, P40511, DOI 10.1074/jbc.M007688200; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Jowsey IR, 2003, PROSTAG OTH LIPID M, V70, P267, DOI 10.1016/S0090-6980(02)00134-X; Juvet LK, 2003, MOL ENDOCRINOL, V17, P172, DOI 10.1210/me.2001-0210; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kanekiyo T, 2007, P NATL ACAD SCI USA, V104, P6412, DOI 10.1073/pnas.0701585104; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Miwa Y, 2004, BIOCHEM BIOPH RES CO, V322, P428, DOI 10.1016/j.bbrc.2004.07.143; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Mohri I, 2006, J NEUROCHEM, V97, P641, DOI 10.1111/j.1471-4159.2006.03753.x; Nadler ST, 2001, J NUTR, V131, P2078, DOI 10.1093/jn/131.8.2078; Qu WM, 2006, P NATL ACAD SCI USA, V103, P17949, DOI 10.1073/pnas.0608581103; Quinkler M, 2006, GENE, V380, P137, DOI 10.1016/j.gene.2006.05.026; Ragolia L, 2005, J BIOL CHEM, V280, P29946, DOI 10.1074/jbc.M502927200; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Urade Y, 2006, LIPOCALINS, P99; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Xie Y, 2006, DIABETES OBES METAB, V8, P83, DOI 10.1111/j.1463-1326.2005.00472.x; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	42	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18458	18466		10.1074/jbc.M701141200	http://dx.doi.org/10.1074/jbc.M701141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17439953	hybrid			2022-12-25	WOS:000247302000052
J	Tzatsos, A; Tsichlis, PN				Tzatsos, Alexandros; Tsichlis, Philip N.			Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; MOUSE SKELETAL-MUSCLE; MAMMALIAN TARGET; AS160 PHOSPHORYLATION; GLUCOSE-TRANSPORT; CANCER-CELLS; IN-VIVO; LKB1; RAPAMYCIN; PATHWAY	Energy depletion activates AMP-activated protein kinase (AMPK) and inhibits cell growth via TSC2-dependent suppression of mTORC1 signaling. Long term energy depletion also induces apoptosis by mechanisms that are not well understood to date. Here we show that AMPK, activated by energy depletion, inhibited cell survival by binding to and phosphorylating IRS-1 at Ser-794. Phosphorylation of IRS-1 at this site inhibited phosphatidylinositol 3- kinase/Akt signaling, suppressed the mitochondrial membrane potential, and promoted apoptosis. Of the treatments promoting energy depletion, glucose deprivation, hypoxia, and inhibition of ATP synthesis in the mitochondria stimulated phosphorylation of IRS-1 at Ser-794 via an LKB1/AMPK-dependent manner, whereas oxidative stress and 2-deoxyglucose stimulated phosphorylation at this site via a Ca2+/calmodulin-dependent protein kinase kinase beta/AMPK axis. These data define a novel pathway that cooperates with other adaptive mechanisms to formulate the cellular response to energy depletion.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Tsichlis, PN (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, 750 Washington St,5609, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA057436] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Heath-Engel HM, 2006, BBA-MOL CELL RES, V1763, P549, DOI 10.1016/j.bbamcr.2006.02.006; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jimenez AI, 2003, CANCER RES, V63, P1382; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Nakano M, 2006, METABOLISM, V55, P300, DOI 10.1016/j.metabol.2005.09.003; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Park SY, 2005, J BIOL CHEM, V280, P9855, DOI 10.1074/jbc.M409399200; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Villena JA, 2004, DIABETES, V53, P2242, DOI 10.2337/diabetes.53.9.2242; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	47	116	120	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18069	18082		10.1074/jbc.M610101200	http://dx.doi.org/10.1074/jbc.M610101200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17459875	hybrid			2022-12-25	WOS:000247302000013
J	Goemaere, EL; Devert, A; Lloubes, R; Cascales, E				Goemaere, Emilie L.; Devert, Anthony; Lloubes, Roland; Cascales, Eric			Movements of the TolR C-terminal domain depend on TolQR ionizable key residues and regulate activity of the tol complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE INTEGRITY; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; OUTER-MEMBRANE; MUTATIONAL ANALYSIS; POTASSIUM CHANNELS; FLAGELLAR MOTOR; INNER MEMBRANE; PAL PROTEINS; TONB	The TolQRA proteins of Escherichia coli form an inner membrane complex involved in the maintenance of the outer membrane stability and in the late stages of cell division. The TolQR complex uses the proton-motive force to regulate TolA conformation and its interaction with the outer membrane Pal lipoprotein. It has been proposed that an ion channel forms at the TolQR transmembrane helix interface. This complex assembles with a minimal TolQ/TolR ratio of 4:2, therefore involving at least 14 transmembrane helices, which may form the ion pathway. The C-terminal periplasmic domain of TolR protein interacts with TolQ and has been proposed to control the TolQR channel activity. Here, we constructed unique cysteine substitutions in the last 27 residues of TolR. Each of the substitutions results in a functional TolR protein. Disulfide cross-linking demonstrates that the TolQR complex is dynamic, involving conformational modifications of TolR C-terminal domain. We monitored these structural changes by cysteine accessibility experiments and showed that the conformation of this domain is responsive to the proton-motive force and on the presence of critical residues of the ion pathway.	CNRS, Lab Ingn Syst Macromol, Inst Biol Struct & Microbiol, UPR 9027, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Cascales, E (corresponding author), CNRS, Lab Ingn Syst Macromol, Inst Biol Struct & Microbiol, UPR 9027, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cascales@ibsm.cnrs-mrs.fr	CASCALES, ERIC/G-7420-2011	CASCALES, ERIC/0000-0003-0611-9179; LLOUBES, Roland/0000-0002-9520-1053				Abergel C, 2001, ACTA CRYSTALLOGR D, V57, P323, DOI 10.1107/S0907444900020837; Blair DF, 2003, FEBS LETT, V545, P86, DOI 10.1016/S0014-5793(03)00397-1; Braun V, 1996, J BACTERIOL, V178, P2836, DOI 10.1128/jb.178.10.2836-2845.1996; Cascales E, 2001, MOL MICROBIOL, V42, P795, DOI 10.1046/j.1365-2958.2001.02673.x; Cascales E, 2000, MOL MICROBIOL, V38, P904, DOI 10.1046/j.1365-2958.2000.02190.x; Cascales E, 2007, MICROBIOL MOL BIOL R, V71, P158, DOI 10.1128/MMBR.00036-06; DEROUICHE R, 1995, J BIOL CHEM, V270, P11078, DOI 10.1074/jbc.270.19.11078; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; Garza AG, 1996, J BACTERIOL, V178, P6116, DOI 10.1128/jb.178.21.6116-6122.1996; Gerding MA, 2007, MOL MICROBIOL, V63, P1008, DOI 10.1111/j.1365-2958.2006.05571.x; Germon P, 1998, J BACTERIOL, V180, P6433, DOI 10.1128/JB.180.24.6433-6439.1998; Germon P, 2001, J BACTERIOL, V183, P4110, DOI 10.1128/JB.183.14.4110-4114.2001; Goemaere EL, 2007, J MOL BIOL, V366, P1424, DOI 10.1016/j.jmb.2006.12.020; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; Hosking ER, 2006, J MOL BIOL, V364, P921, DOI 10.1016/j.jmb.2006.09.035; Journet L, 2001, MOL MICROBIOL, V42, P331, DOI 10.1046/j.1365-2958.2001.02592.x; Journet L, 1999, J BACTERIOL, V181, P4476, DOI 10.1128/JB.181.15.4476-4484.1999; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; LAZZARONI JC, 1995, J MOL BIOL, V246, P1, DOI 10.1006/jmbi.1994.0058; Lloubes R, 2001, RES MICROBIOL, V152, P523, DOI 10.1016/S0923-2508(01)01226-8; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	29	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17749	17757		10.1074/jbc.M701002200	http://dx.doi.org/10.1074/jbc.M701002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442676	hybrid, Green Published			2022-12-25	WOS:000247084500048
J	Nishiyama, K; Takaji, K; Uchijima, Y; Kurihara, Y; Asano, T; Yoshimura, M; Ogawa, H; Kurihara, H				Nishiyama, Koichi; Takaji, Kentaro; Uchijima, Yasunobu; Kurihara, Yukiko; Asano, Tomoichiro; Yoshimura, Michihiro; Ogawa, Hisao; Kurihara, Hiroki			Protein kinase A-regulated nucleocytoplasmic shuttling of Id1 during angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-MEDIATED DEGRADATION; LOOP-HELIX PROTEINS; ENDOTHELIAL-CELL MIGRATION; INDUCED ACTIVATION; LOCALIZATION; INHIBITOR; NUCLEAR; GROWTH; MORPHOGENESIS; SUPPRESSION	Id1, an inhibitory partner of basic-helix-loop-helix transcriptional factors, has recently been recognized as a potent contributor to angiogenesis. However, the molecular mechanism underlying its role in angiogenesis remains essentially unknown. Herein we demonstrate the subcellular localization of Id1 to be altered depending on the cellular context of vascular endothelial cells. Id1 was localized in the nuclei of human umbilical vein endothelial cells (HUVECs) cultured on uncoated plates, whereas it was translocated to the cytoplasm in HUVECs on Matrigel along with the formation of capillary- like structures. Treatment with the nuclear export inhibitor leptomycin B and mutagenesis analysis using green fluorescent protein-fused Id1 revealed CRM1/ exportin-dependent nuclear export of Id1 in HUVECs on Matrigel. This nuclear export of Id1 was inhibited by protein kinase A ( PKA) activation by dibutyryl cyclic AMP and forskolin but was promoted by PKA inactivation by H-89 and MDL-12,330A. Mutagenesis analysis of Id1 showed the phosphorylation of Ser-5 to possibly mediate the effect of PKA. These results suggest the function of Id1 as a transcriptional factor to be controlled by nucleocytoplasmic shuttling during angiogenesis and that PKA might be involved in this process. This may serve as a novel mechanism regulating angiogenesis and as a possible target for therapeutic vascular regeneration.	Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Dev Med Technol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto 8608556, Japan; Kumamoto Univ, Dept Cardiovasc Surg, Grad Sch Med Sci, Kumamoto 8608556, Japan; Jikei Univ, Sch Med, Dept Internal Med, Minato Ku, Tokyo 1058461, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomed Chem, Hiroshima 7348551, Japan	University of Tokyo; University of Tokyo; Kumamoto University; Kumamoto University; Jikei University; Hiroshima University	Nishiyama, K (corresponding author), Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nkanako@bio.m.u-tokyo.ac.jp	Nishiyama, Koichi/H-4275-2014	Nishiyama, Koichi/0000-0003-0529-4207; Kurihara, Hiroki/0000-0002-6476-5593				Bakre MM, 2002, NAT MED, V8, P995, DOI 10.1038/nm753; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Cattaneo MG, 2003, BRIT J PHARMACOL, V138, P377, DOI 10.1038/sj.bjp.0705051; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; de Candia P, 2003, P NATL ACAD SCI USA, V100, P12337, DOI 10.1073/pnas.2031337100; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Hashimoto A, 2006, ATHEROSCLEROSIS, V189, P350, DOI 10.1016/j.atherosclerosis.2006.01.022; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lasorella A, 2006, P NATL ACAD SCI USA, V103, P4976, DOI 10.1073/pnas.0600168103; Lazrak M, 2004, J CELL SCI, V117, P1161, DOI 10.1242/jcs.00969; Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Liu F, 2001, AM J PHYSIOL-LUNG C, V280, pL1309, DOI 10.1152/ajplung.2001.280.6.L1309; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Makita J, 2006, FEBS LETT, V580, P1812, DOI 10.1016/j.febslet.2006.02.038; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nishiyama K, 2005, CIRCULATION, V112, P2840, DOI 10.1161/CIRCULATIONAHA.104.516898; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Seya Y, 2006, EUR J PHARMACOL, V553, P54, DOI 10.1016/j.ejphar.2006.09.048; Shcherbik N, 2004, J CELL BIOCHEM, V93, P11, DOI 10.1002/jcb.20130; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Smith JM, 2004, TRENDS GENET, V20, P4, DOI 10.1016/j.tig.2003.11.007; Sun LP, 2005, J BIOL CHEM, V280, P26448, DOI 10.1074/jbc.M500373200; Tamura Y, 1998, FEBS LETT, V436, P169, DOI 10.1016/S0014-5793(98)01117-X; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Tu X, 2003, EXP CELL RES, V288, P119, DOI 10.1016/S0014-4827(03)00178-2; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	47	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17200	17209		10.1074/jbc.M611609200	http://dx.doi.org/10.1074/jbc.M611609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412691	hybrid			2022-12-25	WOS:000246946500053
J	Kim, HS; Kim, MS; Hancock, AL; Harper, JCP; Park, JY; Poy, G; Perantoni, AO; Cam, M; Malik, K; Lee, SB				Kim, Ho-Shik; Kim, Myoung Shin; Hancock, Anne L.; Harper, James C. P.; Park, Jik Young; Poy, George; Perantoni, Alan O.; Cam, Margaret; Malik, Karim; Lee, Sean Bong			Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; WT1 GENE; BINDING-SITES; EGF RECEPTOR; EXPRESSION; APOPTOSIS; INDUCTION; MOUSE; SLUG	The Wilms' tumor suppressor gene (WT1) encodes a zinc finger transcription factor that is vital during development of several organs including metanephric kidneys. Despite the critical regulatory role of WT1, the pathways and mechanisms by which WT1 orchestrates development remain elusive. To identify WT1 target genes, we performed a genome-wide expression profiling analysis in cells expressing inducible WT1. We identified a number of direct WT1 target genes, including the epidermal growth factor (EGF)-family ligands epiregulin and HB-EGF, the chemokine CX3CL1, and the transcription factors SLUG and JUNB. The target genes were validated using quantitative reverse transcriptase-polymerase chain reaction, small interfering RNA knockdowns, chromatin immunoprecipitation, and luciferase reporter analyses. Immunohistochemistry of fetal kidneys confirmed that a number of the WT1 target genes had overlapping expression patterns with the highly restricted spatiotemporal expression of WT1. Finally, using an in vitro embryonic kidney culture assay, we found that the addition of recombinant epiregulin, amphiregulin, CX3CL1, and interleukin-11 significantly enhanced ureteric bud branching morphogenesis. Our genome-wide screen implicates WT1 in the transcriptional regulation of the EGF-family of growth factors as well as the CX3CL1 chemokine during nephrogenesis.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Microarray Core Facil, NIH, Bethesda, MD 20892 USA; NCI, Lab Comparat Carcinogenesis, Frederick, MD 21702 USA; Univ Bristol, Canc & Leukaemia Childhood Sargent Unit, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bristol	Lee, SB (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10,9D11, Bethesda, MD 20892 USA.	seanL@intra.niddk.nih.gov	Harper, James/AAH-1885-2019	Harper, James/0000-0002-6416-1466; Malik, Karim/0000-0002-8965-200X; Lee, Sean/0000-0001-6211-3498	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056002, Z01DK056002] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVAGNER P, 1997, J CELL BIOL, V137, P1403; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Dallosso AR, 2004, HUM MOL GENET, V13, P405, DOI 10.1093/hmg/ddh038; Davies JA, 2004, HUM MOL GENET, V13, P235, DOI 10.1093/hmg/ddh015; Deiva K, 2004, EUR J NEUROSCI, V20, P3222, DOI 10.1111/j.1460-9568.2004.03800.x; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Graham K, 2006, GENE EXPRESSION, V13, P1, DOI 10.3727/000000006783991953; Grieshammer U, 2005, DEVELOPMENT, V132, P3847, DOI 10.1242/dev.01944; Guo G, 2004, J AM SOC NEPHROL, V15, P2851, DOI 10.1097/01.ASN.0000143474.91362.C4; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1993, CURR OPIN GENET DEV, V3, P408, DOI 10.1016/0959-437X(93)90113-4; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lai PC, 2001, J AM SOC NEPHROL, V12, P2310, DOI 10.1681/ASN.V12112310; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; Menke AL, 2002, CANCER RES, V62, P6615; Moore AW, 1999, DEVELOPMENT, V126, P1845; Morrison DJ, 2005, CANCER RES, V65, P8174, DOI 10.1158/0008-5472.CAN-04-3657; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERANTONI AO, 1991, DIFFERENTIATION, V48, P25, DOI 10.1111/j.1432-0436.1991.tb00239.x; Perantoni AO, 2003, METH MOLEC MED, V86, P179; PETERS KG, 1992, DEVELOPMENT, V114, P233; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Savagner P, 1998, DEV DYNAM, V213, P182, DOI 10.1002/(SICI)1097-0177(199810)213:2<182::AID-AJA3>3.0.CO;2-C; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Scordi IA, 1999, DERMATOLOGY, V199, P296, DOI 10.1159/000018278; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 2002, KIDNEY INT, V61, P1968, DOI 10.1046/j.1523-1755.2002.00358.x; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Udtha M, 2003, ONCOGENE, V22, P3821, DOI 10.1038/sj.onc.1206597; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029	66	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16278	16287		10.1074/jbc.M700215200	http://dx.doi.org/10.1074/jbc.M700215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430890	hybrid			2022-12-25	WOS:000246794300035
J	Yuen, EY; Liu, WH; Yan, Z				Yuen, Eunice Y.; Liu, Wenhua; Yan, Zhen			The phosphorylation state of GluR1 Subunits determines the susceptibility of AMPA receptors to calpain cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; D-ASPARTATE RECEPTORS; TYROSINE PHOSPHORYLATION; MEDIATED PROTEOLYSIS; GLUTAMATE RECEPTORS; KINASE-II; CHANNELS; NEUROTOXICITY; TRAFFICKING; ACTIVATION	The alpha-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor(AMPAR) is an ionotropic glutamate receptor that governs most of excitatory synaptic transmission in neurons. In vitro biochemical assay has shown that calpain, a Ca2+ activated protease, can cleave AMPAR GluR1 subunits. Our physiological study found that calpain, which was activated by prolonged stimulation of the N-methyl-D-aspartate receptor ( 100 mu M, 10 min), caused a substantial suppression of AMPAR currents in cortical neurons. Since the phosphorylation sites of GluR1 by several protein kinases are located in close proximity to the calpain cleavage sites, we investigated the effect of phosphorylation on the susceptibility of GluR1 to calpain cleavage. Interestingly, we found that the calpain regulation of AMPAR currents was diminished by inhibition of Ca2+ /calmodulin-dependent protein kinase II ( CaMKII) but was augmented by inhibition of protein phosphatase 1/2A (PP1/2A). In agreement with this, in vitro assay showed that the calpain-induced proteolytic cleavage of GluR1 C-terminal fusion protein was strongly potentiated by adding the purified active CaMKII, and GluR1 phosphorylated at Ser(831) by CaMKII is much more sensitive to calpain cleavage. Taken together, our data suggest that calpain activation suppresses AMPA receptor currents via proteolytic cleavage of GluR1 subunits, and the susceptibility of AMPARs to calpain cleavage is determined by the phosphorylation state of GluR1 subunits, which is mediated by CaMKII-PP1/2A activity.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu		Liu, Wenhua/0000-0003-0903-8497				Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Bi X, 1996, NEUROSCIENCE, V73, P903, DOI 10.1016/0306-4522(96)00157-1; Bi XN, 1997, J NEUROCHEM, V68, P1484; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Cai XA, 2002, J BIOL CHEM, V277, P36553, DOI 10.1074/jbc.M203752200; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dell'Acqua ML, 2006, EUR J CELL BIOL, V85, P627, DOI 10.1016/j.ejcb.2006.01.010; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MAKI M, 1989, J BIOL CHEM, V264, P18866; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754; Yuen EY, 2005, J NEUROSCI, V25, P5488, DOI 10.1523/JNEUROSCI.1187-05.2005	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16434	16440		10.1074/jbc.M701283200	http://dx.doi.org/10.1074/jbc.M701283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428797	hybrid			2022-12-25	WOS:000246794300051
J	Mitchell, D; O'Meara, SJ; Gaffney, A; Crean, JKG; Kinsella, BT; Godson, C				Mitchell, Derick; O'Meara, Sarah J.; Gaffney, Andrew; Crean, John K. G.; Kinsella, B. Therese; Godson, Catherine			The lipoxin A(4) receptor is coupled to SHP-2 activation - Implications for regulation of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RENAL MESANGIAL CELLS; SIGNAL-TRANSDUCTION; IN-VIVO; PHOSPHOTYROSINE PHOSPHATASE; PEROXIREDOXIN-II; PDGF RECEPTOR; BETA-SUBUNIT; PROTEIN; PHOSPHORYLATION	Mesangial cell proliferation is pivotal to the pathology of glomerular injury in inflammation. We have previously reported that lipoxins, endogenously produced eicosanoids with anti-inflammatory and pro-resolution bioactions, can inhibit mesangial cell proliferation in response to several agents. This process is associated with elaborate receptor cross-talk involving modification receptor tyrosine kinase phosphorylation (McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H. R., and Godson, C. (2002) FASEB J. 16, 1817-1819). Here we demonstrate that the lipoxin A(4) (LXA4) receptor is coupled to activation and recruitment of the SHP-2 (SH2 domain-containing tyrosine phosphatase-2) within a lipid raft microdomain. Using site-directed mutagenesis of the cytosolic domain of the platelet-derived growth factor receptor beta (PDGFR beta), we report that mutation of the sites for phosphatidylinositol 3-kinase (Tyr(740) and Tyr(751)) and SHP-2 (Tyr(763) and Tyr(1009)) recruitment specifically inhibit the effect of LXA4 on the PDGFR beta signaling; furthermore inhibition of SHP-2 expression with short interfering RNA constructs blocked the effect of LXA4 on PDGFR beta phosphorylation. We demonstrate that association of the PDGFR beta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2. These data further elaborate on the potential mechanisms underlying the anti-inflammatory, proresolution, and anti-fibrotic bioactions of lipoxins.	Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; Univ Coll Dublin, Sch Biomol & Biomed Sci, Ctr Diabet Res, UCD Conway Inst, Dublin 4, Ireland	University College Dublin; University College Dublin	Godson, C (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland.	catherine.godson@ucd.ie		Kinsella, B. Therese/0000-0003-3072-941X; Godson, Catherine/0000-0003-0655-1041; /0000-0002-4337-6177	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Duchene J, 2002, J BIOL CHEM, V277, P40375, DOI 10.1074/jbc.M202744200; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fielding PE, 2004, BIOCHEMISTRY-US, V43, P2578, DOI 10.1021/bi035442c; Fiorucci S, 2004, J PHARMACOL EXP THER, V309, P1174, DOI 10.1124/jpet.103.063651; Francois H, 2004, FASEB J, V18, P926, DOI 10.1096/fj.03-0702fje; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Incoronato M, 2004, CELL SIGNAL, V16, P847, DOI 10.1016/j.cellsig.2004.01.002; JOHNSON RJ, 1993, J AM SOC NEPHROL, V4, P119; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMahon B, 2000, J BIOL CHEM, V275, P27566; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Phalen TJ, 2006, J CELL BIOL, V175, P779, DOI 10.1083/jcb.200606005; Rodgers K, 2005, AM J PATHOL, V167, P683, DOI 10.1016/S0002-9440(10)62043-3; Sato Y, 2004, BIOMED PHARMACOTHER, V58, P381, DOI 10.1016/j.biopha.2004.05.006; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035	46	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15606	15618		10.1074/jbc.M611004200	http://dx.doi.org/10.1074/jbc.M611004200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403678	hybrid			2022-12-25	WOS:000246589600038
J	Fratti, RA; Collins, KM; Hickey, CM; Wickner, W				Fratti, Rutilio A.; Collins, Kevin M.; Hickey, Christopher M.; Wickner, William			Stringent 3Q center dot 1R composition of the SNARE 0-layer can be bypassed for fusion by compensatory SNARE mutation or by lipid bilayer modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEX RING DOMAIN; IN-VITRO REACTIONS; MEMBRANE-FUSION; VACUOLE FUSION; T-SNARE; TRANSMEMBRANE SEGMENTS; COMPLEX REVEALS; ALPHA-SNAP; V-SNARES; DOCKING	SNARE proteins form bundles of four alpha-helical SNARE domains with conserved polar amino acids, 3Q and 1R, at the "0-layer" of the bundle. Previous studies have confirmed the importance of 3Q(.)1R for fusion but have not shown whether it regulates SNARE complex assembly or the downstream functions of assembled SNAREs. Yeast vacuole fusion requires regulatory lipids (ergosterol, phosphoinositides, and diacylglycerol), the Rab Ypt7p, the Rab-effector complex HOPS, and 4 SNAREs: the Q-SNAREs Vti1p, Vam3p, and Vam7p and the R-SNARE Nyv1p. We now report that alterations in the 0-layer Gln or Arg residues of Vam7p or Nyv1p, respectively, strongly inhibit fusion. Vacuoles with wild-type Nyv1p show exquisite discrimination for the wild-type Vam7p over Vam7(Q283R), yet Vam7(Q283R) is preferred by vacuoles with Nyv1(R191Q). Rotation of the position of the arginine in the 0-layer increases the K-m for Vam7p but does not affect the maximal rate of fusion. Vam7(Q283R) forms stable 2Q(.)2R complexes that do not promote fusion. However, fusion is restored by the lipophilic amphiphile chlorpromazine or by the phospholipase C inhibitor U73122, perturbants of the lipid phase of the membrane. Thus, SNARE function as regulated by the 0-layer is intimately coupled to the lipids, which must rearrange for fusion.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu	Collins, Kevin/AAA-8989-2019	Collins, Kevin/0000-0001-9930-0924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023377] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM023377] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhalla A, 2006, NAT STRUCT MOL BIOL, V13, P323, DOI 10.1038/nsmb1076; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen XC, 2006, BIOPHYS J, V90, P2062, DOI 10.1529/biophysj.105.071415; Collins KM, 2005, EMBO J, V24, P1775, DOI 10.1038/sj.emboj.7600658; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Dennison SM, 2006, BIOPHYS J, V90, P1661, DOI 10.1529/biophysj.105.069617; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Graf CT, 2005, MOL BIOL CELL, V16, P2263, DOI 10.1091/mbc.E04-09-0830; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hofmann MW, 2006, J MOL BIOL, V364, P1048, DOI 10.1016/j.jmb.2006.09.077; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Jun Y, 2006, EMBO J, V25, P5260, DOI 10.1038/sj.emboj.7601413; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Merz AJ, 2004, P NATL ACAD SCI USA, V101, P11548, DOI 10.1073/pnas.0404583101; Murdock DR, 2005, BIOPHYS J, V89, P4090, DOI 10.1529/biophysj.105.069872; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Oghalai JS, 2000, SCIENCE, V287, P658, DOI 10.1126/science.287.5453.658; Raucher D, 2001, J CELL SCI, V114, P3759; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Siegel DP, 2006, BIOPHYS J, V90, P200, DOI 10.1529/biophysj.105.070466; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	52	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14861	14867		10.1074/jbc.M700971200	http://dx.doi.org/10.1074/jbc.M700971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17400548	hybrid			2022-12-25	WOS:000246589000022
J	Saiz, L; Vilar, JMG				Saiz, Leonor; Vilar, Jose M. G.			Multilevel Deconstruction of the In Vivo Behavior of Looped DNA-Protein Complexes	PLOS ONE			English	Article							LAC REPRESSOR; CRYSTAL-STRUCTURE; NUCLEOPROTEIN COMPLEXES; BINDING; TRANSCRIPTION; CAP; DEPENDENCE; CHROMATIN; TETRAMER; ELEMENTS	Protein-DNA complexes with loops play a fundamental role in a wide variety of cellular processes, ranging from the regulation of DNA transcription to telomere maintenance. As ubiquitous as they are, their precise in vivo properties and their integration into the cellular function still remain largely unexplored. Here, we present a multilevel approach that efficiently connects in both directions molecular properties with cell physiology and use it to characterize the molecular properties of the looped DNA-lac repressor complex while functioning in vivo. The properties we uncover include the presence of two representative conformations of the complex, the stabilization of one conformation by DNA architectural proteins, and precise values of the underlying twisting elastic constants and bending free energies. Incorporation of all this molecular information into gene-regulation models reveals an unprecedented versatility of looped DNA-protein complexes at shaping the properties of gene expression.	[Saiz, Leonor; Vilar, Jose M. G.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, Integrat Biol Modeling Lab, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Vilar, JMG (corresponding author), Mem Sloan Kettering Canc Ctr, Computat Biol Program, Integrat Biol Modeling Lab, 1275 York Ave, New York, NY 10021 USA.	vilar@cbio.mskcc.org	Saiz, Leonor/I-3557-2015; Vilar, Jose MG/A-9069-2013	Saiz, Leonor/0000-0002-6866-9400; Vilar, Jose MG/0000-0003-4037-0746				ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Balaeff A, 2004, STRUCTURE, V12, P123, DOI 10.1016/j.str.2003.12.004; Bates A. D., 2005, DNA TOPOLOGY; Becker NA, 2005, J MOL BIOL, V349, P716, DOI 10.1016/j.jmb.2005.04.035; BELLOMY GR, 1988, BIOCHEMISTRY-US, V27, P3900, DOI 10.1021/bi00411a002; Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE, V1st ed.; Cloutier TE, 2005, P NATL ACAD SCI USA, V102, P3645, DOI 10.1073/pnas.0409059102; Edelman LM, 2003, BIOPHYS J, V84, P1131, DOI 10.1016/S0006-3495(03)74929-7; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Geanacopoulos M, 2001, NAT STRUCT BIOL, V8, P432, DOI 10.1038/87595; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Halford SE, 2000, NAT STRUCT BIOL, V7, P705, DOI 10.1038/78911; Hill T. L., 2012, INTRO STAT THERMODYN; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Li QL, 2006, TRENDS GENET, V22, P197, DOI 10.1016/j.tig.2006.02.004; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; Muller J, 1996, J MOL BIOL, V257, P21, DOI 10.1006/jmbi.1996.0143; Olson WK, 2004, PHILOS T R SOC A, V362, P1403, DOI 10.1098/rsta.2004.1380; PTASHNE M, 2002, GENES SIGNALS; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Ruben GC, 1997, MICROSC RES TECHNIQ, V36, P400, DOI 10.1002/(SICI)1097-0029(19970301)36:5<400::AID-JEMT10>3.0.CO;2-W; Saiz L, 2005, P NATL ACAD SCI USA, V102, P17642, DOI 10.1073/pnas.0505693102; Saiz L, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100061; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; Semsey S, 2005, TRENDS BIOCHEM SCI, V30, P334, DOI 10.1016/j.tibs.2005.04.009; Swigon D, 2006, P NATL ACAD SCI USA, V103, P9879, DOI 10.1073/pnas.0603557103; Talbert PB, 2006, NAT REV GENET, V7, P793, DOI 10.1038/nrg1920; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Vilar JMG, 2005, CURR OPIN GENET DEV, V15, P136, DOI 10.1016/j.gde.2005.02.005; Vilar JMG, 2003, J MOL BIOL, V331, P981, DOI 10.1016/S0022-2836(03)00764-2; Vilar JMG, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.238103; Villa E, 2005, P NATL ACAD SCI USA, V102, P6783, DOI 10.1073/pnas.0409387102; Watson MA, 2000, J MOL BIOL, V298, P461, DOI 10.1006/jmbi.2000.3676; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yan J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.108108; Zhang Y, 2006, BIOPHYS J, V90, P1903, DOI 10.1529/biophysj.105.070490	42	25	25	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e355	10.1371/journal.pone.0000355	http://dx.doi.org/10.1371/journal.pone.0000355			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406679	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445300017
J	Gamm, DM; Wang, SM; Lu, B; Girman, S; Holmes, T; Bischoff, N; Shearer, RL; Sauve, Y; Capowski, E; Svendsen, CN; Lund, RD				Gamm, David M.; Wang, Shaomei; Lu, Bin; Girman, Sergei; Holmes, Toby; Bischoff, Nicholas; Shearer, Rebecca L.; Sauve, Yves; Capowski, Elizabeth; Svendsen, Clive N.; Lund, Raymond D.			Protection of Visual Functions by Human Neural Progenitors in a Rat Model of Retinal Disease	PLOS ONE			English	Article								Background. A promising clinical application for stem and progenitor cell transplantation is in rescue therapy for degenerative diseases. This strategy seeks to preserve rather than restore host tissue function by taking advantage of unique properties often displayed by these versatile cells. In studies using different neurodegenerative disease models, transplanted human neural progenitor cells (hNPC) protected dying host neurons within both the brain and spinal cord. Based on these reports, we explored the potential of hNPC transplantation to rescue visual function in an animal model of retinal degeneration, the Royal College of Surgeons rat. Methodology/ Principal Findings. Animals received unilateral subretinal injections of hNPC or medium alone at an age preceding major photoreceptor loss. Principal outcomes were quantified using electroretinography, visual acuity measurements and luminance threshold recordings from the superior colliculus. At 90100 days postnatal, a time point when untreated rats exhibit little or no retinal or visual function, hNPC-treated eyes retained substantial retinal electrical activity and visual field with near-normal visual acuity. Functional efficacy was further enhanced when hNPC were genetically engineered to secrete glial cell line-derived neurotrophic factor. Histological examination at 150 days postnatal showed hNPC had formed a nearly continuous pigmented layer between the neural retina and retinal pigment epithelium, as well as distributed within the inner retina. A concomitant preservation of host cone photoreceptors was also observed. Conclusions/Significance. Wild type and genetically modified human neural progenitor cells survive for prolonged periods, migrate extensively, secrete growth factors and rescue visual functions following subretinal transplantation in the Royal College of Surgeons rat. These results underscore the potential therapeutic utility of hNPC in the treatment of retinal degenerative diseases and suggest potential mechanisms underlying their effect in vivo.	[Gamm, David M.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; [Svendsen, Clive N.] Univ Wisconsin, Dept Anat, Madison, WI 53706 USA; [Svendsen, Clive N.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; [Gamm, David M.; Shearer, Rebecca L.; Capowski, Elizabeth; Svendsen, Clive N.] Univ Wisconsin, Waisman Ctr Stem Cell Res Program, Madison, WI 53706 USA; [Wang, Shaomei; Lu, Bin; Girman, Sergei; Holmes, Toby; Bischoff, Nicholas; Sauve, Yves; Lund, Raymond D.] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA; [Wang, Shaomei; Lu, Bin; Girman, Sergei; Lund, Raymond D.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA; [Sauve, Yves] Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah; Oregon Health & Science University; University of Alberta	Gamm, DM (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.	dgamm@wisc.edu			Walsh Foundation; Heckrodt Foundation; Foundation Fighting Blindness; Lincy Foundation; NIH [K08EY015138]; Kinetics Foundation and Department of Defense; NATIONAL EYE INSTITUTE [K08EY015138] Funding Source: NIH RePORTER	Walsh Foundation; Heckrodt Foundation; Foundation Fighting Blindness(European Commission); Lincy Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kinetics Foundation and Department of Defense; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	DMG laboratory was supported by grants from Walsh Foundation, Heckrodt Foundation, Foundation Fighting Blindness, Lincy Foundation and NIH K08EY015138. DMG is a recipient of a Research to Prevent Blindness Robert E. McCormick Scholar Award and a Retina Research Foundation Award (Edwin and Dorothy Gamewell Professorship). RDL laboratory was supported by grants from Walsh Foundation, Lincy Foundation, Foundation Fighting Blindness and Wynn Foundation. RDL is a recipient of a Research to Prevent Blindness Senior Scientific Investigator Award. CNS laboratory was supported by Kinetics Foundation and Department of Defense.	Andrieu-Soler C, 2005, MOL VIS, V11; Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Behrstock S, 2006, GENE THER, V13, P379, DOI 10.1038/sj.gt.3302679; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; Blesch A, 2001, J COMP NEUROL, V436, P399, DOI 10.1002/cne.1076; Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275; CAPOWSKI EE, J NEUROSCI IN PRESS; Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023; Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; Hauck SM, 2006, MOL CELL BIOL, V26, P2746, DOI 10.1128/MCB.26.7.2746-2757.2006; Jin KL, 2005, P NATL ACAD SCI USA, V102, P18189, DOI 10.1073/pnas.0506375102; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Jomary C, 2004, INVEST OPHTH VIS SCI, V45, P1240, DOI 10.1167/iovs.03-1122; Keller-Peck CR, 2001, J NEUROSCI, V21, P6136, DOI 10.1523/JNEUROSCI.21-16-06136.2001; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Kretz A, 2006, BRAIN RES, V1090, P1, DOI 10.1016/j.brainres.2006.01.131; Kurimoto Y, 2001, NEUROSCI LETT, V306, P57, DOI 10.1016/S0304-3940(01)01857-2; LaVail M M, 2001, Prog Brain Res, V131, P617; Lawrence JM, 2004, INVEST OPHTH VIS SCI, V45, P267, DOI 10.1167/iovs.03-0093; Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindqvist N, 2004, EXP NEUROL, V187, P487, DOI 10.1016/j.expneurol.2004.02.002; Lu B, 2002, BRAIN RES, V943, P292, DOI 10.1016/S0006-8993(02)02906-2; Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308; Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189; Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; McBride JL, 2004, J COMP NEUROL, V475, P211, DOI 10.1002/cne.20176; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9; Mizumoto H, 2001, CELL TRANSPLANT, V10, P223; Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268; Ogilvie JM, 2000, EXP NEUROL, V161, P676, DOI 10.1006/exnr.1999.7291; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498; Sauve Y, 2006, VISION RES, V46, P1459, DOI 10.1016/j.visres.2005.11.009; Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3; Sauve Y, 2001, NEUROSCIENCE, V103, P51, DOI 10.1016/S0306-4522(00)00557-1; Schwartz Philip H, 2006, Expert Rev Neurother, V6, P153, DOI 10.1586/14737175.6.2.153; Seigel G, 2000, MOL VIS, V6, P157; Spencer B, 2001, MOL THER, V3, P746, DOI 10.1006/mthe.2001.0307; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tai YT, 2004, CURR OPIN PHARMACOL, V4, P98, DOI 10.1016/j.coph.2003.09.006; Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721; Taupin P, 2006, CURR OPIN MOL THER, V8, P156; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279; Wang SM, 2005, J COMP NEUROL, V491, P400, DOI 10.1002/cne.20695; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Wu WC, 2004, MOL VIS, V10, P93; Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869; Zheng WH, 2000, ADV RES NEURODEGENER, V8, P261	67	112	113	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e338	10.1371/journal.pone.0000338	http://dx.doi.org/10.1371/journal.pone.0000338			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17396165	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200021
J	Deshpande, DA; Pascual, RM; Wang, SW; Eckman, DM; Riemer, EC; Funk, CD; Penn, RB				Deshpande, Deepak A.; Pascual, Rodolfo M.; Wang, Si-Wei; Eckman, Delrae M.; Riemer, Ellen C.; Funk, Colin D.; Penn, Raymond B.			PKC-dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation	FASEB JOURNAL			English	Article						G protein-coupled receptor; cysteinyl leukotriene; protein kinase C; desensitization; airway smooth muscle	GENE-TARGETED MICE; ANALGESIC TOLERANCE; CYSLT(1) RECEPTOR; KINASE 1; PROTEIN; EXPRESSION; DESENSITIZATION; RESPONSIVENESS; CELLS; SUPERSENSITIVITY	Leukotrienes are important lipid mediators of asthma that contribute to airway inflammation and bronchoconstriction. Critical mechanisms for physiological regulation of the main G protein-coupled receptor ( GPCR) mediating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor ( CysLT1R), have not been delineated. Although desensitization of GPCRs is a well-established phenomenon, studies demonstrating its physiological relevance are lacking. Here, we demonstrate that relief of PKC-mediated desensitization of endogenous CysLT1Rs augments multiple LTD4- stimulated cellular functions, with associated increases in intracellular signaling events. In analyses of airway smooth muscle contraction ex vivo, PKC inhibition augmented LTD4- stimulated contraction, and increased phosphoinositide hydrolysis and calcium flux in both murine and human airway smooth muscle cells. Similarly, for human monocytes, PKC inhibition augmented LTD4- stimulated calcium flux and cell migration assessed in transwell chamber experiments and also augmented LTD4- induced production of monocyte chemotactic protein assessed by ELISA. In contrast, PKC inhibition had no effect or slightly attenuated these cell functions and signaling events promoted by other receptor agonists, suggesting that despite antithetical effects on downstream events, desensitization of the CysLT1R is the principal mechanism by which PKC regulates the functional consequences of CysLT1R activation.	Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Internal Med, Winston Salem, NC USA; Wake Forest Univ, Ctr Human Genet, Winston Salem, NC USA; Wake Forest Univ, Dept Pathol, Winston Salem, NC USA; Queens Univ, Dept Physiol, Kingston, ON, Canada; Queens Univ, Dept Biochem, Kingston, ON, Canada	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; Queens University - Canada; Queens University - Canada	Penn, RB (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu	Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059755] Funding Source: NIH RePORTER; NIAID NIH HHS [AI059755] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Austen K Frank, 2005, Novartis Found Symp, V271, P166; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Harnett KM, 2005, AM J PHYSIOL-GASTR L, V288, pG407, DOI 10.1152/ajpgi.00398.2004; HOSEY MM, 1995, LIFE SCI, V56, P951; Ichiyama T, 2005, CLIN EXP ALLERGY, V35, P1214, DOI 10.1111/j.1365-2222.2005.02323.x; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Lynch KR, 1999, NATURE, V399, P789; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; METTERS KM, 1994, J PHARMACOL EXP THER, V270, P399; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Murphy Stephen, 2005, Cardiol Rev, V13, P3; Naik S, 2005, J BIOL CHEM, V280, P8722, DOI 10.1074/jbc.M413014200; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; PENN RB, 1998, HDB PHYSL, P125; Premont RT, 2005, NEUROMOL MED, V7, P129, DOI 10.1385/NMM:7:1-2:129; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Tani Eiichi, 2004, Current Vascular Pharmacology, V2, P13, DOI 10.2174/1570161043476492; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; von Zastrow M, 2004, NEUROPHARMACOLOGY, V47, P286, DOI 10.1016/j.neuropharm.2004.05.007; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Yang GC, 2004, AM J PHYSIOL-LUNG C, V286, pL992, DOI 10.1152/ajplung.00367.2003	37	22	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2335	2342		10.1096/fj.06-8060com	http://dx.doi.org/10.1096/fj.06-8060com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392478				2022-12-25	WOS:000248454400008
J	Andrade, J; Karmali, A; Carrondo, MA; Frazao, C				Andrade, Jorge; Karmali, Amin; Carrondo, Maria A.; Frazao, Carlos			Structure of amidase from Pseudomonas aeruginosa showing a trapped acyl transfer reaction intermediate state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID AMIDOHYDROLASE; CRYSTAL-STRUCTURE; ALIPHATIC AMIDASE; ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; GENE; RESOLUTION; NITRILASE; STRAIN	Microbial amidases belong to the thiol nitrilases family and have potential biotechnological applications in chemical and pharmaceutical industries as well as in bioremediation. The amidase from Pseudomonas aeruginosa is a 6 x 38-kDa enzyme that catalyzes the hydrolysis of a small range of short aliphatic amides. The hereby reported high resolution crystallographic structure shows that each amidase monomer is formed by a globular four-layer alpha beta beta alpha sandwich domain with an additional 81-residue long C-terminal segment. This wraps arm-in-arm with a homologous C-terminal chain of another monomer, producing a strongly packed dimer. In the crystal, the biological active homo-hexameric amidase is built grouping three such dimers around a crystallographic 3-fold axis. The structure also elucidates the structural basis for the enzyme activity, with the nitrilases catalytic triad at the bottom of a 13-angstrom deep, funnelshaped pocket, accessible from the solvent through a narrow neck with 3-angstrom diameter. An acyl transfer intermediate, resulting from the purification protocol, was found bound to the amidase nucleophilic agent, Cys166. These results suggest that some pocket defining residues should undergo conformational shifts to allow substrates and products to access and leave the catalytic pocket, for turnover to occur.	Univ Nova Lisboa, Inst Technol Quim & Biol, P-2781 Oeiras, Portugal; Inst Super Engn Lisboa, Ctr Invest Engn Quim & Biotechnol, P-1950 Lisbon, Portugal	Universidade Nova de Lisboa; Polytechnic Institute of Lisbon	Frazao, C (corresponding author), Univ Nova Lisboa, Inst Technol Quim & Biol, Avenida da Republ, P-2781 Oeiras, Portugal.	frazao@itqb.unl.pt	Karmali, Amin/GPX-0993-2022; Karmali, Amin/AAI-4633-2020; Karmali, Amin/E-4787-2011; Andrade, Jorge/AAD-6324-2021; Frazao, Carlos/C-1965-2008	Karmali, Amin/0000-0003-0419-401X; Carrondo, Maria Armenia/0000-0002-1261-1162; Frazao, Carlos/0000-0002-7725-1671; Andrade, Jorge/0000-0002-4577-8620				Agarkar VB, 2006, ACTA CRYSTALLOGR F, V62, P1174, DOI 10.1107/S1744309106043855; Andrade J, 2007, ACTA CRYSTALLOGR F, V63, P214, DOI 10.1107/S1744309107005830; BABU GRV, 1995, APPL MICROBIOL BIOT, V43, P739; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee A, 2002, APPL MICROBIOL BIOT, V60, P33, DOI 10.1007/s00253-002-1062-0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BETZ JL, 1972, J GEN MICROBIOL, V73, P161, DOI 10.1099/00221287-73-1-161; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; Brenner C, 2002, CURR OPIN STRUC BIOL, V12, P775, DOI 10.1016/S0959-440X(02)00387-1; BROWN JE, 1970, J GEN MICROBIOL, V64, P329, DOI 10.1099/00221287-64-3-329; BROWN JE, 1969, J GEN MICROBIOL, V57, P273, DOI 10.1099/00221287-57-2-273; BROWN PR, 1972, J GEN MICROBIOL, V70, P287, DOI 10.1099/00221287-70-2-287; Caliandro R, 2005, ACTA CRYSTALLOGR D, V61, P556, DOI 10.1107/S090744490500404X; Cawston TE, 1996, PHARMACOL THERAPEUT, V70, P163, DOI 10.1016/0163-7258(96)00015-0; CLARKE PH, 1972, J GEN MICROBIOL, V71, P241, DOI 10.1099/00221287-71-2-241; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOMINGOS A, 1989, BIOCHIMIE, V71, P1179, DOI 10.1016/0300-9084(89)90021-7; Farnaud S, 1999, BIOCHEM J, V340, P711, DOI 10.1042/0264-6021:3400711; FINDLATE.JD, 1973, FEBS LETT, V35, P109, DOI 10.1016/0014-5793(73)80588-5; Fournand D, 1998, APPL ENVIRON MICROB, V64, P2844; Fournand D, 1998, J MOL CATAL B-ENZYM, V4, P77, DOI 10.1016/S1381-1177(97)00024-6; Fournand D, 1997, ENZYME MICROB TECH, V20, P424, DOI 10.1016/S0141-0229(96)00170-6; GAO WY, 1995, BIOCHEM PHARMACOL, V50, P274, DOI 10.1016/0006-2952(95)00106-A; GREGORIOU M, 1979, EUR J BIOCHEM, V96, P101, DOI 10.1111/j.1432-1033.1979.tb13018.x; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Karmali A, 2001, MOL BIOTECHNOL, V17, P201, DOI 10.1385/MB:17:3:201; Karmali A, 2000, MOL BIOTECHNOL, V16, P5, DOI 10.1385/MB:16:1:05; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; Kumaran D, 2003, PROTEINS, V52, P283, DOI 10.1002/prot.10417; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li WF, 2005, BIOTECHNOL ADV, V23, P271, DOI 10.1016/j.biotechadv.2005.01.002; MAESTRACCI M, 1986, AGR BIOL CHEM TOKYO, V50, P2237, DOI 10.1080/00021369.1986.10867736; Martins S, 2005, MOL BIOTECHNOL, V30, P207, DOI 10.1385/MB:30:3:207; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; NAWAZ MS, 1991, CAN J MICROBIOL, V37, P411, DOI 10.1139/m91-067; NAWAZ MS, 1991, APPL BIOCHEM BIOTECH, V28-9, P865, DOI 10.1007/BF02922656; NOVO C, 1995, FEBS LETT, V367, P275, DOI 10.1016/0014-5793(95)00585-W; Novo C, 2002, BIOCHEM J, V365, P731, DOI 10.1042/BJ20011714; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; Pacheco R, 2005, ANAL BIOCHEM, V346, P49, DOI 10.1016/j.ab.2005.07.027; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Pearl F, 2005, NUCLEIC ACIDS RES, V33, pD247, DOI 10.1093/nar/gki024; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; STEVENSON DE, 1992, BIOTECHNOL APPL BIOC, V15, P283; STEVENSON DE, 1990, FEBS LETT, V277, P112, DOI 10.1016/0014-5793(90)80821-Y; TATA R, 1994, BBA-PROTEIN STRUCT M, V1205, P139, DOI 10.1016/0167-4838(94)90102-3; Tsafack A, 1996, J LAB CLIN MED, V127, P574, DOI 10.1016/S0022-2143(96)90148-1; Vanjari H, 2003, J PHARMACEUT BIOMED, V33, P783, DOI 10.1016/S0731-7085(03)00282-6; Wang WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/jmbi.2000.4380; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; WOODS MJ, 1979, BIOCHIM BIOPHYS ACTA, V567, P225, DOI 10.1016/0005-2744(79)90189-X; Wu SJ, 1998, DNA CELL BIOL, V17, P915, DOI 10.1089/dna.1998.17.915	67	40	42	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19598	19605		10.1074/jbc.M701039200	http://dx.doi.org/10.1074/jbc.M701039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17442671	hybrid			2022-12-25	WOS:000247650600034
J	Yuzuriha, H; Inui, A; Asakawa, A; Ueno, N; Kasuga, M; Meguid, MM; Miyazaki, JI; Ninomiya, M; Herzog, H; Fujimiya, M				Yuzuriha, Hideki; Inui, Akio; Asakawa, Akihiro; Ueno, Naohiko; Kasuga, Masato; Meguid, Michael M.; Miyazaki, Jun-ichi; Ninomiya, Maiko; Herzog, Herbert; Fujimiya, Mineko			Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development	FASEB JOURNAL			English	Article						neural tube defect; transgenic mice; gut hormone	BODY-WEIGHT REGULATION; FOOD-INTAKE; PANCREATIC-POLYPEPTIDE; MICE; EXPRESSION; RECEPTORS; APPETITE; DEFECTS; STOMACH; MOTILIN	Gastrointestinal (GI) hormones play an important role in GI secretion, motility, and eating behaviors. It was recently suggested that GI hormones may have a trophic role in GI tract. Here we demonstrate that two principal GI hormones, anorexigenic peptide YY (PYY) and orexigenic ghrelin, affect neural tube development. Chronic administration into the pregnant mice or transgenic overexpression of PYY led to a neural tube defect (NTD) in the embryos that was blocked by ghrelin. PYY Y1 receptor antagonist prevented the occurrence of NTD induced not only by PYY but also by vitamin A, a well-known teratogen in humans and animals. Y1 receptor deficiency also engendered NTDs, indicating the need to maintain normal Y1 receptor signaling. The present study is the first linking GI hormones to the leading cause of infant mortality and provides a novel insight for neurogenesis in which materno-fetal communication through GI hormones appears to be important.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Behav Med, Kagoshima, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis, Kobe, Hyogo, Japan; SUNY Upstate Med Univ, Dept Neurosci & Surg, Syracuse, NY USA; Osaka Univ, Grad Sch Med, Dept Physiol Chem & Nutr, Osaka, Japan; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 52021, Japan; Garvan Inst Med Res, Neurobiol Program, Sydney, NSW, Australia	Kagoshima University; Kobe University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Osaka University; Shiga University of Medical Science; Garvan Institute of Medical Research	Inui, A (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Behav & Internal Med, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	inui@m.kufm.kagoshima-u.ac.jp	Herzog, Herbert/B-8294-2008; Miyazaki, Jun-ichi/N-1976-2015; Ueno, Naohiko/W-1723-2017	Miyazaki, Jun-ichi/0000-0003-2475-589X; Ueno, Naohiko/0000-0003-2946-1524; , Herbert/0000-0002-1713-1029				ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P494, DOI 10.1016/0016-5085(85)90442-1; Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Asakawa A, 2003, GUT, V52, P947, DOI 10.1136/gut.52.7.947; Asakawa A, 2003, GASTROENTEROLOGY, V124, P1325, DOI 10.1016/S0016-5085(03)00216-6; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Fujimiya M, 1997, HISTOCHEM CELL BIOL, V107, P105, DOI 10.1007/s004180050094; FUJIMIYA M, 1995, PEPTIDES, V16, P939, DOI 10.1016/0196-9781(95)00062-O; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; Harris MJ, 1999, TERATOLOGY, V60, P292, DOI 10.1002/(SICI)1096-9926(199911)60:5<292::AID-TERA10>3.3.CO;2-Y; Hogan B, 1994, MANIPULATING MOUSE E; Inui A, 2000, PHARMACOL REV, V52, P35; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; JAZIN EE, 1993, DEV BRAIN RES, V76, P105, DOI 10.1016/0165-3806(93)90128-W; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Leroux P, 2002, J COMP NEUROL, V442, P35, DOI 10.1002/cne.1420; Michel MC, 1998, PHARMACOL REV, V50, P143; Nakahara K, 2006, ENDOCRINOLOGY, V147, P1333, DOI 10.1210/en.2005-0708; Neary NM, 2004, J CLIN ENDOCR METAB, V89, P2832, DOI 10.1210/jc.2003-031768; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Rindi G, 2002, HISTOCHEM CELL BIOL, V117, P511, DOI 10.1007/s00418-002-0415-1; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; Tomasetto C, 2000, GASTROENTEROLOGY, V119, P395, DOI 10.1053/gast.2000.9371; Ueno N, 1999, GASTROENTEROLOGY, V117, P1427, DOI 10.1016/S0016-5085(99)70293-3; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	31	17	32	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2108	2112		10.1096/fj.06-7621com	http://dx.doi.org/10.1096/fj.06-7621com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17400914				2022-12-25	WOS:000247500300020
J	Fierro-Fernandez, M; Hernandez, P; Krimer, DB; Schvartzman, JB				Fierro-Fernandez, Marta; Hernandez, Pablo; Krimer, Dora B.; Schvartzman, Jorge B.			Replication fork reversal occurs spontaneously after digestion but is constrained in supercoiled domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; DNA-REPLICATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PLASMID REPLICATION; POTENTIAL ORIGINS; EGG EXTRACTS; TERMINATION; REGRESSION; INITIATION	Replication fork reversal was investigated in undigested and linearized replication intermediates of bacterial DNA plasmids containing a stalled fork. Two-dimensional agarose gel electrophoresis, a branch migration and extrusion assay, electron microscopy, and DNA-psoralen cross-linking were used to show that extensive replication fork reversal and extrusion of the nascent-nascent duplex occurs spontaneously after DNA nicking and restriction enzyme digestion but that fork retreat is severely limited in covalently closed supercoiled domains.	CSIC, Ctr Invest Biol, Dept Biol Celular & Desarrollo, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Schvartzman, JB (corresponding author), CSIC, Ctr Invest Biol, Dept Biol Celular & Desarrollo, Ramiro Maeztu 9, E-28040 Madrid, Spain.	schvartzman@cib.csic.es	Schvartzman, Jorge B/J-9171-2014; Krimer, Dora/J-9176-2014	Krimer, Dora/0000-0001-9972-3994; Pablo, Hernandez/0000-0002-8113-1277				ALLERS T, 2006, NUCLEIC ACIDS RES, V28, pE6; Baharoglu Z, 2006, EMBO J, V25, P596, DOI 10.1038/sj.emboj.7600941; Bastia D., 1996, DNA REPLICATION EUKA, P177; Bates A.D., 2005, DNA TOPOLOGY, P198; Bessler JB, 2004, GENETICS, V168, P1205, DOI 10.1534/genetics.104.028035; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Chow KH, 2004, J BIOL CHEM, V279, P3492, DOI 10.1074/jbc.M311012200; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Duncker BP, 1999, MOL CELL BIOL, V19, P1226; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; Fierro-Fernandez M, 2007, P NATL ACAD SCI USA, V104, P1500, DOI 10.1073/pnas.0609204104; Flores MJ, 2005, MOL MICROBIOL, V57, P1664, DOI 10.1111/j.1365-2958.2005.04753.x; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lopes M, 2003, MOL CELL, V12, P1499, DOI 10.1016/S1097-2765(03)00473-8; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Mirkin EV, 2006, P NATL ACAD SCI USA, V103, P7276, DOI 10.1073/pnas.0601127103; Mohanty BK, 2004, J BIOL CHEM, V279, P1932, DOI 10.1074/jbc.M309078200; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Olavarrieta L, 2002, NUCLEIC ACIDS RES, V30, P656, DOI 10.1093/nar/30.3.656; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; Pohlhaus JR, 2005, MOL MICROBIOL, V56, P1416, DOI 10.1111/j.1365-2958.2005.04638.x; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Santamaria D, 2000, J MOL BIOL, V300, P75, DOI 10.1006/jmbi.2000.3843; Santamaria D, 2000, NUCLEIC ACIDS RES, V28, P2099, DOI 10.1093/nar/28.10.2099; Schvartzman JB, 2004, EMBO REP, V5, P256, DOI 10.1038/sj.embor.7400101; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; SOGO JM, 1989, METHOD ENZYMOL, V170, P142; SOGO JM, 1987, ELECTRON MICROS, P61; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Veaute X, 1997, J BIOL CHEM, V272, P15351, DOI 10.1074/jbc.272.24.15351; Vengrova S, 2004, GENE DEV, V18, P794, DOI 10.1101/gad.289404; Viguera E, 2000, NUCLEIC ACIDS RES, V28, P498, DOI 10.1093/nar/28.2.498; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733	53	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18190	18196		10.1074/jbc.M701559200	http://dx.doi.org/10.1074/jbc.M701559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17456472	Green Submitted, hybrid			2022-12-25	WOS:000247302000025
J	Chun, YJ; Shimada, T; Sanchez-Ponce, R; Martin, MV; Lei, L; Zhao, B; Kelly, SL; Waterman, MR; Lamb, DC; Guengerich, FP				Chun, Young-Jin; Shimada, Tsutomu; Sanchez-Ponce, Raymundo; Martin, Martha V.; Lei, Li; Zhao, Bin; Kelly, Steven L.; Waterman, Michael R.; Lamb, David C.; Guengerich, F. Peter			Electron transport pathway for a Streptomyces cytochrome P450 - Cytochrome P450 105D5-catalyzed fatty acid hydroxylation in Streptomyces coelicolor A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; RATE-LIMITING STEPS; METHYLENE HYDROXYLATION; COMPLEMENT CYPOME; TRANSFER PROTEINS; LIVER MICROSOMES; DOUBLE BOND; REDUCTASE; FERREDOXIN; GRISEUS	Streptomyces and other bacterial actinomycete species produce many important natural products, including the majority of known antibiotics, and cytochrome P450 ( P450) enzymes catalyze important biosynthetic steps. Relatively few electron transport pathways to P450s have been characterized in bacteria, particularly streptomycete species. One of the 18 P450s in Streptomyces coelicolor A3( 2), P450 105D5, was found to bind fatty acids tightly and form hydroxylated products when electrons were delivered from heterologous systems. The six ferredoxin ( Fdx) and four flavoprotein Fdx reductase ( FDR) proteins coded by genes in S. coelicolor were expressed in Escherichia coli, purified, and used to characterize the electron transfer pathway. Of the many possibilities, the primary pathway was NADH -> FDR1 -> Fdx4 -> P450 105D5. The genes coding for FDR1, Fdx4, and P450 105D5 are located close together in the S. coelicolor genome. Several fatty acids examined were substrates, including those found in S. coelicolor extracts, and all yielded several products. Mass spectra of the products of lauric acid imply the 8-, 9-, 10-, and 11-hydroxy derivatives. Hydroxylated fatty acids were also detected in vivo in S. coelicolor. Rates of electron transfer between the proteins were measured; all steps were faster than overall hydroxylation and consistent with rates of NADH oxidation. Substrate binding, product release, and oxygen binding were relatively fast in the catalytic cycle; high kinetic deuterium isotope effects for all four lauric acid hydroxylations indicated that the rate of C-H bond breaking is rate-limiting in every case. Thus, an electron transfer pathway to a functional Streptomyces P450 has been established.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; Univ Coll Swansea, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales; Univ Coll Swansea, Sch Med, Swansea SA2 8PP, W Glam, Wales	Vanderbilt University; Vanderbilt University; Chung Ang University; Swansea University; Swansea University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Shimada, Tsutomu/0000-0003-2552-4348	NATIONAL CANCER INSTITUTE [R37CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069970] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA090426] Funding Source: Medline; NIEHS NIH HHS [T32 ES07028, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [R01 GM069970] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BROWN HC, 1967, J AM CHEM SOC, V89, P1522, DOI 10.1021/ja00982a043; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; Capdevila J., 2005, CYTOCHROME P450 STRU, P531; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; FOUST GP, 1969, J BIOL CHEM, V244, P964; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; Johnson Kenneth A., 2003, P1; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; Krauser JA, 2005, J BIOL CHEM, V280, P19496, DOI 10.1074/jbc.M501854200; Lamb DC, 2003, BIOCHEM BIOPH RES CO, V307, P610, DOI 10.1016/S0006-291X(03)01231-2; Lamb DC, 2002, J BIOL CHEM, V277, P24000, DOI 10.1074/jbc.M111109200; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; Lei L, 2004, P NATL ACAD SCI USA, V101, P494, DOI 10.1073/pnas.2435922100; LU AYH, 1968, J BIOL CHEM, V243, P1331; Matsson O, 1998, ADV PHYS ORG CHEM, V31, P143; McLean KJ, 2006, BIOCHEMISTRY-US, V45, P8427, DOI 10.1021/bi0601609; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; OKEEFE DP, 1991, BIOCHEMISTRY-US, V30, P447, DOI 10.1021/bi00216a021; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; Ortiz de Montellano P.R., 2005, CYTOCHROME P450 STRU, P183, DOI [10.1007/b139087, DOI 10.1007/B139087]; Paine M.J.I., 2005, CYTOCHROME P450 STRU, P115, DOI DOI 10.1007/0-387-27447-2_4; Palmer CNA, 1999, BIOCHEM SOC T, V27, P374, DOI 10.1042/bst0270374; PALMER G, 1992, J BIOL CHEM, V267, P665; Parajuli N, 2004, ARCH BIOCHEM BIOPHYS, V425, P233, DOI 10.1016/j.abb.2004.03.011; PERKINS EG, 1969, LIPIDS, V4, P619, DOI 10.1007/BF02531051; Prough R A, 1978, Methods Enzymol, V52, P372; Puchkaev AV, 2005, ARCH BIOCHEM BIOPHYS, V434, P169, DOI 10.1016/j.abb.2004.10.022; RAMACHANDRA M, 1991, J BACTERIOL, V173, P7106, DOI 10.1128/jb.173.22.7106-7112.1991; ROOME PW, 1988, ARCH BIOCHEM BIOPHYS, V266, P32, DOI 10.1016/0003-9861(88)90233-0; Sasaki M, 2005, APPL ENVIRON MICROB, V71, P8024, DOI 10.1128/AEM.71.12.8024-8030.2005; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Schmid E, 1999, MICROBIOL-SGM, V145, P3331, DOI 10.1099/00221287-145-12-3331; Shimada T, 2005, ARCH BIOCHEM BIOPHYS, V435, P207, DOI 10.1016/j.abb.2004.12.008; Shimada T, 1996, CANCER RES, V56, P2979; Taylor M, 1999, BIOCHEM BIOPH RES CO, V263, P838, DOI 10.1006/bbrc.1999.1427; TROWER MK, 1992, MOL MICROBIOL, V6, P2125, DOI 10.1111/j.1365-2958.1992.tb01386.x; TROWER MK, 1988, BIOCHEM BIOPH RES CO, V157, P1417, DOI 10.1016/S0006-291X(88)81033-7; TROWER MK, 1993, MOL MICROBIOL, V7, P1024, DOI 10.1111/j.1365-2958.1993.tb01194.x; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Ueno M, 2005, J BIOSCI BIOENG, V100, P567, DOI 10.1263/jbb.100.567; WHEELAN P, 1995, J AM SOC MASS SPECTR, V6, P40, DOI 10.1016/1044-0305(94)00090-M; Wood KV, 2001, RAPID COMMUN MASS SP, V15, P873, DOI 10.1002/rcm.285; Wu ZL, 2006, MOL PHARMACOL, V69, P2007, DOI 10.1124/mol.106.023648; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhao B, 2005, J BIOL CHEM, V280, P11599, DOI 10.1074/jbc.M410933200	59	70	75	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17486	17500		10.1074/jbc.M700863200	http://dx.doi.org/10.1074/jbc.M700863200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17446171	hybrid			2022-12-25	WOS:000247084500019
J	Li, YF; D'Aurelio, M; Deng, JH; Park, JS; Manfredi, G; Hu, PQ; Lu, JX; Bai, YD				Li, Youfen; D'Aurelio, Marilena; Deng, Jian-Hong; Park, Jeong-Soon; Manfredi, Giovanni; Hu, Peiqing; Lu, Jianxin; Bai, Yidong			An assembled complex IV maintains the stability and activity of complex I in mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; STOP-CODON MUTATION; RESPIRATORY-CHAIN; OXIDATIVE-PHOSPHORYLATION; NATIVE ELECTROPHORESIS; NADH DEHYDROGENASE; SUBUNIT; CELLS; ASSEMBLY/STABILITY; SUPERCOMPLEXES	In the mammalian mitochondrial electron transfer system, the majority of electrons enter at complex I, go through complexes III and IV, and are finally delivered to oxygen. Previously we generated several mouse cell lines with suppressed expression of the nuclearly encoded subunit 4 of complex IV. This led to a loss of assembly of complex IV and its defective function. Interestingly, we found that the level of assembled complex I and its activity were also significantly reduced, whereas levels and activity of complex III were normal or up-regulated. The structural and functional dependence of complex I on complex IV was verified using a human cell line carrying a nonsense mutation in the mitochondrially encoded complex IV subunit 1 gene. Our work documents that, although there is no direct electron transfer between them, an assembled complex IV helps to maintain complex I in mammalian cells.	Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Wenzhou Med Coll, Zhejiang Prov Key Lab Med Genet, Inst Mol & Cellular Med, Wenzhou 325035, Peoples R China	University of Texas System; University of Texas Health San Antonio; Cornell University; Wenzhou Medical University	Bai, YD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	baiy@uthscsa.edu	Bai, Yidong/A-4959-2012		Telethon [GFP03008] Funding Source: Medline	Telethon(Fondazione Telethon)		Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Bai YD, 2004, ANN NY ACAD SCI, V1011, P272, DOI 10.1196/annals.1293.026; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546; Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200; Deng JH, 2006, MOL CELL BIOL, V26, P1077, DOI 10.1128/MCB.26.3.1077-1086.2006; Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Eubel H, 2004, PLANT PHYSIOL BIOCH, V42, P937, DOI 10.1016/j.plaphy.2004.09.010; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; Lenaz G, 2004, METHOD ENZYMOL, V382, P3; Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Schagger H, 1996, Methods Enzymol, V264, P555, DOI 10.1016/S0076-6879(96)64048-8; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; VOGEL RO, 2007, J BIOL CHEM; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wallace D C, 2001, Novartis Found Symp, V235, P247; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Yadava N, 2004, J BIOL CHEM, V279, P12406, DOI 10.1074/jbc.M313588200	35	89	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17557	17562		10.1074/jbc.M701056200	http://dx.doi.org/10.1074/jbc.M701056200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452320	hybrid			2022-12-25	WOS:000247084500026
J	Mineva, ND; Rothstein, TL; Meyers, JA; Lerner, A; Sonenshein, GE				Mineva, Nora D.; Rothstein, Thomas L.; Meyers, John A.; Lerner, Adam; Sonenshein, Gail E.			CD40 ligand-mediated activation of the de Novo RelB NF-kappa B synthesis pathway in transformed B cells promotes rescue from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; C-MYC EXPRESSION; PROSTATE-CANCER; CROSS-LINKING; DIFFERENTIAL REGULATION; DENDRITIC CELLS; TRANSGENIC MICE; LYMPHOMA-CELLS; IG-RECEPTOR; IN-VIVO	CD40, a tumor necrosis factor receptor family member, is expressed on B lymphocytes. Interaction between CD40 and its ligand ( CD40L), expressed on activated T lymphocytes, is critical for B cell survival. Here, we demonstrate that CD40 signals B cell survival in part via transcriptional activation of the RelB NF-kappa B subunit. CD40L treatment of chronic lymphocytic leukemia cells induced levels of relB mRNA. Similarly, CD40L-mediated rescue of WEHI 231 B lymphoma cells from apoptosis induced upon B cell receptor ( surface IgM) engagement led to increased relB mRNA levels. Recently, we characterized a new de novo synthesis pathway for the RelB NF-kappa B subunit, induced by the cytomegalovirus IE1 protein, in which binding of p50/p65 NF-kappa B and c-Jun/Fra-2 AP-1 complexes to the relB promoter works in synergy to potently activate transcription ( Wang, X., and Sonenshein, G. E. ( 2005) J. Virol. 79, 95-105). CD40L treatment of WEHI 231 cells caused induction of AP-1 family members Fra-2, c-Jun, JunD, and JunB. Cotransfection of Fra-2 with the Jun AP-1 subunits and p50/c-Rel NF-kappa B led to synergistic activation of the relB promoter. Ectopic expression of relB or RelB knockdown using small interfering RNA demonstrated the important role of this subunit in control of WEHI 231 cell survival and implicated activation of the anti-apoptotic factors Survivin and manganese superoxide dismutase. Thus, CD40 engagement of transformed B cells activates relB gene transcription via a process we have termed the de novo RelB synthesis pathway, which protects these cells from apoptosis.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	gsonensh@bu.edu		Meyers, John/0000-0001-9560-5667; Lerner, Adam/0000-0001-9259-7868	NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040181] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA36355] Funding Source: Medline; NIAID NIH HHS [R01 AI40181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bishop GA, 2003, CYTOKINE GROWTH F R, V14, P297, DOI 10.1016/S1359-6101(03)00024-8; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Challa A, 2002, BLOOD, V99, P3411, DOI 10.1182/blood.V99.9.3411; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Clark GJ, 1999, IMMUNOLOGY, V98, P189; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Costello RT, 1999, IMMUNOL TODAY, V20, P488, DOI 10.1016/S0167-5699(99)01507-8; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Foo SY, 1999, TRENDS GENET, V15, P229; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Gilmore TD, 1996, ONCOGENE, V13, P1367; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Gricks CS, 2004, BLOOD, V104, P4002, DOI 10.1182/blood-2004-02-0494; GRUDA MC, 1994, ONCOGENE, V9, P2537; Israel A, 2006, TRENDS IMMUNOL, V27, P395, DOI 10.1016/j.it.2006.07.003; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Jiang HY, 2002, J VIROL, V76, P5737, DOI 10.1128/JVI.76.11.5737-5747.2002; Josson S, 2006, ONCOGENE, V25, P1554, DOI 10.1038/sj.onc.1209186; Kehry MR, 1996, J IMMUNOL, V156, P2345; LA RF, 1994, MOL CELL BIOL, V14, P1039; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; LIU JL, 1991, J IMMUNOL, V146, P1685; LO D, 1992, AM J PATHOL, V141, P1237; Lougaris V, 2005, IMMUNOL REV, V203, P48, DOI 10.1111/j.0105-2896.2005.00229.x; Neumann M, 1996, J IMMUNOL, V157, P4862; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Romano MF, 1998, BLOOD, V92, P990; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; ROONEY JW, 1991, EUR J IMMUNOL, V21, P2993, DOI 10.1002/eji.1830211214; Ruland J, 2003, IMMUNOL REV, V193, P93, DOI 10.1034/j.1600-065X.2003.00049.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Schauer SL, 1996, J IMMUNOL, V157, P81; Schjerven H, 2004, J IMMUNOL, V173, P1849, DOI 10.4049/jimmunol.173.3.1849; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang XB, 2005, J VIROL, V79, P95, DOI 10.1128/JVI.79.1.95-105.2005; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Weih F, 1997, J IMMUNOL, V158, P5211; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Weylie B, 2006, J VASC RES, V43, P61, DOI 10.1159/000089492; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Younes A, 1998, BRIT J HAEMATOL, V100, P135, DOI 10.1046/j.1365-2141.1998.00522.x; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	65	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17475	17485		10.1074/jbc.M607313200	http://dx.doi.org/10.1074/jbc.M607313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17446175	hybrid			2022-12-25	WOS:000247084500018
J	Nebauer, R; Rosenberger, S; Daum, GRN				Nebauer, Ruth; Rosenberger, Sabine; Daum, Guenther			Phosphatidylethanolamine, a limiting factor of autophagy in yeast strains bearing a defect in the carboxypeptidase Y pathway of vacuolar targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-MECHANISM; DEGRADATION; MACHINERY; TRANSPORT; REQUIRES; COMPLEX; MUTANTS; ATPASE; GENES	Vps4p and Vps36p of Saccharomyces cerevisiae are involved in the transport of proteins to the vacuole via the carboxypeptidase Y pathway. We found that deletion of VPS4 and VPS36 caused impaired maturation of the vacuolar proaminopeptidase I (pAPI) via autophagy or the cytosol to vacuole targeting pathway. Supplementation with ethanolamine rescued this defect, leading to an increase of the cellular amount of phosphatidylethanolamine (PtdEtn), an enhanced level of the PtdEtn-binding autophagy protein Atg8p and a balanced rate of autophagy. We also discovered that maturation of pAPI was generally affected by PtdEtn depletion in a psd1 Delta psd2 Delta mutant due to reduced recruitment of Atg8p to the preautophagosomal structure. Ethanolamine supplementation provided the necessary amounts of PtdEtn for complete maturation of pAPI. Since the expression level of Atg8p was not compromised in the psd1 Delta psd2 Delta strain, we concluded that the amount of available PtdEtn was limiting. Thus, PtdEtn appears to be a limiting factor for the balance of the carboxypeptidase Y pathway and autophagy/the cytosol to vacuole targeting pathway in the yeast.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, GRN (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at						Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Birner R, 2003, MOL BIOL CELL, V14, P370, DOI 10.1091/mbc.E02-05-0263; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; Burke D., 2000, METHODS YEAST GENETI; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hanson PK, 2002, J CELL SCI, V115, P2725; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; MENON AK, 1992, J BIOL CHEM, V267, P15277; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Nebauer R, 2004, TOP CURR GENET, V6, P125; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Westphal V, 1996, J BIOL CHEM, V271, P11865, DOI 10.1074/jbc.271.20.11865; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Zahn R, 2001, J CELL SCI, V114, P1935	38	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16736	16743		10.1074/jbc.M611345200	http://dx.doi.org/10.1074/jbc.M611345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428789	hybrid			2022-12-25	WOS:000246946500005
J	Fewou, SN; Ramakrishnan, H; Bussow, H; Gieselmann, V; Eckhardt, M				Fewou, Simon Ngamli; Ramakrishnan, Hariharasubramanian; Buessow, Heinrich; Gieselmann, Volkmar; Eckhardt, Matthias			Down-regulation of polysialic acid is required for efficient myelin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; GROUP-B-MENINGOCOCCI; PSA-NCAM; N-CAM; NEGATIVE REGULATION; ENZYMATIC-ACTIVITY; PRECURSOR CELLS; FYN KINASE; OLIGODENDROCYTES	Oligodendrocyte precursor cells modify the neural cell adhesion molecule ( NCAM) by the attachment of polysialic acid ( PSA). Upon further differentiation into mature myelinating oligodendrocytes, however, oligodendrocyte precursor cells down-regulate PSA synthesis. In order to address the question of whether this down-regulation is a necessary prerequisite for the myelination process, transgenic mice expressing the polysialyltransferase ST8SiaIV under the control of the proteolipid protein promoter were generated. In these mice, postnatal down-regulation of PSA in oligodendrocytes was abolished. Most NCAM-120, the characteristic NCAM isoform in oligodendrocytes, carried PSA in the transgenic mice at all stages of postnatal development. Polysialylated NCAM-120 partially colocalized with myelin basic protein and was present in purified myelin. The permanent expression of PSA-NCAM in oligodendrocytes led to a reduced myelin content in the forebrains of transgenic mice during the period of active myelination and in the adult animal. In situ hybridizations indicated a significant decrease in the number of mature oligodendrocytes in the forebrain. Thus, down-regulation of PSA during oligodendrocyte differentiation is a prerequisite for efficient myelination by mature oligodendrocytes. Furthermore, myelin of transgenic mice exhibited structural abnormalities like redundant myelin and axonal degeneration, indicating that the down-regulation of PSA is also necessary for myelin maintenance.	Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; Univ Bonn, Inst Anat, D-53115 Bonn, Germany	University of Bonn; University of Bonn	Eckhardt, M (corresponding author), Univ Bonn, Inst Physiol Chem, Nussallee 11, D-53115 Bonn, Germany.	eckhardt@institut.physiochem.uni-bonn.de	Messier, Claude/A-2322-2008; Fewou, Simon Ngamli/AAG-3934-2020	Messier, Claude/0000-0002-4791-1763; 				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Bansal R, 1999, J NEUROSCI, V19, P7913; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BHAT S, 1988, J NEUROCHEM, V50, P1830, DOI 10.1111/j.1471-4159.1988.tb02485.x; BUSSOW H, 1978, J NEUROCYTOL, V7, P207, DOI 10.1007/BF01217919; Carenini S, 1997, CELL TISSUE RES, V287, P3; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chazal G, 2000, J NEUROSCI, V20, P1446; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Coman L, 2005, J NEUROL SCI, V233, P67, DOI 10.1016/j.jns.2005.03.029; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Decker L, 2002, MOL CELL NEUROSCI, V19, P225, DOI 10.1006/mcne.2001.1072; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Eckhardt M, 2002, BIOCHEM J, V368, P317, DOI 10.1042/BJ20020946; Fewou SN, 2005, J NEUROCHEM, V94, P469, DOI 10.1111/j.1471-4159.2005.03221.x; FINNE J, 1987, J IMMUNOL, V138, P4402; Franceschini I, 2004, MOL CELL NEUROSCI, V27, P151, DOI 10.1016/j.mcn.2004.05.006; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Fuss B, 2001, MOL CELL NEUROSCI, V18, P221, DOI 10.1006/mcne.2001.1011; Goridis C, 1992, Semin Cell Biol, V3, P189; Harlow E., 1988, ANTIBODIES LAB MANUA; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; LASALLE GL, 1992, J NEUROSCI, V12, P872; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Meyer-Franke A, 1999, MOL CELL NEUROSCI, V14, P385, DOI 10.1006/mcne.1999.0788; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; Spassky N, 1998, J NEUROSCI, V18, P8331; Stoykova LI, 2001, J NEUROSCI RES, V66, P497, DOI 10.1002/jnr.10002; Takikita S, 2004, J NEUROPATH EXP NEUR, V63, P660, DOI 10.1093/jnen/63.6.660; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; Umemori H, 1999, J NEUROSCI, V19, P1393; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Wang C, 1996, J CELL BIOL, V135, P1565, DOI 10.1083/jcb.135.6.1565; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; Yaghootfam A, 2005, EUR J NEUROSCI, V21, P711, DOI 10.1111/j.1460-9568.2005.03891.x; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	56	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16700	16711		10.1074/jbc.M610797200	http://dx.doi.org/10.1074/jbc.M610797200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420257	hybrid			2022-12-25	WOS:000246794300075
J	Andrali, SS; Qian, QW; Ozcan, S				Andrali, Sreenath S.; Qian, Qingwen; Ozcan, Sabire			Glucose mediates the translocation of NeuroD1 by O-linked glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; NUCLEOCYTOPLASMIC PROTEINS; DYNAMIC INTERPLAY; CELL FUNCTION; NUCLEAR; PHOSPHORYLATION; ACTIVATION; EXPRESSION	O-Linked GlcNAc modification of nuclear and cytosolic proteins has been shown to regulate the function of many cellular proteins. Increased O-linked glycosylation, observed under chronic hyperglycemia conditions, has been implicated in the pathogenesis of diabetes. However, the exact role of O-GlcNAc modification in regulating glucose homeostasis remains to be established. We report here that the subcellular localization of the pancreatic beta cell-specific transcription factor NeuroD1 is regulated by O-linked glycosylation in the mouse insulinoma cell line MIN6. Under low glucose conditions, NeuroD1 is mainly in the cytosol. However, treatment of MIN6 cells with high glucose results in O-linked GlcNAc modification of NeuroD1 and its subsequent translocation into the nucleus. Consistent with these data, treatment of MIN6 cells with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)-amino N-phenylcarbamate, an inhibitor of O- GlcNAcase, causes NeuroD1 localization to the nucleus and induction of insulin gene expression even on low glucose. Furthermore, we demonstrate that NeuroD1 interacts with the O- GlcNAc transferase, OGT only at high concentrations of glucose and depletion of OGT by using small interfering RNA oligos interferes with the nuclear localization of NeuroD1 on high glucose. On low glucose NeuroD1 interacts with the O-GlcNAcase and becomes deglycosylated, which is likely to be important for export of NeuroD1 into cytosol in the presence of low glucose. In summary, the presented data suggest that glucose regulates the subcellular localization of NeuroD1 in pancreatic beta cells via O-linked GlcNAc modification of NeuroD1 by OGT.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), 741 S Limestone St,BBSRC B155, Lexington, KY 40536 USA.	sozcan@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065730, R01DK067581] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR20171, P20 RR020171] Funding Source: Medline; NIDDK NIH HHS [R01 DK067581-02, R21 DK065730-02, R01 DK067581, R21 DK065730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Andrali SS, 2005, BIOCHEM BIOPH RES CO, V337, P149, DOI 10.1016/j.bbrc.2005.09.026; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Cooksey RC, 2002, ANN NY ACAD SCI, V967, P102; Dauphinee SM, 2005, J CELL BIOCHEM, V96, P579, DOI 10.1002/jcb.20508; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200; Guinez C, 2005, INT J BIOCHEM CELL B, V37, P765, DOI 10.1016/j.biocel.2004.12.001; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; Juang YT, 2002, J IMMUNOL, V168, P2865, DOI 10.4049/jimmunol.168.6.2865; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lefebvre T, 2003, BBA-GEN SUBJECTS, V1619, P167, DOI 10.1016/S0304-4165(02)00477-4; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; Petersen HV, 2002, FEBS LETT, V528, P241, DOI 10.1016/S0014-5793(02)03318-5; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Roderigo-Milne H, 2002, BIOCHEM BIOPH RES CO, V296, P589, DOI 10.1016/S0006-291X(02)00913-0; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rout UK, 2002, REPROD TOXICOL, V16, P253, DOI 10.1016/S0890-6238(02)00022-9; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Vanderford NL, 2007, J BIOL CHEM, V282, P1577, DOI 10.1074/jbc.M605064200; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005	56	99	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15589	15596		10.1074/jbc.M701762200	http://dx.doi.org/10.1074/jbc.M701762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403669	Green Accepted, hybrid			2022-12-25	WOS:000246589600036
J	Bisaglia, M; Mammi, S; Bubacco, L				Bisaglia, Marco; Mammi, Stefano; Bubacco, Luigi			Kinetic and structural analysis of the early oxidation products of dopamine - Analysis of the interactions with alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN DIHYDROPTERIDINE REDUCTASE; PARKINSONS-DISEASE; QUINONE FORMATION; SUBSTANTIA-NIGRA; CELL-DEATH; NEUROMELANIN; CATECHOLAMINES; RELEVANCE; TRANSPORTER; TOXICITY	Oxidative stress appears to be directly involved in the pathogenesis of several neurodegenerative disorders, including Alzheimer and Parkinson diseases. Nigral dopaminergic neurons are particularly exposed to oxidative stress because a pathological accumulation of cytosolic dopamine gives rise to various toxic molecules, including free radicals and reactive quinones. These latter species can react with proteins preventing them from exerting their physiological functions. Among the possible targets of quinones, alpha-synuclein is of primary interest because of its direct involvement in dopamine metabolism. Contrary to the neurotoxic processes, neuromelanin synthesis seems to play a protective role by its ability to sequester a variety of potentially damaging substances. In this study, we carried out a kinetic and structural analysis of the early oxidation products of dopamine. Specifically, considering the potential high toxicity of aminochrome for both cells and mitochondria, we focused our attention on its rearrangement to 5,6- dihydroxyindole. After the spectroscopic characterization of the products derived from the oxidation of dopamine, the structural information obtained was used to analyze the reactivity of quinones toward alpha-synuclein. Our results suggest that indole-5,6-quinone, rather than dopamine-o-quinone or aminochrome, is the reactive species. We propose that the observed reactivity could represent a general reaction pathway whenever cysteinyl residues are absent in proteins or if they are sterically protected.	Univ Padua, Dept Chem Sci, I-35131 Padua, Italy; Univ Padua, Dept Biol, I-35131 Padua, Italy; CNR, Inst Biomol Chem, I-35131 Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Mammi, S (corresponding author), Univ Padua, Dept Chem Sci, Via Marzolo,1, I-35131 Padua, Italy.	stefano.mammi@unipd.it	Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208				Aime S, 2000, MOVEMENT DISORD, V15, P977, DOI 10.1002/1531-8257(200009)15:5<977::AID-MDS1032>3.0.CO;2-Q; Ancian B, 1997, J MAGN RESON, V125, P348, DOI 10.1006/jmre.1997.1112; ARMAREGO WLF, 1983, BIOCHEM BIOPH RES CO, V113, P895, DOI 10.1016/0006-291X(83)91083-5; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BINDOLI A, 1989, TOXICOL LETT, V48, P3, DOI 10.1016/0378-4274(89)90180-X; CHEDEKEL MR, 1984, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39840001170; Elsworth JD, 1997, EXP NEUROL, V144, P4, DOI 10.1006/exnr.1996.6379; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Fedorow H, 2005, PROG NEUROBIOL, V75, P109, DOI 10.1016/j.pneurobio.2005.02.001; GARCIACARMONA F, 1982, BIOCHIM BIOPHYS ACTA, V717, P124, DOI 10.1016/0304-4165(82)90389-0; GRAHAM DG, 1977, J BIOL CHEM, V252, P5729; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRAHAM DG, 1979, ARCH PATHOL LAB MED, V103, P359; Greggio E, 2005, J NEUROCHEM, V93, P246, DOI 10.1111/j.1471-4159.2005.03019.x; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; ITO S, 1988, BIOCHEM PHARMACOL, V37, P1707, DOI 10.1016/0006-2952(88)90432-7; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; Land EJ, 2003, PIGM CELL RES, V16, P487, DOI 10.1034/j.1600-0749.2003.00082.x; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; MASON HS, 1948, J BIOL CHEM, V172, P83; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Raper HS, 1928, PHYSIOL REV, V8, P245, DOI 10.1152/physrev.1928.8.2.245; Sidhu A, 2004, FASEB J, V18, P637, DOI 10.1096/fj.03-1112rev; SILVERSTEIN RM, 1997, SPECTROMETRIC IDENTI, P144; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; WARING P, 1986, EUR J BIOCHEM, V155, P305, DOI 10.1111/j.1432-1033.1986.tb09491.x; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Xu RD, 1996, BIOORG CHEM, V24, P110, DOI 10.1006/bioo.1996.0011; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zoccarato F, 2005, J BIOL CHEM, V280, P15587, DOI 10.1074/jbc.M500657200	46	213	216	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15597	15605		10.1074/jbc.M610893200	http://dx.doi.org/10.1074/jbc.M610893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395592	hybrid			2022-12-25	WOS:000246589600037
J	Jin, W; Reiley, WR; Lee, AJ; Wright, A; Wu, XF; Zhang, MY; Sun, SC				Jin, Wei; Reiley, William R.; Lee, Andrew J.; Wright, Ato; Wu, Xuefeng; Zhang, Minying; Sun, Shao-Cong			Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR CYLD; T-CELL; SIGNALING PATHWAY; NECROSIS-FACTOR; ACTIVATION; BAFF; BINDING; KINASE; UBIQUITYLATION	Deubiquitinating enzymes (DUB) form a family of cysteine proteases that digests ubiquitin chains and reverses the process of protein ubiquitination. Despite the identification of a large number of DUBs, their physiological functions remain poorly defined. Here we provide genetic evidence that CYLD, a recently identified DUB, plays a crucial role in regulating the peripheral development and activation of B cells. Disruption of the CYLD gene in mice results in B cell hyperplasia and lymphoid organ enlargement. The CYLD-deficient B cells display surface markers indicative of spontaneous activation and are hyperproliferative upon in vitro stimulation. When challenged with antigens, the CYLD-/- mice develop exacerbated lymphoid organ abnormalities and abnormal B cell responses. Although the loss of CYLD has only a minor effect on B cell development in bone marrow, this genetic deficiency disrupts the balance of peripheral B cell populations with a significant increase in marginal zone B cells. In keeping with these functional abnormalities, the CYLD-/- B cells exhibit constitutive activation of the transcription factor NF-kappa B due to spontaneous activation of I kappa B kinase beta and degradation of the NF-kappa B inhibitor I kappa B alpha. These findings demonstrate a critical role for CYLD in regulating the basal activity of NF-kappa B and maintaining the naive phenotype and proper activation of B cells.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu	Wu, Xuefeng/F-5003-2011; Lee, Andrew/GVU-2817-2022		NCI NIH HHS [CA94922] Funding Source: Medline; NIAID NIH HHS [AI064639, R37 AI064639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064639, R37AI064639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bishop GA, 2003, CYTOKINE GROWTH F R, V14, P297, DOI 10.1016/S1359-6101(03)00024-8; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cancro MP, 2004, IMMUNOL REV, V197, P89, DOI 10.1111/j.0105-2896.2004.0099.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Dorner T, 2006, CURR TOP MICROBIOL, V305, P213, DOI 10.1007/3-540-29714-6_11; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gorelik L, 2004, J IMMUNOL, V172, P762, DOI 10.4049/jimmunol.172.2.762; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Kalled SL, 2005, IMMUNOL REV, V204, P43, DOI 10.1111/j.0105-2896.2005.00219.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lian Fangru, 2005, Adv Dermatol, V21, P217, DOI 10.1016/j.yadr.2005.06.005; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Militi S, 2005, CYTOKINE, V31, P314, DOI 10.1016/j.cyto.2005.05.007; Morrison MD, 2005, J BIOL CHEM, V280, P10018, DOI 10.1074/jbc.M413634200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Podojil JR, 2005, TRENDS IMMUNOL, V26, P180, DOI 10.1016/j.it.2005.02.005; Poe J C, 2001, Int Rev Immunol, V20, P739, DOI 10.3109/08830180109045588; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STIEF A, 1994, J IMMUNOL, V152, P3378; Su TT, 2004, IMMUNOL REV, V197, P161, DOI 10.1111/j.0105-2896.2004.0102.x; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vos Q, 2000, IMMUNOL REV, V176, P154; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200	47	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15884	15893		10.1074/jbc.M609952200	http://dx.doi.org/10.1074/jbc.M609952200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17392286	hybrid			2022-12-25	WOS:000246589600063
J	Koike, N; Kassai, Y; Kouta, Y; Miwa, H; Konishi, M; Itoh, N				Koike, Naomi; Kassai, Yoshiaki; Kouta, Yuya; Miwa, Hiroyuki; Konishi, Morichika; Itoh, Nobuyuki			Brorin, a novel secreted bone morphogenetic protein antagonist, promotes neurogenesis in mouse neural precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION PATTERNS; STEM-CELLS; DIFFERENTIATION; CHORDIN; CROSSVEINLESS-2; VERTEBRATES; INHIBITOR; RECEPTORS; PATHWAY; MEMBERS	We identified a gene encoding a novel secreted protein in mice and humans and named it Brorin. Mouse Brorin consists of 324 amino acids with a putative secreted signal sequence at its amino terminus and two cysteine-rich domains in its core region. Positions of 10 cysteine residues in the domains of Brorin are similar to those in the cysteine-rich domains of members of the Chordin family. However, the amino acid sequence of Brorin is not significantly similar to that of any other member of the Chordin family, indicating that Brorin is a unique member of the family. Mouse Brorin protein produced in cultured cells was efficiently secreted into the culture medium. The protein inhibited the activity of bone morphogenetic protein 2 (BMP2) and BMP6 in mouse preosteoblastic MC3T3-E1 cells. Mouse Brorin was predominantly expressed in neural tissues in embryos and also predominantly expressed in the adult brain. In the brain, the expression was detected in neurons, but not glial cells. The neural tissue-specific expression profile of Brorin is quite distinct from that of any other member of the Chordin family. Brorin protein promoted neurogenesis, but not astro-genesis, in mouse neural precursor cells. The present findings indicate that Brorin is a novel secreted BMP antagonist that potentially plays roles in neural development and functions.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kyoto University	Itoh, N (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan.	itohnobu@pharm.kyoto-u.ac.jp		Miwa, Hiroyuki/0000-0001-6899-7028				Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Brunet JF, 2004, GLIA, V46, P8, DOI 10.1002/glia.10348; Chandra A, 2006, BIOCHEM BIOPH RES CO, V344, P786, DOI 10.1016/j.bbrc.2006.03.195; Charytoniuk DA, 2000, NEUROSCIENCE, V100, P33, DOI 10.1016/S0306-4522(00)00246-3; Chen HL, 2003, BRAIN RES, V994, P81, DOI 10.1016/j.brainres.2003.09.020; Coffinier C, 2001, MECH DEVELOP, V100, P119, DOI 10.1016/S0925-4773(00)00507-4; Coffinier C, 2002, MECH DEVELOP, V119, pS179, DOI 10.1016/S0925-4773(03)00113-8; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GERFEN CR, 1989, METHODS NEUROSCIENCE, V60, P101; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647; Kimura I, 2006, J NEUROSCI RES, V83, P1415, DOI 10.1002/jnr.20849; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lein P, 2002, PROG INFLAM RES, P289; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nakayama N, 2004, DEVELOPMENT, V131, P229, DOI 10.1242/dev.00901; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Pappano WN, 1998, GENOMICS, V52, P236, DOI 10.1006/geno.1998.5474; Strelau J, 2000, J NEUROSCI, V20, P8597; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; Ueki T, 2003, J NEUROSCI, V23, P11732; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Yamashita T, 2002, J BIOL CHEM, V277, P28265, DOI 10.1074/jbc.M202527200; Yanagisawa M, 2001, NEUROSCI RES, V41, P391, DOI 10.1016/S0168-0102(01)00297-8; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403	30	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15843	15850		10.1074/jbc.M701570200	http://dx.doi.org/10.1074/jbc.M701570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400546	hybrid			2022-12-25	WOS:000246589600059
J	Markovic, J; Borras, C; Ortega, A; Sastre, J; Vina, J; Pallardo, FV				Markovic, Jelena; Borras, Consuelo; Ortega, Angel; Sastre, Juan; Vina, Jose; Pallardo, Federico V.			Glutathione is recruited into the nucleus in early phases of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; RAT HEPATOCYTES; BCL-2; MITOCHONDRIAL; EXPRESSION; DNA; COMPARTMENTATION; FIBROBLASTS; ONCOPROTEIN; THALIDOMIDE	We have studied the possible correlation between nuclear glutathione distribution and the progression of the cell cycle. The former was studied by confocal microscopy using 5-chloromethyl fluorescein diacetate and the latter by flow cytometry and protein expression of Id2 and p107. In proliferating cells, when 41% of them were in the S + G(2)/M phase of the cell cycle GSH was located mainly in the nucleus. When cells reached confluence (G0/G1) GSH was localized in the cytoplasm with a perinuclear distribution. The nucleus/cytoplasm fluorescence ratio for GSH reached a maximal mean value of 4.2 +/- 0.8 at 6 h after cell plating. A ratio higher than 2 was maintained during exponential cell growth. In the G0/G1 phase of the cell cycle, the nucleus/cytoplasm GSH ratio decreased to values close to 1. We report here that cells concentrate GSH in the nucleus in the early phases of cell growth, when most of the cells are in an active division phase, and that GSH redistributes uniformly between the nucleus and the cytoplasm when cells reach confluence.	Univ Valencia, Fac Med, Dept Fis, E-46010 Valencia, Spain; Univ Valencia, Fac Med, Dept Physiol, Valencia 46010, Spain	University of Valencia; University of Valencia	Pallardo, FV (corresponding author), Univ Valencia, Fac Med, Dept Fis, E-46010 Valencia, Spain.	pallardo@uv.es	Ortega, Angel L./A-4113-2014; borras, consuelo/Y-3407-2019; Pallardo, Federico V./T-1156-2017; Vina, Jose/AAB-3069-2021	Ortega, Angel L./0000-0002-9901-3383; borras, consuelo/0000-0003-4606-1792; Pallardo, Federico V./0000-0003-3715-1980; Vina, Jose/0000-0001-9709-0089				ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; Bellomo G, 1997, MICROSC RES TECHNIQ, V36, P243, DOI 10.1002/(SICI)1097-0029(19970215)36:4<243::AID-JEMT3>3.0.CO;2-N; BIAGLOW JE, 1983, RADIAT RES, V95, P437, DOI 10.2307/3576092; Borras C, 2004, J BIOL CHEM, V279, P34332, DOI 10.1074/jbc.M402425200; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; BRIVIBA K, 1993, BIOCHEM J, V294, P631, DOI 10.1042/bj2940631; Chen JQ, 2003, TOXICOL SCI, V75, P271, DOI 10.1093/toxsci/kfg183; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122; Hansen JM, 2002, J PHARMACOL EXP THER, V300, P768, DOI 10.1124/jpet.300.3.768; HEDLEY DW, 1994, CYTOMETRY, V15, P349, DOI 10.1002/cyto.990150411; Ho Y.F., 1994, TOXICOLOGIST, V14, P178; Hoetelmans RWM, 2003, CELL PROLIFERAT, V36, P35, DOI 10.1046/j.1365-2184.2003.00252.x; Jang JH, 2003, BIOCHEM PHARMACOL, V66, P1371, DOI 10.1016/S0006-2952(03)00487-8; Kim JR, 2004, FEBS LETT, V567, P189, DOI 10.1016/j.febslet.2004.04.055; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MCBRIDE WG, 1961, LANCET, V2, P1358; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rimpler MM, 1999, BIOCHEM J, V340, P291, DOI 10.1042/0264-6021:3400291; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Soderdahl T, 2002, FASEB J, V16, P124, DOI 10.1096/fj.02-0259fje; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THOMAS M, 1995, BRIT J CANCER, V72, P45, DOI 10.1038/bjc.1995.275; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; Vina J., 1990, GLUTATHIONE METABOLI; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273	37	137	140	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20416	20424		10.1074/jbc.M609582200	http://dx.doi.org/10.1074/jbc.M609582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17452333	hybrid			2022-12-25	WOS:000247819300044
J	Lorin, A; Charloteaux, B; Fridmann-Sirkis, Y; Thomas, A; Shai, Y; Brasseur, R				Lorin, Aurelien; Charloteaux, Benoit; Fridmann-Sirkis, Yael; Thomas, Annick; Shai, Yechiel; Brasseur, Robert			Mode of membrane interaction and fusogenic properties of a de Novo transmembrane model peptide depend on the length of the hydrophobic core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELICAL PEPTIDES; SOLID-STATE NMR; LIPID-BILAYERS; PHOSPHATIDYLCHOLINE BILAYERS; FLANKING RESIDUES; AMPHIPHILIC PEPTIDES; MOLECULAR-STRUCTURE; ESCHERICHIA-COLI; CHARGED RESIDUES; DOMAIN FORMATION	Model peptides composed of alanine and leucine residues are often used to mimic single helical transmembrane domains. Many studies have been carried out to determine how they interact with membranes. However, few studies have investigated their lipid-destabilizing effect. We designed three peptides designated KALRs containing a hydrophobic stretch of 14, 18, or 22 alanines/leucines surrounded by charged amino acids. Molecular modeling simulations in an implicit membrane model as well as attenuated total reflection-Fourier transform infrared analyses show that KALR is a good model of a transmembrane helix. However, tryptophan fluorescence and attenuated total reflection-Fourier transform infrared spectroscopy indicate that the extent of binding and insertion into lipids increases with the length of the peptide hydrophobic core. Although binding can be directly correlated to peptide hydrophobicity, we show that insertion of peptides into a membrane is determined by the length of the peptide hydrophobic core. Functional studies were performed by measuring the ability of peptides to induce lipid mixing and leakage of liposomes. The data reveal that whereas KALR(14) does not destabilize liposomal membranes, KALR(18) and KALR(22) induce 40 and 50% of lipid-mixing, and 65 and 80% of leakage, respectively. These results indicate that a transmembrane model peptide can induce liposome fusion in vitro if it is long enough. The reasons for the link between length and fusogenicity are discussed in relation to studies of transmembrane domains of viral fusion proteins. We propose that fusogenicity depends not only on peptide insertion but also on the ability of peptides to destabilize the two leaflets of the liposome membrane.	Gembloux Agr Univ, Ctr Biophys Mol Numerique, B-5030 Gembloux, Belgium; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of Liege; Weizmann Institute of Science	Brasseur, R (corresponding author), Gembloux Agr Univ, Ctr Biophys Mol Numerique, B-5030 Gembloux, Belgium.	brasseur.r@fsagx.ac.be						Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 2001, BIOPHYS J, V81, P2251, DOI 10.1016/S0006-3495(01)75872-9; Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056; Busquets MA, 2003, CURR DRUG TARGETS, V4, P633, DOI 10.2174/1389450033490795; Bystrom T, 2003, COLLOID SURFACE A, V228, P37, DOI 10.1016/S0927-7757(03)00303-0; Cantor RS, 1999, BIOPHYS J, V76, P2625, DOI 10.1016/S0006-3495(99)77415-1; Castano S, 2005, BBA-BIOMEMBRANES, V1715, P81, DOI 10.1016/j.bbamem.2005.07.008; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Charloteaux B, 2006, J MOL BIOL, V359, P597, DOI 10.1016/j.jmb.2006.04.018; Chung LA, 1996, BIOCHEMISTRY-US, V35, P11343, DOI 10.1021/bi960080c; Creighton T. E, 1992, PROTEINS STRUCTURE M, p[182, 221]; DAVIS JH, 1983, BIOCHEMISTRY-US, V22, P5298, DOI 10.1021/bi00292a008; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; de Planque MRR, 2002, BIOCHEMISTRY-US, V41, P8396, DOI 10.1021/bi0257686; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Deber CM, 2002, CURR TOP MEMBR, V52, P465; Dennison SM, 2002, BIOCHEMISTRY-US, V41, P14925, DOI 10.1021/bi0203233; Ducarme P, 1998, PROTEINS, V30, P357, DOI 10.1002/(SICI)1097-0134(19980301)30:4<357::AID-PROT3>3.0.CO;2-G; Eiler S, 2001, PROTEIN EXPRES PURIF, V22, P165, DOI 10.1006/prep.2001.1409; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Harzer U, 2000, BIOCHEMISTRY-US, V39, P13106, DOI 10.1021/bi000770n; HAUSER HGP, 2005, STRUCTURE BIOL MEMBR; Hofmann MW, 2004, P NATL ACAD SCI USA, V101, P14776, DOI 10.1073/pnas.0405175101; Killian JA, 2006, CURR OPIN STRUC BIOL, V16, P473, DOI 10.1016/j.sbi.2006.06.007; Killian JA, 2003, FEBS LETT, V555, P134, DOI 10.1016/S0014-5793(03)01154-2; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Killian JA, 1998, PURE APPL CHEM, V70, P75; Kucerka N, 2005, J MEMBRANE BIOL, V208, P193, DOI 10.1007/s00232-005-7006-8; Langosch D, 2001, J BIOL CHEM, V276, P32016, DOI 10.1074/jbc.M102579200; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lewis RNAH, 2002, BIOELECTROCHEMISTRY, V56, P135, DOI 10.1016/S1567-5394(02)00012-9; Lewis RNAH, 2001, BIOCHEMISTRY-US, V40, P12103, DOI 10.1021/bi010555m; Lins L, 2006, BIOPHYS J, V90, P470, DOI 10.1529/biophysj.105.068213; Lins L, 2001, PROTEINS, V44, P435, DOI 10.1002/prot.1109; Liu F, 2004, BIOCHEMISTRY-US, V43, P3679, DOI 10.1021/bi036214l; Liu F, 2002, BIOCHEMISTRY-US, V41, P9197, DOI 10.1021/bi025661i; Liu F, 2001, BIOCHEMISTRY-US, V40, P760, DOI 10.1021/bi001942j; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; Lorin A, 2006, CHEM PHYS LIPIDS, V141, P185, DOI 10.1016/j.chemphyslip.2006.02.019; Martin I, 2000, BIOSCIENCE REP, V20, P483, DOI 10.1023/A:1010454803579; Milhiet PE, 2001, BIOPHYS J, V81, P547, DOI 10.1016/S0006-3495(01)75721-9; MOLL TS, 1994, BIOCHEMISTRY-US, V33, P15469, DOI 10.1021/bi00255a029; Morein S, 2000, BIOPHYS J, V78, P2475, DOI 10.1016/S0006-3495(00)76792-0; Morein S, 2002, BIOPHYS J, V82, P1405, DOI 10.1016/S0006-3495(02)75495-7; Morein S, 1997, BIOPHYS J, V73, P3078, DOI 10.1016/S0006-3495(97)78335-8; MRSNY RJ, 1986, CHEM PHYS LIPIDS, V39, P185, DOI 10.1016/0009-3084(86)90111-8; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Nakayama M, 2003, BIOCHEM BIOPH RES CO, V312, P825, DOI 10.1016/j.bbrc.2003.10.193; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; OWENS RJ, 1994, J VIROL, V68, P570, DOI 10.1128/JVI.68.1.570-574.1994; Ozdirekcan S, 2005, BIOCHEMISTRY-US, V44, P1004, DOI 10.1021/bi0481242; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Percot A, 1999, BIOPOLYMERS, V50, P647, DOI 10.1002/(SICI)1097-0282(199911)50:6<647::AID-BIP9>3.0.CO;2-T; Pietschmann T, 2000, J VIROL, V74, P4474, DOI 10.1128/JVI.74.10.4474-4482.2000; RAGHEB JA, 1994, J VIROL, V68, P3207, DOI 10.1128/JVI.68.5.3207-3219.1994; RAHMAN M, 1994, J MOL GRAPHICS, V12, P212, DOI 10.1016/0263-7855(94)80090-1; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Rinia HA, 2002, BIOCHEMISTRY-US, V41, P2814, DOI 10.1021/bi011796x; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; Rohl CA, 1999, P NATL ACAD SCI USA, V96, P3682, DOI 10.1073/pnas.96.7.3682; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Salamon Z, 2005, J BIOL CHEM, V280, P11175, DOI 10.1074/jbc.M411197200; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; Sharpe S, 2002, BIOPHYS J, V83, P345, DOI 10.1016/S0006-3495(02)75174-6; Siegel DP, 2006, BIOPHYS J, V90, P200, DOI 10.1529/biophysj.105.070466; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Sparr E, 2005, J BIOL CHEM, V280, P39324, DOI 10.1074/jbc.M502810200; Strandberg E, 2004, BIOPHYS J, V86, P3709, DOI 10.1529/biophysj.103.035402; Strandberg E, 2002, BIOCHEMISTRY-US, V41, P7190, DOI 10.1021/bi012047i; Tristram-Nagle S, 1998, BIOPHYS J, V75, P917, DOI 10.1016/S0006-3495(98)77580-0; Van Bambeke F, 2000, LIPIDS, V35, P213, DOI 10.1007/BF02664772; van der Wel PCA, 2000, BIOCHEMISTRY-US, V39, P3124, DOI 10.1021/bi9922594; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; Weiss TM, 2003, BIOPHYS J, V84, P379, DOI 10.1016/S0006-3495(03)74858-9; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2362, DOI 10.1021/bi00007a032; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2348, DOI 10.1021/bi00007a031; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11579, DOI 10.1021/bi00161a042; Zhang YP, 2001, BIOCHEMISTRY-US, V40, P474, DOI 10.1021/bi002170u; Zhao JB, 1996, BBA-BIOMEMBRANES, V1283, P37, DOI 10.1016/0005-2736(96)00071-5	87	16	16	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18388	18396		10.1074/jbc.M700099200	http://dx.doi.org/10.1074/jbc.M700099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17459883	hybrid			2022-12-25	WOS:000247302000045
J	Malnasi-Csizmadia, A; Toth, J; Pearson, DS; Hetenyi, C; Nyitray, L; Geeves, MA; Bagshaw, CR; Kovacs, M				Malnasi-Csizmadia, Andras; Toth, Judit; Pearson, David S.; Hetenyi, Csaba; Nyitray, Laszlo; Geeves, Michael A.; Bagshaw, Clive R.; Kovacs, Mihaly			Selective perturbation of the myosin recovery stroke by point mutations at the base of the lever arm affects ATP hydrolysis and phosphate release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURES; II MOTOR DOMAIN; KINETIC CHARACTERIZATION; TRYPTOPHAN RESIDUE; MOLECULAR MOTOR; DICTYOSTELIUM; MECHANISM; RESOLUTION; TRANSITION; DYNAMICS	After ATP binding the myosin head undergoes a large structural rearrangement called the recovery stroke. This transition brings catalytic residues into place to enable ATP hydrolysis, and at the same time it causes a swing of the myosin lever arm into a primed state, which is a prerequisite for the power stroke. By introducing point mutations into a subdomain interface at the base of the myosin lever arm at positions Lys(84) and Arg(704), we caused modulatory changes in the equilibrium constant of the recovery stroke, which we could accurately resolve using the fluorescence signal of single tryptophan Dictyostelium myosin II constructs. Our results shed light on a novel role of the recovery stroke: fine-tuning of this reversible equilibrium influences the functional properties of myosin through controlling the effective rates of ATP hydrolysis and phosphate release.	Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Eotvos Lorand University; University of Leicester; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Kent	Kovacs, M (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany P Setany 1-C, H-1117 Budapest, Hungary.	kovacsm@elte.hu	Pearson, David S/A-7892-2010; Bagshaw, Clive R./L-5484-2019; Hetenyi, Csaba/G-5249-2010; Kovacs, Mihaly/A-6841-2011; Csizmadia, András Málnási/K-7632-2018; Nyitray, László/AAE-5910-2020; Geeves, Michael/F-7583-2011	Pearson, David S/0000-0002-4088-8097; Bagshaw, Clive R./0000-0002-5396-153X; Hetenyi, Csaba/0000-0002-8013-971X; Csizmadia, András Málnási/0000-0002-2430-8398; Nyitray, László/0000-0003-4717-5994; Geeves, Michael/0000-0002-9364-8898; Kovacs, Mihaly/0000-0002-1200-4741	FOGARTY INTERNATIONAL CENTER [R01TW006230, R01TW007241] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW006230, R01 TW007241-01] Funding Source: Medline; Wellcome Trust [070021, 071525] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ajtai K, 1999, BIOCHEMISTRY-US, V38, P6428, DOI 10.1021/bi990149r; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; Fischer S, 2005, P NATL ACAD SCI USA, V102, P6873, DOI 10.1073/pnas.0408784102; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Kovacs M, 2004, J MUSCLE RES CELL M, V25, P95, DOI 10.1023/B:JURE.0000021352.80800.b8; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Pearson DS, 2002, BIOCHEM J, V366, P643, DOI 10.1042/BJ20020462; Sellers J. R., 1999, MYOSINS; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Urbanke C, 2001, BIOCHEM J, V358, P165, DOI 10.1042/0264-6021:3580165; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Zeng W, 2004, PHILOS T R SOC B, V359, P1843, DOI 10.1098/rstb.2004.1527	22	22	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17658	17664		10.1074/jbc.M701447200	http://dx.doi.org/10.1074/jbc.M701447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449872	hybrid			2022-12-25	WOS:000247084500038
J	Nitsche-Schmitz, DP; Johansson, HM; Sastalla, I; Reissmann, S; Frick, IM; Chhatwal, GS				Nitsche-Schmitz, D. Patric; Johansson, Helena M.; Sastalla, Inka; Reissmann, Silvana; Frick, Inga-Maria; Chhatwal, Gursharan S.			Group G streptococcal IgG binding molecules FOG and protein G have different impacts on opsonization by C1q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 PARTS; COMPLEMENT; MECHANISM; PYOGENES; IMMUNOLOGY; BACTEREMIA; RECEPTORS; COLLAGEN; TARGETS; REGION	Recent epidemiological data on diseases caused by beta-hemolytic streptococci belonging to Lancefield group C and G ( GCS, GGS) underline that they are an emerging threat to human health. Among various virulence factors expressed by GCS and GGS isolates from human infections, M and M-like proteins are considered important because of their anti-phagocytic activity. In addition, protein G has been implicated in the accumulation of IgG on the bacterial surface through non-immune binding. The function of this interaction, however, is still unknown. Using isogenic mutants lacking protein G or the M-like protein FOG ( group G streptococci), respectively, we could show that FOG contributes substantially to IgG binding. A detailed characterization of the interaction between IgG and FOG revealed its ability to bind the Fc region of human IgG and its binding to the subclasses IgG1, IgG2, and IgG4. FOG was also found to bind IgG of several animal species. Surface plasmon resonance measurements indicate a high affinity to human IgG with a dissociation constant of 2.4 pM. The binding site was localized in a central motif of FOG. It has long been speculated about anti-opsonic functions of streptococcal Fc-binding proteins. The presented data for the first time provide evidence and, furthermore, indicate functional differences between protein G and FOG. By obstructing the interaction between IgG and C1q, protein G prevented recognition by the classical pathway of the complement system. In contrast, IgG that was bound to FOG remained capable of binding C1q, an effect that may have important consequences in the pathogenesis of GGS infections.	Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany; Lund Univ, Biomed Ctr, Dept Clin Sci, Sect Clin & Expt Infect Med, S-22184 Lund, Sweden	Helmholtz Association; Helmholtz-Center for Infection Research; Lund University	Nitsche-Schmitz, DP (corresponding author), Helmholtz Ctr Infect Res, Inhoffenstr 7, D-38124 Braunschweig, Germany.	patric.nitsche@helmholtz-hzi.de		Linge, Helena/0000-0002-8919-0300; Sastalla, Inka/0000-0003-4128-0742				AKERSTROM B, 1986, J BIOL CHEM, V261, P240; Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; BJORCK L, 1984, J IMMUNOL, V133, P969; BOBAK DA, 1987, J IMMUNOL, V138, P1150; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; CLEARY PP, 1991, INFECT IMMUN, V59, P2305, DOI 10.1128/IAI.59.7.2305-2310.1991; Cohen-Poradosu R, 2004, EMERG INFECT DIS, V10, P1455, DOI 10.3201/eid1008.030840; Dinkla K, 2003, MOL MICROBIOL, V47, P861, DOI 10.1046/j.1365-2958.2003.03352.x; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Johansson HM, 2004, MICROBIOL-SGM, V150, P4211, DOI 10.1099/mic.0.27269-0; JOINER K, 1983, J IMMUNOL, V130, P845; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathur P, 2004, INDIAN J MED RES, V120, P199; McLaughlin R E, 1995, Methods Mol Biol, V47, P185; Nitsche DP, 2006, J BIOL CHEM, V281, P1670, DOI 10.1074/jbc.M506776200; NOHLGARD C, 1992, ACTA DERM-VENEREOL, V72, P128; PEREZCASAL J, 1995, MOL MICROBIOL, V15, P907, DOI 10.1111/j.1365-2958.1995.tb02360.x; REIS KJ, 1984, J IMMUNOL, V132, P3098; SIMPSON WJ, 1987, MICROB PATHOGENESIS, V3, P339, DOI 10.1016/0882-4010(87)90004-0; STONE GC, 1989, J IMMUNOL, V143, P565; Sylvetsky N, 2002, AM J MED, V112, P622, DOI 10.1016/S0002-9343(02)01117-8; TENNER AJ, 1982, J IMMUNOL, V128, P2547; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144	28	24	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17530	17536		10.1074/jbc.M702612200	http://dx.doi.org/10.1074/jbc.M702612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449474	hybrid			2022-12-25	WOS:000247084500023
J	Herrera, K; Cahoon, RE; Kumaran, S; Jez, JM				Herrera, Katherine; Cahoon, Rebecca E.; Kumaran, Sangaralingam; Jez, Joseph M.			Reaction mechanism of glutathione synthetase from Arabidopsis thaliana - Site-directed mutagenesis of active residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; BIOTIN CARBOXYLASE; KINETIC MECHANISM; FLEXIBLE LOOP; LIGASE; ATP; MUTATIONS; DEUTERIUM; PHOSPHATE; BINDING	Glutathione is essential for maintaining the intracellular redox environment and is synthesized from gamma-glutamylcysteine, glycine, and ATP by glutathione synthetase (GS). To examine the reaction mechanism of a eukaryotic GS, 24 Arabidopsis thaliana GS (AtGS) mutants were kinetically characterized. Within the gamma-glutamylcysteine/glutathione-binding site, the S153A and S155A mutants displayed less than 4-fold changes in kinetic parameters with mutations of Glu-220 (E220A/E220Q), Gln-226 (Q226A/Q226N), and Arg-274 (R274A/R274K) at the distal end of the binding site resulting in 24-180-fold increases in the K-m values for gamma-glutamylcysteine. Substitution of multiple residues interacting with ATP (K313M, K367M, and E429A/E429Q) or coordinating magnesium ions to ATP (E148A/E148Q, N150A/N150D, and E371A) yielded inactive protein because of compromised nucleotide binding, as determined by fluorescence titration. Other mutations in the ATP-binding site (E371Q, N376A, and K456M) resulted in greater than 30-fold decreases in affinity for ATP and up to 80-fold reductions in turnover rate. Mutation of Arg-132 and Arg-454, which are positioned at the interface of the two substrate-binding sites, affected the enzymatic activity differently. The R132A mutant was inactive, and the R132K mutant decreased kcat by 200-fold; however, both mutants bound ATP with Kd values similar to wild-type enzyme. Minimal changes in kinetic parameters were observed with the R454K mutant, but the R454A mutant displayed a 160-fold decrease in kcat. In addition, the R132K, R454A, and R454K mutations elevated the Km value for glycine up to 11-fold. Comparison of the pH profiles and the solvent deuterium isotope effects of A. thaliana GS and the Arg-132 and Arg-454 mutants also suggest distinct mechanistic roles for these residues. Based on these results, a catalytic mechanism for the eukaryotic GS is proposed.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						Cleland W W, 1979, Methods Enzymol, V63, P103; Dinescu A, 2004, J BIOL CHEM, V279, P22412, DOI 10.1074/jbc.M401334200; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; Gali RR, 1997, BIOCHEM J, V321, P207, DOI 10.1042/bj3210207; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; Jez JM, 2004, J BIOL CHEM, V279, P42726, DOI 10.1074/jbc.M407961200; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; KATSUBE Y, 1993, J MOL BIOL, V229, P1083; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; NISHIMURA JS, 1964, J BIOL CHEM, V239, P2553; Njalsson R, 2000, BIOCHEM J, V349, P275, DOI 10.1042/0264-6021:3490275; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Sloane V, 2001, J BIOL CHEM, V276, P24991, DOI 10.1074/jbc.M101472200; SWAIN CG, 1953, J AM CHEM SOC, V75, P141, DOI 10.1021/ja01097a041; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4325, DOI 10.1021/bi00412a020; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4317, DOI 10.1021/bi00412a019; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	30	17	17	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17157	17165		10.1074/jbc.M700804200	http://dx.doi.org/10.1074/jbc.M700804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17452339	hybrid			2022-12-25	WOS:000246946500049
J	Hou, JH; Shan, QA; Wang, T; Gomes, AS; Yan, QS; Paul, DL; Bleich, M; Goodenough, DA				Hou, Jianghui; Shan, Qixian; Wang, Tong; Gomes, Antonio S.; Yan, QingShang; Paul, David L.; Bleich, Markus; Goodenough, Daniel A.			Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; FAMILIAL HYPOMAGNESEMIA; HENLES LOOP; MG2+ TRANSPORT; RABBIT KIDNEY; EXPRESSION; MOUSE; MICE; INTERFERENCE; NEPHRON	Tight junctions play a key role in mediating paracellular ion reabsorption in the kidney. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a human disorder caused by mutations in the tight junction protein claudin-16. However, the molecular mechanisms underlining the renal handling of magnesium and its dysfunction causing FHHNC are unknown. Here we show that claudin-16 plays a key role in maintaining the paracellular cation selectivity of the thick ascending limbs of the nephron. Using RNA interference, we have generated claudin-16-deficient mouse models. Claudin-16 knock-down (KD) mice exhibit chronic renal wasting of magnesium and calcium and develop renal nephrocalcinosis. Our data suggest that claudin-16 forms a non-selective paracellular cation channel, rather than a selective Mg2+ /Ca2+ channel as previously proposed. Our study highlights the pivotal importance of the tight junction in renal control of ion homeostasis and provides answer to the pathogenesis of FHHNC. We anticipate our study to be a starting point for more sophisticated in vivo analysis of tight junction proteins in renal functions. Furthermore, tight junction proteins could be major targets of drug development for electrolyte disorders.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Univ Kiel, Inst Physiol, D-24098 Kiel, Germany; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Kiel; Yale University	Goodenough, DA (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	daniel_goodenough@hms.harvard.edu	Bleich, Markus/A-2812-2010	Bleich, Markus/0000-0002-1745-2295	NATIONAL EYE INSTITUTE [R01EY014127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018974, R01GM037751, R01GM018974] Funding Source: NIH RePORTER; NEI NIH HHS [EY014127] Funding Source: Medline; NIGMS NIH HHS [GM37751, GM18974] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005; Bailey MA, 2004, J PHYSIOL-LONDON, V561, P765, DOI 10.1113/jphysiol.2004.074716; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DISTEFANO A, 1993, RENAL PHYSIOL BIOCH, V16, P157; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P30, DOI 10.1007/BF00582707; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P315, DOI 10.1007/BF01063937; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; HALPERIN ML, 1986, AM J NEPHROL, V6, P241, DOI 10.1159/000167170; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HEBERT SC, 1981, AM J PHYSIOL, V241, pF412, DOI 10.1152/ajprenal.1981.241.4.F412; Hildebrand T, 1997, J MICROSC-OXFORD, V185, P67, DOI 10.1046/j.1365-2818.1997.1340694.x; Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hou JH, 2005, J CELL SCI, V118, P5109, DOI 10.1242/jcs.02631; Hou JH, 2006, J BIOL CHEM, V281, P36117, DOI 10.1074/jbc.M608853200; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Kausalya PJ, 2006, J CLIN INVEST, V116, P878, DOI 10.1172/JCI26323; Kissler S, 2006, NAT GENET, V38, P479, DOI 10.1038/ng1766; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Konrad M, 2006, AM J HUM GENET, V79, P949, DOI 10.1086/508617; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Kuwertz-Broking E, 2001, CLIN NEPHROL, V56, P155; Liggett SB, 2004, NAT REV GENET, V5, P657, DOI 10.1038/nrg1429; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; MAGALDI AJ, 1989, AM J PHYSIOL, V257, pF738, DOI 10.1152/ajprenal.1989.257.5.F738; MANDON B, 1993, PFLUG ARCH EUR J PHY, V424, P558, DOI 10.1007/BF00374924; ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756-3282(93)90245-6; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PRAGA M, 1995, KIDNEY INT, V47, P1419, DOI 10.1038/ki.1995.199; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SHAREGHI GR, 1982, J CLIN INVEST, V69, P759, DOI 10.1172/JCI110514; Sheehan D, 1980, THEORY PRACTICE HIST, Vsecond, P226; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Swindle CS, 2004, J BIOL CHEM, V279, P34, DOI 10.1074/jbc.M309128200; Weber S, 2001, J AM SOC NEPHROL, V12, P1872, DOI 10.1681/ASN.V1291872; Xia XG, 2006, PLOS GENET, V2, P73, DOI 10.1371/journal.pgen.0020010; Yao SY, 2004, MOL THER, V10, P27, DOI 10.1016/j.ymthe.2004.04.007; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	44	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17114	17122		10.1074/jbc.M700632200	http://dx.doi.org/10.1074/jbc.M700632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17442678	hybrid			2022-12-25	WOS:000246946500044
J	Li, N; Lorinczi, M; Ireton, K; Elferink, LA				Li, Ning; Lorinczi, Marta; Ireton, Keith; Elferink, Lisa A.			Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GRB2 BINDING-SITE; PLECKSTRIN HOMOLOGY DOMAIN; MET RECEPTOR; C-CBL; EGF RECEPTOR; SOMATIC MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; LISTERIA-MONOCYTOGENES; CELL-TRANSFORMATION	Lysosomal degradation of the receptor-tyrosine kinase cMet requires receptor ubiquitination by the E3 ubiquitin ligase Cbl followed by clathrin-dependent internalization. A role for Cbl as an adaptor for cMet internalization has been previously reported. However, the requirement for Cbl ubiquitin ligase activity in this process and its mode of recruitment to cMet has yet to be determined. Cbl can directly bind cMet at phosphotyrosine 1003 or indirectly via Grb2 to phosphotyrosine 1356 in the multisubstrate binding domain of cMet. The direct binding of Cbl with cMet is critical for receptor degradation and not receptor internalization. Here we show a strict requirement for Grb2 and the ubiquitin ligase activity of Cbl for cMet endocytosis. Receptor internalization was impaired by small interfering RNA depletion of Grb2, overexpression of dominant negative Grb2 mutants, and point mutations in the cMet multisubstrate docking site that inhibits the direct association of Grb2 with cMet. The requirement for Grb2 was specific and did not involve the multiadaptor Gab1. cMet internalization was impaired in cells expressing an ubiquitin ligase-deficient Cbl mutant or conjugation-deficient ubiquitin but was unaffected in cells expressing a Cbl mutant that is unable to bind cMet directly. Expression of a Cbl-Grb2 chimera rescued impaired cMet endocytosis in cells depleted of endogenous Grb2. These results indicate that the ubiquitin ligase activity of Cbl is critical for clathrin-dependent cMet internalization and suggest a role for Grb2 as an intermediary linking Cbl ubiquitin ligase activity to this process.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; State University System of Florida; University of Central Florida	Elferink, LA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	laelferi@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA119075, R21CA112605] Funding Source: NIH RePORTER; NCI NIH HHS [CA-119075, CA-112605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Basar T, 2005, INFECT IMMUN, V73, P2061, DOI 10.1128/IAI.73.4.2061-2074.2005; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; CHAN AML, 1988, ONCOGENE, V2, P593; Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cully M, 2004, P NATL ACAD SCI USA, V101, P15358, DOI 10.1073/pnas.0406613101; de Melker AA, 2004, J BIOL CHEM, V279, P55465, DOI 10.1074/jbc.M409765200; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Ieraci A, 2002, P NATL ACAD SCI USA, V99, P15200, DOI 10.1073/pnas.222362099; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Johannessen LE, 2006, MOL CELL BIOL, V26, P389, DOI 10.1128/MCB.26.2.389-401.2006; Kjelsberg C, 1997, AM J PHYSIOL-RENAL, V272, pF222, DOI 10.1152/ajprenal.1997.272.2.F222; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Li N, 2005, TRAFFIC, V6, P459, DOI 10.1111/j.1600-0854.2005.00290.x; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; Mansell A, 2000, CELL MICROBIOL, V2, P127, DOI 10.1046/j.1462-5822.2000.00038.x; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park WS, 1999, CANCER RES, V59, P307; PELICCI G, 1995, ONCOGENE, V10, P1631; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rodrigues G A, 1993, EXS, V65, P167; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Taher TEI, 2002, J IMMUNOL, V169, P3793, DOI 10.4049/jimmunol.169.7.3793; Tanyi J, 1999, Pathol Oncol Res, V5, P187, DOI 10.1053/paor.1999.0219; Veiga E, 2005, NAT CELL BIOL, V7, P894, DOI 10.1038/ncb1292; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Yamazaki T, 2002, J CELL SCI, V115, P1791; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHEN Z, 1994, ONCOGENE, V9, P1691	74	33	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16764	16775		10.1074/jbc.M610835200	http://dx.doi.org/10.1074/jbc.M610835200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17449471	Green Published, hybrid			2022-12-25	WOS:000246946500008
J	Bhattacharyya, S; Mandal, D; Saha, B; Sen, GS; Das, T; Sa, G				Bhattacharyya, Sankar; Mandal, Debaprasad; Saha, Baisakhi; Sen, Gouri Sankar; Das, Tanya; Sa, Gaurisankar			Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CARCINOMA CELLS; SIGNALING PATHWAY; DIETARY SUPPLEMENTATION; CYTOKINE PRODUCTION; THYMIC INVOLUTION; COLORECTAL-CANCER; BREAST-CANCER; JANUS KINASE; EXPRESSION; LYMPHOCYTES	Patients with advanced cancer exhibit multifaceted defects in their immune capacity, which are likely to contribute to an increased susceptibility to infections and disease progression. We demonstrated earlier that curcumin inhibits tumor growth and prevents immune cell death in tumor-bearing hosts. Here we report that tumor-induced immunodepletion involves apoptosis of thymic CD4(+)/CD8(+) single/double positive cells as well as loss of circulating CD4(+)/CD8(+) T cells. Administration of curcumin to tumor-bearing animals resulted in restoration of progenitor, effecter, and circulating T cells. In fact, tumor burden decreased the expression level of the pro-proliferative protein Bcl-2 while increasing the pro-apoptotic protein Bax in T cells. Curcumin down-regulated the Bax level while augmenting Bcl-2 expression in these cells, thereby protecting the immunocytes from tumor-induced apoptosis. A search for the upstream mechanism revealed down-regulation of the common cytokine receptor gamma chain (gamma c) expression in T cells by tumor-secreted prostaglandin E-2. As a result, Jak-3 and Stat-5a phosphorylation and to a lesser extent Stat-5b phosphorylation were also decreased in T cells. These entire phenomena could be reverted back by curcumin, indicating that this phytochemical restored the cytokine-dependent Jak-3/Stat-5a signaling pathway in T cells of tumor bearers. Overexpressed Stat-5a/constitutively active Stat-5a1*6 but not Stat-5b could efficiently elevate Bcl-2 levels and protect T cells from tumor-induced death, whereas C-terminal truncated Stat-5a(713) overexpression failed to do so, indicating the importance of Stat-5a signaling in T cell survival. Thus, these results raise the possibility of inclusion of curcumin in successful therapeutic regimens against cancer.	Calcutta Improvement Trust Scheme M P1 12 7, Bose Inst, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Sa, G (corresponding author), Calcutta Improvement Trust Scheme M P1 12 7, Bose Inst, Kolkata 700054, W Bengal, India.	gauri@bic.boseinst.ernet.in	Bhattacharyya, Sankar/GZH-3091-2022; Bhattacharyya, Sankar/AAK-2204-2020	Bhattacharyya, Sankar/0000-0002-3235-4220; Mandal, Deba Prasad/0000-0002-8052-6576				Adkins B, 2000, J IMMUNOL, V164, P5635, DOI 10.4049/jimmunol.164.11.5635; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; ALEXANDER JP, 1993, CANCER RES, V53, P1380; ARISTA MC, 1994, DIS COLON RECTUM, V37, pS30, DOI 10.1007/BF02048428; Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669; Balasubramanyam M, 2003, J BIOSCIENCES, V28, P715, DOI 10.1007/BF02708432; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Brown DM, 1996, J IMMUNOL, V157, P1359; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; FECCHIO D, 1990, INFLAMMATION, V14, P125, DOI 10.1007/BF00914035; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; Hadden JW, 2003, INT IMMUNOPHARMACOL, V3, P1061, DOI 10.1016/S1567-5769(03)00060-2; Heriot AG, 2000, BRIT J CANCER, V82, P1009, DOI 10.1054/bjoc.1999.1034; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Iqbal M, 2003, PHARMACOL TOXICOL, V92, P33, DOI 10.1034/j.1600-0773.2003.920106.x; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; Kolenko V, 1997, J IMMUNOL, V159, P3057; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; LAMBERT IH, 1987, J MEMBRANE BIOL, V98, P247, DOI 10.1007/BF01871187; LI X, 2002, EXP HEMATOL, V30, P265; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Lopez DM, 2002, J MAMMARY GLAND BIOL, V7, P191, DOI 10.1023/A:1020356020542; Malmberg KJ, 2002, CLIN CANCER RES, V8, P1772; Mandal D, 2005, LIFE SCI, V77, P2703, DOI 10.1016/j.lfs.2005.05.038; MARDEN VS, 2003, ANNU REV IMMUNOL, V21, P71; Mastino A, 1992, Dev Immunol, V2, P263, DOI 10.1155/1992/80863; MATSUDA M, 1995, INT J CANCER, V61, P765, DOI 10.1002/ijc.2910610605; Morales-Montor J, 1998, PARASITOL RES, V84, P616, DOI 10.1007/s004360050460; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Rabinowich H, 1998, J CLIN INVEST, V101, P2579, DOI 10.1172/JCI1518; Reichert TE, 1998, J IMMUNOTHER, V21, P295, DOI 10.1097/00002371-199807000-00007; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Saito T, 2000, CLIN CANCER RES, V6, P1351; Shanker A, 2000, TUMOR BIOL, V21, P288, DOI 10.1159/000030134; Shiku H, 2003, INT J HEMATOL, V77, P435, DOI 10.1007/BF02986610; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Thomis DC, 1997, J EXP MED, V185, P197, DOI 10.1084/jem.185.2.197; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wang H, 2004, LIFE SCI, V74, P1739, DOI 10.1016/j.lfs.2003.07.051; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	47	82	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15954	15964		10.1074/jbc.M608189200	http://dx.doi.org/10.1074/jbc.M608189200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392282	hybrid			2022-12-25	WOS:000246794300004
J	Yamasaki, H; Abdel-Ghany, SE; Cohu, CM; Kobayashi, Y; Shikanai, T; Pilon, M				Yamasaki, Hiroaki; Abdel-Ghany, Salah E.; Cohu, Christopher M.; Kobayashi, Yoshichika; Shikanai, Toshiharu; Pilon, Marinus			Regulation of copper homeostasis by micro-RNA in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; P-TYPE ATPASE; SUPEROXIDE-DISMUTASE; DIFFERENTIAL EXPRESSION; ASCORBATE PEROXIDASE; PLANT MICRORNAS; ELECTRON FLOW; CHLAMYDOMONAS; TRANSPORT; CHAPERONE	Major copper proteins in the cytoplasm of plant cells are plastocyanin, copper/zinc superoxide dismutase, and cytochrome c oxidase. Under copper limited conditions, expression of copper/zinc superoxide dismutase is down-regulated and the protein is replaced by iron superoxide dismutase in chloroplasts. We present evidence that a micro-RNA, miR398, mediates this regulation in Arabidopsis thaliana, by directing the degradation of copper/zinc superoxide dismutase mRNA when copper is limited. Sequence analysis indicated that the transcripts encoding cytosolic copper/zinc superoxide dismutase and COX5b- 1, a subunit of the mitochondrial cytochrome c oxidase, are also targeted by miR398. This regulation via miR398 takes place in response to changes in a low range of copper levels ( 0.2- 0.5 mu M), indicating that miR398 is involved in a response to copper limitation. On the other hand, another major copper protein, plastocyanin, which is involved in photosynthetic electron flow and is essential in higher plants, was not regulated via miR398. We propose that miR398 is a key factor in copper homeostasis in plants and regulates the stability of mRNAs of major copper proteins under copper-limited conditions.	Kyushu Univ, Grad Sch Agr, Fukuoka 8128581, Japan; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Program Mol Plant Biol, Ft Collins, CO 80523 USA	Kyushu University; Colorado State University; Colorado State University	Shikanai, T (corresponding author), Kyushu Univ, Grad Sch Agr, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020					Abdel-Ghany SE, 2005, FEBS LETT, V579, P2307, DOI 10.1016/j.febslet.2005.03.025; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; Andres-Colas N, 2006, PLANT J, V45, P225, DOI 10.1111/j.1365-313X.2005.02601.x; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bari R, 2006, PLANT PHYSIOL, V141, P988, DOI 10.1104/pp.106.079707; Baumberger N, 2005, P NATL ACAD SCI USA, V102, P11928, DOI 10.1073/pnas.0505461102; Bonnet E, 2004, P NATL ACAD SCI USA, V101, P11511, DOI 10.1073/pnas.0404025101; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briat JF, 1997, TRENDS PLANT SCI, V2, P187, DOI 10.1016/S1360-1385(97)85225-9; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chiou TJ, 2006, PLANT CELL, V18, P412, DOI 10.1105/tpc.105.038943; Chu CC, 2005, PLANT PHYSIOL, V139, P425, DOI 10.1104/pp.105.065284; Clifton R, 2006, BBA-BIOENERGETICS, V1757, P730, DOI 10.1016/j.bbabio.2006.03.009; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Fujii H, 2005, CURR BIOL, V15, P2038, DOI 10.1016/j.cub.2005.10.016; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hunter C, 2003, CURR BIOL, V13, P1734, DOI 10.1016/j.cub.2003.09.004; Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; Kropat J, 2005, P NATL ACAD SCI USA, V102, P18730, DOI 10.1073/pnas.0507693102; Kurihara Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI 10.1073/pnas.0403115101; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; Merchant Sabeeha S., 2006, V23, P199; Mittler R, 2004, TRENDS PLANT SCI, V9, P490, DOI 10.1016/j.tplants.2004.08.009; Molina-Heredia FP, 2003, NATURE, V424, P33, DOI 10.1038/424033b; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Munshi MK, 2006, PLANT PHYSIOL, V141, P737, DOI 10.1104/pp.106.080267; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURPHY A, 1995, PLANT PHYSIOL, V108, P29, DOI 10.1104/pp.108.1.29; Ono S, 2004, BIOSCI BIOTECH BIOCH, V68, P803, DOI 10.1271/bbb.68.803; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Petit JM, 2001, BIOCHEM J, V359, P575, DOI 10.1042/0264-6021:3590575; Pilon M, 2006, CURR OPIN PLANT BIOL, V9, P256, DOI 10.1016/j.pbi.2006.03.007; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Storozhenko S, 1998, PLANT PHYSIOL, V118, P1005, DOI 10.1104/pp.118.3.1005; Sunkar R, 2004, PLANT CELL, V16, P2001, DOI 10.1105/tpc.104.022830; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Weigel M, 2003, J BIOL CHEM, V278, P31286, DOI 10.1074/jbc.M302876200; Welchen E, 2004, J EXP BOT, V55, P1997, DOI 10.1093/jxb/erh223; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zhang BH, 2006, DEV BIOL, V289, P3, DOI 10.1016/j.ydbio.2005.10.036	52	305	334	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16369	16378		10.1074/jbc.M700138200	http://dx.doi.org/10.1074/jbc.M700138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405879	hybrid			2022-12-25	WOS:000246794300045
J	Crunkhorn, S; Dearie, F; Mantzoros, C; Gami, H; da Silva, WS; Espinoza, D; Faucette, R; Barry, K; Bianco, AC; Patti, ME				Crunkhorn, Sarah; Dearie, Farrell; Mantzoros, Christos; Gami, Hiral; da Silva, Wagner S.; Espinoza, Daniel; Faucette, Ryan; Barry, Kristen; Bianco, Antonio C.; Patti, Mary Elizabeth			Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity - Potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; GENE-EXPRESSION; ENERGY-EXPENDITURE; TRANSCRIPTIONAL COACTIVATORS; PGC-1-ALPHA TRANSCRIPTION; 1-ALPHA PGC-1-ALPHA; DIABETES-MELLITUS; DOWN-REGULATION; ADIPOSE-TISSUE	Peroxisome proliferator activator receptor-gamma coactivator 1 (PGC-1) is a major candidate gene for diabetes-related metabolic phenotypes, contributing to decreased expression of nuclear-encoded mitochondrial genes in muscle and adipose tissue. We have demonstrated that muscle expression of PGC-1 alpha and -beta is reduced in both genetic (Lepob/Lepob) and acquired obesity ( high fat diet). In C57BL6 mice, muscle PGC-1 alpha expression decreased by 43% (p < 0.02) after 1 week of a high fat diet and persisted more than 11 weeks. In contrast, PGC-1 alpha reductions were not sustained in obesity-resistant A/J mice. To identify mediators of obesity-linked reductions in PGC-1, we tested the effects of cellular nutrients in C2C12 myotubes. Although overnight exposure to high insulin, glucose, glucosamine, or amino acids had no effect, saturated fatty acids potently reduced PGC-1 alpha and -beta mRNA expression. Palmitate decreased PGC-1 alpha and -beta expression by 38% (p = 0.01) and 53% (p = 0.006); stearate similarly decreased expression of PGC-1 alpha and -beta by 22% (p = 0.02) and 39% (p = 0.02). These effects were mediated at a transcriptional level, as indicated by an 11-fold reduction of PGC-1 alpha promoter activity by palmitate and reversal of effects by histone deacetylase inhibition. Palmitate also ( a) reduced expression of tricarboxylic acid cycle and oxidative phosphorylation mitochondrial genes and (b) reduced oxygen consumption. These effects were reversed by overexpression of PGC-1 alpha or -beta, indicating PGC-1 dependence. Palmitate effects also required p38 MAPK, as demonstrated by 1) palmitate-induced increase in p38 MAPK phosphorylation, 2) reversal of palmitate effects on PGC-1 and mitochondrial gene expression by p38 MAPK inhibitors, and 3) reversal of palmitate effects by small interfering RNA-mediated decreases in p38 alpha MAPK. These data indicate that obesity and saturated fatty acids decrease PGC-1 and mitochondrial gene expression and function via p38 MAPK-dependent transcriptional pathways.	Joslin Diabet Ctr, Div Endocrinol, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Thyroid Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Patti, ME (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	mary.elizabeth.patti@joslin.harvard.edu	Mantzoros, Christos/Y-2902-2019; Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008; da Silva, Wagner S/A-7835-2008	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813; da Silva, Wagner S/0000-0002-0001-0386	NIDDK NIH HHS [DK65055, DK060837, DK062948, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062948, P30DK036836, R01DK060837, R01DK065055] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Al-Khalili L, 2005, DIABETOLOGIA, V48, P1173, DOI 10.1007/s00125-005-1741-3; Berkowitz R, 1996, DIABETES, V45, P1572; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Civitarese AE, 2006, CELL METAB, V4, P75, DOI 10.1016/j.cmet.2006.05.002; Coll T, 2006, DIABETES, V55, P2779, DOI 10.2337/db05-1494; Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200; Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229; CRUNKHORN S, 2008, PHYS ACTIVITY TYPE 2; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Esterbauer H, 2002, DIABETES, V51, P1281, DOI 10.2337/diabetes.51.4.1281; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; Li SY, 2005, DIABETES OBES METAB, V7, P448, DOI 10.1111/j.1463-1326.2004.00387.x; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889; Liu HY, 2007, J BIOL CHEM, V282, P14205, DOI 10.1074/jbc.M609701200; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Oberkofler H, 2004, DIABETES, V53, P1385, DOI 10.2337/diabetes.53.5.1385; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Patti ME, 2004, NAT MED, V10, P1049, DOI 10.1038/nm1004-1049; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pihlajamaki J, 2006, ADV MOL CELL ENDOCR, V5, P233, DOI 10.1016/S1569-2566(06)05012-5; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Richardson DK, 2005, J BIOL CHEM, V280, P10290, DOI 10.1074/jbc.M408985200; Russell AP, 2005, FASEB J, V19, P986, DOI 10.1096/fj.04-3168fje; Santomauro ATMG, 1999, DIABETES, V48, P1836, DOI 10.2337/diabetes.48.9.1836; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Sonoda J, 2007, P NATL ACAD SCI USA, V104, P5223, DOI 10.1073/pnas.0611623104; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1055, DOI 10.1152/ajpendo.00554.2001; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Staiger H, 2006, DIABETOLOGIA, V49, P212, DOI 10.1007/s00125-005-0061-y; Staiger H, 2005, DIABETOLOGIA, V48, P2115, DOI 10.1007/s00125-005-1895-z; Suwa M, 2006, J APPL PHYSIOL, V101, P1685, DOI 10.1152/japplphysiol.00255.2006; Tenhunen O, 2006, CIRC RES, V99, P485, DOI 10.1161/01.RES.0000238387.85144.92; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Tremblay F, 2005, CURR OPIN CLIN NUTR, V8, P457, DOI 10.1097/01.mco.0000172589.55434.03; Ukropcova B, 2007, DIABETES, V56, P720, DOI 10.2337/db06-0521; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Wang XL, 2006, DIABETES, V55, P2301, DOI 10.2337/db05-1574; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Watt MJ, 2004, J MOL ENDOCRINOL, V33, P533, DOI 10.1677/jme.1.01499; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Ye JM, 2006, DIABETES, V55, P2797, DOI 10.2337/db05-1315; Yechoor VK, 2004, P NATL ACAD SCI USA, V101, P16525, DOI 10.1073/pnas.0407574101	74	195	202	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15439	15450		10.1074/jbc.M611214200	http://dx.doi.org/10.1074/jbc.M611214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17416903	hybrid			2022-12-25	WOS:000246589600019
J	Fuchs, BB; Tang, RJ; Mylonakis, E				Fuchs, Beth Burgwyn; Tang, Robin J.; Mylonakis, Eleftherios			The Temperature-Sensitive Role of Cryptococcus neoformans ROM2 in Cell Morphogenesis	PLOS ONE			English	Article								ROM2 is associated with Cryptococcus neoformans virulence. We examined additional roles of ROM2 in C. neoformans and found that ROM2 plays a role in several cell functions specifically at high temperature conditions. Morphologically rom2 mutant cells demonstrated a "tear"-like shape and clustered together. A sub-population of cells had a hyperelongated phenotype at restrictive growth conditions. Altered morphology was associated with defects in actin that was concentrated at the cell periphery and with abnormalities in microtubule organization. Interestingly, the ROM2 associated defects in cell morphology, location of nuclei, and actin and microtubule organization were not observed in cells grown at temperatures below 37 degrees C. These results indicate that in C. neoformans, ROM2 is important at restrictive temperature conditions and is involved in several cell maintenance functions.	[Fuchs, Beth Burgwyn; Tang, Robin J.; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Mylonakis, E (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.	emylonakis@partners.org			NIH [AI63084-01]; Ellison Medical Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI063084] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding: A K08 award AI63084-01 from the NIH and a New Scholar Award in Global Infectious Diseases from the Ellison Medical Foundation, to EM, supported this work.	ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Arellano M, 1997, J CELL SCI, V110, P2547; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; Calonge TM, 2003, MOL MICROBIOL, V47, P507, DOI 10.1046/j.1365-2958.2003.03312.x; Chayakulkeeree M, 2006, INFECT DIS CLIN N AM, V20, P507, DOI 10.1016/j.idc.2006.07.001; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; French N, 2002, AIDS, V16, P1031, DOI 10.1097/00002030-200205030-00009; Fujiwara T, 1999, MOL CELL BIOL, V19, P8016; Gerik KJ, 2005, MOL MICROBIOL, V58, P393, DOI 10.1111/j.1365-2958.2005.04843.x; Gumbo T, 2002, PEDIATR INFECT DIS J, V21, P54, DOI 10.1097/00006454-200201000-00012; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Helling H., 1998, J LIE THEORY, V8, P1; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Jacoby JJ, 1998, MOL GEN GENET, V258, P148, DOI 10.1007/s004380050717; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kopecka M, 2001, EUR J CELL BIOL, V80, P303, DOI 10.1078/0171-9335-00157; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Manning BD, 1997, MOL BIOL CELL, V8, P1829, DOI 10.1091/mbc.8.10.1829; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PAGE BD, 1994, J CELL BIOL, V124, P507, DOI 10.1083/jcb.124.4.507; Perfect JR, 2002, INFECT DIS CLIN N AM, V16, P837, DOI 10.1016/S0891-5520(02)00064-8; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Pruyne D, 2000, J CELL SCI, V113, P365; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Tang RJ, 2005, INFECT IMMUN, V73, P8219, DOI 10.1128/IAI.73.12.8219-8225.2005; Thomas CJ, 1998, ANN EPIDEMIOL, V8, P212, DOI 10.1016/S1047-2797(97)00234-2; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; Waugh MS, 2002, MICROBIOL-SGM, V148, P191, DOI 10.1099/00221287-148-1-191; WOODS A, 1989, J CELL SCI, V93, P491	39	12	13	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e368	10.1371/journal.pone.0000368	http://dx.doi.org/10.1371/journal.pone.0000368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426816	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445400008
J	Kobiler, O; Rokney, A; Oppenheim, AB				Kobiler, Oren; Rokney, Assaf; Oppenheim, Amos B.			Phage Lambda CIII: A Protease Inhibitor Regulating the Lysis-Lysogeny Decision	PLOS ONE			English	Article								The ATP-dependent protease FtsH (HflB) complexed with HflKC participates in post-translational control of the lysis-lysogeny decision of bacteriophage lambda by rapid degradation of lambda CII. Both phage-encoded proteins, the CII transcription activator and the CIII polypeptide, are required for efficient lysogenic response. The conserved CIII is both an inhibitor and substrate of FtsH. Here we show that the protease inhibitor CIII is present as oligomeric amphipathic alpha helical structures and functions as a competitive inhibitor of FtsH by preventing binding of the CII substrate. We identified single alanine substitutions in CIII that abolish its activity. We characterize a dominant negative effect of a CIII mutant. Thus, we suggest that CIII oligomrization is required for its function. Real-time analysis of CII activity demonstrates that the effect of CIII is not seen in the absence of either FtsH or HflKC. When CIII is provided ectopically, CII activity increases linearly as a function of the multiplicity of infection, suggesting that CIII enhances CII stability and the lysogenic response. FtsH function is essential for cellular viability as it regulates the balance in the synthesis of phospholipids and lipopolysaccharides. Genetic experiments confirmed that the CIII bacteriostatic effects are due to inhibition of FtsH. Thus, the early presence of CIII following infection stimulates the lysogenic response, while its degradation at later times ensures the reactivation of FtsH allowing the growth of the established lysogenic cell.	[Kobiler, Oren; Rokney, Assaf; Oppenheim, Amos B.] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Genet & Biotechnol, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Kobiler, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Genet & Biotechnol, IL-91010 Jerusalem, Israel.	orenk@ekmd.huji.ac.il	Kobiler, Oren/J-2268-2012	Kobiler, Oren/0000-0001-9914-3770	Israel Science Foundation [489/01-1, 340/04]; NIH [R21A I071240-01]	Israel Science Foundation(Israel Science Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding: This research was supported in part by the Israel Science Foundation (grant # 489/01-1 and 340/04) and by an NIH grant R21A I071240-01.	Ades SE, 2004, CURR BIOL, V14, pR924, DOI 10.1016/j.cub.2004.10.015; ALTUVIA S, 1986, J BACTERIOL, V167, P415, DOI 10.1128/jb.167.1.415-419.1986; BELFORT M, 1975, VIROLOGY, V63, P147, DOI 10.1016/0042-6822(75)90380-3; Cutting S, 1997, J BACTERIOL, V179, P5534, DOI 10.1128/jb.179.17.5534-5542.1997; Dougan DA, 2002, CELL MOL LIFE SCI, V59, P1607, DOI 10.1007/PL00012487; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Herman C, 1997, J BACTERIOL, V179, P358, DOI 10.1128/jb.179.2.358-363.1997; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; Hilliard JJ, 1998, J BIOL CHEM, V273, P524, DOI 10.1074/jbc.273.1.524; Ito K, 2005, ANNU REV MICROBIOL, V59, P211, DOI 10.1146/annurev.micro.59.030804.121316; Jenal U, 2003, CURR OPIN MICROBIOL, V6, P163, DOI 10.1016/S1369-5274(03)00029-8; KAISER AD, 1957, VIROLOGY, V3, P42, DOI 10.1016/0042-6822(57)90022-3; Kanemori M, 1999, J BIOL CHEM, V274, P22002, DOI 10.1074/jbc.274.31.22002; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Kobiler O, 2005, P NATL ACAD SCI USA, V102, P4470, DOI 10.1073/pnas.0500670102; Kobiler O, 2004, J STRUCT BIOL, V146, P72, DOI 10.1016/j.jsb.2003.10.021; Kobiler O, 2002, P NATL ACAD SCI USA, V99, P14964, DOI 10.1073/pnas.222172499; KORNITZER D, 1991, P NATL ACAD SCI USA, V88, P5217, DOI 10.1073/pnas.88.12.5217; KOURILSKY P, 1974, BIOCHIMIE, V56, P1517; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; Obuchowski M, 1997, J BACTERIOL, V179, P5987, DOI 10.1128/jb.179.19.5987-5991.1997; Obuchowski M, 1997, MOL GEN GENET, V254, P304, DOI 10.1007/s004380050420; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Oppenheim AB, 2005, ANNU REV GENET, V39, P409, DOI 10.1146/annurev.genet.39.073003.113656; Oppenheim AB, 2004, VIROLOGY, V319, P185, DOI 10.1016/j.virol.2003.11.007; Prajapati RS, 2000, BBA-GEN SUBJECTS, V1475, P353, DOI 10.1016/S0304-4165(00)00089-1; Ptashne M, 2004, GENETIC SWITCH PHAGE; REICHARDT L, 1971, P NATL ACAD SCI USA, V68, P2185, DOI 10.1073/pnas.68.9.2185; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; Tyler JS, 2004, J BACTERIOL, V186, P7670, DOI 10.1128/JB.186.22.7670-7679.2004; Weichart D, 2003, J BACTERIOL, V185, P115, DOI 10.1128/JB.185.1.115-125.2003	35	29	30	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e363	10.1371/journal.pone.0000363	http://dx.doi.org/10.1371/journal.pone.0000363			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426811	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445400003
J	Gutzman, JH; Rugowski, DE; Nikolai, SE; Schuler, LA				Gutzman, J. H.; Rugowski, D. E.; Nikolai, S. E.; Schuler, L. A.			Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context	ONCOGENE			English	Article						prolactin; breast cancer; AP-1; Stat5	BREAST-CANCER CELLS; C-FOS; TRANSCRIPTION FACTORS; MAMMARY-GLAND; CYCLIN D1; TRANSDUCER; EXPRESSION; PROTEIN-1; INVASION; JUN	The essential role of prolactin (PRL) in normal mammary gland growth and differentiation has implicated this hormone in the development and progression of breast cancer. Although Stat5 is the best-characterized mediator of PRL signals, PRL also activates multiple other signals, whose roles in normal and pathologic processes are not well understood. We have shown that PRL stimulates activating protein-1 (AP-1) activity in breast cancer cells, and can cooperate with estradiol in this pathway. AP-1 modulates many processes critical for carcinogenesis, including cell proliferation, survival, transformation, invasion and angiogenesis, and is elevated in many neoplasms, including breast tumors. Here, we investigated the relationship between PRL signals to AP-1 and Stat5. We found that PRL activation of Stat5a and Stat5b, but not Stat1 or Stat3, reduced PRL signals to AP-1, without altering estradiol-induced AP-1 activity. The truncation mutant, Stat5/Delta 53C, but not Stat5Y699F, was an effective inhibitor, consistent with a requirement for Stat5 dimerization and nuclear accumulation, but not its C-terminal transactivation activity. The association of Stat5 with AP-1 proteins suggests that this underlies the inhibition. Predictably, the ability of PRL to activate Stat5 and AP-1 was inversely related in mammary cell lines. Further, reduction of Stat5 protein with siRNA in T47D cells, which contain elevated Stat5, increased PRL-induced AP-1 signals, transcripts for the AP-1 target, matrix metalloproteinase-2 and associated invasive behavior. This study points to the importance of cell context in determining the spectrum of PRL-induced actions, which is critical for understanding the contributions of PRL to breast cancer.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu	Gutzman, Jennifer/AAA-9058-2020	Gutzman, Jennifer/0000-0002-7725-6923	NATIONAL CANCER INSTITUTE [R01CA078312] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78312, R01 CA078312] Funding Source: Medline; NIDDK NIH HHS [DK07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cao JS, 2004, ENDOCRINOLOGY, V145, P1739, DOI 10.1210/en.2003-0752; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; ORMANDY CJ, 2001, MAMMARY GLAND DEV PR, P219; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Weaver AM, 2006, MOL ENDOCRINOL, V20, P2392, DOI 10.1210/me.2005-0418; Yang E, 2003, J BIOL CHEM, V278, P15794, DOI 10.1074/jbc.M213073200; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	44	37	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6341	6348		10.1038/sj.onc.1210454	http://dx.doi.org/10.1038/sj.onc.1210454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438530	Green Accepted			2022-12-25	WOS:000249583300010
J	Johann, AM; Barra, V; Kuhn, AM; Weigert, A; von Knethen, A; Brune, B				Johann, Axel M.; Barra, Vera; Kuhn, Anne-Marie; Weigert, Andreas; von Knethen, Andreas; Bruene, Bernhard			Apoptotic cells induce arginase II in macrophages, thereby attenuating NO production	FASEB JOURNAL			English	Article						phagocytosis; inflammation; alternative activation; inducible NO synthase	NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; L-ARGININE; ACTIVATION; RECOGNITION; MECHANISMS; EXPRESSION; CLEARANCE; SUBSTRATE	In recent years it has become apparent that removal of apoptotic cells ( AC) by professional phagocytes alters the macrophage phenotype. This change is characterized by attenuated proinflammatory cytokine expression and NO production, which mechanistically remained unexplained. With the intention to explore molecular mechanisms underlying reduced NO formation, we showed that NO production in IFN gamma-stimulated murine RAW264.7 macrophages exposed to AC but not to either necrotic or viable human Jurkat cells was significantly reduced although iNOS expression remained high compared with controls. Analyzing iNOS activity in the cell extracts by using the radioactive L- arginine/ citrulline conversion assay revealed increased ornithine production over citrulline in cells exposed to AC. RT- PCR, Western blot, and luciferase reporter analysis supported the idea of an arginase II increase in response to AC. The involvement of arginase in modulating NO formation in response to AC was substantiated by the arginase inhibitor N omega- hydroxy-nor-L- arginine. Moreover, knockdown of arginase II by siRNA allowed recovery of NO production. Experiments with AC- conditioned medium demonstrated that a soluble lipid factor, rather than phagocytosis of AC, modulated NO production in macrophages. We conclude that AC release a lipid factor to modulate NO formation in macrophages via arginase II up- regulation, thereby contributing to innate immune regulation.	Goethe Univ Frankfurt, Fac Med, Inst Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brune, B (corresponding author), Goethe Univ Frankfurt, Fac Med, Inst Biochem 1, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@zbc.kgu.de	Weigert, Andreas/E-6540-2010	Weigert, Andreas/0000-0002-7529-1952				Balanco JMD, 2001, CURR BIOL, V11, P1870, DOI 10.1016/S0960-9822(01)00563-2; Barksdale AR, 2004, SURGERY, V135, P527, DOI 10.1016/j.surg.2003.10.007; Blaise GA, 2005, TOXICOLOGY, V208, P177, DOI 10.1016/j.tox.2004.11.032; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BOUTARD V, 1995, J IMMUNOL, V155, P2077; Closs EI, 2000, MOL PHARMACOL, V57, P68; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; El-Gayar S, 2003, J IMMUNOL, V171, P4561, DOI 10.4049/jimmunol.171.9.4561; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Topal JLG, 2006, J PHARMACOL EXP THER, V318, P1368, DOI 10.1124/jpet.106.103747; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Johann AM, 2006, CELL DEATH DIFFER, V13, P1533, DOI 10.1038/sj.cdd.4401832; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; Lopez V, 2005, FEBS J, V272, P4540, DOI 10.1111/j.1742-4658.2005.04874.x; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McDonald PP, 1999, J IMMUNOL, V163, P6164; Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S; MORRIS SM, 1998, AM J PHYSIOL, V375, pE740; Munder M, 1999, J IMMUNOL, V163, P3771; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schneemann M, 2002, NAT IMMUNOL, V3, P102, DOI 10.1038/ni0202-102a; Stuehr DJ, 2004, J NUTR, V134, p2748S, DOI 10.1093/jn/134.10.2748S; Tenu JP, 1999, NITRIC OXIDE-BIOL CH, V3, P427, DOI 10.1006/niox.1999.0255; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weigert A, 2006, BLOOD, V108, P1635, DOI 10.1182/blood-2006-04-014852; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu WL, 2004, FASEB J, V18, P1746, DOI 10.1096/fj.04-2317fje; Zamboni DS, 2004, INFECT IMMUN, V72, P2075, DOI 10.1128/IAI.72.4.2075-2080.2004	39	53	53	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2704	2712		10.1096/fj.06-7815com	http://dx.doi.org/10.1096/fj.06-7815com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17456784				2022-12-25	WOS:000249237500012
J	Sung, HY; Guan, HT; Czibula, A; King, AR; Eder, K; Heath, E; Suvarna, SK; Dower, SK; Wilson, AG; Francis, SE; Crossman, DC; Kiss-Toth, E				Sung, Hye Youn; Guan, Hongtao; Czibula, Agnes; King, Andrea R.; Eder, Katalin; Heath, Emily; Suvarna, S. Kim; Dower, Steven K.; Wilson, Anthony G.; Francis, Sheila E.; Crossman, David C.; Kiss-Toth, Endre			Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; AMERICAN-HEART-ASSOCIATION; TUMOR-NECROSIS-FACTOR; HISTOLOGICAL CLASSIFICATION; ATHEROSCLEROTIC LESIONS; ENDOTHELIAL-CELLS; COMPLEMENTATION ASSAYS; EXPRESSION CLONING; VASCULAR-LESIONS; GENE-EXPRESSION	Migration and proliferation of smooth muscle cells are key to a number of physiological and pathological processes, including wound healing and the narrowing of the vessel wall. Previous work has shown links between inflammatory stimuli and vascular smooth muscle cell proliferation and migration through mitogen-activated protein kinase (MAPK) activation, although the molecular mechanisms of this process are poorly understood. Here we report that tribbles-1, a recently described modulator of MAPK activation, controls vascular smooth muscle cell proliferation and chemotaxis via the Jun kinase pathway. Our findings demonstrate that this regulation takes place via direct interactions between tribbles-1 and MKK4/SEK1, a Jun activator kinase. The activity of this kinase is dependent on tribbles-1 levels, whereas the activation and the expression of MKK4/SEK1 are not. In addition, tribbles-1 expression is elevated in human atherosclerotic arteries when compared with non-atherosclerotic controls, suggesting that this protein may play a role in disease in vivo. In summary, the data presented here suggest an important regulatory role for trb-1 in vascular smooth muscle cell biology.	Univ Sheffield, Cardiovasc Res Unit, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Sect Infect Infkam & Immun, Sheffield S10 2TN, S Yorkshire, England; No Gen Hosp, Dept Histopathol, Sheffield S5 7AU, S Yorkshire, England; Inst Biochem, Biol Res Ctr, H-67601 Szeged, Hungary	University of Sheffield; University of Sheffield; Northern General Hospital; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Kiss-Toth, E (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Cardiovasc Res Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	E.Kiss-Toth@sheffield.ac.uk	Kiss-Toth, Endre/AAC-4252-2020; Eder, Katalin/E-2480-2014; Kiss-Toth, Endre/A-8596-2014	Kiss-Toth, Endre/0000-0003-4406-4017; Eder, Katalin/0000-0002-3739-423X; Kiss-Toth, Endre/0000-0003-4406-4017; Czibula, Agnes/0000-0003-4461-2773; Wilson, Anthony Gerard/0000-0003-4855-3926; dower, steve/0000-0002-4675-4225; Francis, Sheila/0000-0001-6552-0339	British Heart Foundation [PG/02/122/14495, PG/05/100/19606] Funding Source: Medline; Medical Research Council [G0301063] Funding Source: Medline; MRC [G0301063] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bonventre JV, 1998, CURR OPIN NEPHROL HY, V7, P425, DOI 10.1097/00041552-199807000-00013; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hegedus Z, 2006, CELL MOL LIFE SCI, V63, P1632, DOI 10.1007/s00018-006-6007-9; Iynedjian PB, 2005, BIOCHEM J, V386, P113, DOI 10.1042/BJ20041425; Jones PL, 1999, J CELL SCI, V112, P435; Ju HS, 2002, J PHARMACOL EXP THER, V301, P15, DOI 10.1124/jpet.301.1.15; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Kiss-Toth E, 2005, BIOCHEM SOC T, V33, P1405, DOI 10.1042/BST0331405; Kiss-Toth E, 2006, CELL SIGNAL, V18, P202, DOI 10.1016/j.cellsig.2005.04.012; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Michnick SW, 2004, DRUG DISCOV TODAY, V9, P262, DOI 10.1016/S1359-6446(03)03022-8; Mii S, 1996, AM J PHYSIOL-HEART C, V270, pH142, DOI 10.1152/ajpheart.1996.270.1.H142; Morton AC, 2005, CARDIOVASC RES, V68, P493, DOI 10.1016/j.cardiores.2005.06.026; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Remy I, 2004, METHODS, V32, P381, DOI 10.1016/j.ymeth.2003.10.011; Remy Ingrid, 2004, Methods Mol Biol, V261, P411; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saka Y, 2004, DEV BIOL, V273, P210, DOI 10.1016/j.ydbio.2004.05.032; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; Satterthwaite G, 2005, AM HEART J, V150, P488, DOI 10.1016/j.ahj.2004.10.025; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Stary HC, 2000, ARTERIOSCL THROM VAS, V20, P1177, DOI 10.1161/01.ATV.20.5.1177; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Takeishi Y, 2001, J MOL CELL CARDIOL, V33, P1989, DOI 10.1006/jmcc.2001.1463; Touyz RM, 2000, PHARMACOL REV, V52, P639; WARNER SJC, 1989, J IMMUNOL, V142, P100; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamakawa T, 1999, ENDOCRINOLOGY, V140, P3562, DOI 10.1210/en.140.8.3562; Yang CM, 2001, BRIT J PHARMACOL, V132, P1531, DOI 10.1038/sj.bjp.0703976; YUE TL, 1994, BIOCHEM BIOPH RES CO, V204, P1186, DOI 10.1006/bbrc.1994.2588	47	76	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18379	18387		10.1074/jbc.M610792200	http://dx.doi.org/10.1074/jbc.M610792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452330	Green Accepted, hybrid			2022-12-25	WOS:000247302000044
J	Qiang, Z; Yu, K; Cui, YY; Ying, C; Hartzell, C				Qiang, Zhi; Yu, Kuai; Cui, Yuan Yuan; Ying, Carl; Hartzell, Criss			Activation of bestrophin Cl- channels is regulated by C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR DYSTROPHY; MOUSE BESTROPHIN-2; CHLORIDE CHANNELS; FAMILY; GENE; IDENTIFICATION; TRANSDUCTION; PROTEIN; VMD2	Bestrophins ( VMD2, VMD2L1, VMD2L2, and VMD2L3) are a new family of anion channels. The mechanisms of their regulation are not yet well understood. Recently, we found that a domain ( amino acids 356-364) in the C terminus of mouse VMD2L3 ( mBest3) inhibited channel activity when it was expressed in HEK293 cells ( Qu, Z., Cui, Y., and Hartzell, H. C. ( 2006) FEBS Lett. 580, 2141-2214). Here we show that this auto-inhibitory ( AI) domain in mBest3 and human ( h) Best3 is composed of seven critical residues, (356)IPSFLGS(362). Replacement of any residue ( except Pro(357)) in the domain with alanine activated Cl- currents. Substitution of Pro357 with other amino acids, especially phenylalanine, did activate currents. Membrane biotinylation demonstrated that nonfunctional mBest3 protein was trafficked to the plasma membrane, implying that the AI domain inhibited channel gating but not trafficking. mBest3-F359A and hBest3-G361A mutations induced outwardly rectifying currents, suggesting that the AI domain is associated with the channel pore or gating mechanism. Supporting this suggestion, the mBest3 AI domain was demonstrated to be located within a membrane-associated region. When the wild-type mBest3 C terminus ( amino acids 292-669) was expressed in HEK293 cells, the protein was located mainly in the particulate fraction, but it became soluble when a sequence containing the AI domain was deleted ( Delta 353-404). There is an AI domain( (357)QPSFQGS(363)) in mouse VMD2L1( mBest2) as well, but its inhibitory effect is competed by a downstream facilitatory sequence ( amino acids 405-454). These results suggest that an auto-inhibitory mechanism in C termini may be universal among bestrophins investigated in the study.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University	Qiang, Z (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 615 Michael St,535 Whitehead Bldg, Atlanta, GA 30322 USA.	zqu@emory.edu			NATIONAL EYE INSTITUTE [R01EY014852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060448] Funding Source: NIH RePORTER; NEI NIH HHS [EY014852] Funding Source: Medline; NIGMS NIH HHS [GM60448] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chien LT, 2006, J GEN PHYSIOL, V128, P247, DOI 10.1085/jgp.200609581; Kramer F, 2004, CYTOGENET GENOME RES, V105, P107, DOI 10.1159/000078016; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Pifferi S, 2006, P NATL ACAD SCI USA, V103, P12929, DOI 10.1073/pnas.0604505103; Qu ZQ, 2007, FEBS LETT, V581, P580, DOI 10.1016/j.febslet.2007.01.012; Qu ZQ, 2006, J NEUROSCI, V26, P5411, DOI 10.1523/JNEUROSCI.5500-05.2006; Qu ZQ, 2006, FEBS LETT, V580, P2141, DOI 10.1016/j.febslet.2006.03.025; Qu ZQ, 2004, J GEN PHYSIOL, V124, P371, DOI 10.1085/jgp.200409108; Qu ZQ, 2004, J GEN PHYSIOL, V123, P327, DOI 10.1085/jgp.200409031; Qu ZQ, 2003, J BIOL CHEM, V278, P49563, DOI 10.1074/jbc.M308414200; SORIA RB, 2006, J BIOL CHEM; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200	17	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17460	17467		10.1074/jbc.M701043200	http://dx.doi.org/10.1074/jbc.M701043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442670	hybrid			2022-12-25	WOS:000247084500016
J	Periz, J; Gill, AC; Hunt, L; Brown, P; Tomley, FM				Periz, Javier; Gill, Andrew C.; Hunt, Lawrence; Brown, Philip; Tomley, Fiona M.			The microneme proteins EtMIC4 and EtMIC5 of Eimeria tenella form a novel, ultra-high molecular mass protein complex that binds target host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PRE-KALLIKREIN; COAGULATION-FACTOR-XI; TOXOPLASMA-GONDII; APICOMPLEXAN PARASITES; APPLE DOMAINS; ACTIN CYTOSKELETON; ADHESION COMPLEX; SURFACE ADHESINS; MAMMALIAN-CELLS; MYOSIN-A	Eimeria tenella, in common with other parasitic protozoa of the phylum Apicomplexa, invades host cells using an actino-myosin-powered "glideosome" complex and requires the secretion of adhesive proteins from the microneme organelles onto the parasite surface. Microneme proteins of E. tenella include EtMIC4, a transmembrane protein that has multiple thrombospondin type I domains and calcium-binding epidermal growth factor-like domains in its extracellular domain, and EtMIC5, a soluble protein composed of 11 tandemly repeated domains that belong to the plasminogen-apple-nematode superfamily. Weshow here that EtMIC4 and EtMIC5 interact to form an oligomeric, ultrahigh molecular mass protein complex. The complex was purified from lysed parasites by non-denaturing techniques, and the stoichiometry was shown to be [EtMIC4] 2:[EtMIC5] 1, with an octamer of EtMIC4 bound noncovalently to a tetramer of EtMIC5. The complex is formed within the parasite secretory pathway and is maintained after secretion onto the surface of the parasite. The purified complex binds to a number of epithelial cell lines in culture. Identification and characterization of this complex contributes to an overall understanding of the role of multimolecular protein complexes in specific interactions between pathogens and their hosts during infection.	Inst Anim Hlth, Newbury RG20 7NN, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tomley, FM (corresponding author), Inst Anim Hlth, Newbury RG20 7NN, Berks, England.	Fiona.tomley@bbsrc.ac.uk	Gill, Andrew C/A-5219-2009; Gill, ANdrew/GRO-1248-2022; Tomley, Fiona/GWM-9070-2022	Gill, Andrew C/0000-0001-5201-9473; Tomley, Fiona/0000-0003-2188-8013	BBSRC [BBS/E/A/00001663] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877, BBS/E/I/00001141, BBS/E/A/00001663] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Brown Philip J., 2003, Journal of Structural and Functional Genomics, V4, P227, DOI 10.1023/B:JSFG.0000016118.87333.03; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brown PJ, 2001, FEBS LETT, V497, P31, DOI 10.1016/S0014-5793(01)02424-3; Bumstead J, 2000, MOL BIOCHEM PARASIT, V110, P311, DOI 10.1016/S0166-6851(00)00280-2; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 2005, MOL MICROBIOL, V55, P1617, DOI 10.1111/j.1365-2958.2005.04483.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JM, 2006, MOL BIOL CELL, V17, P4551, DOI 10.1091/mbc.E06-01-0064; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Jewett TJ, 2004, J BIOL CHEM, V279, P9362, DOI 10.1074/jbc.M312590200; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Keeley A, 2004, TRENDS CELL BIOL, V14, P528, DOI 10.1016/j.tcb.2004.08.002; KING CA, 1988, PARASITOL TODAY, V4, P315, DOI 10.1016/0169-4758(88)90113-5; Klein H, 1998, GLYCOCONJUGATE J, V15, P147, DOI 10.1023/A:1006964105349; Lourenco EV, 2001, GLYCOBIOLOGY, V11, P541, DOI 10.1093/glycob/11.7.541; Lovett JL, 2003, J CELL SCI, V116, P3009, DOI 10.1242/jcs.00596; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Meissner M, 2002, SCIENCE, V298, P837, DOI 10.1126/science.1074553; Meissner M, 2002, J CELL SCI, V115, P563; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; Periz J, 2005, MOL BIOCHEM PARASIT, V143, P192, DOI 10.1016/j.molbiopara.2005.06.003; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; Robibaro B, 2001, INT J PARASITOL, V31, P1343, DOI 10.1016/S0020-7519(01)00252-1; Rodriguez-Boulan E, 2005, BBA-MOL CELL RES, V1744, P455, DOI 10.1016/j.bbamcr.2005.04.007; Rosen H, 2004, BIOCHEM BIOPH RES CO, V315, P671, DOI 10.1016/j.bbrc.2004.01.106; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; Ryan R, 2000, INT J PARASITOL, V30, P1493, DOI 10.1016/S0020-7519(00)00116-8; Saouros S, 2005, J BIOL CHEM, V280, P38583, DOI 10.1074/jbc.C500365200; SHIRLEY MW, 1995, BIOTECHNOLOGY GUIDEL, P1; Tomley F, 1997, METHODS, V13, P171, DOI 10.1006/meth.1997.0509; Tomley FM, 2001, INT J PARASITOL, V31, P1303, DOI 10.1016/S0020-7519(01)00255-7; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; Witcombe DA, 2003, INT J PARASITOL, V33, P691, DOI 10.1016/S0020-7519(03)00086-9	48	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16891	16898		10.1074/jbc.M702407200	http://dx.doi.org/10.1074/jbc.M702407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426025	Green Accepted, hybrid			2022-12-25	WOS:000246946500021
J	Tian, Y; Zhang, Y; Zhong, B; Wang, YY; Diao, FC; Wang, RP; Zhang, M; Chen, DY; Zhai, ZH; Shu, HB				Tian, Yang; Zhang, Yan; Zhong, Bo; Wang, Yan-Yi; Diao, Fei-Ci; Wang, Rui-Peng; Zhang, Min; Chen, Dan-Ying; Zhai, Zhong-He; Shu, Hong-Bing			RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappa B activation by targeting TAB2/3 for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; INTERACTING PROTEIN; MOLECULAR-CLONING; KINASE; IRAK; FAMILY; TRAF6; IL-1; IDENTIFICATION; BINDING	Inflammation is a homeostatic mechanism that limits the effects of infectious agents. Tumor necrosis factor (TNF) and interleukin (IL)-1 are two cytokines that induce inflammation through activation of the transcription factor NF-kappa B. Various studies have suggested that two homologous and structurally related adapter proteins TAB2 and TAB3 play redundant roles in TNF- and IL-1-mediated NF-kappa B activation pathways. Both TAB2 and TAB3 contain CUE, coiled-coil, and nuclear protein localization 4 zinc finger (NZF) domains. The NZF domains of TAB2/ 3 are critical for TAB2/ 3 to bind to Lys63-linked polyubiquitin chains of other adaptor proteins, such as receptor-interacting protein and TRAF6, which are two signaling proteins essential for TNF- and IL-1-induced NF-kappa B activation, respectively. In a search for proteins containing NZF domains conserved with those of TAB2/ 3, we identified RBCK1, which has been shown to act as an E3 ubiquitin ligase in iron metabolism. Overexpression of RBCK1 negatively regulates TAB2/ 3-mediated and TNF- and IL-1-induced NF-kappa B activation, whereas knockdown of RBCK1 by RNA interference potentiates TNF- and IL-1-induced NF-kappa B activation. RBCK1 physically interacts with TAB2/ 3 and facilitates degradation of TAB2/ 3 through a proteasome-dependent process. Taken together, our findings suggest that RBCK1 is involved in negative regulation of inflammatory signaling triggered by TNF and IL-1 through targeting TAB2/ 3 for degradation.	Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Wuhan University; Peking University	Shu, HB (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	shuh@whu.edu.cn	Wang, Ruipeng/I-1407-2013	Wang, Ruipeng/0000-0002-1003-1420				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tatematsu K, 2005, J BIOL CHEM, V280, P22937, DOI 10.1074/jbc.M413476200; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Van der Reijden BA, 1999, PROTEIN SCI, V8, P1557, DOI 10.1110/ps.8.7.1557; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952	38	54	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16776	16782		10.1074/jbc.M701913200	http://dx.doi.org/10.1074/jbc.M701913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17449468	hybrid			2022-12-25	WOS:000246946500009
J	Zhang, ZQ; Klatt, A; Gilmour, DS; Henderson, AJ				Zhang, Zhiqiang; Klatt, Alicia; Gilmour, David S.; Henderson, Andrew J.			Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERMINAL REPEAT; TEFB-MEDIATED PHOSPHORYLATION; TAT-ACTIVATED TRANSCRIPTION; P-TEFB; POSTINTEGRATION LATENCY; HISTONE ACETYLATION; TYPE-1 PROMOTER; HSP70 PROMOTER; CELL-LINE; IN-VITRO	Human immunodeficiency virus (HIV) transcription requires virally encoded Tat and the P-TEFb protein complex, which together associate with the Tat-activating region, a structured region in the nascent transcript. P-TEFb phosphorylates proteins in the transcription elongation complex, including RNA polymerase II (pol II), to stimulate elongation and to overcome premature termination. However, the status of the elongation complex on the HIV long terminal repeat (LTR) in a repressed state is not known. Chromatin immunoprecipitation demonstrated that NELF, a negative transcription elongation factor, was associated with the LTR. Depleting NELF increased processive HIV transcription and replication. Mapping pol II on the LTR showed that pol II was paused and that NELF depletion released pol II. Decreasing NELF also correlated with displacement of a positioned nucleosome and increased acetylation of histone H4, suggesting coupling of transcription elongation and chromatin remodeling. Previous work has indicated that the Tat-activating region plays a critical role in regulating transcription from the LTR. Our results reveal an earlier stage, mediated by NELF, when repression occurs at the HIV LTR.	Penn State Univ, Ctr Mol Immunol & Infect Dis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Grad Program Pathobiol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Henderson, AJ (corresponding author), Boston Univ, Sch Med, Dept Med, Sect Infect Dis,Ctr HIV AIDS Care & Res, EBRC,650 Albany St, Boston, MA 02118 USA.	andrew.henderson@bmc.org	Koukam, Abderrafiaa A/J-2860-2013	Koukam, Abderrafiaa A/0000-0002-7383-5143; Henderson, Andrew/0000-0002-9299-5302	NIAID NIH HHS [AI62467] Funding Source: Medline; NIGMS NIH HHS [GM47477] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI062467, R01AI062467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agbottah E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-48; Aida M, 2006, MOL CELL BIOL, V26, P6094, DOI 10.1128/MCB.02366-05; Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Benjamin LR, 1998, NUCLEIC ACIDS RES, V26, P1051, DOI 10.1093/nar/26.4.1051; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Emiliani S, 1996, P NATL ACAD SCI USA, V93, P6377, DOI 10.1073/pnas.93.13.6377; Emiliani S, 1998, J VIROL, V72, P1666, DOI 10.1128/JVI.72.2.1666-1670.1998; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; Henderson A, 2004, MOL CELL BIOL, V24, P389, DOI 10.1128/MCB.24.1.389-397.2004; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1992, J BIOL CHEM, V267, P17891; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; Kim YK, 2006, EMBO J, V25, P3596, DOI 10.1038/sj.emboj.7601248; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lee ES, 2002, VIROLOGY, V299, P20, DOI 10.1006/viro.2002.1500; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Ping Yueh-Hsin, 2004, Retrovirology, V1, P46, DOI 10.1186/1742-4690-1-46; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Pumfery A, 2003, CURR HIV RES, V1, P343, DOI 10.2174/1570162033485186; Raha T, 2005, PLOS BIOL, V3, P221, DOI 10.1371/journal.pbio.0030044; Rao JN, 2006, BIOCHEM J, V400, P449, DOI 10.1042/BJ20060421; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wu CH, 2005, NUCLEIC ACIDS RES, V33, P1269, DOI 10.1093/nar/gki274; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamaguchi Y, 2002, MOL CELL BIOL, V22, P2918, DOI 10.1128/MCB.22.9.2918-2927.2002; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8	48	81	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16981	16988		10.1074/jbc.M610688200	http://dx.doi.org/10.1074/jbc.M610688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17442680	hybrid			2022-12-25	WOS:000246946500031
J	Litterst, C; Georgakopoulos, A; Shioi, J; Ghersi, E; Wisniewski, T; Wang, R; Ludwig, A; Robakis, NK				Litterst, Claudia; Georgakopoulos, Anastasios; Shioi, Junichi; Ghersi, Enrico; Wisniewski, Thomas; Wang, Rong; Ludwig, Andreas; Robakis, Nikolaos K.			Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-CELL ADHESION; RECEPTOR TYROSINE KINASES; GAMMA-SECRETASE; EPH RECEPTORS; N-CADHERIN; CLEAVAGE; PRESENILIN-1; ENDOCYTOSIS; EPHRINS	Binding of EphB receptors to ephrinB ligands on the surface of adjacent cells initiates signaling cascades that regulate angiogenesis, axonal guidance, and neuronal plasticity. These functions require processing of EphB receptors and removal of EphB-ephrinB complexes from the cell surface, but the mechanisms involved are poorly understood. Here we show that the ectodomain of EphB2 receptor is released to extracellular space following cleavage after EphB2 residue 543. The remaining membrane-associated fragment is cleaved by the presenilin-dependent gamma-secretase activity after EphB2 residue 569 releasing an intracellular peptide that contains the cytoplasmic domain of EphB2. This cleavage is inhibited by presenilin 1 familial Alzheimer disease mutations. Processing of EphB2 receptor depends on specific treatments: ephrinB ligand-induced processing requires endocytosis, and the ectodomain cleavage is sensitive to peptide inhibitor N-benzyloxycarbonyl-Val-Leu-leucinal but insensitive to metalloproteinase inhibitor GM6001. The ligand-induced processing takes place in endosomes and involves the rapid degradation of the extracellular EphB2. EphrinB ligand stimulates ubiquitination of EphB2 receptor. Calcium influx- and N-methyl-D-aspartic acid-induced processing of EphB2 is inhibited by GM6001 and ADAM10 inhibitors but not by N-benzyloxycarbonyl-Val-Leu-leucinal. This processing requires no endocytosis and promotes rapid shedding of extracellular EphB2, indicating that it takes place at the plasma membrane. Our data identify novel cleavages and modifications of EphB2 receptor and indicate that specific conditions determine the proteolytic systems and subcellular sites involved in the processing of this receptor.	NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Psychiat, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Neurosci, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Human Genet, New York, NY 10029 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Univ Hosp Rein, W Fael Tech Hochsch, Inst Mol Cardiovasc Res, D-52056 Aachen, Germany	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; New York University; RWTH Aachen University; RWTH Aachen University Hospital	Robakis, NK (corresponding author), NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Psychiat, 1 Gustave Levy Pl,Box 1229, New York, NY 10029 USA.	nikos.robakis@mssm.edu	Wisniewski, Thomas/Q-6525-2019; Robakis, Nikolaos/AAA-1838-2021; Ludwig, Andreas/I-5685-2012; Wang, Rong/A-8721-2009	Wisniewski, Thomas/0000-0002-3379-8966; Ludwig, Andreas/0000-0001-8536-4986; Georgakopoulos, Anastasios/0000-0001-8241-6306	NATIONAL CANCER INSTITUTE [R24CA088325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005138, R01AG017926, R37AG017926, R01AG008200] Funding Source: NIH RePORTER; NCI NIH HHS [CA088325, R24 CA088325] Funding Source: Medline; NIA NIH HHS [AG-17926, R01 AG008200, P50 AG005138, AG-08200, R01 AG017926, AG-05138, R37 AG017926] Funding Source: Medline; NINDS NIH HHS [R01 NS047229, NS-47229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbenante G, 2000, BIOCHEM BIOPH RES CO, V268, P133, DOI 10.1006/bbrc.2000.2098; Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Ellis C, 1996, ONCOGENE, V12, P1727; Fernandez-Botran R, 1999, CRIT REV CL LAB SCI, V36, P165, DOI 10.1080/10408369991239196; Georgakopoulos A, 2006, EMBO J, V25, P1242, DOI 10.1038/sj.emboj.7601031; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Ghosh A, 2002, SCIENCE, V295, P449, DOI 10.1126/science.1069391; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Mann F, 2003, J NEUROBIOL, V57, P323, DOI 10.1002/neu.10303; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Martinez A, 2005, BRAIN RES REV, V49, P211, DOI 10.1016/j.brainresrev.2005.02.001; McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pascall JC, 2004, BIOCHEM BIOPH RES CO, V317, P244, DOI 10.1016/j.bbrc.2004.03.039; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Robakis N.K., 2006, TRANSCRIPTION FACTOR, P399; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Uyen HD, 2002, J CELL SCI, V115, P3073; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamaguchi Y, 2004, CURR OPIN NEUROBIOL, V14, P288, DOI 10.1016/j.conb.2004.04.003; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	51	98	105	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16155	16163		10.1074/jbc.M611449200	http://dx.doi.org/10.1074/jbc.M611449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428795	Green Published, hybrid			2022-12-25	WOS:000246794300024
J	Xu, J; Bai, XH; Lodyga, M; Han, B; Xiao, H; Keshavjee, S; Hu, J; Zhang, HB; Yang, BB; Liu, MY				Xu, Jing; Bai, Xiao-Hui; Lodyga, Monika; Han, Bing; Xiao, Helan; Keshavjee, Shaf; Hu, Jim; Zhang, Haibo; Yang, Burton B.; Liu, Mingyao			XB130, a novel adaptor protein for signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; EPITHELIAL-CELLS; TNF-ALPHA; KAPPA-B; ACTIVATION; KINASE; EXPRESSION; FAMILY; CAS; PHOSPHORYLATION	Adaptor proteins are important mediators in signal transduction. In the present study, we report the cloning and characterization of a novel adaptor protein, XB130. This gene is located on human chromosome 10q25.3 and encodes a protein of 818 amino acids. It contains several Src homology ( SH)2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and a number of potential tyrosine or serine/ threonine phosphorylation sites. Endogenous XB130 interacts with c-Src tyrosine kinase. Their co-expression in COS-7 cells resulted in activation of c-Src and elevated tyrosine phosphorylation of multiple proteins, including XB130 itself. XB130 expression in HEK293 cells enhanced serum response element- and AP-1-dependent transcriptional activation mediated by c-Src. XB130 Delta N, an N-terminal deletion mutant lacking a putative SH3-binding motif and several putative SH2-binding sites, reduced its ability to mediate Src signal transduction. Down-regulation of endogenous XB130 with siRNA reduced c-Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3 beta, and altered cell cycles in human lung epithelial cells. These data suggest that XB130 as an adaptor may play an important role in the regulation of signal transduction and cellular functions.	Univ Hlth Netwrk, Div Cellular & Mol Biol, Toronto Gen Res Inst, Toronto, ON M5G 1L7, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Liu, MY (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Rm TMDT 2-814,101 Coll St, Toronto, ON M5G 1L7, Canada.	mingyao.liu@utoronto.ca		Keshavjee, Shaf/0000-0003-4547-8094; Hu, Jim/0000-0001-9134-7103; Liu, Mingyao/0000-0002-9188-8417				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cherezova L, 2002, FRONT BIOSCI-LANDMRK, V7, pD164, DOI 10.2741/cherezov; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Flynn DC, 2001, ONCOGENE, V20, P6270, DOI 10.1038/sj.onc.1204769; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gregorieff A, 1998, J BIOL CHEM, V273, P13217, DOI 10.1074/jbc.273.21.13217; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Han B, 2005, J IMMUNOL, V175, P8303, DOI 10.4049/jimmunol.175.12.8303; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Han Bing, 2005, Proc Am Thorac Soc, V2, P181, DOI 10.1513/pats.200501-008AC; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Liu M, 2001, SEPSIS ORGAN DYSFUNC, P37; Lodyga M, 2002, AM J PHYSIOL-LUNG C, V283, pL265, DOI 10.1152/ajplung.00492.2001; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; OKADA M, 1991, J BIOL CHEM, V266, P24249; Okutani D, 2006, AM J PHYSIOL-LUNG C, V291, pL129, DOI 10.1152/ajplung.00261.2005; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Roger T, 1998, BIOCHEM J, V330, P429, DOI 10.1042/bj3300429; SCHLESSINGER I, 2003, SCI STKE, pRE12; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tang PS, 2006, J CELL PHYSIOL, V209, P457, DOI 10.1002/jcp.20751; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Treisman R, 1990, Semin Cancer Biol, V1, P47; Tsygankov AY, 2003, FRONT BIOSCI-LANDMRK, V8, pS595, DOI 10.2741/1106; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu KP, 2006, INVEST OPHTH VIS SCI, V47, P2832, DOI 10.1167/iovs.05-1361; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yeh M, 2004, J BIOL CHEM, V279, P30175, DOI 10.1074/jbc.M312198200; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16401	16412		10.1074/jbc.M701684200	http://dx.doi.org/10.1074/jbc.M701684200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412687	hybrid			2022-12-25	WOS:000246794300048
J	Zhang, W; Liu, WQ; Innocenti, F; Ratain, MJ				Zhang, Wei; Liu, Wanqing; Innocenti, Federico; Ratain, Mark J.			Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A Isoforms	PLOS ONE			English	Article								UDP-glucuronosyltransferases 1A isoforms belong to a superfamily of microsomal enzymes responsible for glucuronidation of numerous endogenous and exogenous compounds. The nine functional UGT1A isoforms are encoded by a single UGT1A gene locus with multiple first exons. The expression of the UGT1A transcripts was measured by quantitative RT-PCR in 23 normal human tissues. The tissue-specific expression patterns were observed in 13 tissues. To understand the regulation mechanism that is responsible for the tissue-specific expression patterns, we scanned the DNA sequence alignments of the putative promoter regions, exon 1 sequences and intron 1 sequences for those expression-pattern-linked nucleotides. Using one of the expression-pattern-linked nucleotides for livers as an example, we showed that a database comprised of these expression-pattern-linked nucleotides could be used to generate focused hypotheses on the problem of tissue-specific expression, which is critical for tissue-specific pharmacodynamics of anticancer drugs.	[Zhang, Wei; Liu, Wanqing; Innocenti, Federico; Ratain, Mark J.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Innocenti, Federico; Ratain, Mark J.] Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA; [Innocenti, Federico; Ratain, Mark J.] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Ratain, MJ (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.	mratain@medicine.bsd.uchicago.edu		Liu, Wanqing/0000-0001-7727-6900	NIH/NIGMS [U01GM61393, U01GM61374]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061374, U01GM061393] Funding Source: NIH RePORTER	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This Pharmacogenetics of Anticancer Agents Research (PAAR) Group (http://pharmacogenetics.org) study was supported by the NIH/NIGMS grant U01GM61393. Data will be deposited into PharmGKB (supported by NIH/NIGMS Pharmacogenetics Research Network and Database grant U01GM61374, http://pharmgkb.org/).	Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BUCKLEY DB, 2006, DRUG METAB DISPOS; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Desai AA, 2003, PHARMACOGENETICS, V13, P517, DOI 10.1097/00008571-200308000-00010; Dutton G.F., 1980, GLUCURONIDATION DRUG; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Green MD, 1996, DRUG METAB DISPOS, V24, P356; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HARDING D, 1990, ANN HUM GENET, V54, P17, DOI 10.1111/j.1469-1809.1990.tb00356.x; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	18	22	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e396	10.1371/journal.pone.0000396	http://dx.doi.org/10.1371/journal.pone.0000396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460763	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445600010
J	Strid, J; Tan, LA; Strobel, S; Londei, M; Callard, R				Strid, Jessica; Tan, Lee Aun; Strobel, Stephan; Londei, Marco; Callard, Robin			Epicutaneous Immunization with Type II Collagen Inhibits both Onset and Progression of Chronic Collagen-Induced Arthritis	PLOS ONE			English	Article								Epicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we investigate whether the autoimmune inflammatory response of chronic collagen-induced arthritis (CCIA) in DBA/1-TCR-beta Tg mice can be modified by epicutaneous immunization. We show that epicutaneous immunization with type II collagen (CII) inhibited development and progression of CCIA and, importantly, also ameliorated ongoing disease as indicated by clinical scores of disease severity, paw swelling and joints histology. Treated mice show reduced CII-driven T cell proliferation and IFN-gamma production, as well as significantly lower levels of CII-specific IgG2a serum antibodies. In contrast, CII-driven IL-4 production and IgE antibody levels were increased consistent with skewing of the CII response from Th1 to Th2 in treated mice. IL-4 production in treated mice was inversely correlated with disease severity. Moreover, T cells from treated mice inhibited proliferation and IFN-gamma production by T cells from CCIA mice, suggesting induction of regulatory T cells that actively inhibit effector responses in arthritic mice. The levels of CD4(+)CD25(+) T cells were however not increased following epicutaneous CII treatment. Together, these results suggest that epicutaneous immunization may be used as an immune-modulating procedure to actively re-programme pathogenic Th1 responses, and could have potential as a novel specific and simple treatment for chronic autoimmune inflammatory diseases such as rheumatoid arthritis.	[Strid, Jessica; Callard, Robin] UCL, Inst Child Hlth, Immunobiol Unit, London, England; [Tan, Lee Aun; Londei, Marco] UCL, Inst Child Hlth, Autoimmun & Gastroenterol Unit, London, England; [Strobel, Stephan] Peninsula Postgrad Hlth Inst, Plymouth, Devon, England	University of London; University College London; University of London; University College London; University of Plymouth	Strid, J (corresponding author), UCL, Inst Child Hlth, Immunobiol Unit, London, England.	jessica.strid@kcl.ac.uk		Strid, Jessica/0000-0003-3690-2201	UK NHS Executive; Arthritis Research Campaign (ARC) UK	UK NHS Executive; Arthritis Research Campaign (ARC) UK(Versus Arthritis)	Research at the Institute of Child Health and Great Ormond Street Hospital for Children National Health Service (NHS) Trust benefits from research and development funding received from the UK NHS Executive. This work was additionally funded by the Arthritis Research Campaign (ARC) UK. Nothing to disclose.	Butler DM, 1999, EUR J IMMUNOL, V29, P2205, DOI 10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z; Bynoe MS, 2003, IMMUNITY, V19, P317, DOI 10.1016/S1074-7613(03)00239-5; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 2001, NAT IMMUNOL, V2, P771, DOI 10.1038/ni0901-771; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Herrick CA, 2003, J IMMUNOL, V170, P2488, DOI 10.4049/jimmunol.170.5.2488; Horsfall AC, 1997, J IMMUNOL, V159, P5687; Itoh M, 1999, J IMMUNOL, V162, P5317; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Malfait AM, 1998, CLIN EXP IMMUNOL, V111, P377; Mauri C, 1997, J IMMUNOL, V159, P5032; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Miossec P, 1997, ARTHRITIS RHEUM-US, V40, P2105, DOI 10.1002/art.1780401203; MORI L, 1992, J EXP MED, V176, P381, DOI 10.1084/jem.176.2.381; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Partidos CD, 2004, VACCINE, V22, P2385, DOI 10.1016/j.vaccine.2003.11.063; Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Strid J, 2006, IMMUNOLOGY, V119, P27, DOI 10.1111/j.1365-2567.2006.02401.x; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szczepanik M, 2005, J NEUROIMMUNOL, V164, P105, DOI 10.1016/j.jneuroim.2005.04.007; Szczepanik M, 2005, IMMUNOLOGY, V115, P42, DOI 10.1111/j.1365-2567.2005.02127.x; von Herrath MG, 1997, RES IMMUNOL, V148, P541, DOI 10.1016/S0923-2494(98)80148-X; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Wang LF, 1996, J IMMUNOL, V156, P4079; Wing K, 2006, INT IMMUNOL, V18, P991, DOI 10.1093/intimm/dxl044; Yates A, 2004, J THEOR BIOL, V231, P181, DOI 10.1016/j.jtbi.2004.06.013; YOSHINO S, 1995, ARTHRITIS RHEUM, V38, P1092, DOI 10.1002/art.1780380811; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zivny JH, 2001, CLIN IMMUNOL, V101, P158, DOI 10.1006/clim.2001.5103	39	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e387	10.1371/journal.pone.0000387	http://dx.doi.org/10.1371/journal.pone.0000387			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440622	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445500017
J	Wile, D; Balaban, E				Wile, Daryl; Balaban, Evan			An Auditory Neural Correlate Suggests a Mechanism Underlying Holistic Pitch Perception	PLOS ONE			English	Article							FREQUENCY-FOLLOWING RESPONSES; DISTORTION PRODUCTS; ORIGINS	Current theories of auditory pitch perception propose that cochlear place (spectral) and activity timing pattern (temporal) information are somehow combined within the brain to produce holistic pitch percepts, yet the neural mechanisms for integrating these two kinds of information remain obscure. To examine this process in more detail, stimuli made up of three pure tones whose components are individually resolved by the peripheral auditory system, but that nonetheless elicit a holistic, "missing fundamental" pitch percept, were played to human listeners. A technique was used to separate neural timing activity related to individual components of the tone complexes from timing activity related to an emergent feature of the complex (the envelope), and the region of the tonotopic map where information could originate from was simultaneously restricted by masking noise. Pitch percepts were mirrored to a very high degree by a simple combination of component-related and envelope-related neural responses with similar timing that originate within higher-frequency regions of the tonotopic map where stimulus components interact. These results suggest a coding scheme for holistic pitches whereby limited regions of the tonotopic map (spectral places) carrying envelope- and component-related activity with similar timing patterns selectively provide a key source of neural pitch information. A similar mechanism of integration between local and emergent object properties may contribute to holistic percepts in a variety of sensory systems.	[Wile, Daryl; Balaban, Evan] McGill Univ, Behav Neurosci Program, Montreal, PQ, Canada; [Balaban, Evan] Scuola Int Super Studi Avanzati, Cognit Neurosci Sector, Trieste, Italy	McGill University; International School for Advanced Studies (SISSA)	Balaban, E (corresponding author), McGill Univ, Behav Neurosci Program, Montreal, PQ, Canada.	evan.balaban@mcgill.ca	Balaban, Evan/AAV-2353-2020	Balaban, Evan/0000-0002-0391-3433	Natural Sciences and Engineering Research Council of Canada; Canadian Fund for Innovation; Scuola Internazionale Superiore di Studi Avanzati (SISSA)	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Fund for Innovation; Scuola Internazionale Superiore di Studi Avanzati (SISSA)	Funding: This work was supported by the Natural Sciences and Engineering Research Council of Canada, the Canadian Fund for Innovation, and the Scuola Internazionale Superiore di Studi Avanzati (SISSA).	Bendor D, 2005, NATURE, V436, P1161, DOI 10.1038/nature03867; Bhagat SP, 2004, HEARING RES, V193, P51, DOI 10.1016/j.heares.2004.04.005; BOER ED, 1969, J ACOUST SOC AM, V46, P1579, DOI 10.1121/1.1911906; Castellan NJ, 1988, NONPARAMETRIC STAT B; Chialvo DR, 2003, CHAOS, V13, P1226, DOI 10.1063/1.1617771; De Cheveigne A, 2005, PITCH NEURAL CODING, P169; GALBRAITH GC, 1994, ELECTROEN CLIN NEURO, V92, P321, DOI 10.1016/0168-5597(94)90100-7; GARDI J, 1979, AUDIOLOGY, V18, P353; GOBLICK TJ, 1969, J ACOUST SOC AM, V46, P924, DOI 10.1121/1.1911812; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GREENBERG S, 1987, HEARING RES, V25, P91, DOI 10.1016/0378-5955(87)90083-9; JARAMILLO F, 1993, NATURE, V364, P527, DOI 10.1038/364527a0; Julicher F, 2001, P NATL ACAD SCI USA, V98, P9080, DOI 10.1073/pnas.151257898; McAlpine D, 2004, J NEUROPHYSIOL, V92, P1295, DOI 10.1152/jn.00034.2004; Pandya Pritesh K, 2004, J Am Acad Audiol, V15, P184, DOI 10.3766/jaaa.15.3.2; PATTERSON RD, 1973, J ACOUST SOC AM, V53, P1565, DOI 10.1121/1.1913504; Plack CJ, 2005, PITCH NEURAL CODING, P7, DOI 10.1007/0-387-28958-5_2; RICKMAN MD, 1991, J ACOUST SOC AM, V89, P2818, DOI 10.1121/1.400720; RITSMA RJ, 1964, J ACOUST SOC AM, V36, P1637, DOI 10.1121/1.1919257; ROBLES L, 1991, NATURE, V349, P413, DOI 10.1038/349413a0; SMITH JC, 1975, ELECTROEN CLIN NEURO, V39, P465, DOI 10.1016/0013-4694(75)90047-4; SMOORENBURG GF, 1976, J ACOUST SOC AM, V59, P945, DOI 10.1121/1.380954; SOHMER H, 1977, ELECTROEN CLIN NEURO, V42, P656, DOI 10.1016/0013-4694(77)90282-6; TURNER RS, 1977, BRIT J HIST SCI, V10, P1, DOI 10.1017/S0007087400015089; WORDEN FG, 1968, ELECTROEN CLIN NEURO, V25, P42, DOI 10.1016/0013-4694(68)90085-0; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	31	22	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e369	10.1371/journal.pone.0000369	http://dx.doi.org/10.1371/journal.pone.0000369			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426817	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445400009
J	Tam, CC; O'Brien, SJ; Petersen, I; Islam, A; Hayward, A; Rodrigues, LC				Tam, Clarence C.; O'Brien, Sarah J.; Petersen, Irene; Islam, Amir; Hayward, Andrew; Rodrigues, Laura C.			Guillain-Barre Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-Barr Virus in the General Practice Research Database	PLOS ONE			English	Article							JEJUNI INFECTION; ANTIBODY-RESPONSES; ASSOCIATION; GALACTOCEREBROSIDE; NEUROPATHY; SPECTRUM; FEATURES; ENGLAND; RATES	Background. A number of infectious agents have previously been suggested as risk factors for the development of Guillain-Barre syndrome (GBS), but robust epidemiologic evidence for these associations is lacking. Methods and Findings. We conducted a nested case-control study using data from the United Kingdom General Practice Research Database between 1991 and 2001. Controls were matched to cases on general practice clinic, sex, year of birth and date of outcome diagnosis in their matched case. We found positive associations between GBS and infection with Campylobacter, Epstein-Barr virus and influenza-like illness in the previous two months, as well as evidence of a protective effect of influenza vaccination. After correction for under-ascertainment of Campylobacter infection, the excess risk of GBS following Campylobacter enteritis was 60-fold and 20% of GBS cases were attributable to this pathogen. Conclusions. Our findings indicate a far greater excess risk of GBS among Campylobacter enteritis patients than previously reported by retrospective serological studies. In addition, they confirm previously suggested associations between infection due to Epstein-Barr virus infection and influenza-like illness and GBS. Finally, we report evidence of a protective effect of influenza vaccination on GBS risk, which may be mediated through protection against influenza disease, or result from a lower likelihood of vaccination among those with recent infection. Cohort studies of GBS incidence in this population would help to clarify the burden of GBS due to influenza, and any potential protective effect of influenza vaccination.	[Tam, Clarence C.; Rodrigues, Laura C.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, London WC1, England; [Tam, Clarence C.] Hlth Protect Agcy Ctr Infect, Environm & Enter Dis Dept, London, England; [O'Brien, Sarah J.] Univ Manchester, Sch Med, Div Med & Neurosci, Salford, Lancs, England; [Petersen, Irene; Islam, Amir; Hayward, Andrew] UCL, Dept Primary Care & Populat Sci, London, England	University of London; London School of Hygiene & Tropical Medicine; Health Protection Agency; University of Manchester; University of London; University College London	Tam, CC (corresponding author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, London WC1, England.	clarence.tam@lshtm.ac.uk	Hayward, Andrew C/C-3268-2013; RODRIGUES, LAURA CUNHA/AAO-4130-2021; Petersen, Irene/I-2751-2012; Petersen, Irene/C-5702-2009	Hayward, Andrew C/0000-0002-3549-6232; Petersen, Irene/0000-0002-0037-7524; O'Brien, Sarah Jane/0000-0003-2896-8999; Rodrigues, Laura Cunha/0000-0001-9008-660X; Tam, Clarence/0000-0003-1697-286X	Medical Research Council [G0601726] Funding Source: Medline; MRC [G0601726] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ang CW, 2002, J NEUROIMMUNOL, V130, P179, DOI 10.1016/S0165-5728(02)00209-6; BERTRAND A, 1971, PRESSE MED, V79, P2328; Bogliun G, 2004, ACTA NEUROL SCAND, V110, P100, DOI 10.1111/j.1600-0404.2004.00272.x; Cawthraw SA, 2002, CLIN EXP IMMUNOL, V130, P101, DOI 10.1046/j.1365-2249.2002.01966.x; COUGHLIN SS, 1994, EPIDEMIOL REV, V16, P51, DOI 10.1093/oxfordjournals.epirev.a036144; ENDERS U, 1993, ANN NEUROL, V34, P136, DOI 10.1002/ana.410340208; FLEGAL KM, 1986, AM J EPIDEMIOL, V123, P736, DOI 10.1093/oxfordjournals.aje.a114294; Guarino M, 1998, Neuroepidemiology, V17, P296; Hao Q, 1998, J NEUROIMMUNOL, V81, P116, DOI 10.1016/S0165-5728(97)00166-5; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; Hughes RA, 2006, ARCH INTERN MED, V166, P1301, DOI 10.1001/archinte.166.12.1301; Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110; Ju YY, 2004, J NEUROIMMUNOL, V149, P160, DOI 10.1016/j.jneuroim.2003.12.011; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; Kinnunen E, 1998, AM J EPIDEMIOL, V147, P69; Koga M, 1998, J NEUROIMMUNOL, V81, P138, DOI 10.1016/S0165-5728(97)00168-9; Kruger H, 1974, Psychiatr Neurol Med Psychol (Leipz), V26, P513; KUROKI S, 1993, ANN NEUROL, V33, P243, DOI 10.1002/ana.410330304; KUROKI S, 1991, PEDIATR INFECT DIS J, V10, P149, DOI 10.1097/00006454-199102000-00014; Lewis JD, 2005, PHARMACOEPIDEM DR S, V14, P443, DOI 10.1002/pds.1115; McCarthy N, 2001, AM J EPIDEMIOL, V153, P610, DOI 10.1093/aje/153.6.610; Migita M, 2001, Eur J Paediatr Neurol, V5, P83, DOI 10.1053/ejpn.2001.0470; MISHU B, 1993, ANN INTERN MED, V118, P947, DOI 10.7326/0003-4819-118-12-199306150-00006; Novak M, 1975, Cesk Neurol Neurochir, V38, P314; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973; Strid MA, 2001, CLIN DIAGN LAB IMMUN, V8, P314, DOI 10.1128/CDLI.8.2.314-319.2001; Susuki K, 2004, NEUROLOGY, V62, P949, DOI 10.1212/01.WNL.0000115123.42929.FD; Tam CC, 2003, CLIN INFECT DIS, V37, P307, DOI 10.1086/375845; Tam CC, 2006, J INFECT DIS, V194, P95, DOI 10.1086/504294; Tam CC, 2006, EMERG INFECT DIS, V12, P1880; Taylor BV, 2004, INTERN MED J, V34, P250, DOI 10.1111/j.1444-0903.2004.00517.x; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WELLS CEC, 1959, ARCH NEURO PSYCHIATR, V81, P699, DOI 10.1001/archneurpsyc.1959.02340180033005; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613	37	129	140	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e344	10.1371/journal.pone.0000344	http://dx.doi.org/10.1371/journal.pone.0000344			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406668	Green Published, gold, Green Accepted			2022-12-25	WOS:000207445300006
J	Ma, C; Ying, CY; Yuan, ZM; Song, B; Li, D; Liu, YL; Lai, BQ; Li, WM; Chen, RZ; Ching, YP; Li, MT				Ma, Chi; Ying, Chunyi; Yuan, Zhongmin; Song, Bin; Li, Dan; Liu, Yulin; Lai, Bingquan; Li, Wenming; Chen, Ruzhu; Ching, Yick-Pang; Li, Mingtao			dp5/HRK is a c-jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ENDOTHELIAL-CELLS; JNK PATHWAY; ACTIVATION; INDUCTION; SURVIVAL; PROTEIN; PHOSPHORYLATION; BIM; KINASE	In cerebellar granule neurons, a BH3-only Bcl-2 family member, death protein 5/harakiri, is up-regulated in a JNK-dependent manner during apoptosis induced by potassium deprivation. However, it is not clear whether c-Jun is directly involved in the induction of dp5. Here, we showed that the up-regulation of dp5, but not fas ligand and bim, after potassium deprivation was suppressed by the expression of a dominant negative form of c-Jun. Deletion analysis of the 5 '-flanking sequence of the dp5 gene revealed that a major responsive element responsible for the induction by potassium deprivation is an ATF binding site located at -116 to -109 relative to the transcriptional start site. Mutation of this site completely abolished promoter activation. Furthermore, a gel shift assay showed that a specific complex containing c-Jun and ATF2 recognized this site and increased in potassium-deprived cerebellar granule neurons. Chromatin immunoprecipitation demonstrated that c-Jun was able to bind to this site in vivo. Finally, we demonstrated that knockdown of Dp5 by small interfering RNA rescued neurons from potassium deprivation-induced apoptosis. Taken together, these results suggest that dp5 is a target gene of c-Jun and plays a critical role in potassium deprivation-induced apoptosis in cerebellar granule neurons.	Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Zhongshan Sch Med, Guangzhou 510089, Peoples R China; Sun Yat Sen Univ, Zhongshan Sch Med, Proteom Ctr, Guangzhou 510089, Peoples R China; Univ Hong Kong, Dept Pathol Biochem, Pokfulam, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Li, MT (corresponding author), Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Zhongshan Sch Med, 74 Zhongshan Rd 2, Guangzhou 510089, Peoples R China.	limt@mail.sysu.edu.cn	Ching, Yick Pang/C-4244-2009	, Chi/0000-0002-4171-0813; CHING, Yick Pang/0000-0002-6461-8358				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris CA, 2001, J BIOL CHEM, V276, P37754; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kalinec GM, 2005, P NATL ACAD SCI USA, V102, P16019, DOI 10.1073/pnas.0508053102; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Ma YH, 2003, MOL CANCER THER, V2, P73; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Shi LY, 2005, NEUROSCI LETT, V375, P7, DOI 10.1016/j.neulet.2004.10.082; Ueno Y, 1999, FEBS LETT, V457, P241, DOI 10.1016/S0014-5793(99)01049-2; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yin KJ, 2005, NEUROBIOL DIS, V20, P881, DOI 10.1016/j.nbd.2005.05.026; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	29	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30901	30909		10.1074/jbc.M608694200	http://dx.doi.org/10.1074/jbc.M608694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17428807	hybrid			2022-12-25	WOS:000250136300058
J	Li, Q; Dashwood, WM; Zhong, X; Nakagama, H; Dashwood, RH				Li, Q.; Dashwood, W. M.; Zhong, X.; Nakagama, H.; Dashwood, R. H.			Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1	ONCOGENE			English	Article						beta-catenin; Bcl-2; c-Myc; E2F1; wnt signaling; colorectal cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; APOPTOSIS; CELLS; INHIBITION; ACTIVATION; EPIGALLOCATECHIN-3-GALLATE; MUTATION; ELEMENT	beta-Catenin/T-cell factor (Tcf) signaling is constitutively active in the majority of human colorectal cancers, and there are accompanying changes in Bcl-2 expression. Similarly, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine(PhIP)-induced colon tumors in the rat have increased beta-catenin and elevated Bcl-2. To examine the possible direct transcriptional regulation of rat Bcl-2 by beta-catenin/Tcf, we cloned and characterized the corresponding promoter region and found 70.1% similarity with its human counterpart, BCL2. Bcl- 2 promoter activity was increased in response to LiCl and exogenous b-catenin, including oncogenic mutants of beta-catenin found in PhIP-induced colon tumors. Protein/DNA arrays identified E2F1, but not beta-catenin/Tcf, as interactingmost strongly with the rat Bcl- 2 promoter. Exogenous E2F1 increased the promoter activity of rat Bcl- 2, except in mutants lacking the E2F1 sites. As expected, b-catenin induced its downstream target c-Myc, as well as E2F1 and Bcl- 2, and this was blocked by siRNA to c-Myc or E2F1. These findings suggest an indirect pathway for Bcl- 2 overexpression in PhIP-induced colon tumors involving beta-catenin, c-Myc and E2F1.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Natl Canc Ctr, Tokyo, Japan	Oregon State University; National Cancer Center - Japan	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst, Weniger 503, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Dashwood, Roderick/AAF-2025-2020; Dashwood, Roderick H/E-9090-2011	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [CA65525, P01 CA090890-01A29001, R01 CA080176-05, R01 CA065525-09, P01 CA090890, P01 CA090890-01A20003, R01 CA080176, CA90890, CA80176, R29 CA065525, P01 CA090890-05, R01 CA065525, R01 CA065525-08] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; BEDI A, 1995, CANCER RES, V55, P1811; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Blumberg Stephen J, 2003, Vital Health Stat 1, P1; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2005, MUTAT RES-FUND MOL M, V591, P161, DOI 10.1016/j.mrfmmm.2005.03.029; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Fujiwara K, 2004, CARCINOGENESIS, V25, P1495, DOI 10.1093/carcin/bgh155; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; GROSS TM, 2000, DIABETES TECHNOL THE, V2, P19, DOI DOI 10.1089/15209150050214087; Harigai M, 1996, ONCOGENE, V12, P1369; Hayashi R, 1996, CANCER RES, V56, P4307; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang XH, 2003, INVEST OPHTH VIS SCI, V44, P347, DOI 10.1167/iovs.02-0198; Li QJ, 2004, J BIOL CHEM, V279, P45669, DOI 10.1074/jbc.M405025200; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Muller M J, 2001, Obes Rev, V2, P15; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ochiai M, 2003, AM J PATHOL, V163, P1607, DOI 10.1016/S0002-9440(10)63517-1; Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zeng GC, 2003, BBA-GENE STRUCT EXPR, V1625, P30, DOI 10.1016/S0167-4781(02)00573-0	32	52	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6194	6202		10.1038/sj.onc.1210438	http://dx.doi.org/10.1038/sj.onc.1210438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404573	Green Accepted			2022-12-25	WOS:000249401300010
J	Mott, JL; Kobayashi, S; Bronk, SF; Gores, GJ				Mott, J. L.; Kobayashi, S.; Bronk, S. F.; Gores, G. J.			mir-29 regulates Mcl-1 protein expression and apoptosis	ONCOGENE			English	Article						apoptosis; post-transcriptional regulation; cholangiocarcinoma; microRNA; TRAIL	CHOLANGIOCARCINOMA CELLS; INDUCE APOPTOSIS; RESISTANCE; CANCER; GENES; MICRORNAS; MECHANISM; LEUKEMIA; TARGETS; RELAPSE	Cellular expression of Mcl-1, an anti-apoptotic Bcl-2 family member, is tightly regulated. Recently, Bcl-2 expression was shown to be regulated by microRNAs, small endogenous RNA molecules that regulate protein expression through sequence-specific interaction with messenger RNA. By analogy, we reasoned that Mcl-1 expression may also be regulated by microRNAs. We chose human immortalized, but non-malignant, H69 cholangiocyte and malignant KMCH cholangiocarcinoma cell lines for these studies, because Mcl-1 is dysregulated in cells with the malignant phenotype. By in silico analysis, we identified a putative target site in the Mcl-1 mRNA for the mir-29 family, and found that mir-29b was highly expressed in cholangiocytes. Interestingly, mir-29b was downregulated in malignant cells, consistent with Mcl-1 protein upregulation. Enforced mir-29b expression reduced Mcl-1 protein expression in KMCH cells. This effect was direct, as mir-29b negatively regulated the expression of an Mcl-1 30 untranslated region (UTR)based reporter construct. Enforced mir-29b expression reduced Mcl-1 cellular protein levels and sensitized the cancer cells to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) cytotoxicity. Transfection of non-malignant cells ( that express high levels of mir-29) with a locked-nucleic acid antagonist of mir-29b increased Mcl-1 levels and reduced TRAIL-mediated apoptosis. Thus mir-29 is an endogenous regulator of Mcl-1 protein expression, and thereby, apoptosis.	Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Mott, Justin/0000-0002-2927-6962	NIDDK NIH HHS [R01 DK059427-08, R01 DK059427, DK59427, R56 DK059427] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059427, R56DK059427] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Neville PJ, 2002, NEOPLASIA, V4, P424, DOI 10.1038/sj.neo.7900254; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoon JH, 2002, CANCER RES, V62, P6500; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	32	662	719	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6133	6140		10.1038/sj.onc.1210436	http://dx.doi.org/10.1038/sj.onc.1210436			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404574	Green Accepted, Green Submitted			2022-12-25	WOS:000249401300003
J	Eijken, M; Swagemakers, S; Koedam, M; Steenbergen, C; Derkx, P; Uitterlinden, AG; van der Spek, PJ; Visser, JA; de Jong, FH; Pols, HAP; van Leeuwen, JPTM				Eijken, Marco; Swagemakers, Sigrid; Koedam, Marijke; Steenbergen, Cobie; Derkx, Pieter; Uitterlinden, Andre G.; van der Spek, Peter J.; Visser, Jenny A.; de Jong, Frank H.; Pols, Huibert A. P.; van Leeuwen, Johannes P. T. M.			The activin A-follistatin system: potent regulator of human extracellular matrix mineralization	FASEB JOURNAL			English	Article						osteoblasts; vascular smooth muscle cells; microarray; autocrine	BONE-MORPHOGENETIC PROTEIN; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; OSTEOBLAST DIFFERENTIATION; FAMILY-MEMBERS; DIRECT BINDING; INHIBIN; CALCIFICATION; CULTURES; FETAL	Bone quality is an important determinant of osteoporosis, and proper osteoblast differentiation plays an important role in the control and maintenance of bone quality. We investigated the impact of activin signaling on human osteoblast differentiation, extracellular matrix formation, and mineralization. Activins belong to the transforming growth factor-beta superfamily and activin A treatment strongly inhibited mineralization in osteoblast cultures, whereas the activin antagonist follistatin increased mineralization. Osteoblasts produced activin A and follistatin in a differentiation-dependent manner, leading to autocrine regulation of extracellular matrix formation and mineralization. In addition, mineralization in a vascular smooth muscle cell-based model for pathological calcification was inhibited. Comparative activin A and follistatin gene expression profiling showed that activin signaling changes the expression of a specific range of extracellular matrix proteins prior to the onset of mineralization, leading to a matrix composition with reduced or no mineralizing capacity. These findings demonstrate the regulation of osteoblast differentiation and matrix mineralization by the activin A-follistatin system, providing the possibility to control bone quality as well as pathological calcifications such as atherosclerosis by using activin A, follistatin, or analogs thereof.-Eijken, M., Swagemakers, S., Koedam, M., Steenbergen, C., Derkx, P., Uitterlinden, A. G., van der Spek, P. J., Visser, J. A., de Jong, F. H., Pols, H. A. P., van Leeuwen, J. P. T. M. The activin A- follistatin system: potent regulator of human extracellular matrix mineralization.	Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Bioinformat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Leeuwen, JPTM (corresponding author), Erasmus MC, Dept Internal Med, Rm Ee585,POB 2040, NL-3000 CA Rotterdam, Netherlands.	vanleeuwen@erasmusmc.nl	De Jong, Frank H/A-9876-2011; van Leeuwen, Johannes/D-5015-2014; Visser, Jenny A./F-8156-2011	De Jong, Frank H/0000-0003-3578-1065; van Leeuwen, Johannes/0000-0002-2282-4006; Eijken, Marco/0000-0002-9043-3971				Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; Bilezikjian LM, 2004, MOL CELL ENDOCRINOL, V225, P29, DOI 10.1016/j.mce.2004.02.010; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; Chen YG, 2006, EXP BIOL MED, V231, P534; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034; Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004-0212; El-Abbadi M, 2005, CURR OPIN NEPHROL HY, V14, P519, DOI 10.1097/01.mnh.0000168335.29381.23; Engelse MA, 1999, CIRC RES, V85, P931; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Fratzl-Zelman N, 1998, BONE, V23, P511, DOI 10.1016/S8756-3282(98)00139-2; Gaddy-Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74; Govoni KE, 2005, PEDIATR NEPHROL, V20, P261, DOI 10.1007/s00467-004-1658-y; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; HASHIMOTO M, 1992, J BIOL CHEM, V267, P4999; Hirotani H, 2002, CALCIFIED TISSUE INT, V70, P330, DOI 10.1007/s00223-001-2037-3; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.3.CO;2-K; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; KANZAKI M, 1995, MOL CELL ENDOCRINOL, V108, P11, DOI 10.1016/0303-7207(94)03451-X; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Pierre A, 2005, REPROD NUTR DEV, V45, P419, DOI 10.1051/rnd:2005031; Raggi P, 2000, CIRCULATION, V101, P850, DOI 10.1161/01.CIR.101.8.850; Robey P.G., 2006, PRIMER METABOLIC BON; Sakai R, 2000, BONE, V27, P91, DOI 10.1016/S8756-3282(00)00307-0; Sakai R, 1999, BONE, V25, P191, DOI 10.1016/S8756-3282(99)00152-0; SAKAI R, 1993, BIOCHEM BIOPH RES CO, V195, P39, DOI 10.1006/bbrc.1993.2006; Sakai R, 2001, MOL CELL ENDOCRINOL, V180, P183, DOI 10.1016/S0303-7207(01)00496-8; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003; SPENCER SJ, 1992, J CLIN INVEST, V90, P142, DOI 10.1172/JCI115827; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; TENENBAUM HC, 1987, BONE MINER, V2, P43; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; Young A, 2005, BIOINFORMATICS, V21, P275, DOI 10.1093/bioinformatics/bth495; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024	58	132	154	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2949	2960		10.1096/fj.07-8080com	http://dx.doi.org/10.1096/fj.07-8080com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449718				2022-12-25	WOS:000249237500035
J	Chorny, M; Polyak, B; Alferiev, IS; Walsh, K; Friedman, G; Levy, RJ				Chorny, Michael; Polyak, Boris; Alferiev, Ivan S.; Walsh, Kenneth; Friedman, Gary; Levy, Robert J.			Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles	FASEB JOURNAL			English	Article						GFP plasmid; magnetic nanoparticles; ion-pair complex; polyethylenimine; adiponectin	TARGETING GENE DELIVERY; IN-VITRO; MAGNETOFECTION; FORMULATION; ACID); SIZE; POLYETHYLENIMINE; TRANSFECTION; ADIPONECTIN; PARTICLES	Targeting gene therapy remains a challenge. The use of magnetic force to achieve this was investigated in the present study. It was hypothesized that nanoparticles with both controllable particle size and magnetic properties would enable magnetically driven gene delivery. We investigated this hypothesis by creating a family of novel biodegradable polymeric superparamagnetic nanoparticle ( MNP) formulations. Polylactide MNP were formulated using a modified emulsification-solvent evaporation methodology with both the incorporation of oleate-coated iron oxide and a polyethylenimine ( PEI) oleate ionpair surface modification for DNA binding. MNP size could be controlled by varying the proportion of the tetrahydrofuran cosolvent. Magnetically driven MNP-mediated gene transfer was studied using a green fluorescent protein reporter plasmid in cultured arterial smooth muscle cells and endothelial cells. MNP-DNA internalization and trafficking were examined by confocal microscopy. Cell growth inhibition after MNP-mediated adiponectin plasmid transfection was studied as an example of a therapeutic end point. MNP-DNA complexes protected DNA from degradation and efficiently transfected quiescent cells under both low and high serum conditions after a 15 min exposure to a magnetic field ( 500 G). There was negligible transfection with MNP in the absence of a magnetic field. Larger sized MNP ( 375 nm diameter) exhibited higher transfection rates compared with 185 nm- and 240 nm- sized MNP. Internalized larger sized MNP escaped lysosomal localization and released DNA in the perinuclear zone. Adiponectin plasmid DNA delivery using MNP resulted in a dose-dependent growth inhibition of cultured arterial smooth muscle cells. It is concluded that magnetically driven plasmid DNA delivery can be achieved using biodegradable MNP containing oleate-coated magnetite and surface modified with PEI oleate ion-pair complexes that enable DNA binding.	Childrens Hosp Philadelphia, Div Cardiol Res, Philadelphia, PA 19104 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA USA; Drexel Univ, Sch Biomed Engn & Hlth Sci, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Boston University; Drexel University	Levy, RJ (corresponding author), Childrens Hosp Philadelphia, Div Cardiol Res, Abramson Res Bldg,Ste 702,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	levyr@email.chop.edu	Chorny, Michael/O-1313-2017		NHLBI NIH HHS [HL72108, R01 HL072108, R56 HL072108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072108, R56HL072108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexiou C, 2000, CANCER RES, V60, P6641; Barry ME, 1999, HUM GENE THER, V10, P2461, DOI 10.1089/10430349950016816; Bivas-Benita M, 2004, EUR J PHARM BIOPHARM, V58, P1, DOI 10.1016/j.ejpb.2004.03.008; Brownlie A, 2004, INT J PHARMACEUT, V274, P41, DOI 10.1016/j.ijpharm.2003.12.029; Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168-3659(02)00211-0; Clamme JP, 2003, BBA-BIOMEMBRANES, V1617, P52, DOI 10.1016/j.bbamem.2003.09.002; Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534; Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095; Ferrari ME, 2001, NUCLEIC ACIDS RES, V29, P1539, DOI 10.1093/nar/29.7.1539; Fishbein I, 2001, ARTERIOSCL THROM VAS, V21, P1434, DOI 10.1161/hq0901.095567; Goodwin SC, 2001, TOXICOL SCI, V60, P177, DOI 10.1093/toxsci/60.1.177; Hafeli UO, 2002, EUR CELLS MATER, V3, P24; Kim IS, 2005, INT J PHARMACEUT, V298, P255, DOI 10.1016/j.ijpharm.2005.04.017; Krotz F, 2003, J VASC RES, V40, P425, DOI 10.1159/000073901; Kuhn SJ, 2006, ANN BIOMED ENG, V34, P51, DOI 10.1007/s10439-005-9004-5; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Lemke AJ, 2004, EUR RADIOL, V14, P1949, DOI 10.1007/s00330-004-2445-7; Lubbe AS, 1996, CANCER RES, V56, P4686; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592; Messai I, 2003, COLLOID SURFACE B, V32, P293, DOI 10.1016/S0927-7765(03)00182-6; Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010; Plank C, 2003, J LIPOSOME RES, V13, P29, DOI 10.1081/LPR-120017486; Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/14712598.3.5.745; Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082; Quintanar-Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571; QuintanarGuerrero D, 1997, COLLOID POLYM SCI, V275, P640, DOI 10.1007/s003960050130; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rolland Alain, 2006, Expert Opin Drug Deliv, V3, P1, DOI 10.1517/17425247.3.1.1; Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624; Song CX, 1997, J CONTROL RELEASE, V43, P197, DOI 10.1016/S0168-3659(96)01484-8; Trimaille T, 2003, COLLOID SURFACE A, V221, P39, DOI 10.1016/S0927-7757(03)00105-5; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; WEHRLE P, 1995, EUR J PHARM BIOPHARM, V41, P19; Xenariou S, 2006, GENE THER, V13, P1545, DOI 10.1038/sj.gt.3302803; Yellen BB, 2005, CIRCULATION, V112, pU715; Yellen BB, 2005, P NATL ACAD SCI USA, V102, P8860, DOI 10.1073/pnas.0500409102	37	92	95	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2510	2519		10.1096/fj.06-8070com	http://dx.doi.org/10.1096/fj.06-8070com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17403937	Green Accepted			2022-12-25	WOS:000248454400025
J	Mazurek, N; Sun, YJ; Liu, KF; Gilcrease, MZ; Schober, W; Nangia-Makker, P; Raz, A; Bresalier, RS				Mazurek, Nachman; Sun, Yun Jie; Liu, Kai-Feng; Gilcrease, Michael Z.; Schober, Wendy; Nangia-Makker, Pratima; Raz, Avraham; Bresalier, Robert S.			Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE B; TRANSCRIPTION FACTOR; SUPPRESSOR PTEN; PROSTATE-CANCER; BINDING PROTEIN; SURVIVAL; DEATH; AKT; ACTIVATION	Galectin-3 (GAL3), a beta-galactoside-binding lectin, confers chemoresistance to a wide variety of cancer cell types. It may exhibit anti- or pro-apoptotic activity depending on the nature of the stimulus. We report here that introducing phosphorylated galectin-3 (P-GAL3) into GAL3-null, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant human breast carcinoma cells promotes TRAIL-induced apoptotic cell death by stimulating the phosphorylation/inactivation of the pro-apoptotic molecule Bad resulting in the inhibition of mitochondrial depolarization and the release of cytochrome c. Exposure of the transfectant cells to TRAIL leads to the recruitment of the initiator capase-8 followed by activation of the effector caspase-9, independent of cytochrome c, and subsequently the processing of the executioner caspase-3. P-GAL3 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) were coordinately expressed, with concomitant dephosphorylation of Akt in TRAIL-sensitive cells. In contrast, overexpression of phospho-mutant GAL3 (incapable of phosphorylation) failed to elicit similar responses. Depletion of PTEN using small interference RNAs reinstated Akt phosphorylation and conferred TRAIL resistance. In addition phosphatidylinositol 3-kinase inhibitors rendered the phospho-mutant GAL3-resistant cells sensitive to TRAIL. These findings suggest a pivotal role for P-GAL3 in promoting TRAIL sensitivity through activation of a nonclassic apoptotic pathway and identify P-GAL3 as a novel regulator of PTEN.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Unit 436, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; Wayne State Univ, Tumor Progress & Metastasis Program, Karmanos Canc Inst, Detroit, MI 48201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Bresalier, RS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Unit 436, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbresali@mdanderson.org		Bresalier, Robert/0000-0002-9740-281X; Nangia-Makker, Pratima/0000-0002-1917-169X	NCI NIH HHS [CA69480, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069480, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Akahani S, 1997, CANCER RES, V57, P5272; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Choi JH, 2004, CANCER BIOL THER, V3, P447, DOI 10.4161/cbt.3.5.808; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukumori T, 2006, CANCER RES, V66, P3114, DOI 10.1158/0008-5472.CAN-05-3750; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Hsu DK, 2002, GLYCOCONJUGATE J, V19, P507, DOI 10.1023/B:GLYC.0000014080.95829.52; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lee YJ, 2003, EXP CELL RES, V288, P21, DOI 10.1016/S0014-4827(03)00211-8; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; Mazurek N, 2005, CANCER RES, V65, P10767, DOI 10.1158/0008-5472.CAN-04-3333; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Oka N, 2005, CANCER RES, V65, P7546, DOI 10.1158/0008-5472.CAN-05-1197; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Shalom-Feuerstein R, 2005, CANCER RES, V65, P7292, DOI 10.1158/0008-5472.CAN-05-0775; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Shin MS, 2001, CANCER RES, V61, P4942; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008-5472.CAN-06-0772; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WZ, 2006, NUCLEIC ACIDS RES, V34, P5166, DOI 10.1093/nar/gkl673; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	57	35	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21337	21348		10.1074/jbc.M608810200	http://dx.doi.org/10.1074/jbc.M608810200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17420249	hybrid			2022-12-25	WOS:000248047500062
J	Miallau, L; Hunter, WN; McSweeney, SM; Leonard, GA				Miallau, Linda; Hunter, William N.; McSweeney, Sean M.; Leonard, Gordon A.			Structures of Staphylococcus aureus D-tagatose-6-phosphate kinase implicate domain motions in specificity and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTOSE METABOLISM; TAGATOSE 6-PHOSPHATE PATHWAY; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PHOSPHOGLYCERATE KINASE; PHOSPHORYL TRANSFER; THYMIDYLATE KINASE; ESCHERICHIA-COLI; ADENOSINE KINASE; LACTOSE OPERON	High resolution structures of Staphylococcus aureus D-tagatose-6-phosphate kinase (LacC) in two crystal forms are herein reported. The structures define LacC in apoform, in binary complexes with ADP or the co-factor analogue AMP-PNP, and in a ternary complex with AMP-PNP and D-tagatose-6-phosphate. The tertiary structure of the LacC monomer, which is closely related to other members of the pfkB subfamily of carbohydrate kinases, is composed of a large alpha/beta core domain and a smaller, largely beta "lid." Four extended polypeptide segments connect these two domains. Dimerization of LacC occurs via interactions between lid domains, which come together to form a beta-clasp structure. Residues from both subunits contribute to substrate binding. LacC adopts a closed structure required for phosphoryl transfer only when both substrate and co-factor are bound. A reaction mechanism similar to that used by other phosphoryl transferases is proposed, although unusually, when both substrate and co-factor are bound to the enzyme two Mg2+ ions are observed in the active site. A new motif of amino acid sequence conservation common to the pfkB subfamily of carbohydrate kinases is identified.	Macomol Crystallography Grp, European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Dundee, Coll Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	European Synchrotron Radiation Facility (ESRF); University of Dundee	Leonard, GA (corresponding author), Macomol Crystallography Grp, European Synchrotron Radiat Facil, 6 Rue Jules Horowitz, F-38043 Grenoble, France.	leonard@esrf.fr	Leonard, Gordon/D-2160-2019; Hunter, William/AAE-3947-2019; Miallau, linda/G-9804-2011	Leonard, Gordon/0000-0001-5030-0122; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Auerbach G, 1997, STRUCTURE, V5, P1475, DOI 10.1016/S0969-2126(97)00297-9; Bettenbrock K, 1999, J BACTERIOL, V181, P225, DOI 10.1128/JB.181.1.225-230.1999; BISSETT DL, 1980, J BIOL CHEM, V255, P8745; BISSETT DL, 1974, J BACTERIOL, V117, P318, DOI 10.1128/JB.117.1.318-320.1974; BORK P, 1993, PROTEIN SCI, V2, P31; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; BRUKER, 2000, SMART SAINT SADABS X; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cook WJ, 2000, PROTEIN SCI, V9, P704; Fioravanti E, 2003, J MOL BIOL, V327, P1077, DOI 10.1016/S0022-2836(03)00202-X; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GASSNER NC, 1999, ACTA CRYSTALLOGR D, V57, P401; GROVE TM, 1992, J DAIRY SCI, V75, P423, DOI 10.3168/jds.S0022-0302(92)77778-9; Hall DR, 2002, J BIOL CHEM, V277, P22018, DOI 10.1074/jbc.M202464200; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOTLARZ D, 1982, METHOD ENZYMOL, V90, P60; LUI JY, 2006, J MOL BIOL, V281, P6601; Matte A, 1998, STRUCT FOLD DES, V6, P413, DOI 10.1016/S0969-2126(98)00043-4; Miallau L, 2003, P NATL ACAD SCI USA, V100, P9173, DOI 10.1073/pnas.1533425100; MORSE ML, 1968, J BACTERIOL, V95, P2270, DOI 10.1128/JB.95.6.2270-2274.1968; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ohshima N, 2004, J MOL BIOL, V340, P477, DOI 10.1016/j.jmb.2004.04.074; OSKOUIAN B, 1990, J BACTERIOL, V172, P3804, DOI 10.1128/jb.172.7.3804-3812.1990; Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0; PAPPU KM, 1994, ARCH BIOCHEM BIOPHYS, V311, P503, DOI 10.1006/abbi.1994.1268; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; ROSEY EL, 1991, J BACTERIOL, V173, P5992, DOI 10.1128/jb.173.19.5992-5998.1991; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; SCHLEIFER KH, 1978, FEMS MICROBIOL LETT, V3, P9, DOI 10.1111/j.1574-6968.1978.tb01873.x; SCHLICTING I, 1996, BIOCHEMISTRY-US, V39, P9290; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Spychala J, 1996, P NATL ACAD SCI USA, V93, P1232, DOI 10.1073/pnas.93.3.1232; STAGNO S, 1980, NEW ENGL J MED, V302, P1073, DOI 10.1056/NEJM198005083021908; VANROOIJEN RJ, 1991, J BIOL CHEM, V266, P7176	47	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19948	19957		10.1074/jbc.M701480200	http://dx.doi.org/10.1074/jbc.M701480200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17459874	hybrid			2022-12-25	WOS:000247650600069
J	Terawaki, S; Kitano, K; Hakoshima, T				Terawaki, Shin-ichi; Kitano, Ken; Hakoshima, Toshio			Structural basis for type II membrane protein binding by ERM proteins revealed by the radixin-neutral endopeptidase 24.11 (NEP) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CD44; RHO; ASSOCIATION; GROWTH; EZRIN; RECOGNITION; INVOLVEMENT; ACTIVATION; MECHANISMS	ERM (Ezrin/Radixin/Moesin) proteins mediate formation of membrane-associated cytoskeletons by simultaneously binding actin filaments and the C-terminal cytoplasmic tails of adhesion molecules (type I membrane proteins). ERM proteins also bind neutral endopeptidase 24.11 (NEP), a type II membrane protein, even though the N-terminal cytoplasmic tail of NEP possesses the opposite peptide polarity to that of type I membrane proteins. Here, we determined the crystal structure of the radixin FERM ( Four point one and ERM) domain complexed with the N-terminal NEP cytoplasmic peptide. In the FERM-NEP complex, the amphipathic region of the peptide forms a beta strand followed by a hairpin that bind to a shallow groove of FERM subdomain C. NEP binding is stabilized by beta-beta interactions and docking of the NEP hairpin into the hydrophobic pocket of subdomain C. Whereas the binding site of NEP on the FERM domain overlaps with the binding site of intercellular adhesion molecule (ICAM)-2, NEP lacks the Motif-1 sequence conserved in ICAM-2 and related adhesion molecules. The NEP hairpin, although lacking the typical inter-chain hydrogen bond but is stabilized by hydrogen bonds with the main chain and side chains of subdomain C, directs the C-terminal basic region of the NEP peptide away from the groove and toward the membrane. The overlap of the binding sites on subdomain C for NEP and Motif-1 adhesion molecules such as CD44 provides the structural basis for the suppression of cell adhesion through interaction between NEP and ERM proteins.	CREST Japan & Technol Agcy, Nara Inst Sci & Technol, Struct Biol Lab, Nara 6300192, Japan	Japan Science & Technology Agency (JST); Nara Institute of Science & Technology	Hakoshima, T (corresponding author), CREST Japan & Technol Agcy, Nara Inst Sci & Technol, Struct Biol Lab, 8916-5 Takayama, Nara 6300192, Japan.	hakosima@bs.naist.jp	Terawaki, Shin-ichi/V-7082-2019	Terawaki, Shin-ichi/0000-0002-2859-0589				Albrecht M, 2003, EUR UROL, V44, P415, DOI 10.1016/S0302-2838(03)00322-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; Freedland SJ, 2003, PROSTATE, V55, P71, DOI 10.1002/pros.10202; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hamada K, 2000, ACTA CRYSTALLOGR D, V56, P922, DOI 10.1107/S0907444900006363; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Harrison GM, 2002, INT J ONCOL, V21, P935; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nanus DM, 2003, CLIN CANCER RES, V9, P6307; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1991, BLOOD, V78, P1834; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2005, BBA-PROTEINS PROTEOM, V1751, P52, DOI 10.1016/j.bbapap.2004.11.001; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Terawaki S, 2006, STRUCTURE, V14, P777, DOI 10.1016/j.str.2006.01.015; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	38	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19854	19862		10.1074/jbc.M609232200	http://dx.doi.org/10.1074/jbc.M609232200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17459884	hybrid			2022-12-25	WOS:000247650600060
J	Wittkowski, M; Mittelstadt, J; Brandau, S; Reiling, N; Lindner, B; Torrelles, J; Brennan, PJ; Holst, O				Wittkowski, Manon; Mittelstaedt, Jessica; Brandau, Sven; Reiling, Norbert; Lindner, Buko; Torrelles, Jordi; Brennan, Patrick J.; Holst, Otto			Capsular arabinomannans from Mycobacterium avium with morphotype-specific structural differences but identical biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN AOYAMA-B; CELL-WALL; MACROPHAGE ACTIVATION; ANTITUMOR ACTIVITIES; INDUCE SECRETION; SURFACE-ANTIGENS; IN-VITRO; TUBERCULOSIS; Z-100; LIPOARABINOMANNAN	The capsules of two colony morphotypes of Mycobacterium avium strain 2151 were investigated, i.e. the virulent smooth-transparent (SmT1) and the nonvirulent smooth-opaque (SmO) types. From both morphotypes we separated a nonacylated arabinomannan (AM) from an acylated polysaccharide fraction by affinity chromatography, of which the AMs were structurally characterized. The AMs from the virulent morphotype, in contrast to that from the nonvirulent form, possessed a larger mannan chain and a shorter arabinan chain. Incubation of murine bone marrow-derived macrophages and human dendritic cells showed that the acylated polysaccharide fractions were potent inducers of tumor necrosis factor-alpha, interleukin-12, and interleukin-10 compared with nonacylated AMs, which led to only a marginal cytokine release. Further in vitro experiments showed that both the acylated polysaccharide fractions and the nonacylated AMs were able to induce in vitro anti-tumor cytotoxicity of human peripheral blood mononuclear cells. Thus, morphotype-specific structural differences in the capsular AMs of M. avium do not correlate with biological activity; however, their acylation is a prerequisite for effective stimulation of murine macrophages and human dendritic cells.	Leibniz Ctr Med & Biosci, Res Ctr, Div Immunotherapy, D-23845 Borstel, Germany; Leibniz Ctr Med & Biosci, Res Ctr, Div Mol Infect Biol, Borstel, Germany; Leibniz Ctr Med & Biosci, Res Ctr, Div Biophys, D-23845 Borstel, Germany; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; Colorado State University	Holst, O (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr, Div Struct Biochem, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Torrelles, Jordi/E-4204-2011; Lindner, Buko/G-9731-2014; Reiling, Norbert/D-6796-2013	Reiling, Norbert/0000-0001-6673-4291; Brandau, Sven/0000-0002-2702-4163	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R22AI018357, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 018357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELBERG R, 1995, CLIN EXP IMMUNOL, V101, P308; APPELBERG R, 1993, IMMUNOLOGY, V80, P352; BELISLE JT, 1993, J BIOL CHEM, V268, P10510; Bhatnagar S, 2006, CELL MICROBIOL, V8, P85, DOI 10.1111/j.1462-5822.2005.00602.x; Blumenthal A, 2002, INFECT IMMUN, V70, P4961, DOI 10.1128/IAI.70.9.4961-4967.2002; Brandau S, 2000, CLIN INFECT DIS, V31, pS94, DOI 10.1086/314068; Brandau S, 2001, EUR UROL, V39, P518, DOI 10.1159/000052497; BRENNAN PJ, 1989, REV INFECT DIS, V11, pS420; CARLSSON SR, 1993, GLYCOBIOLOGY PRACTIC; CHAPMAN GB, 1959, J BACTERIOL, V77, P205, DOI 10.1128/JB.77.2.205-211.1959; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; FREHEL C, 1991, INFECT IMMUN, V59, P2207, DOI 10.1128/IAI.59.6.2207-2214.1991; FURNEY SK, 1992, INFECT IMMUN, V60, P4410, DOI 10.1128/IAI.60.10.4410-4413.1992; Gilleron M, 2005, J BACTERIOL, V187, P854, DOI 10.1128/JB.187.3.854-861.2005; Gilleron M, 1997, J BIOL CHEM, V272, P117; GlatmanFreedman A, 1996, J CLIN MICROBIOL, V34, P2795, DOI 10.1128/JCM.34.11.2795-2802.1996; Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200; Hamasur B, 2003, VACCINE, V21, P4081, DOI 10.1016/S0264-410X(03)00274-3; HAYASHI Y, 1981, MICROBIOL IMMUNOL, V25, P305, DOI 10.1111/j.1348-0421.1981.tb00032.x; INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266, DOI 10.1128/CMR.6.3.266-310.1993; KAWAMURA I, 1990, IMMUNOPHARM IMMUNOT, V12, P331, DOI 10.3109/08923979009006467; Kobayashi M, 1997, ANTI-CANCER DRUG, V8, P156, DOI 10.1097/00001813-199702000-00006; KOBAYASHI M, 1994, IMMUNOL LETT, V40, P199, DOI 10.1016/0165-2478(93)00018-9; Lemassu A, 1996, MICROBIOL-UK, V142, P1513, DOI 10.1099/13500872-142-6-1513; MEYLAN PR, 1990, INFECT IMMUN, V58, P2564, DOI 10.1128/IAI.58.8.2564-2568.1990; Navoa JAD, 2003, CLIN DIAGN LAB IMMUN, V10, P88, DOI 10.1128/CDLI.10.1.88-94.2003; Nigou J, 1999, GLYCOCONJUGATE J, V16, P257, DOI 10.1023/A:1007046609341; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Oka H, 2004, BIOL PHARM BULL, V27, P82, DOI 10.1248/bpb.27.82; Oka H, 2003, BIOL PHARM BULL, V26, P1336; Oka H, 2002, MICROBIOL IMMUNOL, V46, P343, DOI 10.1111/j.1348-0421.2002.tb02705.x; RASTOGI N, 1986, CURR MICROBIOL, V13, P237, DOI 10.1007/BF01568645; RASTOGI N, 1991, RES MICROBIOL, V142, P464, DOI 10.1016/0923-2508(91)90121-P; Reiling N, 2001, IMMUNOBIOLOGY, V204, P558, DOI 10.1078/0171-2985-00093; ROACH TIA, 1993, J IMMUNOL, V150, P1886; Schwebach JR, 2002, INFECT IMMUN, V70, P2566, DOI 10.1128/IAI.70.5.2566-2575.2002; Schwebach JR, 2001, INFECT IMMUN, V69, P5671, DOI 10.1128/IAI.69.9.5671-5678.2001; Shurin MR, 1997, CHEM IMMUNOL, V68, P153; Smith B. J., 2002, PROTEIN PROTOCOLS HD, P237; Tse HM, 2002, J IMMUNOL, V168, P825, DOI 10.4049/jimmunol.168.2.825; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; WHITTAKER DV, 1994, CARBOHYD RES, V253, P247, DOI 10.1016/0008-6215(94)80069-3; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	50	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19103	19112		10.1074/jbc.M611551200	http://dx.doi.org/10.1074/jbc.M611551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17459879	hybrid			2022-12-25	WOS:000247475300052
J	Pozzi, A; Ibanez, MR; Gatica, AE; Yang, S; Wei, S; Mei, S; Falck, JR; Capdevila, JH				Pozzi, Ambra; Ibanez, Maria Raquel; Gatica, Arnaldo E.; Yang, Shilin; Wei, Shouzuo; Mei, Shaojun; Falck, John R.; Capdevila, Jorge H.			Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-1-NULL MICE; INTESTINAL POLYP FORMATION; GROWTH-FACTOR RECEPTOR; ANGIOGENESIS IN-VITRO; ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; COLORECTAL-CANCER; PPAR-ALPHA; GENE-EXPRESSION; CARCINOMA-CELLS	The peroxisomal proliferator-activated nuclear receptor-alpha (PPAR alpha), the target for most hypolipidemic drugs in current clinical use, regulates the transcription of genes involved in lipid metabolism and transport, and energy homeostasis. More recently, PPAR alpha and its ligands have been implicated in inflammatory responses and the regulation of cell proliferation. PPAR alpha also regulates the expression of Cyp4a fatty acid omega-hydroxylases and Cyp2c arachidonic acid epoxygenase genes. To study the role of the PPAR alpha receptor and of its Cyp2c epoxygenase gene target in tumorigenesis, we treated mice injected with tumor cells with Wy-14,643, a PPAR alpha-selective ligand. Compared with untreated controls, Wy-14643-treated animals showed marked reductions in tumor growth and vascularization, which were accompanied by decreases in the plasma levels of pro-angiogenic epoxygenase metabolites (EETs), hepatic EET biosynthesis, and Cyp2c epoxygenase expression. All these Wy-14643-induced responses were absent in PPAR alpha(-/-) mice and are thus PPAR alpha-mediated. Primary cultures of mouse lung endothelial cells treated with Wy-14643 showed reductions in cell proliferation and in the formation of capillary-like structures. These effects were absent in cells obtained from PPRA alpha(-/-) mice and reversed by the addition of EETs. These results identify important anti- angiogenic and anti- tumorigenic roles for PPAR alpha, characterize the contribution of its Cyp2c epoxygenases gene target to these responses, and suggest potential anti-cancer roles for this nuclear receptor and its ligands.	Vanderbilt Univ, Sch Med, Dept Med, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37212 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Capdevila, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Med Ctr, Med Ctr N S-3223, Nashville, TN 37232 USA.	jorge.capdevila@vanderbilt.edu	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; Ibanez, Maria Raquel/0000-0002-3371-2894	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074359, P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278, R01GM037922] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA94849, CA-68485] Funding Source: Medline; NIDDK NIH HHS [P01-DK38226, R01-DK74359] Funding Source: Medline; NIGMS NIH HHS [R01-GM37922, R01-GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARS RG, 1993, BIOCHEM PHARMACOL, V45, P2045, DOI 10.1016/0006-2952(93)90015-O; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bouis D, 2006, PHARMACOL RES, V53, P89, DOI 10.1016/j.phrs.2005.10.006; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Bruce WR, 2000, NUTR CANCER, V37, P19, DOI 10.1207/S15327914NC3701_2; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen XW, 2005, CLIN EXP METASTAS, V22, P185, DOI 10.1007/s10585-005-7453-8; Chen XW, 2005, INT J CANCER, V116, P52, DOI 10.1002/ijc.20997; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; Cowart LA, 2002, J BIOL CHEM, V277, P35105, DOI 10.1074/jbc.M201575200; DeLozier TC, 2004, J PHARMACOL EXP THER, V310, P845, DOI 10.1124/jpet.104.067819; Frank DB, 2005, CIRC RES, V97, P496, DOI 10.1161/01.RES.0000181152.65534.07; Fruchart JC, 2006, DRUGS TODAY, V42, P39, DOI 10.1358/dot.2006.42.1.963528; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Gizard F, 2005, J CLIN INVEST, V115, P3228, DOI 10.1172/JCI22756; Goetze S, 2002, BIOCHEM BIOPH RES CO, V293, P1431, DOI 10.1016/S0006-291X(02)00385-6; Grabacka M, 2004, ARCH DERMATOL RES, V296, P54, DOI 10.1007/s00403-004-0479-y; Grabacka M, 2006, CLIN CANCER RES, V12, P3028, DOI 10.1158/1078-0432.CCR-05-2556; Jarvinen R, 2001, BRIT J CANCER, V85, P357, DOI 10.1054/bjoc.2001.1906; Jiang JG, 2005, CANCER RES, V65, P4707, DOI 10.1158/0008-5472.CAN-04-4173; Johnson EF, 2002, TOXICOLOGY, V181, P203, DOI 10.1016/S0300-483X(02)00282-2; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; Kersten S, 2002, EUR J PHARMACOL, V440, P223, DOI 10.1016/S0014-2999(02)01431-0; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; Medhora M, 2003, AM J PHYSIOL-HEART C, V284, pH215, DOI 10.1152/ajpheart.01118.2001; Meissner M, 2004, CIRC RES, V94, P324, DOI 10.1161/01.RES.0000113781.08139.81; Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Muller DN, 2004, AM J PATHOL, V164, P521, DOI 10.1016/S0002-9440(10)63142-2; Nelson David R, 2006, Methods Mol Biol, V320, P1; Niho N, 2005, P NATL ACAD SCI USA, V102, P2970, DOI 10.1073/pnas.0500153102; Niho N, 2003, CANCER RES, V63, P6090; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Otvos JD, 2006, CIRCULATION, V113, P1556, DOI 10.1161/CIRCULATIONAHA.105.565135; Pandya NM, 2006, VASC PHARMACOL, V44, P265, DOI 10.1016/j.vph.2006.01.005; Pauley CJ, 2002, CELL SIGNAL, V14, P351, DOI 10.1016/S0898-6568(01)00260-1; Peters JM, 2005, J MOL MED-JMM, V83, P774, DOI 10.1007/s00109-005-0678-9; Pighetti GM, 2001, ANTICANCER RES, V21, P825; Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Tsao CC, 2001, J PHARMACOL EXP THER, V299, P39; Varet J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/s00018-003-2322-6; White IR, 2003, PROTEOMICS, V3, P505, DOI 10.1002/pmic.200390064; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yu ST, 2003, CURR MOL MED, V3, P561, DOI 10.2174/1566524033479537	60	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17685	17695		10.1074/jbc.M701429200	http://dx.doi.org/10.1074/jbc.M701429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17405874	hybrid			2022-12-25	WOS:000247084500041
J	Blanc, G; Font, B; Eichenberger, D; Moreau, C; Ricard-Blum, S; Hulmes, DJS; Moali, C				Blanc, Guillaume; Font, Bernard; Eichenberger, Denise; Moreau, Christophe; Ricard-Blum, Sylvie; Hulmes, David J. S.; Moali, Catherine			Insights into how CUB domains can exert specific functions while sharing a common fold - Conserved and specific features of the CUB1 domain contribute to the molecular basis of procollagen C-proteinase enhancer-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; MANNAN-BINDING-LECTIN; X-RAY-STRUCTURE; CLEAVAGE; IDENTIFICATION; FAMILY; BMP-1; SPERMADHESINS; COMPLEMENT; ACTIVATION	Procollagen C-proteinase enhancers (PCPE-1 and -2) are extracellular glycoproteins that can stimulate the C-terminal processing of fibrillar procollagens by tolloid proteinases such as bone morphogenetic protein-1. They consist of two CUB domains (CUB1 and -2) that alone account for PCPE-enhancing activity and one C-terminal NTR domain. CUB domains are found in several extracellular and plasma membrane-associated proteins, many of which are proteases. We have modeled the structure of the CUB1 domain of PCPE-1 based on known three dimensional structures of CUB-containing proteins. Sequence alignment shows conserved amino acids, notably two acidic residues (Asp-68 and Asp-109) involved in a putative surface-located calcium binding site, as well as a conserved tyrosine residue (Tyr-67). In addition, three residues (Glu-26, Thr-89, and Phe-90) are found only in PCPE CUB1 domains, in putative surface exposed loops. Among the conserved residues, it was found that mutations of Asp-68 and Asp-109 to alanine almost completely abolished PCPE-1 stimulating activity, whereas mutation of Tyr-67 led to a smaller reduction of activity. Among residues specific to PCPEs, mutation of Glu-26 and Thr-89 had little effect, whereas mutation of Phe-90 dramatically decreased the activity. Changes in activity were paralleled by changes in binding of different PCPE-1 mutants to a mini-procollagen III substrate, as shown by surface plasmon resonance. We conclude that PCPE-stimulating activity requires a calcium binding motif in the CUB1 domain that is highly conserved among CUB-containing proteins but also that PCPEs contain specific sites that could become targets for the development of novel anti-fibrotic therapies.	Univ Lyon 1, CNRS, Inst Biol & Chim Prot, UMR 5086,Inst Fed Rech Biosci Lyon Gerland 128, F-69367 Lyon 7, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Moali, C (corresponding author), Univ Lyon 1, CNRS, Inst Biol & Chim Prot, UMR 5086,Inst Fed Rech Biosci Lyon Gerland 128, 7 Passage Vercors, F-69367 Lyon 7, France.	d.hulmes@ibcp.fr	MOREAU, Christophe/AAC-7912-2020; MOREAU, Christophe J/D-3736-2009	MOREAU, Christophe/0000-0002-5463-9593; MOREAU, Christophe J/0000-0002-5463-9593; MOALI, Catherine/0000-0003-2479-4290; Hulmes, David/0000-0002-0651-1317; RICARD-BLUM, Sylvie/0000-0001-9263-1851				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Canty EG, 2006, J BIOL CHEM, V281, P13258, DOI 10.1074/jbc.M510483200; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; Christensen EI, 2004, PEDIATR NEPHROL, V19, P714, DOI 10.1007/s00467-004-1494-0; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Deleage G, 2001, COMPUT BIOL MED, V31, P259, DOI 10.1016/S0010-4825(01)00008-7; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; Duke-Cohan JS, 2000, ADV EXP MED BIOL, V477, P173; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060; Ge GX, 2006, J BIOL CHEM, V281, P10786, DOI 10.1074/jbc.M511111200; Ge WT, 2006, J BIOL CHEM, V281, P7406, DOI 10.1074/jbc.M510687200; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; Gregory LA, 2004, J BIOL CHEM, V279, P29391, DOI 10.1074/jbc.M402687200; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; Hooi CSF, 2006, ONCOGENE, V25, P3924, DOI 10.1038/sj.onc.1209418; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Kang WQ, 2003, FEBS LETT, V540, P21, DOI 10.1016/S0014-5793(03)00217-5; KESSLER E, 1978, ANAL BIOCHEM, V86, P463, DOI 10.1016/0003-2697(78)90770-4; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Moali C, 2005, J BIOL CHEM, V280, P24188, DOI 10.1074/jbc.M501486200; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Muraoka O, 2006, NAT CELL BIOL, V8, P329, DOI 10.1038/ncb1379; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Petropoulou V, 2005, J BIOL CHEM, V280, P22616, DOI 10.1074/jbc.M413468200; Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Steiglitz BM, 2006, MOL CELL BIOL, V26, P238, DOI 10.1128/MCB.26.1.238-249.2006; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836; Sugiyama T, 2000, BIOCHEMISTRY-US, V39, P15817, DOI 10.1021/bi001583s; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Tao ZY, 2005, BLOOD, V106, P4139, DOI 10.1182/blood-2005-05-2029; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; Topfer-Petersen E, 1998, ANDROLOGIA, V30, P217; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Zheng Y, 2004, NATURE, V427, P451, DOI 10.1038/nature02244	53	64	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16924	16933		10.1074/jbc.M701610200	http://dx.doi.org/10.1074/jbc.M701610200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17446170	hybrid			2022-12-25	WOS:000246946500025
J	Catlow, K; Ashurst, HL; Varro, A; Dimaline, R				Catlow, Krista; Ashurst, H. Louise; Varro, Andrea; Dimaline, Rod			Identification of a gastrin response element in the vesicular monoamine transporter type 2 promoter and requirement of 20 S proteasome subunits for transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; NUCLEAR-LOCALIZATION; REGULATORY PARTICLE; DEGRADATION; EXPRESSION; ASSOCIATION; RECRUITMENT; ACTIVATION; CELLS; VMAT2	Vesicular monoamine transporter type 2 (VMAT2) is crucial for accumulation of monoamine neurotranmitters into neuronal secretory vesicles and histamine into secretory granules of the enterochromaffin-like cell in the acid-secreting gastric mucosa. Gastric VMAT2 expression is regulated by the antral hormone gastrin acting at the CCK2 receptor. We demonstrate a gastrin response element (-56)ccgccccctc(-47) in the proximal VMAT2 promoter that binds in a gastrin-sensitive manner to nuclear proteins from gastric epithelial cell lines. Mutations within this sequence prevented nuclear protein binding and significantly reduced gastrin-stimulated expression of VMAT2 promoter-reporter constructs in gastric epithelial cells. In a yeast one-hybrid screen of an AR42J cell cDNA library, using the gastrin response element as bait, we identified a beta subunit of the 20 S proteasome, PSMB1, as a potential binding partner. In supershift assays, antibodies to PSMB1 and other proteasome beta subunits disrupted gastrin sensitive nuclear protein binding to the VMAT2 promoter. Moreover, RNA interference of PSMB1 significantly inhibited gastrin-mediated VMAT2 transcription. These data suggest that elements of the 20 S proteasome interact with the VMAT2 promoter to enhance G-protein-coupled receptor-mediated transcription.	Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Dimaline, R (corresponding author), Univ Liverpool, Sch Biomed Sci, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	r.dimaline@liverpool.ac.uk	Varro, Andras/M-2647-2016		Medical Research Council [G8714277, G9900432] Funding Source: Medline; Wellcome Trust [072501/Z/03] Funding Source: Medline; MRC [G9900432, G8714277] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama H, 2005, MATRIX BIOL, V23, P499, DOI 10.1016/j.matbio.2004.10.002; Ashcroft FJ, 2004, BIOCHEM J, V381, P397, DOI 10.1042/BJ20031793; Auld KL, 2006, MOL CELL, V21, P861, DOI 10.1016/j.molcel.2006.02.020; BLACK JW, 1987, TRENDS PHARMACOL SCI, V8, P486, DOI 10.1016/0165-6147(87)90044-7; Blackmore CG, 2001, J PHYSIOL-LONDON, V531, P605, DOI 10.1111/j.1469-7793.2001.0605h.x; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Dennis AP, 2005, J STEROID BIOCHEM, V94, P337, DOI 10.1016/j.jsbmb.2004.11.009; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; Dimaline R, 1996, J PHYSIOL-LONDON, V490, P249, DOI 10.1113/jphysiol.1996.sp021140; DIMALINE R, 1993, AM J PHYSIOL, V264, pG583, DOI 10.1152/ajpgi.1993.264.3.G583; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Folco EJ, 1997, BIOCHEM J, V328, P37; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; Gerhard M, 2001, ENDOCRINOLOGY, V142, P3663, DOI 10.1210/en.142.8.3663; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Glatt CE, 2006, HUM MOL GENET, V15, P299, DOI 10.1093/hmg/ddi445; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; Kariya S, 2005, J MOL NEUROSCI, V27, P277, DOI 10.1385/JMN:27:3:277; Khan ZE, 2003, GASTROENTEROLOGY, V125, P510, DOI 10.1016/S0016-5085(03)00908-9; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lehmann A, 2002, J MOL BIOL, V317, P401, DOI 10.1006/jmbi.2002.5443; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nakamura A, 2006, NEUROSCI LETT, V406, P43, DOI 10.1016/j.neulet.2006.07.050; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ogiso Y, 2002, CANCER RES, V62, P5008; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PETER D, 1994, J BIOL CHEM, V269, P7231; Prinz C, 1999, AM J PHYSIOL-CELL PH, V277, pC845, DOI 10.1152/ajpcell.1999.277.5.C845; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Sikder D, 2006, J BIOL CHEM, V281, P27346, DOI 10.1074/jbc.M604706200; Sulahian R, 2006, NUCLEIC ACIDS RES, V34, P1351, DOI 10.1093/nar/gkl012; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; von Mikecz A, 2006, J CELL SCI, V119, P1977, DOI 10.1242/jcs.03008; Watson F, 2001, J BIOL CHEM, V276, P7661, DOI 10.1074/jbc.M006697200; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	52	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17069	17077		10.1074/jbc.M611421200	http://dx.doi.org/10.1074/jbc.M611421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17442673	hybrid			2022-12-25	WOS:000246946500040
J	Dumay-Odelot, H; Marck, C; Durrieu-Gaillard, S; Lefebvre, O; Jourdain, S; Prochazkova, M; Pflieger, A; Teichmann, M				Dumay-Odelot, Helene; Marck, Christian; Durrieu-Gaillard, Stephanie; Lefebvre, Olivier; Jourdain, Sabine; Prochazkova, Martina; Pflieger, Aude; Teichmann, Martin			Identification, molecular cloning, and characterization of the sixth subunit of human transcription factor TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; 2 FUNCTIONAL COMPONENTS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; YEAST GENOME; FACTOR-TAU; GENE; COMPLEX	TFIIIC in yeast and humans is required for transcription of tRNA and 5 S RNA genes by RNA polymerase III. In the yeast Saccharomyces cerevisiae, TFIIIC is composed of six subunits, five of which are conserved in humans. We report the identification, molecular cloning, and characterization of the sixth subunit of human TFIIIC, TFIIIC35, which is related to the smallest subunit of yeast TFIIIC. Human TFIIIC35 does not contain the phosphoglycerate mutase domain of its yeast counterpart, and these two proteins display only limited homology within a 34-amino acid domain. Homologs of the sixth TFIIIC subunit are also identified in other eukaryotes, and their phylogenic evolution is analyzed. Affinity-purified human TFIIIC from an epitope-tagged TFIIIC35 cell line is active in binding to and in transcription of the VA1 gene in vitro. Furthermore, TFIIIC35 specifically interacts with the human TFIIIC subunits TFIIIC63 and, to a lesser extent, TFIIIC90 in vitro. Finally, we determined a limited region in the smallest subunit of yeast TFIIIC that is sufficient for interacting with the yeast TFIIIC subunit ScTfc1 (orthologous to TFIIIC63) and found it to be adjacent to and overlap the 34-amino acid domain that is conserved from yeast to humans.	Univ Bordeaux 2, IECB, INSERM, U869, F-33607 Pessac, France; CEA, iBiTecS, F-91191 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CEA; UDICE-French Research Universities; Universite Paris Saclay	Teichmann, M (corresponding author), Univ Bordeaux 2, IECB, INSERM, U869, Rue Robert Escarpit, F-33607 Pessac, France.	M.Teichmann@iecb.u-bordeaux.fr	DUMAY-ODELOT, Hélène/M-7751-2014; LEFEBVRE, Olivier/C-3847-2014; Teichmann, Martin/M-7407-2014	LEFEBVRE, Olivier/0000-0002-3903-9450; Teichmann, Martin/0000-0002-5257-0510; DUMAY-ODELOT, Helene/0000-0002-7245-084X				Arrebola R, 1998, MOL CELL BIOL, V18, P1; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CONESA C, 1993, J BIOL CHEM, V268, P18047; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Ducrot C, 2006, J BIOL CHEM, V281, P11685, DOI 10.1074/jbc.M600101200; Dujon B, 2005, CURR OPIN GENET DEV, V15, P614, DOI 10.1016/j.gde.2005.09.005; Dujon B, 2006, TRENDS GENET, V22, P375, DOI 10.1016/j.tig.2006.05.007; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Herve M, 2000, EUR J BIOCHEM, V267, P3337, DOI 10.1046/j.1432-1327.2000.01365.x; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Jourdain S, 2003, J BIOL CHEM, V278, P10450, DOI 10.1074/jbc.M213310200; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Mylona A, 2006, MOL CELL, V24, P221, DOI 10.1016/j.molcel.2006.08.013; Oettel S, 1997, NUCLEIC ACIDS RES, V25, P2440, DOI 10.1093/nar/25.12.2440; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rozenfeld S, 2001, MOL GENET GENOMICS, V265, P705, DOI 10.1007/s004380100467; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Weser S, 2004, J BIOL CHEM, V279, P27022, DOI 10.1074/jbc.M312790200; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	52	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17179	17189		10.1074/jbc.M611542200	http://dx.doi.org/10.1074/jbc.M611542200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17409385	hybrid			2022-12-25	WOS:000246946500051
J	Predescu, SA; Predescu, DN; Knezevic, I; Klein, IK; Malik, AB				Predescu, Sanda A.; Predescu, Dan N.; Knezevic, Ivana; Klein, Irene K.; Malik, Asrar B.			Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			Unspecified	Article							CYTOCHROME-C RELEASE; CLATHRIN-MEDIATED ENDOCYTOSIS; PERMEABILITY TRANSITION PORE; BCL-X-L; MEMBRANE PERMEABILIZATION; OLIGOMERIZES BAK; PROTEIN; FAMILY; DYSFUNCTION; MECHANISMS	Intersectins (ITSNs) are multidomain adaptor proteins implicated in endocytosis, regulation of actin polymerization, and Ras/MAPK signaling. We have previously shown that ITSN-1s is required for caveolae fission and internalization in endothelial cells (ECs). In the present study, using small interfering RNA to knock down ITSN-1s protein expression, we demonstrate a novel role of ITSN-1s as a key antiapoptotic protein. Knockdown of ITSN-1s in ECs activated the mitochondrial pathway of apoptosis as determined by genomic DNA fragmentation, extensive mitochondrial fission, activation of the proapoptotic proteins BAK and BAX, and cytochrome c efflux from mitochondria. ITSN-1 knockdown acts as a proapoptotic signal that causes mitochondrial outer membrane permeabilization, dissipation of the mitochondrial membrane potential, and generation of reactive oxygen species. These effects were secondary to decreased activation of Erk1/2 and its direct activator MEK. Bcl-XL overexpression prevented BAX activation and the apoptotic ECs death induced by suppression of ITSN-1s. Our findings demonstrate a novel role of ITSN-1s as a negative regulator of the mitochondrial pathway-dependent apoptosis secondary to activation of the Erk1/2 survival signaling pathway.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Predescu, SA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	sandap@uic.edu		Predescu, Sanda/0000-0002-9386-6756; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL60678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams A, 2000, J BIOL CHEM, V275, P27414; Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Ding WX, 2000, HEPATOLOGY, V32, P547, DOI 10.1053/jhep.2000.16183; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gogvadze V, 2004, BIOCHEM J, V378, P213, DOI 10.1042/BJ20031193; GOGVADZE V, 2003, CURRENT PROTOCOLS CE; Gogvadze V, 2006, BBA-BIOENERGETICS, V1757, P639, DOI 10.1016/j.bbabio.2006.03.016; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Han JY, 2006, NEUROSCI LETT, V398, P113, DOI 10.1016/j.neulet.2005.12.065; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200; Ma YJ, 2003, J NEUROSCI RES, V71, P468, DOI 10.1002/jnr.10500; Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Pucharcos C, 2001, BBA-GENE STRUCT EXPR, V1521, P1, DOI 10.1016/S0167-4781(01)00276-7; Razani B, 2001, J BIOL CHEM, V276, P38121; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu D, 2006, AM J PHYSIOL-LUNG C, V291, pL966, DOI 10.1152/ajplung.00045.2006; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17166	17178		10.1074/jbc.M608996200	http://dx.doi.org/10.1074/jbc.M608996200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405881	hybrid			2022-12-25	WOS:000246946500050
J	Rasbery, JM; Shan, H; LeClair, RJ; Norman, M; Matsuda, SPT; Bartel, B				Rasbery, Jeanne M.; Shan, Hui; LeClair, Renee J.; Norman, Michael; Matsuda, Seiichi P. T.; Bartel, Bonnie			Arabidopsis thaliana squalene epoxidase 1 is essential for root and seed development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SQUALENE EPOXIDASE; ENCODING LANOSTEROL SYNTHASE; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BRASSINOSTEROID BIOSYNTHESIS; MUTANTS DEFICIENT; GENE; EXPRESSION; CYCLIZATION	Squalene epoxidase converts squalene into oxidosqualene, the precursor of all known angiosperm cyclic triterpenoids, which include membrane sterols, brassinosteroid phytohormones, and non-steroidal triterpenoids. In this work, we have identified six putative Arabidopsis squalene epoxidase (SQE) enzymes and used heterologous expression in yeast to demonstrate that three of these enzymes, SQE1, SQE2, and SQE3, can epoxidize squalene. We isolated and characterized Arabidopsis sqe1 mutants and discovered severe developmental defects, including reduced root and hypocotyl elongation. Adult sqe1-3 and sqe1-4 plants have diminished stature and produce inviable seeds. The sqe1-3 mutant accumulates squalene, consistent with a block in the triterpenoid biosynthetic pathway. Therefore, SQE1 function is necessary for normal plant development, and the five SQE-like genes remaining in this mutant are not fully redundant with SQE1.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Rice University; Rice University	Bartel, B (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 Main St, Houston, TX 77005 USA.	bartel@rice.edu	Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X; LeClair, Renee/0000-0003-1895-2109	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008362] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe I, 2007, BIOCHEM BIOPH RES CO, V352, P259, DOI 10.1016/j.bbrc.2006.11.014; AGETA H, 1990, J NAT PROD, V53, P325, DOI 10.1021/np50068a009; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAI Y, 1989, TETRAHEDRON LETT, V30, P7209, DOI 10.1016/S0040-4039(01)93936-X; Asami T, 2005, VITAM HORM, V72, P479, DOI 10.1016/S0083-6729(05)72014-8; Ausubel F., 1999, CURRENT PROTOCOLS MO; Carland FM, 1999, PLANT CELL, V11, P2123, DOI 10.1105/tpc.11.11.2123; Carland FM, 2002, PLANT CELL, V14, P2045, DOI 10.1105/tpc.003939; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Cunillera N, 2000, PLANT MOL BIOL, V44, P747, DOI 10.1023/A:1026588708849; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; D'Auria JC, 2005, CURR OPIN PLANT BIOL, V8, P308, DOI 10.1016/j.pbi.2005.03.012; Diener AC, 2000, PLANT CELL, V12, P853, DOI 10.1105/tpc.12.6.853; Fazio GC, 2004, J AM CHEM SOC, V126, P5678, DOI 10.1021/ja0318784; Fujioka S, 1997, PLANT CELL, V9, P1951, DOI 10.1105/tpc.9.11.1951; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; Hadacek F, 2002, CRIT REV PLANT SCI, V21, P273, DOI 10.1080/0735-260291044269; Hart EA, 1999, J AM CHEM SOC, V121, P9887, DOI 10.1021/ja992589b; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; Jang JC, 2000, GENE DEV, V14, P1485; KARST F, 1977, MOL GEN GENET, V154, P269, DOI 10.1007/BF00571282; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; LeClere S, 2001, PLANT MOL BIOL, V46, P695, DOI 10.1023/A:1011699722052; Lee HK, 2000, ARCH BIOCHEM BIOPHYS, V381, P43, DOI 10.1006/abbi.2000.1966; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; NADEAU RG, 1969, METHOD ENZYMOL, V15, P346; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Noguchi T, 1999, PLANT PHYSIOL, V120, P833, DOI 10.1104/pp.120.3.833; PATTERSON GW, 1993, PHYTOCHEMISTRY, V33, P1381, DOI 10.1016/0031-9422(93)85095-9; Phillips DR, 2006, CURR OPIN PLANT BIOL, V9, P305, DOI 10.1016/j.pbi.2006.03.004; Pichersky E, 2002, CURR OPIN PLANT BIOL, V5, P237, DOI 10.1016/S1369-5266(02)00251-0; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Schafer UA, 1999, PLANT MOL BIOL, V39, P721, DOI 10.1023/A:1006172120929; Schrick K, 2000, GENE DEV, V14, P1471; Schrick K, 2002, PLANT J, V31, P61, DOI 10.1046/j.1365-313X.2002.01333.x; Shan H, 2005, J AM CHEM SOC, V127, P18008, DOI 10.1021/ja055822g; Shiu SH, 2005, PLANT PHYSIOL, V139, P18, DOI 10.1104/pp.105.065110; Shiu SH, 2004, PLANT CELL, V16, P1220, DOI 10.1105/tpc.020834; Souter M, 2002, PLANT CELL, V14, P1017, DOI 10.1105/tpc.001248; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Suzuki H, 2002, PLANT J, V32, P1033, DOI 10.1046/j.1365-313X.2002.01497.x; Suzuki M, 2004, PLANT J, V37, P750, DOI 10.1111/j.1365-313X.2004.02003.x; SWAIN T, 1977, ANNU REV PLANT PHYS, V28, P479, DOI 10.1146/annurev.pp.28.060177.002403; Swofford D.L., 2001, PAUP PHYLOGENETIC AN; Topping JF, 1997, DEVELOPMENT, V124, P4415; Xu R, 2004, PHYTOCHEMISTRY, V65, P261, DOI 10.1016/j.phytochem.2003.11.014; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	53	69	90	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17002	17013		10.1074/jbc.M611831200	http://dx.doi.org/10.1074/jbc.M611831200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426032	hybrid			2022-12-25	WOS:000246946500033
J	Rodrigues, MA; Gomes, DA; Leite, MF; Grant, W; Zhang, L; Lam, W; Cheng, YC; Bennett, AM; Nathanson, MH				Rodrigues, Michele A.; Gomes, Dawidson A.; Leite, M. Fatima; Grant, Wayne; Zhang, Lei; Lam, Wing; Cheng, Yung-Chi; Bennett, Anton M.; Nathanson, Michael H.			Nucleoplasmic calcium is required for cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYOS; NUCLEAR CALCIUM; CYTOPLASMIC CALCIUM; CA2+ SIGNALS; CYCLE; INOSITOL; MICRODOMAINS; MITOSIS; PHOSPHORYLATION; CHECKPOINTS	Ca2+ signals regulate cell proliferation, but the spatial and temporal specificity of these signals is unknown. Here we use selective buffers of nucleoplasmic or cytoplasmic Ca2+ to determine that cell proliferation depends upon Ca2+ signals within the nucleus rather than in the cytoplasm. Nuclear Ca2+ signals stimulate cell growth rather than inhibit apoptosis and specifically permit cells to advance through early prophase. Selective buffering of nuclear but not cytoplasmic Ca2+ signals also impairs growth of tumors in vivo. These findings reveal a major physiological and potential pathophysiological role for nucleoplasmic Ca2+ signals and suggest that this information can be used to design novel therapeutic strategies to regulate conditions of abnormal cell growth.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Yale University; Universidade Federal de Minas Gerais	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Dept Med, Rm TAC S241D, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	Gomes, Dawidson Assis/O-1372-2013; de Fatima Leite, Maria/AAK-2555-2021	Gomes, Dawidson Assis/0000-0001-7714-991X; Bennett, Anton/0000-0001-5187-7599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045710, P01DK057751, R29DK045710, P30DK034989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34989, P01 DK057751, P01 DK057751-01A1, DK57751, R01 DK045710-06A2, DK45710, R01 DK045710, P30 DK034989-169004, P30 DK034989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Gao WL, 2004, CANCER RES, V64, P678, DOI 10.1158/0008-5472.CAN-03-1904; Gatti L, 2005, METH MOLEC MED, V111, P127; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Grant W., 2006, CALCIUM BINDING PROT, V1, P30; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Itano N, 2003, P NATL ACAD SCI USA, V100, P5181, DOI 10.1073/pnas.0531397100; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; Lam W, 2006, MOL PHARMACOL, V69, P1607, DOI 10.1124/mol.105.021527; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Mendes CCP, 2005, J BIOL CHEM, V280, P40892, DOI 10.1074/jbc.M506623200; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Parry H, 2005, J CELL BIOL, V171, P47, DOI 10.1083/jcb.200503139; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; RASMUSSEN CD, 1989, MOL ENDOCRINOL, V3, P588, DOI 10.1210/mend-3-3-588; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; Whitaker M, 2006, CELL CALCIUM, V40, P585, DOI 10.1016/j.ceca.2006.08.018; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576	41	99	100	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17061	17068		10.1074/jbc.M700490200	http://dx.doi.org/10.1074/jbc.M700490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420246	Green Accepted, hybrid			2022-12-25	WOS:000246946500039
J	Yaghini, FA; Li, F; Malik, KU				Yaghini, Fariborz A.; Li, Fang; Malik, Kafait U.			Expression and mechanism of spleen tyrosine kinase activation by angiotensin II and its implication in protein synthesis in rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; CYTOSOLIC PHOSPHOLIPASE A(2); GROWTH-FACTOR RECEPTOR; ARACHIDONIC-ACID; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; IMMUNOGLOBULIN-E; MAST-CELLS; P38 MAPK	Syk, a 72(kDa tyrosine kinase, is involved in development, differentiation, and signal transduction of hematopoietic and some non(hematopoietic cells. This study determined if Syk is expressed in vascular smooth muscle cells (VSMC) and contributes to angiotensin II (Ang II) signaling and protein synthesis. Syk was found in VSMC and was phosphorylated by Ang II through AT1 receptor. Ang II(induced Syk phosphorylation was inhibited by piceatannol and dominant negative but not wild type Syk mutant. Syk phosphorylation by Ang II was attenuated by cytosolic phospholipase A(2) (cPLA(2)) inhibitor pyrrolidine(1 and retrovirus carrying small interfering RNAs (shRNAs) of this enzyme. Arachidonic acid (AA) increased Syk phosphorylation, and AA(and Ang II(induced phosphorylation was diminished by inhibitors of AA metabolism (5,8,11,14(eicosatetraynoic acid) and lipoxygenase (LO; baicalein) but not cyclooxygenase (indomethacin). AA metabolites formed via LO, 5(S)-, 12(S)-, and 15(S)(hydroxyeicosatetraenoic acids, which activate p38 MAPK, increased Syk phosphorylation. p38 MAPK inhibitor SB202190, and dominant negative p38 MAPK mutant attenuated Ang II(and AA(induced Syk phosphorylation. Adenovirus dominant negative c(Src mutant abolished Ang II (and AA(induced Syk phosphorylation and SB202190, and dominant negative p38 MAPK mutant inhibited Ang II(induced c(Src phosphorylation. Syk dominant negative mutant but not epidermal growth factor receptor blocker AG1478 also inhibited Ang II-induced VSMC protein synthesis. These data suggest that Syk expressed in VSMC is activated by Ang II through p38 MAPK-activated c(Src subsequent to cytosolic phospholipase A2 and generation of AA metabolites via LO, and it mediates Ang II-induced protein synthesis independent of epidermal growth factor receptor transactivation (Ang II -> cPLA(2)-> AAmetabolites of LO -> p38 MAPK -> c(Src -> Syk -> protein synthesis).	Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Ctr Vasc Biol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Ctr Connect Tissue Dis, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Malik, KU (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA.	kmalik@utmem.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007641, R01HL079109] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL79109-02, T32 HL07641A] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Brogelli L, 2002, J CARDIOVASC PHARM, V39, P739, DOI 10.1097/00005344-200205000-00015; Capdevila JH, 2002, PROSTAG OTH LIPID M, V68-9, P325, DOI 10.1016/S0090-6980(02)00038-2; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CIRILLO M, 1993, ENDOCRINOLOGY, V132, P1921, DOI 10.1210/en.132.5.1921; Deschamps JD, 2006, BIOORGAN MED CHEM, V14, P4295, DOI 10.1016/j.bmc.2006.01.057; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; Gold MR, 1999, J IMMUNOL, V163, P1894; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; He JS, 2002, ANTIOXID REDOX SIGN, V4, P509, DOI 10.1089/15230860260196317; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Inatome R, 2001, BIOCHEM BIOPH RES CO, V286, P195, DOI 10.1006/bbrc.2001.5355; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kalyankrishna S, 2003, J PHARMACOL EXP THER, V304, P761, DOI 10.1124/jpet.102.040949; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; LARRUE J, 1983, BIOCHEM BIOPH RES CO, V112, P242, DOI 10.1016/0006-291X(83)91822-3; Li F, 2005, AM J PHYSIOL-HEART C, V288, pH2306, DOI 10.1152/ajpheart.00571.2004; Li F, 2005, J PHARMACOL EXP THER, V312, P1043, DOI 10.1124/jpet.104.076588; Marji JS, 2002, AM J PHYSIOL-RENAL, V283, pF60, DOI 10.1152/ajprenal.00265.2001; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MCGIFF JC, 1981, ANNU REV PHARMACOL, V21, P479, DOI 10.1146/annurev.pa.21.040181.002403; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Muthalif MM, 1998, J PHARMACOL EXP THER, V284, P388; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; NEBIGIL C, 1992, J PHARMACOL EXP THER, V260, P849; Parmentier JH, 2006, AM J PHYSIOL-HEART C, V290, pH46, DOI 10.1152/ajpheart.00769.2005; Parmentier JH, 2005, LIFE SCI, V77, P1015, DOI 10.1016/j.lfs.2005.03.002; Parmentier JH, 2001, J BIOL CHEM, V276, P15704, DOI 10.1074/jbc.M011473200; Raeder EMB, 1999, J IMMUNOL, V163, P6785; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; Reddy MA, 2003, HYPERTENSION, V41, P1294, DOI 10.1161/01.HYP.0000069011.18333.08; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Sheffer I, 2001, J IMMUNOL, V167, P475, DOI 10.4049/jimmunol.167.1.475; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Tkaczyk C, 2001, CLIN IMMUNOL, V99, P198, DOI 10.1006/clim.2001.4992; Touyz RM, 2001, J HYPERTENS, V19, P441, DOI 10.1097/00004872-200103000-00012; Touyz RM, 2000, PHARMACOL REV, V52, P639; Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Uddin MR, 1998, HYPERTENSION, V31, P242, DOI 10.1161/01.HYP.31.1.242; VALLOTTON MB, 1989, AM J PHYSIOL, V257, pE617, DOI 10.1152/ajpendo.1989.257.5.E617; von Willebrand M, 1998, CELL SIGNAL, V10, P407, DOI 10.1016/S0898-6568(97)00139-3; Xu R, 1999, J IMMUNOL, V163, P1110; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Young W, 2000, CIRC RES, V86, P906, DOI 10.1161/01.RES.86.8.906; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200	62	24	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16878	16890		10.1074/jbc.M610494200	http://dx.doi.org/10.1074/jbc.M610494200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17442668	hybrid			2022-12-25	WOS:000246946500020
J	Fernandes, ND; Sun, YL; Price, BD				Fernandes, Norvin D.; Sun, Yingli; Price, Brendan D.			Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA; NEUROTROPHIC FACTOR; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; GENE-EXPRESSION; PROTEIN-KINASE; SH-SY5Y CELLS; DNA-PKCS; AUTOPHOSPHORYLATION	The ATM protein kinase is mutated in ataxia telangiectasia, a genetic disease characterized by defective DNA repair, neurodegeneration, and growth factor signaling defects. The activity of ATM kinase is activated by DNA damage, and this activation is required for cells to survive genotoxic events. In addition to this well characterized role in DNA repair, we now demonstrate a novel role for ATM in the retinoic acid ( RA)induced differentiation of SH-SY5Y neuroblastoma cells into post-mitotic, neuronal-like cells. RA rapidly activates the activity of ATM kinase, leading to the ATM-dependent phosphorylation of the CREB protein, extrusion of neuritic processes, and differentiation of SH-SY5Y cells into neuronal-like cells. When ATM protein expression was suppressed by short hairpin RNA, the ATM-dependent phosphorylation of CREB was blocked. Furthermore, ATM-negative cells failed to differentiate into neuronal-like cells when exposed to retinoic acid; instead, they underwent cell death. Expression of a constitutively active CREBVP16 construct, or exposure to forskolin to induce CREB phosphorylation, rescued ATM negative cells and restored differentiation. Furthermore, when dominant negative CREB proteins with mutations in either the CREB phosphorylation site (CREBS133A) or the DNA binding domain (KCREB) were introduced into SH-SY5Y cells, retinoic acid-induced differentiation was blocked and the cells underwent cell death. The results demonstrate that ATM is required for the retinoic acid-induced differentiation of SH-SY5Y cells through the ATM dependent-phosphorylation of serine 133 of CREB. These results therefore define a novel mechanism for activation of the activity of ATM kinase by RA, and implicate ATM in the regulation of CREB function during RA-induced differentiation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, JF 516, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [T32CA009078, R01CA093602, R01CA064585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067751] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585, CA93602, T32 CA09078] Funding Source: Medline; NIAID NIH HHS [U19AI067751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal S, 2006, MOL BIOL CELL, V17, P566, DOI 10.1091/mbc.E05-06-0519; Allio T, 2000, MUTAT RES-FUND MOL M, V453, P5, DOI 10.1016/S0027-5107(00)00030-0; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Chen P, 2003, J NEUROSCI, V23, P11453; Chen SJ, 2004, BIOCHEM BIOPH RES CO, V317, P1037, DOI 10.1016/j.bbrc.2004.03.149; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Choi SY, 2001, J NEUROCHEM, V79, P303; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Insel PA, 2003, CELL MOL NEUROBIOL, V23, P305, DOI 10.1023/A:1023684503883; Irwin N, 2002, P NATL ACAD SCI USA, V99, P12427, DOI 10.1073/pnas.152457399; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; MacLeod RAF, 1996, MUTAT RES-FUND MOL M, V372, P33, DOI 10.1016/S0027-5107(96)00106-6; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Miloso M, 2004, J NEUROSCI RES, V75, P241, DOI 10.1002/jnr.10848; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ruiz-Leon Y, 2003, NEUROSCIENCE, V120, P1019, DOI 10.1016/S0306-4522(03)00391-9; Ruiz-Leon Y, 2001, J NEUROCHEM, V79, P278, DOI 10.1046/j.1471-4159.2001.00547.x; SEDGEWICK R, 1991, HDB CLIN NEUROLOGY, V61, P347; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200	51	38	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16577	16584		10.1074/jbc.M609628200	http://dx.doi.org/10.1074/jbc.M609628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426037	hybrid			2022-12-25	WOS:000246794300064
J	Ito, I; Fukazawa, J; Yoshida, M				Ito, Ichiaki; Fukazawa, Jutarou; Yoshida, Michiteru			Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL-PROTEINS; MOBILITY GROUP PROTEINS; DNA-BINDING PROTEINS; ANTIBODIES P-ANCA; NUCLEAR-LOCALIZATION; MONOCLONAL-ANTIBODY; CELLS; CHROMATIN; HMG-1; MONOCYTES	High mobility group box 1 (HMGB1) protein plays multiple roles in transcription, replication, and cellular differentiation. HMGB1 is also secreted by activated monocytes and macrophages and passively released by necrotic or damaged cells, stimulating inflammation. HMGB1 is a novel antigen of antineutrophil cytoplasmic antibodies (ANCA) observed in the sera of patients with ulcerative colitis and autoimmune hepatitis, suggesting that HMGB1 is secreted from neutrophils to the extracellular milieu. However, the actual distribution of HMGB1 in the cytoplasm of neutrophils and the mechanisms responsible for it are obscure. Here we show that HMGB1 in neutrophils is post- translationally mono-methylated at Lys42. The methylation alters the conformation of HMGB1 and weakens its DNA binding activity, causing it to become largely distributed in the cytoplasm by passive diffusion out of the nucleus. Thus, post- translational methylation ofHMGB1causes its cytoplasmic localization in neutrophils. This novel pathway explains the distribution of nuclear HMGB1 to the cytoplasm and is important for understanding how neutrophils release HMGB1 to the extracellular milieu.	Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Yoshida, M (corresponding author), Tokyo Univ Sci, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	myoshida@rs.noda.tus.ac.jp	Fukazawa, Jutarou/AAX-7979-2021					ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Bianchi ME, 2004, BBA-GENE STRUCT EXPR, V1677, P181, DOI 10.1016/j.bbaexp.2003.10.017; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CABART P, 1995, CELL BIOCHEM FUNCT, V13, P125, DOI 10.1002/cbf.290130209; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GAJLPECZALSKA KJ, 1975, AM J MED, V59, P674, DOI 10.1016/0002-9343(75)90228-4; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Ito I, 2004, J BIOCHEM, V136, P155, DOI 10.1093/jb/mvh107; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; Passalacqua M, 1997, FEBS LETT, V400, P275, DOI 10.1016/S0014-5793(96)01402-0; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Rendon-Mitchell B, 2003, J IMMUNOL, V170, P3890, DOI 10.4049/jimmunol.170.7.3890; Saito K, 1999, PROTEIN ENG, V12, P235, DOI 10.1093/protein/12.3.235; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shirakawa H, 1997, BIOCHEMISTRY-US, V36, P5992, DOI 10.1021/bi962487n; Sobajima J, 1999, GUT, V44, P867, DOI 10.1136/gut.44.6.867; Sobajima J, 1998, CLIN EXP IMMUNOL, V111, P402; Sobajima J, 1997, CLIN EXP IMMUNOL, V107, P135, DOI 10.1046/j.1365-2249.1997.d01-907.x; STERNER R, 1979, J BIOL CHEM, V254, P1577; STERNER R, 1978, J BIOL CHEM, V253, P7601; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TSUNEOKA M, 1986, J BIOL CHEM, V261, P1829; Uesugi H, 1998, J RHEUMATOL, V25, P703; Ugrinova I, 2001, BIOCHEMISTRY-US, V40, P14655, DOI 10.1021/bi0113364; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	42	159	172	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16336	16344		10.1074/jbc.M608467200	http://dx.doi.org/10.1074/jbc.M608467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403684	hybrid			2022-12-25	WOS:000246794300041
J	Kooren, J; Palstra, RJ; Klous, P; Splinter, E; von Lindern, M; Grosveld, F; de Laat, W				Kooren, Jurgen; Palstra, Robert-Jan; Klous, Petra; Splinter, Erik; von Lindern, Marieke; Grosveld, Frank; de Laat, Wouter			beta-globin active chromatin hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; TRANSCRIPTION FACTOR NF-E2; RNA-POLYMERASE-II; GENE-EXPRESSION; SPATIAL-ORGANIZATION; HISTONE ACETYLATION; IN-VIVO; LCR; GATA-1; RECRUITMENT	Expression of the beta-globin genes proceeds from basal to exceptionally high levels during erythroid differentiation in vivo. High expression is dependent on the locus control region (LCR) and coincides with more frequent LCR-gene contacts. These contacts are established in the context of an active chromatin hub (ACH), a spatial chromatin configuration in which the LCR, together with other regulatory sequences, loops toward the active beta-globin-like genes. Here, we used recently established I/11 cells as a model system that faithfully recapitulates the in vivo erythroid differentiation program to study the molecular events that accompany and underlie ACH formation. Upon I/11 cell induction, histone modifications changed, the ACH was formed, and the beta-globin-like genes were transcribed at rates similar to those observed in vivo. The establishment of frequent LCR-gene contacts coincided with a more efficient loading of polymerase onto the beta-globin promoter. Binding of the transcription factors GATA-1 and EKLF to the locus, although previously shown to be required, was not sufficient for ACH formation. Moreover, we used knock-out mice to show that the erythroid transcription factor p45 NF-E2, which has been implicated in beta-globin gene regulation, is dispensable for beta-globin ACH formation.	Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Hematol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Laat, W (corresponding author), Erasmus MC, Dept Cell Biol & Genet, POB 2040, NL-3000 CA Rotterdam, Netherlands.	w.delaat@erasmusmc.nl	von Lindern, Marieke/AAH-2350-2020	Palstra, Robert-Jan/0000-0003-4600-2303; de Laat, Wouter/0000-0002-6393-595X				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Bender MA, 2006, BLOOD, V108, P1395, DOI 10.1182/blood-2006-04-014431; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bottardi S, 2006, EMBO J, V25, P3586, DOI 10.1038/sj.emboj.7601232; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Dolznig H, 2004, METH MOLEC MED, V105, P323; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kang SHL, 2002, NUCLEIC ACIDS RES, V30; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schubeler D, 2000, GENE DEV, V14, P940; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x	46	64	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16544	16552		10.1074/jbc.M701159200	http://dx.doi.org/10.1074/jbc.M701159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428799	hybrid			2022-12-25	WOS:000246794300061
J	Naslavsky, N; Rahajeng, J; Chenavas, S; Sorgen, PL; Caplan, S				Naslavsky, Naava; Rahajeng, Juliati; Chenavas, Sylvie; Sorgen, Paul L.; Caplan, Steve			EHD1 and Eps15 interact with phosphatidylinositols via their Eps15 homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; RECYCLING COMPARTMENT; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; BINDING PROTEIN; RAB GTPASES; ENDOCYTOSIS; ENDOSOMES; RECOGNITION; DELIVERY	The C-terminal Eps15 homology domain-containing protein, EHD1, regulates the recycling of receptors from the endocytic recycling compartment to the plasma membrane. In cells, EHD1 localizes to tubular and spherical recycling endosomes. To date, the mode by which EHD1 associates with endosomal membranes remains unknown, and it has not been determined whether this interaction is direct or via interacting proteins. Here, we provide evidence demonstrating that EHD1 has the ability to bind directly and preferentially to an array of phospholipids, preferring phosphatidylinositols with a phosphate at position 3. Previous studies have demonstrated that EH domains coordinate calcium binding and interact with proteins containing the tripeptide asparagine-proline-phenylalanine (NPF). Using two-dimensional nuclear magnetic resonance analysis, we now describe a new function for the Eps15 homology ( EH) domain of EHD1 and show that it is capable of directly binding phosphatidylinositol moieties. Moreover, we have expanded our studies to include the C-terminal EH domain of EHD4 and the second of the three N-terminal EH domains of Eps15 and demonstrated that phosphatidylinositol binding may be a more general property shared by certain other EH domains. Further studies identified a positively charged lysine residue ( Lys-483) localized within the third helix of the EH domain, on the opposite face of the NPF-binding pocket, as being critical for the interaction with the phosphatidylinositols.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Sorgen, PL (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	psorgen@unmc.edu; scaplan@unmc.edu			NIGMS NIH HHS [GM072631, GM074876] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072631, R01GM074876] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Blume JJ, 2007, EXP CELL RES, V313, P219, DOI 10.1016/j.yexcr.2006.10.006; Braun A, 2005, MOL BIOL CELL, V16, P3642, DOI 10.1091/mbc.E05-01-0076; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Galperin E, 2002, TRAFFIC, V3, P575, DOI 10.1034/j.1600-0854.2002.30807.x; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Guilherme A, 2004, J BIOL CHEM, V279, P40062, DOI 10.1074/jbc.M401918200; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kauppi M, 2002, J CELL SCI, V115, P899; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kleinschmidt JH, 2002, BIOPHYS J, V83, P994, DOI 10.1016/S0006-3495(02)75225-9; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lee DW, 2005, J BIOL CHEM, V280, P17213, DOI 10.1074/jbc.M412751200; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Lindsay AJ, 2004, J CELL SCI, V117, P4365, DOI 10.1242/jcs.01280; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miliaras NB, 2004, CELL BIOCHEM BIOPHYS, V41, P295, DOI 10.1385/CBB:41:2:295; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Naslavsky N, 2006, MOL BIOL CELL, V17, P163, DOI 10.1091/mbc.e05-05-0466; Naslavsky N, 2005, J CELL SCI, V118, P4093, DOI 10.1242/jcs.02595; Naslavsky N, 2004, MOL BIOL CELL, V15, P2410, DOI 10.1091/mbc.E03-10-0733; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; POLO S, 2003, SCI STKE; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Rapaport D, 2006, TRAFFIC, V7, P52, DOI 10.1111/j.1600-0854.2005.00359.x; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rodman JS, 2000, J CELL SCI, V113, P183; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Simpson JC, 2004, J CELL SCI, V117, P6297, DOI 10.1242/jcs.01560; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Weigert R, 2005, METHOD ENZYMOL, V403, P243, DOI 10.1016/S0076-6879(05)03020-X; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Xu Y, 2004, MOL MEMBR BIOL, V21, P269, DOI 10.1080/09687680410001716871; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	64	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16612	16622		10.1074/jbc.M609493200	http://dx.doi.org/10.1074/jbc.M609493200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412695	hybrid			2022-12-25	WOS:000246794300067
J	de Frutos, S; Spangler, R; Alo, D; Bosc, LVG				de Frutos, Sergio; Spangler, Rhyannon; Alo, Dominique; Bosc, Laura V. Gonzalez			NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIVATED T-CELLS; ANGIOTENSIN-CONVERTING ENZYME; SERUM RESPONSE FACTOR; NUCLEAR FACTOR; GENE-EXPRESSION; MOLECULAR REGULATION; ENDOTHELIN ETA; PROTEIN-KINASE; K+ CHANNELS	Physiological responses to chronic hypoxia include polycythemia, pulmonary arterial remodeling, and vasoconstriction. Chronic hypoxia causes pulmonary arterial hypertension leading to right ventricular hypertrophy and heart failure. During pulmonary hypertension, pulmonary arteries exhibit increased expression of smooth muscle-alpha-actin and -myosin heavy chain. NFATc3 ( nuclear factor of activated T cells isoform c3), which is a Ca2+-dependent transcription factor, has been recently linked to smooth muscle phenotypic maintenance through the regulation of the expression of alpha-actin. The aim of this study was to determine if: ( a) NFATc3 is expressed in murine pulmonary arteries, ( b) hypoxia induces NFAT activation, ( c) NFATc3 mediates the up-regulation of alpha-actin during chronic hypoxia, and ( d) NFATc3 is involved in chronic hypoxia-induced pulmonary vascular remodeling. NFATc3 transcript and protein were found in pulmonary arteries. NFAT-luciferase reporter mice were exposed to normoxia ( 630 torr) or hypoxia ( 380 torr) for 2, 7, or 21 days. Exposure to hypoxia elicited a significant increase in luciferase activity and pulmonary arterial smooth muscle nuclear NFATc3 localization, demonstrating NFAT activation. Hypoxia induced up-regulation of alpha-actin and was prevented by the calcineurin/NFAT inhibitor, cyclosporin A ( 25 mg/kg/day s.c.). In addition, NFATc3 knock-out mice did not showed increased alpha-actin levels and arterial wall thickness after hypoxia. These results strongly suggest that NFATc3 plays a role in the chronic hypoxia-induced vascular changes that underlie pulmonary hypertension.	Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of New Mexico	Bosc, LVG (corresponding author), Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, MSC 08 4750, Albuquerque, NM 87131 USA.	lgonzalezbosc@salud.unm.edu	de Frutos, Sergio/AAE-7761-2021; Alò, Dominique/AAC-9127-2019	de Frutos, Sergio/0000-0002-1225-5911; Alò, Dominique/0000-0003-0579-4156	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088151] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL088151, R01 HL088151-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; AMBERG GC, 2004, J BIOL CHEM; Blumberg FC, 2003, J APPL PHYSIOL, V94, P446, DOI 10.1152/japplphysiol.00239.2002; Bosc LVG, 2005, J BIOL CHEM, V280, P26113, DOI 10.1074/jbc.M411972200; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Chassagne C, 2000, AM J RESP CELL MOL, V22, P323, DOI 10.1165/ajrcmb.22.3.3701; Cheever Kerry H, 2005, J Cardiovasc Nurs, V20, P108; Dumitrascu R, 2006, CIRCULATION, V113, P286, DOI 10.1161/CIRCULATIONAHA.105.581405; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; El-Gamal Y, 2002, ANN ALLERG ASTHMA IM, V88, P370, DOI 10.1016/S1081-1206(10)62366-6; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Fagan KA, 2004, AM J PHYSIOL-LUNG C, V287, pL656, DOI 10.1152/ajplung.00090.2003; FATIGATI V, 1984, J BIOL CHEM, V259, P4383; FERRI C, 1995, J CLIN PATHOL, V48, P519, DOI 10.1136/jcp.48.6.519; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hopkins N, 2002, J ANAT, V201, P335, DOI 10.1046/j.1469-7580.2002.00096.x; Ip SP, 2002, PANCREAS, V25, P296, DOI 10.1097/00006676-200210000-00013; Ivy DD, 1998, AM J PHYSIOL-LUNG C, V274, pL535, DOI 10.1152/ajplung.1998.274.4.L535; Jernigan NL, 2004, AM J PHYSIOL-LUNG C, V287, pL1220, DOI 10.1152/ajplung.00196.2004; Jones R, 1999, AM J RESP CELL MOL, V20, P582, DOI 10.1165/ajrcmb.20.4.3357; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Koulmann N, 2006, AM J RESP CRIT CARE, V174, P699, DOI 10.1164/rccm.200512-1976OC; Li KX, 1999, AM J PHYSIOL-HEART C, V277, pH363, DOI 10.1152/ajpheart.1999.277.1.H363; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MEYRICK B, 1979, ANAT REC, V193, P71, DOI 10.1002/ar.1091930106; MORELLI S, 1993, LUPUS, V2, P367, DOI 10.1177/096120339300200606; MORRELL NW, 1995, J CLIN INVEST, V96, P1823, DOI 10.1172/JCI118228; Nagaoka T, 2006, J APPL PHYSIOL, V100, P996, DOI 10.1152/japplphysiol.01028.2005; Naik JS, 2005, J APPL PHYSIOL, V98, P1119, DOI 10.1152/japplphysiol.00819.2004; Nakayama H, 2006, FASEB J, V20, P1660, DOI 10.1096/fj.05-5560com; Nieves-Cintron M, 2007, J BIOL CHEM, V282, P3231, DOI 10.1074/jbc.M608822200; Nilsson LM, 2007, AM J PHYSIOL-CELL PH, V292, pC1167, DOI 10.1152/ajpcell.00590.2005; Nishida M, 2004, J CARDIOVASC PHARM, V44, P187, DOI 10.1097/00005344-200408000-00007; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1981, P NATL ACAD SCI-BIOL, V78, P7759, DOI 10.1073/pnas.78.12.7759; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Paddenberg R, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-15; PADEH S, 1991, ARTHRITIS RHEUM, V34, P1575; RABINOVITCH M, 1979, AM J PHYSIOL, V236, pH818, DOI 10.1152/ajpheart.1979.236.6.H818; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Resta TC, 1997, AM J PHYSIOL-HEART C, V272, pH806, DOI 10.1152/ajpheart.1997.272.2.H806; Resta TC, 1999, AM J PHYSIOL-HEART C, V276, pH699, DOI 10.1152/ajpheart.1999.276.2.H699; Resta TC, 1998, RESP PHYSIOL, V114, P161, DOI 10.1016/S0034-5687(98)00086-3; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shimoda LA, 2000, PHYSIOL RES, V49, P549; Shimoda LA, 2001, AM J PHYSIOL-LUNG C, V281, pL202, DOI 10.1152/ajplung.2001.281.1.L202; Short M, 2004, AM J PHYSIOL-CELL PH, V286, pC416, DOI 10.1152/ajpcell.00169.2003; Soma S, 1999, AM J RESP CELL MOL, V20, P620, DOI 10.1165/ajrcmb.20.4.3356; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang J, 2006, CIRC RES, V98, P1528, DOI 10.1161/01.RES.0000227551.68124.98; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yaghi A, 2005, AM J PHYSIOL-LUNG C, V289, pL1061, DOI 10.1152/ajplung.00096.2005; Yang XD, 1997, CHINESE MED J-PEKING, V110, P104; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yuan JXJ, 1998, CIRCULATION, V98, P1400, DOI 10.1161/01.CIR.98.14.1400; Yuyama H, 2005, VASC PHARMACOL, V43, P40, DOI 10.1016/j.vph.2005.03.001	75	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15081	15089		10.1074/jbc.M702679200	http://dx.doi.org/10.1074/jbc.M702679200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17403661	Green Accepted, hybrid			2022-12-25	WOS:000246589000048
J	Kinugasa, Y; Hieda, M; Hori, M; Higashiyama, S				Kinugasa, Yumi; Hieda, Miki; Hori, Masatsugu; Higashiyama, Shigeki			The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR ACTIVITY; FINGER ENCODING GENE; CENTER B-CELLS; KERATINOCYTE MIGRATION; HYPERTROPHIC GROWTH; EPITHELIAL-CELLS; IN-VIVO; BCL-6; EXPRESSION	Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family, is synthesized as a type I transmembrane precursor (pro-HB-EGF). Ectodomain shedding of pro-HB-EGF yields an amino-terminal soluble ligand of EGF receptor (HB-EGF) and a carboxyl-terminal fragment (HB-EGF-CTF) consisting of the transmembrane and cytoplasmic domains. We previously showed that the HB-EGF-CTF translocates from the plasma membrane to the nucleus and plays a role as a signaling molecule. Immunoprecipitation showed that HB-EGF-CTF can associate with Bcl6, a transcriptional repressor in mammalian cells. A glutathione S-transferase pulldown assay revealed that HB-EGF-CTF interacted efficiently with zinc fingers 4-6 of Bcl6. A luciferase reporter assay showed that the nuclear translocation of HB-EGF-CTF following shedding reversed transcriptional repression of cyclin D2 by Bcl6. Additionally, the level of cyclin D2 protein increased and Bcl6 interaction with the cyclin D2 promoter decreased in parallel with the shedding of pro-HB-EGF at all endogenous levels. These findings suggest that HB-EGF-CTF is a potent regulator of gene expression via its interaction with the transcriptional repressor Bcl6.	Ehime Univ, Dept Biochem & Mol Genet, Grad Sch Med, Toon, Ehime 7910295, Japan; Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Div Internal Med, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	Ehime University; Osaka University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Dept Biochem & Mol Genet, Grad Sch Med, Toon, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp	Matsumura, Miki/AAD-1823-2021	Hieda, Miki/0000-0002-9492-7506				Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JM, 1998, AM J PHYSIOL-HEART C, V275, pH814, DOI 10.1152/ajpheart.1998.275.3.H814; MIKI T, 1994, BLOOD, V83, P26; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shirakata Y, 2005, J CELL SCI, V118, P2363, DOI 10.1242/jcs.02346; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhong WG, 2006, EMBO J, V25, P3869, DOI 10.1038/sj.emboj.7601252	43	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14797	14806		10.1074/jbc.M611036200	http://dx.doi.org/10.1074/jbc.M611036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392284	hybrid			2022-12-25	WOS:000246589000015
J	Guiyedi, V; Chanseaud, Y; Fesel, C; Snounou, G; Rousselle, JC; Lim, P; Koko, J; Namane, A; Cazenave, PA; Kombila, M; Pied, S				Guiyedi, Vincent; Chanseaud, Youri; Fesel, Constantin; Snounou, Georges; Rousselle, Jean-Claude; Lim, Pharat; Koko, Jean; Namane, Abdelkader; Cazenave, Pierre-Andre; Kombila, Maryvonne; Pied, Sylviane			Self-Reactivities to the Non-Erythroid Alpha Spectrin Correlate with Cerebral Malaria in Gabonese Children	PLOS ONE			English	Article								Background. Hypergammaglobulinemia and polyclonal B-cell activation commonly occur in Plasmodium sp. infections. Some of the antibodies produced recognize self-components and are correlated with disease severity in P. falciparum malaria. However, it is not known whether some self-reactive antibodies produced during P. falciparum infection contribute to the events leading to cerebral malaria (CM). We show here a correlation between self-antibody responses to a human brain protein and high levels of circulating TNF alpha (TNF alpha), with the manifestation of CM in Gabonese children. Methodology. To study the role of self-reactive antibodies associated to the development of P. falciparum cerebral malaria, we used a combination of quantitative immunoblotting and multivariate analysis to analyse correlation between the reactivity of circulating IgG with a human brain protein extract and TNF alpha concentrations in cohorts of uninfected controls (UI) and P. falciparum-infected Gabonese children developing uncomplicated malaria (UM), severe non-cerebral malaria (SNCM), or CM. Results/Conclusion. The repertoire of brain antigens recognized by plasma IgGs was more diverse in infected than in UI individuals. Anti-brain reactivity was significantly higher in the CM group than in the UM and SNCM groups. IgG self-reactivity to brain antigens was also correlated with plasma IgG levels and age. We found that 90% of CM patients displayed reactivity to a high-molecular mass band containing the spectrin non-erythroid alpha chain. Reactivity with this band was correlated with high TNFa concentrations in CM patients. These results strongly suggest that an antibody response to brain antigens induced by P. falciparum infection may be associated with pathogenic mechanisms in patients developing CM.	[Guiyedi, Vincent; Chanseaud, Youri; Lim, Pharat; Cazenave, Pierre-Andre; Pied, Sylviane] Univ Paris 06, CNRS, Inst Pasteur, Unite Immunophysiopathol,URA 1961, Paris, France; [Guiyedi, Vincent; Kombila, Maryvonne; Pied, Sylviane] Univ Sci Sante, Fac Med, Dept Parasitol Mycol Med Trop, Libreville, Gabon; [Chanseaud, Youri; Fesel, Constantin; Pied, Sylviane] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Snounou, Georges] Museum Natl Hist Nat, Dept Ecol & Gest Biodiversite, F-75231 Paris, France; [Koko, Jean] Hop Pediat Owendo, Libreville, Gabon	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Instituto Gulbenkian de Ciencia; Museum National d'Histoire Naturelle (MNHN)	Pied, S (corresponding author), Univ Paris 06, CNRS, Inst Pasteur, Unite Immunophysiopathol,URA 1961, Paris, France.	spied@pasteur.fr	Namane, Abdelkader/O-1857-2013; Snounou, Georges/F-3352-2011; Lim, Pharath/AAF-6699-2020	Namane, Abdelkader/0000-0001-7180-7619; Snounou, Georges/0000-0002-6133-6398; Lim, Pharath/0000-0002-1012-2461; Cazenave, Pierre-Andre/0000-0002-1345-8526; Fesel, Constantin/0000-0003-3537-5243; Pied, Sylviane/0000-0003-0642-1423	French Ministry of Research; Fundacao para a Ciencia e Tecnologia (Portugal); Agence Universitaire de la Francophonie (AUF); Institut Pasteur and Pasteur-Genopole-Ile-de-France	French Ministry of Research(Ministry of Research, FranceEuropean Commission); Fundacao para a Ciencia e Tecnologia (Portugal)(Portuguese Foundation for Science and Technology); Agence Universitaire de la Francophonie (AUF); Institut Pasteur and Pasteur-Genopole-Ile-de-France	This work was part of the CNRS-IGC LEA "Genetique et developpement de la tolerance naturelle'' program. It was supported by the PAL+ program of the French Ministry of Research. Y-C and C-F received a post-doctoral fellowship and S-P a visiting scientist fellowship from the Fundacao para a Ciencia e Tecnologia (Portugal). V-G holds a fellowship from the Agence Universitaire de la Francophonie (AUF). This work was also supported by grants from the Institut Pasteur and Pasteur-Genopole-Ile-de-France.	ADU D, 1982, CLIN EXP IMMUNOL, V49, P310; Akanmori BD, 2000, EUR CYTOKINE NETW, V11, P113; Ballok DA, 2004, J NEUROIMMUNOL, V152, P83, DOI 10.1016/j.jneuroim.2004.04.003; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Breman JG, 2001, AM J TROP MED HYG, V64, pIV, DOI 10.4269/ajtmh.2001.64.iv; Chikkamuniyappa Shylashree, 2004, Dermatol Online J, V10, P7; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; Consigny PH, 2002, CLIN EXP IMMUNOL, V127, P158, DOI 10.1046/j.1365-2249.2002.01722.x; Cooke SP, 1998, ANN MED INTERNE, V149, P30; Daniel-Ribeiro C, 1991, J Clin Lab Immunol, V35, P109; Daniel-Ribeiro CT, 2000, MEM I OSWALDO CRUZ, V95, P199, DOI 10.1590/S0074-02762000000200011; DANIELRIBEIRO C, 1983, T ROY SOC TROP MED H, V77, P185, DOI 10.1016/0035-9203(83)90064-0; Ebringer A, 2000, J MED MICROBIOL, V49, P305, DOI 10.1099/0022-1317-49-4-305; FACER CA, 1994, CLIN EXP IMMUNOL, V95, P304, DOI 10.1111/j.1365-2249.1994.tb06528.x; FREEMAN RR, 1978, CLIN EXP IMMUNOL, V32, P41; GALLIEN S, 2007, J INFECTION, V54, P1; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; Haneji N, 1997, SCIENCE, V276, P604, DOI 10.1126/science.276.5312.604; HAURY M, 1994, SCAND J IMMUNOL, V39, P79, DOI 10.1111/j.1365-3083.1994.tb03343.x; He XP, 1998, NEURON, V20, P153, DOI 10.1016/S0896-6273(00)80443-2; HOLMBERG D, 1984, EUR J IMMUNOL, V14, P435, DOI 10.1002/eji.1830140510; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; Issifou S, 2003, EUR CYTOKINE NETW, V14, P238; JAKOBSEN PH, 1993, IMMUNOLOGY, V79, P653; KENNEDY PGE, 1994, Q J MED, V87, P523; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Krams SM, 1996, CLIN IMMUNOL IMMUNOP, V80, P311, DOI 10.1006/clin.1996.0129; LACROIXDESMAZES S, 1995, EUR J IMMUNOL, V25, P2598, DOI 10.1002/eji.1830250929; Lang B, 2005, J INFECT DIS, V191, P117, DOI 10.1086/426512; Lima MRD, 1996, SCAND J IMMUNOL, V43, P263; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; MALANCHERE E, 1995, EUR J IMMUNOL, V25, P1358, DOI 10.1002/eji.1830250534; Matsumoto J, 2000, INFECT IMMUN, V68, P1183, DOI 10.1128/IAI.68.3.1183-1188.2000; McKnight K, 2005, NEUROLOGY, V65, P1730, DOI 10.1212/01.wnl.0000187129.66353.13; Medana IM, 2007, J INFECT DIS, V195, P921, DOI 10.1086/512089; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Mirilas P, 1999, J CLIN IMMUNOL, V19, P109, DOI 10.1023/A:1020554500266; Mouthon L, 1996, SCAND J IMMUNOL, V44, P243, DOI 10.1046/j.1365-3083.1996.d01-306.x; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newton CRJC, 1996, PEDIATR NEUROL, V15, P41, DOI 10.1016/0887-8994(96)00115-4; NOBREGA A, 1993, EUR J IMMUNOL, V23, P2851, DOI 10.1002/eji.1830231119; Ohno T, 2005, IMMUNOGENETICS, V57, P293, DOI 10.1007/s00251-005-0791-5; Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005; Potter SM, 2006, J NEUROIMMUNOL, V173, P96, DOI 10.1016/j.jneuroim.2005.12.004; Quintana FJ, 2006, LUPUS, V15, P428, DOI 10.1191/0961203306lu2328oa; RALPH C, 2004, ARTHRITIS RHEUMATISM, V50, P1239; Rami A, 2003, NEUROSCI RES, V47, P373, DOI 10.1016/j.neures.2003.07.002; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; RITTER K, 1993, LANCET, V342, P1333, DOI 10.1016/0140-6736(93)92248-R; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Saveanu C, 2003, MOL CELL BIOL, V23, P4449, DOI 10.1128/MCB.23.13.4449-4460.2003; Schutzer SE, 2003, J NEUROIMMUNOL, V138, P156, DOI 10.1016/S0165-5728(03)00120-6; SHAPER AG, 1968, LANCET, V1, P1342; SHUKLA M, 2005, NEUROCHEM INT, V14, P14; SONI PN, 1993, S AFR MED J, V83, P660; Stankova I, 1999, PHYSIOL RES, V48, P383; STEENS SCA, 2006, ARTHRITIS RES THERAP, V8, P1186; Stoute JA, 2003, J INFECT DIS, V187, P522, DOI 10.1086/367712; VARITEK VA, 1981, J NEUROIMMUNOL, V1, P27, DOI 10.1016/0165-5728(81)90005-9; Vuong PN, 1999, PARASITOLOGY, V119, P543, DOI 10.1017/S0031182099005120; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Zephir H, 2006, J NEUROIMMUNOL, V179, P53, DOI 10.1016/j.jneuroim.2006.06.016	64	16	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e389	10.1371/journal.pone.0000389	http://dx.doi.org/10.1371/journal.pone.0000389			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460756	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445600003
J	Abbasi, AA; Paparidis, Z; Malik, S; Goode, DK; Callaway, H; Elgar, G; Grzeschik, KH				Abbasi, Amir Ali; Paparidis, Zissis; Malik, Sajid; Goode, Debbie K.; Callaway, Heather; Elgar, Greg; Grzeschik, Karl-Heinz			Human GLI3 Intragenic Conserved Non-Coding Sequences Are Tissue-Specific Enhancers	PLOS ONE			English	Article							CIS-REGULATORY ELEMENTS; SONIC HEDGEHOG; PHENOTYPE PREDICTION; POINT MUTATIONS; GREIG SYNDROME; DNA-SEQUENCE; FLOOR PLATE; GENE; EXPRESSION; MUTANT	The zinc-finger transcription factor GLI3 is a key regulator of development, acting as a primary transducer of Sonic hedgehog (SHH) signaling in a combinatorial context dependent fashion controlling multiple patterning steps in different tissues/organs. A tight temporal and spatial control of gene expression is indispensable, however, cis-acting sequence elements regulating GLI3 expression have not yet been reported. We show that 11 ancient genomic DNA signatures, conserved from the pufferfish Takifugu (Fugu) rubripes to man, are distributed throughout the introns of human GLI3. They map within larger conserved non-coding elements (CNEs) that are found in the tetrapod lineage. Full length CNEs transiently transfected into human cell cultures acted as cell type specific enhancers of gene transcription. The regulatory potential of these elements is conserved and was exploited to direct tissue specific expression of a reporter gene in zebrafish embryos. Assays of deletion constructs revealed that the human-Fugu conserved sequences within the GLI3 intronic CNEs were essential but not sufficient for full-scale transcriptional activation. The enhancer activity of the CNEs is determined by a combinatorial effect of a core sequence conserved between human and teleosts (Fugu) and flanking tetrapod-specific sequences, suggesting that successive clustering of sequences with regulatory potential around an ancient, highly conserved nucleus might be a possible mechanism for the evolution of cis-acting regulatory elements.	[Abbasi, Amir Ali; Paparidis, Zissis; Malik, Sajid; Grzeschik, Karl-Heinz] Univ Marburg, Inst Human Genet, Marburg, Germany; [Goode, Debbie K.; Callaway, Heather; Elgar, Greg] Queen Mary Univ London, Sch Biol & Chem Sci, London, England	Philipps University Marburg; University of London; Queen Mary University London	Grzeschik, KH (corresponding author), Univ Marburg, Inst Human Genet, Marburg, Germany.	grzeschi@staff.uni-marburg.de	Malik, Sajid/H-7816-2019	Malik, Sajid/0000-0001-5563-9053; Elgar, Greg/0000-0001-7323-1596	Deutsche Forschungsgemeinschaft [Gr373-21, GRK 767]; Stiftung P. E. Kempkes, Marburg, Germany; Higher Education Commission of Pakistan; MRC [G0401138] Funding Source: UKRI; Medical Research Council [G0401138] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Stiftung P. E. Kempkes, Marburg, Germany; Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funding: This work was funded by Deutsche Forschungsgemeinschaft (Gr373-21; GRK 767) and Stiftung P. E. Kempkes, Marburg, Germany. A. A. A. holds a fellowship of Higher Education Commission of Pakistan.	Altaba AR, 2003, CURR OPIN GENET DEV, V13, P513, DOI 10.1016/j.gde.2003.08.005; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Bejerano G, 2005, NAT METHODS, V2, P535, DOI 10.1038/nmeth0705-535; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Biesecker LG, 1998, OTOLARYNG HEAD NECK, V119, P556, DOI 10.1016/S0194-5998(98)70126-3; Boffelli D, 2004, NAT REV GENET, V5, P456, DOI 10.1038/nrg1350; Bose J, 2002, HUM MOL GENET, V11, P1129, DOI 10.1093/hmg/11.9.1129; Brewster R, 2000, DEVELOPMENT, V127, P4395; Brudno M, 2003, BIOINFORMATICS, V19, pi54, DOI 10.1093/bioinformatics/btg1005; Buttitta L, 2003, DEVELOPMENT, V130, P6233, DOI 10.1242/dev.00851; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fisher S, 2006, SCIENCE, V312, P276, DOI 10.1126/science.1124070; Gomez-Skarmeta JL, 2006, DEV DYNAM, V235, P870, DOI 10.1002/dvdy.20659; Goode DK, 2005, GENOMICS, V86, P172, DOI 10.1016/j.ygeno.2005.04.006; Grice EA, 2005, HUM MOL GENET, V14, P3837, DOI 10.1093/hmg/ddi408; Hersh BM, 2005, DEVELOPMENT, V132, P1567, DOI 10.1242/dev.01737; Holstege FCP, 2006, CELL, V124, P21, DOI 10.1016/j.cell.2005.12.026; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Johnston JJ, 2005, AM J HUM GENET, V76, P609, DOI 10.1086/429346; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; KANG S, 1997, NAT GENET, V266, P3; Koziel L, 2005, DEVELOPMENT, V132, P5249, DOI 10.1242/dev.02097; KRUGER G, 1989, AM J MED GENET, V32, P411, DOI 10.1002/ajmg.1320320329; Lettice LA, 2003, HUM MOL GENET, V12, P1725, DOI 10.1093/hmg/ddg180; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; McEwen GK, 2006, GENOME RES, V16, P451, DOI 10.1101/gr.4143406; Moens CB, 1999, METHODS CELL BIOL, V59, P253; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Muller F, 1999, DEVELOPMENT, V126, P2103; Ovcharenko I, 2005, GENOME RES, V15, P137, DOI 10.1101/gr.3015505; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; POHL TM, 1990, DEVELOPMENT, V110, P1153; Poulin F, 2005, GENOMICS, V85, P774, DOI 10.1016/j.ygeno.2005.03.003; Pu YB, 2004, DEV BIOL, V273, P257, DOI 10.1016/j.ydbio.2004.06.002; Radhakrishna U, 1999, AM J HUM GENET, V65, P645, DOI 10.1086/302557; Radhakrishna U, 1997, NAT GENET, V17, P269, DOI 10.1038/ng1197-269; Rallu M, 2002, NAT REV NEUROSCI, V3, P943, DOI 10.1038/nrn989; Robert B, 2006, DEV DYNAM, V235, P2337, DOI 10.1002/dvdy.20890; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sanges R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r56; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; SCHIMMANG T, 1994, MAMM GENOME, V5, P384, DOI 10.1007/BF00356560; SCHIMMANG T, 1992, DEVELOPMENT, V116, P799; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Tyurina OV, 2005, DEV BIOL, V277, P537, DOI 10.1016/j.ydbio.2004.10.003; Ueta Etsuko, 2004, Congenital Anomalies, V44, P27, DOI 10.1111/j.1741-4520.2003.00005.x; VANDERHOEVEN F, 1993, MAMM GENOME, V4, P276, DOI 10.1007/BF00417435; Vanderlaan G, 2005, DEV BIOL, V282, P550, DOI 10.1016/j.ydbio.2005.04.010; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE; Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702; Wild A, 1997, HUM MOL GENET, V6, P1979, DOI 10.1093/hmg/6.11.1979; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007	58	37	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e366	10.1371/journal.pone.0000366	http://dx.doi.org/10.1371/journal.pone.0000366			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426814	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445400006
J	Garske, T; Clarke, P; Ghani, AC				Garske, Tini; Clarke, Paul; Ghani, Azra C.			The Transmissibility of Highly Pathogenic Avian Influenza in Commercial Poultry in Industrialised Countries	PLOS ONE			English	Article								Background. With the increased occurrence of outbreaks of H5N1 worldwide there is concern that the virus could enter commercial poultry farms with severe economic consequences. Methodology/Principal Findings. We analyse data from four recent outbreaks of highly pathogenic avian influenza (HPAI) in commercial poultry to estimate the farm-to-farm reproductive number for HPAI. The reproductive number is a key measure of the transmissibility of HPAI at the farm level because it can be used to evaluate the effectiveness of the control measures. In these outbreaks the mean farm-to-farm reproductive number prior to controls ranged from 1.1 to 2.4, with the maximum farm-based reproductive number in the range 2.2 to 3.2. Enhanced bio-security, movement restrictions and prompt isolation of the infected farms in all four outbreaks substantially reduced the reproductive number, but it remained close to the threshold value 1 necessary to ensure the disease will be eradicated. Conclusions/Significance. Our results show that depending on the particular situation in which an outbreak of avian influenza occurs, current controls might not be enough to eradicate the disease, and therefore a close monitoring of the outbreak is required. The method we used for estimating the reproductive number is straightforward to implement and can be used in real-time. It therefore can be a useful tool to inform policy decisions.	[Garske, Tini; Clarke, Paul; Ghani, Azra C.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England; [Garske, Tini] Univ London Imperial Coll Sci Technol & Med, Inst Math Sci, London, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Garske, T (corresponding author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.	t.garske@imperial.ac.uk	Ghani, Azra/B-8560-2009	Ghani, Azra/0000-0002-0007-4910	UK Department for Environment, Food and Rural Affairs	UK Department for Environment, Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA))	This work was supported by research funding from the UK Department for Environment, Food and Rural Affairs. The views expressed in the paper are those of the authors.	Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7; *CAN FOOD INSP AG, 2004, SHORT SUMM 2004 OUTB; Capua I, 2000, AVIAN PATHOL, V29, P289, DOI 10.1080/03079450050118403; Capua I, 2004, AVIAN PATHOL, V33, P393, DOI 10.1080/03079450410001724085; Capua I, 2002, ACTA TROP, V83, P7, DOI 10.1016/S0001-706X(02)00057-8; Capua I, 1999, AVIAN PATHOL, V28, P455, DOI 10.1080/03079459994470; Capua I, 2006, EMERG INFECT DIS, V12, P1319, DOI 10.3201/eid1209.060430; *COUNC EUR UN, 2005, OFFICIAL J EUROPEAN, P16; Davison AC, 1997, BOOTSTRAP METHODS TH; de Jong MD, 2006, J CLIN VIROL, V35, P2, DOI 10.1016/j.jcv.2005.09.002; Elbers ARW, 2004, AVIAN DIS, V48, P691, DOI 10.1637/7149; Ellis TM, 2004, AVIAN PATHOL, V33, P405, DOI 10.1080/03079450410001724012; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; Lipatov AS, 2004, J VIROL, V78, P8951, DOI 10.1128/JVI.78.17.8951-8959.2004; MANNELLI A, 2004, MARTIGNY, P13; MARANGON S, 2003, CONTROL AVIAN INFLUE, P1997; Press W. H., 1992, ART SCI COMPUTING; SANCO DG, 2003, AVIAN INFLUENZA AI N; Stegeman A, 2004, J INFECT DIS, V190, P2088, DOI 10.1086/425583; STEGEMAN A, 2006, AVIAN INFLUENZA H7N7; Tian GB, 2005, VIROLOGY, V341, P153, DOI 10.1016/j.virol.2005.07.011; Tumpey TM, 2004, AVIAN DIS, V48, P167, DOI 10.1637/7103; van der Goot JA, 2005, P NATL ACAD SCI USA, V102, P18141, DOI 10.1073/pnas.0505098102; Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255	26	52	52	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e349	10.1371/journal.pone.0000349	http://dx.doi.org/10.1371/journal.pone.0000349			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406673	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000207445300011
J	Lusseau, D				Lusseau, David			Why Are Male Social Relationships Complex in the Doubtful Sound Bottlenose Dolphin Population?	PLOS ONE			English	Article							TURSIOPS-TRUNCATUS; GENETIC-ANALYSIS; KINSHIP; STABILITY; EVOLUTION; COMMUNITY; PATTERNS; BEHAVIOR; MODEL; SP.	Background. Access to oestrus females tends to be the main driver of male sociality. This factor can lead to complex behavioural interactions between males and groups of males. Male bottlenose dolphins may form alliances to consort females and to compete with other males. In some populations these alliances may form temporary coalitions when competing for females. I examined the role of dyadic and group interactions in the association patterns of male bottlenose dolphins in Doubtful Sound, New Zealand. There is no apparent mating competition in this population and no consortship has been observed, yet agonistic interactions between males occur regularly. Methodology/Principal Findings. By comparing the network of male interactions in several social dimensions (affiliative, agonistic, and associative) I show that while agonistic interactions relate to dyadic association patterns, affiliative interactions seem to relate to group association patterns. Some evidence suggests that groups of males also formed temporary coalitions during agonistic interactions. While different groups of males had similar relationships with non-oestrus females, the time they spent with oestrus females and mothers of newborns differed greatly. Conclusions/Significance. After considering several hypotheses, I propose that the evolution of these complex relationships was driven by sexual competition probably to out-compete other males for female choice.	[Lusseau, David] Univ Otago, Dept Zool, Dunedin, New Zealand; [Lusseau, David] Dalhousie Univ, Dept Biol, Halifax, NS, Canada	University of Otago; Dalhousie University	Lusseau, D (corresponding author), Univ Otago, Dept Zool, POB 56, Dunedin, New Zealand.	d.lusseau@dal.ca	Lusseau, David/A-8501-2012; Lusseau, David/AAV-9295-2021	Lusseau, David/0000-0003-1245-3747	Killam Postdoctoral Fellowship; New Zealand Whale and Dolphin Trust; Real Journeys Ltd; University of Otago	Killam Postdoctoral Fellowship; New Zealand Whale and Dolphin Trust; Real Journeys Ltd; University of Otago	Analyses were funded by a Killam Postdoctoral Fellowship. Data collection was funded by the New Zealand Whale and Dolphin Trust, Real Journeys Ltd, and the University of Otago. These also provided logistic support during the study.	Barrat A, 2004, P NATL ACAD SCI USA, V101, P3747, DOI 10.1073/pnas.0400087101; CAIRNS SJ, 1987, ANIM BEHAV, V35, P1454, DOI 10.1016/S0003-3472(87)80018-0; CARO TM, 1987, ETHOLOGY, V74, P52; CLUTTONBROCK TH, 1989, PROC R SOC SER B-BIO, V236, P339, DOI 10.1098/rspb.1989.0027; Connor R, 2006, ETHOLOGY, V112, P631, DOI 10.1111/j.1439-0310.2006.01203.x; CONNOR RC, 1982, AM NAT, V119, P358, DOI 10.1086/283915; Connor RC, 2001, P ROY SOC B-BIOL SCI, V268, P263, DOI 10.1098/rspb.2000.1357; de Waal FBM, 2000, SCIENCE, V289, P586, DOI 10.1126/science.289.5479.586; Dugatkin LA, 1998, P ROY SOC B-BIOL SCI, V265, P2121, DOI 10.1098/rspb.1998.0548; Flack JC, 2006, NATURE, V439, P426, DOI 10.1038/nature04326; Gazda SK, 2005, P ROY SOC B-BIOL SCI, V272, P135, DOI 10.1098/rspb.2004.2937; Griffin AS, 2003, BEHAV ECOL, V14, P472, DOI 10.1093/beheco/arg040; Haase PA, 2001, NEW ZEAL J MAR FRESH, V35, P675, DOI 10.1080/00288330.2001.9517034; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; Kappeler PM, 2002, INT J PRIMATOL, V23, P707, DOI 10.1023/A:1015520830318; Krutzen M, 2003, P ROY SOC B-BIOL SCI, V270, P497, DOI 10.1098/rspb.2002.2229; Lusseau D, 2003, P ROY SOC B-BIOL SCI, V270, pS186, DOI 10.1098/rsbl.2003.0057; Lusseau D, 2003, BEHAV ECOL SOCIOBIOL, V54, P396, DOI 10.1007/s00265-003-0651-y; Lusseau D, 2003, J EVOLUTION BIOL, V16, P531, DOI 10.1046/j.1420-9101.2003.00541.x; Lusseau D, 2004, P ROY SOC B-BIOL SCI, V271, pS477, DOI 10.1098/rsbl.2004.0225; Lusseau D, 2006, BEHAV PROCESS, V73, P257, DOI 10.1016/j.beproc.2006.06.006; Mann J, 1999, BEHAVIOUR, V136, P529, DOI 10.1163/156853999501469; Mitani JC, 2003, BEHAVIOUR, V140, P869, DOI 10.1163/156853903770238355; Moller LM, 2001, P ROY SOC B-BIOL SCI, V268, P1941, DOI 10.1098/rspb.2001.1756; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.70.056131]; ODELL DK, 1975, J FISH RES BOARD CAN, V32, P1055, DOI 10.1139/f75-124; Ostman J., 1991, P305; Owen ECG, 2002, CAN J ZOOL, V80, P2072, DOI 10.1139/z02-195; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; Parsons KM, 2003, ANIM BEHAV, V66, P185, DOI 10.1006/anbe.2003.2186; Patterson IAP, 1998, P ROY SOC B-BIOL SCI, V265, P1167, DOI 10.1098/rspb.1998.0414; Puente A.E, 1976, Cetology, VNo. 21, P1; Sakai M, 2006, MAR MAMMAL SCI, V22, P966, DOI 10.1111/j.1748-7692.2006.00082.x; SCHNEIDER K, 1999, BEHAV ECOLOGY BOTTLE, P200; Tyack PL, 2000, CETACEAN SOCIETIES, P270; Watts DP, 1998, BEHAV ECOL SOCIOBIOL, V44, P43, DOI 10.1007/s002650050513; Watts DP, 2002, BEHAVIOUR, V139, P343, DOI 10.1163/156853902760102708; Whitehead H, 1999, ADV STUD BEHAV, V28, P33, DOI 10.1016/S0065-3454(08)60215-6; WRANGHAM RW, 1980, BEHAVIOUR, V75, P262, DOI 10.1163/156853980X00447; WURSIG B, 1977, SCIENCE, V198, P755, DOI 10.1126/science.198.4318.755	40	48	51	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e348	10.1371/journal.pone.0000348	http://dx.doi.org/10.1371/journal.pone.0000348			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406672	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445300010
J	Mei, Y; Xie, C; Xie, W; Wu, Z; Wu, M				Mei, Y.; Xie, C.; Xie, W.; Wu, Z.; Wu, M.			Siah-1S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin	ONCOGENE			English	Article						Siah-1S; beta-catenin; splice variant; self-ubiquitination; tumorigenesis	UBIQUITIN-PROTEASOME PATHWAY; INHIBITS CELL-GROWTH; TRANSCRIPTIONAL REPRESSOR; DEGRADATION PATHWAY; STRUCTURAL-ANALYSIS; MAMMALIAN HOMOLOGS; SIGNALING PATHWAYS; RAPID DEGRADATION; TUMOR SUPPRESSION; SINA GENE	Siah-1 ( seven in absentia homolog) is known to cause indirect degradation of beta-catenin through formation of a complex with Siah-interacting protein ( SIP), Skp1 and Ebi. Here, we report the characterization of a novel splice variant of human Siah-1, designated Siah-1S, which is produced by an alternative splicing mechanism. The novel intron/exon junctions used to generate Siah-1S follow a non-conventional CT-AC rule. Siah-1S exhibits an even shorter half-life than Siah-1 and is able to catalyse self-ubiquitination that results in its subsequent degradation by proteasome. Siah-1S is shown to upregulate beta-catenin-dependent Tcf/Lef transcriptional activation and antagonize Siah-1's potentiation effect on the apoptosis induced by etoposide in MCF-7 cells. Additionally, Siah-1S is found to interact with Siah-1 to form heterodimer or with itself to form homodimer. Unlike homodimer Siah-1*Siah-1, neither Siah-1*Siah-1S nor Siah-1S*Siah-1S is able to bind to Siah-1-interacting protein, which may explain the underlying mechanism for Siah-1S's dominant negative effect on Siah-1. Importantly, results from in vitro soft agar assay demonstrated that Siah-1S displays a promotion effect on cells tumorigenicity.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Wu, Mian/H-2494-2018; Mei, Yide/M-4468-2013; Xie, Chongwei/GOP-0158-2022	Wu, Mian/0000-0002-2714-0500				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Dong XZ, 1999, GENE DEV, V13, P954, DOI 10.1101/gad.13.8.954; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gutierrez GJ, 2006, NAT CELL BIOL, V8, P1084, DOI 10.1038/ncb1472; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Nakamura N, 2004, J PHYS CONF SER, V2, P1, DOI 10.1088/1742-6596/2/1/001; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Oliver PL, 2004, P NATL ACAD SCI USA, V101, P14901, DOI 10.1073/pnas.0406196101; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	49	14	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6319	6331		10.1038/sj.onc.1210449	http://dx.doi.org/10.1038/sj.onc.1210449			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17420721				2022-12-25	WOS:000249583300008
J	Chiti, Z; Teschemacher, AG				Chiti, Zohreh; Teschemacher, Anja G.			Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain	FASEB JOURNAL			English	Article						brainstem; amperometry; organotypic slice culture; viral vector; neurosecretion	DENSE-CORE VESICLES; VESICULAR MONOAMINE TRANSPORTER-2; ADRENAL CHROMAFFIN CELLS; QUANTAL SIZE; TIME-COURSE; TRANSMITTER RELEASE; SYNAPTIC VESICLES; GANGLION NEURONS; SUBSTANTIA-NIGRA; DOPAMINE NEURONS	Norepinephrine secretion from central neurons was widely assumed to occur by exocytosis, but the essential characteristics of this process remained unknown. We developed an approach to study it directly by amperometry using carbon fiber microelectrodes in organotypic rat brainstem slice cultures. Noradrenergic neurons from areas A1 and A2 were fluorescently labeled by an adenoviral vector with noradrenergic-specific promoter. Quantal events, consistent with exocytotic release of norepinephrine, were registered at noradrenergic axonal varicosities as well as at cell bodies. According to their charge integrals, events were grouped into two populations. The majority ( similar to 40 fC) were compatible with full exocytotic fusion of small clear and dense core vesicles shown in previous morphometric studies. The quantal size distribution was modulated by treatment with reserpine and amitriptyline. In addition, much larger quantal events (> 1 pC) occurred at predominantly axonal release sites. The time course of signals was severalfold faster than in adrenal chromaffin cells, suggesting profound differences in the release machinery between these cell types. Tetrodotoxin eliminated the majority of events, indicating that release was partially, but not entirely, action potential driven. In conclusion, central norepinephrine release has unique characteristics, distinguishing it from those of other monoaminergic cells in periphery and brain.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol Heart Inst, Bristol BS8 1TD, Avon, England	University of Bristol	Teschemacher, AG (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol Heart Inst, Univ Walk, Bristol BS8 1TD, Avon, England.	anja.teschemacher@bristol.ac.uk			British Heart Foundation [FS/04/003] Funding Source: Medline; Wellcome Trust Funding Source: Medline	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Amatore C, 2005, BIOPHYS J, V88, P4411, DOI 10.1529/biophysj.104.053736; BLOOM FE, 1968, J PHARMACOL EXP THER, V159, P261; Bruns D, 2000, NEURON, V28, P205, DOI 10.1016/S0896-6273(00)00097-0; Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629; Chen BT, 2001, J NEUROSCI, V21, P7841, DOI 10.1523/JNEUROSCI.21-19-07841.2001; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; Crivellato E, 2005, ANAT EMBRYOL, V210, P25, DOI 10.1007/s00429-005-0002-z; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; FILLENZ M, 1990, NORADRENERGIC NEURON; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; Gong LW, 2003, J NEUROSCI, V23, P7917; Grabner CP, 2005, J NEUROPHYSIOL, V94, P2093, DOI 10.1152/jn.00316.2005; GROVES PM, 1980, J COMP NEUROL, V193, P853, DOI 10.1002/cne.901930403; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; Huang LYM, 1996, NEURON, V17, P135, DOI 10.1016/S0896-6273(00)80287-1; Hwang DY, 2001, HUM GENE THER, V12, P1731, DOI 10.1089/104303401750476230; Jaffe EH, 1998, J NEUROSCI, V18, P3548; JANCSAR SM, 1983, BIOCHEM PHARMACOL, V32, P1569, DOI 10.1016/0006-2952(83)90329-5; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Lonergan T, 2005, PHYSIOL GENOMICS, V20, P165, DOI 10.1152/physiolgenomics.00120.2004; Ludwig M, 2005, J PHYSIOL-LONDON, V564, P515, DOI 10.1113/jphysiol.2005.083931; Mosharov EV, 2005, NAT METHODS, V2, P651, DOI 10.1038/nmeth782; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1997, SYNAPSE, V26, P194; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; Olson VG, 2006, SCIENCE, V311, P1017, DOI 10.1126/science.1119311; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Pickel VM, 1996, J NEUROCYTOL, V25, P843, DOI 10.1007/BF02284846; Pothos EN, 1998, J NEUROSCI, V18, P4106; Puopolo M, 2001, NEURON, V30, P211, DOI 10.1016/S0896-6273(01)00274-4; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Singewald N, 1996, TRENDS PHARMACOL SCI, V17, P356, DOI 10.1016/S0165-6147(96)10042-0; Staal RGW, 2004, NAT NEUROSCI, V7, P341, DOI 10.1038/nn1205; Stjarne L, 2000, J AUTONOM NERV SYST, V81, P236, DOI 10.1016/S0165-1838(00)00119-3; Sulzer D, 2005, NEURON, V46, P1, DOI 10.1016/j.neuron.2005.03.013; Teschemacher AG, 2005, EXP PHYSIOL, V90, P61, DOI 10.1113/expphysiol.2004.028191; Teschemacher AG, 2005, AUTON NEUROSCI-BASIC, V117, P1, DOI 10.1016/j.autneu.2004.10.002; Teschemacher AG, 2005, ADV DRUG DELIVER REV, V57, P79, DOI 10.1016/j.addr.2004.05.004; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; TESCHEMACHER AG, 2004, J PHYSL, V555, pC40; Travis ER, 1998, ANNU REV BIOPH BIOM, V27, P77, DOI 10.1146/annurev.biophys.27.1.77; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; Walker A, 1996, PFLUG ARCH EUR J PHY, V432, P885, DOI 10.1007/s004240050212; Wightman RM, 2002, ANN NY ACAD SCI, V971, P620, DOI 10.1111/j.1749-6632.2002.tb04540.x; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yamaguchi M, 1999, ANAL BIOCHEM, V270, P296, DOI 10.1006/abio.1999.4079; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZHOU Z, 1995, P NATL ACAD SCI USA, V92, P6938, DOI 10.1073/pnas.92.15.6938	58	35	37	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2540	2550		10.1096/fj.06-7342com	http://dx.doi.org/10.1096/fj.06-7342com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17405853				2022-12-25	WOS:000248454400028
J	Gong, XQ; Shao, Q; Langlois, SP; Bai, DL; Laird, DW				Gong, Xiang-Qun; Shao, Qing; Langlois, Stephanie; Bai, Donglin; Laird, Dale W.			Differential potency of dominant negative connexin43 mutants in oculodentodigital dysplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; GREEN FLUORESCENT PROTEIN; FUNCTIONAL-CHARACTERIZATION; MEMBRANE CHANNELS; PLASMA-MEMBRANE; LIVING CELLS; HEARING-LOSS; HELA-CELLS; MUTATIONS; COMMUNICATION	Oculodentodigital dysplasia (ODDD) is a congenital autosomal dominant disorder with phenotypic variability, which has been associated with mutations in the GJA1 gene encoding connexin43 (Cx43). Given that Cx43 mutants are thought to be equally co-expressed with wild-type Cx43 in ODDD patients, it is imperative to examine the consequence of these mutants in model systems that reflect this molar ratio. To that end, we used differential fluorescent protein tagging of mutant and wild-type Cx43 to quantitatively monitor the ratio of mutant/wild-type within the same putative gap junction plaques and co-immunoprecipitation to determine if the mutants interact with wildtype Cx43. Together the fluorescence-based assay was combined with patch clamp analysis to assess the dominant negative potency of Cx43 mutants. Our results revealed that the ODDD-linked Cx43 mutants, G21R and G138R, as well as amino terminus green fluorescent protein-tagged Cx43, were able to co-localize with wild-type Cx43 at the gap junction plaque-like structures and to co-immunoprecipitate with wild-type Cx43. All Cx43 mutants demonstrated dominant negative action on gap junctional conductance of wild-type Cx43 but not that of Cx32. More interestingly, these Cx43 mutants demonstrated different potencies in inhibiting the function of wild-type Cx43 with the G21R mutant being two times more potent than the G138R mutant. The potency difference in the dominant negative properties of ODDD-linked Cx43 mutants may have clinical implications for the various symptoms and disease severity observed in ODDD patients.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Bai, DL (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	donglin.bai@schulich.uwo.ca	Bai, Donglin/A-5799-2008; Laird, Dale w/E-4176-2015; Laird, Dale W/AAL-2407-2020; Bai, Donglin/ABB-9924-2021	Bai, Donglin/0000-0003-1112-6947; Laird, Dale W/0000-0002-4568-3285; Bai, Donglin/0000-0003-1112-6947				Boyadjiev SA, 1999, GENOMICS, V58, P34, DOI 10.1006/geno.1999.5814; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang EH, 2003, EAR HEARING, V24, P314, DOI 10.1097/01.AUD.0000079801.55588.13; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Cottrell GT, 2005, BBA-BIOMEMBRANES, V1711, P126, DOI 10.1016/j.bbamem.2004.11.013; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Falk MM, 2000, J CELL SCI, V113, P4109; Fiorini C, 2004, J CELL SCI, V117, P4665, DOI 10.1242/jcs.01335; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Frasson Maria, 2004, Ophthalmic Genet, V25, P227, DOI 10.1080/13816810490513424; FUJIKURA Y, 1993, ANAT REC, V235, P335, DOI 10.1002/ar.1092350302; Gollob MH, 2006, NEW ENGL J MED, V354, P2677, DOI 10.1056/NEJMoa052800; Gong XQ, 2006, J BIOL CHEM, V281, P31801, DOI 10.1074/jbc.M605961200; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lai A, 2006, J CELL SCI, V119, P532, DOI 10.1242/jcs.02770; Laird DW, 2001, MICROSC RES TECHNIQ, V52, P263, DOI 10.1002/1097-0029(20010201)52:3<263::AID-JEMT1012>3.0.CO;2-Q; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Liew AWC, 2005, BIOINFORMATICS TECHNOLOGIES, P63, DOI 10.1007/3-540-26888-X_4; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; McLachlan E, 2005, CELL COMMUN ADHES, V12, P279, DOI 10.1080/15419060500514143; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Musa H, 2004, J PHYSIOL-LONDON, V557, P863, DOI 10.1113/jphysiol.2003.059386; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Paemeleire K, 2000, MOL BIOL CELL, V11, P1815, DOI 10.1091/mbc.11.5.1815; Pal JD, 1999, AM J PHYSIOL-CELL PH, V276, pC1443, DOI 10.1152/ajpcell.1999.276.6.C1443; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Richard G, 2003, CLIN EXP DERMATOL, V28, P397, DOI 10.1046/j.1365-2230.2003.01312.x; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Rouan F, 2001, J CELL SCI, V114, P2105; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seki A, 2004, HEART RHYTHM, V1, P227, DOI 10.1016/j.hrthm.2004.03.066; Shapiro RE, 1997, AM J MED GENET, V71, P36, DOI 10.1002/(SICI)1096-8628(19970711)71:1<36::AID-AJMG7>3.0.CO;2-O; SHEPPARD D, 1994, AM J RESP CELL MOL, V11, P1; Shibayama J, 2005, CIRC RES, V96, pE83, DOI 10.1161/01.RES.0000168369.79972.d2; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	52	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19190	19202		10.1074/jbc.M609653200	http://dx.doi.org/10.1074/jbc.M609653200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420259	hybrid			2022-12-25	WOS:000247475300060
J	Jin, Q; Ding, W; Mulder, KM				Jin, Qunyan; Ding, Wei; Mulder, Kathleen M.			Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; TGF-BETA; CYTOPLASMIC DYNEIN; DEPENDENT DEGRADATION; ENDOCYTIC RESPONSES; AXONAL-TRANSPORT; DYNACTIN COMPLEX; MICROTUBULES; SMADS; TRANSDUCTION	We have identified km23-1 as a novel transforming growth factor-beta (TGF beta) receptor (T beta R)-interacting protein that is also a light chain of the motor protein dynein (dynein light chain). Herein, we demonstrate by sucrose gradient analyses that, in the presence of TGF beta but not in the absence, km23-1 was present in early endosomes with the T beta Rs. Further, confocal microscopy studies indicate that endogenous km23-1 was co-localized with endogenous Smad2 at early times after TGF beta treatment, prior to Smad2 translocation to the nucleus. In addition, immunoprecipitation/ blot analyses showed that TGF beta regulated the interaction between endogenous km23-1 and endogenous Smad2 in vivo. Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGF beta treatment. This decrease was reversed by lactacystin, a specific inhibitor of the 26 S proteasome, suggesting that knockdown of km23-1 causes proteasomal degradation of phosphorylated (i.e. activated) Smad2. Blockade of km23-1 also resulted in a reduction in TGF beta/Smad2-dependent ARE-Lux transcriptional activity, which was rescued by a km23-1 small interfering RNA-resistant construct. In contrast, a reduction in TGF beta/Smad3-dependent SBE2-Luc transcriptional activity did not occur under similar conditions. Furthermore, overexpression of the dynactin subunit dynamitin, which is known to disrupt dynein-mediated intracellular transport, blocked TGF beta-stimulated nuclear translocation of Smad2. Collectively, our findings indicate for the first time that a dynein light chain is required for a Smad2-dependent TGF beta signaling pathway.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.	kmm15@psu.edu			NCI NIH HHS [CA92889, CA90765, CA100239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092889, R01CA100239, R01CA090765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Bowman AB, 1999, J CELL BIOL, V146, P165; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dhani SU, 2003, J BIOL CHEM, V278, P16262, DOI 10.1074/jbc.M209828200; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ding W, 2005, CANCER RES, V65, P6526, DOI 10.1158/0008-5472.CAN-04-4385; Ding Wei, 2004, Cancer Treat Res, V119, P315; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; Dorweiler IJ, 2006, J VIROL, V80, P3634, DOI 10.1128/JVI.80.7.3634-3643.2006; Ehrlich M, 2001, J CELL SCI, V114, P1777; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Greber UF, 2006, CELL, V124, P741, DOI 10.1016/j.cell.2006.02.018; Grieshaber SS, 2003, J CELL SCI, V116, P3793, DOI 10.1242/jcs.00695; Grigoryev SA, 2004, J CELL SCI, V117, P6153, DOI 10.1242/cs.01537; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jiang JM, 2001, GENE, V281, P103, DOI 10.1016/S0378-1119(01)00787-9; Jin Qunyan, 2008, V1, P169, DOI 10.1007/978-1-59745-292-2_11; Jin QY, 2005, CELL SIGNAL, V17, P1363, DOI 10.1016/j.cellsig.2005.02.004; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; Lassus Patrice, 2002, Sci STKE, V2002, ppl13; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Liu GM, 2006, J BIOL CHEM, V281, P29479, DOI 10.1074/jbc.M600579200; Lo KWH, 2005, J BIOL CHEM, V280, P8172, DOI 10.1074/jbc.M411408200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; Nguyen Q, 2005, J BIOL CHEM, V280, P30185, DOI 10.1074/jbc.M505499200; Nikulina K, 2004, CELL MOTIL CYTOSKEL, V57, P233, DOI 10.1002/cm.10172; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; Okamura SM, 2006, J BIOL CHEM, V281, P36132, DOI 10.1074/jbc.M605093200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Phung-Koskas T, 2005, J BIOL CHEM, V280, P1123, DOI 10.1074/jbc.M409918200; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Runyan CE, 2006, CELL SIGNAL, V18, P2077, DOI 10.1016/j.cellsig.2006.05.009; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Susalka SJ, 2000, BBA-MOL CELL RES, V1496, P76, DOI 10.1016/S0167-4889(00)00010-0; Tang Q, 2002, MOL BIOL CELL, V13, P4484, DOI 10.1091/mbc.e02-05-0245; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Yao DY, 2002, MOL BIOL CELL, V13, P4001, DOI 10.1091/mbc.02-07-0104; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yue JB, 2000, J BIOL CHEM, V275, P35656; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Yue JB, 1999, J CELL PHYSIOL, V178, P387; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	84	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19122	19132		10.1074/jbc.M609915200	http://dx.doi.org/10.1074/jbc.M609915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420258	hybrid			2022-12-25	WOS:000247475300054
J	Marion, S; Fralish, GB; Laporte, S; Caron, MG; Barak, LS				Marion, Sebastien; Fralish, Gregory B.; Laporte, Stephane; Caron, Marc G.; Barak, Larry S.			N-terminal tyrosine modulation of the endocytic adaptor function of the beta-arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAIN; CLATHRIN ADAPTER; SRC; PHOSPHORYLATION; INTERNALIZATION; BETA-ARRESTIN1; ACTIVATION; SEQUENCE	The highly homologous beta-arrestin1 and -2 adaptor proteins play important roles in the function of G protein-coupled receptors. Either beta-arrestin variant can function as a molecular chaperone for clathrin-mediated receptor internalization. This role depends primarily upon two distinct, contiguous C-terminal beta-arrestin motifs recognizing clathrin and the mu-adaptin subunit of AP2. However, a molecular basis is lacking to explain the different endocytic efficacies of the two beta-arrestin isoforms and the observation that beta-arrestin N-terminal substitution mutants can act as dominant negative inhibitors of receptor endocytosis. Despite the near identity of the beta-arrestins throughout their N termini, sequence variability is present at a small number of residues and includes tyrosine to phenylalanine substitutions. Here we show that corresponding N-terminal (Y/F) VTL sequences in beta-arrestin1 and -2 differentially regulate mu-adaptin binding. Our results indicate that the beta-arrestin1 Tyr-54 lessens the interaction with mu-adaptin and moreover is a Src phosphorylation site. Again of endocytic function is obtained with the beta-arrestin1 Y54F substitution, which improves both the beta-arrestin1 interaction with mu-adaptin and the ability to enhance beta 2-adrenergic receptor internalization. These data indicate that beta-arrestin2 utilizes mu-adaptin as an endocytic partner, and that the inability of beta-arrestin1 to sustain a similar degree of interaction with mu-adaptin may result from coordination of Tyr-54 by neighboring residues or its modification by Src kinase. Additionally, these naturally occurring variations in beta-arrestins may also differentially regulate the composition of the signaling complexes organized on the receptor.	Duke Univ, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Caron, MG (corresponding author), Duke Univ, Box 3287, Durham, NC 27710 USA.	m.caron@cellbio.duke.edu; l.barak@cellbio.duke.edu	Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X; Marion, Sebastien/0000-0002-3302-3845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM069086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61365] Funding Source: Medline; NIGMS NIH HHS [GM 069086] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; *DEL SCI, 2002, PYMOL MOL GRAPH SYST; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich EV, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-236; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Mundell SJ, 2002, MOL PHARMACOL, V61, P1114, DOI 10.1124/mol.61.5.1114; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ohno H, 1998, GENE, V210, P187, DOI 10.1016/S0378-1119(97)00649-5; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Wakeham DE, 2000, TRAFFIC, V1, P393, DOI 10.1034/j.1600-0854.2000.010504.x; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4	38	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18937	18944		10.1074/jbc.M700090200	http://dx.doi.org/10.1074/jbc.M700090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17456469	hybrid			2022-12-25	WOS:000247475300035
J	Chou, WL; Chuang, LM; Chou, CC; Wang, AHJ; Lawson, JA; FitzGerald, GA; Chang, ZF				Chou, Wen-Ling; Chuang, Lee-Ming; Chou, Chi-Chi; Wang, Andrew H. -J.; Lawson, John A.; FitzGerald, Garret A.; Chang, Zee-Fen			Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E-2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GENE-EXPRESSION; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; CDNA CLONING; LIGAND; METABOLISM; DEHYDROGENASE; BINDING; OBESITY	This report identifies a novel gene encoding 15-oxoprostaglandin-Delta(13)-reductase (PGR-2), which catalyzes the reaction converting 15-keto-PGE(2) to 13,14-dihydro-15-keto-PGE(2). The expression of PGR-2 is up-regulated in the late phase of 3T3-L1 adipocyte differentiation and predominantly distributed in adipose tissue. Overexpression of PGR-2 in cells decreases peroxisome proliferator-activated receptor gamma ( PPAR gamma)-dependent transcription and prohibits 3T3-L1 adipocyte differentiation without affecting expression of PPAR gamma. Interestingly, we found that 15-keto-PGE(2) can act as a ligand of PPAR gamma to increase coactivator recruitment, thus activating PPAR gamma-mediated transcription and enhancing adipogenesis of 3T3-L1 cells. Overexpression of 15-hydroxyprostaglandin dehydrogenase, which catalyzes the oxidation reaction of PGE(2) to form 15-keto-PGE(2), significantly increased PPAR gamma-mediated transcription in a PGE(2)-dependent manner. Reciprocally, overexpression of wild-type PGR-2, but not the catalytically defective mutant, abolished the effect of 15-keto-PGE(2) on PPAR gamma activation. These results demonstrate a novel link between catabolism of PGE(2) and regulation of ligand-induced PPAR gamma activation.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Core Facilities Proteom Res, Taipei 115, Taiwan; Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; University of Pennsylvania; Pennsylvania Medicine	Chang, ZF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, No 1,Sec 1,Jen Ai Rd, Taipei 100, Taiwan.	ZFCHANG@ha.mc.ntu.edu.tw	Chuang, Lee-Ming/AAF-3324-2019; FitzGerald, Garret A/A-4222-2010; Chou, Chi-Chi/X-6053-2019	Chou, Chi-Chi/0000-0002-7862-7757; CHUANG, LEE-MING/0000-0003-0978-2662				ANGGARD E, 1971, ACTA PHYSIOL SCAND, V81, P396, DOI 10.1111/j.1748-1716.1971.tb04914.x; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Cock TA, 2004, EMBO REP, V5, P142, DOI 10.1038/sj.embor.7400082; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Glass CK, 2000, GENE DEV, V14, P121; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hori T, 2004, J BIOL CHEM, V279, P22615, DOI 10.1074/jbc.M312655200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; RICHELSEN B, 1991, DAN MED BULL, V38, P228; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shiraki T, 2005, J BIOL CHEM, V280, P14145, DOI 10.1074/jbc.M500901200; Shivanandappa T, 1997, ANAL BIOCHEM, V254, P57, DOI 10.1006/abio.1997.2406; Soukas A, 2000, GENE DEV, V14, P963; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844	39	73	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18162	18172		10.1074/jbc.M702289200	http://dx.doi.org/10.1074/jbc.M702289200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17449869	Green Published, hybrid			2022-12-25	WOS:000247302000022
J	Moran-Barrio, J; Gonzalez, JM; Lisa, MN; Costello, AL; Dal Peraro, M; Carloni, P; Bennett, B; Tierney, DL; Limansky, AS; Viale, AM; Vila, AJ				Moran-Barrio, Jorgelina; Gonzalez, Javier M.; Lisa, Maria Natalia; Costello, Alison L.; Dal Peraro, Matteo; Carloni, Paolo; Bennett, Brian; Tierney, David L.; Limansky, Adriana S.; Viale, Alejandro M.; Vila, Alejandro J.			The metallo-ss-lactamase GOB is a mono-Zn(II) enzyme with a novel active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC BETA-LACTAMASE; STENOTROPHOMONAS-MALTOPHILIA; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; CHRYSEOBACTERIUM-MENINGOSEPTICUM; ANTIBIOTIC-RESISTANCE; ANGSTROM RESOLUTION; D-CAPTOPRIL; MECHANISM	Metallo-beta-lactamases (M beta Ls) are zinc-dependent enzymes able to hydrolyze and inactivate most beta-lactam antibiotics. The large diversity of active site structures and metal content among M beta Ls from different sources has limited the design of a pan-M beta L inhibitor. Here we report the biochemical and biophysical characterization of a novel M beta L, GOB-18, from a clinical isolate of a Gram-negative opportunistic pathogen, Elizabethkingia meningoseptica. Different spectroscopic techniques, three-dimensional modeling, and mutagenesis experiments, reveal that the Zn(II) ion is bound to Asp(120), His(121), His(263), and a solvent molecule, i.e. in the canonical Zn2 site of dinuclear M beta Ls. Contrasting all other related M beta Ls, GOB-18 is fully active against a broad range of beta-lactam substrates using a single Zn(II) ion in this site. These data further enlarge the structural diversity of M beta Ls.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Quim Biol, Rosario, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Microbiol, Rosario, Argentina; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Univ Penn, Ctr Mol Modeling, Philadelphia, PA 19104 USA; Sch Adv Int Studies, I-34100 Trieste, Italy; Med Coll Wisconsin, Natl Biomed EPR Ctr, Dept Biophys, Milwaukee, WI 53226 USA	National University of Rosario; National University of Rosario; University of New Mexico; University of Pennsylvania; International School for Advanced Studies (SISSA); Medical College of Wisconsin	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Quim Biol, Rosario, Argentina.	vila@ibr.gov.ar	Carloni, Paolo/H-8736-2013	Moran-Barrio, Jorgelina/0000-0001-5952-9337; Lisa, Maria-Natalia/0000-0001-9630-8090; Vila, Alejandro/0000-0002-7978-3233; Gonzalez, Javier Marcelo/0000-0002-3298-2235	NCRR NIH HHS [RR16480] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; AUSUBEL KFM, 1987, CURRENT PROTOCOLS MO; AVERILL BA, 1993, METHOD ENZYMOL, V226, P33, DOI 10.1016/0076-6879(93)26004-S; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; COSTA GL, 1996, IN VITRO MUTAGENESIS; Costello A, 2006, J BIOL INORG CHEM, V11, P351, DOI 10.1007/s00775-006-0083-z; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; Cricco JA, 1999, COORDIN CHEM REV, V190, P519, DOI 10.1016/S0010-8545(99)00113-7; Cricco JA, 1999, CURR PHARM DESIGN, V5, P915; Crowder MW, 2006, ACCOUNTS CHEM RES, V39, P721, DOI 10.1021/ar0400241; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Docquier JD, 2004, ANTIMICROB AGENTS CH, V48, P4778, DOI 10.1128/AAC.48.12.4778-4783.2004; Docquier JD, 2003, J ANTIMICROB CHEMOTH, V51, P257, DOI 10.1093/jac/dkg067; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Frere JM, 2005, J ANTIMICROB CHEMOTH, V55, P1051, DOI 10.1093/jac/dki155; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garau G, 2005, ANTIMICROB AGENTS CH, V49, P2778, DOI 10.1128/AAC.49.7.2778-2784.2005; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hall BG, 2003, J MOL EVOL, V57, P249, DOI 10.1007/s00239-003-2471-0; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marasinghe GPK, 2005, J BIOL CHEM, V280, P40668, DOI 10.1074/jbc.M509748200; Materon IC, 2004, J MOL BIOL, V344, P653, DOI 10.1016/j.jmb.2004.09.074; McClure CP, 2003, J INORG BIOCHEM, V94, P78, DOI 10.1016/S0162-0134(02)00611-6; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Murphy TA, 2006, J MOL BIOL, V357, P890, DOI 10.1016/j.jmb.2006.01.003; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; QUE L, 1987, J AM CHEM SOC, V109, P5381, DOI 10.1021/ja00252a013; Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2; Sharma NP, 2006, BIOCHEMISTRY-US, V45, P10729, DOI 10.1021/bi060893t; Spencer J, 2005, J AM CHEM SOC, V127, P14439, DOI 10.1021/ja0536062; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Thomas PW, 2005, BIOCHEMISTRY-US, V44, P7559, DOI 10.1021/bi050050m; Toleman MA, 2002, J ANTIMICROB CHEMOTH, V50, P673, DOI 10.1093/jac/dkf210; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Xu DG, 2006, J BIOL CHEM, V281, P8740, DOI 10.1074/jbc.M512517200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	53	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18286	18293		10.1074/jbc.M700467200	http://dx.doi.org/10.1074/jbc.M700467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17403673	hybrid, Green Published			2022-12-25	WOS:000247302000035
J	Deng, X; Yellaturu, C; Cagen, L; Wilcox, HG; Park, EA; Raghow, R; Elam, MB				Deng, Xiong; Yellaturu, Chandrahasa; Cagen, Lauren; Wilcox, Henry G.; Park, Edwards A.; Raghow, Rajendra; Elam, Marshall B.			Expression of the rat sterol regulatory element-binding protein-1c gene in response to insulin is mediated by increased transactivating capacity of specificity protein 1 (Sp1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X RECEPTOR; NUCLEAR FACTOR-Y; O-GLYCOSYLATION; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC ACTIVATION; SREBP-1C PROMOTER; CALMODULIN GENE; COACTIVATOR; GLUCOSE; CELLS	The induction of genes involved in lipid biosynthesis by insulin is mediated in part by the sterol regulatory element-binding protein-1c ( SREBP-1c). SREBP-1c is directly regulated by insulin by transcriptional and post-transcriptional mechanisms. Previously, we have demonstrated that the insulin-responsive cis-acting unit of the rat SREBP-1c promoter is composed of several elements that include a sterol regulatory element, two liver X receptor elements, and a number of conserved GC boxes. Here we systematically dissected the role of these GC boxes and report that five bona fide Sp1-binding elements of the SREBP-1c promoter determine its basal and insulin-induced activation. Luciferase expression driven by the rat SREBP-1c promoter was accelerated by ectopic expression of Sp1, and insulin further enhanced the transactivation potential of Sp1. Introduction of a small interfering RNA against Sp1 reduced both basal and insulin-induced activation of the SREBP-1c promoter. We also found that Sp1 interacted with both SREBP-1c and LXR alpha proteins and that insulin promoted these interactions. Chromatin immunoprecipitation studies revealed that insulin facilitated the recruitment of the steroid receptor coactivator-1 to the SREBP-1c promoter. These studies identify a novel mechanism by which maximal activation of the rat SREBP-1c gene expression by insulin is mediated by Sp1 and its enhanced ability to interact with other transcriptional regulatory proteins.	Dept Vet Affairs Med Ctr, Med & Res Serv, Memphis, TN 38104 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Deng, X (corresponding author), Dept Vet Affairs Med Ctr, Med & Res Serv, Memphis, TN 38104 USA.	xdeng@utmem.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059368] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-059368] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BEYNEN AC, 1979, DIABETES, V28, P828, DOI 10.2337/diabetes.28.9.828; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Elam MB, 2001, J LIPID RES, V42, P2039; Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200; Goldberg HJ, 2006, ENDOCRINOLOGY, V147, P222, DOI 10.1210/en.2005-0523; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Huuskonen J, 2004, ARTERIOSCL THROM VAS, V24, P703, DOI 10.1161/01.ATV.0000121202.72593.da; Jackson SM, 1998, J LIPID RES, V39, P767; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Majumdar G, 2006, J BIOL CHEM, V281, P3642, DOI 10.1074/jbc.M511223200; Majumdar G, 2004, DIABETES, V53, P3184, DOI 10.2337/diabetes.53.12.3184; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Schweizer M, 2002, BIOCHEM SOC T, V30, P1070, DOI 10.1042/BST0301070; Sekar N, 2004, AM J PHYSIOL-ENDOC M, V287, pE128, DOI 10.1152/ajpendo.00400.2003; SOLOMON SS, 2002, RRD ENDOCRINOL 1, V3, P79; Sone H, 2002, AM J PHYSIOL-ENDOC M, V282, pE222, DOI 10.1152/ajpendo.00189.2001; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; Waters L, 2006, J BIOL CHEM, V281, P14787, DOI 10.1074/jbc.M600237200; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yellaturu CR, 2005, BIOCHEM BIOPH RES CO, V332, P174, DOI 10.1016/j.bbrc.2005.04.112; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang SY, 1997, ARCH BIOCHEM BIOPHYS, V338, P227, DOI 10.1006/abbi.1996.9809; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	39	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17517	17529		10.1074/jbc.M702228200	http://dx.doi.org/10.1074/jbc.M702228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449871	hybrid			2022-12-25	WOS:000247084500022
J	Guglielmi, KM; Kirchner, E; Holm, GH; Stehle, T; Dermody, TS				Guglielmi, Kristen M.; Kirchner, Eva; Holm, Geoffrey H.; Stehle, Thilo; Dermody, Terence S.			Reovirus binding determinants in junctional adhesion molecule-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ATTACHMENT PROTEIN; CENTRAL-NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; RHINOVIRUS RECEPTOR; CRYSTAL-STRUCTURE; SIALIC-ACID; SIGMA-1; ADENOVIRUS; IDENTIFICATION; STRAINS	Junctional adhesion molecule-A (JAM-A) serves as a serotype-independent receptor for mammalian orthoreoviruses (reoviruses). The membrane-distal immunoglobulin-like D1 domain of JAM-A is required for homodimerization and binding to reovirus attachment protein sigma 1. We employed a structure-guided mutational analysis of the JAM-A dimer interface to identify determinants of reovirus binding. We purified mutant JAM-A ectodomains for solution-phase and surface plasmon resonance binding studies and expressed mutant forms of full-length JAM-A in Chinese hamster ovary cells to assess reovirus binding and infectivity. Mutation of residues in the JAM-A dimer interface that participate in salt-bridge or hydrogen-bond interactions with apposing JAM-A monomers abolishes the capacity of JAM-A to form dimers. JAM-A mutants incapable of dimer formation form complexes with the sigma 1 head that are indistinguishable from wild-type JAM-A-sigma 1 head complexes, indicating that sigma 1 binds to JAM-A monomers. Residues Glu(61) and Lys(63) of beta-strand C and Leu(72) of beta-strand C' in the dimer interface are required for efficient JAM-A engagement of strain type 3 Dearing sigma 1. Mutation of neighboring residues alters the kinetics of the sigma 1-JAM-A binding interaction. Prototype reovirus strains type 1 Lang and type 2 Jones share similar, although not identical, binding requirements with type 3 Dearing. These results indicate that reovirus engages JAM-A monomers via residues found mainly on beta-strands C and C' of the dimer interface and raise the possibility that the distinct disease phenotypes produced in mice following infection with different strains of reovirus are in part attributable to differences in contacts with JAM-A.	Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Univ Tubingen, Interfak Inst Biochem, D-72076 Tubingen, Germany	Vanderbilt University; Vanderbilt University; Vanderbilt University; Eberhard Karls University of Tubingen	Dermody, TS (corresponding author), Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, D7235 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	terry.dermody@vanderbilt.edu	Ogden, Kristen/AAO-9276-2020; Holm, Geoffrey H./C-3188-2009	Ogden, Kristen/0000-0002-2670-4335; 	NIAID NIH HHS [R37 AI38296, F32 AI071440] Funding Source: Medline; NIGMS NIH HHS [T32 GM08554, R01 GM67853] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI071440, R37AI038296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554, R01GM067853] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Becker MM, 2001, J VIROL, V75, P1459, DOI 10.1128/JVI.75.3.1459-1475.2001; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Campbell JA, 2005, J VIROL, V79, P7967, DOI 10.1128/JVI.79.13.7967-7978.2005; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DeLano W, 2002, PYMOL 0 99; DERMODY TS, 1990, J VIROL, V64, P4842, DOI 10.1128/JVI.64.10.4842-4850.1990; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; DICHTER MA, 1984, ANN NEUROL, V16, P603, DOI 10.1002/ana.410160512; Du Pasquier L, 2004, IMMUNOL REV, V198, P233, DOI 10.1111/j.0105-2896.2004.00122.x; DUNCAN R, 1990, VIROLOGY, V174, P399, DOI 10.1016/0042-6822(90)90093-7; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Forrest JC, 2003, J BIOL CHEM, V278, P48434, DOI 10.1074/jbc.M305649200; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kobayashi T, 2007, CELL HOST MICROBE, V1, P147, DOI 10.1016/j.chom.2007.03.003; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LERNER AM, 1963, VIROLOGY, V19, P58, DOI 10.1016/0042-6822(63)90024-2; Liu Y, 2000, J CELL SCI, V113, P2363; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MORRISON LA, 1991, P NATL ACAD SCI USA, V88, P3852, DOI 10.1073/pnas.88.9.3852; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Schelling P, 2007, J BIOL CHEM, V282, P11582, DOI 10.1074/jbc.M610805200; Smelt SC, 2001, J VIROL, V75, P448, DOI 10.1128/JVI.75.1.448-457.2001; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Stehle T, 2004, VIRAL IMMUNOL, V17, P129, DOI 10.1089/0882824041310621; Stehle T, 2003, REV MED VIROL, V13, P123, DOI 10.1002/rmv.379; TARDIEU M, 1983, ANN NEUROL, V13, P602, DOI 10.1002/ana.410130604; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TYLER KL, 1986, SCIENCE, V233, P770, DOI 10.1126/science.3016895; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WEINER HL, 1977, P NATL ACAD SCI USA, V74, P5744, DOI 10.1073/pnas.74.12.5744; WEINER HL, 1980, J INFECT DIS, V141, P609, DOI 10.1093/infdis/141.5.609; WEINER HL, 1980, J IMMUNOL, V124, P2143; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4	54	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17930	17940		10.1074/jbc.M702180200	http://dx.doi.org/10.1074/jbc.M702180200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452315	hybrid			2022-12-25	WOS:000247084500066
J	Lu, ZL; Coetsee, M; White, CD; Millar, RP				Lu, Zhi-Liang; Coetsee, Marla; White, Colin D.; Millar, Robert P.			Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PHARMACOLOGICAL CHAPERONE ACTION; HORMONE GNRH RECEPTOR; MOLECULAR-BASIS; FUNCTIONAL SELECTIVITY; ADRENERGIC-RECEPTOR; RHODOPSIN-FAMILY; AGONIST BINDING; WILD-TYPE; ACTIVATION	G protein coupled receptors (GPCRs) modulate the majority of physiological processes through specific intermolecular interactions with structurally diverse ligands and activation of differential intracellular signaling. A key issue yet to be resolved is how GPCRs developed selectivity and diversity of ligand binding and intracellular signaling during evolution. We have explored the structural basis of selectivity of naturally occurring gonadotropin-releasing hormones (GnRHs) from different species in the single functional human GnRH receptor. We found that the highly variable amino acids in position 8 of the naturally occurring isoforms of GnRH play a discriminating role in selecting receptor conformational states. The human GnRH receptor has a higher affinity for the cognate GnRH I but a lower affinity for GnRH II and GnRHs from other species possessing substitutions for Arg(8). The latter were partial agonists in the human GnRH receptor. Mutation of Asn(7.45) in transmembrane domain (TM) 7 had no effect on GnRH I affinity but specifically increased affinity for other GnRHs and converted them to full agonists. Using molecular modeling and site-directed mutagenesis, we demonstrated that the highly conserved Asn7.45 makes intramolecular interactions with a highly conserved Cys(6.47) in TM 6, suggesting that disruption of this intramolecular interaction induces a receptor conformational change which allosterically alters ligand specific binding sites and changes ligand selectivity and signaling efficacy. These results reveal GnRH ligand and receptor structural elements for conformational selection, and support co-evolution of GnRH ligand and receptor conformations.	Queens Med Res Inst, MRC, Human Reprod Sci Unit, Ctr Reprod Biol, Edinburgh EH16 4TJ, Midlothian, Scotland; Univ Cape Town, ZA-7925 Cape Town, South Africa	University of Edinburgh; University of Cape Town	Lu, ZL (corresponding author), Queens Med Res Inst, MRC, Human Reprod Sci Unit, Ctr Reprod Biol, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	z.lu@hrsu.mrc.ac.uk	Millar, Robert P/A-4853-2012	Lu, Zhiliang/0000-0002-3442-1415; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [MC_U127685846, U.1276.00.005.00001.01 (85846), MC_U127681325] Funding Source: Medline; MRC [MC_U127681325, MC_U127685846] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Bernier V, 2004, CURR OPIN PHARMACOL, V4, P528, DOI 10.1016/j.coph.2004.08.001; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Betz SF, 2006, J MED CHEM, V49, P637, DOI 10.1021/jm0506928; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Calabro V, 2005, P NATL ACAD SCI USA, V102, P6849, DOI 10.1073/pnas.0409282102; Cheng CK, 2005, ENDOCR REV, V26, P283, DOI 10.1210/er.2003-0039; COETSEE M, 2006, BIOSCIENCE GLASG UK; Cussac D, 2002, MOL PHARMACOL, V62, P578, DOI 10.1124/mol.62.3.578; Darlison MG, 1999, TRENDS NEUROSCI, V22, P81, DOI 10.1016/S0166-2236(98)01333-2; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; Favre N, 2005, BIOCHEMISTRY-US, V44, P9990, DOI 10.1021/bi0509853; Fianagan CA, 1999, J BIOL CHEM, V274, P28880, DOI 10.1074/jbc.274.41.28880; Flanagan CA, 2000, BIOCHEMISTRY-US, V39, P8133, DOI 10.1021/bi000085g; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Furse KE, 2003, J MED CHEM, V46, P4450, DOI 10.1021/jm0301437; Gay EA, 2004, MOL PHARMACOL, V66, P97, DOI 10.1124/mol.66.1.97; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Hawtin SR, 2006, J BIOL CHEM, V281, P14604, DOI 10.1074/jbc.M511610200; Hovelmann S, 2002, BIOCHEMISTRY-US, V41, P1129, DOI 10.1021/bi0113162; Janovick JA, 2006, J BIOL CHEM, V281, P8417, DOI 10.1074/jbc.M510601200; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; Knollman PE, 2005, J BIOL CHEM, V280, P24506, DOI 10.1074/jbc.M501978200; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2005, J BIOL CHEM, V280, P29796, DOI 10.1074/jbc.M413520200; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Mamputha S, 2007, MOL ENDOCRINOL, V21, P281, DOI 10.1210/me.2006-0150; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Millar RP, 2004, ENDOCRINOLOGY, V145, P3590, DOI 10.1210/en.2004-0461; Milligan G, 2002, NEUROSIGNALS, V11, P29, DOI 10.1159/000057319; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Morgan K, 2006, ENDOCRINOLOGY, V147, P5041, DOI 10.1210/en.2006-0222; Nakamichi H, 2006, P NATL ACAD SCI USA, V103, P12729, DOI 10.1073/pnas.0601765103; Nikolaev VO, 2006, J BIOL CHEM, V281, P24506, DOI 10.1074/jbc.M603266200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; ROBB S, 1994, EMBO J, V13, P1325, DOI 10.1002/j.1460-2075.1994.tb06385.x; Robben JH, 2006, MOL BIOL CELL, V17, P379, DOI 10.1091/mbc.E05-06-0579; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Schulz A, 2003, J BIOL CHEM, V278, P35531, DOI 10.1074/jbc.M303346200; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Soderhall JA, 2005, BIOCHEM BIOPH RES CO, V333, P568, DOI 10.1016/j.bbrc.2005.05.142; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Urban JD, 2007, NEUROPSYCHOPHARMACOL, V32, P67, DOI 10.1038/sj.npp.1301071; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801; ZHOU W, 1994, MOL PHARMACOL, V45, P165	61	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17921	17929		10.1074/jbc.M610413200	http://dx.doi.org/10.1074/jbc.M610413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452338	Green Published, hybrid			2022-12-25	WOS:000247084500065
J	Moes, M; Rodius, S; Coleman, SJ; Monkley, SJ; Goormaghtigh, E; Tremuth, L; Kox, C; van der Holst, PPG; Critchley, DR; Kieffer, N				Moes, Michele; Rodius, Sophie; Coleman, Stacey J.; Monkley, Susan J.; Goormaghtigh, Erik; Tremuth, Laurent; Kox, Corinne; van der Holst, Patrick P. G.; Critchley, David R.; Kieffer, Nelly			The integrin binding site 2 (IBS2) in the talin rod domain is essential for linking integrin beta subunits to the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING-SITE; SECONDARY STRUCTURE DETERMINATION; F-ACTIN-BINDING; I/LWEQ MODULE; CYTOPLASMIC TAIL; INFRARED-SPECTRA; PROTEIN TALIN; ACTIVATION; SEQUENCE; ALPHA-IIB-BETA-3	Talin1 is a large cytoskeletal protein that links integrins to actin filaments through two distinct integrin binding sites, one present in the talin head domain (IBS1) necessary for integrin activation and a second (IBS2) that we have previously mapped to talin residues 1984-2113 (fragment J) of the talin rod domain (1 Tremuth, L., Kreis, S., Melchior, C., Hoebeke, J., Ronde, P., Plancon, S., Takeda, K., and Kieffer, N. (2004) J. Biol. Chem. 279, 22258-22266), but whose functional role is still elusive. Using a bioinformatics and cell biology approach, we have determined the minimal structure of IBS2 and show that this integrin binding site corresponds to 23 residues located in alpha helix 50 of the talin rod domain (residues 2077-2099). Alanine mutation of 2 highly conserved residues (L2094A/I2095A) within this alpha helix, which disrupted the alpha- helical structure of IBS2 as demonstrated by infrared spectroscopy and limited trypsin proteolysis, was sufficient to prevent in vivo talin fragment J targeting to alpha IIb ss 3 integrin in focal adhesions and to inhibit in vitro this association as shown by an alpha IIb ss 3 pulldown assay. Moreover, expression of a full-length mouse green fluorescent protein-talin LI/AA mutant in mouse talin1(-/-) cells was unable to rescue the inability of these cells to assemble focal adhesions ( in contrast to green fluorescent protein-talin wild type) despite the presence of IBS1. Our data provide the first direct evidence that IBS2 in the talin rod is essential to link integrins to the cytoskeleton.	Univ Luxembourg, CNRS, Lab Biol & Physiol Integree, GDRE,ITI, L-1511 Luxembourg, Luxembourg; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Libre Bruxelles, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium	University of Luxembourg; University of Leicester; Universite Libre de Bruxelles	Kieffer, N (corresponding author), Univ Luxembourg, CNRS, Lab Biol & Physiol Integree, GDRE,ITI, 162A,Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	nelly.kieffer@uni.lu		Goormaghtigh, Erik/0000-0002-2071-2262; Monkley, Susan/0000-0001-9174-6278				Brett TJ, 2006, NAT STRUCT MOL BIOL, V13, P121, DOI 10.1038/nsmb1043; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Franco SJ, 2006, CELL MOTIL CYTOSKEL, V63, P563, DOI 10.1002/cm.20145; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gingras AR, 2006, BIOCHEMISTRY-US, V45, P1805, DOI 10.1021/bi052136l; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Goormaghtigh E, 2006, BIOPHYS J, V90, P2946, DOI 10.1529/biophysj.105.072017; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Martel V, 2000, J CELL SCI, V113, P1951; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; MOLONY L, 1987, J BIOL CHEM, V262, P7790; Oberg KA, 2004, EUR J BIOCHEM, V271, P2937, DOI 10.1111/j.1432-1033.2004.04220.x; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Patel B, 2006, J BIOL CHEM, V281, P7458, DOI 10.1074/jbc.M508058200; Plancon S, 2001, BIOCHEM J, V357, P529, DOI 10.1042/0264-6021:3570529; Ratnikov BI, 2005, J THROMB HAEMOST, V3, P1783, DOI 10.1111/j.1538-7836.2005.01362.x; Raussens V, 2004, APPL SPECTROSC, V58, P68, DOI 10.1366/000370204322729496; Senetar MA, 2005, GENE, V362, P141, DOI 10.1016/j.gene.2005.08.012; Senetar MA, 2004, BIOCHEMISTRY-US, V43, P15418, DOI 10.1021/bi0487239; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	39	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17280	17288		10.1074/jbc.M611846200	http://dx.doi.org/10.1074/jbc.M611846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430904	hybrid			2022-12-25	WOS:000246946500061
J	Pontarin, G; Ferraro, P; Hakansson, P; Thelander, L; Reichard, P; Bianchi, V				Pontarin, Giovanna; Ferraro, Paola; Hakansson, Pelle; Thelander, Lars; Reichard, Peter; Bianchi, Vera			p53R2-dependent ribonucleotide reduction provides Deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE; CELL-CYCLE; SUBSTRATE CYCLES; DEOXYGUANOSINE KINASE; RECOMBINANT MOUSE; MAMMALIAN-CELLS; RENAL-FAILURE; DNTP POOLS; GENE; P53	Human fibroblasts in culture obtain deoxynucleotides by de novo ribonucleotide reduction or by salvage of deoxynucleosides. In cycling cells the de novo pathway dominates, but in quiescent cells the salvage pathway becomes important. Two forms of active mammalian ribonucleotide reductases are known. Each form contains the catalytic R1 protein, but the two differ with respect to the second protein (R2 or p53R2). R2 is cell cycle-regulated, degraded during mitosis, and absent from quiescent cells. The recently discovered p53-inducible p53R2 was proposed to be linked to DNA repair processes. The protein is not cell cycle-regulated and can provide deoxynucleotides to quiescent mouse fibroblasts. Here we investigate the in situ activities of the R1-p53R2 complex and two other enzymes of the de novo pathway, dCMP deaminase and thymidylate synthase, in confluent quiescent serum-starved human fibroblasts in experiments with [5-H-3] cytidine, [6-H-3] deoxycytidine, and [(CH3)-H-3] thymidine. These cells had increased their content of p53R2 2-fold and lacked R2. From isotope incorporation, we conclude that they have a complete de novo pathway for deoxynucleotide synthesis, including thymidylate synthesis. During quiescence, incorporation of deoxynucleotides into DNA was very low. Deoxynucleotides were instead degraded to deoxynucleosides and exported into the medium as deoxycytidine, deoxyuridine, and thymidine. The rate of export was surprisingly high, 25% of that in cycling cells. Total ribonucleotide reduction in quiescent cells amounted to only 2-3% of cycling cells. We suggest that in quiescent cells an important function of p53R2 is to provide deoxynucleotides for mitochondrial DNA replication.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	University of Padua; Umea University	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@bio.unipd.it		Hakansson, Pelle/0000-0003-0421-2433	Telethon [GGP05001] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; PARK I, 1988, ARCH BIOCHEM BIOPHYS, V266, P51, DOI 10.1016/0003-9861(88)90235-4; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; RODE W, 1980, J BIOL CHEM, V255, P1305; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPYROU G, 1987, J BIOL CHEM, V262, P16425; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thelander L, 1978, Methods Enzymol, V51, P227	35	81	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16820	16828		10.1074/jbc.M701310200	http://dx.doi.org/10.1074/jbc.M701310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416930	hybrid			2022-12-25	WOS:000246946500014
J	Nguyen, C; Nishi, A; Kansy, JW; Fernandez, J; Hayashi, K; Gillardon, F; Hemmings, HC; Nairn, AC; Bibb, JA				Nguyen, Chan; Nishi, Akinori; Kansy, Janice W.; Fernandez, Joseph; Hayashi, Kanehiro; Gillardon, Frank; Hemmings, Hugh C., Jr.; Nairn, Angus C.; Bibb, James A.			Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SYNAPTIC VESICLE ENDOCYTOSIS; CDK5 ACTIVATOR P35; IMMUNOCYTOCHEMICAL LOCALIZATION; NEURONAL PHOSPHOPROTEIN; TYROSINE-HYDROXYLASE; HORMONAL-REGULATION; NMDA RECEPTORS; RAT-BRAIN; PHOSPHORYLATION	Inhibitor-1, the first identified endogenous inhibitor of protein phosphatase 1 ( PP-1), was previously reported to be a substrate for cyclin-dependent kinase 5 (Cdk5) at Ser(67). Further investigation has revealed the presence of an additional Cdk5 site identified by mass spectrometry and confirmed by site-directed mutagenesis as Ser(6). Basal levels of phospho-Ser(6) inhibitor-1, as detected by a phosphorylation state-specific antibody against the site, existed in specific regions of the brain and varied with age. In the striatum, basal in vivo phosphorylation and dephosphorylation of Ser6 were mediated by Cdk5, PP-2A, and PP-1, respectively. Additionally, calcineurin contributed to dephosphorylation under conditions of high Ca2+. In biochemical assays the function of Cdk5-dependent phosphorylation of inhibitor-1 at Ser(6) and Ser(67) was demonstrated to be an intramolecular impairment of the ability of inhibitor-1 to be dephosphorylated at Thr(35); this effect was recapitulated in two systems in vivo. Dephosphorylation of inhibitor-1 at Thr(35) is equivalent to inactivation of the protein, as inhibitor-1 only serves as an inhibitor of PP-1 when phosphorylated by cAMP-dependent kinase ( PKA) at Thr(35). Thus, inhibitor-1 serves as a critical junction between kinase-and phosphatase-signaling pathways, linking PP-1 to not only PKA and calcineurin but also Cdk5.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Kurume Univ, Sch Med, Dept Pharmacol, Kurume, Fukuoka 8300011, Japan; Rockefeller Univ, Prot DNA Technol Ctr, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular & Mol Neurosci, New York, NY 10021 USA; Boehringer Ingelheim Pharmaceut Inc, Cent Nervous Syst Res, D-88397 Biberach, Germany; Cornell Univ, Weill Med Coll, Dept Anesthesiol & Pharmacol, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kurume University; Rockefeller University; Rockefeller University; Boehringer Ingelheim; Cornell University; Yale University	Bibb, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.bibb@utsouthwestern.edu	Hayashi, Kanehiro/L-2777-2013	Nairn, Angus/0000-0002-7075-0195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067777, F30MH072062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016672, P01DA010044] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL077101, HL077101] Funding Source: Medline; NIDA NIH HHS [R01 DA016672, DA10044, P01 DA010044, DA16672] Funding Source: Medline; NIMH NIH HHS [R01 MH067777, F30 MH072062, MH072062, MH67777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; BARBAS H, 1993, J COMP NEUROL, V334, P1, DOI 10.1002/cne.903340102; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Campbell David G, 2002, J Biomol Tech, V13, P119; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; CZERNIK AJ, 1997, REGULATORY PROTEIN M, P219; DIBB JA, 1997, REGULATORY PROTEIN M, P275; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Gillardon F, 2005, J CELL BIOCHEM, V95, P817, DOI 10.1002/jcb.20463; Gillardon F, 2005, PROTEOMICS, V5, P1299, DOI 10.1002/pmic.200400992; Gupta RC, 2005, MOL CELL BIOCHEM, V269, P49, DOI 10.1007/s11010-005-2538-x; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; Hayashi K, 2006, J NEUROCHEM, V99, P237, DOI 10.1111/j.1471-4159.2006.04113.x; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kansy JW, 2004, J NEUROCHEM, V91, P374, DOI 10.1111/j.1471-4159.2004.02723.x; Kerokoski P, 2004, NEUROSCI LETT, V368, P181, DOI 10.1016/j.neulet.2004.07.007; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; Lilja L, 2005, BIOCHEM BIOPH RES CO, V329, P673, DOI 10.1016/j.bbrc.2005.02.017; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morabito MA, 2004, J NEUROSCI, V24, P865, DOI 10.1523/JNEUROSCI.4582-03.2004; Moy LY, 2004, J BIOL CHEM, V279, P54487, DOI 10.1074/jbc.M406636200; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; Nguyen C, 2003, J CELL BIOL, V163, P697, DOI 10.1083/jcb.200310038; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; Paglini G, 1998, J NEUROSCI, V18, P9858; Pigino G, 1997, J CELL SCI, V110, P257; Rosales JL, 2006, BIOESSAYS, V28, P1023, DOI 10.1002/bies.20473; Sahin B, 2006, J BIOL CHEM, V281, P24322, DOI 10.1074/jbc.M603282200; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; SHENOLIKAR S, 1991, ADV 2 MESSENGER PHOS, V23, P1; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vander Mierde D, 2007, ENDOCRINOLOGY, V148, P609, DOI 10.1210/en.2006-1012; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6	76	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16511	16520		10.1074/jbc.M701046200	http://dx.doi.org/10.1074/jbc.M701046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400554	Green Accepted, hybrid			2022-12-25	WOS:000246794300058
J	Murcia-Flores, L; Lorca-Pascual, JM; Garre, V; Torres-Martinez, S; Ruiz-Vazquez, RM				Murcia-Flores, Laura; Lorca-Pascual, Juan M.; Garre, Victoriano; Torres-Martinez, Santiago; Ruiz-Vazquez, Rosa M.			Non-AUG translation initiation of a fungal RING finger repressor involved in photocarotenogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOR-CIRCINELLOIDES; PHYCOMYCES-BLAKESLEEANUS; SACCHAROMYCES-CEREVISIAE; CAROTENOID BIOSYNTHESIS; PROTEIN; GENE; RNA; CAROTENOGENESIS; CODONS; CRGA	The RING finger protein CrgA acts as a negative regulator of light-induced carotene biosynthesis in the fungus Mucor circinelloides. Sequence analysis of the crgA coding region upstream of the first AUG codon revealed the existence of an additional non-canonical RING finger domain at the most N-terminal end of the protein. The newly identified RING finger domain is required for CrgA to regulate photocarotenogenesis, as deduced from site-directed mutagenesis experiments. The role of both RING finger domains in the stability of CrgA has been investigated in a yeast system. Wild type CrgA, but not the RING finger deleted forms, is highly unstable and is stabilized by inhibition of the proteasome function, which suggests that native CrgA is degraded by the proteasome and that active RING finger domains are required for proteasome-mediated CrgA degradation. To identify the translation start of CrgA, a mutational analysis of putative initiation codons in the 5' region of the crgA gene was accomplished. We demonstrated that a GUG codon located upstream of the first AUG is the sole initiator of CrgA translation. To our knowledge, this is the first report of a naturally occurring non-AUG start codon for a RING finger regulatory protein. A combination of suboptimal translation initiation and proteasome degradation may help to maintain the low cellular levels of CrgA observed in wild type cells, which is probably required for accurate regulation of photocarotenogenesis.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain	University of Murcia	Ruiz-Vazquez, RM (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, Campus Espinardo, E-30071 Murcia, Spain.	rmruiz@um.es	Garre, Victoriano/H-2533-2015; Ruiz-Vázquez, Rosa María/K-6778-2014; Torres-Martinez, Santiago/K-7660-2014; Murcia, Laura/AAD-7100-2021	Garre, Victoriano/0000-0001-7605-1726; Ruiz-Vázquez, Rosa María/0000-0002-6675-8506; Torres-Martinez, Santiago/0000-0002-7083-4516; Murcia, Laura/0000-0001-7768-0989				Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Conlon H, 2001, MOL MICROBIOL, V40, P361, DOI 10.1046/j.1365-2958.2001.02399.x; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Gietz R. D., 1998, CELLS LAB MANUAL, VI, P87; GOVIND NS, 1986, J GEN MICROBIOL, V132, P2775; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu G, 1999, MOL CELL BIOL, V19, P724; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Logan IR, 2004, J BIOL CHEM, V279, P11696, DOI 10.1074/jbc.M312712200; Lorca-Pascual JM, 2004, MOL MICROBIOL, V52, P1463, DOI 10.1111/j.1365-2958.2004.04070.x; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; NAMBRU C, 1997, J BIOL CHEM, V272, P32061; Navarro E, 2000, EUR J BIOCHEM, V267, P800, DOI 10.1046/j.1432-1327.2000.01058.x; Navarro E, 2001, MOL GENET GENOMICS, V266, P463, DOI 10.1007/s004380100558; Nicolas FE, 2003, EMBO J, V22, P3983, DOI 10.1093/emboj/cdg384; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PRINTEN JA, 1994, GENETICS, V138, P609; Quiles-Rosillo MD, 2005, FUNGAL GENET BIOL, V42, P141, DOI 10.1016/j.fgb.2004.10.008; Quiles-Rosillo MD, 2003, FUNGAL GENET BIOL, V38, P122, DOI 10.1016/S1087-1845(02)00519-4; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; RONCERO MIG, 1984, CARLSBERG RES COMMUN, V49, P685, DOI 10.1007/BF02907499; Rose MD., 1990, METHODS YEAST GENETI; RUIZPEREZ VL, 1995, CURR GENET, V28, P309, DOI 10.1007/BF00326428; Sambrook J, 2001, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Silva F, 2006, MOL MICROBIOL, V61, P1023, DOI 10.1111/j.1365-2958.2006.05291.x; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; Tang HL, 2004, J BIOL CHEM, V279, P49656, DOI 10.1074/jbc.M408081200; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004	39	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15394	15403		10.1074/jbc.M610366200	http://dx.doi.org/10.1074/jbc.M610366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403679	hybrid			2022-12-25	WOS:000246589600015
J	Stefansson, S; Su, EJ; Ishigami, S; Cale, JM; Gao, YM; Gorlatova, N; Lawrence, DA				Stefansson, Steingrimur; Su, Enming J.; Ishigami, Shoji; Cale, Jacqueline M.; Gao, Yamei; Gorlatova, Natalia; Lawrence, Daniel A.			The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ARG-GLY-ASP; SOMATOMEDIN B-DOMAIN; EXTRACELLULAR-MATRIX; IN-VIVO; MICROTUBULE CYTOSKELETON; ALPHA(V)BETA(5) INTEGRIN; BINDING-SITE; TUMOR-GROWTH; MIGRATION	The serine proteinase inhibitor, plasminogen activator inhibitor type-1 (PAI- 1), binds to the adhesion protein vitronectin with high affinity at a site that is located directly adjacent to the vitronectin RGD integrin binding sequence. The binding of PAI-1 to vitronectin sterically blocks integrin access to this site and completely inhibits the binding of purified integrins to vitronectin; however, its inhibition of endothelial and smooth muscle cell adhesion to vitronectin is at most 50-75%. Because PAI-1 binds vitronectin with similar to 10-100-fold higher affinity than purified integrins, we have analyzed the mechanism whereby these cells are able to overcome this obstacle. Our studies exclude proteolytic removal of PAI-1 from vitronectin as the mechanism, and show instead that cell adhesion in the presence of PAI-1 is dependent on integrin-cytoskeleton engagement. Disrupting endothelial or smooth muscle cell actin polymerization and/or focal adhesion assembly reduces cell adhesion to vitronectin in the presence of PAI-1 to levels similar to that observed for the binding of purified integrins to vitronectin. Furthermore, endothelial cell, but not smooth muscle cell adhesion to vitronectin in the presence of PAI-1 requires both polymerized microtubules and actin, further demonstrating the importance of the cytoskeleton for integrin-mediated adhesion. Finally, we show that cell adhesion in the presence of PAI-1 leads to colocalization of PAI-1 with the integrins alpha v beta 3 and alpha v beta 5 at the cell-matrix interface.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland Baltimore	Stefansson, S (corresponding author), Creatv MicroTech, 11609 Lake Potomac Dr, Potomac, MD 20854 USA.	stenni@creatvmicrotech.com		Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [R01 HL055747, P01 HL054710, HL055374, HL055747, HL054710, HL069624] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL069624, P01HL054710, R01HL055747, R43HL069624, R01HL055374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Graness A, 2006, KIDNEY INT, V69, P1341, DOI 10.1038/sj.ki.5000296; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jin TQ, 2002, J BIOL CHEM, V277, P32963, DOI 10.1074/jbc.M201525200; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin W, 2002, CONNECT TISSUE RES, V43, P22; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Liu SC, 2000, J CELL SCI, V113, P3563; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; Osdoit S, 2001, J BIOL CHEM, V276, P6703, DOI 10.1074/jbc.M008945200; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2004, J BIOL CHEM, V279, P29981, DOI 10.1074/jbc.M401913200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Strachan LR, 2004, J CELL BIOL, V167, P545, DOI 10.1083/jcb.200405024; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; Wang YX, 2006, P NATL ACAD SCI USA, V103, P1774, DOI 10.1073/pnas.0510774103; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	60	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15679	15689		10.1074/jbc.M702125200	http://dx.doi.org/10.1074/jbc.M702125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403662	hybrid			2022-12-25	WOS:000246589600044
J	Xu, SC; Abbasian, M; Patel, P; Jensen-Pergakes, K; Lombardo, CR; Cathers, BE; Xie, WL; Mercurio, F; Pagano, M; Giegel, D; Cox, S				Xu, Shuichan; Abbasian, Mahan; Patel, Palka; Jensen-Pergakes, Kristen; Lombardo, Christian R.; Cathers, Brian E.; Xie, Weilin; Mercurio, Frank; Pagano, Michele; Giegel, David; Cox, Sarah			Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; KAPPA-B-ALPHA; MALIGNANT PHENOTYPE; CDK INHIBITOR; P27(KIP1); COMPLEX; CKS1; P27; SKP2; OVEREXPRESSION	p27, an important cell cycle regulator, blocks the G1/S transition in cells by binding and inhibiting Cdk2/cyclin A and Cdk2/cyclin E complexes (Cdk2/E). Ubiquitination and subsequent degradation play a critical role in regulating the levels of p27 during cell cycle progression. Here we provide evidence suggesting that both Cdk2/E and phosphorylation of Thr187 on p27 are essential for the recognition of p27 by the SCFSkp2/Cks1 complex, the ubiquitin-protein isopeptide ligase (E3). Cdk2/E provides a high affinity binding site, whereas the phosphorylated Thr187 provides a low affinity binding site for the Skp2/Cks1 complex. Furthermore, binding of phosphorylated p27/Cdk2/E to the E3 complex showed positive cooperativity. Consistently, p27 is also ubiquitinated in a similarly cooperative manner. In the absence of p27, Cdk2/E and Cks1 increase Skp2 phosphorylation. This phosphorylation enhances Skp2 auto-ubiquitination, whereas p27 inhibits both phosphorylation and auto- ubiquitination of Skp2.	Signal Pharmaceut LLC, Dept Biochem & Biomarker Dev, San Diego, CA 92121 USA; Signal Pharmaceut LLC, Dept Discovery Biol, San Diego, CA 92121 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Xu, SC (corresponding author), Signal Pharmaceut LLC, Dept Biochem & Biomarker Dev, 4550 Towne Ctr Ct, San Diego, CA 92121 USA.	sxu@celgene.com		Cathers, Brian/0000-0003-2793-7533; pagano, michele/0000-0003-3210-2442				Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Chen J, 1996, ONCOGENE, V13, P1395; Copeland R. A., 2000, ENZYMES PRACTICAL IN, P367; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Havlis J, 2003, ANAL CHEM, V75, P1300, DOI 10.1021/ac026136s; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Masuda T, 2002, CANCER RES, V62, P3819; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nalepa G, 2003, CANCER TREAT REV, V29, P49, DOI 10.1016/S0305-7372(03)00083-5; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reed SI, 2005, MOL CELL, V20, P1, DOI 10.1016/j.molcel.2005.09.011; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stevenson-Lindert LM, 2003, J BIOL CHEM, V278, P50956, DOI 10.1074/jbc.M306546200; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Ungermannova D, 2005, J BIOL CHEM, V280, P30301, DOI 10.1074/jbc.M411103200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu SC, 2005, METHOD ENZYMOL, V399, P729, DOI 10.1016/S0076-6879(05)99048-4; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	35	14	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15462	15470		10.1074/jbc.M610758200	http://dx.doi.org/10.1074/jbc.M610758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409098	hybrid			2022-12-25	WOS:000246589600021
J	Ramanujan, VK; Herman, BA				Ramanujan, V. Krishnan; Herman, Brian A.			Aging process modulates nonlinear dynamics in liver cell metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTAL DYNAMICS; CANCER; MITOCHONDRIA; COMPLEXITY; DISEASE; DAMAGE	Regulatory dynamics of energy metabolism in living cells entails a coordinated response of multiple enzyme networks that operate under non-equilibrium conditions. Here we show that mitochondrial dysfunctions associated with the aging process significantly modify nonlinear dynamical signatures in free radical generation/removal, thereby altering energy metabolism in liver cells. We support our data with a plausible biochemical mechanism for modified bioenergetics that involves uncoupling protein-2 that is up-regulated in aged cells as an adaptive response to mitigate increased oxidative stress. Combining high spatial and temporal resolution imaging and bio-energetic measurements, our work provides experimental support to the hypothesis that mitochondria manifest nonlinear dynamical behavior for efficiently regulating energy metabolism in intact cells, and any partial or complete reduction in this behavior would contribute to organ dysfunctions including the aging process and other disease processes.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Herman, BA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	hermanb@uthscsa.edu	Ramanujan, V Krishnan/A-6395-2011; Ramanujan, V Krishnan/O-2831-2014		NATIONAL INSTITUTE ON AGING [R01AG007218] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG007218-18A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharya UR, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-24; Ashkenazy Y, 2001, PHYS REV LETT, V86, P1900, DOI 10.1103/PhysRevLett.86.1900; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; BEZERIANOS A, 1995, CHAOS, V5, P95, DOI 10.1063/1.166104; Brennan M, 2002, AM J PHYSIOL-HEART C, V283, pH1873, DOI 10.1152/ajpheart.00405.2000; Cadenas Enrique, 2004, Molecular Aspects of Medicine, V25, P17, DOI 10.1016/j.mam.2004.02.005; Campisi J, 2005, MECH AGEING DEV, V126, P51, DOI 10.1016/j.mad.2004.09.024; Echtay KS, 2005, BIOFACTORS, V24, P119, DOI 10.1002/biof.5520240114; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Eke A, 2002, PHYSIOL MEAS, V23, pR1, DOI 10.1088/0967-3334/23/1/201; English BP, 2006, NAT CHEM BIOL, V2, P87, DOI 10.1038/nchembio759; Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25; Gavrilov Leonid A, 2002, ScientificWorldJournal, V2, P339; Genova ML, 1997, FEBS LETT, V410, P467; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Hausdorff JM, 1997, J APPL PHYSIOL, V82, P262; HAVLIN S, 1995, CHAOS SOLITON FRACT, V6, P171, DOI 10.1016/0960-0779(95)80025-C; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; KNOOK D, 1986, HDB CELL BIOL AGING, P229; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Mangel M, 2001, J THEOR BIOL, V213, P559, DOI 10.1006/jtbi.2001.2431; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; Ramanujan VK, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2098753; Ramanujan VK, 2006, BIOPHYS J, V90, pL70, DOI 10.1529/biophysj.106.083501; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; Stam CJ, 2004, HUM BRAIN MAPP, V22, P97, DOI 10.1002/hbm.20016; Stanley HE, 2002, P NATL ACAD SCI USA, V99, P2561, DOI 10.1073/pnas.022582899; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; Vaillancourt DE, 2004, J APPL PHYSIOL, V97, P454, DOI 10.1152/japplphysiol.00244.2004; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698; Zhang YP, 2002, EXP GERONTOL, V37, P777, DOI 10.1016/S0531-5565(02)00013-X	35	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19217	19226		10.1074/jbc.M700572200	http://dx.doi.org/10.1074/jbc.M700572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17446172	hybrid			2022-12-25	WOS:000247475300062
J	Lee, BH; Chen, W; Stippec, S; Cobb, MH				Lee, Byung-Hoon; Chen, Wei; Stippec, Steve; Cobb, Melanie H.			Biological cross-talk between WNK1 and the transforming growth factor beta-Smad signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GENE FAMILY; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; SOMATIC MUTATIONS; BLOOD-PRESSURE; CELLS; CANCER; HYPERTENSION; EXPRESSION; MECHANISM	WNKs (with no lysine (K)), unique serine/threonine protein kinases, have been best studied in the context of cell volume regulation and ion homeostasis. Here we describe a biological link between WNKs and transforming growth factor (TGF) beta-Smad signaling. Both WNK1 and WNK4 directly bind to and phosphorylate Smad2. Knockdown of WNK1 in HeLa cells using small interfering RNA reduces Smad2 protein expression; this decrease is at least partially due to down-regulation of Smad2 transcription. In contrast, phosphorylated Smad2 significantly accumulated in the nucleus as a consequence of depletion of WNK1, resulting in Smad-mediated transcriptional responses. In addition, TGF beta-induced target gene transcripts were increased in WNK1 small interfering RNA cells. These findings suggest WNK1 as a dual modulator of TGF beta-Smad signaling pathways.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Cell Biol, Cambridge, MA 02138 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Cobb, Melanie/0000-0003-0833-5473; Lee, Byung-Hoon/0000-0002-7101-0471	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Anselmo AN, 2006, P NATL ACAD SCI USA, V103, P10883, DOI 10.1073/pnas.0604607103; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Funaba M, 2000, PROTEIN EXPRES PURIF, V20, P507, DOI 10.1006/prep.2000.1315; Ito M, 2001, CANCER RES, V61, P2038; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lazrak A, 2006, P NATL ACAD SCI USA, V103, P1615, DOI 10.1073/pnas.0510609103; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Verissimo F, 2006, ONCOGENE, V25, P4172, DOI 10.1038/sj.onc.1209449; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xie J, 2006, PEDIATR NEPHROL, V21, P1231, DOI 10.1007/s00467-006-0106-6; Xu BE, 2005, J BIOL CHEM, V280, P34218, DOI 10.1074/jbc.M505735200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Yakmovych I, 2001, FASEB J, V15, P553; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zeng GC, 2005, GENE, V344, P233, DOI 10.1016/j.gene.2004.10.003	54	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17985	17996		10.1074/jbc.M702664200	http://dx.doi.org/10.1074/jbc.M702664200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392271	hybrid			2022-12-25	WOS:000247302000005
J	Eto, M; Kirkbride, J; Elliott, E; Lo, SH; Brautigan, DL				Eto, Masumi; Kirkbride, Jason; Elliott, Elizabeth; Lo, Su Hao; Brautigan, David L.			Association of the tensin N-terminal protein-tyrosine phosphatase domain with the alpha isoform of protein phosphatase-1 in focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SUBCELLULAR-LOCALIZATION; MYOSIN PHOSPHATASE; MATRIX ADHESIONS; CELL-MIGRATION; PHOSPHORYLATION; PAXILLIN; INHIBITOR; DYNAMICS; MOTILITY	Focal adhesions attach cultured cells to the extracellular matrix, and we found endogenous protein phosphatase-1 alpha-isoform (PP1 alpha) localized in adhesions across the entire area of adherent fibroblasts. However, in fibroblasts migrating into a scrape wound or spreading after replating PP1 alpha did not appear in adhesions near the leading edge but was recruited into other adhesions coincident in time and space with incorporation of tensin. Endogenous tensin and PP1 alpha co-precipitated from cell lysates with isoform-specific PP1 antibodies. Chemical cross-linking of focal adhesion preparations with Lomant's reagent demonstrated molecular proximity of endogenous PP1 alpha and tensin, whereas neither focal adhesion kinase nor vinculin was cross-linked and co-precipitated with PP1 alpha, suggesting distinct spatial subdomains within adhesions. Transient expression of truncated tensin showed the N-terminal 360 residues, which comprise a protein-tyrosine phosphatase domain, alone were sufficient for isoform-selective co-precipitation of co-expressed PP1 alpha. Human prostate cancer PC3 cells are deficient in tensin relative to fibroblasts and have fewer, mostly peripheral adhesions. Transient expression of green fluorescent protein tensin in these cancer cells induced formation of adhesions and recruited endogenous PP1 alpha into those adhesions. Thus, the protein-tyrosine phosphatase domain of tensin exhibits isoform-specific association with PP1 alpha in a restricted spatial region of adhesions that are formed during cell migration.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Calif Davis, Dept Orthoped Surg, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA	University of Virginia; University of Virginia; University of California System; University of California Davis; Jefferson University	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Box 800577,1400 Jerrson Pk Ave, Charlottesville, VA 22908 USA.	db8g@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836; Lo, Su Hao/0000-0002-2675-9387	NCI NIH HHS [CA 40042] Funding Source: Medline; NIGMS NIH HHS [GM 56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Bianchi M, 2005, BIOCHEM J, V391, P359, DOI 10.1042/BJ20050282; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2003, BIOCHEM J, V370, P1039, DOI 10.1042/BJ20021308; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 2003, METHOD ENZYMOL, V366, P156; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; Eto M, 2005, CELL MOTIL CYTOSKEL, V62, P100, DOI 10.1002/cm.20088; Eto M, 2004, P NATL ACAD SCI USA, V101, P8888, DOI 10.1073/pnas.0307812101; Fresu M, 2001, BIOCHEM J, V358, P407, DOI 10.1042/0264-6021:3580407; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Haynie DT, 1996, PROTEIN SCI, V5, P2643, DOI 10.1002/pro.5560051227; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Kawada M, 1999, BBA-MOL CELL RES, V1452, P209, DOI 10.1016/S0167-4889(99)00126-3; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Murata K, 1997, MOL BIOL CELL, V8, P663, DOI 10.1091/mbc.8.4.663; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Strack S, 1999, J COMP NEUROL, V413, P373; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Villa-Moruzzi E, 1998, CELL ADHES COMMUN, V5, P297, DOI 10.3109/15419069809040299; Webb DJ, 2003, NAT CELL BIOL, V5, P690, DOI 10.1038/ncb0803-690; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb DJ, 2005, J CELL SCI, V118, P4925, DOI 10.1242/jcs.02563; Webb Donna J., 2004, V294, P3; Young MRI, 2002, INT J CANCER, V100, P276, DOI 10.1002/ijc.10491; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 2001, J CELL SCI, V114, P3577	34	16	16	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17806	17815		10.1074/jbc.M700944200	http://dx.doi.org/10.1074/jbc.M700944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17435217	hybrid			2022-12-25	WOS:000247084500054
J	Lanciano, P; Vergnes, A; Grimaldi, S; Guigliarelli, B; Magalon, A				Lanciano, Pascal; Vergnes, Alexandra; Grimaldi, Stephane; Guigliarelli, Bruno; Magalon, Axel			Biogenesis of a respiratory complex is orchestrated by a single accessory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI NITRATE REDUCTASE; ESCHERICHIA-COLI; MOLYBDENUM COFACTOR; FORMATE DEHYDROGENASE; INHIBITOR BINDING; CATALYTIC SUBUNIT; GENE-PRODUCTS; TAT PATHWAY; NARGHI; EPR	The biogenesis of respiratory complexes is a multistep process that requires finely tuned coordination of subunit assembly, metal cofactor insertion, and membrane-anchoring events. The dissimilatory nitrate reductase of the bacterial anaerobic respiratory chain is a membrane-bound heterotrimeric complex nitrate reductase A ( NarGHI) carrying no less than eight redox centers. Here, we identified different stable folding assembly intermediates of the nitrate reductase complex and analyzed their redox cofactor contents using electron paramagnetic resonance spectroscopy. Upon the absence of the accessory protein NarJ, a global defect in metal incorporation was revealed. In addition to the molybdenum cofactor, we show that NarJ is required for specific insertion of the proximal iron-sulfur cluster ( FS0) within the soluble nitrate reductase ( NarGH) catalytic dimer. Further, we establish that NarJ ensures complete maturation of the b-type cytochrome subunit NarI by a proper timing for membrane anchoring of the NarGH complex. Our findings demonstrate that NarJ has a multifunctional role by orchestrating both the maturation and the assembly steps.	CNRS, Inst Biol Struct & Mircobiol, Unite Bioenerget & Ingn Prot, F-13402 Marseille 09, France; CNRS, Inst Biol Struct & Mircobiol, Lab Chim Bacterienne, F-13402 Marseille 09, France; Univ Aix Marseille 1, F-13402 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Magalon, A (corresponding author), CNRS, Inst Biol Struct & Mircobiol, Unite Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 09, France.	magalon@ibsm.cnrs-mrs.fr	Vergnes, Alexandra/AAM-2842-2020; Grimaldi, Stephane/G-9884-2013; Grimaldi, Stephane/AAF-7138-2020	Grimaldi, Stephane/0000-0002-9559-6112; Magalon, Axel/0000-0002-3375-738X				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; Blasco F, 2001, CELL MOL LIFE SCI, V58, P179, DOI 10.1007/PL00000846; Bock A, 2006, ADV MICROB PHYSIOL, V51, P1, DOI 10.1016/S0065-2911(06)51001-X; Grimaldi S, 2005, BIOCHEMISTRY-US, V44, P1300, DOI 10.1021/bi048009r; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kirillova O, 2007, ACTA CRYSTALLOGR D, V63, P348, DOI 10.1107/S0907444906055065; Kloer DP, 2006, STRUCTURE, V14, P1377, DOI 10.1016/j.str.2006.07.001; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; Magalon A, 1997, J BIOL CHEM, V272, P25652, DOI 10.1074/jbc.272.41.25652; Magalon A, 1998, BIOCHEMISTRY-US, V37, P7363, DOI 10.1021/bi972858f; Magalon A, 1998, J BIOL CHEM, V273, P10851, DOI 10.1074/jbc.273.18.10851; MANDRANDBERTHELOT MA, 1988, J GEN MICROBIOL, V134, P3129; McDevitt CA, 2002, MOL MICROBIOL, V44, P1575, DOI 10.1046/j.1365-2958.2002.02978.x; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Nilavongse A, 2006, MICROBIOL-SGM, V152, P3227, DOI 10.1099/mic.0.29157-0; Olmo-Mira MF, 2004, J BIOL CHEM, V279, P49727, DOI 10.1074/jbc.M406502200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Palmer T, 2005, TRENDS MICROBIOL, V13, P175, DOI 10.1016/j.tim.2005.02.002; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Potter LC, 1999, BIOCHEM J, V344, P69, DOI 10.1042/0264-6021:3440069; Ray N, 2003, FEBS LETT, V534, P156, DOI 10.1016/S0014-5793(02)03839-5; Rothery RA, 2001, J MOL MICROB BIOTECH, V3, P273; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Rothery RA, 1999, BIOCHEMISTRY-US, V38, P12747, DOI 10.1021/bi990533o; Rothery RA, 2004, BIOCHEMISTRY-US, V43, P5324, DOI 10.1021/bi049938l; Sargent F, 2002, ARCH MICROBIOL, V178, P77, DOI 10.1007/s00203-002-0434-2; SCHLINDWEIN C, 1990, J BACTERIOL, V172, P6112, DOI 10.1128/jb.172.10.6112-6121.1990; STEWART V, 1991, J BACTERIOL, V173, P4417, DOI 10.1128/JB.173.14.4417-4423.1991; Vergnes A, 2006, J BIOL CHEM, V281, P2170, DOI 10.1074/jbc.M505902200; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200	40	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17468	17474		10.1074/jbc.M700994200	http://dx.doi.org/10.1074/jbc.M700994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442677	hybrid			2022-12-25	WOS:000247084500017
J	Ranjith-Kumar, CT; Miller, W; Sun, JC; Xiong, J; Santos, J; Yarbrough, I; Lamb, RJ; Mills, J; Duffy, KE; Hoose, S; Cunningham, M; Holzenburg, A; Mbow, ML; Sarisky, RT; Kao, CC				Ranjith-Kumar, C. T.; Miller, William; Sun, Jingchuan; Xiong, Jin; Santos, Jon; Yarbrough, Ian; Lamb, Roberta J.; Mills, Juliane; Duffy, Karen E.; Hoose, Scott; Cunningham, Mark; Holzenburg, Andreas; Mbow, M. Lamine; Sarisky, Robert T.; Kao, C. Cheng			Effects of single nucleotide polymorphisms on toll-like receptor 3 activity and expression in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SUBCELLULAR-LOCALIZATION; FUNCTIONAL ANALYSES; RECOGNITION; TLR3; ACTIVATION; RESISTANCE; IMMUNITY	Recognition of double-stranded RNA by Toll-like receptor 3 (TLR3) will increase the production of cytokines and chemokines through transcriptional activation by the NF-kappa B protein. Over 136 single-nucleotide polymorphisms (SNPs) in TLR3 have been identified in the human population. Of these, four alter the sequence of the TLR3 protein. Molecular modeling suggests that two of the SNPs, N284I and L412F, could affect the packing of the leucine-rich repeating units in TLR3. Notably, L412F is reported to be present in 20% of the population and is higher in the asthmatic population. To examine whether the four SNPs affect TLR3 function, each were cloned and tested for their ability to activate the expression of TLR3-dependent reporter constructs. SNP N284I was nearly completely defective for activating reporter activity, and L412F was reduced in activity. These two SNPs did not obviously affect the level of TLR3 expression or their intracellular location in vesicles. However, N284I and L412F were underrepresented on the cell surface, as determined by flow cytometry analysis, and were not efficiently secreted into the culture medium when expressed as the soluble ectodomain. They were also reduced in their ability to act in a dominant negative fashion on the wild type TLR3 allele. These observations suggest that N284I and L412F affect the activities of TLR3 needed for proper signaling.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA; Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Johnson & Johnson; Johnson & Johnson USA	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Kumar CT, Ranjith/J-5701-2016	Miller, William/0000-0002-1518-2973				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Glaubitz JC, 2004, MOL ECOL NOTES, V4, P309, DOI 10.1111/j.1471-8286.2004.00597.x; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Lancaster GI, 2005, J PHYSIOL-LONDON, V563, P945, DOI 10.1113/jphysiol.2004.081224; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lazzaro BP, 2004, SCIENCE, V303, P1873, DOI 10.1126/science.1092447; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Nishiya T, 2005, J BIOL CHEM, V280, P37107, DOI 10.1074/jbc.M504951200; Paxton WA, 1998, SEMIN IMMUNOL, V10, P187, DOI 10.1006/smim.1998.0132; Pirie FJ, 2005, TISSUE ANTIGENS, V66, P125, DOI 10.1111/j.1399-0039.2005.00454.x; Plewniak F, 2003, NUCLEIC ACIDS RES, V31, P3829, DOI 10.1093/nar/gkg518; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200; Salio M, 2005, CURR BIOL, V15, pR336, DOI 10.1016/j.cub.2005.04.025; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Uematsu S, 2006, EXPERT OPIN BIOL TH, V6, P203, DOI 10.1517/14712598.6.3.203; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7	35	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17696	17705		10.1074/jbc.M700209200	http://dx.doi.org/10.1074/jbc.M700209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17434873	hybrid			2022-12-25	WOS:000247084500042
J	Wang, RW; Chen, WQ; Cai, ST; Zhang, J; Bolstad, J; Wagenknecht, T; Liu, Z; Chen, SRW				Wang, Ruiwu; Chen, Wenqian; Cai, Shitian; Zhang, Jing; Bolstad, Jeff; Wagenknecht, Terence; Liu, Zheng; Chen, S. R. Wayne			Localization of an NH2-terminal disease-causing mutation hot spot to the "clamp" region in the three-dimensional structure of the cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; CALCIUM-RELEASE; VENTRICULAR-TACHYCARDIA; CRYOELECTRON MICROSCOPY; MALIGNANT HYPERTHERMIA; FKBP12.6 BINDING; SITE; RECONSTRUCTION; RYR2	A region between residues 414 and 466 in the cardiac ryanodine receptor (RyR2) harbors more than half of the known NH2-terminal mutations associated with cardiac arrhythmias and sudden death. To gain insight into the structural basis of this NH2-terminal mutation hot spot, we have determined its location in the three-dimensional structure of RyR2. Green fluorescent protein (GFP), used as a structural marker, was inserted into the middle of this mutation hot spot after Ser-437 in the RyR2 sequence. The resultant GFP-RyR2 fusion protein, RyR(2S437-GFP), was expressed in HEK293 cells and characterized using Ca2+ release, [H-3] ryanodine binding, and single cell Ca2+ imaging studies. These functional analyses revealed that RyR2(S437-GFP) forms a caffeine-and ryanodine-sensitive Ca2+ release channel that possesses Ca2+ and caffeine dependence of activation indistinguishable from that of wild type (wt) RyR2. HEK293 cells expressing RyR2(S437-GFP) displayed a propensity for store overload-induced Ca2+ release similar to that in cells expressing RyR2-wt. The three-dimensional structure of the purified RyR2(S437-GFP) was reconstructed using cryo-electron microscopy and single particle image processing. Subtraction of the three-dimensional reconstructions of RyR2-wt and RyR2(S437-GFP) revealed the location of the inserted GFP, and hence the NH2-terminal mutation hot spot, in a region between domains 5 and 9 in the clamp-shaped structure. This location is close to a previously mapped central disease-causing mutation site located in a region between domains 5 and 6. These results, together with findings from previous studies, suggest that the proposed interactions between the NH2-terminal and central regions of RyR2 are likely to take place between domains 5 and 6 and that the clamp-shaped structure, which shows substantial conformational differences between the closed and open states, is highly susceptible to disease-causing mutations.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; New York State Dept Hlth, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; University of Calgary; University of Calgary; State University of New York (SUNY) System	Liu, Z (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.	liuz@wadsworth.org; swchen@ucalgary.ca		Liu, Zheng/0000-0001-6952-3406	NCRR NIH HHS [P41 RR001219-21, RR01219, P41 RR001219] Funding Source: Medline; NIAMS NIH HHS [R01 AR040615-15, AR40615, R01 AR040615] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Doi Nobuhide, 2002, Methods Mol Biol, V183, P49; Frank J, 2006, 3 DIMENSIONAL ELECT, P71; George CH, 2003, CIRC RES, V93, P531, DOI 10.1161/01.RES.0000091335.07574.86; Hamilton SL, 2005, CELL CALCIUM, V38, P253, DOI 10.1016/j.ceca.2005.06.037; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Jiang DW, 2004, P NATL ACAD SCI USA, V101, P13062, DOI 10.1073/pnas.0402388101; Jiang DW, 2005, CIRC RES, V97, P1173, DOI 10.1161/01.RES.0000192146.85173.4b; Kontula K, 2005, CARDIOVASC RES, V67, P379, DOI 10.1016/j.cardiores.2005.04.027; Liu Z, 2005, J BIOL CHEM, V280, P37941, DOI 10.1074/jbc.M505714200; Liu Z, 2004, J MOL BIOL, V338, P533, DOI 10.1016/j.jmb.2004.03.011; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; Lyfenko AD, 2004, BIOCHEM BIOPH RES CO, V322, P1256, DOI 10.1016/j.bbrc.2004.08.031; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Murayama T, 2007, BIOCHEM J, V402, P349, DOI 10.1042/BJ20061040; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Priori SG, 2005, J CLIN INVEST, V115, P2033, DOI 10.1172/JCI25664; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scoote M, 2004, BIOCHEM BIOPH RES CO, V322, P1286, DOI 10.1016/j.bbrc.2004.08.034; Serysheva I, 2005, J MOL BIOL, V345, P427, DOI 10.1016/j.jmb.2004.10.073; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Sharma MR, 2002, BIOPHYS J, V82, p644A; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Treves S, 2005, NEUROMUSCULAR DISORD, V15, P577, DOI 10.1016/j.nmd.2005.06.008; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Yano M, 2006, NAT CLIN PRACT CARD, V3, P43, DOI 10.1038/ncpcardio0419; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	42	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17785	17793		10.1074/jbc.M700660200	http://dx.doi.org/10.1074/jbc.M700660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452324	Green Accepted, hybrid			2022-12-25	WOS:000247084500052
J	Hong, SP; Carlson, M				Hong, Seung-Pyo; Carlson, Marian			Regulation of Snf1 protein kinase in response to environmental stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT SIGNALING PATHWAYS; SHOCK TRANSCRIPTION FACTOR; 3 SNF1-ACTIVATING KINASES; HAPLOID INVASIVE GROWTH; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; GLUCOSE STARVATION; SUBCELLULAR-LOCALIZATION; GLYCOGEN ACCUMULATION; UPSTREAM KINASES	The Saccharomyces cerevisiae Snf1 protein kinase, a member of the Snf1/AMPK (AMP-activated protein kinase) family, has important roles in metabolic control, particularly in response to nutrient stress. Here we have addressed the role of Snf1 in responses to other environmental stresses. Exposure of cells to sodium ion stress, alkaline pH, or oxidative stress caused an increase in Snf1 catalytic activity and phosphorylation of Thr-210 in the activation loop, whereas treatment with sorbitol or heat shock did not. Inhibition of respiratory metabolism by addition of antimycin A to cells also increased Snf1 activity. Analysis of mutants indicated that the kinases Sak1, Tos3, and Elm1, which activate Snf1 in response to glucose limitation, are also required under other stress conditions. Each kinase sufficed for activation in response to stress, but Sak1 had the major role. In sak1 Delta tos3 Delta elm1 Delta cells expressing mammalian Ca2+/calmodulin-dependent protein kinase kinase alpha, Snf1 was activated by both sodium ion and alkaline stress, suggesting that stress signals regulate Snf1 activity by a mechanism that is independent of the upstream kinase. Finally, we showed that Snf1 protein kinase is regulated differently during adaptation of cells to NaCl and alkaline pH with respect to both temporal regulation of activation and subcellular localization. Snf1 protein kinase becomes enriched in the nucleus in response to alkaline pH but not salt stress. Such differences could contribute to specificity of the stress responses.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Microbiol, New York, NY 10032 USA	Columbia University; Columbia University	Carlson, M (corresponding author), 701 W 168th,HSC922, New York, NY 10032 USA.	mbc1@columbia.edu	Hong, Raymond/R-6915-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034095, R01GM034095] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034095, GM34095] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, PROTEIN SCI, V13, P155, DOI 10.1110/ps.03340004; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Ashrafi K, 2000, GENE DEV, V14, P1872; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; De Wever V, 2005, EMBO J, V24, P4115, DOI 10.1038/sj.emboj.7600871; Dubacq C, 2004, MOL CELL BIOL, V24, P2560, DOI 10.1128/MCB.24.6.2560-2572.2004; Elbing K, 2006, BIOCHEM J, V393, P797, DOI 10.1042/BJ20051213; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200; Hahn JS, 2004, J BIOL CHEM, V279, P5169, DOI 10.1074/jbc.M311005200; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARDY TA, 1994, J BIOL CHEM, V269, P27907; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Honigberg SM, 1998, MOL CELL BIOL, V18, P4548, DOI 10.1128/MCB.18.8.4548; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim MD, 2005, EUKARYOT CELL, V4, P861, DOI 10.1128/EC.4.5.861-866.2005; Kuchin S, 2002, MOL CELL BIOL, V22, P3994, DOI 10.1128/MCB.22.12.3994-4000.2002; Lin SS, 2003, J BIOL CHEM, V278, P13390, DOI 10.1074/jbc.M212818200; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; McCartney R, 2005, CURR GENET, V47, P335, DOI 10.1007/s00294-005-0576-2; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Orlova M, 2006, EUKARYOT CELL, V5, P1831, DOI 10.1128/EC.00110-06; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Palecek SP, 2002, MOL MICROBIOL, V45, P453, DOI 10.1046/j.1365-2958.2002.03024.x; Platara M, 2006, J BIOL CHEM, V281, P36632, DOI 10.1074/jbc.M606483200; Portillo F, 2005, FEBS LETT, V579, P512, DOI 10.1016/j.febslet.2004.12.019; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; WOODS A, 1994, J BIOL CHEM, V269, P19509; Ye T, 2006, EUKARYOT CELL, V5, P1611, DOI 10.1128/EC.00215-06; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	52	136	141	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16838	16845		10.1074/jbc.M700146200	http://dx.doi.org/10.1074/jbc.M700146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17438333	hybrid			2022-12-25	WOS:000246946500016
J	Pan, XY; Hussain, FN; Iqbal, J; Feuerman, MH; Hussain, MM				Pan, Xiaoyue; Hussain, Farah N.; Iqbal, Jahangir; Feuerman, Miriam H.; Hussain, M. Mahmood			Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRACHLORIDE-INDUCED HEPATOTOXICITY; DIFFERENTIATED CACO-2 CELLS; CARBON-TETRACHLORIDE; APOLIPOPROTEIN-B; ISOLATED HEPATOCYTES; LIPID-PEROXIDATION; MCA-RH7777 CELLS; GENE-EXPRESSION; LIVER STEATOSIS; MTP INHIBITOR	Carbon tetrachloride (CCl4) interferes with triglyceride secretion and causes steatosis, fibrosis, and necrosis. In mice, CCl4 decreased plasma triglyceride-rich lipoproteins, increased cellular lipids, and reduced microsomal triglyceride transfer protein (MTP) without diminishing mRNA levels. Similarly, CCl4 decreased apoB-lipoprotein production and MTP activity but had no effect on mRNA levels in primary enterocytes and colon carcinoma and hepatoma cells. CCl4 did not affect MTP synthesis but induced post-translational degradation involving ubiquitinylation and proteasomes in McA-RH7777 cells. By contrast, MTP inhibitor increased cellular lipids without affecting MTP protein. MTP was covalently modified when cells were incubated with (CCl4)-C-14. This modification was prevented by the inhibition of P450 oxygenases, indicating that CCl3 center dot generated by these enzymes targets MTP for degradation. To determine whether inhibition of proteolysis could prevent CCl4 toxicity, mice were fed with CCl4 with or without lactacystin. Lactacystin increased ubiquitinylated MTP and prevented lipid accumulation in tissues. Thus, CCl4 induces post-translational degradation without affecting lipid transfer activity, whereas MTP antagonist inhibits lipid transfer activity without causing its destruction. These studies identify MTP as a major target of CCl4 and its degradation as a novel mechanism involved in the onset of steatosis, suggesting that inhibition of proteolysis may prevent some forms of steatosis.	Suny Downstate Med Ctr, Dept Anat & Cellular Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Biochem, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cellular Biol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	mhussain@downstate.edu	Iqbal, Jahangir/B-3903-2014	Iqbal, Jahangir/0000-0002-9021-2271	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2003, DRUG DISCOV TODAY, V8, P307, DOI 10.1016/S1359-6446(03)02647-3; Anwar K, 2006, J LIPID RES, V47, P1261, DOI 10.1194/jlr.M500523-JLR200; Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; Bakillah A, 2003, FRONT BIOSCI-LANDMRK, V8, pD294; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Basu S, 2003, TOXICOLOGY, V189, P113, DOI 10.1016/S0300-483X(03)00157-4; Boll M, 2001, Z NATURFORSCH C, V56, P649; Boll M, 2001, Z NATURFORSCH C, V56, P283; Boll M, 2001, Z NATURFORSCH C, V56, P111; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Chandler CE, 2003, J LIPID RES, V44, P1887, DOI 10.1194/jlr.M300094-JLR200; Cuchel M, 2007, NEW ENGL J MED, V356, P148, DOI 10.1056/NEJMoa061189; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006; Fatma S, 2006, J LIPID RES, V47, P2422, DOI 10.1194/jlr.M600211-JLR200; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Harries HM, 2001, TOXICOL IN VITRO, V15, P399, DOI 10.1016/S0887-2333(01)00043-1; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; *INT AG RES CANC, 1999, RISKS HUM, V71, P401; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; LIN MCM, 1995, J LIPID RES, V36, P1073; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mirandola S, 2006, GASTROENTEROLOGY, V130, P1661, DOI 10.1053/j.gastro.2006.02.035; Pan XY, 2002, AM J PHYSIOL-GASTR L, V283, pG57, DOI 10.1152/ajpgi.00545.2001; PENCIL SD, 1984, BIOCHEM PHARMACOL, V33, P2419, DOI 10.1016/0006-2952(84)90713-5; Plaa GL, 2000, ANNU REV PHARMACOL, V40, P43, DOI 10.1146/annurev.pharmtox.40.1.43; POLI G, 1979, EXP MOL PATHOL, V30, P116, DOI 10.1016/0014-4800(79)90086-8; Rava P, 2006, J BIOL CHEM, V281, P11019, DOI 10.1074/jbc.M512823200; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; RECKNAGE RO, 1967, PHARMACOL REV, V19, P145; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; Sugimoto T, 2002, J HEPATOL, V36, P157, DOI 10.1016/S0168-8278(01)00263-X; Terada T, 2005, BIOCHEM PHARMACOL, V70, P1756, DOI 10.1016/j.bcp.2005.09.027; Tietge UJF, 1999, J LIPID RES, V40, P2134; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wong FWY, 1998, TOXICOL APPL PHARM, V153, P109, DOI 10.1006/taap.1998.8547; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhang QY, 2003, DRUG METAB DISPOS, V31, P1346, DOI 10.1124/dmd.31.11.1346	53	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17078	17089		10.1074/jbc.M701742200	http://dx.doi.org/10.1074/jbc.M701742200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405876	hybrid			2022-12-25	WOS:000246946500041
J	Tzelepis, F; Persechini, PM; Rodrigues, MM				Tzelepis, Fanny; Persechini, Pedro M.; Rodrigues, Mauricio M.			Modulation of CD4(+) T Cell-Dependent Specific Cytotoxic CD8(+) T Cells Differentiation and Proliferation by the Timing of Increase in the Pathogen Load	PLOS ONE			English	Article							TRYPANOSOMA-CRUZI INFECTION; MALARIA LIVER STAGES; LISTERIA-MONOCYTOGENES; ANTIGEN PRESENTATION; TOXOPLASMA-GONDII; CD8-T-CELL MEMORY; VIRAL-INFECTION; CD4-T-CELL HELP; DEFICIENT MICE; 3RD SIGNAL	Background. Following infection with viruses, bacteria or protozoan parasites, naive antigen-specific CD8(+) T cells undergo a process of differentiation and proliferation to generate effector cells. Recent evidences suggest that the timing of generation of specific effector CD8(+) T cells varies widely according to different pathogens. We hypothesized that the timing of increase in the pathogen load could be a critical parameter governing this process. Methodology/Principal Findings. Using increasing doses of the protozoan parasite Trypanosoma cruzi to infect C57BL/6 mice, we observed a significant acceleration in the timing of parasitemia without an increase in mouse susceptibility. In contrast, in CD8 deficient mice, we observed an inverse relationship between the parasite inoculum and the timing of death. These results suggest that in normal mice CD8(+) T cells became protective earlier, following the accelerated development of parasitemia. The evaluation of specific cytotoxic responses in vivo to three distinct epitopes revealed that increasing the parasite inoculum hastened the expansion of specific CD8(+) cytotoxic T cells following infection. The differentiation and expansion of T. cruzi-specific CD8(+) cytotoxic T cells is in fact dependent on parasite multiplication, as radiation-attenuated parasites were unable to activate these cells. We also observed that, in contrast to most pathogens, the activation process of T. cruzi-specific CD8(+) cytotoxic T cells was dependent on MHC class II restricted CD4(+) T cells. Conclusions/Significance. Our results are compatible with our initial hypothesis that the timing of increase in the pathogen load can be a critical parameter governing the kinetics of CD4(+) T cell-dependent expansion of pathogen-specific CD8(+) cytotoxic T cells.	[Tzelepis, Fanny; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, Sao Paulo, Brazil; [Tzelepis, Fanny; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil; [Persechini, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Ilha Fundao, Ctr Ciencias Saude, BR-21941 Rio De Janeiro, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Rio de Janeiro	Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, Sao Paulo, Brazil.	mrodrigues@ecb.epm.br	Persechini, Pedro/A-9477-2009; Rodrigues, Mauricio M./B-8512-2012	Persechini, Pedro/0000-0002-3278-1951; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; Millennium Institute for Vaccine Development and Technology [CNPq - 420067/2005-1]; FAPESP; CNPq	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Millennium Institute for Vaccine Development and Technology; FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, and The Millennium Institute for Vaccine Development and Technology (CNPq - 420067/2005-1). FT is a recipient of a fellowship from FAPESP. PMP and MMR are recipients of fellowships from CNPq.	Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Busch DH, 1998, J EXP MED, V188, P61, DOI 10.1084/jem.188.1.61; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; Curtsinger JM, 2003, J EXP MED, V197, P1141, DOI 10.1084/jem.20021910; Da Silva APG, 2003, IMMUNOLOGY, V108, P230, DOI 10.1046/j.1365-2567.2003.01571.x; Datta SK, 2006, IMMUNITY, V25, P143, DOI 10.1016/j.immuni.2006.05.013; Denkers EY, 1997, J IMMUNOL, V159, P1903; Hafalla JCR, 2002, P NATL ACAD SCI USA, V99, P11819, DOI 10.1073/pnas.182189999; Harrington LE, 2002, J VIROL, V76, P3329, DOI 10.1128/JVI.76.7.3329-3337.2002; Harty JT, 2002, CURR OPIN IMMUNOL, V14, P360, DOI 10.1016/S0952-7915(02)00333-3; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kwok LY, 2003, J IMMUNOL, V170, P1949, DOI 10.4049/jimmunol.170.4.1949; Legge KL, 2005, IMMUNITY, V23, P649, DOI 10.1016/j.immuni.2005.11.006; Lutjen S, 2006, INFECT IMMUN, V74, P5790, DOI 10.1128/IAI.00098-06; Luu RA, 2006, J IMMUNOL, V177, P1516, DOI 10.4049/jimmunol.177.3.1516; Martin DL, 2006, PLOS PATHOG, V2, P731, DOI 10.1371/journal.ppat.0020077; Marzo AL, 2004, J IMMUNOL, V173, P969, DOI 10.4049/jimmunol.173.2.969; Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2; MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P145; Morrot A, 2005, J EXP MED, V202, P551, DOI 10.1084/jem.20042463; Morrot A, 2004, IMMUNOL REV, V201, P291, DOI 10.1111/j.0105-2896.2004.00175.x; Muller U, 2003, EUR J IMMUNOL, V33, P70, DOI 10.1002/immu.200390009; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Pope C, 2001, J IMMUNOL, V166, P3402, DOI 10.4049/jimmunol.166.5.3402; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Renggli J, 1997, PARASITE IMMUNOL, V19, P145, DOI 10.1046/j.1365-3024.1997.d01-190.x; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Sano G, 2001, J EXP MED, V194, P173, DOI 10.1084/jem.194.2.173; Schmidt CS, 2002, J IMMUNOL, V168, P5521, DOI 10.4049/jimmunol.168.11.5521; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Tarleton RL, 1996, INT IMMUNOL, V8, P13, DOI 10.1093/intimm/8.1.13; Tsuji M, 2003, TRENDS PARASITOL, V19, P88, DOI 10.1016/S1471-4922(02)00053-3; Tzelepis F, 2006, INFECT IMMUN, V74, P2477, DOI 10.1128/IAI.74.4.2477-2481.2006; Valenzuela J, 2002, J IMMUNOL, V169, P6842, DOI 10.4049/jimmunol.169.12.6842; van Faassen H, 2004, J IMMUNOL, V172, P3491, DOI 10.4049/jimmunol.172.6.3491; Wherry EJ, 2004, J VIROL, V78, P5535, DOI 10.1128/JVI.78.11.5535-5545.2004	40	45	47	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e393	10.1371/journal.pone.0000393	http://dx.doi.org/10.1371/journal.pone.0000393			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460760	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445600007
J	Deppert, W				Deppert, W.			Introduction - Mutant p53: from guardian to fallen angel?	ONCOGENE			English	Editorial Material							MUTATIONS; COMPLEX; GAIN		Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute	Deppert, W (corresponding author), Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271	5	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2142	2144		10.1038/sj.onc.1210276	http://dx.doi.org/10.1038/sj.onc.1210276			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401422				2022-12-25	WOS:000245394800002
J	Joshi, MS; Mineo, C; Shaul, PW; Bauer, JA				Joshi, Mandar S.; Mineo, Chieko; Shaul, Philip W.; Bauer, John Anthony			Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear	FASEB JOURNAL			English	Article						caveolin-1; endothelial nitric oxide synthase; functional genomics; gene polymorphism; protein-protein interactions	NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; PHOSPHORYLATION; HYPERTENSION; CELLS; EXPRESSION; MECHANISM; PROTEINS; CLEAVAGE	Human endothelial nitric oxide synthase ( NOS3) gene polymorphism at Exon 7 ( Glu298Asp) has been linked to vascular endothelial dysfunction, but the mechanisms are not defined. Shear is a key modulator of NOS3 function in vivo and association with caveolae is important for the control of NOS3 protein activity. Here we tested the hypothesis that altered enrichment of NOS3 in the caveolar membrane defines Glu298Asp genotype- specific responses and NOS3 activity. Basal caveolar membrane enrichment was carried out to quantitate the NOS3 enrichment in caveolae. Cells were subjected to shear and NOS3 protein levels, phosphorylation, enzyme function were investigated. Variant genotypes had lower NOx production pre- and post- shear, but no genotype- dependent alterations in pNOS3 were observed. Asp variants had significantly lower NOS3 enrichment in the caveolar membrane fraction. Further, immunoprecipitation studies demonstrated that Asp variants had substantially less NOS3/ Cav- 1 association ( similar to 40%) during static conditions. Furthermore, acute shear causes impaired NOS3/ Cav- 1 dissociation in Asp variants. The results from immunoprecipitation studies were in complete agreement with caveolar membrane preparation findings. Collectively, these data demonstrate functional consequences of the Glu298Asp NOS3 variation and further define disruption of NOS3 caveolar localization and shear- induced mobilization as the primary mechanism responsible for these differences. - Joshi, M. S., Mineo, C., Shaul, P. W., Bauer, J. A. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear.	Columbus Childrens Res Inst, Ctr Cardiovasc Med, Columbus, OH 43205 USA; Univ Texas, SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75235 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bauer, JA (corresponding author), Columbus Childrens Res Inst, Ctr Cardiovasc Med, 700 Childrens Dr, Columbus, OH 43205 USA.	bauerj@ccri.net			NHLBI NIH HHS [R01 HL063067, HL63067, R01 HL058888, HL58888] Funding Source: Medline; NIDDK NIH HHS [DK55053, R01 DK055053] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063067, R01HL058888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055053] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40; Andrews Karen L, 2002, Heart Fail Rev, V7, P423, DOI 10.1023/A:1020702215520; Andrews KL, 2005, EXPERT OPIN THER TAR, V9, P101, DOI 10.1517/14728222.9.1.101; Angus JA, 1996, CLIN EXP PHARMACOL P, V23, pS16, DOI 10.1111/j.1440-1681.1996.tb03036.x; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; AWOLESI MA, 1994, SURGERY, V116, P439; Ballermann BJ, 1998, KIDNEY INT, V54, pS100, DOI 10.1046/j.1523-1755.1998.06720.x; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Boo YC, 2006, FREE RADICAL BIO MED, V41, P144, DOI 10.1016/j.freeradbiomed.2006.03.024; BUSSE R, 1995, ANN MED, V27, P331, DOI 10.3109/07853899509002586; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Fairchild TA, 2001, J BIOL CHEM, V276, P26674, DOI 10.1074/jbc.M103647200; Fike CD, 2004, AM J PHYSIOL-LUNG C, V286, pL1244, DOI 10.1152/ajplung.00345.2003; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521; Hingorani AD, 2003, CURR HYPERTENS REP, V5, P19, DOI 10.1007/s11906-003-0006-0; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Maniatis NA, 2006, CIRC RES, V99, P870, DOI 10.1161/01.RES.0000245187.08026.47; Markus HS, 1998, STROKE, V29, P1908, DOI 10.1161/01.STR.29.9.1908; Mihm MJ, 2003, BIOCHEM PHARMACOL, V65, P1189, DOI 10.1016/S0006-2952(03)00012-1; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; Raij L, 1998, HYPERTENSION, V31, P189, DOI 10.1161/01.HYP.31.1.189; Searles CD, 2006, AM J PHYSIOL-CELL PH, V291, pC803, DOI 10.1152/ajpcell.00457.2005; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Wang XL, 2000, FEBS LETT, V471, P45, DOI 10.1016/S0014-5793(00)01356-9; Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41; Wattanapitayakul SK, 2001, TRENDS PHARMACOL SCI, V22, P361, DOI 10.1016/S0165-6147(00)01692-8; ZWIETERING MH, 1990, APPL ENVIRON MICROB, V56, P1875	35	99	100	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2655	2663		10.1096/fj.06-7088com	http://dx.doi.org/10.1096/fj.06-7088com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449720	Green Accepted			2022-12-25	WOS:000249237500007
J	Tasaki, T; Sohr, R; Xia, Z; Hellweg, R; Hortnagl, H; Varshavsky, A; Kwon, YT				Tasaki, Takafumi; Sohr, Reinhard; Xia, Zanxian; Hellweg, Rainer; Hoertnagl, Heide; Varshavsky, Alexander; Kwon, Yong Tae			Biochemical and genetic studies of UBR3, a ubiquitin ligase with a function in olfactory and other sensory systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; MICE LACKING; CARDIOVASCULAR DEVELOPMENT; PATHWAY; DEGRADATION; RECOGNITION; COMPONENT; PROTEIN; RECEPTORS; APOPTOSIS	Our previous work identified E3 ubiquitin ligases, termed UBR1 - UBR7, that contain the similar to 70-residue UBR box, a motif important for the targeting of N-end rule substrates. In this pathway, specific N-terminal residues of substrates are recognized as degradation signals by UBR box-containing E3s that include UBR1, UBR2, UBR4, and UBR5. The other E3s of this set, UBR3, UBR6, and UBR7, remained uncharacterized. Here we describe the cloning and analyses of mouse UBR3. The similarities of UBR3 to the UBR1 and UBR2 E3s of the N-end rule pathway include the RING and UBR domains. We show that HR6A and HR6B, the E2 enzymes that bind to UBR1 and UBR2, also interact with UBR3. However, in contrast to UBR1 and UBR2, UBR3 does not recognize N-end rule substrates. We also constructed UBR3-lacking mouse strains. In the 129SvImJ background, UBR3(-/-) mice died during embryogenesis, whereas the C57BL/6 background UBR3(-/-) mice exhibited neonatal lethality and suckling impairment that could be partially rescued by litter size reduction. The adult UBR3(-/-) mice had female-specific behavioral anosmia. Cells of the olfactory pathway were found to express beta-galactosidase (LacZ) that marked the deletion/ disruption UBR3(-) allele. The UBR3- specific LacZ expression was also prominent in cells of the touch, vision, hearing, and taste systems, suggesting a regulatory role of UBR3 in sensory pathways, including olfaction. By analogy with functions of the UBR domain in the N-end rule pathway, we propose that the UBR box of UBR3 may recognize small compounds that modulate the targeting, by this E3, of its currently unknown substrates.	Univ Pittsburgh, Ctr Pharmacogenet, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; Univ Med Berlin, Charite, Inst Pharmacol & Toxicol, D-10117 Berlin, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Med Berlin, Charite, Dept Psychiat & Psychotherapy, D-14050 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; California Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kwon, YT (corresponding author), Univ Pittsburgh, Ctr Pharmacogenet, Dept Pharmaceut Sci, 3501 Terrace St, Pittsburgh, PA 15261 USA.	yok5@pitt.edu		Hellweg, Rainer/0000-0001-8033-389X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039520, R01DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074000, R01GM069482, R01GM031530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL083365] Funding Source: Medline; NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM69482, GM074000, GM31530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ache BW, 2005, NEURON, V48, P417, DOI 10.1016/j.neuron.2005.10.022; An JY, 2006, P NATL ACAD SCI USA, V103, P6212, DOI 10.1073/pnas.0601700103; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Burns ME, 2005, NEURON, V48, P387, DOI 10.1016/j.neuron.2005.10.014; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chourbaji S, 2004, MOL BRAIN RES, V121, P28, DOI 10.1016/j.molbrainres.2003.11.002; Dalton P, 2002, NAT NEUROSCI, V5, P199, DOI 10.1038/nn803; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Du FY, 2002, P NATL ACAD SCI USA, V99, P14110, DOI 10.1073/pnas.172527399; Erbse A, 2006, NATURE, V439, P753, DOI 10.1038/nature04412; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; GUAN XB, 1993, BRAIN RES, V622, P51, DOI 10.1016/0006-8993(93)90800-3; Harlow E., 1999, USING ANTIBODIES LAB; Hellweg R, 1996, NEUROREPORT, V7, P777, DOI 10.1097/00001756-199602290-00023; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; Hu RG, 2006, J BIOL CHEM, V281, P32559, DOI 10.1074/jbc.M604355200; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Lin SY, 2005, CURR OPIN NEUROBIOL, V15, P350, DOI 10.1016/j.conb.2005.05.012; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Murphy GJ, 2005, NAT NEUROSCI, V8, P354, DOI 10.1038/nn1403; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Piepponen TP, 2001, J CHROMATOGR B, V757, P277, DOI 10.1016/S0378-4347(01)00156-6; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Scott K, 2005, NEURON, V48, P455, DOI 10.1016/j.neuron.2005.10.015; Sheng J, 2002, EMBO J, V21, P6061, DOI 10.1093/emboj/cdf626; Smeets WJAJ, 2000, BRAIN RES REV, V33, P308, DOI 10.1016/S0165-0173(00)00034-5; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Trinh K, 2003, NAT NEUROSCI, V6, P519, DOI 10.1038/nn1039; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky AV, 2006, PROTEIN SCI, V15, P647, DOI 10.1110/ps.052012306; Wang L, 2004, J BIOL CHEM, V279, P55218, DOI 10.1074/jbc.M410085200; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Yoshida S, 2002, PLANT J, V32, P129, DOI 10.1046/j.1365-313X.2002.01407.x; Zenker M, 2005, NAT GENET, V37, P1345, DOI 10.1038/ng1681	63	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18510	18520		10.1074/jbc.M701894200	http://dx.doi.org/10.1074/jbc.M701894200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17462990	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000247302000056
J	Abe, Y; Jo, T; Matsuda, Y; Matsunaga, C; Katayama, T; Ueda, T				Abe, Yoshito; Jo, Takaaki; Matsuda, Yusaku; Matsunaga, Chika; Katayama, Tsutomu; Ueda, Tadashi			Structure and function of DnaA N-terminal domains - Specific sites and mechanisms in inter-DnaA interaction and in DnaB helicase loading on oriC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI CHROMOSOMAL ORIGIN; HUMAN POLY(C)-BINDING PROTEIN-2; HUMAN TELOMERIC DNA; C-RICH STRAND; ESCHERICHIA-COLI; REPLICATION-ORIGIN; INITIATOR PROTEIN; CONSERVED MOTIF; BINDING DOMAIN; SLIDING CLAMP	DnaA forms a homomultimeric complex with the origin of chromosomal replication (oriC) to unwind duplex DNA. The interaction of the DnaA N terminus with the DnaB helicase is crucial for the loading of DnaB onto the unwound region. Here, we determined the DnaA N terminus structure using NMR. This region (residues 1 -108) consists of a rigid region (domain I) and a flexible region (domain II). Domain I has an alpha-alpha-beta-beta-alpha-beta motif, similar to that of the K homology (KH) domain, and has weak affinity for oriC single-stranded DNA, consistent with KH domain function. A hydrophobic surface carrying Trp-6 most likely forms the interface for domain I dimerization. Glu-21 is located on the opposite surface of domain I from the Trp-6 site and is crucial for DnaB helicase loading. These findings suggest a model for DnaA homomultimer formation and DnaB helicase loading on oriC.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp; ueda@phar.kyushu-u.ac.jp	Abe, Yoshito/AAH-6141-2021; Abe, Yoshito/D-8370-2012	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490; Katayama, Tsutomu/0000-0001-9994-1684				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du ZH, 2005, J BIOL CHEM, V280, P38823, DOI 10.1074/jbc.M508183200; Du ZH, 2004, J BIOL CHEM, V279, P48126, DOI 10.1074/jbc.M405371200; Erzberger JP, 2006, NAT STRUCT MOL BIOL, V13, P676, DOI 10.1038/nsmb1115; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; Felczak MM, 2005, J BIOL CHEM, V280, P24627, DOI 10.1074/jbc.M503684200; Felczak MM, 2004, J BIOL CHEM, V279, P51156, DOI 10.1074/jbc.M409695200; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HWANG DS, 1991, J BIOL CHEM, V266, P7537; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Kaguni JM, 2006, ANNU REV MICROBIOL, V60, P351, DOI 10.1146/annurev.micro.60.080805.142111; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kawakami H, 2005, J BIOL CHEM, V280, P27420, DOI 10.1074/jbc.M502764200; Kawakami H, 2006, J STRUCT BIOL, V156, P220, DOI 10.1016/j.jsb.2006.02.007; Kawakami H, 2006, MOL MICROBIOL, V62, P1310, DOI 10.1111/j.1365-2958.2006.05450.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; Obita T, 2002, BIOCHEM BIOPH RES CO, V299, P42, DOI 10.1016/S0006-291X(02)02590-1; Paziewska A, 2004, FEBS LETT, V577, P134, DOI 10.1016/j.febslet.2004.08.086; Robinson NP, 2005, FEBS J, V272, P3757, DOI 10.1111/j.1742-4658.2005.04768.x; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; Su'etsugu M, 2004, GENES CELLS, V9, P509, DOI 10.1111/j.1356-9597.2004.00741.x; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; Worbs M, 2001, MOL CELL, V7, P1177, DOI 10.1016/S1097-2765(01)00262-3; Yoshida Y, 2003, CELL MOL LIFE SCI, V60, P1998, DOI 10.1007/s00018-003-3176-7	47	84	86	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17816	17827		10.1074/jbc.M701841200	http://dx.doi.org/10.1074/jbc.M701841200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17420252	hybrid			2022-12-25	WOS:000247084500055
J	Khalimonchuk, O; Bird, A; Winge, DR				Khalimonchuk, Oleh; Bird, Amanda; Winge, Dennis R.			Evidence for a pro-oxidant intermediate in the assembly of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; HUMAN SCO1; TRANSLATIONAL ACTIVATOR; CU(I)-BINDING PROTEIN; CRYSTAL-STRUCTURE; YEAST SCO1; COX11; EXPRESSION	The hydrogen peroxide sensitivity of cells lacking two proteins, Sco1 and Cox11, important in the assembly of cytochrome c oxidase (CcO), is shown to arise from the transient accumulation of a pro-oxidant heme A-Cox1 stalled intermediate. The peroxide sensitivity of these cells is abrogated by a reduction in either Cox1 expression or heme A formation but exacerbated by either enhanced Cox1 expression or heme A production arising from overexpression of COX15. Sco1 and Cox11 are implicated in the formation of the Cu-A and Cu-B sites of CcO, respectively. The respective wild-type genes suppress the peroxide sensitivities of sco1 Delta and cox11 Delta cells, but no cross-complementation is seen with noncognate genes. Copper-binding mutant alleles of Sco1 and Cox11 that are nonfunctional in promoting the assembly of CcO are functional in suppressing the peroxide sensitivity of their respective null mutants. Likewise, human Sco1 that is nonfunctional in yeast CcO assembly is able to suppress the peroxide sensitivity of yeast sco1 Delta cells. Thus, a disconnect exists between the respiratory capacity of cells and hydrogen peroxide sensitivity. Hydrogen peroxide sensitivity of sco1 Delta and cox11 Delta cells is abrogated by overexpression of a novel mitochondrial ATPase Afg1 that promotes the degradation of CcO mitochondrially encoded subunits. Studies on the hydrogen peroxide sensitivity in CcO assembly mutants reveal new aspects of the CcO assembly process.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Bird, Amanda Jane/ABD-2295-2021; Winge, Dennis/G-3611-2010; Khalimonchuk, Oleh/AAM-1194-2021	Bird, Amanda Jane/0000-0002-1846-7050; Khalimonchuk, Oleh/0000-0002-3972-8678	NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abajian C, 2006, J BIOL INORG CHEM, V11, P459, DOI 10.1007/s00775-006-0096-7; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Banci L, 2006, P NATL ACAD SCI USA, V103, P8595, DOI 10.1073/pnas.0601375103; Banting GS, 2006, EUKARYOT CELL, V5, P568, DOI 10.1128/EC.5.3.568-578.2006; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2002, FEBS LETT, V516, P119, DOI 10.1016/S0014-5793(02)02514-0; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Carr HS, 2005, J BIOL CHEM, V280, P22664, DOI 10.1074/jbc.M414077200; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110; Cobine PA, 2006, BBA-MOL CELL RES, V1763, P759, DOI 10.1016/j.bbamcr.2006.03.002; DAUM G, 1982, J BIOL CHEM, V257, P3028; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; FIJIKI Y, 1982, J CELL BIOL, V93, P97; Fiori A, 2005, MOL MICROBIOL, V56, P1689, DOI 10.1111/j.1365-2958.2005.04658.x; Fontanesi F, 2006, AM J PHYSIOL-CELL PH, V291, pC1129, DOI 10.1152/ajpcell.00233.2006; Halawani D, 2006, MOL CELL, V22, P713, DOI 10.1016/j.molcel.2006.06.003; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Horan S, 2005, BIOCHEM J, V390, P703, DOI 10.1042/BJ20050598; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; Khalimonchuk O, 2005, CURR GENET, V47, P223, DOI 10.1007/s00294-005-0569-1; Khalimonchuk O, 2006, EUKARYOT CELL, V5, P997, DOI 10.1128/EC.00092-06; LEE YJ, 1992, YEAST, V8, P787, DOI 10.1002/yea.320080912; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; POUTRE CG, 1987, GENETICS, V115, P637; Pungartnik C, 1999, CURR GENET, V36, P124, DOI 10.1007/s002940050481; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seib KL, 2003, FEBS LETT, V546, P411, DOI 10.1016/S0014-5793(03)00632-X; Smith D, 2005, J BIOL CHEM, V280, P17652, DOI 10.1074/jbc.C500061200; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Ye QL, 2005, BIOCHEMISTRY-US, V44, P2934, DOI 10.1021/bi0480537; Zambrano A, 2007, MOL BIOL CELL, V18, P523, DOI 10.1091/mbc.E06-09-0803	47	94	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17442	17449		10.1074/jbc.M702379200	http://dx.doi.org/10.1074/jbc.M702379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430883	Green Published, hybrid			2022-12-25	WOS:000247084500014
J	Barends, TRM; Bultema, JB; Kaper, T; van der Maarel, MJEC; Dijkhuizen, L; Dijkstra, BW				Barends, Thomas R. M.; Bultema, Jelle B.; Kaper, Thijs; van der Maarel, Marc J. E. C.; Dijkhuizen, Lubbert; Dijkstra, Bauke W.			Three-way stabilization of the covalent intermediate in amylomaltase, an alpha-amylase-like transglycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE CYCLIC GLUCANS; THERMUS-AQUATICUS; ESCHERICHIA-COLI; CYCLODEXTRIN GLYCOSYLTRANSFERASE; GLYCOSYL HYDROLASES; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; ENZYME; STARCH; CYCLOAMYLOSE	Amylomaltases are glycosyl hydrolases belonging to glycoside hydrolase family 77 that are capable of the synthesis of large cyclic glucans and the disproportionation of oligosaccharides. Using protein crystallography, we have generated a flip book movie of the amylomaltase catalytic cycle in atomic detail. The structures include a covalent glycosyl enzyme intermediate and a covalent intermediate in complex with an analogue of a cosubstrate and show how the structures of both enzyme and substrate respond to the changes required by the catalytic cycle as it proceeds. Notably, the catalytic nucleophile changes conformation dramatically during the reaction. Also, Gln- 256 on the 250s loop is involved in orienting the substrate in the + 1 site. The absence of a suitable base in the covalent intermediate structure explains the low hydrolysis activity.	Univ Groningen, Lab Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Groningen, TNO, Ctr Carbohydrate Bioproc, NL-9751 NN Haren, Netherlands; Univ Groningen, Microbiol Lab, NL-9751 NN Haren, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Lab Biophys Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@rug.nl	Dijkhuizen, Lubbert/K-3539-2019; Dijkhuizen, Lubbert/E-9454-2014; Dijkstra, Bauke W./H-4308-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162; Dijkstra, Bauke W./0000-0001-9731-6586				Bhuiyan SH, 2003, J MOL CATAL B-ENZYM, V22, P45, DOI 10.1016/S1381-1177(03)00005-5; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1996, BIOCHEM J, V316, P16959; *INT UN PUR APPL C, 1980, PURE APPL CHEM, V53, P1901; Jensen MH, 2004, BIOCHEMISTRY-US, V43, P3104, DOI 10.1021/bi0357762; Kaper T, 2004, BIOCHEM SOC T, V32, P279, DOI 10.1042/BST0320279; Kaper T, 2005, APPL ENVIRON MICROB, V71, P5098, DOI 10.1128/AEM.71.9.5098-5106.2005; Kaper T, 2007, BIOCHEMISTRY-US, V46, P5261, DOI 10.1021/bi602408j; KURIKI T, 1999, PROG BIOPHYS MOL BIO, V67; LIEBL W, 1992, EUR J BIOCHEM, V207, P81, DOI 10.1111/j.1432-1033.1992.tb17023.x; Lovering AL, 2005, J BIOL CHEM, V280, P2105, DOI 10.1074/jbc.M410468200; McPherson A, 2001, PROTEIN SCI, V10, P418, DOI 10.1110/ps.32001; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PEAT S, 1956, J CHEM SOC, P44, DOI 10.1039/jr9560000044; PEAT S, 1953, NATURE, V172, P158, DOI 10.1038/172158a0; Przylas I, 2000, J MOL BIOL, V296, P873, DOI 10.1006/jmbi.1999.3503; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Strater N, 2002, BIOLOGIA, V57, P93; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Takaha T, 1996, J BIOL CHEM, V271, P2902, DOI 10.1074/jbc.271.6.2902; Terada Y, 1999, APPL ENVIRON MICROB, V65, P910; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van der Maarel MJEC, 2005, STARCH-STARKE, V57, P465, DOI 10.1002/star.200500409	37	58	59	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17242	17249		10.1074/jbc.M701444200	http://dx.doi.org/10.1074/jbc.M701444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420245	hybrid, Green Published			2022-12-25	WOS:000246946500057
J	Dissanayake, SK; Wade, M; Johnson, CE; O'Connell, MP; Leotlela, PD; French, AD; Shah, KV; Hewitt, KJ; Rosenthal, DT; Indig, FE; Jiang, Y; Nickoloff, BJ; Taub, DD; Trent, JM; Moon, RT; Bittner, M; Weeraratna, AT				Dissanayake, Samudra K.; Wade, Michael; Johnson, Carrie E.; O'Connell, Michael P.; Leotlela, Poloko D.; French, Amanda D.; Shah, Kavita V.; Hewitt, Kyle J.; Rosenthal, Devin T.; Indig, Fred E.; Jiang, Yuan; Nickoloff, Brian J.; Taub, Dennis D.; Trent, Jeffrey M.; Moon, Randall T.; Bittner, Michael; Weeraratna, Ashani T.			The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MALIGNANT-MELANOMA; MOLECULAR CLASSIFICATION; KISS-1 EXPRESSION; FRIZZLED HOMOLOGS; GENE-EXPRESSION; CARCINOMA-CELLS; DOWN-REGULATION; PROTEIN; INVASION	We have shown that Wnt5A increases the motility of melanoma cells. To explore cellular pathways involving Wnt5A, we compared gain-of-function (WNT5A stable transfectants) versus loss-of-function (siRNA knockdown) of WNT5A by microarray analysis. Increasing WNT5A suppressed the expression of several genes, which were re-expressed after small interference RNA-mediated knockdown of WNT5A. Genes affected by WNT5A include KISS-1, a metastasis suppressor, and CD44, involved in tumor cell homing during metastasis. This could be validated at the protein level using both small interference RNA and recombinant Wnt5A (rWnt5A). Among the genes up-regulated by WNT5A was the gene vimentin, associated with an epithelial to mesenchymal transition (EMT), which involves decreases in E-cadherin, due to up-regulation of the transcriptional repressor, Snail. rWnt5A treatment increases Snail and vimentin expression, and decreases E-cadherin, even in the presence of dominant-negativeTCF4, suggesting that this activation is independent of Wnt/ss-catenin signaling. Because Wnt5A can signal via protein kinase C (PKC), the role of PKC in Wnt5A- mediated motility and EMT was also assessed using PKC inhibition and activation studies. Treating cells expressing low levels of Wnt5A with phorbol ester increased Snail expression inhibiting PKC in cells expressing high levels of Wnt5A	NIA, Immunol Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Washington, Howard Hughes Med Inst, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Inst Stem Cell & Regenerat Med, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Translat Genom Res Inst, Phoenix, AZ 85004 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Loyola University Chicago; Translational Genomics Research Institute	Weeraratna, AT (corresponding author), NIA, Immunol Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019; Hewitt, Kyle/S-6512-2019; Shah, Kavita/Y-9755-2019; O'Connell, Michael/F-9236-2017	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Shah, Kavita/0000-0002-0451-1305; O'Connell, Michael/0000-0002-8615-7660	Intramural NIH HHS [Z01 AG000442-04] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000615, Z01AG000764, Z01AG000442] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Chin D, 2002, BIOCHEMISTRY-US, V41, P14001, DOI 10.1021/bi025640o; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; De Wit Peter E. J., 1996, Current Opinion in Oncology, V8, P143, DOI 10.1097/00001622-199603000-00012; Dhar DK, 2004, INT J CANCER, V111, P868, DOI 10.1002/ijc.20357; Dietrich A, 1997, EUR J CANCER, V33, P926, DOI 10.1016/S0959-8049(96)00512-6; FAASSEN AE, 1993, J CELL SCI, V105, P501; Fink-Puches R, 1993, Exp Dermatol, V2, P17, DOI 10.1111/j.1600-0625.1993.tb00194.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012; Lahn MM, 2004, MELANOMA RES, V14, P85, DOI 10.1097/00008390-200404000-00002; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; LEOTLELA PD, 2006, IN PRESS ONCOGENE; Lewis TB, 2005, CANCER-AM CANCER SOC, V104, P1678, DOI 10.1002/cncr.21372; Li SY, 2005, INT J ONCOL, V27, P1329; MAPELLI E, 1994, INT J CANCER, V57, P281, DOI 10.1002/ijc.2910570225; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NUSSE R, 1985, PROC R SOC SER B-BIO, V226, P3, DOI 10.1098/rspb.1985.0075; Oka M, 2005, CANCER METAST REV, V24, P287, DOI 10.1007/s10555-005-1578-8; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PARKER C, 1992, MELANOMA RES, V2, P337, DOI 10.1097/00008390-199212000-00007; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Sionov RV, 1998, CELL ADHES COMMUN, V6, P503, DOI 10.3109/15419069809010798; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Tzircotis G, 2006, ONCOGENE, V25, P7401, DOI 10.1038/sj.onc.1209724; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Yoshikawa N, 2003, LIFE SCI, V72, P1377, DOI 10.1016/S0024-3205(02)02407-4	48	285	301	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17259	17271		10.1074/jbc.M700075200	http://dx.doi.org/10.1074/jbc.M700075200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426020	hybrid, Green Accepted			2022-12-25	WOS:000246946500059
J	Lorca, GL; Ezersky, A; Lunin, VV; Walker, JR; Altamentova, S; Evdokimova, E; Vedadi, M; Bochkarev, A; Savchenko, A				Lorca, Graciela L.; Ezersky, Alexandra; Lunin, Vladimir V.; Walker, John R.; Altamentova, Svetlana; Evdokimova, Elena; Vedadi, Masoud; Bochkarev, Alexey; Savchenko, Alexei			Glyoxylate and pyruvate are antagonistic effectors of the Escherichia coli IclR transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; METABOLIC FLUX ANALYSIS; C-13-LABELING EXPERIMENTS; ISOCITRATE DEHYDROGENASE; ACETATE OPERON; PROTEIN; GENE; BINDING; EXPRESSION; REPRESSOR	The Escherichia coli isocitrate lyase regulator (IclR) regulates the expression of the glyoxylate bypass operon ( aceBAK). Founding member of a large family of common fold transcriptional regulators, IclR comprises a DNA binding domain that interacts with the operator sequence and a C-terminal domain ( C-IclR) that binds a hitherto unknown small molecule. We screened a chemical library of more than 150 metabolic scaffolds using a high-throughput protein stability assay to identify molecules that bind IclR and then tested the active compounds in in vitro assays of operator binding. Glyoxylate and pyruvate, identified by this method, bound the C-IclR domain with KD values of 0.9 +/- 0.2 and 156.2 +/- 7.9 mu M, as defined by isothermal titration calorimetry. Both compounds altered IclR interactions with operator DNA in electrophoretic mobility shift assays but showed an antagonistic effect. Glyoxylate disrupted the formation of the IclR/operator complex in vitro by favoring the inactive dimeric state of the protein, whereas pyruvate increased the binding of IclR to the aceBAK promoter by stabilizing the active tetrameric form of the protein. Structures of the C-IclR domain alone and in complex with each effector were determined at 2.3 A, confirming the binding of both molecules in the effector recognition site previously characterized for the other representative of the family, the E. coli AllR regulator. Site-directed mutagenesis demonstrated the importance of hydrophobic patch formed by Met- 146, Leu-154, Leu-220, and Leu-143 in interactions with effector molecules. In general, our strategy of combining chemical screens with functional assays and structural studies has uncovered two small molecules with antagonistic effects that regulate the IclR-dependent transcription of the aceBAK operon.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L6, Canada; Ontario Ctr Struct Prot, Toronto, ON M5G 1LG, Canada; Canada Struct Genom Consortium, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Lorca, GL (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	glorca@ufl.edu; alexei.savchenko@utoronto.ca		/0000-0002-5255-895X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carver TE, 2005, J BIOL CHEM, V280, P11704, DOI 10.1074/jbc.M413278200; CHUNG T, 1988, J BACTERIOL, V170, P386, DOI 10.1128/jb.170.1.386-392.1988; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; Cusa E, 1999, J BACTERIOL, V181, P7479, DOI 10.1128/JB.181.24.7479-7484.1999; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIMARCO AA, 1993, J BACTERIOL, V175, P4499, DOI 10.1128/JB.175.14.4499-4506.1993; ELMANSKI EM, 1983, J GEN MICROBIOL, V132, P797; Epelbaum S, 1998, J BACTERIOL, V180, P4056, DOI 10.1128/JB.180.16.4056-4067.1998; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Gerischer U, 1998, J BACTERIOL, V180, P1512, DOI 10.1128/JB.180.6.1512-1524.1998; Gloss LM, 1997, BIOCHEMISTRY-US, V36, P5612, DOI 10.1021/bi970056e; Gorelik M, 2006, PROTEIN SCI, V15, P1506, DOI 10.1110/ps.062146906; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; Gui LZ, 1996, J BACTERIOL, V178, P321, DOI 10.1128/jb.178.1.321-324.1996; Kao KC, 2005, J BIOL CHEM, V280, P36079, DOI 10.1074/jbc.M508202200; KORNBERG HL, 1957, BIOCHIM BIOPHYS ACTA, V24, P651, DOI 10.1016/0006-3002(57)90268-8; KORNBERG HL, 1966, BIOCHEM J, V99, P1; KORNBERG HL, 1967, B SOC CHIM BIOL, V49, P1479; KREBS A, 1980, CAN J BIOCHEM CELL B, V58, P309, DOI 10.1139/o80-041; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; Nasser W, 2007, ANAL BIOANAL CHEM, V387, P381, DOI 10.1007/s00216-006-0702-0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nobeli I, 2006, BIOESSAYS, V28, P534, DOI 10.1002/bies.20414; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; ORNSTON LN, 1969, J BACTERIOL, V98, P1098, DOI 10.1128/JB.98.3.1098-1108.1969; Pan B, 1996, J BACTERIOL, V178, P3982, DOI 10.1128/jb.178.13.3982-3984.1996; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Peng LF, 2004, FEMS MICROBIOL LETT, V235, P17, DOI 10.1016/j.femsle.2004.04.003; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phue JN, 2005, BIOTECHNOL BIOENG, V90, P805, DOI 10.1002/bit.20478; Ponce E, 1998, BIOTECHNOL BIOENG, V58, P292, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<292::AID-BIT25>3.0.CO;2-D; Popp R, 2002, J BACTERIOL, V184, P1988, DOI 10.1128/JB.184.7.1988-1997.2002; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; RAMSEIER TM, 1993, J MOL BIOL, V234, P28, DOI 10.1006/jmbi.1993.1561; Repik A, 2000, MOL MICROBIOL, V36, P806, DOI 10.1046/j.1365-2958.2000.01910.x; Resnik E, 1996, J BACTERIOL, V178, P2715, DOI 10.1128/jb.178.9.2715-2717.1996; REVERCHON S, 1991, MOL MICROBIOL, V5, P2203, DOI 10.1111/j.1365-2958.1991.tb02150.x; Rintoul MR, 2002, J MOL BIOL, V324, P599, DOI 10.1016/S0022-2836(02)01134-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; Sebaihia M, 2006, J BACTERIOL, V188, P6002, DOI 10.1128/JB.01927-05; SENISTERRA G, 2003, Patent No. 03071269; Senisterra GA, 2006, J BIOMOL SCREEN, V11, P940, DOI 10.1177/1087057106294699; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; Siddiquee KA, 2004, FEMS MICROBIOL LETT, V235, P25, DOI 10.1016/j.femsle.2004.04.004; Siddiquee KA, 2004, APPL MICROBIOL BIOT, V63, P407, DOI 10.1007/s00253-003-1357-9; Silhavy T.J., 1984, EXPT GENE FUSIONS; Skubak P, 2004, ACTA CRYSTALLOGR D, V60, P2196, DOI 10.1107/S0907444904019079; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; Steiner P, 1998, GENE, V220, P31, DOI 10.1016/S0378-1119(98)00418-1; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Torres B, 2003, J BIOL CHEM, V278, P27575, DOI 10.1074/jbc.M303245200; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; Walker JR, 2006, J MOL BIOL, V358, P810, DOI 10.1016/j.jmb.2006.02.034; WALSH K, 1985, J BIOL CHEM, V260, P8430; WEBER PC, 1995, ACTA CRYSTALLOGR D, V51, P590, DOI 10.1107/S0907444995001405; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zhang ZG, 2005, J BACTERIOL, V187, P980, DOI 10.1128/JB.187.3.980-990.2005	81	63	65	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16476	16491		10.1074/jbc.M610838200	http://dx.doi.org/10.1074/jbc.M610838200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426033	hybrid			2022-12-25	WOS:000246794300055
J	Murata, T; Lin, MI; Stan, RV; Bauer, PM; Yu, J; Sessa, WC				Murata, Takahisa; Lin, Michelle I.; Stan, Radu V.; Bauer, Phillip Michael; Yu, Jun; Sessa, William C.			Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED CA2+ INFLUX; OXIDE SYNTHASE ENOS; NITRIC-OXIDE; CATION CHANNEL; SMOOTH-MUSCLE; TRPC CHANNELS; MICROVASCULAR PERMEABILITY; TRISPHOSPHATE RECEPTOR; SIGNALING COMPLEX	Various cellular signals initiate calcium entry into cells, and there is evidence that lipid rafts and caveolae may concentrate proteins that regulate transmembrane calcium fluxes. Here, using mice deficient in caveolin-1 (Cav-1) and Cav-1 knock-out reconstituted with endothelium-specific Cav-1, we show that Cav-1 is essential for calcium entry in endothelial cells and governs the localization and protein-protein interactions between transient receptor channels C4 and C1. Thus, Cav-1 is required for calcium entry in vascular endothelial cells and perhaps other specialized cell types containing caveolae.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Dartmouth Med Coll, Dept Pathol, Lebanon, NH 03756 USA	Yale University; Yale University; Dartmouth College	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Stan, Radu/AAE-7574-2021; Sessa, William C/B-6844-2011	Stan, Radu/0000-0003-2969-1725; Sessa, William C/0000-0001-5759-1938; Murata, Takahisa/0000-0002-3328-0796	NHLBI NIH HHS [R01 HL 57665, R01 HL 61371, P01 HL 70295, N01-HV-28186, R01 HL64793] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061371, P01HL070295, R01HL064793, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z; Bauer PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/pnas.0406092102; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Flockerzi V, 2005, PFLUG ARCH EUR J PHY, V451, P81, DOI 10.1007/s00424-005-1443-1; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GABELLA G, 1971, J CELL SCI, V8, P601; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kan H, 1997, J PHARMACOL EXP THER, V282, P113; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kwiatek AM, 2006, MOL PHARMACOL, V70, P1174, DOI 10.1124/mol.105.021741; Lee-Kwon W, 2005, AM J PHYSIOL-CELL PH, V288, pC942, DOI 10.1152/ajpcell.00417.2004; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONCADA S, 1991, PHARMACOL REV, V43, P109; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Poteser M, 2006, J BIOL CHEM, V281, P13588, DOI 10.1074/jbc.M512205200; Razani B, 2002, BIOCHEMISTRY-US, V41, P7914, DOI 10.1021/bi020043n; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Rey O, 2006, J BIOL CHEM, V281, P38730, DOI 10.1074/jbc.M605956200; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Sinkins WG, 2004, J BIOL CHEM, V279, P34521, DOI 10.1074/jbc.M401156200; Stamboulian S, 2005, DEV BIOL, V286, P326, DOI 10.1016/j.ydbio.2005.08.006; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vandebrouck A, 2007, FASEB J, V21, P608, DOI 10.1096/fj.06-6683com; Yip H, 2004, HISTOCHEM CELL BIOL, V122, P553, DOI 10.1007/s00418-004-0720-y; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Yu J, 2006, J CLIN INVEST, V116, P1284, DOI 10.1172/JCI27100; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	53	117	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16631	16643		10.1074/jbc.M607948200	http://dx.doi.org/10.1074/jbc.M607948200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416589	hybrid			2022-12-25	WOS:000246794300069
J	Kong, C; Su, X; Chen, PI; Stahl, PD				Kong, Chen; Su, Xiong; Chen, Pin-I; Stahl, Philip D.			Rin1 interacts with signal-transducing adaptor molecule (STAM) and mediates epidermal growth factor receptor trafficking and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DOWN-REGULATION; UBIQUITIN ISOPEPTIDASE; ENDOSOMAL TRAFFICKING; MULTIVESICULAR-BODY; BINDING-PROTEIN; KINASE-ACTIVITY; RAB5; ENDOCYTOSIS; COMPLEX	Rin1, the prototype of a new family of multidomain Rab5 exchange factors, has been shown to play an important role in the endocytosis of the epidermal growth factor receptor (EGFR). Herein, we examined the role of Rin1 in the down-regulation of EGFR following EGF stimulation. We observed that overexpression of Rin1 accelerates EGFR degradation in EGF-stimulated cells. In concordance, depletion of endogenous Rin1 by RNA interference resulted in a substantial reduction of EGFR degradation. We showed that Rin1 interacts with signal-transducing adaptor molecule 2 (STAM2), a protein that associates with hepatocyte growth factor-regulated substrate and plays a key role in the endosomal sorting machinery. Green fluorescent protein (GFP)-Rin1 co-localizes with hemagglutinin (HA)-STAM2 and with endogenous hepatocyte growth factor-regulated substrate. Furthermore, wild type STAM2, but not a deletion mutant lacking the SH3 domain, co-immunoprecipitates with endogenous Rin1. This interaction is dependent on the proline-rich domain (PRD) of Rin1 as Rin1 Delta PRD, a mutant lacking the PRD, does not interact with STAM2. Moreover, EGFR degradation was not accelerated by expression of the Rin1 Delta PRD mutant. Together these results suggest that Rin1 regulates EGFR degradation in cooperation with STAM, defining a novel role for Rin1 in regulating endosomal trafficking.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid, St Louis, MO 63110 USA.	pstahl@cellbiology.wustl.edu	Stahl, Philip/D-6315-2012		NIGMS NIH HHS [2R01GM42259-31] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Barbieri MA, 2004, EUR J CELL BIOL, V83, P305, DOI 10.1078/0171-9335-00381; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Husnjak K, 2006, NAT CELL BIOL, V8, P787, DOI 10.1038/ncb0806-787; Kajiho H, 2003, J CELL SCI, V116, P4159, DOI 10.1242/jcs.00718; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kimura T, 2006, J BIOL CHEM, V281, P10598, DOI 10.1074/jbc.M510531200; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Stahl Philip D, 2002, Sci STKE, V2002, ppe32, DOI 10.1126/stke.2002.141.pe32; Stetak A, 2006, EMBO J, V25, P2347, DOI 10.1038/sj.emboj.7601137; Su X, 2006, J BIOL CHEM, V281, P27982, DOI 10.1074/jbc.M602873200; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002; Zheng B, 2004, MOL BIOL CELL, V15, p322A, DOI 10.1091/mbc.e04-06-0446	42	32	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15294	15301		10.1074/jbc.M611538200	http://dx.doi.org/10.1074/jbc.M611538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17403676	hybrid			2022-12-25	WOS:000246589000068
J	Ramesh, A; Savva, CG; Holzenburg, A; Sacchettini, JC				Ramesh, Arati; Savva, Christos G.; Holzenburg, Andreas; Sacchettini, James C.			Crystal structure of Rsr, an ortholog of the antigenic Ro protein, links conformational flexibility to RNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; DEINOCOCCUS-RADIODURANS; ELECTRON-DENSITY; A-DOMAIN; AUTOANTIGEN; SYSTEM; IRRADIATION; VALIDATION; SOFTWARE; INSIGHTS	Ro ribonucleoproteins are a class of antigenic ribonucleoproteins associated with rheumatic autoimmune diseases like systemic lupus erythematosus and Sjogrens syndrome in humans. Ro ribonucleoproteins are mostly composed of the 60-kDa Ro protein and small cytoplasmic RNAs, called Y RNAs, of unknown function. In eukaryotes, where Ro has been found to associate with damaged or mutant RNAs, it has been suggested that Ro may play a role in RNA quality control. In the radiation-resistant bacterium Deinococcus radiodurans and some eukaryotes, Ro has also been implicated in cell survival following UV damage. Here we present the first high resolution structure of a prokaryotic Ro ortholog, Rsr from D. radiodurans. The structure has been solved to 1.9 angstrom resolution and shows distinct differences when compared with the eukaryotic apo- and RNA-bound Ro structures. Rsr is composed of two domains: a helical RNA binding domain and a mixed "von Willebrand factor A-like" domain containing a divalent metal binding site. Although the individual domains of Rsr are similar to the eukaryotic Ro, significantly large differences are seen at the interface of the two domains. Since this interface communicates with the conserved central cavity of Ro, which is implicated in RNA binding, changes at this interface could potentially influence RNA binding by Ro. Although the apo- Rsr protein is monomeric, Rsr binds Y RNA to form multimers of similar to 12 molecules of a 1: 1 Rsr-Y RNA complex. Rsr binds D. radiodurans Y RNA with low nanomolar affinity, comparable with previously characterized eukaryotic Ro orthologs.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Struct Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu		Ramesh, Arati/0000-0001-8655-0051				Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BOIRE G, 1990, J CLIN INVEST, V85, P1182, DOI 10.1172/JCI114551; Chen XG, 2000, GENE DEV, V14, P777; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; Chen XG, 2003, CURR BIOL, V13, P2206, DOI 10.1016/j.cub.2003.11.028; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Farris AD, 1999, NUCLEIC ACIDS RES, V27, P1070, DOI 10.1093/nar/27.4.1070; Fuchs G, 2006, NAT STRUCT MOL BIOL, V13, P1002, DOI 10.1038/nsmb1156; Ioerger TR, 2003, METHOD ENZYMOL, V374, P244, DOI 10.1016/S0076-6879(03)74012-9; Jacob J, 1999, BIOPHYS J, V76, P1367, DOI 10.1016/S0006-3495(99)77298-X; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Muzzolini L, 2007, PLOS BIOL, V5, P157, DOI 10.1371/journal.pbio.0050020; OBRIEN CA, 1994, GENE DEV, V8, P2891, DOI 10.1101/gad.8.23.2891; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reddy V, 2003, ACTA CRYSTALLOGR D, V59, P2200, DOI 10.1107/S0907444903020316; Rosenhouse-Dantsker A, 2006, BIOPHYS J, V91, P2860, DOI 10.1529/biophysj.105.080242; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shi H, 1996, RNA, V2, P769; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Tebbe B, 1997, LUPUS, V6, P96, DOI 10.1177/096120339700600204; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Xue DH, 2003, P NATL ACAD SCI USA, V100, P7503, DOI 10.1073/pnas.0832411100; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	38	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14960	14967		10.1074/jbc.M611163200	http://dx.doi.org/10.1074/jbc.M611163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392270	hybrid			2022-12-25	WOS:000246589000034
J	Grenz, A; Zhang, H; Hermes, M; Eckle, T; Klingel, K; Huang, DY; Muller, CE; Robson, SC; Osswald, H; Eltzschig, HK				Grenz, Almut; Zhang, Hua; Hermes, Marina; Eckle, Tobias; Klingel, Karin; Huang, Dan Yang; Mueller, Christa E.; Robson, Simon C.; Osswald, Hartmut; Eltzschig, Holger K.			Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						acute renal failure; kidney; preconditioning; NTPDase	TUBULOGLOMERULAR FEEDBACK; ADENOSINE RECEPTORS; ECTO-5'-NUCLEOTIDASE CD73; ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; MICE LACKING; TRIPHOSPHATE; HYPOXIA; RELEASE; INFLAMMATION	Previous studies showed increased extracellular nucleotides during renal ischemia- reperfusion. While nucleotides represent the main source for extracellular adenosine and adenosine signaling contributes to renal protection from ischemia, we hypothesized a role for ecto- nucleoside- triphosphate- diphosphohydrolases ( E- NTPDases) in renal protection. We used a model of murine ischemia- reperfusion and in situ ischemic preconditioning ( IP) via a hanging weight system for atraumatic renal artery occlusion. Initial studies with a nonspecific inhibitor of E- NTPDases ( POM- 1) revealed inhibition of renal protection by IP. We next pursued transcriptional responses of E- NTPDases ( ENTPDase1 - 3, and 8) to renal IP, and found a robust and selective induction of E- NTPDase1/ CD39 transcript and protein. Moreover, based on clearance studies, plasma electrolytes, and renal tubular histology, IP protection was abolished in gene- targeted mice for cd39 whereas increased renal adenosine content with IP was attenuated. Furthermore, administration of apyrase reconstituted renal protection by IP in cd39 -/ - mice. Finally, apyrase treatment of wild- type mice resulted in increased renal adenosine concentrations and a similar degree of renal protection from ischemia as IP treatment. Taken together, these data identify CD39- dependent nucleotide phosphohydrolysis in renal protection. Moreover, the present studies suggest apyrase treatment as a novel pharmacological approach to renal diseases precipitated by limited oxygen availability.	Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, D-72072 Tubingen, Germany; Univ Tubingen Hosp, Dept Pharmacol & Toxicol, Tubingen, Germany; Univ Tubingen Hosp, Dept Pathol, Tubingen, Germany; Univ Bonn, Inst Pharmaceut, D-5300 Bonn, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Liver & Transplant Ctr, Boston, MA USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Bonn; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Eltzschig, HK (corresponding author), Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Waldhornle Str 22, D-72072 Tubingen, Germany.	hartmut.osswald@uni-tuebingen.de; heltzschig@partners.org	Robson, Simon C./AAA-8537-2021; Müller, Christa Elisabeth/C-7748-2014; Eckle, Tobias/AAE-6705-2020	Müller, Christa Elisabeth/0000-0002-0013-6624; Eckle, Tobias/0000-0002-6065-4669	NHLBI NIH HHS [R01 HL063972, R01 HL063972-04, R01 HL063972-03, 1P01 HL 076540, R01 HL063972-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076540, R01HL063972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bigonnesse F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/bi0362222; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; Day YJ, 2006, J IMMUNOL, V176, P3108, DOI 10.4049/jimmunol.176.5.3108; Eckle T, 2006, AM J PHYSIOL-HEART C, V291, pH2533, DOI 10.1152/ajpheart.00472.2006; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2007, AM J PHYSIOL-RENAL, V292, pF475, DOI 10.1152/ajprenal.00275.2006; Huang DY, 2006, AM J PHYSIOL-RENAL, V291, pF1264, DOI 10.1152/ajprenal.00299.2005; Huang DY, 2006, AM J PHYSIOL-RENAL, V291, pF282, DOI 10.1152/ajprenal.00113.2005; JABLONSKI P, 1983, TRANSPLANTATION, V35, P198, DOI 10.1097/00007890-198303000-00002; Kadereit B, 2005, J AM SOC NEPHROL, V16, P3507, DOI 10.1681/ASN.2005010108; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Lee YJ, 2005, J CELL PHYSIOL, V204, P792, DOI 10.1002/jcp.20342; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Luippold G, 1999, J CHROMATOGR B, V724, P231, DOI 10.1016/S0378-4347(98)00580-5; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Okusa MD, 2001, KIDNEY INT, V59, P2114, DOI 10.1046/j.1523-1755.2001.0590062114.x; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Robson SC, 2005, SEMIN THROMB HEMOST, V31, P217, DOI 10.1055/s-2005-869527; Roos A, 2006, J AM SOC NEPHROL, V17, P1724, DOI 10.1681/ASN.2005090923; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902-05.2006; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Thomson S, 2000, J CLIN INVEST, V106, P289, DOI 10.1172/JCI8761; Vallon V, 2003, NEWS PHYSIOL SCI, V18, P169, DOI 10.1152/nips.01442.2003; Vallon V, 2006, PHYSIOL REV, V86, P901, DOI 10.1152/physrev.00031.2005; Weissmuller Thomas, 2005, Purinergic Signal, V1, P229, DOI 10.1007/s11302-005-6323-9; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	43	130	133	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2863	2873		10.1096/fj.06-7947com	http://dx.doi.org/10.1096/fj.06-7947com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442731				2022-12-25	WOS:000249237500027
J	Herzog, EL; Van Arnam, J; Hu, BQ; Zhang, J; Chen, QS; Haberman, AM; Krause, DS				Herzog, Erica L.; Van Arnam, John; Hu, Buqu; Zhang, Jason; Chen, Qingsheng; Haberman, Ann M.; Krause, Diane S.			Lung-specific nuclear reprogramming is accompanied by heterokaryon formation and Y chromosome loss following bone marrow transplantation and secondary inflammation	FASEB JOURNAL			English	Article						plasticity; fusion	PURKINJE NEURONS; STEM-CELLS; IN-VIVO; SKELETAL-MUSCLE; MURINE LUNG; FUSION; INJURY; EPITHELIUM; EMPHYSEMA; CARDIOMYOCYTES	Cell fusion is one mechanism by which bone marrow-derived cells (BMDCs) take on the gene expression pattern of nonhematopoietic cells. This process occurs in a number of organs with posten-graftment injury but has never been found in the lung. We performed bone marrow (BM) transplant in a murine model of lung inflammation to test whether transplanted BMDCs develop lung-specific gene expression by fusing with diseased pneumocytes. Mice lacking the lung-specific protein surfactant protein C (Sp-C) were lethally irradiated, transplanted with sex mismatched wild-type marrow, and sacrificed 6 months later. Nineteen/38 recipients exhibited Sp-C mRNA (RT-PCR) and/or protein (mean 0.95 +/- 1.18 Sp-C+ cells per 1000 type II pneumocytes by confocal microscopy). In male recipients of female BM, 65% of Sp-C + cells contained the Y chromosome, indicating their origin from fusion. Only 28% of Sp-C + cells in female recipients of male BMDCs contained the Y chromosome, suggesting that 72% of Sp-C-expressing cells lost the Y chromosome. In the setting of post-transplant inflammation, pneumocyte-specific reprogramming of transplanted BMDCs predominantly derives from heterokaryon formation. This process does not reverse inflammation caused by Sp-C deficiency; nevertheless, further investigation may identify phenotypes benefiting from such an approach.	Yale Univ, Sch Med, Internal Med Pulm & Crit Care Div, Dept Internal Med, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06511 USA	Yale University; Yale University; Yale University	Herzog, EL (corresponding author), Yale Univ, Sch Med, Internal Med Pulm & Crit Care Div, Dept Internal Med, 333 Cedar St,TAC 441-S, New Haven, CT 06511 USA.	erica.herzog@yale.edu			NHLBI NIH HHS [1K08HL079066, HL073742] Funding Source: Medline; NIDDK NIH HHS [R01 DK061846, DK61846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073742, K08HL079066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Andrade J, 2005, CARDIOVASC RES, V68, P387, DOI 10.1016/j.cardiores.2005.09.016; Bourbon JR, 2001, COMP BIOCHEM PHYS A, V129, P151, DOI 10.1016/S1095-6433(01)00312-9; Chang JC, 2005, AM J RESP CELL MOL, V33, P335, DOI 10.1165/rcmb.2005-0129OC; Di A, 2006, NAT CELL BIOL, V8, P933, DOI 10.1038/ncb1456; Glasser SW, 2003, J BIOL CHEM, V278, P14291, DOI 10.1074/jbc.M210909200; Gomperts BN, 2006, J IMMUNOL, V176, P1916, DOI 10.4049/jimmunol.176.3.1916; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Held PK, 2006, MOL THER, V13, P49, DOI 10.1016/j.ymthe.2005.09.004; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Herzog EL, 2006, STEM CELLS, V24, P1986, DOI 10.1634/stemcells.2005-0579; Jentsch I, 2001, CHROMOSOME RES, V9, P211, DOI 10.1023/A:1016696303479; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kotton DN, 2005, AM J RESP CELL MOL, V33, P328, DOI 10.1165/rcmb.2005-0175RC; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P476; Loi R, 2006, AM J RESP CRIT CARE, V173, P171, DOI 10.1164/rccm.200502-309OC; MacPherson H, 2005, J CELL SCI, V118, P2441, DOI 10.1242/jcs.02375; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Palermo AT, 2005, DEV BIOL, V279, P336, DOI 10.1016/j.ydbio.2004.12.024; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Summer R, 2004, AM J PHYSIOL-LUNG C, V287, pL477, DOI 10.1152/ajplung.00020.2004; THEISE ND, 2002, J EXP HEM; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Yamada M, 2004, J IMMUNOL, V172, P1266, DOI 10.4049/jimmunol.172.2.1266	31	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2592	2601		10.1096/fj.06-7861com	http://dx.doi.org/10.1096/fj.06-7861com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17449722				2022-12-25	WOS:000248454400032
J	Krishnan, K; Kathiresan, T; Raman, R; Rajini, B; Dhople, VM; Aggrawal, RK; Sharma, Y				Krishnan, Kannan; Kathiresan, Thandavarayan; Raman, Rajeev; Rajini, Bheemreddy; Dhople, Vishnu M.; Aggrawal, Ramesh K.; Sharma, Yogendra			Ubiquitous lens alpha-, beta-, and gamma-crystallins accumulate in anuran cornea as corneal crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARVAL XENOPUS-LAEVIS; ALDEHYDE DEHYDROGENASE; TAU-CRYSTALLIN; ENZYME-CRYSTALLIN; OUTER CORNEA; PROTEINS; REGENERATION; RECRUITMENT; GENE; EPITHELIUM	Corneal epithelium is known to have high levels of some metabolic enzymes such as aldehyde dehydrogenase in mammals, gelsolin in zebrafish, and alpha-enolase in several species. Analogous to lens crystallins, these enzymes and proteins are referred to as corneal crystallins, although their precise function is not established in any species. Although it is known that after lentectomy, the outer cornea undergoes transdifferentiation to regenerate a lens only in anuran amphibians, major proteins expressed in an anuran cornea have not been identified. This study therefore aimed to identify the major corneal proteins in the Indian toad ( Bufo melanostictus) and the Indian frog ( Rana tigrina). Soluble proteins of toad and frog corneas were resolved on two-dimensional gels and identified by matrix-assisted laser desorption ionization time-of-flight/time-of-flight and electrospray ionization quadrupole time-of-flight. We report that anuran cornea is made up of the full complement of ubiquitous lens alpha-, beta-, and gamma-crystallins, mainly localized in the corneal epithelium. In addition, some taxon-specific lens crystallins and novel proteins, such as alpha- or beta-enolase/tau-crystallin, were also identified. Our data present a unique case of the anuran cornea where the same crystallins are used in the lens and in the cornea, thus supporting the earlier idea that crystallins are essential for the visual functions of the cornea as they perform for the lens. High levels of lens alpha-, beta-, and gamma-crystallins have not been reported in the cornea of any species studied so far and may offer a possible explanation for their inability to regenerate a lens after lentectomy. Our data that anuran cornea has an abundant quantity of almost all the lens crystallins are consistent with its ability to form a lens, and this connection is worthy of further studies.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Sharma, Y (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	yogendra@ccmb.res.in	Dhople, Vishnu M/J-5377-2014					ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Agrawal R, 2002, J BIOSCIENCES, V27, P251, DOI 10.1007/BF02704914; Bhat SP, 2004, EXP EYE RES, V79, P809, DOI 10.1016/j.exer.2004.08.020; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Bosco L, 1997, DEVELOPMENT, V124, P421; BOSCO L, 1993, DEV GROWTH DIFFER, V35, P257; Call Mindy K., 2005, Anatomical Record Part B:The New Anatomist, V287, P42, DOI 10.1002/ar.b.20084; Cannata SM, 2003, J EXP ZOOL PART A, V299A, P161, DOI 10.1002/jez.a.10275; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; COOPER DL, 1993, ADV EXP MED BIOL, V328, P169; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; Estey T, 2007, EXP EYE RES, V84, P3, DOI 10.1016/j.exer.2006.04.010; Filoni S, 1982, Acta Embryol Morphol Exp, V3, P15; FILONI S, 1980, J EXP ZOOL, V211, P303, DOI 10.1002/jez.1402110307; FILONI S, 1992, DEV GROWTH DIFFER, V34, P619; FREEMAN G, 1963, J EXP ZOOL, V154, P39, DOI 10.1002/jez.1401540105; FREEMAN J, 1963, J BIOL CHEM, V54, P39; Gopal-Srivastava R, 2000, MECH DEVELOP, V92, P125, DOI 10.1016/S0925-4773(99)00341-X; Henry JJ, 2001, DEV GENES EVOL, V211, P377, DOI 10.1007/s004270100163; Jester JV, 1999, J CELL SCI, V112, P613; Kathiresan T, 2006, FEBS J, V273, P3370, DOI 10.1111/j.1742-4658.2006.05344.x; King G, 1999, ADV EXP MED BIOL, V463, P189; Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216; Mishra AK, 2002, PROTEIN EXPRES PURIF, V25, P59, DOI 10.1006/prep.2001.1609; Mizuno N, 1999, DIFFERENTIATION, V64, P143, DOI 10.1046/j.1432-0436.1999.6430143.x; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Piatigorsky J, 2000, J BIOL CHEM, V275, P41064, DOI 10.1074/jbc.M005625200; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; REEVE JG, 1978, J EMBRYOL EXP MORPH, V48, P205; REYER RW, 1954, Q REV BIOL, V29, P1, DOI 10.1086/399936; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; Shekhawat DS, 2001, J BIOSCIENCES, V26, P571, DOI 10.1007/BF02704755; SINGH SV, 1985, EXP EYE RES, V40, P431, DOI 10.1016/0014-4835(85)90155-1; Sinha D, 1998, Mol Vis, V4, P8; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; Uma L, 1996, EXP EYE RES, V63, P117, DOI 10.1006/exer.1996.0098; Wilmarth PA, 2004, INVEST OPHTH VIS SCI, V45, P2705, DOI 10.1167/iovs.04-0131; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; ZIESKE JD, 1992, DEV BIOL, V151, P18, DOI 10.1016/0012-1606(92)90209-Y	45	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18953	18959		10.1074/jbc.M609275200	http://dx.doi.org/10.1074/jbc.M609275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17452334	hybrid			2022-12-25	WOS:000247475300037
J	Chakrabarti, S; Blair, P; Freedman, JE				Chakrabarti, Subrata; Blair, Price; Freedman, Jane E.			CD40-40L signaling in vascular inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REDOX REGULATION; ENDOTHELIAL-CELLS; P38 MAPK; ACTIVATION; LIGAND; PTEN; PATHWAYS; STRESS; EXPRESSION	Ligation of CD40 in circulating cells or in the vessel wall may promote mononuclear cell recruitment, participate in the weakening of the plaque, and contribute to thrombosis. This process appears to be redox-sensitive, but the precise signaling mechanism by which the interaction between CD40L and its receptor CD40 mediates inflammatory secretion is unclear. Our previous studies have shown that the CD40-CD40L interaction modulates release of reactive oxygen species (ROS) and the current findings demonstrate that in endothelial cells CD40L dose dependently induces intracellular CD40L and MCP1 release in a redox sensitive manner. Pharmacological inhibition of phosphatidylinositol 3-kinase and p38 MAPK as well as adenovirus-mediated inactivation of Akt and p38 MAPK inhibited CD40L effects on endothelial cells. Akt, in particular, appeared to mediate CD40L-induced CD40L synthesis and MCP1 release by endothelial cells in a redox sensitive manner via NF kappa B activation. In addition, using confocal microscopy, exogenous addition of recombinant CD40L or adenoviral mediated CD40L overexpression was found to stimulate nuclear translocation of NF kappa B, which was further augmented by Akt overexpression and inhibited by Akt inactivation. These data support a mechanism whereby redox-sensitive CD40-CD40L interactions induce activation of Akt and p38 MAPK, leading to stimulation of NF kappa B and enhanced synthesis of CD40L and MCP1. Increased CD40L and MCP1 may contribute to the adherence of CD40-positive cells, such as platelets and monocytes, to the vessel wall modulating atherothrombosis.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med, Boston, MA 02118 USA	Boston University	Chakrabarti, S (corresponding author), Boston Univ, Sch Med, 715 Albany St,W507, Boston, MA 02118 USA.	subrata@bu.edu						Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aggeli IKS, 2006, CELL SIGNAL, V18, P1801, DOI 10.1016/j.cellsig.2006.02.001; Aukrust P, 2004, J AM COLL CARDIOL, V43, P2326, DOI 10.1016/j.jacc.2004.03.023; Barford D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI 10.1016/j.sbi.2004.09.012; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Brown GE, 2004, J BIOL CHEM, V279, P27059, DOI 10.1074/jbc.M314258200; Chakrabarti S, 2005, ARTERIOSCL THROM VAS, V25, P2428, DOI 10.1161/01.ATV.0000184765.59207.f3; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; Cipollone F, 2002, CIRCULATION, V106, P399, DOI 10.1161/01.CIR.0000025419.95769.F0; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Djordjevic T, 2005, FREE RADICAL BIO MED, V38, P616, DOI 10.1016/j.freeradbiomed.2004.09.036; Downes CP, 2004, BIOCHEM SOC T, V32, P338, DOI 10.1042/BST0320338; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Flaherty DM, 2006, J BIOL CHEM, V281, P5058, DOI 10.1074/jbc.M508997200; Giles GI, 2006, CURR PHARM DESIGN, V12, P4427, DOI 10.2174/138161206779010549; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Ho FM, 2006, CELL SIGNAL, V18, P391, DOI 10.1016/j.cellsig.2005.05.009; Kaur J, 2001, AM J PHYSIOL-HEART C, V281, pH784, DOI 10.1152/ajpheart.2001.281.2.H784; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; Kikuchi T, 2000, CANCER RES, V60, P6391; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lutgens E, 2002, TRENDS CARDIOVAS MED, V12, P27, DOI 10.1016/S1050-1738(01)00142-6; Mach F, 1998, ATHEROSCLEROSIS, V137, pS89, DOI 10.1016/S0021-9150(97)00309-2; Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823; Mocanu MM, 2007, BRIT J PHARMACOL, V150, P833, DOI 10.1038/sj.bjp.0707155; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Sheu ML, 2005, ARTERIOSCL THROM VAS, V25, P539, DOI 10.1161/01.ATV.0000155462.24263.e4; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Urbich C, 2002, CIRCULATION, V106, P981, DOI 10.1161/01.CIR.0000027107.54614.1A; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wagner AH, 2004, ARTERIOSCL THROM VAS, V24, P715, DOI 10.1161/01.ATV.0000122853.99978.b1; Wang YJ, 2007, AM J RESP CELL MOL, V36, P68, DOI 10.1165/rcmb.2006-0165OC; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	38	71	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18307	18317		10.1074/jbc.M700211200	http://dx.doi.org/10.1074/jbc.M700211200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17459878	hybrid			2022-12-25	WOS:000247302000037
J	Wang, Y; Zhan, QM				Wang, Yang; Zhan, Qimin			Cell cycle-dependent expression of centrosomal ninein-like protein in human cells is regulated by the anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; MEDIATED DEGRADATION; AURORA-B; INSTABILITY; CDC20; PLK1; DESTRUCTION; NLP; COMPLEX/CYCLOSOME; DUPLICATION	The recently identified centrosome protein Nlp (ninein-like protein) is a key regulator in centrosome maturation, which contributes to chromosome segregation and cytokinesis. However, the mechanism(s) controlling Nlp expression remains largely unknown. Here we have shown that Nlp expression is cell cycle-dependent with a peak at G(2)/M transition in human cells. Nlp is a short-lived protein and degraded by the proteasome via the anaphase-promoting cyclosome complex (APC/c) pathway. It interacts with the APC/c through the APC2 or Cdc27 subunits and is ubiquitinated. Following treatment with proteasome inhibitors, its protein level is elevated. Nlp binds in vivo to the degradation-targeting proteins Cdh1 and Cdc20, and overexpression of Cdh1 and Cdc20 enhances Nlp degradation. Using point mutations of the two putative degradation signals in Nlp, we have found that its degradation requires intact KEN-box and D-box. Interestingly, the Lys-Glu-Asn-D-box-mutated Nlp exhibits a much stronger capability of inducing anchorage-independent growth and multinuclearity compared with the wild type Nlp. Taken together, these findings indicate that Nlp expression is cell cycle-dependent and regulated by APC-mediated protein degradation.	Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	Zhanqimin@pumc.edu.cn	Wang, Yang/A-1849-2010	Wang, Yang/0000-0001-9385-7393				Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; de Gramont A, 2006, CELL CYCLE, V5, P2168, DOI 10.4161/cc.5.18.3219; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eytan E, 2006, P NATL ACAD SCI USA, V103, P2081, DOI 10.1073/pnas.0510695103; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fry AM, 2006, CELL CYCLE, V5, P1487, DOI 10.4161/cc.5.14.3003; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Goto H, 2006, NAT CELL BIOL, V8, P180, DOI 10.1038/ncb1350; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Li JJ, 2006, PHARMACOL THERAPEUT, V111, P974, DOI 10.1016/j.pharmthera.2006.02.006; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Maki CG, 1996, CANCER RES, V56, P2649; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pfleger CM, 2000, GENE DEV, V14, P655; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Salisbury JL, 2001, J MAMMARY GLAND BIOL, V6, P203, DOI 10.1023/A:1011312808421; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	31	29	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17712	17719		10.1074/jbc.M701350200	http://dx.doi.org/10.1074/jbc.M701350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403670	hybrid			2022-12-25	WOS:000247084500044
J	Moretti, R; Thorson, JS				Moretti, Rocco; Thorson, Jon S.			Enhancing the latent nucleotide triphosphate flexibility of the glucose-1-phosphate thymidylyltransferase RmlA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GLUCOSE PYROPHOSPHORYLASE; GDP-MANNOSE PYROPHOSPHORYLASE; BIOSYNTHETIC GENE-CLUSTER; IN-VITRO CHARACTERIZATION; CHEMOENZYMATIC SYNTHESIS; SUBSTRATE-SPECIFICITY; SUGAR NUCLEOTIDES; CATALYTIC PROMISCUITY; NATURAL-PRODUCTS; PURIFICATION	Nucleotidyltransferases are central to nearly all glycosylation-dependent processes and have been used extensively for the chemoenzymatic synthesis of sugar nucleotides. The determination of the NTP specificity of the model thymidylyltransferase RmlA revealed RmlA to utilize all eight naturally occurring NTPs with varying levels of catalytic efficiency, even in the presence of nonnative sugar-1-phosphates. Guided by structural models, active site engineering of RmlA led to alterations of the inherent pyrimidine/purine bias by up to three orders of magnitude. This study sets the stage for engineering single universal nucleotidyltransferases and also provides new catalysts for the synthesis of novel nucleotide diphosphosugars.	Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Sch Pharm, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Thorson, JS (corresponding author), Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, 777 Highland Ave, Madison, WI 53705 USA.	jsthorson@pharmacy.wisc.edu	Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721	NCI NIH HHS [CA84374] Funding Source: Medline; NIAID NIH HHS [AI552218] Funding Source: Medline; NIGMS NIH HHS [GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Albermann C, 2003, ORG LETT, V5, P933, DOI 10.1021/ol0341086; ALBRECHT GJ, 1966, J BIOL CHEM, V241, P2868; Amann S, 2001, CARBOHYD RES, V335, P23, DOI 10.1016/S0008-6215(01)00195-1; Aparicio JF, 2003, APPL MICROBIOL BIOT, V61, P179, DOI 10.1007/s00253-002-1183-5; Bae J, 2005, CHEMBIOCHEM, V6, P1963, DOI 10.1002/cbic.200500183; Barton WA, 2002, P NATL ACAD SCI USA, V99, P13397, DOI 10.1073/pnas.192468299; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Borisova SA, 2006, ANGEW CHEM INT EDIT, V45, P2748, DOI 10.1002/anie.200503195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; CABIB E, 1965, J BIOL CHEM, V240, P2114; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Du LC, 2000, CHEM BIOL, V7, P623, DOI 10.1016/S1074-5521(00)00011-9; Elhalabi JM, 1999, CURR MED CHEM, V6, P93; Elling L, 1996, PHYTOCHEMISTRY, V42, P955, DOI 10.1016/0031-9422(96)00089-1; Fu X, 2005, ORG LETT, V7, P1513, DOI 10.1021/ol0501626; Fu X, 2003, NAT BIOTECHNOL, V21, P1467, DOI 10.1038/nbt909; Galm U, 2005, CHEM REV, V105, P739, DOI 10.1021/cr030117g; Griffith BR, 2005, CURR OPIN BIOTECH, V16, P622, DOI 10.1016/j.copbio.2005.10.002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jiang JQ, 2003, CHEMBIOCHEM, V4, P443, DOI 10.1002/cbic.200200566; Jiang JQ, 2001, ANGEW CHEM INT EDIT, V40, P1502, DOI 10.1002/1521-3773(20010417)40:8<1502::AID-ANIE1502>3.0.CO;2-K; Jiang JQ, 2000, J AM CHEM SOC, V122, P6803, DOI 10.1021/ja001444y; KIMATA K, 1966, J BIOL CHEM, V241, P1099; KNOP JK, 1970, J BIOL CHEM, V245, P2499; Ko KS, 2005, J ORG CHEM, V70, P1919, DOI 10.1021/jo048424p; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; Lairson LL, 2004, CHEM COMMUN, P2243, DOI 10.1039/b406490a; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; Liu W, 2005, CHEM BIOL, V12, P293, DOI 10.1016/j.chembiol.2004.12.013; Mizanur RM, 2004, J AM CHEM SOC, V126, P15993, DOI 10.1021/ja046070d; Morrison J F, 1979, Methods Enzymol, V63, P257; Nedal A, 2004, APPL MICROBIOL BIOT, V64, P7, DOI 10.1007/s00253-003-1535-9; Ning BT, 2000, EUR J BIOCHEM, V267, P6866, DOI 10.1046/j.1432-1033.2000.01781.x; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PREISS J, 1964, J BIOL CHEM, V239, P3119; Rupprath C, 2005, CURR MED CHEM, V12, P1637, DOI 10.2174/0929867054367167; Sambrook J., 1989, MOL CLONING LAB MANU; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; SHEN L, 1965, J BIOL CHEM, V240, P2334; SMOOT JW, 1985, EUR J BIOCHEM, V148, P83, DOI 10.1111/j.1432-1033.1985.tb08810.x; Watt GM, 2000, TETRAHEDRON-ASYMMETR, V11, P621, DOI 10.1016/S0957-4166(99)00556-X; WeymouthWilson AC, 1997, NAT PROD REP, V14, P99, DOI 10.1039/np9971400099; WONG CH, 1995, PURE APPL CHEM, V67, P1609, DOI 10.1351/pac199567101609; Yang M, 2005, J AM CHEM SOC, V127, P9336, DOI 10.1021/ja051482n; Yang M, 2005, CHEMBIOCHEM, V6, P346, DOI 10.1002/cbic.200400100; Yoshikuni Y, 2006, NATURE, V440, P1078, DOI 10.1038/nature04607; Zea CJ, 2004, ANAL BIOCHEM, V328, P196, DOI 10.1016/j.ab.2004.01.019; Zhang CS, 2006, J AM CHEM SOC, V128, P16420, DOI 10.1021/ja065950k; Zhang CS, 2007, CHEMBIOCHEM, V8, P385, DOI 10.1002/cbic.200600509; Zhang CS, 2006, SCIENCE, V313, P1291, DOI 10.1126/science.1130028; Zhang ZL, 2005, J BIOL CHEM, V280, P9698, DOI 10.1074/jbc.M411211200	58	38	38	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16942	16947		10.1074/jbc.M701951200	http://dx.doi.org/10.1074/jbc.M701951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17434871	hybrid			2022-12-25	WOS:000246946500027
J	Morgunova, E; Saller, S; Haase, I; Cushman, M; Bacher, A; Fischer, M; Ladenstein, R				Morgunova, Ekaterina; Saller, Sabine; Haase, Ilka; Cushman, Mark; Bacher, Adelbert; Fischer, Markus; Ladenstein, Rudolf			Lumazine synthase from Candida albicans as an anti-fungal target enzyme - Structural and biochemical basis for drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; 3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE; HEAVY RIBOFLAVIN SYNTHASE; BACILLUS-SUBTILIS; BINDING MODE; GENETIC CLASSIFICATION; ANGSTROM RESOLUTION; BIOSYNTHESIS; PROTEIN; INHIBITORS	Lumazine synthase is an enzyme involved in riboflavin biosynthesis in many plants and microorganisms, including numerous human pathogens. The fact that the enzymes of the riboflavin biosynthesis pathway are not present in the human or animal host makes them potential targets for anti-infective agents. The crystal structure of lumazine synthase from Candida albicans was solved by molecular replacement and refined at 2.5-angstrom resolution. The results of crystallographic investigations and sedimentation equilibrium experiments clearly indicated the presence of pentameric assemblies of the enzyme either in crystals or in solution. Isothermal titration calorimetry measurements of the binding reactions of four different inhibitors revealed high affinity for all four compounds with binding constants in the micromolar range. Structural comparison with previously determined structures of the enzyme center dot ligand complexes of other orthologue allowed modeling of the binding of four different inhibitors into the active site of lumazine synthase from Candida albicans.	Karolinska Inst, Novum, Ctr Struct Biochem, S-14157 Huddinge, Sweden; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Hamburg, Inst Biochem & Lebensmittelchem, Abt Lebensmittelchem, D-20146 Hamburg, Germany; Purdue Univ, Sch Pharm & Pharmacal Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA	Karolinska Institutet; Technical University of Munich; University of Hamburg; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Morgunova, E (corresponding author), Karolinska Inst, Novum, Ctr Struct Biochem, Halsovagen 7-9, S-14157 Huddinge, Sweden.	katja.morgunova@biosci.ki.se	Fischer, Markus/AFT-1856-2022; Fischer, Markus/H-2870-2012; Fischer, Markus J./G-9477-2012; Morgunova, Ekaterina/G-2479-2018	Fischer, Markus/0000-0001-7243-4199; Morgunova, Ekaterina/0000-0002-7754-9021	NIGMS NIH HHS [GM51469] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051469] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; BACHER A, 1986, CHEM BIOL CLIN ASPEC, V8, P227; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Bourenkov GP, 2006, ACTA CRYSTALLOGR D, V62, P58, DOI 10.1107/S0907444905033998; Braden BC, 2000, J MOL BIOL, V297, P1031, DOI 10.1006/jmbi.2000.3640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CRESSWELL RM, 1960, J CHEM SOC, P4776, DOI 10.1039/jr9600004776; Cushman M, 2005, J ORG CHEM, V70, P9092, DOI 10.1021/jo056032s; Cushman M, 1999, J ORG CHEM, V64, P3838, DOI 10.1021/jo9821729; Cushman M, 2004, J ORG CHEM, V69, P601, DOI 10.1021/jo030278k; d'Enfert C, 2005, NUCLEIC ACIDS RES, V33, pD353, DOI 10.1093/nar/gki124; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Echt S, 2004, J MOL BIOL, V341, P1085, DOI 10.1016/j.jmb.2004.06.053; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; Graybill JR, 1996, CLIN INFECT DIS, V22, pS166, DOI 10.1093/clinids/22.Supplement_2.S166; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; Klinke S, 2005, J MOL BIOL, V353, P124, DOI 10.1016/j.jmb.2005.08.017; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Laue T.M., 1992, COMPUTER AIDED INTER; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Morgunova E, 2005, BIOCHEMISTRY-US, V44, P2746, DOI 10.1021/bi047848a; Morgunova E, 2006, FEBS J, V273, P4790, DOI 10.1111/j.1742-4658.2006.05481.x; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Persson K, 1999, PROTEIN SCI, V8, P2355; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; Richter G, 1999, EUR J BIOCHEM, V261, P57, DOI 10.1046/j.1432-1327.1999.00211.x; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; SHAVLOVSKII G M, 1982, Mikrobiologiya, V51, P986; SHAVLOVSKY GM, 1979, GENETIKA+, V15, P1561; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Taylor J.R., 1997, INTRO ERROR ANAL STU, P75; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005; WARNOCK DW, 1995, J ANTIMICROB CHEMOTH, V36, P73, DOI 10.1093/jac/36.suppl_B.73; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; Zylberman V, 2004, J BIOL CHEM, V279, P8093, DOI 10.1074/jbc.M312035200	54	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17231	17241		10.1074/jbc.M701724200	http://dx.doi.org/10.1074/jbc.M701724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17446177	hybrid			2022-12-25	WOS:000246946500056
J	Rao, R; Redha, R; Macias-Perez, I; Su, Y; Hao, CM; Zent, R; Breyer, MD; Pozzi, A				Rao, Reena; Redha, Reyadh; Macias-Perez, Ines; Su, Yan; Hao, Chuanming; Zent, Roy; Breyer, Matthew D.; Pozzi, Ambra			Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; PROSTANOID RECEPTORS; TUMOR ANGIOGENESIS; EPITHELIAL-CELLS; P42/44 MAPK; EXPRESSION; EP4; CYCLOOXYGENASE-2; PHOSPHORYLATION	Prostaglandin E2 (PGE(2)), a major product of cyclooxygenase, exerts its functions by binding to four G protein-coupled receptors (EP1-4) and has been implicated in modulating angiogenesis. The present study examined the role of the EP4 receptor in regulating endothelial cell proliferation, migration, and tubulogenesis. Primary pulmonary microvascular endothelial cells were isolated from EP4(flox/flox) mice and were rendered null for the EP4 receptor with adenoCre virus. Whereas treatment with PGE(2) or the EP4 selective agonists PGE(1)-OH and ONO-AE1-329 induced migration, tubulogenesis, ERK activation and cAMP production in control adenovirus-transduced endothelial EP4(flox/flox) cells, no effects were seen in adenoCre-transduced EP4(flox/flox) cells. The EP4 agonist-induced endothelial cell migration was inhibited by ERK, but not PKA inhibitors, defining a functional link between PGE(2)-induced endothelial cell migration and EP4-mediated ERK signaling. Finally, PGE2, as well as PGE1-OH and ONO-AE1 -329, also promoted angiogenesis in an in vivo sponge assay providing evidence that the EP4 receptor mediates de novo vascularization in vivo.	Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vet Affairs Hosp, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Pozzi, A (corresponding author), Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, B3109, Nashville, TN 37232 USA.	pozzi@vanderbilt.edu		Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074116, R01DK069921, R01DK074359] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK74116, R01-DK074359, R01-DK 69921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Aoudjit L, 2006, AM J PHYSIOL-RENAL, V290, pF1534, DOI 10.1152/ajprenal.00267.2005; Axelsson Hans, 2005, Angiogenesis, V8, P339; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Calipel A, 2006, J BIOL CHEM, V281, P9238, DOI 10.1074/jbc.M600228200; Chen KH, 2003, CURR EYE RES, V26, P363, DOI 10.1076/ceyr.26.5.363.15442; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Inoue H, 2002, BRIT J PHARMACOL, V136, P287, DOI 10.1038/sj.bjp.0704705; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Li RC, 2004, CIRC RES, V94, P759, DOI 10.1161/01.RES.0000121568.40692.97; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Muller M, 2006, ENDOCRINOLOGY, V147, P3356, DOI 10.1210/en.2005-1429; Namkoong S, 2005, EXP MOL MED, V37, P588, DOI 10.1038/emm.2005.72; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Pavlovic S, 2006, J BIOL CHEM, V281, P3321, DOI 10.1074/jbc.M506846200; Pearce HR, 2003, J GASTROEN HEPATOL, V18, P1180, DOI 10.1046/j.1440-1746.2003.03152.x; Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Qian JY, 2006, AM J PHYSIOL-HEART C, V290, pH1740, DOI 10.1152/ajpheart.00904.2005; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Rosch S, 2005, BIOCHEM BIOPH RES CO, V338, P1171, DOI 10.1016/j.bbrc.2005.10.051; Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Sun HS, 2003, ENDOCRINOLOGY, V144, P3934, DOI 10.1210/en.2003-0289; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yang L, 2006, CANCER RES, V66, P9665, DOI 10.1158/0008-5472.CAN-06-1271	41	111	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16959	16968		10.1074/jbc.M701214200	http://dx.doi.org/10.1074/jbc.M701214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17401137	hybrid			2022-12-25	WOS:000246946500029
J	Shiokawa, D; Matsushita, T; Shika, Y; Shimizu, M; Maeda, M; Tanuma, SI				Shiokawa, Daisuke; Matsushita, Tokiyoshi; Shika, Yukari; Shimizu, Mamoru; Maeda, Masahiro; Tanuma, Sei-ichi			DNase X is a glycosylphosphatidylinositol-anchored membrane enzyme that provides a barrier to endocytosis-mediated transfer of a foreign gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELICAL PEPTIDES; LIPID RAFTS; DEPENDENT ENDOCYTOSIS; MAMMALIAN-CELLS; PLASMID DNA; HUMAN XQ28; NAKED DNA; PROTEINS; EXPRESSION; ENDOSOMES	DNase X is the first mammalian DNase to be isolated that is homologous to DNase I. In this study, we have examined its function using a novel monoclonal antibody and showed it to be expressed on the cell surface as a glycosylphosphatidylinositol-anchored membrane protein. High level expression was observed in human muscular tissues and in myotubes obtained in vitro from RD rhabdomyosarcoma cells. We observed that RD myotubes incorporated a foreign gene, lacZ, by endocytosis but that expression of the encoded coding product, beta-galactosidase, was strongly inhibited. Overexpression of DNase X inhibited endocytosis-mediated gene transfer, whereas knockdown of DNase X with small interfering RNA had the opposite effect. These results reveal that DNase X provides a cell surface barrier to endocytosis-mediated gene transfer.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, Noda, Chiba 2788510, Japan; Immunobiol Labs Co Ltd, Res & Dev Dept, Fujioka, Gunma 3750005, Japan; Tokyo Univ Sci, Genome & Drug Res Ctr, Noda, Chiba 2788510, Japan	Tokyo University of Science; Immuno-Biological Laboratories Co. Ltd.; Tokyo University of Science	Tanuma, SI (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	tanuma@rs.noda.tus.ac.jp						Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Balicki D, 2002, P NATL ACAD SCI USA, V99, P7467, DOI 10.1073/pnas.102168299; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; Coy JF, 1996, CELL DEATH DIFFER, V3, P199; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; KINEBUCHI M, 1991, J IMMUNOL, V146, P3721; Liu F, 2001, Mol Interv, V1, P168; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOORE S, 1981, ENZYMES A, V14, P281; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307; Ohmori N, 1998, BIOCHEM BIOPH RES CO, V245, P259, DOI 10.1006/bbrc.1998.8408; PARRISH JE, 1995, HUM MOL GENET, V4, P1557, DOI 10.1093/hmg/4.9.1557; Pergolizzi R, 1996, GENE, V168, P267, DOI 10.1016/0378-1119(95)00741-5; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; PRICE PA, 1975, J BIOL CHEM, V250, P1981; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Sawamura D, 2002, CLIN EXP DERMATOL, V27, P480, DOI 10.1046/j.1365-2230.2002.01101.x; Shiokawa D, 2005, BIOCHEM J, V392, P511, DOI 10.1042/BJ20051114; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	32	24	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17132	17140		10.1074/jbc.M610428200	http://dx.doi.org/10.1074/jbc.M610428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416904	hybrid			2022-12-25	WOS:000246946500046
J	Jain, AK; Jaiswal, AK				Jain, Abhinav K.; Jaiswal, Anil K.			GSK-3 beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDOREDUCTASE-1 GENE-EXPRESSION; ELEMENT-MEDIATED EXPRESSION; CUL3-BASED E3 LIGASE; TRANSCRIPTION FACTOR; ANTIOXIDANT INDUCTION; NRF2; PHOSPHORYLATION; ACTIVATION; PROTEIN; KEAP1	NF-E2-related factor 2 (Nrf2) regulates expression and coordinated induction of a battery of chemoprotective genes in response to oxidative and electrophilic stress. This leads to protection against oxidative stress and neoplastic diseases. Nuclear import and export of Nrf2 play a significant role in control of nuclear levels of Nrf2 and thus the expression of Nrf2 downstream genes. Tyrosine kinase Fyn phosphorylates tyrosine 568 of Nrf2 that leads to the nuclear export of Nrf2. In this study, we investigated the upstream factor(s) in regulation of Fyn and Fyn-mediated nuclear export of Nrf2. The investigations shed light on a novel mechanism of Nrf2 regulation in response to oxidative stress. We demonstrate that GSK-3 beta acts upstream of Fyn kinase in control of nuclear export of Nrf2. Chemical and short interfering RNA-mediated inhibition of GSK-3 beta led to nuclear accumulation of Nrf2 and transcriptional activation of the Nrf2 downstream gene nqo1. Chemical and short interfering RNA inhibition of GSK-3 beta and Fyn individually and in combination revealed that both kinases follow the same pathway to regulate nuclear export of Nrf2. We further demonstrate that hydrogen peroxide phosphorylates tyrosine 216 of GSK-3 beta. This leads to activation of GSK-3 beta. The activated GSK-3 beta phosphorylates Fyn at threonine residue( s). Phosphorylated Fyn accumulates in the nucleus and phosphorylates Nrf2 at tyrosine 568. This leads to nuclear export, ubiquitination, and degradation of Nrf2.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Jain, Abhinav K/A-2540-2013	Jain, Abhinav/0000-0003-3268-514X	NIEHS NIH HHS [R01 ES012265] Funding Source: Medline; NIGMS NIH HHS [R01 GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kannan S, 2006, CANCER RES, V66, P8421, DOI 10.1158/0008-5472.CAN-06-1181; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248	22	351	370	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16502	16510		10.1074/jbc.M611336200	http://dx.doi.org/10.1074/jbc.M611336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403689	hybrid			2022-12-25	WOS:000246794300057
J	Xu, Y; Fang, F; Dhar, SK; St Clair, WH; Kasarskis, EJ; St Clair, DK				Xu, Yong; Fang, Fang; Dhar, Sanjit K.; St Clair, William H.; Kasarskis, Edward J.; St Clair, Daret K.			The role of a single-stranded nucleotide loop in transcriptional regulation of the human sod2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SYNERGISTIC ACTIVATION; TRANSGENIC MICE; CANCER-CELLS; FACTOR-ALPHA; DNA; NUCLEOPHOSMIN; MECHANISM	Manganese superoxide dismutase (MnSOD), a mitochondrial antioxidant enzyme, is necessary for survival of aerobic life. Previously, we demonstrated that a Sp1-based promoter is essential for constitutive transcription and a NF-kappa B-based intronic enhancer is responsible for cytokine-mediated induction. Here we show that nucleophosmin (NPM), a RNA-binding protein, binds to an 11G single-stranded loop in the promoter region and serves to integrate the Sp1 and NF-kappa B responses. Disruption of the loop structure causes a reduction of both constitutive and inductive transcription due to loss of the binding motif for NPM. Interaction of NF-kappa B.NPM.Sp1 facilitated by binding of NPM to the loop structure in the promoter region appears to comprise the basic complex for the transcriptional stimulation. These results suggest a novel molecular mechanism for communication between the enhancer and the GC-rich promoter.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	dstc100@uky.edu			NATIONAL CANCER INSTITUTE [R01CA073599, R01CA049797, R29CA049797] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73599, R01 CA073599-09A1, R01 CA049797-17, R01 CA073599, R01 CA049797, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ameres SL, 2005, EMBO J, V24, P358, DOI 10.1038/sj.emboj.7600531; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Granger SW, 1998, J VIROL, V72, P8961, DOI 10.1128/JVI.72.11.8961-8970.1998; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; IKEDA K, 1993, GENE, V136, P341; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Josson S, 2006, ONCOGENE, V25, P1554, DOI 10.1038/sj.onc.1209186; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; MARLHENS F, 1985, BIOCHEM BIOPH RES CO, V129, P300, DOI 10.1016/0006-291X(85)91437-8; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 1986, FREE RADICALS AGING, P325; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; St Clair D, 2005, BIOMED PHARMACOTHER, V59, P209, DOI 10.1016/j.biopha.2005.03.004; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Tamada H, 2006, MOL CELL BIOL, V26, P1259, DOI 10.1128/MCB.26.4.1259-1271.2006; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909	56	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15981	15994		10.1074/jbc.M608979200	http://dx.doi.org/10.1074/jbc.M608979200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426024	Green Accepted, hybrid			2022-12-25	WOS:000246794300007
J	Don, AS; Martinez-Lamenca, C; Webb, WR; Proia, RL; Roberts, E; Rosen, H				Don, Anthony S.; Martinez-Lamenca, Carolina; Webb, William R.; Proia, Richard L.; Roberts, Ed; Rosen, Hugh			Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOMODULATORY DRUG FTY720; 1-PHOSPHATE RECEPTOR AGONIST; MRL-LPR/LPR-MICE; ENDOPLASMIC-RETICULUM; KINASE TYPE-2; IN-VIVO; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE EGRESS; TUMOR-GROWTH	The clinical immunosuppressant FTY720 is a sphingosine analogue that, once phosphorylated by sphingosine kinase 2(Sphk2), is an agonist of multiple receptor subtypes for sphingosine 1-phosphate. Short exposures to FTY720 afford long term protection in lymphoproliferative and autoimmune disease models, presumably by inducing apoptosis in subsets of cells essential for pathogenesis. Sphingosine itself is pro-apoptotic, and apoptosis induced with FTY720 or sphingosine is thought to proceed independently of their phosphorylation. Following chemical mutagenesis of Jurkat cells we isolated mutants that are selectively resistant to FTY720 analogue AAL(R), as well as natural sphingolipid bases, including sphingosine. Cells lacking functional Sphk2 were resistant to apoptosis induced with AAL(R), indicating that apoptosis proceeds through AAL(R) phosphorylation. Phosphorylation of AAL(R) was also required for induction of lymphocyte apoptosis in mice, as apoptosis was not induced with the non-phosphorylatable chiral analogue, AAL(S). Apoptosis was induced in the spleen but not the thymus of mice administered 1 mg/ kg AAL(R), correlating with levels of AAL(R)-phosphate (AFD(R)) in organ extracts. AFD(R) did not induce apoptosis when added to the cell culture medium, indicating that it induces apoptosis through an intracellular target. NBD-labeled AAL(R) localized to the endoplasmic reticulum, and AAL(R) treatment resulted in elevated cytosolic calcium, Bax redistribution from cytosol to mitochondrial and endoplasmic reticulum membranes, and caspase-independent mitochondrial permeabilization in Jurkat cells. We therefore describe an apoptotic pathway triggered by intracellular accumulation of sphingolipid base phosphates and suggest that sphingoid base substrates for Sphk2 acting intracellularly could be useful in the treatment of lymphoproliferative diseases.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; NIDDK, NIH, Bethesda, MD 20892 USA	Scripps Research Institute; Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rosen, H (corresponding author), ICND118,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hrosen@scripps.edu	Don, Anthony Simon/AAE-9687-2021; Proia, Richard L/A-7908-2012	Don, Anthony Simon/0000-0003-1655-1184; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056017, ZIADK056017] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055509] Funding Source: Medline; PHS HHS [NIMH-074404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Azuma H, 2002, CANCER RES, V62, P1410; Bandhuvula P, 2005, J BIOL CHEM, V280, P33697, DOI 10.1074/jbc.C500294200; Billich A, 2004, ANAL BIOCHEM, V326, P114, DOI 10.1016/j.ab.2003.11.018; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANT P, V33, P3078, DOI 10.1016/S0041-1345(01)02312-0; Chiba K, 1999, TRANSPLANT P, V31, P1230, DOI 10.1016/S0041-1345(98)01975-7; Chiba K, 2005, TRANSPL P, V37, P102, DOI 10.1016/j.transproceed.2004.12.286; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; Chua CW, 2005, INT J CANCER, V117, P1039, DOI 10.1002/ijc.21243; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cvijic ME, 2003, J IMMUNOL METHODS, V278, P293, DOI 10.1016/S0022-1759(03)00191-1; Ettmayer P, 2006, BIOORG MED CHEM LETT, V16, P84, DOI 10.1016/j.bmcl.2005.09.038; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107; Ho JWY, 2005, MOL CANCER THER, V4, P1430, DOI 10.1158/1535-7163.MCT-05-0021; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Lee WJ, 2004, EXP MOL MED, V36, P420, DOI 10.1038/emm.2004.54; Lepine S, 2004, J IMMUNOL, V173, P3783, DOI 10.4049/jimmunol.173.6.3783; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Nagahara Y, 2000, IMMUNOPHARMACOLOGY, V48, P75, DOI 10.1016/S0162-3109(00)00181-8; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nagahara Y, 2002, BRIT J PHARMACOL, V137, P953, DOI 10.1038/sj.bjp.0704970; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Okazaki H, 2002, J RHEUMATOL, V29, P707; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Pernmpongkosol S, 2002, INT J CANCER, V98, P167, DOI 10.1002/ijc.10178; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Suzuki S, 1997, CLIN EXP IMMUNOL, V107, P103, DOI 10.1046/j.1365-2249.1997.d01-885.x; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; Welsch CA, 2004, J BIOL CHEM, V279, P36720, DOI 10.1074/jbc.M406179200; Yasui H, 2005, CANCER RES, V65, P7478, DOI 10.1158/0008-5472.CAN-05-0850; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	50	65	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15833	15842		10.1074/jbc.M609124200	http://dx.doi.org/10.1074/jbc.M609124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400555	hybrid			2022-12-25	WOS:000246589600058
J	Edwards, MR; Haas, J; Panettieri, RA; Johnson, M; Johnston, SL				Edwards, Michael R.; Haas, Jennifer; Panettieri, Rey A., Jr.; Johnson, Malcolm; Johnston, Sebastian L.			Corticosteroids and beta(2) Agonists differentially regulate rhinovirus-induced interleukin-6 via distinct cis-acting elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE-CELLS; AIRWAY EPITHELIAL-CELLS; HISTONE ACETYLTRANSFERASE ACTIVITY; RESPONSE ELEMENT; BINDING PROTEIN; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; ASTHMA EXACERBATIONS	Interleukin-6 (IL-6) is a proinflammatory cytokine up-regulated by rhinovirus infection during acute exacerbations of asthma and chronic obstructive pulmonary disease. The role of IL-6 during exacerbations is unclear; however, it is believed IL-6 could contribute to airway and systemic inflammation. In this study we investigate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol and salbutamol on IL-6 production in BEAS-2B and primary bronchial epithelial cells. Salmeterol and salbutamol enhanced rhinovirus- and IL-1 beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein and mRNA. Combined activity of salmeterol and fluticasone at equimolar concentrations had no effect on rhinovirus or IL-1 beta induction of IL-6. The induction of IL- 6 by salmeterol was dependent upon the beta 2 receptor and could also be induced by cAMP or cAMP-elevating agents forskolin and rolipram. Using transfection of IL-6 promoter reporter constructs, dominant negative mutants, and electromobility shift assays, it was found that NF-kappa B was the only transcription factor required for rhinovirus induction of IL-6 gene expression. Salmeterol caused an augmentation of rhinovirus- induced promoter activation via a mechanism dependent upon the c/EBP and/or CRE (cyclic AMP response element) cis-acting sites. The suppressive effect of FP was dependent upon distinct glucocorticoid response element sequences proximal to the transcriptional start site within the IL-6 promoter. The data demonstrate that beta(2) agonists can augment IL-6 expression by other stimuli in an additive manner via cyclic AMP and that the negative effect of steroids is mediated by glucocorticoid response elements within the IL-6 promoter.	Imperial Coll London, Wright Fleming Inst Infect & Immun, London W2 1PG, England; Univ Penn, UK MRC Ctr Allerg Mechan Asthma, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Imperial College London; University of Pennsylvania; University of Pennsylvania	Edwards, MR (corresponding author), St Marys Hosp, Imperial Coll, Dept Resp Med, Natl Heart Lung Inst, London Norfolk Pl, London W2 1PG, England.	michael.edwards@ic.ac.uk	panettieri, reynold/AAG-9485-2019; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Edwards, Michael Robert/0000-0001-6837-0532	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; BOEGE U, 1991, VIROLOGY, V181, P1, DOI 10.1016/0042-6822(91)90464-M; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Flammer JR, 2006, BIOCHEMISTRY-US, V45, P9615, DOI 10.1021/bi052521a; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Funkhouser AW, 2004, PEDIATR RES, V55, P13, DOI 10.1203/01.PDR.0000099801.06360.AB; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; HOLTKAMP W, 1995, J CLIN GASTROENTEROL, V20, P123, DOI 10.1097/00004836-199503000-00010; Hurst JR, 2006, AM J RESP CRIT CARE, V173, P71, DOI 10.1164/rccm.200505-704OC; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Laza-Stanca V, 2006, J VIROL, V80, P8248, DOI 10.1128/JVI.00162-06; Malkoski SP, 1999, MOL ENDOCRINOL, V13, P1629, DOI 10.1210/me.13.10.1629; McCauslin CS, 2006, J BIOL CHEM, V281, P17681, DOI 10.1074/jbc.M600207200; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pelaia G, 2003, LIFE SCI, V72, P1549, DOI 10.1016/S0024-3205(02)02446-3; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Qiu Z, 2004, CLIN EXP ALLERGY, V34, P1321, DOI 10.1111/j.1365-2222.2004.02013.x; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; SPURRELL JC, 2005, AM J PHYSIOL, V28, pL85; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wilkinson TMA, 2006, AM J RESP CRIT CARE, V173, P871, DOI 10.1164/rccm.200509-1489OC; Wilkinson TMA, 2006, CHEST, V129, P317, DOI 10.1378/chest.129.2.317; XIGN Z, 1998, J CLIN IVESTIG, V101, P311; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	57	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15366	15375		10.1074/jbc.M701325200	http://dx.doi.org/10.1074/jbc.M701325200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395587	hybrid, Green Published			2022-12-25	WOS:000246589600012
J	Scoumanne, A; Chen, XB				Scoumanne, Ariane; Chen, Xinbin			The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEMETHYLATION; P53 ACTIVITY; COMPLEX; DOMAIN; IDENTIFICATION; ACETYLATION; REPRESSION; PROTEIN; FAMILY; GENES	The lysine-specific demethylase 1 (LSD1), a component of several histone deacetylase complexes, plays an important role in chromatin remodeling and transcriptional regulation. Here, we generated multiple cell lines in which LSD1 is inducibly expressed or knocked down and found that LSD1 is required for cell proliferation. In addition, we found that deficiency in LSD1 leads to a partial cell cycle arrest in G(2)/M and sensitizes cells to growth suppression induced by DNA damage or MDM2 inhibition in a p53-dependent manner. We also showed that LSD1 deficiency delays p53 stabilization induced by DNA damage, leading to a delayed induction of p21 and MDM2. Finally, we performed a microarray study and identified several novel LSD1 target genes, including S100A8, which encodes a calcium-binding protein, and DEK, a proto-oncogene. Taken together, we uncovered that LSD1 has a pro-oncogenic function by modulating pro-survival gene expression and p53 transcriptional activity.	Univ Calif Davis, Ctr Comparat Oncol, Davis, CA 95616 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA081237, R01CA076069, R01CA102188, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA081237, CA076069, CA102188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kondoh N, 1999, CANCER RES, V59, P4990; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	23	113	142	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15471	15475		10.1074/jbc.M701023200	http://dx.doi.org/10.1074/jbc.M701023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409384	hybrid			2022-12-25	WOS:000246589600022
J	Sobo, K; Chevallier, J; Parton, RG; Gruenberg, J; van der Goot, FG				Sobo, Komla; Chevallier, Julien; Parton, Robert G.; Gruenberg, Jean; van der Goot, F. Gisou			Diversity of Raft-Like Domains in Late Endosomes	PLOS ONE			English	Article							DETERGENT-RESISTANT MEMBRANES; GPI-ANCHORED PROTEINS; LIPID RAFTS; PLASMA-MEMBRANE; ENDOCYTIC PATHWAY; CELL-MEMBRANES; ENDOPLASMIC-RETICULUM; PRION PROTEIN; CHOLESTEROL; TOXIN	Background. Late endosomes, the last sorting station in the endocytic pathway before lysosomes, are pleiomorphic organelles composed of tubular elements as well as vesicular regions with a characteristic multivesicular appearance, which play a crucial role in intracellular trafficking. Here, we have investigated whether, in addition to these morphologically distinguishable regions, late endosomal membranes are additionally sub-compartmentalized into membrane microdomains. Methodology/Principal Findings. Using sub-organellar fractionation techniques, both with and without detergents, combined with electron microscopy, we found that both the limiting membrane of the organel and the intraluminal vesicles contain raft-type membrane domains. Interestingly, these differentially localized domains vary in protein composition and physico-chemical properties. Conclusions/Significance. In addition to the multivesicular organization, we find that late endosomes contain cholesterol rich microdomains both on their limiting membrane and their intraluminal vesicles that differ in composition and properties. Implications of these findings for late endosomal functions are discussed.	[Sobo, Komla; van der Goot, F. Gisou] Univ Geneva, Dept Microbiol & Mol Med, Geneva, Switzerland; [Chevallier, Julien; Gruenberg, Jean] Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; [Parton, Robert G.] Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld, Australia; [Parton, Robert G.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [van der Goot, F. Gisou] Ecole Polytech Fed Lausanne, SV AI Extens, Lausanne, Switzerland	University of Geneva; University of Geneva; University of Queensland; University of Queensland; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	van der Goot, FG (corresponding author), Univ Geneva, Dept Microbiol & Mol Med, Geneva, Switzerland.	gisou.vandergoot@epfl.ch	Chevallier, Julien/AAY-9567-2020; Parton, Robert G/C-5673-2009; van der Goot, Gisou G/B-2279-2012	Chevallier, Julien/0000-0002-4423-9502; Parton, Robert G/0000-0002-7494-5248; van der Goot, Gisou G/0000-0002-8522-274X	Swiss National Science Foundation; National Health and Medical Research Council of Australia; Howard Hughes Medical Institute	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Howard Hughes Medical Institute(Howard Hughes Medical Institute)	This work was supported by a grant from the Swiss National Science Foundation to J. G and to G. v. d. G. and a grant from the National Health and Medical Research Council of Australia to R. P. G. v. d. G is an international Fellow of the Howard Hughes Medical Institute.	Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Babiychuk EB, 2006, BIOCHEM J, V397, P407, DOI 10.1042/BJ20060056; Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; Browman DT, 2006, J CELL SCI, V119, P3149, DOI 10.1242/jcs.03060; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 2006, PHYSIOLOGY, V21, P430, DOI 10.1152/physiol.00032.2006; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; BUCKLEY JT, 1981, CAN J BIOCHEM CELL B, V59, P430, DOI 10.1139/o81-059; Campana V, 2006, J CELL SCI, V119, P433, DOI 10.1242/jcs.02768; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; COELHO VD, 2004, BMC IMMUNOL, V5, P2; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Deinhardt K, 2006, J CELL BIOL, V174, P459, DOI 10.1083/jcb.200508170; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Eberle HB, 2002, J CELL SCI, V115, P827; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Gallegos AM, 2006, BIOCHEMISTRY-US, V45, P12100, DOI 10.1021/bi0602720; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Gruenberg J, 2006, NAT REV MOL CELL BIO, V7, P495, DOI 10.1038/nrm1959; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Ikonen E, 2004, SEMIN CELL DEV BIOL, V15, P445, DOI 10.1016/j.semcdb.2004.03.001; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; LI X, 2007, MOL BIOL CE IN PRESS; Lichtenberg D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/j.tibs.2005.06.004; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Magee T, 2002, BIOL RES, V35, P127, DOI 10.4067/S0716-97602002000200003; Mobius W, 2003, TRAFFIC, V4, P222; Morris R, 2004, SUB CELL BIOCHEM, V37, P35; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Pelkmans L, 2005, BBA-MOL CELL RES, V1746, P295, DOI 10.1016/j.bbamcr.2005.06.009; Pielsticker LK, 2005, BIOCHEM BIOPH RES CO, V330, P163, DOI 10.1016/j.bbrc.2005.02.136; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pimpinelli F, 2005, EUR J NEUROSCI, V21, P2063, DOI 10.1111/j.1460-9568.2005.04049.x; Ritchie K, 2003, MOL MEMBR BIOL, V20, P13, DOI 10.1080/0968768021000055698; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Strauss JF, 2002, STEROIDS, V67, P947, DOI 10.1016/S0039-128X(02)00042-9; van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003	67	61	61	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e391	10.1371/journal.pone.0000391	http://dx.doi.org/10.1371/journal.pone.0000391			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460758	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445600005
J	Shaman, J; Day, JF				Shaman, Jeffrey; Day, Jonathan F.			Reproductive Phase Locking of Mosquito Populations in Response to Rainfall Frequency	PLOS ONE			English	Article							ST-LOUIS ENCEPHALITIS; CULEX-NIGRIPALPUS DIPTERA; DROUGHT-INDUCED AMPLIFICATION; INDIAN-RIVER-COUNTY; WEST-NILE-VIRUS; TAMPA BAY AREA; CLIMATE VARIABILITY; EPIDEMIC; CULICIDAE; MALARIA	The frequency of moderate to heavy rainfall events is projected to change in response to global warming. Here we show that these hydrologic changes may have a profound effect on mosquito population dynamics and rates of mosquito-borne disease transmission. We develop a simple model, which treats the mosquito reproductive cycle as a phase oscillator that responds to rainfall frequency forcing. This model reproduces observed mosquito population dynamics and indicates that mosquito-borne disease transmission can be sensitive to rainfall frequency. These findings indicate that changes to the hydrologic cycle, in particular the frequency of moderate to heavy rainfall events, could have a profound effect on the transmission rates of some mosquito-borne diseases.	[Shaman, Jeffrey] Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; [Day, Jonathan F.] Univ Florida, Inst Food & Agr Sci, Florida Med Entomol Lab, Vero Beach, FL 32962 USA	Oregon State University; State University System of Florida; University of Florida	Shaman, J (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA.	jshaman@coas.oregonstate.edu.edu						CHAMBERLAIN RW, 1964, AM J TROP MED HYG, V13, P456, DOI 10.4269/ajtmh.1964.13.456; CHRISTOPHERS R, 1911, SCI MEMOIRS OFFICERS; CUSHING JM, 1986, THEOR POPUL BIOL, V30, P289, DOI 10.1016/0040-5809(86)90038-9; DAY J F, 1988, Miscellaneous Publications of the Entomological Society of America, V68, P1; Day JF, 1999, J MED ENTOMOL, V36, P176, DOI 10.1093/jmedent/36.2.176; DAY JF, 1993, J AM MOSQUITO CONTR, V9, P249; DAY JF, 1990, J MED ENTOMOL, V27, P43, DOI 10.1093/jmedent/27.1.43; DAY JF, 1989, ANN ENTOMOL SOC AM, V82, P32, DOI 10.1093/aesa/82.1.32; Day Jonathan F., 1994, American Entomologist, V40, P162; DOW RP, 1964, AM J TROP MED HYG, V13, P462, DOI 10.4269/ajtmh.1964.13.462; DOW RP, 1970, ANN ENTOMOL SOC AM, V63, P995, DOI 10.1093/aesa/63.4.995; GILL CA, 1938, SEASONAL PERIODICITY; Gubler DJ, 2001, ENVIRON HEALTH PERSP, V109, P223, DOI 10.2307/3435012; HADDOW AJ, 1945, B ENTOMOL RES, V36, P33, DOI 10.1017/S0007485300023907; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 IMP; Kettle DS, 1995, MED ENTOMOL, P248; Mitchell C.J., 1980, ST LOUIS ENCEPHALITI, P313; MONATH TP, 1980, ST LOUIS ENCEPHALITI, P239; NISBET RM, 1976, J THEOR BIOL, V56, P459, DOI 10.1016/S0022-5193(76)80086-0; Pascual M, 2006, P NATL ACAD SCI USA, V103, P5829, DOI 10.1073/pnas.0508929103; Patz JA, 2002, NATURE, V420, P627, DOI 10.1038/420627a; PITTENDRIGH CS, 1950, EVOLUTION, V4, P43, DOI 10.2307/2405533; PLATT RB, 1957, ECOL MONOGR, V27, P303, DOI 10.2307/1942188; Provost M. W., 1973, Florida Scientist, V36, P217; Reisen WK, 2002, J MED ENTOMOL, V39, P793, DOI 10.1603/0022-2585-39.5.793; Rutledge CR, 2003, J MED ENTOMOL, V40, P253, DOI 10.1603/0022-2585-40.3.253; Sardelis MR, 2001, EMERG INFECT DIS, V7, P1018, DOI 10.3201/eid0706.010617; Shaman J, 2006, ECOL MODEL, V194, P395, DOI 10.1016/j.ecolmodel.2005.10.037; Shaman J, 2005, J MED ENTOMOL, V42, P134, DOI 10.1603/0022-2585(2005)042[0134:DAAETO]2.0.CO;2; Shaman J, 2004, AM J TROP MED HYG, V71, P251, DOI 10.4269/ajtmh.2004.71.251; Shaman J, 2004, EMERG INFECT DIS, V10, P802, DOI 10.3201/eid1005.030246; Shaman J, 2003, J MED ENTOMOL, V40, P547, DOI 10.1603/0022-2585-40.4.547; Shaman J, 2002, EMERG INFECT DIS, V8, P575, DOI 10.3201/eid0806.010417; Shanks GD, 2002, EMERG INFECT DIS, V8, P1404, DOI 10.3201/eid0812.020077; Shroyer D. A., 1991, Journal of the Florida Mosquito Control Association, V62, P69; Singh N, 2002, ANN TROP MED PARASIT, V96, P349, DOI 10.1179/000349802125001113; Strogatz S.H., 1998, NONLINEAR DYNAMICS C; Tong SL, 2001, ENVIRON HEALTH PERSP, V109, P1271, DOI 10.2307/3454750; Trenberth KE, 2003, B AM METEOROL SOC, V84, P1205, DOI 10.1175/BAMS-84-9-1205; Wegbreit J, 2000, J AM MOSQUITO CONTR, V16, P22; Zhou G, 2004, P NATL ACAD SCI USA, V101, P2375, DOI 10.1073/pnas.0308714100; [No title captured]	43	57	57	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e331	10.1371/journal.pone.0000331	http://dx.doi.org/10.1371/journal.pone.0000331			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17396162	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445200014
J	Jin, Z; Mori, Y; Yang, J; Sato, F; Ito, T; Cheng, Y; Paun, B; Hamilton, JP; Kan, T; Olaru, A; David, S; Agarwal, R; Abraham, JM; Beer, D; Montgomery, E; Meltzer, SJ				Jin, Z.; Mori, Y.; Yang, J.; Sato, F.; Ito, T.; Cheng, Y.; Paun, B.; Hamilton, J. P.; Kan, T.; Olaru, A.; David, S.; Agarwal, R.; Abraham, J. M.; Beer, D.; Montgomery, E.; Meltzer, S. J.			Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma	ONCOGENE			English	Article						hypermethylation; NELL1; EAC; ESCC; biomarker	SEGMENT BARRETTS-ESOPHAGUS; PROMOTER HYPERMETHYLATION; FOLLOW-UP; NEOPLASTIC PROGRESSION; CANCER; DYSPLASIA; NELL-1; CRANIOSYNOSTOSIS; INACTIVATION; METHYLATION	The nel-like1 ( NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma ( EAC). NELL1 promoter hypermethylation was examined by real-time methylation-specific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve pro. les, clearly distinguishing esophageal squamous cell carcinoma ( ESCC) and EAC from normal esophagus ( NE) ( P < 0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia ( BE), dysplastic Barrett's ( D) and EAC than in NE ( P < 0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significantly correlation between NELL1 hypermethylation and BE segment length. Three ( 11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P = 0.0264) but not in stages III-IV ( P = 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2'-deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter ( P 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21231 USA; Univ Michigan, Sch Med, Dept Surg, Div Gen Thorac Surg, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21231 USA.	smeltzer@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA001808, R21CA106763, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER; NCI NIH HHS [CA001808, CA085069, CA106763] Funding Source: Medline; NIDDK NIH HHS [T32 DK067872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender CM, 1999, MOL CELL BIOL, V19, P6690; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Fang MZ, 2005, INT J ONCOL, V26, P615; Gleeson CM, 1998, GENE CHROMOSOME CANC, V21, P49, DOI 10.1002/(SICI)1098-2264(199801)21:1<49::AID-GCC7>3.0.CO;2-8; Hage M, 2004, SCAND J GASTROENTERO, V39, P1175, DOI 10.1080/00365520410003524; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; International Union Against Cancer, 2002, TNM CLASS MAL TUM; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753; Lee EJ, 2006, EUR J CANCER, V42, P972, DOI 10.1016/j.ejca.2006.01.021; Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009; MATSUHASHI S, 1995, DEV DYNAM, V203, P212, DOI 10.1002/aja.1002030209; Matsuhashi S, 1996, DEV DYNAM, V207, P233; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Sharma P, 1997, AM J GASTROENTEROL, V92, P2012; Shibata DM, 2002, CANCER RES, V62, P5637; STEWART DM, 2003, WORLD CANC REPORT; WATANABE H, 2002, LANG COMPUT, V38, P273; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Zhang XL, 2006, LAB INVEST, V86, P633, DOI 10.1038/labinvest.3700430; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; Zhang XL, 2003, J BONE MINER RES, V18, P2126, DOI 10.1359/jbmr.2003.18.12.2126	33	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6332	6340		10.1038/sj.onc.1210461	http://dx.doi.org/10.1038/sj.onc.1210461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452981				2022-12-25	WOS:000249583300009
J	Sekaric, P; Shamanin, VA; Luo, J; Androphy, EJ				Sekaric, P.; Shamanin, V. A.; Luo, J.; Androphy, E. J.			HAda3 regulates p14ARF-induced p53 acetylation and senescence	ONCOGENE			English	Article						p53; p14ARF; senescence; papillomavirus E6; hAda3	HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMARY EPITHELIAL-CELLS; E6 ONCOPROTEIN; ONCOGENIC RAS; DNA-DAMAGE; HUMAN ADA3; MDM2; ACTIVATION; IMMORTALIZATION; P21(WAF1/CIP1)	Acetylation is thought to be a key event for p53 activation. We demonstrate that p14ARF-induced senescence of human mammary epithelial cells ( MEC) is associated with p53 acetylation and requires hAda3, a component of histone acetyltransferase complexes and a p53 transcriptional coactivator. Expression of the N-terminal domain of hAda3 that binds p53 but not p300 blocked p14ARF-induced p53 acetylation and protected MECs from senescence. Consistent with these findings, the human papillomavirus 16 E6 mutant Y54D, which selectively targets hAda3 but not p53 for degradation and protects MECs from p14ARF-induced senescence, inhibited p53 acetylation. In H1299 cells, hAda3 overexpression increased p300-mediated p53 acetylation, which conversely decreased following small interfering RNA ( siRNA) knockdown of hAda3. Moreover, depletion of hAda3 by siRNA inhibited endogenous p53 acetylation and accumulation of p21cip1 in response to ectopic p14ARF. These studies reveal that, in addition to its known ability to inhibit Mdm2-mediated p53 degradation, p14ARF signals through hAda3 to stimulate p53 acetylation and the induction of cell senescence.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB328,364 Plantat St, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R01 CA107394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nag A, 2007, J BIOL CHEM, V282, P8812, DOI 10.1074/jbc.M610443200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamanin VA, 2004, MOL CELL BIOL, V24, P2144, DOI 10.1128/MCB.24.5.2144-2152.2004; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; 方岱宁, 1999, [力学与实践, Mechanics in Engineering], V21, P1	33	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6261	6268		10.1038/sj.onc.1210462	http://dx.doi.org/10.1038/sj.onc.1210462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452980				2022-12-25	WOS:000249583300002
J	Doucet, N; Savard, PY; Pelletier, JN; Gagne, SM				Doucet, Nicolas; Savard, Pierre-Yves; Pelletier, Joelle N.; Gagne, Stephane M.			NMR investigation of Tyr(105) mutants in TEM-1 beta-lactamase - Dynamics are correlated with function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; MODEL-FREE APPROACH; ANISOTROPIC ROTATIONAL DIFFUSION; MAGNETIC-RESONANCE RELAXATION; SITE LOOP MOTION; TRIOSEPHOSPHATE ISOMERASE; BACKBONE DYNAMICS; ESCHERICHIA-COLI; ACTIVE-SITE; DIHYDROFOLATE-REDUCTASE	The existence of coupled residue motions on various time scales in enzymes is now well accepted, and their detailed characterization has become an essential element in understanding the role of dynamics in catalysis. To this day, a handful of enzyme systems has been shown to rely on essential residue motions for catalysis, but the generality of such phenomena remains to be elucidated. Using NMR spectroscopy, we investigated the electronic and dynamic effects of several mutations at position 105 in TEM-1 beta-lactamase, an enzyme responsible for antibiotic resistance. Even in absence of substrate, our results show that the number and magnitude of short and long range effects on H-1-N-15 chemical shifts are correlated with the catalytic efficiencies of the various Y105X mutants investigated. In addition, N-15 relaxation experiments on mutant Y105D show that several active-site residues of TEM-1 display significantly altered motions on both picosecond-nanosecond and microsecond-millisecond time scales despite many being far away from the site of mutation. The altered motions among various active-site residues in mutant Y105D may account for the observed decrease in catalytic efficiency, therefore suggesting that short and long range residue motions could play an important catalytic role in TEM-1 beta-lactamase. These results support previous observations suggesting that internal motions play a role in promoting protein function.	Univ Montreal, Dept Chim, Montreal, PQ H3C 3J7, Canada; Univ Laval, Dept Biochim & Microbiol & CREFSIP, Quebec City, PQ G1K 7P4, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Laval University; Universite de Montreal	Gagne, SM (corresponding author), Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	stephane.gagne@rsvs.ulaval.ca						Agarwal PK, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-2; Agarwal PK, 2004, BIOCHEMISTRY-US, V43, P10605, DOI 10.1021/bi0495228; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Agarwal PK, 2000, J AM CHEM SOC, V122, P4803, DOI 10.1021/ja994456w; Akke M, 2002, CURR OPIN STRUC BIOL, V12, P642, DOI 10.1016/S0959-440X(02)00369-X; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; Beach H, 2005, J AM CHEM SOC, V127, P9167, DOI 10.1021/ja0514949; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Billeter SR, 2001, J AM CHEM SOC, V123, P11262, DOI 10.1021/ja011384b; Carnevale V, 2006, J AM CHEM SOC, V128, P9766, DOI 10.1021/ja060896t; Clarkson MW, 2006, BIOCHEMISTRY-US, V45, P7693, DOI 10.1021/bi060652l; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Colby TD, 1998, BIOCHEMISTRY-US, V37, P9295, DOI 10.1021/bi973184b; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Derreumaux P, 1998, BIOPHYS J, V74, P72, DOI 10.1016/S0006-3495(98)77768-9; Desamero R, 2003, BIOCHEMISTRY-US, V42, P2941, DOI 10.1021/bi026994i; Doucet N, 2004, J BIOL CHEM, V279, P46295, DOI 10.1074/jbc.M407606200; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; EPSTEIN DM, 1995, BIOCHEMISTRY-US, V34, P11037, DOI 10.1021/bi00035a009; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; Guallar V, 2004, J MOL BIOL, V337, P227, DOI 10.1016/j.jmb.2003.11.016; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; Jarymowycz VA, 2006, CHEM REV, V106, P1624, DOI 10.1021/cr040421p; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kovrigin EL, 2006, BIOCHEMISTRY-US, V45, P2636, DOI 10.1021/bi0525066; Kovrigin EL, 2006, J AM CHEM SOC, V128, P7724, DOI 10.1021/ja061435a; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Maveyraud L, 1998, J AM CHEM SOC, V120, P9748, DOI 10.1021/ja9818001; Meroueh SO, 2005, J AM CHEM SOC, V127, P15397, DOI 10.1021/ja051592u; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Neet KE, 1998, J BIOL CHEM, V273, P25527, DOI 10.1074/jbc.273.40.25527; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Pawley NH, 2001, J BIOMOL NMR, V20, P149, DOI 10.1023/A:1011249816560; QUENOUILLE MH, 1949, J ROY STAT SOC B, V11, P68; Radkiewicz JL, 2000, J AM CHEM SOC, V122, P225, DOI 10.1021/ja9913838; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Rozovsky S, 2001, J MOL BIOL, V310, P271, DOI 10.1006/jmbi.2001.4673; Sabbagh Y, 1998, ANTIMICROB AGENTS CH, V42, P2319, DOI 10.1128/AAC.42.9.2319; Savard PY, 2006, BIOCHEMISTRY-US, V45, P11414, DOI 10.1021/bi060414q; Savard PY, 2004, J BIOMOL NMR, V29, P433, DOI 10.1023/B:JNMR.0000032503.96942.68; Sosa-Peinado A, 2000, PROTEIN EXPRES PURIF, V19, P235, DOI 10.1006/prep.2000.1243; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tousignant A, 2004, CHEM BIOL, V11, P1037, DOI 10.1016/j.chembiol.2004.06.007; Vakulenko SB, 1999, J BIOL CHEM, V274, P23052, DOI 10.1074/jbc.274.33.23052; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Wand AJ, 2001, SCIENCE, V293; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Xu XP, 2001, J BIOMOL NMR, V21, P321, DOI 10.1023/A:1013324104681; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	63	28	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21448	21459		10.1074/jbc.M609777200	http://dx.doi.org/10.1074/jbc.M609777200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17426035	hybrid			2022-12-25	WOS:000248047500072
J	Stubbs, KA; Balcewich, M; Mark, BL; Vocadlo, DJ				Stubbs, Keith A.; Balcewich, Misty; Mark, Brian L.; Vocadlo, David J.			Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINIDASE; D-GLUCOSAMINIDASE; CITROBACTER-FREUNDII; O-GLCNACASE; CRYSTAL-STRUCTURE; EXPRESSION; MECHANISM; NAGSTATIN; GENE	The increasing spread of plasmid-borne ampC-ampR operons is of considerable medical importance, since the AmpC beta-lactamases they encode confer high level resistance to many third generation cephalosporins. Induction of AmpC beta-lactamase from endogenous or plasmid-borne ampC-ampR operons is mediated by a catabolic inducer molecule, 1,6-anhydro-Nacetylmuramic acid (MurNAc) tripeptide, an intermediate of the cell wall recycling pathway derived from the peptidoglycan. Here we describe a strategy for attenuating the antibiotic resistance associated with the ampC-ampR operon by blocking the formation of the inducer molecule using small molecule inhibitors of NagZ, the glycoside hydrolase catalyzing the formation of this inducer molecule. The structure of the NagZ-inhibitor complex provides insight into the molecular basis for inhibition and enables the development of inhibitors with 100-fold selectivity for NagZ over functionally related human enzymes. These PUGNAc-derived inhibitors reduce the minimal inhibitory concentration (MIC) values for several clinically relevant cephalosporins in both wild-type and AmpC-hyperproducing strains lacking functional AmpD.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada; Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada	Simon Fraser University; University of Manitoba	Vocadlo, DJ (corresponding author), Simon Fraser Univ, Dept Chem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	dvocadlo@sfu.ca	Vocadlo, David J/E-5508-2014; Stubbs, Keith/H-5909-2014	Vocadlo, David J/0000-0001-6897-5558; Stubbs, Keith/0000-0001-6899-402X; Mark, Brian/0000-0002-7344-1355				AOYAGI T, 1992, J ANTIBIOT, V45, P1404, DOI 10.7164/antibiotics.45.1404; Bagge N, 2002, ANTIMICROB AGENTS CH, V46, P3406, DOI 10.1128/AAC.46.11.3406-3411.2002; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barnaud G, 1998, ANTIMICROB AGENTS CH, V42, P2352, DOI 10.1128/AAC.42.9.2352; BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; BEER D, 1990, HELV CHIM ACTA, V73, P1918, DOI 10.1002/hlca.19900730714; Bradford PA, 1997, ANTIMICROB AGENTS CH, V41, P563, DOI 10.1128/AAC.41.3.563; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSH K, 1993, ANTIMICROB AGENTS CH, V37, P851, DOI 10.1128/AAC.37.4.851; Cheng QM, 2000, J BACTERIOL, V182, P4836, DOI 10.1128/JB.182.17.4836-4840.2000; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dennis RJ, 2006, NAT STRUCT MOL BIOL, V13, P365, DOI 10.1038/nsmb1079; Doi Y, 2004, ANTIMICROB AGENTS CH, V48, P2652, DOI 10.1128/AAC.48.7.2652-2658.2004; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Folkesson A, 2005, CELL MICROBIOL, V7, P147, DOI 10.1111/j.1462-5822.2004.00443.x; Fortineau N, 2001, J ANTIMICROB CHEMOTH, V47, P207, DOI 10.1093/jac/47.2.207; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hanson ND, 1999, CURR PHARM DESIGN, V5, P881; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HOLTJE JV, 1994, FEMS MICROBIOL LETT, V122, P159, DOI 10.1111/j.1574-6968.1994.tb07159.x; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Jacobs C, 1997, CELL, V88, P823, DOI 10.1016/S0092-8674(00)81928-5; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Juan C, 2005, ANTIMICROB AGENTS CH, V49, P4733, DOI 10.1128/AAC.49.11.4733-4738.2005; Kadima TA, 1997, ANTIMICROB AGENTS CH, V41, P2177, DOI 10.1128/AAC.41.10.2177; Kong KF, 2005, ANTIMICROB AGENTS CH, V49, P4567, DOI 10.1128/AAC.49.11.4567-4575.2005; Langaee TY, 2000, ANTIMICROB AGENTS CH, V44, P583, DOI 10.1128/AAC.44.3.583-589.2000; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Li CH, 2004, J ANTIMICROB CHEMOTH, V53, P297, DOI 10.1093/jac/dkh057; LINDBERG F, 1987, J BACTERIOL, V169, P1923, DOI 10.1128/jb.169.5.1923-1928.1987; LINDBERG F, 1985, P NATL ACAD SCI USA, V82, P4620, DOI 10.1073/pnas.82.14.4620; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; Macauley MS, 2005, J BIOL CHEM, V280, P25313, DOI 10.1074/jbc.M413819200; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; MILLER DJ, 1993, DEVELOPMENT, V118, P1279; Miriagou V, 2004, ANTIMICROB AGENTS CH, V48, P3172, DOI 10.1128/AAC.48.8.3172-3174.2004; Morandi F, 2003, J AM CHEM SOC, V125, P685, DOI 10.1021/ja0288338; Nakae T, 2000, MICROBIOL IMMUNOL, V44, P997, DOI 10.1111/j.1348-0421.2000.tb02595.x; Nakano R, 2004, ANTIMICROB AGENTS CH, V48, P1151, DOI 10.1128/AAC.48.4.1151-1158.2004; NORMARK S, 1994, N COMP BIOC, V27, P485; PARK JT, 1993, J BACTERIOL, V175, P7, DOI 10.1128/JB.175.1.7-11.1993; Pfeifle D, 2000, ANTIMICROB AGENTS CH, V44, P169, DOI 10.1128/AAC.44.1.169-172.2000; Poirel L, 1999, ANTIMICROB AGENTS CH, V43, P769, DOI 10.1128/AAC.43.4.769; Rao FV, 2006, EMBO J, V25, P1569, DOI 10.1038/sj.emboj.7601026; Reisbig MD, 2003, J ANTIMICROB CHEMOTH, V51, P1141, DOI 10.1093/jac/dkg204; Shanmugasundaram B, 2006, CHEM COMMUN, P4372, DOI 10.1039/b612154c; Steiner RA, 2003, ACTA CRYSTALLOGR D, V59, P2114, DOI 10.1107/S0907444903018675; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Stubbs KA, 2006, ORG BIOMOL CHEM, V4, P839, DOI 10.1039/b516273d; Tatsuta K, 1997, B CHEM SOC JPN, V70, P427, DOI 10.1246/bcsj.70.427; TATSUTA K, 1995, TETRAHEDRON LETT, V36, P6721; TATSUTA K, 1995, J ANTIBIOT, V48, P286, DOI 10.7164/antibiotics.48.286; Terinek M, 2005, HELV CHIM ACTA, V88, P10, DOI 10.1002/hlca.200490286; Thomson KS, 1999, ANTIMICROB AGENTS CH, V43, P1393, DOI 10.1128/AAC.43.6.1393; Tondi D, 2005, J AM CHEM SOC, V127, P4632, DOI 10.1021/ja042984o; Uehara T, 2002, J BACTERIOL, V184, P4233, DOI 10.1128/JB.184.15.4233-4239.2002; Vocadlo DJ, 2005, BIOCHEMISTRY-US, V44, P12809, DOI 10.1021/bi051121k; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; Votsch W, 2000, J BIOL CHEM, V275, P39032, DOI 10.1074/jbc.M004797200; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Woodford N, 2007, J ANTIMICROB CHEMOTH, V59, P102, DOI 10.1093/jac/dkl456; YEM DW, 1976, J BACTERIOL, V125, P324, DOI 10.1128/JB.125.1.324-331.1976	74	96	99	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21382	21391		10.1074/jbc.M700084200	http://dx.doi.org/10.1074/jbc.M700084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17439950	hybrid			2022-12-25	WOS:000248047500066
J	Misra, RS; Russell, JQ; Koenig, A; Hinshaw-Makepeace, JA; Wen, R; Wang, D; Huo, H; Littman, DR; Ferch, U; Ruland, J; Thome, M; Budd, RC				Misra, Ravi S.; Russell, Jennifer Q.; Koenig, Andreas; Hinshaw-Makepeace, Jennifer A.; Wen, Renren; Wang, Demin; Huo, Hairong; Littman, Dan R.; Ferch, Uta; Ruland, Jurgen; Thome, Margot; Budd, Ralph C.			Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappa B adaptors during T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLICE-INHIBITORY PROTEIN; ANTIGEN RECEPTOR; LYMPHOCYTE-ACTIVATION; SIGNALING COMPLEX; MALT LYMPHOMA; LONG FORM; MEMBRANE MICRODOMAINS; UBIQUITIN LIGASE; KINASE COMPLEX; DEATH	Humans and mice lacking functional caspase-8 in T cells manifest a profound immunodeficiency syndrome due to defective T cell antigen receptor (TCR)-induced NF-kappa B signaling and proliferation. It is unknown how caspase-8 is activated following T cell stimulation, and what is the caspase-8 substrate(s) that is necessary to initiate T cell cycling. We observe that following TCR ligation, a small portion of total cellular caspase-8 and c-FLIPL rapidly migrate to lipid rafts where they associate in an active caspase complex. Activation of caspase-8 in lipid rafts is followed by rapid cleavage of c-FLIPL at a known caspase-8 cleavage site. The active caspase (.) c-FLIP complex forms in the absence of Fas(CD95/APO1) and associates with the NF-kappa B signaling molecules RIP1, TRAF2, and TRAF6, as well as upstream NF-kappa B regulators PKC theta, CARMA1, Bcl-10, and MALT1, which connect to the TCR. The lack of caspase-8 results in the absence of MALT1 and Bcl-10 in the active caspase complex. Consistent with this observation, inhibition of caspase activity attenuates NF-kappa B activation. The current findings define a link among TCR, caspases, and the NF-kappa B pathway that occurs in a sequestered lipid raft environment in T cells.	Univ Vermont, Coll Med, Dept Med, Immunobiol Program, Burlington, VT 05405 USA; Blood Ctr Wisconsin, Blood Res Inst, Dept Microbiol & Mol Genet, Milwaukee, WI 53201 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; Tech Univ Munich, Dept Med Hematol Oncol, Munich, Germany; Univ Lausanne, Inst Biochem, Bil Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Vermont; Versiti Blood Center of Wisconsin; Howard Hughes Medical Institute; New York University; New York University; Technical University of Munich; University of Lausanne	Budd, RC (corresponding author), Gieven Med Bldg, Burlington, VT 05405 USA.	ralph.budd@uvm.edu	Huo, Hairong/B-7700-2011; Thome, Margot/F-8167-2011; Wang, Demin/AAX-4449-2020; Ruland, Jürgen/Q-6680-2018	Thome, Margot/0000-0002-5656-2139; Wang, Demin/0000-0001-5549-3795; Ruland, Jürgen/0000-0002-8381-3597	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021905] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036333, P01AI045666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR021905] Funding Source: Medline; NHLBI NIH HHS [HL073284, R01 HL073284] Funding Source: Medline; NIAID NIH HHS [AI36333, P01 AI045666, AI45666, R01 AI036333] Funding Source: Medline; NIAMS NIH HHS [AR043520, R01 AR043520] Funding Source: Medline; NIEHS NIH HHS [T32 ES007122, 5T32ES007122] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Bachmann MF, 1999, J EXP MED, V189, P1521, DOI 10.1084/jem.189.10.1521; Balamuth F, 2001, IMMUNITY, V15, P729, DOI 10.1016/S1074-7613(01)00223-0; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Blank N, 2002, J IMMUNOL METHODS, V271, P25, DOI 10.1016/S0022-1759(02)00335-6; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chau H, 2005, J EXP MED, V202, P405, DOI 10.1084/jem.20050118; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dohrman A, 2005, J IMMUNOL, V175, P311, DOI 10.4049/jimmunol.175.1.311; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Fortner KA, 2005, J IMMUNOL, V175, P4374, DOI 10.4049/jimmunol.175.7.4374; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McLaughlin B, 2004, APOPTOSIS, V9, P111, DOI 10.1023/B:APPT.0000018793.10779.dc; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Misra RS, 2005, J IMMUNOL, V174, P3999, DOI 10.4049/jimmunol.174.7.3999; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sebald A, 2005, EUR J IMMUNOL, V35, P318, DOI 10.1002/eji.200425024; Snipas SJ, 2004, BIOL CHEM, V385, P1093, DOI 10.1515/BC.2004.142; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tavano R, 2004, J IMMUNOL, V173, P5392, DOI 10.4049/jimmunol.173.9.5392; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Tuosto L, 2001, EUR J IMMUNOL, V31, P345, DOI 10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.3.CO;2-C; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Viola A, 2001, TRENDS IMMUNOL, V22, P322, DOI 10.1016/S1471-4906(01)01938-X; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang K, 2004, BIOCHEM BIOPH RES CO, V324, P432, DOI 10.1016/j.bbrc.2004.09.070; Zhang N, 2005, J EXP MED, V202, P395, DOI 10.1084/jem.20050117; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	65	64	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19365	19374		10.1074/jbc.M610610200	http://dx.doi.org/10.1074/jbc.M610610200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17462996	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000247650600011
J	Mori, T; Wada, T; Suzuki, T; Kubota, Y; Inagaki, N				Mori, Tatsuya; Wada, Tomoe; Suzuki, Takahiro; Kubota, Yoshitsugu; Inagaki, Naoyuki			Singar1, a novel RUN domain-containing protein, suppresses formation of surplus axons for neuronal polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; GSK-3-BETA; PHOSPHORYLATION; ESTABLISHMENT; CRMP-2; POLARIZATION; REGULATORS; CULTURE; RAT; CAT	Although neuronal functions depend on their robust polarity, the mechanisms that ensure generation and maintenance of only a single axon remain poorly understood. Using highly sensitive two-dimensional electrophoresis-based proteomics, we identified here a novel protein, single axon-related (singar)1/KIAA0871/RPIPx/RUFY3, which contains a RUN domain and is predominantly expressed in the brain. Singar1 expression became up-regulated during polarization of cultured hippocampal neurons and remained at high levels thereafter. Singar1 was diffusely localized in hippocampal neurons and moderately accumulated in growth cones of minor processes and axons. Overexpression of singar1 did not affect normal neuronal polarization but suppressed the formation of surplus axons induced by excess levels of shootin1, a recently identified protein located upstream of phosphoinositide-3-kinase and involved in neuronal polarization. Conversely, reduction of the expression of singar1 and its splicing variant singar2 by RNA interference led to an increase in the population of neurons bearing surplus axons, in a phosphoinositide-3-kinase-dependent manner. Overexpression of singar2 did not suppress the formation of surplus axons induced by shootin1. We propose that singar1 ensures the robustness of neuronal polarity by suppressing formation of surplus axons.	Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300192, Japan; Kagawa Univ, Fac Med, Dept Transfus Med, Kagawa 7600793, Japan	Nara Institute of Science & Technology; Kagawa University	Inagaki, N (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300192, Japan.	ninagaki@bs.naist.jp		Inagaki, Naoyuki/0000-0002-2664-9196				Arimura N, 2005, NEURON, V48, P881, DOI 10.1016/j.neuron.2005.11.007; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Callebaut I, 2001, TRENDS BIOCHEM SCI, V26, P79, DOI 10.1016/S0968-0004(00)01730-8; Chen YM, 2006, P NATL ACAD SCI USA, V103, P8534, DOI 10.1073/pnas.0509955103; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gartner A, 2006, J CELL SCI, V119, P3927, DOI 10.1242/jcs.03159; GOBEL S, 1975, BRAIN RES, V88, P333, DOI 10.1016/0006-8993(75)90395-9; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Inagaki Naoyuki, 2004, Current Proteomics, V1, P35, DOI 10.2174/1570164043488289; Jiang H, 2005, NAT NEUROSCI, V8, P544, DOI 10.1038/nn0505-544; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Kukimoto-Niino M, 2006, J BIOL CHEM, V281, P31843, DOI 10.1074/jbc.M604960200; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; MEYER G, 1982, BRAIN RES, V232, P455, DOI 10.1016/0006-8993(82)90288-8; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nomura E, 2004, J MASS SPECTROM, V39, P202, DOI 10.1002/jms.578; Oguri T, 2002, PROTEOMICS, V2, P666, DOI 10.1002/1615-9861(200206)2:6<666::AID-PROT666>3.0.CO;2-V; Oliva AA, 2006, J NEUROSCI, V26, P9462, DOI 10.1523/JNEUROSCI.2625-06.2006; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; TAKAGI H, 1984, J NEUROCYTOL, V13, P239, DOI 10.1007/BF01148118; Toriyama M, 2006, J CELL BIOL, V175, P147, DOI 10.1083/jcb.200604160; Watabe-Uchida M, 2006, NEURON, V51, P727, DOI 10.1016/j.neuron.2006.07.020; Wiggin GR, 2005, DEV CELL, V8, P803, DOI 10.1016/j.devcel.2005.05.007; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012	34	52	55	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19884	19893		10.1074/jbc.M700770200	http://dx.doi.org/10.1074/jbc.M700770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17439943	hybrid			2022-12-25	WOS:000247650600063
J	Linster, CL; Gomez, TA; Christensen, KC; Adler, LN; Young, BD; Brenner, C; Clarke, SG				Linster, Carole L.; Gomez, Tara A.; Christensen, Kathryn C.; Adler, Lital N.; Young, Brian D.; Brenner, Charles; Clarke, Steven G.			Arabidopsis VTC2 encodes a GDP-L-galactose phosphorylase, the last unknown enzyme in the Smirnoff-Wheeler pathway to ascorbic acid in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-C; GENETIC-EVIDENCE; BIOSYNTHESIS; MANNOSE; THALIANA; CLONING; IDENTIFICATION; TRANSFERASES; ANTIOXIDANT; PHOSPHATASE	The first committed step in the biosynthesis of L-ascorbate from D-glucose in plants requires conversion of GDP-L-galactose to L-galactose 1-phosphate by a previously unidentified enzyme. Here we show that the protein encoded by VTC2, a gene mutated in vitamin C-deficient Arabidopsis thaliana strains, is a member of the GalT/Apa1 branch of the histidine triad protein superfamily that catalyzes the conversion of GDP-L-galactose to L-galactose 1-phosphate in a reaction that consumes inorganic phosphate and produces GDP. In characterizing recombinant VTC2 from A. thaliana as a specific GDP-L-galactose/GDP-D-glucose phosphorylase, we conclude that enzymes catalyzing each of the ten steps of the Smirnoff-Wheeler pathway from glucose to ascorbate have been identified. Finally, we identify VTC2 homologs in plants, invertebrates, and vertebrates, suggesting that a similar reaction is used widely in nature.	Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA	University of California System; University of California Los Angeles; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	charles.brenner@dartmouth.edu; clarke@mbi.ucla.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226; Linster, Carole/0000-0001-7143-0719	NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER; NCI NIH HHS [CA75954, R01 CA075954, R01 CA075954-11] Funding Source: Medline; NIA NIH HHS [R01 AG018000, AG018000] Funding Source: Medline; NIGMS NIH HHS [GM026020, R01 GM026020, R37 GM026020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; BARBER GA, 1964, BIOCHIM BIOPHYS ACTA, V86, P397, DOI 10.1016/0304-4165(64)90069-8; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; CHATTERJEE IB, 1973, SCIENCE, V182, P1271, DOI 10.1126/science.182.4118.1271; Conklin PL, 2006, J BIOL CHEM, V281, P15662, DOI 10.1074/jbc.M601409200; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1999, P NATL ACAD SCI USA, V96, P4198, DOI 10.1073/pnas.96.7.4198; Conklin PL, 2000, GENETICS, V154, P847; De Tullio MC, 2004, CELL MOL LIFE SCI, V61, P209, DOI 10.1007/s00018-003-3203-8; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Gatzek S, 2002, PLANT J, V30, P541, DOI 10.1046/j.1365-313X.2002.01315.x; Jander G, 2002, PLANT PHYSIOL, V129, P440, DOI 10.1104/pp.003533; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; Laing WA, 2004, P NATL ACAD SCI USA, V101, P16976, DOI 10.1073/pnas.0407453101; Leang K, 2004, J BIOSCI BIOENG, V97, P383, DOI 10.1016/S1389-1723(04)70223-6; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Major LL, 2005, J AM CHEM SOC, V127, P18309, DOI 10.1021/ja056490i; Moreau R, 1998, P NATL ACAD SCI USA, V95, P10279, DOI 10.1073/pnas.95.17.10279; Ning BT, 2000, EUR J BIOCHEM, V267, P6866, DOI 10.1046/j.1432-1033.2000.01781.x; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; PIRO G, 1993, PLANTA, V190, P206, DOI 10.1007/BF00196613; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; Qian WQ, 2007, PLANT J, V49, P399, DOI 10.1111/j.1365-313X.2006.02967.x; Rayon C, 1999, PLANT PHYSIOL, V119, P725, DOI 10.1104/pp.119.2.725; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; Smirnoff N, 2000, CURR OPIN PLANT BIOL, V3, P229, DOI 10.1016/S1369-5266(00)00069-8; Smirnoff N, 2001, ANNU REV PLANT PHYS, V52, P437, DOI 10.1146/annurev.arplant.52.1.437; Valpuesta V, 2004, TRENDS PLANT SCI, V9, P573, DOI 10.1016/j.tplants.2004.10.002; Wheeler GL, 1998, NATURE, V393, P365, DOI 10.1038/30728; Wolucka BA, 2003, J BIOL CHEM, V278, P47483, DOI 10.1074/jbc.M309135200; Wolucka BA, 2001, P NATL ACAD SCI USA, V98, P14843, DOI 10.1073/pnas.011578198; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	35	127	141	4	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18879	18885		10.1074/jbc.M702094200	http://dx.doi.org/10.1074/jbc.M702094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17462988	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000247475300028
J	Steen, M; Kirchberger, T; Guse, AH				Steen, Mareike; Kirchberger, Tanja; Guse, Andreas H.			NAADP mobilizes calcium from the endoplasmic reticular Ca2+ store in T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; BETA-CELLS; RYANODINE RECEPTORS; PANCREATIC-ACINAR; RELEASE; THAPSIGARGIN; SIGNALS; 2ND-MESSENGER	The target calcium store of nicotinic acid adenine dinucleotide phosphate ( NAADP), the most potent endogenous calcium-mobilizing compound known to date, has been proposed to reside in the lysosomal compartment or in the endo/sarcoplasmic reticulum. This study was performed to test the hypothesis of a lysosomal versus an endoplasmic reticular calcium store sensitive to NAADP in T-lymphocytes. Pretreatment of intact Jurkat T cells with glycyl-phenylalanine 2-naphthylamide largely reduced staining of lysosomes by LysoTracker Red and abolished NAADP-induced Ca2+ signaling. However, the inhibitory effect was not specific since Ca2+ mobilization by D-myoinositol 1,4,5-trisphosphate and cyclic ADP-ribose was abolished, too. Bafilomycin A1, an inhibitor of the lysosomal H+-ATPase, did not block or reduce NAADP-induced Ca2+ signaling, although it effectively prevented labeling of lysosomes by LysoTracker Red. Further, previous T cell receptor/CD3 stimulation in the presence of bafilomycin A1, assumed to block refilling of lysosomal Ca2+ stores, did not antagonize subsequent NAADP-induced Ca2+ signaling. In contrast to bafilomycin A1, emptying of the endoplasmic reticulum by thapsigargin almost completely prevented Ca2+ signaling induced by NAADP. In conclusion, in T-lymphocytes, no evidence for involvement of lysosomes in NAADP-mediated Ca2+ signaling was obtained. The sensitivity of NAADP-induced Ca2+ signaling toward thapsigargin, combined with our recent results identifying ryanodine receptors as the target calcium channel of NAADP (Dammermann, W., and Guse, A. H. (2005) J. Biol. Chem. 280, 21394 - 21399), rather suggest that the target calcium store of NAADP in T cells is the endoplasmic reticulum.	Univ Hamburg, Med Ctr Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1,Calcium Signaling Grp, D-20426 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Med Ctr Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1,Calcium Signaling Grp, Martinistr 52, D-20426 Hamburg, Germany.	guse@uke.uni-hamburg.de						Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Berridge G, 2002, J BIOL CHEM, V277, P43717, DOI 10.1074/jbc.M203224200; Brailoiu E, 2006, J BIOL CHEM, V281, P15923, DOI 10.1074/jbc.M602249200; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Churamani D, 2005, BIOCHEM J, V386, P497, DOI 10.1042/BJ20041990; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Dickinson GD, 2003, BIOCHEM J, V375, P805, DOI 10.1042/BJ20030672; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Gasser A, 2006, J BIOL CHEM, V281, P16906, DOI 10.1074/jbc.M601347200; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; GUSE AH, 1995, J IMMUNOL, V155, P3353; Harmer AR, 2001, BIOCHEM J, V353, P555, DOI 10.1042/0264-6021:3530555; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JADOT M, 1984, BIOCHEM J, V219, P965, DOI 10.1042/bj2190965; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; MACGREGOR A, 2007, J BIOL CHEM; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; Patel S, 2000, BIOCHEM J, V352, P725, DOI 10.1042/0264-6021:3520725; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	35	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18864	18871		10.1074/jbc.M610925200	http://dx.doi.org/10.1074/jbc.M610925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17446167	hybrid			2022-12-25	WOS:000247475300026
J	Neeli, I; Siddiqi, SA; Siddiqi, S; Mahan, J; Lagakos, WS; Binas, B; Gheyi, T; Storch, J; Mansbach, CM				Neeli, Indira; Siddiqi, Shadab A.; Siddiqi, Shahzad; Mahan, James; Lagakos, William S.; Binas, Bert; Gheyi, Tarun; Storch, Judith; Mansbach, Charles M., II			Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CYTOPLASMIC TRANSPORT; HELICAL DOMAIN; CACO-2 CELLS; COMPLEX; GOLGI; EXPRESSION; SECRETION; MEMBRANES; DELETION	The rate-limiting step in the transit of absorbed dietary fat across the enterocyte is the generation of the pre-chylomicron transport vesicle (PCTV) from the endoplasmic reticulum (ER). This vesicle does not require coatomer-II (COPII) proteins for budding from the ER membrane and contains vesicle-associated membrane protein 7, found in intestinal ER, which is a unique intracellular location for this SNARE protein. We wished to identify the protein(s) responsible for budding this vesicle from ER membranes in the absence of the requirement for COPII proteins. We chromatographed rat intestinal cytosol on Sephacryl S-100 and found that PCTV budding activity appeared in the low molecular weight fractions. Additional chromatographic steps produced a single major and several minor bands on SDS-PAGE. By tandem mass spectroscopy, the bands contained both liver and intestinal fatty acid-binding proteins (L- and I-FABP) as well as four other proteins. Recombinant proteins for each of the six proteins identified were tested for PCTV budding activity; only L-FABP and I-FABP (23% the activity of L-FABP) were active. The vesicles generated by L- FABP were sealed, contained apolipoproteins B48 and AIV, were of the same size as PCTV on Sepharose CL-6B, and by electron microscopy, excluded calnexin and calreticulin but did not fuse with cis- Golgi nor did L-FABP generate COPII-dependent vesicles. Gene-disrupted L-FABP mouse cytosol had 60% the activity of wild type mouse cytosol. We conclude that L- FABP can select cargo for and bud PCTV from intestinal ER membranes.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol, Memphis, TN 38163 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Pathobiol, College Stn, TX 77843 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Texas A&M University System; Texas A&M University College Station; University of Memphis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Mansbach, CM (corresponding author), Rutgers State Univ, Dept Nutr Sci, Cook Coll, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu; cmansbach@utmem.edu		Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038760, R01DK038389, R01DK074565, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38760, DK74565, R01 DK038389, DK38389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 2006, PHYSIOLOGY OF THE GASTROINTESTINAL TRACT, VOLS 1 AND 2, 4TH EDITION, P1693; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; BASS NM, 1985, J BIOL CHEM, V260, P1432; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Corsico B, 2004, BIOCHEMISTRY-US, V43, P3600, DOI 10.1021/bi0357356; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; Davies JK, 1999, BIOCHEMISTRY-US, V38, P16932, DOI 10.1021/bi991926q; DOLE VP, 1962, PHYSIOL REV, V42, P674, DOI 10.1152/physrev.1962.42.4.674; Drover VA, 2005, J CLIN INVEST, V115, P1290, DOI 10.1172/JCI200521514; Dube N, 2001, J CELL BIOCHEM, V81, P613, DOI 10.1002/jcb.1090; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; GORDON JI, 1985, J BIOL CHEM, V260, P1995; HAYASHI H, 1990, AM J PHYSIOL, V259, pG709, DOI 10.1152/ajpgi.1990.259.5.G709; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; HUBSCHER G, 1965, BIOCHEM J, V97, P629, DOI 10.1042/bj0970629; KELER T, 1993, J CELL PHYSIOL, V157, P33, DOI 10.1002/jcp.1041570105; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kumar NS, 1997, AM J PHYSIOL-GASTR L, V273, pG18, DOI 10.1152/ajpgi.1997.273.1.G18; Kumar NS, 1999, AM J PHYSIOL-GASTR L, V276, pG378, DOI 10.1152/ajpgi.1999.276.2.G378; Lederkremer GZ, 2001, P NATL ACAD SCI USA, V98, P10704, DOI 10.1073/pnas.191359398; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Luxon BA, 1999, AM J PHYSIOL-GASTR L, V277, pG361, DOI 10.1152/ajpgi.1999.277.2.G361; MANOWITZ NR, 1986, J LIPID RES, V27, P196; Mansbach CM, 1998, J LIPID RES, V39, P963; MANSBACH CM, 1975, J CLIN INVEST, V56, P781, DOI 10.1172/JCI108156; MANSBACH CM, 1995, AM J PHYSIOL-GASTR L, V269, pG144, DOI 10.1152/ajpgi.1995.269.1.G144; MANSBACH CM, 1986, AM J PHYSIOL, V251, pG263, DOI 10.1152/ajpgi.1986.251.2.G263; Mansbach CM, 2000, J LIPID RES, V41, P605; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller EA, 2005, MOL BIOL CELL, V16, P3719, DOI 10.1091/mbc.E05-03-0262; MISHKIN S, 1972, BIOCHEM BIOPH RES CO, V47, P997, DOI 10.1016/0006-291X(72)90931-X; Murota K, 2005, J NUTR, V135, P1626, DOI 10.1093/jn/135.7.1626; Newberry EP, 2006, HEPATOLOGY, V44, P1191, DOI 10.1002/hep.21369; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; Pelsers MMAL, 2003, CLIN BIOCHEM, V36, P529, DOI 10.1016/S0009-9120(03)00096-1; Poirier H, 1997, AM J PHYSIOL-GASTR L, V273, pG289, DOI 10.1152/ajpgi.1997.273.2.G289; Schachtrup C, 2004, BIOCHEM J, V382, P239, DOI 10.1042/BJ20031340; SCHOELLER C, 1995, CLIN INVEST MED, V18, P380; SHIELDS HM, 1986, J LIPID RES, V27, P549; Siddiqi SA, 2006, J CELL SCI, V119, P943, DOI 10.1242/jcs.02803; Siddiqi SA, 2003, J CELL SCI, V116, P415, DOI 10.1242/jcs.00215; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; STORCH J, 1990, J BIOL CHEM, V265, P7827; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Weisiger RA, 1996, HEPATOLOGY, V24, P1288; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i	59	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17974	17984		10.1074/jbc.M610765200	http://dx.doi.org/10.1074/jbc.M610765200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17449472	hybrid			2022-12-25	WOS:000247302000004
J	Szalewska-Palasz, A; Johansson, LUM; Bernardo, LMD; Skarfstad, E; Stec, E; Brannstrom, K; Shingler, V				Szalewska-Palasz, Agnieszka; Johansson, Linda U. M.; Bernardo, Lisandro M. D.; Skarfstad, Eleonore; Stec, Ewa; Brannstrom, Kristoffer; Shingler, Victoria			Properties of RNA polymerase bypass mutants - Implications for the role of ppGpp and its co-factor DksA in controlling transcription dependent on sigma(54)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA(54)-DEPENDENT PO PROMOTER; GUANOSINE TETRAPHOSPHATE PPGPP; ESCHERICHIA-COLI; IN-VIVO; ANGSTROM RESOLUTION; FACTOR COMPETITION; AROMATIC-COMPOUNDS; ALARMONE (P)PPGPP; STRUCTURAL BASIS; INITIATION	The bacterial nutritional and stress alarmone ppGpp and its co-factor DksA directly bind RNA polymerase to regulate its activity at certain sigma(70)-dependent promoters. A number of promoters that are dependent on alternative sigma-factors function poorly in the absence of ppGpp. These include the Pseudomonas-derived sigma(54)-dependent Po promoter and several other sigma(54-)promoters, the transcription from which is essentially abolished in Escherichia coli devoid of ppGpp and DksA. However, ppGpp and DksA have no apparent effect on reconstituted in vitro sigma(54)-transcription, which suggests an indirect mechanism of control. Here we report analysis of five hyper-suppressor mutants within the beta- and beta'-subunits of core RNA polymerase that allow high levels of transcription from the sigma(54)-Po promoter in the absence of ppGpp. Using in vitro transcription and competition assays, we present evidence that these core RNA polymerase mutants are defective in one or both of two properties that could combine to explain their hyper-suppressor phenotypes: (i) modulation of competitive association with sigma-factors to favor sigma(54)-holoenzyme formation over that with sigma(70), and (ii) reduced innate stability of RNA polymerase-promoter complexes, which mimics the essential effects of ppGpp and DksA for negative regulation of stringent sigma(70)-promoters. Both these properties of the mutant holoenzymes support a recently proposed mechanism for regulation of sigma(54)-transcription that depends on the potent negative effects of ppGpp and DksA on transcription from powerful stringent sigma(70)-promoters, and suggests that stringent regulation is a key mechanism by which the activity of alternative sigma-factors is controlled to meet cellular requirements.	Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland	Umea University; Fahrenheit Universities; University of Gdansk	Shingler, V (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	victoria.shingler@molbiol.umu.se	Brännström, Kristoffer/D-3648-2009; Brännström, Kristoffer/AAC-1204-2020; Szalewska-Palasz, Agnieszka/AAI-4826-2020	Szalewska-Palasz, Agnieszka/0000-0001-8013-4057; Holmfeldt, Linda/0000-0003-4140-3423; Shingler, Victoria/0000-0002-7349-1678				Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; Bernardo LMD, 2006, MOL MICROBIOL, V60, P749, DOI 10.1111/j.1365-2958.2006.05129.x; Bremer H., 1996, E COLI SALMONELLA CE, V2, P1553; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Carmona M, 2000, J BACTERIOL, V182, P4711, DOI 10.1128/JB.182.17.4711-4718.2000; CASHEL M, 1974, ANAL BIOCHEM, V57, P100, DOI 10.1016/0003-2697(74)90056-6; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Costanzo A, 2006, J BACTERIOL, V188, P4627, DOI 10.1128/JB.01981-05; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; Fujita N, 1996, METHOD ENZYMOL, V273, P121; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; Grigorova IL, 2006, P NATL ACAD SCI USA, V103, P5332, DOI 10.1073/pnas.0600828103; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Haugen SP, 2006, CELL, V125, P1069, DOI 10.1016/j.cell.2006.04.034; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; Laurie AD, 2003, J BIOL CHEM, V278, P1494, DOI 10.1074/jbc.M209268200; Liang ST, 1999, J MOL BIOL, V292, P19, DOI 10.1006/jmbi.1999.3056; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Mukhopadhyay J, 2004, MOL CELL, V14, P739, DOI 10.1016/j.molcel.2004.06.010; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Nystrom T, 2004, MOL MICROBIOL, V54, P855, DOI 10.1111/j.1365-2958.2004.04342.x; Paul BJ, 2005, P NATL ACAD SCI USA, V102, P7823, DOI 10.1073/pnas.0501170102; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; Potrykus K, 2002, J BIOL CHEM, V277, P43785, DOI 10.1074/jbc.M208768200; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider DA, 2002, P NATL ACAD SCI USA, V99, P8602, DOI 10.1073/pnas.132285199; Shingler V, 2003, ENVIRON MICROBIOL, V5, P1226, DOI 10.1111/j.1462-2920.2003.00472.x; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; Sze CC, 2002, J BACTERIOL, V184, P760, DOI 10.1128/JB.184.3.760-770.2002; Sze CC, 1999, MOL MICROBIOL, V31, P1217, DOI 10.1046/j.1365-2958.1999.01264.x; Sze CC, 2001, J BACTERIOL, V183, P2842, DOI 10.1128/JB.183.9.2842-2851.2001; Sze CC, 1996, J BACTERIOL, V178, P3727, DOI 10.1128/jb.178.13.3727-3735.1996; Trautinger BW, 2002, EMBO J, V21, P6944, DOI 10.1093/emboj/cdf654; Trinh V, 2006, MICROBIOL MOL BIOL R, V70, P12, DOI 10.1128/MMBR.70.1.12-36.2006; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; XIAO H, 1991, J BIOL CHEM, V266, P5980; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	47	45	45	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18046	18056		10.1074/jbc.M610181200	http://dx.doi.org/10.1074/jbc.M610181200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17456470	Green Submitted, hybrid			2022-12-25	WOS:000247302000011
J	Hung, RJ; Chien, HS; Lin, RZ; Lin, CT; Vatsyayan, J; Peng, HL; Chang, HY				Hung, Ruei-Jiun; Chien, Han-Sheng; Lin, Ruei-Zeng; Lin, Ching-Ting; Vatsyayan, Jaya; Peng, Hwei-Ling; Chang, Hwan-You			Comparative analysis of two UDP-glucose dehydrogenases in Pseudomonas aeruginosa PAO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ANTIGEN BIOSYNTHESIS; GROUP-A STREPTOCOCCI; SUGAR INTERCONVERSIONS; POLYACRYLAMIDE GELS; TWITCHING MOTILITY; KEY ENZYME; GENE; LIPOPOLYSACCHARIDE; NUCLEOTIDE; DROSOPHILA	UDP-glucose dehydrogenase (UGDH) catalyzes a two-step NAD(+)-dependent oxidation of UDP-glucose to produce UDPglucuronic acid, which is a common substrate for the biosynthesis of exopolysaccharide. Searching the Pseudomonas aeruginosa PAO1 genome data base for a UGDH has helped identify two open reading frames, PA2022 and PA3559, which may encode a UGDH. To elucidate their enzymatic identity, the two genes were cloned and overexpressed in Escherichia coli, and the recombinant proteins were purified. Both the gene products are active as dimers and are capable of utilizing UDP- glucose as a substrate to generate UDP- glucuronic acid. The Km values of PA2022 and PA3559 for UDP-glucose are similar to 0.1 and 0.4 mM, whereas the K-m values for NAD(+) are 0.5 and 2.0 mM, respectively. Compared with PA3559, PA2022 exhibits broader substrate specificity, utilizing TDP-glucose and UDP-N-acetylglucosamine with one-third the velocity of that with UDP- glucose. The PA2022 mutant and PA2022-PA3559 double mutant, but not the PA3559 mutant, are more susceptible to chloramphenicol, cefotaxime, and ampicillin. The PA3559 mutant, however, shows a reduced resistance to polymyxin B compared with wild type PAO1. Finally, real time PCR analysis indicates that PA3559 is expressed primarily in low concentrations of Mg2+, which contrasts with the constitutive expression of PA2022. Although both the enzymes catalyze the same reaction, their enzymatic properties and gene expression profiles indicate that they play distinct physiological roles in P. aeruginosa, as reflected by different phenotypes displayed by the mutants.	Natl Tsing Hua Univ, Inst Mol Med, Hsinchu 300, Taiwan; Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan	National Tsing Hua University; National Yang Ming Chiao Tung University	Chang, HY (corresponding author), Natl Tsing Hua Univ, Inst Mol Med, 101 Kuang Fu Rd,2nd Sec, Hsinchu 300, Taiwan.	hychang@life.nthu.edu.tw						APICELLA MA, 1994, METHOD ENZYMOL, V235, P242; Binari RC, 1997, DEVELOPMENT, V124, P2623; BROWN MRW, 1969, BIOCHEM J, V112, P521, DOI 10.1042/bj1120521; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; CROSS AS, 1990, CURR TOP MICROBIOL, V150, P87; DALESSANDRO G, 1977, BIOCHEM J, V162, P281, DOI 10.1042/bj1620281; DARZINS A, 1993, J BACTERIOL, V175, P5934, DOI 10.1128/JB.175.18.5934-5944.1993; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; FOMSGAARD A, 1990, J CLIN MICROBIOL, V28, P2627, DOI 10.1128/JCM.28.12.2627-2631.1990; Garcia-Garcia MJ, 2003, CELL, V114, P727, DOI 10.1016/S0092-8674(03)00715-3; Gatzeva-Topalova PZ, 2005, STRUCTURE, V13, P929, DOI 10.1016/j.str.2005.03.018; Griffith CL, 2004, J BIOL CHEM, V279, P51669, DOI 10.1074/jbc.M408889200; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HAUSER SC, 1984, J BIOL CHEM, V259, P4527; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hughes JE, 1997, INFECT IMMUN, V65, P4281, DOI 10.1128/IAI.65.10.4281-4287.1997; Kochanowski N, 2006, ANAL BIOCHEM, V348, P243, DOI 10.1016/j.ab.2005.10.027; McPhee JB, 2006, J BACTERIOL, V188, P3995, DOI 10.1128/JB.00053-06; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Princivalle M, 2002, INT J DEV BIOL, V46, P267; Rajan Sujatha, 2002, Semin Respir Infect, V17, P47, DOI 10.1053/srin.2002.31690; Rashid MH, 2000, P NATL ACAD SCI USA, V97, P4885, DOI 10.1073/pnas.060030097; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; RODEN L, 1980, BIOCH GLYCOPROTEINS; ROSSMAN MG, 1981, PHILOS T ROY SOC B, V293, P191, DOI 10.1098/rstb.1981.0072; RYLL T, 1991, J CHROMATOGR-BIOMED, V570, P77, DOI 10.1016/0378-4347(91)80202-N; Sambrook J, 2001, MOL CLONING LAB MANU; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; Seifert GJ, 2004, CURR OPIN PLANT BIOL, V7, P277, DOI 10.1016/j.pbi.2004.03.004; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Snook CF, 2003, BIOCHEMISTRY-US, V42, P4658, DOI 10.1021/bi027328k; WARREN GH, 1955, J BACTERIOL, V70, P152, DOI 10.1128/JB.70.2.152-157.1955; WARREN GH, 1954, J BACTERIOL, V67, P167, DOI 10.1128/JB.67.2.167-170.1954; WATSON DA, 1990, INFECT IMMUN, V58, P3135, DOI 10.1128/IAI.58.9.3135-3138.1990; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994	40	28	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17738	17748		10.1074/jbc.M701824200	http://dx.doi.org/10.1074/jbc.M701824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442666	hybrid			2022-12-25	WOS:000247084500047
J	Shinohara, M; Shang, WH; Kubodera, M; Harada, S; Mitsushita, J; Kato, M; Miyazaki, H; Sumimoto, H; Kamata, T				Shinohara, Masahiro; Shang, Wei-Hao; Kubodera, Makoto; Harada, Saori; Mitsushita, Junji; Kato, Masayoshi; Miyazaki, Hitoshi; Sumimoto, Hideke; Kamata, Tohru			Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HYDROGEN-PEROXIDE; CELL-ADHESION; GROWTH; GENERATION; APOPTOSIS; GTPASES; RAC1; TRANSFORMATION; INACTIVATION	Generation of reactive oxygen species ( ROS) by Ras oncogene-induced NADPH oxidase ( Nox) 1 is required for Ras transformation phenotypes including anchorage-independent growth, morphological transformation, and tumorigenesity, but the signaling mechanism downstream of Nox1 remains elusive. Rho is known to be a critical regulator of actin stress fiber formation. Nonetheless, Rho was reported to no longer couple to loss of actin stress fibers in Ras-transformed Swiss3T3 cells despite the elevation of Rho activity. In this study, however, we demonstrate that Rho is inactivated in K-Ras-transformed normal rat kidney cells, and that abrogation of Nox1-generated ROS by Nox1 small interference RNAs or diphenyleneiodonium restores Rho activation, suggesting that Nox1-generated oxidants mediate down-regulation of the Rho activity. This down-regulation involves oxidative inactivation of the low molecular weight protein-tyrosine phosphatase by Nox1-generated ROS and a subsequent elevation in the tyrosine-phosphorylated active form of p190RhoGAP, the direct target of the phosphatase. Furthermore, the decreased Rho activity leads to disruption of both actin stress fibers and focal adhesions in Ras-transformed cells. As for Rac1, Rac1 also appears to participate in the down-regulation of Rho via Nox1. Our discovery defines a mediating role of Nox1-redox signaling for Ras oncogene-induced actin cytoskeletal changes.	Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; Univ Tsukuba, Ctr Gene Res, Tsukuba 3058572, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan	Shinshu University; University of Tsukuba; Kyushu University	Kamata, T (corresponding author), Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318; Shinohara, Masahiro/0000-0002-5532-1042				Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HUGHES RE, 1997, CELL, P521; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Mochizuki T, 2006, ONCOGENE, V25, P3699, DOI 10.1038/sj.onc.1209406; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Shimizu H, 2001, BIOCHEM BIOPH RES CO, V289, P602, DOI 10.1006/bbrc.2001.6007; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sumimoto H, 2005, BIOCHEM BIOPH RES CO, V338, P677, DOI 10.1016/j.bbrc.2005.08.210; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; van Wetering S, 2002, J CELL SCI, V115, P1837; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	38	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17640	17648		10.1074/jbc.M609450200	http://dx.doi.org/10.1074/jbc.M609450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17435218	hybrid			2022-12-25	WOS:000247084500036
J	Beedle, AM; Nienaber, PM; Campbell, KP				Beedle, Aaron M.; Nienaber, Patricia M.; Campbell, Kevin P.			Fukutin-related protein associates with the sarcolemmal dystrophin-glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; SUBCELLULAR-LOCALIZATION; SKELETAL-MUSCLE; DYSTROGLYCAN; GLYCOSYLATION; MUTATIONS; GLYCOSYLTRANSFERASE; EXPRESSION	Mutations in fukutin-related protein (FKRP) give rise to mild and more severe forms of muscular dystrophy. FKRP patients have reduced glycosylation of the extracellular protein dystroglycan, and FKRP itself shows sequence similarity to glycosyltransferases, implicating FKRP in the processing of dystroglycan. However, FKRP localization is controversial, and no FKRP complexes are known, so any FKRP-dystroglycan link remains elusive. Here, we demonstrate a novel FKRP localization in vivo; in mouse, both endogenous and recombinant FKRP are present at the sarcolemma. Biochemical analyses revealed that mouse muscle FKRP and dystroglycan co-enrich and co-fractionate, indicating that FKRP coexists with dystroglycan in the native dystrophin-glycoprotein complex. Furthermore, FKRP sedimentation shifts with dystroglycan in disease models involving the dystrophin-glycoprotein complex, and sarcolemmal FKRP immunofluorescence mirrors that of dystroglycan in muscular dystrophy mice, suggesting that FKRP localization may be mediated by dystroglycan. These data offer the first evidence of an FKRP complex in muscle and suggest that FKRP may influence the glycosylation status of dystroglycan from within the sarcolemmal dystrophin-glycoprotein complex.	Univ Iowa, Dept Physiol & Mol Biophys, HHMI, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Dept Physiol & Mol Biophys, HHMI, 4283 Carver Biomed Res Bldg,285 Newton Rd, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Beedle, Aaron M/K-1902-2015; Beedle, Aaron/AAI-7014-2020	Beedle, Aaron M/0000-0002-1019-3235; Campbell, Kevin/0000-0003-2066-5889				Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; BEGOVAC PC, 1994, J BIOL CHEM, V269, P31793; Berger EG, 2002, GLYCOBIOLOGY, V12, p29R, DOI 10.1093/glycob/12.2.29R; Brockington M, 2001, HUM MOL GENET, V10, P2851, DOI 10.1093/hmg/10.25.2851; Brockington M, 2001, AM J HUM GENET, V69, P1198, DOI 10.1086/324412; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Dolatshad NF, 2005, EXP CELL RES, V309, P370, DOI 10.1016/j.yexcr.2005.06.017; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 1999, J BIOL CHEM, V274, P26609, DOI 10.1074/jbc.274.37.26609; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Esapa CT, 2005, HUM MOL GENET, V14, P295, DOI 10.1093/hmg/ddi026; Esapa CT, 2002, HUM MOL GENET, V11, P3319, DOI 10.1093/hmg/11.26.3319; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Ma JY, 1997, J BIOL CHEM, V272, P672; MACLEOD H, 2007, NEUROMUSCUL DISORD; Matsumoto H, 2004, J BIOCHEM, V135, P709, DOI 10.1093/jb/mvh086; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Saito T, 2002, J BIOL CHEM, V277, P17002, DOI 10.1074/jbc.M200521200; Salo AM, 2006, J CELL PHYSIOL, V207, P644, DOI 10.1002/jcp.20596; Straub Volker, 2006, Semin Pediatr Neurol, V13, P104, DOI 10.1016/j.spen.2006.06.006; Torelli S, 2005, NEUROMUSCULAR DISORD, V15, P836, DOI 10.1016/j.nmd.2005.09.004; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200	30	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16713	16717		10.1074/jbc.C700061200	http://dx.doi.org/10.1074/jbc.C700061200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17452335	hybrid, Green Submitted			2022-12-25	WOS:000246946500002
J	Pochetti, G; Godio, C; Mitro, N; Caruso, D; Galmozzi, A; Scurati, S; Loiodice, F; Fracchiolla, G; Tortorella, P; Laghezza, A; Lavecchia, A; Novellino, E; Mazza, F; Crestani, M				Pochetti, Giorgio; Godio, Cristina; Mitro, Nico; Caruso, Donatella; Galmozzi, Andrea; Scurati, Samuele; Loiodice, Fulvio; Fracchiolla, Giuseppe; Tortorella, Paolo; Laghezza, Antonio; Lavecchia, Antonio; Novellino, Ettore; Mazza, Fernando; Crestani, Maurizio			Insights into the mechanism of partial agonism - Crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIDIABETIC THIAZOLIDINEDIONE; FATTY-ACIDS; PPAR-ALPHA; SELECTIVITY; REVEALS; CRYSTALLOGRAPHY; TRANSCRIPTION; DETERMINANTS; RECRUITMENT; SPECIFICITY	The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of glucose and lipid metabolism. They are activated by natural ligands, such as fatty acids, and are also targets of synthetic antidiabetic and hypolipidemic drugs. By using cell-based reporter assays, we studied the transactivation activity of two enantiomeric ureidofibrate-like derivatives. In particular, we show that the R-enantiomer, (R)-1, is a full agonist of PPAR gamma, whereas the S-enantiomer, (S)-1, is a less potent partial agonist. Most importantly, we report the x-ray crystal structures of the PPAR gamma ligand binding domain complexed with the R- and the S- enantiomer, respectively. The analysis of the two crystal structures shows that the different degree of stabilization of the helix 12 induced by the ligand determines its behavior as full or partial agonist. Another crystal structure of the PPAR gamma center dot( S)-1 complex, only differing in the soaking time of the ligand, is also presented. The comparison of the two structures of the complexes with the partial agonist reveals significant differences and is suggestive of the possible coexistence in solution of transcriptionally active and inactive forms of helix 12 in the presence of a partial agonist. Mutation analysis confirms the importance of Leu(465), Leu(469), and Ile(472) in the activation by (R)-1 and underscores the key role of Gln(286) in the PPAR gamma activity.	CNR, Ist Cristallog, Area Ric ROMA 1, Monterotondo Stn, I-00016 Rome, Italy; Univ Milan, Lab Giovanni Galli Biochim & Biol Mol Lipidi & Sp, Dipartimento Sci Farmacol, I-20133 Milan, Italy; Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy; Univ Naples Federico II, Dipartimento Chim Farmaceut, I-80131 Naples, Italy; Univ Aquila, Dipartimento Chim Ingn Chim & Mat, I-67010 Laquila, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR); University of Milan; Universita degli Studi di Bari Aldo Moro; University of Naples Federico II; University of L'Aquila	Pochetti, G (corresponding author), CNR, Ist Cristallog, Area Ric ROMA 1, Monterotondo Stn, Sede Monterotondo,Via Salaria Km 29-300, I-00016 Rome, Italy.	giorgio.pochetti@ic.cnr.it	caruso, donatella/A-3332-2014; FRACCHIOLLA, Giuseppe/P-3899-2015; pochetti, giorgio/AAU-7069-2020; Lavecchia, Antonio/P-9476-2017; Laghezza, Antonio/F-7420-2014	caruso, donatella/0000-0003-2115-778X; FRACCHIOLLA, Giuseppe/0000-0003-4991-3962; Lavecchia, Antonio/0000-0002-2181-8026; Novellino, Ettore/0000-0002-2181-2142; Mitro, Nico/0000-0002-5000-3619; Laghezza, Antonio/0000-0001-6221-6155; Godio, Cristina/0000-0003-2639-6368; Crestani, Maurizio/0000-0001-9230-1078				Arakawa K, 2004, CLIN EXP PHARMACOL P, V31, P8, DOI 10.1111/j.1440-1681.2004.03954.x; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ebdrup S, 2003, J MED CHEM, V46, P1306, DOI 10.1021/jm021027r; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gangloff M, 2001, J BIOL CHEM, V276, P15059, DOI 10.1074/jbc.M009870200; Hellal-Levy C, 2000, MOL ENDOCRINOL, V14, P1210, DOI 10.1210/me.14.8.1210; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Love JD, 2002, J BIOL CHEM, V277, P11385, DOI 10.1074/jbc.M110869200; Lu IL, 2006, J MED CHEM, V49, P2703, DOI 10.1021/jm051129s; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Ostberg T, 2004, J BIOL CHEM, V279, P41124, DOI 10.1074/jbc.M401552200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sauerberg P, 2002, J MED CHEM, V45, P789, DOI 10.1021/jm010964g; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Takada I, 2000, MOL ENDOCRINOL, V14, P733, DOI 10.1210/me.14.5.733; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	39	100	103	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17314	17324		10.1074/jbc.M702316200	http://dx.doi.org/10.1074/jbc.M702316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17403688	hybrid			2022-12-25	WOS:000246946500065
J	Wang, LW; Dlugosz, M; Somerville, RPT; Raed, M; Haltiwanger, RS; Apte, SS				Wang, Lauren W.; Dlugosz, Malgosia; Somerville, Robert P. T.; Raed, Mona; Haltiwanger, Robert S.; Apte, Suneel S.			O-fucosylation of thrombospondin type 1 repeats in ADAMTS-like-1/punctin-1 regulates secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-LIKE; ADAMTS FAMILY; EXTRACELLULAR-MATRIX; C-MANNOSYLATION; LIGAND-BINDING; LINKED FUCOSE; GDP-FUCOSE; GLYCOSYLATION; PROTEIN; NOTCH	The ADAMTS superfamily contains several metalloproteases (ADAMTS proteases) as well as ADAMTS-like molecules that lack proteolytic activity. Their common feature is the presence of one or more thrombospondin type-1 repeats (TSRs) within a characteristic modular organization. ADAMTS like-1/punctin-1 has four TSRs. Previously, O-fucosylation on Ser or Thr mediated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the sequence Cys-Xaa(1)-Xaa(2)- Ser/Thr)-Cys-Xaa-Xaa-Gly (where the fucosylated residue is underlined). On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4). Although mass spectral analysis did not unambiguously identify the relevant peptide from TSR1, metabolic labeling of cells expressing TSR1 and the cysteine-rich module led to incorporation of [H-3] fucose into this construct. Mutation of the putative modified Ser/Thr residues in TSR2, TSR3, and TSR4 led to significantly decreased levels of secreted punctin-1. Similarly, expression of punctin-1 in Lec-13 cells that are deficient in conversion of GDP-mannose to GDP-fucose substantially decreased the levels of secreted protein, which were restored upon culture in the presence of exogenous L-fucose. In addition, mutation of the single N-linked oligosaccharide in punctin-1 led to decreased levels of secreted punctin-1. Taken together, the data define a critical role for N-glycosylation and O-fucosylation in the biosynthesis of punctin-1. From a broad perspective, these data suggest that O-fucosylation may be a widespread post-translational modification in members of the ADAMTS superfamily with possible regulatory consequences.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Cleveland Clinic Foundation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NIGMS NIH HHS [GM61126] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049930, R56AR049930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hall NG, 2003, MATRIX BIOL, V22, P501, DOI 10.1016/S0945-053X(03)00075-1; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huxley-Jones J, 2005, INT J BIOCHEM CELL B, V37, P1838, DOI 10.1016/j.biocel.2005.03.009; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Kramerova IA, 2000, DEVELOPMENT, V127, P5475; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nardi JB, 2001, J INSECT PHYSIOL, V47, P997, DOI 10.1016/S0022-1910(01)00074-9; Nita-Lazar A, 2006, METHOD ENZYMOL, V417, P93, DOI 10.1016/S0076-6879(06)17008-1; Nita-Lazar Aleksandra, 2006, V347, P57; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Varki A., 1999, ESSENTIALS GLYCOBIOL; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200	44	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17024	17031		10.1074/jbc.M701065200	http://dx.doi.org/10.1074/jbc.M701065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17395588	hybrid			2022-12-25	WOS:000246946500035
J	Yang, Z; Webb, TI; Lynch, JW				Yang, Zhe; Webb, Timothy I.; Lynch, Joseph W.			Closed-state cross-linking of adjacent beta 1 Subunits in alpha 1 beta 1 GABA(a) receptors via introduced 6 ' cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; GAMMA-AMINOBUTYRIC-ACID; GABA(A) RECEPTORS; GATING MECHANISM; PROTEIN MOBILITY; ION-CHANNEL; PORE; GLYCINE; SEGMENT; GATE	The pore structural changes associated with Cys-loop receptor gating are currently the subject of considerable interest. Several functional approaches have shown that surface exposure of pore-lining side chains does not change significantly during activation. However, a disulfide trapping study on alpha 1(T6 ' C) beta 1(T6 ' C) gamma-aminobutyric acid type A (GABA(A)) receptors (GABA(A)Rs), which showed that adjacent beta subunits cross-link in the open state only, concluded that channel gating is mediated by beta subunits contra-rotating through a summed angle of similar to 120(o). Such a large rotation is not easily reconciled with other evidence. The present study initially sought to investigate an observation that appeared inconsistent with the rotation model: namely that alpha 1(T6 ' C) beta 1(T6 ' C) GABA(A)Rs expressed in HEK293 cells form 6 ' cysteine-mediated disulfide bonds in the closed state. On the basis of electrophysiological and Western blotting experiments, we conclude that adjacent beta(T6 ' C) subunits dimerise efficiently in the closed state via cross-links between their respective 6 ' cysteines and that this locks the channels closed. This questions the beta. subunit contra-rotation model of activation and raises the question of how the closed state cross-links form. We propose that beta subunit 6 ' cysteines move into sufficiently close proximity for disulfide formation via relatively large amplitude random thermal motions that appear to be a unique feature of beta subunits. Because dimerized channels are locked closed, we conclude either that the spontaneous beta subunit movements or asymmetries in the movements of adjacent beta subunits during activation are essential for pore opening. Our results identify a novel feature of GABA(A)R gating that may be important for understanding its activation mechanism.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009; Webb, Timothy I/H-6941-2015	Webb, Timothy I/0000-0002-6263-6296				Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Horenstein J, 2005, J BIOL CHEM, V280, P1573, DOI 10.1074/jbc.M410881200; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Mitra A, 2005, P NATL ACAD SCI USA, V102, P15069, DOI 10.1073/pnas.0505090102; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Paas Y, 2005, P NATL ACAD SCI USA, V102, P15877, DOI 10.1073/pnas.0507599102; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1	21	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16803	16810		10.1074/jbc.M611555200	http://dx.doi.org/10.1074/jbc.M611555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405880	hybrid			2022-12-25	WOS:000246946500012
J	Bocharov, EV; Pustovalova, YE; Pavlov, KV; Volynsky, PE; Goncharuk, MV; Ermolyuk, YS; Karpunin, DV; Schulga, AA; Kirpichnikov, MP; Efremov, RG; Maslennikov, IV; Arseniev, AS				Bocharov, Eduard V.; Pustovalova, Yulia E.; Pavlov, Konstantin V.; Volynsky, Pavel E.; Goncharuk, Marina V.; Ermolyuk, Yaroslav S.; Karpunin, Dmitry V.; Schulga, Alexey A.; Kirpichnikov, Michail P.; Efremov, Roman G.; Maslennikov, Innokenty V.; Arseniev, Alexander S.			Unique dimeric structure of BNip3 transmembrane domain suggests membrane permeabilization as a cell death trigger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDIMENSIONAL NMR EXPERIMENTS; BCL-2 FAMILY; MITOCHONDRIAL PERMEABILITY; OUTER-MEMBRANE; PROTEIN; CHANNEL; HYDROPHOBICITY; APOPTOSIS; DYNAMICS; NECROSIS	BNip3 is a prominent representative of apoptotic Bcl-2 proteins with rather unique properties initiating an atypical programmed cell death pathway resembling both necrosis and apoptosis. Many Bcl-2 family proteins modulate the permeability state of the outer mitochondrial membrane by forming homo-and hetero-oligomers. The structure and dynamics of the homodimeric transmembrane domain of BNip3 were investigated with the aid of solution NMR in lipid bicelles and molecular dynamics energy relaxation in an explicit lipid bilayer. The right-handed parallel helix-helix structure of the domain with a hydrogen bond-rich His-Ser node in the middle of the membrane, accessibility of the node for water, and continuous hydrophilic track across the membrane suggest that the domain can provide an ion-conducting pathway through the membrane. Incorporation of the BNip3 transmembrane domain into an artificial lipid bilayer resulted in pH-dependent conductivity increase. A possible biological implication of the findings in relation to triggering necrosis-like cell death by BNip3 is discussed.	Russian Acad Sci, Struct Biol Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Ingn Prot Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Lab Neuroreceptors & Neuroregulators, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Lab Bioelectrochem, Frumkin Inst Phys Chem & Electrochem, Moscow 119991, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Frumkin Institute of Physical Chemistry & Electrochemistry	Bocharov, EV (corresponding author), Russian Acad Sci, Struct Biol Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16-10, Moscow 117997, Russia.	bon@nmr.ru; aars@nmr.ru	Pavlov, Konstantin/T-6515-2017; Schulga, Alexey/T-3856-2018; Pustovalova, Yulia/AAB-1221-2021; Volynsky, Pavel/A-8360-2014; Maslennikov, Innokentiy/I-2524-2012; Pavlov, Konstantin V./Y-8481-2018; Roman, Efremov/A-7460-2014; Goncharuk, Marina/V-1558-2018	Pavlov, Konstantin/0000-0003-1637-8000; Schulga, Alexey/0000-0003-3425-0828; Pustovalova, Yulia/0000-0003-3024-1764; Volynsky, Pavel/0000-0002-0471-4188; Pavlov, Konstantin V./0000-0003-1637-8000; Roman, Efremov/0000-0002-5474-4721; Maslennikov, Innokentiy/0000-0003-4292-5821				Andersson A, 2005, LANGMUIR, V21, P7702, DOI 10.1021/la0513003; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Bathori G, 2006, J BIOL CHEM, V281, P17347, DOI 10.1074/jbc.M600906200; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; Fernandez C, 2002, P NATL ACAD SCI USA, V99, P13533, DOI 10.1073/pnas.212515099; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Kass I, 2005, STRUCTURE, V13, P1789, DOI 10.1016/j.str.2005.08.022; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee H, 2006, MOL CELLS, V21, P1; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Lemeshko SV, 2004, MOL CELL BIOCHEM, V256, P127, DOI 10.1023/B:MCBI.0000009864.77216.00; Li XX, 2005, BIOPHYS J, V88, P2577, DOI 10.1529/biophysj.104.049403; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; O'Rourke B, 2007, ANNU REV PHYSIOL, V69, P19, DOI 10.1146/annurev.physiol.69.031905.163804; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Porcelli AM, 2005, BIOCHEM BIOPH RES CO, V326, P799, DOI 10.1016/j.bbrc.2004.11.105; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; Sulistijo ES, 2006, J MOL BIOL, V364, P974, DOI 10.1016/j.jmb.2006.09.065; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Walters RFS, 2006, P NATL ACAD SCI USA, V103, P13658, DOI 10.1073/pnas.0605878103; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	47	115	116	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16256	16266		10.1074/jbc.M701745200	http://dx.doi.org/10.1074/jbc.M701745200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412696	hybrid			2022-12-25	WOS:000246794300033
J	D'Andrea-Merrins, M; Chang, L; Lam, AD; Ernst, SA; Stuenkel, EL				D'Andrea-Merrins, Matthew; Chang, Louise; Lam, Alice D.; Ernst, Stephen A.; Stuenkel, Edward L.			Munc18c interaction with syntaxin 4 monomers and SNARE complex intermediates in GLUT4 vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; 3T3-L1 ADIPOCYTES; IN-VIVO; INSULIN; PROTEIN; TRANSLOCATION; CELLS; COMPARTMENTS; SPECIFICITY; INHIBITION	In the process of insulin-stimulated GLUT4 vesicle exocytosis, Munc18c has been proposed to control SNARE complex formation by inactivating syntaxin 4 in a self-associated conformation. Using in vivo fluorescence resonance energy transfer in 3T3L1 adipocytes, co-immunoprecipitation, and in vitro binding assays, we provide data to indicate that Munc18c also associates with nearly equal affinity to a mutant of syntaxin 4 in a constitutively open ( unfolded) state ( L173A/E174A; LE). To bind to the open conformation of syntaxin 4, we found that Munc18c requires an interaction with the N terminus of syntaxin 4, which resembles Sly1 interaction with the N terminus of ER/Golgi syntaxins. However, both N and C termini of syntaxin 4 are required for Munc18c binding, since a mutation in the syntaxin 4 SNARE domain ( I241A) reduces the interaction, irrespective of syntaxin 4 conformation. Using an optical reporter for syntaxin 4-SNARE pairings in vivo, we demonstrate that Munc18c blocks recruitment of SNAP23 to wild type syntaxin 4 yet associates with syntaxin 4(LE)-SNAP23 Q-SNARE complexes. Fluorescent imaging of GLUT4 vesicles in 3T3L1 adipocytes revealed that syntaxin 4(LE) expressed with Munc18c bypasses the requirement of insulin for GLUT4 vesicle plasma membrane docking. This effect was attenuated by reducing the Munc18c-syntaxin 4(LE) interaction with the I241A mutation, indicating that Munc18c facilitates vesicle docking. Therefore, in contradiction to previous models, our data indicates that the conformational "opening" of syntaxin 4 rather than the dissociation of Munc18c is the critical event required for GLUT4 vesicle docking.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Andrea-Merrins, M (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7744 MSII,1153 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mmerrins@umich.edu		Stuenkel, Edward/0000-0001-8225-5725; Chang, Louise/0000-0001-5501-4774; Merrins, Matthew J./0000-0003-1599-9227	NIDDK NIH HHS [DK60591, DK61618] Funding Source: Medline; NINDS NIH HHS [NS039914, NS053978] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060591, R01DK061618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039914, R01NS053978] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Bryant NJ, 2003, J CELL BIOL, V161, P691, DOI 10.1083/jcb.200212078; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Hodgkinson CP, 2005, DIABETOLOGIA, V48, P1627, DOI 10.1007/s00125-005-1819-y; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	38	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16553	16566		10.1074/jbc.M610818200	http://dx.doi.org/10.1074/jbc.M610818200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412693	hybrid			2022-12-25	WOS:000246794300062
J	Hamilton, SR; Fard, SF; Paiwand, FF; Tolg, C; Veiseh, M; Wang, C; McCarthy, JB; Bissell, MJ; Koropatnick, J; Turley, EA				Hamilton, Sara R.; Fard, Shireen F.; Paiwand, Frouz F.; Tolg, Cornelia; Veiseh, Mandana; Wang, Chao; McCarthy, James B.; Bissell, Mina J.; Koropatnick, James; Turley, Eva A.			The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; MAP KINASE; EPITHELIAL-CELLS; BINDING-PROTEIN; PROGNOSTIC-SIGNIFICANCE; MEDIATED MOTILITY; TUMOR PROGRESSION; FACTOR-BETA; EXPRESSION	CD44 is an integral hyaluronan receptor that can promote or inhibit motogenic signaling in tumor cells. Rhamm is a nonintegral cell surface hyaluronan receptor (CD168) and intracellular protein that promotes cell motility in culture. Here we describe an autocrine mechanism utilizing cell surface RhammCD44 interactions to sustain rapid basal motility in invasive breast cancer cell lines that requires endogenous hyaluronan synthesis and the formation of Rhamm-CD44-ERK1,2 complexes. Motile/invasive MDA-MB-231 and Ras-MCF10A cells produce more endogenous hyaluronan, cell surface CD44 and Rhamm, an oncogenic Rhamm isoform, and exhibit more elevated basal activation of ERK1,2 than less invasive MCF7 and MCF10A breast cancer cells. Furthermore, CD44, Rhamm, and ERK1,2 uniquely co-immunoprecipitate and co-localize in MDA-MB-231 and Ras-MCF10A cells. Combinations of anti-CD44, anti-Rhamm antibodies, and a MEK1 inhibitor (PD098059) had less-than-additive blocking effects, suggesting the action of all three proteins on a common motogenic signaling pathway. Collectively, these results show that cell surface Rhamm and CD44 act together in a hyaluronan-dependent autocrine mechanism to coordinate sustained signaling through ERK1,2, leading to high basal motility of invasive breast cancer cells. Therefore, an effect of CD44 on tumor cell motility may depend in part on its ability to partner with additional proteins, such as cell surface Rhamm.	Canc Res Labs, London Reg Canc Program, London, ON N6A 4L6, Canada; Univ Western Ontario, London, ON N6A 4L6, Canada; Hosp Sick Children, Dept Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Minnesota, Ctr Comprehens Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Lawrence Berkeley Natl Labs, Div Life Sci, Berkeley, CA 94720 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Turley, EA (corresponding author), Canc Res Labs, London Reg Canc Program, Rm A4-931,790 Commissioners Rd E, London, ON N6A 4L6, Canada.	eva.turley@lhsc.on.ca		Koropatnick, James/0000-0001-6144-5941; Hamilton, Sara/0000-0001-6062-2037	NCI NIH HHS [R01 CA064786, R01 CA057621-07, U54 CA126552, R01 CA064786-07, R01 CA057621, U54 CA126552-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064786, R01CA057621, U54CA126552] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Agnantis NJ, 2004, IN VIVO, V18, P481; Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Assmann V, 1999, J CELL SCI, V112, P3943; Assmann V, 1998, J CELL SCI, V111, P1685; Auvinen P, 2005, HISTOPATHOLOGY, V47, P420, DOI 10.1111/j.1365-2559.2005.02220.x; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Boldt S, 2004, CURR PHARM DESIGN, V10, P1885, DOI 10.2174/1381612043384420; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; CARNENISCH TD, 2000, J CLIN INVEST, V106, P349; DELOSTOYOS J, 1989, BLOOD, V74, P751; Diaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184; Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; Florquin S, 2003, KIDNEY INT, V64, pS15, DOI 10.1046/j.1523-1755.64.s86.4.x; GALLUZZO E, 1995, EUR J IMMUNOL, V25, P2932, DOI 10.1002/eji.1830251033; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Goebeler M, 1996, J CELL SCI, V109, P1957; Gotte M, 2006, CANCER RES, V66, P10233, DOI 10.1158/0008-5472.CAN-06-1464; Goueffic Y, 2006, CARDIOVASC RES, V72, P339, DOI 10.1016/j.cardiores.2006.07.017; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hall CL, 1996, ONCOGENE, V13, P2213; Hall CL, 2001, MATRIX BIOL, V20, P183, DOI 10.1016/S0945-053X(01)00133-0; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hofmann M, 1998, J CELL SCI, V111, P1673; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Khan SA, 2005, CLIN EXP METASTAS, V22, P663, DOI 10.1007/s10585-006-9007-0; Kondoh K, 2005, CHROMOSOMA, V114, P86, DOI 10.1007/s00412-005-0341-9; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kuida K, 2004, J BIOCHEM, V135, P653, DOI 10.1093/jb/mvh078; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Ma W, 2005, CLIN ONCOL-UK, V17, P258, DOI 10.1016/j.clon.2005.02.007; Marhaba R, 2004, J MOL HISTOL, V35, P211; Martinez-Carpio PA, 1999, CANCER LETT, V147, P25, DOI 10.1016/S0304-3835(99)00261-X; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.e02-07-0377; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Morris SF, 2001, EUR J SURG ONCOL, V27, P527, DOI 10.1053/ejso.2001.1167; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Navolanic PM, 2003, INT J ONCOL, V22, P237; Nedvetzki S, 2004, P NATL ACAD SCI USA, V101, P18081, DOI 10.1073/pnas.0407378102; OCHIENG J, 1991, INVAS METAST, V11, P38; Pilarski LM, 1999, BLOOD, V93, P2918; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Rom J, 2006, PATHOL RES PRACT, V202, P125, DOI 10.1016/j.prp.2005.12.002; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Savani RC, 2000, AM J RESP CELL MOL, V23, P475, DOI 10.1165/ajrcmb.23.4.3944; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sleeman JP, 1996, CANCER RES, V56, P3134; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; SOULE HD, 1990, CANCER RES, V50, P6075; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Thanakit Voranuch, 2005, J Med Assoc Thai, V88 Suppl 4, pS30; Tolg C, 2006, J CELL BIOL, V175, P1017, DOI 10.1083/jcb.200511027; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Vial E, 2004, ANN NY ACAD SCI, V1030, P208, DOI 10.1196/annals.1329.027; Wang C, 1998, CLIN CANCER RES, V4, P567; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Watanabe O, 2005, J EXP CLIN CANC RES, V24, P75; Weber GF, 2002, CANCER RES, V62, P2281; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wells A, 2000, ADV CANCER RES, V78, P31; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zaman A, 2005, AM J RESP CELL MOL, V33, P447, DOI 10.1165/rcmb.2004-0333OC; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	95	201	214	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16667	16680		10.1074/jbc.M702078200	http://dx.doi.org/10.1074/jbc.M702078200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392272	hybrid, Green Accepted			2022-12-25	WOS:000246794300072
J	Pathak, HB; Arnold, JJ; Wiegand, PN; Hargittai, MRS; Cameron, CE				Pathak, Harsh B.; Arnold, Jamie J.; Wiegand, Phillip N.; Hargittai, Michele R. S.; Cameron, Craig E.			Picornavirus genome replication - Assembly and organization of the VPg uridylylation ribonucleoprotein (initiaion) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; STEM-LOOP-D; POLIOVIRUS RNA; POSITIVE-STRAND; NEGATIVE-STRAND; ELEMENT CRE; 5' END; PROTEIN; IDENTIFICATION; 3D(POL)	All picornaviruses have a protein, VPg, covalently linked to the 5 '- ends of their genomes. Uridylylated VPg (VPg- pUpU) is thought to serve as the protein primer for RNA synthesis. VPgpUpU can be produced in vitro by the viral polymerase, 3Dpol, in a reaction in which a single adenylate residue of a stem- loop structure, termed oriI, templates processive incorporation of UMPinto VPg by using a "slide-back" mechanism. This reaction is greatly stimulated by viral precursor protein 3CD or its processed derivative, 3C; both contain RNA-binding and protease activities. We show that the 3C domain encodes specificity for oriI, and the 3D domain enhances the overall affinity for oriI. Thus, 3C(D) stimulation exhibits an RNA length dependence. By using a minimal system to evaluate the mechanism of VPg uridylylation, we show that the active complex contains polymerase, oriI, and 3C(D) at stoichiometry of 1:1:2. Dimerization of 3C(D) is supported by physical and structural data. Polymerase recruitment to and retention in this complex require a proteinprotein interaction between the polymerase and 3C(D). Physical and functional data for this interaction are provided for three picornaviruses. VPg association with this complex is weak, suggesting that formation of a complex containing all necessary components of the reaction is rate- limiting for the reaction. We suggest that assembly of this complex in vivo would be facilitated by use of precursor proteins instead of processed proteins. These data provide a glimpse into the organization of the ribonucleoprotein complex that catalyzes this key step in picornavirus genome replication.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu			NIAID NIH HHS [AI053531, R01 AI053531, R56 AI053531, R37 AI053531, R01 AI053531-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI053531, R01AI053531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5138, DOI 10.1021/bi035213q; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; Boerner JE, 2005, J VIROL, V79, P7803, DOI 10.1128/JVI.79.12.7803-7811.2005; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Cheney IW, 2003, J VIROL, V77, P7434, DOI 10.1128/JVI.77.13.7434-7443.2003; DILDINE SL, 1992, J VIROL, V66, P4364, DOI 10.1128/JVI.66.7.4364-4376.1992; Du ZH, 2004, BIOCHEMISTRY-US, V43, P11959, DOI 10.1021/bi048973p; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Goodfellow IG, 2003, J GEN VIROL, V84, P2359, DOI 10.1099/vir.0.19132-0; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Headey SJ, 2007, RNA, V13, P351, DOI 10.1261/rna.313707; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Huang LY, 2005, J BIOL CHEM, V280, P36417, DOI 10.1074/jbc.M508175200; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; Lobert PE, 1999, P NATL ACAD SCI USA, V96, P11560, DOI 10.1073/pnas.96.20.11560; Marcotte LL, 2007, J VIROL, V81, P3583, DOI 10.1128/JVI.02306-06; Mason PW, 2002, J VIROL, V76, P9686, DOI 10.1128/JVI.76.19.9686-9694.2002; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Nayak A, 2005, J VIROL, V79, P7698, DOI 10.1128/JVI.79.12.7698-7706.2005; Nayak A, 2006, J VIROL, V80, P9865, DOI 10.1128/JVI.00561-06; Ohlenschlager O, 2004, STRUCTURE, V12, P237, DOI 10.1016/j.str.2004.01.014; Parsley TB, 1997, RNA, V3, P1124; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; PATHAK HB, 2006, THESIS PENNSYLVANIA, P173; Paul Aniko V., 2002, P227; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 2003, J BIOL CHEM, V278, P43951, DOI 10.1074/jbc.M307441200; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Rieder E, 2003, J GEN VIROL, V84, P2203, DOI 10.1099/vir.0.19013-0; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; Thiviyanathan V, 2004, P NATL ACAD SCI USA, V101, P12688, DOI 10.1073/pnas.0403079101; van Ooij MJM, 2006, J GEN VIROL, V87, P103, DOI 10.1099/vir.0.81297-0; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Yang Y, 2004, J BIOL CHEM, V279, P12659, DOI 10.1074/jbc.M312992200; Yang Y, 2002, J VIROL, V76, P7485, DOI 10.1128/JVI.76.15.7485-7494.2002; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	48	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16202	16213		10.1074/jbc.M610608200	http://dx.doi.org/10.1074/jbc.M610608200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392285	Green Accepted, hybrid			2022-12-25	WOS:000246794300028
J	Wiradjaja, F; Ooms, LM; Tahirovic, S; Kuhne, E; Devenish, RJ; Munn, AL; Piper, RC; Mayinger, P; Mitchell, CA				Wiradjaja, Fenny; Ooms, Lisa M.; Tahirovic, Sabina; Kuhne, Ellie; Devenish, Rodney J.; Munn, Alan L.; Piper, Robert C.; Mayinger, Peter; Mitchell, Christina A.			Inactivation of the phosphoinositide phosphatases Sac1p and Inp54p leads to accumulation of phosphatidylinositol 4,5-bisphosphate on vacuole membranes and vacuolar fusion defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; YEAST SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID TRANSFER PROTEIN; PLASMA-MEMBRANE; CELL-GROWTH; GENE; GOLGI; MUTATIONS; MUTANTS	Phosphoinositides direct membrane trafficking, facilitating the recruitment of effectors to specific membranes. In yeast phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) is proposed to regulate vacuolar fusion; however, in intact cells this phosphoinositide can only be detected at the plasma membrane. In Saccharomyces cerevisiae the 5-phosphatase, Inp54p, dephosphorylates PtdIns(4,5)P-2 forming PtdIns(4)P, a substrate for the phosphatase Sac1p, which hydrolyzes (PtdIns(4) P). We investigated the role these phosphatases in regulating PtdIns(4,5) P-2 subcellular distribution. PtdIns(4,5)P-2 bioprobes exhibited loss of plasma membrane localization and instead labeled a subset of fragmented vacuoles in Delta sac1 Delta inp54 and sac1(ts) Delta inp54 mutants. Furthermore, sac1(ts) Delta inp54 mutants exhibited vacuolar fusion defects, which were rescued by latrunculin A treatment, or by inactivation of Mss4p, a PtdIns(4)P 5-kinase that synthesizes plasma membrane PtdIns(4,5)P-2. Under these conditions PtdIns(4,5)P-2 was not detected on vacuole membranes, and vacuole morphology was normal, indicating vacuolar PtdIns(4,5)P-2 derives from Mss4p-generated plasma membrane PtdIns(4,5)P-2. Delta sac1 Delta inp54 mutants exhibited delayed carboxypeptidase Y sorting, cargo-selective secretion defects, and defects in vacuole function. These studies reveal PtdIns(4,5)P-2 hydrolysis by lipid phosphatases governs its spatial distribution, and loss of phosphatase activity may result in PtdIns(4,5)P-2 accumulation on vacuole membranes leading to vacuolar fragmentation/fusion defects.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA	Monash University; Ruprecht Karls University Heidelberg; University of Queensland; University of Iowa; Oregon Health & Science University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	Christina.Mitchell@md.monash.edu.au	Ooms, Lisa/AGZ-7420-2022	Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932; Piper, Robert/0000-0001-9995-5699	NIGMS NIH HHS [GM071569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Belgareh-Touze N, 2002, MOL BIOL CELL, V13, P1694, DOI 10.1091/mbc.01-12-0597; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Faulhammer F, 2005, J CELL BIOL, V168, P185, DOI 10.1083/jcb.200407118; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Haucke V, 2005, BIOCHEM SOC T, V33, P1285, DOI 10.1042/BST0331285; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Hongay C, 2002, EMBO J, V21, P4114, DOI 10.1093/emboj/cdf415; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; LaGrassa TJ, 2005, J CELL BIOL, V168, P401, DOI 10.1083/jcb.200407141; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1989, GENETICS, V121, P659; O'Malley CJ, 2001, BIOCHEM J, V355, P805, DOI 10.1042/bj3550805; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Parrish WR, 2004, MOL BIOL CELL, V15, P3567, DOI 10.1091/mbc.E04-03-0209; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rohde HM, 2003, J BIOL CHEM, V278, P52689, DOI 10.1074/jbc.M307983200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Schorr M, 2001, CURR BIOL, V11, P1421, DOI 10.1016/S0960-9822(01)00449-3; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Tahirovic S, 2005, TRAFFIC, V6, P116, DOI 10.1111/j.1600-0854.2004.00255.x; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungewickell A, 2005, P NATL ACAD SCI USA, V102, P18854, DOI 10.1073/pnas.0509740102; Ungewickell AJ, 1999, P NATL ACAD SCI USA, V96, P13342, DOI 10.1073/pnas.96.23.13342; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; Wiradjaja F, 2001, J BIOL CHEM, V276, P7643, DOI 10.1074/jbc.M010471200; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	62	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16295	16307		10.1074/jbc.M701038200	http://dx.doi.org/10.1074/jbc.M701038200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392273	hybrid			2022-12-25	WOS:000246794300037
J	Yang, GD; Yang, W; Wu, LY; Wang, R				Yang, Guangdong; Yang, Wei; Wu, Lingyun; Wang, Rui			H2S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE-GAMMA-LYASE; OXIDE-INDUCED APOPTOSIS; HYDROGEN-SULFIDE; MAP KINASES; ER STRESS; ACTIVATION; P38; RAT; INHIBITION; RELEASE	Cystathionine gamma-lyase ( CSE) is a key enzyme in the transsulfuration pathway, which uses L-cysteine to produce hydrogen sulfide (H2S). Functional changes of pancreatic beta cells induced by endogenous H2S have been reported, but the effect of the CSE/ H2S system on pancreatic beta cell survival has not been known. In this study, we demonstrate that H2S at physiologically relevant concentrations induced apoptosis of INS-1E cells, an insulin-secreting beta cell line. Transfection of INS-1E cells with a recombinant defective adenovirus containing the CSE gene (Ad-CSE) resulted in a significant increase in CSE expression and H2S production. Ad-CSE transfection also stimulated apoptosis. The other two end products of CSE-catalyzed enzymatic reaction, ammonium and pyruvate, had no effects on INS-1E cell apoptosis, indicating that overexpression of CSE may stimulate INS-1E cell apoptosis via increased endogenous production of H2S. Both exogenous H2S ( 100 mu M) and Ad-CSE transfection inhibited ERK1/2 but activated p38 MAPK. Interestingly, BiP and CHOP, two indicators of endoplasmic reticulum ( ER) stress, were up-regulated in H2S- and CSE-mediated apoptosis in INS-1E cells. After suppressing CHOP mRNA expression, H2S- induced apoptosis of INS-1E cells was significantly decreased. Inhibition of p38 MAPK, but not of ERK1/2, inhibited the expression of BiP and CHOP and decreased H2S- stimulated apoptosis, suggesting that p38 MAPK activation functions upstream of ER stress to initiate H2S-induced apoptosis. It is concluded that H2S induces apoptosis of insulin-secreting beta cells by enhancing ER stress via p38 MAPK activation. Our findings may help unmask a novel role of CSE/ H2S system in regulating pancreatic functions under physiological condition and in diabetes.	Lakehead Univ, Fac Sci & Environm Studies, Dept Biol, Thunder Bay, ON P7B 5E1, Canada; Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada	Lakehead University; University of Saskatchewan; University of Saskatchewan	Wang, R (corresponding author), Lakehead Univ, Fac Sci & Environm Studies, Dept Biol, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	rwang@lakeheadu.ca	Wang, Rui/C-7824-2012; Yang, Guangdong/G-4129-2011	Wang, Rui/0000-0003-3825-3620; 				Cao Y, 2006, AM J PHYSIOL-CELL PH, V291, pC503, DOI 10.1152/ajpcell.00547.2005; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Jeon HK, 2005, CELL BIOL TOXICOL, V21, P115, DOI 10.1007/s10565-005-0148-8; JIA X, 2004, CAN J CARDIOL SD, V20, P56; Kaneko Y, 2006, DIABETES, V55, P1391, DOI 10.2337/db05-1082; Lipson KL, 2006, CURR MOL MED, V6, P71, DOI 10.2174/156652406775574613; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; Rinaldi L, 2006, LAB INVEST, V86, P391, DOI 10.1038/labinvest.3700391; Rose P, 2005, WORLD J GASTROENTERO, V11, P3990, DOI 10.3748/wjg.v11.i26.3990; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schicho R, 2006, GASTROENTEROLOGY, V131, P1542, DOI 10.1053/j.gastro.2006.08.035; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Song RP, 2002, AM J RESP CELL MOL, V27, P603, DOI 10.1165/rcmb.4851; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; Tongers J, 2004, CARDIOVASC RES, V63, P545, DOI 10.1016/j.cardiores.2004.04.015; VALITUTTI S, 1990, ANN ALLERGY, V65, P463; Veldman BAJ, 2005, DIABETIC MED, V22, P301, DOI 10.1111/j.1464-5491.2005.01415.x; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang R., 2006, LAB INVEST, V86, P324; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wijekoon EP, 2005, DIABETES, V54, P3245, DOI 10.2337/diabetes.54.11.3245; Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto T, 2006, NEUROSCI LETT, V392, P170, DOI 10.1016/j.neulet.2005.09.012; Yang G, 2006, FASEB J, V20, P553, DOI 10.1096/fj.05-4712fje; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Yang W, 2005, J PHYSIOL-LONDON, V569, P519, DOI 10.1113/jphysiol.2005.097642; Yusuf M, 2005, BIOCHEM BIOPH RES CO, V333, P1146, DOI 10.1016/j.bbrc.2005.06.021; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	47	163	177	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16567	16576		10.1074/jbc.M700605200	http://dx.doi.org/10.1074/jbc.M700605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430888	hybrid			2022-12-25	WOS:000246794300063
J	Ghoneim, C; Soula-Rothhut, M; Blanchevoye, C; Martiny, L; Antonicelli, F; Rothhut, B				Ghoneim, Christelle; Soula-Rothhut, Mahdhia; Blanchevoye, Charlotte; Martiny, Laurent; Antonicelli, Frank; Rothhut, Bernard			Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR-2; SCATTER FACTOR; CARCINOMA-CELLS; PAPILLARY CARCINOMA; EMBRYO FIBROBLASTS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; RESPONSE ELEMENT; FACTOR RECEPTOR	Hepatocyte growth factor (HGF) plays a major role in the pathogenesis of a variety of human epithelial tumors including papillary carcinoma of the thyroid. Previous reports demonstrated that HGF, acting through the Met receptor, repressed thrombospondin-1 (TSP-1) expression. To study the mechanisms by which HGF down-regulated TSP-1 expression, we transiently transfected a panel of deleted human TSP-1 promoter reporter plasmids into papillary thyroid carcinoma cells. Weidentified a region between -1210 and -1123 bp relative to the transcription start site that is responsive to HGF treatment and harbors a cAMP-responsive element (CRE) at position -1199 (TGACGTCC). Overexpression of various members of the CRE-binding protein family identified activating transcription factor-1 (ATF-1) as the transcription factor responsible for HGF-induced repression of TSP-1 promoter activity. This inhibition was associated with a concomitant increase in the abundance of nuclear ATF-1 protein. Gel shift and antibody supershift studies indicated that ATF-1 was involved in DNA binding to the TSP-1-CRE site. Finally, we utilized small hairpin RNA to target ATF-1 and showed that these small interfering RNA constructs significantly inhibited ATF-1 expression at both the RNA and the protein level. ATF-1 knockdown prevented HGF-induced down-regulation of TSP-1 promoter activity and protein expression and also reduced HGF-dependent tumor cell invasion. Taken together, our results indicate that HGF-induced down-regulation of TSP-1 expression is mediated by the interaction of ATF-1 with the CRE binding site in the TSP-1 promoter and that this transcription factor plays a crucial role for tumor invasiveness in papillary carcinoma of the thyroid triggered by HGF.	URCA, CNRS, UMR 6198, Biochem Lab, F-51687 Reims, France; URCA, CNRS, Unite Matrice Extracellulaire & Regulat Cellulair, F-51687 Reims, France; URCA, CNRS, Dept Dermatol, F-51687 Reims, France	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Rothhut, B (corresponding author), URCA, CNRS, UMR 6198, Biochem Lab, Moulin Housse, F-51687 Reims, France.	bernard.rothhut@univ-reims.fr	MARTINY, Laurent/ABI-5531-2020	Rothhut, Bernard/0000-0001-6467-8134				Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003; Belfiore A, 1997, J CLIN ENDOCR METAB, V82, P2322, DOI 10.1210/jc.82.7.2322; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Castle VP, 1997, LAB INVEST, V77, P51; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; Eccles N, 1996, MOL CELL ENDOCRINOL, V117, P247, DOI 10.1016/0303-7207(95)03757-8; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Gutierrez LS, 2003, CARCINOGENESIS, V24, P199, DOI 10.1093/carcin/24.2.199; Heckert LL, 2000, MOL ENDOCRINOL, V14, P1836, DOI 10.1210/me.14.11.1836; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; Hsu SC, 1996, CANCER RES, V56, P5684; HUGO C, 1995, KIDNEY INT, V48, P1846, DOI 10.1038/ki.1995.483; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kim SA, 2001, MOL CELL BIOCHEM, V216, P21, DOI 10.1023/A:1011022822077; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORANDI V, 1994, J CELL PHYSIOL, V160, P367, DOI 10.1002/jcp.1041600218; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scarpino S, 2005, J PATHOL, V205, P50, DOI 10.1002/path.1675; Scarpino S, 1999, J PATHOL, V189, P570; SCHWARTEWALDHOF.I, 2000, P NATL ACAD SCI USA, V97, P9264; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Soula-Rothhut M, 2005, EXP CELL RES, V304, P187, DOI 10.1016/j.yexcr.2004.10.026; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wang SX, 2004, J BIOL CHEM, V279, P34311, DOI 10.1074/jbc.M401629200; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	56	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15490	15497		10.1074/jbc.M610586200	http://dx.doi.org/10.1074/jbc.M610586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409099	hybrid			2022-12-25	WOS:000246589600025
J	Poncelet, AC; Schnaper, HW; Tan, RY; Liu, YH; Runyan, CE				Poncelet, Anne-Christine; Schnaper, H. William; Tan, Ruoyun; Liu, Youhua; Runyan, Constance E.			Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; MESENCHYMAL TRANSITION; RENAL FIBROSIS; MYOFIBROBLAST TRANSITION; SIGNALING PATHWAY; UBIQUITIN LIGASE; I RECEPTOR; EXPRESSION; MECHANISMS	Signaling by transforming growth factor-beta (TGF-beta),a regulator of several biological processes, including renal fibrosis, is mediated, in part, by the Smad proteins. Tight control of Smad level and activity is critical for proper TGF-beta biological functions. Here, we have investigated the mechanisms involved in regulating Smad3 expression. In human glomerular mesangial cells, Smad3 protein levels were specifically reduced by 24 h of TGF-beta 1 treatment, whereas Smad2 and Smad4 levels were not. TGF-beta 1 increased endogenous Smad3 ubiquitination, and proteasome inhibitor treatment blocked TGF-beta 1-mediated Smad3 down-regulation resulting in accumulation of ubiquitinated Smad3. These data support the concept that Smad3 down-regulation occurs via degradation by the ubiquitin/proteasome machinery. However, changes in Smad3 protein levels were also paralleled by changes in Smad3 mRNA expression. TGF-beta 1 did not decrease Smad3 mRNA stability, but it significantly inhibited Smad3 promoter activity. In renal tubular epithelial cells, decreased Smad3 levels were observed only after exposure to TGF-beta 1 for longer time periods (5-7 days) that paralleled epithelial-to-mesenchymal transition, as determined by increased expression of smooth muscle alpha-actin and decreased expression of E-cadherin. Decline in Smad3 expression also occurred in kidneys after unilateral ureteral obstruction, a model of tubulointerstitial fibrosis associated with TGF-beta up-regulation and epithelial-to-mesenchymal transition. Our data show for the first time that TGF-beta 1 modulates the expression of a receptor-activated Smad at both the protein and transcriptional level. Smad3 down-regulation could represent a feedback loop controlling TGF-beta signaling in a cell phenotype-specific manner.	Univ Washington, Sch Med, Dept Med, UW Med S Lake Union, Seattle, WA 98109 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	University of Washington; University of Washington Seattle; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Poncelet, AC (corresponding author), Univ Washington, Sch Med, Dept Med, UW Med S Lake Union, 815 Mercer St,Box 358050,Rm 254, Seattle, WA 98109 USA.	annechr@u.washington.edu		Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK064074, R01DK061408, R21DK053576, R01DK049362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049362, R01 DK49362, R01 DK061408, K01 DK64074] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Inazaki K, 2004, KIDNEY INT, V66, P597, DOI 10.1111/j.1523-1755.2004.00779.x; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kelley TJ, 2001, AM J RESP CELL MOL, V25, P732, DOI 10.1165/ajrcmb.25.6.4574; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0	49	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15534	15540		10.1074/jbc.M701991200	http://dx.doi.org/10.1074/jbc.M701991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400544	hybrid			2022-12-25	WOS:000246589600030
J	Rottner, M; Kunzelmann, C; Mergey, M; Freyssinet, JM; Martinez, MC				Rottner, Mathilde; Kunzelmann, Corinne; Mergey, Martine; Freyssinet, Jean-Marie; Martinez, Maria Carmen			Exaggerated apoptosis and NF-kappa B activation in pancreatic and tracheal cystic fibrosis cells	FASEB JOURNAL			English	Article						CFTR; phosphatidylserine; inflammation; cytokines	TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; PHOSPHATIDYLSERINE; INFLAMMATION; EXPRESSION; SECRETION; INFANTS; DISEASE; FLUID; FAS	The pathophysiologic mechanisms causing inflammation in cystic fibrosis (CF) remain obscure. The effects of proapoptotic agents on pancreatic and tracheal cell lines expressing wild-type CFTR (PANC-1 and NT-1, respectively) or the homozygous CFTR Delta F508 mutation (CFPAC-1 and CFT-2, respectively) were assessed. An increased susceptibility to apoptosis was observed in CFPAC-1 and CFT-2 cells. Apoptosis was reduced by treatment with a pan-caspase inhibitor and by incubation at 27 degrees C, allowing recruitment of CFTR Delta F508 at the plasma membrane. Inhibition of CFTR function in wild-type cells induced an increase of apoptosis. Apoptosis in CFPAC-1, but not in CFT- 2 cells, was associated with overexpression of the proinflammatory mediators interleukin-6 and interleukin-8. In CF cells, apoptosis was linked to NF-kappa B pathway activation. Conditioned medium from actinomycin D-treated CFPAC-1 cells produced an increase in apoptosis of wild-type cells, suggesting that proinflammatory mediators secreted by mutant cells promote apoptosis. This was confirmed through the induction of apoptosis in wild-type cells by exogenous interleukin-6 and interleukin-8. These results suggest that CFTR Delta F508 mutation, apoptosis, and activation of the NF-kappa B pathway contribute to the self-perpetuating inflammatory cycle, at least in pancreatic cells, and provide evidence that excessive apoptosis may account for the exaggerated proinflammatory response observed in CF patients.-Rottner, R., Kunzelmann, C., Mergey, M., Freyssinet, J- M., Marti nez, M. C. Exaggerated apoptosis and NF-kappa B activation in pancreatic and tracheal cystic fibrosis cells.	CNRS, INSERM U 771, UMR 6214, Fac Med, F-49045 Angers, France; INSERM, U770, F-94275 Le Kremlin Bicetre, France; Univ Paris Sud, Hop Bicetre, Fac Med, F-94275 Le Kremlin Bicetre, France; Univ Strasbourg, Fac Med, Inst Hematol & Immunol, Strasbourg, France; INSERM, U680, Paris, France; Univ Paris 06, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Martinez, MC (corresponding author), CNRS, INSERM U 771, UMR 6214, Fac Med, Rue Haute Reculee, F-49045 Angers, France.	carmen.martinez@univ-angers.fr	Freyssinet, Jean-Marie/G-2719-2013					Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Amsellem C, 2002, RESP MED, V96, P244, DOI 10.1053/rmed.2001.1257; ASHCROFT FM, 2000, ION CHANNELS DIS, V12, P211; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Becker MN, 2004, AM J RESP CRIT CARE, V169, P645, DOI 10.1164/rccm.200207-765OC; Cannon CL, 2003, AM J RESP CELL MOL, V29, P188, DOI 10.1165/rcmb.4898; Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006; Dakin CJ, 2002, AM J RESP CRIT CARE, V165, P904, DOI 10.1164/ajrccm.165.7.2010139; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Durieu I, 1999, THORAX, V54, P1093, DOI 10.1136/thx.54.12.1093; Gidon-Jeangirard C, 1999, BIOCHEM BIOPH RES CO, V265, P709, DOI 10.1006/bbrc.1999.1752; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; LEMNAOUAR M, 1993, EUR J CLIN INVEST, V23, P151, DOI 10.1111/j.1365-2362.1993.tb00754.x; Lim M, 2001, Paediatr Respir Rev, V2, P159, DOI 10.1053/prrv.2000.0124; Maiuri L, 1997, FEBS LETT, V408, P225, DOI 10.1016/S0014-5793(97)00347-5; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Puchelle Edith, 2002, Paediatr Respir Rev, V3, P115, DOI 10.1016/S1526-0550(02)00005-7; Ratjen F, 2002, THORAX, V57, P930, DOI 10.1136/thorax.57.11.930; Schwiebert LM, 1999, AM J PHYSIOL-CELL PH, V276, pC700, DOI 10.1152/ajpcell.1999.276.3.C700; TAYLOR CJ, 2002, PAEDIATR RESPIR REV, V1, P77; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Vilela RM, 2006, INT IMMUNOPHARMACOL, V6, P1651, DOI 10.1016/j.intimp.2006.06.012; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; Zaman MM, 2004, CLIN DIAGN LAB IMMUN, V11, P819, DOI 10.1128/CDLI.11.5.819-824.2004; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	28	45	45	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2939	2948		10.1096/fj.06-7614com	http://dx.doi.org/10.1096/fj.06-7614com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442732				2022-12-25	WOS:000249237500034
J	Hashimoto, T; Hussien, R; Oommen, S; Gohil, K; Brooks, GA				Hashimoto, Takeshi; Hussien, Rajaa; Oommen, Saji; Gohil, Kishorchandra; Brooks, George A.			Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis	FASEB JOURNAL			English	Article						muscle; lactate shuttle; lactate oxidation complex; exercise; cell signaling	HUMAN SKELETAL-MUSCLE; MONOCARBOXYLATE TRANSPORTER; GENE-EXPRESSION; EXERCISE; PGC-1-ALPHA; MEMBRANE; CD147; LDH; INCREASES; OXIDATION	We hypothesized that in addition to serving as a fuel source and gluconeogenic precursor, lactate anion (La-) is a signaling molecule. Therefore, we screened genome-wide responses of L6 cells to elevated ( 10 and 20 mM) sodium-La- added to buffered, high-glucose media. Lactate increased reactive oxygen species (ROS) production and up-regulated 673 genes, many known to be responsive to ROS and Ca2+ . The induction of genes encoding for components of the mitochondrial lactate oxidation complex was confirmed by independent methods (PCR and EMSA). Specifically, lactate increased monocarboxylate transporter-1 (MCT1) mRNA and protein expression within 1 h and cytochrome c oxidase ( COX) mRNA and protein expression in 6 h. Increases in COX coincided with increases in peroxisome proliferator activated-receptor gamma coactivator-1 alpha (PGC1 alpha) expression and the DNA binding activity of nuclear respiratory factor (NRF)-2. We conclude that the lactate signaling cascade involves ROS production and converges on transcription factors affecting mitochondrial biogenesis.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA	University of California System; University of California Berkeley; University of California System; University of California Davis	Brooks, GA (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, 5101 VLSB, Berkeley, CA 94720 USA.	gbrooks@berkeley.edu		Brooks, George A./0000-0002-1389-1629	NIAMS NIH HHS [R01 AR050459] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050459] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker SK, 1998, J APPL PHYSIOL, V84, P987, DOI 10.1152/jappl.1998.84.3.987; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; BLAKE DA, 1989, ANAL BIOCHEM, V177, P156, DOI 10.1016/0003-2697(89)90031-6; Bonen A, 2000, AM J PHYSIOL-ENDOC M, V279, pE1131, DOI 10.1152/ajpendo.2000.279.5.E1131; Brooks G. A., 2003, EXERCISE PHYSL PEOPL, P322; Brooks GA, 1998, COMP BIOCHEM PHYS B, V120, P89, DOI 10.1016/S0305-0491(98)00025-X; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Brooks GA, 1999, P NATL ACAD SCI USA, V96, P1129, DOI 10.1073/pnas.96.3.1129; Brooks GA, 1999, J APPL PHYSIOL, V87, P1713, DOI 10.1152/jappl.1999.87.5.1713; Butz CE, 2004, J APPL PHYSIOL, V97, P1059, DOI 10.1152/japplphysiol.00009.2004; Chabi B, 2005, MED SCI SPORT EXER, V37, P2102, DOI 10.1249/01.mss.0000177426.68149.83; CHEETHAM ME, 1986, J APPL PHYSIOL, V61, P54, DOI 10.1152/jappl.1986.61.1.54; Coles L, 2004, J PHYSIOL-LONDON, V561, P253, DOI 10.1113/jphysiol.2004.073478; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; Dubouchaud H, 2000, AM J PHYSIOL-ENDOC M, V278, pE571, DOI 10.1152/ajpendo.2000.278.4.E571; Fasanaro P, 2006, FASEB J, V20, P1242, DOI 10.1096/fj.05-4695fje; Fletcher WM, 1907, J PHYSIOL-LONDON, V35, P247; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Garcia-Roves PM, 2006, AM J PHYSIOL-ENDOC M, V290, pE1172, DOI 10.1152/ajpendo.00633.2005; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hashimoto T, 2005, J PHYSIOL-LONDON, V567, P121, DOI 10.1113/jphysiol.2005.087411; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Hill AV, 1920, J PHYSIOL-LONDON, V54, P84; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Koulmann N, 2006, PFLUG ARCH EUR J PHY, V452, P125, DOI 10.1007/s00424-005-0030-9; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; McClelland GB, 2003, BIOCHEM BIOPH RES CO, V304, P130, DOI 10.1016/S0006-291X(03)00550-3; McClelland GB, 2002, J APPL PHYSIOL, V92, P1573, DOI 10.1152/japplphysiol.01069.2001; Miller BF, 2005, J APPL PHYSIOL, V98, P856, DOI 10.1152/japplphysiol.00753.2004; MOHAZZAB HKM, 1999, AM J PHYSIOL, V276, pH235; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Moyes CD, 2005, J EXP BIOL, V208, P1601, DOI 10.1242/jeb.01502; Nethery D, 2000, J APPL PHYSIOL, V89, P72, DOI 10.1152/jappl.2000.89.1.72; OHKUWA T, 1984, EUR J APPL PHYSIOL O, V53, P213, DOI 10.1007/BF00776592; Ojuka EO, 2004, P NUTR SOC, V63, P275, DOI 10.1079/PNS2004339; Ongwijitwat S, 2005, GENE, V360, P65, DOI 10.1016/j.gene.2005.06.015; Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1305, DOI 10.1167/iovs.02-0552; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Silveira LR, 2006, BBA-MOL CELL RES, V1763, P969, DOI 10.1016/j.bbamcr.2006.06.010; Smith MA, 2006, RESP PHYSIOL NEUROBI, V151, P229, DOI 10.1016/j.resp.2005.12.011; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; TAKIZAWA M, 2006, TOXICOL IN VITRO, DOI DOI 10.1016/J.TIV.2006.1009.1003; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wright DC, 2007, J BIOL CHEM, V282, P194, DOI 10.1074/jbc.M606116200	53	267	278	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2602	2612		10.1096/fj.07-8174com	http://dx.doi.org/10.1096/fj.07-8174com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17395833				2022-12-25	WOS:000248454400033
J	Kim, YM; Ramirez, JA; Mick, JE; Giebler, HA; Yan, JP; Nyborg, JK				Kim, Young-Mi; Ramirez, Julita A.; Mick, Jeanne E.; Giebler, Holli A.; Yan, Jian-Ping; Nyborg, Jennifer K.			Molecular characterization of the tax-containing HTLV-1 enhancer complex reveals a prominent role for CREB phosphorylation in tax transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATOR TAX; BINDING-PROTEIN CREB; TYPE-1 TAX; KIX DOMAIN; COACTIVATOR CBP; T-LYMPHOCYTES; KINASE-A; DNA; RECRUITMENT	Transcriptional activation of human T-cell leukemia virus type 1 (HTLV-1) is mediated by the viral oncoprotein Tax, which utilizes cellular transcriptional machinery to perform this function. The viral promoter carries three cyclic AMP-response elements (CREs), which are recognized by the cellular transcription factor cAMP-response element-binding protein (CREB). Tax binds to GC-rich sequences that immediately flank the CREs. The coactivator CREB-binding protein (CBP)/p300 binds to this promoter-bound ternary complex, which promotes the initiation of HTLV-1 transcription. Protein kinase A phosphorylation of CREB at serine 133 facilitates transcription from cellular CREs by recruiting CBP/p300 via its KIX domain. However, it remains controversial whether CREB phosphorylation plays a role in Tax transactivation. In this study, we biochemically characterized the quaternary complex formed by Tax, CREB, KIX, and the viral CRE by examining the individual molecular interactions that contribute to Tax stabilization in the complex. Our data show KIX, Ser(133)-phosphorylated CREB, and vCRE DNA are all required for stable Tax incorporation into the complex in vitro. Consonant with a fundamental role for CREB phosphorylation in Tax recruitment to the complex, we found that CREB is highly phosphorylated in a panel of HTLV-1-infected human T-cell lines. Significantly, we show that Tax is directly responsible for promoting elevated levels of CREB phosphorylation. Together, these data support a model in which Tax promotes CREB phosphorylation in vivo to ensure availability for Tax transactivation. Because pCREB has been implicated in leukemogenesis, enhancement of CREB phosphorylation by the virus may play a role in the etiology of adult T-cell leukemia.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Jennifer.Nyborg@ColoState.edu			NCI NIH HHS [R01 CA055035, CA55035-S1, R01 CA055035-14, CA55035, R01 CA055035-14S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA055035, R01CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2006, J BIOL CHEM, V281, P13075, DOI 10.1074/jbc.M512193200; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Shankar DB, 2004, LEUKEMIA LYMPHOMA, V45, P265, DOI 10.1080/1042819031000151095; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; Trevisan R, 2006, EXP CELL RES, V312, P1390, DOI 10.1016/j.yexcr.2006.01.009; Trevisan R, 2004, EXP CELL RES, V299, P57, DOI 10.1016/j.yexcr.2004.05.024; Turgeman H, 1998, FEBS LETT, V428, P183, DOI 10.1016/S0014-5793(98)00513-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Vendel AC, 2003, BIOCHEMISTRY-US, V42, P12481, DOI 10.1021/bi0353023; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	36	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18750	18757		10.1074/jbc.M700391200	http://dx.doi.org/10.1074/jbc.M700391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17449469	hybrid			2022-12-25	WOS:000247475300013
J	Dey, S; Hu, ZQ; Xu, XL; Sacchettini, JC; Grant, GA				Dey, Sanghamitra; Hu, Zhiqin; Xu, Xiao Lan; Sacchettini, James C.; Grant, Gregory A.			The effect of hinge mutations on effector binding and domain rotation in Escherichia coli D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END PRODUCT INHIBITION; MODULATED ALLOSTERIC REGULATION; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE BIOSYNTHESIS; HYBRID TETRAMERS; SERA GENE; MECHANISM; COOPERATIVITY; RESIDUES; PURIFICATION	D-3-Phosphoglycerate dehydrogenase (EC 1.1.1.95) from Escherichia coli contains two Gly-Gly sequences that have been shown previously to have the characteristics of hinge regions. One of these, Gly(336)-Gly(337), is found in the loop between the substrate binding domain and the regulatory domain. Changing these glycine residues to valine affected the sensitivity of the enzyme to inhibition by L-serine but not the extent of inhibition. The decrease in sensitivity was caused primarily by a decrease in the affinity of the enzyme for L-serine. These mutations also affected the domain rotation of the subunits in response to L-serine binding. A major conclusion of this study was that it defines a minimal limit on the necessary conformational changes leading to inhibition of enzyme activity. That is, some of the conformational differences seen in the native enzyme upon L-serine binding are not critical for inhibition, whereas others are maintained and may play important roles in inhibition and cooperativity. The structure of G336V demonstrates that the minimal effect of L-serine binding leading to inhibition of enzyme activity requires a domain rotation of approximately only 6 in just two of the four subunits of the enzyme that are oriented diagonally across from each other in the tetramer. Moreover the structures show that both pairs of Asn(190) to Asn(190) hydrogen bonds across the subunit interfaces are necessary for activity. These observations are consistent with the half-the-sites activity, flip-flop mechanism proposed for this and other similar enzymes and suggest that the Asn(190) hydrogen bonds may function in the conformational transition between alternate half-the-site active forms of the enzyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Washington University (WUSTL); Washington University (WUSTL); Texas A&M University System; Texas A&M University College Station	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103, St Louis, MO 63110 USA.	ggrant@wustl.edu	Dey, Sanghamitra/AAV-7921-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ELL JE, 1988, PROTEINS ENZYMES, P465; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 2005, BIOCHEMISTRY-US, V44, P16844, DOI 10.1021/bi051681j; Grant GA, 2004, METHOD ENZYMOL, V380, P106; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2000, ARCH BIOCHEM BIOPHYS, V375, P171, DOI 10.1006/abbi.1999.1652; Grant GA, 2004, J BIOL CHEM, V279, P13452, DOI 10.1074/jbc.M313593200; Grant GA, 2003, J BIOL CHEM, V278, P18170, DOI 10.1074/jbc.M213050200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; Grant GA, 2006, J BIOL CHEM, V281, P33825, DOI 10.1074/jbc.R600024200; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; Leslie A.G.W., 1992, JT CCP4 ESF EAMCB NE, V26; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILO J, 1994, J BIOL CHEM, V269, P27840; Philo JS, 2000, METHOD ENZYMOL, V321, P100; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; ROSENBLO.J, 1968, J BIOL CHEM, V243, P2099; Sauter NK, 2004, J APPL CRYSTALLOGR, V37, P399, DOI 10.1107/S0021889804005874; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUDSON M, 1995, FORBES MEDIA CRITIC, V2, P76; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; Thompson JR, 2005, BIOCHEMISTRY-US, V44, P5763, DOI 10.1021/bi047944b; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996; [No title captured]	41	13	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18418	18426		10.1074/jbc.M701174200	http://dx.doi.org/10.1074/jbc.M701174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17459882	hybrid			2022-12-25	WOS:000247302000048
J	Dul, BE; Walworth, NC				Dul, Barbara E.; Walworth, Nancy C.			The plant homeodomain fingers of fission yeast Msc1 exhibit E3 ubiquitin ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; DNA-REPAIR; CONJUGATING ENZYME; PHD FINGER; FUNCTIONAL HOMOLOG; HISTONE H3K4ME3; PROTEIN; GENE; BINDING; RAD6	The DNA damage checkpoint pathway governs how cells regulate cell cycle progression in response to DNA damage. A screen for suppressors of a fission yeast chk1 mutant defective in the checkpoint pathway identified a novel Schizosaccharomyces pombe protein, Msc1. Msc1 contains 3 plant homeodomain (PHD) finger motifs, characteristically defined by a C4HC3 consensus similar to RING finger domains. PHD finger domains in viral proteins and in the cellular protein kinase MEKK1 (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1) have been implicated as ubiquitin E3 protein ligases that affect protein stability. The close structural relationship of PHD fingers to RING fingers suggests that other PHD domain-containing proteins might share this activity. We show that each of the three PHD fingers of Msc1 can act as ubiquitin E3 ligases, reporting for the first time that PHD fingers from a nuclear protein exhibit E3 ubiquitin ligase activity. The function of the PHD fingers of Msc1 is needed to rescue the DNA damage sensitivity of a chk1 Delta strain. Msc1 co-precipitates Rhp6, the S. pombe homologue of the human ubiquitin-conjugating enzyme Ubc2. Strikingly, deletion of msc1 confers complete suppression of the slow growth phenotype, UV and hydroxyurea sensitivities of an rhp6 deletion strain and restores deficient histone H3 methylation observed in the rhp6 Delta mutant. We speculate that the target of the E3 ubiquitin ligase activity of Msc1 is likely to be a chromatin-associated protein.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Joint Grad Program Cellular & Mol Pharmacol, Newark, NJ 07103 USA; Rutgers State Univ, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Walworth, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	walworna@umdnj.edu		Walworth, Nancy/0000-0001-5940-8236	NIGMS NIH HHS [R01 GM53194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Bottomley MJ, 2005, J BIOL CHEM, V280, P11505, DOI 10.1074/jbc.M413959200; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Catteau A, 2004, INT J ONCOL, V25, P5; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Edmondson DG, 1998, METHODS, V15, P355, DOI 10.1006/meth.1998.0639; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; LEGGETT DS, 1995, DNA CELL BIOL, V14, P883, DOI 10.1089/dna.1995.14.883; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liu HY, 2002, J BIOL CHEM, V277, P2637, DOI 10.1074/jbc.M109016200; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tan K, 2003, J BIOL CHEM, V278, P20507, DOI 10.1074/jbc.M301994200; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Wang SW, 2002, J CELL SCI, V115, P587; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yonashiro R, 2006, EMBO J, V25, P3618, DOI 10.1038/sj.emboj.7601249	46	31	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18397	18406		10.1074/jbc.M700729200	http://dx.doi.org/10.1074/jbc.M700729200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17456468	hybrid			2022-12-25	WOS:000247302000046
J	Furuya, K; Ozaki, T; Hanamoto, T; Hosoda, M; Hayashi, S; Barker, PA; Takano, K; Matsumoto, M; Nakagawara, A				Furuya, Kazushige; Ozaki, Toshinori; Hanamoto, Takayuki; Hosoda, Mitsuchika; Hayashi, Syunji; Barker, Philip A.; Takano, Kunio; Matsumoto, Masahiko; Nakagawara, Akira			Stabilization of p73 by nuclear I kappa B kinase-alpha mediates cisplatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL-INDUCED APOPTOSIS; DEPENDENT GENE-EXPRESSION; ABL TYROSINE KINASE; DNA-DAMAGE; IKK-ALPHA; C-ABL; REGULATES P73; MICE LACKING; CELL-DEATH; SIGNALING PATHWAY	In response to DNA damage, p53 and its homolog p73 have a function antagonistic to NF-kappa B in deciding cell fate. Here, we show for the first time that p73, but not p53, is stabilized by physical interaction with nuclear I kappa B kinase (IKK)-alpha to enhance cisplatin (CDDP)-induced apoptosis. CDDP caused a significant increase in the amounts of nuclear IKK-alpha and p73 alpha in human osteosarcoma-derived U2OS cells. Ectopic expression of IKK-alpha prolonged the half-life of p73 by inhibiting its ubiquitination and thereby enhancing its transactivation and pro-apoptotic activities. Consistent with these results, small interfering RNA-mediated knockdown of endogenous IKK-alpha inhibited the CDDP-mediated accumulation of p73 alpha. The kinase-deficient mutant form of IKK-alpha interacted with p73 alpha, but failed to stabilize it. Furthermore, CDDP-mediated accumulation of endogenous p73 alpha was not detected in mouse embryonic fibroblasts (MEFs) prepared from IKK-alpha-deficient mice, and CDDP sensitivity was significantly decreased in IKK-alpha-deficient MEFs compared with wild-type MEFs. Thus, our results strongly suggest that the nuclear IKK-alpha-mediated accumulation of p73 alpha is one of the novel molecular mechanisms to induce apoptotic cell death in response to CDDP, which may be particularly important in killing tumor cells with p53 mutation.	Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Yamanashi, Sch Med, Dept Surg 2, Yamaguchi 4093898, Japan; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Yamanashi; McGill University	Nakagawara, A (corresponding author), Canc Ctr Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Cusack JC, 2001, CANCER RES, V61, P3535; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Huang Y, 2000, CANCER RES, V60, P4426; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura Y, 2007, BIOCHEM BIOPH RES CO, V354, P892, DOI 10.1016/j.bbrc.2007.01.057; NICKERSON JA, 1992, J CELL BIOL, V116, P977, DOI 10.1083/jcb.116.4.977; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Stiewe T, 2002, CANCER RES, V62, P3598; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU HY, 1994, J BIOL CHEM, V269, P20067; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	67	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18365	18378		10.1074/jbc.M610522200	http://dx.doi.org/10.1074/jbc.M610522200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452332	hybrid			2022-12-25	WOS:000247302000043
J	Llarrull, LI; Fabiane, SM; Kowalski, JM; Bennett, B; Sutton, BJ; Vila, AJ				Llarrull, Leticia I.; Fabiane, Stella M.; Kowalski, Jason M.; Bennett, Brian; Sutton, Brian J.; Vila, Alejandro J.			Asp-120 locates Zn2 for optimal metallo-ss-lactamase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC BETA-LACTAMASE; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; SPECTROSCOPIC CHARACTERIZATION; STRUCTURAL DETERMINANTS; ANTIBIOTIC-RESISTANCE; CATALYTIC MECHANISM; SUBSTRATE-BINDING; SITE	Metallo-beta-lactamases are zinc-dependent hydrolases that inactivate beta-lactam antibiotics, rendering bacteria resistant to them. Asp-120 is fully conserved in all metallo-beta-lactamases and is central to catalysis. Several roles have been proposed for Asp-120, but so far there is no agreed consensus. We generated four site-specifically substituted variants of the enzyme BcII from Bacillus cereus as follows: D120N, D120E, D120Q, and D120S. Replacement of Asp-120 by other residues with very different metal ligating capabilities severely impairs the lactamase activity without abolishing metal binding to the mutated site. A kinetic study of these mutants indicates that Asp-120 is not the proton donor, nor does it play an essential role in nucleophilic activation. Spectroscopic and crystallographic analysis of D120S BcII, the least active mutant bearing the weakest metal ligand in the series, reveals that this enzyme is able to accommodate a dinuclear center and that perturbations in the active site are limited to the Zn2 site. It is proposed that the role of Asp-120 is to act as a strong Zn2 ligand, locating this ion optimally for substrate binding, stabilization of the development of a partial negative charge in the beta-lactam nitrogen, and protonation of this atom by a zinc-bound water molecule.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Celular, Dept Quim Biol Area Biofis, RA-2000 Rosario, Argentina; Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Med Coll Wisconsin, Nat Biomed EPR Ctr, Dept Biophys, Milwaukee, WI 53226 USA	National University of Rosario; University of London; King's College London; Medical College of Wisconsin	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Celular, Dept Quim Biol Area Biofis, Suipacha 531,S2002LRK, RA-2000 Rosario, Argentina.	vila@ibr.gov.ar		Vila, Alejandro/0000-0002-7978-3233	NCRR NIH HHS [RR001980] Funding Source: Medline; NIAID NIH HHS [AI056231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056231] Funding Source: NIH RePORTER; Medical Research Council [G0400503B] Funding Source: researchfish	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARIK S, 1996, SITE DIRECTED MUTAGE, P203; BENNETT B, 1994, EUR J BIOCHEM, V225, P321, DOI 10.1111/j.1432-1033.1994.00321.x; Bienvenue DL, 2003, BIOCHEMISTRY-US, V42, P10756, DOI 10.1021/bi034845+; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Breece RM, 2005, J BIOL CHEM, V280, P11074, DOI 10.1074/jbc.M412582200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; CRICCO JA, 2002, THESIS U ROSARIO ROS; Crowder MW, 2006, ACCOUNTS CHEM RES, V39, P721, DOI 10.1021/ar0400241; Dal Peraro M, 2004, J AM CHEM SOC, V126, P12661, DOI 10.1021/ja048071b; Dal Peraro M, 2003, INORG CHEM, V42, P4245, DOI 10.1021/ic026059j; Dal Peraro M, 2002, J BIOL INORG CHEM, V7, P704, DOI 10.1007/s00775-002-0346-2; Dal Peraro M, 2007, J AM CHEM SOC, V129, P2808, DOI 10.1021/ja0657556; Davies AM, 2005, BIOCHEMISTRY-US, V44, P4841, DOI 10.1021/bi047709t; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Garau G, 2005, ANTIMICROB AGENTS CH, V49, P2778, DOI 10.1128/AAC.49.7.2778-2784.2005; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; LLARRULL LI, 2001, BIOCELL, V25, P62; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Murphy TA, 2006, J MOL BIOL, V357, P890, DOI 10.1016/j.jmb.2006.01.003; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Park H, 2005, J AM CHEM SOC, V127, P4232, DOI 10.1021/ja042607b; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Prosperi-Meys C, 2002, CELL MOL LIFE SCI, V59, P2136, DOI 10.1007/s000180200013; Rasia RM, 2004, J BIOL CHEM, V279, P26046, DOI 10.1074/jbc.M311373200; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENY D, 2002, BIOCHEM J, V363, P687; Spencer J, 2005, J AM CHEM SOC, V127, P14439, DOI 10.1021/ja0536062; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sulton D, 2005, J BIOL CHEM, V280, P35528, DOI 10.1074/jbc.M501251200; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Xu DG, 2006, J BIOL CHEM, V281, P8740, DOI 10.1074/jbc.M512517200; Yamaguchi Y, 2005, J BIOL CHEM, V280, P20824, DOI 10.1074/jbc.M414314200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Yang YJ, 1999, J BIOL CHEM, V274, P15706, DOI 10.1074/jbc.274.22.15706	59	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18276	18285		10.1074/jbc.M700742200	http://dx.doi.org/10.1074/jbc.M700742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17426028	hybrid, Green Submitted			2022-12-25	WOS:000247302000034
J	Lejard, V; Brideau, G; Blais, F; Salingcarnboriboon, R; Wagner, G; Roehrl, MHA; Noda, M; Duprez, D; Houillier, P; Rossert, J				Lejard, Veronique; Brideau, Gaelle; Blais, Frederic; Salingcarnboriboon, Ruchanee; Wagner, Gerhard; Roehrl, Michael H. A.; Noda, Masaki; Duprez, Delphine; Houillier, Pascal; Rossert, Jerome			Scleraxis and NFATc regulate the expression of the pro-alpha 1(I) collagen gene in tendon fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSGENIC MICE; TRANSCRIPTION FACTOR; CONNECTIVE-TISSUE; CARDIAC VALVES; REPORTER GENES; BONE-FORMATION; NF-ATC; CELLS; PROMOTER	The combinatorial action of separate cis-acting elements controls the cell-specific expression of type I collagen genes. In particular, we have shown that two short elements located between -3.2 and -2.3 kb and named TSE1 and TSE2 are needed for expression of the mouse COL1a1 gene in tendon fibroblasts. In this study, we analyzed the trans-acting factors binding to TSE1 and TSE2. Gel shift experiments showed that scleraxis ( SCX), which is a basic helix-loop-helix transcription factor that is expressed selectively in tendon fibroblasts, binds TSE2, preferentially as a SCX/E47 heterodimer. In transfection experiments, overexpression of SCX and E47 strongly enhanced the activity of reporter constructs harboring either four copies of TSE2 cloned upstream of the COL1a1 minimal promoter or a 3.2-kb segment of the COL1a1 proximal promoter. Analysis of TSE1 showed that it contains a consensus binding site for NFATc transcription factors. This led us to show that the NFATc4 gene is expressed in tendons of developing mouse limbs and in TT-D6 cells, a cell line that has characteristics of tendon fibroblasts. In gel shift assays, TSE1 bound NFATc proteins present in nuclear extracts from TT-D6 cells. In transfection experiments, overexpression of NFATc transactivated a reporter construct harboring four copies of TSE1 cloned upstream of the COL1a1 minimal promoter. By contrast, inhibition of the nuclear translocation of NFATc proteins in TT-D6 cells strongly inhibited the expression of the COL1a1 gene. Taken together, these results suggest that SCX and NFATc4 cooperate to activate the COL1a1 gene specifically in tendon fibroblasts.	Inst Biomed Cordeliers, INSERM U652, F-75006 Paris, France; Univ Paris 06, F-75005 Paris, France; Univ Paris 05, F-75006 Paris, France; CNRS, UMR 7622, F-75005 Paris, France; Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Tokyo 1010062, Japan; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Tokyo Medical & Dental University (TMDU); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rossert, J (corresponding author), Inst Biomed Cordeliers, INSERM U652, 15 Rue Ecole Med, F-75006 Paris, France.	jerome.rossert@egp.aphp.fr	Ampornaramveth, Ruchanee Salingcarnboriboon/U-1638-2019; Houillier, Pascal/AAD-4903-2019; Roehrl, Michael/AAU-8506-2020; Duprez, Delphine/K-1856-2017	Houillier, Pascal/0000-0003-4953-6917; Roehrl, Michael/0000-0003-4892-1098; Duprez, Delphine/0000-0003-0248-7417				Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Bonnin MA, 2005, MECH DEVELOP, V122, P573, DOI 10.1016/j.mod.2004.11.005; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Carlberg Alyssa L., 2000, Molecular Cell Biology Research Communications, V3, P82, DOI 10.1006/mcbr.2000.0195; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edom-Vovard F, 2004, DEV DYNAM, V229, P449, DOI 10.1002/dvdy.10481; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hoffmann A, 2006, J CLIN INVEST, V116, P940, DOI 10.1172/JCI22689; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Lange AW, 2006, DEV BIOL, V292, P407, DOI 10.1016/j.ydbio.2006.01.017; Lincoln J, 2006, DEV BIOL, V294, P292, DOI 10.1016/j.ydbio.2006.03.027; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu Y, 1997, J BIOL CHEM, V272, P29880, DOI 10.1074/jbc.272.47.29880; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; OLIVER G, 1995, DEVELOPMENT, V121, P693; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Shukunami C, 2005, BIOCHEM BIOPH RES CO, V333, P299, DOI 10.1016/j.bbrc.2005.05.133; Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036; Terraz C, 2002, J BIOL CHEM, V277, P19019, DOI 10.1074/jbc.M200125200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974	41	179	185	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17665	17675		10.1074/jbc.M610113200	http://dx.doi.org/10.1074/jbc.M610113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430895	hybrid			2022-12-25	WOS:000247084500039
J	Nishimura, H; Myles, DG; Primakoff, P				Nishimura, Hitoshi; Myles, Diana G.; Primakoff, Paul			Identification of an ADAM2-ADAM3 complex on the surface of mouse testicular germ cells and cauda epididymal sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; FERTILIN-ALPHA; MICE; EXPRESSION; PROTEINS; ADAM3; LOCALIZATION; PENETRATION; CYRITESTIN; MEMBRANE	Male mice lacking ADAM2 (fertilin beta) or ADAM3 (cyritestin) are infertile; cauda epididymal sperm (mature sperm) from these mutant mice cannot bind to the egg zona pellucida. ADAM3 is barely present in Adam2-null sperm, despite normal levels of this protein in Adam2-null testicular germ cells (TGCs; sperm precursor cells). Here, we have explored the molecular basis for the loss of ADAM3 in Adam2-null TGCs to clarify the biosynthetic and functional linkage of ADAM2 and ADAM3. A small portion of total ADAM3 was found present on the surface of wild-type and Adam2(-/-) TGCs at similar levels. In the Adam2-null TGCs, however, surface-localized ADAM3 exhibited an increased amount of an endoglycosidase H-resistant form that may be related to instability of ADAM3. Moreover, we found a complex between ADAM2 and ADAM3 on the surface of TGCs and sperm. The intracellular chaperone calnexin was a component of the testicular ADAM2-ADAM3 complex. Our findings suggest that the association with ADAM2 is a key element for stability of ADAM3 in epididymal sperm. The presence of the ADAM2-ADAM3 complex in sperm also suggests a potential role of ADAM2 with ADAM3 in sperm binding to the egg zona pellucida.	Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95618 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95618 USA	University of California System; University of California Davis; University of California System; University of California Davis	Primakoff, P (corresponding author), Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, 1 Shields Ave, Davis, CA 95618 USA.	pdprimakoff@ucdavis.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016580, R01HD016580] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16580] Funding Source: Medline; PHS HHS [U54-29125] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cho CH, 2000, DEV BIOL, V222, P289, DOI 10.1006/dbio.2000.9703; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Claassens OE, 1998, HUM REPROD, V13, P3139, DOI 10.1093/humrep/13.11.3139; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Kim E, 2006, J BIOL CHEM, V281, P5634, DOI 10.1074/jbc.M510558200; Kim E, 2005, P NATL ACAD SCI USA, V102, P18028, DOI 10.1073/pnas.0506825102; Kim E, 2004, J REPROD DEVELOP, V50, P571, DOI 10.1262/jrd.50.571; Kim E, 2003, BIOCHEM BIOPH RES CO, V304, P313, DOI 10.1016/S0006-291X(03)00588-6; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2002, GENE, V291, P67, DOI 10.1016/S0378-1119(02)00540-1; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Stein KK, 2006, PROTEOMICS, V6, P3533, DOI 10.1002/pmic.200500845; Stein KK, 2005, BIOL REPROD, V73, P1032, DOI 10.1095/biolreprod.105.040972; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Yamaguchi R, 2006, BIOL REPROD, V75, P760, DOI 10.1095/biolreprod.106.052977; Yanagimachi R., 1994, P189	26	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17900	17907		10.1074/jbc.M702268200	http://dx.doi.org/10.1074/jbc.M702268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17439939	hybrid			2022-12-25	WOS:000247084500063
J	Pandey, MK; Sandur, SK; Sung, B; Sethi, G; Kunnumakkara, AB; Aggarwal, BB				Pandey, Manoj K.; Sandur, Santosh K.; Sung, Bokyung; Sethi, Gautam; Kunnumakkara, Ajaikumar B.; Aggarwal, Bharat B.			Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappa B and NF-kappa B-regulated gene expression through direct inhibition of I kappa B alpha kinase beta on cysteine 179 residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RHUS-VERNICIFLUA STOKES; TRANSCRIPTIONAL REGULATION; CELL-GROWTH; CONSTITUTIVE ACTIVATION; PLANT POLYPHENOLS; INDUCE APOPTOSIS; TYROSINE KINASE; DOWN-REGULATION; TNF-ALPHA	Although butein (3,4,2', 4'-tetrahydroxychalcone) is known to exhibit anti-inflammatory, anti-cancer, and anti-fibrogenic activities, very little is known about its mechanism of action. Because numerous effects modulated by butein can be linked to interference with the NF-kappa B pathway, we investigated in detail the effect of this chalcone on NF-kappa B activity. As examined by DNA binding, we found that butein suppressed tumor necrosis factor (TNF)-induced NF-kappa B activation in a dose-and time-dependent manner; suppressed the NF-kappa B activation induced by various inflammatory agents and carcinogens; and inhibited the NF-kappa B reporter activity induced by TNFR1, TRADD, TRAF2, NIK, TAK1/ TAB1, and IKK-beta. We also found that butein blocked the phosphorylation and degradation of I kappa B alpha by inhibiting I kappa B alpha kinase (IKK) activation. We found the inactivation of IKK by butein was direct and involved cysteine residue 179. This correlated with the suppression of phosphorylation and the nuclear translocation of p65. In this study, butein also inhibited the expression of the NF-kappa B-regulated gene products involved in anti-apoptosis (IAP2, Bcl-2, and Bcl-xL), proliferation (cyclin D1 and c-Myc), and invasion (COX-2 and MMP-9). Suppression of these gene products correlated with enhancement of the apoptosis induced by TNF and chemotherapeutic agents; and inhibition of cytokine-induced cellular invasion. Overall, our results indicated that antitumor and anti-inflammatory activities previously assigned to butein may be mediated in part through the direct inhibition of IKK, leading to the suppression of the NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Kunnumakkara, Ajaikumar/AAH-5214-2019; Pandey, Manoj K/K-9706-2015; Sung, Bokyung/AAX-5697-2021; Sethi, Gautam/F-2372-2011; Kunnumakkara, Ajaikumar/H-8566-2012; Aggarwal, Bharat B/G-3388-2013	Kunnumakkara, Ajaikumar/0000-0001-9121-6816; Pandey, Manoj K/0000-0002-2767-2929; Sethi, Gautam/0000-0002-8677-8475; Kunnumakkara, Ajaikumar/0000-0001-9121-6816; 	NCI NIH HHS [CA016672-32, P01 CA91844, P50 CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097007, P01CA091844, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Ahmad R, 2006, J BIOL CHEM, V281, P35764, DOI 10.1074/jbc.M607160200; AIZU E, 1986, CARCINOGENESIS, V7, P1809, DOI 10.1093/carcin/7.11.1809; ALBINI A, 1987, CANCER RES, V47, P3239; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Cheng ZJ, 1998, BBA-LIPID LIPID MET, V1392, P291, DOI 10.1016/S0005-2760(98)00043-5; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hayashi K, 1996, EUR J PHARMACOL, V316, P297, DOI 10.1016/S0014-2999(96)00689-9; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwashita K, 2000, BIOSCI BIOTECH BIOCH, V64, P1813, DOI 10.1271/bbb.64.1813; Jang HS, 2005, BBA-GEN SUBJECTS, V1726, P309, DOI 10.1016/j.bbagen.2005.08.010; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Jeon KI, 2003, EXP MOL MED, V35, P61, DOI 10.1038/emm.2003.9; Kang DG, 2004, BIOL PHARM BULL, V27, P366, DOI 10.1248/bpb.27.366; Kang DK, 2003, BIOL PHARM BULL, V26, P1345, DOI 10.1248/bpb.26.1345; Kang HM, 2004, NAT PROD RES, V18, P349, DOI 10.1080/14786410310001622022; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Khatib S, 2005, BIOORGAN MED CHEM, V13, P433, DOI 10.1016/j.bmc.2004.10.010; Kim NY, 2001, PHARMACOL TOXICOL, V88, P261, DOI 10.1034/j.1600-0773.2001.d01-114.x; KUPPUSAMY UR, 1992, BIOCHEM PHARMACOL, V44, P1307, DOI 10.1016/0006-2952(92)90531-M; Lee JC, 2004, FOOD CHEM TOXICOL, V42, P1383, DOI 10.1016/j.fct.2004.03.012; Lee JC, 2002, BBA-GEN SUBJECTS, V1570, P181, DOI 10.1016/S0304-4165(02)00196-4; Lee SH, 2004, BIOCHEM BIOPH RES CO, V323, P125, DOI 10.1016/j.bbrc.2004.08.063; Lee SH, 2003, PLANTA MED, V69, P990, DOI 10.1055/s-2003-45143; Lee SH, 2006, BIOCHEM PHARMACOL, V72, P1322, DOI 10.1016/j.bcp.2006.08.004; Lim SS, 2001, J PHARM PHARMACOL, V53, P653, DOI 10.1211/0022357011775983; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; NELSEN B, 1988, MOL CELL BIOL, V8, P3526, DOI 10.1128/MCB.8.8.3526; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Park MH, 2005, BIOCHEMISTRY-US, V44, P8326, DOI 10.1021/bi050156h; RAMANATHAN R, 1992, CANCER LETT, V62, P217, DOI 10.1016/0304-3835(92)90099-H; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SAMOSZUK M, 2005, BMC COMPLEM ALTERN M, V5, P1; Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200; Selvam C, 2004, PHYTOTHER RES, V18, P582, DOI 10.1002/ptr.1492; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; SOGAWA S, 1994, BIOL PHARM BULL, V17, P251; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takano-Ishikawa Y, 2003, PHYTOTHER RES, V17, P1224, DOI 10.1002/ptr.1371; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THEVENIN C, 1990, New Biologist, V2, P793; THIYAGARAJAH P, 1991, BIOCHEM PHARMACOL, V41, P669, DOI 10.1016/0006-2952(91)90065-D; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang Y, 2005, LIFE SCI, V77, P39, DOI 10.1016/j.lfs.2004.12.014; Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055; Woo SW, 2003, J PHARM PHARMACOL, V55, P347, DOI 10.1211/002235702658; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang EB, 1998, BIOCHEM BIOPH RES CO, V245, P435, DOI 10.1006/bbrc.1998.8452; Yang EB, 2001, BBA-PROTEIN STRUCT M, V1550, P144, DOI 10.1016/S0167-4838(01)00276-X; YIT CC, 1994, CANCER LETT, V82, P65, DOI 10.1016/0304-3835(94)90147-3; YU SM, 1995, EUR J PHARMACOL, V280, P69, DOI 10.1016/0014-2999(95)00190-V; Zhang K, 1997, BIOCHEM J, V325, P417, DOI 10.1042/bj3250417; ZHANG K, 1994, BIOCHEM PHARMACOL, V47, P2063, DOI 10.1016/0006-2952(94)90082-5; Zhang K, 1996, BIOCHEM PHARMACOL, V52, P1631, DOI 10.1016/S0006-2952(96)00570-9; Zhang K, 1997, BIOCHEM PHARMACOL, V54, P1047, DOI 10.1016/S0006-2952(97)00315-8; Zhang K, 2003, LIFE SCI, V72, P2629, DOI 10.1016/S0024-3205(03)00173-5; Zhu LL, 2003, ANAL CHEM, V75, P6381, DOI 10.1021/ac026371a	80	155	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17340	17350		10.1074/jbc.M700890200	http://dx.doi.org/10.1074/jbc.M700890200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17439942	hybrid			2022-12-25	WOS:000247084500004
J	Stockholm, D; Benchaouir, R; Picot, J; Rameau, P; Neildez, TMA; Landini, G; Laplace-Builhe, C; Paldi, A				Stockholm, Daniel; Benchaouir, Rachid; Picot, Julien; Rameau, Philippe; Neildez, Thi My Anh; Landini, Gabriel; Laplace-Builhe, Corinne; Paldi, Andras			The Origin of Phenotypic Heterogeneity in a Clonal Cell Population In Vitro	PLOS ONE			English	Article								Background. The spontaneous emergence of phenotypic heterogeneity in clonal populations of mammalian cells in vitro is a rule rather than an exception. We consider two simple, mutually non-exclusive models that explain the generation of diverse cell types in a homogeneous population. In the first model, the phenotypic switch is the consequence of extrinsic factors. Initially identical cells may become different because they encounter different local environments that induce adaptive responses. According to the second model, the phenotypic switch is intrinsic to the cells that may occur even in homogeneous environments. Principal Findings. We have investigated the "extrinsic" and the "intrinsic" mechanisms using computer simulations and experimentation. First, we simulated in silico the emergence of two cell types in a clonal cell population using a multiagent model. Both mechanisms produced stable phenotypic heterogeneity, but the distribution of the cell types was different. The "intrinsic" model predicted an even distribution of the rare phenotype cells, while in the "extrinsic" model these cells formed small clusters. The key predictions of the two models were confronted with the results obtained experimentally using a myogenic cell line. Conclusions. The observations emphasize the importance of the "ecological" context and suggest that, consistently with the "extrinsic" model, local stochastic interactions between phenotypically identical cells play a key role in the initiation of phenotypic switch. Nevertheless, the "intrinsic" model also shows some other aspects of reality: The phenotypic switch is not triggered exclusively by the local environmental variations, but also depends to some extent on the phenotypic intrinsic robustness of the cells.	[Stockholm, Daniel; Benchaouir, Rachid; Picot, Julien; Rameau, Philippe; Neildez, Thi My Anh; Laplace-Builhe, Corinne; Paldi, Andras] GENETHON, CNRS, UMR 8115, Evry, France; [Neildez, Thi My Anh; Paldi, Andras] Ecole Prat Hautes Etud, Paris, France; [Landini, Gabriel] Univ Birmingham, Sch Dent, Oral Pathol Unit, Birmingham, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); University of Birmingham	Paldi, A (corresponding author), GENETHON, CNRS, UMR 8115, Evry, France.	paldi@genethon.fr	Paldi, Andras/J-5757-2013; Stockholm, Daniel/J-7912-2013; Neildez, Thi My Anh/J-6900-2013; LAPLACE-BUILHE, Corinne/ABD-4479-2020	Landini, Gabriel/0000-0002-9689-0989; LAPLACE-BUILHE, Corinne/0000-0003-2885-6073	Association Francaise contre les Myopathies, Genopole (Evry); Conseil Regional de l'Essonne; Fondation pour la Recherche Medicale	Association Francaise contre les Myopathies, Genopole (Evry)(Association Francaise contre les Myopathies); Conseil Regional de l'Essonne; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was funded by the Association Francaise contre les Myopathies, Genopole (Evry), Conseil Regional de l'Essonne and the Fondation pour la Recherche Medicale.	ACKLIN SE, 1993, DEVELOPMENT, V118, P175; Avery SV, 2005, TRENDS MICROBIOL, V13, P459, DOI 10.1016/j.tim.2005.08.006; Benchaouir R, 2004, EXP CELL RES, V294, P254, DOI 10.1016/j.yexcr.2003.11.005; BENCHAOUIR RP, 2006, CYTOMETRY A IN PRESS; Czirok A, 1998, PHYS REV LETT, V81, P3038, DOI 10.1103/PhysRevLett.81.3038; Decraene C, 2005, PHYSIOL GENOMICS, V23, P132, DOI 10.1152/physiolgenomics.00141.2004; Furusawa C, 2006, INT J DEV BIOL, V50, P223, DOI 10.1387/ijdb.052051cf; KO EP, 1994, PHYSICA D, V75, P81, DOI 10.1016/0167-2789(94)90276-3; KUPIEC JJ, 1983, SPECULAT SCI TECHNOL, V6, P471; Laforge B, 2005, PROG BIOPHYS MOL BIO, V89, P93, DOI 10.1016/j.pbiomolbio.2004.11.004; LAVROVSKY VA, 1992, EUR J CANCER, V28A, P17, DOI 10.1016/0959-8049(92)90375-C; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; Loeffler M, 2004, CURR OPIN HEMATOL, V11, P81, DOI 10.1097/01.moh.0000133648.83991.af; Mombach JCM, 1996, PHYS REV LETT, V76, P3032, DOI 10.1103/PhysRevLett.76.3032; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Paldi A, 2003, CELL MOL LIFE SCI, V60, P1775, DOI 10.1007/s00018-003-23147-z; RIPLEY BD, 1977, J ROY STAT SOC B MET, V39, P172; Rubin H, 2005, P NATL ACAD SCI USA, V102, P9276, DOI 10.1073/pnas.0503688102; RUBIN H, 1993, P NATL ACAD SCI USA, V90, P10715, DOI 10.1073/pnas.90.22.10715; Rubin H, 2001, CANCER RES, V61, P799; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; Sun C, 1996, EUR J CANCER, V32A, P322, DOI 10.1016/0959-8049(95)00581-1; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0	24	63	64	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e394	10.1371/journal.pone.0000394	http://dx.doi.org/10.1371/journal.pone.0000394			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460761	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445600008
J	Kothapalli, KSD; Anthony, JC; Pan, BS; Hsieh, AT; Nathanielsz, PW; Brenna, JT				Kothapalli, Kumar S. D.; Anthony, Joshua C.; Pan, Bruce S.; Hsieh, Andrea T.; Nathanielsz, Peter W.; Brenna, J. Thomas			Differential Cerebral Cortex Transcriptomes of Baboon Neonates Consuming Moderate and High Docosahexaenoic Acid Formulas	PLOS ONE			English	Article							POLYUNSATURATED FATTY-ACIDS; KERATAN SULFATE PROTEOGLYCAN; GLYCINE N-ACYLTRANSFERASE; SORSBYS FUNDUS DYSTROPHY; ALPHA CONVERTING-ENZYME; BREAST-MILK COMPOSITION; CENTRAL-NERVOUS-SYSTEM; BRAIN GENE-EXPRESSION; ANION CHANNEL VDAC; PROTEIN-KINASE-C	Background. Docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (ARA, 20:4n-6) are the major long chain polyunsaturated fatty acids (LCPUFA) of the central nervous system (CNS). These nutrients are present in most infant formulas at modest levels, intended to support visual and neural development. There are no investigations in primates of the biological consequences of dietary DHA at levels above those present in formulas but within normal breastmilk levels. Methods and Findings. Twelve baboons were divided into three formula groups: Control, with no DHA-ARA; "L", LCPUFA, with 0.33% DHA-0.67% ARA; "L3", LCPUFA, with 1.00% DHA-0.67% ARA. All the samples are from the precentral gyrus of cerebral cortex brain regions. At 12 weeks of age, changes in gene expression were detected in 1,108 of 54,000 probe sets (2.05%), with most showing < 2-fold change. Gene ontology analysis assigns them to diverse biological functions, notably lipid metabolism and transport, G-protein and signal transduction, development, visual perception, cytoskeleton, peptidases, stress response, transcription regulation, and 400 transcripts having no defined function. PLA2G6, a phospholipase recently associated with infantile neuroaxonal dystrophy, was downregulated in both LCPUFA groups. ELOVL5, a PUFA elongase, was the only LCPUFA biosynthetic enzyme that was differentially expressed. Mitochondrial fatty acid carrier, CPT2, was among several genes associated with mitochondrial fatty acid oxidation to be downregulated by high DHA, while the mitochondrial proton carrier, UCP2, was upregulated. TIMM8A, also known as deafness/dystonia peptide 1, was among several differentially expressed neural development genes. LUM and TIMP3, associated with corneal structure and age-related macular degeneration, respectively, were among visual perception genes influenced by LCPUFA. TIA1, a silencer of COX2 gene translation, is upregulated by high DHA. Ingenuity pathway analysis identified a highly significant nervous system network, with epidermal growth factor receptor (EGFR) as the outstanding interaction partner. Conclusions. These data indicate that LCPUFA concentrations within the normal range of human breastmilk induce global changes in gene expression across a wide array of processes, in addition to changes in visual and neural function normally associated with formula LCPUFA.	[Kothapalli, Kumar S. D.; Pan, Bruce S.; Hsieh, Andrea T.; Brenna, J. Thomas] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; [Anthony, Joshua C.] Mead Johnson & Co, Evansville, IN USA; [Nathanielsz, Peter W.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA	Cornell University; University of Texas System; University of Texas Health San Antonio	Brenna, JT (corresponding author), Cornell Univ, Div Nutr Sci, Savage Hall, Ithaca, NY 14853 USA.	jtb4@cornell.edu		Brenna, James Thomas/0000-0001-9494-4245; Nathanielsz, Peter/0000-0001-8410-6280	Mead Johnson and Company, Evansville; NIH [NIH Training Grant DK07158]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER	Mead Johnson and Company, Evansville; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funding: Mead Johnson and Company, Evansville, IN. BSP acknowledges support from NIH Training Grant DK07158.	Alessandri JM, 2004, REPROD NUTR DEV, V44, P509, DOI 10.1051/rnd:2004063; Baillie RA, 1999, PROSTAG LEUKOTR ESS, V60, P351, DOI 10.1016/S0952-3278(99)80011-8; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Barcelo-Coblijn G, 2003, P NATL ACAD SCI USA, V100, P11321, DOI 10.1073/pnas.1734008100; Barker DJP, 2003, HORM RES, V59, P35, DOI 10.1159/000067843; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; Baur LA, 1998, METABOLISM, V47, P106, DOI 10.1016/S0026-0495(98)90202-5; Beecher N, 2006, INVEST OPHTH VIS SCI, V47, P146, DOI 10.1167/iovs.05-0907; BENOLKEN RM, 1973, SCIENCE, V182, P1253, DOI 10.1126/science.182.4118.1253; Benvenuti S, 2005, J CLIN ENDOCR METAB, V90, P1775, DOI 10.1210/jc.2004-0066; Berger Alvin, 2002, Lipids Health Dis, V1, P2, DOI 10.1186/1476-511X-1-2; Berger A, 2002, GENOME BIOL, V3; Bernstein HG, 2006, BRAIN RES BULL, V69, P546, DOI 10.1016/j.brainresbull.2006.02.017; Birch EE, 2005, AM J CLIN NUTR, V81, P871, DOI 10.1093/ajcn/81.4.871; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; BLACHLYDYSON E, 1994, GENOMICS, V20, P62, DOI 10.1006/geno.1994.1127; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Brenna JT, 2002, CURR OPIN CLIN NUTR, V5, P127, DOI 10.1097/00075197-200203000-00002; BRENNA JT, 2006, PEDIATRICS UNPUB; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Carlson EC, 2005, J BIOL CHEM, V280, P25541, DOI 10.1074/jbc.M500249200; CHAKRAVARTI S, 1995, MAMM GENOME, V6, P367, DOI 10.1007/BF00364803; CLANDININ MT, 1980, EARLY HUM DEV, V4, P131, DOI 10.1016/0378-3782(80)90016-X; Clandinin MT, 2005, J PEDIATR-US, V146, P461, DOI 10.1016/j.jpeds.2004.11.030; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Clarke M, 2001, BRIT J OPHTHALMOL, V85, P1429, DOI 10.1136/bjo.85.12.1429; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Colville D, 1997, OPHTHALMIC GENET, V18, P119, DOI 10.3109/13816819709057125; Cox LA, 2006, J PHYSIOL-LONDON, V572, P59, DOI 10.1113/jphysiol.2006.105726; CRAWFORD MA, 1976, COMP BIOCHEM PHYS B, V54, P395, DOI 10.1016/0305-0491(76)90264-9; Davy BE, 2003, HUM MOL GENET, V12, P1163, DOI 10.1093/hmg/ddg122; de Rooij SR, 2006, DIABETOLOGIA, V49, P637, DOI 10.1007/s00125-005-0136-9; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Diau GY, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-11; Ding B, 2005, CIRCULATION, V111, P2469, DOI 10.1161/01.CIR.0000165128.39715.87; Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616; Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176; Dufner A, 2006, P NATL ACAD SCI USA, V103, P988, DOI 10.1073/pnas.0510380103; Dumstrei K, 1998, DEVELOPMENT, V125, P3417; Dunlevy JR, 2000, EXP EYE RES, V70, P349, DOI 10.1006/exer.1999.0789; DYCK JR, 2006, AMPK ALTERATIONS CAR; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; EVANS AM, 2006, J PHYSL; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Ferner RE, 2004, J MED GENET, V41, P837, DOI 10.1136/jmg.2004.021683; FINLEY DA, 1985, AM J CLIN NUTR, V41, P787; Flachs P, 2005, DIABETOLOGIA, V48, P2365, DOI 10.1007/s00125-005-1944-7; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200; Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7; Gibson RA, 2001, LIPIDS, V36, P873, DOI 10.1007/s11745-001-0797-2; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Grossfield A, 2006, P NATL ACAD SCI USA, V103, P4888, DOI 10.1073/pnas.0508352103; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Harzenetter MD, 2002, EXP HEMATOL, V30, P306, DOI 10.1016/S0301-472X(02)00772-5; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horiuchi K, 2005, DEV BIOL, V283, P459, DOI 10.1016/j.ydbio.2005.05.004; HSIEH AT, 2007, PED RES IN PRESS; Hun CS, 1999, BIOCHEM BIOPH RES CO, V259, P85, DOI 10.1006/bbrc.1999.0733; INNIS SM, 1988, EARLY HUM DEV, V18, P185, DOI 10.1016/0378-3782(88)90055-2; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jensen CL, 1997, J PEDIATR-US, V131, P200, DOI 10.1016/S0022-3476(97)70154-9; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Khateeb S, 2006, AM J HUM GENET, V79, P942, DOI 10.1086/508572; Kitajka K, 2002, P NATL ACAD SCI USA, V99, P2619, DOI 10.1073/pnas.042698699; Kitajka K, 2004, P NATL ACAD SCI USA, V101, P10931, DOI 10.1073/pnas.0402342101; Kornblum HI, 1998, J NEUROSCI RES, V53, P697, DOI 10.1002/(SICI)1097-4547(19980915)53:6<697::AID-JNR8>3.3.CO;2-M; Kuehn MH, 1999, MATRIX BIOL, V18, P509, DOI 10.1016/S0945-053X(99)00043-8; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuorilehto T, 2006, J HISTOCHEM CYTOCHEM, V54, P363, DOI 10.1369/jhc.5A6784.2005; Kuroda H, 2002, PLANT CELL PHYSIOL, V43, P1073, DOI 10.1093/pcp/pcf151; Kuthe A, 2000, EUR UROL, V38, P108, DOI 10.1159/000020262; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lapillonne A, 2004, CURR OPIN CLIN NUTR, V7, P151, DOI 10.1097/00075197-200403000-00008; Lauritzen L, 2005, REPROD NUTR DEV, V45, P535, DOI 10.1051/rnd:2005044; Lauritzen L, 2002, LIPIDS, V37, P237, DOI 10.1007/s11745-002-0886-2; Leifert WR, 2000, J NUTR BIOCHEM, V11, P38, DOI 10.1016/S0955-2863(99)00069-8; Leon C, 2005, PHARM RES-DORDR, V22, P1578, DOI 10.1007/s11095-005-6306-0; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2002, LIPIDS, V37, P733, DOI 10.1007/s11745-002-0955-6; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu Y, 2001, DEV BIOL, V236, P30, DOI 10.1006/dbio.2000.0146; Lopez-Bendito G, 2006, CELL, V125, P127, DOI 10.1016/j.cell.2006.01.042; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Makrides M, 1996, EUR J CLIN NUTR, V50, P352; Makrides M, 2000, AM J CLIN NUTR, V71, P120; Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624; Martinez M, 1998, J NEUROCHEM, V71, P2528; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Massa R, 2000, J MUSCLE RES CELL M, V21, P433, DOI 10.1023/A:1005688901635; Mathers PH, 2000, CELL MOL LIFE SCI, V57, P186, DOI 10.1007/PL00000683; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mawal Y, 1997, J PEDIATR-US, V130, P1003, DOI 10.1016/S0022-3476(97)70293-2; MAWAL YR, 1994, BIOCHEM BIOPH RES CO, V205, P1373, DOI 10.1006/bbrc.1994.2817; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Miyazaki Akira, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P463, DOI 10.2174/156800605774962040; Morale SE, 2005, EARLY HUM DEV, V81, P197, DOI 10.1016/j.earlhumdev.2004.09.008; Morgan NV, 2006, NAT GENET, V38, P752, DOI 10.1038/ng1826; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Mothes H, 2002, NEPHROL DIAL TRANSPL, V17, P70, DOI 10.1093/ndt/17.1.70; Mullenbach R, 2005, GUT, V54, P829, DOI 10.1136/gut.2004.058115; Narayanan BA, 2001, INT J ONCOL, V19, P1255; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Percy ME, 1998, ANALYST, V123, P41, DOI 10.1039/a706355e; Peri A, 2005, J ENDOCRINOL INVEST, V28, P285, DOI 10.1007/BF03345387; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Picot CR, 2005, FREE RADICAL BIO MED, V39, P1332, DOI 10.1016/j.freeradbiomed.2005.06.017; Puskas LG, 2003, P NATL ACAD SCI USA, V100, P1580, DOI 10.1073/pnas.0337683100; Quantock AJ, 2001, INVEST OPHTH VIS SCI, V42, P1750; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002; Sarkadi-Nagy E, 2004, J LIPID RES, V45, P71, DOI 10.1194/jlr.M300106-JLR200; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Senderek J, 2003, AM J HUM GENET, V73, P1106, DOI 10.1086/379525; Seth D, 2003, AM J PATHOL, V163, P2303, DOI 10.1016/S0002-9440(10)63587-0; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Sokac AM, 2000, INT REV CYTOL, V200, P197, DOI 10.1016/S0074-7696(00)00005-X; Stein O, 2005, ATHEROSCLEROSIS, V178, P217, DOI 10.1016/j.atherosclerosis.2004.10.008; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; Tasheva ES, 2004, MOL VIS, V10, P403; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; Tissir F, 2006, EUR J NEUROSCI, V23, P597, DOI 10.1111/j.1460-9568.2006.04596.x; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Tranebjaerg L, 2001, Ophthalmic Genet, V22, P207; Tranebjaerg L, 2000, EUR J HUM GENET, V8, P464, DOI 10.1038/sj.ejhg.5200483; TREEN M, 1992, ARCH BIOCHEM BIOPHYS, V294, P564, DOI 10.1016/0003-9861(92)90726-D; Usdin TB, 2000, FRONT NEUROENDOCRIN, V21, P349, DOI 10.1006/frne.2000.0203; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; Wada W, 2005, J HEPATOL, V43, P823, DOI 10.1016/j.jhep.2005.04.013; Wada W, 2004, AM J PHYSIOL-ENDOC M, V287, pE247, DOI 10.1152/ajpendo.00390.2003; Wang LW, 2000, PEDIATR INT, V42, P14, DOI 10.1046/j.1442-200x.2000.01169.x; Waterham HR, 2001, AM J HUM GENET, V69, P685, DOI 10.1086/323473; Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weisinger HS, 2001, NAT MED, V7, P258, DOI 10.1038/85354; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Ye X, 2004, MOL BIOL REP, V31, P191, DOI 10.1023/B:MOLE.0000043622.57408.6b; Yu S, 2004, BIOCHEM BIOPH RES CO, V322, P320, DOI 10.1016/j.bbrc.2004.07.120; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176	188	43	45	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e370	10.1371/journal.pone.0000370	http://dx.doi.org/10.1371/journal.pone.0000370			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426818	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445400010
J	Watterson, KR; Berg, KM; Kapitonov, D; Payne, SG; Miner, AS; Bittman, R; Milstien, S; Ratz, PH; Spiegel, S				Watterson, Kenneth R.; Berg, Krystina M.; Kapitonov, Dmitri; Payne, Shawn G.; Miner, Amy S.; Bittman, Robert; Milstien, Sheldon; Ratz, Paul H.; Spiegel, Sarah			Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone	FASEB JOURNAL			English	Article						sphingolipid metabolite; calcium channels	2-AMINOETHOXYDIPHENYL BORATE 2-APB; SMOOTH-MUSCLE; CALCIUM-CHANNEL; SPHINGOSINE 1-PHOSPHATE; DEPENDENT REGULATION; RECEPTOR; ACTIVATION; ENTRY; CONTRACTION; SENSITIVITY	Overactive bladder syndrome ( OBS) results from disturbances of bladder function. Bladder smooth muscle ( detrusor) exhibits spontaneous rhythmic activity ( tone) independent of neurogenic control, which is enhanced in patients with OBS. We have now uncovered a prominent role for the bioactive sphingolipid metabolite, sphingosine- 1- phosphate ( S1P), in regulating rabbit detrusor smooth muscle tone and contraction. S1P- induced contraction of detrusor muscle was dependent on stretch and intracellular calcium. Although detrusor expresses the S1P receptors S1P1 and S1P2, only S1P2 appeared to be involved in S1Pinduced contraction, since SEW2871 ( S1P1 agonist) and dihydro- S1P ( potent agonist for all S1P receptors except S1P2) were poor contractile agents. In agreement, the S1P2 antagonist JTE013 inhibited S1P- induced contraction. The fast, transient muscle contraction ( phasic) mediated by S1P was dependent on phospholipase C ( PLC) whereas the slower, sustained contraction ( tonic) was not. Surprisingly, the immunosuppressant FTY720phosphate, an agonist for all S1P receptors except S1P2, had distinct contractile properties and also induced slow, sustained contraction. Thus, FTY720- phosphate and/ or S1P may regulate calcium channels in an S1P receptor- independent manner. Collectively, our results demonstrate that S1P may regulate detrusor smooth muscle tone and suggest that dysregulation of complex S1P signaling might contribute to OBS.	Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; NIMH, NIH, Bethesda, MD 20892 USA; CUNY, Queens Coll, Dept Chem & Biochem, Flushing, NY USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); City University of New York (CUNY) System; Queens College NY (CUNY)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu		Kapitonov, Dmitri/0000-0001-9177-5239	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01DK059620] Funding Source: Medline; NIGMS NIH HHS [R37 GM043880] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KE, 1986, ACTA PHARMACOL TOX, V58, P193; Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Bai DL, 2006, J PHARMACOL EXP THER, V319, P1452, DOI 10.1124/jpet.106.112045; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; Bjorklund S, 2005, MOL CELL ENDOCRINOL, V231, P65, DOI 10.1016/j.mce.2004.12.001; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107; Hsiao SH, 2005, TOXICOL SCI, V86, P194, DOI 10.1093/toxsci/kfi167; Hu W, 2006, BIOCHEM BIOPH RES CO, V343, P1038, DOI 10.1016/j.bbrc.2006.03.079; HU W, 2006, AM J PHYSIOL, V343, pG605; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Jezior JR, 2001, BRIT J PHARMACOL, V134, P78, DOI 10.1038/sj.bjp.0704241; Kajioka S, 2004, AM J PHYSIOL-RENAL, V286, pF77, DOI 10.1152/ajprenal.00355.2002; KIM MY, 2005, AM J PHYSIOL, V290, pC100; KONO M, 2007, IN PRESS J BIOL CHEM; Koyrakh L, 2005, AM J TRANSPLANT, V5, P529, DOI 10.1111/j.1600-6143.2005.00754.x; LORENZ JN, 2006, AM J PHYSIOL, V292, pR440; Lu XQ, 2006, TETRAHEDRON LETT, V47, P825, DOI 10.1016/j.tetlet.2005.11.092; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200; Moosmang S, 2006, CIRC RES, V98, P105, DOI 10.1161/01.RES.0000197851.11031.9c; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Ohmori T, 2004, J THROMB HAEMOST, V2, P203, DOI 10.1111/j.1538-7836.2004.0562h.x; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Pfaff M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-48; Poburko D, 2004, EUR J PHARMACOL, V505, P19, DOI 10.1016/j.ejphar.2004.09.060; Ratz PH, 2005, AM J PHYSIOL-CELL PH, V288, pC769, DOI 10.1152/ajpcell.00529.2004; Ratz PH, 2003, AM J PHYSIOL-REG I, V284, pR1063, DOI 10.1152/ajpregu.00596.2002; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Salomone S, 2003, EUR J PHARMACOL, V469, P125, DOI 10.1016/S0014-2999(03)01731-X; Shenfeld OZ, 1999, UROL RES, V27, P386, DOI 10.1007/s002400050168; SJOGREN C, 1982, J UROLOGY, V128, P1368, DOI 10.1016/S0022-5347(17)53509-0; SMITH DJ, 1994, NEUROUROL URODYNAM, V34, P14; Song HJ, 2006, MOL CELLS, V21, P42; Speich JE, 2005, AM J PHYSIOL-CELL PH, V289, pC12, DOI 10.1152/ajpcell.00418.2004; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Watterson KR, 2005, CELL SIGNAL, V17, P289, DOI 10.1016/j.cellsig.2004.09.013; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Xu SZ, 2006, CIRC RES, V98, P1381, DOI 10.1161/01.RES.0000225284.36490.a2; Xu SZ, 2005, BRIT J PHARMACOL, V145, P405, DOI 10.1038/sj.bjp.0706197; Zhou HP, 2004, AM J PHYSIOL-CELL PH, V286, pC1130, DOI 10.1152/ajpcell.00429.2003	54	17	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2818	2828		10.1096/fj.06-7326com	http://dx.doi.org/10.1096/fj.06-7326com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449719				2022-12-25	WOS:000249237500023
J	Lella, RK; Sharma, C				Lella, Ravi K.; Sharma, Charu			Eis (enhanced intracellular survival) protein of Mycobacterium tuberculosis disturbs the cross regulation of T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; IFN-GAMMA; EXPRESSION; HELPER; TRANSCRIPTION; REPLICATION; MACROPHAGES; IMMUNOLOGY; ACTIVATION; INDUCTION	The pathogenesis of tuberculosis is complex and its manifestations diverse, reflecting a lifetime of dynamic interactions between mycobacterial virulence factors and the human immune system. The pathogenic mycobacteria have developed strategies to circumvent the major killing mechanisms employed by macrophages and take advantage of the enclosed environment within its host cell to avoid humoral and cell-mediated immune responses. Secretory proteins play a major role in host-pathogen interactions. The eis (Rv2416c) gene has been identified as a secretory protein, and it has been shown that it enhances intracellular survival of Mycobacterium semgmatis in the macrophage cell line. The main aim of this study was to gain insight into the biological role of Eis in the host. Stimulation of T-cells with Eis recombinant protein of Mycobacterium tuberculosis inhibits Con A-mediated T-cell proliferation in vitro. Treatment of T-cells with Eis inhibits ERK1/2, JAK pathway, and subsequent production of tumor necrosis factor-alpha and interleukin-4. On the contrary, there is increased production of interferon-gamma and interleukin- 10, which indicates that immunity in response to Eis treatment is skewed away from a protective T(H)1 response and Eis disturbs the cross regulation of T-cells.	Cent Drug Res Inst, Drug Target Discovery & Dev Div, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Sharma, C (corresponding author), Cent Drug Res Inst, Drug Target Discovery & Dev Div, Lucknow 226001, Uttar Pradesh, India.	chash71@yahoo.com						Blumenthal A, 2002, INFECT IMMUN, V70, P4961, DOI 10.1128/IAI.70.9.4961-4967.2002; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; Cappelli G, 2001, INFECT IMMUN, V69, P7262, DOI 10.1128/IAI.69.12.7262-7270.2001; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Condos R, 1998, AM J RESP CRIT CARE, V157, P729, DOI 10.1164/ajrccm.157.3.9705044; Dahl JL, 2001, INFECT IMMUN, V69, P4295, DOI 10.1128/IAI.69.7.4295-4302.2001; Demissie A, 2006, INFECT IMMUN, V74, P2817, DOI 10.1128/IAI.74.5.2817-2822.2006; DONNELLY RP, 1995, J IMMUNOL, V155, P1420; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; Fietta AM, 2002, CYTOKINE, V19, P242, DOI 10.1006/cyto.2002.1968; Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Fonseca DPAJ, 2001, INFECT IMMUN, V69, P4839, DOI 10.1128/IAI.69.8.4839-4845.2001; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GREENBAUM LA, 1988, J IMMUNOL, V140, P1555; Jo EK, 2003, CURR OPIN INFECT DIS, V16, P205, DOI 10.1097/00001432-200306000-00004; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; Jung SB, 2006, INFECT IMMUN, V74, P2686, DOI 10.1128/IAI.74.5.2686-2696.2006; Kahnert A, 2006, EUR J IMMUNOL, V36, P631, DOI 10.1002/eji.200535496; KREMER L, 1995, MOL MICROBIOL, V17, P913, DOI 10.1111/j.1365-2958.1995.mmi_17050913.x; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; Parra M, 2006, INFECT IMMUN, V74, P786, DOI 10.1128/IAI.74.1.786-789.2006; RAMAKRISHNAN L, 1994, INFECT IMMUN, V62, P3222, DOI 10.1128/IAI.62.8.3222-3229.1994; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Roberts EA, 2004, J BACTERIOL, V186, P5410, DOI 10.1128/JB.186.16.5410-5417.2004; Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x; Song CH, 2003, J CLIN IMMUNOL, V23, P194, DOI 10.1023/A:1023309928879; SWARTZ RP, 1988, INFECT IMMUN, V56, P2223, DOI 10.1128/IAI.56.9.2223-2227.1988; Trajkovic V, 2002, INFECT IMMUN, V70, P6558, DOI 10.1128/IAI.70.12.6558-6566.2002; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; Wei J, 2000, J BACTERIOL, V182, P377, DOI 10.1128/JB.182.2.377-384.2000	33	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18671	18675		10.1074/jbc.C600280200	http://dx.doi.org/10.1074/jbc.C600280200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17449476	hybrid			2022-12-25	WOS:000247475300004
J	Hoshino, A; Hirst, JA; Fujii, H				Hoshino, Akemi; Hirst, John A.; Fujii, Hodaka			Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOKINE-INDUCIBLE GENE; SIGNAL-TRANSDUCTION; EXPRESSION; PROTEIN; STAT5; TRANSCRIPTION; RAT; DIFFERENTIATION; ERYTHROPOIETIN	Extracellular signaling molecules bound to cell surface receptors can regulate nuclear function with consequences for cell proliferation, differentiation, and function. To regulate nuclear function, signals must be transduced across the nuclear envelope to propagate the signal from the cytoplasm to the nucleus. Therefore, many signaling responses induce the nuclear translocation of transcription factors, kinases, and others. By using inducible translocation trap, a reporter gene-based system to detect inducible nuclear translocation, we found that the M2 isoform of pyruvate kinase, a key enzyme in glycolysis, translocates into the nucleus by interleukin-3, but not by epidermal growth factor, stimulation. The C domain of the M2 isoform of pyruvate kinase was sufficient for interleukin-3-induced nuclear translocation. Interleukin-3-induced nuclear translocation of the M2 isoform of pyruvate kinase was dependent on the activation of Jak2. Overexpression of the M2 isoform of pyruvate kinase protein fused with a nuclear localization signal enhanced cell proliferation in the absence of interleukin-3, suggesting that the nuclear pyruvate kinase plays an important role in cell proliferation.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University	Fujii, H (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	hodaka@med.nyu.edu	Fujii, Hodaka/N-9792-2019; Fujii, Hodaka/A-2420-2008	Fujii, Hodaka/0000-0003-1296-4256; Fujii, Hodaka/0000-0003-1296-4256	NIAID NIH HHS [AI059315] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059315] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; DEL PL, 1997, SCIENCE, V278, P687; Fujii H, 2007, BIOCHEM BIOPH RES CO, V354, P825, DOI 10.1016/j.bbrc.2007.01.067; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hoshino A, 2004, MOL CELL, V15, P153, DOI 10.1016/j.molcel.2004.06.017; Hoshino A, 2007, FEBS LETT, V581, P975, DOI 10.1016/j.febslet.2007.01.083; Hoshino A, 2006, BIOCHEM BIOPH RES CO, V346, P1062, DOI 10.1016/j.bbrc.2006.06.026; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IZUMI S, 1995, BBA-MOL CELL RES, V1267, P135, DOI 10.1016/0167-4889(95)00071-Y; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; Munoz ME, 2003, COMP BIOCHEM PHYS B, V135, P197, DOI 10.1016/S1096-4959(03)00081-2; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TREMP GL, 1989, J BIOL CHEM, V264, P19904; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	32	71	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17706	17711		10.1074/jbc.M700094200	http://dx.doi.org/10.1074/jbc.M700094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17446165	hybrid			2022-12-25	WOS:000247084500043
J	Romero, P; Lopez, R; Garcia, E				Romero, Patricia; Lopez, Rubens; Garcia, Ernesto			Key role of amino acid residues in the dimerization and catalytic activation of the autolysin LytA, an important virulence factor in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE-BINDING DOMAIN; PNEUMOCOCCAL CELL-WALL; TEICHOIC-ACID; CRYSTAL-STRUCTURE; CHIMERIC LYSIN; GENE; AMIDASE; INSIGHTS; PURIFICATION; EXPRESSION	LytA, the main autolysin of Streptococcus pneumoniae, was the first member of the bacterial N-acetylmuramoyl-L-alanine amidase (NAM-amidase) family of proteins to be well characterized. This autolysin degrades the peptidoglycan bonds of pneumococcal cell walls after anchoring to the choline residues of the cell wall teichoic acids via its choline-binding module (ChBM). The latter is composed of seven repeats (ChBRs) of similar to 20 amino acid residues. The translation product of the lytA gene is the low-activity E-form of LytA (a monomer), which can be "converted" (activated) in vitro by choline into the fully active C-form at low temperature. The C-form is a homodimer with a boomerang-like shape. To study the structural requirements for the monomer-to-dimer modification and to clarify whether "conversion" is synonymous with dimerization, the biochemical consequences of replacing four key amino acid residues of ChBR6 and ChBR7 (the repeats involved in dimer formation) were determined. The results obtained with a collection of 21 mutated NAM-amidases indicate that Ile-315 is a key amino acid residue in both LytA activity and folding. Amino acids with a marginal position in the solenoid structure of the ChBM were of minor influence in dimer stability; neither the size, polarity, nor aromatic nature of the replacement amino acids affected LytA activity. In contrast, truncated proteins were drastically impaired in their activity and conversion capacity. The results indicate that dimerization and conversion are different processes, but they do not answer the questions of whether conversion can only be achieved after a dimer formation step.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Garcia, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro de Maeztu,9, E-28006 Madrid, Spain.	e.garcia@cib.csic.es		Partearroyo Lacaba, Olvido/0000-0002-1692-4481				Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BRIESE T, 1985, EUR J BIOCHEM, V146, P417, DOI 10.1111/j.1432-1033.1985.tb08668.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buey RM, 2007, J MOL BIOL, V365, P411, DOI 10.1016/j.jmb.2006.09.091; Demarest SJ, 2005, J MOL BIOL, V346, P1197, DOI 10.1016/j.jmb.2004.12.059; DIAZ E, 1992, J BACTERIOL, V174, P5516; Fernandez-Tornero C, 2002, J MOL BIOL, V321, P163, DOI 10.1016/S0022-2836(02)00596-X; Fernandez-Tornero C, 2002, ACTA CRYSTALLOGR D, V58, P556, DOI 10.1107/S0907444902000537; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; Fischer W, 2000, RES MICROBIOL, V151, P421, DOI 10.1016/S0923-2508(00)00174-1; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA E, 1985, FEMS MICROBIOL LETT, V29, P77; GARCIA E, 1985, MOL GEN GENET, V201, P225, DOI 10.1007/BF00425663; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GIUDICELLI S, 1984, J BACTERIOL, V158, P1188, DOI 10.1128/JB.158.3.1188-1190.1984; Hermoso JA, 2005, NAT STRUCT MOL BIOL, V12, P533, DOI 10.1038/nsmb940; Hermoso JA, 2003, STRUCTURE, V11, P1239, DOI 10.1016/j.str.2003.09.005; Ho JGS, 2005, P NATL ACAD SCI USA, V102, P18373, DOI 10.1073/pnas.0506391102; HOLTJE JV, 1976, J BIOL CHEM, V251, P4199; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanie JA, 2007, J BACTERIOL, V189, P38, DOI 10.1128/JB.01148-06; Levine OS, 2006, LANCET, V367, P1880, DOI 10.1016/S0140-6736(06)68703-5; Llull D, 2006, J CLIN MICROBIOL, V44, P1250, DOI 10.1128/JCM.44.4.1250-1256.2006; Lopez R, 2004, FEMS MICROBIOL REV, V28, P553, DOI 10.1016/j.femsre.2004.05.002; Lopez R, 2004, PNEUMOCCOCUS, P75; LUND E, 1978, METHOD MICROBIOL, V12, P241; Maestro B, 2005, BIOCHEM J, V387, P479, DOI 10.1042/BJ20041194; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOSSER JL, 1970, J BIOL CHEM, V245, P287; Obregon V, 2002, J CLIN MICROBIOL, V40, P2545, DOI 10.1128/JCM.40.7.2545-2554.2002; OTTOLENGHI E, 1962, J EXP MED, V116, P491, DOI 10.1084/jem.116.4.491; Rane L, 1940, J BACTERIOL, V40, P695, DOI 10.1128/JB.40.5.695-704.1940; Romero P, 2004, J BACTERIOL, V186, P8229, DOI 10.1128/JB.186.24.8229-8239.2004; RONDA C, 1987, EUR J BIOCHEM, V164, P621, DOI 10.1111/j.1432-1033.1987.tb11172.x; Saiz JL, 2002, PROTEIN SCI, V11, P1788, DOI 10.1110/ps.4680102; Sambrook J, 2001, MOL CLONING LAB MANU; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZPUELLES JM, 1992, EUR J BIOCHEM, V203, P153, DOI 10.1111/j.1432-1033.1992.tb19840.x; SANCHEZPUELLES JM, 1986, EUR J BIOCHEM, V158, P289, DOI 10.1111/j.1432-1033.1986.tb09749.x; SANCHEZPUELLES JM, 1987, GENE, V61, P13, DOI 10.1016/0378-1119(87)90360-X; Sheehan MM, 1997, MOL MICROBIOL, V25, P717, DOI 10.1046/j.1365-2958.1997.5101880.x; Swiatlo E, 2004, PNEUMOCCOCUS, P49; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; TOMASZ A, 1971, P NATL ACAD SCI USA, V68, P2627, DOI 10.1073/pnas.68.11.2627; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; Varea J, 2004, J BIOL CHEM, V279, P43697, DOI 10.1074/jbc.M407067200; Varea J, 2000, J BIOL CHEM, V275, P26842	54	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17729	17737		10.1074/jbc.M611795200	http://dx.doi.org/10.1074/jbc.M611795200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17439951	hybrid, Green Published			2022-12-25	WOS:000247084500046
J	Wang, JH; Zhang, Z; Palzkill, T; Chow, DC				Wang, Jihong; Zhang, Zhen; Palzkill, Timothy; Chow, Dar-Chone			Thermodynamic investigation of the role of contact residues of beta-lactamase-inhibitory protein for binding to TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; LIGAND-BINDING; INTERFACE; RECOGNITION; COMPLEXES; AFFINITY	We have determined the thermodynamics of binding for the interaction between TEM-1 beta-lactamase and a set of alanine substituted contact residue mutants of beta-lactamase-inhibitory protein ( BLIP) using isothermal titration calorimetry. The binding enthalpies for these interactions are highly temperature dependent, with negative binding heat capacity changes ranging from -800 to -271 cal mol(-1) K-1. The isoenthalpic temperatures ( at which the binding enthalpy is zero) of these interactions range from 5 to 38 C. The changes in isoenthalpic temperature were used as an indicator of the changes in enthalpy and entropy driving forces, which in turn are related to hydrophobic and hydrophilic interactions. A contact residue of BLIP is categorized as a canonical residue if its alanine substitution mutant exhibits a change of isoenthalpic temperature matching the change of hydrophobicity because of the mutation. A contact position exhibiting a change in isoenthalpic temperature that does not match the change in hydrophobicity is categorized as an anti-canonical residue. Our experimental results reveal that the majority of residues where alanine substitution results in a loss of affinity are canonical ( 7 of 10), and about half of the residues where alanine substitutions have a minor effect are canonical. The interactions between TEM-1 beta-lactamase and BLIP canonical contact residues contribute directly to binding free energy, suggesting potential anchoring sites for binding partners. The anti-canonical behavior of certain residues may be the result of mutation-induced modifications such as structural rearrangements affecting contact residue configurations. Structural inspection of BLIP suggests that the Lys(74) side chain electrostatically holds BLIP loop 2 in position to bind to TEM-1 beta-lactamase, explaining a large loss of entropy-driven binding energy of the K74A mutant and the resulting anti-canonical behavior. The anticanonical behavior of the W150A mutant may also be due to structural rearrangements. Finally, the affinity enhancing effect of the contact residue mutant Y50A may be due to energetic coupling interactions between Asp(49) and His(41).	Univ Houston, Dept Chem, Houston, TX 77204 USA; Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	University of Houston System; University of Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chow, DC (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.	dchow@mail.uh.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956, R37AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brooijmans N, 2002, PROTEINS, V48, P645, DOI 10.1002/prot.10139; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Majiduddin FK, 2002, INT J MED MICROBIOL, V292, P127, DOI 10.1078/1438-4221-00198; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Reynolds KA, 2006, J BIOL CHEM, V281, P26745, DOI 10.1074/jbc.M603878200; Rudgers GW, 2001, PROTEIN ENG, V14, P487, DOI 10.1093/protein/14.7.487; Rudgers GW, 2001, ANTIMICROB AGENTS CH, V45, P3279, DOI 10.1128/AAC.45.12.3279-3286.2001; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Velazquez-Campoy Adrian, 2004, Methods Mol Biol, V261, P35; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	32	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17676	17684		10.1074/jbc.M611548200	http://dx.doi.org/10.1074/jbc.M611548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430899	hybrid			2022-12-25	WOS:000247084500040
J	Woeller, CF; Anderson, DD; Szebenyi, DME; Stover, PJ				Woeller, Collynn F.; Anderson, Donald D.; Szebenyi, Doletha M. E.; Stover, Patrick J.			Evidence for small ubiquitin-like modifier-dependent nuclear import of the thymidylate biosynthesis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SERINE HYDROXYMETHYLTRANSFERASE; ONE-CARBON METABOLISM; DNA POSTREPLICATION REPAIR; SACCHAROMYCES-CEREVISIAE; PROTEIN MODIFICATION; CONJUGATING ENZYME; COLORECTAL-CANCER; MOUSE FIBROBLASTS; SUMO MODIFICATION; GENE-EXPRESSION	Perturbations in folate-mediated one-carbon metabolism increase rates of uracil misincorporation into DNA during replication, impair cellular methylation reactions, and increase risk for neural tube defects and cancer. One-carbon metabolism is compromised by folate deficiency and common genetic polymorphisms. In this study, the mechanism for the preferential partitioning of cytoplasmic serine hydroxymethyltransferase ( cSHMT)-derived methylenetetrahydrofolate to de novo thymidylate biosynthesis was investigated. The cSHMT enzyme was shown to interact with UBC9 and was a substrate for UBC9-catalyzed small ubiquitin-like modifier ( SUMO) modification in vitro. SUMOylated cSHMT was detected in extracts from S phase MCF-7 cells, and cSHMT was shown to localize to the nucleus and nuclear periphery during the S and G(2)/M phases of the cell cycle. A common single nucleotide polymorphism ( L474F-cSHMT) impaired the UBC9-cSHMT interaction and inhibited cSHMT SUMOylation in vitro. The three folate-dependent enzymes that constitute the de novo thymidylate biosynthesis pathway, cSHMT, thymidylate synthase, and dihydrofolate reductase, all contain SUMO modification consensus sequences. Compartmentation of the folate-dependent de novo thymidylate biosynthesis pathway in the nucleus accounts for the preferential partitioning of cSHMT-derived folate-activated one-carbon units into thymidylate biosynthesis; the efficiency of nuclear folate metabolism is likely to be modified by the cSHMT L474F polymorphism.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA; Cornell Univ, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	PJS13@cornell.edu	Szebenyi, Marian/GMX-2709-2022; Woeller, Collynn/U-3877-2019	Woeller, Collynn/0000-0001-7197-5057	NIDDK NIH HHS [DK58144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058144, R37DK058144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashley C, 2002, GENE, V285, P183, DOI 10.1016/S0378-1119(02)00409-2; Azuma Y, 2002, DEV CELL, V2, P130, DOI 10.1016/S1534-5807(02)00124-7; BARLOWE C K, 1988, Biofactors, V1, P171; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bissoon-Haqqani S, 2006, J HISTOCHEM CYTOCHEM, V54, P19, DOI 10.1369/jhc.5A6642.2005; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BOORSTEIN RJ, 1983, BIOCHEM BIOPH RES CO, V117, P30, DOI 10.1016/0006-291X(83)91536-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christensen KE, 2006, BIOESSAYS, V28, P595, DOI 10.1002/bies.20420; Chu E, 1996, ADV ENZYME REGUL, V36, P143, DOI 10.1016/0065-2571(95)00004-6; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Donnelly JG, 2001, CRIT REV CL LAB SCI, V38, P183, DOI 10.1080/20014091084209; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hughes M, 1998, J CELL SCI, V111, P3017; Jang HR, 2005, J NUTR, V135, p2967S, DOI 10.1093/jn/135.12.2967S; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lim U, 2005, J NUTR, V135, P1989, DOI 10.1093/jn/135.8.1989; LOO D, 1994, CELL BIOL LAB HDB, P45; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Ma J, 1997, CANCER RES, V57, P1098; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Molloy A M, 1999, Haematologica, V84 Suppl EHA-4, P53; NAGARAJAN M, 1989, EXP CELL RES, V181, P289, DOI 10.1016/0014-4827(89)90203-6; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; Papouli E, 2005, MOL CELL, V19, P123, DOI 10.1016/j.molcel.2005.06.001; Pastushok L, 2004, ADV PROTEIN CHEM, V69, P279; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; POON PP, 1994, J BIOL CHEM, V269, P8341; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; Reed MC, 2006, J NUTR, V136, P2653, DOI 10.1093/jn/136.10.2653; Saitoh N, 2006, EXP CELL RES, V312, P1418, DOI 10.1016/j.yexcr.2006.01.013; Schirch V, 2005, CURR OPIN CHEM BIOL, V9, P482, DOI 10.1016/j.cbpa.2005.08.017; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCOTT JM, 1981, LANCET, V2, P337; SHIN YS, 1976, BIOCHIM BIOPHYS ACTA, V444, P794; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Skibola CF, 2002, BLOOD, V99, P3786, DOI 10.1182/blood.V99.10.3786; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Stempak JM, 2005, CARCINOGENESIS, V26, P981, DOI 10.1093/carcin/bgi037; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; STRONG WB, 1990, J BIOL CHEM, V265, P12149; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Wang QE, 2005, NUCLEIC ACIDS RES, V33, P4023, DOI 10.1093/nar/gki684; Watts FZ, 2004, SEMIN CELL DEV BIOL, V15, P211, DOI 10.1016/j.semcdb.2003.12.002; Yurchenko V, 2006, MOL CELL BIOL, V26, P1786, DOI 10.1128/MCB.26.5.1786-1794.2006; Zanetti KA, 2003, J BIOL CHEM, V278, P10142, DOI 10.1074/jbc.M211569200	64	89	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17623	17631		10.1074/jbc.M702526200	http://dx.doi.org/10.1074/jbc.M702526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17446168	hybrid			2022-12-25	WOS:000247084500034
J	Yoo, HY; Kumagai, A; Shevchenko, A; Shevchenko, A; Dunphy, WG				Yoo, Hae Yong; Kumagai, Akiko; Shevchenko, Anna; Shevchenko, Andrej; Dunphy, William G.			Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION CHECKPOINT; DOUBLE-STRAND BREAKS; XENOPUS EGG EXTRACTS; POLYMERASE-ALPHA; PROTEIN; DAMAGE; CHK1; CLASPIN; CHROMATIN; RESPONSES	ATM ( ataxia-telangiectasia mutated) is necessary for activation of Chk1 by ATR ( ATM and Rad3-related) in response to double-stranded DNA breaks ( DSBs) but not to DNA replication stress. TopBP1 has been identified as a direct activator of ATR. We show that ATM regulates Xenopus TopBP1 by phosphorylating Ser-1131 and thereby strongly enhancing association of TopBP1 with ATR. Xenopus egg extracts containing a mutant of TopBP1 that cannot be phosphorylated on Ser-1131 are defective in the ATR-dependent phosphorylation of Chk1 in response to DSBs but not to DNA replication stress. Thus, TopBP1 is critical for the ATM-dependent activation of ATR following production of DSBs in the genome.	CALTECH, Div Cell Biol, Pasadena, CA 91125 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	California Institute of Technology; Max Planck Society	Dunphy, WG (corresponding author), CALTECH, Div Cell Biol, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NIGMS NIH HHS [GM043974, GM070891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043974, R01GM070891, R37GM043974] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hashimoto Y, 2006, GENES CELLS, V11, P993, DOI 10.1111/j.1365-2443.2006.00998.x; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kobayashi T, 2002, J CELL SCI, V115, P3159; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 2006, CELL CYCLE, V5, P1265, DOI 10.4161/cc.5.12.2834; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Wielsch N, 2006, J PROTEOME RES, V5, P2448, DOI 10.1021/pr060200v; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yan S, 2006, J CELL BIOL, V173, P181, DOI 10.1083/jcb.200601076; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	31	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17501	17506		10.1074/jbc.M701770200	http://dx.doi.org/10.1074/jbc.M701770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17446169	hybrid, Green Accepted			2022-12-25	WOS:000247084500020
J	Adams, CM				Adams, Christopher M.			Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING RESPONSE PATHWAY; GENE-EXPRESSION; AMINO-ACID; HEPATIC GLUCONEOGENESIS; MAMMALIAN TARGET; SKELETAL-MUSCLE; PROTEIN; RAPAMYCIN; CELLS; MICE	In most mammalian cells, insulin and glucocorticoids promote anabolism and catabolism, respectively. Whereas the opposing effects of insulin and glucocorticoids on catabolic gene expression have been explained at the molecular level, comparatively little is known about how these hormones alter anabolic gene expression. These studies identify ATF4 as an anabolic transcription factor that is repressed by glucocorticoids and induced by insulin. Insulin-mediated induction of ATF4 required the mammalian target of rapamycin complex 1, was required for the activation of a genetic program for the cellular uptake of essential amino acids and the synthesis of nonessential amino acids and aminoacyl-tRNAs, and was coupled to the repression of Foxo-dependent genes needed for protein and lipid catabolism. These results suggest that ATF4 plays a central role in hormonal regulation of amino acid and protein anabolism by coupling amino acid uptake and synthesis, as well as the generation of charged tRNAs, to mammalian target of rapamycin complex 1-mediated mRNA translation.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Adams, CM (corresponding author), Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.	christopher-adams@uiowa.edu		Adams, Christopher/0000-0002-5795-7212				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; BERDANIER CD, 1979, J NUTR, V109, P1766, DOI 10.1093/jn/109.10.1766; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; EAGLE HARRY, 1955, JOUR BIOL CHEM, V214, P839; Foster DW, 1996, TXB ENDOCRINE PHYSL, P309; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Kimball SR, 2005, SEMIN CELL DEV BIOL, V16, P21, DOI 10.1016/j.semcdb.2004.11.009; KLEBANOV S, 1995, J GERONTOL A-BIOL, V50, pB78, DOI 10.1093/gerona/50A.2.B78; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lassot I, 2005, J BIOL CHEM, V280, P41537, DOI 10.1074/jbc.M505294200; LEUNG K, 1975, ANNU REV PHYSIOL, V37, P245, DOI 10.1146/annurev.ph.37.030175.001333; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Lopez AB, 2007, BIOCHEM J, V402, P163, DOI 10.1042/BJ20060941; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRATT WB, 1966, J BIOL CHEM, V241, P5244; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; SARRAJ JA, 2005, BIOL CHEM, V386, P873; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200	46	128	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16744	16753		10.1074/jbc.M610510200	http://dx.doi.org/10.1074/jbc.M610510200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430894	hybrid			2022-12-25	WOS:000246946500006
J	O'Shaughnessy, RFL; Welti, JC; Cooke, JC; Avilion, AA; Monks, B; Birnbaum, MJ; Byrne, C				O'Shaughnessy, Ryan F. L.; Welti, Jonathan C.; Cooke, James C.; Avilion, Ariel A.; Monks, Bobby; Birnbaum, Morris J.; Byrne, Carolyn			AKT-dependent HspB1 (hsp27) activity in epidermal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; KINASE-B-GAMMA; BARRIER FUNCTION; HUMAN KERATINOCYTES; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-HOMEOSTASIS; STRESS-PROTEIN; HAIR FOLLICLE; MICE LACKING; SKIN	AKT activity has been reported in the epidermis associated with keratinocyte survival and differentiation. We show in developing skin that Akt activity associates first with post-proliferative, para-basal keratinocytes and later with terminally differentiated keratinocytes that are forming the fetal stratum corneum. In adult epidermis the dominant Akt activity is in these highly differentiated granular keratinocytes, involved in stratum corneum assembly. Stratum corneum is crucial for protective barrier activity, and its formation involves complex and poorly understood processes such as nuclear dissolution, keratin filament aggregation, and assembly of a multiprotein cell cornified envelope. A key protein in these processes is filaggrin. We show that one target of Akt in granular keratinocytes is HspB1 ( heat shock protein 27). Loss of epidermal HspB1 caused hyperkeratinization and misprocessing of filaggrin. Akt-mediated HspB1 phosphorylation promotes a transient interaction with filaggrin and intracellular redistribution of HspB1. This is the first demonstration of a specific interaction between HspB1 and a stratum corneum protein and indicates that HspB1 has chaperone activity during stratum corneum formation. This work demonstrates a new role for Akt in epidermis.	Barts & London Queen Mary Univ London, Ctr Cutaneous Res, Inst Cell & Mol Sci, London E1 2AT, England; Barts & London Queen Mary Univ London, Canc Res UK Skin Tumour Lab, Inst Cell & Mol Sci, London E1 2AT, England; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London; University of Pennsylvania; Howard Hughes Medical Institute	Byrne, C (corresponding author), Queen Mary Univ London, Ctr Cutaneous Res, Inst Cell & Mol Sci, London E1 2AT, England.	c.r.byrne@qmul.ac.uk		Welti, Jonathan/0000-0002-9433-8138; Birnbaum, Morris/0000-0001-9972-8680; O'Shaughnessy, Ryan/0000-0002-3701-0267	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK56886] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adly MA, 2006, J AM ACAD DERMATOL, V54, P811, DOI 10.1016/j.jaad.2005.11.1097; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Boros S, 2006, PROTEINS, V62, P1044, DOI 10.1002/prot.20837; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; CANDI E, 2005, J BIOL CHEM, V31, P31; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; Dorion S, 2002, CELL STRESS CHAPERON, V7, P200, DOI 10.1379/1466-1268(2002)007<0200:AOTMAP>2.0.CO;2; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; GANDOUREDWARDS R, 1994, AM J DERMATOPATH, V16, P504, DOI 10.1097/00000372-199410000-00005; Hardman MJ, 1999, J INVEST DERMATOL, V113, P1106, DOI 10.1046/j.1523-1747.1999.00800.x; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hewett DR, 2005, HUM MOL GENET, V14, P335, DOI 10.1093/hmg/ddi030; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jarnik M, 2002, J INVEST DERMATOL, V118, P102, DOI 10.1046/j.0022-202x.2001.01661.x; Jonak C, 2005, HUM PATHOL, V36, P686, DOI 10.1016/j.humpath.2005.04.009; Jonak C, 2002, BRIT J DERMATOL, V147, P13, DOI 10.1046/j.1365-2133.2002.04667.x; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Lippens S, 2005, CELL DEATH DIFFER, V12, P1497, DOI 10.1038/sj.cdd.4401722; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; Monastirli A, 2005, ACTA DERM-VENEREOL, V85, P389, DOI 10.1080/00015550510032869; Moskowitz DG, 2004, J PEDIATR-US, V145, P82, DOI 10.1016/j.jpeds.2004.03.052; Nozaki J, 1997, PHOTOCHEM PHOTOBIOL, V65, P843, DOI 10.1111/j.1751-1097.1997.tb01932.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pankow S, 2006, J CELL SCI, V119, P4033, DOI 10.1242/jcs.03175; Pasonen-Seppanen S, 2001, HISTOCHEM CELL BIOL, V116, P287, DOI 10.1007/s004180100312; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Presland RB, 2001, EXP CELL RES, V270, P199, DOI 10.1006/excr.2001.5348; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Steinert PM, 2000, J CELL BIOL, V151, pF5, DOI 10.1083/jcb.151.2.F5; Suzuki A, 2003, CANCER RES, V63, P674; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Vertii A, 2006, J BIOL CHEM, V281, P26966, DOI 10.1074/jbc.M602134200; Wong JW, 2000, J INVEST DERMATOL, V115, P427, DOI 10.1046/j.1523-1747.2000.00077.x; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561	46	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17297	17305		10.1074/jbc.M610386200	http://dx.doi.org/10.1074/jbc.M610386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439945	hybrid			2022-12-25	WOS:000246946500063
J	Ihara, M; Koyama, H; Uchimura, Y; Saitoh, H; Kikuchi, A				Ihara, Motomasa; Koyama, Hirofumi; Uchimura, Yasuhiro; Saitoh, Hisato; Kikuchi, Akira			Noncovalent binding of small ubiquitin-related modifier (SUMO) protease to SUMO is necessary for enzymatic activities and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; BETA-CATENIN; DEPENDENT ACTIVATION; YEAST; ISOPEPTIDASE; PROTEINS; ULP1; SPECIFICITY; CONJUGATION; AUTOPHAGY	SUMO proteases possess two enzymatic activities to hydrolyze the C-terminal region of SUMOs ( hydrolase activity) and to remove SUMO from SUMO-conjugated substrates ( isopeptidase activity). SUMO proteases bind to SUMOs noncovalently, but the physiological roles of the binding in the functions of SUMO proteases are not well understood. In this study we found that SUMO proteases ( Axam, SENP1, and yeast Ulp1) show different preferences for noncovalent binding to various SUMOs ( SUMO-1, -2, -3, and yeast Smt3) and that the hydrolase and isopeptidase activities of SUMO proteases are dependent on their binding to SUMOs through salt bridge. Expression of Smt3 suppressed the phenotype of yeast mutant lacking smt3, which exhibits growth arrest, and the binding of Ulp1 to Smt3 was essential for this rescue activity. Although expression of an Smt3 mutant ( smt3R64E(GG)), which conjugates to substrate but loses the ability to bind to Ulp1, rescued the phenotype of yeast lacking smt3 partially, the mutant cells showed an increment in the doubling time and a delay of desumoylation of Smt3-conjugated Cdc3. These results indicate that the noncovalent binding of SUMO protease to SUMO through salt bridge is essential for the enzymatic activities and that the balance between sumoylation and desumoylation is important for cell growth control.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kumamoto Univ, Inst Mol Embryol Genet, Dept Regulat Med, Kumamoto 8600811, Japan	Hiroshima University; Kumamoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp						Amar N, 2006, EMBO REP, V7, P635, DOI 10.1038/sj.embor.7400698; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Ihara M, 2005, MOL CELL BIOL, V25, P3506, DOI 10.1128/MCB.25.9.3506-3518.2005; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Rose MD., 1990, METHODS YEAST GENETI; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shen LN, 2006, BIOCHEM J, V397, P279, DOI 10.1042/BJ20052030; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Uchimura Y, 2004, FEBS LETT, V564, P85, DOI 10.1016/S0014-5793(04)00321-7; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	30	20	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16465	16475		10.1074/jbc.M610723200	http://dx.doi.org/10.1074/jbc.M610723200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428805	hybrid			2022-12-25	WOS:000246794300054
J	Kunita, R; Otomo, A; Mizumura, H; Suzuki-Utsunomiya, K; Hadano, S; Ikeda, JE				Kunita, Ryota; Otomo, Asako; Mizumura, Hikaru; Suzuki-Utsunomiya, Kyoko; Hadano, Shinji; Ikeda, Joh-E			The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEREDITARY SPASTIC PARALYSIS; ALS2 GENE; SIGNAL-TRANSDUCTION; HOMOLOGY DOMAIN; PROTEIN; RECEPTOR; MUTATION; RHO; GTPASES	Mutations in the ALS2 gene cause a number of recessive motor neuron diseases, indicating that the ALS2 protein ( ALS2/ alsin) is vital for motor neurons. ALS2 acts as a guanine nucleotide exchange factor ( GEF) for Rab5 ( Rab5GEF) and is involved in endosome dynamics. However, the spatiotemporal regulation of the ALS2-mediated Rab5 activation is unclear. Here we identified an upstream activator for ALS2 and showed a functional significance of the ALS2 activation in endosome dynamics. ALS2 preferentially interacts with activated Rac1. In the cells activated Rac1 recruits cytoplasmic ALS2 to membrane ruffles and subsequently to nascent macropinosomes via Rac1-activated macropinocytosis. At later endocytic stages macropinosomal ALS2 augments fusion of the ALS2-localized macropinosomes with the transferrin-positive endosomes, depending on the ALS2-associated Rab5GEF activity. These results indicate that Rac1 promotes the ALS2 membranous localization, thereby rendering ALS2 active via Rac1-activated endocytosis. Thus, ALS2 is a novel Rac1 effector and is involved in Rac1-activated macropinocytosis. All together, loss of ALS2 may perturb macropinocytosis and/or the following membrane trafficking, which gives rise to neuronal dysfunction in the ALS2-linked motor neuron diseases.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Isehara, Kanagawa 2591193, Japan; Univ Ottawa, Fac Med, Dept Paediat, Ottawa, ON K1H 8M5, Canada	Tokai University; Japan Science & Technology Agency (JST); Tokai University; University of Ottawa	Ikeda, JE (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan.	jeikeda3@is.icc.u-tokai.ac.jp	Hadano, Shinji/ABA-5052-2021; Otomo, Asako/AAA-6374-2019	Hadano, Shinji/0000-0002-4997-3968; Otomo, Asako/0000-0002-7849-4309				Araki N, 2006, CELL STRUCT FUNCT, V31, P145, DOI 10.1247/csf.06029; Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; Brown B, 2001, J LAW MED ETHICS, V29, P166; Cai HB, 2005, J NEUROSCI, V25, P7567, DOI 10.1523/JNEUROSCI.1645-05.2005; Carney DS, 2006, TRENDS CELL BIOL, V16, P27, DOI 10.1016/j.tcb.2005.11.001; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Devon RS, 2006, P NATL ACAD SCI USA, V103, P9595, DOI 10.1073/pnas.0510197103; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hamasaki M, 2004, ANAT REC PART A, V277A, P298, DOI 10.1002/ar.a.20027; Hunker CM, 2006, EXP CELL RES, V312, P1106, DOI 10.1016/j.yexcr.2005.12.021; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Im YJ, 2007, J BIOL CHEM, V282, P5443, DOI 10.1074/jbc.M611342200; Jacquier A, 2006, ANN NEUROL, V60, P105, DOI 10.1002/ana.20886; Kalia M, 2006, MOL BIOL CELL, V17, P3689, DOI 10.1091/mbc.E05-10-0980; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kress JA, 2005, ANN NEUROL, V58, P800, DOI 10.1002/ana.20665; Kunita R, 2004, J BIOL CHEM, V279, P38626, DOI 10.1074/jbc.M406120200; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lesca G, 2003, NEUROLOGY, V60, P674, DOI 10.1212/01.WNL.0000048207.28790.25; Li GP, 1997, J BIOL CHEM, V272, P10337; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Panzeri C, 2006, BRAIN, V129, P1710, DOI 10.1093/brain/awl104; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Su X, 2006, J BIOL CHEM, V281, P27982, DOI 10.1074/jbc.M602873200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Tudor EL, 2005, J BIOL CHEM, V280, P34735, DOI 10.1074/jbc.M506216200; Yamanaka K, 2003, P NATL ACAD SCI USA, V100, P16041, DOI 10.1073/pnas.2635267100; Yamanaka K, 2006, ANN NEUROL, V60, P95, DOI 10.1002/ana.20888; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	52	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16599	16611		10.1074/jbc.M610682200	http://dx.doi.org/10.1074/jbc.M610682200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17409386	hybrid			2022-12-25	WOS:000246794300066
J	Michaluk, P; Kolodziej, L; Mioduszewska, B; Wilczynski, GM; Dzwonek, J; Jaworski, J; Gorecki, DC; Ottersen, OP; Kaczmarek, L				Michaluk, Piotr; Kolodziej, Lukasz; Mioduszewska, Barbara; Wilczynski, Grzegorz M.; Dzwonek, Joanna; Jaworski, Jacek; Gorecki, Dariusz C.; Ottersen, Ole Petter; Kaczmarek, Leszek			beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; NMDA RECEPTORS; MATRIX-METALLOPROTEINASE-9; EXPRESSION; BRAIN; MEMBRANE; KINASE; BIOSYNTHESIS	Matrix metalloproteinase-9 has recently emerged as an important molecule in control of extracellular proteolysis in the synaptic plasticity. However, no synaptic targets for its enzymatic activity had been identified before. In this report, we show that beta-dystroglycan comprises such a neuronal activity-driven target for matrix metalloproteinase-9. This notion is based on the following observations. (i) Recombinant, autoactivating matrix metalloproteinase-9 produces limited proteolytic cleavage of beta-dystroglycan. (ii) In neuronal cultures, beta-dystroglycan proteolysis occurs in response to stimulation with either glutamate or bicuculline and is blocked by tissue inhibitor of metalloproteinases-1, a metalloproteinase inhibitor. (iii) beta-Dystroglycan degradation is also observed in the hippocampus in vivo in response to seizures but not in the matrix metalloproteinase 9 knock-out mice. (iv) beta-Dystroglycan cleavage correlates in time with increased matrix metalloproteinase-9 activity. (v) Finally, beta-dystroglycan and matrix metalloproteinase-9 colocalize in postsynaptic elements in the hippocampus. In conclusion, our data identify the beta-dystroglycan as a first matrix metalloproteinase-9 substrate digested in response to enhanced synaptic activity. This demonstration may help to understand the possible role of both proteins in neuronal functions, especially in synaptic plasticity, learning, and memory.	Nencki Inst, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland; Nencki Inst, Dept Neurophysiol, PL-02093 Warsaw, Poland; Univ Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Int Inst Mol & Cell biol, PL-02109 Warsaw, Poland; Int Inst Mol & Cell Biol, Lab Mol & Cellular Neurobiol, PL-02109 Warsaw, Poland; Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed Sci & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Univ Oslo, Ctr Mol Biol & Neurosci, Inst Basic Med Sci, N-0317 Oslo, Norway	Polish Academy of Sciences; Polish Academy of Sciences; Utrecht University; Utrecht University; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Portsmouth; University of Oslo	Kaczmarek, L (corresponding author), Nencki Inst, Dept Mol & Cellular Neurobiol, Pasteura 3, PL-02093 Warsaw, Poland.	l.kaczmarek@nencki.gov.pl	Kolodziej, Lukas/J-2978-2014; Kaczmarek, Leszek/B-6171-2008; Michaluk, Piotr/AAR-5238-2021; Kaczmarek, Leszek/AHA-0076-2022	Kolodziej, Lukas/0000-0002-0400-7918; Kaczmarek, Leszek/0000-0002-7207-3490; Michaluk, Piotr/0000-0003-2306-3314; Kaczmarek, Leszek/0000-0002-7207-3490; Wilczynski, Grzegorz/0000-0001-6667-0291; Dzwonek, Joanna/0000-0002-3834-2175; Gorecki, Dariusz/0000-0003-3584-1654; Kolodziej, Lukasz/0000-0002-9814-9158; Jaworski, Jacek/0000-0001-8760-7865	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; Bruno MA, 2006, P NATL ACAD SCI USA, V103, P6735, DOI 10.1073/pnas.0510645103; CALABRESI P, 1990, J NEUROPHYSIOL, V63, P651, DOI 10.1152/jn.1990.63.4.651; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Culligan Kevin, 2002, Journal of Biomedicine and Biotechnology, V2, P31, DOI 10.1155/S1110724302000347; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Fisher KE, 2002, BIOCHEMISTRY-US, V41, P8289, DOI 10.1021/bi012076t; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gorecki DC, 1999, MOL CELL NEUROSCI, V13, P218, DOI 10.1006/mcne.1999.0740; Gorecki DC, 1998, NEUROSCIENCE, V84, P467, DOI 10.1016/S0306-4522(97)00562-9; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hnia K, 2006, NEUROSCIENCE, V141, P607, DOI 10.1016/j.neuroscience.2006.04.043; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Matsumura K, 2005, NEUROMUSCULAR DISORD, V15, P336, DOI 10.1016/j.nmd.2005.01.007; Matsumura K, 2003, NEUROMUSCULAR DISORD, V13, P796, DOI 10.1016/S0960-8966(03)00139-1; Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; OKULSKI P, 2007, IN PRESS BIOL PSYCHI; REVAH F, 1996, PROTOCOLS GENE TRANS, P81; Sadatmansoori S, 2001, PROTEIN EXPRES PURIF, V23, P447, DOI 10.1006/prep.2001.1542; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WILCZYNSKI GM, IN PRESS REGULATION; Woessner J.F., 2000, PROTEIN PROFILE SER; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamada H, 2001, HUM MOL GENET, V10, P1563, DOI 10.1093/hmg/10.15.1563; Yang YC, 2003, J NEUROSCI, V23, P4072; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6; Zagulska-Szymczak S, 2001, NEUROCHEM INT, V38, P485, DOI 10.1016/S0197-0186(00)00101-7; Zhong D, 2006, BIOCHEM BIOPH RES CO, V345, P867, DOI 10.1016/j.bbrc.2006.05.004	46	156	159	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16036	16041		10.1074/jbc.M700641200	http://dx.doi.org/10.1074/jbc.M700641200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426029	hybrid			2022-12-25	WOS:000246794300011
J	Rezvani, HR; Dedieu, S; North, S; Belloc, F; Rossignol, R; Letellier, T; de Verneuil, H; Taieb, A; Mazurier, F				Rezvani, Hamid Reza; Dedieu, Sophie; North, Sophie; Belloc, Francis; Rossignol, Rodrigue; Letellier, Thierry; de Verneuil, Hubert; Taieb, Alain; Mazurier, Frederic			Hypoxia-inducible factor-1 alpha, a key factor in the keratinocyte response to UVB exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-B IRRADIATION; ACTIVATED PROTEIN-KINASE; FACTOR-I; ANTIOXIDANT ENZYMES; INDUCED APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; DOWN-REGULATION; FACTOR 1-ALPHA; NITRIC-OXIDE	Hypoxia-inducible factor-1 (HIF-1) is a major transcription factor sensitive to oxygen levels, which responds to stress factors under both hypoxic and nonhypoxic conditions. UV irradiation being a common stressor of skin, we looked at the effect of UVB on HIF-1 alpha expression in keratinocytes. We found that UVB induces a biphasic HIF-1 alpha variation through reactive oxygen species ( ROS) generation. Whereas rapid production of cytoplasmic ROS down-regulates HIF-1 alpha expression, delayed mitochondrial ROS generation results in its up-regulation. Indeed, activation of p38 MAPK and JNK1 mediated by mitochondrial ROS were required for HIF-1 alpha phosphorylation and accumulation after UVB irradiation. Our experiments also revealed a key role of HIF-1 alpha in mediating UVB-induced apoptosis. We conclude that the broad impact of the HIF- 1 transcription factor on gene expression could make it a key regulator of UV-responsive genes and photocarcinogenesis.	INSERM, U876, F-33000 Bordeaux, France; Univ Bordeaux, F-33000 Bordeaux, France; INSERM, U668, F-33000 Bordeaux, France; Ctr Hosp Univ Bordeaux, Dept Dermatol, Natl Reference Ctr Rare Skin Dis, Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux	Mazurier, F (corresponding author), INSERM, U876, F-33000 Bordeaux, France.	mazurier@u-bordeaux2.fr	Mazurier, FrÃ©dÃ©ric/O-1619-2018; TAIEB, ALAIN/AAB-1085-2021; Rezvani, Hamid Reza/G-3734-2013	Rezvani, Hamid Reza/0000-0001-8067-1338; Mazurier, Frederic/0000-0002-6984-7096				Assefa Z, 2005, BBA-REV CANCER, V1755, P90, DOI 10.1016/j.bbcan.2005.04.001; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Beak SM, 2004, BIOCHIMIE, V86, P425, DOI 10.1016/j.biochi.2004.06.010; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bell EL, 2005, MITOCHONDRION, V5, P322, DOI 10.1016/j.mito.2005.06.005; Blaudschun R, 2000, FEBS LETT, V474, P195, DOI 10.1016/S0014-5793(00)01605-7; BODE AM, 2003, SCI STKE, pRE2; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Comerford KM, 2004, CANCER RES, V64, P9057, DOI 10.1158/0008-5472.CAN-04-1919; Corre S, 2004, J BIOL CHEM, V279, P51226, DOI 10.1074/jbc.M409768200; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Garmyn M, 1997, J PHOTOCH PHOTOBIO B, V37, P125, DOI 10.1016/S1011-1344(96)07340-X; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kietzmann T, 2003, THROMB HAEMOSTASIS, V89, P666; Kim MS, 2006, J INVEST DERMATOL, V126, P2697, DOI 10.1038/sj.jid.5700463; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Maalouf S, 2002, MOL CARCINOGEN, V34, P121, DOI 10.1002/mc.10055; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; Matsumura Yasuhiro, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S146239940200532X; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; McArdle F, 2002, FREE RADICAL BIO MED, V33, P1355, DOI 10.1016/S0891-5849(02)01042-0; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; PUNNONEN K, 1991, PHOTODERMATOL PHOTO, V8, P3; Rezvani HR, 2007, CANCER GENE THER, V14, P174, DOI 10.1038/sj.cgt.7701000; Rezvani HR, 2006, J BIOL CHEM, V281, P17999, DOI 10.1074/jbc.M600536200; Rossignol F, 2002, GENE, V299, P135, DOI 10.1016/S0378-1119(02)01049-1; Ryan HE, 2000, CANCER RES, V60, P4010; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHINDO Y, 1994, PHOTODERMATOL PHOTO, V10, P183; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tyrrell RM, 1995, BIOCHEM SOC SYMP, P47, DOI 10.1042/bss0610047; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 1999, CANCER RES, V59, P5830	56	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16413	16422		10.1074/jbc.M611397200	http://dx.doi.org/10.1074/jbc.M611397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400550	hybrid			2022-12-25	WOS:000246794300049
J	Duensing, A; Liu, Y; Perdreau, SA; Kleylein-Sohn, J; Nigg, EA; Duensing, S				Duensing, A.; Liu, Y.; Perdreau, S. A.; Kleylein-Sohn, J.; Nigg, E. A.; Duensing, S.			Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates	ONCOGENE			English	Article						centrioles; proteasome; CDK2; cyclin e; PLK4; HPV-16E7	CENTROSOME DUPLICATION; CYCLIN-E; CELLS; ASSOCIATION; INSTABILITY; DISRUPTION; DEFECTS	Abnormal centrosome numbers are detected in virtually all cancers. The molecular mechanisms that underlie centrosome amplification, however, are poorly characterized. Based on the model that each maternal centriole serves as a template for the formation of one and only one daughter centriole per cell division cycle, the prevailing view is that centriole overduplication arises from successive rounds of centriole reproduction. Here, we provide evidence that a single maternal centriole can concurrently generate multiple daughter centrioles. This mechanism was initially identified in cells treated with the peptide vinyl sulfone proteasome inhibitor Z- L3VS. We subsequently found that the formation of more than one daughter at maternal centrioles requires cyclin E/cyclin-dependent kinase 2 as well as Polo-like kinase 4 and that overexpression of these proteins mimics this phenotype in the absence of a proteasome inhibitor. Moreover, we show that the human papillomavirus type 16 E7 oncoprotein stimulates aberrant daughter centriole numbers in part through the formation of more than one daughter centriole at single maternal templates. These results help to explain how oncogenic stimuli can rapidly induce abnormal centriole numbers within a single cell-division cycle and provide insights into the regulation of centriole duplication.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Max Planck Society; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, A (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		nigg, erich/0000-0003-4835-5719; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RG, 1971, J CELL BIOL, V50, P10, DOI 10.1083/jcb.50.1.10; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; DIRKSEN ER, 1971, J CELL BIOL, V51, P286, DOI 10.1083/jcb.51.1.286; Duensing A, 2007, ONCOGENE, V26, P215, DOI 10.1038/sj.onc.1209782; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NIGG EA, 2004, CENTROSOMES DEV DIS; Pihan GA, 1998, CANCER RES, V58, P3974; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 2004, CENTROSOMES DEV DIS, P167, DOI DOI 10.1002/3527603808.CH9; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Vidwans SJ, 2003, J CELL SCI, V116, P137, DOI 10.1242/jcs.00204; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X	37	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6280	6288		10.1038/sj.onc.1210456	http://dx.doi.org/10.1038/sj.onc.1210456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438528	Green Accepted			2022-12-25	WOS:000249583300004
J	Agouni, A; Mostefai, HA; Porro, C; Carusio, N; Favre, J; Richard, V; Henrion, D; Martinez, MC; Andriantsitohaina, R				Agouni, Abdelali; Mostefai, H. Ahmed; Porro, Chiarra; Carusio, Nunzia; Favre, Julie; Richard, Vincent; Henrion, Daniel; Martinez, M. Carmen; Andriantsitohaina, Ramaroson			Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release	FASEB JOURNAL			English	Article						microvesicles; NO-synthase; MPs; PI3-kinase inhibitor	SHED MEMBRANE MICROPARTICLES; GENE-THERAPY; CELLS; PROLIFERATION; MICROVESICLES; DYSFUNCTION; ADHESION	Microparticles ( MPs) are small fragments generated from the plasma membrane after cell stimulation. Among the candidate proteins harbored by MPs, we recently showed that sonic hedgehog ( Shh) is present in MPs generated from activated/ apoptotic human T lymphocytes [ Martinez et al., Blood ( 2006) vol. 108, 3012 - 3020]. We show here that Shh carried by MPs induces nitric oxide ( NO) release from endothelial cells, triggers changes in the expression and phosphorylation of enzymes related to the NO pathway, and decreases production of reactive oxygen species. When PI3- kinase and ERK signaling were specifically inhibited, the effects of MPs were reversed. In vivo injection of MPs in mice was also able to improve endothelial function by increasing NO release, and it reversed endothelial dysfunction after ischemia/ reperfusion. Silencing the effects of Shh with cyclopamine, a specific inhibitor of Shh, or siRNA, an inhibitor of the Shh receptor Patched, strongly reduced production of NO elicited by MPs. Taken together, we propose that the biological message carried by MPs harboring Shh may represent a new therapeutic approach against endothelial dysfunction during acute severe endothelial injury.	Univ Angers, Fac Med, INSERM, CNRS,UMR 6214,U771, F-49045 Angers, France; Univ Rouen, INSERM, UFR Med Pharmacie, U644, Rouen, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Andriantsitohaina, R (corresponding author), Univ Angers, Fac Med, INSERM, CNRS,UMR 6214,U771, Rue Haute Reculee, F-49045 Angers, France.	ramaroson.andriantsitohaina@univ-angers.fr	Henrion, Daniel/AAK-1995-2021; Agouni, Abdelali/AAP-5298-2020; PORRO, CHIARA/G-7849-2018; Richard, Vincent/B-1059-2014	Henrion, Daniel/0000-0003-1094-0285; Agouni, Abdelali/0000-0002-8363-1582; PORRO, CHIARA/0000-0002-7526-6968; Richard, Vincent/0000-0003-0590-0158; andriantsitohaina, ramaroson/0000-0002-4770-3585				Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167; Baj-Krzyworzeka M, 2002, EXP HEMATOL, V30, P450, DOI 10.1016/S0301-472X(02)00791-9; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jimenez JJ, 2003, BRIT J HAEMATOL, V123, P896, DOI 10.1046/j.1365-2141.2003.04716.x; Kaeffer N, 1997, CIRCULATION, V96, P2311; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Kayed H, 2006, PANCREAS, V32, P119, DOI 10.1097/01.mpa.0000202937.55460.0c; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E; Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004; Mezentsev A, 2005, AM J PHYSIOL-HEART C, V289, pH1106, DOI 10.1152/ajpheart.00265.2005; Moens AL, 2005, INT J CARDIOL, V100, P179, DOI 10.1016/j.ijcard.2004.04.013; Nomura S, 2001, ATHEROSCLEROSIS, V158, P277, DOI 10.1016/S0021-9150(01)00433-6; Podlasek CA, 2005, CURR PHARM DESIGN, V11, P4011, DOI 10.2174/138161205774913408; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; RICHARD V, 1994, CIRCULATION, V89, P1254, DOI 10.1161/01.CIR.89.3.1254; RIOBO NA, 2006, J BIOL CHEM, V103, P4505; Sabatier F, 2002, DIABETES, V51, P2840, DOI 10.2337/diabetes.51.9.2840; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Tesse A, 2005, ARTERIOSCL THROM VAS, V25, P2522, DOI 10.1161/01.ATV.0000189298.62240.5d; Vokes SA, 2004, DEVELOPMENT, V131, P4371, DOI 10.1242/dev.01304; Yang HY, 2007, MOL IMMUNOL, V44, P1577, DOI 10.1016/j.molimm.2006.08.017	30	111	120	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2735	2741		10.1096/fj.07-8079com	http://dx.doi.org/10.1096/fj.07-8079com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17428963	Green Submitted			2022-12-25	WOS:000249237500015
J	Althaus, M; Bogdan, R; Clauss, WG; Fronius, M				Althaus, Mike; Bogdan, Roman; Clauss, Wolfgang G.; Fronius, Martin			Mechano-sensitivity of epithelial sodium channels (ENaCs): laminar shear stress increases ion channel open probability	FASEB JOURNAL			English	Article						DEG/ENaC family; patch-clamp; outside-out; Xenopus oocyte	VASCULAR ENDOTHELIAL-CELLS; CORTICAL COLLECTING TUBULE; NA+ CHANNEL; XENOPUS OOCYTES; CAENORHABDITIS-ELEGANS; FROG-SKIN; MEMBRANE; FLOW; MECHANOTRANSDUCTION; STIMULATION	Epithelial cells are exposed to a variety of mechanical forces, but little is known about the impact of these forces on epithelial ion channels. Here we show that mechanical activation of epithelial sodium channels ( ENaCs), which are essential for electrolyte and water balance, occurs via an increased ion channel open probability. ENaC activity of heterologously expressed rat ( rENaC) and Xenopus ( xENaC) orthologs was measured by whole-cell as well as single-channel recordings. Laminar shear stress ( LSS), producing shear forces in physiologically relevant ranges, was used to mechanically stimulate ENaCs and was able to activate ENaC currents in whole-cell recordings. Preceding pharmacological activation of rENaC with Zn2+ and xENaC with gadolinium and glibenclamide largely prevented LSS-activated currents. In contrast, proteolytic cleavage with trypsin potentiated the LSS effect on rENaC whereas the LSS effect on xENaC was reversed ( inhibition of xENaC current). Further, we found that exposure of excised outside-out patches to LSS led to an increased ion channel open probability without affecting the number of active channels. We suggest that mechano-sensitivity of ENaC may represent a ubiquitous feature for the physiology of epithelia, providing a putative mechanism for coupling transepithelial Na+ reabsorption to luminal transport.	Univ Giessen, Inst Anim Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Fronius, M (corresponding author), Univ Giessen, Inst Anim Physiol, Wartweg 95, D-35392 Giessen, Germany.	martin.fronius@bio.uni-giessen.de	Fronius, Martin/K-4118-2013	Althaus, Mike/0000-0002-3554-7538				Anantharam A, 2006, J PHYSIOL-LONDON, V574, P333, DOI 10.1113/jphysiol.2006.109173; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Barakat AI, 1999, CIRC RES, V85, P820, DOI 10.1161/01.RES.85.9.820; Brakemeier S, 2003, CARDIOVASC RES, V60, P488, DOI 10.1016/j.cardiores.2003.09.010; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2004, J BIOL CHEM, V279, P4120, DOI 10.1074/jbc.M311783200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Chraibi A, 1999, J PHARMACOL EXP THER, V290, P341; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Drummond HA, 2000, BRAIN RES, V884, P1, DOI 10.1016/S0006-8993(00)02831-6; Drummond HA, 2004, HYPERTENSION, V44, P643, DOI 10.1161/01.HYP.0000144465.56360.ad; Drummond HA, 2001, ANN NY ACAD SCI, V940, P42; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Friis S, 2001, J MEMBRANE BIOL, V184, P291, DOI 10.1007/s00232-001-0100-7; Fronius M, 2003, J MEMBRANE BIOL, V195, P43, DOI 10.1007/s00232-003-2043-7; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jernigan NL, 2005, AM J PHYSIOL-RENAL, V289, pF891, DOI 10.1152/ajprenal.00019.2005; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; KOEFOEDJOHNSEN V, 1958, ACTA PHYSIOL SCAND, V42, P298, DOI 10.1111/j.1748-1716.1958.tb01563.x; Lieu DK, 2004, AM J PHYSIOL-CELL PH, V286, pC1367, DOI 10.1152/ajpcell.00243.2003; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MCNAUGHTON KJ, 1966, J FLUID MECH, V25, P367, DOI 10.1017/S0022112066001708; Morimoto T, 2006, AM J PHYSIOL-RENAL, V291, pF663, DOI 10.1152/ajprenal.00514.2005; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rossier BC, 1998, J GEN PHYSIOL, V112, P95, DOI 10.1085/jgp.112.2.95; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Schnizler M, 2003, BBA-BIOMEMBRANES, V1609, P170, DOI 10.1016/S0005-2736(02)00684-3; Sheng SH, 2004, J BIOL CHEM, V279, P31687, DOI 10.1074/jbc.M405224200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Tavernarakis N, 2001, ANN NY ACAD SCI, V940, P28; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329	52	84	86	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2389	2399		10.1096/fj.06-7694com	http://dx.doi.org/10.1096/fj.06-7694com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426066				2022-12-25	WOS:000248454400014
J	Lin, Q; Weis, S; Yang, G; Weng, YH; Helston, R; Rish, K; Smith, A; Bordner, J; Polte, T; Gaunitz, F; Dennery, PA				Lin, Qing; Weis, Sebastian; Yang, Guang; Weng, Yi-Hao; Helston, Rachel; Rish, Kimberly; Smith, Ann; Bordner, Jessica; Polte, Tobias; Gaunitz, Frank; Dennery, Phyllis A.			Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; MOUSE HEPATOMA-CELLS; HYDROGEN-PEROXIDE; OXIDANT STRESS; MU-CALPAIN; GENE; INDUCTION; EXPORT; PROLIFERATION; PATHWAY	Heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme degradation, is an integral membrane protein of the smooth endoplasmic reticulum. However, we detected an HO-1 immunoreactive signal in the nucleus of cultured cells after exposure to hypoxia and heme or heme/hemopexin. Under these conditions, a faster migrating HO-1 immunoreactive band was enriched in nuclear extracts, suggesting that HO-1 was cleaved to allow nuclear entry. This was confirmed by the absence of immunoreactive signal with an antibody against the C terminus and the lack of a C-terminal sequence by gas chromatography-mass spectrometry. Incubation with leptomycin B prior to hypoxia abolished nuclear HO-1 and the faster migrating band on Western analysis, suggesting that this process was facilitated by CRM1. Furthermore, preincubation with a cysteine protease inhibitor prevented nuclear entry of green fluorescent protein-labeled HO-1, demonstrating that protease-mediated C-terminal cleavage was also necessary for nuclear transport of HO-1. Nuclear localization was also associated with reduction of HO activity. HO-1 protein, whether it was enzymatically active or not, mediated activation of oxidant-responsive transcription factors, including activator protein-1. Nevertheless, nuclear HO-1 protected cells against hydrogen peroxide-mediated injury equally as well as cytoplasmic HO-1. We speculate that nuclear localization of HO-1 protein may serve to up-regulate genes that promote cytoprotection against oxidative stress.	Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Stanford Univ, Dept Pediat, Palo Alto, CA 94305 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; Univ Leipzig, Interdisziplinares Zentrum, D-04107 Leipzig, Germany	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Stanford University; University of Missouri System; University of Missouri Kansas City; Leipzig University	Dennery, PA (corresponding author), Childrens Hosp, Div Neonatol, 34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	dennery@email.chop.edu	Weis, Sebastian/P-9016-2014; Gaunitz, Frank/A-2641-2008; Dennery, Phyllis/GQG-9113-2022	Weis, Sebastian/0000-0003-3201-2375; Gaunitz, Frank/0000-0001-6628-0605; Dennery, Phyllis/0000-0001-5745-1855; Helston, Rachel/0000-0001-6022-6755	NHLBI NIH HHS [HL 58752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1989, J BIOL CHEM, V264, P6371; APPLEGATE LA, 1991, CANCER RES, V51, P974; Bhattacharya A, 2003, CANCER RES, V63, P8167; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; Chen M, 2005, BIOCHEM BIOPH RES CO, V330, P714, DOI 10.1016/j.bbrc.2005.03.029; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Hajdena-Dawson Monica, 2003, Mol Imaging, V2, P138, DOI 10.1162/153535003322556886; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Hori R, 2002, J BIOL CHEM, V277, P10712, DOI 10.1074/jbc.M107749200; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jager R, 2003, MOL CANCER RES, V1, P921; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kitchin KT, 2001, J IMMUNOL METHODS, V247, P153, DOI 10.1016/S0022-1759(00)00325-2; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lischka P, 2006, J VIROL, V80, P10274, DOI 10.1128/JVI.00995-06; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Pae HO, 2004, J IMMUNOL, V172, P4744, DOI 10.4049/jimmunol.172.8.4744; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SMITH A, 1988, BIOCHEM J, V256, P941, DOI 10.1042/bj2560941; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Tsutsumi S, 2003, CANCER RES, V63, P4882; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yan JL, 2004, NAT STRUCT MOL BIOL, V11, P901, DOI 10.1038/nsmb819; Yang G, 2004, J CLIN INVEST, V114, P669, DOI 10.1172/JCI200419300; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7803; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200	61	313	323	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20621	20633		10.1074/jbc.M607954200	http://dx.doi.org/10.1074/jbc.M607954200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17430897	hybrid			2022-12-25	WOS:000247819300065
J	Koller-Eichhorn, R; Marquardt, T; Gail, R; Wittinghofer, A; Kostrewa, D; Kutay, U; Kambach, C				Koller-Eichhorn, Roland; Marquardt, Tobias; Gail, Robert; Wittinghofer, Alfred; Kostrewa, Dirk; Kutay, Ulrike; Kambach, Christian			Human OLA1 defines an ATPase subfamily in the Obg family of GTP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; P-LOOP; SWITCH; RAS; TRANSLATION; VALIDATION; EVOLUTION; GTPASES; YCHF; P21	Purine nucleotide-binding proteins build the large family of P-loop GTPases and related ATPases, which perform essential functions in all kingdoms of life. The Obg family comprises a group of ancient GTPases belonging to the TRAFAC (for translation factors) class and can be subdivided into several distinct protein subfamilies. The founding member of one of these subfamilies is the bacterial P-loop NTPase YchF, which had so far been assumed to act as GTPase. We have biochemically characterized the human homologue of YchF and found that it binds and hydrolyzes ATP more efficiently than GTP. For this reason, we have termed the protein hOLA1, for human Obg-like ATPase 1. Further biochemical characterization of YchF proteins from different species revealed that ATPase activity is a general but previously missed feature of the YchF subfamily of Obg-like GTPases. To explain ATP specificity of hOLA1, we have solved the x-ray structure of hOLA1 bound to the nonhydrolyzable ATP analogue AMPPCP. Our structural data help to explain the altered nucleotide specificity of YchF homologues and identify the Ola1/YchF subfamily of the Obg-related NTPases as an exceptional example of a single protein subfamily, which has evolved altered nucleotide specificity within a distinct protein family of GTPases.	ETH, Inst Biochem, CH-8093 Zurich, Switzerland; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Max Planck Society	Kutay, U (corresponding author), ETH, Inst Biochem, Schafmattstr 18, CH-8093 Zurich, Switzerland.	ulrike.kutay@bc.biol.ethz.ch; christian.kambach@psi.ch						Buglino J, 2002, STRUCTURE, V10, P1581, DOI 10.1016/S0969-2126(02)00882-1; Caldon CE, 2003, CURR OPIN MICROBIOL, V6, P135, DOI 10.1016/S1369-5274(03)00037-7; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Danese I, 2004, INFECT IMMUN, V72, P5783, DOI 10.1128/IAI.72.10.5783-5790.2004; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Lin B, 1999, J BACTERIOL, V181, P5825, DOI 10.1128/JB.181.18.5825-5832.1999; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Michel B, 2005, DEV CELL, V8, P300, DOI 10.1016/j.devcel.2005.02.002; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; Morimoto T, 2002, MICROBIOL-SGM, V148, P3539, DOI 10.1099/00221287-148-11-3539; NUR EKMS, 1992, MOL BIOL CELL, V3, P1437; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Sikora AE, 2006, BIOCHEM BIOPH RES CO, V339, P1165, DOI 10.1016/j.bbrc.2005.11.129; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Teplyakov A, 2003, J BACTERIOL, V185, P4031, DOI 10.1128/JB.185.14.4031-4037.2003; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WELSH KM, 1994, J BACTERIOL, V176, P7161, DOI 10.1128/JB.176.23.7161-7168.1994; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	32	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19928	19937		10.1074/jbc.M700541200	http://dx.doi.org/10.1074/jbc.M700541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17430889	Green Published, hybrid			2022-12-25	WOS:000247650600067
J	Dinkla, K; Nitsche-Schmitz, DP; Barroso, V; Reissmann, S; Johansson, HM; Frick, IM; Rohde, M; Chhatwal, GS				Dinkla, Katrin; Nitsche-Schmitz, D. Patric; Barroso, Vanessa; Reissmann, Silvana; Johansson, Helena M.; Frick, Inga-Maria; Rohde, Manfred; Chhatwal, Gursharan S.			Identification of a streptococcal octapeptide motif involved in acute rheumatic fever	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART-DISEASE; M-PROTEIN; FOG; PATHOGENESIS; PHARYNGITIS; INFECTIONS; ANTIGENS; CHAIN; LINKS	Acute rheumatic fever is a serious autoimmune sequela of pharyngitis caused by certain group A streptococci. One mechanism applied by streptococcal strains capable of causing acute rheumatic fever is formation of an autoantigenic complex with human collagen IV. In some geographic regions with a high incidence of acute rheumatic fever pharyngeal carriage of group C and group G streptococci prevails. Examination of such strains revealed the presence of M-like surface proteins that bind human collagen. Using a peptide array and recombinant proteins with targeted amino acid substitutions, we could demonstrate that formation of collagen complexes during streptococcal infections depends on an octapeptide motif, which is present in collagen binding M and M-like proteins of different beta-hemolytic streptococcal species. Mice immunized with streptococcal proteins that contain the collagen binding octapeptide motif developed high serum titers of anti-collagen antibodies. In sera of rheumatic fever patients such a collagen autoimmune response was accompanied by specific reactivity against the collagen-binding proteins, linking the observed effect to clinical cases. Taken together, the data demonstrate that the identified octapeptide motif through its action on collagen plays a crucial role in the pathogenesis of rheumatic fever. Eradication of streptococci that express proteins with the collagen binding motif appears advisable for controlling rheumatic fever.	Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, D-38124 Braunschweig, Germany; Lund Univ, Dept Clin Sci, S-22184 Lund, Sweden	Helmholtz Association; Helmholtz-Center for Infection Research; Lund University	Chhatwal, GS (corresponding author), Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, Inhoffenstr 7, D-38124 Braunschweig, Germany.	gsc@helmholtz-hzi.de		Linge, Helena/0000-0002-8919-0300				Afek A, 1999, LUPUS, V8, P502, DOI 10.1191/096120399678840873; Ahmed J, 2003, Bangladesh Med Res Counc Bull, V29, P113; BARACCO GJ, 2006, GRAM POSITIVE PATHOG, P223; Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; Carapetis JR, 2005, LANCET, V366, P155, DOI 10.1016/S0140-6736(05)66874-2; Carapetis JR, 1997, ADV EXP MED BIOL, V418, P233; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677; Dinkla K, 2003, J CLIN INVEST, V111, P1905, DOI 10.1172/JCI200317247; Ellis NMJ, 2005, J IMMUNOL, V175, P5448, DOI 10.4049/jimmunol.175.8.5448; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Haidan A, 2000, LANCET, V356, P1167, DOI 10.1016/S0140-6736(00)02765-3; HARTAS J, 1995, MICROB PATHOGENESIS, V18, P345, DOI 10.1006/mpat.1995.0031; Johansson HM, 2004, MICROBIOL-SGM, V150, P4211, DOI 10.1099/mic.0.27269-0; Kaplan EL, 2006, CLIN INFECT DIS, V43, P690, DOI 10.1086/506944; Kaplan EL, 2005, HEART, V91, P3, DOI 10.1136/hrt.2004.034744; Kumar Rajesh, 2002, Indian Heart J, V54, P54; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; MAJEED HA, 1986, ZBL BAKT-INT J MED M, V262, P346; McDonald M, 2004, LANCET INFECT DIS, V4, P240, DOI 10.1016/S1473-3099(04)00975-2; McDonald MI, 2006, CLIN INFECT DIS, V43, P683, DOI 10.1086/506938; MOSHER DF, 1984, ANNU REV MED, V35, P561, DOI 10.1146/annurev.me.35.020184.003021; Nitsche DP, 2006, J BIOL CHEM, V281, P1670, DOI 10.1074/jbc.M506776200; Nitsche-Schmitz DP, 2007, J BIOL CHEM, V282, P17530, DOI 10.1074/jbc.M702612200; POTTER EV, 1978, J PEDIATR-US, V92, P325, DOI 10.1016/S0022-3476(78)80036-5; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; Saxena Anita, 2002, Curr Treat Options Cardiovasc Med, V4, P309, DOI 10.1007/s11936-002-0011-7; SIMPSON WJ, 1987, MICROB PATHOGENESIS, V3, P339, DOI 10.1016/0882-4010(87)90004-0; Staali L, 2003, CELL MICROBIOL, V5, P253, DOI 10.1046/j.1462-5822.2003.00272.x; Stollerman G H, 1990, Adv Intern Med, V35, P1; Tontsch D, 2000, CLIN EXP IMMUNOL, V121, P270, DOI 10.1046/j.1365-2249.2000.01283.x; Veasy LG, 2004, PEDIATRICS, V113, pE168, DOI 10.1542/peds.113.3.e168; WANNAMAKER LW, 1973, CIRCULATION, V48, P9, DOI 10.1161/01.CIR.48.1.9; WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease, 2001, WHO TECHN REP SER, V923; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	37	45	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18686	18693		10.1074/jbc.M701047200	http://dx.doi.org/10.1074/jbc.M701047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17452321	hybrid			2022-12-25	WOS:000247475300006
J	Izawa, K; Kitaura, J; Yamanishi, Y; Matsuoka, T; Oki, T; Shibata, F; Kumagai, H; Nakajima, H; Maeda-Yamamoto, M; Hauchins, JP; Tybulewicz, VLJ; Takai, T; Kitamura, T				Izawa, Kumi; Kitaura, Jiro; Yamanishi, Yoshinori; Matsuoka, Takayuki; Oki, Toshihiko; Shibata, Fumi; Kumagai, Hidetoshi; Nakajima, Hideaki; Maeda-Yamamoto, Mari; Hauchins, Jeffrey P.; Tybulewicz, Victor L. J.; Takai, Toshiyuki; Kitamura, Toshio			Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; IMMUNOGLOBULIN-LIKE RECEPTORS; MAST-CELL ACTIVATION; FC-EPSILON-RI; TYROSINE KINASE; MYELOID CELLS; CMRF-35-LIKE MOLECULE-1; GENE SUPERFAMILY; DENDRITIC CELLS; IMMUNE-SYSTEM	The leukocyte mono-Ig-like receptor (LMIR) belongs to a new family of paired immunoreceptors. In this study, we analyzed activating receptor LMIR4/CLM-5 as a counterpart of inhibitory receptor LMIR3/CLM-1. LMIR4 is expressed in myeloid cells, including granulocytes, macrophages, and mast cells, whereas LMIR3 is more broadly expressed. The association of LMIR4 with Fc receptor-gamma among immunoreceptor tyrosine-based activation motif-bearing molecules was indispensable for LMIR4-mediated functions of bone marrow-derived mast cells, but dispensable for its surface expression. Cross-linking of LMIR4 led to Lyn- and Syk-dependent activation of bone marrow-derived mast cells, resulting in cytokine production and degranulation, whereas that of LMIR3 did not. The triggering of LMIR4 and TLR4 synergistically caused robust cytokine production in accordance with enhanced activation of ERK, whereas the co-ligation of LMIR4 and LMIR3 dramatically abrogated cytokine production. Notably, intraperitoneal administration of lipopolysaccharide strikingly up-regulated LMIR3 and down-regulated LMIR4, whereas that of granulocyte colony-stimulating factor up-regulated both LMIR3 and LMIR4 in granulocytes. Cross-linking of LMIR4 in bone marrow granulocytes also resulted in their activation, which was enhanced by lipopolysaccharide. Collectively, these results suggest that the innate immune system is at least in part regulated by the qualitative and quantitative balance of the paired receptors LMIR3 and LMIR4.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan; Natl Agr Res Org, Natl Inst Vegetable & Tea Sci, Shizuoka 4288501, Japan; R&D Syst Inc, Minneapolis, MN 55413 USA; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Tohoku Univ, Dept Expt Immunol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan	University of Tokyo; National Agriculture & Food Research Organization - Japan; MRC National Institute for Medical Research; Tohoku University	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	kitamura@ims.u-tokyo.ac.jp	Kitamura, Toshio/AAA-2071-2021	Maeda-Yamamoto, Mari/0000-0002-4494-7509; Tybulewicz, Victor/0000-0003-2439-0798	MRC [MC_U117527252] Funding Source: UKRI; Medical Research Council [MC_U117527252] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alvarez-Errico D, 2004, EUR J IMMUNOL, V34, P3690, DOI 10.1002/eji.200425433; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L; Chung DH, 2003, J IMMUNOL, V171, P6541, DOI 10.4049/jimmunol.171.12.6541; Clark GJ, 2001, TISSUE ANTIGENS, V57, P415, DOI 10.1034/j.1399-0039.2001.057005415.x; Colonna M, 1999, J LEUKOCYTE BIOL, V66, P718, DOI 10.1002/jlb.66.5.718; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Costello PS, 1996, ONCOGENE, V13, P2595; DAISH A, 1993, IMMUNOLOGY, V79, P55; Dietrich J, 2000, MICROBES INFECT, V2, P323, DOI 10.1016/S1286-4579(00)00294-X; EISEMAN E, 1992, NATURE, V355, P78; Fujimoto M, 2006, INT IMMUNOL, V18, P1499, DOI 10.1093/intimm/dxl083; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Green BJ, 1998, INT IMMUNOL, V10, P891, DOI 10.1093/intimm/10.7.891; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; King RG, 2006, J IMMUNOL, V176, P6012, DOI 10.4049/jimmunol.176.10.6012; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kumagai H, 2003, BIOCHEM BIOPH RES CO, V307, P719, DOI 10.1016/S0006-291X(03)01245-2; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; Luo K, 2001, BIOCHEM BIOPH RES CO, V287, P35, DOI 10.1006/bbrc.2001.5539; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Oki T, 2006, J IMMUNOL, V176, P52, DOI 10.4049/jimmunol.176.1.52; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Pereira S, 2001, J IMMUNOL, V166, P4115, DOI 10.4049/jimmunol.166.6.4115; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; Speckman RA, 2003, HUM GENET, V112, P34, DOI 10.1007/s00439-002-0851-y; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Toyama-Sorimachi N, 2005, J IMMUNOL, V174, P4621, DOI 10.4049/jimmunol.174.8.4621; Turnbull IR, 2005, J EXP MED, V202, P363, DOI 10.1084/jem.20050986; Uehara T, 2001, J CLIN INVEST, V108, P1041, DOI 10.1172/JCI200112195; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yotsumoto K, 2003, J EXP MED, V198, P223, DOI 10.1084/jem.20021825	56	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17997	18008		10.1074/jbc.M701100200	http://dx.doi.org/10.1074/jbc.M701100200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17438331	hybrid			2022-12-25	WOS:000247302000006
J	Kirmse, R; Portet, S; Mucke, N; Aebi, U; Herrmann, H; Langowski, J				Kirmse, Robert; Portet, Stephanie; Muecke, Norbert; Aebi, Ueli; Herrmann, Harald; Langowski, Jorg			A quantitative kinetic model for the in vitro assembly of intermediate filaments from tetrameric vimentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; ACTIN; ARCHITECTURE; NUCLEATION; PROTEINS; DYNAMICS; ELEMENTS; DISEASE; UNITS	In vitro assembly of intermediate filament proteins is a very rapid process. It starts without significant delay by lateral association of tetramer complexes into unit-length filaments (ULFs) after raising the ionic strength from low salt to physiological conditions ( 100 mM KCl). We employed electron and scanning force microscopy complemented by mathematical modeling to investigate the kinetics of in vitro assembly of human recombinant vimentin. From the average length distributions of the resulting filaments measured at increasing assembly times we simulated filament assembly and estimated specific reaction rate parameters. We modeled eight different potential pathways for vimentin filament elongation. Comparing the numerical with the experimental data we conclude that a two-step mechanism involving rapid formation of ULFs followed by ULF and filament annealing is the most robust scenario for vimentin assembly. These findings agree with the first two steps of the previously proposed three-step assembly model (Herrmann, H., and Aebi, U. ( 1998) Curr. Opin. Struct. Biol. 8, 177 - 185). In particular, our modeling clearly demonstrates that end-to-end annealing of ULFs and filaments is obligatory for forming long filaments, whereas tetramer addition to filament ends does not contribute significantly to filament elongation.	German Canc Res Ctr, Div Biophys Macromol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; Univ Manitoba, Dept Math, Winnipeg, MB R3T 2N2, Canada; Univ Basel, Inst Biol Struct, CH-4056 Basel, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Manitoba; University of Basel	Langowski, J (corresponding author), German Canc Res Ctr, Div Biophys Macromol, D-69120 Heidelberg, Germany.	jl@dkfz.de	Langowski, Jörg/A-1843-2011	Langowski, Jörg/0000-0001-8600-0666; Portet, Stephanie/0000-0002-8802-8184; Mucke, Norbert/0000-0002-0683-4386				Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Ando S, 2004, BBA-PROTEINS PROTEOM, V1702, P53, DOI 10.1016/j.bbapap.2004.07.008; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Bar H, 2004, J STRUCT BIOL, V148, P137, DOI 10.1016/j.jsb.2004.04.003; Bar H, 2005, P NATL ACAD SCI USA, V102, P15099, DOI 10.1073/pnas.0504568102; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; FARDEAU M, 2007, HUM MUTAT, V28, P374; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goldfarb LG, 2004, BRAIN, V127, P723, DOI 10.1093/brain/awh033; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Helfand BT, 2003, J CELL SCI, V116, P2345, DOI 10.1242/jcs.00526; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 2003, INT REV CYTOL, V223, P83; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Kaminska A, 2004, HUM GENET, V114, P306, DOI 10.1007/s00439-003-1057-7; Kerssemakers JWJ, 2006, NATURE, V442, P709, DOI 10.1038/nature04928; Mucke N, 2005, J STRUCT BIOL, V150, P268, DOI 10.1016/j.jsb.2005.02.012; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Mucke N, 2004, J MOL BIOL, V335, P1241, DOI 10.1016/j.jmb.2003.11.038; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Oosawa F, 2000, GENES CELLS, V5, P9, DOI 10.1046/j.1365-2443.2000.00304.x; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P41; PARRY DAD, 1995, INTERMEDIATE FILAMEN; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard Thomas D, 2002, Harvey Lect, V98, P1; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; Sokolova AV, 2006, P NATL ACAD SCI USA, V103, P16206, DOI 10.1073/pnas.0603629103; STEINERT PM, 1982, BIOCHEMISTRY-US, V21, P177, DOI 10.1021/bi00530a030; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; VOTER WA, 1984, J BIOL CHEM, V259, P430; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5	37	64	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18563	18572		10.1074/jbc.M701063200	http://dx.doi.org/10.1074/jbc.M701063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17403663	hybrid			2022-12-25	WOS:000247302000061
J	Kuttner-Kondo, L; Hourcade, DE; Anderson, VE; Muqim, N; Mitchell, L; Soares, DC; Barlow, PN; Medof, ME				Kuttner-Kondo, Lisa; Hourcade, Dennis E.; Anderson, Vernon E.; Muqim, Nasima; Mitchell, Lynne; Soares, Dinesh C.; Barlow, Paul N.; Medof, M. Edward			Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT CONTROL PROTEIN; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MEMBRANE COFACTOR PROTEIN; RECEPTOR-TYPE 1; HERPESVIRUS HUMAN-HERPESVIRUS-8; REGULATORY ACTIVITY; FUNCTIONAL DOMAINS; ALPHA-CHAIN; INHIBITOR; CD35	Focused complement activation on foreign targets depends on regulatory proteins that decay the bimolecular C3 convertases. Although this process is central to complement control, how the convertases engage and disassemble is not established. The second and third complement control protein (CCP) modules of the cell surface regulator, decay-accelerating factor (DAF, CD55), comprise the simplest structure mediating this activity. Positioning the functional effects of 31 substitution mutants of DAF CCP2 to - 4 on partial structures was previously reported. In light of the high resolution crystal structure of the DAF four-CCP functional region, we now reexamine the effects of these and 40 additional mutations. Moreover, we map six monoclonal antibody epitopes and overlap their effects with those of the amino acid substitutions. The data indicate that the interaction of DAF with the convertases is mediated predominantly by two patches similar to 13 angstrom apart, one centered around Arg(69) and Arg(96) on CCP2 and the other around Phe(148) and Leu(171) on CCP3. These patches on the same face of the adjacent modules bracket an intermodular linker of critical length ( 16 angstrom). Although the key DAF residues in these patches are present or there are conservative substitutions in all other C3 convertase regulators that mediate decay acceleration and/or provide factor I-cofactor activity, the linker region is highly conserved only in the former. Intra-CCP regions also differ. Linker region comparisons suggest that the active CCPs of the decay accelerators are extended, whereas those of the cofactors are tilted. Intra-CCP comparisons suggest that the two classes of regulators bind different regions on their respective ligands.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Edinburgh, Sch Chem, Inst Struct & Mol Biol, Edinburgh EH9 3JJ, Midlothian, Scotland	Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL); University of Edinburgh	Medof, ME (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 2085 Adelbert Rd,RM 301, Cleveland, OH 44106 USA.	mxm16@po.cwru.edu	Soares, Dinesh C/A-4425-2012; Barlow, Paul N/G-2853-2011	Soares, Dinesh C/0000-0001-7557-0495; Anderson, Vernon Emmett/0000-0002-1699-7621	Medical Research Council [G0001089] Funding Source: Medline; NIAID NIH HHS [R01 AI23598, R01 AI05143] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Bhella D, 2004, J BIOL CHEM, V279, P8325, DOI 10.1074/jbc.M311334200; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brodbeck WG, 1997, TRANSFUS CLIN BIOL, V4, P125, DOI 10.1016/S1246-7820(97)80026-2; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; COYNE KE, 1992, J IMMUNOL, V149, P2906; Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3; IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; Kraus DM, 2006, J IMMUNOL, V176, P4419, DOI 10.4049/jimmunol.176.7.4419; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Krych-Goldberg M, 2005, J IMMUNOL, V175, P4528, DOI 10.4049/jimmunol.175.7.4528; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; Liszewski MK, 2006, J IMMUNOL, V176, P3725, DOI 10.4049/jimmunol.176.6.3725; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; LUBLIN DM, 1986, J IMMUNOL, V137, P1629; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Mark L, 2004, J BIOL CHEM, V279, P45093, DOI 10.1074/jbc.M407558200; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MORGAN BP, 1999, COMPLEMENT REGULATOR, P1; Mullick J, 2005, J VIROL, V79, P12382, DOI 10.1128/JVI.79.19.12382-12393.2005; Mullick J, 2005, J VIROL, V79, P5850, DOI 10.1128/JVI.79.9.5850-5856.2005; Mullick J, 2003, J VIROL, V77, P3878, DOI 10.1128/JVI.77.6.3878-3881.2003; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143; Singh AK, 2006, J BIOL CHEM, V281, P23119, DOI 10.1074/jbc.M603085200; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200; Zhang L, 2006, BIOPHYS J, V90, P3106, DOI 10.1529/biophysj.105.068130	41	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18552	18562		10.1074/jbc.M611650200	http://dx.doi.org/10.1074/jbc.M611650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17395591	hybrid			2022-12-25	WOS:000247302000060
J	Tate, JJ; Cooper, TG				Tate, Jennifer J.; Cooper, Terrance G.			Stress-responsive Gln3 localization in Saccharomyces cerevisiae is separable from and can overwhelm nitrogen source regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RSP5-BUL1/2 UBIQUITIN LIGASE; TOR SIGNALING NETWORK; CELL-GROWTH CONTROL; HEAVY-METAL ION; CATABOLITE REPRESSION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; CARBON STARVATION; 2A PHOSPHATASES	Intracellular localization of Saccharomyces cerevisiae GATA family transcription activator, Gln3, is used as a downstream readout of rapamycin-inhibited Tor1,2 control of Tap42 and Sit4 activities. Gln3 is cytoplasmic in cells provided with repressive nitrogen sources such as glutamine and is nuclear in cells growing with a derepressive nitrogen source such as proline or those treated with rapamycin or methionine sulfoximine (Msx). Although gross Gln3-Myc(13) phosphorylation levels in wild type cells do not correlate with nitrogen source-determined intracellular Gln3-Myc(13) localization, the phosphorylation levels are markedly influenced by several environmental perturbations. Msx treatment increases Snf1-independent Gln3-Myc(13) phosphorylation, whereas carbon starvation increases both Snf1-dependent and - independent Gln3-Myc(13) phosphorylation. Here we demonstrate that a broad spectrum of environmental stresses ( temperature, osmotic, and oxidative) increase Gln3-Myc(13) phosphorylation. In parallel, these stresses elicit rapid (< 5 min for NaCl) Gln3-Myc(13) relocalization from the nucleus to the cytoplasm. The response of Gln3-Myc(13) localization to stressful conditions can completely overwhelm its response to nitrogen source quality or inhibitor-generated disruption of the Tor1,2 signal transduction pathway. Adding NaCl to cells cultured under conditions in which Gln3-Myc(13) is normally nuclear, i.e. proline-grown, nitrogen-starved, Msx-, caffeine-, and rapamycin-treated wild type cells, or ure2 Delta cells, results in its prompt relocalization to the cytoplasm. Together these data identify a major new level of regulation to which Gln3 responds, and adds a new dimension to mechanistic studies of the regulation of this transcription factor.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [R01 GM035642, GM-35642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cooper TG, 2004, TOP CURR GENET, V7, P225; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Cox KH, 2004, J BIOL CHEM, V279, P19294, DOI 10.1074/jbc.M309240200; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Crespo JL, 2004, J BIOL CHEM, V279, P37512, DOI 10.1074/jbc.M407372200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dann SG, 2006, FEBS LETT, V580, P2821, DOI 10.1016/j.febslet.2006.04.068; De Virgilio C, 2006, INT J BIOCHEM CELL B, V38, P1476, DOI 10.1016/j.biocel.2006.02.013; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Feller A, 2006, J BIOL CHEM, V281, P28546, DOI 10.1074/jbc.M605551200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kuranda K, 2006, MOL MICROBIOL, V61, P1147, DOI 10.1111/j.1365-2958.2006.05300.x; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendizabal I, 2001, MOL GENET GENOMICS, V265, P801, DOI 10.1007/s004380100474; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Proft M, 1999, MOL CELL BIOL, V19, P537; Rai R, 2005, YEAST, V22, P343, DOI 10.1002/yea.1215; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Reinke A, 2006, J BIOL CHEM, V281, P31616, DOI 10.1074/jbc.M603107200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Schluter Michael, 2005, Am Heart Hosp J, V3, P182, DOI 10.1111/j.1541-9215.2005.04407.x; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Soliman GA, 2005, CURR OPIN LIPIDOL, V16, P317, DOI 10.1097/01.mol.0000169352.35642.06; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Tate JJ, 2006, J BIOL CHEM, V281, P37980, DOI 10.1074/jbc.M606973200; Tate JJ, 2006, J BIOL CHEM, V281, P28460, DOI 10.1074/jbc.M604171200; Tate JJ, 2005, J BIOL CHEM, V280, P27195, DOI 10.1074/jbc.M504052200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THOMAS G, 2004, CURR TOP MICROBIOL I, V279; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 2004, ANNU REV GENET, V38, P681, DOI 10.1146/annurev.genet.38.072902.092200; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Withee JL, 1998, GENETICS, V149, P865; Yan GH, 2006, EMBO J, V25, P3546, DOI 10.1038/sj.emboj.7601239	51	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18467	18480		10.1074/jbc.M609550200	http://dx.doi.org/10.1074/jbc.M609550200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17439949	hybrid, Green Accepted			2022-12-25	WOS:000247302000053
J	Kicinska, A; Swida, A; Bednarczyk, P; Koszela-Piotrowska, I; Choma, K; Dolowy, K; Szewczyk, A; Jarmuszkiewicz, W				Kicinska, Anna; Swida, Aleksandra; Bednarczyk, Piotr; Koszela-Piotrowska, Izabela; Choma, Katarzyna; Dolowy, Krzysztof; Szewczyk, Adam; Jarmuszkiewicz, Wieslawa			ATP-sensitive potassium channel in mitochondria of the eukaryotic microorganism Acanthamoeba castellanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; PLANT-MITOCHONDRIA; PERMEABILITY TRANSITION; ALTERNATIVE OXIDASE; HEART-MITOCHONDRIA; INNER MEMBRANE; STEADY-STATE; OPENERS; 5-HYDROXYDECANOATE; IDENTIFICATION	We describe the existence of a potassium ion transport mechanism in the mitochondrial inner membrane of a lower eukaryotic organism, Acanthamoeba castellanii. We found that substances known to modulate potassium channel activity influenced the bioenergetics of A. castellanii mitochondria. In isolated mitochondria, the rate of resting respiration is increased by about 10% in response to potassium channel openers, i.e. diazoxide and BMS-191095, during succinate-, malate-, or NADH-sustained respiration. This effect is strictly dependent on the presence of potassium ions in an incubation medium and is reversed by glibenclamide (a potassium channel blocker). Diazoxide and BMS-191095 also caused a slight but statistically significant depolarization of mitochondrial membrane potential (measured with a TPP+- specific electrode), regardless of the respiratory substrate used. The resulting steady state value of membrane potential was restored after treatment with glibenclamide or 1 mM ATP. Additionally, the electrophysiological properties of potassium channels present in the A. castellanii inner mitochondrial membrane are described in the reconstituted system, using black lipid membranes. Conductance from 90 +/- 7 to 166 +/- 10 picosiemens, inhibition by 1mM ATP/ Mg2+ or glibenclamide, and activation by diazoxide were observed. These results suggest that an ATP- sensitive potassium channel similar to that of mammalian mitochondria is present in A. castellanii mitochondria.	Adam Mickiewicz Univ, Lab Bioenerget, PL-61614 Poznan, Poland; M Nencki Inst Expt Biol, Lab Intracellular Ion Channels, PL-02093 Warsaw, Poland; Agr Univ Warsaw, Dept Biophys, PL-02766 Warsaw, Poland	Adam Mickiewicz University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Warsaw University of Life Sciences	Jarmuszkiewicz, W (corresponding author), Adam Mickiewicz Univ, Lab Bioenerget, Umultowska 89, PL-61614 Poznan, Poland.	wiesiaj@amu.edu.pl	Bednarczyk, Piotr/B-4973-2018; Dolowy, Krzysztof/AGG-0462-2022	Bednarczyk, Piotr/0000-0002-7125-0715; Dolowy, Krzysztof/0000-0003-3673-0542; Kicinska, Anna/0000-0003-4293-762X; Szewczyk, Adam/0000-0001-5519-260X; Jarmuszkiewicz, Wieslawa/0000-0001-8550-8337				Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; Ardehali H, 2004, P NATL ACAD SCI USA, V101, P11880, DOI 10.1073/pnas.0401703101; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; Bednarczyk P, 2004, J MEMBRANE BIOL, V199, P63, DOI 10.1007/s00232-004-0676-9; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Cancherini DV, 2003, AM J PHYSIOL-RENAL, V285, pF1291, DOI 10.1152/ajprenal.00103.2003; Dahlem YA, 2004, BBA-BIOENERGETICS, V1656, P46, DOI 10.1016/j.bbabio.2004.01.003; Debska G, 2002, BBA-BIOENERGETICS, V1556, P97, DOI 10.1016/S0005-2728(02)00340-7; Debska G, 2001, BRAIN RES, V892, P42, DOI 10.1016/S0006-8993(00)03187-5; Drose S, 2006, J BIOL CHEM, V281, P23733, DOI 10.1074/jbc.M602570200; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Garlid KD, 2006, AM J PHYSIOL-HEART C, V291, pH152, DOI 10.1152/ajpheart.01233.2005; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Grover GJ, 2001, J PHARMACOL EXP THER, V297, P1184; Hille B, 2001, SELECTIVE PERMEABILI, P441; Hordejuk R, 2004, MOL MEMBR BIOL, V21, P307, DOI 10.1080/10647440400003899; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jarmuszkiewicz W, 1997, FEBS LETT, V411, P110, DOI 10.1016/S0014-5793(97)00676-5; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P10174, DOI 10.1074/jbc.273.17.10174; Jarmuszkiewicz W, 2001, BIOSCIENCE REP, V21, P213, DOI 10.1023/A:1013656510245; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kopustinskiene DM, 2003, J BIOENERG BIOMEMBR, V35, P141, DOI 10.1023/A:1023746103401; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; Mackenzie S, 1999, PLANT CELL, V11, P571, DOI 10.1105/tpc.11.4.571; Mannhold R, 2006, CURR TOP MED CHEM, V6, P1031, DOI 10.2174/156802606777323647; O'Rourke B, 2007, ANNU REV PHYSIOL, V69, P19, DOI 10.1146/annurev.physiol.69.031905.163804; Pastore D, 1999, J BIOL CHEM, V274, P26683, DOI 10.1074/jbc.274.38.26683; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Ruy F, 2004, J BIOENERG BIOMEMBR, V36, P195, DOI 10.1023/B:JOBB.0000023623.70126.04; Sluse FE, 2002, HANDBOOK OF PLANT GROWTH: PH AS THE MASTER VARIABLE, P173; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Szewczyk A, 2006, BBA-BIOENERGETICS, V1757, P715, DOI 10.1016/j.bbabio.2006.05.002; Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; Wojtkowska M, 2005, J BIOENERG BIOMEMBR, V37, P261, DOI 10.1007/s10863-005-6636-y; Zhou M, 1999, MOL BRAIN RES, V74, P15, DOI 10.1016/S0169-328X(99)00232-6	38	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17433	17441		10.1074/jbc.M701496200	http://dx.doi.org/10.1074/jbc.M701496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430885	hybrid			2022-12-25	WOS:000247084500013
J	Deval, J; D'Abramo, CM; Zhao, ZJ; McCormick, S; Coutsinos, D; Hess, S; Kvaratskhelia, M; Gotte, M				Deval, Jerome; D'Abramo, Claudia M.; Zhao, Zhuojun; McCormick, Suzanne; Coutsinos, Dimitrios; Hess, Sonja; Kvaratskhelia, Mamuka; Gotte, Matthias			High resolution footprinting of the hepatitis C virus polymerase NS5B in complex with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; HIV-1 REVERSE-TRANSCRIPTASE; REPLICATION-PROTEIN-A; VIRAL-RNA; CRYSTAL-STRUCTURE; NONNUCLEOSIDE INHIBITORS; BINDING; SITE; DNA; MODULATION	The nucleic acid binding channel of the hepatitis C virus RNA polymerase remains to be defined. Here we employed complementary footprinting techniques and show that the enzyme binds to a newly synthesized duplex of approximately seven to eight base pairs. Comparative analysis of surface topologies of free enzyme versus the nucleoprotein complex revealed certain lysines and arginines that are protected from chemical modification upon RNA binding. The protection pattern helps to define the trajectory of the nucleic acid substrate. Lys(81), Lys(98), Lys(100), Lys(106), Arg(158), Arg(386), and Arg(394) probably interact with the bound RNA. The selective protection of amino acids of the arginine-rich region in helix T points to RNA-induced conformational rearrangements. Together, these findings suggest that RNA-protein interaction through the entire substrate binding channel can modulate intradomain contacts at the C terminus.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 2B4, Canada; Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; NIDDK, NIH, Bethesda, MD 20892 USA	McGill University; McGill University; McGill University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gotte, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, Duff Med Bldg,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	matthias.gotte@mcgill.ca	Hess, Sonja/K-4842-2013	Hess, Sonja/0000-0002-5904-9816	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062520] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI062520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Biswal BK, 2006, J MOL BIOL, V361, P33, DOI 10.1016/j.jmb.2006.05.074; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cai ZH, 2005, J VIROL, V79, P11607, DOI 10.1128/JVI.79.18.11607-11617.2005; Choi HB, 2003, EXP MOL MED, V35, P475, DOI 10.1038/emm.2003.62; D'Abramo CM, 2004, J MOL BIOL, V337, P1, DOI 10.1016/j.jmb.2004.01.030; Di Marco S, 2005, J BIOL CHEM, V280, P29765, DOI 10.1074/jbc.M505423200; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Kim YC, 2005, J BIOL CHEM, V280, P38011, DOI 10.1074/jbc.M508145200; Kvaratskhelia M, 2002, P NATL ACAD SCI USA, V99, P15988, DOI 10.1073/pnas.252550199; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; Lai VCH, 2003, J VIROL, V77, P2295, DOI 10.1128/JVI.77.3.2295-2300.2003; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu YY, 2005, J BIOL CHEM, V280, P32775, DOI 10.1074/jbc.M505705200; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Makeyev EV, 2000, EMBO J, V19, P6275, DOI 10.1093/emboj/19.22.6275; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Ranjith-Kumar CT, 2004, J VIROL, V78, P12207, DOI 10.1128/JVI.78.22.12207-12217.2004; Ranjith-Kumar CT, 2003, J MOL BIOL, V330, P675, DOI 10.1016/S0022-2836(03)00613-2; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Shkriabai N, 2006, BIOCHEMISTRY-US, V45, P4077, DOI 10.1021/bi052308e; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	37	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16907	16916		10.1074/jbc.M701973200	http://dx.doi.org/10.1074/jbc.M701973200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17449464	hybrid			2022-12-25	WOS:000246946500023
J	McCloskey, DT; Doherty, L; Dai, YP; Miller, L; Hume, JR; Yamboliev, IA				McCloskey, Diana T.; Doherty, Lynda; Dai, Yan-Ping; Miller, Lisa; Hume, Joseph R.; Yamboliev, Ilia A.			Hypotonic activation of short ClC3 isoform is modulated by direct interaction between its cytosolic C-terminal tail and subcortical actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL REGULATION; VOLUME REGULATION; CBS DOMAINS; PHOSPHORYLATION; CELLS; CIC-2; IDENTIFICATION; CYTOSKELETON; EXPRESSION; MUTATIONS	Short ClC3 isoform (sClC3) functions as a volume-sensitive outwardly rectifying anion channel (VSOAC) in some cell types. In previous studies, we have shown that the hypotonic activation of sClC3 is linked to cell swelling-mediated remodeling of the actin cytoskeleton. In the present study, we have tested the hypothesis that the cytosolic tails of sClC3 bind to actin directly and that binding modulates the hypotonic activation of the channel. Co-sedimentation assays in vitro demonstrated a strong binding between the glutathione S-transferase-fused cytosolic C terminus of sClC3 (GST-sClC3-CT) to filamentous actin (F-actin) but not to globular monomeric actin (G-actin). The GST-fused N terminus (GST-sClC3-NT) exhibited low binding affinity to both G-and F-actin. Co-sedimentation experiments with progressively truncated GST-sClC3-CT indicated that the F-actin binding region is located between amino acids 690 and 760 of sClC3. Two synthetic peptides mapping basic clusters of the cytosolic sClC3-CT (CTP2, isoleucine 716 to leucine 734; and CTP3, proline 688 to proline 709) prevented binding of GST-sClC3-CT to F-actin in vitro. Dialysis into NIH/3T3 cells of these two peptides (but not of synthetic peptide CTP1 (isoleucine 737 to glutamine 748)) reduced the maximal current density by 60 and 38%, respectively. Based on these results, we have concluded that, by direct interaction with subcortical actin filaments, sClC3 contributes to the hypotonic stress-induced VSOACs in NIH/3T3 cells.	Univ Nevada, Reno Sch Med, Dept Pharmacol, Reno, NV 89557 USA; Univ Nevada, Reno Sch Med, Ctr Biomed Res Excellence, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Yamboliev, IA (corresponding author), Univ Nevada, Reno Sch Med, Dept Pharmacol, MS 318, Reno, NV 89557 USA.	iyamboliev@medicine.nevada.edu			NCRR NIH HHS [P21RR 15581] Funding Source: Medline; NHLBI NIH HHS [HL49254] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049254, R01HL049254] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed N, 2000, BIOCHEM J, V352, P789, DOI 10.1042/0264-6021:3520789; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Britton FC, 2005, J BIOL CHEM, V280, P25871, DOI 10.1074/jbc.M502826200; Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861; Do CW, 2005, INVEST OPHTH VIS SCI, V46, P948, DOI 10.1167/iovs.04-1004; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Furukawa T, 2002, J PHYSIOL-LONDON, V540, P883; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; Greenwood IA, 2004, J PHYSIOL-LONDON, V557, P343, DOI 10.1113/jphysiol.2004.063750; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Hatton WJ, 2002, BIOPHYS J, V82, p242A; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2004, J BIOL CHEM, V279, P13140, DOI 10.1074/jbc.M312649200; Henson JH, 1999, MICROSC RES TECHNIQ, V47, P155, DOI 10.1002/(SICI)1097-0029(19991015)47:2<155::AID-JEMT7>3.0.CO;2-T; Hermoso M, 2002, J BIOL CHEM, V277, P40066, DOI 10.1074/jbc.M205132200; Ignoul S, 2005, AM J PHYSIOL-CELL PH, V289, pC1369, DOI 10.1152/ajpcell.00282.2005; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jin NG, 2003, AM J PHYSIOL-GASTR L, V285, pG938, DOI 10.1152/ajpgi.00470.2002; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lemonnier L, 2004, CANCER RES, V64, P4841, DOI 10.1158/0008-5472.CAN-03-3223; LEVITAN I, 1995, J MEMBRANE BIOL, V147, P283; Li SJ, 2006, J BIOCHEM, V139, P813, DOI 10.1093/jb/mvj099; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Nagasaki M, 2000, J PHYSIOL-LONDON, V523, P705, DOI 10.1111/j.1469-7793.2000.00705.x; Pedersen SF, 1999, EXP CELL RES, V252, P63, DOI 10.1006/excr.1999.4615; Robinson NC, 2004, J PHYSIOL-LONDON, V556, P353, DOI 10.1113/jphysiol.2003.058032; Rossow CF, 2006, ACTA PHYSIOL, V187, P5, DOI 10.1111/j.1748-1716.2006.01550.x; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vessey JP, 2004, BIOCHEM CELL BIOL, V82, P708, DOI 10.1139/O04-107; Wang GX, 2005, J MEMBRANE BIOL, V208, P15, DOI 10.1007/s00232-005-0815-y; Wang GX, 2004, AM J PHYSIOL-HEART C, V287, pH533, DOI 10.1152/ajpheart.00228.2003; Wang GX, 2003, AM J PHYSIOL-HEART C, V285, pH1453, DOI 10.1152/ajpheart.00244.2003; Wang XQ, 2006, NEURON, V52, P321, DOI 10.1016/j.neuron.2006.08.035; Weinreich F, 2001, J BIOL CHEM, V276, P2347, DOI 10.1074/jbc.M005733200; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Yoshikawa M, 2002, GENES CELLS, V7, P597, DOI 10.1046/j.1365-2443.2002.00539.x; Zheng YJ, 2002, J BIOL CHEM, V277, P32268, DOI 10.1074/jbc.M202105200; Zhong JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1627, DOI 10.1152/ajpcell.00152.2001; Zhou JG, 2005, J BIOL CHEM, V280, P7301, DOI 10.1074/jbc.M412813200	47	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16871	16877		10.1074/jbc.M700379200	http://dx.doi.org/10.1074/jbc.M700379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17442672	hybrid			2022-12-25	WOS:000246946500019
J	Meares, GP; Jope, RS				Meares, Gordon P.; Jope, Richard S.			Resolution of the nuclear localization mechanism of glycogen synthase kinase-3 - Functional effects in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; CELL-SURVIVAL; PHOSPHORYLATION; 3-BETA; GSK3; SUPPRESSION; IDENTIFICATION; ACTIVATION; PROTEIN	Mechanisms regulating the nuclear localization of glycogen synthase kinase-3 beta (GSK3 beta) remained enigmatic despite the crucial regulation by nuclear GSK3 beta of important cellular functions. These include regulation of gene expression, cell cycle progression, and apoptosis, achieved by the phosphorylation by GSK3 of nuclear substrates (e.g. numerous transcription factors). We resolved this mechanism by identifying a bipartite nuclear localization sequence (NLS) that is necessary for the nuclear accumulation of GSK3 beta and is sufficient to drive yellow fluorescent protein into the nucleus. Despite the NLS, most GSK3 beta is cytosolic, sequestered in protein complexes that, although still mobile in the cytosol, block the NLS. Conditions promoting nuclear translocation of GSK3 beta release it from cytosolic complexes, allowing the NLS to direct nuclear import. Using this information to prepare a nucleus-excluded active GSK3 construct, we found that the antiapoptotic effect of GSK3 beta in tumor necrosis factor-induced apoptosis is mediated by cytosolic, not nuclear, GSK3 beta. Identification of a GSK3 beta NLS allows new strategies to decipher and manipulate its subcellular actions regulating gene expression and apoptosis and its involvement in diseases.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 7th Ave S,SC1057, Birmingham, AL 35294 USA.	jope@uab.edu	Meares, Gordon/AAJ-6716-2020	Meares, Gordon/0000-0002-0805-0155	NIA NIH HHS [R01 AG021045, AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752, R01 MH038752-23] Funding Source: Medline; NINDS NIH HHS [R01 NS037768, R01 NS037768-04, R01 NS037768-09, NS37768] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Liao XB, 2003, MOL CANCER THER, V2, P1215; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Nair R, 2003, NUCLEIC ACIDS RES, V31, P397, DOI 10.1093/nar/gkg001; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Rottmann S, 2005, P NATL ACAD SCI USA, V102, P15195, DOI 10.1073/pnas.0505114102; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Woodgett J. R., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P281, DOI 10.2174/1568008033340153; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	35	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16989	17001		10.1074/jbc.M700610200	http://dx.doi.org/10.1074/jbc.M700610200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17438332	Green Accepted, hybrid			2022-12-25	WOS:000246946500032
J	Bandyopadhyay, B; Li, GB; Yin, HS; Kuret, J				Bandyopadhyay, Bhaswati; Li, Guibin; Yin, Haishan; Kuret, Jeff			Tau aggregation and toxicity in a cell culture model of tauopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED-HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3-BETA; UBIQUITIN-PROTEASOME SYSTEM; ALZHEIMERS-DISEASE; PHOSPHORYLATED-TAU; NEUROFIBRILLARY TANGLES; CONFORMATIONAL-CHANGES; MEDIATED CYTOTOXICITY; COGNITIVE IMPAIRMENT; MICROTUBULE-BINDING	Intracellular aggregation of the microtubule-associated protein tau into filamentous inclusions is a defining characteristic of Alzheimer disease. Because appearance of tau-aggregate bearing lesions correlates with both cognitive decline and neurodegeneration, it has been hypothesized that tau aggregation may be directly toxic to cells that harbor them. Testing this hypothesis in cell culture has been complicated by the resistance of full-length tau isoforms to aggregation over experimentally tractable time periods. To overcome this limitation, a small-molecule agonist of the tau aggregation reaction, Congo red, was used to drive aggregation within HEK-293 cells expressing full-length tau isoform htau40. Formation of detergent-insoluble aggregates was both time and agonist concentration dependent. At 10 mu M Congo red, detergent-insoluble aggregates appeared with pseudo-first order kinetics and a half-life of approximately 5 days. By 7 days in culture, total tau levels increased 2-fold, with -30% of total tau converted into detergent-insoluble aggregates. Agonist addition also led to rapid losses in the tubulin binding activity of tau, although tau was not hyperphosphorylated as judged by occupancy of phosphorylation sites Ser(396)/ Ser(404). Tau aggregation was associated with decreased viability as detected by ToPro-3 uptake. The results, which establish a new approach for analysis of tau aggregation in cells independent of tau hyperphosphorylation, suggest that conformational changes associated with aggregation are incompatible with microtubule binding, and that toxicity associated with intracellular tau aggregation is not acute but develops over a period of days.	Ohio State Univ, Dept Mol & Cellular Biochem, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu	Li, Guibin/E-3507-2011		NIA NIH HHS [AG14452] Funding Source: Medline; NINDS NIH HHS [P30-NS045758] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bao YP, 2004, J MED GENET, V41, P47, DOI 10.1136/jmg.2003.014548; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chambard JM, 2003, J PHYSIOL-LONDON, V550, P667, DOI 10.1113/jphysiol.2003.039321; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2005, BIOCHEMISTRY-US, V44, P5862, DOI 10.1021/bi0500123; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; DiTella MC, 1996, J CELL SCI, V109, P467; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; Falke E, 2003, AM J PATHOL, V163, P1615, DOI 10.1016/S0002-9440(10)63518-3; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; GOLDSTEIN A, PRINCIPLES DRUG ACTI; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; HAMOS JE, 1989, NEUROLOGY, V39, P355, DOI 10.1212/WNL.39.3.355; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Hyman BT, 2005, BBA-MOL BASIS DIS, V1739, P150, DOI 10.1016/j.bbadis.2004.06.015; Ikegami S, 2000, NEUROSCI LETT, V279, P129, DOI 10.1016/S0304-3940(99)00964-7; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KHATOON S, 1994, FEBS LETT, V351, P80, DOI 10.1016/0014-5793(94)00829-9; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; King ME, 2001, AM J PATHOL, V158, P1481, DOI 10.1016/S0002-9440(10)64099-0; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; KsiezakReding H, 1996, AM J PATHOL, V149, P639; Kuret J, 2005, MICROSC RES TECHNIQ, V67, P141, DOI 10.1002/jemt.20187; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; Lu PJ, 1999, NATURE, V399, P784; Lund ET, 2001, J NEUROCHEM, V76, P1221, DOI 10.1046/j.1471-4159.2001.00130.x; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Mitchell TW, 2000, J HISTOCHEM CYTOCHEM, V48, P1627, DOI 10.1177/002215540004801206; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morfini G, 2005, TRENDS MOL MED, V11, P64, DOI 10.1016/j.molmed.2004.12.002; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Sergeant N, 2003, NEUROSCIENCE, V117, P293, DOI 10.1016/S0306-4522(02)00747-9; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Tint I, 1998, J NEUROSCI, V18, P8660; Vila-Ortiz GJ, 2001, CELL MOL NEUROBIOL, V21, P535, DOI 10.1023/A:1013823524302; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; Wilkinson RW, 2001, J IMMUNOL METHODS, V258, P183, DOI 10.1016/S0022-1759(01)00474-4; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Wyman J, 1990, BINDING LINKAGE FUNC; Yasojima K, 1999, BRAIN RES, V831, P301, DOI 10.1016/S0006-8993(99)01486-9	76	105	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16454	16464		10.1074/jbc.M700192200	http://dx.doi.org/10.1074/jbc.M700192200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428800	hybrid			2022-12-25	WOS:000246794300053
J	Leach, MR; Zhang, JW; Zamble, DB				Leach, Michael R.; Zhang, Jie Wei; Zamble, Deborah B.			The role of complex formation between the Escherichia coli hydrogenase accessory factors HypB and SlyD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASES; METAL-BINDING; HELICOBACTER-PYLORI; BRADYRHIZOBIUM-JAPONICUM; PROLYL ISOMERASE; ACTIVE-SITE; MUTATIONAL ANALYSIS; CHAPERONE FUNCTION; NIFE-HYDROGENASES; NICKEL-BINDING	The Escherichia coli protein SlyD is a member of the FK-506-binding protein family of peptidylprolyl isomerases. In addition to its peptidylprolyl isomerase domain, SlyD is composed of a molecular chaperone domain and a C-terminal tail rich in potential metal-binding residues. SlyD interacts with the [NiFe]-hydrogenase accessory protein HypB and contributes to nickel insertion during biosynthesis of the hydrogenase metallocenter. This study examines the HypB-SlyD complex and its significance in hydrogenase activation. Protein variants were prepared to delineate the interface between HypB and SlyD. Complex formation requires the HypB linker region located between the high affinity N-terminal Ni(II) site and the GTPase domain of the protein. In the case of SlyD, the deletion of a short loop in the chaperone domain abrogates the interaction with HypB. Mutations in either protein that disrupt complex formation in vitro also result in deficient hydrogenase production in vivo, indicating that the contact between HypB and SlyD is important for hydrogenase maturation. Surprisingly, SlyD stimulates release of nickel from the high affinity Ni(II)-binding site of HypB, an activity that is also disrupted by mutations that affect complex formation. Furthermore, a SlyD truncation lacking the C-terminal metal-binding tail still interacts with HypB but is deficient in stimulating metal release and is not functional in vivo. These results suggest that SlyD could activate metal release from HypB during metallation of the [NiFe] hydrogenase.	Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	University of Toronto	Zamble, DB (corresponding author), Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 3H6, Canada.	dzamble@chem.utoronto.ca		Zamble, Deborah/0000-0002-8976-3375				Arie JP, 2001, MOL MICROBIOL, V39, P199, DOI 10.1046/j.1365-2958.2001.02250.x; Atanassova A, 2005, J BACTERIOL, V187, P4689, DOI 10.1128/JB.187.14.4689-4697.2005; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Barik S, 2006, CELL MOL LIFE SCI, V63, P2889, DOI 10.1007/s00018-006-6215-3; BEGG YA, 1977, FEMS MICROBIOL LETT, V2, P47, DOI 10.1111/j.1574-6968.1977.tb00905.x; Bernhardt TG, 2002, MOL MICROBIOL, V45, P99, DOI 10.1046/j.1365-2958.2002.02984.x; Blokesch M, 2004, EUR J BIOCHEM, V271, P3428, DOI 10.1111/j.1432-1033.2004.04280.x; Blokesch M, 2004, J BACTERIOL, V186, P2603, DOI 10.1128/JB.186.9.2603-2611.2004; Blokesch M, 2002, BIOCHEM SOC T, V30, P674, DOI 10.1042/BST0300674; Blokesch M, 2004, J MOL BIOL, V344, P155, DOI 10.1016/j.jmb.2004.09.040; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Casalot L, 2001, TRENDS MICROBIOL, V9, P228, DOI 10.1016/S0966-842X(01)02009-1; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; Gasper R, 2006, J BIOL CHEM, V281, P27492, DOI 10.1074/jbc.M600809200; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Ge RG, 2006, BIOCHEM J, V393, P285, DOI 10.1042/BJ20051160; GILBERT JV, 1995, INFECT IMMUN, V63, P2682, DOI 10.1128/IAI.63.7.2682-2688.1995; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; Janowski B, 1997, ANAL BIOCHEM, V252, P299, DOI 10.1006/abio.1997.2330; Kansau I, 1996, MOL MICROBIOL, V22, P1013, DOI 10.1046/j.1365-2958.1996.01536.x; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Leach MR, 2005, BIOCHEMISTRY-US, V44, P12229, DOI 10.1021/bi050993j; Loscher S, 2005, FEBS LETT, V579, P4287, DOI 10.1016/j.febslet.2005.06.063; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER RJ, 2007, BIOMETALS; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; McCafferty DG, 1997, BIOCHEMISTRY-US, V36, P10498, DOI 10.1021/bi970543u; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; Mendel S, 2006, MICROBIOL-SGM, V152, P2959, DOI 10.1099/mic.0.28776-0; Olson JW, 1997, MOL MICROBIOL, V24, P119, DOI 10.1046/j.1365-2958.1997.3251690.x; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rodrigue A, 2005, J BACTERIOL, V187, P2912, DOI 10.1128/JB.187.8.2912-2916.2005; ROOF WD, 1994, J BIOL CHEM, V269, P2902; Roof WD, 1997, MOL MICROBIOL, V25, P1031, DOI 10.1046/j.1365-2958.1997.5201884.x; Rowe JL, 2005, J BACTERIOL, V187, P6317, DOI 10.1128/JB.187.18.6317-6323.2005; Sanokawa-Akakura R, 2004, J BIOL CHEM, V279, P27845, DOI 10.1074/jbc.C400118200; Scholz C, 2006, BIOCHEMISTRY-US, V45, P20, DOI 10.1021/bi051922n; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Suzuki R, 2003, J MOL BIOL, V328, P1149, DOI 10.1016/S0022-2836(03)00379-6; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; Winter G, 2005, FEBS LETT, V579, P4292, DOI 10.1016/j.febslet.2005.06.064; WULFING C, 1994, J BIOL CHEM, V269, P2895; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang JW, 2005, J BIOL CHEM, V280, P4360, DOI 10.1074/jbc.M411799200	55	67	74	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16177	16186		10.1074/jbc.M610834200	http://dx.doi.org/10.1074/jbc.M610834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426034	hybrid			2022-12-25	WOS:000246794300026
J	Nomikos, M; Mulgrew-Nesbitt, A; Pallavi, P; Mihalyne, G; Zaitseva, I; Swann, K; Lai, FA; Murray, D; McLaughlin, S				Nomikos, Michail; Mulgrew-Nesbitt, Anna; Pallavi, Payal; Mihalyne, Gyongyi; Zaitseva, Irina; Swann, Karl; Lai, F. Anthony; Murray, Diana; McLaughlin, Stuart			Binding of phosphoinositide-specific phospholipase C-zeta (PLC-zeta) to phospholipid membranes - Potential role of an unstructured cluster of basic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGERS CA2+ OSCILLATIONS; EGG ACTIVATION; HIGH-AFFINITY; SPERM FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ELECTROSTATIC SEQUESTRATION; INOSITOL TRISPHOSPHATE; NUCLEAR TRANSLOCATION; CALCIUM OSCILLATIONS; KINASE SUBSTRATE	Phospholipase C- zeta ( PLC- zeta) is a sperm- specific enzyme that initiates the Ca2+ oscillations in mammalian eggs that activate embryo development. It shares considerable sequence homology with PLC-delta 1, but lacks the PH domain that anchors PLC-delta 1 to phosphatidylinositol 4,5-bisphosphate, PIP2. Thus it is unclear how PLC-zeta interacts with membranes. The linker region between the X and Y catalytic domains of PLC-zeta, however, contains a cluster of basic residues not present in PLC-zeta 1. Application of electrostatic theory to a homology model of PLC-zeta suggests this basic cluster could interact with acidic lipids. We measured the binding of catalytically competent mouse PLC-zeta to phospholipid vesicles: for 2: 1 phosphatidylcholine/phosphatidylserine (PC/ PS) vesicles, the molar partition coefficient, K, is too weak to be of physiological significance. Incorporating 1% PIP2 into the 2: 1 PC/ PS vesicles increases K about 10-fold, to 5 X 103 M-1, a biologically relevant value. Expressed fragments corresponding to the PLC- zeta X-Y linker region also bind with higher affinity to polyvalent than monovalent phosphoinositides on nitrocellulose filters. A peptide corresponding to the basic cluster (charge = +7) within the linker region, PLC-zeta-( 374-385), binds to PC/ PS vesicles with higher affinity than PLC-zeta, but its binding is less sensitive to incorporating PIP2. The acidic residues flanking this basic cluster in PLC-zeta may account for both these phenomena. FRET experiments suggest the basic cluster could not only anchor the protein to the membrane, but also enhance the local concentration of PIP2 adjacent to the catalytic domain.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Cardiff Univ, Sch Med, Wales Heart Res Inst, Cell Signaling Lab, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Sch Med, Dept Obstet & Gynaecol, Cardiff CF14 4XN, S Glam, Wales; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cardiff University; Cardiff University; Cornell University	McLaughlin, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	stuart.mclaughlin@stonybrook.edu		Swann, Karl/0000-0002-4355-1449; Lai, Tony/0000-0003-2852-8547; Nomikos, Michail/0000-0001-9761-6327	NIGMS NIH HHS [GM24971] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Buser CA, 1998, METH MOL B, V84, P267; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fujimoto S, 2004, DEV BIOL, V274, P370, DOI 10.1016/j.ydbio.2004.07.025; Gallagher K, 1998, BIOPHYS J, V75, P769, DOI 10.1016/S0006-3495(98)77566-6; Gambhir A, 2004, BIOPHYS J, V86, P2188, DOI 10.1016/S0006-3495(04)74278-2; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Grobler JA, 1996, PROTEIN SCI, V5, P680; Halet G, 2002, J CELL SCI, V115, P2139; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; JOENS KT, 2000, BIOCHEM J, V346, P743; Jones KT, 1998, FEBS LETT, V437, P297, DOI 10.1016/S0014-5793(98)01254-X; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kouchi Z, 2005, J BIOL CHEM, V280, P21015, DOI 10.1074/jbc.M412123200; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Kuroda K, 2006, J BIOL CHEM, V281, P27794, DOI 10.1074/jbc.M603473200; Kurokawa M, 2004, BIOL CELL, V96, P37, DOI 10.1016/j.biolcel.2003.11.003; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Malcuit C, 2006, J CELL PHYSIOL, V206, P565, DOI 10.1002/jcp.20471; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Murray D, 2002, CURR TOP MEMBR, V52, P277; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nomikos M, 2005, J BIOL CHEM, V280, P31011, DOI 10.1074/jbc.M500629200; Okada M, 2005, FEBS LETT, V579, P4949, DOI 10.1016/j.febslet.2005.07.082; Okeley NM, 2004, J BIOL CHEM, V279, P21833, DOI 10.1074/jbc.M313469200; Parrington J, 2002, REPRODUCTION, V123, P31, DOI 10.1530/rep.0.1230031; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rice A, 2000, DEV BIOL, V228, P125, DOI 10.1006/dbio.2000.9929; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Saunders CM, 2007, BIOCHEM SOC SYMP, V74, P23, DOI 10.1042/BSS2007c03; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Stallings JD, 2005, J BIOL CHEM, V280, P22060, DOI 10.1074/jbc.M413813200; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Swann K, 2006, SEMIN CELL DEV BIOL, V17, P264, DOI 10.1016/j.semcdb.2006.03.009; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wang JY, 2004, BIOPHYS J, V86, P1969, DOI 10.1016/S0006-3495(04)74260-5; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; Winters MJ, 2005, MOL CELL, V20, P21, DOI 10.1016/j.molcel.2005.08.020; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	67	80	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16644	16653		10.1074/jbc.M701072200	http://dx.doi.org/10.1074/jbc.M701072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430887	hybrid			2022-12-25	WOS:000246794300070
J	Ojala, JRM; Pikkarainen, T; Tuuttila, A; Sandalova, T; Tryggvason, K				Ojala, Juha R. M.; Pikkarainen, Timo; Tuuttila, Ari; Sandalova, Tatyana; Tryggvason, Karl			Crystal structure of the cysteine-rich domain of scavenger receptor MARCO reveals the presence of a basic and an acidic cluster that both contribute to ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIA-BINDING; SRCR DOMAIN; ANTIBACTERIAL PROTEIN; CLONING; ANCIENT; IDENTIFICATION; CONFORMATION; EXPRESSION; SEQUENCE; PROGRAM	MARCO is a trimeric class A scavenger receptor of macrophages and dendritic cells that recognizes polyanionic particles and pathogens. The distal, scavenger receptor cysteine-rich (SRCR) domain of the extracellular part of this receptor has been implicated in ligand binding. To provide a structural basis for understanding the ligand-binding mechanisms of MARCO, we have determined the crystal structure of the mouse MARCO SRCR domain. The recombinant SRCR domain purified as monomeric and dimeric forms, and their structures were determined at 1.78 and 1.77A resolution, respectively. The monomer has a compact globular fold with a twisted five-stranded antiparallel beta-sheet and a long loop covering a single beta-helix, whereas the dimer is formed via beta-strand swapping of two monomers, thus containing a large eight- stranded beta-sheet. Calculation of the surface electrostatic potential revealed that the beta-sheet region with several arginines forms a basic cluster. Unexpectedly, an acidic cluster was found in the long loop region. In the monomer, the acidic cluster is involved in metal ion binding. Studies with cells expressing various SRCR domain mutants showed that all of the arginines of the basic cluster are involved in ligand binding, suggesting a cooperative binding mechanism. Ligand binding is also dependent on the acidic cluster and Ca2+ ions whose depletion appears to affect ligand binding at least by modulating the electrostatic potential or relative domain orientation. We propose that the SRCR domain dimerization can contribute to the recognition of large ligands by providing a means for the MARCO receptor oligomerization.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Scheeles Vag 2,B1, S-17177 Stockholm, Sweden.	karl.tryggvason@ki.se		Ojala, Juha/0000-0003-2018-6124; Sandalova, Tatyana/0000-0002-7694-6420				ACTON S, 1993, J BIOL CHEM, V268, P3530; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Arredouani MS, 2004, CELL MOL BIOL, V50, P657; Arredouani MS, 2005, J IMMUNOL, V175, P6058, DOI 10.4049/jimmunol.175.9.6058; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bikker FJ, 2004, J BIOL CHEM, V279, P47699, DOI 10.1074/jbc.M406095200; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YY, 2006, J BIOL CHEM, V281, P12767, DOI 10.1074/jbc.M513628200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOI T, 1993, J BIOL CHEM, V268, P2126; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Elshourbagy MA, 2000, EUR J BIOCHEM, V267, P919, DOI 10.1046/j.1432-1327.2000.01077.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HANZAWA H, 1990, FEBS LETT, V269, P413, DOI 10.1016/0014-5793(90)81206-4; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kvell K, 2006, BIOCHEM BIOPH RES CO, V341, P1193, DOI 10.1016/j.bbrc.2006.01.083; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pikkarainen T, 1999, J BIOL CHEM, V274, P10975, DOI 10.1074/jbc.274.16.10975; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rast JP, 2006, SCIENCE, V314, P952, DOI 10.1126/science.1134301; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Sankala M, 2002, J BIOL CHEM, V277, P33378, DOI 10.1074/jbc.M204494200; Santiago-Garcia J, 2003, J BIOL CHEM, V278, P6942, DOI 10.1074/jbc.M208358200; Sarraj MA, 2005, DEV DYNAM, V234, P1026, DOI 10.1002/dvdy.20594; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Sarrias MR, 2005, J BIOL CHEM, V280, P35391, DOI 10.1074/jbc.M505042200; Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5; Takeuchi K, 2004, J BIOL CHEM, V279, P4981, DOI 10.1074/jbc.M307815200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1	58	76	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16654	16666		10.1074/jbc.M701750200	http://dx.doi.org/10.1074/jbc.M701750200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405873	hybrid			2022-12-25	WOS:000246794300071
J	Stack, CM; Donnelly, S; Lowther, J; Xu, WB; Collins, PR; Brinen, LS; Dalton, JP				Stack, Colin M.; Donnelly, Sheila; Lowther, Jonathan; Xu, Weibo; Collins, Peter R.; Brinen, Linda S.; Dalton, John P.			The major secreted cathepsin L1 protease of the liver fluke, Fasciola hepatica - A Leu(-12) to Pro(-12) replacement in the nonconserved C-terminal region of the prosegment prevents complete enzyme autoactivation and allows definition of the molecular events in prosegment removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROCATHEPSIN-B; L IN-VITRO; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; CYSTEINE PROTEASES; CRYSTAL-STRUCTURE; BORDETELLA-PERTUSSIS; PAPAIN PRECURSOR; PICHIA-PASTORIS; CLEAVAGE SITES	A protease secreted by the parasitic helminth Fasciola hepatica, a 37-kDa procathepsin L1 (FheproCL1), autocatalytically processes and activates to its mature enzyme (FheCL1) over a wide pH range of 7.3 to 4.0, although activation is more rapid at low pH. Maturation initiates with cleavages of a small proportion of molecules within the central region of the prosegment, possibly by intramolecular events. However, activation to fully mature enzymes is achieved by a precise intermolecular cleavage at a Leu (-12)-Ser(-11) down arrow His(-)10 sequence within the nonconserved C-terminal region of the prosegment. The importance of this cleavage site in enzyme activation was demonstrated using an active site variant FheproCL1Gly(26) ( Cys(26) to Gly(26)) and a double variant FheproCL1Pro(-12)/Gly(26) ( Leu (-)12 to Pro(-12)), and although both of these variants cannot autocatalytically process, the former is susceptible to trans-processing at a Leu(-12)-Ser-11 down arrow His-10 sequence by pre- activated FheCL1, but the latter is not. Another F. hepatica secreted protease FheCL2, which, unlike FheCL1, can readily accept proline in the S2 subsite of its active site, can trans-process the double variant FheproCL1Pro(-12)/Gly(26) by cleavage at the Pro (-12) -Ser(-11 down arrow)2His(-10) sequence. Furthermore, the autoactivation of a variant enzyme with a single replacement, FheproCL1Pro(-12), was very slow but was increased 40-fold in the presence of FheCL2. These studies provide a molecular insight into the regulation of FheproCL1 autocatalysis.	Univ Technol Sydney, Inst Biotechnol Infect Dis, Fac Sci, Sydney, NSW 2007, Australia; Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of Technology Sydney; Dublin City University; University of California System; University of California San Francisco	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Fac Sci, Bldg 4,Thomas & Harris St,, Sydney, NSW 2007, Australia.	john.dalton@uts.edu.au	Stack, Colin M/D-4601-2009; Dalton, John/K-4457-2014; Donnelly, Sheila/H-7733-2014	Donnelly, Sheila/0000-0003-2005-3698; Stack, Colin/0000-0002-7539-7677	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews SJ, 1999, FASCIOLOSIS, P1; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker KC, 1996, PROTEIN ENG, V9, P525, DOI 10.1093/protein/9.6.525; Brady MT, 1999, INFECT IMMUN, V67, P5372, DOI 10.1128/IAI.67.10.5372-5378.1999; BRINDLEY PJ, 2004, HDB PROTEOLYTIC ENZY, P1305; Brix K, 2001, BIOL CHEM, V382, P717, DOI 10.1515/BC.2001.087; Cappetta M, 2002, BIOL CHEM, V383, P1215, DOI 10.1515/BC.2002.134; Collins PR, 2004, J BIOL CHEM, V279, P17038, DOI 10.1074/jbc.M308831200; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Dalton JP, 2004, CAN J ZOOL, V82, P211, DOI [10.1139/z03-213, 10.1139/Z03-213]; Dalton JP, 2003, INT J PARASITOL, V33, P621, DOI 10.1016/S0020-7519(03)00057-2; Dalton JP, 1996, INFECT IMMUN, V64, P5066, DOI 10.1128/IAI.64.12.5066-5074.1996; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOWD AJ, 1994, EUR J BIOCHEM, V223, P91, DOI 10.1111/j.1432-1033.1994.tb18969.x; Dowd AJ, 1997, MOL BIOCHEM PARASIT, V88, P163, DOI 10.1016/S0166-6851(97)00090-X; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; Guo YL, 2000, FEBS LETT, V469, P203, DOI 10.1016/S0014-5793(00)01281-3; Halton DW, 1997, INT J PARASITOL, V27, P693, DOI 10.1016/S0020-7519(97)00011-8; HALTON DW, 1967, PARASITOLOGY, V57, P639, DOI 10.1017/S003118200007311X; Higgins DR, 1998, METH MOL B, V103, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishidoh K, 1998, BIOL CHEM, V379, P131; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; Linder S, 1996, BIOTECHNIQUES, V20, P980; MACH L, 1994, J BIOL CHEM, V269, P13036; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Mulcahy G, 1998, VACCINE, V16, P932, DOI 10.1016/S0264-410X(97)00289-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; O'Neill SM, 2001, PARASITE IMMUNOL, V23, P541, DOI 10.1046/j.1365-3024.2001.00411.x; Ogino T, 1999, J BIOCHEM-TOKYO, V126, P78, DOI 10.1093/oxfordjournals.jbchem.a022439; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 2001, J BIOL CHEM, V276, P8118, DOI 10.1074/jbc.M005851200; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Roche L, 1997, EUR J BIOCHEM, V245, P373, DOI 10.1111/j.1432-1033.1997.t01-1-00373.x; Roche L, 1999, MOL BIOCHEM PARASIT, V98, P271, DOI 10.1016/S0166-6851(98)00164-9; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Sivaraman J, 1999, PROTEIN SCI, V8, P283; Tepel C, 2000, J CELL SCI, V113, P4487; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; Turk B, 1999, EUR J BIOCHEM, V259, P926, DOI 10.1046/j.1432-1327.1999.00145.x; Turk D, 2003, ACTA CRYSTALLOGR D, V59, P203, DOI 10.1107/S0907444902021479; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; Wiederanders B, 2003, CURR PROTEIN PEPT SC, V4, P309, DOI 10.2174/1389203033487081	56	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16532	16543		10.1074/jbc.M611501200	http://dx.doi.org/10.1074/jbc.M611501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403677	hybrid			2022-12-25	WOS:000246794300060
J	Wang, H; Lu, YF; Huang, WQ; Papoutsakis, ET; Fuhrken, P; Eklund, EA				Wang, Hao; Lu, YuFeng; Huang, Weiqi; Papoutsakis, E. Terry; Fuhrken, Peter; Eklund, Elizabeth A.			HoxA10 activates transcription of the gene encoding mitogen-activated protein kinase phosphatase 2 (Mkp2) in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC-CELLS; N-TERMINAL KINASE; DNA-BINDING; MYELOGENOUS LEUKEMIA; EXPRESSION; DIFFERENTIATION; APOPTOSIS; SUBPOPULATIONS; INTERRUPTION; REPRESSION	HoxA10 is a homeodomain transcription factor that is frequently overexpressed in human acute myeloid leukemia. In murine bone marrow transplantation studies, HoxA10 overexpression induces a myeloproliferative disorder with accumulation of mature phagocytes in the peripheral blood and tissues. Over time, differentiation block develops in these animals, resulting in acute myeloid leukemia. In immature myeloid cells, HoxA10 represses transcription of some genes that confer the mature phagocyte phenotype. Therefore, overexpressed HoxA10 blocks differentiation by repressing myeloid-specific gene transcription in differentiating myeloid cells. In contrast, target genes involved in myeloproliferation due to HoxA10 overexpression have not been identified. To identify such genes, we screened aCpGisland microarray with HoxA10 co-immunoprecipitating chromatin. We identified the DUSP4 gene, which encodes mitogen-activated protein kinase phosphatase 2 (Mkp2), as a HoxA10 target gene. We analyzed the DUSP4 5 '- flank and identified two proximal-promoter cis elements that are activated by HoxA10. We find that DUSP4 transcription and Mkp2 expression decrease during normal myelopoiesis. However, this down-regulation is impaired in myeloid cells overexpressing HoxA10. In hematopoietic cells, c-Jun N-terminal kinases (Jnk) are the preferred substrates for Mkp2. Therefore, Mkp2 inhibits apoptosis by dephosphorylating (inactivating) Jnk. Consistent with this, HoxA10 overexpression decreases apoptosis in differentiating myeloid cells. Therefore, our studies identify a mechanism by which overexpressed HoxA10 contributes to inappropriate cell survival during myelopoiesis.	Northwestern Univ, Fineberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA; Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Fineberg Sch Med, 710 N Fairbanks Ct,Olson 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu	Papoutsakis, Eleftherios/B-7612-2009; Huang, Weiqi/E-4341-2010; Papoutsakis, Eleftherios T/A-5254-2010	Wang, Hao/0000-0003-2131-0377				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Daftary GS, 2002, MOL ENDOCRINOL, V16, P571, DOI 10.1210/me.16.3.571; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEVY R, 1990, J IMMUNOL, V145, P2595; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Mc Gee MM, 2002, J BIOL CHEM, V277, P18383, DOI 10.1074/jbc.M112058200; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	27	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16164	16176		10.1074/jbc.M610556200	http://dx.doi.org/10.1074/jbc.M610556200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430893	hybrid			2022-12-25	WOS:000246794300025
J	Hosoda, K; Matsuura, T; Kita, H; Ichihashi, N; Tsukada, K; Yomo, T				Hosoda, Kazufumi; Matsuura, Tomoaki; Kita, Hiroshi; Ichihashi, Norikazu; Tsukada, Koji; Yomo, Tetsuya			Kinetic analysis of the entire RNA amplification process by Q beta replicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; COLIPHAGE Q-BETA; PHAGE-Q-BETA; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; PROTEIN INTERACTIONS; EF-TS; TEMPLATE; POLYMERASE; BINDING	The kinetics of the RNA replication reaction by Q beta replicase were investigated. Q beta replicase is an RNA-dependent RNA polymerase responsible for replicating the RNA genome of coliphage Q beta and plays a key role in the life cycle of the Q beta phage. Although the RNA replication reaction using this enzyme has long been studied, a kinetic model that can describe the entire RNA amplification process has yet to be determined. In this study, we propose a kinetic model that is able to account for the entire RNA amplification process. The key to our proposed kinetic model is the consideration of nonproductive binding (i.e. binding of an enzyme to the RNA where the enzyme cannot initiate the reaction). By considering nonproductive binding and the notable enzyme inactivation we observed, the previous observations that remained unresolved could also be explained. Moreover, based on the kinetic model and the experimental results, we determined rate and equilibrium constants using template RNAs of various lengths. The proposed model and the obtained constants provide important information both for understanding the basis of Q beta phage amplification and the applications using Q beta replicase.	Osaka Univ, Dept Bioinformat Engn, Grad Sch Informat Sci & Technol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biotechnol, Grad Sch Engn, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Complex Syst Biol Project, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yomo, T (corresponding author), Osaka Univ, Dept Bioinformat Engn, Grad Sch Informat Sci & Technol, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yomo@ist.osaka-u.ac.jp	Matsuura, Tomoaki/W-6086-2019; Ichihashi, Norikazu/AAY-6897-2020; matsuura, tomoaki/O-7368-2018	Matsuura, Tomoaki/0000-0003-1015-6781; matsuura, tomoaki/0000-0003-1015-6781				Abramson Richard D., 1993, Current Opinion in Biotechnology, V4, P41, DOI 10.1016/0958-1669(93)90030-Z; ALBE KR, 1990, J THEOR BIOL, V143, P163, DOI 10.1016/S0022-5193(05)80266-8; Alberts B., 2002, MOL BIOL CELL, P191; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; AXELROD VD, 1991, VIROLOGY, V184, P595, DOI 10.1016/0042-6822(91)90430-J; BIEBRICHER CK, 1984, BIOCHEMISTRY-US, V23, P3186, DOI 10.1021/bi00309a012; BIEBRICHER CK, 1986, NATURE, V321, P89, DOI 10.1038/321089a0; BIEBRICHER CK, 1981, J MOL BIOL, V148, P391, DOI 10.1016/0022-2836(81)90183-2; BIEBRICHER CK, 1983, BIOCHEMISTRY-US, V22, P2544, DOI 10.1021/bi00279a036; BLUMENTHAL T, 1977, BIOCHIM BIOPHYS ACTA, V478, P201, DOI 10.1016/0005-2787(77)90183-6; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14775, DOI 10.1021/bi00045a019; CALENDAR R, 2006, BACTERIOPHAGES, P175; Chetverin AB, 1997, CELL, V88, P503, DOI 10.1016/S0092-8674(00)81890-5; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; CHETVERIN AB, 1995, PROG NUCLEIC ACID RE, V51, P225, DOI 10.1016/S0079-6603(08)60880-6; EIGEN M, 1991, BIOCHEMISTRY-US, V30, P11005, DOI 10.1021/bi00110a001; Fersht A., 1999, STRUCTURE MECH PROTE, P114; HARUNA I, 1965, P NATL ACAD SCI USA, V54, P579, DOI 10.1073/pnas.54.2.579; Inokuchi Y, 1997, J BIOL CHEM, V272, P15339, DOI 10.1074/jbc.272.24.15339; INOKUCHI Y, 1994, J BIOCHEM-TOKYO, V116, P1275, DOI 10.1093/oxfordjournals.jbchem.a124675; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; KACIAN DL, 1972, P NATL ACAD SCI USA, V69, P3038, DOI 10.1073/pnas.69.10.3038; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kim H, 2004, BIOTECHNOL BIOENG, V88, P148, DOI 10.1002/bit.20226; Kita H, 2006, J BIOSCI BIOENG, V101, P421, DOI 10.1263/jbb.101.421; Klovins J, 1998, RNA, V4, P948, DOI 10.1017/S1355838298980177; KNUTH DE, 1992, AM MATH MON, V99, P403, DOI 10.2307/2325085; KONDO M, 1972, EUR J BIOCHEM, V24, P530, DOI 10.1111/j.1432-1033.1972.tb19715.x; Kopsidas G, 2006, IMMUNOL LETT, V107, P163, DOI 10.1016/j.imlet.2006.09.004; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LANGOWSKI J, 1980, NUCLEIC ACIDS RES, V8, P4727, DOI 10.1093/nar/8.20.4727; LIN SY, 1970, NATURE, V228, P1184, DOI 10.1038/2281184a0; LIZARDI PM, 1988, BIO-TECHNOL, V6, P1197, DOI 10.1038/nbt1088-1197; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Messias AC, 2004, ACCOUNTS CHEM RES, V37, P279, DOI 10.1021/ar030034m; MILLS DR, 1979, P NATL ACAD SCI USA, V76, P2232, DOI 10.1073/pnas.76.5.2232; MILLS DR, 1978, CELL, V15, P541, DOI 10.1016/0092-8674(78)90022-3; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; Nakaishi T, 2002, J BIOSCI BIOENG, V93, P322, DOI 10.1263/jbb.93.322; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; Ortin J, 2006, ANNU REV MICROBIOL, V60, P305, DOI 10.1146/annurev.micro.60.080805.142248; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; Preuss R, 1997, J MOL BIOL, V273, P600, DOI 10.1006/jmbi.1997.1343; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; Schuppli D, 1997, P NATL ACAD SCI USA, V94, P10239, DOI 10.1073/pnas.94.19.10239; Susa M, 2002, J BIOL CHEM, V277, P15407, DOI 10.1074/jbc.M112481200; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; Tretheway DM, 2001, J VIROL, V75, P11373, DOI 10.1128/JVI.75.23.11373-11383.2001; Tyagi S, 1996, P NATL ACAD SCI USA, V93, P5395, DOI 10.1073/pnas.93.11.5395; Ugarov VI, 2003, J BIOL CHEM, V278, P44139, DOI 10.1074/jbc.M305992200; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WERNER M, 1991, BIOCHEMISTRY-US, V30, P5832, DOI 10.1021/bi00238a004; Yoshinari S, 2000, VIROLOGY, V271, P363, DOI 10.1006/viro.2000.0334; ZAMORA H, 1995, BIOCHEMISTRY-US, V34, P1261, DOI 10.1021/bi00004a020	58	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15516	15527		10.1074/jbc.M700307200	http://dx.doi.org/10.1074/jbc.M700307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17412690	hybrid			2022-12-25	WOS:000246589600028
J	Ribeiro, I; Kawakami, Y; Buscher, D; Raya, A; Rodriguez-Leon, J; Morita, M; Esteban, CR; Belmonte, JCI				Ribeiro, Ines; Kawakami, Yasuhiko; Buescher, Dirk; Raya, Angel; Rodriguez-Leon, Joaquin; Morita, Masanobu; Esteban, Concepcion Rodriguez; Izpisua Belmonte, Juan Carlos			Tbx2 and Tbx3 Regulate the Dynamics of Cell Proliferation during Heart Remodeling	PLOS ONE			English	Article							GENOTYPE-PHENOTYPE RELATIONSHIP; HOLT-ORAM-SYNDROME; T-BOX GENES; MOUSE HEART; MORPHOGENESIS; MUTATIONS; DEFECTS; DIFFERENTIATION; LIMB; GROWTH	Background. The heart forms from a linear tube that is subject to complex remodeling during embryonic development. Hallmarks of this remodeling are the looping of the heart tube and the regionalization into chamber and non-chamber myocardium. Cardiomyocytes in the future chamber myocardium acquire different cellular and physiological characteristics through activation of a chamber-specific genetic program, which is in part mediated by T-box genes. Methodology/Principal Finding. We characterize two new zebrafish T-box transcription factors, tbx3b and tbx2a, and analyze their role during the development of the atrioventricular canal. Loss-and gain-of-function analyses demonstrate that tbx3b and tbx2a are necessary to repress the chamber-genetic program in the non-chamber myocardium. We also show that tbx3b and tbx2a are required to control cell proliferation in the atrioventricular canal and that misregulation of cell proliferation in the heart tube influences looping. Furthermore, we characterize the heart phenotype of a novel Tbx3 mutation in mice and show that both the control of cell proliferation and the repression of chamber-specific genetic program in the non-chamber myocardium are conserved roles of Tbx3 in this species. Conclusions/Significance. Taken together, our results uncover an evolutionarily conserved role of Tbx2/3 transcription factors during remodeling of the heart myocardium and highlight the importance of controlling cell proliferation as a driving force of morphogenesis.	[Ribeiro, Ines; Kawakami, Yasuhiko; Buescher, Dirk; Raya, Angel; Morita, Masanobu; Esteban, Concepcion Rodriguez; Izpisua Belmonte, Juan Carlos] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Rodriguez-Leon, Joaquin] Inst Gulbenkian Ciencias, Unidade Desenvolvimento, Oeiras, Portugal	Salk Institute; Instituto Gulbenkian de Ciencia	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	Leon, Joaquin Maria Rodriguez/C-6957-2013; Raya, Angel/E-6205-2010; Leon, Joaquin Maria Rodriguez/S-9814-2019; Ribeiro, Ines MA/AAK-4091-2020	Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Raya, Angel/0000-0003-2189-9775; Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Ribeiro, Ines MA/0000-0002-7480-6918; Kawakami, Yasuhiko/0000-0002-0043-9705	Fundacao para a Ciencia e Tecnologia and dissertation; Instituto Gulbenkian Ciencia; Fundacao para a Ciencia e a Tecnologia; Foundation Inbiomed; G. Harold and Leila Y. Mathers Charitable Foundation; National Institutes of Health	Fundacao para a Ciencia e Tecnologia and dissertation; Instituto Gulbenkian Ciencia; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Foundation Inbiomed; G. Harold and Leila Y. Mathers Charitable Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	I. R. was supported by a predoctoral fellowship from the Fundacao para a Ciencia e Tecnologia and dissertation fellowship from Instituto Gulbenkian Ciencia; J. R. L. was partially supported by a fellowship from Fundacao para a Ciencia e a Tecnologia, and A. R. and C. R. E. were partially supported by Foundation Inbiomed. This work was supported by grants from the G. Harold and Leila Y. Mathers Charitable Foundation, and the National Institutes of Health to J. C. I. B.	Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bamshad M, 1999, AM J HUM GENET, V64, P1550, DOI 10.1086/302417; Bartram U, 2001, CIRCULATION, V103, P2745; Berdougo E, 2003, DEVELOPMENT, V130, P6121, DOI 10.1242/dev.00838; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Bussen M, 2004, GENE DEV, V18, P1209, DOI 10.1101/gad.300104; Cai CL, 2005, DEVELOPMENT, V132, P2475, DOI 10.1242/dev.01832; Charng MJ, 1998, DEV BIOL, V199, P72, DOI 10.1006/dbio.1998.8905; Chen HY, 2004, DEVELOPMENT, V131, P2219, DOI 10.1242/dev.01094; Christoffels VM, 2004, TRENDS CARDIOVAS MED, V14, P301, DOI 10.1016/j.tcm.2004.09.002; Christoffels VM, 2004, DEV DYNAM, V229, P763, DOI 10.1002/dvdy.10487; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Garrity DM, 2002, DEVELOPMENT, V129, P4635; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Harrelson Z, 2004, DEVELOPMENT, V131, P5041, DOI 10.1242/dev.01378; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hoogaars WMH, 2004, CARDIOVASC RES, V62, P489, DOI 10.1016/j.cardiores.2004.01.030; Huang CJ, 2003, DEV DYNAM, V228, P30, DOI 10.1002/dvdy.10356; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kang JS, 2004, MECH DEVELOP, V121, P301, DOI 10.1016/j.mod.2004.01.007; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Li QY, 1997, NAT GENET, V15, P21; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Matsui T, 2005, GENE DEV, V19, P164, DOI 10.1101/gad.1253605; Meneghini V, 2006, EUR J MED GENET, V49, P151, DOI 10.1016/j.ejmg.2005.04.021; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; MOENS CB, 1993, DEVELOPMENT, V119, P485; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Naiche LA, 2005, ANNU REV GENET, V39, P219, DOI 10.1146/annurev.genet.39.073003.105925; Neuhaus H, 1999, MECH DEVELOP, V80, P181, DOI 10.1016/S0925-4773(98)00221-4; Ng JK, 2002, DEVELOPMENT, V129, P5161; Palmer S, 2001, J CELL BIOL, V153, P985, DOI 10.1083/jcb.153.5.985; Paxton C, 2002, GENE, V283, P117, DOI 10.1016/S0378-1119(01)00878-2; Rasskin-Gutman D, 2004, BIOESSAYS, V26, P405, DOI 10.1002/bies.10410; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Sedmera D, 2003, ANAT REC PART A, V274A, P773, DOI 10.1002/ar.a.10085; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; Singh MK, 2005, MECH DEVELOP, V122, P131, DOI 10.1016/j.mod.2004.10.011; Singh MK, 2005, DEVELOPMENT, V132, P2697, DOI 10.1242/dev.01854; Stennard FA, 2005, DEVELOPMENT, V132, P2451, DOI 10.1242/dev.01799; Szeto DP, 2002, DEVELOPMENT, V129, P5093; Taber LA, 2006, INT J DEV BIOL, V50, P323, DOI 10.1387/ijdb.052045lt; Takeuchi JK, 2005, DEVELOPMENT, V132, P2463, DOI 10.1242/dev.01827; THOMPSON RP, 1990, DEVELOPMENTAL CARDIOLOGY, P219; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Walton RZ, 2006, DEV BIOL, V289, P482, DOI 10.1016/j.ydbio.2005.10.040; Yamamoto A, 1998, DEVELOPMENT, V125, P3389	51	73	75	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e398	10.1371/journal.pone.0000398	http://dx.doi.org/10.1371/journal.pone.0000398			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460765	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445600012
J	Capone, C; Frigerio, S; Fumagalli, S; Gelati, M; Principato, MC; Storini, C; Montinaro, M; Kraftsik, R; De Curtis, M; Parati, E; De Simoni, MG				Capone, Carmen; Frigerio, Simona; Fumagalli, Stefano; Gelati, Maurizio; Principato, Maria-Cristina; Storini, Claudio; Montinaro, Mery; Kraftsik, Rudolf; De Curtis, Marco; Parati, Eugenio; De Simoni, Maria-Grazia			Neurosphere-Derived Cells Exert a Neuroprotective Action by Changing the Ischemic Microenvironment	PLOS ONE			English	Article								Background. Neurosphere-derived cells (NC), containing neural stem cells, various progenitors and more differentiated cells, were obtained from newborn C57/BL6 mice and infused in a murine model of focal ischemia with reperfusion to investigate if: 1) they decreased ischemic injury and restored brain function; 2) they induced changes in the environment in which they are infused; 3) changes in brain environment consequent to transient ischemia were relevant for NC action. Methodology/Principal Findings. NC were infused intracerebroventricularly 4 h or 7 d after 30 min middle cerebral artery occlusion. In ischemic mice receiving cells at 4 h, impairment of open field performance was significantly improved and neuronal loss significantly reduced 7-14 d after ischemia compared to controls and to ischemic mice receiving cells at 7 d. Infusion of murine foetal fibroblast in the same experimental conditions was not effective. Assessment of infused cell distribution revealed that they migrated from the ventricle to the parenchyma, progressively decreased in number but they were observable up to 14 d. In mice receiving NC at 7 d and in sham-operated mice, few cells could be observed only at 24 h, indicating that the survival of these cells in brain tissue relates to the ischemic environment. The mRNA expression of trophic factors such as Insulin Growth Factor-1, Vascular Endothelial Growth Factor-A, Transforming Growth Factor-beta 1, Brain Derived Neurotrophic Factor and Stromal Derived Factor-1 alpha, as well as microglia/macrophage activation, increased 24 h after NC infusion in ischemic mice treated at 4 h compared to sham-operated and to mice receiving cells at 7 d. Conclusions/Significance. NC reduce functional impairment and neuronal damage after ischemia/reperfusion injury. Several lines of evidence indicate that the reciprocal interaction between NC and the ischemic environment is crucial for NC protective actions. Based on these results we propose that a bystander control of the ischemic environment may be the mechanism used by NC to rapidly restore acutely injured brain function.	[Capone, Carmen; Fumagalli, Stefano; Principato, Maria-Cristina; Storini, Claudio; Montinaro, Mery; De Simoni, Maria-Grazia] Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Milan, Italy; [Frigerio, Simona; Gelati, Maurizio; Parati, Eugenio] Ist Nazl Neurol Carlo Besta, Lab Neurobiol & Neuroregenerat Therapies, Milan, Italy; [Kraftsik, Rudolf] Univ Lausanne, Dept Cell Biol & Morphol, Lausanne, Switzerland; [De Curtis, Marco] Ist Nazl Neurol Carlo Besta, Clin Epileptol & Expt Neurophysiol Unit, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta; University of Lausanne; IRCCS Istituto Neurologico Besta	De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Milan, Italy.	desimoni@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Gelati, Maurizio/T-4538-2019; Parati, Eugenio A/G-8765-2011; de Curtis, Marco M/J-8704-2016; Frigerio, Simona/AAI-3264-2021; Fumagalli, Stefano/I-3097-2019; Parati, Eugenio Agostino/AAN-5893-2021	De Simoni, Maria Grazia/0000-0001-6695-5297; Gelati, Maurizio/0000-0002-4828-9849; de Curtis, Marco M/0000-0001-7443-6737; Frigerio, Simona/0000-0001-7078-075X; Parati, Eugenio Agostino/0000-0001-5020-6523; de Curtis, Marco/0000-0002-5608-929X; Fumagalli, Stefano/0000-0003-3598-6263	Fondazione Cariplo [2005.1208/10.4963]; Istituto Superiore di Sanita [Conv.N.530/F-A11]	Fondazione Cariplo(Fondazione Cariplo); Istituto Superiore di Sanita	The work was partially supported by Fondazione Cariplo, grant 2005.1208/10.4963 and by Istituto Superiore di Sanita Conv.N.530/F-A11.	Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Belmadani A, 2005, J NEUROSCI, V25, P3995, DOI 10.1523/JNEUROSCI.4631-04.2005; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Conti L, 2003, PHARMACOL RES, V47, P289, DOI 10.1016/S1043-6618(03)00038-0; De Simoni MG, 2004, AM J PATHOL, V164, P1857, DOI 10.1016/S0002-9440(10)63744-3; De Simoni MG, 2003, J CEREBR BLOOD F MET, V23, P232, DOI 10.1097/01.WCB.0000046146.31247.A1; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Francia N, 2006, EUR J NEUROSCI, V23, P711, DOI 10.1111/j.1460-9568.2006.04585.x; Gorski JA, 2003, J NEUROSCI, V23, P6856; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1139/y05-143; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Lopez-Lopez C, 2004, P NATL ACAD SCI USA, V101, P9833, DOI 10.1073/pnas.0400337101; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Pallini R, 2005, NEUROSURGERY, V57, P1014, DOI 10.1227/01.NEU.0000180058.58372.4c; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Savitz Sean I, 2004, NeuroRx, V1, P406; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; Storini C, 2006, J PHARMACOL EXP THER, V318, P849, DOI 10.1124/jpet.106.105064; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Troglio F, 2004, P NATL ACAD SCI USA, V101, P15476, DOI 10.1073/pnas.0403283101; Tschenett A, 2003, EUR J NEUROSCI, V18, P143, DOI 10.1046/j.1460-9568.2003.02725.x; Wada T, 2006, J NEUROSCI, V26, P6803, DOI 10.1523/JNEUROSCI.0526-06.2006; WANG XK, 1995, BRAIN RES BULL, V36, P607, DOI 10.1016/0361-9230(94)00243-T; Wirenfeldt M, 2005, J NEUROSCI RES, V82, P507, DOI 10.1002/jnr.20659; Yan YP, 2006, EUR J NEUROSCI, V24, P45, DOI 10.1111/j.1460-9568.2006.04872.x	44	96	102	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e373	10.1371/journal.pone.0000373	http://dx.doi.org/10.1371/journal.pone.0000373			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440609	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445500004
J	Lindqvist, C; Janczak, AM; Natt, D; Baranowska, I; Lindqvist, N; Wichman, A; Lundeberg, J; Lindberg, J; Torjesen, PA; Jensen, P				Lindqvist, Christina; Janczak, Andrew M.; Natt, Daniel; Baranowska, Izabella; Lindqvist, Niclas; Wichman, Anette; Lundeberg, Joakim; Lindberg, Johan; Torjesen, Peter A.; Jensen, Per			Transmission of Stress-Induced Learning Impairment and Associated Brain Gene Expression from Parents to Offspring in Chickens	PLOS ONE			English	Article							RED JUNGLEFOWL; WHITE LEGHORN; BEHAVIOR; TRAITS; GROWTH	Background. Stress influences many aspects of animal behaviour and is a major factor driving populations to adapt to changing living conditions, such as during domestication. Stress can affect offspring through non-genetic mechanisms, but recent research indicates that inherited epigenetic modifications of the genome could possibly also be involved. Methodology/Principal Findings. Red junglefowl (RJF, ancestors of modern chickens) and domesticated White Leghorn (WL) chickens were raised in a stressful environment (unpredictable light-dark rhythm) and control animals in similar pens, but on a 12/12 h light-dark rhythm. WL in both treatments had poorer spatial learning ability than RJF, and in both populations, stress caused a reduced ability to solve a spatial learning task. Offspring of stressed WL, but not RJF, raised without parental contact, had a reduced spatial learning ability compared to offspring of non-stressed animals in a similar test as that used for their parents. Offspring of stressed WL were also more competitive and grew faster than offspring of non-stressed parents. Using a whole-genome cDNA microarray, we found that in WL, the same changes in hypothalamic gene expression profile caused by stress in the parents were also found in the offspring. In offspring of stressed WL, at least 31 genes were up- or down-regulated in the hypothalamus and pituitary compared to offspring of non-stressed parents. Conclusions/Significance. Our results suggest that, in WL the gene expression response to stress, as well as some behavioural stress responses, were transmitted across generations. The ability to transmit epigenetic information and behaviour modifications between generations may therefore have been favoured by domestication. The mechanisms involved remain to be investigated; epigenetic modifications could either have been inherited or acquired de novo in the specific egg environment. In both cases, this would offer a novel explanation to rapid evolutionary adaptation of a population.	[Lindqvist, Christina; Natt, Daniel; Baranowska, Izabella; Lindqvist, Niclas; Jensen, Per] Linkoping Univ, IFM Biol, Linkoping, Sweden; [Janczak, Andrew M.] Norwegian Univ Life Sci, Dept Anim & Aquacultural Sci, As, Norway; [Wichman, Anette] Swedish Univ Agr Sci, Dept Anim Environm & Hlth, Skara, Sweden; [Lundeberg, Joakim; Lindberg, Johan] Royal Inst Technol, Sch Biotechnol, Dept Gene Technol, Stockholm, Sweden; [Torjesen, Peter A.] Aker Univ Hosp, Hormone Lab, Oslo, Norway	Linkoping University; Norwegian University of Life Sciences; Swedish University of Agricultural Sciences; Royal Institute of Technology; University of Oslo	Jensen, P (corresponding author), Linkoping Univ, IFM Biol, Linkoping, Sweden.	perje@ifm.liu.se	Lindberg, Johan/F-4104-2011; Janczak, Andrew M/B-4113-2013; Nätt, Daniel/E-9693-2011; Natt, Daniel/AAR-3928-2021	Janczak, Andrew M/0000-0002-1141-8272; Nätt, Daniel/0000-0002-3801-5705; Natt, Daniel/0000-0001-9182-9401; Lindberg, Johan/0000-0003-3610-6774	Wallenberg Consortium North; Swedish Reseach Council for Environment, Agricultural Sciences and Spatial Planning; Swedish Research Council; Norwegian Research Council; Norwegian Centre of Poultry Science	Wallenberg Consortium North; Swedish Reseach Council for Environment, Agricultural Sciences and Spatial Planning(Swedish Research Council Formas); Swedish Research Council(Swedish Research CouncilEuropean Commission); Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Centre of Poultry Science	Funding: This project was supported by grants from Wallenberg Consortium North, the Swedish Reseach Council for Environment, Agricultural Sciences and Spatial Planning, the Swedish Research Council, the Norwegian Research Council and the Norwegian Centre of Poultry Science.	BELYAEV DK, 1985, APPL ANIM BEHAV SCI, V13, P359, DOI 10.1016/0168-1591(85)90015-2; BELYAEV DK, 1969, SCI J, V5, P47; Braastad BO, 1998, APPL ANIM BEHAV SCI, V61, P159, DOI 10.1016/S0168-1591(98)00188-9; de Kloet ER, 2005, NEUROSCI BIOBEHAV R, V29, P271, DOI 10.1016/j.neubiorev.2004.10.008; FITZIMMONS C, 2006, EXPLORING REALM GENE; FUMIHITO A, 1994, P NATL ACAD SCI USA, V91, P12505, DOI 10.1073/pnas.91.26.12505; Groothuis TGG, 2005, NEUROSCI BIOBEHAV R, V29, P329, DOI 10.1016/j.neubiorev.2004.12.002; Hansen SW, 1996, APPL ANIM BEHAV SCI, V49, P137, DOI 10.1016/0168-1591(96)01045-3; Hayward LS, 2004, GEN COMP ENDOCR, V135, P365, DOI 10.1016/j.ygcen.2003.11.002; Jablonka E., 1995, EPIGENETIC INHERITAN; Kaiser S, 2005, NEUROSCI BIOBEHAV R, V29, P283, DOI 10.1016/j.neubiorev.2004.09.015; LOFTHUS R, 1986, J STEROID BIOCHEM, V25, P541, DOI 10.1016/0022-4731(86)90400-0; Molinier J, 2006, NATURE, V442, P1046, DOI 10.1038/nature05022; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Price E.O., 2002, ANIMAL DOMESTICATION; Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834; Rozen S, 2000, Methods Mol Biol, V132, P365; Savolainen P, 2005, CYTOGENET GENOME RES, V111, P79, DOI 10.1159/000085674; Schutz KE, 2004, BEHAV GENET, V34, P121, DOI 10.1023/B:BEGE.0000009481.98336.fc; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276	20	72	74	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e364	10.1371/journal.pone.0000364	http://dx.doi.org/10.1371/journal.pone.0000364			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426812	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445400004
J	Nishida, M; Walker, MP				Nishida, Masaki; Walker, Matthew P.			Daytime Naps, Motor Memory Consolidation and Regionally Specific Sleep Spindles	PLOS ONE			English	Article							STAGE-2 SLEEP; TIME-COURSE; STIMULATION; EEG; SEQUENCE	Background. Increasing evidence demonstrates that motor-skill memories improve across a night of sleep, and that non-rapid eye movement (NREM) sleep commonly plays a role in orchestrating these consolidation enhancements. Here we show the benefit of a daytime nap on motor memory consolidation and its relationship not simply with global sleep-stage measures, but unique characteristics of sleep spindles at regionally specific locations; mapping to the corresponding memory representation. Methodology/Principal Findings. Two groups of subjects trained on a motor-skill task using their left hand-a paradigm known to result in overnight plastic changes in the contralateral, right motor cortex. Both groups trained in the morning and were tested 8 hr later, with one group obtaining a 60-90 minute intervening midday nap, while the other group remained awake. At testing, subjects that did not nap showed no significant performance improvement, yet those that did nap expressed a highly significant consolidation enhancement. Within the nap group, the amount of offline improvement showed a significant correlation with the global measure of stage-2 NREM sleep. However, topographical sleep spindle analysis revealed more precise correlations. Specifically, when spindle activity at the central electrode of the non-learning hemisphere (left) was subtracted from that in the learning hemisphere (right), representing the homeostatic difference following learning, strong positive relationships with offline memory improvement emerged-correlations that were not evident for either hemisphere alone. Conclusions/Significance. These results demonstrate that motor memories are dynamically facilitated across daytime naps, enhancements that are uniquely associated with electrophysiological events expressed at local, anatomically discrete locations of the brain.	[Nishida, Masaki; Walker, Matthew P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Sleep & Neuroimaging Lab,Dept Psychiat, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Walker, MP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Sleep & Neuroimaging Lab,Dept Psychiat, Boston, MA 02215 USA.	mwalker@hms.harvard.edu	Nishida, Masaki/O-7439-2018	Nishida, Masaki/0000-0003-2661-4425	National Institutes of Health [MH069935, MH48832, MH65292, MH67754]; American Academy of Sleep Medicine; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH067754, R03MH069935, R01MH065292] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Sleep Medicine; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported in part by grants from the National Institutes of Health (MH069935, MH48832, MH65292 and MH67754), and the American Academy of Sleep Medicine.	Cantero JL, 2002, J NEUROSCI, V22, P4702, DOI 10.1523/JNEUROSCI.22-11-04702.2002; De Gennaro L, 2000, J SLEEP RES, V9, P155, DOI 10.1046/j.1365-2869.2000.00193.x; FERRARELLI F, AM J PSYCHI IN PRESS; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; Fogel SM, 2006, J SLEEP RES, V15, P250, DOI 10.1111/j.1365-2869.2006.00522.x; Grafton ST, 2002, EXP BRAIN RES, V146, P369, DOI 10.1007/s00221-002-1181-y; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huber R, 2006, NAT NEUROSCI, V9, P1169, DOI 10.1038/nn1758; IYAMA A, 1992, CLIN ELECTROENCEPHAL, V23, P137, DOI 10.1177/155005949202300308; KATTLER H, 1994, J SLEEP RES, V3, P159, DOI 10.1111/j.1365-2869.1994.tb00123.x; Korman M, 2003, P NATL ACAD SCI USA, V100, P12492, DOI 10.1073/pnas.2035019100; Kuriyama K, 2004, LEARN MEMORY, V11, P705, DOI 10.1101/lm.76304; MEDNICK SC, 2002, NAT NEUROSCI, V28, P28; PETERS K, J COGN NEUR IN PRESS; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Robertson EM, 2004, CURR BIOL, V14, P208, DOI 10.1016/j.cub.2004.01.027; Robertson EM, 2004, NAT REV NEUROSCI, V5, P576, DOI 10.1038/nrn1426; Sejnowski TJ, 2000, BRAIN RES, V886, P208, DOI 10.1016/S0006-8993(00)03007-9; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; SMITH C, 1994, J SLEEP RES, V3, P206, DOI 10.1111/j.1365-2869.1994.tb00133.x; Smith CT, 2004, PSYCHOL BELG, V44, P81; Steriade M., 2001, INTACT SLICED BRAIN; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; TUCKER MA, 2006, NEUROBIOL LEARN MEM; Vyazovskiy V, 2000, J SLEEP RES, V9, P367, DOI 10.1046/j.1365-2869.2000.00230.x; Walker MP, 2006, ANNU REV PSYCHOL, V57, P139, DOI 10.1146/annurev.psych.56.091103.070307; Walker MP, 2005, BEHAV BRAIN SCI, V28, P51, DOI 10.1017/S0140525X05000026; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Walker MP, 2003, LEARN MEMORY, V10, P275, DOI 10.1101/lm.58503; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8; Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930; Zeitlhofer J, 1997, J SLEEP RES, V6, P149, DOI 10.1046/j.1365-2869.1997.00046.x	32	342	343	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e341	10.1371/journal.pone.0000341	http://dx.doi.org/10.1371/journal.pone.0000341			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406665	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445300003
J	Reynolds, AM; Frye, MA				Reynolds, Andy M.; Frye, Mark A.			Free-Flight Odor Tracking in Drosophila Is Consistent with an Optimal Intermittent Scale-Free Search	PLOS ONE			English	Article								During their trajectories in still air, fruit flies (Drosophila melanogaster) explore their landscape using a series of straight flight paths punctuated by rapid 90 degrees body-saccades [1]. Some saccades are triggered by visual expansion associated with collision avoidance. Yet many saccades are not triggered by visual cues, but rather appear spontaneously. Our analysis reveals that the control of these visually independent saccades and the flight intervals between them constitute an optimal scale-free active searching strategy. Two characteristics of mathematical optimality that are apparent during free-flight in Drosophila are inter-saccade interval lengths distributed according to an inverse square law, which does not vary across landscape scale, and 90 degrees saccade angles, which increase the likelihood that territory will be revisited and thereby reduce the likelihood that near-by targets will be missed. We also show that searching is intermittent, such that active searching phases randomly alternate with relocation phases. Behaviorally, this intermittency is reflected in frequently occurring short, slow speed inter-saccade intervals randomly alternating with rarer, longer, faster inter-saccade intervals. Searching patterns that scale similarly across orders of magnitude of length (i.e., scale-free) have been revealed in animals as diverse as microzooplankton, bumblebees, albatrosses, and spider monkeys, but these do not appear to be optimised with respect to turning angle, whereas Drosophila free-flight search does. Also, intermittent searching patterns, such as those reported here for Drosophila, have been observed in foragers such as planktivorous fish and ground foraging birds. Our results with freely flying Drosophila may constitute the first reported example of searching behaviour that is both scale-free and intermittent.	[Reynolds, Andy M.] Rothamsted Res, Harpenden, Herts, England; [Frye, Mark A.] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; University of California System; University of California Los Angeles	Reynolds, AM (corresponding author), Rothamsted Res, Harpenden, Herts, England.	andy.reynolds@bbsrc.ac.uk		Frye, Mark/0000-0003-3277-3094	Biotechnology and Biological Sciences Research Council [BB/D007453/1]; Sloan Research Fellowship; UCLA; BBSRC [BB/D007453/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Sloan Research Fellowship(Alfred P. Sloan Foundation); UCLA; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Biotechnology and Biological Sciences Research Council (Grant BB/D007453/1) (A. M. R.) and by a Sloan Research Fellowship and UCLA Faculty Career award (M. A. F.). Rothamsted Research receives grant aided assistance from the Biotechnological and Biological Sciences Research Council.	Atkinson RPD, 2002, OIKOS, V98, P134, DOI 10.1034/j.1600-0706.2002.980114.x; Bartumeus F, 2005, ECOLOGY, V86, P3078, DOI 10.1890/04-1806; Bartumeus F, 2003, P NATL ACAD SCI USA, V100, P12771, DOI 10.1073/pnas.2137243100; Brown CT, 2007, HUM ECOL, V35, P129, DOI 10.1007/s10745-006-9083-4; Chapman SC, 2005, NONLINEAR PROC GEOPH, V12, P767, DOI 10.5194/npg-12-767-2005; Chechkin AV, 2000, CHAOS SOLITON FRACT, V11, P2379, DOI 10.1016/S0960-0779(99)00168-X; COLE BJ, 1995, ANIM BEHAV, V50, P1317, DOI 10.1016/0003-3472(95)80047-6; DICKE M, 1988, PHYSIOL ENTOMOL, V13, P393, DOI 10.1111/j.1365-3032.1988.tb01122.x; FOURCASSIE V, 1992, NATURWISSENSCHAFTEN, V79, P87, DOI 10.1007/BF01131811; Fry SN, 2003, SCIENCE, V300, P495, DOI 10.1126/science.1081944; Frye MA, 2003, J EXP BIOL, V206, P843, DOI 10.1242/jeb.00175; HOFFMANN G, 1983, BEHAV ECOL SOCIOBIOL, V13, P81, DOI 10.1007/BF00293798; Kramer DL, 2001, AM ZOOL, V41, P137, DOI 10.1668/0003-1569(2001)041[0137:TBEOIL]2.0.CO;2; LAND MF, 1992, J INSECT PHYSIOL, V38, P939, DOI 10.1016/0022-1910(92)90002-U; Martin JR, 1999, J COMP PHYSIOL A, V184, P73, DOI 10.1007/s003590050307; Martin JR, 2004, BEHAV PROCESS, V67, P207, DOI 10.1016/j.beproc.2004.04.003; Martin JR, 2001, J NEUROGENET, V15, P205, DOI 10.3109/01677060109167377; Murdie G., 1973, MATH THEORY DYNAMICS, P87; Nakao H, 2000, PHYS LETT A, V266, P282, DOI 10.1016/S0375-9601(00)00059-1; OBRIEN WJ, 1990, AM SCI, V78, P152; Peng C-K., 1995, LEVY FLIGHTS RELATED, P313; Ramos-Fernandez G, 2004, BEHAV ECOL SOCIOBIOL, V55, P223, DOI 10.1007/s00265-003-0700-6; Reynolds AM, 2006, EUROPHYS LETT, V75, P517, DOI 10.1209/epl/i2006-10157-x; Segev R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.118102; SHIMADA I, 1993, BIOL CYBERN, V68, P477, DOI 10.1007/BF00200806; Shlesinger M. F., 1986, On Growth and Form - Fractal and Non-Fractal Patterns in Physics. Proceedings of the NATO Advanced Study Institute, P279; Tammero LF, 2002, J EXP BIOL, V205, P327; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0; Viswanathan GM, 1999, NATURE, V401, P911, DOI 10.1038/44831; WEHNER R, 1981, J COMP PHYSIOL, V142, P315, DOI 10.1007/BF00605445; WIENS JA, 1995, ECOLOGY, V76, P663, DOI 10.2307/1941226	31	275	284	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e354	10.1371/journal.pone.0000354	http://dx.doi.org/10.1371/journal.pone.0000354			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406678	Green Published, gold			2022-12-25	WOS:000207445300016
J	Lim, SK; Gopalan, G				Lim, S. K.; Gopalan, G.			Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A	ONCOGENE			English	Article						degradation; antizyme; Aurora-A; ubiquitin-independent	ORNITHINE-DECARBOXYLASE-ANTIZYME; CELL-GROWTH; PROTEASOME PATHWAY; PROTEIN-KINASE; PROLIFERATION; POLYAMINES; EXPRESSION; MECHANISM; CANCER; OVEREXPRESSION	Overexpression of Aurora- A oncogene has been shown to induce genomic instability and tumorigenesis. Cellular levels of Aurora- A are regulated by multiple mechanisms including the proteasome- dependent degradation of Aurora-A protein. Cell- cycle- dependent turnover of Aurora- A protein is mediated by cdh1 through ubiquitin ( Ub)- and proteasome- dependent pathway. However, Aurora- A kinase interacting protein 1 ( AURKAIP1), a negative regulator of Aurora- A, also promotes proteasome- dependent Aurora- A degradation through an Ub- independent mechanism. In an attempt to understand how AURKAIP1 promotes Aurora- A degradation through Ub- independent pathway, we demonstrate here that antizyme1 ( Az1), a well- studied mediator of Ub- independent protein degradation pathway, regulates Aurora- A protein stability. We show that ectopic or polyamine- induced expression of Az1 can lower the steady- state levels of Aurora- A. The effect of Az1 on Aurora- A turnover was shown to be proteasome-dependent, but Ub- independent. Az1 interacts with Aurora-A in vivo and the interaction between Aurora- A and Az1 is essential for the Az1- mediated Aurora- A degradation. Furthermore, we observed that AURKAIP1 could not promote degradation of Aurora- A mutant, which is defective in Az1 interaction. Coexpression of the Az inhibitor ( AzI), which downregulates Az1 functions, also abrogated AURKAIP1- mediated degradation of Aurora- A. We further demonstrated that AURKAIP1, Az1 and Aurora- A could exist as a ternary complex and AURKAIP1 enhances the interaction between Az1 and Aurora-A. We propose that AURKAIP1 might function upstream of the Az1 by enhancing the binding affinity of Az1 to Aurora- A to promote recognition, targeting to proteasome and subsequent degradation.	Natl Canc Ctr, Div Mol & Cellular Res, Gene Struct & Express Lab, Singapore, Singapore	National Cancer Centre Singapore (NCCS)	Gopalan, G (corresponding author), 03-03 Singhlth Res Facil,Block A 7 Hosp Dr, Singapore 169611, Singapore.	cmrgop@nccs.com.sg						Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247; Cheng N, 2002, MOL CANCER RES, V1, P2; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gardini G, 2003, J HEPATOL, V39, P793, DOI 10.1016/S0168-8278(03)00386-6; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hoffman DW, 2005, BIOCHEMISTRY-US, V44, P11777, DOI 10.1021/bi051081k; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Koike C, 1999, CANCER RES, V59, P6109; Li DH, 2003, CLIN CANCER RES, V9, P991; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mangold U, 2006, CELL MOL LIFE SCI, V63, P2095, DOI 10.1007/s00018-005-5583-4; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka T, 1999, CANCER RES, V59, P2041; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	43	60	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6593	6603		10.1038/sj.onc.1210482	http://dx.doi.org/10.1038/sj.onc.1210482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17452972				2022-12-25	WOS:000250081500002
J	Markey, MP; Bergseid, J; Bosco, EE; Stengel, K; Xu, H; Mayhew, C; Schwemberger, SJ; Braden, WA; Jiang, Y; Babcock, G; Jegga, AG; Aronow, BJ; Reed, MF; Wang, JYJ; Knudsen, ES				Markey, M. P.; Bergseid, J.; Bosco, E. E.; Stengel, K.; Xu, H.; Mayhew, Cn; Schwemberger, S. J.; Braden, W. A.; Jiang, Y.; Babcock, Gf; Jegga, A. G.; Aronow, B. J.; Reed, M. F.; Wang, J. Y. J.; Knudsen, E. S.			Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function	ONCOGENE			English	Article						RB; E2F; transcriptional repression; inflammation; cell cycle	ELEMENT CLUSTERS; GAMMA-INDUCTION; RB; PROTEIN; E2F; EXPRESSION; IDENTIFICATION; REPLICATION; ACTIVATION; TRANSITION	Functional inactivation of the retinoblastoma tumor suppressor gene product (RB) is a common event in human cancers. Classically, RB functions to constrain cellular proliferation, and loss of RB is proposed to facilitate the hyperplastic proliferation associated with tumorigenesis. To understand the repertoire of regulatory processes governed by RB, two models of RB loss were utilized to perform microarray analysis. In murine embryonic fibroblasts harboring germline loss of RB, there was a striking deregulation of gene expression, wherein distinct biological pathways were altered. Specifically, genes involved in cell cycle control and classically associated with E2F-dependent gene regulation were upregulated via RB loss. In contrast, a program of gene expression associated with immune function and response to pathogens was significantly downregulated with the loss of RB. To determine the specific influence of RB loss during a defined period and without the possibility of developmental compensation as occurs in embryonic fibroblasts, a second system was employed wherein Rb was acutely knocked out in adult fibroblasts. This model confirmed the distinct regulation of cell cycle and immune modulatory genes through RB loss. Analyses of cis-elements supported the hypothesis that the majority of those genes upregulated with RB loss are regulated via the E2F family of transcription factors. In contrast, those genes whose expression was reduced with the loss of RB harbored different promoter elements. Consistent with these analyses, we found that disruption of E2F-binding function of RB was associated with the upregulation of gene expression. In contrast, cells harboring an RB mutant protein ( RB-750F) that retains E2F-binding activity, but is specifically deficient in the association with LXCXE-containing proteins, failed to upregulate these same target genes. However, downregulation of genes involved in immune function was readily observed with disruption of the LXCXE-binding function of RB. Thus, these studies demonstrate that RB plays a significant role in both the positive and negative regulations of transcriptional programs and indicate that loss of RB has distinct biological effects related to both cell cycle control and immune function.	Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Jegga, Anil/H-6140-2011; Aronow, Bruce J/F-8438-2012; Mayhew, Christopher N/AGB-4929-2022	Jegga, Anil/0000-0002-4881-7752; Stengel, Kristy/0000-0002-8330-5744; Markey, Michael/0000-0002-8593-2290; Reed, Michael/0000-0001-8478-8605	NATIONAL CANCER INSTITUTE [T32CA117846, R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA117846, F32 CA174162, R01 CA058320] Funding Source: Medline; NIGMS NIH HHS [R35 GM147213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arany I, 1996, SEX TRANSM DIS, V23, P475, DOI 10.1097/00007435-199611000-00007; Batsche E, 2005, J BIOL CHEM, V280, P16088, DOI 10.1074/jbc.M413427200; Black EP, 2003, CANCER RES, V63, P3716; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Eason DD, 2001, CANCER LETT, V171, P209, DOI 10.1016/S0304-3835(01)00603-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jegga AG, 2005, NUCLEIC ACIDS RES, V33, pW408, DOI 10.1093/nar/gki486; Jegga AG, 2002, GENOME RES, V12, P1408, DOI 10.1101/gr.255002; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Le Buanec H, 1999, BIOMED PHARMACOTHER, V53, P424, DOI 10.1016/S0753-3322(99)80122-X; LU YM, 1994, ONCOGENE, V9, P1015; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Osborne AR, 2004, J BIOL CHEM, V279, P28911, DOI 10.1074/jbc.M403118200; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Xin H, 2003, ONCOGENE, V22, P4775, DOI 10.1038/sj.onc.1206780; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	40	59	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6307	6318		10.1038/sj.onc.1210450	http://dx.doi.org/10.1038/sj.onc.1210450			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452985				2022-12-25	WOS:000249583300007
J	Dai, B; Kang, SH; Gong, W; Liu, M; Aldape, KD; Sawaya, R; Huang, S				Dai, B.; Kang, S-H; Gong, W.; Liu, M.; Aldape, K. D.; Sawaya, R.; Huang, S.			Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells	ONCOGENE			English	Article						FoxM1B; MMP-2; glioma; invasion	GENE-EXPRESSION; IV COLLAGENASE; MALIGNANT GLIOMAS; GELATINASE-A; ACTIVATION; ANGIOPOIETIN-2; GROWTH; STAT3; TUMORIGENICITY; INVASIVENESS	We recently showed that FoxM1 is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly invasive glioblastoma multiforme (GBM) in nude mice. However, the molecular mechanisms by which FoxM1 enhances glioma invasion are unknown. In this study, we found that FoxM1 overexpression increased matrix metalloproteinase (MMP)-2 expression in glioma cells, whereas blockade of FoxM1 expression suppressed MMP-2 expression. Transfection of FoxM1 into glioma cells directly activated the MMP-2 promoter, whereas inhibition of FoxM1 expression by FoxM1-siRNA suppressed its activation. We identified a FoxM1-binding site in the MMP-2 promoter and demonstrated that FoxM1 protein bound directly to it. Mutation of this FoxM1-binding site significantly attenuated MMP-2 promoter activity. Furthermore, FoxM1 overexpression increased the invasiveness of glioma cells, whereas inhibition of FoxM1 expression suppressed the invasiveness of GBM cells. Inhibition of MMP-2 by a specific MMP-2 inhibitor reversed the invasive phenotype of glioma cells overexpressing FoxM1. Finally, immunohistochemical analysis of 45 human GBM specimens showed a significant correlation between FoxM1 overexpression and elevated MMP-2 expression. Collectively, these findings provide evidence that FoxM1 contributes to glioma progression by enhancing MMP-2 gene transcription and thus tumor-cell invasion.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Huang, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	suhuang@mdanderson.org	Dai, Bingbing/B-8417-2012	gang, sinhyeog/0000-0002-8912-7985	NCI NIH HHS [R01-CA116528, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116528, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Allred DC, 1998, MODERN PATHOL, V11, P155; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Emonard H, 1999, ANN NY ACAD SCI, V878, P647, DOI 10.1111/j.1749-6632.1999.tb07751.x; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002-9440(10)63905-3; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 2002, J NATL CANCER I, V94, P1134; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rickman DS, 2001, CANCER RES, V61, P6885; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Teh MT, 2002, CANCER RES, V62, P4773; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang H, 2003, CANCER RES, V63, P4315; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wild-Bode C, 2001, CANCER RES, V61, P2744; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	33	156	164	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6212	6219		10.1038/sj.onc.1210443	http://dx.doi.org/10.1038/sj.onc.1210443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404569				2022-12-25	WOS:000249401300012
J	Iwata, T; Mizusawa, N; Taketani, Y; Itakura, M; Yoshimoto, K				Iwata, T.; Mizusawa, N.; Taketani, Y.; Itakura, M.; Yoshimoto, K.			Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen	ONCOGENE			English	Article						HRPT2; parafibromin; SV40 large T antigen; tumorigenesis; tumor suppressor	FAMILIAL ISOLATED HYPERPARATHYROIDISM; RNA-POLYMERASE-II; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; GENE HRPT2; HUMAN PAF1; MUTATIONS; COMPLEX; TRANSFORMATION; TRANSCRIPTION	Parabromin (PF) is a 531-amino acid protein encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal-dominant hyperparathyroidism-jaw tumor familial cancer syndrome and sporadic parathyroid carcinoma. To investigate effects of PF's overexpression on cell proliferation, we performed assays in four different cell lines. The transient overexpression of PF inhibited cell growth in HEK293 and NIH3T3 cells, but enhanced cell growth in the SV40 large T antigen-expressing cell lines such as 293FT and COS7 cells. In 293FT cells, PF was found to interact with SV40 large T antigen and its overexpression promoted entry into the S phase, implying that the interaction enhanced progression through the cell cycle. The tumor suppressor protein PF acts as a positive regulator of cell growth similar to an oncoprotein in the presence of SV40 large T antigen.	Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Nutr, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Div Genet Informat, Tokushima, Japan	Tokushima University; Tokushima University; Tokushima University	Yoshimoto, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, 3-18-15 Kuramoto-cho, Tokushima, Japan.	yoshimot@dent.tokushima-u.ac.jp						Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arnold A, 2002, J BONE MINER RES, V17, pN30; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Grimelius L, 1997, SEMIN SURG ONCOL, V13, P142, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<142::AID-SSU10>3.0.CO;2-0; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; JACKSON CE, 1990, SURGERY, V108, P1006; KASSEM M, 1994, CLIN ENDOCRINOL, V41, P415, DOI 10.1111/j.1365-2265.1994.tb02570.x; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Mizusawa N, 2006, CLIN ENDOCRINOL, V65, P9, DOI 10.1111/j.1365-2265.2006.02534.x; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; ROWLAND BD, 2006, NAT REV CANCER, V6, P293; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Wassif WS, 1999, CLIN ENDOCRINOL, V50, P191, DOI 10.1046/j.1365-2265.1999.00633.x; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	29	26	28	4	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6176	6183		10.1038/sj.onc.1210445	http://dx.doi.org/10.1038/sj.onc.1210445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404568				2022-12-25	WOS:000249401300008
J	Merolla, F; Pentimalli, F; Pacelli, R; Vecchio, G; Fusco, A; Grieco, M; Celetti, A				Merolla, F.; Pentimalli, F.; Pacelli, R.; Vecchio, G.; Fusco, A.; Grieco, M.; Celetti, A.			Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; DNA damage; ATM; thyroid	THYROID PAPILLARY CARCINOMAS; FACTOR RECEPTOR-BETA; GENOMIC INSTABILITY; CHECKPOINT PATHWAY; IONIZING-RADIATION; CANCER; RET; REARRANGEMENTS; KINASE; CELLS	H4(D10S170) gene has been identified upon its frequent rearrangement with RET in papillary thyroid tumours (RET/PTC1). The kinase ataxia telangectasia mutated (ATM) phosphorylates a limited number of downstream protein targets in response to DNA damage. We investigated the potential role of H4( D10S170) in DNA damage signaling pathways. We found that in cells treated with etoposide or ionizing radiation (IR), H4( D10S170) underwent ATM-mediated phosphorylation at Thr 434, stabilizing nuclear H4. In ataxia telangectasia cells (A-T), endogenous H4( D10S170) was localized to cytoplasm and was excluded from the nucleus. Moreover, H4( D10S170) was not phosphorylated in ATM-deficient lymphoblasts after ionizing irradiation. Inhibition of ATM kinase interfered with H4( D10S170) apoptotic activity, and expression of H4 with threonine 434 mutated in Alanine, H4(T434A), protected the cells from genotoxic stress-induced apoptosis. Most importantly, after exposure to IR we found that silencing of H4( D10S170) in mammalian cells increased cell survival, as shown by clonogenic assay, allows for DNA synthesis as evaluated by bromodeoxyuridine incorporation and permits cells to progress into mitosis as demonstrated by phosphorylation on Histone H3. Our results suggest that H4( D10S170) is involved in cellular response to DNA damage ATM-mediated, and that the impairment of H4( D10S170) gene function might have a role in thyroid carcinogenesis.	Univ Naples Federico II, Dipartimento Biol Patol Cellulare Mol, Naples, Italy; CNR, Ist Biostrutt Bioimmagini, Naples, Italy; Magna Graecia Univ Catanzaro, Dipartimento Med Speriment Clin, Catanzaro, Italy; Ist Endocrinol Oncol Speriment, CNR, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Celetti, A (corresponding author), Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale, CNR, Dipartimento Biol Patol Cellulare Mol, Via S Parsini, Naples, Italy.	celetti@unina.it2	Pentimalli, Francesca/K-4936-2014; Celetti, Angela/AAY-7172-2020; Pacelli, Roberto/AFS-0333-2022	Pentimalli, Francesca/0000-0003-4740-6801; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Pacelli, Roberto/0000-0002-2048-7675				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P25331; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Penserga ETP, 2007, ONCOGENE, V26, P11, DOI 10.1038/sj.onc.1209756; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Puxeddu E, 2005, MUTAT RES-FUND MOL M, V570, P17, DOI 10.1016/j.mrfmmm.2004.09.010; Radivoyevitch T, 2001, RADIAT ENVIRON BIOPH, V40, P191, DOI 10.1007/s004110100108; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smith LE, 2003, HEALTH PHYS, V85, P23, DOI 10.1097/00004032-200307000-00006; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145	38	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6167	6175		10.1038/sj.onc.1210446	http://dx.doi.org/10.1038/sj.onc.1210446			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420723				2022-12-25	WOS:000249401300007
J	Chassot, AA; Turchi, L; Virolle, T; Fitsialos, G; Batoz, M; Deckert, M; Dulic, V; Meneguzzi, G; Busca, R; Ponzio, G				Chassot, A-A; Turchi, L.; Virolle, T.; Fitsialos, G.; Batoz, M.; Deckert, M.; Dulic, V.; Meneguzzi, G.; Busca, R.; Ponzio, G.			Id3 is a novel regulator of p27(kip1) mRNA in early G1 phase and is required for cell-cycle progression	ONCOGENE			English	Article						Ids; cell-cycle; p27mRNA; wound healing	LOOP-HELIX PROTEINS; CDK INHIBITOR P27; P16(INK4A) EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; PROLIFERATION; FIBROBLASTS; DEGRADATION; SENESCENCE; PATHWAYS	P27kip is a key inhibitory protein of the cell-cycle progression, which is rapidly downregulated in early G1 phase by a post-translational mechanism involving the proteosomal degradation. In this study, using a wounding model that induces cell-cycle entry of human dermal fibroblasts, we demonstrate that p27mRNA is downregulated when cells progress into the G1 phase, and then it returns to its basal level when cells approach the S phase. By using a quantitative polymerase chain reaction screening we identified inhibitors of differentiation (10), a bHLH transcriptional repressor, as a candidate mediator accounting for p27 mRNA decrease. Id3 silencing, using an small interfering RNA approach, reversed the injury mediated p27 downregulation demonstrating that 143 is involved in the transcriptional repression of p27. Reporter gene experiments and a chromatin immunoprecipitation assay showed that Id3 likely exerts its repressive action through ELK1 inhibition. By inhibiting early p27 downregulation, Id3 depletion blocked (i) the G1-phase progression as assessed by the inhibition of pRb phosphorylation and p130 degradation and (ii) the G1/S transition as observed by the inhibition of cyclin A induction, demonstrating that p27 mRNA decrease is required for cell proliferation. Apart from its effect on the early p27 diminution, 143 appears also involved in the control of the steady-state level of p27 at the G1/S boundary. In conclusion, this study identifies a novel mechanism of p27 regulation which besides p27 protein degradation also implicates a transcriptional mechanism mediated by 10.	Univ Nice, Fac Med, INSERM, U634, F-06107 Nice 02, France; Univ Nice, Hop Larchet, INSERM, U576, Nice, France; CNRS, CRBM, FRE 2593, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Univ Nice, Fac Med, INSERM, U634, 28 Ave Valombrose, F-06107 Nice 02, France.	ponzio@unice.fr	Chassot, Anne-Amandine/O-2102-2016; Virolle, Thierry/E-5838-2016; Ponzio, Gilles/Q-1256-2016; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	Chassot, Anne-Amandine/0000-0003-1242-9456; Ponzio, Gilles/0000-0003-2741-0248; Deckert, Marcel/0000-0003-2094-559X; Dulic, Vjekoslav/0000-0003-1201-3901; Turchi, Laurent/0000-0003-2020-5831; Meneguzzi, Guerrino/0000-0002-1609-6540				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Benezra R, 2001, ONCOGENE, V20, P8288, DOI 10.1038/sj.onc.1205161; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chraibi H, 2004, J Wound Care, V13, P447; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kee Y, 2005, GENE DEV, V19, P744, DOI 10.1101/gad.1257405; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kudo Y, 2005, ORAL ONCOL, V41, P105, DOI 10.1016/j.oraloncology.2004.05.003; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Loots MAM, 1999, ARCH DERMATOL RES, V291, P93, DOI 10.1007/s004030050389; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Okabe M, 2001, MODERN PATHOL, V14, P1008, DOI 10.1038/modpathol.3880426; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sharma A, 1997, MOL ENDOCRINOL, V11, P1608, DOI 10.1210/me.11.11.1608; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Takahashi E, 2004, BIOCHEM BIOPH RES CO, V325, P1136, DOI 10.1016/j.bbrc.2004.10.148; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	48	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5772	5783		10.1038/sj.onc.1210386	http://dx.doi.org/10.1038/sj.onc.1210386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17404577				2022-12-25	WOS:000248885100009
J	Resseguie, M; Song, JN; Niculescu, MD; da Costa, KA; Randall, TA; Zeisel, SH				Resseguie, Mary; Song, Jiannan; Niculescu, Mihai D.; da Costa, Kerry-Ann; Randall, Thomas A.; Zeisel, Steven H.			Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes	FASEB JOURNAL			English	Article						choline; 17-beta-estradiol; bioinformatics; ERE; evolutionarily conserved gene motifs	CHOLINE AVAILABILITY ALTERS; RESPONSE ELEMENTS; RECEPTOR BINDING; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; VERTEBRATE GENOMES; SPATIAL MEMORY; RAT PITUITARY; HIGH-DENSITY; LIVER; HIPPOCAMPUS	Choline is an essential nutrient for humans, though some of the requirement can be met by endogenous synthesis catalyzed by phosphatidylethanolamine N-methyltransferase ( PEMT). Premenopausal women are relatively resistant to choline deficiency compared with postmenopausal women and men. Studies in animals suggest that estrogen treatment can increase PEMT activity. In this study we investigated whether the PEMT gene is regulated by estrogen. PEMT transcription was increased in a dose-dependent manner when primary mouse and human hepatocytes were treated with 17-beta-estradiol for 24 h. This increased message was associated with an increase in protein expression and enzyme activity. In addition, we report a region that contains a perfect estrogen response element (ERE) similar to 7.5 kb from the transcription start site corresponding to transcript variants NM_007169 and NM-008819 of the human and murine PEMT genes, respectively, three imperfect EREs in evolutionarily conserved regions and multiple imperfect EREs in nonconserved regions in the putative promoter regions. We predict that both the mouse and human PEMT genes have three unique transcription start sites, which are indicative of either multiple promoters and/or alternative splicing. This study is the first to explore the underlying mechanism of why dietary requirements for choline vary with estrogen status in humans.	Univ N Carolina, Sch Publ Hlth, Inst Nutr Res, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Ctr Bioinformat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Inst Nutr Res, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu		Randall, Thomas/0000-0002-4605-7606	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350, R01DK055865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG009525, P01 AG009525-160005, AG09525] Funding Source: Medline; NIDDK NIH HHS [R01 DK055865-07, DK55865, DK56350, P30 DK056350, R01 DK055865, P30 DK056350-08] Funding Source: Medline; NIEHS NIH HHS [ES10126, P30 ES010126-089008, P30 ES010126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal A, 2002, MOL HUM REPROD, V8, P167, DOI 10.1093/molehr/8.2.167; Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1998, NEUROCHEM RES, V23, P751, DOI 10.1023/A:1022411510636; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; AUDUBERT F, 1983, J BIOL CHEM, V258, P695; Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; da Costa KA, 2005, AM J CLIN NUTR, V81, P440; da Costa KA, 2004, AM J CLIN NUTR, V80, P163; da Costa KA, 2006, FASEB J, V20, P1336, DOI 10.1096/fj.06-5734com; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; DROUVA SV, 1987, ENDOCRINOLOGY, V121, P569, DOI 10.1210/endo-121-2-569; Elnitski L, 2003, GENOME RES, V13, P64, DOI 10.1101/gr.817703; FISCHER L, 2007, IN PRESS AM J CLIN N; Fischer LM, 2005, J NUTR, V135, P826, DOI 10.1093/jn/135.4.826; Fisher MC, 2001, TERATOLOGY, V64, P114, DOI 10.1002/tera.1053; Guba SC, 1996, AM J CLIN PATHOL, V106, P709; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572, DOI 10.1093/ajcn/64.4.572; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; LeCluyse Edward L, 2005, Methods Mol Biol, V290, P207; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez D, 2002, ENDOCRINOLOGY, V143, P2155, DOI 10.1210/en.143.6.2155; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MCMAHON KE, 1985, CLIN CHIM ACTA, V149, P1, DOI 10.1016/0009-8981(85)90267-0; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Mellott TJ, 2004, FASEB J, V18, P545, DOI 10.1096/fj.03-0877fje; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Peck JD, 2002, CANCER EPIDEM BIOMAR, V11, P361; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Shields DJ, 2001, BBA-MOL CELL BIOL L, V1532, P105, DOI 10.1016/S1388-1981(01)00122-6; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; SWEIRY JH, 1986, J DEV PHYSIOL, V8, P435; SWEIRY JH, 1985, J PHYSIOL-LONDON, V366, P251, DOI 10.1113/jphysiol.1985.sp015795; Tang SS, 2004, NUCLEIC ACIDS RES, V32, P6212, DOI 10.1093/nar/gkh943; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Vance DE, 1998, BIOCHEM SOC T, V26, P337, DOI 10.1042/bst0260337; Vigo C, 1981, Biochem Soc Trans, V9, P98; VIGO C, 1981, BIOCHIM BIOPHYS ACTA, V665, P546, DOI 10.1016/0005-2760(81)90269-1; VIGO C, 1981, BIOCHEM J, V200, P321, DOI 10.1042/bj2000321; Walkey CJ, 1996, J LIPID RES, V37, P2341; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Xie T, 1999, MOL PHARMACOL, V56, P31, DOI 10.1124/mol.56.1.31; YOUNG DL, 1971, J LIPID RES, V12, P590; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	69	152	155	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2622	2632		10.1096/fj.07-8227com	http://dx.doi.org/10.1096/fj.07-8227com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17456783	Green Accepted, Green Submitted			2022-12-25	WOS:000248454400035
J	Horsman, GP; Bhowmik, S; Seah, SYK; Kumar, P; Bolin, JT; Eltis, LD				Horsman, Geoff P.; Bhowmik, Shiva; Seah, Stephen Y. K.; Kumar, Pravindra; Bolin, Jeffrey T.; Eltis, Lindsay D.			The tautomeric half-reaction of BphD, a C-C bond hydrolase - Kinetic and structural evidence supporting a key role for histidine 265 of the catalytic triad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYDROXY-6-KETO-NONA-2,4-DIENE-1,9-DIOIC ACID 5,6-HYDROLASE; MICROBIAL-DEGRADATION; POLYCHLORINATED-BIPHENYLS; SERINE HYDROLASE; MECHANISM; ENZYMES; MHPC; CRYSTALLOGRAPHY; IDENTIFICATION; INTERMEDIATE	BphD of Burkholderia xenovorans LB400 catalyzes an unusual C-C bond hydrolysis of 2-hydroxy-6-oxo-6-phenyl-hexa-2,4-dienoic acid ( HOPDA) to afford benzoic acid and 2-hydroxy-2,4-pentadienoic acid (HPD). An enol-keto tautomerization has been proposed to precede hydrolysis via a gemdiol intermediate. The role of the canonical catalytic triad (Ser-112, His-265, Asp-237) in mediating these two half-reactions remains unclear. We previously reported that the BphD-catalyzed hydrolysis of HOPDA (lambda(max) is 434 nm for the free enolate) proceeds via an unidentified intermediate with a red-shifted absorption spectrum (lambda(max) is 492 nm) (Horsman, G. P., Ke, J., Dai, S., Seah, S. Y. K., Bolin, J. T., and Eltis, L. D. ( 2006) Biochemistry 45, 11071-11086). Here we demonstrate that the S112A variant generates and traps a similar intermediate (lambda(max) is 506 nm) with a similar rate, 1/tau similar to 500 s(-1). The crystal structure of the S112A: HOPDA complex at 1.8-angstrom resolution identified this intermediate as the keto tautomer, (E)-2,6-dioxo-6-phenyl-hex-3- enoate. This keto tautomer did not accumulate in either the H265A or the S112A/H265A double variants, indicating that His-265 catalyzes tautomerization. Consistent with this role, the wild type and S112A enzymes catalyzed tautomerization of the product HPD, whereas H265A variants did not. This study thus identifies a keto intermediate, and demonstrates that the catalytic triad histidine catalyzes the tautomerization half-reaction, expanding the role of this residue from its purely hydrolytic function in other serine hydrolases. Finally, the S112A: HOPDA crystal structure is more consistent with hydrolysis occurring via an acyl-enzyme intermediate than a gem- diol intermediate as solvent molecules have poor access to C6, and the closest ordered water is 7 angstrom away.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Life Sci Inst, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Life Sci Inst, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Purdue Univ, Ctr Canc, Markey Ctr Struct Biol, Dept Biol Sci, W Lafayette, IN 47907 USA	University of British Columbia; University of British Columbia; University of British Columbia; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Eltis, LD (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 1365-2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	leltis@interchange.ubc.ca	Horsman, Geoff/AAQ-2349-2020; KUMAR, PRAVINDRA/AAF-2859-2020; Eltis, Lindsay D/J-8272-2015	Horsman, Geoff/0000-0002-2023-2349; KUMAR, PRAVINDRA/0000-0003-2128-7736; Eltis, Lindsay D/0000-0002-6774-8158				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bugg TDH, 2004, BIOORG CHEM, V32, P367, DOI 10.1016/j.bioorg.2004.05.005; DIAZ E, 1995, J BIOL CHEM, V270, P6403, DOI 10.1074/jbc.270.11.6403; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P12635, DOI 10.1021/bi00208a014; Dunn G, 2005, J MOL BIOL, V346, P253, DOI 10.1016/j.jmb.2004.11.033; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; FOX MA, 1994, ORGANIC CHEM, P204; Furukawa K, 2003, TRENDS BIOTECHNOL, V21, P187, DOI 10.1016/S0167-7799(03)00054-4; Fushinobu S, 2002, PROTEIN SCI, V11, P2184, DOI 10.1110/ps.0209602; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Henderson IMJ, 1997, BIOCHEMISTRY-US, V36, P12252, DOI 10.1021/bi971116j; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Horsman GP, 2006, BIOCHEMISTRY-US, V45, P11071, DOI 10.1021/bi0611098; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lam WWY, 1997, BIOCHEMISTRY-US, V36, P12242, DOI 10.1021/bi971115r; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li C, 2005, J MOL BIOL, V346, P241, DOI 10.1016/j.jmb.2004.11.032; Li JJ, 2007, ORG BIOMOL CHEM, V5, P507, DOI 10.1039/b615605c; Li JJ, 2006, BIOCHEMISTRY-US, V45, P12461, DOI 10.1021/bi0612519; Li JJ, 2005, CHEM COMMUN, P130, DOI 10.1039/b415491f; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nandhagopal N, 2001, J MOL BIOL, V309, P1139, DOI 10.1006/jmbi.2001.4737; Nerdinger S, 1999, CHEM COMMUN, P2259, DOI 10.1039/a907279i; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Seah SYK, 1998, J BIOL CHEM, V273, P22943, DOI 10.1074/jbc.273.36.22943; Seah SYK, 2000, J BIOL CHEM, V275, P15701, DOI 10.1074/jbc.275.21.15701; Sekharan S, 2007, ANGEW CHEM INT EDIT, V46, P269, DOI 10.1002/anie.200603306; Speare DM, 2004, ORG BIOMOL CHEM, V2, P2942, DOI 10.1039/b410322j; Speare DM, 2002, CHEM COMMUN, P2304, DOI 10.1039/b208168g; Takahashi Y, 2003, BIOCHEMISTRY-US, V42, P6025, DOI 10.1021/bi020629+; Tian T, 2006, ANGEW CHEM INT EDIT, V45, P7763, DOI 10.1002/anie.200602720; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaillancourt FH, 2006, CRIT REV BIOCHEM MOL, V41, P241, DOI 10.1080/10409230600817422; Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104; Williams DH., 1995, SPECTROSCOPIC METHOD, P14; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401	39	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19894	19904		10.1074/jbc.M702237200	http://dx.doi.org/10.1074/jbc.M702237200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17442675	hybrid			2022-12-25	WOS:000247650600064
J	Furland, NE; Zanetti, SR; Oresti, GM; Maldonado, EN; Aveldano, MI				Furland, Natalia E.; Zanetti, Samanta R.; Oresti, Gerardo M.; Maldonado, Eduardo N.; Aveldano, Marta I.			Ceramides and sphingomyelins with high proportions of very long-chain polyunsaturated fatty acids in mammalian germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGEVITY ASSURANCE GENES; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; APOPTOSIS; RAT; TESTIS; SPERMATOGENESIS; CRYPTORCHIDISM; RETINA; IDENTIFICATION; SPERMATOGONIA	Very long-chain polyunsaturated fatty acids (VLCPUFA) have previously been shown to be components of sphingomyelin (SM) of mammalian testis and spermatozoa. Here we examined the fatty acids of testicular ceramide (Cer) in comparison with those of SM in some mammals with a special focus on the rat testis. In bull, cat, dog, rabbit, mouse, and rat, VLCPUFA were found in both testicular lipids, Cer having a higher percentage of VLCPUFA than SM. Rat testis had the highest percentage of VLCPUFA in both lipids, the major ones being 28:4n-6 and 30:5n-6. VLCPUFA-containing SM and Cer occurred in cells located in the seminiferous tubules, where germ cells had a higher percentage of these species than Sertoli cells. Seminiferous tubule fractionation showed that SM and Cer of mitochondria and lysosomes had mostly saturates and negligible VLCPUFA, the latter being important in the SM and Cer of microsomes and other membrane fractions. VLCPUFA were absent from the SM and Cer of rat prepuberal testis, increased with the onset of spermatogenesis to account for nearly 15 and 40% of the total fatty acids of testicular SM and Cer, respectively, remained at those levels throughout the adult life of fertile rats and tended to decrease at advanced ages. Four conditions that lead to selective death of germ cells in vivo, namely experimental cryptorchidism, post-ischemic reperfusion, focalized x-ray irradiation and treatments with the antineoplasic drug doxorubicin, caused the VLCPUFA to disappear from the testicular SM and Cer of adult fertile rats, showing that these lipids are specific traits of spermatogenic cells.	Univ Nacl Sur, Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, RA-8000 Bahia Blanca, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South	Aveldano, MI (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Reg Invest Basicas & Aplicadas Bahia Blanca, INIBIBB, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	avelda@criba.edu.ar	Maldonado, Eduardo/AAN-3907-2020	Maldonado, Eduardo/0000-0002-5285-3027				Antollini SS, 2002, J LIPID RES, V43, P1440, DOI 10.1194/jlr.M200057-JLR200; Anway MD, 2003, BIOL REPROD, V68, P996, DOI 10.1095/biolreprod.102.008045; AVELDANO MI, 1993, J BIOL CHEM, V268, P11663; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; Barqawi A, 2004, ASIAN J ANDROL, V6, P47; BECKMAN JK, 1979, LIPIDS, V14, P262, DOI 10.1007/BF02533912; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Blauer M, 1999, BIOL REPROD, V60, P588, DOI 10.1095/biolreprod60.3.588; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN ER, 1994, LIPIDS, V29, P825, DOI 10.1007/BF02536249; Christie W.W., 2003, LIPID ANAL; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Dufau M L, 1975, Methods Enzymol, V39, P252; Farooqui SM, 1997, BIOCHEM BIOPH RES CO, V236, P407, DOI 10.1006/bbrc.1997.6954; Furland NE, 2007, J BIOL CHEM, V282, P18151, DOI 10.1074/jbc.M700709200; Furland NE, 2003, LIPIDS, V38, P73, DOI 10.1007/s11745-003-1033-9; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Henriksen K, 1996, J ANDROL, V17, P394; Hikim APS, 1999, REV REPROD, V4, P38; Ito K, 1997, J VET MED SCI, V59, P353, DOI 10.1292/jvms.59.353; Kangasniemi M, 1996, BIOL REPROD, V54, P1200, DOI 10.1095/biolreprod54.6.1200; Kato Masashi, 2001, Journal of Toxicological Sciences, V26, P51, DOI 10.2131/jts.26.51; Kocak I, 2002, ASIAN J ANDROL, V4, P183; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; Mizutani Y, 2006, BIOCHEM J, V398, P531, DOI 10.1042/BJ20060379; Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; Ramstedt B, 1999, EUR J BIOCHEM, V266, P997, DOI 10.1046/j.1432-1327.1999.00938.x; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROTSTEIN NP, 1987, LIPIDS, V22, P253, DOI 10.1007/BF02533988; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saether T, 2003, BIOL REPROD, V69, P117, DOI 10.1095/biolreprod.102.014035; Shetty G, 2004, ENDOCRINOLOGY, V145, P4461, DOI 10.1210/en.2004-0440; Shinoda K, 1999, ARCH TOXICOL, V73, P274, DOI 10.1007/s002040050617; SINGH H, 1994, J BIOL CHEM, V269, P21388; Suomalainen L, 2003, J CLIN ENDOCR METAB, V88, P5572, DOI 10.1210/jc.2003-030776; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Tilly JL, 1999, CHEM PHYS LIPIDS, V102, P149, DOI 10.1016/S0009-3084(99)00083-3; TURNER TT, 1993, BIOL REPROD, V49, P401, DOI 10.1095/biolreprod49.2.401; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Vietzke JP, 2001, LIPIDS, V36, P299, DOI 10.1007/s11745-001-0721-9; ZANATO VF, 1994, BRAZ J MED BIOL RES, V27, P1273; Ziulkoski AL, 2001, BIOCHEM BIOPH RES CO, V281, P971, DOI 10.1006/bbrc.2001.4440	52	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18141	18150		10.1074/jbc.M700708200	http://dx.doi.org/10.1074/jbc.M700708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392276	hybrid			2022-12-25	WOS:000247302000020
J	Mokranjac, D; Berg, A; Adam, A; Neupert, W; Hell, K				Mokranjac, Dejana; Berg, Annette; Adam, Alexander; Neupert, Walter; Hell, Kai			Association of the Tim14 center dot Tim16 subcomplex with the TIM23 translocase is crucial for function of the mitochondrial protein import motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE; PREPROTEIN TRANSLOCASE; PRESEQUENCE TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; DYNAMIC INTERACTION; YEAST MITOCHONDRIA; J-DOMAIN; HSP70; COMPLEX; MATRIX	Tim14 and Tim16 are essential components of the import motor of the mitochondrial TIM23 preprotein translocase. Tim14 contains a J domain in the matrix space that is anchored in the inner membrane by a transmembrane segment. Tim16 is a J-related protein with a moderately hydrophobic segment at its N terminus. The J and J-like domains function in the regulation of the ATPase activity of the Hsp70 chaperone of the import motor. We report here on the role of the hydrophobic segments of Tim16 and Tim14 in the TIM23 translocase. Yeast cells lacking the hydrophobic N-terminal segment in either Tim16 or Tim14 are viable but show growth defects and decreased import rates of matrix-targeted preproteins into mitochondria. The interaction of the Tim14 center dot Tim16 complex with the core complex of the TIM23 translocase is destabilized in these cells. In particular, the N-terminal domain of Tim16 is crucial for the interaction of the Tim14 center dot Tim16 complex with the TIM23 preprotein translocase. Deletion of hydrophobic segments in both, Tim16 and Tim14, is lethal. We conclude that import into the matrix space of mitochondria requires association of the co-chaperones Tim16 and Tim14 with the TIM23 preprotein translocase.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Hell, K (corresponding author), Univ Munich, Inst Physiol Chem, Butenantstr 5, D-81377 Munich, Germany.	hell@med.uni-muenchen.de		Mokranjac, Dejana/0000-0002-4005-6979				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; D'Silva PR, 2005, P NATL ACAD SCI USA, V102, P12419, DOI 10.1073/pnas.0505969102; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; FOELSCH H, 1996, EMBO J, V15, P479; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; Martinez-Caballero S, 2007, J BIOL CHEM, V282, P3584, DOI 10.1074/jbc.M607551200; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Milisav I, 2001, J BIOL CHEM, V276, P25856, DOI 10.1074/jbc.M102132200; Mokranjac D, 2005, J BIOL CHEM, V280, P31608, DOI 10.1074/jbc.M502397200; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Mokranjac D, 2006, EMBO J, V25, P4675, DOI 10.1038/sj.emboj.7601334; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; NEUPERT W, 2007, ANNU REV BIOCHEM, V76, P609; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; van der Laan M, 2005, MOL CELL BIOL, V25, P7449, DOI 10.1128/MCB.25.17.7449-7458.2005; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	44	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18037	18045		10.1074/jbc.M701895200	http://dx.doi.org/10.1074/jbc.M701895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452317	hybrid			2022-12-25	WOS:000247302000010
J	Richman, JG; Kanemitsu-Parks, M; Gaidarov, I; Cameron, JS; Griffin, P; Zheng, H; Guerra, NC; Cham, L; Maciejewski-Lenoir, D; Behan, DP; Boatman, D; Chen, RP; Skinner, P; Ornelas, P; Waters, MG; Wright, SD; Semple, G; Connolly, DT				Richman, Jeremy G.; Kanemitsu-Parks, Martha; Gaidarov, Ibragim; Cameron, Jill S.; Griffin, Peter; Zheng, Hong; Guerra, Nuvia C.; Cham, Linda; Maciejewski-Lenoir, Dominique; Behan, Dominic P.; Boatman, Doug; Chen, Ruoping; Skinner, Philip; Ornelas, Pricilla; Waters, M. Gerard; Wright, Samuel D.; Semple, Graeme; Connolly, Daniel T.			Nicotinic acid receptor agonists differentially activate downstream effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FREE FATTY ACIDS; PUMA-G; MOLECULAR-IDENTIFICATION; PROSTAGLANDIN D-2; LANGERHANS CELLS; ADIPOSE TISSUE; CHOLESTEROL; EFFICACY; NIACIN	Nicotinic acid remains the most effective therapeutic agent for the treatment and prevention of atherosclerosis resulting from low high density lipoprotein cholesterol. The therapeutic actions of nicotinic acid are mediated by GPR109A, a G(i) protein-coupled receptor, expressed primarily on adipocytes, Langerhans cells, and macrophage. Unfortunately, a severe, cutaneous flushing side effect limits its use and patient compliance. The mechanism of high density lipoprotein elevation is not clearly established but assumed to be influenced by an inhibition of lipolysis in the adipose. The flushing side effect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin. We hypothesized that the signal transduction pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that agonists may be identified that are capable of selectively eliciting the therapeutic, anti-lipolytic pathway while avoiding the activation of the parallel flush-inducing pathway. We have identified a number of GPR109A pyrazole agonists that are capable of fully inhibiting lipolysis in vitro and in vivo and not only fail to elicit a flushing response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo. In contrast to flushing agonists, exposure of cells expressing GPR109A to the non-flushing agonists fails to induce internalization of the receptor or to activate ERK 1/2 mitogen- activated protein kinase phosphorylation.	Arena Pharmaceut Inc, San Diego, CA 92121 USA; Merck Res Labs, Div Cardiovasc Dis, Rahway, NJ 07065 USA	Merck & Company	Richman, JG (corresponding author), Arena Pharmaceut Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121 USA.	jrichman@arenapharm.com						[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; Backstrom JR, 1999, NEUROPSYCHOPHARMACOL, V21, pS77, DOI 10.1038/sj.npp.1395329; Benyo Z, 2005, J CLIN INVEST, V115, P3634, DOI 10.1172/JCI23626; Benyo Z, 2006, MOL PHARMACOL, V70, P1844, DOI 10.1124/mol.106.030833; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; CARLSON LA, 1965, ANN NY ACAD SCI, V131, P119, DOI 10.1111/j.1749-6632.1965.tb34784.x; CARLSON LA, 1962, ACTA MED SCAND, V172, P641; Carlson LA, 2005, J INTERN MED, V258, P94, DOI 10.1111/j.1365-2796.2005.01528.x; CARLSON LA, 1963, ACTA MED SCAND, V173, P719; CARLSON LA, 1965, J ATHEROSCLER RES, V20, P436; Cheng K, 2006, P NATL ACAD SCI USA, V103, P6682, DOI 10.1073/pnas.0601574103; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Hiatt JG, 1999, AM J MANAG CARE, V5, P437; Jin FY, 1997, ARTERIOSCL THROM VAS, V17, P2020, DOI 10.1161/01.ATV.17.10.2020; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; Maciejewski-Lenoir D, 2006, J INVEST DERMATOL, V126, P2637, DOI 10.1038/sj.jid.5700586; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; Offermanns S, 2006, TRENDS PHARMACOL SCI, V27, P384, DOI 10.1016/j.tips.2006.05.008; Roelen H, 1996, J MED CHEM, V39, P1463, DOI 10.1021/jm950267m; Sakai T, 2001, ARTERIOSCL THROM VAS, V21, P1783, DOI 10.1161/hq1001.096624; Soga T, 2003, BIOCHEM BIOPH RES CO, V303, P364, DOI 10.1016/S0006-291X(03)00342-5; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Tan CM, 2002, P NATL ACAD SCI USA, V99, P12471, DOI 10.1073/pnas.122368499; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; van Herk T, 2003, J MED CHEM, V46, P3945, DOI 10.1021/jm030888c; van Schaick EA, 1998, BRIT J PHARMACOL, V124, P607, DOI 10.1038/sj.bjp.0701868; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200	28	82	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18028	18036		10.1074/jbc.M701866200	http://dx.doi.org/10.1074/jbc.M701866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452318	hybrid			2022-12-25	WOS:000247302000009
J	Conner, M; Hawtin, SR; Simms, J; Wootten, D; Lawson, Z; Conner, AC; Parslow, RA; Wheatley, M				Conner, Matthew; Hawtin, Stuart R.; Simms, John; Wootten, Denise; Lawson, Zoe; Conner, Alex C.; Parslow, Rosemary A.; Wheatley, Mark			Systematic analysis of the entire second extracellular loop of the V-1a vasopressin receptor - Key residues, conserved throughout a G-protein-coupled receptor family, identified	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; HIGH-AFFINITY BINDING; OXYTOCIN RECEPTOR; AGONIST BINDING; N-TERMINUS; MOLECULAR CHARACTERIZATION; CHEMOKINE RECEPTOR; HORMONE-RECEPTOR; DISULFIDE BOND; V1A RECEPTORS	The roles of extracellular residues of G-protein-coupled receptors (GPCRs) are not well defined compared with residues in transmembrane helices. Nevertheless, it has been established that extracellular domains of both peptide-GPCRs and amine-GPCRs incorporate functionally important residues. Extracellular loop 2 (ECL2) has attracted particular interest, because the x-ray structure of bovine rhodopsin revealed that ECL2 projects into the binding crevice within the transmembrane bundle. Our study provides the first comprehensive investigation into the role of the individual residues comprising the entire ECL2 domain of a small peptide-GPCR. Using the V-1a vasopressin receptor, systematic substitution of all of the ECL2 residues by Ala generated 30 mutant receptors that were characterized pharmacologically. The majority of these mutant receptor constructs (24 in total) had essentially wild-type ligand binding and intracellular signaling characteristics, indicating that these residues are not critical for normal receptor function. However, four aromatic residues Phe(189), Trp(206), Phe(209), and Tyr(218) are important for agonist binding and receptor activation and are highly conserved throughout the neurohypophysial hormone subfamily of peptide-GPCRs. Located in the middle of ECL2, juxtaposed to the highly conserved disulfide bond, Trp(206) and Phe(209) project into the binding crevice. Indeed, Phe(209) is part of the Cys-X-X-X-Ar (where Ar is an aromatic residue) motif, which is well conserved in both peptide-GPCRs and amine-GPCRs. In contrast, Phe(189) and Tyr(218), located at the extreme ends of ECL2, may be important for determining the position of the ECL2 cap over the binding crevice. This study provides mechanistic insight into the roles of highly conserved ECL2 residues.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Wheatley, M (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	m.wheatley@bham.ac.uk	Wootten, Denise/ABD-5703-2021	Wootten, Denise/0000-0003-4563-1642; Simms, John/0000-0002-4675-0902; Wheatley, Mark/0000-0001-6261-5682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Birnbaumer R, 1999, ARCH MED RES, V30, P465, DOI 10.1016/S0188-4409(99)00063-6; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Cavalli A, 1996, FEBS LETT, V399, P9, DOI 10.1016/S0014-5793(96)01286-0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; Fourmy D, 2002, PHARMACOL TOXICOL, V91, P313, DOI 10.1034/j.1600-0773.2002.910608.x; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gnagey AL, 1999, MOL PHARMACOL, V56, P1245, DOI 10.1124/mol.56.6.1245; Hawtin SR, 2005, FEBS LETT, V579, P349, DOI 10.1016/j.febslet.2004.10.108; Hawtin SR, 2005, MOL ENDOCRINOL, V19, P2871, DOI 10.1210/me.2005-0148; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hawtin SR, 2001, BIOCHEM J, V357, P73, DOI 10.1042/0264-6021:3570073; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; Hawtin SR, 2006, J BIOL CHEM, V281, P38478, DOI 10.1074/jbc.M607639200; Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; Howl J, 1997, FASEB J, V11, P582, DOI 10.1096/fasebj.11.7.9212082; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; Lequin O, 2002, J BIOL CHEM, V277, P22386, DOI 10.1074/jbc.M110614200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Li SH, 2001, J BIOL CHEM, V276, P7968, DOI 10.1074/jbc.M010482200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; NODA K, 1994, J BIOL CHEM, V269, P6743; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Patel AB, 2005, J MOL BIOL, V347, P803, DOI 10.1016/j.jmb.2005.01.069; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; Scarselli M, 2007, J BIOL CHEM, V282, P7385, DOI 10.1074/jbc.M610394200; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHARIF M, 1992, NATURE, V357, P279, DOI 10.1038/357279a0; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; Wesley VJ, 2002, BIOCHEMISTRY-US, V41, P5086, DOI 10.1021/bi015990v; Wurch T, 2000, J NEUROCHEM, V75, P1180, DOI 10.1046/j.1471-4159.2000.0751180.x; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zhang L, 2002, BIOCHEMISTRY-US, V41, P61, DOI 10.1021/bi0117955; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200	56	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17405	17412		10.1074/jbc.M702151200	http://dx.doi.org/10.1074/jbc.M702151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403667	Green Accepted, hybrid			2022-12-25	WOS:000247084500010
J	Kim, HT; Kim, KP; Lledias, F; Kisselev, AF; Scaglione, KM; Skowyra, D; Gygi, SP; Goldberg, AL				Kim, Hyoung Tae; Kim, Kwang Pyo; Lledias, Fernando; Kisselev, Alexei F.; Scaglione, K. Matthew; Skowyra, Dorota; Gygi, Steven P.; Goldberg, Alfred L.			Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; RING FINGER; DNA-REPAIR; 26S PROTEASOME; DEGRADATION; COMPLEX; SUBSTRATE; DOMAIN; LYSINE	It is generally assumed that a specific ubiquitin ligase (E3) links protein substrates to polyubiquitin chains containing a single type of isopeptide linkage, and that chains composed of linkages through Lys(48), but not through Lys(63), target proteins for proteasomal degradation. However, when we carried out a systematic analysis of the types of ubiquitin (Ub) chains formed by different purified E3s and Ub-conjugating enzymes (E2s), we found, using Ub mutants and mass spectrometry, that the U-box E3, CHIP, and Ring finger E3s, MuRF1 and Mdm2, with the E2, UbcH5, form a novel type of Ub chain that contains all seven possible linkages, but predominantly Lys(48), Lys(63), and Lys(11) linkages. Also, these heterogeneous chains contain forks (bifurcations), where two Ub molecules are linked to the adjacent lysines at Lys(6) + Lys(11), Lys(27) + Lys(29), or Lys(29) + Lys(33) on the preceding Ub molecule. However, the HECT domain E3s, E6AP and Nedd4, with the same E2, UbcH5, form homogeneous chains exclusively, either Lys48 chains (E6AP) or Lys(63) chains (Nedd4). Furthermore, with other families of E2s, CHIP and MuRF1 synthesize homogeneous Ub chains on the substrates. Using the dimeric E2, UbcH13/ Uev1a, they attach Lys(63) chains, but with UbcH1 (E2-25K), MuRF1 synthesizes Lys(48) chains on the substrate. We then compared the capacity of the forked heterogeneous chains and homogeneous chains to support proteasomal degradation. When troponin I was linked by MuRF1 to a Lys(48)-Ub chain or, surprisingly, to a Lys(63)-Ub chain, troponin I was degraded rapidly by pure 26S proteasomes. However, when linked to the mixed forked chains, troponin I was degraded quite poorly, and its polyUb chain, especially the forked linkages, was disassembled slowly by proteasome- associated isopeptidases. Because these Ring finger and U- box E3s with UbcH5 target proteins for degradation in vivo, but Lys(63) chains do not, cells probably contain additional factors that prevent formation of such nondegradable Ub- conjugates and that protect proteins linked to Lys(63)-Ub chains from proteasomal degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Konkuk Univ, Dept Mol Biotechnol, Inst Biomed Sci, Seoul 143701, South Korea	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Saint Louis University; Konkuk University	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu	Kim, Kwang Pyo/AAG-1815-2020	Scaglione, Kenneth/0000-0002-3858-9418; Lledias, Fernando/0000-0002-2141-8727; Kim, Hyoung Tae/0000-0002-0270-2749	NIGMS NIH HHS [R01 GM051923, R01 GM051923-12, R01 GM65267, R01 GM065267] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065267, R01GM051923] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Gazdoiu S, 2005, P NATL ACAD SCI USA, V102, P15053, DOI 10.1073/pnas.0507646102; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Merkley N, 2004, J BIOL CHEM, V279, P47139, DOI 10.1074/jbc.M409576200; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Park KC, 1997, ARCH BIOCHEM BIOPHYS, V347, P78, DOI 10.1006/abbi.1997.0311; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wang M, 2005, EMBO J, V24, P4324, DOI 10.1038/sj.emboj.7600895; Wang M, 2006, EMBO J, V25, P1710, DOI 10.1038/sj.emboj.7601061; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023	60	337	357	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17375	17386		10.1074/jbc.M609659200	http://dx.doi.org/10.1074/jbc.M609659200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17426036	hybrid			2022-12-25	WOS:000247084500007
J	Feinberg, H; Taylor, ME; Weis, WI				Feinberg, Hadar; Taylor, Maureen E.; Weis, William I.			Scavenger receptor C-type lectin binds to the leukocyte cell surface glycan Lewis(x) by a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CRYSTAL-STRUCTURE; LIGAND-BINDING; DC-SIGN; RECOGNITION; OLIGOSACCHARIDES; DOMAIN; ARRAY	The scavenger receptor C-type lectin (SRCL) is unique in the family of class A scavenger receptors, because in addition to binding sites for oxidized lipoproteins it also contains a C-type carbohydrate-recognition domain (CRD) that interacts with specific glycans. Both human and mouse SRCL are highly specific for the Lewis(x) trisaccharide, which is commonly found on the surfaces of leukocytes and some tumor cells. Structural analysis of the CRD of mouse SRCL in complex with Lewisx and mutagenesis show the basis for this specificity. The interaction between mouse SRCL and Lewisx is analogous to the way that selectins and DC-SIGN bind to related fucosylated glycans, but the mechanism of the interaction is novel, because it is based on a primary galactose-binding site similar to the binding site in the asialoglycoprotein receptor. Crystals of the human receptor lacking bound calcium ions reveal an alternative conformation in which a glycan ligand would be released during receptor-mediated endocytosis.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94306 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94306 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	Stanford University; Stanford University; Imperial College London	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr, W Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Taylor, Maureen/0000-0001-8300-4987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R01GM050565] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM062116, GM62116, R01 GM050565, GM50565] Funding Source: Medline; Wellcome Trust [075565] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coombs PJ, 2006, GLYCOBIOLOGY, V16, p1C, DOI 10.1093/glycob/cwj126; Coombs PJ, 2005, J BIOL CHEM, V280, P22993, DOI 10.1074/jbc.M504197200; Elola MT, 2007, BREAST CANCER RES TR, V101, P161, DOI 10.1007/s10549-006-9286-9; Feinberg H, 2000, J BIOL CHEM, V275, P35176, DOI 10.1074/jbc.M005557200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; NAKAMURA K, 2001, BIOCHEM BIOPH RES CO, V280, P183; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Perret S, 2005, BIOCHEM J, V389, P325, DOI 10.1042/BJ20050079; Poget SF, 2001, BIOCHEMISTRY-US, V40, P10966, DOI 10.1021/bi002698z; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walker JR, 2004, BIOCHEMISTRY-US, V43, P3783, DOI 10.1021/bi035871a; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	24	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17250	17258		10.1074/jbc.M701624200	http://dx.doi.org/10.1074/jbc.M701624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420244	hybrid, Green Accepted			2022-12-25	WOS:000246946500058
J	Matsumoto, K; Yu, ST; Jia, YZ; Ahmed, MR; Viswakarma, N; Sarkar, J; Kashireddy, PV; Rao, MS; Karpus, W; Gonzalez, FJ; Reddy, JK				Matsumoto, Kojiro; Yu, Songtao; Jia, Yuzhi; Ahmed, Mohamed R.; Viswakarma, Navin; Sarkar, Joy; Kashireddy, Papreddy V.; Rao, M. Sambasiva; Karpus, William; Gonzalez, Frank J.; Reddy, Janardan K.			Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPAR alpha ligand-induced liver tumor development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE-LIVER; PARTIAL-HEPATECTOMY; NUCLEAR RECEPTORS; PROTEIN; EXPRESSION; MECHANISM; CAR; PBP; HEPATOTOXICITY; INTERACTS	Disruption of the gene encoding for the transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP/TRAP220/DRIP205/Med1) in the mouse results in embryonic lethality. Here, we have reported that targeted disruption of the Pbp/Pparbp gene in hepatocytes (Pbp(Delta Liv)) impairs liver regeneration with low survival after partial hepatectomy. Analysis of cell cycle progression suggests a defective exit from quiescence, reduced BrdUrd incorporation, and diminished entry into G(2)/M phase in Pbp(Delta Liv) hepatocytes after partial hepatectomy. Pbp(Delta Liv) hepatocytes failed to respond to hepatocyte growth factor/scatter factor, implying that hepatic PBP deficiency affects c-met signaling. Pbp gene disruption also abolishes primary mitogen-induced liver cell proliferative response. Striking abrogation of CCl4-induced hepatocellular proliferation and hepatotoxicity occurred in Pbp(Delta Liv) mice pretreated with phenobarbital due to lack of expression of xenobiotic metabolizing enzymes necessary for CCl4 activation. Pbp(Delta Liv) mice, chronically exposed to Wy-14,643, a PPAR alpha ligand, revealed a striking proliferative response and clonal expansion of a few Pbp(fl/fl) hepatocytes that escaped Cre-mediated gene deletion in Pbp(Delta Liv) livers, but no proliferative expansion of PBP null hepatocytes was observed. In these Pbp(Delta Liv) mice, none of the Wy-14,643-induced hepatic adenomas and hepatocellular carcinomas was derived from PBP Delta Liv hepatocytes; all liver tumors developing in Pbp(Delta Liv) mice maintained non-recombinant Pbp alleles and retained PBP expression. These studies provide direct evidence in support of a critical role of PBP/TRAP220 in liver regeneration, induction of hepatotoxicity, and hepatocarcinogenesis.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Canc Res Ctr, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA	Reddy, JK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NCI NIH HHS [CA104578] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708, R01CA104578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Costa RH, 2005, HEPATOLOGY, V42, P1004, DOI 10.1002/hep.20953; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Fernandez MA, 2006, SCIENCE, V313, P1628, DOI 10.1126/science.1130773; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Guo DS, 2006, BIOCHEM BIOPH RES CO, V347, P485, DOI 10.1016/j.bbrc.2006.06.129; Higgins GM, 1931, ARCH PATHOL, V12, P186; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Jia YZ, 2005, P NATL ACAD SCI USA, V102, P12531, DOI 10.1073/pnas.0506000102; Jia YZ, 2004, J BIOL CHEM, V279, P24427, DOI 10.1074/jbc.M402391200; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kitamura K, 2005, DEV GROWTH DIFFER, V47, P537; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Locker J, 2003, HEPATOLOGY, V38, P314, DOI 10.1053/jhep.2003.50299; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Oliver JR, 2005, EXP BIOL MED, V230, P61; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RAO MS, 1987, CARCINOGENESIS, V8, P631; Reddy JK, 2006, AD DEV BIOL, V16, P389, DOI 10.1016/S1574-3349(06)16012-3; Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005; Reddy JK, 2004, AM J PATHOL, V164, P2305, DOI 10.1016/S0002-9440(10)63787-X; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Sherr CJ, 2000, CANCER RES, V60, P3689; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Togo S, 2004, J HEPATOL, V40, P464, DOI 10.1016/j.jhep.2003.11.005; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Yamazaki Y, 2005, WORLD J GASTROENTERO, V11, P5966, DOI 10.3748/wjg.v11.i38.5966; YU S, 2007, IN PRESS BIOCH BIOPH; Yu ST, 2004, BIOCHIMIE, V86, P743, DOI 10.1016/j.biochi.2004.09.015; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	37	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17053	17060		10.1074/jbc.M701956200	http://dx.doi.org/10.1074/jbc.M701956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17438330	hybrid			2022-12-25	WOS:000246946500038
J	Kalamajski, S; Aspberg, A; Oldberg, A				Kalamajski, Sebastian; Aspberg, Anders; Oldberg, Ake			The decorin sequence SYIRIADTNIT binds collagen type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; SMALL PROTEOGLYCAN; TARGETED DISRUPTION; CORE; FIBROMODULIN; BIGLYCAN; LUMICAN; IDENTIFICATION; EXPRESSION; HOMOLOGY	Decorin belongs to the small leucine-rich repeat proteoglycan family, interacts with fibrillar collagens, and regulates the assembly, structure, and biomechanical properties of connective tissues. The decorin-collagen type I-binding region is located in leucine-rich repeats 5-6. Site-directed mutagenesis of this 54-residue-long collagen-binding sequence identifies Arg-207 and Asp-210 in leucine-rich repeat 6 as crucial for the binding to collagen. The synthetic peptide SYIRIADTNIT, which includes Arg-207 and Asp-210, inhibits the binding of full-length recombinant decorin to collagen in vitro. These collagen-binding amino acids are exposed on the exterior of the beta-sheet-loop structure of the leucine-rich repeat. This resembles the location of interacting residues in other leucine-rich repeat proteins.	Lund Univ, Dept Expt Med Sci, BMC B12, SE-22184 Lund, Sweden; Univ Copenhagen, Dept Mol Biol, DK-2100 Copenhagen, Denmark	Lund University; University of Copenhagen	Oldberg, A (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B12, SE-22184 Lund, Sweden.	Ake.Oldberg@med.lu.se		Kalamajski, Sebastian/0000-0002-6600-9302; Aspberg, Anders/0000-0002-6588-6944				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kvist AJ, 2006, J BIOL CHEM, V281, P33127, DOI 10.1074/jbc.M607892200; Liu XH, 2005, BIOCHEM BIOPH RES CO, V338, P1342, DOI 10.1016/j.bbrc.2005.10.096; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Nareyeck G, 2004, EUR J BIOCHEM, V271, P3389, DOI 10.1111/j.1432-1033.2004.04273.x; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Shimizu A, 2004, J BIOL CHEM, V279, P16285, DOI 10.1074/jbc.M307230200; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	33	59	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16062	16067		10.1074/jbc.M700073200	http://dx.doi.org/10.1074/jbc.M700073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426031	hybrid			2022-12-25	WOS:000246794300014
J	Munoz-Espin, D; Fuertes, MA; Jimenez, M; Villar, L; Alonso, C; Rivas, G; Salas, M; Meijer, WJJ				Munoz-Espin, Daniel; Fuertes, Miguel A.; Jimenez, Mercedes; Villar, Laurentino; Alonso, Carlos; Rivas, German; Salas, Margarita; Meijer, Wilfried J. J.			Structural and functional analysis of phi 29 p16.7C dimerization mutants - Identification of a novel aromatic cage dimerization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; DNA-REPLICATION; CELL-MEMBRANE; RNA-POLYMERASE; ASSOCIATION; ULTRACENTRIFUGATION; VISUALIZATION; MODEL	Prokaryotic DNA replication is compartmentalized at the cellular membrane. The Bacillus subtilis phage phi 29-encoded membrane protein p16.7 is one of the few proteins known to be involved in the organization of prokaryotic membrane-associated DNA replication. The functional DNA binding domain of p16.7 is constituted by its C-terminal half, p16.7C, which forms high affinity dimers in solution and which can form higher order oligomers. Recently, the solution and crystal structures of p16.7C and the crystal structure of the p16.7C-DNA complex have been solved. Here, we have studied the p16.7C dimerization process and the structural and functional roles of p16.7 residues Trp-116 and Asn-120 and its last nine C-terminal amino acids, which form an extended tail. The results obtained show that transition of folded dimers into unfolded monomers occurs without stable intermediates and that both Trp-116 and the C-terminal tail are important for dimerization and functionality of p16.7C. Residue Trp-116 is involved in formation of a novel aromatic cage dimerization motif, which we call "Pro cage." Finally, whereas residue Asn-120 plays a minor role in p16.7C dimerization, we show that it is critical for both oligomerization and DNA binding, providing further evidence that DNA binding and oligomerization of p16.7C are coupled processes.	Univ Autonoma Madrid, CSIC, Ctr Mol Biol, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Mol Biol, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.	msalas@cbm.uam.es	Salas, Margarita/J-9873-2014; Rivas, German/AFL-7528-2022; Rivas, German/AAG-7458-2022; Jimenez Sarmiento, Mercedes/K-2691-2014	Salas, Margarita/0000-0001-5939-3441; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Jimenez Sarmiento, Mercedes/0000-0003-2006-1903; Meijer, Wilfried/0000-0003-1842-0049				Albert A, 2005, J BIOL CHEM, V280, P42486, DOI 10.1074/jbc.C500429200; Asensio JL, 2005, J BIOL CHEM, V280, P20730, DOI 10.1074/jbc.M501687200; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Cole JL, 2004, METHOD ENZYMOL, V384, P212; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Firshein W, 1997, MOL MICROBIOL, V23, P1, DOI 10.1046/j.1365-2958.1997.2061569.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Howlett GJ, 2006, CURR OPIN CHEM BIOL, V10, P430, DOI 10.1016/j.cbpa.2006.08.017; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; IVARIE RD, 1973, VIROLOGY, V52, P351, DOI 10.1016/0042-6822(73)90330-9; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kruppa GH, 2003, RAPID COMMUN MASS SP, V17, P155, DOI 10.1002/rcm.885; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Munoz-Espin D, 2004, J BIOL CHEM, V279, P50437, DOI 10.1074/jbc.M403297200; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rivas G, 2003, BIOCHEM SOC T, V31, P1015; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Serna-Rico A, 2002, J BIOL CHEM, V277, P6733, DOI 10.1074/jbc.M109312200; Serna-Rico A, 2003, EMBO J, V22, P2297, DOI 10.1093/emboj/cdg221; Shao X, 1997, BIOCHEMISTRY-US, V36, P9941, DOI 10.1021/bi9707786; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sueoka N, 1998, PROG NUCLEIC ACID RE, V59, P35; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	1	2	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16521	16531		10.1074/jbc.M611778200	http://dx.doi.org/10.1074/jbc.M611778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426023	hybrid, Green Published			2022-12-25	WOS:000246794300059
J	Sharma, SM; Bronisz, A; Hu, R; Patel, K; Mansky, KC; Sif, S; Ostrowski, MC				Sharma, Sudarshana M.; Bronisz, Agnieszka; Hu, Rong; Patel, Krupen; Mansky, Kim C.; Sif, Said; Ostrowski, Michael C.			MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; FACTOR FAMILY; TERMINAL DIFFERENTIATION; NUCLEAR FACTOR; C-FOS; EXPRESSION; ACTIVATION; RECEPTOR; MOUSE; CELLS	Transcription factors NFATc1, PU.1, and MITF collaborate to regulate specific genes in response to colony-stimulating factor-1 (CSF-1) and receptor activator of NF-kappa B ligand (RANKL) signaling during osteoclast differentiation. However, molecular details concerning timing and mechanism of specific events remain ill-defined. In bone marrow-derived precursors, CSF-1 alone promoted assembly of MITF-PU.1 complexes at osteoclast target gene promoters like cathepsin K and acid 5 phosphatase without increasing gene expression. The combination of RANKL and CSF-1 concurrently increased the levels of MAPK-phosphorylated forms of MITF, p38 MAPK, and SWI/SNF chromatin-remodeling complexes bound to these target promoters and markedly increased expression of the genes. NFATc1 was subsequently recruited to complexes at the promoters during terminal stages of osteoclast differentiation. Genetic analysis of Mitf and Pu.1 in mouse models supported the critical interaction of these genes in osteoclast differentiation. The results define MITF and PU.1 as nuclear effectors that integrate CSF-1/RANKL signals during osteoclast differentiation to initiate expression of target genes, whereas a complex that includes NFATc1 may act to maintain target gene expression in differentiated cells.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Minnesota, Div Orthodont, Dept Dev & Surg Sci, Sch Dent, Minneapolis, MN 55455 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 37OA Tzagoumis Med Res Facil,420 W 12th Ave, Columbus, OH 43210 USA.	michael.ostrowski@osumc.edu	Bronisz, Agnieszka/M-3485-2019; Sharma, Sudarshana Mangalore/AAI-2475-2019; Bronisz, Agnieszka/G-5980-2019; Ostrowski, Michael/H-3108-2011	Bronisz, Agnieszka/0000-0002-5841-1051; Bronisz, Agnieszka/0000-0002-5841-1051; Sif, Said/0000-0001-6268-1145; Ostrowski, Michael/0000-0003-2948-6297; Mansky, Kim/0000-0002-2826-5030; Sharma, Sudarshana/0000-0002-9745-0061	NIAMS NIH HHS [R01-AR-0447129, R01 AR044719] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044719] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06-05-0470; Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Sankar U, 2004, J BONE MINER RES, V19, P1339, DOI 10.1359/JBMR.040321; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	33	135	138	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15921	15929		10.1074/jbc.M609723200	http://dx.doi.org/10.1074/jbc.M609723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403683	hybrid			2022-12-25	WOS:000246589600067
J	Andersen, DS; Leevers, SJ				Andersen, Ditte S.; Leevers, Sally J.			The essential Drosophila ATP-binding cassette domain protein, pixie, binds the 40 S ribosome in an ATP-dependent manner and is required for translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-L INHIBITOR; 2-5A/RNASE L PATHWAY; EIF3; BIOGENESIS; COMPLEX; GENE	The Drosophila gene, pixie, is an essential gene required for normal growth and translation. Pixie is the fly ortholog of human RLI, which was first identified as an RNase L inhibitor, and yeast Rli1p, which has recently been shown to play a role in translation initiation and ribosome biogenesis. These proteins are all soluble ATP-binding cassette proteins with two N-terminal iron-sulfur clusters. Here we demonstrate that Pixie can be isolated from cells in complex with eukaryotic translation initiation factor 3 and ribosomal proteins of the small subunit. In addition, our analysis of polysome profiles reveals that double-stranded RNA interference-mediated depletion of Pixie results in an increase in empty 80 S ribosomes and a corresponding decrease in polysomes. Thus Pixie is required for normal levels of translation initiation. We also find that Pixie associates with the 40 S subunit on sucrose density gradients in an ATP-dependent manner. Our observations are consistent with Pixie playing a catalytic role in the assembly of complexes required for translation initiation. Thus, the function of this soluble ATP-binding cassette domain protein family in translation initiation has been conserved from yeast through to higher eukaryotes.	Canc Res UK London Res Inst, Growth Regulat Lab, London WC2A 3PX, England	Cancer Research UK	Leevers, SJ (corresponding author), Canc Res UK London Res Inst, Growth Regulat Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.	sally.leevers@cancer.org.uk		Andersen, Ditte/0000-0003-1209-6102				Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Chen ZQ, 2006, J BIOL CHEM, V281, P7452, DOI 10.1074/jbc.M510603200; Coelho CMA, 2005, DEVELOPMENT, V132, P5411, DOI 10.1242/dev.02148; Coelho CMA, 2005, GENETICS, V171, P597, DOI 10.1534/genetics.105.045021; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Gabaldon T, 2004, CELL MOL LIFE SCI, V61, P930, DOI 10.1007/s00018-003-3387-y; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kolupaeva VG, 2005, RNA, V11, P470, DOI 10.1261/rna.7215305; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; Le Roy F, 2005, NAT STRUCT MOL BIOL, V12, P505, DOI 10.1038/nsmb944; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zachariou A, 2003, EMBO J, V22, P6642, DOI 10.1093/emboj/cdg617; Zhao ZY, 2004, BIOCHEM BIOPH RES CO, V323, P104, DOI 10.1016/j.bbrc.2004.08.068	24	55	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14752	14760		10.1074/jbc.M701361200	http://dx.doi.org/10.1074/jbc.M701361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392269	hybrid			2022-12-25	WOS:000246589000010
J	Babu, H; Cheung, G; Kettenmann, H; Palmer, TD; Kempermann, G				Babu, Harish; Cheung, Giselle; Kettenmann, Helmut; Palmer, Theo D.; Kempermann, Gerd			Enriched Monolayer Precursor Cell Cultures from Micro-Dissected Adult Mouse Dentate Gyrus Yield Functional Granule Cell-Like Neurons	PLOS ONE			English	Article								Background. Stem cell cultures are key tools of basic and applied research in Regenerative Medicine. In the adult mammalian brain, lifelong neurogenesis originating from local precursor cells occurs in the neurogenic regions of the hippocampal dentate gyrus. Despite widespread interest in adult hippocampal neurogenesis and the use of mouse models to study it, no protocol existed for adult murine long-term precursor cell cultures with hippocampus-specific differentiation potential. Methodology/Principal Findings. We describe a new strategy to obtain serum-free monolayer cultures of neural precursor cells from microdissected dentate gyrus of adult mice. Neurons generated from these adherent hippocampal precursor cell cultures expressed the characteristic markers like transcription factor Prox1 and showed the TTX-sensitive sodium currents of mature granule cells in vivo. Similar to granule cells in vivo, treatment with kainic acid or brain derived neurotrophic factor (BDNF) elicited the expression of GABAergic markers, further supporting the correspondence between the in vitro and in vivo phenotype. When plated as single cells (in individual wells) or at lowest density for two to three consecutive generations, a subset of the cells showed self-renewal and gave rise to cells with properties of neurons, astrocytes and oligodendrocytes. The precursor cell fate was sensitive to culture conditions with their phenotype highly influenced by factors within the media (sonic hedgehog, BMP, LIF) and externally applied growth factors (EGF, FGF2, BDNF, and NT3). Conclusions/Significance. We report the conditions required to generate adult murine dentate gyrus precursor cell cultures and to analyze functional properties of precursor cells and their differentiated granule cell-like progeny in vitro.	[Babu, Harish; Cheung, Giselle; Kettenmann, Helmut; Kempermann, Gerd] Max Delbruck Ctr Mol Med MDC Berlin Buch, Berlin, Germany; [Babu, Harish; Kempermann, Gerd] Charite, Dept Expt Neurol, VolkswagenStiftung Res Grp, D-13353 Berlin, Germany; [Palmer, Theo D.] Stanford Univ, Dept Neurosurg, Palo Alto, CA 94304 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Volkswagen; Volkswagen Germany; Stanford University	Kempermann, G (corresponding author), Max Delbruck Ctr Mol Med MDC Berlin Buch, Berlin, Germany.	gerd.kempermann@mdc-berlin.de	Palmer, Theo/GSI-6635-2022; Kettenmann, Helmut/AAJ-5142-2021; Kempermann, Gerd/F-5416-2010	Kempermann, Gerd/0000-0002-5304-4061; Palmer, Theo/0000-0002-6266-1862; Kettenmann, Helmut/0000-0001-8208-0291; Cheung, Giselle/0000-0001-8457-2572	Volkswagenstiftung, Thyssen Stiftung; Deutsche Forschungsgemeinschaft (DFG)	Volkswagenstiftung, Thyssen Stiftung(Volkswagen); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The work was supported by grants from Volkswagenstiftung, Thyssen Stiftung, and Deutsche Forschungsgemeinschaft (DFG).	Adachi T, 2005, J NEUROSCI RES, V79, P608, DOI 10.1002/jnr.20373; Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; Barami K, 2001, NEUROL RES, V23, P321, DOI 10.1179/016164101101198686; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Ernst C, 2005, EUR J NEUROSCI, V22, P3059, DOI 10.1111/j.1460-9568.2005.04499.x; Filippov V, 2003, MOL CELL NEUROSCI, V23, P373, DOI 10.1016/S1044-7431(03)00060-5; Friedman WJ, 1998, NEUROSCIENCE, V84, P101, DOI 10.1016/S0306-4522(97)00526-5; Fukuda S, 2003, J NEUROSCI, V23, P9357; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Gutierrez R, 2005, TRENDS NEUROSCI, V28, P297, DOI 10.1016/j.tins.2005.04.005; JESSBERGER S, 2006, STEM CELLS; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2006, P NATL ACAD SCI USA, V103, P780, DOI 10.1073/pnas.0510291103; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Li GN, 2005, DEV NEUROSCI-BASEL, V27, P93, DOI 10.1159/000085980; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Noctor SC, 2002, J NEUROSCI, V22, P3161, DOI 10.1523/JNEUROSCI.22-08-03161.2002; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roy NS, 2000, NAT MED, V6, P271; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; SANDLER R, 1991, J COMP NEUROL, V303, P177, DOI 10.1002/cne.903030202; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seki T, 1999, J COMP NEUROL, V410, P503, DOI 10.1002/(SICI)1096-9861(19990802)410:3<503::AID-CNE11>3.0.CO;2-H; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Singec I, 2002, J COMP NEUROL, V452, P139, DOI 10.1002/cne.10371; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; THALLMAIR M, 2006, EXP NEUROL; Tozuka Y, 2005, NEURON, V47, P803, DOI 10.1016/j.neuron.2005.08.023; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Wang LP, 2005, MOL CELL NEUROSCI, V29, P181, DOI 10.1016/j.mcn.2005.02.002; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037	63	119	121	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e388	10.1371/journal.pone.0000388	http://dx.doi.org/10.1371/journal.pone.0000388			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460755	gold, Green Published, Green Accepted			2022-12-25	WOS:000207445600002
J	Kouprina, N; Noskov, VN; Pavlicek, A; Collins, NK; Bortz, PDS; Ottolenghi, C; Loukinov, D; Goldsmith, P; Risinger, JI; Kim, JH; Westbrook, VA; Solomon, G; Sounders, H; Herr, JC; Jurka, J; Lobanenkov, V; Schlessinger, D; Larionov, V				Kouprina, Natalay; Noskov, Vladimir N.; Pavlicek, Adam; Collins, N. Keith; Bortz, Pamela D. Schoppee; Ottolenghi, Chris; Loukinov, Dmitri; Goldsmith, Paul; Risinger, John I.; Kim, Jung-Hyun; Westbrook, V. Anne; Solomon, Gregory; Sounders, Hanna; Herr, John C.; Jurka, Jerzy; Lobanenkov, Victor; Schlessinger, David; Larionov, Vladimir			Evolutionary Diversification of SPANX-N Sperm Protein Gene Structure and Expression	PLOS ONE			English	Article								The sperm protein associated with nucleus in the X chromosome (SPANX) genes cluster at Xq27 in two subfamilies, SPANX-A/D and SPANX-N. SPANX-A/D is specific for hominoids and is fairly well characterized. The SPANX-N gave rise to SPANX-A/D in the hominoid lineage similar to 7 MYA. Given the proposed role of SPANX genes in spermatogenesis, we have extended studies to SPANX-N gene evolution, variation, regulation of expression, and intra-sperm localization. By immunofluorescence analysis, SPANX-N proteins are localized in post-meiotic spermatids exclusively, like SPANX-A/D. But in contrast to SPANX-A/D, SPANX-N are found in all ejaculated spermatozoa rather than only in a subpopulation, are localized in the acrosome rather than in the nuclear envelope, and are expressed at a low level in several nongametogenic adult tissues as well as many cancers. Presence of a binding site for CTCF and its testis-specific paralogue BORIS in the SPANX promoters suggests, by analogy to MAGE-A1 and NY-ESO-1, that their activation in spermatogenesis is mediated by the programmed replacement of CTCF by BORIS. Based on the relative density of CpG, the more extended expression of SPANX-N compared to SPANX-A/D in nongametogenic tissues is likely attributed to differences in promoter methylation. Our findings suggest that the recent duplication of SPANX genes in hominoids was accompanied by different localization of SPANX-N proteins in post-meiotic sperm and additional expression in several nongonadal tissues. This suggests a corresponding functional diversification of SPANX gene families in hominoids. SPANX proteins thus provide unique targets to investigate their roles in the function of spermatozoa, selected malignancies, and for SPANX-N, in other tissues as well.	[Kouprina, Natalay; Noskov, Vladimir N.; Collins, N. Keith; Goldsmith, Paul; Risinger, John I.; Kim, Jung-Hyun; Larionov, Vladimir] NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; [Pavlicek, Adam; Jurka, Jerzy] Genet Informat Res Inst, Mountain View, CA USA; [Bortz, Pamela D. Schoppee; Herr, John C.] Univ Virginia Hlth Syst, Dept Cell Biol, Charlottesville, VA USA; [Ottolenghi, Chris; Schlessinger, David] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; [Loukinov, Dmitri; Lobanenkov, Victor] NIAID, Immunol Lab, Bethesda, MD 20892 USA; [Westbrook, V. Anne] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA; [Solomon, Gregory; Sounders, Hanna] NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kouprina, N (corresponding author), NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.	kouprinn@mail.nih.gov	Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021; Ottolenghi, Chris/H-3745-2017	Ottolenghi, Chris/0000-0002-0734-344X; Lobanenkov, Victor/0000-0001-6665-3635; Westbrook, Anne/0000-0003-4570-0126	NIH; National Cancer Institute; Center for Cancer Research; National Institute on Aging, NIA; NATIONAL CANCER INSTITUTE [ZIABC010413, Z01BC010413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000860, ZIAAI000860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000647, Z01AG000647] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging, NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by the intramural research program of the NIH, National Cancer Institute, Center for Cancer Research and National Institute on Aging, NIA.	Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Baffoe-Bonnie AB, 2005, HUM GENET, V117, P307, DOI 10.1007/s00439-005-1306-z; Ball MA, 2003, J THEOR BIOL, V224, P27, DOI 10.1016/S0022-5193(03)00118-8; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Bray N, 2004, GENOME RES, V14, P693, DOI 10.1101/gr.1960404; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; Goydos JS, 2001, J SURG RES, V98, P76, DOI 10.1006/jsre.2001.6148; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Hao ZL, 2002, BIOL REPROD, V66, P735, DOI 10.1095/biolreprod66.3.735; HERR JC, 1990, BIOL REPROD, V42, P181, DOI 10.1095/biolreprod42.1.181; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Jagadish N, 2005, BIOCHEM J, V389, P73, DOI 10.1042/BJ20041577; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; KANG Y, 2007, ONCOGENE IN PRESS; Kim M, 2006, J BIOL CHEM, V281, P34288, DOI 10.1074/jbc.M607168200; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Kouprina N, 2005, GENOME RES, V15, P1477, DOI 10.1101/gr.4212705; Kouprina N, 2004, P NATL ACAD SCI USA, V101, P3077, DOI 10.1073/pnas.0308532100; Kouprina Natalay, 2006, V349, P85; Kouprina N, 2006, NAT REV GENET, V7, P805, DOI 10.1038/nrg1943; Lim JH, 2005, INT J CANCER, V116, P200, DOI 10.1002/ijc.21007; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nayernia K, 1996, INT J DEV BIOL, V40, P379; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Ohno S., 1970, EVOLUTION GENE DUPLI; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; Salemi Michele, 2006, Hum Cell, V19, P87, DOI 10.1111/j.1749-0774.2006.00014.x; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Shetty J, 2003, J BIOL CHEM, V278, P30506, DOI 10.1074/jbc.M301713200; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Suri A, 2005, EXPERT OPIN BIOL TH, V5, P381, DOI 10.1517/14712598.5.3.381; Swanson WJ, 2004, GENETICS, V168, P1457, DOI 10.1534/genetics.104.030478; Toshimori K, 2003, ARCH HISTOL CYTOL, V66, P383, DOI 10.1679/aohc.66.383; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Wang XX, 2004, GENETICS, V167, P879, DOI 10.1534/genetics.103.025072; Wang ZQ, 2006, INT J CANCER, V118, P1436, DOI 10.1002/ijc.21499; Wang ZQ, 2003, BLOOD, V101, P955, DOI 10.1182/blood-2002-06-1930; Westbrook VA, 2006, MOL HUM REPROD, V12, P703, DOI 10.1093/molehr/gal079; Westbrook VA, 2000, BIOL REPROD, V63, P469, DOI 10.1093/biolreprod/63.2.469; Westbrook VA, 2004, CLIN CANCER RES, V10, P101, DOI 10.1158/1078-0432.CCR-0647-3; Westbrook VA, 2001, BIOL REPROD, V64, P345; Wolkowicz MJ, 2003, BIOL REPROD, V69, P735, DOI 10.1095/biolreprod.103.016675; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yamshchikov GV, 2001, INT J CANCER, V92, P703, DOI 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Zendman AJW, 2003, GENE, V309, P125, DOI 10.1016/S0378-1119(03)00497-9; Zendman AJW, 1999, CANCER RES, V59, P6223; Zhao L, 2004, WORLD J GASTROENTERO, V10, P2034, DOI 10.3748/wjg.v10.i14.2034	57	28	29	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e359	10.1371/journal.pone.0000359	http://dx.doi.org/10.1371/journal.pone.0000359			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406683	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445300021
J	Stang, MT; Armstrong, MJ; Watson, GA; Sung, KY; Liu, Y; Ren, B; Yim, JH				Stang, M. T.; Armstrong, M. J.; Watson, G. A.; Sung, K. Y.; Liu, Y.; Ren, B.; Yim, J. H.			Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; IRF-1; breast cancer; FADD	TRAIL-INDUCED APOPTOSIS; FACTOR-I; GROWTH-INHIBITION; TUMOR-GROWTH; IRF-1; GAMMA; ACTIVATION; EXPRESSION; INDUCTION; CASPASE-8	Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and established anti-tumor agents, including the anti-estrogens tamoxifen and faslodex. Here we demonstrate that in MDA468 breast cancer cells, apoptosis by IFN-gamma is mediated by IRF-1 and IFN-gamma, and IRF-1-induced apoptosis is caspase-mediated. IRF-1 induction results in cleavage of caspase-8, -3 and -7, and application of caspase inhibitors attenuate activated cleavage products. IRF-1-induced apoptosis involves caspase-8 since apoptosis is significantly decreased by the caspase-8-specific inhibitor IETD, c-FLIP expression and in caspase-8-deficient cancer cells. Furthermore, we demonstrate that IRF-1-induced apoptosis requires fas-associated death domain (FADD) since dominant-negative FADD expressing cells resist IRF-1-induced apoptosis and activated downstream products. Immunofluorescent studies demonstrate perinuclear colocalization of FADD and caspase-8. Despite the known role of FADD in mediating death-ligand induced apoptosis, neutralizing antibodies against classical death receptors do not inhibit IRF-1 induced apoptosis, and no secreted ligand appears to be involved since MDA468 coincubated with IRF-1 transfected cells do not apoptose. Therefore, we demonstrate that IRF-1 induces a ligand-independent FADD/caspase-8-mediated apoptosis in breast cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, Pittsburgh, PA 15261 USA; Catholic Univ Korea, Dept Surg, Seoul, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Catholic University of Korea	Yim, JH (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, 497 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	yimjh@upmc.edu	Yim, John/R-7555-2019	Watson, Gregory/0000-0001-7729-4818	NCI NIH HHS [CA098403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA098403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Billecke CA, 2002, ONCOGENE, V21, P4481, DOI 10.1038/sj.onc.1205546; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2007, ONCOGENE, V26, P2017, DOI 10.1038/sj.onc.1210013; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Gupta V, 2005, P NATL ACAD SCI USA, V102, P3219, DOI 10.1073/pnas.0409709102; Keane MM, 1996, CANCER RES, V56, P4791; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Park SY, 2004, EUR J BIOCHEM, V271, P4222, DOI 10.1111/j.1432-1033.2004.04362.x; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Shinoura N, 2000, HUM GENE THER, V11, P1123, DOI 10.1089/10430340050015185; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wang X, 2005, MOL CELL BIOL, V25, P4742, DOI 10.1128/MCB.25.11.4742-4751.2005; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yim JH, 1997, J IMMUNOL, V158, P1284	27	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6420	6430		10.1038/sj.onc.1210470	http://dx.doi.org/10.1038/sj.onc.1210470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452973				2022-12-25	WOS:000249737600006
J	Hwa, AJ; Fry, RC; Sivaraman, A; So, PT; Samson, LD; Stolz, DB; Griffith, LG				Hwa, Albert J.; Fry, Rebecca C.; Sivaraman, Anand; So, Peter T.; Samson, Leona D.; Stolz, Donna B.; Griffith, Linda G.			Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused co-cultures with hepatocytes	FASEB JOURNAL			English	Article						tissue engineering; liver; microvascular	DECAY-ACCELERATING FACTOR; GROWTH-FACTOR; IN-VITRO; NONPARENCHYMAL CELLS; EXPRESSION; INDUCTION; MORPHOGENESIS; LOCALIZATION; ANGIOGENESIS; GELSOLIN	Liver sinusoidal endothelial cells (SECs) are generally refractory to extended in vitro culture. In an attempt to recreate some features of the complex set of cues arising from the liver parenchyma, we cocultured adult rat liver SECs, identified by the expression of the marker SE-1, with primary adult rat hepatocytes in a 3D culture system that provides controlled microscale perfusion through the tissue mass. The culture was established in a medium containing serum and VEGF, and these factors were then removed to assess whether cells with the SE-1 phenotype could be supported by the local microenvironment in vitro. Rats expressing enhanced green fluorescent protein (EGFP) in all liver cells were used for isolation of the SE-1-positive cells added to cocultures. By the 13th day of culture, EGFP-expressing cells had largely disappeared from 2D control cultures but exhibited moderate proliferation in 3D perfused cultures. SE-1-positive cells were present in 3D cocultures after 13 days, and these cultures also contained Kupffer cells, stellate cells, and CD31-expressing endothelial cells. Global transcriptional profiling did not reveal profound changes between 2D and 3D cultures in expression of most canonical angiogenic factors but suggested changes in several pathways related to endothelial cell function.	MIT, Biol Engn Div, Dept Biol Engn, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Griffith, LG (corresponding author), MIT, Biol Engn Div, Dept Biol Engn, 16-429,77 Mass Ave, Cambridge, MA 02139 USA.	griff@mit.edu		Griffith, Linda/0000-0002-1801-5548; Fry, Rebecca/0000-0003-0899-9018	NCI NIH HHS [CA76541] Funding Source: Medline; NIEHS NIH HHS [U19ES011399-05S1, ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076541, R29CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES011399, P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; ARIAS IM, 2001, LIVER BIOL PATHOBIOL; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Braet F, 1997, J MICROSC-OXFORD, V186, P84, DOI 10.1046/j.1365-2818.1997.1940755.x; BRAET F, 1994, LAB INVEST, V70, P944; Braet Filip, 2004, Comp Hepatol, V3, P7, DOI 10.1186/1476-5926-3-7; Braet Filip, 2002, Comp Hepatol, V1, P1, DOI 10.1186/1476-5926-1-1; Brun P, 2005, AM J PHYSIOL-GASTR L, V289, pG571, DOI 10.1152/ajpgi.00537.2004; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cogger VC, 2006, ATHEROSCLEROSIS, V189, P273, DOI 10.1016/j.atherosclerosis.2005.12.025; COUVELARD A, 1993, AM J PATHOL, V143, P738; de Haas RR, 1999, J HISTOCHEM CYTOCHEM, V47, P183, DOI 10.1177/002215549904700207; DeLeve LD, 2006, AM J PHYSIOL-GASTR L, V291, pG1187, DOI 10.1152/ajpgi.00229.2006; DeLeve LD, 2004, AM J PHYSIOL-GASTR L, V287, pG757, DOI 10.1152/ajpgi.00017.2004; DeLeve LD, 2002, SEMIN LIVER DIS, V22, P27, DOI 10.1055/s-2002-23204; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DOMANSKY K, 2005, P 9 INT C MIN SYST C, P853; DOMANSKY K, 2004, LAB ON CHIPS CELLOMI, P319; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; Edwards S, 2005, HEPATOLOGY, V41, P451, DOI 10.1002/hep.20585; Endo D, 2004, J HEPATOL, V40, P399, DOI 10.1016/j.jhep.2003.11.019; Enomoto Katsuhiko, 2004, Medical Electron Microscopy, V37, P208, DOI 10.1007/s00795-004-0261-4; Eschbach E, 2005, J CELL BIOCHEM, V95, P243, DOI 10.1002/jcb.20360; GERLACH JC, 1994, INT J ARTIF ORGANS, V17, P301; Gomez-Lechon MJ, 1998, J CELL PHYSIOL, V177, P553, DOI 10.1002/(SICI)1097-4652(199812)177:4<553::AID-JCP6>3.0.CO;2-F; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Harada K, 2003, J HEPATOL, V39, P716, DOI 10.1016/S0168-8278(03)00412-4; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Helm CLE, 2005, P NATL ACAD SCI USA, V102, P15779, DOI 10.1073/pnas.0503681102; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; ISOM H, 1987, J CELL BIOL, V105, P2877, DOI 10.1083/jcb.105.6.2877; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Iwatani H, 2004, KIDNEY INT, V65, P1604, DOI 10.1111/j.1523-1755.2004.00561.x; Krause P, 2000, J HEPATOL, V32, P718, DOI 10.1016/S0168-8278(00)80239-1; Lai WK, 2006, AM J PATHOL, V169, P200, DOI 10.2353/ajpath.2006.051191; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Lee SH, 2004, BIOCHEM PHARMACOL, V68, P1391, DOI 10.1016/j.bcp.2004.06.009; Leifeld L, 2006, AM J PATHOL, V168, P778, DOI 10.2353/ajpath.2006.050323; Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834; MALICK LE, 1975, STAIN TECHNOL, V50, P265, DOI 10.3109/10520297509117069; Manganini M, 2000, ONCOGENE, V19, P124, DOI 10.1038/sj.onc.1203225; Maru Y, 2000, EUR J CELL BIOL, V79, P130, DOI 10.1078/S0171-9335(04)70015-1; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G; Michalopoulos GK, 1999, HEPATOLOGY, V29, P90, DOI 10.1002/hep.510290149; Michalopoulos GK, 2001, AM J PATHOL, V159, P1877, DOI 10.1016/S0002-9440(10)63034-9; Mitaka T, 1999, HEPATOLOGY, V29, P111, DOI 10.1002/hep.510290103; Nahmias Y, 2006, TISSUE ENG, V12, P1627, DOI 10.1089/ten.2006.12.1627; Neubauer K, 2003, HISTOCHEM CELL BIOL, V120, P265, DOI 10.1007/s00418-003-0564-x; Oh SH, 2002, SEMIN CELL DEV BIOL, V13, P405, DOI 10.1016/S1084952102001271; Ohi N, 2006, AM J PATHOL, V168, P1097, DOI 10.2353/ajpath.2006.050462; OHMURA T, 1993, J HISTOCHEM CYTOCHEM, V41, P1253, DOI 10.1177/41.8.8331290; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; POPPER H, 1978, AM J PATHOL, V92, P349; Powers MJ, 2002, BIOTECHNOL BIOENG, V78, P257, DOI 10.1002/bit.10143; Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745; Ranucci CS, 2000, BIOMATERIALS, V21, P783, DOI 10.1016/S0142-9612(99)00238-0; Ross MA, 2001, HEPATOLOGY, V34, P1135, DOI 10.1053/jhep.2001.29624; Semino CE, 2006, EXP CELL RES, V312, P289, DOI 10.1016/j.yexcr.2005.10.029; Semler EJ, 2005, BIOTECHNOL BIOENG, V89, P296, DOI 10.1002/bit.20328; SHAKADO S, 1995, HEPATOLOGY, V22, P969, DOI 10.1016/0270-9139(95)90322-4; Sivaraman A, 2005, CURR DRUG METAB, V6, P569, DOI 10.2174/138920005774832632; Suhler E, 1997, CRIT CARE MED, V25, P594, DOI 10.1097/00003246-199704000-00007; Tanikawa K., 1999, LIVER DIS HEPATIC SI; TOHYAMA C, 1993, HEPATOLOGY, V18, P1193; Tokairin T, 2002, J HEPATOL, V36, P725, DOI 10.1016/S0168-8278(02)00048-X; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Ueda A, 2004, AM J PHYSIOL-HEART C, V287, pH994, DOI 10.1152/ajpheart.00400.2003; VILLASCHI S, 1994, LAB INVEST, V71, P291; Wells RG, 2005, J CLIN GASTROENTEROL, V39, pS158, DOI 10.1097/01.mcg.0000155516.02468.0f; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; Wu F J, 1995, Tissue Eng, V1, P29, DOI 10.1089/ten.1995.1.29; YU ZW, 1994, BIOSCIENCE REP, V14, P259, DOI 10.1007/BF01199051; Zeilinger K, 2004, TISSUE ENG, V10, P1113, DOI 10.1089/1076327041887899	77	91	91	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2564	2579		10.1096/fj.06-7473com	http://dx.doi.org/10.1096/fj.06-7473com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426068				2022-12-25	WOS:000248454400030
J	Kornyei, Z; Gocza, E; Ruhl, R; Orsolits, B; Voros, E; Szabo, B; Vagovits, B; Madarasz, E				Kornyei, Z.; Gocza, E.; Ruhl, R.; Orsolits, B.; Voros, E.; Szabo, B.; Vagovits, B.; Madarasz, E.			Astroglia-derived retinoic acid is a key factor in glia-induced neurogenesis	FASEB JOURNAL			English	Article						RA; astrocyte; stem cell; neuronal differentiation	EMBRYONIC STEM-CELLS; ADULT; ASTROCYTES; BRAIN; DIFFERENTIATION; EXPRESSION; INDUCTION; MICE; PROLIFERATION; SURVIVAL	Astroglial cells are essential components of the neurogenic niches within the central nervous system. Emerging evidence suggests that they are among the key regulators of postnatal neurogenesis. Although astrocytes have been demonstrated to possess the potential to instruct stem cells to adopt a neuronal fate, little is known about the nature of the glia-derived instructive signals. Here we propose that all-trans retinoic acid, one of the most powerful morphogenic molecules regulating neuronal cell fate commitment, may be one of the glia-derived factors directing astroglia-induced neurogenesis. According to data obtained from several complementary approaches, we show that cultured astrocytes express the key enzyme mRNAs of retinoic acid biosynthesis and actively produce all-trans retinoic acid. We show that blockage of retinoic acid signaling by the pan-RAR antagonist AGN193109 prevents glia-induced neuron formation by noncommitted stem cells. Therefore, we provide strong in vitro evidence for retinoic acid action in astroglia-induced neuronal differentiation.	Hungarian Acad Sci, Lab Cellular & Dev Neurobiol, Inst Expt Med, H-1083 Budapest, Hungary; Agr Biotechnol Ctr, Godollo, Hungary; Univ Debrecen, Dept Biochem & Mol Biol, Debrecen, Hungary; Eotvos Lorand Univ, Dept Biol Phys, Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Debrecen; Eotvos Lorand University	Kornyei, Z (corresponding author), Hungarian Acad Sci, Lab Cellular & Dev Neurobiol, Inst Expt Med, H-1083 Budapest, Hungary.	kornyei@koki.hu	Gocza, Elen/C-9883-2014; Gocza, Elen/A-8838-2012	Gocza, Elen/0000-0001-7720-4720; Gocza, Elen/0000-0001-7720-4720				ALOISI F, 1994, J IMMUNOL, V152, P5022; Aouadi M, 2006, STEM CELLS, V24, P1399, DOI 10.1634/stemcells.2005-0398; Asson-Batres MA, 2006, J COMP NEUROL, V496, P149, DOI 10.1002/cne.20904; Castelo-Branco GA, 2006, MOL CELL NEUROSCI, V31, P251, DOI 10.1016/j.mcn.2005.09.014; Cedazo-Minguez A, 2001, NEUROSCIENCE, V105, P651, DOI 10.1016/S0306-4522(01)00224-X; Chadashvili T, 2006, J COMP NEUROL, V498, P1, DOI 10.1002/cne.21009; Chattopadhyay N, 2001, MOL BRAIN RES, V92, P172, DOI 10.1016/S0169-328X(01)00155-3; Chen Y, 2005, EXP NEUROL, V196, P87, DOI 10.1016/j.expneurol.2005.07.010; Choi WH, 2005, BIOCHEM BIOPH RES CO, V329, P125, DOI 10.1016/j.bbrc.2005.01.110; Crandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101; Demeter K, 2004, EXP NEUROL, V188, P254, DOI 10.1016/j.expneurol.2004.04.011; Denisenko-Nehrbass NI, 2000, NEURON, V27, P359, DOI 10.1016/S0896-6273(00)00043-X; ESFANDIARI A, 1994, GLIA, V11, P255, DOI 10.1002/glia.440110306; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hall AC, 2003, GLIA, V43, P47, DOI 10.1002/glia.10229; Haskell GT, 2005, J NEUROSCI, V25, P7636, DOI 10.1523/JNEUROSCI.0485-05.2005; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Keegan BR, 2005, SCIENCE, V307, P247, DOI 10.1126/science.1101573; Kornyei Z, 2005, GLIA, V49, P430, DOI 10.1002/glia.20123; Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Luo TL, 2004, J COMP NEUROL, V470, P297, DOI 10.1002/cne.20013; Ma DK, 2005, CURR OPIN NEUROBIOL, V15, P514, DOI 10.1016/j.conb.2005.08.003; McCaffery P, 2006, J NEUROBIOL, V66, P780, DOI 10.1002/neu.20237; McCaffery P, 2004, DEV BRAIN RES, V153, P233, DOI 10.1016/j.devbrainres.2004.09.003; Mey J, 2004, NEUROSCIENTIST, V10, P409, DOI 10.1177/1073858404263520; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A, 2003, MANIPULATING MOUSE E, P453; Nakayama T, 2003, NEUROSCI RES, V46, P241, DOI 10.1016/S0168-0102(03)00063-4; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Nolte C, 2001, GLIA, V33, P72; Romand R, 2006, J COMP NEUROL, V496, P643, DOI 10.1002/cne.20936; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Ruhl R, 2006, RAPID COMMUN MASS SP, V20, P2497, DOI 10.1002/rcm.2621; Schlett K, 2000, J NEUROSCI RES, V60, P184; Schlett K, 1997, J NEUROSCI RES, V47, P405; Schmidt CK, 2003, ANAL BIOCHEM, V315, P36, DOI 10.1016/S0003-2697(02)00662-0; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sonneveld E, 1999, EXP CELL RES, V250, P284, DOI 10.1006/excr.1999.4513; Tarnok K, 2002, EUR J CELL BIOL, V81, P403, DOI 10.1078/0171-9335-00262; Ueki T, 2003, J NEUROSCI, V23, P11732; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wang TW, 2005, DEVELOPMENT, V132, P2721, DOI 10.1242/dev.01867; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; WUARIN L, 1990, INT J DEV NEUROSCI, V8, P317, DOI 10.1016/0736-5748(90)90038-4	50	54	56	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2496	2509		10.1096/fj.06-7756com	http://dx.doi.org/10.1096/fj.06-7756com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17438145				2022-12-25	WOS:000248454400024
J	Drosatos, K; Sanoudou, D; Kypreos, KE; Kardassis, D; Zannis, VI				Drosatos, Konstantinos; Sanoudou, Despina; Kypreos, Kyriakos E.; Kardassis, Dimitris; Zannis, Vassilis I.			A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; LOW-DENSITY-LIPOPROTEIN; NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASES; CARBOXY-TERMINAL DOMAIN; APOLIPOPROTEIN-E; DNA-BINDING; IN-VIVO; V-JUN; 3T3-L1 PREADIPOCYTES	c-Jun is a transcription factor activated by phosphorylation by the stress-activated protein kinase/c-Jun N-terminal kinase pathway in response to extracellular signals and cytokines. We show that adenovirus-mediated gene transfer of the dominant negative form of c-Jun (dn-c-Jun)in C57BL/6 mice increased greatly apoE hepatic mRNA and plasma levels, increased plasma cholesterol, triglyceride, and very low density lipoprotein levels, and resulted in the accumulation of discoidal high density lipoprotein particles. A similar but more severe phenotype was generated by overexpression of the mouse apoE in C57BL/6 mice, suggesting that dyslipidemia induced by dn-c-Jun was the result of apoE overexpression. Unexpectedly, infection of apoE(-/-) mice with adenovirus expressing dn-c-Jun reduced plasma cholesterol by 70%, suggesting that dn-c-Jun affected other genes that control plasma cholesterol levels. To identify these genes, we performed whole genome expression analysis (34,000 genes) of isolated livers from two groups of five apoE(-/-) mice, infected with adenoviruses expressing either the dn-c-Jun or the green fluorescence protein. Bioinformatic analysis and Northern blotting validation revealed that dn-c-Jun increased 40-fold the apoE mRNA and reduced by 70% the Scd-1 (stearoyl-CoA-desaturase 1) mRNA. The involvement of Scd-1 in lowering plasma cholesterol was confirmed by restoration of high cholesterol levels of apoE(-/-) mice following coinfection with adenoviruses expressing dn-c-Jun and Scd-1. In conclusion, dn-c-Jun appears to trigger two opposing events in mice that affect plasma cholesterol and triglyceride levels as follows: one results in apoE overexpression and triggers dyslipidemia and the other results in inhibition of Scd-1 and offsets dyslipidemia.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece; Acad Athens, Fdn Biomed Res, Ctr Basic Res, Div Mol Biol, GR-11527 Athens, Greece; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Dept Biochem, Boston, MA 02118 USA	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Academy of Athens; Boston University; Boston University	Zannis, VI (corresponding author), 700 Albany St,W509, Boston, MA 02118 USA.	vzannis@bu.edu	KYPREOS, KYRIAKOS/AAN-4485-2020; Drosatos, Konstantinos/H-9153-2013; Kypreos, Kyriakos/AAG-1745-2020; Sanoudou, Despina/AAD-8139-2019	Drosatos, Konstantinos/0000-0003-0903-834X; Kypreos, Kyriakos/0000-0001-6784-2710; Sanoudou, Despina/0000-0003-3704-1941; Zannis, Vassilis/0000-0002-1295-7155	NHLBI NIH HHS [R01 HL068216, R01 HL033952, HL33952, R01 HL048739, HL48739, R01 HL068216-05A1, R01 HL048739-11] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068216, R01HL033952, R01HL048739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Beers A, 2006, BIOCHEMISTRY-US, V45, P2408, DOI 10.1021/bi0518040; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P316, DOI 10.1016/0005-2760(89)90116-1; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Chang YS, 2005, J LIPID RES, V46, P2624, DOI 10.1194/jlr.M500154-JLR200; De Cesaris P, 1999, J BIOL CHEM, V274, P28978, DOI 10.1074/jbc.274.41.28978; Dewberry R, 2000, ARTERIOSCL THROM VAS, V20, P2394, DOI 10.1161/01.ATV.20.11.2394; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; HIRAI SI, 1990, ONCOGENE, V5, P39; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ioroi T, 2003, J PHARMACOL SCI, V91, P145; Isoda K, 2004, ARTERIOSCL THROM VAS, V24, P1068, DOI 10.1161/01.ATV.0000127025.48140.a3; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kypreos KE, 2005, J BIOL CHEM, V280, P6276, DOI 10.1074/jbc.M413458200; Kypreos KE, 2003, BIOCHEMISTRY-US, V42, P9841, DOI 10.1021/bi0271796; Kypreos KE, 2001, BIOCHEMISTRY-US, V40, P6027, DOI 10.1021/bi002414a; Kypreos KE, 2001, FASEB J, V15, P1598, DOI 10.1096/fj.00-0882fje; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Li XP, 2003, BIOCHEMISTRY-US, V42, P10406, DOI 10.1021/bi027093c; Marculescu R, 2002, DIABETES, V51, P3582, DOI 10.2337/diabetes.51.12.3582; Merhi-Soussi F, 2005, CARDIOVASC RES, V66, P583, DOI 10.1016/j.cardiores.2005.01.008; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Miller YI, 2005, ARTERIOSCL THROM VAS, V25, P1213, DOI 10.1161/01.ATV.0000159891.73193.31; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Murphy N, 2002, ATHEROSCLEROSIS, V163, P69, DOI 10.1016/S0021-9150(01)00755-9; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Ricci R, 2004, SCIENCE, V306, P1558, DOI 10.1126/science.1101909; Sanoudou D, 2005, PHYSIOL GENOMICS, V21, P131, DOI 10.1152/physiolgenomics.00259.2004; Sanoudou D, 2003, P NATL ACAD SCI USA, V100, P4666, DOI 10.1073/pnas.0330960100; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Singh NN, 2006, ARTERIOSCL THROM VAS, V26, P1323, DOI 10.1161/01.ATV.0000220383.19192.55; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	66	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19556	19564		10.1074/jbc.M700986200	http://dx.doi.org/10.1074/jbc.M700986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17456467	hybrid, Green Accepted			2022-12-25	WOS:000247650600030
J	Murthy, N; Ollagnier-de-Choudens, S; Sanakis, Y; Abdel-Ghany, SE; Rousset, C; Ye, H; Fontecave, M; Pilon-Smits, EAH; Pilon, M				Murthy, Narayana; Ollagnier-de-Choudens, Sandrine; Sanakis, Yiannis; Abdel-Ghany, Salah E.; Rousset, Carine; Ye, Hong; Fontecave, Marc; Pilon-Smits, Elizabeth A. H.; Pilon, Marinus			Characterization of Arabidopsis thaliana SufE2 and SufE3 - Functions in chloroplast iron-sulfur cluster assembly and NAD synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; CYSTEINE DESULFURASE CPNIFS; ESCHERICHIA-COLI; SCAFFOLD PROTEIN; QUINOLINATE SYNTHETASE; AZOTOBACTER-VINELANDII; BIOGENESIS; FERREDOXIN; NIFS; BIOSYNTHESIS	In this study we characterize two novel chloroplast SufE- like proteins from Arabidopsis thaliana. Other SufE- like proteins, including the previously described A. thaliana CpSufE, participate in sulfur mobilization for Fe-S biosynthesis through activation of cysteine desulfurization by NifS-like proteins. In addition to CpSufE, the Arabidopsis genome encodes two other proteins with SufE domains, SufE2 and SufE3. SufE2 has plastid targeting information. Purified recombinant SufE2 could activate the cysteine desulfurase activity of CpNifS 40-fold. SufE2 expression was flower-specific and high in pollen; we therefore hypothesize that SufE2 has a specific function in pollen Fe-S cluster biosynthesis. SufE3, also a plastid targeted protein, was expressed at low levels in all major plant organs. The mature SufE3 contains two domains, one SufE- like and one with similarity to the bacterial quinolinate synthase, NadA. Indeed SufE3 displayed both SufE activity (stimulating CpNifS cysteine desulfurase activity 70-fold) and quinolinate synthase activity. The full-length protein was shown to carry a highly oxygen-sensitive (4Fe-4S) cluster at its NadA domain, which could be reconstituted by its own SufE domain in the presence of CpNifS, cysteine and ferrous iron. Knock-out of SufE3 in Arabidopsis is embryo-lethal. We conclude that SufE3 is the NadA enzyme of A. thaliana, involved in a critical step during NAD biosynthesis.	Colorado State Univ, Program Mol Plant Biol, Dept Biol, Ft Collins, CO 80523 USA; CNRS, Inst Rech Technol & Sci Vivant, CEA, UMR UJF 5249, F-38054 Grenoble, France; CNRS, Inst Rech Technol & Sci Vivant, Lab Chim & Biol Metaux, F-38054 Grenoble, France; NCSR Demokritos, Inst Mat Sci, Athens, Greece	Colorado State University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); National Centre of Scientific Research "Demokritos"	Pilon, M (corresponding author), Colorado State Univ, Program Mol Plant Biol, Dept Biol, Ft Collins, CO 80523 USA.	pilon@lamar.colostate.edu	Pilon-Smits, Elizabeth/AAN-4117-2020	Pilon-Smits, Elizabeth/0000-0003-1205-8798; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Abdel-Ghany SE, 2005, PLANT PHYSIOL, V138, P161, DOI 10.1104/pp.104.058602; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cicchillo RM, 2005, J AM CHEM SOC, V127, P7310, DOI 10.1021/ja051369x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Huynen MA, 2005, FEBS LETT, V579, P591, DOI 10.1016/j.febslet.2004.11.111; Johnson DC, 2005, BIOCHEM SOC T, V33, P90, DOI 10.1042/BST0330090; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Katoh A, 2006, PLANT PHYSIOL, V141, P851, DOI 10.1104/pp.106.081091; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; LEMAIR ESD, 2005, PHOTOSYNTH RES, V79, P305; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; NASU S, 1982, J BIOL CHEM, V257, P626; Ollagnier-de Choudens S, 2005, FEBS LETT, V579, P3737, DOI 10.1016/j.febslet.2005.05.065; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Pilon-Smits EAH, 2002, PLANT PHYSIOL, V130, P1309, DOI [10.1104/pp.102.010280, 10.1104/pp.010280]; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; SUZUKI S, 1991, PLANT PHYSIOL, V97, P375, DOI 10.1104/pp.97.1.375; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; Touraine B, 2004, PLANT J, V40, P101, DOI 10.1111/j.1365-313X.2004.02189.x; Van Hoewyk D, 2007, P NATL ACAD SCI USA, V104, P5686, DOI 10.1073/pnas.0700774104; WISE RR, 2005, STRUCTURE FUNCTION P, P3; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Xu XM, 2006, EMBO J, V25, P900, DOI 10.1038/sj.emboj.7600968; Xu XM, 2005, J BIOL CHEM, V280, P6648, DOI 10.1074/jbc.M413082200; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Yabe T, 2006, BIOCHEM BIOPH RES CO, V340, P1047, DOI 10.1016/j.bbrc.2005.12.104; Yabe T, 2004, PLANT CELL, V16, P993, DOI 10.1105/tpc.020511; Ye H, 2006, J BIOL CHEM, V281, P8958, DOI 10.1074/jbc.M512737200; Ye H, 2005, PLANTA, V220, P602, DOI 10.1007/s00425-004-1388-1; Ye H, 2006, NEW PHYTOL, V171, P285, DOI 10.1111/j.1469-8137.2006.01751.x; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	57	60	64	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18254	18264		10.1074/jbc.M701428200	http://dx.doi.org/10.1074/jbc.M701428200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452319	hybrid			2022-12-25	WOS:000247302000032
J	Nagae, M; Tsuchiya, A; Katayama, T; Yamamoto, K; Wakatsuki, S; Kato, R				Nagae, Masamichi; Tsuchiya, Atsuko; Katayama, Takane; Yamamoto, Kenji; Wakatsuki, Soichi; Kato, Ryuichi			Structural basis of the catalytic reaction mechanism of novel 1,2-alpha-L-fucosidase from Bifidobacterium bifidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-L-FUCOSIDASE; SUBSTRATE-ASSISTED CATALYSIS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; INSIGHTS; ADHESION; GLYCOSIDASES; COMPLEX; ENZYME; PHOSPHORYLASE	1,2-alpha-L-Fucosidase (AfcA), which hydrolyzes the glycosidic linkage of Fuc alpha 1-2Gal via an inverting mechanism, was recently isolated from Bifidobacterium bifidum and classified as the first member of the novel glycoside hydrolase family 95. To better understand the molecular mechanism of this enzyme, we determined the x-ray crystal structures of the AfcA catalytic (Fuc) domain in unliganded and complexed forms with deoxyfuconojirimycin ( inhibitor), 2'-fucosyllactose ( substrate), and L-fucose and lactose ( products) at 1.12 - 2.10 angstrom resolution. The AfcA Fuc domain is composed of four regions, an N-terminal beta region, a helical linker, an (alpha/alpha)(6) helical barrel domain, and a C-terminal beta region, and this arrangement is similar to bacterial phosphorylases. In the complex structures, the ligands were buried in the central cavity of the helical barrel domain. Structural analyses in combination with mutational experiments revealed that the highly conserved Glu(566) probably acts as a general acid catalyst. However, no carboxylic acid residue is found at the appropriate position for a general base catalyst. Instead, a water molecule stabilized by Asn(423) in the substrate-bound complex is suitably located to perform a nucleophilic attack on the C1 atom of L-fucose moiety in 2'-fucosyllactose, and its location is nearly identical near the O1 atom of beta-L-fucose in the products-bound complex. Based on these data, we propose and discuss a novel catalytic reaction mechanism of AfcA.	Photon Factory, Struct Biol Res Ctr, Inst Mat Struct Sci, High Energy Accelerator Res Org, Tsukuba, Ibaraki 305, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrat Life Sci, Sakyo Ku, Kyoto 606, Japan; Ishikawa Prefectural Univ, Res Inst Bioresources & Biotechnol, Nonoichi, Ishikawa 921, Japan	High Energy Accelerator Research Organization (KEK); Kyoto University; Ishikawa Prefecture University	Kato, R (corresponding author), Photon Factory, Struct Biol Res Ctr, Inst Mat Struct Sci, High Energy Accelerator Res Org, Tsukuba, Ibaraki 305, Japan.	ryuichi.kato@kek.jp		Katayama, Takane/0000-0003-4009-7874; Wakatsuki, Soichi/0000-0001-5896-7968; Nagae, Masamichi/0000-0002-5470-3807; Kato, Ryuichi/0000-0003-2087-2896				AbdelAleem H, 1996, INT J GYNECOL OBSTET, V55, P273, DOI 10.1016/S0020-7292(96)02770-1; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERNET MF, 1993, APPL ENVIRON MICROB, V59, P4121, DOI 10.1128/AEM.59.12.4121-4128.1993; Brameld KA, 1998, J AM CHEM SOC, V120, P3571, DOI 10.1021/ja972282h; COHENFORD MA, 1989, ANAL BIOCHEM, V177, P172, DOI 10.1016/0003-2697(89)90035-3; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; Femia AP, 2002, CARCINOGENESIS, V23, P1953, DOI 10.1093/carcin/23.11.1953; Fernandez-Rodriguez J, 2000, CANCER DETECT PREV, V24, P143; FLEET GWJ, 1985, J CHEM SOC CHEM COMM, P841, DOI 10.1039/c39850000841; FUKUDA M, 1995, BIOORGAN MED CHEM, V3, P207, DOI 10.1016/0968-0896(95)00014-8; GIBSON GR, 1994, J APPL BACTERIOL, V77, P412, DOI 10.1111/j.1365-2672.1994.tb03443.x; Guimaraes BG, 2002, J MOL BIOL, V320, P587, DOI 10.1016/S0022-2836(02)00497-7; Heikinheimo P, 2003, J MOL BIOL, V327, P631, DOI 10.1016/S0022-2836(03)00172-4; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Hidaka M, 2004, STRUCTURE, V12, P937, DOI 10.1016/j.str.2004.03.027; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; HOSKINS LC, 1985, J CLIN INVEST, V75, P944, DOI 10.1172/JCI111795; Hosono J, 1998, J SURG ONCOL, V67, P77, DOI 10.1002/(SICI)1096-9098(199802)67:2<77::AID-JSO2>3.0.CO;2-I; Ishizuka H, 1999, INTERNAL MED, V38, P927, DOI 10.2169/internalmedicine.38.927; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Katayama T, 2005, J BIOSCI BIOENG, V99, P457, DOI 10.1263/jbb.99.457; Katayama T, 2004, J BACTERIOL, V186, P4885, DOI 10.1128/JB.186.15.4885-4893.2004; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LARSON G, 1988, J BIOL CHEM, V263, P10790; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Macauley MS, 2005, J BIOL CHEM, V280, P25313, DOI 10.1074/jbc.M413819200; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizuno M, 2004, J BIOL CHEM, V279, P10575, DOI 10.1074/jbc.M310771200; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Ouwehand A., 2002, European Journal of Nutrition, V41; Parsiegla G, 2000, BIOCHEMISTRY-US, V39, P11238, DOI 10.1021/bi001139p; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; Rapoport E, 1999, GLYCOBIOLOGY, V9, P1337, DOI 10.1093/glycob/9.12.1337; Roujeinikova A, 2001, J MOL BIOL, V312, P119, DOI 10.1006/jmbi.2001.4944; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; SINCOTT ML, 1990, CHEM REV, V90, P1171; Song JF, 2002, ANAL BIOCHEM, V304, P126, DOI 10.1006/abio.2001.5589; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stam MR, 2005, CARBOHYD RES, V340, P2728, DOI 10.1016/j.carres.2005.09.018; Sulzenbacher G, 2004, J BIOL CHEM, V279, P13119, DOI 10.1074/jbc.M313783200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Varrot A, 2003, CHEM COMMUN, P946, DOI 10.1039/b301592k; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	62	92	93	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18497	18509		10.1074/jbc.M702246200	http://dx.doi.org/10.1074/jbc.M702246200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17459873	hybrid			2022-12-25	WOS:000247302000055
J	Crepaldi, L; Lackner, C; Corti, C; Ferraguti, F				Crepaldi, Luca; Lackner, Carmen; Corti, Corrado; Ferraguti, Francesco			Transcriptional activators and repressors for the neuron-specific expression of a metabotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; D-ASPARTATE RECEPTORS; MICE LACKING MGLUR1; NERVE GROWTH-FACTOR; SPLICE VARIANTS; MESSENGER-RNA; FACTOR-I; DIFFERENTIAL DISTRIBUTION; FUNCTIONAL-ANALYSIS; RAT	Metabotropic glutamate receptor 1 (mGlu1) has a discrete distribution in the central nervous system restricted to neurons. Its expression undergoes important changes during development and in response to physiological and pathological modifications. Here, we have determined the structure of the mGlu1 gene and demonstrated that mGlu1 transcription takes places at alternative first exons. Moreover, we have identified active promoter regions upstream from the two most expressed first exons by means of luciferase reporter gene assays performed in primary cerebellar granule neurons. Targeted mutations of active elements constituting the core promoter and electrophoretic mobility shift assays demonstrated that the factors thyroid transcription factor-1 and CCAAT/enhancer-binding proteins beta act synergistically to promote mGlu1 transcription. We have also elucidated the molecular bases for the neuron-specific expression of mGlu1 identifying a neural restrictive silencing element and a regulatory factor for X box element, which suppressed mGlu1 expression in nonneuronal cells. These results reveal the molecular bases for cell-and context-specific expression of an important glutamate receptor critically involved in synaptogenesis, neuronal differentiation, synaptic transmission, and plasticity.	Innsburck Med Univ, Dept Pharmacol, A-6020 Innsbruck, Austria; GlaxoSmithKline Med Res Ctr, Dept Psychiat, I-37135 Verona, Italy; GlaxoSmithKline Med Res Ctr, Biol Ctr Excellence Drug Discovery, I-37135 Verona, Italy	Medical University of Innsbruck; GlaxoSmithKline; GlaxoSmithKline	Ferraguti, F (corresponding author), Innsburck Med Univ, Dept Pharmacol, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	francesco.ferraguti@i-med.ac.at		Corti, Corrado/0000-0002-7876-9114; Ferraguti, Francesco/0000-0002-3843-5857				ARONICA E, 1993, MOL PHARMACOL, V44, P981; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Berthele A, 1998, NEUROSCIENCE, V85, P733, DOI 10.1016/S0306-4522(97)00670-2; BESSHO Y, 1993, J NEUROCHEM, V60, P253, DOI 10.1111/j.1471-4159.1993.tb05845.x; Bingle CD, 1997, INT J BIOCHEM CELL B, V29, P1471, DOI 10.1016/S1357-2725(97)00007-1; Borges K, 2001, J BIOL CHEM, V276, P25929, DOI 10.1074/jbc.M009105200; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Chew LJ, 2001, J BIOL CHEM, V276, P42162, DOI 10.1074/jbc.M101895200; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Corti C, 2003, J BIOL CHEM, V278, P33105, DOI 10.1074/jbc.M212380200; Corti C, 2001, BIOCHEM BIOPH RES CO, V286, P381, DOI 10.1006/bbrc.2001.5391; Ferraguti F, 2004, HIPPOCAMPUS, V14, P193, DOI 10.1002/hipo.10163; Ferraguti F, 1998, J COMP NEUROL, V400, P391; Ferraguti F, 2006, CELL TISSUE RES, V326, P483, DOI 10.1007/s00441-006-0266-5; Gill SS, 1999, BRAIN RES BULL, V48, P143, DOI 10.1016/S0361-9230(98)00154-3; Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200; Kane MD, 1998, NEUROSCI LETT, V252, P1, DOI 10.1016/S0304-3940(98)00484-4; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; KURAMOTO T, 1994, GENOMICS, V19, P358, DOI 10.1006/geno.1994.1069; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Laurie DJ, 1996, EUR J PHARMACOL, V296, pR1, DOI 10.1016/0014-2999(95)00868-3; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu AG, 2003, J BIOL CHEM, V278, P26423, DOI 10.1074/jbc.M211165200; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Ma KW, 2006, J BIOL CHEM, V281, P21250, DOI 10.1074/jbc.M600521200; Marin YE, 2004, J MOL MED, V82, P735, DOI 10.1007/s00109-004-0566-8; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakayama A, 2003, J BIOL CHEM, V278, P233, DOI 10.1074/jbc.M209574200; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Ovcharenko I, 2005, GENOME RES, V15, P184, DOI 10.1101/gr.3007205; Reynolds PR, 2005, J BIOL CHEM, V280, P32548, DOI 10.1074/jbc.M502231200; Rich A, 2003, NAT REV GENET, V4, P566, DOI 10.1038/nrg1115; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stadler F, 2005, J NEUROCHEM, V94, P324, DOI 10.1111/j.1471-4159.2005.03190.x; Stephan D, 1996, NEUROPHARMACOLOGY, V35, P1649, DOI 10.1016/S0028-3908(96)00108-6; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Suzuki K, 1998, ENDOCRINOLOGY, V139, P3014, DOI 10.1210/en.139.6.3014; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Toshiyuki N, 2004, MOL BRAIN RES, V125, P47, DOI 10.1016/j.molbrainres.2004.03.017; TRENCKNER E, 1991, CULTURING NERVE CELL; WANG K, 1995, J VIROL, V69, P2873, DOI 10.1128/JVI.69.5.2873-2880.1995; Werner T, 2003, FASEB J, V17, P1228, DOI 10.1096/fj.02-0955rev; Zhu H, 1999, MOL BRAIN RES, V73, P93, DOI 10.1016/S0169-328X(99)00239-9	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17877	17889		10.1074/jbc.M700149200	http://dx.doi.org/10.1074/jbc.M700149200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430891	hybrid			2022-12-25	WOS:000247084500061
J	Gold, VAM; Robson, A; Clarke, AR; Collinson, I				Gold, Vicki A. M.; Robson, Alice; Clarke, Anthony R.; Collinson, Ian			Allosteric regulation of SecA - Magnesium-mediated control of conformation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN TRANSLOCATION; BACILLUS-SUBTILIS SECA; COLI PLASMA-MEMBRANE; ATP-BINDING-SITE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; DIMERIC SECA; PREPROTEIN TRANSLOCATION; ACIDIC PHOSPHOLIPIDS; CONDUCTING CHANNEL	In bacteria, the SecA protein associates with a ubiquitous protein channel SecYEG where it drives the post-translational secretion of pre-proteins across the plasma membrane. The high-resolution structures of both proteins have been determined in their resting states; however, the mechanism that couples ATP hydrolysis to active transport of substrate proteins through the membrane is not well understood. An analysis of the steady-state ATPase activity of the enzyme reveals that there is an allosteric binding site for magnesium distinct from that associated with hydrolysis of ATP. We have demonstrated that this regulation involves a large conformational change to the SecA dimer, which exerts a strong influence on the turnover and affinity for ATP, as well as the affinity for ADP. The strong inhibitory influence of magnesium on the ATPase activity can be countered by cardiolipin and conditions that promote protein translocation.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Collinson, I (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	ian.collinson@bristol.ac.uk		Gold, Vicki/0000-0002-6908-0745; Collinson, Ian/0000-0002-3931-0503; Robson, Alice/0000-0003-3338-2626	Biotechnology and Biological Sciences Research Council [BB/C503538/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BRENZA JM, 1985, BIOCHEM PHARMACOL, V34, P4291, DOI 10.1016/0006-2952(85)90287-4; BREUKINK E, 1993, FEBS LETT, V331, P19, DOI 10.1016/0014-5793(93)80289-7; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DEMELER B, 2005, COMPREHENSIVE DATA A, P210; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Fak JJ, 2004, BIOCHEMISTRY-US, V43, P7307, DOI 10.1021/BI0357208; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Froschauer EM, 2004, FEMS MICROBIOL LETT, V237, P49, DOI 10.1016/j.femsle.2004.06.013; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2006, J BACTERIOL, V188, P335, DOI 10.1128/JB.188.1.335-338.2006; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; Papanikolau Y, 2007, J MOL BIOL, V366, P1545, DOI 10.1016/j.jmb.2006.12.049; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Smith MA, 2005, J BACTERIOL, V187, P6454, DOI 10.1128/JB.187.18.6454-6465.2005; SQUIRE PG, 1979, ARCH BIOCHEM BIOPHYS, V196, P165, DOI 10.1016/0003-9861(79)90563-0; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; Tomkiewicz D, 2006, J BIOL CHEM, V281, P15709, DOI 10.1074/jbc.M600205200; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; Vassylyev DG, 2006, J MOL BIOL, V364, P248, DOI 10.1016/j.jmb.2006.09.061; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Zimmer J, 2006, J MOL BIOL, V364, P259, DOI 10.1016/j.jmb.2006.08.044	47	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17424	17432		10.1074/jbc.M702066200	http://dx.doi.org/10.1074/jbc.M702066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17416585	hybrid			2022-12-25	WOS:000247084500012
J	Li, H; Yao, J; Tong, XT; Guo, ZH; Wu, Y; Sun, L; Pan, N; Wu, HM; Xu, T; Ding, JP				Li, Hui; Yao, Jing; Tong, Xiaotian; Guo, Zhaohua; Wu, Ying; Sun, Liang; Pan, Na; Wu, Houming; Xu, Tao; Ding, Jiuping			Interaction sites between the Slo1 pore and the NH2 terminus of the beta(2) subunit, probed with a three-residue sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SHAKER K-CHANNELS; BK CHANNELS; INACTIVATION GATE; AUXILIARY SUBUNIT; CRYSTAL-STRUCTURE; CHROMAFFIN CELLS; MOLECULAR-BASIS; VOLTAGE; CA2+	Calcium- and voltage-gated (BK) K+ channels encoded by Slo1 play an essential role in nervous systems. Although it shares many common features with voltage-dependent KV channels, the BK channel exhibits differences in gating and inactivation. Using a mutant in which FWI replaces three residues (FIW) in the NH2 terminus of wild-type beta 2-subunits, in conjunction with alanine-scanning mutagenesis of the Slo1 S6 segment, we identify that the NH2 terminus of beta 2-subunits interacts with the residues near the cytosolic superficial mouth of BK channels during inactivation. The cytosolic blockers did not share the sites with NH2 terminus of beta 2-subunits. A novel blocking-inactivating scheme was proposed to account for the observed noncompetition inactivation. Our results also suggest that the residue Ile-323 plays a dual role in interacting with the NH2 terminus of beta 2-subunits and modulating the gating of BK channels.	Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS	Xu, T (corresponding author), Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China.	xutao@ibp.ac.cn; jpding@mail.hust.edu.cn	Xu, Tao/G-5474-2010; Sun, Liang/D-4857-2018	Yao, Jing/0000-0003-1844-3988; Sun, Liang/0000-0002-7817-5121				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Benzinger GR, 2006, J GEN PHYSIOL, V127, P119, DOI 10.1085/jgp.200509425; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; Li WY, 2004, J GEN PHYSIOL, V124, P43, DOI 10.1085/jgp.200409067; Lingle C J, 1996, Ion Channels, V4, P261; Lingle CJ, 2001, J GEN PHYSIOL, V117, P583, DOI 10.1085/jgp.117.6.583; Lippiat JD, 2000, J PHYSIOL-LONDON, V529, P131, DOI 10.1111/j.1469-7793.2000.00131.x; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SAKMANN B, 1995, SINGLE CHANNEL RECOR, P408; Solaro CR, 1997, BIOPHYS J, V73, P819, DOI 10.1016/S0006-3495(97)78114-1; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Xia XM, 2003, J GEN PHYSIOL, V121, P125, DOI 10.1085/jgp.20028667; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xia XM, 2000, J NEUROSCI, V20, P4890; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	34	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17720	17728		10.1074/jbc.M607063200	http://dx.doi.org/10.1074/jbc.M607063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430898	hybrid			2022-12-25	WOS:000247084500045
J	Mori, H; Shukunami, C; Furuyama, A; Notsu, H; Nishizaki, Y; Hiraki, Y				Mori, Hajime; Shukunami, Chisa; Furuyama, Akiko; Notsu, Hiroyuki; Nishizaki, Yuriko; Hiraki, Yuji			Immobilization of bioactive fibroblast growth factor-2 into cubic proteinous microcrystals (Bombyx mori cypovirus polyhedra) that are insoluble in a physiological cellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROGENIC DIFFERENTIATION; HEPARIN; FGF; EXPRESSION; BINDING	The supramolecular architecture of the extracellular matrix and the disposition of its specific accessory molecules give rise to variable heterotopic signaling cues for single cells. Here we have described the successful occlusion of human fibroblast growth factor-2 (FGF-2) into the cubic inclusion bodies (FGF-2 polyhedra) of the Bombyx mori cytoplasmic polyhedrosis virus (BmCPV). The polyhedra are proteinous cubic crystals of several microns in size that are insoluble in the extracellular milieu. Purified FGF-2 polyhedra were found to stimulate proliferation and phosphorylation of p44/p42 mitogen-activated protein kinase in cultured fibroblasts. Moreover, cellular responses were blocked by a synthetic inhibitor of the FGF signaling pathway, SU5402, suggesting that FGF-2 polyhedra indeed act through FGF receptors. Furthermore, FGF-2 polyhedra retained potent growth stimulatory properties even after desiccation. We have demonstrated that BmCPV polyhedra microcrystals that occlude extracellular signaling proteins are a novel and versatile tool that can be employed to analyze cellular behavior at the single cell level.	Kyoto Univ, Dept Cellular Differences, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Inst Technol, Insect Biomed Res Ctr, Sakyo Ku, Kyoto 6068585, Japan; Prot Crystal Corp, Chuo Ku, Osaka 5410053, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Kyoto Institute of Technology; Japan Science & Technology Agency (JST)	Hiraki, Y (corresponding author), Kyoto Univ, Dept Cellular Differences, Inst Frontier Med Sci, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hiraki@frontier.kyoto-u.ac.jp	Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761; Mori, Hajime/0000-0001-9219-6140				Belloncik S, 1998, VIRUSES, P337; Coulibaly F, 2007, NATURE, V446, P97, DOI 10.1038/nature05628; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Hosokawa Y, 2007, BIOMED MICRODEVICES, V9, P105, DOI 10.1007/s10544-006-9001-y; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Ikeda K, 2006, PROTEOMICS, V6, P54, DOI 10.1002/pmic.200500022; Ikeda K, 1998, ARCH VIROL, V143, P241, DOI 10.1007/s007050050283; Ikeda K, 2001, J VIROL, V75, P988, DOI 10.1128/JVI.75.2.988-995.2001; L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MORI H, 1993, J GEN VIROL, V74, P99, DOI 10.1099/0022-1317-74-1-99; Ramirez F, 2003, MATRIX BIOL, V22, P101, DOI 10.1016/S0945-053X(03)00002-7; ROHRMANN GF, 1986, J GEN VIROL, V67, P1499, DOI 10.1099/0022-1317-67-8-1499; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shimizu A, 2001, J BIOL CHEM, V276, P11031, DOI 10.1074/jbc.M003535200; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; VEMURI S, 1994, J PHARM PHARMACOL, V46, P481, DOI 10.1111/j.2042-7158.1994.tb03831.x	22	31	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17289	17296		10.1074/jbc.M608106200	http://dx.doi.org/10.1074/jbc.M608106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430896	hybrid			2022-12-25	WOS:000246946500062
J	Ricketts, LM; Dlugosz, M; Luther, KB; Haltiwanger, RS; Majerus, EM				Ricketts, Lindsay M.; Dlugosz, Malgosia; Luther, Kelvin B.; Haltiwanger, Robert S.; Majerus, Elaine M.			O-fucosylation is required for ADAMTS13 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOSPONDIN TYPE-1 REPEATS; VON-WILLEBRAND-FACTOR; GROWTH FACTOR-LIKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; HAMSTER OVARY CELLS; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; GDP-FUCOSE; MOLECULAR-CLONING; PROTEIN O-FUCOSYL-TRANSFERASE-1	ADAMTS13 is a plasma metalloproteinase that cleaves von Willebrand factor to smaller, less thrombogenic forms. Deficiency of ADAMTS13 activity in plasma leads to thrombotic thrombocytopenic purpura. ADAMTS13 contains eight thrombospondin type 1 repeats (TSR), seven of which contain a consensus sequence for the direct addition of fucose to the hydroxyl group of serine or threonine. Mass spectral analysis of tryptic peptides derived from human ADAMTS13 indicate that at least six of the TSRs are modified with an O-fucose disaccharide. Analysis of [H-3] fucose metabolically incorporated into ADAMTS13 demonstrated that the disaccharide has the structure glucose-beta 1,3-fucose. Mutation of the modified serine to alanine in TSR2, TSR5, TSR7, and TSR8 reduced the secretion of ADAMTS13. Mutation of more than one site dramatically reduced secretion regardless of the sites mutated. When the expression of protein O-fucosyltransferase 2 (POFUT2), the enzyme that transfers fucose to serines in TSRs, was reduced using siRNA, the secretion of ADAMTS13 decreased. A similar outcome was observed when ADAMTS13 was expressed in a cell line unable to synthesize the donor for fucose addition, GDP-fucose. Although overexpression of POFUT2 did not affect the secretion of wild-type ADAMTS13, it did increase the secretion of the ADAMTS13 TSR1,2 double mutant but not that of ADAMTS13 TSR1-8 mutant. Together these findings indicate that O-fucosylation is functionally significant for secretion of ADAMTS13.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Majerus, EM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.	emajerus@im.wustl.edu		Luther, Kelvin/0000-0001-9438-9675	NATIONAL CANCER INSTITUTE [R01CA123071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA123071-01A1, R01 CA123071] Funding Source: Medline; NIGMS NIH HHS [GM61126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; CHANEY W, 1986, J BIOL CHEM, V261, P551; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Imperiali B, 1999, CURR OPIN CHEM BIOL, V3, P643, DOI 10.1016/S1367-5931(99)00021-6; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; LIEBLER DC, 2002, INTRO PROTEOMICS TOO, P89; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morais VA, 2006, BBA-MOL BASIS DIS, V1762, P802, DOI 10.1016/j.bbadis.2006.06.018; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nita-Lazar A, 2006, METHOD ENZYMOL, V417, P93, DOI 10.1016/S0076-6879(06)17008-1; OConnor SE, 1996, CHEM BIOL, V3, P803, DOI 10.1016/S1074-5521(96)90064-2; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Purvis AR, 2004, J BIOL CHEM, V279, P49982, DOI 10.1074/jbc.M408727200; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200; Zhou WH, 2005, J BIOL CHEM, V280, P39934, DOI 10.1074/jbc.M504919200	52	81	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17014	17023		10.1074/jbc.M700317200	http://dx.doi.org/10.1074/jbc.M700317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17395589	hybrid			2022-12-25	WOS:000246946500034
J	Blobaum, AL; Marnett, LJ				Blobaum, Anna L.; Marnett, Lawrence J.			Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ARTHRITIS RESEARCH; RANDOMIZED CONTROLLED-TRIAL; COX-2; IBUPROFEN; NAPROXEN; TARGET	Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo. However, the molecular basis of its COX-2 inhibition has not been completely defined. Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2. The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme. Kinetic studies with lumiracoxib demonstrated that it was a time-dependent and slowly reversible inhibitor of human COX-2 that exhibited at least two binding steps during inhibition. Derivatives of lumiracoxib were synthesized with or without the methyl group on the phenylacetic acid ring and with various substitutions on the lower aniline ring. Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity. The chemical identity and position of the substituents on the lower aniline ring were important in determining the potency and extent of COX inhibition as well as COX-2 selectivity. Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs. Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency. Taken together with a recent crystal structure of a lumiracoxib-COX- 2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.	Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, 23rd Ave S Pierce, Nashville, TN 37232 USA.	larry.marnett@vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009582, F32CA119629, R01CA089450] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009582, CA09582, CA119629, CA89450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acemoglu M, 2004, TETRAHEDRON, V60, P11571, DOI 10.1016/j.tet.2004.09.064; BROOKS CD, 1999, Patent No. 5863946; CLARK K, 2004, AM CHEM SOC, P22; Esser R, 2005, BRIT J PHARMACOL, V144, P538, DOI 10.1038/sj.bjp.0706078; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lyseng-Williamson KA, 2004, DRUGS, V64, P2237, DOI 10.2165/00003495-200464190-00008; MOSER P, 1990, J MED CHEM, V33, P2358, DOI 10.1021/jm00171a008; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Prusakiewicz JJ, 2004, BIOCHEMISTRY-US, V43, P15439, DOI 10.1021/bi048534q; Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; Sorbera LA, 2002, DRUG FUTURE, V27, P740, DOI 10.1358/dof.2002.027.08.692497; Tannenbaum H, 2004, DRUGS, V64, P2247, DOI 10.2165/00003495-200464190-00010	16	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16379	16390		10.1074/jbc.M609883200	http://dx.doi.org/10.1074/jbc.M609883200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17434872	hybrid			2022-12-25	WOS:000246794300046
J	Mizuta, T; Shimizu, S; Matsuoka, Y; Nakagawa, T; Tsujimoto, Y				Mizuta, Takeshi; Shimizu, Shigeomi; Matsuoka, Yousuke; Nakagawa, Takashi; Tsujimoto, Yoshihide			A Bax/Bak-independent mechanism of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED NEURONAL DEATH; CELL-DEATH; SERINE-PROTEASE; ARACHIDONIC-ACID; APOPTOSIS; BAX; BCL-2; FAMILY; INHIBITORS	Bax and Bak are multidomain pro-apoptotic members of the Bcl- 2 family of proteins that regulate mitochondria-mediated apoptosis by direct modulation of mitochondrial membrane permeability. Since double-knock-out mouse embryonic fibroblasts with deficiency of Bax and Bak are resistant to multiple apoptotic stimuli, Bax and Bak are considered to be an essential gateway for various apoptotic signals. Here we showed that the combination of calcium ionophore A23187 and arachidonic acid induced cytochrome c release and caspase-dependent death of double-knock-out mouse embryonic fibroblasts, indicating that other mechanisms of cytochrome c release exist. Furthermore, A23187/arachidonic acid (ArA)induced caspase-dependent death was significantly suppressed by the treatment of several serine protease inhibitors including 4-(2-aminoethyl) benzenesulfonylfluoride and L-1-chloro- 3-(4-tosylamido)-4-phenyl-2-butanone but not the overexpression of anti-apoptotic Bcl- 2 family of proteins or the inhibition of mitochondrial membrane permeability transition. These results indicate that there are at least two mechanisms of cytochrome c release leading to caspase activation, a Bax/Bak-dependent mechanism and a Bax/Bak- independent, but serine protease(s)-dependent, mechanism.	Osaka Univ, Sch Med, Dept Med Genet, Lab Mol Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Solut Oritented Res Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Med Genet, Lab Mol Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Nakagawa, Takashi/F-3015-2010	Nakagawa, Takashi/0000-0001-5539-7605				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Brune B, 2003, CELL DEATH DIFFER, V10, P864, DOI 10.1038/sj.cdd.4401261; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; DILISA F, 1985, BIOCHEM BIOPH RES CO, V131, P968, DOI 10.1016/0006-291X(85)91334-8; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HAMEM R, 1998, CELL, V94, P339; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; MARKWARDT F, 1974, BIOCHEM PHARMACOL, V23, P2247, DOI 10.1016/0006-2952(74)90554-1; MATSUOKA Y, 1994, J CELL SCI, V107, P693; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pompeia C, 2003, CELL BIOCHEM FUNCT, V21, P97, DOI 10.1002/cbf.1012; Rideout HJ, 2001, NEUROSCIENCE, V107, P339, DOI 10.1016/S0306-4522(01)00322-0; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	28	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16623	16630		10.1074/jbc.M611060200	http://dx.doi.org/10.1074/jbc.M611060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17409097	hybrid			2022-12-25	WOS:000246794300068
J	Takagi, Y; Sindkar, S; Ekonomidis, D; Hall, MP; Ho, CK				Takagi, Yuko; Sindkar, Shalaka; Ekonomidis, Dimitra; Hall, Megan P.; Ho, C. Kiong			Trypanosoma brucei encodes a bifunctional capping enzyme essential for cap 4 formation on the spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE N-7 METHYLTRANSFERASE; INDUCIBLE EXPRESSION SYSTEM; CARBOXYL-TERMINAL DOMAIN; PRE-MESSENGER-RNA; POLYMERASE-II; VACCINIA VIRUS; ENCEPHALITOZOON-CUNICULI; 5'-CAPPING ENZYME; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; SACCHAROMYCES-CEREVISIAE	The 5' end of kinetoplastid mRNA possesses a hypermethylated cap 4 structure, which is derived from standard m7GpppN (cap 0) with additional methylations at seven sites within the first four nucleosides on the spliced leader RNA. In addition to TbCe1 guanylyltransferase and TbCmt1 (guanine N-7) methyltransferase, Trypanosoma brucei encodes a second cap 0 forming enzyme. TbCgm1 (T. brucei cap guanylyltransferase-methyltransferase) is a novel bifunctional capping enzyme consisting of an amino-terminal guanylyltransferase domain and a carboxyl-terminal methyltransferase domain. Recombinant TbCgm1 transfers the GMP to spliced leader RNA (SL RNA) via a covalent enzyme-GMP intermediate, and methylates the guanine N-7 position of the GpppN-terminated RNA to form cap 0 structure. The two domains can function autonomously in vitro. TbCGM1 is essential for parasite growth. Silencing of TbCGM1 by RNA interference increased the abundance of uncapped SL RNA and lead to accumulation of hypomethylated SL RNA. In contrast, silencing of TbCE1 and TbCMT1 did not affect parasite growth or SL RNA capping. We conclude that TbCgm1 specifically cap SL RNA, and cap 0 is a prerequisite for subsequent methylation events leading to the formation of mature SL RNA.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ho, CK (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.	kiongho@buffalo.edu	Takagi, Yuko/M-3283-2018; Ho, KIong/GPP-6051-2022	Takagi, Yuko/0000-0002-4567-0986; /0000-0002-7300-5027				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Arhin GK, 2006, MOL BIOCHEM PARASIT, V147, P137, DOI 10.1016/j.molbiopara.2006.01.011; Arhin GK, 2006, RNA, V12, P53, DOI 10.1261/rna.2223406; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Dong HP, 2007, J VIROL, V81, P4412, DOI 10.1128/JVI.02455-06; EVERS R, 1989, NUCLEIC ACIDS RES, V17, P3403, DOI 10.1093/nar/17.9.3403; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; GUNZL A, 1995, J BIOL CHEM, V270, P17287, DOI 10.1074/jbc.270.29.17287; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hall MP, 2006, NUCLEIC ACIDS RES, V34, P5594, DOI 10.1093/nar/gkl573; Hall MP, 2006, RNA, V12, P488, DOI 10.1261/rna.2250606; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; Hausmann S, 2005, J BIOL CHEM, V280, P12077, DOI 10.1074/jbc.M412063200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; Li HJ, 2005, MOL CELL BIOL, V25, P2216, DOI 10.1128/MCB.25.6.2216-2226.2005; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Lockless SW, 1998, BIOCHEMISTRY-US, V37, P8564, DOI 10.1021/bi980178m; Marchetti MA, 1998, NUCLEIC ACIDS RES, V26, P3591, DOI 10.1093/nar/26.15.3591; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; Ogino T, 2007, MOL CELL, V25, P85, DOI 10.1016/j.molcel.2006.11.013; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; SMITH JL, 1989, J BIOL CHEM, V264, P18091; Takagi T, 2003, J BIOL CHEM, V278, P14174, DOI 10.1074/jbc.M212101200; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zamudio JR, 2006, EUKARYOT CELL, V5, P905, DOI 10.1128/EC.00080-06; Zheng SS, 2006, J BIOL CHEM, V281, P35904, DOI 10.1074/jbc.M607292200	64	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15995	16005		10.1074/jbc.M701569200	http://dx.doi.org/10.1074/jbc.M701569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416901	hybrid			2022-12-25	WOS:000246794300008
J	Torgersen, ML; Walchli, S; Grimmer, S; Skanland, SS; Sandvig, K				Torgersen, Maria L.; Walchli, Sebastien; Grimmer, Stine; Skanland, Sigrid S.; Sandvig, Kirsten			Protein kinase C delta is activated by Shiga toxin and regulates its transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE TRANSPORT; GLOBOTRIAOSYL CERAMIDE; EARLY/RECYCLING ENDOSOMES; TYROSINE SULFATION; GOLGI-APPARATUS; B-SUBUNIT; ALPHA; CLATHRIN; BINDING; CELLS	Protein kinase C (PKC) isozymes regulate different vesicular trafficking steps in the recycling or degradative pathways. However, a possible role of these kinases in the retrograde pathway from endosomes to the Golgi complex has previously not been investigated. We report here the involvement of a specific PKC isozyme, PKC delta, in the intracellular transport of the glycolipid-binding Shiga toxin (Stx), which utilizes the retrograde pathway to intoxicate cells. Upon binding to cells, Stx was shown to specifically activate PKC delta and not PKC alpha. The involvement of PKC delta and PKC alpha in the retrograde transport of Stx was then monitored biochemically and by immunofluorescence after inhibition or depletion of the isozymes. PKC delta, but not PKC alpha, was shown to selectively regulate the endosome-to-Golgi transport of StxB. Upon inhibition or knockdown of PKC delta, StxB molecules colocalized less with giantin and more with EEA1, indicating that the molecules were accumulated in endosomes, unable to reach the Golgi complex. The inhibition of Golgi transport of Stx was reflected by a strong reduction in the toxic effect, demonstrating that transport of Stx to the cytosol is dependent on PKC delta activity. These results are in agreement with our previous data, which show that Stx is able to stimulate its own transport.	Univ Oslo, Inst Canc Res, Fac Div, Norwegian Radium Hosp, N-0310 Oslo, Norway; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Sandvig, K (corresponding author), Univ Oslo, Inst Canc Res, Fac Div, Norwegian Radium Hosp, N-0310 Oslo, Norway.	ksandvig@radium.uio.no	Torgersen, Maria Lyngaas L/F-3492-2017; Skånland, Sigrid S/AAW-4817-2021; Torgersen, Maria Lyngaas/O-6240-2019	Torgersen, Maria Lyngaas L/0000-0003-2616-7194; Torgersen, Maria Lyngaas/0000-0003-2616-7194; Skanland, Sigrid S./0000-0003-1630-356X; Walchli, Sebastien/0000-0001-5869-1746				Alvi F, 2007, CELL MOL LIFE SCI, V64, P263, DOI 10.1007/s00018-006-6363-5; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Badizadegan K, 2004, AM J PHYSIOL-CELL PH, V287, pC1453, DOI 10.1152/ajpcell.00189.2004; Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; Chen YW, 2004, TRAFFIC, V5, P577, DOI 10.1111/j.1600-0854.2004.00202.x; Cherla RP, 2003, FEMS MICROBIOL LETT, V228, P159, DOI 10.1016/S0378-1097(03)00761-4; Chu JJH, 2006, VIROLOGY, V349, P463, DOI 10.1016/j.virol.2006.01.022; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Falguieres T, 2006, FEBS J, V273, P5205, DOI 10.1111/j.1742-4658.2006.05516.x; Foster GH, 2000, INFECT IMMUN, V68, P5183, DOI 10.1128/IAI.68.9.5183-5189.2000; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Hehnly H, 2006, MOL BIOL CELL, V17, P4379, DOI 10.1091/mbc.E06-04-0310; Hermoso M, 2004, J BIOL CHEM, V279, P17681, DOI 10.1074/jbc.M304506200; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Inoue R, 2005, BIOCHEM BIOPH RES CO, V330, P1314, DOI 10.1016/j.bbrc.2005.03.117; Ishiki M, 2005, ENDOCRINOLOGY, V146, P5071, DOI 10.1210/en.2005-0850; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Lauvrak SU, 2006, MOL BIOL CELL, V17, P1096, DOI 10.1091/mbc.E05-08-0766; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; Li J, 2005, J BIOL CHEM, V280, P8351, DOI 10.1074/jbc.M409431200; Liedtke CM, 2003, AM J PHYSIOL-CELL PH, V284, pC487, DOI 10.1152/ajpcell.00357.2002; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Mori T, 2000, EXP HEMATOL, V28, P1260, DOI 10.1016/S0301-472X(00)00538-5; Murata K, 2006, BBA-MOL BASIS DIS, V1762, P835, DOI 10.1016/j.bbadis.2006.07.004; Oliva JL, 2005, GROWTH FACTORS, V23, P245, DOI 10.1080/08977190500366043; Perego C, 2002, BIOCHEM BIOPH RES CO, V294, P127, DOI 10.1016/S0006-291X(02)00448-5; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Saint-Pol A, 2004, DEV CELL, V6, P525, DOI 10.1016/S1534-5807(04)00100-5; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; SANDVIG K, 1981, BIOCHEM J, V194, P821, DOI 10.1042/bj1940821; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; Sandvig K, 2001, TOXICON, V39, P1629, DOI 10.1016/S0041-0101(01)00150-7; Seaman MNJ, 2005, TRENDS CELL BIOL, V15, P68, DOI 10.1016/j.tcb.2004.12.004; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; Tai GH, 2004, MOL BIOL CELL, V15, P4011, DOI 10.1091/mbc.E03-12-0876; Takenouchi H, 2004, J CELL SCI, V117, P3911, DOI 10.1242/jcs.01246; Tapia JA, 2006, BBA-MOL CELL RES, V1763, P25, DOI 10.1016/j.bbamcr.2005.10.007; Torgersen ML, 2005, FEBS J, V272, P4103, DOI 10.1111/j.1742-4658.2005.04835.x; Utskarpen A, 2006, TRAFFIC, V7, P663, DOI 10.1111/j.1600-0854.2006.00418.x; Weinberger A, 2005, MOL BIOL CELL, V16, P4918, DOI 10.1091/mbc.E05-02-0101; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Yang H, 2002, HYPERTENSION, V39, P567, DOI 10.1161/hy0202.103052	61	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16317	16328		10.1074/jbc.M610886200	http://dx.doi.org/10.1074/jbc.M610886200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403690	hybrid			2022-12-25	WOS:000246794300039
J	Taubert, D; Grimberg, G; Stenzel, W; Schomig, E				Taubert, Dirk; Grimberg, Gundula; Stenzel, Werner; Schoemig, Edgar			Identification of the Endogenous Key Substrates of the Human Organic Cation Transporter OCT2 and Their Implication in Function of Dopaminergic Neurons	PLOS ONE			English	Article								Background. The etiology of neurodegenerative disorders, such as the accelerated loss of dopaminergic neurons in Parkinson's disease, is unclear. Current hypotheses suggest an abnormal function of the neuronal sodium-dependent dopamine transporter DAT to contribute to cell death in the dopaminergic system, but it has not been investigated whether sodium-independent amine transporters are implicated in the pathogenesis of Parkinson's disease. Methodology/Principal Findings. By the use of a novel tandem-mass spectrometry-based substrate search technique, we have shown that the dopaminergic neuromodulators histidyl-proline diketopiperazine (cyclo(his-pro)) and salsolinol were the endogenous key substrates of the sodium-independent organic cation transporter OCT2. Quantitative real-time mRNA expression analysis revealed that OCT2 in contrast to its related transporters was preferentially expressed in the dopaminergic regions of the substantia nigra where it colocalized with DAT and tyrosine hydroxylase. By assessing cell viability with the MTT reduction assay, we found that salsolinol exhibited a selective toxicity toward OCT2-expressing cells that was prevented by cyclo(hispro). A frequent genetic variant of OCT2 with the amino acid substitution R400C reduced the transport efficiency for the cytoprotective cyclo(his-pro) and thereby increased the susceptibility to salsolinol-induced cell death. Conclusions/Significance. Our findings indicate that the OCT2-regulated interplay between cyclo(his-pro) and salsolinol is crucial for nigral cell integrity and that a shift in transport efficiency may impact the risk of Parkinson's disease.	[Taubert, Dirk; Grimberg, Gundula; Schoemig, Edgar] Univ Cologne, Hosp Med, Dept Pharmacol, Cologne, Germany; [Stenzel, Werner] Univ Cologne, Hosp Med, Div Neuropathol, Cologne, Germany	University of Cologne; University of Cologne	Taubert, D (corresponding author), Univ Cologne, Hosp Med, Dept Pharmacol, Cologne, Germany.	dirk.taubert@medizin.uni-koeln.de		Stenzel, Werner/0000-0002-1143-2103				AntkiewiczMichaluk L, 1997, BIOL PSYCHIAT, V42, P514, DOI 10.1016/S0006-3223(96)00408-8; AUGUSTIN M, 1966, J PRAKT CHEM, V32, P158, DOI 10.1002/prac.19660320307; Busch AE, 1998, MOL PHARMACOL, V54, P342, DOI 10.1124/mol.54.2.342; Caccamo D, 2004, AMINO ACIDS, V27, P373, DOI 10.1007/s00726-004-0117-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Grundemann D, 1998, J BIOL CHEM, V273, P30915, DOI 10.1074/jbc.273.47.30915; Grundemann D, 1997, J BIOL CHEM, V272, P10408; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; Hayer-Zillgen M, 2002, BRIT J PHARMACOL, V136, P829, DOI 10.1038/sj.bjp.0704785; IKEGAMI H, 1990, PEPTIDES, V11, P145, DOI 10.1016/0196-9781(90)90123-M; Jonker JW, 2004, J PHARMACOL EXP THER, V308, P2, DOI 10.1124/jpet.103.053298; Koepsell H, 2004, TRENDS PHARMACOL SCI, V25, P375, DOI 10.1016/j.tips.2004.05.005; Leabman MK, 2002, PHARMACOGENETICS, V12, P395, DOI 10.1097/00008571-200207000-00007; Lesch K. P., 2004, MEMBRANE TRANSPORTER, P349; Mravec B, 2006, PHYSIOL RES, V55, P353, DOI 10.33549/physiolres.930810; Naoi M, 2002, NEUROTOXICOL TERATOL, V24, P579, DOI 10.1016/S0892-0362(02)00211-8; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Prasad C, 1998, THYROID, V8, P969, DOI 10.1089/thy.1998.8.969; Schomig E, 2006, HANDB EXP PHARM, V175, P151; Storch A, 1999, NEUROCHEM INT, V35, P393, DOI 10.1016/S0197-0186(99)00083-2; Storch A, 2002, BIOCHEM PHARMACOL, V63, P909, DOI 10.1016/S0006-2952(01)00922-4; Taubert D, 2006, CLIN PHARMACOL THER, V80, P486, DOI 10.1016/j.clpt.2006.07.007; Toth BE, 2002, NEUROTOXICOL TERATOL, V24, P655, DOI 10.1016/S0892-0362(02)00216-7	26	46	47	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e385	10.1371/journal.pone.0000385	http://dx.doi.org/10.1371/journal.pone.0000385			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460754	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445600001
J	Nato, F; Phalipon, A; Lan, PTN; Diep, TT; Sansonetti, P; Germani, Y				Nato, Faridabano; Phalipon, Armelle; Lan Phuong Thi Nguyen; Diep, Tai The; Sansonetti, Philippe; Germani, Yves			Dipstick for Rapid Diagnosis of Shigella flexneri 2a in Stool	PLOS ONE			English	Article							ENTEROINVASIVE ESCHERICHIA-COLI; VIBRIO-CHOLERAE O1; B-CELL EPITOPES; DYSENTERY PATIENTS; PCR ASSAY; INVASION; IDENTIFICATION; ANTIGEN; AMPLIFICATION; SURVEILLANCE	Background. Shigellosis or bacillary dysentery, an acute bloody diarrhoea, is a major public health burden in developing countries. In the absence of prompt and appropriate treatment, the infection is often fatal, particularly in young malnourished children. Here, we describe a new diagnostic test for rapid detection, in stool, at the bedside of patients, of Shigella flexneri 2a, the most predominant agent of the endemic form of the disease. Methodology/Principal Findings. The test is based on the detection of S. flexneri 2a lipopolysaccharide (LPS) using serotype 2a-specific monoclonal antibodies coupled to gold particles and displayed on one-step immunochromatographic dipstick. A concentration as low as 20 ng/ml of LPS is detected in distilled water and in reconstituted stools in under 15 minutes. The threshold of detection corresponds to a concentration of 5 x 10(7) CFU/ml of S. flexneri 2a, which provides an unequivocal positive reaction in three minutes in distilled water and reconstituted stools. The specificity is 100% when tested with a battery of Shigella and unrelated strains, in culture. When tested in Vietnam, on clinical samples, the specificity and sensitivity were 99.2 and 91.5%, respectively. A decrease of the sensitivity during the evaluation on stool samples was observed after five weeks at room temperature and was due to moistening of the dipsticks caused by the humidity of the air during the fifth week of the evaluation. This drawback is now overcome by improving the packaging and providing dipsticks individually wrapped in waterproof bags. Conclusion. This simple dipstick-bases test represents a powerful tool for case management and epidemiological surveys.	[Phalipon, Armelle; Sansonetti, Philippe; Germani, Yves] Inst Pasteur, Unite Pathogenie Microbienne Mol, Paris, France; [Phalipon, Armelle; Sansonetti, Philippe; Germani, Yves] INSERM, U786, Paris, France; [Lan Phuong Thi Nguyen; Diep, Tai The] Inst Pasteur, Ho Chi Minh City, Vietnam	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Germani, Y (corresponding author), Inst Pasteur, Unite Pathogenie Microbienne Mol, Paris, France.	ygermani@pasteur.fr	Diep, Tai/ABG-9477-2021	Diep, Tai/0000-0001-7166-6369; Nguyen Thi Phuong, Lan/0000-0003-4027-6872	Institut Pasteur, Paris [ACIP, PTR 179]; TOTAL SA	Institut Pasteur, Paris; TOTAL SA(Total SA)	This work was supported by the Institut Pasteur, Paris (grant ACIP and PTR 179). Part of the work was funded by a grant from TOTAL SA.	BARZU S, 1993, INFECT IMMUN, V61, P3825, DOI 10.1128/IAI.61.9.3825-3831.1993; Bhuiyan NA, 2003, J CLIN MICROBIOL, V41, P3939, DOI 10.1128/JCM.41.8.3939-3941.2003; BRENNER DJ, 1984, INT J SYST BACTERIOL, V34, P87, DOI 10.1099/00207713-34-1-87; Chanteau S, 2003, LANCET, V361, P211, DOI 10.1016/S0140-6736(03)12270-2; Chanteau S, 2006, PLOS MED, V3, P1579, DOI 10.1371/journal.pmed.0030337; Chompook P, 2005, B WORLD HEALTH ORGAN, V83, P739; Diniz-Santos Daniel R., 2005, Braz J Infect Dis, V9, P77, DOI 10.1590/S1413-86702005000100013; FRANKEL G, 1990, J INFECT DIS, V161, P1252, DOI 10.1093/infdis/161.6.1252; Gaudio PA, 1997, J INFECT DIS, V176, P1013, DOI 10.1086/516531; Germani Y, 1998, AM J TROP MED HYG, V59, P1008, DOI 10.4269/ajtmh.1998.59.1008; Houng HSH, 1997, DIAGN MICR INFEC DIS, V28, P19, DOI 10.1016/S0732-8893(97)89154-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; Lee LA, 1995, B WORLD HEALTH ORGAN, V73, P779; Legros D, 1999, TROP MED INT HEALTH, V4, P428, DOI 10.1046/j.1365-3156.1999.00413.x; LINDBERG AA, REV INFECT DIS S4, V13, pS279; Nato F, 2003, CLIN DIAGN LAB IMMUN, V10, P476, DOI 10.1128/CDLI.10.3.476-478.2003; Nguyen TV, 2006, INT J INFECT DIS, V10, P298, DOI 10.1016/j.ijid.2005.05.009; Paek SH, 2000, METHODS, V22, P53, DOI 10.1006/meth.2000.1036; Phalipon A, 2006, J IMMUNOL, V176, P1686, DOI 10.4049/jimmunol.176.3.1686; PHALIPON A, 1992, INFECT IMMUN, V60, P1919, DOI 10.1128/IAI.60.5.1919-1926.1992; Sansonetti PJ, 1999, CLIN INFECT DIS, V28, P466, DOI 10.1086/515150; SETHABUTR O, 1994, J DIARRHOEAL DIS RES, V12, P265; SETHABUTR O, 1993, J INFECT DIS, V167, P458, DOI 10.1093/infdis/167.2.458; Shears P, 1996, ANN TROP MED PARASIT, V90, P105, DOI 10.1080/00034983.1996.11813034; TAYLOR WI, 1975, J CLIN MICROBIOL, V2, P281; Thiem VD, 2004, J CLIN MICROBIOL, V42, P2031, DOI 10.1128/JCM.42.5.2031-2035.2004; Toma C, 2003, J CLIN MICROBIOL, V41, P2669, DOI 10.1128/JCM.41.6.2669-2671.2003; von Seidlein L, 2006, PLOS MED, V3, P1556, DOI 10.1371/journal.pmed.0030353; WESTPHAL O, 1965, METHODS CARBOHYDR RE, V5, P91; *WHO, 2005, WEEKLY EPIDEMIOLOGIC, V80, P93; Wierzba TF, 2006, AM J TROP MED HYG, V74, P148, DOI 10.4269/ajtmh.2006.74.148	32	21	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e361	10.1371/journal.pone.0000361	http://dx.doi.org/10.1371/journal.pone.0000361			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440606	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500001
J	Pfister, P; Randall, J; Montoya-Burgos, JI; Rodriguez, I				Pfister, Patrick; Randall, Jerome; Montoya-Burgos, Juan I.; Rodriguez, Ivan			Divergent Evolution among Teleost V1r Receptor Genes	PLOS ONE			English	Article								The survival of vertebrate species is dependent on the ability of individuals to adequately interact with each other, a function often mediated by the olfactory system. Diverse olfactory receptor repertoires are used by this system to recognize chemicals. Among these receptors, the V1rs, encoded by a very large gene family in most mammals, are able to detect pheromones. Teleosts, which also express V1r receptors, possess a very limited V1r repertoire. Here, taking advantage of the possibility to unequivocally identify V1r orthologs in teleosts, we analyzed the olfactory expression and evolutionary constraints of a pair of clustered fish V1r receptor genes, V1r1 and V1r2. Orthologs of the two genes were found in zebrafish, medaka, and threespine stickleback, but a single representative was observed in tetraodontidae species. Analysis of V1r1 and V1r2 sequences from 12 different euteleost species indicate different evolutionary rates between the two paralogous genes, leading to a highly conserved V1r2 gene and a V1r1 gene under more relaxed selective constraint. Moreover, positively-selected sites were detected in specific branches of the V1r1 clade. Our results suggest a conserved agonist specificity of the V1R2 receptor between euteleost species, its loss in the tetraodontidae lineage, and the acquisition of different chemosensory characteristics for the V1R1 receptor.	[Pfister, Patrick; Randall, Jerome; Montoya-Burgos, Juan I.; Rodriguez, Ivan] Univ Geneva, Dept Zool & Anim Biol, Geneva, Switzerland; [Pfister, Patrick; Randall, Jerome; Rodriguez, Ivan] Univ Geneva, Natl Ctr Competence Res Frontiers Genet, Geneva, Switzerland	University of Geneva; University of Geneva	Rodriguez, I (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Geneva, Switzerland.	ivan.rodriguez@zoo.unige.ch		Pfister, Patrick/0000-0002-1192-8600; Montoya-Burgos, Juan I./0000-0001-9080-9820; rodriguez, ivan/0000-0002-6468-0565	Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was funded by the Swiss National Science Foundation.	Alioto TS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-173; Alioto TS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-309; Bielawski JP, 2004, J MOL EVOL, V59, P121, DOI 10.1007/s00239-004-2597-8; Bjarndottir TK, 2005, GENE, V362, P70, DOI 10.1016/j.gene.2005.07.029; Boschat C, 2002, NAT NEUROSCI, V5, P1261, DOI 10.1038/nn978; Cao YX, 1998, P NATL ACAD SCI USA, V95, P11987, DOI 10.1073/pnas.95.20.11987; Chen WJ, 2004, TRENDS GENET, V20, P424, DOI 10.1016/j.tig.2004.07.005; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; CrnogoracJurcevic T, 1997, GENOMICS, V41, P177, DOI 10.1006/geno.1997.4646; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Del Punta K, 2002, NATURE, V419, P70, DOI 10.1038/nature00955; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Furutani-Seiki M, 2004, MECH DEVELOP, V121, P629, DOI 10.1016/j.mod.2004.05.010; Gloriam DEI, 2005, MOL PHYLOGENET EVOL, V35, P470, DOI 10.1016/j.ympev.2004.12.003; Grus WE, 2005, P NATL ACAD SCI USA, V102, P5767, DOI 10.1073/pnas.0501589102; Grus WE, 2004, GENE, V340, P303, DOI 10.1016/j.gene.2004.07.037; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hashiguchi Y, 2005, GENE, V362, P19, DOI 10.1016/j.gene.2005.07.044; Lane RP, 2004, GENOME RES, V14, P603, DOI 10.1101/gr.2117004; Lane RP, 2002, P NATL ACAD SCI USA, V99, P291, DOI 10.1073/pnas.012608399; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Mundy NI, 2003, MOL BIOL EVOL, V20, P1805, DOI 10.1093/molbev/msg192; Pfister P, 2005, P NATL ACAD SCI USA, V102, P5489, DOI 10.1073/pnas.0402581102; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Robinson-Rechavi M, 2000, BIOINFORMATICS, V16, P296, DOI 10.1093/bioinformatics/16.3.296; Rodriguez I, 2002, NAT NEUROSCI, V5, P134, DOI 10.1038/nn795; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shi P, 2005, J MOL EVOL, V60, P566, DOI 10.1007/s00239-004-0172-y; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Young JM, 2005, GENOME RES, V15, P231, DOI 10.1101/gr.3339905; Zhang JZ, 2005, MOL BIOL EVOL, V22, P2472, DOI 10.1093/molbev/msi237; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009	39	25	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e379	10.1371/journal.pone.0000379	http://dx.doi.org/10.1371/journal.pone.0000379			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440615	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500010
J	Gomez-Zurita, J; Hunt, T; Kopliku, F; Vogler, AP				Gomez-Zurita, Jesus; Hunt, Toby; Kopliku, Fatos; Vogler, Alfried P.			Recalibrated Tree of Leaf Beetles (Chrysomelidae) Indicates Independent Diversification of Angiosperms and Their Insect Herbivores	PLOS ONE			English	Article							MOLECULAR SYSTEMATICS; INORDINATE FONDNESS; SEQUENCE ALIGNMENT; DIVERGENCE TIMES; PLANTS; PHYLOGENIES; COLEOPTERA; BIOGEOGRAPHY; COEVOLUTION; LIKELIHOOD	Background. The great diversity of the "Phytophaga" (weevils, longhorn beetles and leaf beetles) has been attributed to their co-radiation with the angiosperms based on matching age estimates for both groups, but phylogenetic information and molecular clock calibrations remain insufficient for this conclusion. Methodology. A phylogenetic analysis of the leaf beetles (Chrysomelidae) was conducted based on three partial ribosomal gene markers (mitochondrial rrnL, nuclear small and large subunit rRNA) including over 3000 bp for 167 taxa representing most major chrysomelid lineages and outgroups. Molecular clock calibrations and confidence intervals were based on paleontological data from the oldest (K-T boundary) leaf beetle fossil, ancient feeding traces ascribed to hispoid Cassidinae, and the vicariant split of Nearctic and Palearctic members of the Timarchini. Principal Findings. The origin of the Chrysomelidae was dated to 73-79 Mya (confidence interval 63-86 Mya), and most subfamilies were post-Cretaceous, consistent with the ages of all confirmed body fossils. Two major monocot feeding chrysomelid lineages formed widely separated clades, demonstrating independent colonization of this ancient (early Cretaceous) angiosperm lineage. Conclusions. Previous calibrations proposing a much older origin of Chrysomelidae were not supported. Therefore, chrysomelid beetles likely radiated long after the origin of their host lineages and their diversification was driven by repeated radiaton on a pre-existing diverse resource, rather than ancient host associations.	[Gomez-Zurita, Jesus; Hunt, Toby; Kopliku, Fatos; Vogler, Alfried P.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England; [Gomez-Zurita, Jesus; Hunt, Toby; Kopliku, Fatos; Vogler, Alfried P.] Univ London Imperial Coll Sci Technol & Med, Div Biol, Ascot, Berks, England; [Gomez-Zurita, Jesus] Zool Staatssammlung Munchen, Munich, Germany	Natural History Museum London; Imperial College London	Gomez-Zurita, J (corresponding author), Nat Hist Museum, Dept Entomol, Cromwell Rd, London SW7 5BD, England.	jgzurita@um.es	Gomez-Zurita, Jesus/C-4248-2008	Gomez-Zurita, Jesus/0000-0001-7337-6541; Hunt, Toby/0000-0001-8377-0841	Marie Curie Action [HPMF-CT-2000-00744]; Humboldt Research Fellowship; NERC CASE studentship; Leverhulme Trust [F/969/H]	Marie Curie Action(European Commission); Humboldt Research Fellowship(Alexander von Humboldt Foundation); NERC CASE studentship(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Leverhulme Trust(Leverhulme Trust)	Funding: This study benefited from Marie Curie Action HPMF-CT-2000-00744 and a Humboldt Research Fellowship to JGZ, a NERC CASE studentship to TH, and Leverhulme Trust grant F/969/H to APV and P. Hammond.	[Anonymous], 2005, PHYLIP PHYLOGENY INF; Baldwin BG, 1998, P NATL ACAD SCI USA, V95, P9402, DOI 10.1073/pnas.95.16.9402; Barraclough TG, 1998, CURR BIOL, V8, pR843, DOI 10.1016/S0960-9822(07)00527-1; Barrett PM, 2000, TRENDS ECOL EVOL, V15, P99, DOI 10.1016/S0169-5347(99)01782-6; Becerra JX, 2003, P NATL ACAD SCI USA, V100, P12804, DOI 10.1073/pnas.2133013100; Becerra JX, 1997, SCIENCE, V276, P253, DOI 10.1126/science.276.5310.253; Belshaw R, 2005, BIOINFORMATICS, V21, P122, DOI 10.1093/bioinformatics/bth459; BLAY JAS, 1994, NOVEL ASPECTS BIOL C, P1; Bremer K, 2000, P NATL ACAD SCI USA, V97, P4707, DOI 10.1073/pnas.080421597; Carpenter F. M., 1992, TREATISE INVERTEBR R; Chase MW, 2004, AM J BOT, V91, P1645, DOI 10.3732/ajb.91.10.1645; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Crowson R.A., 1981, BIOL COLEOPTERA, P802; Duckett Catherine N., 2004, P3; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; Erber D., 1988, BIOL CHRYSOMELIDAE, P513, DOI DOI 10.1007/978-94-009-3105-3_; Farrell BD, 1998, SCIENCE, V281, P555, DOI 10.1126/science.281.5376.555; Farrell BD, 2004, EVOLUTION, V58, P1984; Friis EM, 2004, P NATL ACAD SCI USA, V101, P16565, DOI 10.1073/pnas.0407174101; Gascuel O, 1997, MOL BIOL EVOL, V14, P685, DOI 10.1093/oxfordjournals.molbev.a025808; Giannini NP, 2003, CLADISTICS, V19, P496, DOI 10.1111/j.1096-0031.2003.tb00385.x; Gomez-Zurita J, 2005, MOL PHYLOGENET EVOL, V34, P584, DOI 10.1016/j.ympev.2004.11.022; Gomez-Zurita J, 2004, MOL PHYLOGENET EVOL, V32, P647, DOI 10.1016/j.ympev.2004.02.009; Grimaldi David, 2005, pi; Grove SJ, 2000, INVERTEBR TAXON, V14, P733, DOI 10.1071/IT00023; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; HAMMOND PM, 1992, GLOBAL BIODIVERSITY, V17; Heads M, 2005, CLADISTICS, V21, P62, DOI 10.1111/j.1096-0031.2005.00052.x; JANZEN DH, 1980, EVOLUTION, V34, P611, DOI 10.1111/j.1558-5646.1980.tb04849.x; Jolivet P, 2002, BIOL LEAF BEETLES; Labandeira Conrad C., 2002, P26; Lopez-Vaamonde C, 2006, J EVOLUTION BIOL, V19, P1314, DOI 10.1111/j.1420-9101.2005.01070.x; Magallon SA, 2004, INT J PLANT SCI, V165, pS7, DOI 10.1086/383336; Magallon SA, 2005, EVOLUTION, V59, P1653, DOI 10.1554/04-565.1; Mantovani A., 2005, P153; Marvaldi AE, 2002, SYST BIOL, V51, P761, DOI 10.1080/10635150290102465; McKenna DD, 2006, P NATL ACAD SCI USA, V103, P10947, DOI 10.1073/pnas.0602712103; MEDVEDEV LN, 1968, S JURASSIC INSECTS K, P155; MITTER C, 1991, INSECT PLANT INTERAC, V3, P35; Moreau CS, 2006, SCIENCE, V312, P101, DOI 10.1126/science.1124891; Napp Dilma Solange, 1994, Revista Brasileira de Entomologia, V38, P265; Ogden TH, 2005, CLADISTICS, V21, P295, DOI 10.1111/j.1096-0031.2005.00061.x; Poinar Jr. G.O., 1999, AMBER FOREST; Ponomarenko A.G., 1995, P155; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Reid C.A.M., 1995, P559; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanmartin I, 2004, SYST BIOL, V53, P216, DOI 10.1080/10635150490423430; Sanmartin I, 2001, BIOL J LINN SOC, V73, P345, DOI 10.1006/bijl.2001.0542; Shull VL, 2001, SYST BIOL, V50, P945, DOI 10.1080/106351501753462894; Sun G, 2002, SCIENCE, V296, P899, DOI 10.1126/science.1069439; Svacha P, 1997, ANN SOC ENTOMOL FR, V33, P323; Wheeler W, 1996, CLADISTICS, V12, P1, DOI 10.1111/j.1096-0031.1996.tb00189.x; WHEELER WC, 2002, POY VERSION 3 0; Wilf P, 2000, SCIENCE, V289, P291, DOI 10.1126/science.289.5477.291	55	125	148	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e360	10.1371/journal.pone.0000360	http://dx.doi.org/10.1371/journal.pone.0000360			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426809	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445400001
J	Tchougounova, E; Kastemar, M; Brasater, D; Holland, EC; Westermark, B; Uhrbom, L				Tchougounova, E.; Kastemar, M.; Brasater, D.; Holland, E. C.; Westermark, B.; Uhrbom, L.			Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma	ONCOGENE			English	Article						oligodendroglioma; PDGF; mouse model; ink4a; Arf; p70S6K	GROWTH-FACTOR RECEPTOR; NEURAL PROGENITORS; STEM-CELL; INK4A LOCUS; EXPRESSION; SUPPRESSION; P16(INK4A); P19(ARF); MICE; DIFFERENTIATION	In a subset of gliomas, the platelet-derived growth factor ( PDGF) signaling pathway is perturbed. This is usually an early event occurring in low-grade tumors. In high-grade gliomas, the subsequent loss of the INK4a-ARF locus is one of the most common mutations. Here, we dissected the separate roles of Ink4a and Arf in PDGFB-induced oligodendroglioma development in mice. We found that there were differential functions of the two tumor suppressor genes. In tumors induced from astrocytes, both Ink4a-loss and Arf-loss caused a significantly increased incidence compared to wild-type mice. In tumors induced from glial progenitor cells there was a slight increase in tumor incidence in Ink4a -/- mice and Ink4a- Arf -/- mice compared to wild-type mice. In both progenitor cells and astrocytes, Arf-loss caused a pronounced increase in tumor malignancy compared to Ink4a- loss. Hence, Ink4a- loss contributed to tumor initiation from astrocytes and Arf-loss caused tumor progression from both glial progenitor cells and astrocytes. Results from in vitro studies on primary brain cell cultures suggested that the PDGFB-induced activation of the mitogen-activated protein kinase pathway via extracellular signal-regulated kinase was involved in the initiation of low-grade oligodendrogliomas and that the additional loss of Arf may contribute to tumor progression through increased levels of cyclin D1 and a phosphoinositide 3-kinase-dependent activation of p70 ribosomal S6 kinase causing a strong proliferative response of tumor cells.	Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Uppsala University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	lene.uhrbom@genpat.uu.se		Westermark, Bengt/0000-0001-7153-5545				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Charest A, 2006, CANCER RES, V66, P7473, DOI 10.1158/0008-5472.CAN-06-1193; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; FISCHER AN, 2006, ONCOGENE; Grewe M, 1999, CANCER RES, V59, P3581; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JEN J, 1994, CANCER RES, V54, P6353; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1997, PATHOLOGY GENETICS; Reifenberger J, 1996, AM J PATHOL, V149, P29; SCHERER H. J., 1938, AMER JOUR CANCER, V34, P333; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schumacher A, 2003, MOL CELL NEUROSCI, V23, P669, DOI 10.1016/S1044-7431(03)00170-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VanBrocklyn JR, 1997, J NEUROCHEM, V69, P116; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	24	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6289	6296		10.1038/sj.onc.1210455	http://dx.doi.org/10.1038/sj.onc.1210455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438529				2022-12-25	WOS:000249583300005
J	Nakanishi, K; Dohmae, N; Morishima, N				Nakanishi, Keiko; Dohmae, Naoshi; Morishima, Nobuhiro			Endoplasmic reticulum stress increases myofiber formation in vitro	FASEB JOURNAL			English	Article						apoptosis; Bcl-xL; caspase-12; IGF-II; myoblast	GROWTH-FACTOR-II; UNFOLDED PROTEIN RESPONSE; SKELETAL-MUSCLE; ER STRESS; INDUCED APOPTOSIS; STRIATED-MUSCLE; DNA-SYNTHESIS; CELL-DEATH; INSULIN; DIFFERENTIATION	Myoblast differentiation involves myoblast fusion followed by myofiber formation. We recently demonstrated that endoplasmic reticulum (ER) stress signaling occurs during myoblast differentiation in vivo. This signaling results in apoptosis in a subpopulation of myoblasts. In a cell culture model of myogenesis, inhibition of ER stress signaling blocked apoptosis and myoblast differentiation. To further examine the role of ER stress during myogenesis, we exposed cultured myoblasts to ER stress inducers during the transition from proliferation to differentiation. The stress inducers tunicamycin (an inhibitor of N-glycosylation in the ER) and thapsigargin (an inhibitor of ER-specific calcium ATPase) were used at doses that induce 40-50% apoptosis in myoblast cultures. Increased ER stress enhanced differentiation-associated apoptosis of myoblasts. It is likely that apoptosis induced by ER stress selectively eliminates vulnerable cells. We found that the surviving myoblast cells were even more resistant to apoptosis. Remarkably, the surviving cells efficiently differentiated into contracting myofibers that are rarely found in culture models of myogenesis. Our observations suggest that ER stress exerts a positive effect on myofiber formation, possibly mimicking the action of signals that drive apoptosis and differentiation in vivo. These results may provide important insight for developing therapies to improve myofiber formation.-Nakanishi, K., Dohmae, N., Morishima, N. Endoplasmic reticulum stress increases myofiber formation in vitro.	RIKEN, Biomol Characterizat Team, Wako, Saitama 3510198, Japan; RIKEN, Bioarchitect Res Grp, Wako, Saitama 3510198, Japan	RIKEN; RIKEN	Morishima, N (corresponding author), RIKEN, Biomol Characterizat Team, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morishim@postman.riken.jp	Dohmae, Naoshi/C-2040-2011; Morishima, Nobuhiro/D-3946-2017; Nakanishi, Keiko/B-9963-2013	Dohmae, Naoshi/0000-0002-5242-9410; 				Bach AD, 2004, J CELL MOL MED, V8, P413, DOI 10.1111/j.1582-4934.2004.tb00466.x; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; COUSINS JC, 2000, PRINCIPLES TISSUE EN; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DELAGUILA LF, 1999, AM J PHYSIOL, V276, pE845; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Friedman AD, 1996, CANCER RES, V56, P3250; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Miller JB, 1999, CURR TOP DEV BIOL, V43, P191; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakanishi K, 2005, J CELL BIOL, V169, P555, DOI 10.1083/jcb.200412024; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; OKA Y, 1985, J BIOL CHEM, V260, P9435; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; Polesskaya A, 2002, DEV CELL, V3, P757, DOI 10.1016/S1534-5807(02)00372-6; Powell CA, 2002, AM J PHYSIOL-CELL PH, V283, pC1557, DOI 10.1152/ajpcell.00595.2001; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Sultan KR, 2006, AM J PHYSIOL-CELL PH, V290, pC650, DOI 10.1152/ajpcell.00163.2005; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vandenburgh H, 1996, HUM GENE THER, V7, P2195, DOI 10.1089/hum.1996.7.17-2195; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	43	80	84	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2994	3003		10.1096/fj.06-6408com	http://dx.doi.org/10.1096/fj.06-6408com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435177				2022-12-25	WOS:000249237500039
J	Lee, WC; Tsoi, YK; Troendle, FJ; DeLucia, MW; Ahmed, Z; Dicky, CA; Dickson, DW; Eckman, CB				Lee, Wing C.; Tsoi, Yuen K.; Troendle, Frederick J.; DeLucia, Michael W.; Ahmed, Zeshan; Dicky, Chad A.; Dickson, Dennis W.; Eckman, Christopher B.			Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy	FASEB JOURNAL			English	Article						Krabbe disease; enzyme replacement therapy; psychosine; twitcher	TWITCHER MOUSE; PSYCHOSINE CYTOTOXICITY; PHORBOL ESTER; MURINE MODEL; GLIAL-CELLS; GALACTOSYLSPHINGOSINE; OLIGODENDROCYTES; TRANSPLANTATION; REPLACEMENT; EXPRESSION	Globoid cell leukodystrophy ( GLD), also known as Krabbe disease, is a devastating, degenerative neurological disorder. It is inherited as an autosomal recessive trait caused by loss-of-function mutations in the galactocerebrosidase ( GALC) gene. Previously, we have shown that peripheral injection of recombinant GALC, administered every other day, results in a substantial improvement in early clinical phenotype in the twitcher mouse model of GLD. While we did detect active enzyme in the brain following peripheral administration, most of the administered enzyme was localized to the periphery. Given the substantial central nervous system ( CNS) involvement in this disease, we were interested in determining whether or not a single-dose administration of the recombinant enzyme directly to the CNS, which could potentially be achieved clinically, would result in any substantial improvement. Following intracerebroventricular ( icv) administration of GALC we noted a significant, 16.5%, reduction in the GALC substrate psychosine, the abnormal accumulation of which is believed to play a pivotal role in the CNS pathology observed in this disease. Moreover, recombinant GALC was found not only in periventricular regions but also at sites distant to the injection such as the cerebral cortex and cerebellum. Most importantly, animals receiving a single icv dose of the enzyme at postnatal day 20 survived up to 51 days, which compares favorably to the control twitcher animals, which normally only live to postnatal day 40/42. These results indicate that even a single icv administration of the recombinant enzyme can have significant clinical impact and suggests that other lysosomal storage disorders with significant CNS involvement may similarly benefit.	Mayo Clin Jacksonville, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin Jacksonville, Coll Med, Dept Pharmacol, Birdsall Bldg Rm 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	eckman@mayo.edu	Ahmed, Zeshan/E-6225-2011	Lee, Chris/0000-0001-9068-5274; Dickson, Dennis W/0000-0001-7189-7917				Caniglia M, 2002, PEDIATR TRANSPLANT, V6, P427, DOI 10.1034/j.1399-3046.2002.02026.x; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; Escolar ML, 2005, NEW ENGL J MED, V352, P2069, DOI 10.1056/NEJMoa042604; GAL AE, 1977, CLIN CHIM ACTA, V77, P53, DOI 10.1016/0009-8981(77)90401-6; Haq E, 2003, J NEUROCHEM, V86, P1428, DOI 10.1046/j.1471-4159.2003.01941.x; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Jatana M, 2002, NEUROSCI LETT, V330, P183, DOI 10.1016/S0304-3940(02)00655-9; Kanazawa T, 2000, J CELL BIOL, V149, P943, DOI 10.1083/jcb.149.4.943; KOBAYASHI T, 1980, BRAIN RES, V202, P479, DOI 10.1016/0006-8993(80)90159-6; KOLODNY EH, 1996, HDB CLIN NEUROLOGY, V22, P187; Kondo Y, 2005, P NATL ACAD SCI USA, V102, P18670, DOI 10.1073/pnas.0506473102; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Lee WC, 2005, FASEB J, V19, P1549, DOI 10.1096/fj.05-3826fje; Lee WC, 2006, NEUROBIOL DIS, V23, P273, DOI 10.1016/j.nbd.2006.03.005; Luddi A, 2001, NEUROBIOL DIS, V8, P600, DOI 10.1006/nbdi.2001.0407; OLMSTEAD CE, 1987, BEHAV BRAIN RES, V25, P143, DOI 10.1016/0166-4328(87)90007-6; Rafi MA, 1996, BIOCHEM MOL MED, V58, P142, DOI 10.1006/bmme.1996.0042; Sakai N, 1996, J NEUROCHEM, V66, P1118, DOI 10.1046/j.1471-4159.1996.66031118.x; Scriver C.R., 2001, METABOLIC MOL BASES, P3669; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; Shen JS, 2002, J NEUROSCI RES, V68, P588, DOI 10.1002/jnr.10247; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUGAMA S, 1991, BRAIN DEV-JPN, V13, P104, DOI 10.1016/S0387-7604(12)80116-1; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Tohyama J, 2001, NEUROCHEM RES, V26, P667, DOI 10.1023/A:1010991420942; Wenger D.A., 1997, MOL GENETIC BASIS NE, P421; Wenger DA, 2000, MOL GENET METAB, V70, P1, DOI 10.1006/mgme.2000.2990; Zaka M, 2004, NEUROSCI LETT, V358, P205, DOI 10.1016/j.neulet.2003.12.126	31	76	86	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2520	2527		10.1096/fj.06-6169com	http://dx.doi.org/10.1096/fj.06-6169com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17403939				2022-12-25	WOS:000248454400026
J	Barlic, J; Zhang, Y; Murphy, PM				Barlic, Jana; Zhang, Yuan; Murphy, Philip M.			Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNF alpha-NF kappa B-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FRACTALKINE RECEPTOR CX(3)CR1; AMERICAN-HEART-ASSOCIATION; NECROSIS-FACTOR-ALPHA; GENETIC RISK-FACTOR; OXIDIZED LDL; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; HISTOLOGICAL CLASSIFICATION; MOLECULE EXPRESSION	Recent genetic evidence has implicated the adhesive chemokine CX3CL1 and its leukocyte receptor CX3CR1 in atherosclerosis. We previously proposed a mechanism involving foam cell anchorage to vascular smooth muscle cells because: 1) CX3CL1 and CX3CR1 are expressed by both cell types in mouse and human atherosclerotic lesions; 2) foam cells are reduced in lesions in cx3cr1(-/-) apoE(-/-) mice; and 3) proatherogenic lipids ( oxidized low density lipoprotein [oxLDL] and oxidized linoleic acid derivatives) induce adhesion of primary human macrophages to primary human coronary artery smooth muscle cells (CASMCs) in vitro in a macrophage CX3CR1-dependent manner. Here we analyze this concept further by testing whether atherogenic lipids regulate expression and function of CX3CL1 and CX3CR1 on CASMCs. We found that both oxLDL and oxidized linoleic acid derivatives indirectly up-regulated CASMC CX3CL1 at both the protein and mRNA levels through an autocrine feedback loop involving tumor necrosis factor alpha production and NF-kappa B signaling. Oxidized lipids also up-regulated CASMC CX3CR1 but through a different mechanism. Oxidized lipid stimulation also increased adhesion of macrophages to CASMCs when CASMCs were stimulated prior to assay, and a synergistic pro-adhesive effect was observed when both cell types were prestimulated. Selective inhibition with a CX3CL1-specific blocking antibody indicated that adhesion was strongly CASMC CX3CL1-dependent. These findings support the hypothesis that CX3CR1 and CX3CL1 mediate heterotypic anchorage of foam cells to CASMCs in the context of atherosclerosis and suggest that this chemokine/chemokine receptor pair may be considered as a pro-inflammatory target for therapeutic intervention in atherosclerotic cardiovascular disease.	NIH, NIAID, Mol Signalling Sect, Lab Mol Immunol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Murphy, PM (corresponding author), NIH, Bldg 10,Rm 11N113,9000 Rockville Pike, Bethesda, MD 20892 USA.	pmm@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615, ZIAAI000615] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; Barlic J, 2006, CIRCULATION, V114, P807, DOI 10.1161/CIRCULATIONAHA.105.602359; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Damas JK, 2005, ARTERIOSCL THROM VAS, V25, P2567, DOI 10.1161/01.ATV.0000190672.36490.7b; Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200; Dwivedi A, 2001, BIOCHEM BIOPH RES CO, V284, P239, DOI 10.1006/bbrc.2001.4955; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Ghilardi G, 2004, STROKE, V35, P1276, DOI 10.1161/01.STR.0000128528.56009.d4; GLAVIND J, 1951, EXPERIENTIA, V7, P464, DOI 10.1007/BF02168696; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; Heermeier K, 2001, J AM SOC NEPHROL, V12, P456, DOI 10.1681/ASN.V123456; Holm T, 2003, J THROMB HAEMOST, V1, P257, DOI 10.1046/j.1538-7836.2003.00065.x; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15; Jira W, 1998, CHEM PHYS LIPIDS, V91, P1, DOI 10.1016/S0009-3084(97)00095-9; Lei ZB, 2002, CARDIOVASC RES, V53, P524, DOI 10.1016/S0008-6363(01)00491-6; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Lucas AD, 2003, CIRCULATION, V108, P2498, DOI 10.1161/01.CIR.0000097119.57756.EF; Ludwig A, 2002, J IMMUNOL, V168, P604, DOI 10.4049/jimmunol.168.2.604; MacKenzie CJ, 2007, CELL SIGNAL, V19, P75, DOI 10.1016/j.cellsig.2006.06.001; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Ollivier W, 2003, CYTOKINE, V21, P303, DOI 10.1016/S1043-4666(03)00112-1; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schecter AD, 2003, MICROCIRCULATION, V10, P265, DOI 10.1038/sj.mn.7800192; Sizemore N, 2004, P NATL ACAD SCI USA, V101, P7994, DOI 10.1073/pnas.0401593101; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Stary HC, 2000, ARTERIOSCL THROM VAS, V20, P1177, DOI 10.1161/01.ATV.20.5.1177; STARY HC, 1992, VIRCHOWS ARCH A, V421, P277, DOI 10.1007/BF01660974; Takei A, 2001, ATHEROSCLEROSIS, V154, P79, DOI 10.1016/S0021-9150(00)00465-2; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Teupser D, 2004, P NATL ACAD SCI USA, V101, P17795, DOI 10.1073/pnas.0408096101; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; Tobe M, 2003, BIOORGAN MED CHEM, V11, P609, DOI 10.1016/S0968-0896(02)00338-3; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Voisard R, 2001, BMC Mol Biol, V2, P7, DOI 10.1186/1471-2199-2-7; Voisard R, 1998, CORONARY ARTERY DIS, V9, P737, DOI 10.1097/00019501-199809110-00006; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Wong BWC, 2002, CARDIOVASC PATHOL, V11, P332, DOI 10.1016/S1054-8807(02)00111-4; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; Zeiffer U, 2004, CIRC RES, V94, P776, DOI 10.1161/01.RES.0000121105.72718.5C	55	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19167	19176		10.1074/jbc.M701642200	http://dx.doi.org/10.1074/jbc.M701642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17456471	hybrid			2022-12-25	WOS:000247475300058
J	Santos, SG; Campbell, EC; Lynch, S; Wong, V; Antoniou, AN; Powis, SJ				Santos, Susana G.; Campbell, Elaine C.; Lynch, Sarah; Wong, Vincent; Antoniou, Antony N.; Powis, Simon J.			Major histocompatibility complex class I-ERp57-tapasin interactions within the peptide-loading complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; DEPENDENT REDUCTASE ERP57; ENDOPLASMIC-RETICULUM; OXIDOREDUCTASE ERP57; HEAVY-CHAIN; CELL-LINE; MOLECULES; TAPASIN; HLA-B27; TAP	The endoplasmic reticulum-located multimolecular peptide-loading complex functions to load optimal peptides onto major histocompatibility complex ( MHC) class I molecules for presentation to CD8(+) T lymphocytes. Two oxidoreductases, ERp57 and protein-disulfide isomerase, are known to be components of the peptide-loading complex. Within the peptide-loading complex ERp57 is normally found disulfide-linked to tapasin, through one of its two thioredoxin-like redox motifs. We describe here a novel trimeric complex that disulfide links together MHC class I heavy chain, ERp57 and tapasin, and that is found in association with the transporter associated with antigen processing peptide transporter. The trimeric complex normally represents a small subset of the total ERp57-tapasin pool but can be significantly increased by altering intracellular oxidizing conditions. Direct mutation of a conserved structural cysteine residue implicates an interaction between ERp57 and the MHC class I peptide-binding groove. Taken together, our studies demonstrate for the first time that ERp57 directly interacts with MHC class I molecules within the peptide-loading complex and suggest that ERp57 and protein-disulfide isomerase act in concert to regulate the redox status of MHC class I during antigen presentation.	Univ St Andrews, Bute Med Sch, St Andrews KY16 9TS, Fife, Scotland; Univ Southampton, Sch Med, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of St Andrews; University of Southampton	Powis, SJ (corresponding author), Univ St Andrews, Bute Med Sch, St Andrews KY16 9TS, Fife, Scotland.	sjp10@st-andrews.ac.uk	Santos, Susana G/L-9351-2013	Santos, Susana G/0000-0002-8604-2978; Williams, Sarah/0000-0003-1574-3328; Antoniou, Antony/0000-0002-6536-7781; Powis, Simon/0000-0003-4218-2984				Allen RL, 1999, J IMMUNOL, V162, P5045; Antoniou AN, 2004, J BIOL CHEM, V279, P8895, DOI 10.1074/jbc.M311757200; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; Deverson EV, 2001, GENES IMMUN, V2, P48, DOI 10.1038/sj.gene.6363727; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lindquist JA, 2001, FASEB J, V15, P1448, DOI 10.1096/fj.00-0720fje; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Mear JP, 1999, J IMMUNOL, V163, P6665; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; Park B, 2006, CELL, V127, P369, DOI 10.1016/j.cell.2006.08.041; Paulsson KM, 2004, FASEB J, V18, P31, DOI 10.1096/fj.03-0846rev; Paulsson KM, 2001, INT IMMUNOL, V13, P1063, DOI 10.1093/intimm/13.8.1063; Peaper DR, 2005, EMBO J, V24, P3613, DOI 10.1038/sj.emboj.7600814; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Tran TM, 2004, J IMMUNOL, V172, P5110, DOI 10.4049/jimmunol.172.8.5110; Zhang YN, 2006, J BIOL CHEM, V281, P14622, DOI 10.1074/jbc.M512073200	32	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17587	17593		10.1074/jbc.M702212200	http://dx.doi.org/10.1074/jbc.M702212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17459881	hybrid			2022-12-25	WOS:000247084500030
J	Hansson, M; Dupuis, T; Stromquist, R; Andersson, B; Vener, AV; Carlberg, I				Hansson, Maria; Dupuis, Tiphaine; Stromquist, Ragna; Andersson, Bertil; Vener, Alexander V.; Carlberg, Inger			The mobile thylakoid phosphoprotein TSP9 interacts with the light-harvesting complex II and the peripheries of both photosystems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; STATE TRANSITIONS; CHLOROPLAST PHOSPHOPROTEINS; PHOTOSYNTHETIC MEMBRANES; 3-DIMENSIONAL STRUCTURE; ARABIDOPSIS-THALIANA; STRUCTURAL-CHANGES; ANTENNA; ORGANIZATION; POLYPEPTIDES	The localization of the plant-specific thylakoid-soluble phosphoprotein of 9 kDa, TSP9, within the chloroplast thylakoid membrane of spinach has been established by the combined use of fractionation, immunoblotting, cross-linking, and mass spectrometry. TSP9 was found to be exclusively confined to the thylakoid membranes, where it is enriched in the stacked grana membrane domains. After mild solubilization of the membranes, TSP9 migrated together with the major light-harvesting antenna (LHCII) of photosystem II (PSII) and with PSII-LHCII supercomplexes upon separation of the protein complexes by either native gel electrophoresis or sucrose gradient centrifugation. Studies with a cleavable cross-linking agent revealed the interaction of TSP9 with both major and minor LHCII proteins as identified by mass spectrometric sequencing. Cross-linked complexes that in addition to TSP9 contain the peripheral PSII subunits CP29, CP26, and PsbS, which form the interface between LHCII and the PSII core, were found. Our observations also clearly suggest an interaction of TSP9 with photosystem I (PSI) as shown by both immunodetection and mass spectrometry. Sequencing identified the peripheral PSI subunits PsaL, PsaF, and PsaE, originating from cross-linked protein complexes of around 30 kDa that also contained TSP9. The distribution of TSP9 among the cross-linked forms was found to be sensitive to conditions such as light exposure. An association of TSP9 with LHCII as well as the peripheries of the photosystems suggests its involvement in regulation of photosynthetic light harvesting.	[Hansson, Maria; Andersson, Bertil; Vener, Alexander V.] Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden; [Dupuis, Tiphaine; Stromquist, Ragna; Andersson, Bertil; Carlberg, Inger] Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden	Stockholm University; Linkoping University	Carlberg, I (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden.	ingerc@dbb.su.se	Andersson, Bertil/C-9328-2009					ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; Allen JF, 2003, SCIENCE, V299, P1530, DOI 10.1126/science.1082833; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; Antonkine ML, 2003, J MOL BIOL, V327, P671, DOI 10.1016/S0022-2836(03)00145-1; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; BENNETT J, 1987, FEBS LETT, V210, P22, DOI 10.1016/0014-5793(87)81290-5; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; Bergantino E, 2003, P NATL ACAD SCI USA, V100, P15265, DOI 10.1073/pnas.2533072100; BHALLA P, 1987, ARCH BIOCHEM BIOPHYS, V252, P97, DOI 10.1016/0003-9861(87)90012-9; Boekema EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/bi9827161; Carlberg I, 1999, BIOCHEMISTRY-US, V38, P3197, DOI 10.1021/bi982506o; Carlberg I, 2003, P NATL ACAD SCI USA, V100, P757, DOI 10.1073/pnas.0235452100; CARLBERG I, 1992, BIOCHIM BIOPHYS ACTA, V1099, P111, DOI 10.1016/0304-4173(92)90015-7; Ciambella C, 2005, PROTEOMICS, V5, P746, DOI 10.1002/pmic.200401129; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j; Fromme P, 2003, FEBS LETT, V555, P40, DOI 10.1016/S0014-5793(03)01124-4; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hammer MF, 1997, PLANT PHYSIOL, V113, P227, DOI 10.1104/pp.113.1.227; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Hansson M, 2003, MOL CELL PROTEOMICS, V2, P550, DOI 10.1074/mcp.M300050-MCP200; Holt NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/bi0494020; Horton P, 2005, J EXP BOT, V56, P365, DOI 10.1093/jxb/eri023; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Jolley C, 2005, J BIOL CHEM, V280, P33627, DOI 10.1074/jbc.M500937200; Kargul J, 2005, FEBS J, V272, P4797, DOI 10.1111/j.1742-4658.2005.04894.x; Kouril R, 2005, BIOCHEMISTRY-US, V44, P10935, DOI 10.1021/bi051097a; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Lindahl M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P321; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MICHEL H, 1991, J BIOL CHEM, V266, P17584; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; Niyogi KK, 2005, J EXP BOT, V56, P375, DOI 10.1093/jxb/eri056; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shevchenko A, 2002, MOL BIOTECHNOL, V20, P107, DOI 10.1385/MB:20:1:107; Snyders S, 2001, J BIOL CHEM, V276, P32169, DOI 10.1074/jbc.M102539200; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; Song JK, 2006, BIOCHEMISTRY-US, V45, P15633, DOI 10.1021/bi062148m; Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x; Takahashi H, 2006, P NATL ACAD SCI USA, V103, P477, DOI 10.1073/pnas.0509952103; Turkina MV, 2006, MOL CELL PROTEOMICS, V5, P1412, DOI 10.1074/mcp.M600066-MCP200; Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747; Vainonen JP, 2005, J BIOL CHEM, V280, P33679, DOI 10.1074/jbc.M505729200; Vener AV, 2006, ADV PHOTO RESPIRAT, V21, P107; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; Walcher W, 2003, ANAL CHEM, V75, P6775, DOI 10.1021/ac034866+; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; Yakushevska AE, 2001, EUR J BIOCHEM, V268, P6020, DOI 10.1046/j.0014-2956.2001.02505.x; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200	66	18	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16214	16222		10.1074/jbc.M605833200	http://dx.doi.org/10.1074/jbc.M605833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400553	hybrid			2022-12-25	WOS:000246794300029
J	Montecinos, V; Guzman, P; Barra, V; Villagran, M; Munoz-Montesino, C; Sotomayor, K; Escobar, E; Godoy, A; Mardones, L; Sotomayor, P; Guzman, C; Vasquez, O; Gallardo, V; van Zundert, B; Bono, MR; Onate, SA; Bustamante, M; Carcamo, JG; Rivas, CI; Vera, JC				Montecinos, Viviana; Guzman, Paula; Barra, Valeria; Villagran, Marcelo; Munoz-Montesino, Carola; Sotomayor, Kirsty; Escobar, Elizabeth; Godoy, Alejandro; Mardones, Lorena; Sotomayor, Paula; Guzman, Catherine; Vasquez, Osman; Gallardo, Victoria; van Zundert, Brigitte; Bono, Maria Rosa; Onate, Sergio A.; Bustamante, Marcelo; Carcamo, Juan G.; Rivas, Coralia I.; Vera, Juan Carlos			Vitamin C is an essential antioxidant that enhances survival of oxidatively stressed human vascular endothelial cells in the presence of a vast molar excess of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMMENDED DIETARY ALLOWANCE; BLOOD-BRAIN-BARRIER; ASCORBIC-ACID; DEHYDROASCORBIC ACID; THIOREDOXIN REDUCTASE; TRANSPORT; EXPRESSION; ACCUMULATION; IDENTIFICATION; GLUTAREDOXIN	Cellular glutathione levels may exceed vitamin C levels by 10-fold, generating the question about the real antioxidant role that low intracellular concentrations of vitamin C can play in the presence of a vast molar excess of glutathione. We characterized the metabolism of vitamin C and its relationship with glutathione in primary cultures of human endothelial cells oxidatively challenged by treatment with hydrogen peroxide or with activated cells undergoing the respiratory burst, and analyzed the manner in which vitamin C interacts with glutathione to increase the antioxidant capacity of cells. Our data indicate that: (i) endothelial cells express transporters for reduced and oxidized vitamin C and accumulate ascorbic acid with participation of glutathione-dependent dehydroascorbic acid reductases, (ii) although increased intracellular levels of vitamin C or glutathione caused augmented resistance to oxidative stress, 10-times more glutathione than vitamin C was required, (iii) full antioxidant protection required the simultaneous presence of intracellular and extracellular vitamin C at concentrations normally found in vivo, and (iv) intracellular vitamin C cooperated in enhancing glutathione recovery after oxidative challenge thus providing cells with enhanced survival potential, while extracellular vitamin C was recycled through a mechanism involving the simultaneous neutralization of oxidant species. Therefore, in endothelial cells under oxidative challenge, vitamin C functions as an essential cellular antioxidant even in the presence of a vast molar excess of glutathione.	Univ Concepcion, Dept Fisiopatol, Fac Ciencias Biol, Concepcion, Chile; Univ Chile, Fac Ciencias, Dept Bioquim, Santiago, Chile; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Univ Catolica Santisima Concepcion, Fac Med, Concepcion, Chile; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile	Universidad de Concepcion; Universidad de Chile; Roswell Park Cancer Institute; Universidad Catolica de la Santisima Concepcion; Universidad Austral de Chile	Vera, JC (corresponding author), Univ Concepcion, Dept Fisiopatol, Fac Ciencias Biol, Barrio Univ S-N,Casilla 160C, Concepcion, Chile.	juvera@udec.cl	Mardones, Lorena/Z-4896-2019; Godoy, Alejandro/GPS-4942-2022; Bono, Maria/G-7461-2014; Villagran, Marcelo/AAP-1171-2020	Mardones, Lorena/0000-0001-8037-4296; Villagran, Marcelo/0000-0003-3645-5659; Munoz, Carola/0000-0003-1851-0167; Carcamo, Juan Guillermo/0000-0002-2595-4375; Escobar Sagredo, Maria Elizabeth/0000-0002-9706-4312				Baekkevold ES, 1999, LAB INVEST, V79, P327; Best KA, 2005, MOL CELL BIOCHEM, V271, P43, DOI 10.1007/s11010-005-3442-0; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; Castro A, 1996, EUR J CELL BIOL, V70, P61; Duelli R, 2001, NEWS PHYSIOL SCI, V16, P71; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Godoy A, 2007, J BIOL CHEM, V282, P615, DOI 10.1074/jbc.M608300200; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Koshiishi I, 1998, BBA-GEN SUBJECTS, V1425, P209, DOI 10.1016/S0304-4165(98)00073-7; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Lovering AL, 2004, CANCER RES, V64, P1802, DOI 10.1158/0008-5472.CAN-03-2847; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 2003, BBA-MOL CELL RES, V1640, P153, DOI 10.1016/S0167-4889(03)00043-0; May JM, 2001, BIOCHEM PHARMACOL, V62, P873, DOI 10.1016/S0006-2952(01)00736-5; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; Nualart FJ, 2003, J BIOL CHEM, V278, P10128, DOI 10.1074/jbc.M210686200; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Regina A, 1997, BBA-GEN SUBJECTS, V1335, P135, DOI 10.1016/S0304-4165(96)00131-6; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Rivas CI, 1997, J BIOL CHEM, V272, P5814, DOI 10.1074/jbc.272.9.5814; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Seno T, 2004, J VASC RES, V41, P345, DOI 10.1159/000080525; Simpson IA, 2001, J BIOL CHEM, V276, P12725, DOI 10.1074/jbc.M010897200; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Tsukimori K, 2005, HYPERTENSION, V46, P696, DOI 10.1161/01.HYP.0000184197.11226.71; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wilson JX, 2005, ANNU REV NUTR, V25, P105, DOI 10.1146/annurev.nutr.25.050304.092647; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489	45	63	64	4	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15506	15515		10.1074/jbc.M608361200	http://dx.doi.org/10.1074/jbc.M608361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403685	hybrid			2022-12-25	WOS:000246589600027
J	Wei, Q; Yokota, C; Semenov, MV; Doble, B; Woodgett, J; He, X				Wei, Qiou; Yokota, Chika; Semenov, Mikhail V.; Doble, Brad; Woodgett, Jim; He, Xi			R-spondin1 is a high affinity ligand for LRP6 and induces LRP6 phosphorylation and beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; DUAL-KINASE MECHANISM; DISHEVELLED PHOSPHORYLATION; NEGATIVE REGULATOR; REPEAT DOMAIN; WNT PROTEINS; R-SPONDIN; PATHWAY; AXIN; ACTIVATION	R-spondin proteins are newly identified secreted molecules that activate beta-catenin signaling. However, the mechanism of R-spondin action and its relationship with Wnt signaling remain unclear. Here we show that human R-spondin1 (hRspo1) is a high affinity ligand for the Wnt co-receptor LRP6 (K-d = 1.2 nM). hRspo1 induces glycogen synthase kinase 3-dependent phosphorylation and activation of LRP6. DKK1, an LRP6 antagonist, inhibits hRspo1-induced LRP6 phosphorylation. We further demonstrate that hRspo1 synergizes with Frizzled5 in Xenopus axis induction assays and induces the phosphorylation of Dishevelled, a cytoplasmic component downstream of Frizzled function. Our study reveals interesting similarity and distinction between Wnt and R-spondin signaling.	Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol,Program Neurobiol, Boston, MA 02115 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	He, X (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol,Program Neurobiol, 300 Longwood Ave, Boston, MA 02115 USA.	Xi.He@childrens.harvard.edu	Doble, Bradley/V-7848-2019; Woodgett, Jim/F-1087-2010; Doble, Brad/L-7551-2016	Doble, Bradley/0000-0002-0260-2983; Woodgett, Jim/0000-0003-3731-5797; Doble, Brad/0000-0002-0260-2983				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Chen JZ, 2002, MOL BIOL REP, V29, P287, DOI 10.1023/A:1020479301379; Darras S, 1997, DEVELOPMENT, V124, P4275; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kato Y, 1999, J NEUROSCI, V19, P9364; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2004, PLOS BIOL, V2, P486, DOI 10.1371/journal.pbio.0020095; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	48	153	171	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15903	15911		10.1074/jbc.M701927200	http://dx.doi.org/10.1074/jbc.M701927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400545	hybrid			2022-12-25	WOS:000246589600065
J	Cox, SE; Doherty, C; Atkinson, SH; Nweneka, CV; Fulford, AJC; Ghattas, H; Rockett, KA; Kwiatkowski, DP; Prentice, AM				Cox, Sharon E.; Doherty, Conor; Atkinson, Sarah H.; Nweneka, Chidi V.; Fulford, Anthony J. C.; Ghattas, Hala; Rockett, Kirk A.; Kwiatkowski, Dominic P.; Prentice, Andrew M.			Haplotype Association between Haptoglobin (Hp2) and Hp Promoter SNP (A-61C) May Explain Previous Controversy of Haptoglobin and Malaria Protection	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; SICKLE-CELL TRAIT; GENE DELETION; 2-2 PHENOTYPE; IRON STATUS; IN-VITRO; POLYMORPHISM; HEMOGLOBIN; GENOTYPE; AHAPTOGLOBINEMIA	Background. Malaria is one of the strongest recent selective pressures on the human genome, as evidenced by the high levels of varying haemoglobinopathies in human populations-despite the increased risk of mortality in the homozygous states. Previously, functional polymorphisms of Hp, coded by the co-dominant alleles Hp1 and Hp2, have been variously associated with several infectious diseases, including malaria susceptibility. Methodology/Principal Findings. Risk of a clinical malarial episode over the course of a malarial transmission season was assessed using active surveillance in a cohort of Gambian children aged 10-72 months. We report for the first time that the major haplotype for the A-61C mutant allele in the promoter of haptoglobin (Hp)-an acute phase protein that clears haemoglobin released from haemolysis of red cells-is associated with protection from malarial infection in older children, (children aged >= 36 months, > 500 parasites/ul and temperature > 37.5 degrees C; OR = 0.42; [95% CI 0.24-0.73] p = 0.002) (Ir test for interaction, < 36 vs >= 36 months, p = 0.014). Protection was also observed using two other definitions, including temperature > 37.5 degrees C, dipstick positive, plus clinical judgement of malaria blinded to dipstick result (all ages, OR = 0.48, [95% CI 0.30-0.78] p = 0.003; >= 36 months, OR = 0.31, [95% CI 0.15-0.62] p = 0.001). A similar level of protection was observed for the known protective genetic variant, sickle cell trait (HbAS). Conclusions/Significance. We propose that previous conflicting results between Hp phenotypes/ genotypes and malaria susceptibility may be explained by differing prevalence of the A-61C SNP in the populations studied, which we found to be highly associated with the Hp2 allele. We report the -61C allele to be associated with decreased Hp protein levels (independent of Hp phenotype), confirming in vitro studies. Decreased Hp expression may lead to increased oxidant stress and increased red cell turnover, and facilitate the development of acquired immunity, similar to a mechanism suggested for sickle cell trait.	[Cox, Sharon E.; Atkinson, Sarah H.; Fulford, Anthony J. C.; Ghattas, Hala; Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1, England; [Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford, England; [Doherty, Conor; Atkinson, Sarah H.; Nweneka, Chidi V.] MRC Labs, MRC Keneba, Keneba, Gambia	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; Wellcome Centre for Human Genetics; MRC Laboratory Molecular Biology	Cox, SE (corresponding author), London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1, England.	Sharon.cox@lshtm.ac.uk	Prentice, Andrew/AAG-1961-2019; Cox, Sharon E/ABA-7986-2020; Ghattas, Hala/K-5661-2016; Nweneka, Chidi/AAH-9947-2021	Cox, Sharon E/0000-0002-9908-2936; Nweneka, Chidi/0000-0002-7278-2035; Kwiatkowski, Dominic/0000-0002-5023-0176	UK Medical Research Council; Medical Research Council [G19/9, G9505090] Funding Source: researchfish; MRC [G9505090, G19/9] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding: This study was funded by UK Medical Research Council who had no part in the design or analysis of the study.	Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x; Asleh R, 2005, CIRC RES, V96, P435, DOI 10.1161/01.RES.0000156653.05853.b9; Asleh R, 2003, CIRC RES, V92, P1193, DOI 10.1161/01.RES.0000076889.23082.F1; Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868; Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8; Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820; Bienzle U, 2005, TROP MED INT HEALTH, V10, P668, DOI 10.1111/j.1365-3156.2005.01444.x; BOREHAM PFL, 1981, T ROY SOC TROP MED H, V75, P193, DOI 10.1016/0035-9203(81)90316-3; Cabrera G, 2005, J INFECT DIS, V191, P1631, DOI 10.1086/429832; Calderoni DR, 2006, ANN TROP MED PARASIT, V100, P213, DOI 10.1179/136485906X86356; CLAYTON D, SNPHAP PROGRAM ESTIM; Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009; Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2; ElGhmati SM, 1996, J IMMUNOL, V156, P2542; Fowkes FJI, 2006, AM J TROP MED HYG, V74, P26, DOI 10.4269/ajtmh.2006.74.26; Friis T, 2003, JAIDS-J ACQ IMM DEF, V33, P74, DOI 10.1097/00126334-200305010-00011; GRANT DJ, 1993, AM J HUM GENET, V52, P974; GUETTA J, 2006, ATHEROSCLEROSIS; Hunt NH, 2001, REDOX REP, V6, P389, DOI 10.1179/135100001101536508; Imrie H, 2006, AM J TROP MED HYG, V74, P965, DOI 10.4269/ajtmh.2006.74.965; Imrie H, 2004, MOL BIOCHEM PARASIT, V133, P93, DOI 10.1016/j.molbiopara.2003.07.007; Koch W, 2003, CLIN CHEM, V49, P1937, DOI 10.1373/clinchem.2003.022442; Koch W, 2002, CLIN CHEM, V48, P1377; Koda Y, 1998, AM J HUM GENET, V62, P245, DOI 10.1086/301701; Koda Y, 2000, BLOOD, V95, P1138, DOI 10.1182/blood.V95.4.1138.004k27_1138_1143; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Langlois M, 1997, EUR J CLIN CHEM CLIN, V35, P199; Langlois MR, 2000, CLIN CHEM, V46, P1619; Langlois MR, 1997, AM J CLIN NUTR, V66, P606, DOI 10.1093/ajcn/66.3.606; Langlois MR, 1996, CLIN CHEM, V42, P1589; MAEDA N, 1991, AM J HUM GENET, V49, P158; MARSH K, 1988, T ROY SOC TROP MED H, V82, P532, DOI 10.1016/0035-9203(88)90495-6; McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Minang JT, 2004, ACTA TROP, V90, P107, DOI 10.1016/j.actatropica.2003.10.016; Mustafa S, 2004, DIABETES CARE, V27, P2103, DOI 10.2337/diacare.27.9.2103; Okazaki T, 1997, CLIN CHEM, V43, P2012; Okazaki T, 1997, CLIN CHIM ACTA, V258, P137, DOI 10.1016/S0009-8981(96)06468-6; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Quaye IK, 2006, J ATHEROSCLER THROMB, V13, P90, DOI 10.5551/jat.13.90; Quaye IKE, 2000, HUM HERED, V50, P382, DOI 10.1159/000022944; Quaye IKE, 2000, T ROY SOC TROP MED H, V94, P216, DOI 10.1016/S0035-9203(00)90281-5; ROUGEMONT A, 1988, LANCET, V2, P709; SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596; TAKIZAWA T, 1987, Genomics, V1, P228, DOI 10.1016/0888-7543(87)90048-6; Teye K, 2003, CLIN GENET, V64, P439, DOI 10.1034/j.1399-0004.2003.00149.x; Teye K, 2006, HUM BIOL, V78, P121, DOI 10.1353/hub.2006.0029; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7; TRAPE JF, 1988, AM J EPIDEMIOL, V127, P1282, DOI 10.1093/oxfordjournals.aje.a114920; Williams TN, 2006, MOL BIOCHEM PARASIT, V149, P121, DOI 10.1016/j.molbiopara.2006.05.007; Williams TN, 2005, PLOS MED, V2, P441, DOI 10.1371/journal.pmed.0020128; Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744; Yano A, 1998, ACTA MED OKAYAMA, V52, P173	53	39	39	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e362	10.1371/journal.pone.0000362	http://dx.doi.org/10.1371/journal.pone.0000362			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426810	Green Published, Green Accepted, gold			2022-12-25	WOS:000207445400002
J	Zhu, MJ; Ou, WB; Fletcher, CDM; Cohen, P; Demetri, GD; Fletcher, JA				Zhu, M-J; Ou, W-B; Fletcher, C. D. M.; Cohen, P. S.; Demetri, G. D.; Fletcher, J. A.			KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance	ONCOGENE			English	Article						KIT; PDGFRA; kinase; interaction; signal transduction	OF-FUNCTION MUTATIONS; C-KIT; IMATINIB MESYLATE; ACTIVATION; CELL; KINASE; SURVIVAL; PROLIFERATION; MECHANISMS; INHIBITOR	Most gastrointestinal stromal tumors (GISTs) express oncogenic and constitutively active forms of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinase proteins, and these kinase oncoproteins serve as targets for effective therapies. Given that mutant KIT oncoproteins serve crucial transforming roles in GISTs, we evaluated interactions with the KIT oncoproteins and determined signaling pathways that are dependent on KIT oncogenic activation in GISTs. Tyrosine-phosphorylated KIT oncoproteins interacted with PDGFRA, PDGFRB, phosphatidylinositol 3-kinase (PI3-K) and PKC theta in GIST cells, and these interactions were abolished by KIT inhibition with imatinib or PKC412 or KIT RNAi. Notably, tyrosine-phosphorylated PDGFRA was prominent in frozen GIST tumors expressing KIT oncoproteins, suggesting that KIT-mediated PDGFRA phosphorylation is an efficient and biologically consequential mechanism in GISTs. Activated signaling intermediates were identified by immuno affinity purification of tyrosine-phosphorylated proteins in GIST cells before and after treatment with KIT inhibitors, and these analyses show that GRB2, SHC, CBL and MAPK activation are largely KIT dependent in GISTs, whereas PI3-K, STAT1 and STAT3 activation are partially KIT dependent. In addition, we found that phosphorylation of several tyrosine kinase proteinsincluding JAK1 and EPHA4 -did not depend on KIT activation. Likewise, paxillin activation was independent of the KIT oncogenic signal. These studies identify signaling pathways that can provide both KIT-dependent and KIT-independent therapeutic synergies in GIST, and thereby highlight clinical strategies that might consolidate GIST therapeutic response to KIT/PDGFRA inhibition.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Novartis Oncol, Florham Pk, NJ USA; Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Harvard University; Dana-Farber Cancer Institute	Zhu, MJ (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	mzhu2@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442				Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; Rubin BP, 2001, CANCER RES, V61, P8118; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378	22	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6386	6395		10.1038/sj.onc.1210464	http://dx.doi.org/10.1038/sj.onc.1210464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452978				2022-12-25	WOS:000249737600003
J	Wan, M; Sabirsh, A; Wetterholm, A; Agerberth, B; Haeggstrom, JZ				Wan, Min; Sabirsh, Alan; Wetterholm, Anders; Agerberth, Birgitta; Haeggstrom, Jesper Z.			Leukotriene B-4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses	FASEB JOURNAL			English	Article						phagocytosis; inflammation	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INVASIVE BACTERIAL-INFECTION; SRC FAMILY KINASES; ANTIMICROBIAL PEPTIDES; A(4) HYDROLASE; DEFICIENT MICE; 5-LIPOXYGENASE; RECEPTOR; ACTIVATION; PROTEIN	In humans, the antimicrobial peptide LL- 37 and the potent chemotactic lipid leukotriene B-4 ( LTB4) are important mediators of innate immunity and host defense. Here we show that LTB4, at very low ( 1 nM) concentrations, strongly promotes release of LL- 37 peptides from human neutrophils ( PMNs) in a time- and dose- dependent manner, as determined by Western blot, enzyme- linked immunoassay ( ELISA), and antibacterial activity. The LTB4- induced LL- 37 release is mediated by the BLT1 receptor, and protein phosphatase- 1 ( PP- 1) inhibits the release by suppressing the BLT1- mediated exocytosis of PMN granules. Conversely, LL- 37 elicits translocation of 5- lipoxygenase ( 5- LO) from the cytosol to the perinuclear membrane in PMNs and promotes the synthesis and release of LTB4, particularly from cells primed with LPS or GM- CSF. Furthermore, LL- 37 stimulates PMN phagocytosis of Escherichia coli particles, a functional response that is enhanced by LTB4, especially in GM- CSF pretreated cells. In these cells, LL- 37 also enhances LTB4- induced phagocytosis. Hence, in human PMNs, positive feedback circuits exist between LL- 37 and LTB4 that reciprocally stimulate the release of these mediators with the potential for synergistic bioactions and enhanced immune responses. Moreover, these novel lipid- peptide signaling pathways may offer new opportunities for pharmacological intervention and treatment of chronic inflammatory diseases.	Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Div Chem 2, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jesper.haeggstrom@ki.se		Sabirsh, Alan/0000-0001-5310-0281				Bailie MB, 1996, J IMMUNOL, V157, P5221; Borregaard N, 1997, ANN NY ACAD SCI, V832, P62, DOI 10.1111/j.1749-6632.1997.tb46237.x; Byrum RS, 1999, J IMMUNOL, V163, P6810; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; CSERNOK E, 1990, AM J PATHOL, V137, P1113; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Edfeldt K, 2006, ARTERIOSCL THROM VAS, V26, P1551, DOI 10.1161/01.ATV.0000223901.08459.57; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; HAFSTROM I, 1981, FEBS LETT, V130, P146, DOI 10.1016/0014-5793(81)80684-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103; Raqib R, 2006, P NATL ACAD SCI USA, V103, P9178, DOI 10.1073/pnas.0602888103; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Serezani CHC, 2005, BLOOD, V106, P1067, DOI 10.1182/blood-2004-08-3323; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Surette ME, 1998, FASEB J, V12, P1521, DOI 10.1096/fasebj.12.14.1521; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Varoga D, 2005, ANN ANAT, V187, P499, DOI 10.1016/j.aanat.2005.03.004; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; Zasloff M, 2002, LANCET, V360, P1116, DOI 10.1016/S0140-6736(02)11239-6; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	45	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2897	2905		10.1096/fj.06-7974com	http://dx.doi.org/10.1096/fj.06-7974com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17446260				2022-12-25	WOS:000249237500030
J	Li, YC; Boehning, DF; Qian, T; Popov, VL; Weinman, SA				Li, Yanchun; Boehning, Darren F.; Qian, Ting; Popov, Vsevolod L.; Weinman, Steven A.			Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity	FASEB JOURNAL			English	Article						HCV core; mitochondria; cytosolic Ca2+; MAVS	ANTIVIRAL SIGNALING PROTEIN; OXIDATIVE STRESS; PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; MOLECULAR DETERMINANTS; INNATE IMMUNITY; CALCIUM; MECHANISMS; EXPRESSION	Many viruses have evolved mechanisms to alter mitochondrial function. The hepatitis C virus (HCV) produces a viral core protein that targets to mitochondria and increases Ca2(+)- dependent ROS production. The aim of this study was to determine whether core's effects are mediated by changes in mitochondrial Ca2+ uptake. Core expression caused enhanced mitochondrial Ca2+ uptake in response to ER Ca2+ release induced by thapsigargin or ATP. It also increased mitochondrial superoxide production and mitochondrial permeability transition ( MPT). Incubating mouse liver mitochondria with an HCV core ( 100 ng/mg) in vitro increased Ca2+ entry rate by similar to 2-fold. Entry was entirely inhibited by the mitochondrial Ca2+ uniporter inhibitor, Ru-360, but not influenced by an Na+/ Ca2+ exchanger inhibitor or ROS scavengers. These results indicate that core directly increases mitochondrial Ca2+ uptake via a primary effect on the uniporter. This enhanced the ability of mitochondria to sequester Ca2+ in response to ER Ca2+ release, and increased mitochondrial ROS production and MPT. Thus, the mitochondrial Ca2+ uniporter is a newly identified target for viral modification of cell function.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Weinman, Steven/E-7012-2011; li, yan/GTI-4638-2022; Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NIAAA NIH HHS [AA12863] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Camello-Almaraz C, 2006, AM J PHYSIOL-CELL PH, V291, pC1082, DOI 10.1152/ajpcell.00217.2006; Chinopoulos C, 2006, FEBS J, V273, P433, DOI 10.1111/j.1742-4658.2005.05103.x; Choi J, 2006, AM J PHYSIOL-GASTR L, V290, pG847, DOI 10.1152/ajpgi.00522.2005; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chou AH, 2005, J IMMUNOL, V174, P2160, DOI 10.4049/jimmunol.174.4.2160; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Griffin S, 2005, J VIROL, V79, P15525, DOI 10.1128/JVI.79.24.15525-15536.2005; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Hernandez-SanMiguel E, 2006, CELL CALCIUM, V40, P53, DOI 10.1016/j.ceca.2006.03.009; JOHONSON D, 1967, METHOD ENZYMOL, V10, P94; Julian D, 2005, J EXP BIOL, V208, P4109, DOI 10.1242/jeb.01867; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; KOIKE K, 2005, CLIN GASTROENTEROL H, V3, P132; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Meyer K, 2005, VIROLOGY, V336, P198, DOI 10.1016/j.virol.2005.03.016; Michelangeli F, 2005, CURR OPIN CELL BIOL, V17, P135, DOI 10.1016/j.ceb.2005.01.005; Moreau B, 2006, CURR BIOL, V16, P1672, DOI 10.1016/j.cub.2006.06.059; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Otani K, 2005, GASTROENTEROLOGY, V128, P96, DOI 10.1053/j.gastro.2004.10.045; OTT MT, 1989, J SURG RES, V47, P248, DOI 10.1016/0022-4804(89)90115-7; Piccoli C, 2006, BBA-BIOENERGETICS, V1757, P1429, DOI 10.1016/j.bbabio.2006.05.018; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Shoshan-Barmatz V, 2004, BBA-BIOENERGETICS, V1657, P105, DOI 10.1016/j.bbabio.2004.02.009; Suzuki R, 2005, J VIROL, V79, P1271, DOI 10.1128/JVI.79.2.1271-1281.2005; Suzuki R, 1999, INTERVIROLOGY, V42, P145, DOI 10.1159/000024973; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Tillmann HL, 2005, SEMIN LIVER DIS, V25, P84, DOI 10.1055/s-2005-864784; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; Wang D, 2006, IEEE AERO EL SYS MAG, V21, P3, DOI 10.1109/MAES.2006.1705163; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zheng Y, 2005, J MICROBIOL, V43, P529	48	129	133	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2474	2485		10.1096/fj.06-7345com	http://dx.doi.org/10.1096/fj.06-7345com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392480				2022-12-25	WOS:000248454400022
J	Nemeth, ZH; Bleich, D; Csoka, B; Pacher, P; Mabley, JG; Himer, L; Vizi, ES; Deitch, EA; Szabo, C; Cronstein, BN; Hasko, G				Nemeth, Zoltan H.; Bleich, David; Csoka, Balazs; Pacher, Pal; Mabley, Jon G.; Himer, Leonora; Vizi, E. Sylvester; Deitch, Edwin A.; Szabo, Csaba; Cronstein, Bruce N.; Hasko, Gyorgy			Adenosine receptor activation ameliorates type 1 diabetes	FASEB JOURNAL			English	Article						immune; islet; inflammation	RAT PANCREATIC-ISLETS; IFN-GAMMA; INSULIN-SECRETION; A(2B) RECEPTORS; A(2A) RECEPTOR; CELL-LINE; TNF-ALPHA; T-CELLS; EXPRESSION; MACROPHAGES	Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin ( MLDS) treatment and in nonobese diabetic ( NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'- N- ethylcarboxamidoadenosine ( NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A(2B) receptor antagonist N-( 4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide ( MRS 1754). The selective A(1) receptor agonist 2-chloro-N-6-cyclopentyladenosine ( CCPA) and A(3) receptor agonist N-6-( 3-iodobenzyl)-adenosine-5'-N-methyluronamide ( IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A(2A) receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine ( CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1 alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.	UMDNJ, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; UMDNJ, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; Natl Inst Alcohol Abuse & Alcoholism, Lab Physiol Studies, Sect Oxidat Stress & Tissue Injury, NIH, Bethesda, MD USA; Univ Brighton, Sch Pharm & Biomol Sci, Brighton, E Sussex, England; Hungarian Acad Sci, Inst Expt Med, Dept Pharmacol, H-1051 Budapest, Hungary; NYU, Sch Med, Dept Med, Div Clin Pharmacol, New York, NY USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Brighton; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; New York University	Hasko, G (corresponding author), UMDNJ, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.	haskoge@umdnj.edu	Szabo, Csaba/D-1882-2013; Mabley, Jon G/D-2296-2010; Pacher, Pal/B-6378-2008; Cronstein, Bruce N/D-4678-2011; Szabo, Csaba/ABG-2644-2021	Pacher, Pal/0000-0001-7036-8108; Cronstein, Bruce N/0000-0002-4295-7383; Csoka, Balazs/0000-0002-7562-1130; Mabley, Jon/0000-0001-9423-6230	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM66189, R01 GM066189-02, R01 GM066189, R01 GM066189-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cameron MJ, 2000, J IMMUNOL, V165, P1102, DOI 10.4049/jimmunol.165.2.1102; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; Eiselein L, 2004, ILAR J, V45, P231, DOI 10.1093/ilar.45.3.231; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016; Kukreja A, 1999, J CLIN ENDOCR METAB, V84, P4371, DOI 10.1210/jc.84.12.4371; Lai EY, 2007, DIABETES, V56, P107, DOI 10.2337/db06-0623; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Mabley JG, 2003, MOL MED, V9, P96, DOI 10.2119/2003-00016.Mabley; Mirabet M, 1999, J CELL SCI, V112, P491; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; Nemeth ZH, 2006, J IMMUNOL, V176, P5616, DOI 10.4049/jimmunol.176.9.5616; NISHIDA Y, 1984, INT J IMMUNOPHARMACO, V6, P335, DOI 10.1016/0192-0561(84)90051-1; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Olsson R, 2000, TRANSPLANTATION, V70, P280, DOI 10.1097/00007890-200007270-00007; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Ralevic V, 1998, PHARMACOL REV, V50, P413; SANDBERG G, 1983, INT J IMMUNOPHARMACO, V5, P259, DOI 10.1016/0192-0561(83)90027-9; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Verspohl EJ, 2002, CAN J PHYSIOL PHARM, V80, P562, DOI 10.1139/Y02-079; Xaus J, 1999, J IMMUNOL, V162, P3607; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933	38	85	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2379	2388		10.1096/fj.07-8213com	http://dx.doi.org/10.1096/fj.07-8213com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17405852	Green Accepted			2022-12-25	WOS:000248454400013
J	Yuan, CJ; Sato, M; Lanier, SM; Smrcka, AV				Yuan, Chujun; Sato, Motohiko; Lanier, Stephen M.; Smrcka, Alan V.			Signaling by a non-dissociated complex of G protein beta gamma and alpha subunits stimulated by a receptor-independent activator of G protein signaling, AGS8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; YEAST G-PROTEIN; AMINO-TERMINUS; CELLS; REARRANGEMENT; DETERMINANTS; INHIBITION; MECHANISMS; EFFECTORS; BINDING	Accumulating evidence suggests that heterotrimeric G protein activation may not require G protein subunit dissociation. Results presented here provide evidence for a subunit dissociation-independent mechanism for G protein activation by a receptor-independent activator of G protein signaling, AGS8. AGS8 is a member of the AGS group III family of AGS proteins thought to activate G protein signaling primarily through interactions with G beta gamma subunits. Results are presented demonstrating that AGS8 binds to the effector and alpha subunit binding "hot spot" on G beta gamma yet does not interfere with G alpha subunit binding to G beta gamma or phospholipase C beta 2 activation. AGS8 stimulates activation of phospholipase C beta 2 by heterotrimeric G alpha beta gamma and forms a quaternary complex with G alpha(i1), G beta(1)gamma(2), and phospholipase C beta 2. AGS8 rescued phospholipase C beta binding and regulation by an inactive beta subunit with a mutation in the hot spot (beta(1)(W99A)gamma(2)) that normally prevents binding and activation of phospholipase C beta 2. This demonstrates that, in the presence of AGS8, the hot spot is not used for G beta gamma interactions with phospholipase C beta 2. Mutation of an alternate binding site for phospholipase C beta 2 in the amino- terminal coiled- coil region of G beta gamma prevented AGS8- dependent phospholipase C binding and activation. These data implicate a mechanism for AGS8, and potentially other G beta gamma binding proteins, for directing G beta gamma signaling through alternative effector activation sites on G beta gamma in the absence of subunit dissociation.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; Yokohama City Univ, Sch Med, Cardiovasc Res Inst, Yokohama, Kanagawa 236, Japan; Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	University of Rochester; Yokohama City University; University of Rochester; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	Alan_Smrcka@urmc.rochester.edu		Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286, R01GM053536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM060286, GM053536] Funding Source: Medline; NIMH NIH HHS [MH55391] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blumer JB, 2005, TRENDS PHARMACOL SCI, V26, P470, DOI 10.1016/j.tips.2005.07.003; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Bonacci TM, 2005, J BIOL CHEM, V280, P10174, DOI 10.1074/jbc.M412514200; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Davis TL, 2005, BIOCHEMISTRY-US, V44, P10593, DOI 10.1021/bi050655i; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goubaeva F, 2003, J BIOL CHEM, V278, P19634, DOI 10.1074/jbc.M300052200; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARTMAN IVJ, 1999, J BIOL CHEM, V271, P22591; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Levitzki A, 2002, CHEMBIOCHEM, V3, P815, DOI 10.1002/1439-7633(20020902)3:9<815::AID-CBIC815>3.0.CO;2-E; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NEER EJ, 1988, J BIOL CHEM, V263, P8996; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Riven I, 2006, NEURON, V51, P561, DOI 10.1016/j.neuron.2006.08.017; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Sato M, 2006, P NATL ACAD SCI USA, V103, P797, DOI 10.1073/pnas.0507467103; Sato M, 2006, ANNU REV PHARMACOL, V46, P151, DOI 10.1146/annurev.pharmtox.46.120604.141115; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Ugur O, 2005, MOL PHARMACOL, V68, P720, DOI 10.1124/mol.104.010306; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yoshikawa DM, 2001, J BIOL CHEM, V276, P11246, DOI 10.1074/jbc.M006073200	39	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19938	19947		10.1074/jbc.M700396200	http://dx.doi.org/10.1074/jbc.M700396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17446173	hybrid			2022-12-25	WOS:000247650600068
J	Philip, F; Sengupta, P; Scarlata, S				Philip, Finly; Sengupta, Parijat; Scarlata, Suzanne			Signaling through a G protein-coupled receptor and its corresponding G protein follows a stoichiometrically limited model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; RESONANCE ENERGY-TRANSFER; BRADYKININ B-2 RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; LATERAL MOBILITY; ACTIVATION; MEMBRANE; DYNAMICS; CELLS; TRAFFICKING	The bradykinin receptor is a G protein-coupled receptor (GPCR) that is coupled to the G alpha(q) family of heterotrimeric G proteins. In general, a GPCR can exert intracellular signals either by transiently associating with multiple diffusing G protein subunits or by activating a G protein that is stably bound to the receptor, thus generating a signal that is limited by the stoichiometry of the complex. Here we have distinguished between these models by monitoring the association of type 2 bradykinin receptor (B2R) and the G alpha(q)/G beta gamma heterotrimer in living human embryonic kidney 293 cells expressing fluorescent-tagged proteins. Stable B2R-G alpha(.)(q)G beta gamma complexes are observed in resting cells by fluorescence resonance energy transfer from either G alpha(q)-eCFP or eCFP-G beta gamma to B2R-eYFP. Stimulating the cells with bradykinin causes detachment of B2R from the G protein subunits as the receptor internalizes into early endosomes, with a corresponding elimination of B2R-G protein fluorescence resonance energy transfer because G alpha(q) and its associated G beta gamma remain on the plasma membrane. Single point and scanning fluorescence correlation spectroscopy measurements show that a portion of B2R molecules diffuses with a mobility corresponding to dimers or small oligomers, whereas a second fraction diffuses in higher order molecular assemblies. Our studies support a model in which receptors are pre-coupled with their corresponding G proteins in the basal state of cells thereby limiting the response to an external signal to a defined stoichiometry that allows for a rapid and directed cellular response.	SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	Suzanne.Scarlata@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P734; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; BLANKAT A, 2000, MOL CELL BIOL, V20, P6837; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Briddon SJ, 2004, P NATL ACAD SCI USA, V101, P4673, DOI 10.1073/pnas.0400420101; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Chen Y, 1999, METHODS, V19, P234, DOI 10.1006/meth.1999.0854; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Haasemann M, 1998, J CELL SCI, V111, P917; Hegener O, 2004, BIOCHEMISTRY-US, V43, P6190, DOI 10.1021/bi035928t; HENIS YI, 1982, P NATL ACAD SCI-BIOL, V79, P2907, DOI 10.1073/pnas.79.9.2907; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hynes TR, 2004, J BIOL CHEM, V279, P44101, DOI 10.1074/jbc.M405151200; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Liang W, 2004, J CELL SCI, V117, P723, DOI 10.1242/jcs.00878; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Maier C, 2005, J CELL SCI, V118, P3353, DOI 10.1242/jcs.02462; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; Myung CS, 2006, MOL PHARMACOL, V69, P877, DOI 10.1124/mol.105.018994; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; PETERS R, 1988, FEBS LETT, V234, P1, DOI 10.1016/0014-5793(88)81290-0; Philip F, 2004, BIOCHEMISTRY-US, V43, P11691, DOI 10.1021/bi049381+; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ricupero DA, 1997, BIOCHEM J, V327, P803; Riven I, 2006, NEURON, V51, P561, DOI 10.1016/j.neuron.2006.08.017; Ruan QQ, 2004, BIOPHYS J, V87, P1260, DOI 10.1529/biophysj.103.036483; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Sengupta P, 2002, METHODS, V27, P374, DOI 10.1016/S1046-2023(02)00096-8; SMRCKA AV, 2003, USE GREEN FLUORESCEN, P223; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	46	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19203	19216		10.1074/jbc.M701558200	http://dx.doi.org/10.1074/jbc.M701558200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420253	hybrid			2022-12-25	WOS:000247475300061
J	Liu, JY; Seibold, SA; Rieke, CJ; Song, I; Cukier, RI; Smith, WL				Liu, Jiayan; Seibold, Steve A.; Rieke, Caroline J.; Song, Inseok; Cukier, Robert I.; Smith, William L.			Prostaglandin endoperoxide H synthases - Peroxidase hydroperoxide specificity and cyclooxygenase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; POLYUNSATURATED FATTY-ACIDS; MANGANO PROTOPORPHYRIN-IX; SITE-DIRECTED MUTAGENESIS; HIGHER OXIDATION-STATES; COMPOUND-I; SUBCELLULAR-LOCALIZATION; PRODUCTIVE CONFORMATION; HORSERADISH-PEROXIDASE; INACTIVATION KINETICS	The cyclooxygenase (COX) activity of prostaglandin endoperoxide H synthases (PGHSs) converts arachidonic acid and O-2 to prostaglandin G(2) (PGG(2)). PGHS peroxidase (POX) activity reduces PGG(2) to PGH(2). The first step in POX catalysis is formation of an oxyferryl heme radical cation (Compound I), which undergoes intramolecular electron transfer forming Intermediate II having an oxyferryl heme and a Tyr-385 radical required for COX catalysis. PGHS POX catalyzes heterolytic cleavage of primary and secondary hydroperoxides much more readily than H2O2, but the basis for this specificity has been unresolved. Several large amino acids form a hydrophobic "dome" over part of the heme, but when these residues were mutated to alanines there was little effect on Compound I formation from H2O2 or 15-hydroperoxyeicosatetraenoic acid, a surrogate substrate for PGG(2). Ab initio calculations of heterolytic bond dissociation energies of the peroxyl groups of small peroxides indicated that they are almost the same. Molecular Dynamics simulations suggest that PGG(2) binds the POX site through a peroxyl-iron bond, a hydrogen bond with His-207 and van der Waals interactions involving methylene groups adjoining the carbon bearing the peroxyl group and the protoporphyrin IX. We speculate that these latter interactions, which are not possible with H2O2, are major contributors to PGHS POX specificity. The distal Gln-203 four residues removed from His-207 have been thought to be essential for Compound I formation. However, Q203V PGHS-1 and PGHS-2 mutants catalyzed heterolytic cleavage of peroxides and exhibited native COX activity. PGHSs are homodimers with each monomer having a POX site and COX site. Cross-talk occurs between the COX sites of adjoining monomers. However, no cross-talk between the POX and COX sites of monomers was detected in a PGHS-2 heterodimer comprised of a Q203R monomer having an inactive POX site and a G533A monomer with an inactive COX site.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Michigan State University; Michigan State University; University of Michigan System; University of Michigan	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5301 Med Sci Res Bldg III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	smithww@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BACH RD, 1994, J AM CHEM SOC, V116, P5379, DOI 10.1021/ja00091a049; Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; BRASH AR, 1991, J BIOL CHEM, V266, P22926; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Case DA, 2002, AMBER SIMULATION SOF; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Chubb AJ, 2006, BIOCHEMISTRY-US, V45, P811, DOI 10.1021/bi051973k; Cremer D., 1983, CHEM PEROXIDES; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEMONTELLANO PO, 1995, CYTOCHROME P450 STRU, P49; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DIX TA, 1985, J BIOL CHEM, V260, P5351; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FRISCH MJ, 2001, GAUSSIAN 98; Girotti AW, 1998, J LIPID RES, V39, P1529; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HSI LC, 1995, BIOCHEM BIOPH RES CO, V207, P652, DOI 10.1006/bbrc.1995.1237; Huyett JE, 1998, INORG CHEM, V37, P1361, DOI 10.1021/ic9703639; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kelley SO, 1999, MET IONS BIOL SYST, V36, P211; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 2003, PROG LIPID RES, V42, P377, DOI 10.1016/S0163-7827(03)00023-7; Kulmacz RJ, 2005, BIOCHEM BIOPH RES CO, V338, P25, DOI 10.1016/j.bbrc.2005.08.030; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Landino LM, 1996, BIOCHEMISTRY-US, V35, P2637, DOI 10.1021/bi952546h; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; OHKI S, 1979, J BIOL CHEM, V254, P829; OTTO JC, 1995, ADV PROSTAG THROMB L, V23, P29; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Putter J, 1975, METHOD ENZYMAT AN, P685; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; Seibold SA, 2000, BIOCHEMISTRY-US, V39, P6616, DOI 10.1021/bi0002333; Seibold SA, 2004, J PHYS CHEM B, V108, P9297, DOI 10.1021/jp049844l; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; SMITH W L, 1981, Progress in Lipid Research, V20, P103, DOI 10.1016/0163-7827(81)90020-5; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; Svistunenko DA, 2005, BBA-BIOENERGETICS, V1707, P127, DOI 10.1016/j.bbabio.2005.01.004; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1997, J BIOL CHEM, V272, P8885; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; Wu G, 2003, BIOCHEMISTRY-US, V42, P13772, DOI 10.1021/bi035415m; Wu G, 2001, J BIOL CHEM, V276, P19879, DOI 10.1074/jbc.M100628200; Yu Y, 2006, NAT MED, V12, P699, DOI 10.1038/nm1412; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103; 2003, MOL OPERATING ENV	81	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18233	18244		10.1074/jbc.M701235200	http://dx.doi.org/10.1074/jbc.M701235200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17462992	hybrid			2022-12-25	WOS:000247302000030
J	Vunta, H; Davis, F; Palempalli, UD; Bhat, D; Arner, RJ; Thompson, JT; Peterson, DG; Reddy, CC; Prabhu, KS				Vunta, Hema; Davis, Faith; Palempalli, Umamaheswari D.; Bhat, Deepa; Arner, Ryan J.; Thompson, Jerry T.; Peterson, Devin G.; Reddy, C. Channa; Prabhu, K. Sandeep			The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta(12,14)-prostaglandin J(2) in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	9th International Symposium on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases	2004	San Francisco, CA				NF-KAPPA-B; ACTIVATED RECEPTOR-GAMMA; PROSTATE-CANCER; GENE-TRANSCRIPTION; SERUM SELENIUM; UP-REGULATION; DNA-BINDING; PPAR-GAMMA; SYNTHASE; CELLS	Selenium is an essential micronutrient that suppresses the redox-sensitive transcription factor NF-kappa B-dependent pro-inflammatory gene expression. To understand the molecular mechanisms underlying the anti-inflammatory property of selenium, we examined the activity of a key kinase of the NF-kappa B cascade, I kappa B- kinase beta (IKK beta) subunit, as a function of cellular selenium status in murine primary bone marrow- derived macrophages and RAW264.7 macrophage-like cell line. In vitro kinase assays revealed that selenium supplementation decreased the activity of IKK beta in lipopolysaccharide (LPS)-treated macrophages. Stimulation by LPS of selenium-supplemented macrophages resulted in a time-dependent increase in 15-deoxy-Delta(12,14)- prostaglandin J(2) (15d- PGJ(2)) formation, an endogenous inhibitor of IKK beta activity. Further analysis revealed that inhibition of IKK beta activity in selenium-supplemented cells correlated with the Michael addition product of 15d- (P)GJ(2) with Cys-179 of IKK beta, while the formation of such an adduct was significantly decreased in the selenium-deficient macrophages. In addition, anti-inflammatory activities of selenium were also mediated by the 15d-PGJ(2)-dependent activation of the peroxisome proliferator-activated nuclear receptor-gamma in macrophages. Experiments using specific cyclooxygenase (COX) inhibitors and genetic knockdown approaches indicated that COX-1, and not the COX-2 pathway, was responsible for the increased synthesis of 15dP-GJ(2) in selenium-supplemented macrophages. Taken together, our results suggest that selenium supplementation increases the production of 15d- PGJ(2) as an adaptive response to protect cells against oxidative stress-induced pro-inflammatory gene expression. More specifically, modification of protein thiols by 15d- PGJ(2) represents a previously undescribed code for redox regulation of gene expression by selenium.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Immunol & Infect Dis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; Penn State Univ, Dept Food Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Prabhu, KS (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, 115 William L Henning Bldg, University Pk, PA 16802 USA.	ksp4@psu.edu						Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Ausubel FM, 2005, NAT IMMUNOL, V6, P973, DOI 10.1038/ni1253; Bailey ST, 2005, NAT IMMUNOL, V6, P966, DOI 10.1038/ni1005-966; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Breedlove HA, 2006, BREAST CANCER RES TR, V97, P225, DOI 10.1007/s10549-005-9012-z; BURK RF, 1990, PHARMACOL THERAPEUT, V45, P383, DOI 10.1016/0163-7258(90)90073-B; Carcamo JM, 2002, BIOCHEMISTRY-US, V41, P12995, DOI 10.1021/bi0263210; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Cole Suzanne B, 2005, Nutr Clin Pract, V20, P662, DOI 10.1177/0115426505020006662; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Foster HD, 2004, MED HYPOTHESES, V62, P549, DOI 10.1016/j.mehy.2003.12.009; Gasparian AV, 2002, MOL CANCER THER, V1, P1079; Hadley KB, 2001, J NUTR BIOCHEM, V12, P693, DOI 10.1016/S0955-2863(01)00189-9; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hartikainen H, 2005, J TRACE ELEM MED BIO, V18, P309, DOI 10.1016/j.jtemb.2005.02.009; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; Klein EA, 2004, ANN NY ACAD SCI, V1031, P234, DOI 10.1196/annals.1331.023; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Moosmann B, 2004, LANCET, V363, P892, DOI 10.1016/S0140-6736(04)15739-5; Moskovitz J, 2003, P NATL ACAD SCI USA, V100, P7486, DOI 10.1073/pnas.1332607100; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Prabhu KS, 2002, BIOCHEM J, V366, P203, DOI 10.1042/BJ20020256; Prabhu KS, 2005, J BIOL CHEM, V280, P19895, DOI 10.1074/jbc.M502621200; PRESTON AM, 1991, PROG FOOD NUTR SCI, V15, P183; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rojas Armando, 2006, Current Vascular Pharmacology, V4, P277, DOI 10.2174/157016106777698441; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rouzer CA, 2005, J LIPID RES, V46, P1027, DOI 10.1194/jlr.M500006-JLR200; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sonn GA, 2005, PROSTATE CANCER P D, V8, P304, DOI 10.1038/sj.pcan.4500825; Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193; SPEER CP, 1989, MONATSSCHR KINDERH, V137, P390; Tamura T, 2002, METHOD ENZYMOL, V347, P297; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Vogt TM, 2003, INT J CANCER, V103, P664, DOI 10.1002/ijc.10866; Zamamiri-Davis F, 2002, FREE RADICAL BIO MED, V32, P890, DOI 10.1016/S0891-5849(02)00775-X	46	166	173	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17964	17973		10.1074/jbc.M703075200	http://dx.doi.org/10.1074/jbc.M703075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	179PK	17439952	hybrid			2022-12-25	WOS:000247302000003
J	Wang, JL; Shen, WH; Jin, YJ; Brandt-Rauf, PW; Yin, YX				Wang, Jianli; Shen, Wen Hong; Jin, Yan J.; Brandt-Rauf, Paul W.; Yin, Yuxin			A molecular link between E2F-1 and the MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-PROLIFERATION; PROTEIN-KINASES; P53; GROWTH; INHIBITION; EXPRESSION; PHOSPHATASES	Transcription factor E2F-1 mediates apoptosis and suppresses tumorigenesis. The mechanisms by which E2F-1 functions in these processes are largely unclear. We report here that E2F-1 acts as a transcriptional regulator of MKP-2 ( MAPK phosphatase-2), a dual specificity protein phosphatase (DUSP4) with stringent substrate specificity for MAPKs. We show that E2F-1 is required for the cellular apoptotic response to oxidative damage. MKP-2 is greatly increased following oxidative stress, and E2F-1 is necessary for that induction. We found that E2F-1 is physically associated with the MKP-2 promoter and can transactivate the promoter of the MKP-2 gene. Specifically, E2F-1 binds to a perfect palindromic motif in the MKP-2 promoter. Finally, we show that this E2F-1/MKP-2 pathway mediates apoptosis under oxidative stress and that MKP-2 suppresses tumor formation in nude mice. Our findings demonstrate that E2F-1 is a transcriptional activator of MKP-2 and that MKP-2 is an essential cell death mediator in the E2F-1 pathway. Characterization of MKP-2 as a cell death mediator may lead to the development of new strategies for cancer treatment.	Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Yin, YX (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA.	yy151@columbia.edu		SHEN, WEN/0000-0002-5830-6518	NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER; NCI NIH HHS [R0 CA102447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kundu N, 2002, CANCER RES, V62, P2343; Lala PK, 1997, INT J CANCER, V73, P371, DOI 10.1002/(SICI)1097-0215(19971104)73:3<371::AID-IJC12>3.0.CO;2-G; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki Y, 1996, IMMUNOLOGY, V87, P396, DOI 10.1046/j.1365-2567.1996.431546.x; Theodosiou A, 2002, GENOME BIOL, V3; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	71	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18521	18531		10.1074/jbc.M610538200	http://dx.doi.org/10.1074/jbc.M610538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452331	hybrid			2022-12-25	WOS:000247302000057
J	Nonaka, M; Ma, BY; Ohtani, M; Yamamoto, A; Murata, M; Totani, K; Ito, Y; Miwa, K; Nogami, W; Kawasaki, N; Kawasaki, T				Nonaka, Motohiro; Ma, Bruce Yong; Ohtani, Misato; Yamamoto, Akitsugu; Murata, Masayuki; Totani, Kiichiro; Ito, Yukishige; Miwa, Keiko; Nogami, Wataru; Kawasaki, Nobuko; Kawasaki, Toshisuke			Subcellular localization and physiological significance of intracellular mannan-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; RAT-LIVER; LECTIN ERGIC-53; QUALITY-CONTROL; HIV TYPE-1; TRANSPORT; RECEPTOR	Mannan-binding protein (MBP) is a C-type mammalian lectin specific for mannose and N-acetylglucosamine. MBP is mainly synthesized in the liver and occurs naturally in two forms, serum MBP (S-MBP) and intracellular MBP (I-MBP). S-MBP activates complement in association with MBP-associated serine proteases via the lectin pathway. Despite our previous study (Mori, K., Kawasaki, T., and Yamashina, I. (1984) Arch. Biochem. Biophys. 232, 223 -233), the subcellular localization of I-MBP and its functional implication have not been clarified yet. Here, as an extension of our previous studies, we have demonstrated that the expression of human MBP cDNA reproduces native MBP differentiation of S-MBP and I-MBP in human hepatoma cells. I-MBP shows distinct accumulation in cytoplasmic granules, and is predominantly localized in the endoplasmic reticulum (ER) and involved in COPII vesicle-mediated ER-to-Golgi transport. However, the subcellular localization of either a mutant (C236S/ C244S) I-MBP, which lacks carbohydrate-binding activity, or the wild-type I-MBP in tunicamycin-treated cells shows an equally diffuse cytoplasmic distribution, suggesting that the unique accumulation of I-MBP in the ER and COPII vesicles is mediated by an N-glycan-lectin interaction. Furthermore, the binding of I-MBP with glycoprotein intermediates occurs in the ER, which is carbohydrate-and pH-dependent, and is affected by glucose-trimmed high-mannose-type oligosaccharides. These results strongly indicate that I-MBP may function as a cargo transport lectin facilitating ER-to-Golgi traffic in glycoprotein quality control.	Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Shiga 5260829, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Ritsumeikan University; Kyoto University; University of Tokyo	Kawasaki, T (corresponding author), Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan.	byma@fc.ritsumei.ac.jp; tkawasak@fc.ritsumei.ac.jp	Ito, Yukishige/M-5119-2014	Ito, Yukishige/0000-0001-6251-7249				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Hart ML, 2003, J GEN VIROL, V84, P353, DOI 10.1099/vir.0.18734-0; Hart ML, 2002, AIDS RES HUM RETROV, V18, P1311, DOI 10.1089/088922202320886352; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Kamiya Y, 2005, J BIOL CHEM, V280, P37178, DOI 10.1074/jbc.M505757200; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; Ma BY, 2004, BIOCHEM BIOPH RES CO, V317, P60, DOI 10.1016/j.bbrc.2004.03.012; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; MIZUNO Y, 1981, J BIOL CHEM, V256, P4247; MORI K, 1988, ARCH BIOCHEM BIOPHYS, V264, P647, DOI 10.1016/0003-9861(88)90331-1; MORI K, 1984, ARCH BIOCHEM BIOPHYS, V232, P223, DOI 10.1016/0003-9861(84)90538-1; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Totani K, 2005, ANGEW CHEM INT EDIT, V44, P7950, DOI 10.1002/anie.200502723; Weisz OA, 2003, INT REV CYTOL, V226, P259, DOI 10.1016/S0074-7696(03)01005-2; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; YAMAMOTO A, 1991, CELL STRUCT FUNCT, V16, P419, DOI 10.1247/csf.16.419; Ying HY, 2004, AIDS RES HUM RETROV, V20, P327, DOI 10.1089/088922204322996563	35	22	24	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17908	17920		10.1074/jbc.M700992200	http://dx.doi.org/10.1074/jbc.M700992200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442667	hybrid			2022-12-25	WOS:000247084500064
J	Luan, Y; Yu, XP; Xu, K; Ding, B; Yu, J; Huang, Y; Yang, N; Lengyel, P; Di Cesare, PE; Liu, CJ				Luan, Yi; Yu, Xiu-Ping; Xu, Ke; Ding, Bo; Yu, Jin; Huang, Yan; Yang, Ning; Lengyel, Peter; Di Cesare, Paul E.; Liu, Chuan-Ju			The retinoblastoma protein is an essential mediator of osteogenesis that links the p204 protein to the Cbfa1 transcription factor thereby increasing its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BEATING CARDIAC MYOCYTES; INDUCIBLE 204 GENE; OSTEOBLAST DIFFERENTIATION; BONE-FORMATION; MYOBLAST DIFFERENTIATION; OSTEOCALCIN GENE; BETA INTERACTS; INTERFERON; EXPRESSION	Bone formation requires the coordinated activity of numerous proteins including the transcription factor core-binding factor alpha 1 (Cbfa1). Deregulation of Cbfa1 results in metabolic bone diseases including osteoporosis and osteopetrosis. The retinoblastoma protein (pRb) that is required for osteogenesis binds Cbfa1. We reported earlier that the p200 family protein p204, which is known to be involved in the differentiation of skeletal muscle myotubes, cardiac myocytes, and macrophages, also serves as a cofactor of Cbfa1 and promotes osteogenesis. In this study we established that suppression of p204 expression by an adenovirus construct encoding p204 antisense RNA inhibited osteoblast-specific gene activation by Cbfa1 in an osteogenesis assay involving the pluripotent C2C12 mesenchymal cell line. Using protein-protein interaction assays we established that Cbfa1, pRb, and p204 form a ternary complex in which pRb serves as a linker connecting p204 and Cbfa1. Chromatin immunoprecipitation assays revealed the binding of such a p204-pRbCbfa1 transcription factor complex to the promoter of the osteocalcin gene. The pRb requirement of the stimulation of Cbfa1 activity by p204 was established in experiments involving p204 mutants lacking one or two pRb binding (LXCXE) motifs. Such mutants failed to enhance the Cbfa1-dependent transactivation of gene expression as well as osteogenesis. Furthermore, as revealed in reporter gene and in vitro osteogenesis assays p204 synergized with pRb in the stimulation of Cbfa1-dependent gene activation and osteoblast differentiation.	NYU, Med Ctr, Dept Orthoped Surg, New York, NY 10003 USA; Shandong Univ, Sch Med, Inst Pathogen Biol, Shandong 250012, Peoples R China; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med & Cardiol, New Haven, CT 06520 USA; Univ Calif Davis, Med Ctr, Dept Orthoped Surg, Sacramento, CA 95817 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; Shandong University; Yale University; Yale University; University of California System; University of California Davis; New York University	Liu, CJ (corresponding author), NYU, Med Ctr, Dept Orthoped Surg, Rm 1608,HJD,301 E 17th St, New York, NY 10003 USA.	chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021	Xu, Ke Kate/0000-0002-2453-4475; liu, chuanju/0000-0002-7181-8032	NIAID NIH HHS [AI-12320] Funding Source: Medline; NIAMS NIH HHS [AR052022, AR050620, R03 AR052022-02, R03 AR052022, R21 AR052676-02, R21 AR052676, R21 AR052676-01A1, R03 AR052022-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320, R01AI012320, R21AI012320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022, R21AR052676] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Abboud SL, 2002, ENDOCRINOLOGY, V143, P1942, DOI 10.1210/en.143.5.1942; Asefa B, 2006, FEBS LETT, V580, P1205, DOI 10.1016/j.febslet.2006.01.032; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Dauffy J, 2006, J LEUKOCYTE BIOL, V79, P173, DOI 10.1189/jlb.0205083; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Ding B, 2006, J BIOL CHEM, V281, P14882, DOI 10.1074/jbc.M511747200; Ding B, 2006, J BIOL CHEM, V281, P14893, DOI 10.1074/jbc.M511748200; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2005, J BIOL CHEM, V280, P2788, DOI 10.1074/jbc.M412604200; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Munz B, 2002, MOL CELL BIOL, V22, P5879, DOI 10.1128/MCB.22.16.5879-5886.2002; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105-2896.2005.00337.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang WF, 2004, DEV BIOL, V270, P364, DOI 10.1016/j.ydbio.2004.03.003; Wang WF, 2002, DEV DYNAM, V224, P79, DOI 10.1002/dvdy.10089; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xie WF, 2000, MATRIX BIOL, V19, P501, DOI 10.1016/S0945-053X(00)00087-1; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	62	40	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16860	16870		10.1074/jbc.M610943200	http://dx.doi.org/10.1074/jbc.M610943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439944	hybrid			2022-12-25	WOS:000246946500018
J	Haince, JF; Kozlov, S; Dawson, VL; Dawson, TM; Hendzel, MJ; Lavin, MF; Poirier, GG				Haince, Jean-Francois; Kozlov, Sergei; Dawson, Valina L.; Dawson, Ted M.; Hendzel, Michael J.; Lavin, Martin F.; Poirier, Guy G.			Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-H2AX FOCI FORMATION; STRAND BREAK REPAIR; CELL-CYCLE ARREST; IONIZING-RADIATION; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; PROTEOMIC APPROACH; ACTIVATES ATM; PARP-1; POLYMERASE	Poly(ADP- ribosyl)ation is a post-translational modification that is instantly stimulated by DNA strand breaks creating a unique signal for the modulation of protein functions in DNA repair and cell cycle checkpoint pathways. Here we report that lack of poly( ADP- ribose) synthesis leads to a compromised response to DNA damage. Deficiency in poly( ADP- ribosyl) ation metabolism induces profound cellular sensitivity to DNA-damaging agents, particularly in cells deficient for the protein kinase ataxia telangiectasia mutated ( ATM). At the biochemical level, we examined the significance of poly( ADP- ribose) synthesis on the regulation of early DNA damage-induced signaling cascade initiated by ATM. Using potent PARP inhibitors and PARP-1 knock-out cells, we demonstrate a functional interplay between ATM and poly( ADP- ribose) that is important for the phosphorylation of p53, SMC1, and H2AX. For the first time, we demonstrate a functional and physical interaction between the major DSB signaling kinase, ATM and poly( ADP- ribosyl) ation by PARP-1, a key enzyme of chromatin remodeling. This study suggests that poly( ADP- ribose) might serve as a DNA damage sensory molecule that is critical for early DNA damage signaling.	CHU Laval, Fac Med, Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada; Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Alberta, Fac Med, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada	Laval University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Alberta; University of Alberta	Poirier, GG (corresponding author), CHU Laval, Fac Med, Hlth & Environm Unit, 2705 Blvd Laurier,RC-9700, Quebec City, PQ G1V 4G2, Canada.	guy.poirier@crchul.ulaval.ca	Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019; Hendzel, Michael/C-3391-2009; Lavin, Martin F/F-5961-2014; Dawson, Valina/Y-9757-2019	Kozlov, Sergei/0000-0001-6183-7339; Hendzel, Michael/0000-0002-9603-7945; Lavin, Martin F/0000-0002-5940-4769; Poirier, Guy/0000-0002-4869-1424; Dawson, Valina/0000-0002-2915-3970	NINDS NIH HHS [NS39148] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Beardsley DI, 2005, MOL PHARMACOL, V68, P1049, DOI 10.1124/mol.105.013888; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chang P, 2005, NAT CELL BIOL, V7, P1133, DOI 10.1038/ncb1322; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Du YC, 2006, MOL CELL PROTEOMICS, V5, P1033, DOI 10.1074/mcp.M500327-MCP200; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; Haince JF, 2005, TRENDS MOL MED, V11, P456, DOI 10.1016/j.molmed.2005.08.003; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; JACOBSON EL, 1985, CARCINOGENESIS, V6, P711, DOI 10.1093/carcin/6.5.711; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2005, BIOCHEM CELL BIOL, V83, P354, DOI 10.1139/o05-038; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Noel G, 2006, MOL CANCER THER, V5, P564, DOI 10.1158/1535-7163.MCT-05-0418; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Plummer ER, 2006, CURR OPIN PHARMACOL, V6, P364, DOI 10.1016/j.coph.2006.02.004; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stojic L, 2005, CELL CYCLE, V4, P473, DOI 10.4161/cc.4.3.1528; Takahashi A, 2005, CANCER LETT, V229, P171, DOI 10.1016/j.canlet.2005.07.016; Tartier L, 2003, MUTAGENESIS, V18, P411, DOI 10.1093/mutage/geg015; Valenzuela MT, 2002, ONCOGENE, V21, P1108, DOI 10.1038/sj.onc.1205169; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Yu YK, 2006, TOXICOL IN VITRO, V20, P959, DOI 10.1016/j.tiv.2006.01.004; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200	60	203	215	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16441	16453		10.1074/jbc.M608406200	http://dx.doi.org/10.1074/jbc.M608406200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428792	hybrid			2022-12-25	WOS:000246794300052
J	Stalder, L; Muhlemann, O				Stalder, Lukas; Muehlemann, Oliver			Transcriptional silencing of nonsense codon-containing immunoglobulin mu genes requires translation of its mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; MEDIATED DECAY; TERMINATION; EXPRESSION; COMPLEX; BINDING; YEAST; EXON; UPF1	Eukaryotes have evolved quality control mechanisms that prevent the expression of genes in which the protein coding potential is crippled by the presence of a premature translation-termination codon (PTC). In addition to nonsense-mediated mRNA decay (NMD), a well documented posttranscriptional consequence of the presence of a PTC in an mRNA, we recently reported the transcriptional silencing of PTC-containing immunoglobulin (Ig) mu and gamma minigenes when they are stably integrated into the genome of HeLa cells. Here we demonstrate that this transcriptional silencing of PTC-containing Ig-mu constructs requires active translation of the cognate mRNA, as it is not observed under conditions where translation of the PTC-containing mRNA is inhibited through an iron-responsive element in the 5'-untranslated region. Furthermore, RNA interference-mediated depletion of the essential NMD factor Upf1 not only abolishes NMD but also reduces the extent of nonsense-mediated transcriptional gene silencing (NMTGS). Collectively, our data indicate that NMTGS and NMD are linked, relying on the same mechanism for PTC recognition, and that the NMTGS pathway branches from the NMD pathway at a step after Upf1 function.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland	University of Bern	Stalder, L (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	oliver.muehlemann@izb.unibe.ch						Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Amrani N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/nrm1942; Arciga-Reyes L, 2006, PLANT J, V47, P480, DOI 10.1111/j.1365-313X.2006.02802.x; Behm-Ansmant I, 2006, GENE DEV, V20, P391, DOI 10.1101/gad.1407606; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Buhler M, 2005, MOL CELL, V18, P307, DOI 10.1016/j.molcel.2005.03.030; Buhler M, 2004, NUCLEIC ACIDS RES, V32, P3304, DOI 10.1093/nar/gkh651; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Fasken MB, 2005, NAT STRUCT MOL BIOL, V12, P482, DOI 10.1038/nsmb945; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Paillusson A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni052; Peters AHFM, 2005, CURR OPIN CELL BIOL, V17, P230, DOI 10.1016/j.ceb.2005.02.006; Rehwinkel A, 2005, RNA, V11, P1530, DOI 10.1261/rna.2160905; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Wittmann J, 2006, MOL CELL BIOL, V26, P1272, DOI 10.1128/MCB.26.4.1272-1287.2006	25	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16079	16085		10.1074/jbc.M610595200	http://dx.doi.org/10.1074/jbc.M610595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428806	hybrid			2022-12-25	WOS:000246794300016
J	Valente, L; Nishikura, K				Valente, Louis; Nishikura, Kazuko			RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSCRIPTOME; INTERFERON ACTION; CANDIDATE ENZYME; EDITING ENZYME; DSRNA-BINDING; 2 FORMS; GLUR-B; ADAR2; DOMAIN; INOSINE	RNA editing that converts adenosine to inosine in double-stranded RNA (dsRNA) is mediated by adenosine deaminases acting on RNA (ADAR). ADAR1 and ADAR2 form respective homodimers, and this association is essential for their enzymatic activities. In this investigation, we set out experiments aiming to determine whether formation of the homodimer complex is mediated by an amino acid interface made through protein-protein interactions of two monomers or via binding of the two subunits to a dsRNA substrate. Point mutations were created in the dsRNA binding domains (dsRBDs) that abolished all RNA binding, as tested for two classes of ADAR ligands, long and short dsRNA. The mutant ADAR dimer complexes were intact, as demonstrated by their ability to co-purify in a sequential affinity-tagged purification and also by their elution at the dimeric fraction position on a size fractionation column. Our results demonstrated ADAR dimerization independent of their binding to dsRNA, establishing the importance of protein-protein interactions for dimer formation. As expected, these mutant ADARs could no longer perform their catalytic function due to the loss in substrate binding. Surprisingly, a chimeric dimer consisting of one RNA binding mutant monomer and a wild type partner still abolished its ability to bind and edit its substrate, indicating that ADAR dimers require two subunits with functional dsRBDs for binding to a dsRNA substrate and then for editing activity to occur.	Wistar Inst Anat & Biol, Dept Gene Express & Regulat, Philadelphia, PA 19104 USA	The Wistar Institute	Valente, L (corresponding author), Wistar Inst Anat & Biol, Dept Gene Express & Regulat, Philadelphia, PA 19104 USA.	lvalente@wistar.org			NATIONAL CANCER INSTITUTE [P01CA072765, T32CA009171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009171, T32 CA09171, P01 CA072765, P01 CA072765-050002] Funding Source: Medline; NHLBI NIH HHS [R01 HL070045-04, R01 HL070045] Funding Source: Medline; NIGMS NIH HHS [R01 GM040536, R01 GM040536-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Blow M, 2004, GENOME RES, V14, P2379, DOI 10.1101/gr.2951204; Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chilibeck KA, 2006, J BIOL CHEM, V281, P16530, DOI 10.1074/jbc.M511831200; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; DeCerbo J, 2005, CURR OPIN CELL BIOL, V17, P302, DOI 10.1016/j.ceb.2005.04.008; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Gerber A, 1997, RNA, V3, P453; Hallegger M, 2006, RNA, V12, P1993, DOI 10.1261/rna.125506; Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; Jaikaran DCJ, 2002, J BIOL CHEM, V277, P37624, DOI 10.1074/jbc.M204126200; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Maas Stefan, 2006, RNA Biol, V3, P1; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Macbeth MR, 2004, RNA, V10, P1563, DOI 10.1261/rna.7920904; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048; Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrm2061; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2006, RNA, V12, P1350, DOI 10.1261/rna.2314406; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Reenan RA, 2001, TRENDS GENET, V17, P53, DOI 10.1016/S0168-9525(00)02169-7; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sansam CL, 2003, P NATL ACAD SCI USA, V100, P14018, DOI 10.1073/pnas.2336131100; Schmauss C, 2003, NEUROSCIENTIST, V9, P237, DOI 10.1177/1073858403253669; Stefl R, 2006, STRUCTURE, V14, P345, DOI 10.1016/j.str.2005.11.013; Toth AM, 2006, PROG NUCLEIC ACID RE, V81, P369, DOI 10.1016/S0079-6603(06)81010-X; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Xu M, 2006, MOL BIOL CELL, V17, P3211, DOI 10.1091/mbc.E06-02-0162; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200	48	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16054	16061		10.1074/jbc.M611392200	http://dx.doi.org/10.1074/jbc.M611392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428802	hybrid, Green Accepted			2022-12-25	WOS:000246794300013
J	Winter, JM; Moffitt, MC; Zazopoulos, E; McAlpine, JB; Dorrestein, PC; Moore, BS				Winter, Jaclyn M.; Moffitt, Michelle C.; Zazopoulos, Emmanuel; McAlpine, James B.; Dorrestein, Pieter C.; Moore, Bradley S.			Molecular basis for chloronium-mediated meroterpene cyclization - Cloning, sequencing, and heterologous expression of the napyradiomycin biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS CURVULARIA-INAEQUALIS; COMPLETE GENOME SEQUENCE; VANADIUM CHLOROPEROXIDASE; FURAQUINOCIN-A; SYNTHASE GENE; STREPTOMYCES; ACTINOMYCETE; BROMOPEROXIDASE; IDENTIFICATION; ALIGNMENT	Structural inspection of the bacterial meroterpenoid antibiotics belonging to the napyradiomycin family of chlorinated dihydroquinones suggests that the biosynthetic cyclization of their terpenoid subunits is initiated via a chloronium ion. The vanadium-dependent haloperoxidases that catalyze such reactions are distributed in fungi and marine algae and have yet to be characterized from bacteria. The cloning and sequence analysis of the 43-kb napyradiomycin biosynthetic cluster ( nap) from Streptomyces aculeolatus NRRL 18422 and from the undescribed marine sediment-derived Streptomyces sp. CNQ-525 revealed 33 open reading frames, three of which putatively encode vanadium-dependent chloroperoxidases. Heterologous expression of the CNQ-525-based nap biosynthetic cluster in Streptomyces albus produced at least seven napyradiomycins, including the new analog 2-deschloro-2-hydroxy-A80915C. These data not only revealed the molecular basis behind the biosynthesis of these novel meroterpenoid natural products but also resulted in the first in vivo verification of vanadium-dependent haloperoxidases.	Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, La Jolla, CA 92037 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego	Moore, BS (corresponding author), Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, 8655 Discovery Way, La Jolla, CA 92037 USA.	bsmoore@ucsd.edu	Dorrestein, Pieter/ABF-2930-2020; Moffitt, Michelle/C-2471-2014; Dorrestein, Pieter/D-5012-2012	Moffitt, Michelle/0000-0001-9872-3175; Moore, Bradley/0000-0002-4652-1253; Winter, Jaclyn/0000-0001-6273-5377	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM067550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52445] Funding Source: Medline; NIGMS NIH HHS [GM067550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banskota AH, 2006, J ANTIBIOT, V59, P168, DOI 10.1038/ja.2006.24; Barnett P, 1998, J BIOL CHEM, V273, P23381, DOI 10.1074/jbc.273.36.23381; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Butler A, 2004, NAT PROD REP, V21, P180, DOI 10.1039/b302337k; Carter-Franklin JN, 2004, J AM CHEM SOC, V126, P15060, DOI 10.1021/ja047925p; FUKUDA DS, 1990, J ANTIBIOT, V43, P623, DOI 10.7164/antibiotics.43.623; Funa N, 2005, J BIOL CHEM, V280, P14514, DOI 10.1074/jbc.M500190200; FUNAYAMA S, 1990, J ORG CHEM, V55, P1132, DOI 10.1021/jo00291a003; GOMI S, 1987, J ANTIBIOT, V40, P740, DOI 10.7164/antibiotics.40.740; Haagen Y, 2006, CHEMBIOCHEM, V7, P2016, DOI 10.1002/cbic.200600338; Hofrichter M, 2006, APPL MICROBIOL BIOT, V71, P276, DOI 10.1007/s00253-006-0417-3; IDEDA M, 2003, APPL MICROBIOL BIOT, V62, P99; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; Ishikawa J, 2004, P NATL ACAD SCI USA, V101, P14925, DOI 10.1073/pnas.0406410101; Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1111/j.1574-6968.1999.tb13576.x; Kalaitzis JA, 2003, ORG LETT, V5, P4449, DOI 10.1021/ol035748b; Kawasaki T, 2006, J BACTERIOL, V188, P1236, DOI 10.1128/JB.188.4.1236-1244.2006; Kawasaki T, 2004, J ANTIBIOT, V57, P739, DOI 10.7164/antibiotics.57.739; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kuzuyama T, 2005, NATURE, V435, P983, DOI 10.1038/nature03668; Littlechild J, 2002, J MOL RECOGNIT, V15, P291, DOI 10.1002/jmr.590; Liu W, 2002, SCIENCE, V297, P1170, DOI 10.1126/science.1072110; Lombo F, 2006, CHEMBIOCHEM, V7, P366, DOI 10.1002/cbic.200500325; Mongodin EF, 2005, P NATL ACAD SCI USA, V102, P18147, DOI 10.1073/pnas.0509073102; Moore BS, 2006, NAT PROD REP, V23, P615, DOI 10.1039/b508781n; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Otsuka M, 2004, ANTIMICROB AGENTS CH, V48, P3468, DOI 10.1128/AAC.48.9.3468-3476.2004; Raugei S, 2006, J PHYS CHEM B, V110, P3747, DOI 10.1021/jp054901b; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHIOMI K, 1987, J ANTIBIOT, V40, P1740, DOI 10.7164/antibiotics.40.1740; SHIOMI K, 1987, J ANTIBIOT, V40, P1213, DOI 10.7164/antibiotics.40.1213; SHIOMI K, 1986, J ANTIBIOT, V39, P494, DOI 10.7164/antibiotics.39.494; Soria-Mercado IE, 2005, J NAT PROD, V68, P904, DOI 10.1021/np058011z; Soria-Mercado IE, 2004, ACTA CRYSTALLOGR E, V60, pO1627, DOI 10.1107/S1600536804020094; Takagi M, 2000, J BACTERIOL, V182, P4153, DOI 10.1128/JB.182.15.4153-4157.2000; Takahashi S, 1999, J BACTERIOL, V181, P1256, DOI 10.1128/JB.181.4.1256-1263.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaillancourt FH, 2006, CHEM REV, V106, P3364, DOI 10.1021/cr050313i; VANPEE HK, 1996, ANNU REV MICROBIOL, V50, P275; VANPEE HK, 2003, CHEMOSPHERE, V52, P200; VANSCHIJNDEL JWPM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P249, DOI 10.1016/0167-4838(93)90221-C; VITLER H, 1984, PHYTOCHEMISTRY, V23, P387; Wendt-Pienkowski E, 2005, J AM CHEM SOC, V127, P16442, DOI 10.1021/ja054376u	48	123	128	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16362	16368		10.1074/jbc.M611046200	http://dx.doi.org/10.1074/jbc.M611046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392281	hybrid			2022-12-25	WOS:000246794300044
J	Kong, XG; Alvarez-Castelao, B; Lin, Z; Castano, JG; Caro, J				Kong, Xianguo; Alvarez-Castelao, Beatriz; Lin, Zhao; Castano, Jose G.; Caro, Jaime			Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTORS; TARGET GENES; UBIQUITIN; TRANSCRIPTION; HIF-2-ALPHA; HIF-1-ALPHA; COMPLEX; FAMILY; VHL; HYDROXYLATION	The transcriptional activator complex HIF-1 plays a key role in the long term adaptation of cells and tissues to their hypoxic microenvironment by stimulating the expression of genes involved in angiogenesis and glycolysis. The expression of the HIF-1 complex is regulated by the levels of its HIF-alpha subunits that are degraded under normoxic conditions by the ubiquitin-proteasome system. Whereas this pathway of HIF-alpha protein degradation has been well characterized, little is known of their turnover during prolonged hypoxic conditions. Herein, we describe a pathway by which HIF-1 alpha and HIF-2 alpha proteins are constitutively degraded during hypoxia by the proteasome system, although without requirement of prior ubiquitylation. The constitutive/hypoxic degradation of HIF-alpha proteins is independent of the presence of VHL, binding to DNA, or the formation of a transcriptionally active HIF-1 complex. These results are further strengthened by the demonstration that HIF-alpha proteins are directly degraded in a reconstituted in vitro assay by the proteasome. Finally, we demonstrate that the persistent down-regulation of HIF-1 alpha during prolonged hypoxia is mainly caused by a decreased production of the protein without change in its degradation rate. This constitutive, ubiquitin-independent proteasomal degradation pathway of HIF-alpha proteins has to be taken into account in understanding the biology as well as in the development of therapeutic interventions of highly hypoxic tumors.	Thomas Jefferson Univ, Cardeza Fdn, Philadelphia, PA 19107 USA; UAM, Fac Med, CSIC, Dept Bioquim, Madrid, Spain; UAM, Inst Invest Biomed Alberto Sols, CSIC, Fac Med, Madrid, Spain	Jefferson University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Caro, J (corresponding author), Thomas Jefferson Univ, Cardeza Fdn, 1015 Walnut St, Philadelphia, PA 19107 USA.	jaime.caro@jefferson.edu	alvarez-castelao, beatriz/W-1707-2018	alvarez-castelao, beatriz/0000-0001-7505-1855; G. Castano, Jose/0000-0002-6579-8442	NATIONAL CANCER INSTITUTE [R01CA089212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA089212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Castelao B, 2005, FEBS LETT, V579, P4797, DOI 10.1016/j.febslet.2005.07.060; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Brahimi-Horn Christiane, 2006, Bull Cancer, V93, pE73; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gruber M, 2006, CURR OPIN HEMATOL, V13, P169, DOI 10.1097/01.moh.0000219663.88409.35; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Lee H, 2006, J BIOL CHEM, V281, P26876, DOI 10.1074/jbc.M605366200; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200	35	60	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15498	15505		10.1074/jbc.M700704200	http://dx.doi.org/10.1074/jbc.M700704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403672	hybrid			2022-12-25	WOS:000246589600026
J	Pai, NP; Joshi, R; Dogra, S; Taksande, B; Kalantri, SP; Pai, M; Narang, P; Tulsky, JP; Reingold, AL				Pai, Nitika Pant; Joshi, Rajnish; Dogra, Sandeep; Taksande, Bharati; Kalantri, S. P.; Pai, Madhukar; Narang, Pratibha; Tulsky, Jacqueline P.; Reingold, Arthur L.			Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India	PLOS ONE			English	Article								Background. Oral fluid-based rapid tests are promising for improving HIV diagnosis and screening. However, recent reports from the United States of false-positive results with the oral OraQuick (R) ADVANCE HIV1/2 test have raised concerns about their performance in routine practice. We report a field evaluation of the diagnostic accuracy, client preference, and feasibility for the oral fluid-based OraQuick (R) Rapid HIV1/2 test in a rural hospital in India. Methodology/Principal Findings.. A cross-sectional, hospital-based study was conducted in 450 consenting participants with suspected HIV infection in rural India. The objectives were to evaluate performance, client preference and feasibility of the OraQuick (R) Rapid HIV-1/2 tests. Two Oraquick (R) Rapid HIV1/2 tests (oral fluid and finger stick) were administered in parallel with confirmatory ELISA/Western Blot (reference standard). Pre- and post-test counseling and face to face interviews were conducted to determine client preference. Of the 450 participants, 146 were deemed to be HIV sero-positive using the reference standard (seropositivity rate of 32% (95% confidence interval [CI] 28%, 37%)). The OraQuick test on oral fluid specimens had better performance with a sensitivity of 100% (95% CI 98, 100) and a specificity of 100% (95% CI 99, 100), as compared to the OraQuick test on finger stick specimens with a sensitivity of 100% (95% CI 98, 100), and a specificity of 99.7% (95% CI 98.4, 99.9). The OraQuick oral fluid-based test was preferred by 87% of the participants for first time testing and 60% of the participants for repeat testing. Conclusion/Significance. In a rural Indian hospital setting, the OraQuick (R) Rapid-HIV1/2 test was found to be highly accurate. The oral fluid-based test performed marginally better than the finger stick test. The oral OraQuick test was highly preferred by participants. In the context of global efforts to scale-up HIV testing, our data suggest that oral fluid-based rapid HIV testing may work well in rural, resource-limited settings.	[Pai, Nitika Pant] McGill Univ, Immunodeficiency Serv, Montreal Chest Inst, Ctr Hlth, Montreal, PQ, Canada; [Joshi, Rajnish; Taksande, Bharati; Kalantri, S. P.; Narang, Pratibha] Mahatma Gandhi Inst Med Sci, Sevagram, Maharashtra, India; [Dogra, Sandeep] Acharya Shri Chander Coll Med Sci, Jammu, India; [Pai, Madhukar] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Tulsky, Jacqueline P.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; [Reingold, Arthur L.] Univ Calif Berkeley, Div Epidemiol, Berkeley, CA 94720 USA	McGill University; Mahatma Gandhi Institute of Medical Sciences, Sevagram; McGill University; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Pai, NP (corresponding author), McGill Univ, Immunodeficiency Serv, Montreal Chest Inst, Ctr Hlth, Montreal, PQ, Canada.	Nitika.Pai@mcgill.ca	PAL, MRINAL/ABG-9676-2020; Pai, Madhukar/AAX-9901-2021; Dogra, Sandeep/AAS-6079-2021; Kalantri, Shriprakash/ABG-9318-2021; Taksande, Amar/ABA-4130-2020	PAL, MRINAL/0000-0002-1032-272X; Pai, Madhukar/0000-0003-3667-4536; Kalantri, Shriprakash/0000-0002-1633-1029; Taksande, Amar/0000-0003-3097-7405; Narang, Pratibha/0000-0001-6135-1857; Joshi, Rajnish/0000-0002-4702-0522; Pant Pai, Nitika/0000-0002-4672-0500	UCB/UCSF Fogarty AIDS International Research and Training Grant [AITRP] [I-D43-TW00008-16]; Orasure Technologies PA USA	UCB/UCSF Fogarty AIDS International Research and Training Grant [AITRP](UCB Pharma SA); Orasure Technologies PA USA	Funding: We acknowledge the support of UCB/UCSF Fogarty AIDS International Research and Training Grant [AITRP] (I-D43-TW00008-16). We acknowledge the support of Orasure Technologies, PA USA for their generous donation of kits. Orasure Technologies, Philadelphia, USA, did not provide funding for this study. Neither Fogarty AITRP (I-D43-TW00008-16) nor Orasure Technologies, PA, USA had any role in the design and conduct of the study nor preparation of the manuscript.	Aaron Erika, 2006, AIDS Read, V16, P22; Bhore AV, 2003, INT J STD AIDS, V14, P37, DOI 10.1258/095646203321043246; Brahme RG, 2005, AIDS CARE, V17, P377, DOI 10.1080/09540120412331299771; Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219; CHASSANY O, 1994, AIDS, V8, P713, DOI 10.1097/00002030-199405000-00026; De Cock KM, 2006, NEW ENGL J MED, V354, P440, DOI 10.1056/NEJMp058327; Delaney KP, 2006, AIDS, V20, P1655, DOI 10.1097/01.aids.0000238412.75324.82; Granade TC, 2004, J CLIN VIROL, V30, P229, DOI 10.1016/j.jcv.2003.12.006; Greensides DR, 2003, PUBLIC HEALTH REP, V118, P531, DOI 10.1016/S0033-3549(04)50289-3; Greenwald JL, 2006, AIDS PATIENT CARE ST, V20, P311, DOI 10.1089/apc.2006.20.311; Jafa K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000185; Kumar R, 2006, LANCET, V367, P1164, DOI 10.1016/S0140-6736(06)68435-3; Liang TS, 2005, AIDS PATIENT CARE ST, V19, P253, DOI 10.1089/apc.2005.19.253; *NAT AIDS CONTR OR, 2006, NACO GUID HIV TEST; *UNAIDS, 2006, REP GLOB AIDS EPID M; Wesolowski LG, 2006, AIDS, V20, P1661, DOI 10.1097/01.aids.0000238413.13442.ed	17	50	53	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e367	10.1371/journal.pone.0000367	http://dx.doi.org/10.1371/journal.pone.0000367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426815	Green Published, gold			2022-12-25	WOS:000207445400007
J	Meng, X; Fan, J; Shen, Z				Meng, X.; Fan, J.; Shen, Z.			Roles of BCCIP in chromosome stability and cytokinesis	ONCOGENE			English	Article						cytokinesis; chromosome instability; BRCA2; BCCIP; polyploidy	CENTROSOME AMPLIFICATION; CANCER SUSCEPTIBILITY; PROTEIN; BRCA2; P53; INHIBITION; EXPRESSION; PATHWAYS; ARREST; BREAST	The BRCA2 gene is involved in recombinational DNA repair and cytokinesis. BRCA2 defects are associated with chromosomal abnormalities, which is a hallmark of genomic instability that contributes to tumorigenesis. Here, we show that downregulation of a BRCA2 interacting protein ( BCCIP) in HT1080 cells leads to chromosomal polyploidization, centrosome amplification and abnormal mitotic spindle formation. The BCCIP knockdown cells can enter mitosis and retain spindle checkpoint, but fail to complete cytokinesis. Our data suggest an essential role of BCCIP in the maintenance of genomic integrity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of New Mexico	Shen, Z (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	shenzh@umdnj.edu		Shen, Zhiyuan/0000-0003-2834-0309; meng, xiangbing/0000-0002-9612-6438	NCI NIH HHS [R01 CA115488, R01 CA115488-04, R01 CA115488-02, R01 CA115488-01, R01 CA115488-03, CA115488] Funding Source: Medline; NIEHS NIH HHS [ES08353, R01 ES008353, R29 ES008353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Geddis AE, 2004, BLOOD, V104, P1017, DOI 10.1182/blood-2004-02-0419; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2004, J BIOL CHEM, V279, P6098, DOI 10.1074/jbc.M306794200; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Rudkin TM, 2005, TRENDS MOL MED, V11, P145, DOI 10.1016/j.molmed.2005.02.003; SHINMURA K, 2006, ONCOGENE; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	29	38	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6253	6260		10.1038/sj.onc.1210460	http://dx.doi.org/10.1038/sj.onc.1210460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452982	Green Accepted			2022-12-25	WOS:000249583300001
J	Bai, XY; Chen, XM; Sun, AQ; Feng, Z; Hou, K; Fu, B				Bai, Xue-Yuan; Chen, Xiangmei; Sun, An-Qiang; Feng, Zhe; Hou, Kai; Fu, Bo			Membrane topology structure of human high-affinity, sodium-dependent dicarboxylate transporter	FASEB JOURNAL			English	Article						Krebs cycle; immunofluorescence; SCAM; Flag; localization	TRANSMEMBRANE PROTEIN TOPOLOGY; NA+/DICARBOXYLATE COTRANSPORTER; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-PROPERTIES; EXPRESSION; PREDICTION; ACCESSIBILITY; CHANNEL; CLONING; CITRATE	High-affinity, sodium-dependent dicarboxylate transporter (NaDC3) is responsible for transport of Krebs cycle intermediates and may involve in regulation of aging and life span. Hydropathy analysis predicts that NaDC3 contains 11 or 12 hydrophobic transmembrane (TM)domains. However, the actual membrane topological structure of NaDC3 remains unknown. In this study, confocal immunofluorescence microscopy and membrane biotinylation of epitope-tagged N and C termini of NaDC3 provide evidence of an extracellular C terminus and an intracellular N terminus, indicating an odd number of transmembrane regions. The position of hydrophilic loops within NaDC3 was identified with antibodies against the loops domains combined with cysteine accessibility methods. A confocal image of membrane localization and transport activity assay of the cysteine insertion mutants show behavior similar to that of wild-type NaDC3 in transfected HEK293 cells, suggesting that these mutants retain a native protein configuration. We find that NaDC3 contains 11 transmembrane helices. The loops 1, 3, 5, 7, and 9 face the extracellular side, and loops 2, 4, 6, and 10 face the cytoplasmic side. A re-entrant loop-like structure between TM8 and TM9 may protrude into the membrane. Our results support the topography of 11 transmembrane domains with an extracellular C terminus and an intracellular N terminus of NaDC3, and for the first time provide experimental evidence for a novel topological model for NaDC3	Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Dept Biochem & Mol Biol, Beijing 100853, Peoples R China; Mil Med Postgrad Coll, Beijing 100853, Peoples R China; Mt Sinai Sch Med, Dept Pediat, New York, NY USA	Chinese People's Liberation Army General Hospital; Icahn School of Medicine at Mount Sinai	Bai, XY (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Dept Biochem & Mol Biol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	baixy@301hospital.com.cn; xmchen@public.bta.net.cn						[白雪源 Bai Xueyuan], 2004, [中国生物化学与分子生物学报, Chinese Journal of Biochemistry and Molecular Biology], V20, P615; Bai XY, 2006, J CELL PHYSIOL, V206, P821, DOI 10.1002/jcp.20553; Bai XY, 2004, SCI CHINA SER C, V47, P530, DOI 10.1360/03yc0044; BLANKA R, 2000, SCIENCE, V290, P2137; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; CHEN WP, 1999, J CHEM SOC P1, V2, P103; Chen XM, 2005, J GERONTOL A-BIOL, V60, P709, DOI 10.1093/gerona/60.6.709; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Fei YJ, 2003, J BIOL CHEM, V278, P6136, DOI 10.1074/jbc.M208763200; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Markovich D, 2004, PFLUG ARCH EUR J PHY, V447, P594, DOI 10.1007/s00424-003-1128-6; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Oshiro N, 2005, AM J PHYSIOL-CELL PH, V289, pC1159, DOI 10.1152/ajpcell.00295.2004; Pajor AM, 2006, PFLUG ARCH EUR J PHY, V451, P597, DOI 10.1007/s00424-005-1487-2; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; PAK CYC, 1987, MINER ELECTROL METAB, V13, P257; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Steffgen J, 1999, J BIOL CHEM, V274, P20191, DOI 10.1074/jbc.274.29.20191; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Zhang C, 2001, J POROUS MEDIA, V4, P89	35	13	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2409	2417		10.1096/fj.06-7652com	http://dx.doi.org/10.1096/fj.06-7652com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17426067				2022-12-25	WOS:000248454400016
J	Dagon, Y; Avraham, Y; Ilan, Y; Mechoulam, R; Berry, EM				Dagon, Yossi; Avraham, Yosefa; Ilan, Yaron; Mechoulam, Raphael; Berry, Elliot M.			Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase	FASEB JOURNAL			English	Article						liver disease; hepatic encephalopathy; AMPK; endocannabinoid receptor	HEPATIC-ENCEPHALOPATHY; SYNAPTIC PLASTICITY; MAGNETIC-RESONANCE; BRAIN CONSTITUENT; ENERGY-METABOLISM; FOOD-INTAKE; IN-VIVO; RECEPTOR; RATS; MICE	Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of cerebral AMP-activated protein kinase (AMPK), a major intracellular energy sensor, is a compensatory response to liver failure. This function of AMPK is regulated by endo-cannabinoids. The cannabinoid system controls systemic energy balance via the cannabinoid receptors CB-1 and CB-2. Under normal circumstances, AMPK activity is mediated by CB-1 while CB- 2 is barely detected. However, CB- 2 is strongly stimulated in response to liver failure. Administration of Delta 9-tetrahydrocannabinol( THC) augmented AMPK activity and restored brain function in WT mice but not in their CB- 2 KO littermates. These results suggest that HE is a disease of energy flux. CB- 2 signaling is a cerebral stress response mechanism and makes AMPK a promising target for its treatment by modulating the cannabinoid system.	Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, Braun Sch Publ Hlth,Dept Human Nutr & Metab, Jerusalem, Israel; Hadassah Univ Hosp, Liver Unit, Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Berry, EM (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, Braun Sch Publ Hlth,Dept Human Nutr & Metab, Jerusalem, Israel.	berry@md.huji.ac.il	Dagon, Yossi/AAI-5882-2020					Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Avraham Y, 2006, NEUROBIOL DIS, V21, P237, DOI 10.1016/j.nbd.2005.07.008; Avraham Y, 1996, BRAIN RES, V732, P133, DOI 10.1016/0006-8993(96)00514-8; Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Barbiroli B, 2002, BRAIN RES BULL, V59, P75, DOI 10.1016/S0361-9230(02)00839-0; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNARD A, 1967, SCIENCE, V158, P1600; Berry EM, 2002, PHARMACOL THERAPEUT, V95, P185, DOI 10.1016/S0163-7258(02)00257-7; Bezuglov V, 2001, BIOORG MED CHEM LETT, V11, P447, DOI 10.1016/S0960-894X(00)00689-2; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; Campas C, 2003, BLOOD, V101, P3674, DOI 10.1182/blood-2002-07-2339; Cheer JF, 2004, J NEUROSCI, V24, P4393, DOI 10.1523/JNEUROSCI.0529-04.2004; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159; Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; FITZHUGH OG, 1948, SCIENCE, V108, P626, DOI 10.1126/science.108.2814.626; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; Gerber T, 2000, DRUGS, V60, P1353, DOI 10.2165/00003495-200060060-00008; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; HOYER S, 1993, ANN NY ACAD SCI, V695, P77, DOI 10.1111/j.1749-6632.1993.tb23032.x; IVERSEN LL, 2000, SCI MARIJUANA, P36; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Martin BR, 2005, LIFE SCI, V77, P1543, DOI 10.1016/j.lfs.2005.05.005; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Mishima K, 2001, JPN J PHARMACOL, V87, P297, DOI 10.1254/jjp.87.297; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Molina-Holgado F, 2005, MOL CELL NEUROSCI, V28, P189, DOI 10.1016/j.mcn.2004.09.004; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Ott P, 2005, NEUROCHEM INT, V47, P13, DOI 10.1016/j.neuint.2005.04.002; Pagotto U, 2005, ANN MED, V37, P270, DOI 10.1080/07853890510037419; PICK CG, 1983, INT J NEUROSCI, V21, P63, DOI 10.3109/00207458308986121; Rose C, 2005, METAB BRAIN DIS, V20, P275, DOI 10.1007/s11011-005-7906-4; ROSS BD, 1989, M SOC MAGN RES MED A, P465; Sulcova E, 1998, PHARMACOL BIOCHEM BE, V59, P347, DOI 10.1016/S0091-3057(97)00422-X; SUMMERSKILL WHJ, 1956, Q J MED, V25, P245; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; ZIMMERMANN C, 1989, HEPATOLOGY, V9, P594, DOI 10.1002/hep.1840090414; ZIMMERMANN T, 1992, HEPATOLOGY, V15, P467; Zwingmann C, 2003, HEPATOLOGY, V37, P420, DOI 10.1053/jhep.2003.50052	52	35	39	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2431	2441		10.1096/fj.06-7705com	http://dx.doi.org/10.1096/fj.06-7705com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17431095				2022-12-25	WOS:000248454400018
J	Huber, I; Itzhaki, I; Caspi, O; Arbel, G; Tzukerman, M; Gepstein, A; Habib, M; Yankelson, L; Kehat, I; Gepstein, L				Huber, Irit; Itzhaki, Ilanit; Caspi, Oren; Arbel, Gil; Tzukerman, Maty; Gepstein, Amira; Habib, Manhal; Yankelson, Lior; Kehat, Izhak; Gepstein, Lior			Identification and selection of cardiomyocytes during human embryonic stem cell differentiation	FASEB JOURNAL			English	Article						myogenesis; myosin light chain 2-V; promoter; selectable marker; embryoid body; cardiac differentiation	GREEN FLUORESCENT PROTEIN; CARDIAC PRECURSOR CELLS; IN-VITRO; HUMAN BLASTOCYSTS; EXPRESSION; HEART; ATRIAL; LINES; GENE; EXCITABILITY	Human embryonic stem cells (hESC) are pluripotent lines that can differentiate in vitro into cell derivatives of all three germ layers, including cardiomyocytes. Successful application of these unique cells in the areas of cardiovascular research and regenerative medicine has been hampered by difficulties in identifying and selecting specific cardiac progenitor cells from the mixed population of differentiating cells. We report the generation of stable transgenic hESC lines, using lentiviral vectors, and single-cell clones that express a reporter gene (eGFP) under the transcriptional control of a cardiac-specific promoter (the human myosin light chain-2V promoter). Our results demonstrate the appearance of eGFP-expressing cells during the differentiation of the hESC as embryoid bodies (EBs) that can be identified and sorted using FACS (purity > 95%, viability > 85%). The eGFP-expressing cells were stained positively for cardiac-specific proteins (> 93%), expressed cardiac-specific genes, displayed cardiac-specific action-potentials,and could form stable myocardial cell grafts following in vivo cell transplantation. The generation of these transgenic hESC lines may be used to identify and study early cardiac precursors for developmental studies, to robustly quantify the extent of cardiomyocyte differentiation, to label the cells for in vivo grafting, and to allow derivation of purified cell populations of cardiomyocytes for future myocardial cell therapy strategies.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sohis Family Res Lab Regenerat Funct Myocardium, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gepstein, L (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sohis Family Res Lab Regenerat Funct Myocardium, 2 Efron St,POB 9649, IL-31096 Haifa, Israel.	mdlior@tx.technion.ac.il	Gepstein, Lior/H-9458-2012	kehat, izhak/0000-0002-4388-1579				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Andressen C, 2001, STEM CELLS, V19, P419, DOI 10.1634/stemcells.19-5-419; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Cohn JN, 1997, CIRCULATION, V95, P766; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Feld Y, 2002, CIRCULATION, V105, P522, DOI 10.1161/hc0402.102661; Gassanov N, 2004, FASEB J, V18, P1710, DOI 10.1096/fj.04-1619fje; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Houweling AC, 2005, CARDIOVASC RES, V67, P583, DOI 10.1016/j.cardiores.2005.06.013; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kehat I, 2002, CIRC RES, V91, P659, DOI 10.1161/01.RES.0000039084.30342.9B; Kehat I, 2004, NAT BIOTECHNOL, V22, P1282, DOI 10.1038/nbt1014; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 2005, FASEB J, V19, P577, DOI 10.1096/fj.03-1451fje; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lang RJ, 2004, EUR J NEUROSCI, V20, P3209, DOI 10.1111/j.1460-9568.2004.03782.x; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Murry CE, 2005, CIRCULATION, V112, P3174, DOI 10.1161/CIRCULATIONAHA.105.546218; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Reinlib L, 2000, CIRCULATION, V101, pE182; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Satin J, 2004, J PHYSIOL-LONDON, V559, P479, DOI 10.1113/jphysiol.2004.068213; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Xue T, 2005, CIRCULATION, V111, P11, DOI 10.1161/01.CIR.0000151313.18547.A2; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	42	207	218	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2551	2563		10.1096/fj.05-5711com	http://dx.doi.org/10.1096/fj.05-5711com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435178				2022-12-25	WOS:000248454400029
J	Lun, SC; Bishai, WR				Lun, Shichun; Bishai, William R.			Characterization of a novel cell wall-anchored protein with carboxylesterase activity required for virulence in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESSENTIAL GENES; LIPOPROTEIN; EXPRESSION; MECHANISM; INHIBITION; SMEGMATIS; ESTERASES; SURVIVAL; LATENCY	Pooled mutant competition assays have shown that the Mycobacterium tuberculosis MT2282 gene (Rv2224c, annotated as encoding a proteinase) is required for bacterial survival in mice. To understand the mechanism of this requirement, we conducted a genetic and biochemical study of the MT2282 gene and its product. MT2282 encodes a member of the microbial esterase/lipase family with active site consensus sequences of G-X-S-X-G, and we have concluded that the MT2282 protein is, in fact, a cell wall-associated carboxylesterase rather than a proteinase, as initially annotated. The MT2282 gene product preferentially hydrolyzes ester bonds of substrates with intermediate carbon chain length. Purified MT2282 is a monomer with enzymatic catalysis properties that fit in the Michaelis-Menten kinetic model. Esterase activity was inhibited by paraoxon and dichlorvos. Replacement of Ser(215), Asp(450), and His(477) by Ala in the consensus motifs completely abolishes esterase activity, suggesting that Ser(215)-Asp(450)-His(477) forms a catalytic triad with Ser(215) as an active site residue. To evaluate the role of the MT2282 in pathogenesis, the gene was deleted from the M. tuberculosis genome. BALB/c mouse aerosol infections showed reduced colony-forming unit loads in lungs and spleens and less lung pathology for the Delta MT2282 mutant. High dose intravenous infection of mice with the mutant resulted in a significantly delayed time to death compared with the wild type or complemented mutant. These results indicate that MT2282 encodes a cell wall-associated carboxylesterase, which is required for full virulence of M. tuberculosis. We propose that MT2282 (Rv2224c) and its adjacent paralogous gene MT2281 (Rv2223c) be named caeA and caeB respectively, for carboxylesterase A and B.	Johns Hopkins Univ, Sch Med, Ctr TB Res, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University	Bishai, WR (corresponding author), Johns Hopkins Univ, Sch Med, Ctr TB Res, Dept Med, 1550 Orleans St, Baltimore, MD 21231 USA.	wbishai@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036973, R01AI043846, R01AI036973, R01AI037856] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37856, AI43846, AI36973] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 2006, CURRENT PROTOCOLS MO, V2; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dannenberg AM, 2006, PATHOGENESIS OF HUMAN PULMONARY TUBERCULOSIS: INSIGHTS FROM THE RABBIT MODEL, P1; Draper P, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P261; Dubnau E, 2002, INFECT IMMUN, V70, P2787, DOI 10.1128/IAI.70.6.2787-2795.2002; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fojan P, 2000, BIOCHIMIE, V82, P1033, DOI 10.1016/S0300-9084(00)01188-3; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; KHULLER GK, 1982, AUST J EXP BIOL MED, V60, P541, DOI 10.1038/icb.1982.58; Kinsella RJ, 2003, P NATL ACAD SCI USA, V100, P10320, DOI 10.1073/pnas.1737230100; KLEIN P, 1988, PROTEIN ENG, V2, P15, DOI 10.1093/protein/2.1.15; KONDO E, 1977, JPN J MED SCI BIOL, V30, P171, DOI 10.7883/yoken1952.30.171; Lamichhane G, 2005, INFECT IMMUN, V73, P2533, DOI 10.1128/IAI.73.4.2533-2540.2005; Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100; LANZ WW, 1973, J BACTERIOL, V113, P1170, DOI 10.1128/JB.113.3.1170-1176.1973; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Liu P, 2004, J MOL BIOL, V342, P551, DOI 10.1016/j.jmb.2004.06.069; MATTAR S, 1994, J BIOL CHEM, V269, P14939; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885OC; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pai RK, 2003, J IMMUNOL, V171, P175, DOI 10.4049/jimmunol.171.1.175; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; PATEL D, 1991, BIOCHEM PHARMACOL, V42, P1577, DOI 10.1016/0006-2952(91)90427-7; Pethe K, 2004, P NATL ACAD SCI USA, V101, P13642, DOI 10.1073/pnas.0401657101; Post FA, 2001, INFECT IMMUN, V69, P1433, DOI 10.1128/IAI.69.3.1433-1439.2001; Qamra R, 2006, BIOCHEMISTRY-US, V45, P6997, DOI 10.1021/bi0606445; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rosenfeld CA, 2006, TOXICOL SCI, V90, P460, DOI 10.1093/toxsci/kfj094; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Sinha S, 2005, MICROBIOL-SGM, V151, P2411, DOI 10.1099/mic.0.27799-0; Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T	43	63	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18348	18356		10.1074/jbc.M700035200	http://dx.doi.org/10.1074/jbc.M700035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17428787	hybrid			2022-12-25	WOS:000247302000041
J	Houston, CM; Lee, HHC; Hosie, AM; Moss, SJ; Smart, TG				Houston, Catriona M.; Lee, Henry H. C.; Hosie, Alastair M.; Moss, Stephen J.; Smart, Trevor G.			Identification of the sites for CaMK-II-dependent phosphorylation of GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; TYROSINE PHOSPHORYLATION; A RECEPTOR; INTRACELLULAR DOMAINS; SYNAPTIC-TRANSMISSION; COUPLED RECEPTORS	Phosphorylation can affect both the function and trafficking of GABA(A) receptors with significant consequences for neuronal excitability. Serine/threonine kinases can phosphorylate the intracellular loops between M3-4 of GABA(A) receptor beta and gamma subunits thereby modulating receptor function in heterologous expression systems and in neurons (1, 2). Specifically, CaMK-II has been demonstrated to phosphorylate the M3 -4 loop of GABAA receptor subunits expressed as GST fusion proteins (3, 4). It also increases the amplitude of GABAA receptor-mediated currents in a number of neuronal cell types (5 -7). To identify which substrate sites CaMK-II might phosphorylate and the consequent functional effects, we expressed recombinant GABAA receptors in NG108-15 cells, which have previously been shown to support CaMK-II modulation of GABAA receptors containing the beta 3 subunit (8). We now demonstrate that CaMK-II mediates its effects on alpha 1 beta 3 receptors via phosphorylation of Ser(383) within the M3-4 domain of the beta subunit. Ablation of beta 3 subunit phosphorylation sites for CaMK-II revealed that for alpha beta gamma receptors, CaMK-II has a residual effect on GABA currents that is not mediated by previously identified sites of CaMK-II phosphorylation. This residual effect is abolished by mutation of tyrosine phosphorylation sites, Tyr(365) and Tyr(367), on the gamma 2S subunit, and by the tyrosine kinase inhibitor genistein. These results suggested that CaMK-II is capable of directly phosphorylating GABAA receptors and activating endogenous tyrosine kinases to phosphorylate the gamma 22 subunit in NG108-15 cells. These findings were confirmed in a neuronal environment by expressing recombinant GABAA receptors in cerebellar granule neurons.	UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA	University of London; University College London; University of Pennsylvania	Smart, TG (corresponding author), UCL, Dept Pharmacol, Gower St, London WC1E 6BT, England.	t.smart@ucl.ac.uk	Lee, Henry/GVS-2114-2022; Lee, Henry HC/S-6014-2016	Lee, Henry HC/0000-0003-4975-7330	MRC [G0601529] Funding Source: UKRI; Medical Research Council [G0601529] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1418; Boxall AR, 1998, EUR J NEUROSCI, V10, P2; Boxall AR, 2000, J PHYSIOL-LONDON, V524, P677, DOI 10.1111/j.1469-7793.2000.00677.x; Brandon NJ, 2001, NEUROPHARMACOLOGY, V41, P745, DOI 10.1016/S0028-3908(01)00121-6; Brandon NJ, 2000, J BIOL CHEM, V275, P38856, DOI 10.1074/jbc.M004910200; Churn SB, 2002, J NEUROCHEM, V82, P1065, DOI 10.1046/j.1471-4159.2002.01032.x; Churn SB, 1998, BRAIN RES, V809, P68, DOI 10.1016/S0006-8993(98)00834-8; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DeLorey TM, 1998, J NEUROSCI, V18, P8505; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fan RS, 2005, J BIOL CHEM, V280, P24212, DOI 10.1074/jbc.M500716200; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101; Ginnan R, 2004, AM J PHYSIOL-CELL PH, V286, pC1281, DOI 10.1152/ajpcell.00202.2003; Ginnan R, 2002, AM J PHYSIOL-CELL PH, V282, pC754, DOI 10.1152/ajpcell.00335.2001; Guo J, 2004, NEUROSCI LETT, V355, P177, DOI 10.1016/j.neulet.2003.10.076; Heidinger V, 2002, J NEUROSCI, V22, P5452; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Houston CM, 2006, EUR J NEUROSCI, V24, P2504, DOI 10.1111/j.1460-9568.2006.05145.x; Huang CC, 1999, J PHYSIOL-LONDON, V520, P783, DOI 10.1111/j.1469-7793.1999.00783.x; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Jovanovic JN, 2004, J NEUROSCI, V24, P522, DOI 10.1523/JNEUROSCI.3606-03.2004; Kano M, 1996, P NATL ACAD SCI USA, V93, P13351, DOI 10.1073/pnas.93.23.13351; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lin YF, 1996, MOL PHARMACOL, V50, P185; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Ma XH, 2003, J NEUROSCI, V23, P1159, DOI 10.1523/JNEUROSCI.23-04-01159.2003; Magoski NS, 2005, J NEUROSCI, V25, P8037, DOI 10.1523/JNEUROSCI.1903-05.2005; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1997, NEUROPHARMACOLOGY, V36, P1377, DOI 10.1016/S0028-3908(97)00111-1; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Nakazawa T, 2006, EMBO J, V25, P2867, DOI 10.1038/sj.emboj.7601156; Nelson AB, 2005, NEURON, V46, P623, DOI 10.1016/j.neuron.2005.04.009; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; SUZUKITAKEUCHI E, 1992, PROTEIN EXPRES PURIF, V3, P160; Terunuma M, 2004, J NEUROSCI, V24, P7074, DOI 10.1523/JNEUROSCI.1323-04.2004; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; WANG RA, 1995, J NEUROPHYSIOL, V73, P2099, DOI 10.1152/jn.1995.73.5.2099; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; Wei J, 2004, NEUROSCIENCE, V127, P637, DOI 10.1016/j.neuroscience.2004.05.056; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	60	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17855	17865		10.1074/jbc.M611533200	http://dx.doi.org/10.1074/jbc.M611533200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442679	hybrid			2022-12-25	WOS:000247084500059
J	Ishima, R; Torchia, DA; Louis, JM				Ishima, Rieko; Torchia, Dennis A.; Louis, John M.			Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; HUMAN-IMMUNODEFICIENCY; POL POLYPROTEIN; STABILITY; KINETICS; MECHANISM; PEPTIDES; PROTEINS; INHIBITION; SUBSTRATE	An experimental protocol for folding the mature human immunodeficiency virus-1 (HIV- 1) protease is presented that facilitates NMR studies at a low protein concentration of similar to 20 mu M. Under these conditions, NMRspectra show that the mature protease lacking its terminal beta-sheet residues 1-4 and 96-99 (PR5-95) exhibits a stable monomer fold spanning the region 10-90 that is similar to that of the single subunit of the wild-type dimer and the dimer bearing a D25N mutation (PRD25N). Urea- induced unfolding monitored both by changes in H-1- N-15 heteronuclear single quantum correlation spectra and by protein fluorescence indicates that although PR5-95 monomer displays a transition profile similar to that of the PRD25N dimer ( 50% unfolded (U-50) = similar to 1.9 M), extending the protease with 4 residues ( SFNF) of its N- terminally flanking sequence in the Gag-Pol precursor ((PRD25N)-P-SFNF) decreases the stability of the fold (U-50 = similar to 1.5 M). Assigned backbone chemical shifts were used to elucidate differences in the stability of the PRT26A (U50 = 2.5 M) and (PRD25N)-P-SFNF monomers and compared with PRD25N/T26A monomer. Discernible differences in the backbone chemical shifts were observed for N- terminal protease residues 3-6 of (PRD25N)-P-SFNF that may relate to the increase in the equilibrium dissociation constant ( Kd) and the very low catalytic activity of the protease prior to its autoprocessing at its N terminus from the Gag- Pol precursor.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA; NIDCR, Mol Struct Biol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B2-29,LCP, Bethesda, MD 20892 USA.	johnl@intra.niddk.nih.gov		Louis, John M/0000-0002-0052-1899	Intramural NIH HHS [Z99 DK999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bowman MJ, 2002, BIOPOLYMERS, V66, P126, DOI 10.1002/bip.10232; Cherry E, 1998, J MOL BIOL, V284, P43, DOI 10.1006/jmbi.1998.1968; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Katoh E, 2003, PROTEIN SCI, V12, P1376, DOI 10.1110/ps.0300703; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; Louis J M, 2000, Adv Pharmacol, V49, P111; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Park SH, 2000, NAT BIOTECHNOL, V18, P847, DOI 10.1038/78451; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Rodriguez-Barrios F, 2004, CURR TOP MED CHEM, V4, P991, DOI 10.2174/1568026043388529; ROSE JR, 1993, J BIOL CHEM, V268, P11939; Sluis-Cremer N, 2004, INT J BIOCHEM CELL B, V36, P1836, DOI 10.1016/j.biocel.2004.02.020; Sluis-Cremer N, 2002, EUR J BIOCHEM, V269, P5103, DOI 10.1046/j.1432-1033.2002.03216.x; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Szeltner Z, 1996, J BIOL CHEM, V271, P5458, DOI 10.1074/jbc.271.10.5458; Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8; WEBER IT, 1990, J BIOL CHEM, V265, P10492; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	36	49	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17190	17199		10.1074/jbc.M701304200	http://dx.doi.org/10.1074/jbc.M701304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412697	hybrid			2022-12-25	WOS:000246946500052
J	Ivanisevic, L; Zheng, WH; Woo, SB; Neet, KE; Saragovi, HU				Ivanisevic, Ljubica; Zheng, WenHua; Woo, Sang B.; Neet, Kenneth E.; Saragovi, H. Uri			TrkA receptor "Hot spots" for binding of NT-3 as a heterologous ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; EXTRACELLULAR DOMAIN; NEUROTROPHIN RECEPTORS; SYMPATHETIC NEURONS; CRYSTAL-STRUCTURE; P75; ACTIVATION; NGF; SURVIVAL	Neurotrophins signal via Trk tyrosine kinase receptors. Nerve growth factor (NGF) is the cognate ligand for TrkA, the brain-derived neurotrophic factor for TrkB, and NT-3 for TrkC. NT-3 also binds TrkA as a lower affinity heterologous ligand. Because neurotrophin-3 (NT-3) interactions with TrkA are biologically relevant, we aimed to define the TrkA "hot spot" functional docking sites of NT-3. The Trk extracellular domain consists of two cysteine-rich subdomains (D1 and D3), flanking a leucine-rich subdomain (D2), and two immunoglobulin-like subdomains IgC1(D4) and IgC2(D5). Previously, the D5 subdomain was defined as the primary ligand-binding site of neurotrophins for their cognate receptors (e.g. NGF binds and activates through TRKA-D5 hot spots). Here binding studies with truncated and chimeric extracellular subdomains show that TRKA-D5 also includes an NT-3 docking and activation hot spot (site 1), and competition studies show that the NGF and NT-3 hot spots on TRKA-D5 are distinct but partially overlapping. In addition, ligand binding studies provide evidence for an NT-3-binding/allosteric site on TRKA-D4 (site 2). NT-3 docking on sites 1 and/ or 2 partially blocks NGF binding. Functional survival studies showed that sites 1 and 2 regulate TrkA activation. NT-3 docking on both sites 1 and 2 affords full agonism, which can be additive with NGF activation of Trk. However, NT-3 docking solely on site 1 is partially agonistic but noncompetitively antagonizes NGF binding and activation of Trk. This study demonstrates that Trk signaling is more complex than previously thought because it involves several receptor subdomains and hot spots.	Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA; McGill Univ, Oncol Canc Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada	Rosalind Franklin University Medical & Science; McGill University; McGill University; Lady Davis Institute; McGill University	Neet, KE (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA.	Kenneth.neet@rosalindfranklin.edu; uri.saragovi@mcgill.ca			NATIONAL CANCER INSTITUTE [R01CA082642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380, R01NS036700, R01NS038569] Funding Source: NIH RePORTER; NCI NIH HHS [CA82642] Funding Source: Medline; NINDS NIH HHS [NS24380, NS36700, R01NS38569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arevalo JC, 2001, ONCOGENE, V20, P1229, DOI 10.1038/sj.onc.1204215; Banfield MJ, 2001, STRUCTURE, V9, P1191, DOI 10.1016/S0969-2126(01)00681-5; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; Francis N, 1999, DEV BIOL, V210, P411, DOI 10.1006/dbio.1999.9269; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; Kuruvilla R, 2004, CELL, V118, P243, DOI 10.1016/j.cell.2004.06.021; LeSauteur L, 1996, J NEUROSCI, V16, P1308; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Miller FD, 2001, NEURON, V32, P767, DOI 10.1016/S0896-6273(01)00529-3; Mischel PS, 2002, BIOPHYS J, V83, P968, DOI 10.1016/S0006-3495(02)75222-3; Mufson EJ, 1997, EXP NEUROL, V146, P91, DOI 10.1006/exnr.1997.6504; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Saragovi HU, 2002, CURR PHARM DESIGN, V8, P2201, DOI 10.2174/1381612023393215; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Wehrman T, 2007, NEURON, V53, P25, DOI 10.1016/j.neuron.2006.09.034; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Woo SB, 1998, PROTEIN SCI, V7, P1006; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	34	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16754	16763		10.1074/jbc.M701996200	http://dx.doi.org/10.1074/jbc.M701996200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439940	hybrid			2022-12-25	WOS:000246946500007
J	Outchkourov, N; Vermunt, A; Jansen, J; Kaan, A; Roeffen, W; Teelen, K; Lasonder, E; Braks, A; van de Vegte-Bolmer, M; Qiu, LY; Sauerwein, R; Stunnenberg, HG				Outchkourov, Nikolay; Vermunt, Adriaan; Jansen, Josephine; Kaan, Anita; Roeffen, Will; Teelen, Karina; Lasonder, Edwin; Braks, Anneke; van de Vegte-Bolmer, Marga; Qiu, Li Yan; Sauerwein, Robert; Stunnenberg, Hendrik G.			Epitope analysis of the malaria surface antigen Pfs48/45 identifies a subdomain that elicits transmission blocking antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; VACCINE CANDIDATE; PROTEIN; PFS230; EXPRESSION; REACTIVITY; TARGET	Pfs48/45, a member of a Plasmodium-specific protein family, displays conformation-dependent epitopes and is an important target for malaria transmission-blocking (TB) immunity. To design a recombinant Pfs48/45-based TB vaccine, we analyzed the conformational TB epitopes of Pfs48/ 45. The Pfs48/ 45 protein was found to consist of a C-terminal six-cysteine module recognized by anti-epitope I antibodies, a middle four-cysteine module recognized by anti-epitopes IIb and III, and an N-terminal module recognized by anti-epitope V antibodies. Refolding assays identified that a fragment of 10 cysteines (10C), comprising the middle four-cysteine and the C-terminal six-cysteine modules, possesses superior refolding capacity. The refolded and partially purified 10C conformer elicited antibodies in mice that targeted at least two of the TB epitopes (I and III). The induced antibodies could block the fertilization of Plasmodium falciparum gametes in vivo in a concentration-dependent manner. Our results provide important insight into the structural organization of the Pfs48/45 protein and experimental support for a Pfs48/45-based subunit vaccine.	Radboud Univ Nijmegen, Dept Biol Mol, NCMLS, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Stunnenberg, HG (corresponding author), Radboud Univ Nijmegen, Dept Biol Mol, NCMLS, M850-3-79,POB 9101, NL-6500 HB Nijmegen, Netherlands.	h.stunnenberg@ncmls.ru.nl	Sauerwein, Robert/C-8519-2013; Roeffen, W.F.G./L-4607-2015; Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Lasonder, Edwin/0000-0003-2582-3444				CARTER R, 1990, PARASITE IMMUNOL, V12, P587, DOI 10.1111/j.1365-3024.1990.tb00990.x; CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; Gerloff DL, 2005, P NATL ACAD SCI USA, V102, P13598, DOI 10.1073/pnas.0502378102; Harlow E., 1988, ANTIBODIES LAB MANUA; Kaslow DC, 2002, CHEM IMMUNOL, V80, P287; KOCKEN CHM, 1993, MOL BIOCHEM PARASIT, V61, P59, DOI 10.1016/0166-6851(93)90158-T; Kubler-Kielb J, 2007, P NATL ACAD SCI USA, V104, P293, DOI 10.1073/pnas.0609885104; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Lensen A, 1996, T ROY SOC TROP MED H, V90, P20, DOI 10.1016/S0035-9203(96)90464-2; Milek RLB, 1998, PARASITE IMMUNOL, V20, P377, DOI 10.1046/j.1365-3024.1998.00171.x; PONNUDURAI T, 1989, PARASITOLOGY, V98, P165, DOI 10.1017/S0031182000062065; PONNUDURAI T, 1987, T ROY SOC TROP MED H, V81, P491, DOI 10.1016/0035-9203(87)90172-6; Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x; ROEFFEN W, 1995, AM J TROP MED HYG, V52, P60, DOI 10.4269/ajtmh.1995.52.60; Roeffen W, 2001, EXP PARASITOL, V97, P45, DOI 10.1006/expr.2000.4586; Roeffen WFG, 2001, J BIOL CHEM, V276, P19807, DOI 10.1074/jbc.M100562200; Schneider P, 2007, AM J TROP MED HYG, V76, P470, DOI 10.4269/ajtmh.2007.76.470; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; TARGETT GAT, 1990, IMMUNOL LETT, V25, P77, DOI 10.1016/0165-2478(90)90095-8; van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460; VERMEULEN AN, 1985, DEV BIOL STAND, V62, P91; Williamson KC, 2003, PARASITE IMMUNOL, V25, P351, DOI 10.1046/j.1365-3024.2003.00643.x; Wu YM, 2006, P NATL ACAD SCI USA, V103, P18243, DOI 10.1073/pnas.0608545103	27	59	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17148	17156		10.1074/jbc.M700948200	http://dx.doi.org/10.1074/jbc.M700948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426022	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000246946500048
J	Smith, BD; Sanders, JL; Porubsky, PR; Lushington, GH; Stout, CD; Scott, EE				Smith, Brian D.; Sanders, Jason L.; Porubsky, Patrick R.; Lushington, Gerald H.; Stout, C. David; Scott, Emily E.			Structure of the human lung cytochrome P450 2A13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO-SPECIFIC CARCINOGEN; AMINO-ACID-RESIDUES; METABOLIC-ACTIVATION; HUMAN CYP2A13; GENETIC POLYMORPHISMS; HYDROXYLASE-ACTIVITY; AFLATOXIN B-1; IDENTIFICATION; EXPRESSION; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	The human lung cytochrome P450 2A13 (CYP2A13) activates the nicotine- derived procarcinogen 4-( methylnitrosamino)- 1(3-pyridyl)-1-butanone (NNK) into DNA- altering compounds that cause lung cancer. Another cytochrome P450, CYP2A6, is also present in human lung, but at much lower levels. Although these two enzymes are 93.5% identical, CYP2A13 metabolizes NNK with much lower K-m values than does CYP2A6. To investigate the structural differences between these two enzymes the structure of CYP2A13 was determined to 2.35 angstrom A by x- ray crystallography and compared with structures of CYP2A6. As expected, the overall CYP2A13 and CYP2A6 structures are very similar with an average root mean square deviation of 0.5 angstrom for the C alpha atoms. Like CYP2A6, the CYP2A13 active site cavity is small and highly hydrophobic with a cluster of Phe residues composing the active site roof. Active site residue Asn(297) is positioned to hydrogen bond with an adventitious ligand, identified as indole. Amino acid differences between CYP2A6 and CYP2A13 at positions 117, 300, 301, and 208 relate to different orientations of the ligand plane in the two protein structures and may underlie the significant variations observed in binding and catalysis of many CYP2A ligands. In addition, docking studies suggest that residues 365 and 366 may also contribute to differences in NNK metabolism.	Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Univ Kansas, Mol Graph & Modeling Lab, Lawrence, KS 66045 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Kansas; University of Kansas; Scripps Research Institute	Scott, EE (corresponding author), 1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	eescott@ku.edu	Lushington, Gerald/AAH-3205-2020; Lushington, Gerald/P-8421-2019	Lushington, Gerald/0000-0001-5821-4253; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708, P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061545, R01GM076343] Funding Source: NIH RePORTER; NCRR NIH HHS [RR016475, RR017708] Funding Source: Medline; NIGMS NIH HHS [GM61545, GM076343] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Crawford EL, 1998, CARCINOGENESIS, V19, P1867, DOI 10.1093/carcin/19.10.1867; Fukami T, 2007, DRUG METAB DISPOS, V35, P335, DOI 10.1124/dmd.106.011064; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; He XY, 2006, INT J CANCER, V118, P2665, DOI 10.1002/ijc.21665; He XY, 2004, DRUG METAB DISPOS, V32, P1516, DOI 10.1124/dmd.104.001370; He XY, 2004, ARCH BIOCHEM BIOPHYS, V427, P143, DOI 10.1016/j.abb.2004.03.016; IWASAKI M, 1995, BIOCHEMISTRY-US, V34, P5054, DOI 10.1021/bi00015a016; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; Jalas JR, 2003, DRUG METAB DISPOS, V31, P1199, DOI 10.1124/dmd.31.10.1199; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LINDBERG RLP, 1992, PHARMACOGENETICS, V2, P32, DOI 10.1097/00008571-199202000-00006; Mace K, 1998, EUR J CANCER, V34, P914, DOI 10.1016/S0959-8049(98)00034-3; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Patten CJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P127, DOI 10.1006/abbi.1996.0373; Pelkonen P, 1997, CHEM RES TOXICOL, V10, P85, DOI 10.1021/tx960078m; Rarey M, 1997, J COMPUT AID MOL DES, V11, P369, DOI 10.1023/A:1007913026166; Raunio H, 1998, Arch Toxicol Suppl, V20, P465; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Su T, 2000, CANCER RES, V60, P5074; TURNER JM, 1961, BIOCHEM J, V78, P790, DOI 10.1042/bj0780790; Uno T, 1997, BIOCHEMISTRY-US, V36, P3193, DOI 10.1021/bi962654j; Wang HJ, 2003, CANCER RES, V63, P8057; Wang SL, 2006, TOXICOL SCI, V94, P38, DOI 10.1093/toxsci/kfl081; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Zhang XL, 2002, J PHARMACOL EXP THER, V302, P416, DOI 10.1124/jpet.302.2.416; Zhu LR, 2006, DRUG METAB DISPOS, V34, P1672, DOI 10.1124/dmd.106.011049	35	81	86	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17306	17313		10.1074/jbc.M702361200	http://dx.doi.org/10.1074/jbc.M702361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428784	hybrid			2022-12-25	WOS:000246946500064
J	Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apte, SS				Koo, Bon-Hun; Longpre, Jean-Michel; Somerville, Robert P. T.; Alexander, J. Preston; Leduc, Richard; Apte, Suneel S.			Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; TRANS-GOLGI NETWORK; CYSTEINE SWITCH; GENE FAMILY; CAENORHABDITIS-ELEGANS; PRECURSOR PROTEINS; IN-VIVO; METALLOPROTEASE; ACTIVATION; MATRIX	ADAMTS9 is a secreted, cell-surface-binding metalloprotease that cleaves the proteoglycans versican and aggrecan. Unlike most precursor proteins, the ADAMTS9 zymogen (proADAMTS9) is resistant to intracellular processing. Instead, proADAMTS9 is processed by furin at the cell surface. Here, we investigated the role of the ADAMTS9 propeptide in regulating its secretion and proteolytic activity. Removal of the propeptide abrogated secretion of the ADAMTS9 catalytic domain, and secretion was inefficiently restored by expression of the propeptide in trans. Substitution of Ala for Asn residues within each of three consensus N-linked glycosylation sites in the propeptide abrogated ADAMTS9 secretion. Thus, the propeptide is an intramolecular chaperone whose glycosylation is critical for secretion of the mature enzyme. In addition to two previously identified furin-processing sites (Arg(74)down arrow and Arg(287)down arrow) the ADAMTS9 propeptide was also furin-processed at Arg209. Substitution of Ala for Arg(74), Arg(209), and Arg(287) resulted in secretion of an unprocessed zymogen. Unexpectedly, versican incubated with cells expressing this pro-ADAMTS9 was processed to a greater extent than when incubated with cells expressing wild-type, furin-processable ADAMTS9. Moreover, cells and medium treated with the proprotein convertase inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone had greater versicancleaving activity than untreated cells. Following furin processing of pro-ADAMTS9, propeptide fragments maintained a non-covalent association with the catalytic domain. Collectively, these observations suggest that, unlike other metalloproteases, furin processing of the ADAMTS9 propeptide reduces its catalytic activity. Thus, the propeptide is a key functional domain of ADAMTS9, mediating an unusual regulatory mechanism that may have evolved to ensure maximal activity of this protease at the cell surface.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Triple Point Biol, Forest Grove, OR 97116 USA; Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49930] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Gauster M, 2005, J LIPID RES, V46, P977, DOI 10.1194/jlr.M400500-JLR200; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; Lee NV, 2005, J BIOL CHEM, V280, P34796, DOI 10.1074/jbc.M506980200; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Longpre JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Somerville RPT, 2004, J BIOL CHEM, V279, P51208, DOI 10.1074/jbc.M409036200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Torres-Collado AX, 2006, J BIOL CHEM, V281, P17827, DOI 10.1074/jbc.M513465200; Tortorella MD, 2005, ARCH BIOCHEM BIOPHYS, V444, P34, DOI 10.1016/j.abb.2005.09.018; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wewer UM, 2006, J BIOL CHEM, V281, P9418, DOI 10.1074/jbc.M513580200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	42	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16146	16154		10.1074/jbc.M610161200	http://dx.doi.org/10.1074/jbc.M610161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403680	hybrid			2022-12-25	WOS:000246794300023
J	Mendillo, ML; Putnam, CD; Kolodner, RD				Mendillo, Marc L.; Putnam, Christopher D.; Kolodner, Richard D.			Escherichia coli MutS tetramerization domain structure reveals that stable dimers but not tetramers are essential for DNA mismatch repair in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY SOLUTION SCATTERING; SMALL-ANGLE SCATTERING; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; MUTATION AVOIDANCE; PROTEIN-STRUCTURE; MALTOSE-BINDING; ATP HYDROLYSIS; PROGRAM; COMPLEX	The Escherichia coli mispair-binding protein MutS forms dimers and tetramers in vitro, although the functional form in vivo is under debate. Here we demonstrate that the MutS tetramer is extended in solution using small angle x-ray scattering and the crystal structure of the C-terminal 34 amino acids of MutS containing the tetramer-forming domain fused to maltose-binding protein ( MBP). Wild-type C-terminal MBP fusions formed tetramers and could bind MutS and MutS-MutL-DNA complexes. In contrast, D835R and R840E mutations predicted to disrupt tetrameric interactions only allowed dimerization of MBP. A chromosomal MutS truncation mutation eliminating the dimerization/tetramerization domain eliminated mismatch repair, whereas the tetramer-disrupting MutS D835R and R840E mutations only modestly affected MutS function. These results demonstrate that dimerization but not tetramerization of the MutS C terminus is essential for mismatch repair.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu	Classen, Scott/AAY-8176-2020	Putnam, Christopher/0000-0002-6145-1265; Mendillo, Marc/0000-0001-8128-0128	NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [R01 GM050006, GM50006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calmann MA, 2005, J BACTERIOL, V187, P6577, DOI 10.1128/JB.187.18.6577-6579.2005; Calmann MA, 2005, NUCLEIC ACIDS RES, V33, P1193, DOI 10.1093/nar/gki263; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; Duan XQ, 2001, J MOL BIOL, V306, P1115, DOI 10.1006/jmbi.2001.4456; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; FENG G, 1995, BIOTECHNIQUES, V19, P956; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lamers MH, 2004, J BIOL CHEM, V279, P43879, DOI 10.1074/jbc.M406380200; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; de Saro FJL, 2006, J BIOL CHEM, V281, P14340, DOI 10.1074/jbc.M601264200; Luria SE, 1943, GENETICS, V28, P491; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Manelyte L, 2006, NUCLEIC ACIDS RES, V34, P5270, DOI 10.1093/nar/gkl489; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MILLER J, 1992, SHORT COURSE BACTERI, P81; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Poteete AR, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-22; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Stanislawska-Sachadyn A, 2003, PROTEIN EXPRES PURIF, V28, P69, DOI 10.1016/S1046-5928(02)00649-6; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Telmer PG, 2003, J BIOL CHEM, V278, P34555, DOI 10.1074/jbc.M301004200; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	54	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16345	16354		10.1074/jbc.M700858200	http://dx.doi.org/10.1074/jbc.M700858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426027	hybrid			2022-12-25	WOS:000246794300042
J	Hsu, CY; Ko, FY; Li, CW; Fann, K; Lue, JT				Hsu, Chin-Yuan; Ko, Fu-Yao; Li, Chia-Wei; Fann, Kuni; Lue, Juh-Tzeng			Magnetoreception System in Honeybees (Apis mellifera)	PLOS ONE			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; IRON-CONTAINING CELLS; ELF MAGNETIC-FIELD; PULSED ELECTROMAGNETIC-FIELDS; BEES; GRANULES; ORIENTATION; CA2+; NANOPARTICLES; MAGNETOSOMES	Honeybees (Apis mellifera) undergo iron biomineralization, providing the basis for magnetoreception. We showed earlier the presence of superparamagnetic magnetite in iron granules formed in honeybees, and subscribed to the notion that external magnetic fields may cause expansion or contraction of the superparamagnetic particles in an orientation-specific manner, relaying the signal via cytoskeleton (Hsu and Li 1994). In this study, we established a size-density purification procedure, with which quantitative amount of iron granules was obtained from honey bee trophocytes and characterized; the density of iron granules was determined to be 1.25 g/cm(3). While we confirmed the presence of superparamagnetic magnetite in the iron granules, we observed changes in the size of the magnetic granules in the trophycytes upon applying additional magnetic field to the cells. A concomitant release of calcium ion was observed by confocal microscope. This size fluctuation triggered the increase of intracellular Ca+2, which was inhibited by colchicines and latrunculin B, known to be blockers for microtubule and microfilament syntheses, respectively. The associated cytoskeleton may thus relay the magnetosignal, initiating a neural response. A model for the mechanism of magnetoreception in honeybees is proposed, which may be applicable to most, if not all, magnetotactic organisms.	[Hsu, Chin-Yuan] Chang Gung Univ, Dept Life Sci, Tao Yuan, Taiwan; [Ko, Fu-Yao; Li, Chia-Wei] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Fann, Kuni] York Univ, Atkinson Coll, Dept Philosophy, Toronto, ON M3J 2R7, Canada; [Lue, Juh-Tzeng] Natl Tsing Hua Univ, Dept Phys, Hsinchu, Taiwan	Chang Gung University; National Tsing Hua University; York University - Canada; National Tsing Hua University	Hsu, CY (corresponding author), Chang Gung Univ, Dept Life Sci, Tao Yuan, Taiwan.	hsu@mail.cgu.edu.tw			National Science Council [NSC 94-2311-B-182-008]	National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by a grant (NSC 94-2311-B-182-008) from the National Science Council, R. O. C.	Abracado LG, 2005, J MAGN RESON, V175, P309, DOI 10.1016/j.jmr.2005.05.006; Acosta-Avalos D, 1999, J EXP BIOL, V202, P2687; Aldinucci C, 2000, BBA-MOL CELL RES, V1499, P101, DOI 10.1016/S0167-4889(00)00111-7; Alerstam T, 2006, SCIENCE, V313, P791, DOI 10.1126/science.1129048; Alves OC, 2004, J MAGN RESON, V168, P246, DOI 10.1016/j.jmr.2004.03.010; Balcavage WX, 1996, BIOCHEM BIOPH RES CO, V222, P374, DOI 10.1006/bbrc.1996.0751; BECKER L, 1958, Z VERGL PHYSIOL, V41, P1; Bersani F, 1997, BIOELECTROMAGNETICS, V18, P463, DOI 10.1002/(SICI)1521-186X(1997)18:7<463::AID-BEM1>3.0.CO;2-0; Bianchi MG, 2006, NEUROCHEM INT, V48, P341, DOI 10.1016/j.neuint.2005.11.013; BLAKEMORE R, 1975, SCIENCE, V190, P377, DOI 10.1126/science.170679; Boyain-Goitia AR, 2003, APPL OPTICS, V42, P6119, DOI 10.1364/AO.42.006119; Capaldi EA, 2000, NATURE, V403, P537, DOI 10.1038/35000564; COLLETT TS, 1994, NATURE, V368, P137, DOI 10.1038/368137a0; Desoil M, 2005, J PHYS CONF SER, V17, P45, DOI 10.1088/1742-6596/17/1/007; Diebel CE, 2000, NATURE, V406, P299, DOI 10.1038/35018561; Dowell ML, 2005, J APPL PHYSIOL, V98, P489, DOI 10.1152/japplphysiol.01378.2003; DYER FC, 1981, SCIENCE, V214, P1041, DOI 10.1126/science.214.4524.1041; El-Jaick LJ, 2001, EUR BIOPHYS J BIOPHY, V29, P579, DOI 10.1007/s002490000115; Esch HE, 2001, NATURE, V411, P581, DOI 10.1038/35079072; Esquivel DMS, 1999, NATURWISSENSCHAFTEN, V86, P30, DOI 10.1007/s001140050564; Ferreira J, 2005, J MAGN MAGN MATER, V289, P442, DOI 10.1016/j.jmmm.2004.11.124; Flipo D, 1998, J TOXICOL ENV HEAL A, V54, P63; Frier HJ, 1996, J EXP BIOL, V199, P1353; GOULD JL, 1980, J EXP BIOL, V86, P1; GOULD JL, 1986, SCIENCE, V232, P861, DOI 10.1126/science.232.4752.861; GOULD JL, 1978, SCIENCE, V201, P1026, DOI 10.1126/science.201.4360.1026; Haskew-Layton RE, 2005, J BIOL CHEM, V280, P3548, DOI 10.1074/jbc.M409803200; HSU CY, 1994, SCIENCE, V265, P95, DOI 10.1126/science.265.5168.95; HSU CY, 1993, J EXP BIOL, V180, P1; Ikehara T, 2005, BBA-GEN SUBJECTS, V1724, P8, DOI 10.1016/j.bbagen.2005.03.008; Ikehara T, 2003, BIOELECTROMAGNETICS, V24, P457, DOI 10.1002/bem.10120; Kalmijn AJ., 1978, ANIMAL MIGRATION NAV, P354; Keim CN, 2002, MICRON, V33, P53, DOI 10.1016/S0968-4328(00)00071-8; Kirschvink JL, 1997, J EXP BIOL, V200, P1363; KIRSCHVINK JL, 1981, BIOSYSTEMS, V13, P181, DOI 10.1016/0303-2647(81)90060-5; KIRSCHVINK JL, 1992, BIOELECTROMAGNETICS, V13, P401, DOI 10.1002/bem.2250130507; KIRSCHVINK JL, 1991, AM ZOOL, V31, P169; KIRSCHVINK JL, 1995, SCIENCE, V269, P1889, DOI 10.1126/science.269.5232.1889; Komeili A, 2006, SCIENCE, V311, P242, DOI 10.1126/science.1123231; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Koronkiewicz S, 2001, BBA-BIOMEMBRANES, V1510, P300, DOI 10.1016/S0005-2736(00)00362-X; KREBS AT, 1965, NATURE, V207, P1412, DOI 10.1038/2071412a0; KUTERBACH DA, 1986, J EXP BIOL, V126, P375; KUTERBACH DA, 1986, J EXP BIOL, V126, P389; KUTERBACH DA, 1982, SCIENCE, V218, P695, DOI 10.1126/science.218.4573.695; Lechaire JP, 2002, BIOL CELL, V94, P243, DOI 10.1016/S0248-4900(02)01199-1; Lins U, 1999, FEMS MICROBIOL LETT, V172, P23, DOI 10.1016/S0378-1097(99)00011-7; Lucano MJ, 2006, BIOMETALS, V19, P295, DOI 10.1007/s10534-005-0520-4; Manni V, 2004, BIOELECTROMAGNETICS, V25, P118, DOI 10.1002/bem.10158; Menzel R, 2005, P NATL ACAD SCI USA, V102, P3040, DOI 10.1073/pnas.0408550102; Morgado-Valle C, 1998, CELL TISSUE RES, V291, P217, DOI 10.1007/s004410050992; Pessina GP, 2001, BIOELECTROMAGNETICS, V22, P503, DOI 10.1002/bem.79; Petersen OH, 1996, NEWS PHYSIOL SCI, V11, P13; Rasa M, 2002, J COLLOID INTERF SCI, V250, P303, DOI 10.1006/jcis.2002.8345; Riley JR, 2005, NATURE, V435, P205, DOI 10.1038/nature03526; ROSSEL S, 1986, NATURE, V323, P128, DOI 10.1038/323128a0; ROSSEL S, 1984, J COMP PHYSIOL, V154, P607, DOI 10.1007/BF01350213; ROSSEL S, 1984, J COMP PHYSIOL, V155, P605, DOI 10.1007/BF00610846; Santoro N, 1997, BBA-MOL CELL RES, V1357, P281, DOI 10.1016/S0167-4889(97)00032-3; Scheffel A, 2006, NATURE, V440, P110, DOI 10.1038/nature04382; SMITH OM, 1991, BIOELECTROMAGNETICS, V12, P197, DOI 10.1002/bem.2250120307; Srinivasan MV, 2000, SCIENCE, V287, P851, DOI 10.1126/science.287.5454.851; Tautz J, 2004, PLOS BIOL, V2, P915, DOI 10.1371/journal.pbio.0020211; TOWNE WF, 1985, MAGNETITE BIOMINERAL, P385; von Frisch K., 1967, DANCE LANGUAGE ORIEN; Wajnberg E, 2000, BIOPHYS J, V78, P1018, DOI 10.1016/S0006-3495(00)76660-4; Wajnberg E, 2001, J MAGN RESON, V153, P69, DOI 10.1006/jmre.2001.2430; Wakatsuki T, 2001, J CELL SCI, V114, P1025; WALKER MM, 1989, J COMP PSYCHOL, V103, P62; WALKER MM, 1989, J EXP BIOL, V145, P489; WALKER MM, 1985, J COMP PHYSIOL A, V157, P67, DOI 10.1007/BF00611096; WALKER MM, 1989, J EXP BIOL, V141, P447; Winston M.L., 1991, BIOL HONEY BEE	73	72	77	4	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e395	10.1371/journal.pone.0000395	http://dx.doi.org/10.1371/journal.pone.0000395			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460762	Green Published, gold			2022-12-25	WOS:000207445600009
J	Dingli, D; Traulsen, A; Pacheco, JM				Dingli, David; Traulsen, Arne; Pacheco, Jorge M.			Compartmental Architecture and Dynamics of Hematopoiesis	PLOS ONE			English	Article								Background. Blood cell formation is maintained by the replication of hematopoietic stem cells (HSC) that continuously feed downstream "compartments" where amplification and differentiation of cells occurs, giving rise to all blood lineages. Whereas HSC replicate slowly, committed cells replicate faster as they become more differentiated. Methodology/Significant Finding. We propose a multi-compartment model of hematopoiesis, designed on the principle of cell flow conservation under stationary conditions. Cells lost from one compartment due to differentiation are replaced by cells from the upstream compartment. We assume that there is a constant relationship between cell input and output in each compartment and fix the single parameter of the model using data available for granulocyte maturation. We predict that similar to 31 mitotic events separate the HSC from the mature cells observed in the circulation. Besides estimating the number of compartments, our model allows us to estimate the size of each compartment, the rate of cell replication within each compartment, the mean time a given cell type contributes to hematopoiesis, the amplification rate in each compartment, as well as the mean time separating stem-cell replication and mature blood-cell formation. Conclusions. Despite its simplicity, the model agrees with the limited in vivo data available and can make testable predictions. In particular, our prediction of the average lifetime of a PIG-A mutated clone agrees closely with the experimental results available for the PIG-A gene mutation in healthy adults. The present elucidation of the compartment structure and dynamics of hematopoiesis may prove insightful in further understanding a variety of hematopoietic disorders.	[Dingli, David] Mayo Clin, Coll Med, Div Hematol, Rochester, MN 55905 USA; [Dingli, David; Traulsen, Arne; Pacheco, Jorge M.] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA; [Pacheco, Jorge M.] Univ Lisbon, Fac Ciencias, Dept Fis, Lisbon, Portugal; [Pacheco, Jorge M.] Ctr Fis Teor & Computac, Lisbon, Portugal	Mayo Clinic; Harvard University; Universidade de Lisboa; Universidade de Lisboa	Dingli, D (corresponding author), Mayo Clin, Coll Med, Div Hematol, Rochester, MN 55905 USA.	dingli.david@mayo.edu	Pacheco, Jorge M/B-6116-2008; Traulsen, Arne/A-4955-2009; Pacheco, Jorge M./O-8184-2019	Pacheco, Jorge M/0000-0002-2579-8499; Traulsen, Arne/0000-0002-0669-5267; Pacheco, Jorge M./0000-0002-2579-8499				Araten DJ, 2006, BLOOD, V108, P734, DOI 10.1182/blood-2006-01-0256; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Colijn C, 2005, J THEOR BIOL, V237, P133, DOI 10.1016/j.jtbi.2005.03.034; Colijn C, 2005, J THEOR BIOL, V237, P117, DOI 10.1016/j.jtbi.2005.03.033; CRONKITE EP, 1964, NEW ENGL J MED, V270, P1347, DOI 10.1056/NEJM196406182702506; DINGLI D, 2007, PLOS COMPUT IN PRESS; Dingli D, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000002; DONOHUE DM, 1958, J CLIN INVEST, V37, P1571, DOI 10.1172/JCI103750; FINCH CA, 1977, BLOOD, V50, P699; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Mackey MC, 2001, CELL PROLIFERAT, V34, P71, DOI 10.1046/j.1365-2184.2001.00195.x; Marley SB, 2003, BRIT J HAEMATOL, V121, P643, DOI 10.1046/j.1365-2141.2003.04338.x; Marley SB, 2001, BONE MARROW TRANSPL, V27, P241, DOI 10.1038/sj.bmt.1702777; McCulloch EA, 2005, NAT MED, V11, P1026, DOI 10.1038/nm1005-1026; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Obeyesekere MN, 2004, CELL PROLIFERAT, V37, P279, DOI 10.1111/j.1365-2184.2004.00312.x; Panetta JC, 2003, MATH BIOSCI, V186, P29, DOI 10.1016/j.mbs.2003.07.002; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Shochat E, 2002, B MATH BIOL, V64, P861, DOI 10.1006/bulm.2002.0305; Vainstein V, 2005, J THEOR BIOL, V234, P311, DOI 10.1016/j.jtbi.2004.11.026; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WALKER RI, 1964, BLOOD, V23, P795, DOI 10.1182/blood.V23.6.795.795	23	64	64	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e345	10.1371/journal.pone.0000345	http://dx.doi.org/10.1371/journal.pone.0000345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406669	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445300007
J	Aoki, H; Iwado, E; Eller, MS; Kondo, Y; Fujiwara, K; Li, GZ; Hess, KR; Siwak, DR; Sawaya, R; Mills, GB; Gilchrest, BA; Kondo, S				Aoki, Hiroshi; Iwado, Eiji; Eller, Mark S.; Kondo, Yasuko; Fujiwara, Keishi; Li, Guang-Zhi; Hess, Kenneth R.; Siwak, Doris R.; Sawaya, Raymond; Mills, Gordon B.; Gilchrest, Barbara A.; Kondo, Seiji			Telomere 3 ' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells	FASEB JOURNAL			English	Article						T-oligos; mTOR	PATHWAY; DEATH; APOPTOSIS; RADIATION; SURVIVAL; THERAPY; HOMOLOG; END; P53	Telomere 3' overhang-specific DNA oligonucleotides (T-oligos) induce cell death in cancer cells, presumably by mimicking telomere loop disruption. Therefore, T-oligos are considered an exciting new therapeutic strategy. The purpose of this study was to elucidate how T-oligos exert antitumor effects on human malignant glioma cells in vitro and in vivo. We demonstrated that T-oligos inhibited the proliferation of malignant glioma cells through induction of nonapoptotic cell death and mitochondria hyperpolarization, whereas normal astrocytes were resistant to T-oligos. Tumor cells treated with T-oligos developed features compatible with autophagy, with development of autophagic vacuoles and conversion of an autophagy-related protein, microtubule-associated protein 1 light chain 3 from type I ( cytoplasmic form) to type II ( membrane form of autophagic vacuoles). A reverse-phase protein microarray analysis and Western blotting revealed that treatment with T-oligos inhibited the mammalian target of the rapamycin ( mTOR) and the signal transducer and activator of transcription 3 (STAT3). Moreover, pretreatment with T-oligos significantly prolonged the survival time of mice inoculated intracranially with malignant glioma cells compared with that of untreated mice and those treated with control oligonucleotides ( P = 0.0065 and P = 0.043, respectively). These results indicate that T-oligos stimulate the induction of nonapoptotic autophagic also known as type II programmed cell death and are thus promising in the treatment of malignant glioma.-Aoki, H., Iwado, E., Eller, M. S., Kondo, Y., Fujiwara, K., Li, G.-Z., Hess, K. R., Siwak, D. R., Sawaya, R., Mills, G. B., Gilchrest, B. A., Kondo, S. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	seikondo@mdanderson.org	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	NCI NIH HHS [CA-088936, CA-108558, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA088936, R01CA108558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Eller MS, 2006, P NATL ACAD SCI USA, V103, P15073, DOI 10.1073/pnas.0607332103; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; Goukassian DA, 2004, P NATL ACAD SCI USA, V101, P3933, DOI 10.1073/pnas.0306389101; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; IWAMARU A, 2006, ONCOGENE; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Li GZ, 2004, EXP CELL RES, V301, P189, DOI 10.1016/j.yexcr.2004.08.019; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Marwaha V, 2005, J BIOL CHEM, V280, P32379, DOI 10.1074/jbc.M503245200; Mitchell P, 2005, LANCET NEUROL, V4, P413, DOI 10.1016/S1474-4422(05)70118-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Mukai S, 2000, CANCER RES, V60, P4461; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Paglin S, 2001, CANCER RES, V61, P439; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sonoda Y, 2001, CANCER RES, V61, P4956; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378	48	53	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2918	2930		10.1096/fj.06-6941com	http://dx.doi.org/10.1096/fj.06-6941com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17449721				2022-12-25	WOS:000249237500032
J	Siegmund, SV; Qian, T; de Minicis, S; Harvey-White, J; Kunos, G; Vinod, KY; Hungund, B; Schwabe, RF				Siegmund, Soeren V.; Qian, Ting; de Minicis, Samuele; Harvey-White, Judith; Kunos, George; Vinod, K. Y.; Hungund, Basalingappa; Schwabe, Robert F.			The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species	FASEB JOURNAL			English	Article						ROS; 2-AG; HSC; hepatocyte; fibrosis	CANNABINOID-RECEPTOR; LIVER FIBROSIS; KAPPA-B; PERMEABILITY TRANSITION; NADPH OXIDASE; ANANDAMIDE; APOPTOSIS; PROLIFERATION; ACTIVATION; RESOLUTION	The endocannabinoid system is an important regulator of hepatic fibrogenesis. In this study, we determined the effects of 2- arachidonoyl glycerol ( 2- AG) on hepatic stellate cells ( HSCs), the main fibrogenic cell type in the liver. Culture- activated HSCs were highly susceptible to 2- AG- induced cell death with > 50% cell death at 10 mu M after 18 h of treatment. 2- AG- induced HSC death showed typical features of apoptosis such as PARP- and caspase 3- cleavage and depended on reactive oxygen species ( ROS) formation. Confocal microscopy revealed mitochondria as primary site of ROS production and demonstrated mitochondrial depolarization and increased mitochondrial permeability after 2- AG treatment. 2- AG- induced cell death was independent of cannabinoid receptors but required the presence of membrane cholesterol. Primary hepatocytes were resistant to 2- AG- induced ROS induction and cell death but became susceptible after GSH depletion suggesting antioxidant defenses as a critical determinant of 2- AG sensitivity. Hepatic levels of 2- AG were significantly elevated in two models of experimental fibrogenesis and reached concentrations that are sufficient to induce death in HSCs. These findings suggest that 2- AG may act as an antifibrogenic mediator in the liver by inducing cell death in activated HSCs but not hepatocytes.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Heidelberg Univ, Med Fac Mannheim, Dept Med 2, D-6800 Mannheim, Germany; Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77550 USA; NIAAA, NIH, Bethesda, MD USA; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA	Columbia University; Ruprecht Karls University Heidelberg; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Nathan Kline Institute for Psychiatric Research; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavill,Rm 415,1150 St Nicholas Ave, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021					Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bataller R, 2001, SEMIN LIVER DIS, V21, P437, DOI 10.1055/s-2001-17558; Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; De Minicis S, 2006, GASTROENTEROLOGY, V131, P272, DOI 10.1053/j.gastro.2006.05.048; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; Derkinderen P, 2003, J NEUROSCI, V23, P2371; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Galli A, 2005, HEPATOLOGY, V41, P1074, DOI 10.1002/hep.20683; Gallop JR, 1995, CERN REPORT, V95, P1; Hammel P, 2001, NEW ENGL J MED, V344, P418, DOI 10.1056/NEJM200102083440604; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; Kweon YO, 2003, J HEPATOL, V39, P38, DOI 10.1016/S0168-8278(03)00178-8; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Lemasters JJ, 1998, GASTROENTEROLOGY, V115, P783, DOI 10.1016/S0016-5085(98)70160-X; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Magness ST, 2004, HEPATOLOGY, V40, P1151, DOI 10.1002/hep.20427; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; McCarron RM, 2003, ACTA NEUROCHIR SUPPL, V86, P271; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Oakley F, 2005, GASTROENTEROLOGY, V128, P108, DOI 10.1053/j.gastro.2004.10.003; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Saile B, 1997, AM J PATHOL, V151, P1265; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Siegmund SV, 2006, J BIOL CHEM, V281, P10431, DOI 10.1074/jbc.M509706200; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Tian XY, 2005, J BIOL CHEM, V280, P29788, DOI 10.1074/jbc.M502925200; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	53	102	110	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2798	2806		10.1096/fj.06-7717com	http://dx.doi.org/10.1096/fj.06-7717com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17440119				2022-12-25	WOS:000249237500021
J	Liang, J; Pan, YL; Zhang, DX; Guo, CC; Shi, YQ; Wang, JB; Chen, Y; Wang, X; Liu, J; Guo, XG; Chen, Z; Qiao, TD; Fan, DM				Liang, Jie; Pan, Yanglin; Zhang, Dexin; Guo, Changcun; Shi, Yongquan; Wang, Jingbo; Chen, Yu; Wang, Xin; Liu, Jie; Guo, Xuegang; Chen, Zheng; Qiao, Taidong; Fan, Daiming			Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS	FASEB JOURNAL			English	Article						PrPC proliferation; cyclinD1; PI3K/Akt; octa-peptide repeat region	TERMINAL SH3 DOMAIN; GASTROINTESTINAL-TRACT; SIGNAL-TRANSDUCTION; EXPRESSION; GENE; PHOSPHATIDYLINOSITOL; SURVIVAL; KINASE; LINE; PRPC	The function of cellular prion protein ( PrPC), the essential protein for the pathogenesis and transmission of prion diseases, is still largely unknown. The putative roles of PrPC are thought to be related to cell signaling, survival, and differentiation. In a previous study, we showed that PrPC was overexpressed in gastric cancer tissues. In the present report, we show that ectopic expression of PrPC could promote tumorigenesis, proliferation, and G1/S transition in gastric cancer cells. Furthermore, CyclinD1, a protein related to cell cycle, was shown to be significantly up-regulated by PrPC at both mRNA and protein levels. PI3K/Akt pathway mediated above PrPC signal since PrPC increased the expression of phosphorylated Akt, and the specific inhibitor of Akt, LY294002, could markedly suppress growth of SGC7901 and transactivation of CyclinD1 induced by PrPC. Octapeptide repeat region played a vital role in this function, as deletion of this region abolished or reduced these effects. Collectively, this study demonstrates that overexpression of PrPC might promote the tumorigenesis and proliferation of gastric cancer cells at least partially through activation of PI3K/ Akt pathway and subsequent transcriptional activation of CyclinD1 to regulate the G1/S phase transition, in which octapeptide repeat region might be an indispensable region.-Liang, J., Pan, Y., Zhang, D., Guo, C., Shi, Y., Wang, J., Chen, Y., Wang, X., Liu, J., Guo, X., Chen, Z., Qiao, T., Fan, D. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Peoples R China	Air Force Military Medical University	Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, 15 W Chang Le Rd, Xian, Peoples R China.	fandaim@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020	Guo, Changcun/0000-0002-9016-9699				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Comincini S, 2004, ANTICANCER RES, V24, P1507; Couzin J, 2006, SCIENCE, V311, P1091, DOI 10.1126/science.311.5764.1091; Daggett V, 1998, CURR OPIN BIOTECH, V9, P359, DOI 10.1016/S0958-1669(98)80008-6; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Du JP, 2005, INT J CANCER, V113, P213, DOI 10.1002/ijc.20570; Even Y, 2006, J CELL BIOCHEM, V99, P890, DOI 10.1002/jcb.20986; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Gougoumas DD, 2001, EXP CELL RES, V264, P408, DOI 10.1006/excr.2001.5151; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Kikuchi Y, 2002, BIOL PHARM BULL, V25, P728, DOI 10.1248/bpb.25.728; Konturek PC, 2005, WORLD J GASTROENTERO, V11, P7651, DOI 10.3748/wjg.v11.i48.7651; Krebs B, 2006, BIOCHEM BIOPH RES CO, V340, P13, DOI 10.1016/j.bbrc.2005.11.158; Liang J, 2006, TUMOR BIOL, V27, P84, DOI 10.1159/000092488; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Pammer J, 2000, VIRCHOWS ARCH, V436, P466, DOI 10.1007/s004280050474; Pammer J, 1999, LANCET, V354, P1702, DOI 10.1016/S0140-6736(99)02800-7; Pan YL, 2007, CANCER LETT, V246, P129, DOI 10.1016/j.canlet.2006.02.010; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Tang X, 2007, CELL DEATH DIFFER, V14, P368, DOI 10.1038/sj.cdd.4402011; Tu YP, 2000, CANCER RES, V60, P6763; Vassallo N, 2005, BIOCHEM BIOPH RES CO, V332, P75, DOI 10.1016/j.bbrc.2005.04.099; Watt NT, 2005, J BIOL CHEM, V280, P35914, DOI 10.1074/jbc.M507327200; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yin SM, 2006, J BIOL CHEM, V281, P10698, DOI 10.1074/jbc.M511819200; Yy, 2006, EXCLI J, V5, P11; Zhao YQ, 2002, CANCER LETT, V185, P211, DOI 10.1016/S0304-3835(02)00264-1	36	75	85	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2247	2256		10.1096/fj.06-7799com	http://dx.doi.org/10.1096/fj.06-7799com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17409275				2022-12-25	WOS:000247500300033
J	Davis, ML; Thoden, JB; Holden, HM				Davis, Melissa L.; Thoden, James B.; Holden, Hazel M.			The X-ray structure of dTDP-4-keto-6-deoxy-D-glucose-3,4-ketoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-LAYER; CUPIN SUPERFAMILY; BIOSYNTHESIS; PROTEINS; BACTERIA; EVOLUTION; GENES	The repeating unit of the glycan chain in the S-layer of the bacterium Aneurinibacillus thermoaerophilus L420-91(T) is composed of four alpha-D-rhamnose molecules and two 3-acetamido3,6- dideoxy-alpha-D-galactose moieties (abbreviated as Fucp3NAc). Formation of the glycan layer requires nucleotide-activated sugars as the donor molecules. Whereas the enzymes involved in the synthesis of GDP-rhamnose have been well characterized, less is known regarding the structures and enzymatic mechanisms of the enzymes required for the production of dTDP-Fucp3NAc. One of the enzymes involved in the biosynthesis of dTDP-Fucp3NAc is a 3,4-ketoisomerase, hereafter referred to as FdtA. Here we describe the first three-dimensional structure of this sugar isomerase complexed with dTDP and solved to 1.5 A resolution. The FdtA dimer assumes an almost jellyfish-like appearance with the sole alpha-helices representing the tentacles. Formation of the FdtA dimer represents a classical example of domain swapping whereby beta-strands 2 and 3 from one subunit form part of a beta-sheet in the second subunit. The active site architecture of FdtA is characterized by a cluster of three histidine residues, two of which, His(49) and His(51), appear to be strictly conserved in the amino acid sequences deposited to date. Site-directed mutagenesis experiments, enzymatic assays, and x-ray crystallographic analyses suggest that His(49) functions as an active site base.			Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett MJ, 2006, STRUCTURE, V14, P811, DOI 10.1016/j.str.2006.03.011; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Claus H, 2005, CAN J MICROBIOL, V51, P731, DOI 10.1139/W05-093; DeLano W.L., 2003, PYMOL REFERENCE MANU; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Garduno R, 2000, CAN J MICROBIOL, V46, P660, DOI 10.1139/cjm-46-7-660; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; He XM, 2002, CURR OPIN CHEM BIOL, V6, P590, DOI 10.1016/S1367-5931(02)00367-8; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; Johnson D. A., 1999, COMPREHENSIVE NATURA, P311; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KOSMA P, 1995, GLYCOCONJUGATE J, V12, P99, DOI 10.1007/BF00731875; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Melancon CE, 2007, BIOCHEMISTRY-US, V46, P577, DOI 10.1021/bi061907y; Michalopoulos I, 2004, NUCLEIC ACIDS RES, V32, pD251, DOI 10.1093/nar/gkh060; Novotny R, 2003, GLYCOCONJUGATE J, V20, P435, DOI 10.1023/B:GLYC.0000038290.74944.65; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfoestl A, 2003, J BIOL CHEM, V278, P26410, DOI 10.1074/jbc.M300858200; Rupprath C, 2005, CURR MED CHEM, V12, P1637, DOI 10.2174/0929867054367167; Sabet M, 2003, MICROBIOL-SGM, V149, P3617, DOI 10.1099/mic.0.26535-0; Sambrook J, 2001, MOL CLONING LAB MANU; Samuel G, 2003, CARBOHYD RES, V338, P2503, DOI 10.1016/j.carres.2003.07.009; Schaffer C, 2005, MICROBIOL-SGM, V151, P643, DOI 10.1099/mic.0.27749-0; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trefzer A, 1999, NAT PROD REP, V16, P283, DOI 10.1039/a804431g; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012	31	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19227	19236		10.1074/jbc.M702529200	http://dx.doi.org/10.1074/jbc.M702529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17459872	hybrid			2022-12-25	WOS:000247475300063
J	Iinuma, T; Shiga, A; Nakamoto, K; O'Brien, MB; Aridor, M; Arimitsu, N; Tagaya, M; Tani, K				Iinuma, Takayuki; Shiga, Akiko; Nakamoto, Koji; O'Brien, Matthew B.; Aridor, Meir; Arimitsu, Nagisa; Tagaya, Mitsuo; Tani, Katsuko			Mammalian Sec16/p250 plays a role in membrane traffic from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITIONAL ER ORGANIZATION; COPII-COATED VESICLE; DE-NOVO FORMATION; EXIT SITES; GOLGI-APPARATUS; SEC23P-INTERACTING PROTEIN; CARGO SELECTION; PICHIA-PASTORIS; SUBUNIT INTERACTIONS; PHOSPHOLIPASE A(1)	Coat protein complex II ( COPII)-coated vesicles/carriers, which mediate export of proteins from the endoplasmic reticulum ( ER), are formed at special ER subdomains in mammals, termed ER exit sites or transitional ER. The COPII coat consists of a small GTPase, Sar1, and two protein complexes, Sec23-Sec24 and Sec13-Sec31. Sec23-Sec24 and Sec13-Sec31 appear to constitute the inner and the outermost layers of the COPII coat, respectively. We previously isolated two mammalian proteins ( p125 and p250) that bind to Sec23. p125 was found to be a mammalian-specific, phospholipase A(1)-like protein that participates in the organization of ER exit sites. Here we show that p250 is encoded by the KIAA0310 clone and has sequence similarity to yeast Sec16 protein. Although KIAA0310p was found to be localized at ER exit sites, subcellular fractionation revealed its predominant presence in the cytosol. Cytosolic KIAA0310p was recruited to ER membranes in a manner dependent on Sar1. Depletion of KIAA0310p mildly caused disorganization of ER exit sites and delayed protein transport from the ER, suggesting its implication in membrane traffic out of the ER. Overexpression of KIAA0310p affected ER exit sites in a manner different from that of p125. Binding experiments suggested that KIAA0310p interacts with both the inner and the outermost layer coat complexes, whereas p125 binds principally to the inner layer complex. Our results suggest that KIAA0310p, a mammalian homologue of yeast Sec16, builds up ER exit sites in cooperation with p125 and plays a role in membrane traffic from the ER.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Tokyo University of Pharmacy & Life Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tani, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.	tani@ls.toyaku.ac.jp			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062318, R56DK062318] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK062318, DK062318] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Bhattacharyya D, 2007, MOL BIOL CELL, V18, P839, DOI 10.1091/mbc.E06-08-0707; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Blumental-Perry A, 2006, DEV CELL, V11, P671, DOI 10.1016/j.devcel.2006.09.001; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Connerly PL, 2005, CURR BIOL, V15, P1439, DOI 10.1016/j.cub.2005.06.065; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kondylis V, 2003, J CELL BIOL, V162, P185, DOI 10.1083/jcb.200301136; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Misawa H, 2001, INT J MOL MED, V8, P513; Mizoguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P144, DOI 10.1006/bbrc.2000.3846; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Okazaki N, 2003, DNA RES, V10, P35, DOI 10.1093/dnares/10.1.35; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Sawada N, 2005, INT J MOL MED, V16, P1049; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shimoi W, 2005, J BIOL CHEM, V280, P10141, DOI 10.1074/jbc.M409673200; Soderholm J, 2004, DEV CELL, V6, P649, DOI 10.1016/S1534-5807(04)00129-7; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Stephens DJ, 2004, J CELL SCI, V117, P3635, DOI 10.1242/jcs.01269; Stephens DJ, 2003, EMBO REP, V4, P210, DOI 10.1038/sj.embor.embor736; Supek F, 2002, J CELL BIOL, V158, P1029, DOI 10.1083/jcb.200207053; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Tani K, 1999, FEBS LETT, V447, P247, DOI 10.1016/S0014-5793(99)00303-8; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Watson P, 2006, TRAFFIC, V7, P1678, DOI 10.1111/j.1600-0854.2006.00493.x; Weissman JT, 2001, TRAFFIC, V2, P465, DOI 10.1034/j.1600-0854.2001.20704.x; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zeuschner D, 2006, NAT CELL BIOL, V8, P377, DOI 10.1038/ncb1371	56	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17632	17639		10.1074/jbc.M611237200	http://dx.doi.org/10.1074/jbc.M611237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428803	hybrid			2022-12-25	WOS:000247084500035
J	Kriek, M; Martins, F; Leonardi, R; Fairhurst, SA; Lowe, DJ; Roach, PL				Kriek, Marco; Martins, Filipa; Leonardi, Roberta; Fairhurst, Shirley A.; Lowe, David J.; Roach, Peter L.			Thiazole synthase from Escherichia coli - An investigation of the substrates and purified proteins required for activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; ELECTRON-PARAMAGNETIC-RESONANCE; ADENOSYL-L-METHIONINE; THIAMIN BIOSYNTHESIS; LYSINE 2,3-AMINOMUTASE; BACILLUS-SUBTILIS; PHOSPHATE MOIETY; BIOTIN SYNTHASE; IRON; IDENTIFICATION	Thiamine is biosynthesized by combining two heterocyclic precursors. In Escherichia coli and other anaerobes, one of the heterocycles, 4-methyl-5-(beta-hydroxyethyl) thiazole phosphate, is biosynthesized from 1-deoxyxylulose-5-phosphate, tyrosine, and cysteine. Genetic evidence has identified thiH, thiG, thiS, and thiF as essential for thiazole biosynthesis in E. coli. In this paper, we describe the measurement of the thiazole phosphate-forming reaction using purified protein components. The activity is shown to require four proteins isolated as heterodimers: ThiGH and ThiFS. Reconstitution of the [4Fe-4S] cluster in ThiH was essential for activity, as was the use of ThiS in the thiocarboxylate form. Spectroscopic studies with ThiGH strongly suggested that S-adenosylmethionine ( AdoMet) bound to the [4Fe-4S] cluster, which became more susceptible to reduction to the +1 state. Assays of thiazole phosphate formation showed that, in addition to the proteins, Dxp, tyrosine, AdoMet, and a reductant were required. The analysis showed that no more than 1 mol eq of thiazole phosphate was formed per ThiGH. Furthermore, for each mole of thiazole-P formed, 1 eq of AdoMet and 1 eq of tyrosine were utilized, and 1 eq of 5'-deoxyadenosine was produced. These results demonstrate that ThiH is a member of the "radical-AdoMet" family and support a mechanistic hypothesis in which AdoMet is reductively cleaved to yield a highly reactive 5'-deoxyadenosyl radical. This radical is proposed to abstract the phenolic hydrogen atom from tyrosine, and the resultant substrate radical cleaves to yield dehydroglycine, which is required by ThiG for the thiazole cyclization reaction.	Univ Southampton, Sch Chem, Biol Chem Sect, Southampton SO17 1BJ, Hants, England; John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	University of Southampton; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Roach, PL (corresponding author), Univ Southampton, Sch Chem, Biol Chem Sect, Southampton SO17 1BJ, Hants, England.	plr2@soton.ac.uk	Roach, Peter/AAW-7071-2021; Roach, Peter/C-6248-2013	Roach, Peter/0000-0001-9880-2877				ANDERSAG H, 1937, CHEM BER           B, V70, P2035; BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Cavazza C, 2006, STRUCTURE, V14, P217, DOI 10.1016/j.str.2005.10.013; Chatterjee A, 2006, J AM CHEM SOC, V128, P7158, DOI 10.1021/ja061413o; Chatterjee A, 2006, ANGEW CHEM INT EDIT, V45, P3507, DOI 10.1002/anie.200504614; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P6378, DOI 10.1021/bi049528x; Dorrestein PC, 2004, CHEM BIOL, V11, P1373, DOI 10.1016/j.chembiol.2004.08.009; Dorrestein PC, 2004, J AM CHEM SOC, V126, P3091, DOI 10.1021/ja039616p; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gerrits J, 1997, METHOD ENZYMOL, V279, P74; HEWITSON KS, 2000, THESIS OXFORD U; Hinckley GT, 2006, BIOCHEMISTRY-US, V45, P3219, DOI 10.1021/bi0519497; Iwig DF, 2004, BIOCHEMISTRY-US, V43, P13496, DOI 10.1021/bi048693+; KAWASAKI T, 1969, J BIOCHEM-TOKYO, V65, P407, DOI 10.1093/oxfordjournals.jbchem.a129028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawhorn BG, 2004, ORG BIOMOL CHEM, V2, P2538, DOI 10.1039/b405429f; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; Lehmann C, 2006, BIOCHEMISTRY-US, V45, P11, DOI 10.1021/bi051502y; Leonardi R, 2004, J BIOL CHEM, V279, P17054, DOI 10.1074/jbc.M312714200; Leonardi R, 2003, FEBS LETT, V539, P95, DOI 10.1016/S0014-5793(03)00204-7; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Martinez-Gomez NC, 2004, J BIOL CHEM, V279, P40505, DOI 10.1074/jbc.M403985200; NEWELL PC, 1966, BIOCHEM J, V100, P517, DOI 10.1042/bj1000517; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Park JH, 2004, J BACTERIOL, V186, P1571, DOI 10.1128/JB.186.5.1571-1573.2004; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Pohl M, 2004, CURR OPIN BIOTECH, V15, P335, DOI 10.1016/j.copbio.2004.06.002; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; Serganov A, 2006, NATURE, V441, P1167, DOI 10.1038/nature04740; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Spenser ID, 1997, ANGEW CHEM INT EDIT, V36, P1033; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Taylor SV, 1998, J ORG CHEM, V63, P2375, DOI 10.1021/jo971933p; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Wright CM, 2006, CHEM COMMUN, P3104, DOI 10.1039/b604040c; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	47	70	74	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17413	17423		10.1074/jbc.M700782200	http://dx.doi.org/10.1074/jbc.M700782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403671	hybrid			2022-12-25	WOS:000247084500011
J	Liu, M; Li, DW; Aneja, R; Joshi, HC; Xie, SB; Zhang, C; Zhou, J				Liu, Min; Li, Dengwen; Aneja, Ritu; Joshi, Harish C.; Xie, Songbo; Zhang, Chao; Zhou, Jun			PO2-dependent differential regulation of multidrug resistance 1 gene expression by the c-jun NH2-terminal Kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; P-GLYCOPROTEIN EXPRESSION; MULTIDRUG-RESISTANCE; MDR1 GENE; HISTONE DEACETYLASES; TRANSCRIPTION FACTOR; CELLULAR-RESPONSE; PROMOTER ACTIVITY; BINDING-PROTEIN; CANCER-CELLS	Hypoxia-induced multidrug resistance 1 ( MDR1) gene expression is known to be mediated by c-Jun NH2-terminal kinase ( JNK) activation. However, the molecular mechanisms underlying this action of JNK remain elusive. On the contrary, there has been increasing evidence for a negative correlation of JNK activity with MDR1 expression under normoxic conditions. Here, we present evidence that the JNK pathway represses MDR1 expression in normoxia and activates MDR1 expression in hypoxia. Our data show that JNK pathway-induced MDR1 repression in normoxia is mediated by increased c-Jun binding to activator protein 1 site, located in the MDR1 promoter, and requires the activity of histone deacetylase 5. In contrast, JNK pathway-induced MDR1 activation in hypoxia is independent of the activator protein 1 site. Rather, this action is dependent on increased hypoxia-inducible factor 1 ( HIF1) binding to the hypoxia response element in the MDR1 promoter, which is promoted by the interaction of HIF1 alpha with c-Jun in the nucleus and requires the activity of the p300/CBP ( CREB-binding protein) coactivator.	Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin 300071, Peoples R China; Nankai Univ, Coll Life Sci, Key Lab Bioact Mat, Minist Educ, Tianjin 300071, Peoples R China; Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Nankai University; Nankai University; Emory University	Zhou, J (corresponding author), Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, 94 Weijin Rd, Tianjin 300071, Peoples R China.	junzhou@nankai.edu.cn	Zhou, Jun/D-4654-2017; Xie, Songbo/AAD-9850-2020	Zhou, Jun/0000-0001-7858-8260; 				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Baker EK, 2004, CANCER BIOL THER, V3, P819, DOI 10.4161/cbt.3.9.1101; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Brown JM, 1998, CANCER RES, V58, P1408; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Comerford KM, 2004, CANCER RES, V64, P9057, DOI 10.1158/0008-5472.CAN-04-1919; Comerford KM, 2002, CANCER RES, V62, P3387; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kang CD, 2000, EXP CELL RES, V256, P300, DOI 10.1006/excr.2000.4807; Lecureur V, 2001, ONCOGENE, V20, P303, DOI 10.1038/sj.onc.1204065; Ledoux S, 2003, CANCER RES, V63, P7284; Li ZH, 1997, CANCER LETT, V119, P177, DOI 10.1016/S0304-3835(97)00267-X; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Miao ZH, 2003, CANCER RES, V63, P4527; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; UEDA K, 1987, J BIOL CHEM, V262, P17432; Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje; Zhou J, 2006, CANCER RES, V66, P445, DOI 10.1158/0008-5472.CAN-05-1779; Zhou J, 2002, J BIOL CHEM, V277, P39777, DOI 10.1074/jbc.M203927200	32	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17581	17586		10.1074/jbc.M702206200	http://dx.doi.org/10.1074/jbc.M702206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452336	hybrid			2022-12-25	WOS:000247084500029
J	Schlaepfer, DD; Hou, SH; Lim, ST; Tomar, A; Yu, HG; Lim, YM; Hanson, DA; Uryu, SA; Molina, J; Mitra, SK				Schlaepfer, David D.; Hou, Shihe; Lim, Ssang-Taek; Tomar, Alok; Yu, Honggang; Lim, Yangmi; Hanson, Dan A.; Uryu, Sean A.; Molina, John; Mitra, Satyajit K.			Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSES APOPTOSIS; CELL MOTILITY; GROWTH-FACTOR; DEATH-DOMAIN; FAK; INFLAMMATION; CANCER; PHOSPHORYLATION; METASTASIS	Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that promotes cell migration, survival, and gene expression. Here we show that FAK signaling is important for tumor necrosis factor-alpha (TNF alpha)-induced interleukin 6 (IL-6) mRNA and protein expression in breast (4T1), lung (A549), prostate (PC-3), and neural (NB-8) tumor cells by FAK short hairpin RNA knockdown and by comparisons of FAK-null (FAK(-/)-) and FAK(+/+) mouse embryo fibroblasts. FAK promoted TNF alpha-stimulated MAPK activation needed for maximal IL-6 production. FAK was not required for TNF alpha-mediated nuclear factor-kappa beta or c-Jun N-terminal kinase activation. TNF alpha-stimulated FAK catalytic activation and IL-6 production were inhibited by FAK N-terminal but not FAK C-terminal domain overexpression. Analysis of FAK(-/)-fibroblasts stably reconstituted with wild type or various FAK point mutants showed that FAK catalytic activity, Tyr-397 phosphorylation, and the Pro-712/713 proline-rich region of FAK were required for TNF alpha-stimulated MAPK activation and IL-6 production. Constitutively activated MAPK kinase-1 (MEK1) expression in FAK(-/)-and A549 FAK short hairpin RNA-expressing cells rescued TNF alpha-stimulated IL-6 production. Inhibition of Src protein-tyrosine kinase activity or mutation of Src phosphorylation sites on FAK (Tyr-861 or Tyr-925) did not affect TNF alpha-stimulated IL-6 expression. Moreover, analyses of Src(-/-), Yes(-/-), and Fyn(-/)-fibroblasts showed that Src expression was inhibitory to TNF alpha-stimulated IL-6 production. These studies provide evidence for a novel Src-independent FAK to MAPK signaling pathway regulating IL-6 expression with potential importance to inflammation and tumor progression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607	NATIONAL CANCER INSTITUTE [R01CA087038, R29CA075240, R01CA075240, R01CA102310] Funding Source: NIH RePORTER; NCI NIH HHS [CA87038, CA102310, CA75240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956; Ceccarelli DFJ, 2006, J BIOL CHEM, V281, P252, DOI 10.1074/jbc.M509188200; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Cohen LA, 2005, J BIOL CHEM, V280, P8197, DOI 10.1074/jbc.M412021200; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Corredor J, 2003, AM J PHYSIOL-CELL PH, V284, pC953, DOI 10.1152/ajpcell.00309.2002; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Funakoshi-Tago M, 2003, J BIOL CHEM, V278, P29359, DOI 10.1074/jbc.M213115200; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang D, 2007, AM J PHYSIOL-CELL PH, V292, pC1339, DOI 10.1152/ajpcell.00144.2006; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mon NN, 2006, CANCER RES, V66, P6778, DOI 10.1158/0008-5472.CAN-05-4159; Neff L, 2003, J BIOL CHEM, V278, P27721, DOI 10.1074/jbc.M212065200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; TAKAHASHI R, 2006, BIOCHIM BIOPHYS ACTA, V1770, P518; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Watanabe Y, 2003, KIDNEY INT, V64, P431, DOI 10.1046/j.1523-1755.2003.00122.x; Zeisel MB, 2005, J IMMUNOL, V174, P7393, DOI 10.4049/jimmunol.174.11.7393; Zhang HFM, 2006, AM J PHYSIOL-CELL PH, V290, pC1310, DOI 10.1152/ajpcell.00450.2005	38	44	46	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17450	17459		10.1074/jbc.M610672200	http://dx.doi.org/10.1074/jbc.M610672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17438336	hybrid			2022-12-25	WOS:000247084500015
J	Stevens, HC; Nichols, JW				Stevens, Haley C.; Nichols, J. Wylie			The proton electrochemical gradient across the plasma membrane of yeast is necessary for phospholipid flip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; SACCHAROMYCES-CEREVISIAE; AMINOPHOSPHOLIPID TRANSLOCASE; LABELED PHOSPHATIDYLCHOLINE; TRANSPORT; ASYMMETRY; IDENTIFICATION	Recently, two members of the P4 family of P-type ATPases, Dnf1p and Dnf2p, were shown to be necessary for the internalization ( flip) of fluorescent, 7-nitrobenz-2-oxa-1,3-diazol-4-yl( NBD)-labeled phospholipids across the plasma membrane of Saccharomyces cerevisiae. In the current study, we have demonstrated that ATP hydrolysis is not sufficient for phospholipid flip in the absence of the proton electrochemical gradient across the plasma membrane. This requirement was demonstrated by two independent means. First, collapse of the plasma membrane proton electrochemical gradient by the protonophore, carbonyl cyanide m-chlorophenylhydrazone ( CCCP) almost completely blocked NBD-phospholipid flip while only moderately reducing the cytosolic ATP concentration. Second, strains with point mutations in PMA1, which encodes the plasma membrane proton pump that generates the proton electrochemical gradient, are defective in NBD-PC flip, whereas their cytosolic ATP content is actually increased. These results establish that the proton electrochemical gradient is required for NBD-phospholipid flip across the plasma membrane of yeast and raise the question whether it contributes an additional required driving force or whether it functions as a regulatory signal.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Nichols, JW (corresponding author), Emory Univ, Sch Med, Dept Physiol, 615 Michael St,605G Whitehead, Atlanta, GA 30322 USA.	wylie.nichols@emory.edu			NIGMS NIH HHS [GM64770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alder-Baerens N, 2006, MOL BIOL CELL, V17, P1632, DOI 10.1091/mbc.E05-10-0912; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; Catty P, 1997, FEBS LETT, V409, P325, DOI 10.1016/S0014-5793(97)00446-8; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Devaux PF, 2006, CHEM PHYS LIPIDS, V141, P119, DOI 10.1016/j.chemphyslip.2006.02.007; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; Elvington SM, 2005, J BIOL CHEM, V280, P40957, DOI 10.1074/jbc.M507926200; FOX TD, 1991, METHODS ENZYMOLOGY, V194, P149; Gomes E, 2000, PLANT CELL, V12, P2441, DOI 10.1105/tpc.12.12.2441; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Ikeda M, 2006, BIOL PHARM BULL, V29, P1542, DOI 10.1248/bpb.29.1542; Liang M, 2007, J BIOL CHEM, V282, P10585, DOI 10.1074/jbc.M609181200; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; MORIYAMA Y, 1991, ARCH BIOCHEM BIOPHYS, V286, P252, DOI 10.1016/0003-9861(91)90037-J; Moye-Rowley WS, 2005, GENE, V354, P15, DOI 10.1016/j.gene.2005.03.019; Natarajan P, 2004, P NATL ACAD SCI USA, V101, P10614, DOI 10.1073/pnas.0404146101; Paterson JK, 2006, BIOCHEMISTRY-US, V45, P5367, DOI 10.1021/bi052359b; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; Pomorski T, 2006, CELL MOL LIFE SCI, V63, P2908, DOI 10.1007/s00018-006-6167-7; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Ujhazy P, 2001, HEPATOLOGY, V34, P768, DOI 10.1053/jhep.2001.27663; Yamaji-Hasegawa A, 2006, BIOL PHARM BULL, V29, P1547, DOI 10.1248/bpb.29.1547	28	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17563	17567		10.1074/jbc.M700454200	http://dx.doi.org/10.1074/jbc.M700454200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452326	hybrid			2022-12-25	WOS:000247084500027
J	Chew, EH; Hagen, T				Chew, Eng-Hui; Hagen, Thilo			Substrate-mediated regulation of cullin neddylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASES; COP9 SIGNALOSOME; NEDD8 MODIFICATION; CONJUGATING ENZYMES; STRUCTURAL BASIS; COMPLEX; SCF; PROTEIN; CUL1; RECOGNITION	Cullin-based E3 ligases are a large family of multi-subunit ubiquitin ligases with diverse cellular functions, including the regulation of the cell cycle, of the DNA damage response, and of various transcription factors. These ligases are composed of one of six mammalian cullin homologs (Cul1, Cul2, Cul3, Cul4a, Cul4b, and Cul5), the Ring finger containing protein Roc1/Rbx1, and cullin homolog-specific adaptor and substrate recognition subunits. To be active, cullin-based ligases require the covalent modification of a conserved lysine residue in the cullin protein with the ubiquitin-like protein Nedd8. We show in this study that in intact cells Cul1 neddylation is dependent on binding to adaptor proteins and substrate recognition subunits. Mutant Cul1 that is unable to recruit adaptor and substrate recognition subunits exhibits markedly reduced neddylation, and inhibiting binding of adaptor and substrate recognition subunits to wild type Cul1 reduces Nedd8 modification. This regulatory mechanism also extends to other cullin-based E3 ligases, including Cul2, Cul3, and Cul4a. The regulation of cullin neddylation by adaptor proteins and substrate recognition subunits in cells was found to be independent of both CAND1 and the COP9 signalosome, two negative regulators of cullin Nedd8 modification. Using hypoxia-inducible factor-1 alpha (HIF-1 alpha), a substrate of the Elongin B/C-Cul2-VHL ligase, we demonstrate the critical role of substrate binding to promote Cul2 neddylation in a manner that does not require substrate ubiquitination but may involve a conformational change. These findings suggest a mechanism through which availability of substrate recognition subunits and substrates can regulate the ubiquitin ligase activity.	Univ Nottingham, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England	University of Nottingham	Hagen, T (corresponding author), Univ Nottingham, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England.	thilo.hagen@nottingham.ac.uk	Chew, Eng Hui/D-8975-2016	Chew, Eng Hui/0000-0002-2615-8987				Bornstein G, 2006, P NATL ACAD SCI USA, V103, P11515, DOI 10.1073/pnas.0603921103; Chew EH, 2007, CELL SIGNAL, V19, P1071, DOI 10.1016/j.cellsig.2006.12.002; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Sakata E, 2007, NAT STRUCT MOL BIOL, V14, P167, DOI 10.1038/nsmb1191; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Sufan RI, 2006, NEOPLASIA, V8, P956, DOI 10.1593/neo.06520; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0	32	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17032	17040		10.1074/jbc.M701153200	http://dx.doi.org/10.1074/jbc.M701153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439941	hybrid			2022-12-25	WOS:000246946500036
J	Song, YJ; Benison, G; Nyarko, A; Hays, TS; Barbar, E				Song, Yujuan; Benison, Gregory; Nyarko, Afua; Hays, Thomas S.; Barbar, Elisar			Potential role for phosphorylation in differential regulation of the assembly of dynein light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; TCTEX-1; LC8; PROTEIN; DIMERIZATION; RECEPTOR; LIGHT-CHAIN-1; DIMER; TRANSPORT	The homodimeric light chains LC8 and Tctex-1 are integral parts of the microtubule motor cytoplasmic dynein, as they directly associate with dynein intermediate chain IC and various cellular cargoes. These light chains appear to regulate assembly of the dynein complex by binding to and promoting dimerization of IC. In addition, both LC8 and Tctex-1 play roles in signaling, apoptosis, and neuronal development that are independent of their function in dynein, but it is unclear how these various activities are modulated. Both light chains undergo specific phosphorylation, and here we present biochemical and NMR analyses of phosphomimetic mutants that indicate how phosphorylation may regulate light chain function. For both LC8 and Tctex-1, phosphorylation promotes dissociation from IC while retaining their binding activity with other non- dynein proteins. Although LC8 and Tctex-1 are homologs having a common fold, their reduced affinity for IC upon phosphorylation arises by different mechanisms. In the case of Tctex-1, phosphorylation directly masks the IC binding site at the dimer interface, whereas for LC8, phosphorylation dissociates the dimer and indirectly eliminates the binding site. This modulation of the monomer-dimer equilibrium by phosphorylation provides a novel mechanism for discrimination among LC8 binding partners.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Oregon State University; University of Minnesota System; University of Minnesota Twin Cities	Barbar, E (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	barbare@science.oregonstate.edu	Nyarko, Afua/R-9872-2019	Barbar, Elisar/0000-0003-4892-5259	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044757] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbar E, 2001, BIOCHEMISTRY-US, V40, P1596, DOI 10.1021/bi002278+; Benison G, 2006, J MOL BIOL, V362, P1082, DOI 10.1016/j.jmb.2006.08.006; Campbell KS, 1998, J IMMUNOL, V161, P1728; Chuang JZ, 2005, DEV CELL, V9, P75, DOI 10.1016/j.devcel.2005.04.003; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jin QY, 2005, CELL SIGNAL, V17, P1363, DOI 10.1016/j.cellsig.2005.02.004; Kaiser FJ, 2003, HUM MOL GENET, V12, P1349, DOI 10.1093/hmg/ddg145; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Li MG, 2004, MOL BIOL CELL, V15, P3005, DOI 10.1091/mbc.E04-01-0013; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2006, J BIOL CHEM, V281, P9552, DOI 10.1074/jbc.M511721200; Lo KWH, 2005, J BIOL CHEM, V280, P8172, DOI 10.1074/jbc.M411408200; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; Nyarko A, 2005, BIOCHEMISTRY-US, V44, P14248, DOI 10.1021/bi0512694; Nyarko A, 2004, BIOCHEMISTRY-US, V43, P15595, DOI 10.1021/bi048451+; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Song J, 2005, J MOL BIOL, V354, P1043, DOI 10.1016/j.jmb.2005.10.017; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Talbott M, 2006, BIOCHEMISTRY-US, V45, P6793, DOI 10.1021/bi0600345; Tang Q, 2002, MOL BIOL CELL, V13, P4484, DOI 10.1091/mbc.e02-05-0245; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Wang L, 2004, BIOCHEMISTRY-US, V43, P4611, DOI 10.1021/bi036328x; Williams JC, 2005, J BIOL CHEM, V280, P21981, DOI 10.1074/jbc.M414643200; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013; Yang ZB, 2005, J BIOL CHEM, V280, P654, DOI 10.1074/jbc.M408486200	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17272	17279		10.1074/jbc.M610445200	http://dx.doi.org/10.1074/jbc.M610445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428790	hybrid			2022-12-25	WOS:000246946500060
J	Swiercz, R; Cheng, DH; Kim, D; Bedford, MT				Swiercz, Rafal; Cheng, Donghang; Kim, Daehoon; Bedford, Mark T.			Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE N-METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; MOUSE DEVELOPMENT; HELA-CELLS; PRMT3; METHYLATION; N-METHYLTRANSFERASE-3; OLIGOMERIZATION; DROSOPHILA; MEMBRANE	PRMT3 is a type I arginine methyltransferase that resides in the cytoplasm. A large proportion of this cystosolic PRMT3 is found associated with ribosomes. It is tethered to the ribosomes through its interaction with rpS2, which is also its substrate. Here we show that mouse embryos with a targeted disruption of PRMT3 are small in size but survive after birth and attain a normal size in adulthood, thus displaying Minute-like characteristics. The ribosome protein rpS2 is hypomethylated in the absence of PRMT3, demonstrating that it is a bona fide, in vivo PRMT3 substrate that cannot be modified by other PRMTs. Finally, the levels 40 S, 60 S, and 80 S monosomes and polyribosomes are unaffected by the loss of PRMT3, but there are additional as yet unidentified proteins that co-fractionate with ribosomes that are also dedicated PRMT3 substrates.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Bedford, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.	mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011		NCI NIH HHS [CA016672] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bachand F, 2006, MOL CELL BIOL, V26, P1731, DOI 10.1128/MCB.26.5.1731-1742.2006; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; BEDFORD MT, 2006, FAMILY PROTEIN ARGIN, P31; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; CHANG FN, 1978, BIOCHIM BIOPHYS ACTA, V518, P89, DOI 10.1016/0005-2787(78)90118-1; CHANG FN, 1976, ARCH BIOCHEM BIOPHYS, V172, P627, DOI 10.1016/0003-9861(76)90117-X; CRAMTON SE, 1994, GENETICS, V137, P1039; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Ikenaka K, 2006, NEUROSCIENCE, V141, P1971, DOI 10.1016/j.neuroscience.2006.05.022; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; Joyner AL, 1994, GENE TARGETING PRACT; Kim J, 2004, J BIOL CHEM, V279, P25339, DOI 10.1074/jbc.M402544200; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	27	94	97	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16917	16923		10.1074/jbc.M609778200	http://dx.doi.org/10.1074/jbc.M609778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439947	hybrid			2022-12-25	WOS:000246946500024
J	Wang, R; Yin, YJ; Wang, F; Li, M; Feng, J; Zhang, HM; Zhang, JP; Liu, SJ; Chang, WR				Wang, Rui; Yin, Ya-Jie; Wang, Feng; Li, Mei; Feng, Jie; Zhang, Hong-Mei; Zhang, Ji-Ping; Liu, Shuang-Jiang; Chang, Wen-Rui			Crystal structures and site-directed mutagenesis of a mycothiol-dependent enzyme reveal a novel folding and molecular basis for mycothiol-mediated maleylpyruvate isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLOGRAPHIC STRUCTURE DETERMINATION; MYCOBACTERIUM-SMEGMATIS MUTANTS; CORYNEBACTERIUM-GLUTAMICUM; BIOSYNTHESIS; SOFTWARE; PROGRAM; THIOL; IDENTIFICATION; TUBERCULOSIS; ANTIBIOTICS	Mycothiol (MSH) is the major low molecular mass thiols in many Gram- positive bacteria such as Mycobacterium tuberculosis and Corynebacterium glutamicum. The physiological roles of MSH are believed to be equivalent to those of GSH in Gramnegative bacteria, but current knowledge of MSH is limited to detoxification of alkalating chemicals and protection from host cell defense/killing systems. Recently, an MSH-dependent maleylpyruvate isomerase (MDMPI) was discovered from C. glutamicum, and this isomerase represents one example of many putative MSH-dependent enzymes that take MSH as cofactor. In this report, fourteen mutants of MDMPI were generated. The wild type and mutant (H52A) MDMPIs were crystallized and their structures were solved at 1.75 and 2.05 A resolution, respectively. The crystal structures reveal that this enzyme contains a divalent metal- binding domain and a C-terminal domain possessing a novel folding pattern (alpha beta alpha beta beta alpha fold). The divalent metal-binding site is composed of residues His(52), Glu(144), and His(148) and is located at the bottom of a surface pocket. Combining the structural and site- directed mutagenesis studies, it is proposed that this surface pocket including the metal ion and MSH moiety formed the putative catalytic center.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resource, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Chang, WR (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resource, Beijing 100080, Peoples R China.	wrchang@sun5.ibp.ac.cn	Liu, Shuang-Jiang/E-5756-2013	Li, Mei/0000-0002-1742-2360				Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Buchmeier NA, 2006, J BACTERIOL, V188, P6245, DOI 10.1128/JB.00393-06; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Feng J, 2006, J BIOL CHEM, V281, P10778, DOI 10.1074/jbc.M513192200; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Newton GL, 2006, J BIOL CHEM, V281, P33910, DOI 10.1074/jbc.M604724200; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen XH, 2005, APPL ENVIRON MICROB, V71, P3442, DOI 10.1128/AEM.71.7.3442-3452.2005; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	26	20	20	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16288	16294		10.1074/jbc.M610347200	http://dx.doi.org/10.1074/jbc.M610347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428791	hybrid			2022-12-25	WOS:000246794300036
J	Neeper, MP; Liu, Y; Hutchinson, TL; Wang, Y; Flores, CM; Qin, N				Neeper, Michael P.; Liu, Yi; Hutchinson, Tasha L.; Wang, Yan; Flores, Christopher M.; Qin, Ning			Activation properties of heterologously expressed mammalian TRPV2 - Evidence for species dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN-RECEPTOR HOMOLOG; VANILLOID RECEPTOR-1; CATION CHANNEL; SPLICE VARIANT; ION-CHANNEL; RAT; TRANSLOCATION; SENSITIVITY; STIMULI; LACKING	TRPV2 has been proposed as a potential pain target, in part due to its relatedness to the nociceptor TRPV1 and to its reported activation by noxious high temperatures (> 52 degrees C). However, TRPV2 responses to heat as well as to the nonselective agonist 2-aminoethoxydiphenyl borate (2-APB) have not been universally reproduced in other laboratories, leading to debate about the activation properties of this channel. Here, we report the expression of rat, mouse, and human TRPV2 in HEK293 cells and the differential properties of their responses to heat and 2-APB. Expression of mouse or rat TRPV2 in HEK293 cells resulted in robust channel activation when induced by either temperature (> 53 degrees C) or 2-APB. By contrast, expression of human TRPV2 did not lead to detectable activation by either of these stimuli. Human TRPV2 protein was expressed at levels comparable with those of rat TRPV2, exhibited similar surface localization and responded to a novelly identified TRPV2 agonist, Delta(9)-tetrahydrocannabinol, indicating that human TRPV2 is functionally expressed on the cell surface. Studies using deletion mutants and chimeras between rat and human TRPV2 indicated that both amino- and carboxyl-cytoplasmic termini of rat TRPV2 are important for responses to heat and 2-APB but can be supplied in trans to form an active channel. The present study not only confirms and extends previous reports demonstrating that rat and mouse TRPV2 respond to 2-APB and noxious heat but also indicates that further investigation will be required to elucidate TRPV2 activation and regulatory mechanisms.	Johnson & Johnson Pharmaceut Res & Dev LLC, Analges Team, E Coast Res & Early Dev, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA	Qin, N (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, Analges Team, E Coast Res & Early Dev, Welsch & McKean Rd,POB 776, Spring House, PA 19477 USA.	nqin@prdus.jnj.com						Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; Bender FLP, 2005, CELL PHYSIOL BIOCHEM, V15, P183, DOI 10.1159/000083651; Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; Boels K, 2001, J CELL SCI, V114, P3599; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Gaudet AD, 2004, BRAIN RES, V1017, P155, DOI 10.1016/j.brainres.2004.05.045; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Lewinter RD, 2004, J COMP NEUROL, V470, P400, DOI 10.1002/cne.20024; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu Y, 2006, EUR J PHARMACOL, V530, P23, DOI 10.1016/j.ejphar.2005.11.033; Liu Y, 2006, EPILEPSY RES, V70, P263, DOI 10.1016/j.eplepsyres.2006.03.007; Muraki K, 2003, CIRC RES, V93, P829, DOI 10.1161/01.RES.0000097263.10220.0C; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Shimosato G, 2005, PAIN, V119, P225, DOI 10.1016/j.pain.2005.10.002; Stokes AJ, 2005, J CELL BIOCHEM, V94, P669, DOI 10.1002/jcb.20331; Stokes AJ, 2004, J EXP MED, V200, P137, DOI 10.1084/jem.20032082; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Tian W, 2006, AM J PHYSIOL-RENAL, V290, pF117, DOI 10.1152/ajprenal.00143.2005; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Wang HB, 2005, NEURON, V46, P9, DOI 10.1016/j.neuron.2005.03.011; Wirkner K, 2005, NEUROREPORT, V16, P997, DOI 10.1097/00001756-200506210-00023	32	123	124	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15894	15902		10.1074/jbc.M608287200	http://dx.doi.org/10.1074/jbc.M608287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395593	hybrid			2022-12-25	WOS:000246589600064
J	Du, JM; Wang, H; Zhong, C; Peng, BZ; Zhang, ML; Li, BH; Huo, S; Guo, YJ; Ding, JP				Du, Jiamu; Wang, Hao; Zhong, Chen; Peng, Baozhen; Zhang, Meilan; Li, Bohua; Huo, Sheng; Guo, Yajun; Ding, Jianping			Structural basis for recognition of CD20 by therapeutic antibody rituximab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FINE SPECIFICITY; LYMPHOMA; REDISTRIBUTION; EPITOPES; SEQUENCE	Rituximab is a widely used monoclonal antibody drug for treating certain lymphomas and autoimmune diseases. To understand the molecular mechanism of recognition of human CD20 by Rituximab, we determined the crystal structure of the Rituximab Fab in complex with a synthesized peptide comprising the CD20 epitope ( residues 163-187) at 2.6-angstrom resolution. The combining site of the Fab consists of four complementarity determining regions that form a large, deep pocket to accommodate the epitope peptide. The bound peptide assumes a unique cyclic conformation that is constrained by a disulfide bond and a rigid proline residue ( Pro(172)). The (170)ANPS(173) motif of CD20 is deeply embedded into the pocket on the antibody surface and plays an essential role in the recognition and binding of Rituximab. The antigen-antibody interactions involve both hydrogen bonds and van der Waals contacts and display a high degree of structural and chemical complementarity. These results provide a molecular basis for the specific recognition of CD20 by Rituximab as well as valuable information for development of improved antibody drugs with better specificity and higher affinity.	Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Naval Medical University	Ding, JP (corresponding author), 800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	jpding@sibs.ac.cn	Li, Bo/AAA-8968-2020; Du, Jiamu/G-3308-2010; Du, Jiamu/I-1334-2013	Li, Bo/0000-0002-7294-6888; Du, Jiamu/0000-0002-1337-0786; ding, jian ping/0000-0001-7029-7346				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ANDERSON DR, 1998, Patent No. 5843439; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banfield MJ, 1997, PROTEINS, V29, P161, DOI 10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO;2-G; Binder M, 2006, BLOOD, V108, P1975, DOI 10.1182/blood-2006-04-014639; Boye J, 2003, ANN ONCOL, V14, P520, DOI 10.1093/annonc/mdg175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chan HTC, 2003, CANCER RES, V63, P5480; Check E, 2004, NATURE, V428, P786, DOI 10.1038/428786b; Cohen Y, 2004, AUTOIMMUN REV, V3, P111, DOI 10.1016/S1568-9972(03)00083-1; Cragg Mark S., 2005, V8, P140; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; DeLano W, 2002, PYMOL 0 99; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Garber K, 2003, J NATL CANCER I, V95, P189, DOI 10.1093/jnci/95.3.189; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating M, 2000, SEMIN ONCOL, V27, P86; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leget Gail A., 1998, Current Opinion in Oncology, V10, P548, DOI 10.1097/00001622-199811000-00012; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Martin ACR, 1996, PROTEINS, V25, P130, DOI 10.1002/(SICI)1097-0134(199605)25:1<130::AID-PROT11>3.3.CO;2-Y; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McLaughlin P, 2000, SEMIN ONCOL, V27, P37, DOI 10.1053/sonc.2000.20438; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perosa F, 2006, BLOOD, V107, P1070, DOI 10.1182/blood-2005-04-1769; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; PRESS OW, 1994, BLOOD, V83, P1390; REFF ME, 1994, BLOOD, V83, P435; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	42	86	103	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15073	15080		10.1074/jbc.M701654200	http://dx.doi.org/10.1074/jbc.M701654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395584	hybrid			2022-12-25	WOS:000246589000047
J	Drosopoulos, S; Windau, E; Wagner, U; Born, J				Drosopoulos, Spyridon; Windau, Eike; Wagner, Ullrich; Born, Jan			Sleep Enforces the Temporal Order in Memory	PLOS ONE			English	Article							DECLARATIVE MEMORY; BACKWARD RECALL; SEQUENCES; HIPPOCAMPUS; CONSOLIDATION; RETRIEVAL; REPLAY; OSCILLATIONS; EXPERIENCE; NEOCORTEX	Background. Temporal sequence represents the main principle underlying episodic memory. The storage of temporal sequence information is thought to involve hippocampus-dependent memory systems, preserving temporal structure possibly via chaining of sequence elements in heteroassociative networks. Converging evidence indicates that sleep enhances the consolidation of recently acquired representations in the hippocampus-dependent declarative memory system. Yet, it is unknown if this consolidation process comprises strengthening of the temporal sequence structure of the representation as well, or is restricted to sequence elements independent of their temporal order. To address this issue we tested the influence of sleep on the strength of forward and backward associations in word-triplets. Methodology/Principal Findings. Subjects learned a list of 32 triplets of unrelated words, presented successively (A-B-C) in the center of a screen, and either slept normally or stayed awake in the subsequent night. After two days, retrieval was assessed for the triplets sequentially either in a forward direction (cueing with A and B and asking for B and C, respectively) or in a backward direction (cueing with C and B and asking for B and A, respectively). Memory was better for forward than backward associations (p<0.01). Sleep did not affect backward associations, but enhanced forward associations, specifically for the first (AB) transitions (p<0.01), which were generally more difficult to retrieve than the second transitions. Conclusions/Significance. Our data demonstrate that consolidation during sleep strengthens the original temporal sequence structure in memory, presumably as a result of a replay of new representations during sleep in forward direction. Our finding suggests that the temporally directed replay of memory during sleep, apart from strengthening those traces, could be the key mechanism that explains how temporal order is integrated and maintained in the trace of an episodic memory.	[Drosopoulos, Spyridon; Windau, Eike; Wagner, Ullrich; Born, Jan] Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany	University of Lubeck	Born, J (corresponding author), Med Univ Lubeck, Dept Neuroendocrinol, D-23538 Lubeck, Germany.	born@kfg.uni-luebeck.de	Born, Jan/K-2596-2016	Born, Jan/0000-0002-1847-6248	German Research Foundation [SFB654]	German Research Foundation(German Research Foundation (DFG))	This work was supported by the German Research Foundation (SFB654 "Plasticity and Sleep''). The authors have no financial interest in the manuscript.	ASCHBRENNER S, 2000, REGENSBURGER WORTFLU; Born J, 2004, ANN NY ACAD SCI, V1032, P198, DOI 10.1196/annals.1314.020; Born J, 2006, NEUROSCIENTIST, V12, P410, DOI 10.1177/1073858406292647; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; Caplan JB, 2003, J NEUROSCI, V23, P4726; de Quervain DJF, 2000, NAT NEUROSCI, V3, P313, DOI 10.1038/73873; Dragoi G, 2006, NEURON, V50, P145, DOI 10.1016/j.neuron.2006.02.023; Drosopoulos S, 2005, LEARN MEMORY, V12, P44, DOI 10.1101/lm.83805; DROSOPOULOS S, 2007, J EXP PSYCH IN PRESS; Ellenbogen JM, 2006, CURR BIOL, V16, P1290, DOI 10.1016/j.cub.2006.05.024; Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; Foster DJ, 2006, NATURE, V440, P680, DOI 10.1038/nature04587; Gais S, 2004, LEARN MEMORY, V11, P679, DOI 10.1101/lm.80504; Gais S, 2006, LEARN MEMORY, V13, P259, DOI 10.1101/lm.132106; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P1877, DOI 10.1016/j.neuropsychologia.2004.05.008; Ji DY, 2007, NAT NEUROSCI, V10, P100, DOI 10.1038/nn1825; Johnson A, 2005, NEURAL NETWORKS, V18, P1163, DOI 10.1016/j.neunet.2005.08.009; Kahana MJ, 1996, MEM COGNITION, V24, P103, DOI 10.3758/BF03197276; Kahana MJ, 2002, MEM COGNITION, V30, P841, DOI 10.3758/BF03195770; Kuriyama K, 2004, LEARN MEMORY, V11, P705, DOI 10.1101/lm.76304; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; Leibold C, 2006, NEURAL COMPUT, V18, P904, DOI 10.1162/089976606775774714; LI SC, 1995, J EXP PSYCHOL LEARN, V21, P837, DOI 10.1037/0278-7393.21.4.837; Lisman JE, 2005, NEURAL NETWORKS, V18, P1191, DOI 10.1016/j.neunet.2005.08.008; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Marshall L, 2006, NATURE, V444, P610, DOI 10.1038/nature05278; Marshuetz C, 2006, NEUROSCIENCE, V139, P195, DOI 10.1016/j.neuroscience.2005.08.024; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McGaugh JL, 2002, CURR OPIN NEUROBIOL, V12, P205, DOI 10.1016/S0959-4388(02)00306-9; Mehta MR, 2002, NATURE, V417, P741, DOI 10.1038/nature00807; Molle M, 2006, J NEUROPHYSIOL, V96, P62, DOI 10.1152/jn.00014.2006; Morita M, 1996, COGNITIVE BRAIN RES, V5, P137, DOI 10.1016/S0926-6410(96)00050-X; Nadasdy Z, 1999, J NEUROSCI, V19, P9497; Orban P, 2006, P NATL ACAD SCI USA, V103, P7124, DOI 10.1073/pnas.0510198103; Peigneux P, 2004, NEURON, V44, P535, DOI 10.1016/j.neuron.2004.10.007; Plihal W, 1997, J COGNITIVE NEUROSCI, V9, P534, DOI 10.1162/jocn.1997.9.4.534; Rasch B, 2007, SCIENCE, V315, P1426, DOI 10.1126/science.1138581; Rauchs G, 2004, SLEEP, V27, P395, DOI 10.1093/sleep/27.3.395; Rechtschaffen A, 1968, NIH PUBLICATION, V204; Sirota A, 2003, P NATL ACAD SCI USA, V100, P2065, DOI 10.1073/pnas.0437938100; Thomas JG, 2003, PSYCHOL SCI, V14, P169, DOI 10.1111/1467-9280.01437; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Tsukiura T, 2002, HUM BRAIN MAPP, V17, P203, DOI 10.1002/hbm.10068; Tucker MA, 2006, NEUROBIOL LEARN MEM, V86, P241, DOI 10.1016/j.nlm.2006.03.005; Wagner U, 2005, BIOL PSYCHIAT, V58, P885, DOI 10.1016/j.biopsych.2005.05.008; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; WAUGH NC, 1970, ACTA PSYCHOL, V33, P326, DOI 10.1016/0001-6918(70)90144-7; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517	49	33	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e376	10.1371/journal.pone.0000376	http://dx.doi.org/10.1371/journal.pone.0000376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440612	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445500007
J	Fox, JH; Kama, JA; Lieberman, G; Chopra, R; Dorsey, K; Chopra, V; Volitakis, I; Cherny, RA; Bush, AI; Hersch, S				Fox, Jonathan H.; Kama, Jibrin A.; Lieberman, Gregory; Chopra, Raman; Dorsey, Kate; Chopra, Vanita; Volitakis, Irene; Cherny, Robert A.; Bush, Ashley I.; Hersch, Steven			Mechanisms of Copper Ion Mediated Huntington's Disease Progression	PLOS ONE			English	Article							HYDROGEN-PEROXIDE; MOUSE MODEL; OXIDATIVE DAMAGE; IN-VITRO; BRAIN; 3-HYDROXYKYNURENINE; DYSFUNCTION; TOXICITY; FERRITIN; ALPHA	Huntington's disease (HD) is caused by a dominant polyglutamine expansion within the N-terminus of huntingtin protein and results in oxidative stress, energetic insufficiency and striatal degeneration. Copper and iron are increased in the striata of HD patients, but the role of these metals in HD pathogenesis is unknown. We found, using inductively-coupled-plasma mass spectroscopy, that elevations of copper and iron found in human HD brain are reiterated in the brains of affected HD transgenic mice. Increased brain copper correlated with decreased levels of the copper export protein, amyloid precursor protein. We hypothesized that increased amounts of copper bound to low affinity sites could contribute to pro-oxidant activities and neurodegeneration. We focused on two proteins:huntingtin, because of its centrality to HD, and lactate dehydrogenase (LDH), because of its documented sensitivity to copper, necessity for normoxic brain energy metabolism and evidence for altered lactate metabolism in HD brain. The first 171 amino acids of wild-type huntingtin, and its glutamine expanded mutant form, interacted with copper, but not iron. N171 reduced Cu2+ in vitro in a 1:1 copper:protein stoichiometry indicating that this fragment is very redox active. Further, copper promoted and metal chelation inhibited aggregation of cell-free huntingtin. We found decreased LDH activity, but not protein, and increased lactate levels in HD transgenic mouse brain. The LDH inhibitor oxamate resulted in neurodegeneration when delivered intra-striatially to healthy mice, indicating that LDH inhibition is relevant to neurodegeneration in HD. Our findings support a role of pro-oxidant copper-protein interactions in HD progression and offer a novel target for pharmacotherapeutics.	[Fox, Jonathan H.; Kama, Jibrin A.; Lieberman, Gregory; Chopra, Raman; Dorsey, Kate; Chopra, Vanita; Hersch, Steven] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Bush, Ashley I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA; [Bush, Ashley I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA 02129 USA; [Volitakis, Irene; Cherny, Robert A.; Bush, Ashley I.] Univ Melbourne, Oxidat Disorders Lab, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; [Volitakis, Irene; Cherny, Robert A.; Bush, Ashley I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Melbourne; University of Melbourne	Hersch, S (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.	HERSCH@HELIX.MGH.HARVARD.EDU	Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Volitakis, Irene/0000-0003-0766-817X	Huntington's Disease Society of America (HDSA); HighQ Foundation; NIH/NINDS [NS35255, NS045242]; NIH/NCCAM [AT00613]; Australian Research Council; National Health and Research Council of Australia; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000613] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [U01AT000613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035255, P01NS045242] Funding Source: NIH RePORTER	Huntington's Disease Society of America (HDSA); HighQ Foundation; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH/NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Australian Research Council(Australian Research Council); National Health and Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Support was provided by the Huntington's Disease Society of America (HDSA), The HighQ Foundation, NIH/NINDS (NS35255 and NS045242) and NIH/NCCAM (AT00613). The Australian Research Council and the National Health and Research Council of Australia supported RAC, IV and AIB.	ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; Bartzokis G, 2000, CELL MOL BIOL, V46, P821; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Brewer GJ, 1999, SEMIN NEUROL, V19, P261, DOI 10.1055/s-2008-1040842; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Chen Chun-Wei David, 2006, Current Alzheimer Research, V3, P63, DOI 10.2174/156720506775697205; CHENG RZ, 1994, EUR J BIOCHEM, V223, P759, DOI 10.1111/j.1432-1033.1994.tb19050.x; Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Eaton A.D., 1998, STANDARD METHODS EXA, V20th; Ehrnhoefer DE, 2006, HUM MOL GENET, V15, P2743, DOI 10.1093/hmg/ddl210; Firdaus WJJ, 2006, FEBS J, V273, P5428, DOI 10.1111/j.1742-4658.2006.05537.x; Fox JH, 2004, J NEUROCHEM, V91, P413, DOI 10.1111/j.1471-4159.2004.02726.x; Ghosh KS, 2006, FEBS LETT, V580, P4703, DOI 10.1016/j.febslet.2006.07.054; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Guidetti P, 2003, ADV EXP MED BIOL, V527, P137; Guidetti P, 2006, NEUROBIOL DIS, V23, P190, DOI 10.1016/j.nbd.2006.02.011; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; Heron P, 2001, LIFE SCI, V68, P1575, DOI 10.1016/S0024-3205(01)00948-1; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Kitzberger R, 2005, METAB BRAIN DIS, V20, P295, DOI 10.1007/s11011-005-7910-8; Kogel D, 2003, J NEUROCHEM, V87, P248, DOI 10.1046/j.1471-4159.2003.02000.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mancuso M, 2005, J NEUROPATH EXP NEUR, V64, P280, DOI 10.1093/jnen/64.4.280; Maynard CJ, 2006, J INORG BIOCHEM, V100, P952, DOI 10.1016/j.jinorgbio.2006.02.010; Menalled LB, 2003, J COMP NEUROL, V465, P11, DOI 10.1002/cne.10776; Nguyen T, 2005, P NATL ACAD SCI USA, V102, P11840, DOI 10.1073/pnas.0502177102; Pamp K, 2005, FREE RADICAL RES, V39, P31, DOI 10.1080/10715760400023671; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Seong IS, 2005, HUM MOL GENET, V14, P2871, DOI 10.1093/hmg/ddi319; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Sheline CT, 2004, ANN NEUROL, V55, P645, DOI 10.1002/ana.20047; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TACHON P, 1989, FREE RADICAL RES COM, V7, P1, DOI 10.3109/10715768909088155; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Yanai A, 2006, NAT NEUROSCI, V9, P824, DOI 10.1038/nn1702; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	51	136	138	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e334	10.1371/journal.pone.0000334	http://dx.doi.org/10.1371/journal.pone.0000334			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17396163	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200017
J	Ji, J; Liu, R; Tong, T; Song, Y; Jin, S; Wu, M; Zhan, Q				Ji, J.; Liu, R.; Tong, T.; Song, Y.; Jin, S.; Wu, M.; Zhan, Q.			Gadd45a regulates beta-catenin distribution and maintains cell-cell adhesion/contact	ONCOGENE			English	Article						Gadd45a; cell-cell adhesion; cell contact; inhibition; beta-catenin	DECREASED DNA-REPAIR; PROTEIN-COMPONENT; STRESS-PROTEIN; EXPRESSION; P53; COMPLEX; KINASE; GROWTH; INHIBITION; TYROSINE	Gadd45a, a growth arrest and DNA-damage gene, plays important roles in the control of cell cycle checkpoints, DNA repair and apoptosis. We show here that Gadd45a is involved in the control of cell contact inhibition and cell cell adhesion. Gadd45a can serve as an adapter to enhance the interaction between beta-catenin and Caveolin-1, and in turn induces beta-catenin translocation to cell membrane for maintaining cell - cell adhesion/contact inhibition. This is coupled with reduction of b-catenin in cytoplasm and nucleus following Gadd45a induction, which is reflected by the downregulation of cyclin D1, one of the beta-catenin targeted genes. Additionally, Gadd45a facilitates ultraviolet radiation-induced degradation of cytoplasmic and nuclear beta-catenin in a p53-dependent manner via activation of p38 kinase. These findings define a novel link that connects Gadd45a to cell - cell adhesion and cell contact inhibition, which might contribute to the role of Gadd45a in inhibiting tumorigenesis.	Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, Q (corresponding author), Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	zhanqimin@pumc.edu.cn						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, BIOESSAYS, V22, P961; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRO MJ, 1994, COLLECT MATH, V45, P53; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato Y, 2005, LUNG CANCER, V48, P323, DOI 10.1016/j.lungcan.2004.11.012; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Leali D, 2001, J BIOL CHEM, V276, P37900; Li G, 1996, AM J PATHOL, V148, P1113; MARCHENKO GN, 2002, BIOCHEM J, V363, P263; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Salon C, 2004, HUM PATHOL, V35, P1148, DOI 10.1016/j.humpath.2004.04.015; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XH, 2003, ONCOGENE, V22, P4166, DOI 10.1038/sj.onc.1206599	49	24	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6396	6405		10.1038/sj.onc.1210469	http://dx.doi.org/10.1038/sj.onc.1210469			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452974				2022-12-25	WOS:000249737600004
J	Tanaka, K; Imoto, I; Inoue, J; Kozaki, K; Tsuda, H; Shimada, Y; Aiko, S; Yoshizumi, Y; Iwai, T; Kawano, T; Inazawa, J				Tanaka, K.; Imoto, I.; Inoue, J.; Kozaki, K.; Tsuda, H.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Iwai, T.; Kawano, T.; Inazawa, J.			Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma	ONCOGENE			English	Article						esophageal squamous-cell carcinoma; CRABP1; DNA methylation; BAMCA; tumor suppressor	ACID-BINDING-PROTEIN; PAPILLARY THYROID-CARCINOMA; CPG ISLAND AMPLIFICATION; RETINOIC-ACID; COLORECTAL-CANCER; I GENE; LYMPH-NODES; EXPRESSION; IDENTIFICATION; PROMOTER	Epigenetic alterations and the resulting inactivation of tumor suppressor genes often contribute to the development of various cancers. To identify novel candidates that may be silenced by aberrant methylation in esophageal squamous-cell carcinoma (ESCC), we analysed ESCC cell lines by a recently developed method known as bacterial artificial chromosome array-based methylated CpG island amplification (BAMCA), and selected candidates through BAMCA-assisted strategy. In the course of this program, we identified frequent CpG methylation-dependent silencing of the gene encoding cellular retinoic acid binding protein 1 (CRABP1) in our panel of ESCC cell lines. Expression of CRABP1 mRNA was restored in gene-silenced ESCC cells after treatment with 5-aza 2'-deoxycytidine. The DNA methylation status of the CRABP1 CpG island with clear promoter activity correlated inversely with expression of this gene. CpG methylation of CRABP1 was frequently observed in primary ESCC tissues as well. Restoration of CRABP1 expression in ESCC cells lacking the protein reduced cell growth by inducing arrest at G(0)-G(1), whereas knockdown of the gene in cells expressing CRABP1 promoted cell growth. Among 113 primary ESCC tumors, the absence of immunoreactive CRABP1 was significantly associated with de-differentiation of cancer cells and with distant lymph-node metastases in the patients. These results indicate that CRABP1 appears to have a tumor-suppressor function in esophageal epithelium, and its epigenetic silencing may play a pivotal role during esophageal carcinogenesis. Its expression status in biopsies or resected tumors might serve as an index for identifying ESCC patients for whom combined therapeutic modalities would be recommended.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Vasc & Appl Surg, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Dept Genome Med, Tokyo 1138510, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan; Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan; Hyogo Med Univ, Dept Surg 1, Nishinomiya, Hyogo, Japan; Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 359, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Mol Destruct, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); National Defense Medical College - Japan; Hyogo College of Medicine; University of Hyogo; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X				DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; DONOVAN M, 1995, J STEROID BIOCHEM, V53, P459, DOI 10.1016/0960-0760(95)00092-E; DOWLATSHAHI K, 1984, CANCER, V54, P308, DOI 10.1002/1097-0142(19840715)54:2<308::AID-CNCR2820540221>3.0.CO;2-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Imoto I, 2001, CANCER RES, V61, P6629; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Ito T, 2003, CANCER RES, V63, P6320; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Kuroki T, 2003, CANCER RES, V63, P3724; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Means AL, 2000, CELL GROWTH DIFFER, V11, P71; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ohtsu Atsushi, 2004, Int J Clin Oncol, V9, P444, DOI 10.1007/s10147-004-0454-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pfoertner S, 2005, TUMOR BIOL, V26, P313, DOI 10.1159/000089262; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; RODER JD, 1994, BRIT J SURG, V81, P410, DOI 10.1002/bjs.1800810330; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Shibata H, 2001, PATHOL RES PRACT, V197, P157, DOI 10.1078/0344-0338-00027; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shirakawa Y, 2000, CLIN CANCER RES, V6, P541; Sobin LH., 2002, INT UNION CANC UICC, V6; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stein HJ, 2005, ANN SURG, V242, P566, DOI 10.1097/01.sla.0000184211.75970.85; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P2307; Venepally P, 1996, ARCH BIOCHEM BIOPHYS, V336, P231, DOI 10.1006/abbi.1996.0553; WEI LN, 1994, DEV DYNAM, V201, P1, DOI 10.1002/aja.1002010102; Wei LN, 1996, J BIOL CHEM, V271, P5073; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	43	57	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6456	6468		10.1038/sj.onc.1210459	http://dx.doi.org/10.1038/sj.onc.1210459			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17438526				2022-12-25	WOS:000249737600010
J	Urayama, K; Guilini, C; Messaddeq, N; Hu, K; Steenman, M; Kurose, H; Ert, G; Nebigil, CG				Urayama, Kyoji; Guilini, Celia; Messaddeq, Nadia; Hu, Kai; Steenman, Marja; Kurose, Hitoshi; Ert, Georg; Nebigil, Canan G.			The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis	FASEB JOURNAL			English	Article						PKR1; MI	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; HEART-FAILURE; MICE LACKING; IDENTIFICATION; EXPRESSION; CELLS; BV8; ACTIVATION	Prokineticins are potent angiogenic factors that bind to two G protein-coupled receptors to initiate their biological effects. We hypothesize that prokineticin receptor-1 (PKR1/GPR73) signaling may contribute to cardiomyocyte survival or repair in myocardial infarction. Since we showed that prokineticin-2 and PKR1 are expressed in adult mouse heart and cardiac cells, we investigated the role of prokineticin-2 on capillary endothelial cell and cardiomyocyte function. In cultured cardiac endothelial cells, prokineticin-2 or overexpression of PKR1 induces vessel-like formation without increasing VEGF levels. In cardiomyocytes and H9c2 cells, prokineticin-2 or overexpressing PKR1 activates Akt to protect cardiomyocytes against oxidative stress. The survival and angiogenesis promoting effects of prokineticin-2 in cardiac cells were completely reversed by siRNA-PKR1, indicating PKR1 involvement. We thus, further investigated whether intramyocardial gene transfer of DNA encoding PKR1 may rescue the myocardium against myocardial infarction in mouse model. Transient PKR1 gene transfer after coronary ligation reduces mortality and preserves left ventricular function by promoting neovascularization and protecting cardiomyocytes without altering VEGF levels. In human end-stage failing heart samples, reduced PKR1 and prokineticin-2 transcripts and protein levels implicate a more important role for prokineticin2/PKR1 signaling in heart. Our results suggest that PKR1 may represent a novel therapeutic target to limit myocardial injury following ischemic events. Urayama, K., Guilini, C., Messaddeq, N., Hu, K., Steenman, M., Kurose, H., Ert, G., Nebigil, C. G. The prokineticin receptor-1(GPR73) promotes cardiomyocyte survival and angiogenesis.	Univ Strasbourg 1, CNRS, UMR 7175, F-67412 Illkirch Graffenstaden, France; Inst Genet Biol Mol, Illkirch Graffenstaden, France; Univ Wurzburg, Ctr Cardiovasc Med, Wurzburg, Germany; INSERM U533, L Inst Thorax, Nantes, France; Kyushu Univ, Dept Pharmacol & Toxicol, Fukuoka 812, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Wurzburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Kyushu University	Nebigil, CG (corresponding author), Univ Strasbourg 1, CNRS, UMR 7175, Bld Sebastien Brandt BP 10413, F-67412 Illkirch Graffenstaden, France.	nebigil@esbs.u-strasbg.fr	Steenman, Marja/D-3618-2015; Steenman, Marja/S-8433-2019; Nebigil, Canan/AAK-7162-2021	Steenman, Marja/0000-0003-4547-4448; Steenman, Marja/0000-0003-4547-4448; Nebigil, Canan/0000-0002-2035-5795				Abraham D, 2000, CIRC RES, V87, P644, DOI 10.1161/01.RES.87.8.644; Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29; Bullock CM, 2004, MOL PHARMACOL, V65, P582, DOI 10.1124/mol.65.3.582; Chen JC, 2005, MOL PHARMACOL, V67, P2070, DOI 10.1124/mol.105.011619; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Chotteau-Lelievre Anne, 2006, Methods Mol Biol, V326, P61; Dorsch M, 2005, J LEUKOCYTE BIOL, V78, P426, DOI 10.1189/jlb.0205061; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Howes AL, 2006, J MOL CELL CARDIOL, V40, P597, DOI 10.1016/j.yjmcc.2005.12.003; Kan H, 2004, AM J PHYSIOL-CELL PH, V286, pC1, DOI 10.1152/ajpcell.00059.2003; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Kisliouk T, 2005, ENDOCRINOLOGY, V146, P3950, DOI 10.1210/en.2005-0297; Lamirault G, 2006, J MOL CELL CARDIOL, V40, P173, DOI 10.1016/j.yjmcc.2005.09.004; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; LeCouter J, 2003, P NATL ACAD SCI USA, V100, P2685, DOI 10.1073/pnas.0337667100; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Martucci C, 2006, BRIT J PHARMACOL, V147, P225, DOI 10.1038/sj.bjp.0706467; Masuda Y, 2002, BIOCHEM BIOPH RES CO, V293, P396, DOI 10.1016/S0006-291X(02)00239-5; McLaughlin JN, 2005, J BIOL CHEM, V280, P22172, DOI 10.1074/jbc.M500721200; Mialet-Perez J, 2006, ARCH MAL COEUR VAISS, V99, P616; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nagoshi T, 2005, J CLIN INVEST, V115, P2128, DOI 10.1172/JCI23073; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2003, FASEB J, V17, P1373, DOI 10.1096/fj.02-1122fje; Negri L, 2005, BRIT J PHARMACOL, V146, P625, DOI 10.1038/sj.bjp.0706376; Negri L, 2006, J NEUROSCI, V26, P6716, DOI 10.1523/JNEUROSCI.5403-05.2006; Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Okada H, 2005, CIRCULATION, V111, P2430, DOI 10.1161/01.CIR.0000165066.71481.8E; Parker R, 2000, BBA-GENE STRUCT EXPR, V1491, P369, DOI 10.1016/S0167-4781(00)00023-3; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; Tang CM, 2004, TRENDS CARDIOVAS MED, V14, P94, DOI 10.1016/j.tcm.2003.12.007; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100	46	78	84	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2980	2993		10.1096/fj.07-8116com	http://dx.doi.org/10.1096/fj.07-8116com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17442730				2022-12-25	WOS:000249237500038
J	Cendron, L; Berni, R; Folli, C; Ramazzina, I; Percudani, R; Zanotti, G				Cendron, Laura; Berni, Rodolfo; Folli, Claudia; Ramazzina, Ileana; Percudani, Riccardo; Zanotti, Giuseppe			The structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase provides insights into the mechanism of uric acid degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSTHYRETIN-RELATED PROTEIN; CRYSTAL-STRUCTURE; PRODUCT; 5-HYDROXYISOURATE; CRYSTALLOGRAPHY; IDENTIFICATION; PATHWAY; ENZYME	The complete degradation of uric acid to (S)-allantoin, as recently elucidated, involves three enzymatic reactions. Inactivation by pseudogenization of the genes of the pathway occurred during hominoid evolution, resulting in a high concentration of urate in the blood and susceptibility to gout. Here, we describe the 1.8 angstrom resolution crystal structure of the homodimeric 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase, which catalyzes the last step in the urate degradation pathway, for both ligand-free enzyme and enzyme in complex with the substrate analogs (R)-allantoin and guanine. Each monomer comprises ten alpha-helices, grouped into two domains and assembled in a novel fold. The structure and the mutational analysis of the active site have allowed us to identify some residues that are essential for catalysis, among which His-67 and Glu-87 appear to play a particularly significant role. Glu-87 may facilitate the exit of the carboxylate group because of electrostatic repulsion that destabilizes the ground state of the substrate, whereas His-67 is likely to be involved in a protonation step leading to the stereoselective formation of the (S)-allantoin enantiomer as reaction product. The structural and functional characterization of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase can provide useful information in view of the potential use of this enzyme in the enzymatic therapy of gout.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Padua, Dept Chem, Inst Chim Biomol Consiglio Nazl Ric, Sect Padua, I-35131 Padua, Italy; Venetian Inst Mol Med, I-35127 Padua, Italy	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Padua; Veneto Institute Molecular Medicine	Percudani, R (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Viale Sci 23-A, I-43100 Parma, Italy.	riccardo.percudani@unipr.it; giuseppe.zanotti@unipd.it	cendron, Laura/A-5202-2014; percudani, riccardo/B-4872-2011	percudani, riccardo/0000-0001-8452-1062; Berni, Rodolfo/0000-0002-1839-0479; Cendron, Laura/0000-0002-0125-0461; Ramazzina, Ileana/0000-0003-1009-2917; Zanotti, Giuseppe/0000-0002-0945-6501				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2004, CURR OPIN CHEM BIOL, V8, P508, DOI 10.1016/j.cbpa.2004.08.004; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colloc'h N, 2000, PROTEINS, V39, P142, DOI 10.1002/(SICI)1097-0134(20000501)39:2<142::AID-PROT4>3.0.CO;2-X; Colloch N, 1997, NAT STRUCT BIOL, V4, P947, DOI 10.1038/nsb1197-947; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gabison L, 2006, FEBS LETT, V580, P2087, DOI 10.1016/j.febslet.2006.03.007; Hennebry SC, 2006, J MOL BIOL, V359, P1389, DOI 10.1016/j.jmb.2006.04.057; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P116; Jung DK, 2006, P NATL ACAD SCI USA, V103, P9790, DOI 10.1073/pnas.0600523103; Kahn K, 1997, J AM CHEM SOC, V119, P5435, DOI 10.1021/ja970375t; KHAN K, 1997, BIOCHEMISTRY-US, V36, P4731; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee Susan J, 2006, Curr Rheumatol Rep, V8, P224, DOI 10.1007/s11926-996-0029-z; Lee Y, 2005, FEBS LETT, V579, P4769, DOI 10.1016/j.febslet.2005.07.056; Lundberg E, 2006, J STRUCT BIOL, V155, P445, DOI 10.1016/j.jsb.2006.04.002; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; MODRIC N, 1992, TETRAHEDRON LETT, V33, P6691, DOI 10.1016/S0040-4039(00)61021-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OLEARY MH, 1992, ENZYMES, V20, P235; Ramazzina I, 2006, NAT CHEM BIOL, V2, P144, DOI 10.1038/nchembio768; Sarma AD, 1999, J BIOL CHEM, V274, P33863, DOI 10.1074/jbc.274.48.33863; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Zanotti G, 2006, J MOL BIOL, V363, P1, DOI 10.1016/j.jmb.2006.07.079	33	37	40	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18182	18189		10.1074/jbc.M701297200	http://dx.doi.org/10.1074/jbc.M701297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17428786	hybrid			2022-12-25	WOS:000247302000024
J	Furland, NE; Oresti, GM; Antollini, SS; Venturino, A; Maldonado, EN; Aveldano, MI				Furland, Natalia E.; Oresti, Gerardo M.; Antollini, Silvia S.; Venturino, Andres; Maldonado, Eduardo N.; Aveldano, Marta I.			Very long-chain polyunsaturated fatty acids are the major acyl groups of sphingomyelins and ceramides in the head of mammalian spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; ACROSOME REACTION; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; DISPLACES CHOLESTEROL; PLASMA-MEMBRANE; SPERM; CAPACITATION; FERTILIZATION; ASSOCIATION; ACTIVATION	Very long-chain (C24 to C34) polyunsaturated fatty acids (VLCPUFA) are important constituents of sphingomyelin (SM) and ceramide (Cer) in testicular germ cells. In the present paper we focused on the SM and Cer and their fatty acids in spermatozoa and their main regions, heads and tails. In bull and ram spermatozoa, SM was the third most abundant phospholipid and VLCPUFA were the major acyl groups (similar to 70%) of SM and Cer. In rat epididymal spermatozoa the SM/Cer ratio was low in the absence of and could be maintained high in the presence of the cation chelator EDTA, added to the medium used for sperm isolation. This fact points to the occurrence of an active divalent cation-dependent sphingomyelinase. Bull and rat sperm had an uneven head-tail distribution of phospholipid, with virtually all the VLCPUFA-rich SM located at the head, the lower SM content in the rat being determined by the lower sperm head/tail size ratio. Most of the SM from bull sperm heads was readily solubilized with 1% Triton X-100 at 4 degrees C. The detergent-soluble SM fraction was richer in VLCPUFA than the nonsoluble fraction and richer in saturated fatty acids. Cer was produced at the expense of SM, thus decreasing severalfold the SM/Cer ratio in rat spermatozoa incubated for 2 h in presence of the sperm-capacitating agents, calcium, bicarbonate, and albumin. The generation of Cer from SM in the sperm head surface may be an early step among the biochemical and biophysical changes known to take place in the spermatozoon in the physiological events preceding fertilization.	Univ Nacl Sur, Inst Invest Bioquim, Consejo Natl Invest Cient & Tecn, RA-8000 Bahia Blanca, Argentina; Univ Nacl Comahue, Consejo Natl Invest Cient & Tecn, Lab Teriogenol, RA-8300 Neuquen, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional del Comahue	Aveldano, MI (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Reg Invest Basicas & Aplicadas Bahia Blanca, INIBIBB, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	avelda@criba.edu.ar	Maldonado, Eduardo/AAN-3907-2020	Maldonado, Eduardo/0000-0002-5285-3027				Antollini SS, 2002, J LIPID RES, V43, P1440, DOI 10.1194/jlr.M200057-JLR200; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1992, BIOCHEM J, V283, P235, DOI 10.1042/bj2830235; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; BALDI E, 2001, FRONT BIOSCI, V5, P110; Barenholz Y, 2004, SUB CELL BIOCHEM, V37, P167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN ER, 1994, LIPIDS, V29, P825, DOI 10.1007/BF02536249; CHRISTIE WW, 1982, LIPID ANAL, P51; Contreras FX, 2005, BIOPHYS J, V88, P348, DOI 10.1529/biophysj.104.050690; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Cross NL, 2000, BIOL REPROD, V63, P1129, DOI 10.1095/biolreprod63.4.1129; Cross NL, 2004, BIOL REPROD, V71, P1367, DOI 10.1095/biolreprod.104.030502; DAVIS BK, 1981, P NATL ACAD SCI-BIOL, V78, P7560, DOI 10.1073/pnas.78.12.7560; DESNOYERS L, 1992, J BIOL CHEM, V267, P10149; Fisch JD, 1998, HUM REPROD, V13, P1248, DOI 10.1093/humrep/13.5.1248; Flesch FM, 2000, BBA-REV BIOMEMBRANES, V1469, P197, DOI 10.1016/S0304-4157(00)00018-6; Furland NE, 2007, J BIOL CHEM, V282, P18141, DOI 10.1074/jbc.M700708200; Gitlits VM, 2000, EUR J CELL BIOL, V79, P104, DOI 10.1078/S0171-9335(04)70012-6; HINKOVSKA VT, 1987, BIOCHEM CELL BIOL, V65, P525, DOI 10.1139/o87-067; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Holopainen JM, 2001, BIOPHYS J, V80, P765, DOI 10.1016/S0006-3495(01)76056-0; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Li XM, 2000, BIOPHYS J, V78, P1921, DOI 10.1016/S0006-3495(00)76740-3; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207; Martinez P, 1996, FRONT BIOSCI, V1, P103; Murase T, 2004, J REPROD DEVELOP, V50, P667, DOI 10.1262/jrd.50.667; NIKOLOPOULOU M, 1986, LIPIDS, V21, P566, DOI 10.1007/BF02534053; NIKOLOPOULOU M, 1986, ARCH BIOCHEM BIOPHYS, V250, P30, DOI 10.1016/0003-9861(86)90698-3; Nixon B, 2006, BIOL REPROD, V74, P275, DOI 10.1095/biolreprod.105.044644; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROLDAN ERS, 1994, J BIOL CHEM, V269, P23583; Roldan ERS, 1996, FEBS LETT, V396, P227, DOI 10.1016/0014-5793(96)01110-6; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Sleight SB, 2005, BIOL REPROD, V73, P721, DOI 10.1095/biolreprod.105.041533; Therien I, 2001, BIOL REPROD, V65, P41, DOI 10.1095/biolreprod65.1.41; TOYODA Y, 1974, J REPROD FERTIL, V36, P9, DOI 10.1530/jrf.0.0360009; van Gestel RA, 2005, MOL HUM REPROD, V11, P583, DOI 10.1093/molehr/gah200; WILLIAMS RM, 1991, BIOL REPROD, V44, P1080, DOI 10.1095/biolreprod44.6.1080; Wolfe CA, 1998, BIOL REPROD, V59, P1506, DOI 10.1095/biolreprod59.6.1506; Yanagimachi R., 1994, P189; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200	51	61	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18151	18161		10.1074/jbc.M700709200	http://dx.doi.org/10.1074/jbc.M700709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392275	Green Published, hybrid			2022-12-25	WOS:000247302000021
J	Johnson, BJ; Cohen, J; Welford, RW; Pearson, AR; Schulten, K; Klinman, JP; Wilmot, CM				Johnson, Bryan J.; Cohen, Jordi; Welford, Richard W.; Pearson, Arwen R.; Schulten, Klaus; Klinman, Judith P.; Wilmot, Carrie M.			Exploring molecular oxygen pathways in Hansenula polymorpha copper-containing amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE COFACTOR BIOGENESIS; OXIDATIVE HALF-REACTION; PASTORIS LYSYL OXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; LIGAND MIGRATION; BOVINE SERUM; CATALYTIC MECHANISM; ADHESION PROTEIN-1; ESCHERICHIA-COLI	The accessibility of large substrates to buried enzymatic active sites is dependent upon the utilization of proteinaceous channels. The necessity of these channels in the case of small substrates is questionable because diffusion through the protein matrix is often assumed. Copper amine oxidases contain a buried protein-derived quinone cofactor and a mononuclear copper center that catalyze the conversion of two substrates, primary amines and molecular oxygen, to aldehydes and hydrogen peroxide, respectively. The nature of molecular oxygen migration to the active site in the enzyme from Hansenula polymorpha is explored using a combination of kinetic, x-ray crystallographic, and computational approaches. A crystal structure of H. polymorpha amine oxidase in complex with xenon gas, which serves as an experimental probe for molecular oxygen binding sites, reveals buried regions of the enzyme suitable for transient molecular oxygen occupation. Calculated O-2 free energy maps using copper amine oxidase crystal structures in the absence of xenon correspond well with later experimentally observed xenon sites in these systems, and allow the visualization of O-2 migration routes of differing probabilities within the protein matrix. Site-directed mutagenesis designed to block individual routes has little effect on overall k(cat)/K-m (O-2), supporting multiple dynamic pathways for molecular oxygen to reach the active site.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wilmot, CM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	wilmo004@umn.edu	Schulten, Klaus/D-5561-2009	Pearson, Arwen/0000-0001-8499-7490	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025765, T32GM008700, R01GM025765, R01GM066569] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR005969, P41-RR05969] Funding Source: Medline; NIGMS NIH HHS [R37 GM025765, GM-66569, R01 GM025765, GM-25765, T32 GM008700, R01 GM066569-05, R01 GM066569, GM-008700] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Airenne TT, 2005, PROTEIN SCI, V14, P1964, DOI 10.1110/ps.051438105; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; Chiu YC, 2006, BIOCHEMISTRY-US, V45, P4105, DOI 10.1021/bi052464l; Cohen J, 2005, STRUCTURE, V13, P1321, DOI 10.1016/j.str.2005.05.013; Cohen J, 2006, BIOPHYS J, V91, P1844, DOI 10.1529/biopbysj.106.085746; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CRUIKSHANK DWJ, 2006, INT TABLES CRYSTALLO, P403; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; DeLano WL, 2002, PYMOL USERS MANUAL; Dooley DM, 1998, J AM CHEM SOC, V120, P2599, DOI 10.1021/ja970312a; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; Dooley DM, 1999, J BIOL INORG CHEM, V4, P1, DOI 10.1007/s007750050283; Dove JE, 2001, ADV PROTEIN CHEM, V58, P141; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; DuBois JL, 2004, METHOD ENZYMOL, V378, P17; Duff AP, 2006, ACTA CRYSTALLOGR D, V62, P1073, DOI 10.1107/S0907444906026333; Duff AP, 2004, J MOL BIOL, V344, P599, DOI 10.1016/j.jmb.2004.09.075; Duff AP, 2003, BIOCHEMISTRY-US, V42, P15148, DOI 10.1021/bi035338v; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goto Y, 2002, BIOCHEMISTRY-US, V41, P13637, DOI 10.1021/bi0204591; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Hevel JM, 1999, BIOCHEMISTRY-US, V38, P3683, DOI 10.1021/bi982199m; Hirota S, 2001, BIOCHEMISTRY-US, V40, P15789, DOI 10.1021/bi011631o; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Jakobsson E, 2005, ACTA CRYSTALLOGR D, V61, P1550, DOI 10.1107/S0907444905028805; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Kim M, 2002, NAT STRUCT BIOL, V9, P591, DOI 10.1038/nsb824; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Knapp MJ, 2003, BIOCHEMISTRY-US, V42, P11466, DOI 10.1021/bi0300884; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; Lunelli M, 2005, J MOL BIOL, V346, P991, DOI 10.1016/j.jmb.2004.12.038; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Medda R, 1999, FEBS LETT, V453, P1, DOI 10.1016/S0014-5793(99)00675-4; Medda R, 2006, BIOCHIMIE, V88, P827, DOI 10.1016/j.biochi.2006.01.011; Mills SA, 2000, J AM CHEM SOC, V122, P9897, DOI 10.1021/ja000325f; Mills SA, 2002, BIOCHEMISTRY-US, V41, P10577, DOI 10.1021/bi0200864; Mure M, 2002, BIOCHEMISTRY-US, V41, P9269, DOI 10.1021/bi020246b; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okajima T, 2005, BIOCHEMISTRY-US, V44, P12041, DOI 10.1021/bi051070r; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padiglia A, 2001, EUR J BIOCHEM, V268, P4686, DOI 10.1046/j.1432-1327.2001.02390.x; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Plastino J, 1999, BIOCHEMISTRY-US, V38, P8204, DOI 10.1021/bi9826660; Samuels NM, 2005, BIOCHEMISTRY-US, V44, P14308, DOI 10.1021/bi051176m; Schmidt M, 2005, P NATL ACAD SCI USA, V102, P11704, DOI 10.1073/pnas.0504932102; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Schwartz B, 2001, BIOCHEMISTRY-US, V40, P2954, DOI 10.1021/bi0021378; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; Takahashi K, 2006, BIOCHEMISTRY-US, V45, P4683, DOI 10.1021/bi0521893; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; Wilmot CM, 1997, BIOCHEMISTRY-US, V36, P1608, DOI 10.1021/bi962205j	62	67	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17767	17776		10.1074/jbc.M701308200	http://dx.doi.org/10.1074/jbc.M701308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17409383	Green Accepted, hybrid			2022-12-25	WOS:000247084500050
J	Luttichau, HR; Johnsen, AH; Jurlander, J; Rosenkilde, MM; Schwartz, TW				Luttichau, Hans R.; Johnsen, Anders H.; Jurlander, Jesper; Rosenkilde, Mette M.; Schwartz, Thue W.			Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CHEMOKINE LYMPHOTACTIN; HHV8 ASSOCIATED DISEASES; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; VMIP-I; MOLLUSCUM CONTAGIOSUM; GENE-EXPRESSION; XCR1 RECEPTOR; IDENTIFICATION; PROTEIN	Large DNA viruses such as herpesvirus and poxvirus encode proteins that target and exploit the chemokine system of their host. These proteins have the potential to block or change the orchestrated recruitment of leukocytes to sites of viral infection. The genome of Kaposi sarcoma-associated herpes virus (KSHV) encodes three chemokine-like proteins named vCCL1, vCCL2, and vCCL3. In this study vCCL3 was probed in parallel with vCCL1 and vCCL2 against a panel of the 18 classified human chemokine receptors. In calcium mobilization assays vCCL1 acted as a selective CCR8 agonist, whereas vCCL2 was found to act as a broad spectrum chemokine antagonist of human chemokine receptors, including the lymphotactin receptor. In contrast vCCL3 was found to be a highly selective agonist for the human lymphotactin receptor XCR1. The potency of vCCL3 was found to be 10-fold higher than the endogenous human XCL1 chemokine in respect to phosphatidylinositol turnover and calcium mobilization as well as chemotaxis. High expression of XCR1 was found in placenta and neutrophils by real-time PCR. These data are consistent with reports of different expression profiles for vCCL2 and vCCL3 during the life cycle of KSHV, indicate a novel, sophisticated exploitation by the virus of specifically the lymphotactin receptor by both agonist and antagonist mechanisms, and suggest a unique physiological importance of this (somewhat overlooked) chemokine receptor.	Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark; 7TM Pharma AS, DK-2970 Horsholm, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Luttichau, HR (corresponding author), Panum Inst, Mol Pharmacol Lab, 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	hrl@molpharm.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904				Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Borthwick NJ, 1997, IMMUNOLOGY, V90, P272, DOI 10.1046/j.1365-2567.1997.00154.x; Cairns CM, 2001, J IMMUNOL, V167, P57, DOI 10.4049/jimmunol.167.1.57; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Dewin DR, 2006, J IMMUNOL, V176, P544, DOI 10.4049/jimmunol.176.1.544; Dong C, 2005, J IMMUNOL METHODS, V302, P136, DOI 10.1016/j.jim.2005.05.008; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W; Giancarlo B, 1996, EUR J IMMUNOL, V26, P3238, DOI 10.1002/eji.1830261260; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HENG MCY, 1989, AM J DERMATOPATH, V11, P248, DOI 10.1097/00000372-198906000-00009; Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3; Hengge UR, 2002, LANCET INFECT DIS, V2, P344, DOI 10.1016/S1473-3099(02)00288-8; Houssiau F, 1996, J IMMUNOL, V157, P2570; Huang H, 2001, BIOCHEM BIOPH RES CO, V281, P378, DOI 10.1006/bbrc.2001.4363; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Lindow M, 2003, TRENDS PHARMACOL SCI, V24, P126, DOI 10.1016/S0165-6147(03)00033-6; Lindow M, 2003, J VIROL, V77, P7393, DOI 10.1128/JVI.77.13.7393-7400.2003; Louahed J, 2003, EUR J IMMUNOL, V33, P494, DOI 10.1002/immu.200310025; Lu M, 2004, J VIROL, V78, P13637, DOI 10.1128/JVI.78.24.13637-13652.2004; Luttichau HR, 2003, J BIOL CHEM, V278, P10928, DOI 10.1074/jbc.M211329200; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; MULLER S, 1995, EUR J IMMUNOL, V25, P1744, DOI 10.1002/eji.1830250638; Murphy PM, 2000, PHARMACOL REV, V52, P145; Najarro P, 2003, J GEN VIROL, V84, P3325, DOI 10.1099/vir.0.19591-0; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Peterson FC, 2004, J BIOL CHEM, V279, P12598, DOI 10.1074/jbc.M311633200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Seet BT, 2003, P NATL ACAD SCI USA, V100, P15137, DOI 10.1073/pnas.2336648100; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551	49	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17794	17805		10.1074/jbc.M702001200	http://dx.doi.org/10.1074/jbc.M702001200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403668	hybrid			2022-12-25	WOS:000247084500053
J	Masuda, K; Ouchida, R; Hikida, M; Kurosaki, T; Yokoi, M; Masutani, C; Seki, M; Wood, RD; Hanaoka, F; O-Wang, J				Masuda, Keiji; Ouchida, Rika; Hikida, Masaki; Kurosaki, Tomohiro; Yokoi, Masayuki; Masutani, Chikahide; Seki, Mineaki; Wood, Richard D.; Hanaoka, Fumio; O-Wang, Jiyang			DNA polymerases eta and theta function in the same genetic pathway to generate mutations at A/T during somatic hypermutation of Ig genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; EMBRYONIC LETHALITY; TRANSLESION SYNTHESIS; IMMUNOGLOBULIN GENES; V(D)J RECOMBINATION; ANTIBODY DIVERSITY; MICE DEFICIENT; ZETA; ERROR; MOUSE	Somatic hypermutation of the Ig genes requires the activity of multiple DNA polymerases to ultimately introduce mutations at both A/T and C/G base pairs. Mice deficient for DNA polymerase eta (POLH) exhibited an similar to 80% reduction of the mutations at A/T, whereas absence of polymerase theta( POLQ) resulted in similar to 20% reduction of both A/T and C/G mutations. To investigate whether the residual A/T mutations observed in the absence of POLH are generated by POLQ and how these two polymerases might cooperate or compete with each other to generate A/T mutations, here we have established mice deficient for both POLH and POLQ. Polq(-/-) Polh(-/-) mice, however, did not show a further decrease of A/T mutations as compared with Polh(-/-) mice, suggesting that POLH and POLQ function in the same genetic pathway in the generation of these mutations. Frequent misincorporation of nucleotides, in particular opposite template T, is a known feature of POLH, but the efficiency of extension beyond the misincorporation differs significantly depending on the nature of the mispairing. Remarkably, we found that POLQ catalyzed extension more efficiently than POLH from all types of mispaired termini opposite A or T. Moreover, POLQ was able to extend mispaired termini generated by POLH albeit at a relatively low efficiency. These results reveal genetic and biochemical interactions between POLH and POLQ and suggest that POLQ might cooperate with POLH to generate some of the A/T mutations during the somatic hypermutation of Ig genes.	RIKEN, Yokohama Inst, Lab Immune Divers, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; RIKEN, Yokohama Inst, Lab Lymphocyte Differentiat, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, SORST, Suita, Osaka 5650871, Japan; Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA	RIKEN; RIKEN; Osaka University; Japan Science & Technology Agency (JST); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	O-Wang, J (corresponding author), RIKEN, Yokohama Inst, Lab Immune Divers, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan.	oh@rcai.riken.jp	Masutani, Chikahide/I-6160-2014; Kurosaki, Tomohiro/D-1306-2009; Wood, Richard D/M-6319-2018	Kurosaki, Tomohiro/0000-0002-6352-304X; Wood, Richard D/0000-0002-9495-6892; Yokoi, Masayuki/0000-0001-9727-0258; Masutani, Chikahide/0000-0002-8600-8227	NCI NIH HHS [CA101980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arakawa H, 2006, PLOS BIOL, V4, P1947, DOI 10.1371/journal.pbio.0040366; Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Delbos F, 2005, J EXP MED, V201, P1191, DOI 10.1084/jem.20050292; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jansen JG, 2006, J EXP MED, V203, P319, DOI 10.1084/jem.20052227; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kajiwara K, 2001, GENES CELLS, V6, P99, DOI 10.1046/j.1365-2443.2001.00410.x; Martomo SA, 2006, DNA REPAIR, V5, P392, DOI 10.1016/j.dnarep.2005.12.006; Martomo SA, 2005, P NATL ACAD SCI USA, V102, P8656, DOI 10.1073/pnas.0501852102; Martomo SA, 2004, J EXP MED, V200, P61, DOI 10.1084/jem.20040691; Masuda K, 2005, P NATL ACAD SCI USA, V102, P13986, DOI 10.1073/pnas.0505636102; Masuda K, 2006, DNA REPAIR, V5, P1384, DOI 10.1016/j.dnarep.2006.06.006; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2005, NAT REV IMMUNOL, V5, P171, DOI 10.1038/nri1553; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ohkumo T, 2006, MOL CELL BIOL, V26, P7696, DOI 10.1128/MCB.01076-06; Pavlov YI, 2002, P NATL ACAD SCI USA, V99, P9954, DOI 10.1073/pnas.152126799; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schenten D, 2002, EUR J IMMUNOL, V32, P3152, DOI 10.1002/1521-4141(200211)32:11<3152::AID-IMMU3152>3.0.CO;2-2; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Shimizu T, 2005, IMMUNOL LETT, V98, P259, DOI 10.1016/j.imlet.2004.11.022; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9; Zan H, 2005, EMBO J, V24, P3757, DOI 10.1038/sj.emboj.7600833; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X	45	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17387	17394		10.1074/jbc.M611849200	http://dx.doi.org/10.1074/jbc.M611849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449470	hybrid			2022-12-25	WOS:000247084500008
J	Pearce, G; Siems, WF; Bhattacharya, R; Chen, YC; Ryan, CA				Pearce, Gregory; Siems, William F.; Bhattacharya, Ramcharan; Chen, Yu-Chi; Ryan, Clarence A.			Three hydroxyproline-rich glycopeptides derived from a single petunia polyprotein precursor activate defensin I, a pathogen defense response gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANTS; PEPTIDES; LOCALIZATION; ARABIDOPSIS; COMPONENTS; IMMUNITY; RECEPTOR; HORMONES; ANIMALS; SYSTEM	Hydroxyproline-rich glycopeptides (HypSys peptides) are recently discovered 16 -20-amino acid defense signals in tobacco and tomato leaves that are derived from cell wall-associated precursors. The peptides are powerful wound signals that activate the expression of defensive genes in tobacco and tomato leaves in response to herbivore attacks. We have isolated a cDNA from petunia (Petunia hybrida) leaves encoding a putative protein of 214 amino acids that is a homolog of tobacco and tomato HypSys peptide precursors and is inducible by wounding and MeJA. The deduced protein contains a leader sequence and four predicted proline-rich peptides of 18-21 amino acids. Three of the four peptides were isolated from leaves, and each peptide contained hydroxylated prolines and glycosyl residues. Each of the peptides has a -GR-motif at its N terminus, indicating that it may be the substrate site for a processing enzyme. The peptides were active in a petunia suspension culture bioassay at nanomolar concentrations, but they did not induce the expression of defense genes that are directed against herbivores, as found in tobacco and tomato leaves. They did, however, activate expression of defensin 1, a gene associated with inducible defense responses against pathogens.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA; Indian Agr Res Inst, Natl Res Ctr Plant Biotechnol, New Delhi 110012, India	Washington State University; Washington State University; Indian Council of Agricultural Research (ICAR); ICAR - Indian Agricultural Research Institute; ICAR - National Institute For Plant Biotechnology (NIPB)	Ryan, CA (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	cabudryan@hotmail.com						Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boller T, 2005, CURR OPIN CELL BIOL, V17, P116, DOI 10.1016/j.ceb.2005.02.007; Chen H, 2005, P NATL ACAD SCI USA, V102, P19237, DOI 10.1073/pnas.0509026102; Doyle J. J., 1987, PHYTOCHEMISTRY B, V19, P11, DOI DOI 10.2307/4119796; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; Howe GA, 1999, GENETICS, V153, P1411; Huffaker A, 2006, P NATL ACAD SCI USA, V103, P10098, DOI 10.1073/pnas.0603727103; Lay FT, 2005, CURR PROTEIN PEPT SC, V6, P85, DOI 10.2174/1389203053027575; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; Menezes H, 2002, COMP BIOCHEM PHYS C, V132, P1, DOI 10.1016/S1532-0456(02)00043-1; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Narvaez-Vasquez J, 2005, P NATL ACAD SCI USA, V102, P12974, DOI 10.1073/pnas.0505248102; Narvaez-Vasquez J, 2004, PLANTA, V218, P360, DOI 10.1007/s00425-003-1115-3; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Parker JE, 2003, TRENDS PLANT SCI, V8, P245, DOI 10.1016/S1360-1385(03)00105-5; Pearce G, 2003, J BIOL CHEM, V278, P30044, DOI 10.1074/jbc.M304159200; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1993, PLANT PHYSIOL, V102, P639, DOI 10.1104/pp.102.2.639; Pearce G, 2001, NATURE, V411, P817, DOI 10.1038/35081107; Rath A, 2005, BIOPOLYMERS, V80, P179, DOI 10.1002/bip.20227; Ren F, 2006, PLANT SCI, V171, P286, DOI 10.1016/j.plantsci.2006.04.001; ROCHAGRANADOS MC, 2005, PLANTA, V222, P794, DOI DOI 10.1007/S00425-005-0024-Z; Ryan CA, 2000, BBA-PROTEIN STRUCT M, V1477, P112, DOI 10.1016/S0167-4838(99)00269-1; Ryan CA, 2002, P NATL ACAD SCI USA, V99, P6519, DOI 10.1073/pnas.112196499; RYAN CA, 2004, ENCY BIOL CHEM, V3, P381; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Yamaguchi Y, 2006, P NATL ACAD SCI USA, V103, P10104, DOI 10.1073/pnas.0603729103	29	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17777	17784		10.1074/jbc.M701543200	http://dx.doi.org/10.1074/jbc.M701543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449475	hybrid			2022-12-25	WOS:000247084500051
J	Torres, MP; Borchers, CH				Torres, Matthew P.; Borchers, Christoph H.			Mitotic phosphorylation of the anaphase-promoting complex inhibitory subunit Mnd2 is necessary for efficient progression through meiosis I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE STABILIZES; TUMOR-SUPPRESSOR RASSF1A; CELL-CYCLE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; SUBSTRATE RECOGNITION; DEPENDENT PROTEOLYSIS; MASS-SPECTROMETRY; UBIQUITIN LIGASE; MITOSIS	The yeast anaphase-promoting complex (APC) subunit Mnd2 is necessary for maintaining sister chromatid cohesion in prophase I of meiosis by inhibiting premature ubiquitination and subsequent degradation of substrates by the APC(Ama1) ubiquitin ligase. In a proteomics screen for post-translational modifications on the APC, we discovered that Mnd2 is phosphorylated during mitosis in a cell cycle-dependent manner. We identified and characterized the sites of mitotic Mnd2 phosphorylation during the cell cycle. Collective mutation of Mnd2 phosphorylation sites to alanine had no effect on vegetative growth but a striking effect (> 85% reduction) on the percentage of tetrad-forming cells compared with the wild type strain. Similar to the MND2 deletion strain, cells harboring the alanine mutant that did not form spores arrested after premeiotic S phase with a single undivided nucleus and low levels of the APCAma1 meiotic substrate, Clb5, relative to wild type cells. In contrast, collective mutation of Mnd2 phosphorylation sites to aspartic acid resulted in partial suppression of the sporulation defect. No differences were observed in the binding between each Mnd2 isoform and the APC in vitro. However, in vivo, we observed a gradient in the abundance of APC-associated Mnd2 in each strain that was proportional to the observed differences in sporulation and Clb5 levels. Taken together, these data suggest that mitotic phosphorylation of Mnd2 is necessary for APC-mediated progression beyond the first meiotic nuclear division.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8Z 7X8, Canada; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Victoria; University of North Carolina; University of North Carolina Chapel Hill	Borchers, CH (corresponding author), Univ Victoria, Proteom Ctr, Vancouver Isl Technol Pk,3101-4464 Markham St, Victoria, BC V8Z 7X8, Canada.	christoph@proteincentre.com	BORCHERS, Christoph/U-5964-2019	Torres, Matthew/0000-0001-7296-4536				Bardin AJ, 2003, MOL CELL BIOL, V23, P5018, DOI 10.1128/MCB.23.14.5018-5030.2003; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Blanco MA, 2001, J CELL SCI, V114, P2135; Borchers C, 2000, ANAL CHEM, V72, P1163, DOI 10.1021/ac990937m; CHEN M, 1989, J BIOL CHEM, V264, P14282; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Eckerdt F, 2005, J BIOL CHEM, V280, P36575, DOI 10.1074/jbc.M504548200; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hall MC, 2004, CELL CYCLE, V3, P1278, DOI 10.4161/cc.3.10.1153; Hall MC, 2003, J BIOL CHEM, V278, P16698, DOI 10.1074/jbc.M213109200; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hershko A, 2005, CELL DEATH DIFFER, V12, P1191, DOI 10.1038/sj.cdd.4401702; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Oelschlaegel T, 2005, CELL, V120, P773, DOI 10.1016/j.cell.2005.01.032; Page AM, 2005, GENETICS, V170, P1045, DOI 10.1534/genetics.104.040105; Parker Carol E., 2005, V301, P117; Passmore LA, 2005, MOL CELL, V20, P855, DOI 10.1016/j.molcel.2005.11.003; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Penkner AM, 2005, CELL, V120, P789, DOI 10.1016/j.cell.2005.01.017; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Song MS, 2004, CELL CYCLE, V3, P574; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Torres MP, 2005, J PROTEOME RES, V4, P1628, DOI 10.1021/pr050129d; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Yamasaki L, 2004, CURR OPIN CELL BIOL, V16, P623, DOI 10.1016/j.ceb.2004.08.005; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou Y, 2003, BIOCHEM J, V374, P349, DOI 10.1042/BJ20030600	53	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17351	17362		10.1074/jbc.M610841200	http://dx.doi.org/10.1074/jbc.M610841200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17459880	hybrid, Green Published			2022-12-25	WOS:000247084500005
J	Garg, H; Joshi, A; Freed, EO; Blumenthal, R				Garg, Himanshu; Joshi, Anjali; Freed, Eric O.; Blumenthal, Robert			Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 T-CELLS; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; IN-VIVO; TYPE-1 ENVELOPE; INFLUENZA HEMAGGLUTININ; VIROLOGICAL SYNAPSE; PROTEASE INHIBITOR; CYTOPLASMIC TAIL	The loss of CD4(+) T cells in HIV-1 infections is hypothesized to be caused by apoptosis of bystander cells mediated by cell surface-expressed HIV-1 Env glycoprotein. However, the mechanism by which Env mediates this process remains controversial. Specifically, the role of HIV-1 gp120 binding to CD4 and CXCR4 versus the fusion process mediated by gp41 remains unresolved. Env-induced apoptosis in bystander cells has been shown to be gp41-dependent and correlates with the redistribution of membrane lipids between Env-expressing cells and target cells (hemifusion). Using a rational mutagenesis approach aimed at targeting Env function via the gp41 subunit, we examined the role of HIV gp41 in bystander apoptosis. A mutation in the fusion domain of gp41 (V513E) resulted in a fusion-defective Env that failed to induce apoptosis. A mutation in the gp41 N-terminal helix (G547D) reduced cell fusion capacity and apoptosis; conversely, an Env mutant with a deletion of the gp41 cytoplasmic tail (Ct Del) enhanced both cell-to-cell fusion and apoptosis. Most significantly, an Env mutant containing a substitution in the loop region of gp41 (D589L) mediated transfer of lipids (hemifusion) to bystander cells but was defective in cell-to-cell and to a lesser degree virus-to-cell fusion. This mutant was still able to induce apoptosis in bystander cells. Hence, we have provided the first direct evidence that gp41-mediated hemifusion is both required and sufficient for induction of apoptosis in bystander cells. These results may help to explain the mechanism of HIV-1 Env-induced T cell depletion.	NCI, Membrane Struct & Funct Sect, Canc Res Ctr, Nanobiol Program,NIH, Frederick, MD 21702 USA; NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumenthal, R (corresponding author), NCI, Membrane Struct & Funct Sect, Canc Res Ctr, Nanobiol Program,NIH, Frederick, MD 21702 USA.	blumen@helix.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010776, Z01BC010777, ZIABC010777, Z01BC010775, Z01BC010776, Z01BC008303, ZIABC010775, ZIABC008303] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Aquaro S, 2006, J ANTIMICROB CHEMOTH, V58, P714, DOI 10.1093/jac/dkl306; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Biard-Piechaczyk M, 2000, VIROLOGY, V268, P329, DOI 10.1006/viro.1999.0151; Blanco J, 2003, VIROLOGY, V305, P318, DOI 10.1006/viro.2002.1764; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; CAO J, 1994, J VIROL, V68, P4662, DOI 10.1128/JVI.68.7.4662-4668.1994; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Chinnaiyan AM, 1997, NAT MED, V3, P333, DOI 10.1038/nm0397-333; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Etemad-Moghadam B, 2000, J VIROL, V74, P4433, DOI 10.1128/JVI.74.9.4433-4440.2000; Etemad-Moghadam B, 2001, J VIROL, V75, P5646, DOI 10.1128/JVI.75.12.5646-5655.2001; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Garg H, 2006, J LEUKOCYTE BIOL, V79, P351, DOI 10.1189/jlb.0805430; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; Jekle A, 2003, J VIROL, V77, P5846, DOI 10.1128/JVI.77.10.5846-5854.2003; Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kinomoto M, 2005, J VIROL, V79, P5996, DOI 10.1128/JVI.79.10.5996-6004.2005; Labonte JA, 2000, J VIROL, V74, P10690, DOI 10.1128/JVI.74.22.10690-10698.2000; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; MACHO A, 1995, BLOOD, V86, P2481; Meissner EG, 2006, J VIROL, V80, P11019, DOI 10.1128/JVI.01382-06; Miro S, 2005, ANTIVIR THER, V10, P945; Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343; Perfettini JL, 2005, CELL DEATH DIFFER, V12, P916, DOI 10.1038/sj.cdd.4401584; Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812; Reeves JD, 2005, J VIROL, V79, P4991, DOI 10.1128/JVI.79.8.4991-4999.2005; Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001; Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005	43	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16899	16906		10.1074/jbc.M701701200	http://dx.doi.org/10.1074/jbc.M701701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416587	hybrid			2022-12-25	WOS:000246946500022
J	Higa, MM; Alam, SL; Sundquist, WI; Ullman, KS				Higa, Meda M.; Alam, Steven L.; Sundquist, Wesley I.; Ullman, Katharine S.			Molecular characterization of the ran-binding zinc finger domain of Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; NUCLEOPORIN NUP153; ENVELOPE BREAKDOWN; IMPORTIN-BETA; J-COUPLINGS; NUCLEOCYTOPLASMIC TRANSPORT; UBIQUITIN INTERACTIONS; CRYSTAL-STRUCTURE; SH3 DOMAIN	The nuclear pore complex is the gateway for selective traffic between the nucleus and cytoplasm. To learn how building blocks of the pore can create specific docking sites for transport receptors and regulatory factors, we have studied a zinc finger module present in multiple copies within the nuclear pores of higher eukaryotes. All four zinc fingers of human Nup153 were found to bind the small GTPase Ran with dissociation constants ranging between 5 and 40 mu M. In addition a fragment of Nup153 encompassing the four tandem zinc fingers was found to bind Ran with similar affinity. NMR structural studies revealed that a representative Nup153 zinc finger adopts the same zinc ribbon structure as the previously characterized Npl4 NZF module. Ran binding was mediated by a three-amino acid motif (Leu(13)/Val(14)/Asn(25)) located within the two zinc coordination loops. Nup153 ZnFs bound GDP and GTP forms of Ran with similar affinities, indicating that this interaction is not influenced by a nucleotide-dependent conformational switch. Taken together, these studies elucidate the Ran-binding interface on Nup153 and, more broadly, provide insight into the versatility of this zinc finger binding module.	Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Ullman, KS (corresponding author), Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA.	alam@biochem.utah.edu; katharine.ullman@hci.utah.edu		Ullman, Katharine/0000-0003-3693-2830	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051174, R01AI045405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM082545, T32GM007464, R01GM061275] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIAID NIH HHS [R01 AI051174, R01 AI45405] Funding Source: Medline; NIGMS NIH HHS [T32 GM07464, R01 GM061275, R01 GM61275, R01 GM061275-07, P50 GM082545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Arrigoni R, 2006, FEBS LETT, V580, P6233, DOI 10.1016/j.febslet.2006.10.027; Ball JR, 2005, CHROMOSOMA, V114, P319, DOI 10.1007/s00412-005-0019-3; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; BAX A, 1994, METHOD ENZYMOL, V239, P79; BAX A, 1994, J BIOMOL NMR, V4, P787, DOI 10.1007/BF00398409; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Devos D, 2006, P NATL ACAD SCI USA, V103, P2172, DOI 10.1073/pnas.0506345103; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Forler D, 2004, MOL CELL BIOL, V24, P1155, DOI 10.1128/MCB.24.3.1155-1167.2004; Gebauer D, 2004, BIOCHEMISTRY-US, V43, P14873, DOI 10.1021/bi049498y; Gill DJ, 2007, EMBO J, V26, P600, DOI 10.1038/sj.emboj.7601501; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lim RYH, 2006, CHROMOSOMA, V115, P15, DOI 10.1007/s00412-005-0037-1; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Liu J, 2003, DEV CELL, V5, P487, DOI 10.1016/S1534-5807(03)00262-4; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Plambeck CA, 2003, J BIOL CHEM, V278, P22805, DOI 10.1074/jbc.M301896200; Porter FW, 2006, P NATL ACAD SCI USA, V103, P12417, DOI 10.1073/pnas.0605375103; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; Prunuske AJ, 2006, MOL BIOL CELL, V17, P760, DOI 10.1091/mbc.E05-06-0485; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Schwartz TU, 2005, CURR OPIN STRUC BIOL, V15, P221, DOI 10.1016/j.sbi.2005.03.003; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Slupsky CM, 1998, BIOCHEM CELL BIOL, V76, P379, DOI 10.1139/bcb-76-2-3-379; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; VUISTER GW, 1993, J BIOMOL NMR, V3, P297, DOI 10.1007/BF00212516; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; Yu GW, 2006, PROTEIN SCI, V15, P384, DOI 10.1110/ps.051927306; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	70	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17090	17100		10.1074/jbc.M702715200	http://dx.doi.org/10.1074/jbc.M702715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426026	hybrid			2022-12-25	WOS:000246946500042
J	Ma, CL; Remani, S; Sun, JK; Kotaria, R; Mayor, JA; Walters, DE; Kaplan, RS				Ma, Chunlong; Remani, Sreevidya; Sun, Jiakang; Kotaria, Rusudan; Mayor, June A.; Walters, D. Eric; Kaplan, Ronald S.			Identification of the substrate binding sites within the yeast mitochondrial citrate transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BOVINE HEART-MITOCHONDRIA; TRANSMEMBRANE DOMAIN-III; FATTY-ACID SYNTHESIS; SECONDARY STRUCTURE; REACTION-MECHANISM; ADP/ATP CARRIER; TRICARBOXYLATE CARRIER; TRANSLOCATION PATHWAY; LIKELY COMPRISE	The objective of the present investigation was to identify the substrate binding site(s) within the yeast mitochondrial citrate transport protein (CTP). Our strategy involved kinetically characterizing 30 single-Cys CTP mutants that we had previously constructed based on their hypothesized importance in the structure-based mechanism of this carrier. As part of these studies, a modified transport assay was developed that permitted, for the first time, the accurate determination of Km values that were elevated > 100-fold compared with the Cys- less control value. We identified 10 single-Cys CTP mutants that displayed sharply elevated Km values ( i. e. 5 to > 300-fold). Each of these mutants displayed Vmax values that were reduced by >= 98% and resultant catalytic efficiencies that were reduced by >= 99.9%. Importantly, superposition of this functional data onto the three-dimensional homology- modeled CTP structure, which we previously had developed, revealed that nine of these ten residues form two topographically distinct clusters. Additional modeling showed that: (i) each cluster is capable of forming numerous hydrogen bonds with citrate and (ii) the two clusters are sufficiently distant from one another such that citrate is unlikely to interact with all of these residues at the same time. We deduced from these findings that the CTP contains at least two citrate binding sites per monomer, which are located at increasing depths within the translocation pathway. The identification of these sites, combined with an initial assessment of the citrate- amino acid side- chain interactions that may occur at these sites, substantiallyextendsourunderstanding of CTP functioning at the molecular level.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kaplan, RS (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	Ronald.Kaplan@rosalindfranklin.edu	Ma, Chunlong/AAT-7097-2021; Walters, D. Eric/C-9626-2010; Mayor, June/AAP-1544-2021	Walters, D. Eric/0000-0002-1513-3522; KAPLAN, RONALD/0000-0001-9164-0297	NIGMS NIH HHS [GM-054642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Cascio M, 2004, J BIOENERG BIOMEMBR, V36, P429, DOI 10.1023/B:JOBB.0000047325.48943.71; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Eriks LR, 2003, ANAL BIOCHEM, V323, P234, DOI 10.1016/j.ab.2003.09.002; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; INDIVERI C, 1991, EUR J BIOCHEM, V198, P339, DOI 10.1111/j.1432-1033.1991.tb16021.x; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kihira Y, 2006, J BIOCHEM, V139, P575, DOI 10.1093/jb/mvj052; Kotaria R, 1999, J BIOENERG BIOMEMBR, V31, P543, DOI 10.1023/A:1005460810527; Ma CL, 2006, BBA-BIOENERGETICS, V1757, P1271, DOI 10.1016/j.bbabio.2006.06.011; Ma CL, 2005, J BIOL CHEM, V280, P2331, DOI 10.1074/jbc.M411474200; Ma CL, 2004, J BIOL CHEM, V279, P1533, DOI 10.1074/jbc.M310866200; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Michaelis L, 1913, BIOCHEM Z, V49, P333; Miller C, 2006, NATURE, V440, P484, DOI 10.1038/nature04713; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Robinson AJ, 2006, P NATL ACAD SCI USA, V103, P2617, DOI 10.1073/pnas.0509994103; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; Walters DE, 2004, BIOPHYS J, V87, P907, DOI 10.1529/biophysj.104.042127; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Xu Y, 2000, J BIOL CHEM, V275, P7117, DOI 10.1074/jbc.275.10.7117; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	35	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17210	17220		10.1074/jbc.M611268200	http://dx.doi.org/10.1074/jbc.M611268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17400551	hybrid			2022-12-25	WOS:000246946500054
J	Zederbauer, M; Furtmuller, PG; Bellei, M; Stampler, J; Jakopitsch, C; Battistuzzi, G; Moguilevsky, N; Obinger, C				Zederbauer, Martina; Furtmueller, Paul G.; Bellei, Marzia; Stampler, Johanna; Jakopitsch, Christa; Battistuzzi, Gianantonio; Moguilevsky, Nicole; Obinger, Christian			Disruption of the aspartate to heme ester linkage in human myeloperoxidase - Impact on ligand binding, redox chemistry, and interconversion of redox intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; HUMAN RECOMBINANT MYELOPEROXIDASE; SITE-DIRECTED MUTAGENESIS; EOSINOPHIL PEROXIDASE; HYDROGEN-PEROXIDE; COMPOUND-I; ANGSTROM RESOLUTION; LACTOPEROXIDASE; THIOCYANATE; MUTANTS	In human heme peroxidases the prosthetic group is covalently attached to the protein via two ester linkages between conserved glutamate and aspartate residues and modified methyl groups on pyrrole rings A and C. Here, monomeric recombinant myeloperoxidase (MPO) and the variants D94V and D94N were produced in Chinese hamster ovary cell lines. Disruption of the Asp(94) to heme ester bond decreased the one-electron reduction potential E '(0) [Fe(III)/ Fe(II)] from 1 to -55 mV at pH 7.0 and 25 C, whereas the kinetics of binding of low spin ligands and of compound I formation was unaffected. By contrast, in both variants rates of compound I reduction by chloride and bromide (but not iodide and thiocyanate) were substantially decreased compared with the wild-type protein. Bimolecular rates of compound II (but not compound I) reduction by ascorbate and tyrosine were slightly diminished in D94V and D94N. The presented biochemical and biophysical data suggest that the Asp94 to heme linkage is no precondition for the autocatalytic formation of the other two covalent links found in MPO. The findings are discussed with respect to the known active site structure of MPO and its complexes with ligands.	BOKU Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, A-1190 Vienna, Austria; Univ Modena, Dept Chem, I-41100 Modena, Italy; Univ Namur, Technol Transfer Off, B-5000 Namur, Belgium	University of Natural Resources & Life Sciences, Vienna; Universita di Modena e Reggio Emilia; University of Namur	Obinger, C (corresponding author), BOKU Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Battistuzzi, Gianantonio/L-7183-2015; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Battistuzzi, Gianantonio/0000-0003-4716-5745; Jakopitsch, Christa/0000-0002-5855-2057; Obinger, Christian/0000-0002-7133-3430				Arnhold J, 2003, REDOX REP, V8, P179, DOI 10.1179/135100003225002664; Arnhold J, 2001, EUR J BIOCHEM, V268, P5142, DOI 10.1046/j.0014-2956.2001.02449.x; Battistuzzi G, 2006, BIOCHEMISTRY-US, V45, P12750, DOI 10.1021/bi061647k; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brogioni S, 2006, J RAMAN SPECTROSC, V37, P263, DOI 10.1002/jrs.1442; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Colas C, 2004, J BIOL CHEM, V279, P24131, DOI 10.1074/jbc.M401687200; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; DAIVASU H, 2000, J MOL EVOL, V31, P433; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; Dunforb HB, 1999, HEME PEROXIDASES, P349; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Ferrari RP, 1997, J INORG BIOCHEM, V68, P17, DOI 10.1016/S0162-0134(97)00003-2; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PG, 2000, FEBS LETT, V484, P139, DOI 10.1016/S0014-5793(00)02143-8; Furtmuller PG, 2006, ARCH BIOCHEM BIOPHYS, V445, P199, DOI 10.1016/j.abb.2005.09.017; Furtmuller PG, 2005, J INORG BIOCHEM, V99, P1220, DOI 10.1016/j.jinorgbio.2005.02.021; Furtmuller PG, 2002, BIOCHEMISTRY-US, V41, P11895, DOI 10.1021/bi026326x; Furtmuller PG, 2001, FEBS LETT, V503, P147, DOI 10.1016/S0014-5793(01)02725-9; Furtmuller PG, 2000, BIOCHEMISTRY-US, V39, P15578, DOI 10.1021/bi0020271; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; Ihalin R, 2006, ARCH BIOCHEM BIOPHYS, V445, P261, DOI 10.1016/j.abb.2005.07.004; JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y; JACQUET A, 1994, BIOCHEM BIOPH RES CO, V202, P73, DOI 10.1006/bbrc.1994.1895; Jantschko W, 2002, ARCH BIOCHEM BIOPHYS, V398, P12, DOI 10.1006/abbi.2001.2674; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Kooter IM, 1997, J BIOL INORG CHEM, V2, P191, DOI 10.1007/s007750050124; Kooter IM, 1999, EUR J BIOCHEM, V264, P211, DOI 10.1046/j.1432-1327.1999.00606.x; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; SMULEVICH G, 1995, BIOCHEMISTRY-US, V34, P13485, DOI 10.1021/bi00041a028; Suriano G, 2001, BIOORG MED CHEM LETT, V11, P2827, DOI 10.1016/S0960-894X(01)00533-9; Taurog A, 1999, BIOCHIMIE, V81, P557, DOI 10.1016/S0300-9084(99)80110-2; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; Wang JG, 2006, ARCH BIOCHEM BIOPHYS, V445, P256, DOI 10.1016/j.abb.2005.10.008; Zederbauer M, 2005, BIOCHEMISTRY-US, V44, P6482, DOI 10.1021/bi0501737; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	50	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17041	17052		10.1074/jbc.M610685200	http://dx.doi.org/10.1074/jbc.M610685200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17438335	hybrid			2022-12-25	WOS:000246946500037
J	Guazzaroni, ME; Gallegos, MT; Ramos, JL; Krell, T				Guazzaroni, Maria-Eugenia; Gallegos, Maria-Trinidad; Ramos, Juan L.; Krell, Tino			Different modes of binding of mono- and biaromatic effectors to the transcriptional regulator - Role in differential derepression from its cognate operator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMP; PSEUDOMONAS-PUTIDA DOT-T1E; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; MUTATIONAL ANALYSIS; PROTEIN; INDOLE; EXPRESSION	Members of the IclR family of regulators exhibit a highly conserved effector recognition domain and interact with a limited number of effectors. In contrast with most IclR family members, TtgV, the transcriptional repressor of the TtgGHI efflux pump, exhibits multidrug recognition properties. A three-dimensional model of the effector domain of TtgV was generated based on the available three- dimensional structure of several IclR members, and a series of point mutants was created. Using isothermal titration calorimetry, we determined the binding parameters of the most efficient effectors for TtgV and its mutant variants. All mutants bound biaromatic compounds with higher affinity than the wild-type protein, whereas monoaromatic compounds were bound with lower affinity. This tendency was particularly pronounced for mutants F134A and H200A. TtgVF134A bound 4-nitrotoluene with an affinity 13- old lower than that of TtgV (17.4 +/- 0.6 mu M). This mutant bound 1-naphthol with an affinity of 5.7 mu M, which is seven times as great as that of TtgV (40 mu M). The TtgVV223A mutant bound to DNA with the same affinity as the wild- type TtgV protein, but it remained bound to the target operator in the presence of effectors, suggesting that Val-223 could be part of an intra- TtgV signal recognition pathway. Thermodynamic analyses of the binding of effectors to TtgV and to its mutants in complex with their target DNA revealed that the binding of biaromatic compounds resulted in a more efficient release of the repressor protein than the binding of monoaromatics. The physiological significance of these findings is discussed.	CSIC, Estac Expt Zaidin, Dept Environm Protect, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Ramos, JL (corresponding author), CSIC, Estac Expt Zaidin, Dept Environm Protect, Calle Prof Albareda,Numero 1, E-18008 Granada, Spain.	jlramos@eez.csic.es	Guazzaroni, María Eugenia MEG/E-2599-2013; Krell, Tino/G-7296-2015; Gallegos, María-Trinidad M.T./K-6501-2014; Guazzaroni, María-Eugenia/Y-9268-2019	Guazzaroni, María Eugenia MEG/0000-0002-4657-3731; Krell, Tino/0000-0002-9040-3166; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Guazzaroni, María-Eugenia/0000-0002-4657-3731; Ramos, Juan L./0000-0002-8731-7435				AHMED M, 1994, J BIOL CHEM, V28, P506; Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; CLAUS G, 1983, SYST APPL MICROBIOL, V4, P169, DOI 10.1016/S0723-2020(83)80046-0; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Desrosiers DC, 2005, J MOL BIOL, V354, P375, DOI 10.1016/j.jmb.2005.09.045; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Fasolini M, 2003, J BIOL CHEM, V278, P21092, DOI 10.1074/jbc.M301781200; Friemann R, 2005, J MOL BIOL, V348, P1139, DOI 10.1016/j.jmb.2005.03.052; Garbe TR, 2000, ARCH MICROBIOL, V173, P78, DOI 10.1007/s002030050012; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; Guazzaroni ME, 2004, J BACTERIOL, V186, P2921, DOI 10.1128/JB.186.10.2921-2927.2004; Hirakawa H, 2005, MOL MICROBIOL, V55, P1113, DOI 10.1111/j.1365-2958.2004.04449.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Kahramanoglou C, 2006, J BACTERIOL, V188, P3199, DOI 10.1128/JB.188.9.3199-3207.2006; KAMATH AV, 1990, APPL ENVIRON MICROB, V56, P275, DOI 10.1128/AEM.56.1.275-280.1990; Kawamura-Sato K, 1999, FEMS MICROBIOL LETT, V179, P345, DOI 10.1016/S0378-1097(99)00433-4; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Krell T, 2006, PROTEIN SCI, V15, P1207, DOI 10.1110/ps.051857206; MADSEN EL, 1988, APPL ENVIRON MICROB, V54, P74, DOI 10.1128/AEM.54.1.74-78.1988; Molina-Henares AJ, 2006, FEMS MICROBIOL REV, V30, P157, DOI 10.1111/j.1574-6976.2005.00008.x; Mosqueda G, 2000, J BACTERIOL, V182, P937, DOI 10.1128/JB.182.4.937-943.2000; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Reed WL, 1999, J MOL BIOL, V294, P417, DOI 10.1006/jmbi.1999.3224; Rintoul MR, 2002, J MOL BIOL, V324, P599, DOI 10.1016/S0022-2836(02)01134-8; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Salto R, 1998, J BACTERIOL, V180, P600, DOI 10.1128/JB.180.3.600-604.1998; Sazinsky MH, 2004, J BIOL CHEM, V279, P30600, DOI 10.1074/jbc.M400710200; Scholz O, 2003, J MOL BIOL, V329, P217, DOI 10.1016/S0022-2836(03)00427-3; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; Su CC, 2006, J BACTERIOL, V188, P7290, DOI 10.1128/JB.00684-06; Teran W, 2006, J BIOL CHEM, V281, P7102, DOI 10.1074/jbc.M511095200; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Walker JR, 2006, J MOL BIOL, V358, P810, DOI 10.1016/j.jmb.2006.02.034; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; ZHOU LM, 1990, J BACTERIOL, V172, P3707, DOI 10.1128/jb.172.7.3707-3710.1990	52	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16308	16316		10.1074/jbc.M610032200	http://dx.doi.org/10.1074/jbc.M610032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416591	hybrid			2022-12-25	WOS:000246794300038
J	May, MJ; Madge, LA				May, Michael J.; Madge, Lisa A.			Caspase inhibition sensitizes inhibitor of NF-kappa B kinase beta-deficient fibroblasts to caspase-independent cell death via the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; IKK-ALPHA; GENE-EXPRESSION; ENDOTHELIAL-CELLS; JNK ACTIVATION; TARGET GENES; RECEPTOR; REVEALS; BAX	Cells lacking functional NF-kappa B die after ligation of some tumor necrosis factor (TNF) receptor family members through failure to express NF-kappa B-dependent anti-apoptotic genes. NF-kappa B activation requires the I kappa B kinase (IKK) complex containing two catalytic subunits named IKK alpha and IKK beta that regulate distinct NF-kappa B pathways. IKK beta is critical for classical signaling that induces pro- inflammatory and anti-apoptotic gene profiles, whereas IKK alpha regulates the non-canonical pathway involved in lymphoid organogenesis and B- cell development. To determine whether IKK alpha and IKK alpha differentially function in rescuing cells from death induced by activators of the classical and non-canonical pathways, we analyzed death after ligation of the TNF and lymphotoxin-receptors, respectively. Using murine embryonic fibroblasts (MEFs) lacking each of the IKKs, the caspase inhibitor benzyloxycarbonyl- Val-Ala-Asp-fluoromethyl ketone, and dominant negative Fas-associated death domain protein, we found that deletion of these kinases sensitized MEFs to distinct cell death pathways. MEFs lacking IKK alpha were sensitized to death in response to both cytokines that was entirely caspase-dependent, demonstrating that IKK beta functions in this process. Surprisingly, death of IKK beta(-/-) MEFs was not blocked by caspase inhibition, demonstrating that IKK beta negatively regulates caspase-independent cell death (CICD). CICD was strongly activated by both TNF and lymphotoxin-beta receptor ligation in IKK beta(-/-) MEFs and was accompanied by loss of mitochondrial membrane potential and the generation of reactive oxygen species. CICD was inhibited by the anti- oxidant butylated hydroxyanosole and overexpression of Bcl-2, neither of which blocked caspase-dependent apoptosis. Our findings, therefore, demonstrate that both IKK alpha and IKK beta regulate cytokineinduced apoptosis, and IKK beta additionally represses reactive oxygen species- and mitochondrial- dependent CICD.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu		May, Michael/0000-0002-2485-3716	NHLBI NIH HHS [1R01HL080612-01A1, R01 HL080612, R01 HL080612-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; CHINNAIYAN AM, 1995, CELL, V81, P512; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Massa PE, 2005, J BIOL CHEM, V280, P14057, DOI 10.1074/jbc.M414401200; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thon L, 2005, FASEB J, V19, P1945, DOI 10.1096/fj.05-3726com; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16105	16116		10.1074/jbc.M611115200	http://dx.doi.org/10.1074/jbc.M611115200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430892	hybrid, Green Accepted			2022-12-25	WOS:000246794300019
J	Si, J; Fu, XY; Behar, J; Wands, J; Beer, DG; Souza, RF; Spechler, SJ; Lambeth, D; Cao, WB				Si, Jin; Fu, Xiaoying; Behar, Jose; Wands, Jack; Beer, David G.; Souza, Rhonda F.; Spechler, Stuart J.; Lambeth, David; Cao, Weibiao			NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappa B in Barrett's esophageal adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-2; SELECTIVE-INHIBITION; COX-2 INHIBITORS; CAT ESOPHAGEAL; APOPTOSIS; CANCER; PURIFICATION; CONTRACTION; INCREASES; REFLUX	We have shown that the NADPH oxidase NOX5-S may play an important role in the progression from Barrett's esophagus to esophageal adenocarcinoma (EA) by increasing cell proliferation and decreasing apoptosis. However, the mechanism of the acid-induced NOX5-S-mediated increase in cell proliferation is not known. We found that, in SEG1 EA cells, the acid- induced increase in prostaglandin E-2 (PGE(2)) production was mediated by activation of cyclooxygenase-2 (COX2) but not by COX1. Acid treatment increased intracellular Ca2+, and a blockade of intracellular Ca2+ increase inhibited the acid-induced increase in COX2 expression and PGE(2) production. Knockdown of NOX5-S or NF-kappa B1 p50 by their small interfering RNA significantly inhibited acid- induced COX2 expression and PGE(2) production in SEG1 cells. Acid treatment significantly decreased I kappa B alpha and increased luciferase activity when SEG1 cells were transfected with an NF-kappa B in vivo activation reporter plasmid, pNF-kappa B-Luc. In a novel Barrett's cell line overexpressing NOX5-S, I kappa B alpha was significantly reduced, and luciferase activity increased when these Barrett's cells were transfected with pNF-kappa B-Luc. Overexpression of NOX5-S in Barrett's cells significantly increased H2O2 production, COX2 expression, PGE(2) production, and thymidine incorporation. The increase in thymidine incorporation occurring in NOX5-S-overexpressing Barrett's cells or induced by acid treatment in SEG1 EA cells was significantly decreased by COX2 inhibitors or small interfering RNA. We conclude that acid-induced COX2 expression and PGE(2) production depend on an increase in cytosolic Ca2+ and sequential activation of NOX5-S and NF-kappa B in SEG1 cells. COX2-derived PGE(2) production may contribute to NOX5-S-mediated cell proliferation in SEG1 cells.	Brown Univ, Dept Med, Sch Med, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Div Gastroenterol, Dallas, TX 76235 USA; Univ Texas, SW Med Ctr, Dallas, TX 76235 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Michigan System; University of Michigan; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cao, WB (corresponding author), Brown Univ, Dept Med, Sch Med, 55 Claverick St,Rm 337, Providence, RI 02903 USA.	wcao@hotmail.com			NCRR NIH HHS [P20 RR17695] Funding Source: Medline; NIDDK NIH HHS [R21 DK073327-01, R21 DK073327] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073327] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cao W, 2001, AM J PHYSIOL-CELL PH, V280, pC980, DOI 10.1152/ajpcell.2001.280.4.C980; Cao WB, 2004, AM J PHYSIOL-GASTR L, V286, pG833, DOI 10.1152/ajpgi.00414.2003; Cao WB, 2003, AM J PHYSIOL-GASTR L, V285, pG86, DOI 10.1152/ajpgi.00156.2002; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu Y, 2003, J BIOL CHEM, V278, P17210, DOI 10.1074/jbc.M210314200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Habeeb AG, 2000, DRUG DEVELOP RES, V51, P273, DOI 10.1002/ddr.9; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; Hughes SJ, 1997, CANCER RES, V57, P5571; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Liu XH, 1998, CANCER RES, V58, P4245; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Morales CP, 2003, GUT, V52, P327, DOI 10.1136/gut.52.3.327; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Paik JH, 2000, J BIOL CHEM, V275, P28173; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Shaheen NJ, 2005, GASTROENTEROLOGY, V128, P1554, DOI 10.1053/j.gastro.2005.03.032; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Sooriakumaran P, 2006, POSTGRAD MED J, V82, P242, DOI 10.1136/pgmj.2005.042234; Souza RF, 2000, CANCER RES, V60, P5767; Souza RF, 2004, AM J PHYSIOL-GASTR L, V287, pG743, DOI 10.1152/ajpgi.00144.2004; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Trier J S, 1980, Methods Cell Biol, V21B, P365; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166; Yan XJ, 2002, BIOL REPROD, V66, P1667, DOI 10.1095/biolreprod66.6.1667; Zimmermann KC, 1999, CANCER RES, V59, P198	52	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16244	16255		10.1074/jbc.M700297200	http://dx.doi.org/10.1074/jbc.M700297200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403674	hybrid			2022-12-25	WOS:000246794300032
J	Moulson, CL; Lin, MH; White, JM; Newberry, EP; Davidson, NO; Miner, JH				Moulson, Casey L.; Lin, Meei-Hua; White, J. Michael; Newberry, Elizabeth P.; Davidson, Nicholas O.; Miner, Jeffrey H.			Keratinocyte-specific expression of fatty acid transport protein 4 rescues the wrinkle-free phenotype in Slc27a4/Fatp4 mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; HUMAN INVOLUCRIN PROMOTER; PERMEABILITY BARRIER FUNCTION; RESTRICTIVE DERMOPATHY; HARLEQUIN ICHTHYOSIS; TETRAPLOID CELLS; LAMIN-A; MOUSE; PROTEIN-4; SKIN	FATP4 (fatty acid transport protein 4; also known as SLC27A4) is the most widely expressed member of a family of six long chain fatty acid transporters. FATP4 is highly expressed in enterocytes and has therefore been proposed to be a major importer of dietary fatty acids. Two independent mutations in Fatp4 cause mice to be born with thick, tight, shiny, "wrinkle-free" skin and a defective skin barrier; they die within hours of birth from dehydration and restricted movements. In contrast, induced keratinocyte-specific deficiency of FATP4 in adult mice causes only mild skin abnormalities. Therefore, whether the loss of FATP4 from skin or a systemic gestational metabolic defect causes the severe skin defects and neonatal lethality remain important unanswered questions. To investigate the basis for the phenotype, we first generated wild-type tetraploid/mutant diploid aggregates that should lead to rescue of any abnormalities caused by loss of FATP4 from the placenta. However, the skin phenotype was not ameliorated. We then generated transgenic mice expressing exogenous FATP4 either widely or specifically in suprabasal keratinocytes, and we bred the transgenes onto the Fatp4(-/-) background. Both modes of FATP4 expression led to rescue of the neonatally lethal skin defects, and the resulting mice were viable and fertile. Keratinocyte expression of an FATP4 variant with mutations in the acyl-CoA synthetase domain did not provide any degree of rescue. We conclude that expression of FATP4 with an intact acyl-CoA synthetase domain in suprabasal keratinocytes is necessary for normal skin development and that FATP4 functions in establishing the cornified envelope.	Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Miner, JH (corresponding author), Washington Univ, Sch Med, Div Renal, Dept Internal Med, 660 S Euclid Ave,Box 8126, St Louis, MO 63110 USA.	minerj@wustl.edu		White, James Michael/0000-0001-5110-6567	NCRR NIH HHS [C06RR015502, P41RR000954] Funding Source: Medline; NHLBI NIH HHS [R37HL038180] Funding Source: Medline; NIAMS NIH HHS [R01 AR049269-02, R01 AR049269-03, R01AR049269, R01 AR049269-01A1, R01 AR049269] Funding Source: Medline; NIDDK NIH HHS [P60DK020579, P30 DK056341-06, P30DK056341, P30 DK056341-07, P30 DK056341, K01DK075811, R01DK056260, P30DK052574] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015502, P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK056341, P30DK052574, K01DK075811, R01DK056260] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI24834; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cameron DJ, 2007, INT J BIOL SCI, V3, P111; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; DiRusso CC, 2005, J BIOL CHEM, V280, P16829, DOI 10.1074/jbc.M409598200; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; ELIAS PM, 1978, LAB INVEST, V39, P574; FOUNDATION N, 1969, NUTR REV, V27, P85; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; Goto Y, 2002, INT J DEV BIOL, V46, P741; Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11; Haggarty P, 2004, EUR J CLIN NUTR, V58, P1559, DOI 10.1038/sj.ejcn.1602016; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Herrera E, 2002, PLACENTA, V23, pS9, DOI 10.1053/plac.2002.0771; Herrmann T, 2005, J INVEST DERMATOL, V125, P1228, DOI 10.1111/j.0022-202X.2005.23972.x; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hovnanian A, 2005, J CLIN INVEST, V115, P1708, DOI 10.1172/JCI25736; JAMES RM, 1995, DEV BIOL, V167, P213, DOI 10.1006/dbio.1995.1018; Larque E, 2006, EARLY HUM DEV, V82, P697, DOI 10.1016/j.earlhumdev.2006.02.001; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Li WM, 2007, INT J BIOL SCI, V3, P120; Milger K, 2006, J CELL SCI, V119, P4678, DOI 10.1242/jcs.03280; MIYAZAKI J, 1989, GENE, V79, P269; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; Moulson CL, 2005, J INVEST DERMATOL, V125, P913, DOI 10.1111/j.0022-202X.2005.23846.x; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Navarro CL, 2004, HUM MOL GENET, V13, P2493, DOI 10.1093/hmg/ddh265; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; PROTTEY C, 1976, BRIT J DERMATOL, V94, P579, DOI 10.1111/j.1365-2133.1976.tb05151.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rossant J., 2002, MOUSE DEV PATTERNING, P155; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schmuth M, 2005, J INVEST DERMATOL, V125, P1174, DOI 10.1111/j.0022-202X.2005.23934.x; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; Tanaka M, 2000, METH MOL B, V158, P135; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; VERGROESEN AJ, 1976, BIBL NUTR DIET, P19	53	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15912	15920		10.1074/jbc.M701779200	http://dx.doi.org/10.1074/jbc.M701779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17401141	hybrid			2022-12-25	WOS:000246589600066
J	Onofri, F; Messa, M; Matafora, V; Bonanno, G; Corradi, A; Bachi, A; Valtorta, F; Benfenati, F				Onofri, Franco; Messa, Mirko; Matafora, Vittoria; Bonanno, Giambattista; Corradi, Anna; Bachi, Angela; Valtorta, Flavia; Benfenati, Fabio			Synapsin phosphorylation by Src tyrosine kinase enhances Src activity in synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NEUROTRANSMITTER RELEASE; F-ACTIN; GLUTAMATE RELEASE; NERVE-TERMINALS; FAMILY KINASES; SH2 DOMAINS; C-SRC; PROTEIN; SYNAPTOSOMES	Synapsins are synaptic vesicle-associated phosphoproteins implicated in the regulation of neurotransmitter release. Synapsin I is the major binding protein for the SH3 domain of the kinase c-Src in synaptic vesicles. Its binding leads to stimulation of synaptic vesicle-associated c-Src activity. We investigated the mechanism and role of Src activation by synapsins on synaptic vesicles. We found that synapsin is tyrosine phosphorylated by c-Src in vitro and on intact synaptic vesicles independently of its phosphorylation state on serine. Mass spectrometry revealed a single major phosphorylation site at Tyr(301), which is highly conserved in all synapsin isoforms and orthologues. Synapsin tyrosine phosphorylation triggered its binding to the SH2 domains of Src or Fyn. However, synapsin selectively activated and was phosphorylated by Src, consistent with the specific enrichment of c-Src in synaptic vesicles over Fyn or n-Src. The activity of Src on synaptic vesicles was controlled by the amount of vesicle-associated synapsin, which is in turn dependent on synapsin serine phosphorylation. Synaptic vesicles depleted of synapsin in vitro or derived from synapsin null mice exhibited greatly reduced Src activity and tyrosine phosphorylation of other synaptic vesicle proteins. Disruption of the Src-synapsin interaction by internalization of either the Src SH3 or SH2 domains into synaptosomes decreased synapsin tyrosine phosphorylation and concomitantly increased neurotransmitter release in response to Ca(2+-)ionophores. We conclude that synapsin is an endogenous substrate and activator of synaptic vesicle-associated c-Src and that regulation of Src activity on synaptic vesicles participates in the regulation of neurotransmitter release by synapsin.	Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Italian Inst Technol, Cent Lab, Dept Neurosci & Brain Technol, I-16163 Genoa, Italy; Ist Sci San Raffaele, I-20132 Milan, Italy; San Raffaele Vita Salute Univ, I-20132 Milan, Italy; Italian Inst Technol, Unit Mol Neurosci, I-20132 Milan, Italy	University of Genoa; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Istituto Italiano di Tecnologia - IIT	Benfenati, F (corresponding author), Via Benedetto XV N3, I-16132 Genoa, Italy.	benfenat@unige.it	bachi, angela/B-3527-2015; Corradi, Anna/AAC-5209-2022; Bonanno, Giambattista/C-5856-2008; Flavia, Valtorta/F-3450-2012	bachi, angela/0000-0003-4842-6556; Flavia, Valtorta/0000-0001-9556-4746; matafora, vittoria/0000-0002-4311-998X; Bonanno, Giambattista/0000-0003-3744-5786	Telethon [GGP05134] Funding Source: Medline	Telethon(Fondazione Telethon)		Areces LB, 2004, EUR J MASS SPECTROM, V10, P383, DOI 10.1255/ejms.601; Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; Baldelli P., 2006, MOL MECH EXOCYTOSIS, P1; Baldwin ML, 2006, NEUROCHEM INT, V49, P80, DOI 10.1016/j.neuint.2006.01.002; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Benfenati F, 1999, PHILOS T R SOC B, V354, P243, DOI 10.1098/rstb.1999.0376; Bonanomi D, 2005, J NEUROSCI, V25, P7299, DOI 10.1523/JNEUROSCI.1573-05.2005; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Charpantier E, 2005, J NEUROSCI, V25, P9836, DOI 10.1523/JNEUROSCI.3497-05.2005; Cheetham JJ, 2001, BIOCHEM J, V354, P57, DOI 10.1042/0264-6021:3540057; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Giovedi S, 2004, J BIOL CHEM, V279, P43769, DOI 10.1074/jbc.M404168200; Gitler D, 2004, J NEUROSCI, V24, P11368, DOI 10.1523/JNEUROSCI.3795-04.2004; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hayashi T, 2004, J NEUROSCI, V24, P6152, DOI 10.1523/JNEUROSCI.0799-04.2004; Hilfiker S, 2005, J NEUROSCI, V25, P2658, DOI 10.1523/JNEUROSCI.4278-04.2005; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JENSEN ES, 1998, P 11 INT WORLD FERT, V2, P89; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kalia LV, 2004, ONCOGENE, V23, P8007, DOI 10.1038/sj.onc.1208158; Kao HT, 1999, J EXP ZOOL, V285, P360, DOI 10.1002/(SICI)1097-010X(19991215)285:4<360::AID-JEZ4>3.3.CO;2-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nielander HB, 1997, EUR J NEUROSCI, V9, P2712, DOI 10.1111/j.1460-9568.1997.tb01700.x; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OKADA M, 1991, J BIOL CHEM, V266, P24249; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Purcell AL, 2003, TRENDS NEUROSCI, V26, P625, DOI 10.1016/j.tins.2003.09.005; Raiteri M, 2000, J NEUROCHEM, V74, P423, DOI 10.1046/j.1471-4159.2000.0740423.x; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; Schenk U, 2005, J NEUROSCI, V25, P1654, DOI 10.1523/JNEUROSCI.3074-04.2005; Sheinerman FB, 2003, J MOL BIOL, V334, P823, DOI 10.1016/j.jmb.2003.09.075; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shyu KG, 2005, NEUROREPORT, V16, P1969, DOI 10.1097/01.wnr.0000189758.57164.85; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; Stefani G, 1997, J PHYSIOL-LONDON, V504, P501, DOI 10.1111/j.1469-7793.1997.501bd.x; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Stigliani S, 2003, J NEUROCHEM, V85, P409, DOI 10.1046/j.1471-4159.2003.01689.x; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Vaccaro P, 1997, MOL BRAIN RES, V52, P1, DOI 10.1016/S0169-328X(97)00219-2; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; Wang SJ, 2003, NEUROREPORT, V14, P1519, DOI 10.1097/00001756-200308060-00024; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15754	15767		10.1074/jbc.M701051200	http://dx.doi.org/10.1074/jbc.M701051200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400547	hybrid			2022-12-25	WOS:000246589600051
J	Soltani, CE; Hotze, EM; Johnson, AE; Tweten, RK				Soltani, Casie E.; Hotze, Eileen M.; Johnson, Arthur E.; Tweten, Rodney K.			Specific protein-membrane contacts are required for prepore and pore assembly by a cholesterol-dependent cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE BETA-HAIRPINS; THIOL-ACTIVATED CYTOLYSIN; TOXIN PERFRINGOLYSIN-O; CLOSTRIDIUM-PERFRINGENS; THETA-TOXIN; CONFORMATIONAL-CHANGES; TRYPTOPHAN RESIDUES; LIPOSOMAL MEMBRANES; BINDING CYTOLYSIN; MECHANISM	Three short hydrophobic loops and a conserved undecapeptide at the tip of domain 4 (D4) of the cholesterol-dependent cytolysins (CDCs) mediate the binding of the CDC monomers to cholesterol-rich cell membranes. But intermedilysin (ILY), from Streptococcus intermedius, does not bind to cholesterol-rich membranes unless they contain the human protein CD59. This observation suggested that the D4 loops, which include loops L1-L3 and the undecapeptide, of ILY were no longer required for its cell binding. However, we show here that membrane insertion of the D4 loops is required for the cytolysis by ILY. Receptor binding triggers changes in the structure of ILY that are necessary for oligomerization, but membrane insertion of the D4 loops is critical for oligomer assembly and pore formation. Defects that prevent membrane insertion of the undecapeptide also block assembly of the prepore oligomer, while defects in the membrane insertion of the L1-L3 loops prevent the conversion of the prepore oligomer to the pore complex. These studies reveal that pore formation by ILY, and probably other CDCs, is affected by an intricate and coupled sequence of interactions between domain 4 and the membrane.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem & Biochem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biophys, College Stn, TX 77843 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, BMSB 1053, Oklahoma City, OK 73104 USA.	Rod-Tweten@ouhsc.edu	Johnson, Arthur E/G-3457-2012		NIAID NIH HHS [R01 AI037657, R37 AI037657, AI037657] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; ALOUF JE, 1999, BACTERIAL TOXINS COM; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Heuck AP, 2003, J BIOL CHEM, V278, P31218, DOI 10.1074/jbc.M303151200; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; IWAMOTO M, 1987, EUR J BIOCHEM, V167, P425, DOI 10.1111/j.1432-1033.1987.tb13355.x; Nagamune H, 2004, MICROBIOL IMMUNOL, V48, P677, DOI 10.1111/j.1348-0421.2004.tb03479.x; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; OHNOIWASHITA Y, 1991, J BIOCHEM-TOKYO, V110, P369, DOI 10.1093/oxfordjournals.jbchem.a123588; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Polekhina G, 2005, P NATL ACAD SCI USA, V102, P600, DOI 10.1073/pnas.0403229101; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Ramachandran R, 2005, P NATL ACAD SCI USA, V102, P7139, DOI 10.1073/pnas.0500556102; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SekinoSuzuki N, 1996, EUR J BIOCHEM, V241, P941, DOI 10.1111/j.1432-1033.1996.00941.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Shimada Y, 2002, EUR J BIOCHEM, V269, P6195, DOI 10.1046/j.1432-1033.2002.03338.x; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033	31	65	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15709	15716		10.1074/jbc.M701173200	http://dx.doi.org/10.1074/jbc.M701173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17412689	Green Accepted, hybrid			2022-12-25	WOS:000246589600047
J	Bayburt, TH; Leitz, AJ; Xie, GF; Oprian, DD; Sligar, SG				Bayburt, Timothy H.; Leitz, Andrew J.; Xie, Guifu; Oprian, Daniel D.; Sligar, Stephen G.			Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GTP-BINDING PROTEIN; METARHODOPSIN-II; LIGHT-SCATTERING; DIMERS; CYTOCHROME-P450; RECONSTITUTION; NANODISCS; COMPLEX; ENERGY	Nanodiscs are nanometer scale planar membranes of controlled size that are rendered soluble in aqueous solution via an encircling amphipathic membrane scaffold protein "belt" (Bayburt, T. H., Grinkova, Y. V., and Sligar, S. G. (2002) Nano. Lett. 2, 853-856). Integral membrane proteins can be self-assembled into the Nanodisc bilayer with defined stoichiometry, which allows an unprecedented opportunity to investigate the nature of the oligomerization state of a G-protein-coupled receptor and its coupling to heterotrimeric G-proteins. We generated Nanodiscs having one and two rhodopsins present in the 10-nm-diameter lipid bilayer domain. Efficient transducin activation and isolation of a high affinity transducin-metarhodopsin II complex was demonstrated for a monodisperse and monomeric receptor. A population of Nanodiscs containing two rhodopsins was generated using an increased ratio of receptor to membrane scaffold protein in the self-assembly mixture. The two-rhodopsin population was isolated and purified by density gradient centrifugation. Interestingly, in this case, only one of the two receptors present in the Nanodisc was able to form a stable metarhodopsin II-G-protein complex. Thus there is clear evidence that a monomeric rhodopsin is capable of full coupling to transducin. Importantly, presumably due to steric interactions, it appears that only a single receptor in the Nanodiscs containing two rhodopsins can interact with G-protein. These results have important implications for the stoichiometry of receptor-G-protein coupling and cross talk in signaling pathways.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, 116 Morrill Hall,505 S Goodwin, Urbana, IL 61801 USA.	s-sligar@uiuc.edu			NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775, R41GM075362] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2006, ARCH BIOCHEM BIOPHYS, V450, P215, DOI 10.1016/j.abb.2006.03.013; BENNETT N, 1985, J BIOL CHEM, V260, P4156; Boldog T, 2006, P NATL ACAD SCI USA, V103, P11509, DOI 10.1073/pnas.0604988103; BOROCHOVNEORI H, 1983, BIOCHEMISTRY-US, V22, P206, DOI 10.1021/bi00270a030; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CROUCH R, 1975, P NATL ACAD SCI USA, V72, P1538, DOI 10.1073/pnas.72.4.1538; Denisov IG, 2005, J PHYS CHEM B, V109, P15580, DOI 10.1021/jp051385g; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; EMEIS D, 1981, FEBS LETT, V136, P201, DOI 10.1016/0014-5793(81)80618-7; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Funari SS, 2001, P NATL ACAD SCI USA, V98, P8938, DOI 10.1073/pnas.161160998; Gibson SK, 1998, BIOCHEMISTRY-US, V37, P11393, DOI 10.1021/bi980933w; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; Milligan G, 2005, FEBS J, V272, P2914, DOI 10.1111/j.1742-4658.2005.04731.x; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; TAYA K, 2002, T MAT RES SOC JPN, V27, P605; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697	46	290	297	0	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14875	14881		10.1074/jbc.M701433200	http://dx.doi.org/10.1074/jbc.M701433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395586	hybrid			2022-12-25	WOS:000246589000024
J	Leucht, P; Kim, JB; Currey, JA; Brunski, J; Helms, JA				Leucht, Philipp; Kim, Jae-Beom; Currey, Jennifer A.; Brunski, John; Helms, Jill A.			FAK-Mediated Mechanotransduction in Skeletal Regeneration	PLOS ONE			English	Article							IN-VITRO; MECHANICAL STRAIN; STEM-CELLS; ARTICULAR-CARTILAGE; FOCAL ADHESIONS; POISSONS RATIO; BONE; DIFFERENTIATION; OSTEOBLAST; COLLAGEN	The majority of cells are equipped to detect and decipher physical stimuli, and then react to these stimuli in a cell type-specific manner. Ultimately, these cellular behaviors are synchronized to produce a tissue response, but how this is achieved remains enigmatic. Here, we investigated the genetic basis for mechanotransduction using the bone marrow as a model system. We found that physical stimuli produced a pattern of principal strain that precisely corresponded to the site-specific expression of sox9 and runx2, two transcription factors required for the commitment of stem cells to a skeletogenic lineage, and the arrangement and orientation of newly deposited type I collagen fibrils. To gain insights into the genetic basis for skeletal mechanotransduction we conditionally inactivated focal adhesion kinase (FAK), an intracellular component of the integrin signaling pathway. By doing so we abolished the mechanically induced osteogenic response and thus identified a critical genetic component of the molecular machinery required for mechanotransduction. Our data provide a new framework in which to consider how physical forces and molecular signals are synchronized during the program of skeletal regeneration.	[Leucht, Philipp; Kim, Jae-Beom; Helms, Jill A.] Stanford Univ, Dept Surg, Div Plast & Reconstruct Surg, Stanford, CA 94305 USA; [Leucht, Philipp] Univ Frankfurt Main, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany; [Currey, Jennifer A.; Brunski, John] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA	Stanford University; Goethe University Frankfurt; Rensselaer Polytechnic Institute	Helms, JA (corresponding author), Stanford Univ, Dept Surg, Div Plast & Reconstruct Surg, Stanford, CA 94305 USA.	jhelms@stanford.edu	Leucht, Philipp/H-7238-2019	Leucht, Philipp/0000-0002-8409-8513; Helms, Jill/0000-0002-0463-396X	NIH [RO1-EB00504]; CA Arthritis Foundation;  [FA9550-04-1-0075]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE024000] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CA Arthritis Foundation; ; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Supported by NIH RO1-EB00504 (JBB), N. CA Arthritis Foundation (JBK), and FA9550-04-1-0075 (JAH).	Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Angele P, 2003, J ORTHOPAED RES, V21, P451, DOI 10.1016/S0736-0266(02)00230-9; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Carter DR, 1998, CLIN ORTHOP RELAT R, pS41; Carter DR, 2001, SKELETAL FUNCTION FO; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Claes LE, 1998, CLIN ORTHOP RELAT R, pS132; CLIFFORD DH, 1984, PREANESTHESIA ANESTH, P527; Cummings CL, 2004, BIOMATERIALS, V25, P3699, DOI 10.1016/j.biomaterials.2003.10.073; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; HENCH LL, 1973, J BIOMED MATER RES, V7, P25, DOI 10.1002/jbm.820070304; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ignatius A, 2005, BIOMATERIALS, V26, P311, DOI 10.1016/j.biomaterials.2004.02.045; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Isaksson H, 2006, J BIOMECH, V39, P1507, DOI 10.1016/j.jbiomech.2005.01.037; Jin H, 2004, J BIOMECH ENG-T ASME, V126, P138, DOI 10.1115/1.1688772; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Kim DG, 2005, P I MECH ENG H, V219, P119, DOI 10.1243/095441105X9291; KIM J, 2007, BONE IN PRESS; Kiviranta P, 2006, J ORTHOP RES, V24, P690, DOI 10.1002/jor.20107; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Kurata K, 2001, J BONE MINER RES, V16, P722, DOI 10.1359/jbmr.2001.16.4.722; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Nelson CM, 2004, MOL BIOL CELL, V15, P2943, DOI 10.1091/mbc.E03-10-0745; Nelson CM, 2005, P NATL ACAD SCI USA, V102, P11594, DOI 10.1073/pnas.0502575102; Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471-4914(03)00021-2; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rubin J, 1999, J ORTHOPAED RES, V17, P639, DOI 10.1002/jor.1100170504; Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P103; Shemesh T, 2005, P NATL ACAD SCI USA, V102, P12383, DOI 10.1073/pnas.0500254102; SOBALLE K, 1992, ACTA ORTHOP SCAND, V63, P128, DOI 10.3109/17453679209154808; Thomas GP, 1996, CALCIFIED TISSUE INT, V58, P101, DOI 10.1007/s002239900018; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; WASEEM NH, 1990, J CELL SCI, V96, P121; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021-9290(01)00107-5	48	62	66	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e390	10.1371/journal.pone.0000390	http://dx.doi.org/10.1371/journal.pone.0000390			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460757	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445600004
J	Opel, M; Lando, D; Bonilla, C; Trewick, SC; Boukaba, A; Walfridsson, J; Cauwood, J; Werler, PJH; Carr, AM; Kouzarides, T; Murzina, NV; Allshire, RC; Ekwall, K; Laue, ED				Opel, Michael; Lando, David; Bonilla, Carolina; Trewick, Sarah C.; Boukaba, Abdelhalim; Walfridsson, Julian; Cauwood, James; Werler, Petra J. H.; Carr, Antony M.; Kouzarides, Tony; Murzina, Natalia V.; Allshire, Robin C.; Ekwall, Karl; Laue, Ernest D.			Genome-Wide Studies of Histone Demethylation Catalysed by the Fission Yeast Homologues of Mammalian LSD1	PLOS ONE			English	Article								In order to gain a more global view of the activity of histone demethylases, we report here genome-wide studies of the fission yeast SWIRM and polyamine oxidase (PAO) domain homologues of mammalian LSD1. Consistent with previous work we find that the two S. pombe proteins, which we name Swm1 and Swm2 (after SWIRM1 and SWIRM2), associate together in a complex. However, we find that this complex specifically demethylates lysine 9 in histone H3 (H3K9) and both up-and down-regulates expression of different groups of genes. Using chromatin-immunoprecipitation, to isolate fragments of chromatin containing either H3K4me2 or H3K9me2, and DNA microarray analysis (ChIP-chip), we have studied genome-wide changes in patterns of histone methylation, and their correlation with gene expression, upon deletion of the swm1(+) gene. Using hyper-geometric probability comparisons we uncover genetic links between lysine-specific demethylases, the histone deacetylase Clr6, and the chromatin remodeller Hrp1. The data presented here demonstrate that in fission yeast the SWIRM/PAO domain proteins Swm1 and Swm2 are associated in complexes that can remove methyl groups from lysine 9 methylated histone H3. In vitro, we show that bacterially expressed Swm1 also possesses lysine 9 demethylase activity. In vivo, loss of Swm1 increases the global levels of both H3K9me2 and H3K4me2. A significant accumulation of H3K4me2 is observed at genes that are up-regulated in a swm1 deletion strain. In addition, H3K9me2 accumulates at some genes known to be direct Swm1/2 targets that are down-regulated in the swm1 Delta strain. The in vivo data indicate that Swm1 acts in concert with the HDAC Clr6 and the chromatin remodeller Hrp1 to repress gene expression. In addition, our in vitro analyses suggest that the H3K9 demethylase activity requires an unidentified post-translational modification to allow it to act. Thus, our results highlight complex interactions between histone demethylase, deacetylase and chromatin remodelling activities in the regulation of gene expression.	[Trewick, Sarah C.; Boukaba, Abdelhalim; Allshire, Robin C.] Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland; [Opel, Michael; Cauwood, James; Murzina, Natalia V.; Laue, Ernest D.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Lando, David; Kouzarides, Tony] Gurdon Inst, Cambridge, England; [Lando, David; Kouzarides, Tony] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; [Bonilla, Carolina; Walfridsson, Julian; Ekwall, Karl] Univ Coll Sodertorn, Karolinska Inst, Sch Life Sci, Dept Biosci, Huddinge, Sweden; [Werler, Petra J. H.; Carr, Antony M.] Univ Sussex, Sch Biol Sci, Genome Damage & Stabil Ctr, Falmer, Sussex, England	University of Edinburgh; University of Cambridge; University of Cambridge; Karolinska Institutet; Sodertorn University; University of Sussex	Allshire, RC (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland.	robin.allshire@ed.ac.uk; karl.ekwall@sh.se; e.d.laue@bioc.cam.ac.uk	Lando, David/AAH-3052-2019; Lando, David/A-2546-2010	Lando, David/0000-0001-5783-8769; Ekwall, Karl/0000-0002-3029-4041; Carr, Antony Michael/0000-0002-2028-2389; Laue, Ernest/0000-0002-7476-4148; Allshire, Robin/0000-0002-8005-3625; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust; Knut and Alice Wallenberg Foundation; Swedish Cancer Society; Swedish Research Council; Royal Society; National Health and Medical Research Council of Australia; Medical Research Council [G0001129] Funding Source: researchfish; MRC [G0001129] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Royal Society(Royal Society of London); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	R. C. A. and E. D. L. thank the Wellcome Trust for financial support. K. E. is a Royal Swedish Academy of Sciences Research Fellow supported by grants from the Knut and Alice Wallenberg Foundation, Swedish Cancer Society, Swedish Research Council (VR) M. Bergvalls stiftelse and the EU The Epigenome NoE network. R. C. A is a Wellcome Trust Principal Research Fellow; S. C. T is a Dorothy Hodgkin Fellow of the Royal Society; D. L. is a CJ Martin Fellow of the National Health and Medical Research Council of Australia.	Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bjerling P, 2002, MOL CELL BIOL, V22, P2170, DOI 10.1128/MCB.22.7.2170-2181.2002; Buck MJ, 2004, GENOMICS, V83, P349, DOI 10.1016/j.ygeno.2003.11.004; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Grewal SIS, 1998, GENETICS, V150, P563; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; KLEEBERG U, 1982, J PHARMACOL METHOD, V8, P19, DOI 10.1016/0160-5402(82)90004-3; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Nakayama J, 2003, EMBO J, V22, P2776, DOI 10.1093/emboj/cdg248; Nicolas E, 2006, J BIOL CHEM, V281, P35983, DOI 10.1074/jbc.M606349200; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Robyr D, 2003, METHODS, V31, P83, DOI 10.1016/S1046-2023(03)00091-4; Schneider R, 2002, METHODS, V26, P226, DOI 10.1016/S1046-2023(02)00026-9; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Sinha I, 2006, CHROMOSOME RES, V14, P95, DOI 10.1007/s10577-005-1023-4; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Werler PJH, 2003, GENE, V304, P133, DOI 10.1016/S0378-1119(03)00402-5; Wiren M, 2005, EMBO J, V24, P2906, DOI 10.1038/sj.emboj.7600758; Xue YT, 2004, YEAST, V21, P25, DOI 10.1002/yea.1053; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027	34	30	35	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e386	10.1371/journal.pone.0000386	http://dx.doi.org/10.1371/journal.pone.0000386			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440621	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000207445500016
J	Chaudhuri, RR; Ren, CP; Desmond, L; Vincent, GA; Silman, NJ; Brehm, JK; Elmore, MJ; Hudson, MJ; Forsman, M; Isherwood, KE; Gurycova, D; Minton, NP; Titball, RW; Pallen, MJ; Vipond, R				Chaudhuri, Roy R.; Ren, Chuan-Peng; Desmond, Leah; Vincent, Gemma A.; Silman, Nigel J.; Brehm, John K.; Elmore, Michael J.; Hudson, Michael J.; Forsman, Mats; Isherwood, Karen E.; Gurycova, Darina; Minton, Nigel P.; Titball, Richard W.; Pallen, Mark J.; Vipond, Richard			Genome Sequencing Shows that European Isolates of Francisella tularensis Subspecies tularensis Are Almost Identical to US Laboratory Strain Schu S4	PLOS ONE			English	Article								Background. Francisella tularensis causes tularaemia, a life-threatening zoonosis, and has potential as a biowarfare agent. F. tularensis subsp. tularensis, which causes the most severe form of tularaemia, is usually confined to North America. However, a handful of isolates from this subspecies was obtained in the 1980s from ticks and mites from Slovakia and Austria. Our aim was to uncover the origins of these enigmatic European isolates. Methodology/Principal Findings. We determined the complete genome sequence of FSC198, a European isolate of F. tularensis subsp. tularensis, by whole-genome shotgun sequencing and compared it to that of the North American laboratory strain Schu S4. Apparent differences between the two genomes were resolved by re-sequencing discrepant loci in both strains. We found that the genome of FSC198 is almost identical to that of Schu S4, with only eight SNPs and three VNTR differences between the two sequences. Sequencing of these loci in two other European isolates of F. tularensis subsp. tularensis confirmed that all three European isolates are also closely related to, but distinct from Schu S4. Conclusions/Significance. The data presented here suggest that the Schu S4 laboratory strain is the most likely source of the European isolates of F. tularensis subsp. tularensis and indicate that anthropogenic activities, such as movement of strains or animal vectors, account for the presence of these isolates in Europe. Given the highly pathogenic nature of this subspecies, the possibility that it has become established wild in the heartland of Europe carries significant public health implications.	[Chaudhuri, Roy R.; Ren, Chuan-Peng; Pallen, Mark J.] Univ Birmingham, Div Immun & Infect, Edgbaston, England; [Desmond, Leah; Vincent, Gemma A.; Silman, Nigel J.; Brehm, John K.; Elmore, Michael J.; Hudson, Michael J.; Minton, Nigel P.; Vipond, Richard] Ctr Emergency Preparedness & Response, Hlth Protect Agcy, Salisbury, Wilts, England; [Forsman, Mats] FOI Swedish Def Res Agcy, Div NBC Def, Dept NBC Anal, Umea, Sweden; [Isherwood, Karen E.] Def Sci & Technol Lab, Salisbury, Wilts, England; [Gurycova, Darina] Comenius Univ, Med Facil, Dept Epidemiol, Bratislava, Slovakia; [Minton, Nigel P.] Univ Nottingham, Ctr Biomol Sci, Inst Infect Immun & Inflammat, Nottingham NG7 2RD, England	University of Birmingham; Health Protection Agency; FOI - Swedish Defence Research Agency; Defence Science & Technology Laboratory; Comenius University Bratislava; University of Nottingham	Pallen, MJ (corresponding author), Univ Birmingham, Div Immun & Infect, Edgbaston, England.	m.pallen@bham.ac.uk	Chaudhuri, Roy/E-3774-2014; Forsman, Mats/A-1426-2016; Pallen, Mark J./E-7619-2011	Chaudhuri, Roy/0000-0001-5037-2695; Forsman, Mats/0000-0002-4466-5325; Pallen, Mark/0000-0003-1807-3657; Minton, Nigel/0000-0002-9277-1261; Vincent, Gemma/0000-0003-1479-0114	U.K. Department of Health	U.K. Department of Health	This research was funded by the U.K. Department of Health. The funding sources had no influence upon the study design, collection, analysis and interpretation of the data, or on the preparation of the manuscript.	Ben Zakour N, 2004, NUCLEIC ACIDS RES, V32, P17, DOI 10.1093/nar/gkg928; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; Chaudhuri RR, 2006, NUCLEIC ACIDS RES, V34, pD335, DOI 10.1093/nar/gkj140; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; DIENST F T Jr, 1963, J La State Med Soc, V115, P114; *DIR CULT CULT NAT, 2001, BERN CONV ACT INV AL; EIGELSBACH H, 1961, J IMMUNOL, V87, P415; EIGELSBACH HT, 1951, J BACTERIOL, V61, P557, DOI 10.1128/JB.61.5.557-569.1951; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Farlow J, 2005, EMERG INFECT DIS, V11, P1835, DOI 10.3201/eid1112.050728; Feldman KA, 2003, EMERG INFECT DIS, V9, P350, DOI 10.3201/eid0903.020462; Feldman KA, 2001, NEW ENGL J MED, V345, P1601, DOI 10.1056/NEJMoa011374; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gurycova D, 1998, EUR J EPIDEMIOL, V14, P797, DOI 10.1023/A:1007537405242; HESSELBROCK W, 1945, J BACTERIOL, V49, P209, DOI 10.1128/JB.49.3.209-231.1945; Johansson A, 2004, J BACTERIOL, V186, P5808, DOI 10.1128/JB.186.17.5808-5818.2004; Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12; Larsson P, 2005, NAT GENET, V37, P153, DOI 10.1038/ng1499; Ohnishi M, 2002, P NATL ACAD SCI USA, V99, P17043, DOI 10.1073/pnas.262441699; Oyston PCF, 2004, NAT REV MICROBIOL, V2, P967, DOI 10.1038/nrmicro1045; Petrosino JF, 2006, J BACTERIOL, V188, P6977, DOI 10.1128/JB.00506-06; Pop M, 2004, BRIEF BIOINFORM, V5, P237, DOI 10.1093/bib/5.3.237; Ren CP, 2004, J BACTERIOL, V186, P3547, DOI 10.1128/JB.186.11.3547-3560.2004; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; Rozen S, 2000, Methods Mol Biol, V132, P365; SANDSTORM G, 1994, J CHEM TECHNOL BIOT, V59, P315, DOI 10.1002/jctb.280590402; Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602; SYRJALA H, 1985, SCAND J INFECT DIS, V17, P371; TARNVIK A, 1989, REV INFECT DIS, V11, P440; Tropp BE, 1997, BBA-LIPID LIPID MET, V1348, P192, DOI 10.1016/S0005-2760(97)00100-8; Whipp MJ, 2003, J MED MICROBIOL, V52, P839, DOI 10.1099/jmm.0.05245-0	33	41	312	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e352	10.1371/journal.pone.0000352	http://dx.doi.org/10.1371/journal.pone.0000352			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406676	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445300014
J	Gillet, L; Adler, H; Stevenson, PG				Gillet, Laurent; Adler, Heiko; Stevenson, Philip G.			Glycosaminoglycan Interactions in Murine Gammaherpesvirus-68 Infection	PLOS ONE			English	Article								Glycosaminoglycans (GAGs) commonly participate in herpesvirus entry. They are thought to provide a reversible attachment to cells that promotes subsequent receptor binding. Murine gamma-herpesvirus-68 (MHV-68) infection of fibroblasts and epithelial cells is highly GAG-dependent. This is a function of the viral gp150, in that gp150-deficient mutants are much less GAG-dependent than wild-type. Here we show that the major MHV-68 GAG-binding protein is not gp150 but gp70, a product of ORF4. Surprisingly, ORF4-deficient MHV-68 showed normal cell binding and was more sensitive than wild-type to inhibition by soluble heparin rather than less. Thus, the most obvious viral GAG interaction made little direct contribution to infection. Indeed, a large fraction of the virion gp70 had its GAG-binding domain removed by post-translational cleavage. ORF4 may therefore act mainly to absorb soluble GAGs and prevent them from engaging gp150 prematurely. In contrast to gp70, gp150 bound poorly to GAGs, implying that it provides little in the way of adhesion. We hypothesize that it acts instead as a GAG-sensitive switch that selectively activates MHV-68 entry at cell surfaces.	[Gillet, Laurent; Stevenson, Philip G.] Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England; [Adler, Heiko] GSF, Res Ctr Environm & Hlth, Inst Mol Immunol, Clin Cooperat Grp Hematopoiet Cell Transplantat, Munichmm, Germany	University of Cambridge; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Stevenson, PG (corresponding author), Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England.	pgs27@cam.ac.uk	Stevenson, Philip g/F-9688-2014; Adler, Heiko/M-7355-2014; Stevenson, Philip/F-6651-2011	Stevenson, Philip g/0000-0002-3520-5060; Adler, Heiko/0000-0002-6481-6709; Gillet, Laurent/0000-0002-1047-2525	Fonds National Belge de la Recherche Scientifique (FNRS); Wellcome Trust [GR076956MA]; Medical Research Council [G0400427, G9800903]; CRUK; MRC [G0400427, G9800943] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: researchfish	Fonds National Belge de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Laurent Gillet is a Postdoctoral Researcher of the Fonds National Belge de la Recherche Scientifique (FNRS). Philip Stevenson is a Wellcome Trust Senior Clinical Fellow (GR076956MA). This work was also supported by Medical Research Council grants G0400427 and G9800903 and a CRUK project grant.	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Akula SM, 2001, VIROLOGY, V284, P235, DOI 10.1006/viro.2001.0921; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Boname JM, 2004, IMMUNITY, V20, P305, DOI 10.1016/S1074-7613(04)00047-0; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Coleman HM, 2003, J VIROL, V77, P2410, DOI 10.1128/JVI.77.4.2410-2417.2003; De Lima BD, 2004, J VIROL, V78, P5103, DOI 10.1128/JVI.78.10.5103-5112.2004; Flano E, 2000, J IMMUNOL, V165, P1074, DOI 10.4049/jimmunol.165.2.1074; Fusco D, 2005, P NATL ACAD SCI USA, V102, P9323, DOI 10.1073/pnas.0503907102; Gill MB, 2006, J GEN VIROL, V87, P1465, DOI 10.1099/vir.0.81760-0; Gillet L, 2007, J VIROL, V81, P280, DOI 10.1128/JVI.01616-06; Gillet L, 2006, J GEN VIROL, V87, P3515, DOI 10.1099/vir.0.82313-0; Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Kapadia SB, 1999, J VIROL, V73, P7658, DOI 10.1128/JVI.73.9.7658-7670.1999; Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875; Lopes FB, 2004, J VIROL, V78, P13370, DOI 10.1128/JVI.78.23.13370-13375.2004; Mark L, 2006, MOL IMMUNOL, V43, P1665, DOI 10.1016/j.molimm.2005.09.016; May JS, 2005, J GEN VIROL, V86, P919, DOI 10.1099/vir.0.80661-0; May JS, 2005, J VIROL, V79, P3459, DOI 10.1128/JVI.79.6.3459-3467.2005; Means RE, 2004, VIROLOGY, V326, P67, DOI 10.1016/j.virol.2004.05.015; MISTRIKOVA J, 1985, ACTA VIROL, V29, P312; NASH AA, 1994, CURR OPIN IMMUNOL, V6, P560, DOI 10.1016/0952-7915(94)90141-4; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Spiller OB, 2003, J VIROL, V77, P592, DOI 10.1128/JVI.77.1.592-599.2003; Stevenson PG, 2005, VIRAL IMMUNOL, V18, P445, DOI 10.1089/vim.2005.18.445; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P3275, DOI 10.1099/0022-1317-73-12-3275; TRYBALA E, 1993, J VIROL, V67, P1278, DOI 10.1128/JVI.67.3.1278-1285.1993; VANDERPLASSCHEN A, 1993, VIROLOGY, V196, P232, DOI 10.1006/viro.1993.1471; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; Weck KE, 1999, J VIROL, V73, P3273, DOI 10.1128/JVI.73.4.3273-3283.1999; Williams RK, 1997, J VIROL, V71, P1375, DOI 10.1128/JVI.71.2.1375-1380.1997	39	48	48	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e347	10.1371/journal.pone.0000347	http://dx.doi.org/10.1371/journal.pone.0000347			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406671	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445300009
J	King, EMJ; van der Sar, SJA; Hardwick, KG				King, Emma M. J.; van der Sar, Sjaak J. A.; Hardwick, Kevin G.			Mad3 KEN Boxes Mediate both Cdc20 and Mad3 Turnover, and Are Critical for the Spindle Checkpoint	PLOS ONE			English	Article							ANAPHASE-PROMOTING COMPLEX; MITOTIC CHECKPOINT; PROTEIN BUBR1; ASSEMBLY CHECKPOINT; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; KINETOCHORES; INHIBITION; ACTIVATION; RECOGNITION	Mitotic progression is controlled by proteolytic destruction of securin and cyclin. The mitotic E3 ubiquitin ligase, known as the anaphase promoting complex or cyclosome (APC/C), in partnership with its activators Cdc20p and Cdh1p, targets these proteins for degradation. In the presence of defective kinetochore-microtubule interactions, APC/C-Cdc20 is inhibited by the spindle checkpoint, thereby delaying anaphase onset and providing more time for spindle assembly. Cdc20p interacts directly with Mad2p, and its levels are subject to careful regulation, but the precise mode(s) of APC/C-Cdc20 inhibition remain unclear. The mitotic checkpoint complex (MCC, consisting of Mad3p, Mad2p, Bub3p and Cdc20p in budding yeast) is a potent APC/C inhibitor. Here we focus on Mad3p and how it acts, in concert with Mad2p, to efficiently inhibit Cdc20p. We identify and analyse the function of two motifs in Mad3p, KEN30 and KEN296, which are conserved from yeast Mad3p to human BubR1. These KEN amino acid sequences resemble 'degron' signals that confer interaction with APC/C activators and target proteins for degradation. We show that both Mad3p KEN boxes are necessary for spindle checkpoint function. Mutation of KEN30 abolished MCC formation and stabilised Cdc20p in mitosis. In addition, mutation of Mad3-KEN30, APC/C subunits, or Cdh1p, stabilised Mad3p in G1, indicating that the N-terminal KEN box could be a Mad3p degron. To determine the significance of Mad3p turnover, we analysed the consequences of MAD3 overexpression and found that four-fold overproduction of Mad3p led to chromosome bi-orientation defects and significant chromosome loss during recovery from anti-microtubule drug induced checkpoint arrest. In conclusion, Mad3p KEN30 mediates interactions that regulate the proteolytic turnover of Cdc20p and Mad3p, and the levels of both of these proteins are critical for spindle checkpoint signaling and high fidelity chromosome segregation.	[King, Emma M. J.; van der Sar, Sjaak J. A.; Hardwick, Kevin G.] Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland	University of Edinburgh	Hardwick, KG (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland.	Kevin.Hardwick@ed.ac.uk		Hardwick, Kevin/0000-0002-6462-1047	Wellcome Trust; BBSRC	Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	KGH and SJAvdS are funded by the Wellcome Trust, of which KGH is a Senior Research Fellow. EMJK was funded by a BBSRC Studentship.	Bolanos-Garcia VM, 2005, BIOPHYS J, V89, P2640, DOI 10.1529/biophysj.105.063511; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Davenport J, 2006, EXP CELL RES, V312, P1831, DOI 10.1016/j.yexcr.2006.02.018; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Larsen NA, 2004, J MOL BIOL, V344, P885, DOI 10.1016/j.jmb.2004.09.094; Larsen NA, 2007, P NATL ACAD SCI USA, V104, P1201, DOI 10.1073/pnas.0610358104; Logarinho E, 2004, J CELL SCI, V117, P1757, DOI 10.1242/jcs.01033; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pan J, 2004, GENE DEV, V18, P1439, DOI 10.1101/gad.1184204; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Poddar A, 2005, EUKARYOT CELL, V4, P867, DOI 10.1128/EC.4.5.867-878.2005; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 2001, MOL CLONING LAB MANU; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Snaith HA, 2005, EMBO J, V24, P3690, DOI 10.1038/sj.emboj.7600838; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 2004, CHROMOSOME RES, V12, P599, DOI 10.1023/B:CHRO.0000036610.78380.51; Vink M, 2006, CURR BIOL, V16, P755, DOI 10.1016/j.cub.2006.03.057; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yu HT, 2006, J CELL BIOL, V173, P153, DOI 10.1083/jcb.200601172; Zur A, 2002, EMBO J, V21, P4500, DOI 10.1093/emboj/cdf452	57	109	109	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e342	10.1371/journal.pone.0000342	http://dx.doi.org/10.1371/journal.pone.0000342			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406666	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445300004
J	Nariai, N; Kolaczyk, ED; Kasif, S				Nariai, Naoki; Kolaczyk, Eric D.; Kasif, Simon			Probabilistic Protein Function Prediction from Heterogeneous Genome-Wide Data	PLOS ONE			English	Article								Dramatic improvements in high throughput sequencing technologies have led to a staggering growth in the number of predicted genes. However, a large fraction of these newly discovered genes do not have a functional assignment. Fortunately, a variety of novel high-throughput genome-wide functional screening technologies provide important clues that shed light on gene function. The integration of heterogeneous data to predict protein function has been shown to improve the accuracy of automated gene annotation systems. In this paper, we propose and evaluate a probabilistic approach for protein function prediction that integrates protein-protein interaction (PPI) data, gene expression data, protein motif information, mutant phenotype data, and protein localization data. First, functional linkage graphs are constructed from PPI data and gene expression data, in which an edge between nodes (proteins) represents evidence for functional similarity. The assumption here is that graph neighbors are more likely to share protein function, compared to proteins that are not neighbors. The functional linkage graph model is then used in concert with protein domain, mutant phenotype and protein localization data to produce a functional prediction. Our method is applied to the functional prediction of Saccharomyces cerevisiae genes, using Gene Ontology (GO) terms as the basis of our annotation. In a cross validation study we show that the integrated model increases recall by 18%, compared to using PPI data alone at the 50% precision. We also show that the integrated predictor is significantly better than each individual predictor. However, the observed improvement vs. PPI depends on both the new source of data and the functional category to be predicted. Surprisingly, in some contexts integration hurts overall prediction accuracy. Lastly, we provide a comprehensive assignment of putative GO terms to 463 proteins that currently have no assigned function.	[Nariai, Naoki; Kasif, Simon] Boston Univ, Bioinformat Program, Boston, MA 02215 USA; [Kolaczyk, Eric D.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; [Kasif, Simon] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Nariai, N (corresponding author), Boston Univ, Bioinformat Program, Boston, MA 02215 USA.	nariai@bu.edu			NSF [ITR-048715]; NHGRI [R01 HG003367-01A1]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003367] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by NSF grant ITR-048715 and NHGRI grant R01 HG003367-01A1.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Butte A J, 2000, Pac Symp Biocomput, P418; Deng MH, 2004, J COMPUT BIOL, V11, P463, DOI 10.1089/1066527041410346; Domingos P, 1997, MACH LEARN, V29, P103, DOI 10.1023/A:1007413511361; Dwight SS, 2004, BRIEF BIOINFORM, V5, P9, DOI 10.1093/bib/5.1.9; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Escusa S, 2006, MOL MICROBIOL, V60, P1014, DOI 10.1111/j.1365-2958.2006.05153.x; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gaasterland T, 1998, Microb Comp Genomics, V3, P199; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Karaoz U, 2004, P NATL ACAD SCI USA, V101, P2888, DOI 10.1073/pnas.0307326101; Lanckriet GRG, 2004, BIOINFORMATICS, V20, P2626, DOI 10.1093/bioinformatics/bth294; Lee I, 2004, SCIENCE, V306, P1555, DOI 10.1126/science.1099511; Letovsky S, 2003, BIOINFORMATICS, V19, pi197, DOI 10.1093/bioinformatics/btg1026; Lu LJ, 2005, GENOME RES, V15, P945, DOI 10.1101/gr.3610305; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Protchenko O, 2006, J BIOL CHEM, V281, P21445, DOI 10.1074/jbc.M512812200; RACHLIN J, 1994, INT C MACH LEARN, P242; Rempola B, 2006, BIOCHEM BIOPH RES CO, V346, P546, DOI 10.1016/j.bbrc.2006.05.140; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Storey JD, 2005, PLOS BIOL, V3, P1380, DOI 10.1371/journal.pbio.0030267; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Troyanskaya OG, 2003, P NATL ACAD SCI USA, V100, P8348, DOI 10.1073/pnas.0832373100; Wade CH, 2006, YEAST, V23, P293, DOI 10.1002/yea.1353; Wong SL, 2005, TRENDS GENET, V21, P424, DOI 10.1016/j.tig.2005.06.006; Yanai I., 2002, GENOME BIOL, V3, P0064; Zhou XH, 2002, P NATL ACAD SCI USA, V99, P12783, DOI 10.1073/pnas.192159399	35	70	73	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e337	10.1371/journal.pone.0000337	http://dx.doi.org/10.1371/journal.pone.0000337			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17396164	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445200020
J	Klucky, B; Wintersberger, E				Klucky, B.; Wintersberger, E.			Polyomavirus small T antigen transactivates genes by its ability to provoke the synthesis and the stabilization of MYC	ONCOGENE			English	Article						polyomavirus; T antigens; MYC; S-phase induction	SIMIAN-VIRUS-40 SMALL-T; PROTEIN PHOSPHATASE 2A; HUMAN CELL-TRANSFORMATION; SMALL TUMOR-ANTIGEN; MOUSE FIBROBLASTS; CYCLIN-A; S-PHASE; C-MYC; INDUCTION; PATHWAY	DNA tumor viruses are capable of driving quiescent cells into the cell cycle. In case of polyomaviridae, two viral proteins, the large and the small ( ST) T antigens are responsible for this outcome. ST interacts with the protein phosphatase PP2A and with chaperons of the dnaK type and leads to the transactivation of several genes, which play a role in S-phase induction. One of these is the transcription factor myelocytomatosis ( MYC), which by itself is an important regulator of growth. Microarray analysis has revealed several ST-induced genes, which are also targets of MYC; hence, ST may induce these genes via MYC. Experiments shown here are in line with this assumption. MYC-regulated genes are induced by ST at later times than MYC and a MYC responsive promoter is stimulated by ST. Regulation of MYC occurs through signal transduction pathways, which are co-ordinated by PP2A suggesting that they may be targets of ST. Here, we show that this is the case as important kinases involved in these pathways appear in the active phosphorylated form in the presence of ST. Inhibition of these kinases interferes with MYC induction and inhibition of MYC activity blocks ST-mediated transactivation.	Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Wintersberger, E (corresponding author), Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, Dr Bohrgasse 9, A-1030 Vienna, Austria.	erhard.wintersberger@meduniwien.ac.at						Barker N, 2000, ADV CANCER RES, V77, P1; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Howe AK, 1998, J VIROL, V72, P9637, DOI 10.1128/JVI.72.12.9637-9644.1998; Klucky B, 2004, ONCOGENE, V23, P4707, DOI 10.1038/sj.onc.1207640; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PASSAMATO R, 2004, CANCER CELL, V5, P127; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Reiss K, 2003, ONCOGENE, V22, P6517, DOI 10.1038/sj.onc.1206959; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	28	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6356	6360		10.1038/sj.onc.1210458	http://dx.doi.org/10.1038/sj.onc.1210458			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438527				2022-12-25	WOS:000249583300012
J	Adiga, SK; Toyoshima, M; Shiraishi, K; Shimura, T; Takeda, J; Taga, M; Nagai, H; Kumar, P; Niwa, O				Adiga, S. K.; Toyoshima, M.; Shiraishi, K.; Shimura, T.; Takeda, J.; Taga, M.; Nagai, H.; Kumar, P.; Niwa, O.			p21 provides stage specific DNA damage control to preimplantation embryos	ONCOGENE			English	Article						radiation; p21 activation; preimplantation stage embryos	CELL-CYCLE; MOUSE DEVELOPMENT; GENE-EXPRESSION; CARCINOMA-CELLS; IN-VITRO; X-RAY; APOPTOSIS; P21(WAF1/CIP1); ACTIVATION; SPERM	The early stage embryogenesis of higher eukaryotes lacks some of the damage response pathways such as G1/S checkpoint, G2/M checkpoint and apoptosis. We examined here the damage response of preimplantation stage embryos after fertilization with 6 Gy irradiated sperm. Sperm-irradiated embryos developed normally for the first 2.5 days, but started to exhibit a developmental delay at day 3.5. p21 was activated in the delayed embryos, which carried numerous micronuclei owing to delayed chromosome instability. Apoptosis was observed predominantly in the inner cell mass of the day 4.0 embryos. Sperm-irradiated p21 -/- embryos lacked the delay, but chromosome instability and apoptosis were more pronounced than the corresponding p21 wild-type embryos. We conclude from the result that damage responses come in a stagespeci. c manner during preimplantation stage development; p53-dependent S checkpoint at the zygote stage, p21-mediated cell cycle arrest at the morula/blastocyst stages and apoptosis after the blastocyst stage in the inner cell mass.	Kasturba Med Coll & Hosp, Manipal, India; Kyoto Univ, Radiat Biol Ctr, Kyoto, Japan; Osaka Prefecture Univ, Adv Sci & Technol Inst, Osaka, Japan; RIKEN, Genome Damage Respone Res Unit, Wako, Saitama, Japan	Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Manipal; Kyoto University; Osaka Metropolitan University; RIKEN	Niwa, O (corresponding author), Kyoto Univ, Studies Rdiat Biol Ctr, Yoshida konoe Sakyo-ku, Kyoto 606850, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697; , pratap kumar/0000-0002-7245-1746				Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; FENECH M, 1993, ENVIRON HEALTH PERSP, V101, P101, DOI 10.2307/3431708; FLEMING TP, 2001, FRONT BIOSCI, V6, P2566; FRIESNER JD, 2005, MOL BIOL CELL, V16, pD1000; Gartel AL, 2002, MOL CANCER THER, V1, P639; GOLDSTEIN LS, 1975, RADIAT RES, V62, P276, DOI 10.2307/3574220; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Heyer BS, 2000, GENE DEV, V14, P2072; Ikegami R, 1997, ZYGOTE, V5, P153, DOI 10.1017/S0967199400003828; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jeong YJ, 2005, MOL REPROD DEV, V71, P284, DOI 10.1002/mrd.20269; Jurisicova A, 1998, MOL HUM REPROD, V4, P139, DOI 10.1093/molehr/4.2.139; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kamjoo M, 2002, MOL REPROD DEV, V61, P67, DOI 10.1002/mrd.1132; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; MUKHERJEE AB, 1976, P NATL ACAD SCI USA, V73, P1608, DOI 10.1073/pnas.73.5.1608; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Taga M, 2000, J RADIAT RES, V41, P227, DOI 10.1269/jrr.41.227; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Wright SJ, 1999, CURR TOP DEV BIOL, V46, P133, DOI 10.1016/S0070-2153(08)60328-2; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZIOMEK CA, 1980, CELL, V21, P935, DOI 10.1016/0092-8674(80)90457-2	33	54	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6141	6149		10.1038/sj.onc.1210444	http://dx.doi.org/10.1038/sj.onc.1210444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420724				2022-12-25	WOS:000249401300004
J	Zhang, M; Hu, PR; Krois, CR; Kane, MA; Napoli, JL				Zhang, Min; Hu, Peirong; Krois, Charles R.; Kane, Maureen A.; Napoli, Joseph L.			Altered vitamin A homeostasis and increased size and adiposity in the rdh1-null mouse	FASEB JOURNAL			English	Article						retinoic acid; retinol; short-chain dehydrogenase/reductase	RETINOL-BINDING-PROTEIN; ALL-TRANS-RETINOL; SHORT-CHAIN DEHYDROGENASE/REDUCTASE; ACID-METABOLIZING ENZYME; ALCOHOL-DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CDNA CLONING; EXPRESSION; IDENTIFICATION; RAT	Rat RoDH performs efficiently ( V-m/ K-m) in a pathwayof all- trans- retinoic acid biosynthesis in cells and recognizes the physiological form of vitamin A, i. e., retinol bound with cellular retinol binding-protein, type I. Here we report that mouse embryo ( e7.5 to e18.5) and liver ( e12.5 to P2M) display inversely related mRNA expression of an Rodh ortholog, rdh1, and a major retinoic acid catabolic enzyme, cyp26a1, suggesting coordinate modulation of retinoic acid homeostasis. Rdh1 inactivation by homologous recombination produces mice with decreased liver cyp26a1 mRNA and protein and increased liver and kidney retinoid stores, when fed vitamin A- restricted diets. Thus, null mice autocompensate by down- regulating cyp26a1 and sparing retinoids, indicating that rdh1 metabolizes retinoids in vivo. Surprisingly, rdh1-null mice grow longer than wild type, with increased weight and adiposity, when restricted in vitamin A. Liver, kidney, and multiple fat pads increase in weight. Some differences reflect the larger sizes of rdh1- null mice, but mesentery, femoral, and inguinal fat pads grow disproportionately larger. These data reveal an unexpected contribution of Rdh1 to size and adiposity and provide the first genetic evidence of a candidate retinol dehydrogenase affecting either vitamin A- related homeostasis physiologically or vitamin A- related gene expression or biological function in vivo.	Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@berkeley.edu			NIDDK NIH HHS [DK-36970] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Andreola F, 2004, J BIOL CHEM, V279, P3434, DOI 10.1074/jbc.M305832200; Berdanier CD, 2001, DIABETES RES CLIN PR, V54, pS11, DOI 10.1016/S0168-8227(01)00331-X; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chiu S, 2004, OBES RES, V12, P1243, DOI 10.1038/oby.2004.158; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; E XP, 2002, J BIOL CHEM, V277, P36617, DOI 10.1074/jbc.M205519200; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Ganji V, 2003, INT J FOOD SCI NUTR, V54, P485, DOI 10.1080/09637480310001622341; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Heise R, 2006, J INVEST DERMATOL, V126, P2473, DOI 10.1038/sj.jid.5700432; Hernandez RE, 2007, DEVELOPMENT, V134, P177, DOI 10.1242/dev.02706; Huang FJ, 2006, HUM REPROD, V21, P202, DOI 10.1093/humrep/dei286; Jian Z, 2004, REPROD TOXICOL, V19, P103, DOI 10.1016/j.reprotox.2004.06.012; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lin M, 2000, J BIOL CHEM, V275, P40106, DOI 10.1074/jbc.M008027200; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; MADSEN M, 2001, PRO NUT SOC, V59, P65; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Markova NG, 2003, MOL GENET METAB, V78, P119, DOI 10.1016/S1096-7192(02)00226-3; Martras S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/j.1432-1033.2004.04058.x; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; National Research Council, 1995, NUTR REQ LAB AN; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; PARES X, 1990, METHOD ENZYMOL, V189, P436; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Reeves PG, 1997, J NUTR, V127, pS838; REINTJES S, 2004, DEV DYNAM, V230, P509; Rexer BN, 2002, BIOL REPROD, V67, P1555, DOI 10.1095/biolreprod.102.007021; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Villarroya F, 1999, INT J OBESITY, V23, P1, DOI 10.1038/sj.ijo.0800799; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WOLF G, 1995, NUTR REV, V53, P230, DOI 10.1111/j.1753-4887.1995.tb01558.x; Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; Zhang M, 2004, J BIOL CHEM, V279, P51482, DOI 10.1074/jbc.M409051200; Zhang M, 2003, GENE, V305, P121, DOI 10.1016/S0378-1119(02)01236-2; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	60	69	69	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2886	2896		10.1096/fj.06-7964com	http://dx.doi.org/10.1096/fj.06-7964com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17435174				2022-12-25	WOS:000249237500029
J	Endo, Y; Marusawa, H; Kinoshita, K; Morisawa, T; Sakurai, T; Okazaki, IM; Watashi, K; Shimotohno, K; Honjo, T; Chiba, T				Endo, Y.; Marusawa, H.; Kinoshita, K.; Morisawa, T.; Sakurai, T.; Okazaki, I-M; Watashi, K.; Shimotohno, K.; Honjo, T.; Chiba, T.			Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappa B signaling	ONCOGENE			English	Article						activation-induced cytidine deaminase; TNF-alpha; NF-kappa B; hepatocellular carcinoma; hepatitis C virus; chronic hepatitis	CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; HEPATOCELLULAR-CARCINOMA; FACTOR-ALPHA; MEDIATED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA; MOUSE MODEL; C-MYC; AID	Activation-induced cytidine deaminase (AID) is involved in somatic DNA alterations of the immunoglobulin gene for amplification of immune diversity. The fact that constitutive expression of AID in mice causes tumors in various organs, including lymphoid tissues and lungs, suggests the important role of the aberrant editing activity of AID on various tumor-related genes for carcinogenesis. AID expression, however, is restricted to activated B cells under physiological conditions. We demonstrate here that ectopic AID expression is induced in response to tumor necrosis factor-alpha stimulation in cultured human hepatocytes. The proinflammatory cytokine-mediated expression of AID is achieved by I kappa B kinase-dependent nuclear factor (NF)-kappa B signaling pathways. Hepatitis C virus, one of the leading causes of hepatocellular carcinoma (HCC), enhanced AID expression via NF-kappa B activation through expression of viral core protein. The aberrant expression of AID in hepatoma-derived cells resulted in accumulation of genetic alterations in the c-myc and pim1 genes, suggesting that inappropriate expression of AID acts as a DNA mutator that enhances the genetic susceptibility to mutagenesis in human hepatocytes. Our current findings indicate that the inappropriate expression of AID is induced by proinflammatory cytokine stimulation and may provide the link between hepatic inflammation and the development of HCC.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Shiga Med Ctr Res Inst, Moriyama, Japan; Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawara Cho,Shogoin, Kyoto 6068507, Japan.	chiba@kuhp.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Marusawa, Hiroyuki/0000-0002-4286-2712				Aly HH, 2007, J HEPATOL, V46, P26, DOI 10.1016/j.jhep.2006.08.018; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; Feitelson MA, 2006, CANCER LETT, V239, P10, DOI 10.1016/j.canlet.2005.07.009; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Heintel D, 2004, LEUKEMIA, V18, P756, DOI 10.1038/sj.leu.2403294; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Ishii N, 2006, J VIROL, V80, P4510, DOI 10.1128/JVI.80.9.4510-4520.2006; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Marusawa H, 2000, HEPATOLOGY, V31, P488, DOI 10.1002/hep.510310232; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Marusawa H, 2001, MICROBIOL IMMUNOL, V45, P483, DOI 10.1111/j.1348-0421.2001.tb02648.x; Matsumoto T, 2006, FEBS LETT, V580, P731, DOI 10.1016/j.febslet.2005.12.081; MURAKAMI H, 1993, CANCER RES, V53, P1719; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tateno C, 2000, HEPATOLOGY, V31, P65, DOI 10.1002/hep.510310113; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	44	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5587	5595		10.1038/sj.onc.1210344	http://dx.doi.org/10.1038/sj.onc.1210344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17404578	Green Submitted			2022-12-25	WOS:000248801900004
J	Ammons, MCB; Siemsen, DW; Nelson-Overton, LK; Quinn, MT; Gauss, KA				Ammons, Mary Cloud B.; Siemsen, Daniel W.; Nelson-Overton, Laura K.; Quinn, Mark T.; Gauss, Katherine A.			Binding of pleomorphic adenoma gene-like 2 to the tumor necrosis factor (TNF)-alpha-responsive region of the NCF2 promoter regulates p67(phox) expression and NADPH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; SUPEROXIDE-PRODUCTION; CYTOSOLIC COMPONENT; GENE-EXPRESSION; FAMILY-MEMBERS; PLAG FAMILY; IN-VITRO; ACTIVATION; P47(PHOX); SUMOYLATION	NCF2, the gene encoding the NADPH oxidase cytosolic component p67(phox), is up-regulated by TNF-alpha, and we recently mapped a region in the NCF2 promoter that was required for this TNF-alpha-dependent response. Because this TNF-alpha-responsive region (TRR) lacked recognizable transcription factor binding elements, we performed studies to identify factors involved in regulating NCF2 via the TRR. Using the TRR sequence as bait in a yeast one-hybrid screen, we identified the zinc finger transcription factor Pleomorphic Adenoma Gene-Like 2 (PLAGL2) as a candidate regulator of NCF2 expression. PLAGL2-specific antibodies were generated that detected the native and SUMO1-modified forms of endogenous PLAGL2. EMSA and DNA-binding protein affinity purification analyses demonstrated specific binding of in vitro-translated as well as endogenously expressed PLAGL2 to the TRR, and chromatin immunoprecipitation assays demonstrated enhanced binding of endogenous PLAGL2 to the TRR in vivo with TNF-alpha treatment. Knockdown of PLAGL2 protein inhibited up-regulation of NCF2 transcript, p67phox protein expression, and subsequent superoxide production in response to TNF-alpha. Furthermore, relative levels of native and SUMO1-modified endogenous PLAGL2 protein were modulated in a time-dependant manner in response to TNF-alpha treatment. These data clearly identify PLAGL2 as a novel regulator of NCF2 gene expression as well as NADPH oxidase activity and contribute to a greater understanding of the transcriptional regulation of NCF2.	Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Gauss, KA (corresponding author), Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA.	kgauss@montana.edu		Quinn, Mark/0000-0001-8114-5073; Ammons, Mary Cloud/0000-0002-9717-0844	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042426] Funding Source: NIH RePORTER; NCRR NIH HHS [RR020185] Funding Source: Medline; NIAMS NIH HHS [AR42426, R01 AR042426] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abdollahi A, 2007, J CELL PHYSIOL, V210, P16, DOI 10.1002/jcp.20835; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635; BEUTLER B, 1995, J INVEST MED, V43, P227; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; Bylund J, 2005, ADV EXP MED BIOL, V568, P67; CASSATELLA MA, 1991, J BIOL CHEM, V266, P22079; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Dang PMC, 2000, BIOCHEMISTRY-US, V39, P3069, DOI 10.1021/bi9919807; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; Gauss KA, 2005, J LEUKOCYTE BIOL, V77, P267, DOI 10.1189/jlb.0604329; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; GrazianiBowering GM, 1997, J IMMUNOL METHODS, V207, P157, DOI 10.1016/S0022-1759(97)00114-2; Hensen K, 2002, CANCER RES, V62, P1510; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hilgarth Roland S., 2005, V301, P329; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Hua J, 2000, J LEUKOCYTE BIOL, V68, P216; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY R, 1991, J IMMUNOL, V147, P3066; Liu GQ, 2004, COMPUT SYST SCI ENG, V19, P39; Mizrahi A, 2006, J LEUKOCYTE BIOL, V79, P881, DOI 10.1189/jlb.1005553; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; Quinn MT, 2006, CLIN SCI, V111, P1, DOI 10.1042/cs20060059; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Skalnik DG, 2002, GENE, V284, P1, DOI 10.1016/S0378-1119(02)00387-6; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Van Dyck F, 2004, J BIOL CHEM, V279, P36121, DOI 10.1074/jbc.M401753200; Voz ML, 2000, CANCER RES, V60, P106; Weissmann G, 2004, JCR-J CLIN RHEUMATOL, V10, pS26, DOI 10.1097/01.rhu.0000130687.75646.44; Yang MCW, 2005, AM J RESP CELL MOL, V32, P35, DOI 10.1165/rcmb.2003-0422OC; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Zheng G, 2005, J BIOL CHEM, V280, P40773, DOI 10.1074/jbc.M504334200	45	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17941	17952		10.1074/jbc.M610618200	http://dx.doi.org/10.1074/jbc.M610618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17462995	hybrid			2022-12-25	WOS:000247084500067
J	Deschenes, J; Bourdeau, V; White, JH; Mader, S				Deschenes, Julie; Bourdeau, Veronique; White, John H.; Mader, Sylvie			Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RESPONSE ELEMENTS; TARGET GENES; EXPRESSION; IDENTIFICATION; PROLIFERATION; RESISTANCE; TAMOXIFEN; THERAPY	Estrogen receptors activate transcription in part through direct interactions with specific DNA motifs, called estrogen response elements (EREs). Here we show that the strong and sustained induction of the gene regulated in breast cancer 1 (GREB1), a gene of unknown function that has been previously suggested to play a role in the effects of estradiol on breast cancer cell proliferation (Rae, J. M., Johnson, M. D., Scheys, J. O., Cordero, K. E., Larios, J. M., and Lippman, M. E. (2005) Breast Cancer Res. Treat 92, 141-149), is mediated by binding of estrogen receptor alpha(ER alpha) to three consensus EREs spread over similar to 20 kb of upstream flanking sequences. In addition to ER alpha, coactivator SRC-3, acetylated histones and phosphorylated RNA polymerase II (P-polII) were detected on all three EREs in the presence of estrogen, while basal recruitment of ER alpha and P-polII was observed only on the proximal element. Chromatin loops were formed between each ERE and the GREB1 transcriptional start site in the presence of estrogen but not of a total antiestrogen. Furthermore, estradiol induced physical association between EREs, suggesting that these elements function as a potent multipartite enhancer to regulate GREB1 transcription.	Univ Montreal, IRIC, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A4, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University	Mader, S (corresponding author), Univ Montreal, IRIC, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	sylvie.mader@umontreal.ca	white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Button K, 2005, TRANSPORT POLICY, V12, P47, DOI 10.1016/j.tranpol.2004.09.003; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Ghosh MG, 2000, CANCER RES, V60, P6367; Howell A, 2004, J CLIN ONCOL, V22, P1605, DOI 10.1200/JCO.2004.02.112; Hui R, 2002, CANCER RES, V62, P6916; Jordan VC, 2001, JNCI-J NATL CANCER I, V93, P2, DOI 10.1093/jnci/93.1.2; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mukherjee S, 2005, J BIOL CHEM, V280, P17617, DOI 10.1074/jbc.M502278200; O'Regan RM, 2002, LANCET ONCOL, V3, P207, DOI 10.1016/S1470-2045(02)00711-8; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; Rocha W, 2005, MOL PHARMACOL, V68, P1852, DOI 10.1124/mol.105.014514; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Vega VB, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r82	33	79	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17335	17339		10.1074/jbc.C700030200	http://dx.doi.org/10.1074/jbc.C700030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17463000	hybrid			2022-12-25	WOS:000247084500003
J	Paczkowski, FA; Sharpe, IA; Dutertre, S; Lewis, RJ				Paczkowski, Filip A.; Sharpe, Iain A.; Dutertre, Sebastien; Lewis, Richard J.			chi-conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NORADRENALINE TRANSPORTER; HUMAN DOPAMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; MONOAMINE TRANSPORTERS; COCAINE BINDING; MECHANISM; DESIPRAMINE; CONOPEPTIDE; EXPRESSION; RECEPTORS	Monoamine neurotransmitter transporters for norepinephrine (NE), dopamine and serotonin are important targets for antidepressants and analgesics. The conopeptide chi-MrIA is a noncompetitive and highly selective inhibitor of the NE transporter (NET) and is being developed as a novel intrathecal analgesic. We used site-directed mutagenesis to generate a suite of mutated transporters to identify two amino acids (Leu(469) and Glu(382)) that affected the affinity of chi-MrIA to inhibit [H-3] NE uptake through human NET. Residues that increased the Kd of a tricyclic antidepressant (nisoxetine) were also identified (Phe(207), Ser(225), His(296), Thr(381), and Asp(473)). Phe(207), Ser(225), His(296), and Thr(381) also affected the rate of NE transport without affecting NE Km. In a new model of NET constructed from the bLeuT crystal structure, chi-MrIA-interacting residues were located at the mouth of the transporter near residues affecting the binding of small molecule inhibitors.	Univ Queensland, Inst Mol Biosci QBP, Brisbane, Qld 4072, Australia	University of Queensland	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci QBP, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X; Dutertre, Sebastien/0000-0002-2945-1484				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Appell M, 2004, BIOCHEM PHARMACOL, V67, P293, DOI 10.1016/j.bcp.2003.09.013; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; Bonisch H, 1999, J AUTON PHARMACOL, V19, P327; Bryan-Lluka LJ, 2003, J BIOL CHEM, V278, P40324, DOI 10.1074/jbc.M213101200; Dutertre S, 2004, EUR J BIOCHEM, V271, P2327, DOI 10.1111/j.1432-1033.2004.04147.x; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Nielsen CK, 2005, PAIN, V118, P112, DOI 10.1016/j.pain.2005.08.002; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Paczkowski FA, 2004, J NEUROCHEM, V88, P203, DOI 10.1046/j.1471-4159.2003.02149.x; Paczkowski FA, 2001, MOL BRAIN RES, V97, P32, DOI 10.1016/S0169-328X(01)00295-9; Petrek M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-316; Rasmussen SGF, 2003, EUR J PHARMACOL, V479, P13, DOI 10.1016/j.ejphar.2003.08.053; Ravna AW, 2003, J COMPUT AID MOL DES, V17, P367, DOI 10.1023/A:1026116017725; Ravna AW, 2003, J PHARMACOL EXP THER, V307, P34, DOI 10.1124/jpet.103.054593; Ravna AW, 2001, J MOL GRAPH MODEL, V20, P133, DOI 10.1016/S1093-3263(01)00112-7; Roubert C, 2001, J BIOL CHEM, V276, P8254, DOI 10.1074/jbc.M009798200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schroeter S, 2000, J COMP NEUROL, V420, P211; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Sharpe IA, 2003, J BIOL CHEM, V278, P40317, DOI 10.1074/jbc.M213030200; Stahl SM, 2003, J CLIN PSYCHIAT, V64, P230; Sucic S, 2002, MOL BRAIN RES, V108, P40, DOI 10.1016/S0169-328X(02)00512-0; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	34	45	47	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17837	17844		10.1074/jbc.M610813200	http://dx.doi.org/10.1074/jbc.M610813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428804	Green Published, hybrid			2022-12-25	WOS:000247084500057
J	D'Haeze, W; Leoff, C; Freshour, G; Noel, KD; Carlson, RW				D'Haeze, Wim; Leoff, Christine; Freshour, Glenn; Noel, K. Dale; Carlson, Russell W.			Rhizobium etli CE3 bacteroid lipopolysaccharides are structurally similar but not identical to those produced by cultured CE3 bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ANTIGENIC POLYSACCHARIDE; LIPID-A; SALMONELLA-TYPHIMURIUM; POLYMYXIN-RESISTANT; ESCHERICHIA-COLI; GENETIC-LOCUS; ROOT-NODULES; MUTANTS; EXPRESSION; DEFICIENT	Rhizobium etli CE3 bacteroids were isolated from Phaseolus vulgaris root nodules. The lipopolysaccharide (LPS) from the bacteroids was purified and compared with the LPS from laboratory-cultured R. etli CE3 and from cultures grown in the presence of anthocyanin. Comparisons were made of the O-chain polysaccharide, the core oligosaccharide, and the lipid A. Although LPS from CE3 bacteria and bacteroids are structurally similar, it was found that bacteroid LPS had specific modifications to both the O-chain polysaccharide and lipid A portions of their LPS. Cultures grown with anthocyanin contained modifications only to the O-chain polysaccharide. The changes to the O-chain polysaccharide consisted of the addition of a single methyl group to the 2-position of a fucosyl residue in one of the five O-chain trisaccharide repeat units. This same change occurred for bacteria grown in the presence of anthocyanin. This methylation change correlated with the inability of bacteroid LPS and LPS from anthocyanin-containing cultures to bind the monoclonal antibody JIM28. The core oligosaccharide region of bacteroid LPS and from anthocyanin-grown cultures was identical to that of LPS from normal laboratory-cultured CE3. The lipid A from bacteroids consisted exclusively of a tetraacylated species compared with the presence of both tetra-and pentaacylated lipid A from laboratory cultures. Growth in the presence of anthocyanin did not affect the lipid A structure. Purified bacteroids that could resume growth were also found to be more sensitive to the cationic peptides, poly-L-lysine, polymyxin-B, and melittin.	Univ Georgia, Comples Carbohydrate Res Ctr, Athens, GA 30602 USA; Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA	University System of Georgia; University of Georgia; Marquette University	Carlson, RW (corresponding author), Univ Georgia, Comples Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	rcarlson@ccrc.uga.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banba M, 2001, MOL PLANT MICROBE IN, V14, P173, DOI 10.1094/MPMI.2001.14.2.173; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Bechinger B, 2004, CRIT REV PLANT SCI, V23, P271, DOI 10.1080/07352680490452825; BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Brewin NJ, 2004, CRIT REV PLANT SCI, V23, P293, DOI 10.1080/07352680490480734; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHING TM, 1977, PLANT PHYSIOL, V60, P771, DOI 10.1104/pp.60.5.771; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; D'Haeze W, 2004, TRENDS MICROBIOL, V12, P555, DOI 10.1016/j.tim.2004.10.009; D'Haeze W, 2004, MOL MICROBIOL, V52, P485, DOI 10.1111/j.1365-2958.2004.03989.x; D'Haeze W, 2003, P NATL ACAD SCI USA, V100, P11789, DOI 10.1073/pnas.1333899100; D'Haeze W, 2002, GLYCOBIOLOGY, V12, p79R, DOI 10.1093/glycob/12.6.79R; DIEBOLD R, 1989, J BACTERIOL, V171, P4821, DOI 10.1128/jb.171.9.4821-4830.1989; Duelli DM, 2001, J BACTERIOL, V183, P6054, DOI 10.1128/JB.183.20.6054-6064.2001; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2003, J BIOL CHEM, V278, P51347, DOI 10.1074/jbc.M309016200; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; Fraysse N, 2002, GLYCOBIOLOGY, V12, P741, DOI 10.1093/glycob/cwf078; Geurtsen J, 2005, J BIOL CHEM, V280, P8248, DOI 10.1074/jbc.M414235200; Gonzalez V, 2006, P NATL ACAD SCI USA, V103, P3834, DOI 10.1073/pnas.0508502103; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1989, J BACTERIOL, V171, P4543, DOI 10.1128/jb.171.9.4543-4548.1989; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; LULLIEN V, 1987, PLANT MOL BIOL, V9, P469, DOI 10.1007/BF00015878; Ma Y, 2001, J BACTERIOL, V183, P250, DOI 10.1128/JB.183.1.250-256.2001; Mergaert P, 2006, P NATL ACAD SCI USA, V103, P5230, DOI 10.1073/pnas.0600912103; Noel KD, 2004, APPL ENVIRON MICROB, V70, P1537, DOI 10.1128/AEM.70.3.1537-1544.2004; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 1996, MOL PLANT MICROBE IN, V9, P180, DOI 10.1094/MPMI-9-0180; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 2005, J BACTERIOL, V187, P6479, DOI 10.1128/JB.187.18.6479-6487.2005; Reynolds CM, 2006, J BIOL CHEM, V281, P21974, DOI 10.1074/jbc.M603527200; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ridley BL, 2000, GLYCOBIOLOGY, V10, P1013, DOI 10.1093/glycob/10.10.1013; ROWLEY JC, 1975, ULTRAMICROSCOPY, V1, P151, DOI 10.1016/S0304-3991(75)80018-0; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; Tran AX, 2005, J BIOL CHEM, V280, P28186, DOI 10.1074/jbc.M505020200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vedam V, 2004, MOL PLANT MICROBE IN, V17, P283, DOI 10.1094/MPMI.2004.17.3.283; Vedam V, 2003, J BACTERIOL, V185, P1841, DOI 10.1128/JB.185.6.1841-1850.2003; WESTPHAL O, 1965, METHODS CARBOHYDR RE, V5, P91; Xi CW, 2000, P NATL ACAD SCI USA, V97, P11114, DOI 10.1073/pnas.210181097; YORK WS, 1986, METHOD ENZYMOL, V118, P3; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	63	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17101	17113		10.1074/jbc.M611669200	http://dx.doi.org/10.1074/jbc.M611669200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420254	hybrid, Green Submitted			2022-12-25	WOS:000246946500043
J	Gruber, F; Oskolkova, O; Leitner, A; Mildner, M; Mlitz, V; Lengauer, B; Kadl, A; Mrass, P; Kronke, G; Binder, BR; Bochkov, VN; Leitinger, N; Tschachler, E				Gruber, Florian; Oskolkova, Olga; Leitner, Alexander; Mildner, Michael; Mlitz, Veronika; Lengauer, Barbara; Kadl, Alexandra; Mrass, Paul; Kroenke, Gerhard; Binder, Bernd R.; Bochkov, Valery N.; Leitinger, Norbert; Tschachler, Erwin			Photooxidation generates biologically active phospholipids that induce heme oxygenase-1 in skin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDATION-SPECIFIC EPITOPES; TANDEM MASS-SPECTROMETRY; ULTRAVIOLET-A RADIATION; 32-KDA STRESS PROTEIN; OXIDIZED PHOSPHOLIPIDS; SINGLET OXYGEN; APOPTOTIC CELLS; UVA RADIATION; MONOCLONAL AUTOANTIBODIES	Heme oxygenase-1 (HO-1) is a key enzyme in the cellular response to tissue injury and oxidative stress. HO-1 enzymatic activity results in the formation of the cytoprotective metabolites CO and biliverdin. In the skin, HO-1 is strongly induced after long wave ultraviolet radiation (UVA-1). Here we show that UVA-1 irradiation generates oxidized phospholipids derived from 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) that mediate the expression of HO-1 in skin cells. Using EO6 antibodies that recognize oxidized phospholipids, we show that UVA-1 irradiation of dermal fibroblasts generates oxidation-specific epitopes. Irradiation of arachidonatecontaining phospholipids with UVA-1 led to formation of defined lipid oxidation products including epoxyisoprostane-phosphatidylcholine that induced HO-1 expression in dermal fibroblasts, in keratinocytes, and in a three-dimensional epidermal equivalent model. In addition, we demonstrate that the oxidation of PAPC by UVA-1 is a singlet oxygen-dependent mechanism. Together, we present a novel mechanism of UVA-1- induced HO-1 expression that is mediated by the generation of biologically active phospholipid oxidation products. Because UVA-1 irradiation is a mainstay treatment of several inflammatory skin diseases, structural identification of UVA-1-generated biomolecules with HO-1-inducing capacity should lead to the development of drugs that could substitute for irradiation.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Vienna, Dept Analyt Chem & Food Chem, A-1090 Vienna, Austria; CERIES, F-92200 Neuilly sur Seine, France	University of Virginia; Medical University of Vienna; Medical University of Vienna; University of Vienna	Leitinger, N (corresponding author), Univ Virginia, Cardiovasc Res Ctr, POB 801394, Charlottesville, VA 22908 USA.	nl2q@virginia.edu	Leitner, Alexander/U-1601-2019; Krönke, Gerhard/C-6615-2014; Kadl, Alexandra/AAV-3395-2021	Leitner, Alexander/0000-0003-4126-0725; Krönke, Gerhard/0000-0002-7566-4325; Tschachler, Erwin/0000-0002-0248-1798; Gruber, Florian/0000-0003-1094-5641; Mildner, Michael/0000-0002-6892-925X; Oskolkova, Olga/0000-0001-9443-8705	NHLBI NIH HHS [R01 HL084422-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084422] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BasuModak S, 1996, FREE RADICAL BIO MED, V20, P887, DOI 10.1016/0891-5849(95)02182-5; BASUMODAK S, 1993, CANCER RES, V53, P4505; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Bluml S, 2005, J IMMUNOL, V175, P501, DOI 10.4049/jimmunol.175.1.501; Bochkov VN, 2003, J MOL MED, V81, P613, DOI 10.1007/s00109-003-0467-2; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; BOSE B, 1994, J PHOTOCH PHOTOBIO B, V23, P119, DOI 10.1016/1011-1344(94)06995-6; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; Dissemond J, 2003, BRIT J DERMATOL, V149, P341, DOI 10.1046/j.1365-2133.2003.05457.x; Furnkranz A, 2004, CURR PHARM DESIGN, V10, P915, DOI 10.2174/1381612043452929; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Grether-Beck S, 2000, METHOD ENZYMOL, V319, P280; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; GretherBeck S, 1997, BIOL CHEM, V378, P1231; Hanselmann C, 2001, BIOCHEM J, V353, P459, DOI 10.1042/0264-6021:3530459; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huber J, 2002, ARTERIOSCL THROM VAS, V22, P101, DOI 10.1161/hq0102.101525; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537-1891(02)00172-6; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; Klotz LO, 2000, METHOD ENZYMOL, V319, P130; Kronke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200; Krutmann J, 2000, J DERMATOL SCI, V23, pS22, DOI 10.1016/S0923-1811(99)00077-8; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Li RS, 2006, CIRC RES, V98, P642, DOI 10.1161/01.RES.0000207394.39249.fc; Mang R, 2005, PHOTODERMATOL PHOTO, V21, P103, DOI 10.1111/j.1600-0781.2005.00146.x; Marathe GK, 2005, J BIOL CHEM, V280, P35448, DOI 10.1074/jbc.M503811200; Matroule JY, 2000, METHOD ENZYMOL, V319, P119; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reis A, 2005, BIOMED CHROMATOGR, V19, P129, DOI 10.1002/bmc.429; Reis A, 2004, J MASS SPECTROM, V39, P1513, DOI 10.1002/jms.751; Reis A, 2004, RAPID COMMUN MASS SP, V18, P2849, DOI 10.1002/rcm.1686; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Szegedi A, 2005, RHEUMATOLOGY, V44, P925, DOI 10.1093/rheumatology/keh643; Tyrrell RM, 1997, METHODS, V11, P313, DOI 10.1006/meth.1996.0425; Tyrrell RM, 2004, ANTIOXID REDOX SIGN, V6, P835, DOI 10.1089/1523086041798033; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wagener FADTG, 2003, BLOOD, V102, P521, DOI 10.1182/blood-2002-07-2248; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Williams SD, 2000, J LIPID RES, V41, P1585; Zhang QW, 2005, J BIOL CHEM, V280, P73, DOI 10.1074/jbc.M409795200	58	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16934	16941		10.1074/jbc.M702523200	http://dx.doi.org/10.1074/jbc.M702523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17449870	hybrid, Green Published			2022-12-25	WOS:000246946500026
J	Huh, YH; Ryu, JH; Chun, JS				Huh, Yun Hyun; Ryu, Je-Hwang; Chun, Jang-Soo			Regulation of type II collagen expression by histone deacetylase in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED PHENOTYPE; GENE-EXPRESSION; PROTEIN-KINASE; CARTILAGE; INHIBITION; OSTEOARTHRITIS; CHONDROGENESIS; MECHANISMS; REPRESSION; APOPTOSIS	Histone deacetylase (HDAC) regulates various cellular processes by modulating gene expression. Here, we investigated the role of HDAC in the expression of type II collagen, a marker of differentiated chondrocytes. We found that HDAC activity in primary articular chondrocytes decreases during dedifferentiation induced by serial monolayer culture and that the activity recovered during redifferentiation induced by three-dimensional culture in a cell pellet. Inhibition of HDAC with trichostatin A or PXD101 was sufficient to block type II collagen expression in primary culture chondrocytes. HDAC inhibition also blocked the redifferentiation of dedifferentiated chondrocytes by suppressing the synthesis and accumulation of type II collagen. HDAC inhibition promoted the expression of Wnt-5a, which is known to inhibit type II collagen expression, and knockdown of Wnt-5a blocked the ability of HDAC inhibitors to suppress type II collagen expression. In addition, the induction of Wnt-5a expression by HDAC inhibitors was associated with acetylation of the Wnt-5a promoter. Taken together, our results suggest that HDAC promotes type II collagen expression by suppressing the transcription of Wnt-5a.	Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea.	jschun@gist.ac.kr						Aigner T, 2003, CURR OPIN RHEUMATOL, V15, P634, DOI 10.1097/00002281-200309000-00019; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Eyre DR, 2004, CLIN ORTHOP RELAT R, pS118, DOI 10.1097/01.blo.0000144855.48640.b9; Ghosh P, 2002, BIOGERONTOLOGY, V3, P85, DOI 10.1023/A:1015219716583; Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Li XH, 2006, CANCER RES, V66, P9323, DOI 10.1158/0008-5472.CAN-06-1578; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Monneret C, 2005, EUR J MED CHEM, V40, P1, DOI 10.1016/j.ejmech.2004.10.001; Mort JS, 2005, ARTHRITIS RES THER, V7, P155, DOI 10.1186/ar1781; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Pillai R, 2004, DEV DYNAM, V231, P647, DOI 10.1002/dvdy.20168; Plumb JA, 2003, MOL CANCER THER, V2, P721; Ryu JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601804200; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Shim JS, 2004, ONCOGENE, V23, P1704, DOI 10.1038/sj.onc.1207289; Suzuki F, 1996, CONNECT TISSUE RES, V35, P303, DOI 10.3109/03008209609029204; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702	37	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17123	17131		10.1074/jbc.M700599200	http://dx.doi.org/10.1074/jbc.M700599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428794	hybrid			2022-12-25	WOS:000246946500045
J	Tanner, MJ; Hanel, W; Gaffen, SL; Lin, X				Tanner, Matthew J.; Hanel, Walter; Gaffen, Sarah L.; Lin, Xin			CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL10; KINASE; PHOSPHORYLATION; LYMPHOCYTE; REGULATOR; MALT1; RECRUITMENT; CARD	T lymphocyte (T cell) activation and proliferation is induced by the activation of multiple signal transduction pathways. Earlier studies indicate that CARMA1, a Caspase Recruitment Domain (CARD) and Membrane-associated GUanylate Kinase domain (MAGUK)-containing scaffold protein, plays an essential role in NF-kappa B activation induced by the costimulation of T cell receptor (TCR) and CD28 molecules. However, the molecular mechanism by which CARMA1 mediates TCR-CD28 costimulation-induced NF-kappa B activation is not fully understood. Here we show that CARMA1 is constitutively oligomerized. This oligomerization of CARMA1 is through its Coiled-coil domain. Disruption of the predicted structure of the Coiled-coil domain of CARMA1 impaired its oligomerization and, importantly, abrogated CARMA1-mediated NF-kappa B activation. Interestingly, disruption of the CC1 domain abrogates CARMA1 localization, whereas disruption of the CC2 domain seems to inhibit CARMA1 self-association. Together, our results demonstrate that the oligomerization of CARMA1 is required for TCR-induced NF-kappa B activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14214 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Lin, X (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	xllin@mdanderson.org	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Tanner, Matthew/0000-0002-4392-5535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329, R01AI050848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065899, R01GM065899] Funding Source: NIH RePORTER; NIAID NIH HHS [AI049329, AI050848] Funding Source: Medline; NIGMS NIH HHS [GM065899] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	26	44	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17141	17147		10.1074/jbc.M700169200	http://dx.doi.org/10.1074/jbc.M700169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428801	hybrid			2022-12-25	WOS:000246946500047
J	Holmes, D; Knudsen, G; Mackey-Cushman, S; Su, LS				Holmes, Derek; Knudsen, Geoffry; Mackey-Cushman, Stephanie; Su, Lishan			FoxP3 enhances HIV-1 gene expression by modulating NF kappa B occupancy at the long terminal repeat in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED SYNDROME; TRANSCRIPTIONAL ACTIVITY; IMMUNE DYSREGULATION; PERIPHERAL-BLOOD; SOOTY MANGABEYS; IN-VITRO; VIRUS; CD4(+); INFECTION; SIV	FoxP3 determines the development of CD4+ CD25+ regulatory T (Treg) cells and represses interleukin-2 (IL-2) expression in Treg cells. However, human immunodeficiency virus type 1 (HIV-1) infects and replicates efficiently in FoxP3+ Treg cells. We report that, while inhibiting IL-2 gene expression, FoxP3 enhances gene expression from HIV-1 long terminal repeat (LTR). This FoxP3 activity requires both the N- and C-terminal domains and is inactivated by human IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) mutations. FoxP3 enhances HIV-1 LTR via its specific NF kappa B binding sequences in an NF kappa B-dependent fashion in T cells but not in HEK293 cells. FoxP3 decreases level of histone acetylation at the interleukin-2 locus but not at the HIV-1 LTR. Although NF kappa B nuclear translocation is not altered, FoxP3 enhances NF kappa B-p65 binding to HIV-1 LTR. These data suggest that FoxP3 modulates gene expression in a promoter sequence-dependent fashion by modulating chromatin structure and NF kappa B activity. HIV-1 LTR has evolved to both highjack the T-cell activation pathway for expression and to resist FoxP3-mediated suppression of T-cell activation.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Su, LS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.	lsu@med.unc.edu			NIAID NIH HHS [R01 AI077454, 5T32AI07273, AI048407, T32 AI007273, R01 AI048407, R56 AI048407] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048407, T32AI007273, R01AI048407, R01AI077454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson J, 2005, J IMMUNOL, V174, P3143, DOI 10.4049/jimmunol.174.6.3143; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Apoil PA, 2005, JAIDS-J ACQ IMM DEF, V39, P381, DOI 10.1097/01.qai.0000169662.30783.2d; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Beilharz MW, 2004, J IMMUNOL, V172, P4917, DOI 10.4049/jimmunol.172.8.4917; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Boettler T, 2005, J VIROL, V79, P7860, DOI 10.1128/JVI.79.12.7860-7867.2005; Boyer O, 2004, BLOOD, V103, P3428, DOI 10.1182/blood-2003-07-2598; Brenchley JM, 2006, J VIROL, V80, P6801, DOI 10.1128/JVI.00070-06; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coffield VM, 2003, NAT BIOTECHNOL, V21, P1321, DOI 10.1038/nbt889; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dittmer U, 2004, IMMUNITY, V20, P293, DOI 10.1016/S1074-7613(04)00054-8; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GIORGI JV, 1993, ANN NY ACAD SCI, V677, P126, DOI 10.1111/j.1749-6632.1993.tb38771.x; GIORGI JV, 1987, J CLIN IMMUNOL, V7, P140, DOI 10.1007/BF00916008; GRANT C, 2006, PLOS PATHOG, V2, pS33; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hornum Lars, 2004, Curr Diab Rep, V4, P135, DOI 10.1007/s11892-004-0069-6; Jiang Qi, 2006, BMC Immunol, V7, P6, DOI 10.1186/1471-2172-7-6; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Joshi A, 2005, J VIROL, V79, P4965, DOI 10.1128/JVI.79.8.4965-4976.2005; Joshi A, 2004, VIROLOGY, V321, P307, DOI 10.1016/j.virol.2004.01.014; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Kovalev GI, 2001, J IMMUNOL, V167, P3285, DOI 10.4049/jimmunol.167.6.3285; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Montes M, 2006, AIDS, V20, P1669, DOI 10.1097/01.aids.0000238415.98194.38; Morse SS, 1999, J IMMUNOL, V162, P5309; Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Silvestri G, 2005, J VIROL, V79, P4043, DOI 10.1128/JVI.79.7.4043-4054.2005; Silvestri G, 2005, J MED PRIMATOL, V34, P243, DOI 10.1111/j.1600-0684.2005.00122.x; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Sugimoto K, 2005, J VIROL, V79, P6976, DOI 10.1128/JVI.79.11.6976-6983.2005; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Torgerson TR, 2002, CURR OPIN ALLERGY CL, V2, P481, DOI 10.1097/00130832-200212000-00002; Tsunemi S, 2005, AIDS, V19, P879, DOI 10.1097/01.aids.0000171401.23243.56; Udalova IA, 2002, P NATL ACAD SCI USA, V99, P8167, DOI 10.1073/pnas.102674699; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	63	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15973	15980		10.1074/jbc.M702051200	http://dx.doi.org/10.1074/jbc.M702051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416586	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000246794300006
J	Medvedev, AE; Piao, W; Shoenfelt, J; Rhee, SH; Chen, HY; Basu, S; Wahl, LM; Fenton, MJ; Vogel, SN				Medvedev, Andrei E.; Piao, Wenji; Shoenfelt, Joanna; Rhee, Sang Hoon; Chen, Haiyan; Basu, Subhendu; Wahl, Larry M.; Fenton, Matthew J.; Vogel, Stefanie N.			Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED-RNA; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; RECEPTOR-ASSOCIATED KINASE-1; BRUTONS TYROSINE KINASE; TOLL-LIKE RECEPTOR-2; HUMAN NK CELLS; ADAPTER MOLECULE; INNATE IMMUNITY; DOWN-REGULATION	In this study, we examined whether tyrosine phosphorylation of the Toll-IL-1 resistance (TIR) domain of Toll-like receptor (TLR) 4 is required for signaling and blocked in endotoxin tolerance. Introduction of the P712H mutation, responsible for lipopolysaccharide (LPS) unresponsiveness of C3H/HeJ mice, into the TIR domain of constitutively active mouse Delta TLR4 and mutation of the homologous P714 in human CD4-TLR4 rendered them signaling-incompetent and blocked TLR4 tyrosine phosphorylation. Mutations of tyrosine residues Y674A and Y680A within the TIR domains of CD4-TLR4 impaired its ability to elicit phosphorylation of p38 and JNK mitogen-activated protein kinases, I kappa B-alpha degradation, and activation of NF-kappa B and RANTES reporters. Likewise, full-length human TLR4 expressing Y674A or Y680A mutations showed suppressed capacities to mediate LPS-inducible cell activation. Signaling deficiencies of the Y674A and Y680A TLR4s correlated with altered MyD88-TLR4 interactions, increased associations with a short IRAK-1 isoform, and decreased amounts of activated IRAK-1 in complex with TLR4. Pretreatment of human embryonic kidney (HEK) 293/TLR4/MD-2 cells with protein tyrosine kinase or Src kinase inhibitors suppressed LPS-driven TLR4 tyrosine phosphorylation, p38 and NF-kappa B activation. TLR2 and TLR4 agonists induced TLR tyrosine phosphorylation in HEK293 cells overexpressing CD14, MD-2, and TLR4 or TLR2. Induction of endotoxin tolerance in HEK293/TLR4/MD-2 transfectants and in human monocytes markedly suppressed LPS-mediated TLR4 tyrosine phosphorylation and recruitment of Lyn kinase to TLR4, but did not affect TLR4-MD-2 interactions. Thus, our data demonstrate that TLR4 tyrosine phosphorylation is important for signaling and is impaired in endotoxin-tolerant cells, and suggest involvement of Lyn kinase in these processes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; NIDCR, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Medvedev, AE (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.	amedvedev@som.umaryland.edu	Chen, Haiyan/HGB-6216-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059524, R01AI057490, R01AI044936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000456] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-059524, R01 AI044936, R01 AI044936-06, AI-057490, R01 AI057490, R01 AI059524-04, R01 AI057490-04, AI-44936, R01 AI059524] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005; Adib-Conquy M, 2002, J BIOL CHEM, V277, P27927, DOI 10.1074/jbc.M200705200; Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen LY, 2003, AM J PHYSIOL-LUNG C, V284, pL607, DOI 10.1152/ajplung.00116.2002; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; FAHMI H, 1993, CELL IMMUNOL, V150, P219, DOI 10.1006/cimm.1993.1191; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Goriely S, 2006, BLOOD, V107, P1078, DOI 10.1182/blood-2005-06-2416; Gray P, 2006, J BIOL CHEM, V281, P10489, DOI 10.1074/jbc.M508892200; Hart OM, 2005, J IMMUNOL, V175, P1636, DOI 10.4049/jimmunol.175.3.1636; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HENRICSON BE, 1995, MOL MED, V1, P428, DOI 10.1007/BF03401580; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Ingalls RR, 1997, J IMMUNOL, V159, P433; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Johnsen IB, 2006, EMBO J, V25, P3335, DOI 10.1038/sj.emboj.7601222; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Li LW, 2003, J ENDOTOXIN RES, V9, P39, DOI 10.1179/096805103125001324; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; Medvedev AE, 2005, J IMMUNOL, V174, P6587, DOI 10.4049/jimmunol.174.11.6587; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2003, J ENDOTOXIN RES, V9, P60, DOI 10.1179/096805103125001360; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medvedev AE, 2006, J ENDOTOXIN RES, V12, P133, DOI 10.1179/096805106X102255; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nimah M, 2005, SHOCK, V23, P80, DOI 10.1097/01.shk.0000145206.28812.60; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogawa H, 2003, J IMMUNOL, V170, P5956, DOI 10.4049/jimmunol.170.12.5956; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322; Rao N, 2005, MOL CELL BIOL, V25, P6521, DOI 10.1128/MCB.25.15.6521-6532.2005; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Ronni T, 2003, MOL CELL BIOL, V23, P2543, DOI 10.1128/MCB.23.7.2543-2555.2003; Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Savedra R, 1996, J IMMUNOL, V157, P2549; Schade FU, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P751; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Tada H, 2005, INFECT IMMUN, V73, P7967, DOI 10.1128/IAI.73.12.7967-7976.2005; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Viriyakosol S, 2005, INFECT IMMUN, V73, P1553, DOI 10.1128/IAI.73.3.1553-1560.2005; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986	89	152	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16042	16053		10.1074/jbc.M606781200	http://dx.doi.org/10.1074/jbc.M606781200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392283	hybrid, Green Accepted			2022-12-25	WOS:000246794300012
J	Knox, S; Ge, H; Dimitroff, BD; Ren, Y; Howe, KA; Arsham, AM; Easterday, MC; Neufeld, TP; O'Connor, MB; Selleck, SB				Knox, Sarah; Ge, Hong; Dimitroff, Brian D.; Ren, Yi; Howe, Katie A.; Arsham, Andrew M.; Easterday, Mathew C.; Neufeld, Thomas P.; O'Connor, Michael B.; Selleck, Scott B.			Mechanisms of TSC-mediated Control of Synapse Assembly and Axon Guidance	PLOS ONE			English	Article							CELL-GROWTH; DROSOPHILA TARGET; II RECEPTOR; SIZE; PROLIFERATION; PATHWAY; NUMBER; GIGAS; RHEB; MORPHOLOGY	Tuberous sclerosis complex is a dominant genetic disorder produced by mutations in either of two tumor suppressor genes, TSC1 and TSC2; it is characterized by hamartomatous tumors, and is associated with severe neurological and behavioral disturbances. Mutations in TSC1 or TSC2 deregulate a conserved growth control pathway that includes Ras homolog enriched in brain (Rheb) and Target of Rapamycin (TOR). To understand the function of this pathway in neural development, we have examined the contributions of multiple components of this pathway in both neuromuscular junction assembly and photoreceptor axon guidance in Drosophila. Expression of Rheb in the motoneuron, but not the muscle of the larval neuromuscular junction produced synaptic overgrowth and enhanced synaptic function, while reductions in Rheb function compromised synapse development. Synapse growth produced by Rheb is insensitive to rapamycin, an inhibitor of Tor complex 1, and requires wishful thinking, a bone morphogenetic protein receptor critical for functional synapse expansion. In the visual system, loss of Tsc1 in the developing retina disrupted axon guidance independently of cellular growth. Inhibiting Tor complex 1 with rapamycin or eliminating the Tor complex 1 effector, S6 kinase (S6k), did not rescue axon guidance abnormalities of Tsc1 mosaics, while reductions in Tor function suppressed those phenotypes. These findings show that Tsc-mediated control of axon guidance and synapse assembly occurs via growth-independent signaling mechanisms, and suggest that Tor complex 2, a regulator of actin organization, is critical in these aspects of neuronal development.	[Knox, Sarah; Ge, Hong; Dimitroff, Brian D.; Ren, Yi; Howe, Katie A.; Easterday, Mathew C.; Selleck, Scott B.] Univ Minnesota, Dept Pediat, Ctr Dev Biol, Minneapolis, MN 55455 USA; [Dimitroff, Brian D.; Ren, Yi; Howe, Katie A.; Arsham, Andrew M.; Easterday, Mathew C.; Neufeld, Thomas P.; O'Connor, Michael B.; Selleck, Scott B.] Univ Minnesota, Ctr Dev Biol, Dept Genet Cell Biol & Dev, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Selleck, SB (corresponding author), Univ Minnesota, Dept Pediat, Ctr Dev Biol, Minneapolis, MN 55455 USA.	selle011@umn.edu	O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Arsham, Andrew/0000-0002-5274-8710; Neufeld, Thomas/0000-0001-5659-4811	NIH [GM54832-09, RO1 GMO62509]; Martin Lenz Harrison Endowment; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054832, R01GM062509] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Martin Lenz Harrison Endowment; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH contract grant number GM54832-09 to SBS, the Martin Lenz Harrison Endowment to SBS, and NIH grant RO1 GMO62509 to TN. MBO is an investigator with the Howard Hughes Medical Institute.	Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; Acebes A, 2001, J NEUROSCI, V21, P6264, DOI 10.1523/JNEUROSCI.21-16-06264.2001; ANG LH, 2006, DEV BIOL; Bateman JM, 2004, CELL, V119, P87, DOI 10.1016/j.cell.2004.08.028; Blair SS, 2000, DROSOPHILA PROTOCOLS, P159; Canal I, 1998, J NEUROSCI, V18, P999; Chalhoub N, 2006, BRAIN RES, V1100, P32, DOI 10.1016/j.brainres.2006.05.013; Coyle IP, 2004, NEURON, V41, P521, DOI 10.1016/S0896-6273(04)00016-9; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Ess Kevin C, 2006, Semin Pediatr Neurol, V13, P37, DOI 10.1016/j.spen.2006.01.009; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Huang H, 1999, DEVELOPMENT, V126, P5365; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Marques G, 2003, DEVELOPMENT, V130, P5457, DOI 10.1242/dev.00772; Marques G, 2002, NEURON, V33, P529, DOI 10.1016/S0896-6273(02)00595-0; Martin-Pena A, 2006, J NEUROSCI, V26, P10199, DOI 10.1523/JNEUROSCI.1223-06.2006; Mast JD, 2006, SEMIN CELL DEV BIOL, V17, P42, DOI 10.1016/j.semcdb.2005.11.004; McCabe BD, 2004, NEURON, V41, P891, DOI 10.1016/S0896-6273(04)00073-X; MEINERTZHAGEN IA, 1994, J NEUROGENET, V9, P157, DOI 10.3109/01677069409167277; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murthy V, 2004, J BIOL CHEM, V279, P1351, DOI 10.1074/jbc.M310208200; Neufeld TP, 2003, CURR TOP MICROBIOL, V279, P139; Newsome TP, 2000, DEVELOPMENT, V127, P851; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Prokop A, 2006, SEMIN CELL DEV BIOL, V17, P20, DOI 10.1016/j.semcdb.2005.11.010; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Rao Y, 2005, INT J BIOL SCI, V1, P80; Rawson JM, 2003, J NEUROBIOL, V55, P134, DOI 10.1002/neu.10189; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; von der Brelie C, 2006, EUR J NEUROSCI, V23, P686, DOI 10.1111/j.1460-9568.2006.04594.x; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	47	41	41	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e375	10.1371/journal.pone.0000375	http://dx.doi.org/10.1371/journal.pone.0000375			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440611	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445500006
J	Zhang, KL; Mangeat, B; Ortiz, M; Zoete, V; Trono, D; Telenti, A; Michielin, O				Zhang, Kun-Lin; Mangeat, Bastien; Ortiz, Millan; Zoete, Vincent; Trono, Didier; Telenti, Amalio; Michielin, Olivier			Model Structure of Human APOBEC3G	PLOS ONE			English	Article								Background. APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) has antiretroviral activity associated with the hypermutation of viral DNA through cytosine deamination. APOBEC3G has two cytosine deaminase (CDA) domains; the catalytically inactive amino-terminal domain of APOBEC3G (N-CDA) carries the Vif interaction domain. There is no 3-D structure of APOBEC3G solved by X-ray or nuclear magnetic resonance. Methodology/Principal Findings. We predicted the structure of human APOBEC3G based on the crystal structure of APOBEC2. To assess the model structure, we evaluated 48 mutants of APOBEC3G N-CDA that identify novel variants altering Delta Vif HIV-1 infectivity and packaging of APOBEC3G. Results indicated that the key residue D128 is exposed at the surface of the model, with a negative local electrostatic potential. Mutation D128K changes the sign of that local potential. In addition, two novel functionally relevant residues that result in defective APOBEC3G encapsidation, R122 and W127, cluster at the surface. Conclusions/Significance. The structure model identifies a cluster of residues important for packaging of APOBEC3G into virions, and may serve to guide functional analysis of APOBEC3G.	[Zhang, Kun-Lin; Ortiz, Millan; Telenti, Amalio] Univ Lausanne, Inst Microbiol, Univ Hosp Ctr, Lausanne, Switzerland; [Mangeat, Bastien; Trono, Didier] Ecole Polytech Fed Lausanne, Lausanne, Switzerland; [Zoete, Vincent; Michielin, Olivier] Swiss Inst Bioinformat, Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute of Bioinformatics	Telenti, A (corresponding author), Univ Lausanne, Inst Microbiol, Univ Hosp Ctr, Lausanne, Switzerland.	amalio.telenti@chuv.ch; olivier.michielin@unil.ch	Michielin, Olivier/ABE-7924-2020; Telenti, Amalio/AAY-1674-2021	Mangeat, Bastien/0000-0003-2592-0236	Swiss National Science Foundation [310000-110012/1]; SCORE funds [3232B0-103172, 3200B0-103173]; Faculty of Biology and Medicine of the University of Lausanne; Foundation for advancement in Microbiology and Infectious Diseases	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); SCORE funds; Faculty of Biology and Medicine of the University of Lausanne; Foundation for advancement in Microbiology and Infectious Diseases	Supported by Swiss National Science Foundation grant no. 310000-110012/1 (to A. T.), SCORE funds 3232B0-103172 and 3200B0-103173 (to O.M.) and a grant for interdisciplinary research from the Faculty of Biology and Medicine of the University of Lausanne (to A. T. and O.M.). KZ received a postdoctoral award from the Foundation for advancement in Microbiology and Infectious Diseases. The funding agencies had no role in the design or interpretation of the study.	Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Harris RS, 2006, NAT STRUCT MOL BIOL, V13, P380, DOI 10.1038/nsmb0506-380; Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038; HUTHOFF H, 2007, J VIROL; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Melo F, 1997, J MOL BIOL, V267, P207, DOI 10.1006/jmbi.1996.0868; Melo F, 1998, J MOL BIOL, V277, P1141, DOI 10.1006/jmbi.1998.1665; Melo F, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P187; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Ohkura S, 2006, J VIROL, V80, P8554, DOI 10.1128/JVI.00688-06; Ortiz M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-11; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PROCHNOW C, 2006, NATURE; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Scott J, 1998, ATHEROSCLEROSIS, V141, pS17, DOI 10.1016/S0021-9150(98)00213-5; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu XF, 2006, CURR OPIN HIV AIDS, V1, P187, DOI 10.1097/01.COH.0000221590.03670.32; Zaim J, 2003, NAT IMMUNOL, V4, P1153, DOI 10.1038/ni1203-1153; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004	45	45	48	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e378	10.1371/journal.pone.0000378	http://dx.doi.org/10.1371/journal.pone.0000378			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440614	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500009
J	Lee, Y; Kawagoe, R; Sasai, K; Li, Y; Russell, HR; Curran, T; McKinnon, PJ				Lee, Y.; Kawagoe, R.; Sasai, K.; Li, Y.; Russell, H. R.; Curran, T.; McKinnon, P. J.			Loss of suppressor-of-fused function promotes tumorigenesis	ONCOGENE			English	Article						suppressor of fused; sufu; patched1; medulloblastoma; hedgehog; HhAntag	MEDULLOBLASTOMA CELLS; SONIC HEDGEHOG; MICE; PATHWAY; GLI; SUFU; TRANSCRIPTION; DISRUPTION; REGULATOR; PROTEINS	The Sonic Hedgehog (SHH) signaling pathway is indispensable for development, and functions to activate a transcriptional program modulated by the GLI transcription factors. Here, we report that loss of a regulator of the SHH pathway, Suppressor of Fused (Sufu), resulted in early embryonic lethality in the mouse similar to inactivation of another SHH regulator, Patched1 (Ptch1). In contrast to Ptch(+/-) mice, Sufu(+/-) mice were not tumor prone. However, in conjunction with p53 loss, Sufu(+/-) animals developed tumors including medulloblastoma and rhabdomyosarcoma. Tumors present in Sufu(+/-) p53(-/-) animals resulted from Sufu loss of heterozygosity. Sufu(+/-) p53(-/-) medulloblastomas also expressed a signature gene expression pro. le typical of aberrant SHH signaling, including upregulation of N-myc, Sfrp1, Ptch2 and cyclin D1. Finally, the Smoothened inhibitor, hedgehog antagonist, did not block growth of tumors arising from Sufu inactivation. These data demonstrate that Sufu is essential for development and functions as a tumor suppressor.	St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	McKinnon, PJ (corresponding author), St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.mckinnon@stjude.org	Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Lee, Youngsoo/0000-0003-4773-6464	NCI NIH HHS [CA-21765, P30-CA21765] Funding Source: Medline; NINDS NIH HHS [NS-37956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037956, R56NS037956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Dellovade T, 2006, ANNU REV NEUROSCI, V29, P539, DOI 10.1146/annurev.neuro.29.051605.112858; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dunaeva M, 2003, J BIOL CHEM, V278, P5116, DOI 10.1074/jbc.M209492200; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lee Y, 2003, CANCER RES, V63, P5428; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103	27	171	182	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6442	6447		10.1038/sj.onc.1210467	http://dx.doi.org/10.1038/sj.onc.1210467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452975				2022-12-25	WOS:000249737600008
J	Sharon, M; Witt, S; Glasmacher, E; Baumeister, W; Robinson, CV				Sharon, Michal; Witt, Susanne; Glasmacher, Elke; Baumeister, Wolfgang; Robinson, Carol V.			Mass spectrometry reveals the missing links in the assembly pathway of the bacterial 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME BIOGENESIS; MACROMOLECULAR ASSEMBLIES; THERMOPLASMA-ACIDOPHILUM; RHODOCOCCUS PROTEASOME; 26S PROTEASOME; ACTIVE-SITES; DISSOCIATION; DEGRADATION; MATURATION; COMPLEX	The 20 S proteasome is an essential proteolytic particle, responsible for degrading short-lived and abnormal intracellular proteins. The 700-kDa assembly is comprised of 14 alpha-type and 14 beta-type subunits, which form a cylindrical architecture composed of four stacked heptameric rings (alpha(7)beta(7)beta(7)alpha(7)). The formation of the 20 S proteasome is a complex process that involves a cascade of folding, assembly, and processing events. To date, the understanding of the assembly pathway is incomplete due to the experimental challenges of capturing short-lived intermediates. In this study, we have applied a real-time mass spectrometry approach to capture transient species along the assembly pathway of the 20 S proteasome from Rhodococcus erythropolis. In the course of assembly, we observed formation of an early alpha/beta-heterodimer as well as an unprocessed half-proteasome particle. Formation of mature holoproteasomes occurred in concert with the disappearance of half-proteasomes. We also analyzed the beta-subunits before and during assembly and reveal that those with longer propeptides are incorporated into half- and full proteasomes more rapidly than those that are heavily truncated. To characterize the preholo-proteasome, formed by docking of two unprocessed half- proteasomes and not observed during assembly of wild type subunits, we trapped this intermediate using a beta-subunit mutational variant. In summary, this study provides evidence for transient intermediates in the assembly pathway and reveals detailed insight into the cleavage sites of the propeptide.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany	University of Cambridge; Max Planck Society	Baumeister, W (corresponding author), GSF Inst Mol Immunol, Marchioninistr 25, D-81377 Munich, Germany.	baumeist@biochem.mpg.de; cvr24@cam.ac.uk	Glasmacher, Elke/B-8939-2015	Glasmacher, Elke/0000-0003-1265-2543; Sharon, Michal/0000-0003-3933-0595; robinson, carol/0000-0001-7829-5505				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Benesch JL, 2006, CURR OPIN STRUC BIOL, V16, P245, DOI 10.1016/j.sbi.2006.03.009; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Chernushevich IV, 2004, ANAL CHEM, V76, P1754, DOI 10.1021/ac035406j; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; Gerards WLH, 1998, CELL MOL LIFE SCI, V54, P253, DOI 10.1007/s000180050147; Groll M, 2003, J MOL BIOL, V327, P75, DOI 10.1016/S0022-2836(03)00080-9; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1994, EUR J BIOCHEM, V223, P1061, DOI 10.1111/j.1432-1033.1994.tb19084.x; Heinemeyer W, 2004, CELL MOL LIFE SCI, V61, P1562, DOI 10.1007/s00018-004-4130-z; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hernandez H, 2007, NAT PROTOC, V2, P715, DOI 10.1038/nprot.2007.73; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Kwon YD, 2004, J MOL BIOL, V335, P233, DOI 10.1016/j.jmb.2003.08.029; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Loo JA, 2005, J AM SOC MASS SPECTR, V16, P998, DOI 10.1016/j.jasms.2005.02.017; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; Mayr U, 1998, J STRUCT BIOL, V124, P179, DOI 10.1006/jsbi.1998.4068; Nagy I, 1998, J BACTERIOL, V180, P5448, DOI 10.1128/JB.180.20.5448-5453.1998; Remaut H, 2006, MOL CELL, V22, P831, DOI 10.1016/j.molcel.2006.05.033; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 2001, ENZYMES, V22, P335; Sharon M, 2006, J BIOL CHEM, V281, P9569, DOI 10.1074/jbc.M511951200; Sobott F, 2003, INT J MASS SPECTROM, V230, P193, DOI 10.1016/j.ijms.2003.09.008; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilson HL, 2000, J BACTERIOL, V182, P1680, DOI 10.1128/JB.182.6.1680-1692.2000; Witt S, 2006, STRUCTURE, V14, P1179, DOI 10.1016/j.str.2006.05.019; Zuhl F, 1997, FEBS LETT, V418, P189, DOI 10.1016/S0014-5793(97)01370-7; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2; ZWICK LP, 1994, NAT STRUCT BIOL, V1, P765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	38	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18448	18457		10.1074/jbc.M701534200	http://dx.doi.org/10.1074/jbc.M701534200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17430901	hybrid			2022-12-25	WOS:000247302000051
J	Zhu, SC; Wang, W; Clarke, DC; Liu, XD				Zhu, Songcheng; Wang, Wei; Clarke, David C.; Liu, Xuedong			Activation of Mps1 promotes transforming growth factor-beta-independent Smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; EPITHELIAL-CELLS; CENTROSOME DUPLICATION; MITOTIC CHECKPOINT; RECEPTOR; KINASE; PHOSPHORYLATION; PROTEINS; NUCLEUS; TRANSDUCTION	The primary intracellular mediators of TGF-beta signaling are the Smad proteins. Phosphorylation of R-Smad at the C-terminal SSXS motif by the activated TGF-beta type I receptor kinase triggers a conformation change in R-Smad and facilitates complex formation between R- Smad and Smad4, which shuttle into the nucleus where they interact with DNA and other transcription factors to regulate gene expression. In an attempt to identify proteins interacting with activated Smad signaling complex, we discovered that Mps1, a protein kinase that plays important roles in normal mitotic progression and mitotic checkpoint signaling, co-purifies with this complex. We demonstrated that Smad2 and Smad3 but not Smad4 are substrates of Mps1 in vitro and in vivo. Mps1 phosphorylates Smad2 and Smad3 at the SSXS motif in their C-terminal regions in vitro and in vivo. Disruption of microtubule networks by nocodazole activates Mps1 and promotes TGF-beta-independent activation of Smad signaling. We found that Mps1 is involved in turning on Smad signaling by phosphorylating R-Smads. Our results reveal a novel functional link between Mps1 and Smads in a non-canonical Smad signaling pathway.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, UCB 215, Boulder, CO 80309 USA.	Xuedong.Liu@colorado.edu	Clarke, Dave/AAF-7278-2019	Clarke, David/0000-0002-1520-5426; LIU, XUEDONG/0000-0001-7209-4964	NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NCI NIH HHS [CA095527, R01 CA095527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Clarke DC, 2006, IEE P SYST BIOL, V153, P412, DOI 10.1049/ip-syb:20050055; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kfir S, 2005, MOL CELL BIOL, V25, P8239, DOI 10.1128/MCB.25.18.8239-8250.2005; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Knuesel M, 2003, MOL CELL PROTEOMICS, V2, P1225, DOI 10.1074/mcp.T300007-MCP200; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leng M, 2006, P NATL ACAD SCI USA, V103, P11485, DOI 10.1073/pnas.0601828103; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Murphy SJ, 2004, MOL BIOL CELL, V15, P2853, DOI 10.1091/mbc.E04-02-0097; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Piek E, 1999, J CELL SCI, V112, P4557; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Poss KD, 2004, GENE DEV, V18, P1527, DOI 10.1101/gad.1182604; Schutte M, 1996, CANCER RES, V56, P2527; Shi MJ, 2001, INT IMMUNOL, V13, P733, DOI 10.1093/intimm/13.6.733; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stucke VM, 2004, CHROMOSOMA, V113, P1, DOI 10.1007/s00412-004-0288-2; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	46	50	51	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18327	18338		10.1074/jbc.M700636200	http://dx.doi.org/10.1074/jbc.M700636200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452325	hybrid			2022-12-25	WOS:000247302000039
J	Ditsworth, D; Zong, WX; Thompson, CB				Ditsworth, Dara; Zong, Wei-Xing; Thompson, Craig B.			Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY GROUP BOX-1; CHROMATIN PROTEIN HMGB1; GLYCATION END-PRODUCTS; ADP-RIBOSYLATION; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE-1; NEURITE OUTGROWTH; HUMAN TELOMERES; NECROTIC CELLS; INTACT-CELLS	Necrotic cells release inflammatory mediators that activate cytokine production from innate immune cells. One mediator of this activation is high mobility group box 1 protein (HMGB1). HMGB1 is normally a chromatin-associated protein and is sequestered at condensed chromatin during apoptosis. How it is released from chromatin during necrotic cell death is not known. Here we show that after DNA-alkylating damage, the activation of poly(ADP)-ribose polymerase (PARP) regulates the translocation of HMGB1 from the nucleus to the cytosol. This displaced HMGB1 is subject to release if the cell then loses plasma membrane integrity as a result of necrosis. Both full-length HMGB1 and a truncated form of HMGB1 lacking the highly conserved glutamate-rich C-terminal tail can induce macrophage activation and tumor necrosis factor-alpha production. However, displacement of HMGB1 from the nucleus following PARP activation requires the presence of the glutamate-rich C-terminal tail. Although the C-terminal tail is not the sole substrate for PARP modification of HMGB1, it appears to be required to destabilize HMGB1 association with chromatin following PARP-dependent chromatin modifications. These data suggest that PARP-dependent nuclear-to-cytosolic translocation of HMGB1 serves to establish the ability of cells to release this potent inflammatory mediator upon subsequent necrotic death.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu			NCI NIH HHS [K01 CA098092-04, K01 CA098092-02, K01 CA098092-01A2, K01 CA098092-03, K01 CA098092-06, K01 CA098092, K01 CA098092-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTHAUS FR, 1992, J CELL SCI, V102, P663; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; BERGERON S, 2005, J BIOL CHEM; Bianchi ME, 2004, TRENDS CELL BIOL, V14, P287, DOI 10.1016/j.tcb.2004.04.004; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Knapp S, 2004, BIOCHEMISTRY-US, V43, P11992, DOI 10.1021/bi049364k; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Muller S, 2001, BIOCHEMISTRY-US, V40, P10254, DOI 10.1021/bi0100900; OGATA N, 1980, J BIOL CHEM, V255, P7610; OGATA N, 1980, J BIOL CHEM, V255, P7616; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, EUR J BIOCHEM, V127, P437; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; TANUMA S, 1983, J BIOL CHEM, V258, P4067; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Thorslund T, 2005, MOL CELL BIOL, V25, P7625, DOI 10.1128/MCB.25.17.7625-7636.2005; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200; ZHANG J, 1993, BIOCHEMISTRY-US, V32, P2228, DOI 10.1021/bi00060a014; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	48	160	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17845	17854		10.1074/jbc.M701465200	http://dx.doi.org/10.1074/jbc.M701465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430886	hybrid, Green Accepted			2022-12-25	WOS:000247084500058
J	Wallden, K; Stenmark, P; Nyman, T; Flodin, S; Graslund, S; Loppnau, P; Bianchi, V; Nordlund, P				Wallden, Karin; Stenmark, Pal; Nyman, Tomas; Flodin, Susanne; Graslund, Susanne; Loppnau, Peter; Bianchi, Vera; Nordlund, P.			Crystal structure of human cytosolic 5 '-nucleotidase II - Insights into allosteric regulation and substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE ACTIVITY; 5-NUCLEOTIDASE; RESISTANCE; CLONING; ENZYME; IMP; PHOSPHORYLATION; OVEREXPRESSION; SPECIFICITY; EXPRESSION	Cytosolic 5'-nucleotidase II catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates and regulates the IMP and GMP pools within the cell. It possesses phosphotransferase activity and thereby also catalyzes the reverse reaction. Both reactions are allosterically activated by adenine-based nucleotides and 2,3-bisphosphoglycerate. We have solved structures of cytosolic 5'-nucleotidase II as native protein (2.2 angstrom) and in complex with adenosine (1.5 angstrom) and beryllium trifluoride (2.15 angstrom). The tetrameric enzyme is structurally similar to enzymes of the haloacid dehalogenase (HAD) superfamily, including mitochondrial 5'(3')-deoxyribonucleotidase and cytosolic 5'-nucleotidase III but possesses additional regulatory regions that contain two allosteric effector sites. At effector site 1 located near a subunit interface we modeled diadenosine tetraphosphate with one adenosine moiety in each subunit. This efficiently glues the tetramer subunits together in pairs. The model shows why diadenosine tetraphosphate but not diadenosine triphosphate activates the enzyme and supports a role for cN-II during apoptosis when the level of diadenosine tetraphosphate increases. We have also modeled 2,3-bisphosphoglycerate in effector site 1 using one phosphate site from each subunit. By comparing the structure of cytosolic 5'-nucleotidase II with that of mitochondrial 5'(3')deoxyribonucleotidase in complex with dGMP, we identified residues involved in substrate recognition.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Struct Genom Consortium, S-17177 Stockholm, Sweden; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Padua, Dept Biol, I-35131 Padua, Italy; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; University of Toronto; Structural Genomics Consortium; University of Padua; Karolinska Institutet	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Par.Nordlund@ki.se	Gräslund, Susanne/ABB-6339-2020	Wallden, Karin/0000-0002-7391-1003; Graslund, Susanne/0000-0003-0077-8333; Stenmark, Pal/0000-0003-4777-3417	Telethon [GGP05001] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; Bitto E, 2006, J BIOL CHEM, V281, P20521, DOI 10.1074/jbc.M602000200; Bretonnet AS, 2005, FEBS LETT, V579, P3363, DOI 10.1016/j.febslet.2005.05.014; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027; Galmarini CM, 2003, BRIT J HAEMATOL, V122, P53, DOI 10.1046/j.1365-2141.2003.04386.x; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; Himo F, 2005, J PHYS CHEM B, V109, P20004, DOI 10.1021/jp0546150; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; Hunsucker SA, 2005, PHARMACOL THERAPEUT, V107, P1, DOI 10.1016/j.pharmthera.2005.01.003; ITOH R, 1967, BIOCHIM BIOPHYS ACTA, V146, P151, DOI 10.1016/0005-2744(67)90081-2; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESFEAMCB; Lotfi K, 2001, BRIT J HAEMATOL, V113, P339, DOI 10.1046/j.1365-2141.2001.02751.x; Marques AFP, 1998, J NEUROCHEM, V71, P1241; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pesi R, 1998, BIOL CHEM, V379, P699, DOI 10.1515/bchm.1998.379.6.699; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Pesi R, 2000, NEUROREPORT, V11, P1827, DOI 10.1097/00001756-200006260-00006; PINTO RM, 1986, BIOCHEM BIOPH RES CO, V138, P261, DOI 10.1016/0006-291X(86)90274-3; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 1999, EUR J BIOCHEM, V261, P689, DOI 10.1046/j.1432-1327.1999.00320.x; Randitelli S, 1996, INT J BIOCHEM CELL B, V28, P711, DOI 10.1016/1357-2725(95)00171-9; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; Schirmer M, 1998, EXP HEMATOL, V26, P1223; Spychala J, 1999, EUR J BIOCHEM, V259, P851, DOI 10.1046/j.1432-1327.1999.00099.x; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; Suzuki NN, 2004, STRUCTURE, V12, P751, DOI 10.1016/j.str.2004.02.038; TOZZI MG, 1991, ARCH BIOCHEM BIOPHYS, V291, P212, DOI 10.1016/0003-9861(91)90125-3; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; Vartanian AA, 2003, BIOCHEM PHARMACOL, V65, P227, DOI 10.1016/S0006-2952(02)01481-8; Wallden K, 2005, STRUCTURE, V13, P1081, DOI 10.1016/j.str.2005.04.023; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; Wu JZ, 2005, ANTIMICROB AGENTS CH, V49, P2164, DOI 10.1128/AAC.49.6.2164-2171.2005; Yamamoto S, 2007, INT J HEMATOL, V85, P108, DOI 10.1532/IJH97.06177	52	58	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17828	17836		10.1074/jbc.M700917200	http://dx.doi.org/10.1074/jbc.M700917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17405878	hybrid			2022-12-25	WOS:000247084500056
J	Charrier, L; Yan, YT; Nguyen, HTT; Dalmasso, G; Laboisse, CL; Gewirtz, AT; Sitaraman, SV; Merlin, D				Charrier, Laetitia; Yan, Yutao; Nguyen, Hang Thi Thu; Dalmasso, Guillaume; Laboisse, Christian L.; Gewirtz, Andrew T.; Sitaraman, Shanthi V.; Merlin, Didier			ADAM-15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INFLAMMATORY-BOWEL-DISEASE; ADHESION MOLECULE-1 ICAM-1; CROHNS-DISEASE; CELIAC-DISEASE; E-CADHERIN; INTEGRIN ALPHA(E)BETA(7); GENE-EXPRESSION; N-CADHERIN; FAMILY	Intestinal epithelial cells (IEC) play an immunoregulatory role in the intestine. This role involves cell-cell interactions with intraepithelial lymphocytes that may also play a role in some enteropathies. The discovery of the RGD motif-containing protein ADAM-15 (a disintegrin and metalloprotease-15) raises the question of its involvement in these cell-cell interactions. Cell adhesion assays were performed using the Jurkat E6.1 T cell line as a model of T lymphocytes and Caco2-BBE monolayers as a model of intestinal epithelia. Our results show that an anti-ADAM- 15 ectodomain antibody inhibited the attachment of Jurkat cells on Caco2-BBE monolayers. Overexpression of ADAM-15 in Caco2-BBE cells enhanced Jurkat cell binding, and overexpression of ADAM-15 in Jurkat cells enhanced their aggregation. Mutagenesis experiments showed that both the mutation of ADAM-15 RGD domain or the deletion of its cytoplasmic tail decreased these cell-cell interactions. Moreover, wound-healing experiments showed that epithelial ADAM-15 mediated Jurkat cell adhesion to Caco2-BBE cells enhances the mechanisms of wound repair. We also found that ADAM-15 mediated aggregation of Jurkat cells increases the expression of tumor necrosis factor-alpha mRNA. These results demonstrate the following: 1) ADAM-15 is involved in heterotypic adhesion of intraepithelial lymphocytes to IEC as well as in homotypic aggregation of T cells; 2) both the RGD motif and the cytoplasmic tail of ADAM-15 are involved for these cell-cell interactions; and 3) ADAM-15-mediated cell-cell interactions are involved in mechanisms of epithelial restitution and production of pro-inflammatory mediators. Altogether these findings point to ADAM-15 as a possible therapeutic target for prevention of inappropriate T cell activation involved in some pathologies.	Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; INSERM, U539, F-44035 Nantes, France	Emory University; Emory University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Charrier, L (corresponding author), Emory Univ, Dept Med, Div Digest Dis, 615 Michael st, Atlanta, GA 30322 USA.	lcharri@emory.edu	Dalmasso, Guillaume/N-2443-2018; Nguyen, Hang/N-2441-2018	Dalmasso, Guillaume/0000-0002-3433-870X; Nguyen, Hang/0000-0001-7431-5126	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850, R01DK061417, R56DK061941, R01DK061941, R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK061417, DK55850, R24-DK064399, DK061941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR OPIN CELL BIOL, V12, P563, DOI 10.1016/S0955-0674(00)00132-0; BEAULIEU JF, 1992, J CELL SCI, V102, P427; Borley NR, 2000, J PATHOL, V190, P196; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Buyse M, 2003, AM J PATHOL, V163, P1969, DOI 10.1016/S0002-9440(10)63555-9; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CEPEK KL, 1993, J IMMUNOL, V150, P3459; Charrier L, 2005, AM J PHYSIOL-GASTR L, V288, pG346, DOI 10.1152/ajpgi.00262.2004; Desloges N, 1998, J CELL BIOCHEM, V71, P536; Dignass AU, 1996, EXP CELL RES, V225, P422, DOI 10.1006/excr.1996.0193; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; FERGUSON A, 1976, ACTA PAEDIATR SCAND, V65, P541, DOI 10.1111/j.1651-2227.1976.tb04929.x; Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724; FUKUSHIMA K, 1991, GASTROENTEROLOGY, V101, P670, DOI 10.1016/0016-5085(91)90524-O; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; HALSTENSEN TS, 1990, EUR J IMMUNOL, V20, P1825, DOI 10.1002/eji.1830200829; HASKARD D, 1986, J IMMUNOL, V137, P2901; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Higgins JMG, 2000, J BIOL CHEM, V275, P25652, DOI 10.1074/jbc.M001228200; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAISERLIAN D, 1991, EUR J IMMUNOL, V21, P2415, DOI 10.1002/eji.1830211018; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kawamura-Kodama K, 1999, J INVEST DERMATOL, V112, P62, DOI 10.1046/j.1523-1747.1999.00479.x; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LAZENBY AJ, 1989, HUM PATHOL, V20, P18, DOI 10.1016/0046-8177(89)90198-6; Liu X, 2003, J BIOL CHEM, V278, P23672, DOI 10.1074/jbc.M302777200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Makagiansar IT, 2002, MOL CELL BIOCHEM, V233, P1, DOI 10.1023/A:1015556625038; MAKI M, 1991, GUT, V32, P1412, DOI 10.1136/gut.32.11.1412; MENTZER SJ, 1986, J IMMUNOL, V137, P108; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Mosnier JF, 2006, LAB INVEST, V86, P1064, DOI 10.1038/labinvest.3700465; Naganuma M, 2002, AM J GASTROENTEROL, V97, P1741; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; RICKERT RR, 1980, J CLIN GASTROENTEROL, V2, P11, DOI 10.1097/00004836-198003000-00003; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; ROSS IN, 1981, Q J MED, V50, P435; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; Sanders DSA, 2005, J CLIN PATHOL, V58, P568, DOI 10.1136/jcp.2004.021840; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; SPENCER J, 1989, GUT, V30, P339, DOI 10.1136/gut.30.3.339; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; Taraszka KS, 2000, J EXP MED, V191, P1555, DOI 10.1084/jem.191.9.1555; VINAYAK VK, 1991, MICROB PATHOGENESIS, V10, P343, DOI 10.1016/0882-4010(91)90079-P; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714; Yusuf-Makagiansar H, 2001, INFLAMMATION, V25, P203, DOI 10.1023/A:1011044616170; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	56	22	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16948	16958		10.1074/jbc.M700158200	http://dx.doi.org/10.1074/jbc.M700158200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416588	hybrid			2022-12-25	WOS:000246946500028
J	Zhu, JW; Yu, D; Zeng, XC; Zhou, K; Zhan, X				Zhu, Jianwei; Yu, Dan; Zeng, Xian-Chun; Zhou, Kang; Zhan, Xi			Receptor-mediated endocytosis involves tyrosine phosphorylation of cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; COATED-PIT INVAGINATION; ACTIN POLYMERIZATION; IN-VITRO; CONSTITUTIVE INTERNALIZATION; DEPENDENT ENDOCYTOSIS; TRANSFERRIN RECEPTORS; SIGNALING PATHWAY; DYNAMIC ACTIN; CLATHRIN	Efficient internalization of cell surface receptors requires actin polymerization mediated by Arp2/3 complex and cortactin, a prominent substrate of the protein-tyrosine kinase Src. However, the significance of cortactin tyrosine phosphorylation in endocytosis is unknown. We found that overexpression of a cortactin mutant deficient in tyrosine phosphorylation decreased transferrin uptake. Suppression of cortactin expression by RNA interference also reduced transferrin internalization. Such inhibition was effectively rescued by overexpressing wild-type cortactin but not a cortactin mutant deficient in tyrosine phosphorylation or a mutant with deletion of the Src homology 3 domain. Likewise, purified phosphorylation-null cortactin failed to restore the formation of clathrin-coated vesicles in a cortactin-depleted cell extract. In vitro analysis revealed that Src-mediated phosphorylation enhanced the association of cortactin with dynamin-2 in a tyrosine phosphorylation-dependent manner. Quantitative analysis demonstrated that Src enhances the affinity of cortactin for dynamin-2 by more than 3-fold. On the other hand, Src-treated dynamin-2 had no effect on its interaction with cortactin. These data indicate that Src kinase is implicated in clathrin-mediated endocytosis by phosphorylation of cortactin.	Univ Maryland, Sch Med, Dept Pathol, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; Nantong Univ, Affiliated Hosp, Nantong 226001, Peoples R China; Univ Maryland, Sch Med, Dept Pathol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Penn State Univ, Biochem Microbiol & Mol Biol Program, University Pk, PA 16802 USA	University System of Maryland; University of Maryland Baltimore; Nantong University; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhan, X (corresponding author), Univ Maryland, Sch Med, Dept Pathol, Ctr Vasc & Inflammatory Dis, 800 W Baltimore St, Baltimore, MD 21201 USA.	xzhan@som.umaryland.edu		Zeng, Xian-Chun/0000-0003-2675-2596	NATIONAL CANCER INSTITUTE [R01CA091984, R01CA113809] Funding Source: NIH RePORTER; NCI NIH HHS [CA091984, CA113809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Broudy VC, 1999, BLOOD, V94, P1979; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Chao C, 2005, J BIOL CHEM, V280, P33368, DOI 10.1074/jbc.M506337200; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HOLEN I, 1995, BIOCHEM J, V311, P317, DOI 10.1042/bj3110317; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Huang ZY, 2006, J LEUKOCYTE BIOL, V80, P1553, DOI 10.1189/jlb.0106019; Ihara Y, 2002, BIOCHEM BIOPH RES CO, V297, P353, DOI 10.1016/S0006-291X(02)02195-2; Illes A, 2006, CELL SIGNAL, V18, P830, DOI 10.1016/j.cellsig.2005.07.012; Kaksonen M, 2000, J CELL SCI, V113, P4421; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Korolchuk V, 2003, BIOCHEM SOC T, V31, P857, DOI 10.1042/BST0310857; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Li YS, 2001, CANCER RES, V61, P6906; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; MAA MC, 1992, ONCOGENE, V7, P2429; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Qualmann B, 2002, INT REV CYTOL, V220, P93; SALAMERO J, 1995, EUR J IMMUNOL, V25, P2757, DOI 10.1002/eji.1830251007; Sauvonnet N, 2005, J CELL BIOL, V168, P155, DOI 10.1083/jcb.200406174; Schmid RS, 2000, J NEUROSCI, V20, P4177; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06-03-0187; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhu JW, 2005, J CELL SCI, V118, P807, DOI 10.1242/jcs.01668	57	41	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16086	16094		10.1074/jbc.M701997200	http://dx.doi.org/10.1074/jbc.M701997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420251	hybrid			2022-12-25	WOS:000246794300017
J	Samson, T; Will, C; Knoblauch, A; Sharek, L; von der Mark, K; Burridge, K; Wixler, V				Samson, Thomas; Will, Carola; Knoblauch, Alexander; Sharek, Lisa; von der Mark, Klaus; Burridge, Keith; Wixler, Viktor			Def-6, a guanine nucleotide exchange factor for Rac1, interacts with the skeletal muscle integrin chain alpha 7A and influences myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-7-BETA-1 INTEGRIN; CELL-ADHESION; BINDING-PROTEIN; RHO-GTPASES; EXPRESSION PATTERNS; CYTOPLASMIC DOMAINS; MUSCULAR-DYSTROPHY; LAMININ; RECEPTOR; MIGRATION	Integrin alpha 7 beta 1 is the major laminin binding integrin receptor of muscle cells. The alpha 7 chain occurs in several splice isoforms, of which alpha 7A and alpha 7B differ in their intracellular domains only. The fact that the expression of alpha 7A and alpha 7B is tightly regulated during skeletal muscle development suggests different and distinct roles for both isoforms. However, so far, functional properties and interacting proteins were described for the alpha 7B chain only. Using a yeast two-hybrid screen, we have found that Def-6, a guanine nucleotide exchange factor for Rac1, binds to the intracellular domain of the alpha 7A subunit. The specificity of the Def-6-alpha 7A interaction has been shown by direct yeast two-hybrid binding assays and coprecipitation experiments. This is the first description of an alpha 7A-specific and -exclusive interaction, because Def-6 did not bind to any other tested integrin cytoplasmic domain. Interestingly, the binding of Def-6 to alpha 7A was abolished, when cells were cotransfected with an Src-related kinase, which is known to phosphorylate Def-6 and stimulate its exchange activity. We found expression of Def-6 was not only restricted to T-lymphocytes as described thus far but in a more widespread manner, including different muscle tissues. In cells, Def-6 is seen in newly forming cell protrusions and focal adhesions, and its localization partially overlaps with the alpha 7A integrin receptor. C2C12 myoblasts overexpressing Def-6 show a delay of Rac1 inactivation during myogenic differentiation and abnormal myotube formation. Thus, our data suggest a role for Def-6 in the fine regulation of Rac1 during myogenesis with the integrin alpha 7A chain guiding this regulation in a spatio-temporal manner.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Klinikum Munster, Inst Mol Virol, Zentrum Mol Biol Entzundung, D-48149 Munster, Germany; Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum, D-91054 Erlangen, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of Munster; University of Erlangen Nuremberg	Samson, T (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, CB 7295, Chapel Hill, NC 27599 USA.	thomas_samson@med.unc.edu	von+der+Mark, Klaus/AAJ-1443-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO;2-J; Borggrefe T, 2001, EUR J IMMUNOL, V31, P2467, DOI 10.1002/1521-4141(200108)31:8<2467::AID-IMMU2467>3.0.CO;2-P; Bryan BA, 2005, MOL CELL BIOL, V25, P11089, DOI 10.1128/MCB.25.24.11089-11101.2005; Bryan BA, 2005, CELL MOL LIFE SCI, V62, P1547, DOI 10.1007/s00018-005-5029-z; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Chen EH, 2003, CELL, V114, P751, DOI 10.1016/S0092-8674(03)00720-7; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; COLLO G, 1993, J BIOL CHEM, V268, P19019; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gross B, 2002, EUR J IMMUNOL, V32, P1121; Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; Kaariainen M, 2002, AM J PATHOL, V161, P1023, DOI 10.1016/S0002-9440(10)64263-0; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Li J, 2003, DEV BIOL, V261, P209, DOI 10.1016/S0012-1606(03)00304-X; Markowitz D G, 1988, Trans Assoc Am Physicians, V101, P212; Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nawrotzki R, 2003, HUM MOL GENET, V12, P483, DOI 10.1093/hmg/ddg047; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rosoff WJ, 2002, J CELL PHYSIOL, V193, P328, DOI 10.1002/jcp.10182; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Schober S, 2000, EXP CELL RES, V255, P303, DOI 10.1006/excr.2000.4806; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; SONG WK, 1993, J CELL SCI, V106, P1139; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Vignier N, 1999, BIOCHEM BIOPH RES CO, V260, P357, DOI 10.1006/bbrc.1999.0916; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	63	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15730	15742		10.1074/jbc.M611197200	http://dx.doi.org/10.1074/jbc.M611197200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403664	hybrid, Green Published			2022-12-25	WOS:000246589600049
J	Nawroth, R; van Zante, A; Cervantes, S; McManus, M; Hebrok, M; Rosen, SD				Nawroth, Roman; van Zante, Annemieke; Cervantes, Sara; McManus, Michael; Hebrok, Matthias; Rosen, Steven D.			Extracellular Sulfatases, Elements of the Wnt Signaling Pathway, Positively Regulate Growth and Tumorigenicity of Human Pancreatic Cancer Cells	PLOS ONE			English	Article								Background. Heparan sulfate proteoglycans (HSPGs) are control elements in Wnt signaling, which bind extracellularly to Wnt ligands and regulate their ability to interact with signal transduction receptors on the cell surface. Sulf-1 and Sulf-2 are novel extracellular sulfatases that act on internal glucosamine-6-sulfate (6S) modifications within HSPGs and thereby modulate HSPG interactions with various signaling molecules, including Wnt ligands. Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma. Principle Findings. Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines. Expression of human extracellular sulfatases Sulf-1 and Sulf-2 enhanced Wnt signaling in a reconstituted system. Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling. Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth. Sulf-2 silencing in two of these lines resulted in markedly reduced tumorigenesis in immunocompromised mice. Conclusions/Significance. We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells. Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer. Our results run counter to the prevailing view in the literature that the Sulfs are negative regulators of tumorigenesis.	[Nawroth, Roman; Rosen, Steven D.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [van Zante, Annemieke] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Cervantes, Sara; McManus, Michael; Hebrok, Matthias] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; [Hebrok, Matthias; Rosen, Steven D.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	steven.rosen@ucsf.edu	mcmanus, michael/AAB-1239-2020	mcmanus, michael/0000-0003-3013-6569; Rosen, Steven/0000-0002-6245-701X	Susan Komen Breast Cancer Foundation [PDF0402844]; German Research Foundation [NA439/1-1]; Ministerio de Educacion, Cultura y Deporte of the Spanish Government (SC); National Institute of Health [GM57411, CA122025, HL075602, CA112537]; NATIONAL CANCER INSTITUTE [R21CA122025, R01CA112537] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057411] Funding Source: NIH RePORTER	Susan Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); German Research Foundation(German Research Foundation (DFG)); Ministerio de Educacion, Cultura y Deporte of the Spanish Government (SC); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The research was supported by a Susan Komen Breast Cancer Foundation Grant PDF0402844 (RN and SDR), the German Research Foundation Grant NA439/1-1 (RN), Ministerio de Educacion, Cultura y Deporte of the Spanish Government (SC) and National Institute of Health Grants GM57411 (SDR), CA122025 (SDR), HL075602 (SDR) and CA112537 (MH). The preparation of the lentiviruses was subsidized by the Sandler Lentivirus Core Facility at UCSF. The sponsors had no role in design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Ai XB, 2006, J BIOL CHEM, V281, P4969, DOI 10.1074/jbc.M511902200; Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Chada S, 2005, MOL THER, V11, P724, DOI 10.1016/j.ymthe.2004.12.021; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Galli LM, 2006, DEV DYNAM, V235, P681, DOI 10.1002/dvdy.20681; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; He B, 2005, CANCER RES, V65, P743; Heller RS, 2003, GENE EXPRESSION, V11, P141, DOI 10.3727/000000003108749035; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Kakinuma Y, 2004, J NEUROSCI RES, V77, P653, DOI 10.1002/jnr.20197; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Laheru D, 2005, NAT REV CANCER, V5, P459, DOI 10.1038/nrc1630; Lai JP, 2006, GASTROENTEROLOGY, V130, P2130, DOI 10.1053/j.gastro.2006.02.056; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lamanna WC, 2006, BIOCHEM J, V400, P63, DOI 10.1042/BJ20060848; Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lowy AM, 2003, ANN SURG ONCOL, V10, P284, DOI 10.1245/ASO.2003.05.003; Lum DH, 2007, MOL CELL BIOL, V27, P678, DOI 10.1128/MCB.01279-06; Marcao A, 2003, BIOCHEM BIOPH RES CO, V306, P293, DOI 10.1016/S0006-291X(03)00969-0; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2003, TRENDS GLYCOSCI GLYC, V15, P159, DOI 10.4052/tigg.15.159; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Su AI, 2001, CANCER RES, V61, P7388; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607	50	141	143	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e392	10.1371/journal.pone.0000392	http://dx.doi.org/10.1371/journal.pone.0000392			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460759	Green Published, gold			2022-12-25	WOS:000207445600006
J	Kiya, T; Kunieda, T; Kubo, T				Kiya, Taketoshi; Kunieda, Takekazu; Kubo, Takeo			Increased Neural Activity of a Mushroom Body Neuron Subtype in the Brains of Forager Honeybees	PLOS ONE			English	Article								Honeybees organize a sophisticated society, and the workers transmit information about the location of food sources using a symbolic dance, known as 'dance communication'. Recent studies indicate that workers integrate sensory information during foraging flight for dance communication. The neural mechanisms that account for this remarkable ability are, however, unknown. In the present study, we established a novel method to visualize neural activity in the honeybee brain using a novel immediate early gene, kakusei, as a marker of neural activity. The kakusei transcript was localized in the nuclei of brain neurons and did not encode an open reading frame, suggesting that it functions as a non-coding nuclear RNA. Using this method, we show that neural activity of a mushroom body neuron subtype, the small-type Kenyon cells, is prominently increased in the brains of dancer and forager honeybees. In contrast, the neural activity of the two mushroom body neuron subtypes, the small-and large-type Kenyon cells, is increased in the brains of re-orienting workers, which memorize their hive location during re-orienting flights. These findings demonstrate that the small-type Kenyon cell-preferential activity is associated with foraging behavior, suggesting its involvement in information integration during foraging flight, which is an essential basis for dance communication.	[Kiya, Taketoshi; Kunieda, Takekazu; Kubo, Takeo] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan	University of Tokyo	Kiya, T (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan.	kiya@biol.s.u-tokyo.ac.jp; stkubo@biol.s.u-tokyo.ac.jp	Kiya, Taketoshi/J-9032-2015; Kiya, Taketoshi/ABE-6519-2020; KUBO, TAKEO/G-4951-2014; Kunieda, Takekazu/G-4946-2014	Kiya, Taketoshi/0000-0002-5709-8016; Kubo, Takeo/0000-0002-5914-5269; Kunieda, Takekazu/0000-0002-6256-1335	Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN); Japan Society for the Promotion of Science (JSPS)	Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN). T. Kiya is the recipient of a Grant-in-Aid for Japan Society for the Promotion of Science (JSPS) Fellows.	Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; Ben-Shahar Y, 2003, J EXP BIOL, V206, P2507, DOI 10.1242/jeb.00442; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Dyer FC, 2002, ANNU REV ENTOMOL, V47, P917, DOI 10.1146/annurev.ento.47.091201.145306; Ehmer B, 2002, J COMP NEUROL, V451, P362, DOI 10.1002/cne.10355; Esch HE, 2001, NATURE, V411, P581, DOI 10.1038/35079072; Farris SM, 2001, J NEUROSCI, V21, P6395, DOI 10.1523/JNEUROSCI.21-16-06395.2001; Fitzpatrick MJ, 2005, TRENDS ECOL EVOL, V20, P96, DOI 10.1016/j.tree.2004.11.017; Giurfa M, 2003, CURR OPIN NEUROBIOL, V13, P726, DOI 10.1016/j.conb.2003.10.015; Gronenberg W, 2001, J COMP NEUROL, V435, P474, DOI 10.1002/cne.1045; Grunewald B, 1999, J COMP NEUROL, V404, P114; Guzowski JF, 2001, J NEUROSCI, V21, P5089, DOI 10.1523/JNEUROSCI.21-14-05089.2001; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Ismail N, 2006, P NATL ACAD SCI USA, V103, P207, DOI 10.1073/pnas.0508318102; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Klein ME, 2005, CURR OPIN NEUROBIOL, V15, P507, DOI 10.1016/j.conb.2005.08.011; Komischke B, 2005, EUR J NEUROSCI, V21, P477, DOI 10.1111/j.1460-9568.2005.03879.x; Malun D, 2002, J NEUROBIOL, V53, P343, DOI 10.1002/neu.10119; MELLO CV, 1992, P NATL ACAD SCI USA, V89, P6818, DOI 10.1073/pnas.89.15.6818; Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801; Menzel R, 2005, P NATL ACAD SCI USA, V102, P3040, DOI 10.1073/pnas.0408550102; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; Nieh JC, 2000, J EXP BIOL, V203, P1573; Paul RK, 2005, INSECT MOL BIOL, V14, P9, DOI 10.1111/j.1365-2583.2004.00524.x; Riley JR, 2005, NATURE, V435, P205, DOI 10.1038/nature03526; Robinson GE, 2005, NAT REV GENET, V6, P257, DOI 10.1038/nrg1575; RYBAK J, 1993, J COMP NEUROL, V334, P444, DOI 10.1002/cne.903340309; Sakata S, 2002, EUR J NEUROSCI, V15, P735, DOI 10.1046/j.1460-9568.2002.01905.x; Sandeman DC, 1996, J EXP BIOL, V199, P2585; Sawata M, 2002, RNA, V8, P772, DOI 10.1017/S1355838202028790; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Schroter U, 2003, J COMP NEUROL, V465, P168, DOI 10.1002/cne.10843; Seeley T., 1995, WISDOM HIVE SOCIAL P; SEELEY TD, 1988, BEHAV ECOL SOCIOBIOL, V22, P229, DOI 10.1007/BF00299837; Srinivasan MV, 2000, SCIENCE, V287, P851, DOI 10.1126/science.287.5454.851; Strausfeld NJ, 2002, J COMP NEUROL, V450, P4, DOI 10.1002/cne.10285; Takeuchi H, 2003, INSECT MOL BIOL, V12, P291, DOI 10.1046/j.1365-2583.2003.00414.x; Takeuchi H, 2002, FEBS LETT, V513, P230, DOI 10.1016/S0014-5793(02)02319-0; Takeuchi H, 2001, INSECT MOL BIOL, V10, P487, DOI 10.1046/j.0962-1075.2001.00288.x; Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102; von Frisch K, 1969, DANCE LANGUAGE ORIEN; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; WILSON EO, 1975, SCIOBIOLOGY NEW SYNT; Winston M.L., 1991, BIOL HONEY BEE; Yang H, 1999, J HISTOCHEM CYTOCHEM, V47, P431, DOI 10.1177/002215549904700402	48	48	48	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e371	10.1371/journal.pone.0000371	http://dx.doi.org/10.1371/journal.pone.0000371			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440607	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500002
J	Wang, N; Lin, KK; Lu, Z; Lam, KS; Newton, R; Xu, X; Yu, Z; Gill, GN; Andersen, B				Wang, N.; Lin, K. K.; Lu, Z.; Lam, K. S.; Newton, R.; Xu, X.; Yu, Z.; Gill, G. N.; Andersen, B.			The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells	ONCOGENE			English	Article						breast cancer; lim domain; LMO; proliferation; apoptosis; HDAC	BONE MORPHOGENETIC PROTEIN-7; CANCER PROGRESSION; DOMAIN; RECEPTOR; GROWTH; GLAND; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; INVASION	The nuclear LIM-only protein 4 (LMO4) is upregulated in breast cancer, especially estrogen receptor-negative tumors, and its overexpression in mice leads to hyperplasia and tumor formation. Here, we show that deletion of LMO4 in the mammary glands of mice leads to impaired lobuloalveolar development due to decreased epithelial cell proliferation. With the goal of discovering potential LMO4-target genes, we also developed a conditional expression system in MCF-7 cells for both LMO4 and a dominant negative (DN) form of its co-regulator, cofactor of LIM domains (Clim/Ldb/Nli). We then used DNA microarrays to identify genes responsive to LMO4 and DN-Clim upregulation. One of the genes common to both data sets was bone morphogenic protein 7 (BMP7), whose expression is also significantly correlated with LMO4 transcript levels in a large dataset of human breast cancers, suggesting that BMP7 is a bona. de target gene of LMO4 in breast cancer. Inhibition of BMP7 partially blocks the effects of LMO4 on apoptosis, indicating that BMP7 mediates at least some functions of LMO4. Gene transfer studies show that LMO4 regulates the BMP7 promoter, and chromatin immunoprecipitation studies show that LMO4 and its cofactor Clim2 are recruited to the BMP7 promoter. Furthermore, we demonstrate that HDAC2 recruitment to the BMP7 promoter is inhibited by upregulation of LMO4 and that HDAC2 knockdown upregulates the promoter. These studies suggest a novel mechanism of action for LMO4: LMO4, Clim2 and HDAC2 are part of a transcriptional complex, and increased LMO4 levels can disrupt the complex, leading to decreased HDAC2 recruitment and increased promoter activity.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lin, Kevin/C-1959-2009; Lu, ZX/G-4586-2010	Lin, Kevin/0000-0003-4305-8352	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44882] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dean C, 2004, DEVELOPMENT, V131, P4155, DOI 10.1242/dev.01285; Deane JE, 2004, EMBO J, V23, P3589, DOI 10.1038/sj.emboj.7600376; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gruvberger S, 2001, CANCER RES, V61, P5979; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kusumegi T, 2004, J BIOCHEM MOL TOXIC, V18, P1, DOI 10.1002/jbt.20004; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lu Z, 2006, ONCOGENE, V25, P2920, DOI 10.1038/sj.onc.1209318; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Monroe DG, 2000, MOL CELL BIOL, V20, P4626, DOI 10.1128/MCB.20.13.4626-4634.2000; Mousses S, 2002, CANCER RES, V62, P1256; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Ryan DP, 2006, J MOL BIOL, V359, P66, DOI 10.1016/j.jmb.2006.02.074; Singh RR, 2005, CANCER RES, V65, P10594, DOI 10.1158/0008-5472.CAN-05-2268; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288	36	51	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6431	6441		10.1038/sj.onc.1210465	http://dx.doi.org/10.1038/sj.onc.1210465			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452977				2022-12-25	WOS:000249737600007
J	Sariahmetoglu, M; Crawford, BD; Leon, H; Sawicka, J; Li, LJ; Ballermann, BJ; Holmes, C; Berthiaume, LG; Holt, A; Sawicki, G; Schulz, R				Sariahmetoglu, Meltem; Crawford, Bryan D.; Leon, Hernando; Sawicka, Jolanta; Li, Laiji; Ballermann, Barbara J.; Holmes, Charles; Berthiaume, Luc G.; Holt, Andrew; Sawicki, Grzegorz; Schulz, Richard			Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation	FASEB JOURNAL			English	Article						dephosphorylation; gelatinase; alkaline phosphate; protein kinase C; mass spectrometry	GELATINASE-A; REPERFUSION INJURY; IN-VITRO; ACTIVATION; INFLAMMATION; EXPRESSION; INHIBITORS; ISCHEMIA; INVASION; ACCOUNTS	The regulation of matrix metalloproteinases (MMP) has been studied extensively due to the fundamental roles these zinc-endopeptidases play in diverse physiological and pathological processes. However, phosphorylation has not previously been considered as a potential modulator of MMP activity. The ubiquitously expressed MMP-2 contains 29 potential phosphorylation sites. Mass spectrometry reveals that at least five of these sites are phosphorylated in hrMMP-2 expressed in mammalian cells. Treatment of HT1080 cells with an activator of protein kinase C results in a change in MMP-2 immunoreactivity on 2D immunoblots consistent with phosphorylation, and purified MMP-2 is phosphorylated by protein kinase C in vitro. Furthermore, MMP-2 from HT1080 cell-conditioned medium is immunoreactive with antibodies directed against phosphothreonine and phosphoserine, which suggests that it is phosphorylated. Analysis of MMP-2 activity by zymography, gelatin dequenching assays, and measurement of kinetic parameters shows that the phosphorylation status of MMP-2 significantly affects its enzymatic properties. Consistent with this, dephosphorylation of MMP-2 immunoprecipitated from HT1080 conditioned medium with alkaline phosphatase significantly increases its activity. We conclude that MMP-2 is modulated by phosphorylation on multiple sites and that protein kinase C may be a regulator of this protease in vivo.	Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Cadiovasc Res Grp, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Schulz, R (corresponding author), Univ Alberta, Dept Pediat, 462 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	richard.schulz@ualberta.ca	Schulz, Richard/A-8739-2012; Schulz, Richard/M-3518-2019; Ballermann, Barbara J/G-5349-2016; Sawicki, Grzegorz/ABA-3357-2021	Schulz, Richard/0000-0002-5045-3193; Schulz, Richard/0000-0002-5045-3193; Ballermann, Barbara J/0000-0002-8220-6381; Berthiaume, Luc/0000-0003-0926-059X; Crawford, Bryan/0000-0002-0512-4649				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chow AK, 2007, J MOL CELL CARDIOL, V42, P896, DOI 10.1016/j.yjmcc.2007.01.008; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Gao CQ, 2003, CARDIOVASC RES, V57, P426; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Klein G, 2004, CRIT REV ONCOL HEMAT, V50, P87, DOI 10.1016/j.critevonc.2003.09.001; Kwan JA, 2004, FASEB J, V18, P690, DOI 10.1096/fj.02-1202fje; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Prevostel C, 2000, J CELL SCI, V113, P2575; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawicki G, 1998, J CANCER RES CLIN, V124, P245, DOI 10.1007/s004320050161; Sawicki G, 2005, CIRCULATION, V112, P544, DOI 10.1161/CIRCULATIONAHA.104.531616; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shipley JM, 1996, J BIOL CHEM, V271, P4335; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang FQ, 2006, INT J CANCER, V118, P879, DOI 10.1002/ijc.21421; Wang WJ, 2002, CIRCULATION, V106, P1543, DOI 10.1161/01.CIR.0000028818.33488.7B; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; ZOELLNER HFA, 1989, J HISTOCHEM CYTOCHEM, V37, P1893, DOI 10.1177/37.12.2584695	32	114	118	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2486	2495		10.1096/fj.06-7938com	http://dx.doi.org/10.1096/fj.06-7938com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435175				2022-12-25	WOS:000248454400023
J	Khan, S; Bijker, MS; Weterings, JJ; Tanke, HJ; Adema, GJ; van Hall, T; Drijfhout, JW; Melief, CJM; Overkleeft, HS; van der Marel, GA; Filippov, DV; van der Burg, SH; Ossendorp, F				Khan, Selina; Bijker, Martijn S.; Weterings, Jimmy J.; Tanke, Hans J.; Adema, Gosse J.; van Hall, Thorbald; Drijfhout, Jan W.; Melief, Cornelis J. M.; Overkleeft, Hermen S.; van der Marel, Gijsbert A.; Filippov, Dmitri V.; van der Burg, Sjoerd H.; Ossendorp, Ferry			Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIDED CROSS-PRESENTATION; IMMUNOSTIMULATORY DNA; ANTIGEN PRESENTATION; CPG-DNA; PROTEIN; RECOGNITION; INHIBITORS; EXPRESSION; RESPONSES; IMMUNITY	Covalent conjugation of Toll-like receptor ligands (TLR-L) to synthetic antigenic peptides strongly improves antigen presentation in vitro and T lymphocyte priming in vivo. These molecularly well defined TLR-L-peptide conjugates, constitute an attractive vaccination modality, sharing the peptide antigen and a defined adjuvant in one single molecule. We have analyzed the intracellular trafficking and processing of two TLR-L conjugates in dendritic cells (DCs). Long synthetic peptides containing an ovalbumin cytotoxic T-cell epitope were chemically conjugated to two different TLR-Ls the TLR2 ligand, Pam(3)CysSK(4) (Pam) or the TLR9 ligand CpG. Rapid and enhanced uptake of both types of TLR-L-conjugated peptide occurred in DCs. Moreover, TLR-L conjugation greatly enhanced antigen presentation, a process that was dependent on endosomal acidification, proteasomal cleavage, and TAP translocation. The uptake of the CpG similar to conjugate was independent of endosomally-expressed TLR9 as reported previously. Unexpectedly, we found that Pam similar to conjugated peptides were likewise internalized independently of the expression of cell surface-expressed TLR2. Further characterization of the uptake mechanisms revealed that TLR2-L employed a different uptake route than TLR9-L. Inhibition of clathrin- or caveolin-dependent endocytosis greatly reduced uptake and antigen presentation of the Pam-conjugate. In contrast, internalization and antigen presentation of CpG similar to conjugates was independent of clathrin- coated pits but partly dependent on caveolae formation. Importantly, in contrast to the TLR-independent uptake of the conjugates, TLR expression and downstream TLR signaling was required for dendritic cell maturation and for priming of naive CD8(+) T-cells. Together, our data show that targeting to two distinct TLRs requires distinct uptake mechanism but follows similar trafficking and intracellular processing pathways leading to optimal antigen presentation and T-cell priming.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Radboud Univ Nijmegen Med Ctr, Immunol Lab, NL-6500 HB Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen	Ossendorp, F (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, POB 9600, NL-2300 RC Leiden, Netherlands.	f.a.ossendorp@lumc.nl	van der Burg, Sjoerd H/T-1875-2017; Drijfhout, Jan Wouter/ABA-6318-2021; Adema, G.J./H-8007-2014; Filippov, Dmitri/J-7612-2017; van Hall, Thorbald/Y-5651-2018	van der Burg, Sjoerd H/0000-0002-6556-0354; Drijfhout, Jan Wouter/0000-0003-4808-5296; Filippov, Dmitri/0000-0002-6978-7425; van Hall, Thorbald/0000-0002-9115-558X; Overkleeft, Herman/0000-0001-6976-7005				Ackerman AL, 2006, IMMUNITY, V25, P607, DOI 10.1016/j.immuni.2006.08.017; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; BRADLEY JR, 1993, J IMMUNOL, V150, P5544; Chan WC, 2000, PRACT APPROACH SER, V222, P41; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; GRANDAS A, 2003, CURRENT PROTOCOLS NU; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; Heit A, 2003, J IMMUNOL, V170, P2802, DOI 10.4049/jimmunol.170.6.2802; Heit A, 2005, J IMMUNOL, V174, P4373, DOI 10.4049/jimmunol.174.7.4373; Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584; Jeannin P, 2002, VACCINE, V20, pA23, DOI 10.1016/S0264-410X(02)00383-3; Jeannin P, 2005, IMMUNITY, V22, P551, DOI 10.1016/j.immuni.2005.03.008; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; Kaisho T, 2001, ACTA ODONTOL SCAND, V59, P124, DOI 10.1080/000163501750266701; KALINA M, 1991, J HISTOCHEM CYTOCHEM, V39, P1337, DOI 10.1177/39.10.1658127; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975; Matyszak MK, 2000, EUR J IMMUNOL, V30, P1233, DOI 10.1002/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NANDI PK, 1981, BIOCHEMISTRY-US, V20, P6706, DOI 10.1021/bi00526a028; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240; Schuurhuis DH, 2000, J EXP MED, V192, P145, DOI 10.1084/jem.192.1.145; Schwarz K, 2000, J IMMUNOL, V164, P6147, DOI 10.4049/jimmunol.164.12.6147; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Shen LJ, 2004, IMMUNITY, V21, P155, DOI 10.1016/j.immuni.2004.07.004; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Sin N, 1999, BIOORG MED CHEM LETT, V9, P2283, DOI 10.1016/S0960-894X(99)00376-5; Steinman RM, 1999, HUM IMMUNOL, V60, P562, DOI 10.1016/S0198-8859(99)00030-0; STUKART MJ, 1984, J IMMUNOL, V133, P24; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Triantafilou M, 2004, J BIOL CHEM, V279, P40882, DOI 10.1074/jbc.M400466200; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905	51	141	145	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21145	21159		10.1074/jbc.M701705200	http://dx.doi.org/10.1074/jbc.M701705200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17462991	hybrid, Green Published			2022-12-25	WOS:000248047500041
J	Melkonian, KA; Maier, KC; Godfrey, JE; Rodgers, M; Schroer, TA				Melkonian, Karin A.; Maier, Kerstin C.; Godfrey, Jamie E.; Rodgers, Michael; Schroer, Trina A.			Mechanism of dynamitin-mediated disruption of dynactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; MOLECULAR CHARACTERIZATION; CYTOPLASMIC DYNEIN; IN-VITRO; COMPLEX; TRANSPORT; COMPONENT; SUBUNIT; REVEALS; PURIFICATION	Dynamitin is a commonly used inhibitor of cytoplasmic dynein-based motility in living cells. Dynamitin does not inhibit dynein directly but instead acts by causing disassembly of dynactin, a multiprotein complex required for dynein-based movement. In dynactin, dynamitin is closely associated with the subunits p150(Glued) and p24, which together form the shoulder and projecting arm structures of the dynactin molecule. In this study, we explore the way in which exogenous dynamitin effects dynactin disruption. We find that pure, recombinant dynamitin is an elongated protein with a strong propensity for self-assembly. Titration experiments reveal that free dynamitin binds dynactin before it causes release of subunits. When dynamitin is added to dynactin at an equimolar ratio of exogenous dynamitin subunits to endogenous dynamitin subunits (1 x = 4 mol of exogenous dynamitin per mole of dynactin), exogenous dynamitin exchanges with endogenous dynamitin, and partial release of p150(Glued) is observed. When added in vast excess (>= 25 x; 100 mol of exogenous dynamitin per mole of dynactin), recombinant dynamitin causes complete release of both p150(Glued) subunits, two dynamitins and one p24, but not other dynactin subunits. Our data suggest that dynamitin mediates disruption of dynactin by binding to endogenous dynamitin subunits. This binding destabilizes the shoulder structure that links the p150(Glued) arm to the Arp1 filament and leads to subunit release.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schroer, TA (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	schroer@jhu.edu		Schroer, Trina/0000-0002-5065-1835	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044589, R56GM044589] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044589, GM44589] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berezuk MA, 2007, TRAFFIC, V8, P124, DOI 10.1111/j.1600-0854.2006.00517.x; Bingham JB, 1998, METHOD ENZYMOL, V298, P171, DOI 10.1016/S0076-6879(98)98017-X; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; COHN EJ, 1943, PROTEINS AMINO ACIDS, V370; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Hodgkinson JL, 2005, P NATL ACAD SCI USA, V102, P3667, DOI 10.1073/pnas.0409506102; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Imai H, 2006, J MOL BIOL, V359, P833, DOI 10.1016/j.jmb.2006.03.071; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; Pfister KK, 1998, CELL MOTIL CYTOSKEL, V41, P154, DOI 10.1002/(SICI)1097-0169(1998)41:2<154::AID-CM6>3.0.CO;2-E; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; van Holde K. E., 1998, PRINCIPLE PHYS BIOCH, P192; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wittmann T, 1999, METHOD CELL BIOL, V61, P137	34	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19355	19364		10.1074/jbc.M700003200	http://dx.doi.org/10.1074/jbc.M700003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17449914	hybrid			2022-12-25	WOS:000247650600010
J	Faccio, R; Takeshita, S; Colaianni, G; Chappel, J; Zallone, A; Teitelbaum, SL; Ross, FP				Faccio, Roberta; Takeshita, Sunao; Colaianni, Graziana; Chappel, Jean; Zallone, Alberta; Teitelbaum, Steven L.; Ross, F. Patrick			M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; OSTEOCLAST CYTOSKELETON; GROWTH-FACTOR; PI-3 KINASE; MACROPHAGE; CBL; PODOSOMES	M-CSF is known to induce cytoskeletal reorganization in macrophages and osteoclasts by activation of phosphatidylinositol 3-kinase (PI3K) and c-Src, but the detailed mechanisms remain unclear. We find, unexpectedly, that tyrosine (Tyr) to phenylalanine (Phe) mutation of Tyr-721, the PI3K binding site in the M-CSF receptor c-Fms, fails to suppress cytoskeletal remodeling or actin ring formation. In contrast, mutation of c-Fms Tyr-559 to Phe blocks M-CSF-induced cytoskeletal reorganization by inhibiting formation of a Src Family Kinase SFK(.)cCbl (.) PI3K complex and the downstream activation of Vav3 and Rac, two key mediators of actin remodeling. Using an add-back approach in which specific Tyr residues are reinserted into c-Fms inactivated by the absence of all seven functionally important Tyr residues, we find that Tyr-559 is necessary but not sufficient to transduce M-CSF-dependent cytoskeletal reorganization. Furthermore, this same add-back approach identifies important roles for Tyr-697 and Tyr-721 in collaborating with Tyr-559 to recruit a multimeric signaling complex that can transduce signals from c-Fms to the actin cytoskeleton.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Univ Bari, Sch Med, Dept Human Anat, I-70100 Bari, Italy; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Bone & Joint Dis, Aichi 4748522, Japan	Washington University (WUSTL); Washington University (WUSTL); Universita degli Studi di Bari Aldo Moro; National Center for Geriatrics & Gerontology	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu		Colaianni, Graziana/0000-0001-8501-5399; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR48853, AR52921, AR48812, AR46852, AR46523, AR32788] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046523, R37AR046523, R01AR048812, R01AR048853, R01AR032788, R01AR046852] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOOCOCK CA, 1989, J CELL SCI, V93, P447; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Caveggion E, 2003, J CELL PHYSIOL, V195, P276, DOI 10.1002/jcp.10236; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012-1606(03)00299-9; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; GAVAZZI I, 1989, J CELL SCI, V94, P85; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hurst IR, 2004, J BONE MINER RES, V19, P499, DOI 10.1359/JBMR.0301238; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014-4827(03)00318-5; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; LOTZE MT, 2003, CYTOKINE HDB, P545; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Munugalavadla V, 2005, BLOOD, V106, P103, DOI 10.1182/blood-2004-10-4041; Nakagawa H, 2001, J CELL SCI, V114, P1555; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527; Palacio S, 2001, EUR J ENDOCRINOL, V144, P431, DOI 10.1530/eje.0.1440431; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pfaff M, 2001, J CELL SCI, V114, P2775; Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171-9335(99)80058-2; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STICKEL SK, 1987, J CELL BIOL, V104, P1521, DOI 10.1083/jcb.104.6.1521; Takenawa T, 2001, J CELL SCI, V114, P1801; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Vedham V, 2005, MOL CELL BIOL, V25, P4211, DOI 10.1128/MCB.25.10.4211-4220.2005; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997	60	38	39	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18991	18999		10.1074/jbc.M610937200	http://dx.doi.org/10.1074/jbc.M610937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420256	hybrid			2022-12-25	WOS:000247475300041
J	Takeshita, S; Faccio, R; Chappel, J; Zheng, L; Feng, X; Weber, JD; Teitelbaum, SL; Ross, FP				Takeshita, Sunao; Faccio, Roberta; Chappel, Jean; Zheng, Ling; Feng, Xu; Weber, Jason D.; Teitelbaum, Steven L.; Ross, F. Patrick			c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-SITE; V-FMS; KINASE; PROTEIN; ACTIVATION; SRC; DIFFERENTIATION	The molecular mechanisms by which binding of monocyte/macrophage colony-stimulating factor to its receptor c-Fms promotes replication in primary macrophages are incompletely understood, as all previous studies involved overexpression of receptor mutants in transformed cells not endogenously expressing the receptor. To address this issue we retrovirally expressed, in bone marrow-derived macrophages, a chimeric receptor containing a range of tyrosine to phenylalanine mutations in the c-Fms cytoplasmic tail. We measured incorporation of bromodeoxyuridine as a marker of proliferation and phosphorylation of ERKs, Akt, and the receptor itself. Our data indicate that tyrosine 559 is the major mediator of receptor activation and cell death, intracellular signaling, and cell proliferation and that the tyrosine residues at positions 697 and 807 play lesser roles in these events. Importantly, we find that activation of the ERK and Akt pathways is necessary but not sufficient for induction of macrophage proliferation. Using specific small molecule inhibitors we find that a combination of the Src family kinase, phosphatidylinositol 3-kinase/Akt, phospholipase C, and ERK pathways mediates macrophage proliferation in response to M-CSF.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Bone & Joint Dis, Aichi 4748522, Japan; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Center for Geriatrics & Gerontology; University of Alabama System; University of Alabama Birmingham	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Weber, Jason/0000-0002-1069-6983	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R37AR046523, R01AR046523, R01AR048812, R01AR048853, R01AR046852] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR48853, AR46523, AR48812, AR46852] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Bunney TD, 2006, TRENDS CELL BIOL, V16, P640, DOI 10.1016/j.tcb.2006.10.007; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Faccio R, 2007, J BIOL CHEM, V282, P18991, DOI 10.1074/jbc.M610937200; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Heo JS, 2006, AM J PHYSIOL-CELL PH, V290, pC123, DOI 10.1152/ajpcell.00142.2005; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; LOTZE MT, 2003, CYTOKINE HDB, P545; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; Roussel MF, 1997, MOL REPROD DEV, V46, P11, DOI 10.1002/(SICI)1098-2795(199701)46:1<11::AID-MRD3>3.0.CO;2-U; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tari AM, 2001, SEMIN ONCOL, V28, P142, DOI 10.1053/sonc.2001.28555; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Zhou P, 2006, J IMMUNOL, V177, P8777, DOI 10.4049/jimmunol.177.12.8777	46	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18980	18990		10.1074/jbc.M610938200	http://dx.doi.org/10.1074/jbc.M610938200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420255	hybrid			2022-12-25	WOS:000247475300040
J	Thakurta, AG; Selvanathan, SP; Patterson, AD; Gopal, G; Dhar, R				Thakurta, Anjan G.; Selvanathan, Saravana P.; Patterson, Andrew D.; Gopal, Ganesh; Dhar, Ravi			The nuclear export signal of splicing factor Uap56p interacts with nuclear pore-associated protein Rae1p for mRNA export in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-4A; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; COMPLEX; HOMOLOG; TRANSCRIPTION; MACHINERY; MEX67P; YRA1P; SUB2P	Mammalian UAP56 or its homolog Sub2p in Saccharomyces cerevisiae are members of the ATP-dependent RNA helicase family and are required for splicing and nuclear export of mRNA. Previously we showed that in Schizosaccharomyces pombe Uap56p is critical for mRNA export. It links the mRNA adapter Mlo3p, a homolog of Yra1p in S. cerevisiae or Aly in mammals, to nuclear pore-associated mRNA export factor Rae1p. In this study we show that, in contrast to S. cerevisiae, Uap56p in S. pombe is not required for pre-mRNA splicing. The putative RNA helicase function of Uap56p is not required for mRNA export. However, the RNA-binding motif of Uap56p is critical for nuclear export of mRNA. Within Uap56p we identified nuclear import and export signals that may allow it to shuttle between the nucleus and the cytoplasm. Wefound that Uap56p interacts with Rae1p directly via its nuclear export signal, and this interaction is critical for the nuclear export activity of Uap56p as well as for exporting mRNA. RNA binding and the ability to shuttle between the nucleus and cytoplasm are important features of mRNA export carriers such as HIV-Rev. Our results suggest that Uap56p could function similarly as an export carrier of mRNA in S. pombe.	NCI, Basic Res Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Metab Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NIGMS, Pharmacol Res Associate Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS)	Dhar, R (corresponding author), NCI, Basic Res Lab, Canc Res Ctr, NIH, Bldg 37,Rm 5016,37 Convent Dr,9000 Rockville Pike, Bethesda, MD 20892 USA.	dharr@mail.nih.gov	Patterson, Andrew/ABF-1575-2020; Patterson, Andrew/G-3852-2012	Patterson, Andrew/0000-0003-2073-0070; Patterson, Andrew/0000-0003-2073-0070	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alfa C., 1993, EXPT FISSION YEAST; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Kaufer NF, 2000, NUCLEIC ACIDS RES, V28, P3003, DOI 10.1093/nar/28.16.3003; Kiesler E, 2002, CURR BIOL, V12, P859, DOI 10.1016/S0960-9822(02)00840-0; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kozak L, 2002, J BIOL CHEM, V277, P33580, DOI 10.1074/jbc.M205415200; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Partridge JF, 2000, GENE DEV, V14, P783; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; Shi H, 2004, P NATL ACAD SCI USA, V101, P17628, DOI 10.1073/pnas.0408172101; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Thakurta AG, 2004, J BIOL CHEM, V279, P17434, DOI 10.1074/jbc.M309731200; Thakurta AG, 2005, EMBO J, V24, P2512, DOI 10.1038/sj.emboj.7600713; Thakurta AG, 2002, MOL BIOL CELL, V13, P2571, DOI 10.1091/mbc.E01-11-0133; Whalen WA, 1999, GENETICS, V152, P827; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17507	17516		10.1074/jbc.M609727200	http://dx.doi.org/10.1074/jbc.M609727200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449473	hybrid			2022-12-25	WOS:000247084500021
J	Waxman, EA; Baconguis, I; Lynch, DR; Robinson, MB				Waxman, Elisa A.; Baconguis, Isabelle; Lynch, David R.; Robinson, Michael B.			N-methyl-D-aspartate receptor-dependent regulation of the glutamate transporter excitatory amino acid carrier 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; DIFFERENTIAL SYNAPTIC LOCALIZATION; CELL-SURFACE EXPRESSION; GLYCINE TRANSPORTER; HIPPOCAMPAL CA1; NMDA RECEPTORS; POSTSYNAPTIC DENSITY-95; MEDIATED RESPONSES; MACAQUE MONKEY	The neuronal transporter excitatory amino acid carrier 1 ( EAAC1) is enriched in perisynaptic regions, where it may regulate synaptic spillover of glutamate. In this study we examined potential interactions between EAAC1 and ionotropic glutamate receptors. N-Methyl-D-aspartate ( NMDA) receptor subunits NR1, NR2A, and NR2B, but not the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluR2, were co-immunoprecipitated with EAAC1 from neuron-enriched hippocampal cultures. A similar interaction was observed in C6 glioma and human embryonic kidney cells after co-transfection with Myc epitope-tagged EAAC1 and NMDA receptor subunits. Co-transfection of C6 glioma with the combination of NR1 and NR2 subunits dramatically increased ( similar to 3-fold) the amount of Myc-EAAC1 that can be labeled with a membrane-impermeable biotinylating reagent. In hippocampal cultures, brief ( 5 min), robust ( 100 mu M NMDA, 10 mu M glycine) activation of the NMDA receptor decreased biotinylated EAAC1 to similar to 50% of control levels. This effect was inhibited by an NMDA receptor antagonist, intracellular or extracellular calcium chelators, or hypertonic sucrose. Glutamate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with cyclothiazide, and thapsigargin mimicked the effects of NMDA. These studies suggest that NMDA receptors interact with EAAC1, facilitate cell surface expression of EAAC1 under basal conditions, and control internalization of EAAC1 upon activation. ThisNMDAreceptor-dependent regulation of EAAC1 provides a novel mechanism that may shape excitatory signaling during synaptic plasticity and/or excitotoxicity.	Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Lynch, DR (corresponding author), Childrens Hosp Philadelphia, Dept Pharmacol, 502 Abramson Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	lynch@pharm.med.upenn.edu	Baconguis, Isabelle/AAH-3790-2021	Baconguis, Isabelle/0000-0002-5440-2289; Waxman, Elisa/0000-0003-4562-7969	NINDS NIH HHS [NS39011, NS45986] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS045986, R01NS039011, R01NS045986] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara S G, 1998, Adv Pharmacol, V42, P164; Ambrosio AF, 2000, EUR J NEUROSCI, V12, P2021, DOI 10.1046/j.1460-9568.2000.00091.x; ANEGAWA NJ, 1995, J NEUROCHEM, V64, P2004; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; BECKMAN ML, 2005, 35 ANN M SOC NEUR NO; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; Bingol B, 2004, NEUROPHARMACOLOGY, V47, P755, DOI 10.1016/j.neuropharm.2004.07.028; Brustovetsky T, 2004, EXP NEUROL, V189, P222, DOI 10.1016/j.expneurol.2004.03.021; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chen L, 2003, J NEUROPHYSIOL, V89, P691, DOI 10.1152/jn.00680.2002; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; Cubelos B, 2005, J NEUROCHEM, V95, P1047, DOI 10.1111/j.1471-4159.2005.03438.x; Cubelos B, 2005, CEREB CORTEX, V15, P448, DOI 10.1093/cercor/bhh147; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dong YN, 2006, J NEUROCHEM, V99, P206, DOI 10.1111/j.1471-4159.2006.04096.x; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gebhardt C, 2002, J CEREBR BLOOD F MET, V22, P569, DOI 10.1097/00004647-200205000-00008; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Grant ER, 1997, J BIOL CHEM, V272, P647; Guillet B, 2002, NEUROCHEM INT, V40, P661, DOI 10.1016/S0197-0186(01)00110-3; Guillet BA, 2005, NEUROCHEM INT, V46, P337, DOI 10.1016/j.neuint.2004.10.006; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hanley JG, 2000, J BIOL CHEM, V275, P840, DOI 10.1074/jbc.275.2.840; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Harney SC, 2006, J NEUROSCI, V26, P1128, DOI 10.1523/JNEUROSCI.2753-05.2006; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2001, NEUROSCI LETT, V311, P161, DOI 10.1016/S0304-3940(01)02180-2; He Y, 2000, J COMP NEUROL, V418, P255; Hori K, 2005, J NEUROSCI, V25, P2670, DOI 10.1523/JNEUROSCI.3638-04.2005; Huang CC, 2006, J NEUROCHEM, V96, P179, DOI 10.1111/j.1471-4159.2005.03527.x; Huang CC, 2004, J BIOL CHEM, V279, P12286, DOI 10.1074/jbc.M312868200; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Jensen JB, 1998, NEUROCHEM INT, V32, P505, DOI 10.1016/S0197-0186(97)00130-7; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Li SM, 2006, J NEUROSCI, V26, P1721, DOI 10.1523/JNEUROSCI.3990-05.2006; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Lu W, 2005, NEURON, V47, P407, DOI 10.1016/j.neuron.2005.07.006; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Martin Sally, 1999, Cell Biochemistry and Biophysics, V30, P89, DOI 10.1007/BF02737886; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Mitani A, 1998, J CEREBR BLOOD F MET, V18, P1088, DOI 10.1097/00004647-199810000-00005; Morishita W, 2005, NAT NEUROSCI, V8, P1043, DOI 10.1038/nn1506; Najimi M, 2005, BBA-BIOMEMBRANES, V1668, P195, DOI 10.1016/j.bbamem.2004.12.008; Najimi M, 2002, FEBS LETT, V523, P224, DOI 10.1016/S0014-5793(02)02981-2; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; O'Donnell LA, 2006, J NEUROSCI, V26, P981, DOI 10.1523/JNEUROSCI.4617-05.2006; Okada T, 1999, EUR J NEUROSCI, V11, P1085, DOI 10.1046/j.1460-9568.1999.00516.x; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Patrick GN, 2003, CURR BIOL, V13, P2073, DOI 10.1016/j.cub.2003.10.028; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Sheldon AL, 2006, J BIOL CHEM, V281, P4876, DOI 10.1074/jbc.M504983200; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Supplisson S, 1997, J NEUROSCI, V17, P4580; Tovar KR, 1999, J NEUROSCI, V19, P4180; Toyoda H, 2005, EUR J NEUROSCI, V22, P485, DOI 10.1111/j.1460-9568.2005.04236.x; Volk LJ, 2006, J NEUROPHYSIOL, V95, P2427, DOI 10.1152/jn.00383.2005; Watabe AM, 2002, J NEUROPHYSIOL, V87, P1395, DOI 10.1152/jn.00723.2001; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; WILCOX KS, 1994, SYNAPSE, V18, P128, DOI 10.1002/syn.890180206; Yang YX, 2004, J NEUROCHEM, V88, P1361, DOI 10.1046/j.1471-4159.2003.02279.x; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zuo ZY, 2005, J EXP BIOL, V208, P2063, DOI 10.1242/jeb.01595	82	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17594	17607		10.1074/jbc.M702278200	http://dx.doi.org/10.1074/jbc.M702278200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17459877	hybrid			2022-12-25	WOS:000247084500031
J	Bonner, A; Perrier, C; Corthesy, B; Perkins, SJ				Bonner, Alexandra; Perrier, Clementine; Corthesy, Blaise; Perkins, Stephen J.			Solution structure of human secretory component and implications for biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; POLYMERIC IG; NEUTRON-SCATTERING; ANALYTICAL ULTRACENTRIFUGATION; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGLOBULIN-A; BINDING; ANTIGEN; PURIFICATION; EXPRESSION	Secretory component (SC) in association with polymeric IgA (pIgA) forms secretory IgA, the major antibody active at mucosal surfaces. SC also exists in the free form, with innate-like neutralizing properties against pathogens. Free SC consists of five glycosylated variable (V)-type Ig domains (D1-D5), whose structure was determined by x-ray and neutron scattering, ultracentrifugation, and modeling. With a radius of gyration of 3.53-3.63 nm, a length of 12.5 nm, and a sedimentation coefficient of 4.0 S, SC possesses an unexpected compact structure. Constrained scattering modeling based on up to 13,000 trial models shows that SC adopts a J-shaped structure in which D4 and D5 are folded back against D2 and D3. The seven glycosylation sites are located on one side of SC, leaving known IgAbinding motifs free to interact with pIgA. This work represents the first analysis of the three-dimensional structure of full-length free SC and paves the way to a better understanding of the association between SC and its potential ligands, i. e. pIgA and pathogenic-associated motifs.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; CHU Vaudois, Serv Immunol & Allergie, CH-1011 Lausanne, Switzerland	University of London; University College London; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Perkins, SJ (corresponding author), UCL, Dept Biochem & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	s.perkins@medsch.ucl.ac.uk	Perrier, Clementine/A-3925-2011					Almogren A, 2007, IMMUNOLOGY, V120, P273, DOI 10.1111/j.1365-2567.2006.02498.x; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; Boehm MK, 2000, FEBS LETT, V475, P11, DOI 10.1016/S0014-5793(00)01612-4; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Braathen R, 2006, J BIOL CHEM, V281, P7075, DOI 10.1074/jbc.M508509200; BRANDTZAEG P, 1995, APMIS, V103, P1, DOI 10.1111/j.1699-0463.1995.tb01073.x; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Heenan RK, 1997, J APPL CRYSTALLOGR, V30, P1140, DOI 10.1107/S0021889897002173; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Hu YL, 2005, J MOL BIOL, V350, P553, DOI 10.1016/j.jmb.2005.04.031; Hughes GJ, 1997, FEBS LETT, V410, P443, DOI 10.1016/S0014-5793(97)00629-7; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MCRORIE DK, 1993, SELF ASSOCIATING SYS, P9; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; Nezlin R, 1998, IMMUNOGLOBULINS, P3, DOI 10.1016/B978-012517970-6/50001-1; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PERKINS SJ, 1988, BIOCHEM J, V254, P313, DOI 10.1042/bj2540313; Perkins SJ, 1998, INT J BIOL MACROMOL, V22, P1, DOI 10.1016/S0141-8130(97)00088-3; Perkins SJ, 2001, BIOPHYS CHEM, V93, P129, DOI 10.1016/S0301-4622(01)00216-2; Perrier C, 2006, J BIOL CHEM, V281, P14280, DOI 10.1074/jbc.M512958200; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; STERNBERG MJE, 1996, PROTEIN STRUCTURE PR, P111; Sun Z, 2005, J MOL BIOL, V353, P155, DOI 10.1016/j.jmb.2005.07.072; White KD, 2002, J EXP MED, V196, P551, DOI 10.1084/jem.20020581	45	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16969	16980		10.1074/jbc.M701281200	http://dx.doi.org/10.1074/jbc.M701281200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428798	hybrid			2022-12-25	WOS:000246946500030
J	Zhang, FJ; Strom, AL; Fukada, K; Lee, S; Hayward, LJ; Zhu, HN				Zhang, Fujian; Strom, Anna-Lena; Fukada, Kei; Lee, Sangmook; Hayward, Lawrence J.; Zhu, Haining			Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALS-LINKED SOD1; MOTOR-NEURON DEGENERATION; FAST AXONAL-TRANSPORT; SUPEROXIDE-DISMUTASE MUTANTS; COPPER-BINDING-SITE; TRANSGENIC MICE; MOUSE MODEL; MUTATION; DISEASE; PROTEINS	Amyotrophic lateral sclerosis ( ALS) is a neurodegenerative disorder characterized by progressive motor neuron death. More than 90 mutations in the copper-zinc superoxide dismutase (SOD1) gene cause a subset of familial ALS. Toxic properties have been proposed for the ALS-linked SOD1 mutants, but the nature of the toxicity has not been clearly specified. Cytoplasmic inclusion bodies containing mutant SOD1 and a number of other proteins are a pathological hallmark of mutant SOD1-mediated familial ALS, but whether such aggregates are toxic to motor neurons remains unclear. In this study, we identified a dynein subunit as a component of the mutant SOD1-containing high molecular weight complexes using proteomic techniques. We further demonstrated interaction and colocalization between dynein and mutant SOD1, but not normal SOD1, in cultured cells and also in G93A and G85R transgenic rodent tissues. Moreover, the interaction occurred early, prior to the onset of symptoms in the ALS animal models and increased over the disease progression. Motor neurons with long axons are particularly susceptible to defects in axonal transport. Our results demonstrate a direct "gain-of-interaction" between mutant SOD1 and dynein, which may provide insights into the mechanism by which mutant SOD1 could contribute to a defect in retrograde axonal transport or other dynein functions. The aberrant interaction is potentially critical to the formation of mutant SOD1 aggregates as well as the toxic cascades leading to motor neuron degeneration in ALS.	Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA	University of Kentucky; University of Massachusetts System; University of Massachusetts Worcester	Zhu, HN (corresponding author), 741 S Limestone St, Lexington, KY 40536 USA.	haining@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES012025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170, R01NS049126] Funding Source: NIH RePORTER; NIEHS NIH HHS [R21-ES12025] Funding Source: Medline; NINDS NIH HHS [R01-NS49126, R01-NS44170, R01 NS044170] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BREUER AC, 1987, NEUROLOGY, V37, P738, DOI 10.1212/WNL.37.5.738; BREUER AC, 1988, CELL MOTIL CYTOSKEL, V10, P321, DOI 10.1002/cm.970100136; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruns CK, 2007, EMBO J, V26, P855, DOI 10.1038/sj.emboj.7601528; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fukada K, 2004, MOL CELL PROTEOMICS, V3, P1211, DOI 10.1074/mcp.M400094-MCP200; Fukada K, 2001, EUR J NEUROSCI, V14, P2032, DOI 10.1046/j.0953-816x.2001.01828.x; Gaudette M, 2000, AMYOTROPH LATERAL SC, V1, P83, DOI 10.1080/14660820050515377; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Holzbaur ELF, 2004, TRENDS CELL BIOL, V14, P233, DOI 10.1016/j.tcb.2004.03.009; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kieran D, 2005, J CELL BIOL, V169, P561, DOI 10.1083/jcb.200501085; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Ligon LA, 2005, NEUROREPORT, V16, P533, DOI 10.1097/00001756-200504250-00002; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Lu XN, 2005, MOL CELL PROTEOMICS, V4, P1948, DOI 10.1074/mcp.M500138-MCP200; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Munch C, 2004, NEUROLOGY, V63, P724, DOI 10.1212/01.WNL.0000134608.83927.B1; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sasaki S, 1996, NEUROLOGY, V47, P535, DOI 10.1212/WNL.47.2.535; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Teuchert M, 2006, EXP NEUROL, V198, P271, DOI 10.1016/j.expneurol.2005.12.005; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang LJ, 2002, J NEUROSCI, V22, P6920; Warita H, 1999, BRAIN RES, V819, P120, DOI 10.1016/S0006-8993(98)01351-1; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhang FJ, 2006, BBA-GEN SUBJECTS, V1760, P404, DOI 10.1016/j.bbagen.2005.11.024; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	48	134	136	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16691	16699		10.1074/jbc.M609743200	http://dx.doi.org/10.1074/jbc.M609743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403682	hybrid			2022-12-25	WOS:000246794300074
J	Lerch, TF; Shimasaki, S; Woodruff, TK; Jardetzky, TS				Lerch, Thomas F.; Shimasaki, Shunichi; Woodruff, Teresa K.; Jardetzky, Theodore S.			Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; TGF-BETA; GROWTH-FACTOR; SULFATE-BINDING; INHIBITION; COMPLEX; EXPRESSION; PROTEOGLYCANS; MEMBRANE; INSIGHTS	Follistatin (FS) regulates transforming growth factor-beta superfamily ligands and is necessary for normal embryonic and ovarian follicle development. Follistatin is expressed as two splice variants (FS288 and FS315). Previous studies indicated differences in heparin binding between FS288 and FS315, potentially influencing the physiological functions and locations of these isoforms. We have determined the structure of the FS315-activin A complex and quantitatively compared heparin binding by the two isoforms. The FS315 complex structure shows that both isoforms inhibit activin similarly, but FS315 exhibits movements within follistatin domain 3 (FSD3) apparently linked to binding of the C-terminal extension. Surprisingly, the binding affinities of FS288 and FS315 for heparin are similar at lower ionic strengths with FS315 binding decreasing more sharply as a function of salt concentration. When bound to activin, FS315 binds heparin similarly to the FS288 isoform, consistent with the structure of the complex, in which the acidic residues of the C-terminal extension cannot interact with the heparin-binding site. Activin-induced binding of heparin is unique to the FS315 isoform and may stimulate clearance of FS315 complexes.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Northwestern University; University of California System; University of California San Diego; Northwestern University; Feinberg School of Medicine	Jardetzky, TS (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Cook Hall,Rm 4133,2205 Tech Dr, Evanston, IL 60208 USA.	tedj@northwestern.edu		Woodruff, Teresa/0000-0002-1197-3399	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD041857] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD041857] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cook RW, 2005, J BIOL CHEM, V280, P40177, DOI 10.1074/jbc.M504591200; Glister C, 2004, REPRODUCTION, V127, P239, DOI 10.1530/rep.1.00090; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898-6568(00)00099-1; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; INOUYE S, 1992, MOL CELL ENDOCRINOL, V90, P1, DOI 10.1016/0303-7207(92)90094-M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; Kogure K, 1996, HEPATOLOGY, V24, P361; Lee PY, 2002, J VIROL, V76, P6302, DOI 10.1128/JVI.76.12.6302-631-.2002; Lerch TF, 2007, MOL CELL ENDOCRINOL, V267, P1, DOI 10.1016/j.mce.2006.10.018; Lin SJ, 2006, REPRODUCTION, V132, P179, DOI 10.1530/rep.1.01072; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; Otsuka F, 2001, BIOCHEM BIOPH RES CO, V289, P961, DOI 10.1006/bbrc.2001.6103; Phillips DJ, 2000, J CLIN ENDOCR METAB, V85, P2411, DOI 10.1210/jc.85.7.2411; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458; Roehrl MHA, 2004, BIOCHEMISTRY-US, V43, P16056, DOI 10.1021/bi048233g; Schneyer AL, 2004, J CLIN ENDOCR METAB, V89, P5067, DOI 10.1210/jc.2004-0162; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIMONAKA M, 1991, ENDOCRINOLOGY, V128, P3313, DOI 10.1210/endo-128-6-3313; Sidis Y, 2005, ENDOCRINOLOGY, V146, P130, DOI 10.1210/en.2004-1041; Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006-0089; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Whitman M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.64.re1; Woodruff TK, 1998, BIOCHEM PHARMACOL, V55, P953, DOI 10.1016/S0006-2952(97)00477-2; Yamamoto TS, 2000, INT J DEV BIOL, V44, P341; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375	50	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15930	15939		10.1074/jbc.M700737200	http://dx.doi.org/10.1074/jbc.M700737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409095	hybrid			2022-12-25	WOS:000246589600068
J	DeKoter, RP; Schweitzer, BL; Kamath, MB; Jones, D; Tagoh, H; Bonifer, C; Hildeman, DA; Huang, KJ				DeKoter, Rodney P.; Schweitzer, Brock L.; Kamath, Meghana B.; Jones, Darrel; Tagoh, Hiromi; Bonifer, Constanze; Hildeman, David A.; Huang, Kelly J.			Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON LYMPHOID PROGENITORS; MURINE INTERLEUKIN-7; GAMMA CHAIN; BONE-MARROW; INITIATOR ACTIVITY; GENE-EXPRESSION; DEFICIENT MICE; IL-7 RECEPTOR; CORE PROMOTER; T-CELLS	Signaling through the IL-7 receptor (IL-7R) is required for development and maintenance of the immune system. The receptor for IL-7 is heterodimeric, consisting of a common gamma chain (gamma c, encoded by Il2rg) and an alpha subunit (IL-7R alpha, encoded by Il7r). The Il7r gene is expressed specifically in the immune system in a developmental stage-specific manner. It is not known how the Il7r gene is transcriptionally regulated during B cell development. The goal of this study is to elucidate the function of the Il7r promoter region in developing B cells. Using a combination of 5' rapid amplification of cDNA ends analysis, transient transfection assays, and DNase I hypersensitivity mapping, we identified the location of the Il7r promoter. Using a combination of electrophoretic mobility shift analysis, chromatin immunoprecipitation experiments, and RNA interference experiments, we found that the Ets transcription factors PU.1 and GA-binding protein (GABP) activate the Il7r promoter by interacting with a highly conserved Ets binding site. In committed B lineage cells, GABP can promote Il7r transcription in the absence of PU.1. However, the results of retroviral gene transfer experiments suggest that PU.1 is uniquely required to initiate transcription of the Il7r locus at the earliest stages of progenitor B cell generation. In summary, these results suggest that Il7r transcription is regulated by both PU.1 and GABP in developing B cells.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Univ Leeds, St James Univ Hosp, Div Expt Hematol, LIMM, Leeds LS9 7TF, W Yorkshire, England	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Saint James's University Hospital; University of Leeds	DeKoter, RP (corresponding author), 231 Albert Sabin Way,MSB 3256, Cincinnati, OH 45267 USA.	dekoterp@ucmail.uc.edu	Hildeman, David/AAA-1757-2020; Tagoh, Hiromi/B-2954-2009; DeKoter, Rodney/A-9415-2009; Hildeman, David/I-4884-2015; Bonifer, Constanze/B-3000-2009	Hildeman, David/0000-0002-0421-8483; Tagoh, Hiromi/0000-0001-9905-6992; DeKoter, Rodney/0000-0002-9201-1983; Hildeman, David/0000-0002-0421-8483; Bonifer, Constanze/0000-0002-4267-0825; Schweitzer, Brock/0000-0003-0178-5594	NIAID NIH HHS [AI052175, R56 AI057753, AI057753, R01 AI052175, R01 AI057753] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052175, R56AI057753, R01AI057753] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chinenov Y, 2000, J BIOL CHEM, V275, P7749, DOI 10.1074/jbc.275.11.7749; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dias S, 2005, J EXP MED, V201, P971, DOI 10.1084/jem.20042393; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Giliani S, 2005, IMMUNOL REV, V203, P110, DOI 10.1111/j.0105-2896.2005.00234.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; Hildeman D, 1997, J VIROL, V71, P9672, DOI 10.1128/JVI.71.12.9672-9678.1997; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; JACOBSEN FW, 1994, J IMMUNOL, V153, P270; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Lee HC, 2005, J IMMUNOL, V174, P7800, DOI 10.4049/jimmunol.174.12.7800; Lefevre P, 2005, J BIOL CHEM, V280, P27552, DOI 10.1074/jbc.M502422200; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; Medina KL, 2004, DEV CELL, V7, P607, DOI 10.1016/j.devcel.2004.08.006; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; Polli M, 2005, BLOOD, V106, P2083, DOI 10.1182/blood-2005-01-0283; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; ROLINK A, 1993, BLOOD, V81, P2290; Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005; Schweitzer BL, 2006, J IMMUNOL, V177, P2195, DOI 10.4049/jimmunol.177.4.2195; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Van de Wiele CJV, 2004, J IMMUNOL, V172, P4235, DOI 10.4049/jimmunol.172.7.4235; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Xue HH, 2004, NAT IMMUNOL, V5, P1036, DOI 10.1038/ni1117; Ye M, 2005, J EXP MED, V202, P1411, DOI 10.1084/jem.20051089; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14194	14204		10.1074/jbc.M700377200	http://dx.doi.org/10.1074/jbc.M700377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17392277	hybrid, Green Accepted			2022-12-25	WOS:000246245800030
J	Liu, YT; Carson, DA				Liu, Yu-Tsueng; Carson, Dennis A.			A Novel Approach for Determining Cancer Genomic Breakpoints in the Presence of Normal DNA	PLOS ONE			English	Article							MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; METHYLTHIOADENOSINE PHOSPHORYLASE GENE; CHROMOSOME 9P21 DELETIONS; TIME QUANTITATIVE PCR; BARR-VIRUS DNA; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETIONS; B-CELL; HYBRIDIZATION	CDKN2A (encodes p16(INK4A) and p14(ARF)) deletion, which results in both Rb and p53 inactivation, is the most common chromosomal anomaly in human cancers. To precisely map the deletion breakpoints is important to understanding the molecular mechanism of genomic rearrangement and may also be useful for clinical applications. However, current methods for determining the breakpoint are either of low resolution or require the isolation of relatively pure cancer cells, which can be difficult for clinical samples that are typically contaminated with various amounts of normal host cells. To overcome this hurdle, we have developed a novel approach, designated Primer Approximation Multiplex PCR (PAMP), for enriching breakpoint sequences followed by genomic tiling array hybridization to locate the breakpoints. In a series of proof-of-concept experiments, we were able to identify cancer-derived CDKN2A genomic breakpoints when more than 99.9% of wild type genome was present in a model system. This design can be scaled up with bioinformatics support and can be applied to validate other candidate cancer-associated loci that are revealed by other more systemic but lower throughput assays.	[Liu, Yu-Tsueng; Carson, Dennis A.] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Liu, YT (corresponding author), Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA.	ytliu@ucsd.edu			National Institutes of Health [CA119335, CA23100, AI36214-12S1]; NATIONAL CANCER INSTITUTE [U54CA119335, P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work is supported in part by grants for the UCSD NanoTumor Center of Excellence for Cancer Nanotechnology (CA119335), CA23100 (D. A. C.) and AI36214-12S1 (Y-T L.) from the National Institutes of Health.	Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Armour JAL, 2002, HUM MUTAT, V20, P325, DOI 10.1002/humu.10133; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Cazzaniga G, 2006, ANN MED, V38, P512, DOI 10.1080/07853890600978123; Dijkman R, 2006, J CLIN ONCOL, V24, P296, DOI 10.1200/JCO.2005.02.0842; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goulden N, 2006, BRIT J HAEMATOL, V134, P273, DOI 10.1111/j.1365-2141.2006.06182.x; Heisterkamp N, 2002, ONCOGENE, V21, P8536, DOI 10.1038/sj.onc.1206080; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Janz S, 2006, DNA REPAIR, V5, P1213, DOI 10.1016/j.dnarep.2006.05.017; JOOS S, 1992, HUM MOL GENET, V1, P625, DOI 10.1093/hmg/1.8.625; JOOS S, 1992, CANCER RES, V52, P6547; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kees UR, 2005, LEUKEMIA RES, V29, P165, DOI 10.1016/j.leukres.2004.05.021; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; M'soka TJ, 2000, LEUKEMIA, V14, P935, DOI 10.1038/sj.leu.2401771; Maley CC, 2005, SEMIN CANCER BIOL, V15, P474, DOI 10.1016/j.semcancer.2005.06.004; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1995, P NATL ACAD SCI USA, V92, P6489, DOI 10.1073/pnas.92.14.6489; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; QUELLE DE, 1995, CELL, V83, P993; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Szczepanski T, 2007, LEUKEMIA, V21, P622, DOI 10.1038/sj.leu.2404603; To EWH, 2003, CLIN CANCER RES, V9, P3254; van der Velden VHJ, 2003, LEUKEMIA, V17, P1013, DOI 10.1038/sj.leu.2402922; Vastag B, 2006, J NATL CANCER I, V98, P162, DOI 10.1093/jnci/djj062; Vogelstein B., 2002, GENETIC BASIS HUMAN; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002; Wang HY, 2005, GENOME RES, V15, P276, DOI 10.1101/gr.2885205; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	59	12	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e380	10.1371/journal.pone.0000380	http://dx.doi.org/10.1371/journal.pone.0000380			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440616	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445500011
J	Karlsson, J; Pietras, A; Beckman, S; Pettersson, HM; Larsson, C; Pahlman, S				Karlsson, J.; Pietras, A.; Beckman, S.; Pettersson, H. M.; Larsson, C.; Pahlman, S.			Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax	ONCOGENE			English	Article						arsenic trioxide; neuroblastoma; Bax; calpain; nuclear localization	ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; POLY(ADP-RIBOSE) POLYMERASE; CALPAIN ACTIVATION; CLEAVAGE; PROTEIN; BCL-2; LINES; P53	Arsenic trioxide (As2O3) is toxic to multidrug-resistant neuroblastoma cells in vivo and in vitro. In neuroblastoma, As2O3 does not exert its cell death-promoting effects via a classical apoptotic pathway. A death mechanism involving proteolytic cleavage of Bax to a p18 form seems to be of importance, because inhibition of Bax cleavage coincides with diminished cell death. As existing models of cell death implicate Bax in the intrinsic apoptotic pathway, triggering death after Bax translocation to the mitochondria, we investigated the cellular localization of p18 Bax by subcellular fractionation. After As2O3 treatment, p18 Bax was only present in nuclei-enriched, mitochondria-depleted fractions. Cytoplasmic p21 Bax levels decreased, whereas total (p21 and p18) nuclear Bax increased. Overexpressed p21 Bax localized to the cytoplasm and nuclei, whereas overexpressed p18 Bax localized to extranuclear structures only. The inability of overexpressed p18 Bax to locate to the nucleus, and the As2O3-induced reduction of p21 Bax in the cytosol, suggest an As2O3-induced mechanism where p18 Bax gets cleaved and 'trapped' in the nucleus. This model is strengthened by the observation that calpain, the protease responsible for p18 Bax generation, is present in the nuclei, and that nuclear calpain is induced by increasing As2O3 and Ca-2(+) levels.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden.	sven.pahlman@med.lu.se		Pietras, Alexander/0000-0002-5783-9347; Karlsson, Jenny/0000-0001-7681-0059				Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Karlsson J, 2005, MOL CANCER THER, V4, P1128, DOI 10.1158/1535-7163.MCT-05-0047; Karlsson J, 2004, CLIN CANCER RES, V10, P3179, DOI 10.1158/1078-0432.CCR-03-0309; Keshelava N, 2001, CANCER RES, V61, P6185; Keshelava N, 1998, CANCER RES, V58, P5396; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller WH, 2002, CANCER RES, V62, P3893; Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Ora I, 2000, BIOCHEM BIOPH RES CO, V277, P179, DOI 10.1006/bbrc.2000.3651; Pearson ADJ, 2000, NEUROBLASTOMA, P551; Philip T, 1997, EUR J CANCER, V33, P2130, DOI 10.1016/S0959-8049(97)00324-9; Poot M, 1997, CYTOMETRY, V27, P358, DOI 10.1002/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Tweddle DA, 2001, CANCER RES, V61, P8; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	43	15	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6150	6159		10.1038/sj.onc.1210439	http://dx.doi.org/10.1038/sj.onc.1210439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404572				2022-12-25	WOS:000249401300005
J	Birukova, AA; Alekseeva, E; Mikaelyan, A; Birukov, KG				Birukova, Anna A.; Alekseeva, Elena; Mikaelyan, Arsen; Birukov, Konstantin G.			HGF attenuates thrombin-induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway	FASEB JOURNAL			English	Article						small GTPases; pulmonary endothelium; actin; cytoskeleton	HEPATOCYTE GROWTH-FACTOR; LIGHT-CHAIN KINASE; BARRIER DYSFUNCTION; CYTOSKELETAL REARRANGEMENT; SPHINGOSINE 1-PHOSPHATE; DIFFERENTIAL REGULATION; EXCHANGE FACTORS; ARP2/3 COMPLEX; SCATTER FACTOR; CELLS	Reorganization of the endothelial cell ( EC) cytoskeleton and cell adhesive complexes provides a structural basis for increased vascular permeability implicated in the pathogenesis of many diseases, including asthma, sepsis, and acute respiratory distress syndrome ( ARDS). We have recently described the barrier- protective effects of hepatocyte growth factor ( HGF) on the human pulmonary EC. In the present study, we explored the involvement of Rac- GTPase and Rac- specific nucleotide exchange factor Tiam1 in the mechanisms of EC barrier protection by HGF. HGF protected EC monolayers from thrombin- induced hyperpermeability, disruption of intercellular junctions, and formation of stress fibers and paracellular gaps by inhibiting thrombin- induced activation of Rho GTPase, Rho association with nucleotide exchange factor p115RhoGEF, and myosin light chain phosphorylation, which was opposed by stimulation of Rac- dependent signaling. The pharmacological Rac inhibitor or silencing RNA ( siRNA) based depletion of either Rac or Tiam1 significantly attenuated HGF- induced peripheral translocation of Rac effector cortactin, cortical actin ring formation, and EC barrier enhancement. Moreover, Tiam1 knockdown using the siRNA approach, attenuated the protective effect of HGF against thrombininduced activation of Rho signaling, monolayer disruption, and EC hyperpermeability. This study demonstrates the Tiam1/ Rac- dependent mechanism of HGF- induced EC barrier protection and provides novel mechanistic insights into regulation of EC permeability via dynamic interactions between Rho- and Tiam1/ Rac- mediated pathways.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University of Chicago	Birukova, AA (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 929 E 57th St,CIS Bldg,W410, Chicago, IL 60637 USA.	abirukov@medicine.bsd.uchicago.edu	Birukov, Konstantin/FJB-5755-2022		NHLBI NIH HHS [HL-075349, HL-076259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076259, R01HL075349] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Aoki M, 2000, J Atheroscler Thromb, V7, P71; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007; Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431; Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Date I, 2004, BIOCHEM BIOPH RES CO, V319, P1152, DOI 10.1016/j.bbrc.2004.05.100; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Geiser T, 2003, SWISS MED WKLY, V133, P586; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Herbrand U, 2006, BIOL CHEM, V387, P311, DOI 10.1515/BC.2006.041; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Manser E, 2002, DEV CELL, V3, P323, DOI 10.1016/S1534-5807(02)00268-X; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Petrache I, 2003, BIOCHEM BIOPH RES CO, V306, P244, DOI 10.1016/S0006-291X(03)00945-8; Rosen EM, 1995, ADV CANCER RES, V67, P257, DOI 10.1016/S0065-230X(08)60715-0; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Tomita N, 2000, J Atheroscler Thromb, V7, P1; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Wong KW, 2006, J BIOL CHEM, V281, P40379, DOI 10.1074/jbc.M605387200; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	64	104	107	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2776	2786		10.1096/fj.06-7660com	http://dx.doi.org/10.1096/fj.06-7660com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17428964				2022-12-25	WOS:000249237500019
J	Yerbury, JJ; Poon, S; Meehan, S; Thompson, B; Kumita, JR; Dobson, CM; Wilson, MR				Yerbury, Justin J.; Poon, Stephen; Meehan, Sarah; Thompson, Brianna; Kumita, Janet R.; Dobson, Christopher M.; Wilson, Mark R.			The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures	FASEB JOURNAL			English	Article						protein aggregation; chaperone : substrate ratio; amyloid fibrils; cytoprotection	APOLIPOPROTEIN-J; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; IN-VITRO; PROTEIN; AGGREGATION; SOLUBILITY; DEPOSITION; PEPTIDE; MECHANISM	Clusterin is an extracellular chaperone present in all disease-associated extracellular amyloid deposits, but its roles in amyloid formation and protein deposition in vivo are poorly understood. The current study initially aimed to characterize the effects of clusterin on amyloid formation in vitro by a panel of eight protein substrates. Two of the substrates ( Alzheimer's beta peptide and a PI3-SH3 domain) were then used in further experiments to examine the effects of clusterin on amyloid cytotoxicity and to probe the mechanism of clusterin action. We show that clusterin exerts potent effects on amyloid formation, the nature and extent of which vary greatly with the clusterin: substrate ratio, and provide evidence that these effects are exerted via interactions with prefibrillar species that share common structural features. Proamyloidogenic effects of clusterin appear to be restricted to conditions in which the substrate protein is present at a very large molar excess; under these same conditions, clusterin coincorporates with substrate protein into insoluble aggregates. However, when clusterin is present at much higher but still substoichiometric levels ( e. g., a molar ratio of clusterin: substrate = 1: 10), it potently inhibits amyloid formation and provides substantial cytoprotection. These findings suggest that clusterin is an important element in the control of extracellular protein misfolding.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Univ Cambridge, Dept Chem, Cambridge, England; Univ Adelaide, Sch Chem & Phys, Adelaide, SA, Australia	University of Wollongong; University of Cambridge; University of Adelaide	Wilson, MR (corresponding author), Univ Wollongong, Sch Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	mrw@uow.edu.au	Yerbury, Justin/AAC-7054-2022; Wilson, Mark R/B-3254-2018; Kumita, Janet/AAO-5254-2021	Yerbury, Justin/0000-0003-2528-7039; Wilson, Mark R/0000-0002-9551-7445; 	Biotechnology and Biological Sciences Research Council [BB/E019927/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Boggs LN, 1996, J NEUROCHEM, V67, P1324; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L; Chiesa R, 1996, EUR J NEUROSCI, V8, P589, DOI 10.1111/j.1460-9568.1996.tb01244.x; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Freixes M, 2004, ACTA NEUROPATHOL, V108, P295, DOI 10.1007/s00401-004-0891-6; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hatters DM, 2002, EUR J BIOCHEM, V269, P2789, DOI 10.1046/j.1432-1033.2002.02957.x; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Kammerer RA, 2004, P NATL ACAD SCI USA, V101, P4435, DOI 10.1073/pnas.0306786101; KIDA E, 1995, BRAIN RES, V685, P211, DOI 10.1016/0006-8993(95)00482-6; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; KUMITA JR, 2007, IN PRESS J MOL BIOL; Lakins JN, 2002, BIOCHEMISTRY-US, V41, P282, DOI 10.1021/bi0157666; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; MaatSchieman MLC, 1996, BRAIN PATHOL, V6, P115, DOI 10.1111/j.1750-3639.1996.tb00794.x; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McHattie S, 1999, BIOCHEM BIOPH RES CO, V259, P336, DOI 10.1006/bbrc.1999.0781; Morrissey C, 2001, J BIOCHEM BIOPH METH, V48, P13, DOI 10.1016/S0165-022X(00)00137-8; Nishida I, 1999, BRIT J OPHTHALMOL, V83, P1178, DOI 10.1136/bjo.83.10.1178; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Poon S, 2002, J BIOL CHEM, V277, P39532, DOI 10.1074/jbc.M204855200; Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; WITTE DP, 1993, AM J PATHOL, V143, P763; Yerbury JJ, 2005, EMBO REP, V6, P1131, DOI 10.1038/sj.embor.7400586; Zenkel M, 2006, INVEST OPHTH VIS SCI, V47, P1982, DOI 10.1167/iovs.05-1580	36	233	241	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2312	2322		10.1096/fj.06-7986com	http://dx.doi.org/10.1096/fj.06-7986com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17412999				2022-12-25	WOS:000248454400006
J	Liu, Q; Ponnuraj, K; Xu, Y; Ganesh, VK; Sillanpaa, J; Murray, BE; Narayana, SVL; Hook, M				Liu, Qing; Ponnuraj, Karthe; Xu, Yi; Ganesh, Vannakambadi K.; Sillanpaa, Jouko; Murray, Barbara E.; Narayana, Sthanam V. L.; Hook, Magnus			The Enterococcus faecalis MSCRAMM ACE binds its ligand by the collagen hug model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESIVE MATRIX MOLECULES; STAPHYLOCOCCUS-AUREUS; DOMAIN; PROTEIN; RESISTANCE; FIBRINOGEN; VIRULENCE; CNA	We have determined the crystal structure of the ligand binding segment of the Enterococcus faecalis collagen binding MSCRAMM ACE ( microbial surface components recognizing adhesive matrix molecules adhesin of collagen from enterococci). This segment is composed of two subdomains, N1 and N2, each adopting an IgG-like fold and forming a putative collagen binding surface at the interface between the two subdomains. This structure is very similar to that recently reported for CNA, the collagen binding MSCRAMM of Staphylococcus aureus, for which a unique ligand binding mechanism called the Collagen Hug was proposed. We suggest that ACE binds collagen by a similar mechanism and present the first biochemical evidence for this binding model. Replacing residues in the putative collagen binding trench of ACE N2 with Ala residues affected collagen binding. A closed conformation of ACE stabilized by an engineered disulfide bond is unable to bind collagen. Finally, the importance of the residues in the N2 extension in stabilizing the MSCRAMM-ligand complex is demonstrated by selected point and truncation mutations.	Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Dept Internal Med,Div Infect Dis, Houston, TX 77030 USA; Univ Madras, Dept Crystallog & Biophys, Madras 600025, Tamil Nadu, India	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Madras	Hook, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd,Suite 603, Houston, TX 77030 USA.	mhook@ibt.tamhsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624, R37AI047923] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624, R37 AI 47923] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON MJ, 1997, J MOL GRAPHICS, V5, P103; CLEWELL DB, 1990, EUR J CLIN MICROBIOL, V9, P90, DOI 10.1007/BF01963632; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HORODNICEANU T, 1979, ANTIMICROB AGENTS CH, V16, P686, DOI 10.1128/AAC.16.5.686; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Murray BE, 1999, P ASSOC AM PHYSICIAN, V111, P328, DOI 10.1046/j.1525-1381.1999.99241.x; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nallapareddy SR, 2000, INFECT IMMUN, V68, P5218, DOI 10.1128/IAI.68.9.5218-5224.2000; Nallapareddy SR, 2000, INFECT IMMUN, V68, P5210, DOI 10.1128/IAI.68.9.5210-5217.2000; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Ponnuraj K, 2002, BBA-PROTEIN STRUCT M, V1596, P173, DOI 10.1016/S0167-4838(01)00328-4; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; PONNURAJ K, 2007, IN PRESS PROTEINS; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Visai L, 2000, J BIOL CHEM, V275, P39837, DOI 10.1074/jbc.M005297200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zong YN, 2005, EMBO J, V24, P4224, DOI 10.1038/sj.emboj.7600888	31	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19629	19637		10.1074/jbc.M611137200	http://dx.doi.org/10.1074/jbc.M611137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17392280	hybrid			2022-12-25	WOS:000247650600037
J	Hartl, L; Kubicek, CP; Seiboth, B				Hartl, Lukas; Kubicek, Christian P.; Seiboth, Bernhard			Induction of the gal pathway and cellulase genes involves no transcriptional inducer function of the galactokinase in Hypocrea jecorina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; D-GALACTOSE; KLUYVEROMYCES-LACTIS; LACTOSE METABOLISM; EXPRESSION; GROWTH; TRANSFORMATION	The Saccharomyces cerevisiae galactokinase ScGal1, a key enzyme for D-galactose metabolism, catalyzes the conversion of D-galactose to D-galactose 1-phosphate, whereas its catalytically inactive paralogue, ScGal3, activates the transcription of the GAL pathway genes. In Kluyveromyces lactis the transcriptional inducer function and the galactokinase activity are encoded by a single bifunctional KlGal1. Here, we investigated the cellular function of the single galactokinase GAL1 in the multicellular ascomycete Hypocrea jecorina ( = Trichoderma reesei) in the induction of the gal genes and of the galactokinase-dependent induction of the cellulase genes by lactose (1,4-O-beta-D-galactopyranosyl-D- glucose). A comparison of the transcriptional response of a strain deleted in the gal1 gene ( no putative transcriptional inducer and no galactokinase activity), a strain expressing a catalytically inactive GAL1 version ( no galactokinase activity but a putative inducer function), and a strain expressing the Escherichia coli galK ( no putative transcriptional inducer but galactokinase activity) showed that, in contrast to the two yeasts, both the GAL1 protein and the galactokinase activity are fully dispensable for induction of the Leloir pathway gene gal7 by D-galactose and that only the galactokinase activity is required for cellulase induction by lactose. The data document a fundamental difference in the mechanisms by which yeasts and multicellular fungi respond to the presence of D-galactose, showing that the Gal1/Gal3-Gal4 - Gal80- dependent regulatory circuit does not operate in multicellular fungi.	Vienna Univ Technol, Inst Chem Engn, Res Area Gene Technol& Appl Biochem, Mol Biotechnol Grp, A-1060 Vienna, Austria	Technische Universitat Wien	Hartl, L (corresponding author), Vienna Univ Technol, Inst Chem Engn, Res Area Gene Technol& Appl Biochem, Mol Biotechnol Grp, Getreidemark 9-166, A-1060 Vienna, Austria.	lhartl@mail.zserv.tuwien.ac.at						BHAT PJ, 1990, GENETICS, V125, P281; Bhat PJ, 2001, MOL MICROBIOL, V40, P1059, DOI 10.1046/j.1365-2958.2001.02421.x; Fekete E, 2004, ARCH MICROBIOL, V181, P35, DOI 10.1007/s00203-003-0622-8; Fekete E, 2002, ARCH MICROBIOL, V179, P7, DOI 10.1007/s00203-002-0491-6; Fekete E, 2007, MICROBIOL-SGM, V153, P507, DOI 10.1099/mic.0.2006/001602-0; GRUBER F, 1990, CURR GENET, V18, P71, DOI 10.1007/BF00321118; Grun CH, 2005, GLYCOBIOLOGY, V15, P245, DOI 10.1093/glycob/cwi002; Kainuma M, 2001, YEAST, V18, P533, DOI 10.1002/yea.708; Karaffa L, 2006, MICROBIOL-SGM, V152, P1507, DOI 10.1099/mic.0.28719-0; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Lesage G, 2006, MICROBIOL MOL BIOL R, V70, P317, DOI 10.1128/MMBR.00038-05; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; MANDELS M, 1978, PROCESS BIOCHEM, V13, P6; MEYER J, 1991, MOL CELL BIOL, V11, P5454, DOI 10.1128/MCB.11.11.5454; Penttila M., 2004, Handbook of fungal biotechnology, P413; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; ROBERTS CF, 1970, BIOCHIM BIOPHYS ACTA, V201, P267, DOI 10.1016/0304-4165(70)90301-6; Rubio-Texeira M, 2005, FEMS YEAST RES, V5, P1115, DOI 10.1016/j.femsyr.2005.05.003; Sambrook J., 2001, MOL CLONING LAB MANU; Schaffrath R, 2000, FUNGAL GENET BIOL, V30, P173, DOI 10.1006/fgbi.2000.1221; Seiboth B, 2004, MOL MICROBIOL, V51, P1015, DOI 10.1046/j.1365-2958.2003.03901.x; Seiboth B, 2002, GENE, V295, P143, DOI 10.1016/S0378-1119(02)00834-X; Seiboth B, 2002, MOL GENET GENOMICS, V267, P124, DOI 10.1007/s00438-002-0654-9; Seiboth Bernhard, 2007, Fungal Biology Reviews, V21, P42, DOI 10.1016/j.fbr.2007.02.006; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZACHARIAE W, 1993, MOL CELL BIOL, V13, P3058, DOI 10.1128/MCB.13.5.3058	27	32	34	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18654	18659		10.1074/jbc.M700955200	http://dx.doi.org/10.1074/jbc.M700955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452322	hybrid			2022-12-25	WOS:000247302000070
J	Bowzard, JB; Cheng, D; Peng, J; Kahn, RA				Bowzard, J. Bradford; Cheng, Dongmei; Peng, Junmin; Kahn, Richard A.			ELMOD2 is an Arl2 GTPase-activating protein that also acts on Arfs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; BINDING PROTEINS; RAS SUPERFAMILY; DOWNSTREAM ACTIVATION; GENOMIC ANALYSIS; COFACTOR-D; FAMILY; GENE; GAP; HYDROLYSIS	Regulatory GTPases in the Ras superfamily employ a cycle of alternating GTP binding and hydrolysis, controlled by guanine nucleotide exchange factors and GTPase-activating proteins ( GAPs), as essential features of their actions in cells. Studies of these GAPs and guanine nucleotide exchange factors have provided important insights into our understanding of GTPase signaling and biology. Within the Ras superfamily, the Arf family is composed of 30 members in mammals, including 22 Arf-like ( Arl) proteins. Much less is known about the mechanisms of cell regulation by Arls than by Arfs. We report the purification from bovine testis of an Arl2 GAP and its identity as ELMOD2, a protein with no previously described function. ELMOD2 is one of six human proteins that contain an ELMO domain, and a second member, ELMOD1, was also found to have Arl2 GAP activity. Surprisingly, ELMOD2 also exhibited GAP activity against Arf proteins even though it does not contain the canonical Arf GAP sequence signature. The broader specificity of ELMOD2, as well as the previously described role for ELMO1 and ELMO2 in linking Arf6 and Rac1 signaling, suggests that ELMO family members may play a more general role in integrating signaling pathways controlled by Arls and other GTPases.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Human Genet, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Peng, Junmin/N-2614-2018; Kahn, Richard/ABD-2666-2020	Peng, Junmin/0000-0003-0472-7648; Kahn, Richard/0000-0002-0259-0601	NIA NIH HHS [AG025688] Funding Source: Medline; NIGMS NIH HHS [GM24680, GM067465, R01 GM090158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM067465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG025688] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Bowzard JB, 2005, METHOD ENZYMOL, V404, P453, DOI 10.1016/S0076-6879(05)04040-1; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Calin GA, 2005, NEW ENGL J MED, V352, P1667, DOI 10.1056/NEJMoa042280; Cassel D, 2003, PROTEINS CELL REG, V1, P137; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Chiang AP, 2004, AM J HUM GENET, V75, P475, DOI 10.1086/423903; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; Echard A, 2004, CURR BIOL, V14, P1685, DOI 10.1016/j.cub.2004.08.063; Fan YL, 2004, NAT GENET, V36, P989, DOI 10.1038/ng1414; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Ha VL, 2005, METHOD ENZYMOL, V404, P164, DOI 10.1016/S0076-6879(05)04016-4; Hodgson U, 2006, AM J HUM GENET, V79, P149, DOI 10.1086/504639; Hofmann I, 2006, J CELL SCI, V119, P1494, DOI 10.1242/jcs.02958; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Jacques KM, 2002, J BIOL CHEM, V277, P47235, DOI 10.1074/jbc.M208875200; Kahn RA, 2006, J CELL BIOL, V172, P645, DOI 10.1083/jcb.200512057; Katoh H, 2006, BRAIN RES, V1073, P103, DOI 10.1016/j.brainres.2005.12.085; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Li YW, 2004, FASEB J, V18, P1834, DOI 10.1096/fj.04-2273com; Lia LJ, 2004, J BIOL CHEM, V279, P37061, DOI 10.1074/jbc.M403672200; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; Liu YW, 2005, MOL BIOL CELL, V16, P4024, DOI 10.1091/mbc.E05-01-0023; Luo RB, 2005, CURR BIOL, V15, P2164, DOI 10.1016/j.cub.2005.10.065; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Mesmin B, 2007, BIOCHEMISTRY-US, V46, P1779, DOI 10.1021/bi062288w; Okai T, 2004, J CELL SCI, V117, P4705, DOI 10.1242/jcs.01347; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Petrocca F, 2006, CANCER RES, V66, P10287, DOI 10.1158/0008-5472.CAN-06-2289; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 2005, CURR BIOL, V15, P1749, DOI 10.1016/j.cub.2005.08.052; Scheffzek K, 2005, CELL MOL LIFE SCI, V62, P3014, DOI 10.1007/s00018-005-5136-x; Schrick JJ, 2006, AM J PATHOL, V168, P1288, DOI 10.2353/ajpath.2006.050941; Seewald MJ, 2003, MOL CELL BIOL, V23, P8124, DOI 10.1128/MCB.23.22.8124-8136.2003; Sharer JD, 2002, MOL BIOL CELL, V13, P71, DOI 10.1091/mbc.01-05-0245; Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200; STEARNS T, 1990, GENETICS, V124, P251; Tomoda T, 2004, GENE DEV, V18, P541, DOI 10.1101/gad.1151204; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; WEISS O, 1989, J BIOL CHEM, V264, P21066; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yanagisawa LL, 2002, MOL BIOL CELL, V13, P2193, DOI 10.1091/mbc.01-11-0563; Yang JS, 2006, NAT CELL BIOL, V8, P1376, DOI 10.1038/ncb1503; Yoon HY, 2006, J CELL SCI, V119, P4650, DOI 10.1242/jcs.03237; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zhou CJ, 2006, MOL BIOL CELL, V17, P2476, DOI 10.1091/mbc.E05-10-0929	65	58	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17568	17580		10.1074/jbc.M701347200	http://dx.doi.org/10.1074/jbc.M701347200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452337	hybrid			2022-12-25	WOS:000247084500028
J	DeHaven, WI; Smyth, JT; Boyles, RR; Putney, JW				DeHaven, Wayne I.; Smyth, Jeremy T.; Boyles, Rebecca R.; Putney, James W., Jr.			Calcium inhibition and calcium potentiation of Orai1, Orai2, and Orai3 calcium release-activated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURRENT I-CRAC; CA2+ CHANNELS; STORE DEPLETION; PROTEIN-KINASE; T-LYMPHOCYTES; CELLS; INFLUX; STIM1; JURKAT; INACTIVATION	The recent discoveries of Stim1 and Orai proteins have shed light on the molecular makeup of both the endoplasmic reticulum Ca2+ sensor and the calcium release-activated calcium ( CRAC) channel, respectively. In this study, we investigated the regulation of CRAC channel function by extracellular Ca2+ for channels composed primarily of Orai1, Orai2, and Orai3, by coexpressing these proteins together with Stim1, as well as the endogenous channels in HEK293 cells. As reported previously, Orai1 or Orai2 resulted in a substantial increase in CRAC current ( I-crac), but Orai3 failed to produce any detectable Ca2+ selective currents. However, sodium currents measured in the Orai3-expressing HEK293 cells were significantly larger in current density than Stim1-expressing cells. Moreover, upon switching to divalent free external solutions, Orai3 currents were considerably more stable than Orai1 or Orai2, indicating that Orai3 channels undergo a lesser degree of depotentiation. Additionally, the difference between depotentiation from Ca2+ and Ba2+ or Mg2+ solutions was significantly less for Orai3 than for Orai1 or -2. Nonetheless, the Na+ currents through Orai1, Orai2, and Orai3, as well as the endogenous store-operated Na+ currents in HEK293 cells, were all inhibited by extracellular Ca2+ with a half-maximal concentration of similar to 20 mu M. We conclude that Orai1, -2, and -3 channels are similarly inhibited by extracellular Ca2+, indicating similar affinities for Ca2+ within the selectivity filter. Orai3 channels appeared to differ from Orai1 and -2 in being somewhat resistant to the process of Ca2+ depotentiation.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789; Boyles, Rebecca/0000-0003-0073-6854	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087, ZIAES090087] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Christian EP, 1996, J MEMBRANE BIOL, V150, P63, DOI 10.1007/s002329900030; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Lewis RS, 1996, SOC GEN PHY, V51, P241; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Prakriya M, 2006, J GEN PHYSIOL, V128, P373, DOI 10.1085/jgp.200609588; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Su ZC, 2004, BIOPHYS J, V86, P805, DOI 10.1016/S0006-3495(04)74156-9; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	28	194	199	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17548	17556		10.1074/jbc.M611374200	http://dx.doi.org/10.1074/jbc.M611374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452328	hybrid			2022-12-25	WOS:000247084500025
J	Kumagai, K; Kawano, M; Shinkai-Ouchi, F; Nishijima, M; Hanada, K				Kumagai, Keigo; Kawano, Miyuki; Shinkai-Ouchi, Fumiko; Nishijima, Masahiro; Hanada, Kentaro			Interorganelle trafficking of ceramide is regulated by phosphorylation-dependent cooperativity between the PH and START domains of CERT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN SYNTHESIS; GOODPASTURE ANTIGEN; BINDING-PROTEIN; GOLGI; TRANSPORT; LOCALIZATION; RESISTANT	The synthesis and transport of lipids are essential events for membrane biogenesis. However, little is known about how intracellular trafficking of lipids is regulated. Ceramide is synthesized at the endoplasmic reticulum (ER) and transported by the ceramide transfer protein CERT to the Golgi apparatus, where it is converted to sphingomyelin. CERT has a phosphoinositidebinding pleckstrin homology (PH) domain for Golgi-targeting and a lipid transfer START domain for intermembrane transfer of ceramide. We here show that CERT receives multiple phosphorylations at a serine-repeat motif, a possibe site for casein kinase I, and that the phosphorylation down-regulates the ER-to-Golgi transport of ceramide. In vitro assays show that the phosphorylation induces an autoinhibitory interaction between the PH and START domains and consequently inactivates both the phosphoinositide binding and ceramide transfer activities of CERT. Loss of sphingomyelin and cholesterol from cells causes dephosphorylation of CERT to activate it. The cooperative control of functionally distinct domains of CERT is a novel molecular event to regulate the intracellular trafficking of ceramide.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	hanak@nih.go.jp	Kumagai, Keigo/AAG-1385-2021; Shinkai-ouchi, Fumiko/E-3207-2010	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Hanada, Kentaro/0000-0003-1383-2781; Kumagai, Keigo/0000-0002-1663-2905; KAWANO-KAWADA, Miyuki/0000-0002-1168-9291				Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Kawano M, 2006, J BIOL CHEM, V281, P30279, DOI 10.1074/jbc.M605032200; Kumagai K, 2005, J BIOL CHEM, V280, P6488, DOI 10.1074/jbc.M409290200; Kuyama H, 2003, RAPID COMMUN MASS SP, V17, P1493, DOI 10.1002/rcm.1078; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Mogelsvang S, 2004, TRAFFIC, V5, P338, DOI 10.1111/j.1398-9219.2004.00186.x; Mohammadi A, 2001, J LIPID RES, V42, P1062; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tafesse FG, 2006, J BIOL CHEM, V281, P29421, DOI 10.1074/jbc.R600021200; Toth B, 2006, J BIOL CHEM, V281, P36369, DOI 10.1074/jbc.M604935200; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Yanagisawa Y, 2006, J PATHOL, V209, P464, DOI 10.1002/path.2012; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200	31	86	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17758	17766		10.1074/jbc.M702291200	http://dx.doi.org/10.1074/jbc.M702291200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17442665	hybrid			2022-12-25	WOS:000247084500049
J	McMillan, DGG; Keis, S; Dimroth, P; Cook, GM				McMillan, Duncan G. G.; Keis, Stefanie; Dimroth, Peter; Cook, Gregory M.			A specific adaptation in the a subunit of thermoalkaliphilic F1F0-ATP synthase enables ATP synthesis at high pH but not at neutral pH values	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN TA2.A1; COLI MEMBRANE-VESICLES; BACILLUS-FIRMUS OF4; PROTON-TRANSLOCATING ATPASE; AQUEOUS ACCESS CHANNELS; ESCHERICHIA-COLI; ALKALIPHILIC BACILLUS; ACTIVE-TRANSPORT; MOLECULAR CHARACTERIZATION; PROPIONIGENIUM-MODESTUM	Analysis of the atp operon from the thermoalkaliphilic Bacillus sp. TA2. A1 and comparison with other atp operons from alkaliphilic bacteria reveals the presence of a conserved lysine residue at position 180 (Bacillus sp. TA2. A1 numbering) within the a subunit of these F1Fo-ATP synthases. We hypothesize that the basic nature of this residue is ideally suited to capture protons from the bulk phase at high pH. To test this hypothesis, a heterologous expression system for the ATP synthase from Bacillus sp. TA2.A1 (TA2F(1)F(o)) was developed in Escherichia coli DK8 (Delta atp). Amino acid substitutions were made in the a subunit of TA2F(1)F(o) at position 180. Lysine (aK180) was substituted for the basic residues histidine (aK180H) or arginine (aK180R), and the uncharged residue glycine (aK180G). ATP synthesis experiments were performed in ADP plus P-i- loaded right-side-out membrane vesicles energized by ascorbate- phenazine methosulfate. When these enzyme complexes were examined for their ability to perform ATP synthesis over the pH range from 7.0 to 10.0, TA2F(1)F(o) and aK180R showed a similar pH profile having optimum ATP synthesis rates at pH 9.0-9.5 with no measurable ATP synthesis at pH 7.5. Conversely, aK180H and aK180G showed maximal ATP synthesis at pH values 8.0 and 7.5, respectively. ATP synthesis under these conditions for all enzyme forms was sensitive to DCCD. These data strongly imply that amino acid residue Lys(180) is a specific adaptation within the a subunit of TA2F(1)F(o) to facilitate proton capture at high pH. At pH values near the pK(a) of Lys(180), the trapped protons readily dissociate to reach the subunit c binding sites, but this dissociation is impeded at neutral pH values causing either a blocking of the proposed H+ channel and/or mechanism of proton translocation, and hence ATP synthesis is inhibited.	Univ Otago, Otago Sch Med Sci, Dept Microbiol & Immunol, Dunedin, New Zealand; ETH Honggerberg, Inst Mikrobiol, CH-8093 Zurich, Switzerland	University of Otago; Swiss Federal Institutes of Technology Domain; ETH Zurich	Cook, GM (corresponding author), Univ Otago, Otago Sch Med Sci, Dept Microbiol & Immunol, POB 56, Dunedin, New Zealand.	greg.cook@stonebow.otago.ac.nz	McMillan, Duncan/AAT-7415-2021; Cook, Gregory/E-5665-2011	McMillan, Duncan/0000-0001-6614-4494; 				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENDORF KH, 1974, J BACTERIOL, V117, P888, DOI 10.1128/JB.117.2.888-899.1974; Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; Cook GM, 2003, J BACTERIOL, V185, P4442, DOI 10.1128/JB.185.15.4442-4449.2003; Dimroth P, 2006, EMBO REP, V7, P276, DOI 10.1038/sj.embor.7400646; Dimroth P, 2004, ADV MICROB PHYSIOL, V49, P175, DOI 10.1016/S0065-2911(04)49004-3; Ferguson SA, 2006, J BACTERIOL, V188, P5045, DOI 10.1128/JB.00128-06; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; GUFFANTI AA, 1984, J BIOL CHEM, V259, P2971; GUFFANTI AA, 1985, ARCH BIOCHEM BIOPHYS, V239, P327, DOI 10.1016/0003-9861(85)90695-2; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HICKS DB, 1990, J BIOL CHEM, V265, P20547; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANN A, 1990, EUR J BIOCHEM, V194, P423, DOI 10.1111/j.1432-1033.1990.tb15635.x; HOFFMANN A, 1991, EUR J BIOCHEM, V201, P467, DOI 10.1111/j.1432-1033.1991.tb16304.x; Horikoshi K, 1999, MICROBIOL MOL BIOL R, V63, P735, DOI 10.1128/MMBR.63.4.735-750.1999; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; IVEY DM, 1992, RES MICROBIOL, V143, P467, DOI 10.1016/0923-2508(92)90092-3; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1971, J BIOL CHEM, V246, P5523; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; KAIM G, 1995, J MOL BIOL, V253, P726, DOI 10.1006/jmbi.1995.0586; KASHKET ER, 1985, ANNU REV MICROBIOL, V39, P219, DOI 10.1146/annurev.mi.39.100185.001251; Keis S, 2004, BBA-GENE STRUCT EXPR, V1676, P112, DOI 10.1016/j.bbaexp.2003.11.002; Keis S, 2006, J BACTERIOL, V188, P3796, DOI 10.1128/JB.00040-06; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Meier T, 2002, EMBO REP, V3, P1094, DOI 10.1093/embo-reports/kvf216; Meier T, 2006, J BACTERIOL, V188, P7759, DOI 10.1128/JB.00934-06; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Olsson K, 2003, J BACTERIOL, V185, P461, DOI 10.1128/JB.185.2.461-465.2003; Pogoryelov D, 2005, EMBO REP, V6, P1040, DOI 10.1038/sj.embor.7400517; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P848, DOI 10.1021/bi00624a006; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTANA M, 1994, J BACTERIOL, V176, P6802, DOI 10.1128/JB.176.22.6802-6811.1994; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; Seelert H, 2003, J MOL BIOL, V333, P337, DOI 10.1016/j.jmb.2003.08.046; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P5032, DOI 10.1073/pnas.71.12.5032; SHORT SA, 1975, J BIOL CHEM, V250, P4291; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stocker A, 2005, J STRUCT BIOL, V152, P140, DOI 10.1016/j.jsb.2005.08.005; STURR MG, 1994, J BACTERIOL, V176, P3111, DOI 10.1128/jb.176.11.3111-3116.1994; Tomashek JJ, 2004, J BIOL CHEM, V279, P4465, DOI 10.1074/jbc.M310826200; TSUCHIYA T, 1976, J BIOL CHEM, V251, P5315; TSUCHIYA T, 1977, J BACTERIOL, V129, P763, DOI 10.1128/JB.129.2.763-769.1977; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wang ZX, 2004, J BIOL CHEM, V279, P26546, DOI 10.1074/jbc.M401206200; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	63	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17395	17404		10.1074/jbc.M611709200	http://dx.doi.org/10.1074/jbc.M611709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17434874	hybrid			2022-12-25	WOS:000247084500009
J	Bei, L; Lu, Y; Bellis, SL; Zhou, W; Horvath, E; Eklund, EA				Bei, Ling; Lu, YuFeng; Bellis, Susan L.; Zhou, Wei; Horvath, Elizabeth; Eklund, Elizabeth A.			Identification of a HoxA10 activation domain necessary for transcription of the gene encoding beta 3 integrin during myeloid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC-CELLS; BONE-MARROW-CELLS; DNA-BINDING; FIBRONECTIN RECEPTORS; VITRONECTIN RECEPTOR; INTERFERON-GAMMA; EXPRESSION; PROTEINS; FAMILY; BETA-1-INTEGRIN	Transcription of the ITGB3 gene, which encodes beta 3 integrin, increases during myeloid differentiation. alpha v beta 3 integrin mediates adhesion to fibronectin or vitronectin and regulates various aspects of the inflammatory response in mature phagocytes. In these studies, we found that the homeodomain transcription factor HoxA10 interacted with a specific ITGB3 cis element and activated transcription of this gene during myeloid differentiation. We also found that increased fibronectin adhesion in differentiating myeloid cells was dependent upon this HoxA10-induced increase in beta 3 integrin expression. We determined that activation of ITGB3 transcription required a HoxA10 domain that was not identical to the "hexapeptide" that mediates interaction of Hox and Pbx proteins. This activation domain was also not identical to a previously identified HoxA10 repression domain that mediates interaction with transcriptional co-repressors. Instead, this HoxA10 activation domain had homology to "PQ" protein-protein interaction domains that have been described previously in other transcription factors. Consistent with this, we found that the HoxA10 PQ-like domain recruited the CREB-binding protein (CBP) to the ITGB3 promoter. This was associated with an increase in local histone acetylation in vivo. In immature myeloid cells, we previously determined that HoxA10 repressed transcription of the CYBB and NCF2 genes, which encode the phagocyte oxidase proteins gp91(PHOX) and p67(PHOX), respectively. Therefore, our studies indicated that HoxA10 either activates or represses gene transcription at various points during myelopoiesis. Our studies also suggested that HoxA10 is a bifunctional protein that is involved in dynamic regulation of multiple aspects of phagocyte phenotype and function.	Northwestern Univ, Dept Med, Feinberg Sch, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Jesse Brown Vet Hlth Adm Hosp, Chicago, IL 60612 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Northwestern Univ, Dept Med, Feinberg Sch, 710 N Fairbanks Ct,Olson 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu						ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bhatia R, 2002, EXP HEMATOL, V30, P324, DOI 10.1016/S0301-472X(01)00799-8; Bruyninckx WJ, 2001, BLOOD, V97, P3251, DOI 10.1182/blood.V97.10.3251; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Daftary GS, 2002, MOL ENDOCRINOL, V16, P571, DOI 10.1210/me.16.3.571; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Eklund EA, 2006, CURR OPIN HEMATOL, V13, P67, DOI 10.1097/01.moh.0000208467.63861.d6; FADOK VA, 1992, J IMMUNOL, V149, P4029; GARCIAVILLA M, 1994, BLOOD, V83, P668; HILL HR, 1993, INFECT IMMUN, V61, P2334, DOI 10.1128/IAI.61.6.2334-2339.1993; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; KLINGEMANN HG, 1989, BLOOD, V74, P1348; LARRICK JW, 1980, J IMMUNOL, V125, P6; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Seales EC, 2005, J BIOL CHEM, V280, P37610, DOI 10.1074/jbc.M508476200; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERFAILLIE CM, 1991, J EXP MED, V174, P693, DOI 10.1084/jem.174.3.693; Wall CD, 1997, BLOOD CELL MOL DIS, V23, P361, DOI 10.1006/bcmd.1997.0153; Yan SR, 1999, CELL IMMUNOL, V195, P119, DOI 10.1006/cimm.1999.1524	37	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16846	16859		10.1074/jbc.M609744200	http://dx.doi.org/10.1074/jbc.M609744200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439948	hybrid			2022-12-25	WOS:000246946500017
J	Selent, J; Kaleta, J; Li, ZQ; Lalmanach, G; Bromme, D				Selent, Jana; Kaleta, Jadwiga; Li, Zhenqiang; Lalmanach, Gilles; Bromme, Dieter			Selective inhibition of the collagenase activity of cathepsin K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; COLLAGENOLYTIC ACTIVITY; MOLECULAR-CLONING; COMPLEX-FORMATION; OSTEOCLASTS; EXPRESSION; DESIGN; UNIQUE	Cathepsin K, the main bone degrading protease, and chondroitin 4-sulfate (C4-S) form a complex with enhanced collagenase activity. In this report, we demonstrate the specific inhibition of the collagenase activity of cathepsin K by negatively charged polymers without affecting the overall proteolytic activity of the protease. Three different mechanisms to interfere with cathepsin-catalyzed collagen degradation are discussed: 1) inhibition of the formation of the cathepsin K/C4-S complex, 2) inhibition of the attachment of C4-S to collagen, and 3) masking of the collagenase cleavage sites in collagen. By targeting these interaction sites, collagen degradation can be modulated while the non-collagenolytic activities of cathepsin K remain intact. The main inhibitory effect on collagen degradation is due to the impeding effect on the active cathepsin K/C4-S complex. Essential structural elements in the inhibitor molecules are negative charges which compete with the sulfate groups of C4-S in the cathepsin K/C4-S complex. The inhibitory effect can be controlled by length and charge of the polymers. Longer negatively charged polymers ( e.g. polyglutamates, oligonucleotides) tend to inhibit all three mechanisms, whereas shorter ones preferentially affect the cathepsin K/C4-S complex.	Univ British Columbia, Fac Dent, Dept Oral & Biol Sci, Vancouver, BC V6J 1Z3, Canada; Univ British Columbia, Ctr Blood Res, Vancouver, BC V6J 1Z3, Canada; Bristol Myers Squibb Co, Pennington, NJ 08534 USA; Univ Tours, INSERM, U618, IFR135,Fac Med, F-37032 Tours, France	University of British Columbia; University of British Columbia; Bristol-Myers Squibb; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours	Bromme, D (corresponding author), Univ British Columbia, Fac Dent, Dept Oral & Biol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6J 1Z3, Canada.	dbromme@interchange.ubc.ca	Selent, Jana/E-6912-2015	Selent, Jana/0000-0002-1844-4449; Lalmanach, Gilles/0000-0001-8562-4821	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072070] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 48669] Funding Source: Medline; NIDDK NIH HHS [DK 072070] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Godat E, 2004, BIOCHEM J, V383, P501, DOI 10.1042/BJ20040864; Hou WS, 2003, BIOL CHEM, V384, P891, DOI 10.1515/BC.2003.100; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; Jameson DM, 1999, METHODS, V19, P222, DOI 10.1006/meth.1999.0853; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; KRANE SM, 1994, SCI AM MED, V3, P1; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; OBRINK B, 1971, BIOCHEM J, V121, P227; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; Thompson MJ, 1997, PROTEIN SCI, V6, P1963, DOI 10.1002/pro.5560060917; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013	21	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16492	16501		10.1074/jbc.M700242200	http://dx.doi.org/10.1074/jbc.M700242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426030	hybrid			2022-12-25	WOS:000246794300056
J	Zhong, Q; Li, GL; Gvozdenovic-Jeremic, J; Greenberg, ML				Zhong, Quan; Li, Guiling; Gvozdenovic-Jeremic, Jelena; Greenberg, Miriam L.			Up-regulation of the cell integrity pathway in Saccharomyces cerevisiae suppresses temperature sensitivity of the pgs1 Delta mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; YEAST 1,3-BETA-GLUCAN SYNTHASE; GENOME-WIDE ANALYSIS; MAP KINASE; CARDIOLIPIN SYNTHASE; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; 1,3-BETA-D-GLUCAN SYNTHASE; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; GENE-EXPRESSION	We have previously shown that mutants in the cardiolipin (CL) pathway exhibit temperature-sensitive growth defects that are not associated with mitochondrial dysfunction. The pgs1 Delta mutant, lacking the first enzyme of the CL pathway, phosphatidylglycerolphosphate synthase (Pgs1p), has a defective cell wall due to decreased beta-1,3-glucan (Zhong, Q., Gvozdenovic-Jeremic, J., Webster, P., Zhou, J., and Greenberg, M. L. (2005) Mol. Biol. Cell 16, 665-675). Disruption of KRE5, a gene involved in cell wall biogenesis, restores beta-1,3-glucan synthesis and suppresses pgs1 Delta temperature sensitivity. To gain insight into the mechanisms underlying the cell wall defect in pgs1 Delta, we show in the current report that pgs1 Delta cells have reduced glucan synthase activity and diminished levels of Fks1p, the glucan synthase catalytic subunit. In addition, activation of Slt2p, the downstream effector of the protein kinase C (PKC)-activated cell integrity pathway, was defective in pgs1 Delta. The kre5(W1166X) suppressor restored Slt2p activation and dramatically increased (> 10-fold) mRNA levels of FKS2, the alternate catalytic subunit of glucan synthase, partially restoring glucan synthase activity. Consistent with these results, up-regulation of PKC-Slt2 signaling and overexpression of FKS1 or FKS2 alleviated sensitivity of pgs1 Delta to cell wall-perturbing agents and restored growth at elevated temperature. These findings demonstrate that functional Pgs1p is essential for cell wall biogenesis and activation of the PKC-Slt2 signaling pathway.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu	zhong, quan/AAE-8893-2021	Zhong, Quan/0000-0003-2910-5597	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Frederick RL, 2004, J CELL BIOL, V167, P87, DOI 10.1083/jcb.200405100; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; He Q, 2004, MOL MICROBIOL, V53, P1243, DOI 10.1111/j.1365-2958.2004.04202.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Inoue SB, 1999, J BIOL CHEM, V274, P38119, DOI 10.1074/jbc.274.53.38119; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Lussier M, 1997, GENETICS, V147, P435; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Su XF, 2006, MOL CELL BIOL, V26, P743, DOI 10.1128/MCB.26.3.743-753.2006; Terashima H, 2000, MOL GEN GENET, V264, P64, DOI 10.1007/s004380000285; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Utsugi T, 2002, GENES CELLS, V7, P1, DOI 10.1046/j.1356-9597.2001.00495.x; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Watanabe D, 2001, YEAST, V18, P943, DOI 10.1002/yea.742; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Xu Y, 2006, J BIOL CHEM, V281, P39217, DOI 10.1074/jbc.M606100200; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Zahedi RP, 2006, MOL BIOL CELL, V17, P1436, DOI 10.1091/mbc.E05-08-0740; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013; Zhong Q, 2005, MOL BIOL CELL, V16, P665, DOI 10.1091/mbc.E04-09-0808; Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200	62	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15946	15953		10.1074/jbc.M701055200	http://dx.doi.org/10.1074/jbc.M701055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426021	hybrid			2022-12-25	WOS:000246794300003
J	Zhang, HC; Bialkowska, A; Rusovici, R; Chanchevalap, S; Shim, H; Katz, JP; Yang, VW; Yun, CC				Zhang, Huanchun; Bialkowska, Agnieszka; Rusovici, Raluca; Chanchevalap, Sengthong; Shim, Hyunsuk; Katz, Jonathan P.; Yang, Vincent W.; Yun, C. Chris			Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR-5; GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; KINASE-C-DELTA; TRANSCRIPTION FACTOR; BETA-CATENIN; INTERLEUKIN-8 SECRETION; EPITHELIAL-CELLS; ACTIVATION; PHOSPHORYLATION	Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated. A recent study showed that LPA-mediated proliferation of colon cancer cells requires activation of beta-catenin. However, the majority of colon cancer cells have deregulation of the Wnt/beta-catenin pathway. This prompted us to hypothesize the presence of additional pathway(s) activated by LPA resulting in an increase in the proliferation of colon cancer cells. Kruppel-like factor 5 (KLF5) is a transcriptional factor highly expressed in the crypt compartment of the intestinal epithelium. In this work, we investigated a role of KLF5 in LPA-mediated proliferation. We show that LPA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA2 and LPA3. Silencing of KLF5 expression by small interfering RNA significantly attenuated LPA-mediated proliferation of SW480 and HCT116 cells. LPA-mediated KLF5 induction was partially blocked by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta. Moreover, we observed that LPA regulates KLF5 expression via eukaryotic elongation factor 2 kinase (eEF2k). Inhibition of calmodulin or silencing of eEF2k blocked the stimulation in KLF5 expression. Knockdown of eEF2k specifically inhibited KLF5 induction by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate. These results identify KLF5 as a target of LPA-mediated signaling and suggest a role of KLF5 in promoting proliferation of intestinal epithelia in response to LPA.	Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA	Emory University; Emory University; University of Pennsylvania	Yun, CC (corresponding author), Whitehead Bldg,Rm 201,615 Michael St, Atlanta, GA 30322 USA.	ccyun@emory.edu			NIDDK NIH HHS [R01 DK071597-01A2, R01 DK071597, R24 DK064399, DK071597, DK64399] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071597, R24DK064399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Aoki J, 2000, ANN NY ACAD SCI, V905, P263; Cechin SR, 2005, NEUROCHEM RES, V30, P603, DOI 10.1007/s11064-005-2747-4; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chanchevalap S, 2004, FEBS LETT, V578, P99, DOI 10.1016/j.febslet.2004.10.079; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dewael Y, 2002, COMP BIOCHEM PHYS C, V131, P153, DOI 10.1016/S1532-0456(01)00288-5; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Du JX, 2007, J BIOL CHEM, V282, P4782, DOI 10.1074/jbc.M603413200; Engelender S, 1996, MOL PHARMACOL, V50, P1243; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goetzl EJ, 1999, CANCER RES, V59, P4732; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hilal-Dandan R, 2004, J MOL CELL CARDIOL, V36, P481, DOI 10.1016/j.yjmcc.2003.12.010; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; HUGHES SJ, 1993, BIOCHEM J, V289, P795, DOI 10.1042/bj2890795; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kim J, 2006, CELL SIGNAL, V18, P1695, DOI 10.1016/j.cellsig.2006.01.009; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai R, 2005, J THROMB HAEMOST, V3, P1569, DOI 10.1111/j.1538-7836.2005.01366.x; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Sengupta P, 2007, J BIOL CHEM, V282, P8474, DOI 10.1074/jbc.M607211200; Shida D, 2003, CANCER RES, V63, P1706; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Sturm A, 2002, BBA-MOL CELL BIOL L, V1582, P282, DOI 10.1016/S1388-1981(02)00182-8; Subramanian N, 2006, NAT IMMUNOL, V7, P583, DOI 10.1038/ni1336; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	69	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15541	15549		10.1074/jbc.M700702200	http://dx.doi.org/10.1074/jbc.M700702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17430902	Green Accepted, hybrid			2022-12-25	WOS:000246589600031
J	Coolen, M; Sauka-Spengler, T; Nicolle, D; Le-Mentec, C; Lallemand, Y; Da Silva, C; Plouhinec, JL; Robert, B; Wincker, P; Shi, DL; Mazan, S				Coolen, Marion; Sauka-Spengler, Tatjana; Nicolle, Delphine; Le-Mentec, Chantal; Lallemand, Yvan; Da Silva, Corinne; Plouhinec, Jean-Louis; Robert, Benoit; Wincker, Patrick; Shi, De-Li; Mazan, Sylvie			Evolution of Axis Specification Mechanisms in Jawed Vertebrates: Insights from a Chondrichthyan	PLOS ONE			English	Article							ANTERIOR VISCERAL ENDODERM; NODAL-RELATED SIGNALS; GERM-LAYER FORMATION; PRIMITIVE STREAK FORMATION; EARLY CHICK BLASTODERM; EARLY MOUSE EMBRYO; HOMEOBOX GENE; NEURAL INDUCTION; SPEMANNS ORGANIZER; FOREBRAIN DEVELOPMENT	The genetic mechanisms that control the establishment of early polarities and their link with embryonic axis specification and patterning seem to substantially diverge across vertebrates. In amphibians and teleosts, the establishment of an early dorsoventral polarity determines both the site of axis formation and its rostro-caudal orientation. In contrast, amniotes retain a considerable plasticity for their site of axis formation until blastula stages and rely on signals secreted by extraembryonic tissues, which have no clear equivalents in the former, for the establishment of their rostro-caudal pattern. The rationale for these differences remains unknown. Through detailed expression analyses of key development genes in a chondrichthyan, the dogfish Scyliorhinus canicula, we have reconstructed the ancestral pattern of axis specification in jawed vertebrates. We show that the dogfish displays compelling similarities with amniotes at blastula and early gastrula stages, including the presence of clear homologs of the hypoblast and extraembryonic ectoderm. In the ancestral state, these territories are specified at opposite poles of an early axis of bilateral symmetry, homologous to the dorso-ventral axis of amphibians or teleosts, and aligned with the later forming embryonic axis, from head to tail. Comparisons with amniotes suggest that a dorsal expansion of extraembryonic ectoderm, resulting in an apparently radial symmetry at late blastula stages, has taken place in their lineage. The synthesis of these results with those of functional analyses in model organisms supports an evolutionary link between the dorso-ventral polarity of amphibians and teleosts and the embryonic-extraembryonic organisation of amniotes. It leads to a general model of axis specification in gnathostomes, which provides a comparative framework for a reassessment of conservations both among vertebrates and with more distant metazoans.	[Coolen, Marion; Nicolle, Delphine; Plouhinec, Jean-Louis; Mazan, Sylvie] Univ Orleans, UMR 6218, Equipe Dev & Evolut Vertebres, Orleans, France; [Sauka-Spengler, Tatjana; Le-Mentec, Chantal] Univ Paris 11, UPRES A 8080, Equipe Dev & Evolut Vertebres, Orsay, France; [Da Silva, Corinne; Wincker, Patrick] CNRS, UMR 8030, Evry, France; [Shi, De-Li] Univ Paris 06, UMR7622, Paris, France; [Lallemand, Yvan; Robert, Benoit] Inst Pasteur, CNRS, URA 2578, Unite Genet Mol Morphogenese, Paris, France	Universite de Orleans; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mazan, S (corresponding author), Univ Orleans, UMR 6218, Equipe Dev & Evolut Vertebres, Orleans, France.	mazan@cnrs-orleans.fr	Shi, De-Li/AAG-1807-2021	DA SILVA, Corinne/0000-0002-7618-7831; Coolen, Marion/0000-0001-5658-5296; Sauka-Spengler, Tatjana/0000-0001-9289-0263	CNRG; Groupement d'Interet Scientifique "Genomique marine''; Centre National de la Recherche Scientifique, Universite Paris-Sud; Universite d'Orleans; MRT; AMX; BDI-CNRS	CNRG; Groupement d'Interet Scientifique "Genomique marine''; Centre National de la Recherche Scientifique, Universite Paris-Sud(Centre National de la Recherche Scientifique (CNRS)); Universite d'Orleans; MRT; AMX; BDI-CNRS	EST sequencing was funded by CNRG. This work was supported by a Groupement d'Interet Scientifique "Genomique marine'', the Centre National de la Recherche Scientifique, Universite Paris-Sud and Universite d'Orleans. T. S. S., J.L.P. and M. C. were recipients of MRT, AMX and BDI-CNRS fellowships respectively.	Agius E, 2000, DEVELOPMENT, V127, P1173; ALBAZERCHI A, 2006, DEV BIOL; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andreazzoli M, 1997, DEVELOPMENT, V124, P1733; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1994, DEVELOPMENT, V120, P2979; Arendt D, 1999, MECH DEVELOP, V81, P3, DOI 10.1016/S0925-4773(98)00226-3; Arendt D, 2003, INT J DEV BIOL, V47, P563; Bachiller D, 2000, NATURE, V403, P658, DOI 10.1038/35001072; BALLARD WW, 1993, J EXP ZOOL, V267, P318, DOI 10.1002/jez.1402670309; BALLYCUIF L, 1995, MECH DEVELOP, V49, P49, DOI 10.1016/0925-4773(94)00301-3; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Ben-Haim N, 2006, DEV CELL, V11, P313, DOI 10.1016/j.devcel.2006.07.005; Bertocchini F, 2002, DEV CELL, V3, P735, DOI 10.1016/S1534-5807(02)00318-0; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Bouillet P, 1996, MECH DEVELOP, V58, P141, DOI 10.1016/S0925-4773(96)00569-2; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; BURIAN RM, 1993, J HIST BIOL, V26, P351, DOI 10.1007/BF01061974; CALLEBAUT M, 1995, EUR J MORPHOL, V33, P221; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chapman SC, 2003, DEVELOPMENT, V130, P5091, DOI 10.1242/dev.00712; Chazaud C, 2006, DEVELOPMENT, V133, P3379, DOI 10.1242/dev.02523; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; COOPER MS, 2007, J EXP ZOOLOG B; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; De Robertis EM, 2006, NAT REV MOL CELL BIO, V7, P296, DOI 10.1038/nrm1855; Delaune E, 2005, DEVELOPMENT, V132, P299, DOI 10.1242/dev.01582; Erter CE, 2001, DEVELOPMENT, V128, P3571; Erwin DH, 2002, DEVELOPMENT, V129, P3021; Fekany K, 1999, DEVELOPMENT, V126, P1427; Fekany-Lee K, 2000, DEVELOPMENT, V127, P2333; Feldman B, 2000, CURR BIOL, V10, P531, DOI 10.1016/S0960-9822(00)00469-3; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Foley AC, 2000, DEVELOPMENT, V127, P3839; Foley AC, 2001, J ANAT, V199, P35; Force A, 1999, GENETICS, V151, P1531; Fredieu JR, 1997, DEV BIOL, V186, P100, DOI 10.1006/dbio.1997.8566; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Gardner RL, 1997, DEVELOPMENT, V124, P289; Georgiades P, 2006, DEVELOPMENT, V133, P1059, DOI 10.1242/dev.02277; GERHARDT J, 1997, CELLS EMBRYOS EVOLUT; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GODSAVE S, 1994, DEV BIOL, V166, P465, DOI 10.1006/dbio.1994.1330; Gore AV, 2005, NATURE, V438, P1030, DOI 10.1038/nature04184; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hashimoto H, 2000, DEV BIOL, V217, P138, DOI 10.1006/dbio.1999.9537; Heasman J, 2006, DEVELOPMENT, V133, P1205, DOI 10.1242/dev.02304; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Ho CY, 1999, CURR BIOL, V9, P1131, DOI 10.1016/S0960-9822(99)80485-0; HUME CR, 1993, DEVELOPMENT, V119, P1147; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Jiang YM, 1998, DEV GENET, V22, P263, DOI 10.1002/(SICI)1520-6408(1998)22:3<263::AID-DVG8>3.0.CO;2-4; Jones CM, 1999, CURR BIOL, V9, P946, DOI 10.1016/S0960-9822(99)80421-7; Joubin K, 2001, INT J DEV BIOL, V45, P165; Kablar B, 1996, MECH DEVELOP, V55, P145, DOI 10.1016/0925-4773(96)00497-2; KELLY GM, 1995, DEVELOPMENT, V121, P1787; Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Klingensmith J, 1999, DEV BIOL, V216, P535, DOI 10.1006/dbio.1999.9525; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Locascio A, 2002, P NATL ACAD SCI USA, V99, P16841, DOI 10.1073/pnas.262525399; Martyn U, 2003, DEV BIOL, V260, P58, DOI 10.1016/S0012-1606(03)00221-5; MERCIER P, 1995, INT J DEV BIOL, V39, P559; Mesnard D, 2006, DEVELOPMENT, V133, P2497, DOI 10.1242/dev.02413; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Niehrs C, 2001, INT J DEV BIOL, V45, P237; Nieuwkoop PD, 1967, NORMAL TABLES XENOPU; PANNESE M, 1995, DEVELOPMENT, V121, P707; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; Perea-Gomez A, 2002, DEV CELL, V3, P745, DOI 10.1016/S1534-5807(02)00321-0; Perea-Gomez A, 2001, INT J DEV BIOL, V45, P311; Plouhinec JL, 2005, DEV BIOL, V278, P560, DOI 10.1016/j.ydbio.2004.11.019; Psychoyos D, 1996, DEVELOPMENT, V122, P1523; Reece-Hoyes JS, 2002, DEV DYNAM, V223, P134, DOI 10.1002/dvdy.1234; Reversade B, 2005, CELL, V123, P1147, DOI 10.1016/j.cell.2005.08.047; Rhinn M, 1998, DEVELOPMENT, V125, P845; Richardson L, 2006, MECH DEVELOP, V123, P288, DOI 10.1016/j.mod.2006.01.004; Robinson-Rechavi M, 2004, MOL BIOL EVOL, V21, P580, DOI 10.1093/molbev/msh046; Rodriguez TA, 2005, DEVELOPMENT, V132, P2513, DOI 10.1242/dev.01847; Sauka-Spengler T, 2003, DEV BIOL, V263, P296, DOI 10.1016/j.ydbio.2003.07.009; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Schneider VA, 1999, CURR BIOL, V9, P800, DOI 10.1016/S0960-9822(99)80363-7; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Skromne I, 2002, MECH DEVELOP, V114, P115, DOI 10.1016/S0925-4773(02)00034-5; Skromne I, 2001, DEVELOPMENT, V128, P2915; Smith JL, 1998, CURR TOP DEV BIOL, V40, P79, DOI 10.1016/S0070-2153(08)60365-8; SPRATT NT, 1960, J EXP ZOOL, V145, P97, DOI 10.1002/jez.1401450202; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; Stern CD, 2001, NAT REV NEUROSCI, V2, P92, DOI 10.1038/35053563; STERN CD, 2004, GASTRULATION CELLS E, pR9; STERN CD, 2004, GASTRULATION CELLS E, P219; Stern CD, 2006, CURR OPIN GENET DEV, V16, P413, DOI 10.1016/j.gde.2006.06.005; Streit A, 1998, DEVELOPMENT, V125, P507; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Takaoka K, 2006, DEV CELL, V10, P451, DOI 10.1016/j.devcel.2006.02.017; Takemoto T, 2006, DEVELOPMENT, V133, P297, DOI 10.1242/dev.02196; Tam PPL, 1999, DEVELOPMENT, V126, P5171; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Vandebroek G., 1936, Archives de Biologie Liege, V47, P499; Wilson SI, 2001, NAT NEUROSCI, V4, P1161, DOI 10.1038/nn747; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yamamoto M, 2004, NATURE, V428, P387, DOI 10.1038/nature02418; Yao J, 2001, DEVELOPMENT, V128, P2975; Yu JK, 2007, NATURE, V445, P613, DOI 10.1038/nature05472	121	42	42	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e374	10.1371/journal.pone.0000374	http://dx.doi.org/10.1371/journal.pone.0000374			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440610	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000207445500005
J	Takafuji, V; Forgues, M; Unsworth, E; Goldsmith, P; Wang, XW				Takafuji, V.; Forgues, M.; Unsworth, E.; Goldsmith, P.; Wang, X. W.			An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma	ONCOGENE			English	Article						osteopontin; hepatocellular carcinoma; metastasis; cellular invasion; MMP-9; CD44	METASTASIS FORMATION; PROTEIN EXPRESSION; PLASMA OSTEOPONTIN; SURVIVAL; CANCER; CD44; TRANSGLUTAMINASE; BREAST; OVEREXPRESSION; PROGRESSION	Tumor cell invasion is a primary event in the metastatic progression of hepatocellular carcinoma (HCC). Our recent results indicate a concordant elevated expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in primary metastatic HCC. This study hypothesizes an MMP-9-directed cleavage of OPN that biologically contributes to HCC metastasis. We found that MMP-9 cleaved OPN into specific fragments in vitro, of which three could be identified by Edman degradation amino-acid sequencing. On e of these fragments (OPN-5 kDa, residues 167-210) induced low-metastatic HCC cellular invasion via CD44 receptors, which was effectively blocked by the addition of small peptides within the region of OPN-5 kDa. In creased expression of an OPN splice variant (OPN-c) was associated with clinical metastatic HCC. Overexpression of OPN-c with physiological levels of MMP-9 enhanced cellular invasion and coincided with elevated OPN-5 kDa levels. Our data suggest that an alternative splicing event (OPN-c) promotes extracellular cleavage of OPN by MMP-9, thus releasing a distinct region of OPN (OPN-5 kDa) that is essential for HCC cellular invasion and appears to correlate with metastatic potential. The findings of this study may help to improve advanced-stage HCC prognosis and suggest the utility of small peptides for novel therapies.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Antibody & Protein Purificat Grp, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, 37-3044A,37 Convent Dr MSC 4258, Bethesda, MD 20892 USA.	xw3u@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X	NATIONAL CANCER INSTITUTE [Z01BC010313, ZIABC010313] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Ashida K, 1996, AM J PATHOL, V149, P1803; Blum HE, 2005, EUR J GASTROEN HEPAT, V17, P475, DOI 10.1097/00042737-200505000-00001; BUTLER WT, 1995, ANN NY ACAD SCI, V760, P6, DOI 10.1111/j.1749-6632.1995.tb44615.x; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Endo K, 2000, J HEPATOL, V32, P78, DOI 10.1016/S0168-8278(00)80192-0; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; FRANCO D, 1990, GASTROENTEROLOGY, V98, P733, DOI 10.1016/0016-5085(90)90296-D; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Hotte SJ, 2002, CANCER-AM CANCER SOC, V95, P506, DOI 10.1002/cncr.10709; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; Kaneyoshi T, 2001, CLIN CANCER RES, V7, P4027; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; McKenna GJ, 2002, AM J SURG, V183, P588, DOI 10.1016/S0002-9610(02)00833-4; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudzki Z, 1997, J CLIN PATHOL-MOL PA, V50, P57, DOI 10.1136/mp.50.2.57; SAITOH Y, 1995, LAB INVEST, V72, P55; SENGER DR, 1988, CANCER RES, V48, P5770; Si MS, 2003, AM SURGEON, V69, P879; Singhal H, 1997, CLIN CANCER RES, V3, P605; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; Takahashi K, 1998, BIOCHEM MOL BIOL INT, V46, P1081; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang XW, 2005, HEPATOLOGY, V42, p391A; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	39	137	146	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6361	6371		10.1038/sj.onc.1210463	http://dx.doi.org/10.1038/sj.onc.1210463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452979				2022-12-25	WOS:000249737600001
J	Gutierrez-Fernandez, A; Inada, M; Balbin, M; Fueyo, A; Pitiot, AS; Astudillo, A; Hirose, K; Hirata, M; Shapiro, SD; Noel, A; Werb, Z; Krane, SM; Lopez-Otin, C; Puente, XS				Gutierrez-Fernandez, Ana; Inada, Masaki; Balbin, Milagros; Fueyo, Antonio; Pitiot, Ana S.; Astudillo, Aurora; Hirose, Kenji; Hirata, Michiko; Shapiro, Steven D.; Noel, Agnes; Werb, Zena; Krane, Stephen M.; Lopez-Otin, Carlos; Puente, Xose S.			Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8)	FASEB JOURNAL			English	Article						neutrophil; MMP-9; cancer; protease; degradome	MATRIX-METALLOPROTEINASE; KERATINOCYTE MIGRATION; NEUTROPHIL GELATINASE; RESISTANT MOUSE; EXPRESSION; CELLS; CANCER; GROWTH; TISSUE; REGENERATION	Matrix metalloproteinases (MMPs) have been implicated in numerous tissue-remodeling processes. The finding that mice deficient in collagenase-2 (MMP-8) are more susceptible to develop skin cancer, prompted us to investigate the role of this protease in cutaneous wound healing. We have observed a significant delay in wound closure in MMP8(-/-) mice and an altered inflammatory response in their wounds, with a delay of neutrophil infiltration during the first days and a persistent inflammation at later time points. These changes were accompanied by alterations in the TGF-beta 1 signaling pathway and by an apoptosis defect in MMP8(-/-) mice. The delay in wound healing observed in MMP8(-/-) mice was rescued by bone marrow transplantation from wildtype mice. Analysis of other MMPs showed that MMP8(-/-) mice had a significant increase in the expression of MMP-9, suggesting that both proteases might act coordinately in this process. This possibility was further supported by the novel finding that MMP-8 and MMP-9 form specific complexes in vivo. Taken together, these data indicate that MMP-8 participates in wound repair by contributing to the resolution of inflammation and open the possibility to develop new strategies for treating wound healing defects.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Inst Univ Oncol, E-33006 Oviedo, Spain; Univ Oviedo, Hosp Cent Asturias, Serv Oncol Mol, E-33080 Oviedo, Spain; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Pulm & Crit Care, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Central University Hospital Asturias; University of Oviedo; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Liege; University of California System; University of California San Francisco	Puente, XS (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	xspuente@uniovi.es	inada, masaki/D-1581-2013; Puente, Xosé S./ADB-0672-2022; Pitiot, Ana S/AAA-9161-2020; Hirata, Michiko/D-2351-2013; Gutierrez-Fernandez, Ana/AAS-9954-2021; Fueyo, Antonio/ABH-3243-2020; Balbín, Milagros/I-4206-2015; Gutierrez-Fernandez, Ana/ABG-6678-2020; López-Otín, Carlos/AAB-2106-2020	inada, masaki/0000-0002-5066-8506; Puente, Xosé S./0000-0001-9525-1483; Pitiot, Ana S/0000-0002-5318-3168; Hirata, Michiko/0000-0002-5291-6112; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; Fueyo, Antonio/0000-0002-7121-9398; Balbín, Milagros/0000-0001-5325-0407; López-Otín, Carlos/0000-0001-6964-1904; Astudillo Gonzalez, Maria Aurora/0000-0001-8947-8809; Noel, Agnes/0000-0002-7670-6179	NCI NIH HHS [CA105379, P01 CA072006, U01 CA105379-05, CA072006, P01 CA072006-10, U01 CA105379] Funding Source: Medline; NIAMS NIH HHS [R01 AR044815-10, R01 AR044815, AR044815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006, U01CA105379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahokas K, 2005, J INVEST DERMATOL, V124, P849, DOI 10.1111/j.0022-202X.2005.23640.x; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Beare AHM, 2005, WOUND REPAIR REGEN, V13, P27, DOI 10.1111/j.1067-1927.2005.130105.x; Beare AHM, 2003, J INVEST DERMATOL, V120, P153, DOI 10.1046/j.1523-1747.2003.12019.x; Bullard KM, 1999, ANN SURG, V230, P260, DOI 10.1097/00000658-199908000-00017; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gueders MM, 2005, J IMMUNOL, V175, P2589, DOI 10.4049/jimmunol.175.4.2589; Hart R, 2006, J MINIM INVAS GYN, V13, P126, DOI 10.1016/j.jmig.2005.11.015; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Hieta N, 2003, J INVEST DERMATOL, V121, P997, DOI 10.1046/j.1523-1747.2003.12533.x; Hosokawa R, 2005, J INVEST DERMATOL, V125, P1302, DOI 10.1111/j.0022-202X.2005.23963.x; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Kiili M, 2002, J CLIN PERIODONTOL, V29, P224, DOI 10.1034/j.1600-051x.2002.290308.x; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lobmann R, 2002, DIABETOLOGIA, V45, P1011, DOI 10.1007/s00125-002-0868-8; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; Lund LR, 2006, EMBO J, V25, P2686, DOI 10.1038/sj.emboj.7601173; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Marini S, 2000, J BIOL CHEM, V275, P18657, DOI 10.1074/jbc.M000283200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mirastschijski U, 2004, EXP CELL RES, V299, P465, DOI 10.1016/j.yexcr.2004.06.007; Mirastschijski U, 2004, J INVEST DERMATOL, V123, P600, DOI 10.1111/j.0022-202X.2004.23230.x; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Nwomeh BC, 1999, J SURG RES, V81, P189, DOI 10.1006/jsre.1998.5495; Nwomeh Benedict C., 1998, Wound Repair and Regeneration, V6, P127, DOI 10.1046/j.1524-475X.1998.60206.x; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Peters KS, 2005, J PHYS ORG CHEM, V18, P1, DOI 10.1002/poc.849; Peters T, 2005, EMBO J, V24, P3400, DOI 10.1038/sj.emboj.7600809; Pirila E, 2001, CURR MED CHEM, V8, P281, DOI 10.2174/0929867013373552; Pirila E, 2003, DIGEST DIS SCI, V48, P93, DOI 10.1023/A:1021790532723; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Salonurmi T, 2004, CELL TISSUE RES, V315, P27, DOI 10.1007/s00441-003-0814-1; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Van Lint P, 2005, J IMMUNOL, V175, P7642, DOI 10.4049/jimmunol.175.11.7642; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Westerhof GR, 2000, CANCER RES, V60, P5470; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200	51	193	198	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2580	2591		10.1096/fj.06-7860com	http://dx.doi.org/10.1096/fj.06-7860com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392479	Green Accepted			2022-12-25	WOS:000248454400031
J	Iguchi, H; Urashima, Y; Inagaki, Y; Ikeda, Y; Okamura, M; Tanaka, T; Uchida, A; Yamamoto, TT; Kodama, T; Sakai, J				Iguchi, Haruhisa; Urashima, Yasuyo; Inagaki, Yosuke; Ikeda, Yukio; Okamura, Masashi; Tanaka, Toshiya; Uchida, Aoi; Yamamoto, Tokuo T.; Kodama, Tatsuhiko; Sakai, Juro			SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; INSULIN-SECRETION; COLON-CARCINOMA; GENE; DIFFERENTIATION; EXPRESSION; PATHWAY; L-SOX5; RATHER	Sex-determining region Y-box (SOX) 6 negatively regulates glucose-stimulated insulin secretion from beta-cells and is a down-regulated transcription factor in the pancreatic islet cells of hyperinsulinemic obese mice. To determine the contribution of SOX6 to insulin resistance, we analyzed the effects of SOX6 on cell proliferation. Small interfering RNA-mediated attenuation of SOX6 expression stimulated the proliferation of insulinoma INS-1E and NIH-3T3 cells, whereas retroviral overexpression resulted in inhibition of cell growth. Quantitative real time-PCR analysis revealed that the levels of cyclin D1 transcripts were markedly decreased by SOX6 overexpression. Luciferase-reporter assay with beta-catenin showed that SOX6 suppresses cyclin D1 promoter activities. In vitro binding experiments showed that the LZ/Q domain of SOX6 physically interacts with armadillo repeats 1-4 of beta-catenin. Furthermore, chromatin immunoprecipitation assay revealed that increased SOX6 expression significantly reduced the levels of acetylated histones H3 and H4 at the cyclin D1 promoter. By using a histone deacetylase (HDAC) inhibitor and co-immunoprecipitation analysis, we showed that SOX6 suppressed cyclin D1 activities by interacting with beta-catenin and HDAC1. The data presented suggest that SOX6 may be an important factor in obesity-related insulin resistance.	Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Japn Sci & Technol Agcy, Exploratory Res Adv Technol, Tokyo 1358904, Japan; Tohoku Univ, Ctr Adv Genome Res, Inst Dev Aging & Canc, Sendai, Miyagi 9818555, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Tohoku University	Sakai, J (corresponding author), Dainippon Sumitomo Pharma Co Ltd, Gen Sci Lab, Takarazuka, Hyogo 6650051, Japan.	jmsakai-tky@umin.ac.jp		Sakai, Juro/0000-0003-4043-1035				Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Iguchi H, 2005, J BIOL CHEM, V280, P37669, DOI 10.1074/jbc.M505392200; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kitamura T, 1998, INT J HEMATOL, V67, P351; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sambrook J, 2001, MOL CLONING LAB MANU; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Takayasu S, 2006, P NATL ACAD SCI USA, V103, P7438, DOI 10.1073/pnas.0602371103; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200	26	113	118	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19052	19061		10.1074/jbc.M700460200	http://dx.doi.org/10.1074/jbc.M700460200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17412698	hybrid			2022-12-25	WOS:000247475300047
J	Ambrosio, ALB; Dias, SMG; Polikarpov, I; Zurier, RB; Burstein, SH; Garratt, RC				Ambrosio, Andre L. B.; Dias, Sandra M. G.; Polikarpov, Igor; Zurier, Robert B.; Burstein, Sumner H.; Garratt, Richard C.			Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL AGONIST; PPAR; ALPHA; DESIGN; SELECTIVITY; CRYSTALLOGRAPHY; RECRUITMENT; EXPRESSION; MOLECULE; PATHWAYS	Ajulemic acid (AJA) is a synthetic analog of THC-11-oic acid, a metabolite of tetrahydrocannabinol (THC), the major active ingredient of the recreational drug marijuana derived from the plant Cannabis sativa. AJA has potent analgesic and anti-inflammatory activity in vivo, but without the psychotropic action of THC. However, its precise mechanism of action remains unknown. Biochemical studies indicate that AJA binds directly and selectively to the isotype gamma of the peroxisome proliferator-activated receptor (PPAR gamma) suggesting that this may be a pharmacologically relevant receptor for this compound and a potential target for drug development in the treatment of pain and inflammation. Here, we report the crystal structure of the ligand binding domain of the gamma isotype of human PPAR in complex with ajulemic acid, determined at 2.8-angstrom resolution. Our results show a binding mode that is compatible with other known partial agonists of PPAR, explaining their moderate activation of the receptor, as well as the structural basis for isotype selectivity, as observed previously in vitro. The structure also provides clues to the understanding of partial agonism itself, suggesting a rational approach to the design of molecules capable of activating the receptor at levels that avoid undesirable side effects.	Univ Sao Paulo, Inst Fis, Ctr Biotechnol Mol Estrutural, BR-13560970 Sao Paulo, Brazil; Cornell Univ, Ctr Vet Med, Ithaca, NY 14853 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	Universidade de Sao Paulo; Cornell University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Garratt, RC (corresponding author), Univ Sao Paulo, Inst Fis, Ctr Biotechnol Mol Estrutural, BR-13560970 Sao Paulo, Brazil.	ala48@cornell.edu; richard@if.sc.usp.br	Polikarpov, Igor/D-2575-2012; Ambrosio, Andre/AAB-1178-2020; garratt, richard c/F-6921-2011; Dias, Sandra/AAB-7042-2019; Ambrosio, Andre/C-9089-2012	Ambrosio, Andre/0000-0002-9515-930X; garratt, richard/0000-0002-2016-3179; Polikarpov, Igor/0000-0001-9496-4174	NIAID NIH HHS [U19 AI056362] Funding Source: Medline; NIDA NIH HHS [R01 DA13691] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Albers M, 2006, J BIOL CHEM, V281, P4920, DOI 10.1074/jbc.M510101200; Arnold LA, 2005, J BIOL CHEM, V280, P43048, DOI 10.1074/jbc.M506693200; Bouaboula M, 2005, EUR J PHARMACOL, V517, P174, DOI 10.1016/j.ejphar.2005.05.032; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; BURSTEIN S, 1981, DRUG METAB DISPOS, V9, P94; BURSTEIN S, 1972, SCIENCE, V176, P422, DOI 10.1126/science.176.4033.422; BURSTEIN S, 1987, EXPERIENTIA, V43, P402, DOI 10.1007/BF01940427; BURSTEIN SH, 1970, NATURE, V225, P87, DOI 10.1038/225087a0; Burstein SH, 2004, LIFE SCI, V75, P1513, DOI 10.1016/j.lfs.2004.04.010; BURSTEIN SH, 1971, CHEM-BIOL INTERACT, V3, P316, DOI 10.1016/0009-2797(71)90078-0; Cobb JE, 1998, J MED CHEM, V41, P5055, DOI 10.1021/jm980414r; Cock TA, 2004, EMBO REP, V5, P142, DOI 10.1038/sj.embor.7400082; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Dyson A, 2005, PAIN, V116, P129, DOI 10.1016/j.pain.2005.03.037; Ebdrup S, 2003, J MED CHEM, V46, P1306, DOI 10.1021/jm021027r; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fyffe SA, 2006, J MOL BIOL, V356, P1005, DOI 10.1016/j.jmb.2005.12.047; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2; Haffner CD, 2004, J MED CHEM, V47, P2010, DOI 10.1021/jm030565g; Hamuro Y, 2006, PROTEIN SCI, V15, P1883, DOI 10.1110/ps.062103006; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Klaholz BP, 2000, ACTA CRYSTALLOGR D, V56, P933, DOI 10.1107/S090744490000634X; Klaholz BP, 2000, J MOL BIOL, V302, P155, DOI 10.1006/jmbi.2000.4032; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KLEYWEGT GJ, 1997, CCP4 ESF EACBM NEWSL, V34, P5; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li Y, 2005, P NATL ACAD SCI USA, V102, P9505, DOI 10.1073/pnas.0501204102; Liu JL, 2003, MOL PHARMACOL, V63, P983, DOI 10.1124/mol.63.5.983; Lu IL, 2006, J MED CHEM, V49, P2703, DOI 10.1021/jm051129s; Mahindroo N, 2006, J MED CHEM, V49, P1212, DOI 10.1021/jm0510373; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Mitchell VA, 2005, NEUROSCI LETT, V382, P231, DOI 10.1016/j.neulet.2005.03.019; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; O'Sullivan SE, 2005, BIOCHEM BIOPH RES CO, V337, P824, DOI 10.1016/j.bbrc.2005.09.121; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Ostberg T, 2004, J BIOL CHEM, V279, P41124, DOI 10.1074/jbc.M401552200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rockwell CE, 2006, MOL PHARMACOL, V70, P101, DOI 10.1124/mol.105.019117; Sauerberg P, 2002, J MED CHEM, V45, P789, DOI 10.1021/jm010964g; Shi GQ, 2005, J MED CHEM, V48, P4457, DOI 10.1021/jm0502135; Sung B, 2004, J GERONTOL A-BIOL, V59, P997; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a	62	50	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18625	18633		10.1074/jbc.M702538200	http://dx.doi.org/10.1074/jbc.M702538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17462987	hybrid			2022-12-25	WOS:000247302000067
J	Taylor, KR; Yamasaki, K; Radek, KA; Di Nardo, A; Goodarzi, H; Golenbock, D; Beutler, B; Gallo, RL				Taylor, Kristen R.; Yamasaki, Kenshi; Radek, Katherine A.; Di Nardo, Anna; Goodarzi, Heidi; Golenbock, Douglas; Beutler, Bruce; Gallo, Richard L.			Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; GROUP-A STREPTOCOCCUS; TIR ADAPTER PROTEINS; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; GENETIC-ANALYSIS; DENDRITIC CELLS; KAPPA-B; EXPRESSION; ENDOTOXIN	Inflammation under sterile conditions is not well understood despite its importance in trauma and autoimmune disease. To investigate this process we established mouse models of sterile injury and explored the role of hyaluronan in mediating inflammation following injury. The response of cultured monocytes to hyaluronan was different than the response to lipopolysaccharide (LPS) despite both being dependent on Toll-like receptor 4 (TLR4). Cultured cells exposed to hyaluronan showed a pattern of gene induction that mimics the response seen in mouse skin after sterile injury with an increase in molecules such as transforming growth factor-beta 2 and matrix metalloproteinase-13. These factors were not induced by LPS despite the mutual dependence of both hyaluronan and LPS on TLR4. Explanation for the unique response to hyaluronan was provided by observations that a lack of TLR4 or CD44 in mice diminished the response to sterile injury, and together with MD-2, was required for responsiveness to hyaluronan in vitro. Thus, a unique complex of TLR4, MD-2, and CD44 recognizes hyaluronan. Immunoprecipitation experiments confirmed the physical association of TLR4 and CD44. Taken together, our results define a previously unknown mechanism for initiation of sterile inflammation that involves recognition of released hyaluronan fragments as an endogenous signal of tissue injury.	Univ Calif San Diego, Vet Affairs Med Ctr, Div Dermatol, San Diego, CA 92161 USA; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Massachusetts System; University of Massachusetts Worcester; Scripps Research Institute	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, MC 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	di nardo, anna/AAI-1629-2020; Yamasaki, Kenshi/C-8905-2018; Gallo, Richard L/A-8931-2009	di nardo, anna/0000-0002-5575-9968; Yamasaki, Kenshi/0000-0002-5495-4956; Gallo, Richard L/0000-0002-1401-7861	NHLBI NIH HHS [P01 HL057345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler B, 2005, ADV EXP MED BIOL, V560, P29; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; del Fresno C, 2005, J IMMUNOL, V174, P3032, DOI 10.4049/jimmunol.174.5.3032; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Oertl A, 2005, WORLD J GASTROENTERO, V11, P6243, DOI 10.3748/wjg.v11.i40.6243; Ohno S, 2006, J BIOL CHEM, V281, P17952, DOI 10.1074/jbc.M602750200; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stern R, 2001, EXP CELL RES, V266, P167, DOI 10.1006/excr.2001.5206; Stojanov S, 2005, CURR OPIN RHEUMATOL, V17, P586, DOI 10.1097/bor.0000174210.78449.6b; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zaman A, 2005, AM J RESP CELL MOL, V33, P447, DOI 10.1165/rcmb.2004-0333OC; Zmolik JM, 2005, J HISTOCHEM CYTOCHEM, V53, P745, DOI 10.1369/jhc.4A6491.2005	51	297	310	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18265	18275		10.1074/jbc.M606352200	http://dx.doi.org/10.1074/jbc.M606352200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17400552	hybrid			2022-12-25	WOS:000247302000033
J	Viswakarma, N; Yu, S; Naik, S; Kashireddy, P; Matsumoto, K; Sarkar, J; Surapureddi, S; Jia, Y; Rao, MS; Reddy, JK				Viswakarma, Navin; Yu, Songtao; Naik, Swati; Kashireddy, Papreddy; Matsumoto, Kojiro; Sarkar, Joy; Surapureddi, Sailesh; Jia, Yuzhi; Rao, M. Sambasiva; Reddy, Janardan K.			Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; GENE-EXPRESSION; DEFICIENT MICE; RESPONSE ELEMENTS; RETINOIC ACID; TARGET GENES; PPAR-GAMMA; FAMILY; METABOLISM; OBESITY	Cidea ( cell death-inducing DNA fragmentation factor alpha-like effector A), a member of a novel family of proapoptotic proteins, is expressed abundantly in the brown adipose tissue of the mouse. Although Cidea mRNA is not detectable in the mouse liver, we now show that peroxisome proliferator-activated receptor ( PPAR) alpha ligandsWy-14,643 and ciprofibrate increase the Cidea mRNA level in a PPAR alpha-dependent manner, whereas Cidea induction in liver by PPAR gamma overexpression is PPAR alpha independent. Increase in Cidea mRNA content in liver did not alter the expression of uncoupling protein 1 (Ucp1) gene, which regulates thermogenesis, lipolysis, and conservation of energy. Although Cidea is considered to be a proapoptotic factor, Cidea induction in liver did not result in increased apoptosis. To elucidate the mechanism by which PPAR alpha and PPAR gamma regulate Cidea gene expression in the liver, we analyzed the promoter region of the Cidea gene. Three putative peroxisome proliferator response elements (PPREs) are found in the Cidea gene promoter. Transactivation, gel-shift, and chromatin immunoprecipitation assays indicated that the proximal PPRE in Cidea gene (Cidea-PPRE1 at - 680/ - 668) is functional for both PPAR alpha and -gamma. We conclude that Cidea is a novel target gene for both PPAR alpha and -gamma in the liver where these two transcription factors utilize the same PPRE region for dual regulation. The induction of Cidea in liver with these PPAR alpha and -gamma agonists suggests a possible role for Cidea in energy metabolism and a less likely role in hepatocyte apoptosis.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Reddy, JK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NCI NIH HHS [CA104578] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Cherkaoui-Malki M, 2001, GENE EXPRESSION, V9, P291, DOI 10.3727/000000001783992533; CHU RY, 1995, J BIOL CHEM, V270, P29636; Da L, 2006, BIOCHEM J, V393, P779, DOI 10.1042/BJ20051027; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hasmall SC, 2000, MUTAT RES-FUND MOL M, V448, P193, DOI 10.1016/S0027-5107(99)00236-5; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jia YZ, 2004, J BIOL CHEM, V279, P24427, DOI 10.1074/jbc.M402391200; Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lemay DG, 2006, J LIPID RES, V47, P1583, DOI 10.1194/jlr.M500504-JLR200; Liang L, 2003, BIOCHEM J, V370, P195, DOI 10.1042/BJ20020656; Lin SC, 2004, TRENDS MOL MED, V10, P434, DOI 10.1016/j.molmed.2004.07.005; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Meyer K, 2003, CARCINOGENESIS, V24, P975, DOI 10.1093/carcin/bgg040; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Nielsen R, 2006, MOL CELL BIOL, V26, P5698, DOI 10.1128/MCB.02266-05; Nordstrom EA, 2005, DIABETES, V54, P1726, DOI 10.2337/diabetes.54.6.1726; Peters JM, 2005, J MOL MED-JMM, V83, P774, DOI 10.1007/s00109-005-0678-9; Reddy JK, 2006, AD DEV BIOL, V16, P389, DOI 10.1016/S1574-3349(06)16012-3; Reddy JK, 2004, AM J PATHOL, V164, P2305, DOI 10.1016/S0002-9440(10)63787-X; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SHAH YM, 2007, MOL CELL BIOL; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wheelan SJ, 2001, GENOME RES, V11, P1952, DOI 10.1101/gr.195301; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; YU S, 2007, BIOCH BIOPHYS ACTA; Yu ST, 2004, BIOCHIMIE, V86, P743, DOI 10.1016/j.biochi.2004.09.015; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	47	77	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18613	18624		10.1074/jbc.M701983200	http://dx.doi.org/10.1074/jbc.M701983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17462989	hybrid			2022-12-25	WOS:000247302000066
J	Lu, B; Yadav, S; Shah, PG; Liu, T; Tian, B; Pukszta, S; Villaluna, N; Kutejova, E; Newlon, CS; Santos, JH; Suzuki, CK				Lu, Bin; Yadav, Swati; Shah, Parul G.; Liu, Tong; Tian, Bin; Pukszta, Sebastian; Villaluna, Nerissa; Kutejova, Eva; Newlon, Carol S.; Santos, Janine H.; Suzuki, Carolyn K.			Roles for the human ATP-dependent lon protease in mitochondrial DNA maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OXIDATIVE STRESS; BINDING PROTEIN; IN-VITRO; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; CROSS-LINKING; YEAST; REPAIR; REPLICATION	Human mitochondrial Lon is an ATP-powered proteolytic machine that specifically binds to single-stranded G-rich DNA and RNA in vitro. However, it is unknown whether Lon binds mitochondrial DNA (mtDNA) in living cells or functions in mtDNA integrity. Here, we demonstrate that Lon interacts with the mitochondrial genome in cultured cells using mtDNA immunoprecipitation (mIP). Lon associates with sites distributed primarily within one-half of the genome and preferentially with the control region for mtDNA replication and transcription. Bioinformatic analysis of mIP data revealed a G-rich consensus sequence. Consistent with these findings, in vitro experiments showed that the affinity of Lon for single-stranded DNA oligonucleotides correlates with conformity to this consensus. To examine the role of Lon in mtDNA maintenance, cells carrying an inducible short hairpin RNA for Lon depletion were used. In control and Lon-depleted cells, mtDNA copy number was essentially the same in the presence or absence of oxidative stress. However when oxidatively stressed, control cells exhibited an increased frequency of mtDNA lesions, whereas Lon-depleted cells showed little if any mtDNA damage. This suggests that oxidative mtDNA damage is permitted when Lon is present and prevented when Lon is substantially depleted. Upon oxidative stress, mIP showed reduced Lon binding to mtDNA; however binding to the control region was unaffected. It is unlikely that oxidative modification of Lon blocks its ability to bind DNA in vivo as results show that oxidized purified Lon retains sequence-specific DNA binding. Taken together, these results demonstrate that mtDNA binding is a physiological function of Lon and that cellular levels of Lon influence sensitivity to mtDNA damage. These findings suggest roles for Lon in linking protein and mtDNA quality control.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Slovak Acad Sci, Inst Mol Biol, Bratislava 84551, Slovakia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Slovak Academy of Sciences	Suzuki, CK (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07101 USA.	suzukick@umdnj.edu	Kutejova, Eva/AAI-2544-2021; Lu, Bin/GQQ-3590-2022; Kutejova, Eva/K-6550-2014	Kutejova, Eva/0000-0002-0973-679X; Kutejova, Eva/0000-0002-0973-679X; Tian, Bin/0000-0001-8903-8256				ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054; Bailey T L, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P21; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Bretz J, 2002, MOL MICROBIOL, V45, P397, DOI 10.1046/j.1365-2958.2002.03008.x; Bulteau AL, 2006, EXP GERONTOL, V41, P653, DOI 10.1016/j.exger.2006.03.013; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; CHUNG CH, 1982, P NATL ACAD SCI-BIOL, V79, P795, DOI 10.1073/pnas.79.3.795; Clayton DA, 2003, IUBMB LIFE, V55, P213, DOI 10.1080/1521654031000134824; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; Das PM, 2004, BIOTECHNIQUES, V37, P961, DOI 10.2144/04376RV01; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; EICHLER DC, 1977, J BIOL CHEM, V252, P7888; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fernandez-Silva P, 1996, Methods Enzymol, V264, P129, DOI 10.1016/S0076-6879(96)64014-2; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Gonzalez M, 1998, GENE DEV, V12, P3889, DOI 10.1101/gad.12.24.3889; Hazra TK, 2003, CARCINOGENESIS, V24, P155, DOI 10.1093/carcin/24.2.155; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Hu JP, 2005, J BIOL CHEM, V280, P40544, DOI 10.1074/jbc.M508772200; Jones BD, 2005, J MICROBIOL, V43, P110; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee AYL, 2004, J BIOL CHEM, V279, P34903, DOI 10.1074/jbc.M403562200; Liu JJ, 1999, MOL MICROBIOL, V33, P415, DOI 10.1046/j.1365-2958.1999.01489.x; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; MIYAKAWA I, 1987, J CELL SCI, V88, P431; Nomura K, 2004, J BIOL CHEM, V279, P34406, DOI 10.1074/jbc.M404725200; Nonn L, 2003, MOL CANCER RES, V1, P682; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Santos Janine H, 2006, Methods Mol Biol, V314, P183; Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Shah IM, 2006, MOL MICROBIOL, V60, P199, DOI 10.1111/j.1365-2958.2006.05086.x; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; TOZAWA K, 1992, J BIOL CHEM, V267, P16484; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043	60	107	114	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17363	17374		10.1074/jbc.M611540200	http://dx.doi.org/10.1074/jbc.M611540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17420247	hybrid			2022-12-25	WOS:000247084500006
J	Lin, YF; Yang, JB; Rosen, BP				Lin, Yung-Feng; Yang, Jianbo; Rosen, Barry P.			ArsD residues Cys(12), Cys(13), and Cys(18) form an As(III)-binding site required for arsenic metallochaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUPEROXIDE-DISMUTASE; PROTEIN INTERACTIONS; COPPER TRAFFICKING; ATPASE; CHAPERONE; METALLOACTIVATION; RESISTANCE; REPRESSOR; PUMP	The ArsA ATPase is the catalytic subunit of the ArsAB pump encoded by the arsRDABC operon of Escherichia coli plasmid R773. ArsD is a metallochaperone that delivers As(III) to ArsA, increasing its affinity for As(III), thus conferring resistance to environmental concentrations of arsenic. R773 ArsD is a homodimer with three vicinal cysteine pairs, Cys(12)-Cys(13), Cys(112)-Cys(113), and Cys(119)-Cys(120), in each subunit. Each vicinal pair binds As(III) or Sb(III). Alignment of the primary sequence of homologues of ArsD indicates that only the first vicinal cysteine pair, Cys(12)-Cys(13), and an additional cysteine, Cys(18), are conserved. The effect of cysteine-to-alanine substitutions and truncations were examined. By yeast two-hybrid analysis, nearly all of the ArsD mutants were able to interact with wild type ArsD, indicating that the mutations do not interfere with dimerization. ArsD mutants with alanines substituting for Cys(112), Cys(113), Cys(119), or Cys(120) individually or in pairs or truncations lacking the vicinal pairs retained ability to interact with ArsA and to activate its ATPase activity. Cells expressing these mutants retained ArsD-enhanced As(III) efflux and resistance. In contrast, mutants with substitutions of conserved Cys(12), Cys(13), or Cys(18), individually or in pairs, were unable to activate ArsA or to enhance the activity of the ArsAB pump. We propose that ArsD residues Cys(12), Cys(13), and Cys(18), but not Cys(112), Cys(113), Cys(119), or Cys(120), are required for delivery of As(III) to and activation of the ArsAB pump.	Wayne State Univ, Dept Biochem & Mol Biol, Sch Med, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Dept Biochem & Mol Biol, Sch Med, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Yang, Jianbo/G-1254-2013; Lin, Yung-Feng/H-3289-2019	Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy CO, 2003, J NUTR, V133, p1536S, DOI 10.1093/jn/133.5.1536S; Arnesano F, 2004, STRUCTURE, V12, P669, DOI 10.1016/j.str.2004.03.006; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; Bhattacharjee H, 2000, BIOMETALS, V13, P281, DOI 10.1023/A:1009200215328; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chen YX, 1997, J BIOL CHEM, V272, P14257, DOI 10.1074/jbc.272.22.14257; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Freeman LEB, 2004, AM J EPIDEMIOL, V160, P679, DOI 10.1093/aje/kwh267; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HSU CM, 1989, J BIOL CHEM, V264, P17349; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Li JX, 2000, MOL MICROBIOL, V35, P361, DOI 10.1046/j.1365-2958.2000.01696.x; Li S, 2002, J BIOL CHEM, V277, P25992, DOI 10.1074/jbc.M201619200; Li S, 2001, MOL MICROBIOL, V41, P687, DOI 10.1046/j.1365-2958.2001.02546.x; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lin YF, 2006, P NATL ACAD SCI USA, V103, P15617, DOI 10.1073/pnas.0603974103; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Ruan X, 2006, J BIOL CHEM, V281, P9925, DOI 10.1074/jbc.M600125200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; Zhou T, 2000, EMBO J, V19, P1	36	29	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16783	16791		10.1074/jbc.M700886200	http://dx.doi.org/10.1074/jbc.M700886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17439954	hybrid			2022-12-25	WOS:000246946500010
J	Maruyama, D; Nishitani, Y; Nonaka, T; Kita, A; Fukami, TA; Mio, T; Yamada-Okabe, H; Yamada-Okabe, T; Miki, K				Maruyama, Daisuke; Nishitani, Yuichi; Nonaka, Tsuyoshi; Kita, Akiko; Fukami, Takaaki A.; Mio, Toshiyuki; Yamada-Okabe, Hisafumi; Yamada-Okabe, Toshiko; Miki, Kunio			Crystal structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans and catalytic reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ESCHERICHIA-COLI; URIDYLTRANSFERASE; SITE; IDENTIFICATION; PURIFICATION; 1-PHOSPHATE; CLONING; GLMU	Uridine-diphospho-N-acetylglucosamine (UDP-GlcNAc) is a precursor of the bacterial and fungal cell wall. It is also used in a component of N-linked glycosylation and the glycosylphosphoinositol anchor of eukaryotic proteins. It is synthesized from N-acetylglucosamine-1-phosphate (GlcNAc-1-P) and uridine-5'-triphosphate (UTP) by UDP-GlcNAc pyrophosphorylase (UAP). This is an S(N)2 reaction; the non-esterified oxygen atom of the GlcNAc-1-P phosphate group attacks the alpha-phosphate group of UTP. We determined crystal structures of UAP from Candida albicans (CaUAP1) without any ligands and also complexed with its substrate or with its product. The series of structures in different forms shows the induced fit movements of CaUAP1. Three loops approaching the ligand molecule close the active site when ligand is bound. In addition, Lys-421, instead of the metal ion in prokaryotic UAPs, is coordinated by both phosphate groups of UDP- GlcNAc and acts as a cofactor. However, a magnesium ion enhances the enzymatic activity of CaUAP1, and thus we propose that the magnesium ion increases the affinity between UTP and the enzyme by coordinating to the alpha- and gamma- phosphate group of UTP.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Kamakura, Kanagawa 2478530, Japan; Yokohama City Univ, Sch Med, Dept Hyg, Yokohama, Kanagawa 2360004, Japan; RIKEN, Harima Inst, SPring Ctr 8, Sayocho, Hyogo 6795148, Japan	Kyoto University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Yokohama City University; RIKEN	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	miki@kuchem.kyoto-u.ac.jp						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulik DA, 1998, MOL BIOCHEM PARASIT, V95, P135, DOI 10.1016/S0166-6851(98)00076-0; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kostrewa D, 2001, J MOL BIOL, V305, P279, DOI 10.1006/jmbi.2000.4296; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maruyama D, 2006, ACTA CRYSTALLOGR F, V62, P1206, DOI 10.1107/S1744309106044186; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Mio T, 2000, BBA-GENE STRUCT EXPR, V1492, P369, DOI 10.1016/S0167-4781(00)00120-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; ROGERS TJ, 1980, MICROBIOL REV, V44, P660, DOI 10.1128/MMBR.44.4.660-682.1980; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SHEU KFR, 1978, J BIOL CHEM, V253, P3378; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433	36	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17221	17230		10.1074/jbc.M611873200	http://dx.doi.org/10.1074/jbc.M611873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17392279	hybrid			2022-12-25	WOS:000246946500055
J	Slack-Davis, JK; Martin, KH; Tilghman, RW; Iwanicki, M; Ung, EJ; Autry, C; Luzzio, MJ; Cooper, B; Kath, JC; Roberts, WG; Parsons, JT				Slack-Davis, Jill K.; Martin, Karen H.; Tilghman, Robert W.; Iwanicki, Marcin; Ung, Ethan J.; Autry, Christopher; Luzzio, Michael J.; Cooper, Beth; Kath, John C.; Roberts, W. Gregory; Parsons, J. Thomas			Cellular characterization of a novel focal adhesion kinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT SPECKLE MICROSCOPY; MIGRATING CELLS; FAK; APOPTOSIS; PROTEIN; CANCER; EXPRESSION; PATHWAYS; SURVIVAL; MOTILITY	Focal adhesion kinase (FAK) is a member of a family of nonreceptor protein-tyrosine kinases that regulates integrin and growth factor signaling pathways involved in cell migration, proliferation, and survival. FAK expression is increased in many cancers, including breast and prostate cancer. Here we describe perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228. In vitro, this compound inhibited purified recombinant catalytic fragment of FAK with an IC50 of 4 nM. In cultured cells, PF-573,228 inhibited FAK phosphorylation on Tyr(397) with an IC50 of 30-100 nM. Treatment of cells with concentrations of PF-573,228 that significantly decreased FAK Tyr(397) phosphorylation failed to inhibit cell growth or induce apoptosis. In contrast, treatment with PF-573,228 inhibited both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover. These studies show that PF-573,228 serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compounds amenable for preclinical and patient trials.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Hlth Sci Syst, Charlottesville, VA 22908 USA; Pfizer Inc, Discovery Oncol, Groton, CT 06340 USA	University of Virginia; University of Virginia; Pfizer	Parsons, JT (corresponding author), Univ Virginia, Dept Microbiol, POB 800734,Jordan Hall,1300 Jefferson Park Ave, Charlottesville, VA 22908 USA.	jtp@virginia.edu		Martin, Karen/0000-0001-8916-4092				Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Choi HS, 2006, BIOORG MED CHEM LETT, V16, P2689, DOI 10.1016/j.bmcl.2006.02.032; Choi HS, 2006, BIOORG MED CHEM LETT, V16, P2173, DOI 10.1016/j.bmcl.2006.01.053; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hauck CR, 2001, CANCER RES, V61, P7079; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KATH JC, 2004, Patent No. 2004056786; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; LUZZIO MJ, P ANN M AM ASS CANC, V48, P1283; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Niwa S., 2006, J CLIN ONCOL, V24, P13163, DOI [10.1200/jco.2006.24.18_suppl.13163, DOI 10.1200/JCO.2006.24.18_SUPPL.13163]; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Roberts Walter G., 2007, Proceedings of the American Association for Cancer Research Annual Meeting, V48, P1282; Salmon WC, 2002, J CELL BIOL, V158, P31, DOI 10.1083/jcb.200203022; SHI QAB, 2007, MOL CARCINOGEN, V9999; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; UNG EJ, 2002, Patent No. 004027018; Vallotton P, 2004, P NATL ACAD SCI USA, V101, P9660, DOI 10.1073/pnas.0300552101; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	38	383	394	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14845	14852		10.1074/jbc.M606695200	http://dx.doi.org/10.1074/jbc.M606695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395594	hybrid			2022-12-25	WOS:000246589000020
J	Catic, A; Misaghi, S; Korbel, GA; Ploegh, HL				Catic, Andre; Misaghi, Shahram; Korbel, Gregory A.; Ploegh, Hidde L.			ElaD, a Deubiquitinating Protease Expressed by E. coli	PLOS ONE			English	Article							COMPLETE GENOME SEQUENCE; FUNCTIONAL PROTEOMICS; STRUCTURAL BASIS; UBIQUITIN; ACTIVATION; MECHANISM; PROTEINS; EFFECTOR; NEDD8; EXPLOITATION	Background. Ubiquitin and ubiquitin-like proteins (Ubl) are designed to modify polypeptides in eukaryotes. Covalent binding of ubiquitin or Ubls to substrate proteins can be reversed by specific hydrolases. One particular set of cysteine proteases, the CE clan, which targets ubiquitin and Ubls, has homologs in eukaryotes, prokaryotes, and viruses. Findings. We have cloned and analyzed the E. coli protein elaD, which is distantly related to eukaryotic CE clan members of the ULP/SENP protease family that are specific for SUMO and Nedd8. Previously misannotated as a putative sulfatase/phosphatase, elaD is an efficient and specific deubiquitinating enzyme in vitro. Interestingly, elaD is present in all intestinal pathogenic E. coli strains, but conspicuously absent from extraintestinal pathogenic strains (ExPECs). Further homologs of this protease can be found in Acanthamoeba Polyphaga Mimivirus, and in Alpha-, Beta-and Gammaproteobacteria. Conclusion. The expression of ULP/SENP-related hydrolases in bacteria therefore extends to plant pathogens and medically relevant strains of Escherichia coli, Legionella pneumophila, Rickettsiae, Chlamydiae, and Salmonellae, in which the elaD ortholog sseL has recently been identified as a virulence factor with deubiquitinating activity. As a counterpoint, our phylogenetic and functional examination reveals that ancient eukaryotic ULP/SENP proteases also have the potential of ubiquitin-specific hydrolysis, suggesting an early common origin of this peptidase clan.	[Catic, Andre; Misaghi, Shahram; Korbel, Gregory A.; Ploegh, Hidde L.] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; [Catic, Andre; Misaghi, Shahram; Korbel, Gregory A.; Ploegh, Hidde L.] MIT, Dept Biol, Cambridge, MA USA; [Catic, Andre] Harvard Univ, Sch Med, Program Immunol, Boston, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA.	ploegh@wi.mit.edu		Catic, Andre/0000-0002-3572-7598	NIH; AstraZeneca	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca)	This work was supported by grants from the NIH and from AstraZeneca. The sponsors were neither involved in the conduct of the study, nor in collection, analysis, or interpretation of the data.	Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Andres G, 2001, J BIOL CHEM, V276, P780, DOI 10.1074/jbc.M006844200; Angot A, 2007, PLOS PATHOG, V3, P1, DOI 10.1371/journal.ppat.0030003; Baba Tomoya, 2006, Mol Syst Biol, V2; Balakirev MY, 2002, J VIROL, V76, P6323, DOI 10.1128/JVI.76.12.6323-6331.2002; Barrett AJ, 2001, J STRUCT BIOL, V134, P95, DOI 10.1006/jsbi.2000.4332; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Brzuszkiewicz E, 2006, P NATL ACAD SCI USA, V103, P12879, DOI 10.1073/pnas.0603038103; Cazalet C, 2004, NAT GENET, V36, P1165, DOI 10.1038/ng1447; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Golubtsov A, 2006, FEBS LETT, V580, P1502, DOI 10.1016/j.febslet.2006.01.071; Gurlebeck D, 2006, J PLANT PHYSIOL, V163, P233, DOI 10.1016/j.jplph.2005.11.011; Hemelaar J, 2004, J PROTEOME RES, V3, P268, DOI 10.1021/pr0341080; Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004; HINGAMP PM, 1992, EMBO J, V11, P361, DOI 10.1002/j.1460-2075.1992.tb05058.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Iyer LM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r60; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; McCluskey K, 2003, ADV APPL MICROBIOL, V52, P245, DOI 10.1016/S0065-2164(03)01010-4; Misaghi S, 2006, MOL MICROBIOL, V61, P142, DOI 10.1111/j.1365-2958.2006.05199.x; Mittal R, 2006, P NATL ACAD SCI USA, V103, P18574, DOI 10.1073/pnas.0608995103; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485; Reverter D, 2006, NAT STRUCT MOL BIOL, V13, P1060, DOI 10.1038/nsmb1168; Roden J, 2004, MOL PLANT MICROBE IN, V17, P633, DOI 10.1094/MPMI.2004.17.6.633; RODRIGUEZ JM, 1992, VIROLOGY, V186, P40, DOI 10.1016/0042-6822(92)90059-X; Ruzindana-Umunyana A, 2002, VIRUS RES, V89, P41, DOI 10.1016/S0168-1702(02)00111-9; Rytkonen A, 2007, P NATL ACAD SCI USA, V104, P3502, DOI 10.1073/pnas.0610095104; Schlieker C, 2005, J VIROL, V79, P15582, DOI 10.1128/JVI.79.24.15582-15585.2005; Shen LN, 2005, EMBO J, V24, P1341, DOI 10.1038/sj.emboj.7600628; Strunnikov AV, 2001, GENETICS, V158, P95; Sulea T, 2006, BIOL CHEM, V387, P853, DOI 10.1515/BC.2006.106; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tobe T, 2006, P NATL ACAD SCI USA, V103, P14941, DOI 10.1073/pnas.0604891103; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; Wenzl P, 2005, MOL BIOL EVOL, V22, P308, DOI 10.1093/molbev/msi018; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wolf YI, 1999, TRENDS GENET, V15, P173, DOI 10.1016/S0168-9525(99)01704-7; Xu JJ, 2006, P NATL ACAD SCI USA, V103, P11625, DOI 10.1073/pnas.0604876103; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; Zhou HL, 2005, J EXP MED, V202, P1327, DOI 10.1084/jem.20051194	56	51	55	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e381	10.1371/journal.pone.0000381	http://dx.doi.org/10.1371/journal.pone.0000381			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440617	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445500012
J	Henderson, SO; Haiman, CA; Wilkens, LR; Kolonel, LN; Wan, P; Pike, MC				Henderson, Sean O.; Haiman, Christopher A.; Wilkens, Lynne R.; Kolonel, Laurence N.; Wan, Peggy; Pike, Malcolm C.			Established Risk Factors Account for Most of the Racial Differences in Cardiovascular Disease Mortality	PLOS ONE			English	Article								Background. Cardiovascular disease (CVD) mortality varies across racial and ethnic groups in the U. S., and the extent that known risk factors can explain the differences has not been extensively explored. Methods. We examined the risk of dying from acute myocardial infarction (AMI) and other heart disease (OHD) among 139,406 African-American (AA), Native Hawaiian (NH), Japanese-American (JA), Latino and White men and women initially free from cardiovascular disease followed prospectively between 1993-1996 and 2003 in the Multiethnic Cohort Study (MEC). During this period, 946 deaths from AMI and 2,323 deaths from OHD were observed. Relative risks of AMI and OHD mortality were calculated accounting for established CVD risk factors: body mass index (BMI), hypertension, diabetes, smoking, alcohol consumption, amount of vigorous physical activity, educational level, diet and, for women, type and age at menopause and hormone replacement therapy (HRT) use. Results. Established CVD risk factors explained much of the observed racial and ethnic differences in risk of AMI and OHD mortality. After adjustment, NH men and women had greater risks of OHD than Whites (69% excess, P<0.001 and 62% excess, P = 0.003, respectively), and AA women had greater risks of AMI (48% excess, P = 0.01) and OHD (35% excess, P = 0.007). JA men had lower risks of AMI (51% deficit, P<0.001) and OHD (27% deficit, P = 0.001), as did JA women (AMI, 37% deficit, P = 0.03; OHD, 40% deficit, P = 0.001). Latinos had underlying lower risk of AMI death (26% deficit in men and 35% in women, P = 0.03). Conclusion. Known risk factors explain the majority of racial and ethnic differences in mortality due to AMI and OHD. The unexplained excess in NH and AA and the deficits in JA suggest the presence of unmeasured determinants for cardiovascular mortality that are distributed unequally across these populations.	[Henderson, Sean O.; Haiman, Christopher A.; Wan, Peggy; Pike, Malcolm C.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Henderson, Sean O.] Univ So Calif, Keck Sch Med, Dept Emergency Med, Los Angeles, CA 90033 USA; [Wilkens, Lynne R.; Kolonel, Laurence N.] Univ Hawaii, Canc Res Ctr Hawaii, Program Epidemiol, Honolulu, HI 96813 USA	University of Southern California; University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System	Henderson, SO (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.	sohender@hsc.usc.edu			US National Cancer Institute [R37 CA54281]; NATIONAL CANCER INSTITUTE [R37CA054281] Funding Source: NIH RePORTER	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Public Health Service Grant R37 CA54281 from the US National Cancer Institute.	Altieri A, 2004, ANN EPIDEMIOL, V14, P461, DOI 10.1016/j.annepidem.2003.11.005; ALULI NE, 1991, AM J CLIN NUTR, V53, pS1556, DOI 10.1093/ajcn/53.6.1556S; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Anderson I, 2006, LANCET, V367, P1775, DOI 10.1016/S0140-6736(06)68773-4; Bauman WA, 1998, ARCH PHYS MED REHAB, V79, P176, DOI 10.1016/S0003-9993(98)90296-9; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; Braun KL, 1996, AM J PUBLIC HEALTH, V86, P888, DOI 10.2105/AJPH.86.6.888; Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1139, DOI 10.1161/01.ATV.13.8.1139; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; CURB JD, 1991, AM J PUBLIC HEALTH, V81, P164, DOI 10.2105/AJPH.81.2.164; D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9; Dorn JP, 1999, ANN EPIDEMIOL, V9, P366, DOI 10.1016/S1047-2797(99)00025-3; Fang J, 1996, NEW ENGL J MED, V335, P1545, DOI 10.1056/NEJM199611213352101; Finkelstein EA, 2004, J WOMENS HEALTH, V13, P503, DOI 10.1089/1540999041280963; Fukiyama K, 2000, HYPERTENS RES, V23, P127, DOI 10.1291/hypres.23.127; Geronimus AT, 1996, NEW ENGL J MED, V335, P1552, DOI 10.1056/NEJM199611213352102; Haapanen N, 1997, INT J EPIDEMIOL, V26, P739, DOI 10.1093/ije/26.4.739; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Henderson SO, 2001, ACAD EMERG MED, V8, P1163, DOI 10.1111/j.1553-2712.2001.tb01134.x; Henderson SO, 2000, AM J MED SCI, V320, P18, DOI 10.1097/00000441-200007000-00004; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346, DOI 10.1093/oxfordjournals.aje.a010213; Luc G, 2002, ARTERIOSCL THROM VAS, V22, P1155, DOI 10.1161/01.ATV.0000022850.59845.E0; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mau MK, 1997, DIABETES CARE, V20, P1376, DOI 10.2337/diacare.20.9.1376; Mitchell B D, 1991, Ann Epidemiol, V1, P415; MOKUAU N, 1995, HEALTH SOC WORK, V20, P46, DOI 10.1093/hsw/20.1.46; Mukamal KJ, 2001, JAMA-J AM MED ASSOC, V285, P1965, DOI 10.1001/jama.285.15.1965; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Pike MC, 2000, STEROIDS, V65, P659, DOI 10.1016/S0039-128X(00)00122-7; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Shimamoto T, 1996, J Epidemiol, V6, pS43; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4; Suka M, 2001, HYPERTENS RES, V24, P685, DOI 10.1291/hypres.24.685; Tanasescu N, 2002, JAMA-J AM MED ASSOC, V288, P1994, DOI 10.1001/jama.288.16.1994; Thomas AJ, 2005, AM J PUBLIC HEALTH, V95, P1417, DOI 10.2105/AJPH.2004.048165; Ueshima H, 2000, J HUM HYPERTENS, V14, P765, DOI 10.1038/sj.jhh.1001054; Ueshima H, 2003, J HUM HYPERTENS, V17, P631, DOI 10.1038/sj.jhh.1001606; *US BUR CENS, 2004, STAT ABSTR US 2004 2, P81; Wannamethee SG, 2001, SPORTS MED, V31, P101, DOI 10.2165/00007256-200131020-00003; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	41	40	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e377	10.1371/journal.pone.0000377	http://dx.doi.org/10.1371/journal.pone.0000377			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440613	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500008
J	Viveiros, M; Dupont, M; Rodrigues, L; Couto, I; Davin-Regli, A; Martins, M; Pages, JM; Amaral, L				Viveiros, Miguel; Dupont, Myrielle; Rodrigues, Liliana; Couto, Isabel; Davin-Regli, Anne; Martins, Marta; Pages, Jean-Marie; Amaral, Leonard			Antibiotic Stress, Genetic Response and Altered Permeability of E. coli	PLOS ONE			English	Article								Background. Membrane permeability is the first step involved in resistance of bacteria to an antibiotic. The number and activity of efflux pumps and outer membrane proteins that constitute porins play major roles in the definition of intrinsic resistance in Gram-negative bacteria that is altered under antibiotic exposure. Methodology/Principal Findings. Here we describe the genetic regulation of porins and efflux pumps of Escherichia coli during prolonged exposure to increasing concentrations of tetracycline and demonstrate, with the aid of quantitative real-time reverse transcriptase-polymerase chain reaction methodology and western blot detection, the sequence order of genetic expression of regulatory genes, their relationship to each other, and the ensuing increased activity of genes that code for transporter proteins of efflux pumps and down-regulation of porin expression. Conclusions/Significance. This study demonstrates that, in addition to the transcriptional regulation of genes coding for membrane proteins, the post-translational regulation of proteins involved in the permeability of Gram-negative bacteria also plays a major role in the physiological adaptation to antibiotic exposure. A model is presented that summarizes events during the physiological adaptation of E. coli to tetracycline exposure.	[Viveiros, Miguel; Rodrigues, Liliana; Couto, Isabel; Martins, Marta; Amaral, Leonard] Univ Nova Lisboa, Unit Mycobacteriol, UPMM, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal; [Dupont, Myrielle; Davin-Regli, Anne; Pages, Jean-Marie] Univ Mediterranee, UMR MD 1, IFR48, Fac Med & Pharm, Marseille, France; [Couto, Isabel] Univ Nova Lisboa, Ctr Recursos Microbiol CREM, Fac Ciencias & Tecnol, P-1200 Lisbon, Portugal	Universidade Nova de Lisboa; Institute of Hygiene & Tropical Medicine - UNL; UDICE-French Research Universities; Aix-Marseille Universite; Universidade Nova de Lisboa	Amaral, L (corresponding author), Univ Nova Lisboa, Unit Mycobacteriol, UPMM, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal.	lamaral@ihmt.unl.pt	Amaral, Leonard/I-2112-2012; MARTINS, MARTA/I-3015-2012; Rodrigues, Liliana/N-2463-2014; Couto, Isabel/I-2640-2012; Viveiros, Miguel/A-7326-2008; PAGES, jean-marie/F-2555-2013	Amaral, Leonard/0000-0003-3127-1295; Rodrigues, Liliana/0000-0002-2094-2666; Couto, Isabel/0000-0003-3536-2733; Viveiros, Miguel/0000-0001-9676-6251; PAGES, jean-marie/0000-0001-7092-7977; Martins, Marta/0000-0002-0323-2857	Luso-French Integrated Actions [CRUP/2006-F-33/06]; EU [FSE/FEDER-POCI/SAU-MMO/59370/2004]; Universite de la Mediterranee; Service de Sante des Armees; Eloi Collery Prix Academie Nationale de Medecine; Fundacao para a Ciencia e Tecnologia (FCT) of Portugal [SFRH/BD/24931/2005, SFRH/BD/14319/2003]	Luso-French Integrated Actions; EU(European Commission); Universite de la Mediterranee; Service de Sante des Armees; Eloi Collery Prix Academie Nationale de Medecine; Fundacao para a Ciencia e Tecnologia (FCT) of Portugal(Portuguese Foundation for Science and Technology)	Funding: This work was supported by grants (i) Luso-French Integrated Actions (CRUP/2006-F-33/06) (ii) EU-FSE/FEDER-POCI/SAU-MMO/59370/2004 and (iii) the Universite de la Mediterranee, the Service de Sante des Armees and from Eloi Collery Prix Academie Nationale de Medecine (J.-M.P.). L. Rodrigues and M. Martins were supported by grants SFRH/BD/24931/2005 and SFRH/BD/14319/2003, respectively, from Fundacao para a Ciencia e Tecnologia (FCT) of Portugal.	ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; Baquero F, 2001, DRUG RESIST UPDATE, V4, P93, DOI 10.1054/drup.2001.0196; Barbosa TM, 2000, J BACTERIOL, V182, P3467, DOI 10.1128/JB.182.12.3467-3474.2000; Basle A, 2006, J MOL BIOL, V362, P933, DOI 10.1016/j.jmb.2006.08.002; BOHNERT JA, 2007, J ANTIMICRO IN PRESS; BOLLA JM, 1988, EMBO J, V7, P3595, DOI 10.1002/j.1460-2075.1988.tb03237.x; BRANLANT G, 1985, EUR J BIOCHEM, V150, P61, DOI 10.1111/j.1432-1033.1985.tb08988.x; Castillo-Keller M, 2006, J BACTERIOL, V188, P576, DOI 10.1128/JB.188.2.576-586.2006; Charlson ES, 2006, J BACTERIOL, V188, P7186, DOI 10.1128/JB.00571-06; Chen S, 2004, J BACTERIOL, V186, P6689, DOI 10.1128/JB.186.20.6689-6697.2004; COHEN SP, 1993, J BACTERIOL, V175, P1484, DOI 10.1128/JB.175.5.1484-1492.1993; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Davin-Regli A., 2006, ANTIMICROBIAL RESIST, P55; De E, 2001, MOL MICROBIOL, V41, P189, DOI 10.1046/j.1365-2958.2001.02501.x; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; Douchin V, 2006, J BIOL CHEM, V281, P12253, DOI 10.1074/jbc.M600819200; Dupont M, 2004, FEBS LETT, V569, P27, DOI 10.1016/j.febslet.2004.05.047; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; Ferenci T, 2005, MOL MICROBIOL, V57, P1, DOI 10.1111/j.1365-2958.2005.04649.x; GAMBINO L, 1993, J BACTERIOL, V175, P2888, DOI 10.1128/JB.175.10.2888-2894.1993; Gootz TD, 2006, BIOCHEM PHARMACOL, V71, P1073, DOI 10.1016/j.bcp.2005.11.006; Guillier M, 2006, GENE DEV, V20, P2338, DOI 10.1101/gad.1457506; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; Kawamura-Sato K, 1999, FEMS MICROBIOL LETT, V179, P345, DOI 10.1016/S0378-1097(99)00433-4; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Liu XQ, 2001, MICROBIOL-SGM, V147, P2981, DOI 10.1099/00221287-147-11-2981; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Mallea M, 1998, MICROBIOL-UK, V144, P3003, DOI 10.1099/00221287-144-11-3003; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Martins M, 2006, IN VIVO, V20, P657; Michan C, 2002, J BACTERIOL, V184, P4733, DOI 10.1128/JB.184.17.4733-4738.2002; NAKAJIMA H, 1995, APPL ENVIRON MICROB, V61, P2302, DOI 10.1128/AEM.61.6.2302-2307.1995; NARODITSKAYA V, 1993, BIOCHEM BIOPH RES CO, V196, P803, DOI 10.1006/bbrc.1993.2320; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Nikaido H, 2001, SEMIN CELL DEV BIOL, V12, P215, DOI 10.1006/scdb.2000.0247; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Pages JM, 2005, TRENDS MOL MED, V11, P382, DOI 10.1016/j.molmed.2005.06.006; Piddock LJV, 2006, NAT REV MICROBIOL, V4, P629, DOI 10.1038/nrmicro1464; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; PUREWAL AS, 1991, FEMS MICROBIOL LETT, V82, P229, DOI 10.1111/j.1574-6968.1991.tb04870.x; Randall LP, 2002, RES VET SCI, V72, P87, DOI 10.1053/rvsc.2001.0537; Rosenberg EY, 2000, J BACTERIOL, V182, P1754, DOI 10.1128/JB.182.6.1754-1756.2000; Ruiz N, 2006, NAT REV MICROBIOL, V4, P57, DOI 10.1038/nrmicro1322; Turner RJ, 1997, ANTIMICROB AGENTS CH, V41, P440, DOI 10.1128/AAC.41.2.440; Viveiros M, 2005, ANTIMICROB AGENTS CH, V49, P3578, DOI 10.1128/AAC.49.8.3578-3582.2005; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015	52	159	167	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2007	2	4							e365	10.1371/journal.pone.0000365	http://dx.doi.org/10.1371/journal.pone.0000365			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DT	17426813	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445400005
J	Bendle, GM; Xue, SA; Holler, A; Stauss, HJ				Bendle, Gavin M.; Xue, Shao-An; Holler, Angelika; Stauss, Hans J.			A Study of T Cell Tolerance to the Tumor-Associated Antigen MDM2: Cytokines Can Restore Antigen Responsiveness, but Not High Avidity T Cell Function	PLOS ONE			English	Article							CLASS-I MOLECULES; TRANSGENIC MICE; P53 PROTEIN; GRANZYME-B; GENE; LYMPHOCYTES; INDUCTION; AMPLIFICATION; EXPRESSION; RECEPTOR	Background. Most tumor-associated antigens (TAA) currently used for immunotherapy of cancer are also expressed in normal tissues, which may induce tolerance and impair T cell-mediated immunity. However, there is limited information about how physiological expression in normal tissues alters the function of TAA-specific T cells. Methodology/Principal Findings. We used a T cell receptor transgenic model to study how MDM2 expression in normal tissues affects the function of T cells specific for this TAA that is found at high levels in many different types of tumors. We found that some MDM2-specific T cells escaped thymic deletion and persisted in the peripheral T cell pool. When stimulated with antigen, these T cells readily initiated cell division but failed to proliferate and expand, which was associated with a high rate of apoptosis. Both IL-2 and IL-15 efficiently rescued T cell survival and antigen-specific T cell proliferation, while IL-7 and IL-21 were ineffective. Antigen-stimulated T cells showed impaired expression of the effector molecules CD43, granzyme-B and IFN-gamma, a defect that was completely restored when T cells were stimulated in the presence of IL-2. In contrast, IL-15 and IL-21 only restored the expression of CD43 and granzyme-B, but not IFN-gamma production. Finally, peptide titration experiments with IL-2 rescued T cells indicated that they were of lower avidity than non-tolerant control T cells expressing the same TCR. Conclusions/Significance. These data indicate that cytokines can rescue the antigen-specific proliferation and effector function of MDM2-specific T cells, although this does not lead to the recovery of high avidity T cell function. This study sheds light on possible limitations of immunotherapy approaches that target widely expressed TAA, such as MDM2.				h.stauss@medsch.ucl.ac.uk	Stauss, Hans J/A-6569-2011; Xue, Shao-An/A-2735-2011		Leukaemia Research Fund (LRF), UK	Leukaemia Research Fund (LRF), UK	This work was funded by a research grant of the Leukaemia Research Fund (LRF), UK. The LRF was not involved in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Alves NL, 2005, J IMMUNOL, V175, P755, DOI 10.4049/jimmunol.175.2.755; Barouch-Bentov R, 2005, J IMMUNOL, V175, P5126, DOI 10.4049/jimmunol.175.8.5126; Bendle GM, 2004, CANCER RES, V64, P8052, DOI 10.1158/0008-5472.CAN-04-0630; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Dahl AM, 1996, J IMMUNOL, V157, P239; Freedman DA, 1999, CANCER RES, V59, P1; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Klebanoff CA, 2004, P NATL ACAD SCI USA, V101, P1969, DOI 10.1073/pnas.0307298101; LADANYI M, 1993, CANCER RES, V53, P16; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MCCOY JL, 1967, CANCER RES, V27, P1743; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 2004, P NATL ACAD SCI USA, V101, P14639, DOI 10.1073/pnas.0405730101; SADOVNIKOVA E, 1994, INT IMMUNOL, V6, P289, DOI 10.1093/intimm/6.2.289; Sadovnikova E, 1996, P NATL ACAD SCI USA, V93, P13114, DOI 10.1073/pnas.93.23.13114; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Stanislawski T, 2001, NAT IMMUNOL, V2, P962, DOI 10.1038/ni1001-962; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Teague RM, 2006, NAT MED, V12, P335, DOI 10.1038/nm1359; Trapani JA, 2003, CURR OPIN IMMUNOL, V15, P533, DOI 10.1016/S0952-7915(03)00107-9; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057	44	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e353	10.1371/journal.pone.0000353	http://dx.doi.org/10.1371/journal.pone.0000353			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406677	Green Published, gold			2022-12-25	WOS:000207445300015
J	Clarke, AR; Jones, N; Pryde, F; Adachi, Y; Sansom, OJ				Clarke, A. R.; Jones, N.; Pryde, F.; Adachi, Y.; Sansom, O. J.			53BP1 deficiency in intestinal enterocytes does not alter the immediate response to ionizing radiation, but leads to increased nuclear area consistent with polyploidy	ONCOGENE			English	Article						polyploidy; 53BP1; mice; apoptosis; DNA damage; p53	DNA-DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; GENOMIC INSTABILITY; GAMMA-IRRADIATION; PROTEIN 53BP1; P53; ACTIVATION; APOPTOSIS; MICE; TUMORIGENESIS	The p53-binding protein 53BP1 has been implicated in the DNA damage response and genomic instability. Previous reports have highlighted these roles in vivo in haematopoietic lineages. To investigate the importance of 53BP1 to the DNA damage response in epithelial cells in vivo, we have investigated the role of 53BP1 in mediating apoptosis and proliferation within the murine small intestine following gamma-irradiation. 53BP1 deficiency does not affect the immediate response to gamma-irradiation with normal levels of apoptosis, proliferation and p53 and p21 accumulation. However, 48 h post-gamma-irradiation there was a significant accumulation of cells with much larger nuclei marked by p53 and p21 accumulation. These data reflect increases in polyploidy observed 53BP1 -/- deficient fibroblasts following gamma-irradiation. At 72 h post-irradiation both the 4N and 8N populations were significantly increased in 53BP1 -/- MEFS. Taken together, these results show that following in vivo exposure to gamma-irradiation, 53BP1 is dispensable for signalling apoptosis and cell-cycle arrest in the intestinal epithelium. However, it is important for prevention of genomic instability within this epithelial cell population.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland; Univ Cardiff Wales, Cardiff Sch Biosci, Inst Cell Biol, Cardiff, Wales	Beatson Institute; University of Edinburgh; Cardiff University	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Adachi, Yasuhisa/0000-0003-4197-092X; Clarke, Alan/0000-0002-4281-426X	MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Finke D, 2001, CURR OPIN GENET DEV, V11, P561, DOI 10.1016/S0959-437X(00)00233-1; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Marshman E, 2001, J PATHOL, V195, P285; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Motohashi Y, 2004, NUTR METAB CARDIOVAS, V14, P6, DOI 10.1016/S0939-4753(04)80041-3; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Senger P, 2004, PROG PART NUCL PHYS, V53, P1, DOI 10.1016/j.ppnp.2004.02.005; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shigeta T, 1999, CANCER RES, V59, P2602; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	32	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6349	6355		10.1038/sj.onc.1210457	http://dx.doi.org/10.1038/sj.onc.1210457			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452983				2022-12-25	WOS:000249583300011
J	Hinz, B; Cheremina, O; Bachmakov, J; Renner, B; Zolk, O; Fromm, MF; Brune, K				Hinz, Burkhard; Cheremina, Olga; Bachmakov, Jouri; Renner, Bertold; Zolk, Oliver; Fromm, Martin F.; Brune, Kay			Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic	FASEB JOURNAL			English	Article						dipyrone metabolites; human whole blood assay; pharmacokinetics	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NONNARCOTIC ANALGESICS; METAMIZOL DIPYRONE; HEALTHY-SUBJECTS; PHARMACOKINETICS; INFLAMMATION; METABOLITES; DICLOFENAC; DAMAGE; COX-3	Dipyrone ( INN, metamizol) is a common analgesic used worldwide. Its widespread prescription or over-the-counter use in many countries ( e. g., Brazil, Israel, Mexico, Russia, Spain) requires insight into its mode of action. This study therefore addressed the impact of its metabolites 4-methyl-amino-antipyrine ( MAA) and 4-amino-antipyrine ( AA) on peripheral cyclooxygenases ( COX). Pharmacokinetics of metabolites and ex vivo COX inhibition were assessed in five volunteers receiving dipyrone at single oral doses of 500 or 1000 mg. Coagulation-induced thromboxane B-2 formation and lipopolysaccharide-induced prostaglandin E-2 synthesis were measured in vitro and ex vivo in human whole blood as indices of COX-1 and COX-2 activity. In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA ( IC50 = 2.55 mu mol/ L for COX-1; IC50 = 4.65 mu mol/ L for COX-2), being similar to 8.2- or 9-fold more potent than AA. After administration of dipyrone, MAA plasma concentrations remained above the IC50 values for each isoform for at least 8 h ( 500 mg) and 12 h ( 1000 mg) postdose. COX inhibition correlated with MAA plasma levels ( ex vivo IC50 values of 1.03 mu mol/ L [COX-1] and 0.87 mu mol/ L [ COX-2]). By contrast, plasma peak concentrations of AA after the 1000 mg dose were 2.8- and 6.5- fold below its IC50 values for COX-1 and COX-2, respectively. Maximal inhibitions of COX-1 and COX-2 were 94% and 87% ( 500 mg), 97% and 94% ( 1000 mg). Taken together, dipyrone elicits a substantial and virtually equipotent inhibition of COX isoforms via MAA. Given the profound COX-2 suppression by dipyrone, which was considerably above COX-2 inhibition by single analgesic doses of celecoxib and rofecoxib, a significant portion of its analgesic action may be ascribed to peripheral mechanisms. In view of the observed COX-1 suppression, physicochemical factors ( lack of acidity) rather than differential COX-1 inhibition may be responsible for dipyrone's favorable gastrointestinal tolerability compared with acidic COX inhibitors.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-erlangen.de	Renner, Bertold/ABD-8212-2021	Renner, Bertold/0000-0003-0845-6793; Zolk, Oliver/0000-0002-8220-3834				Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778; Andrade SE, 1998, J CLIN EPIDEMIOL, V51, P1357, DOI 10.1016/S0895-4356(98)00076-6; ASMARDI G, 1983, J CHROMATOGR, V277, P183, DOI 10.1016/S0378-4347(00)84835-5; ASMARDI G, 1985, EUR J DRUG METAB PH, V10, P121, DOI 10.1007/BF03189705; *AV PHARM DEUTSCHL, 2004, NOV FACH PROD INF; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; BRUNE K, 1983, AGENTS ACTIONS, V13, P360, DOI 10.1007/BF01971489; BRUNE K, 1980, BRIT J CLIN PHARMACO, V10, pS279, DOI 10.1111/j.1365-2125.1980.tb01810.x; Campos C, 1999, EUR J PHARMACOL, V378, P339, DOI 10.1016/S0014-2999(99)00477-X; CARLSSON KH, 1986, PAIN, V27, P373, DOI 10.1016/0304-3959(86)90161-2; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; DEMBINSKAKIEC A, 1976, ADV PROSTAG THROMB R, V1, P99; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; ELDOR A, 1984, EUR J CLIN PHARMACOL, V26, P171, DOI 10.1007/BF00630282; Ergun H, 2004, J PHARMACEUT BIOMED, V35, P479, DOI 10.1016/j.jpba.2004.02.004; Frolich J C, 1986, Agents Actions Suppl, V19, P155; Galati G, 2002, CHEM-BIOL INTERACT, V142, P25, DOI 10.1016/S0009-2797(02)00052-2; Geisslinger G, 1996, THROMB HAEMOSTASIS, V76, P592; GELGOR L, 1992, PAIN, V50, P323, DOI 10.1016/0304-3959(92)90038-D; Hackenthal E, 1997, SCHMERZ, V11, P269, DOI 10.1007/s004820050097; Hinz B, 2007, Handb Exp Pharmacol, P65; Hinz B, 2006, ARTHRITIS RHEUM-US, V54, P282, DOI 10.1002/art.21540; Hinz B, 2003, CLIN PHARMACOL THER, V74, P222, DOI 10.1016/S0009-9236(03)00167-X; Ibanez L, 2005, EUR J CLIN PHARMACOL, V60, P821, DOI 10.1007/s00228-004-0836-y; KAUFMAN DW, 1981, MONOGRAPHS EPIDEMIOL, V18; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LANZ R, 1986, EUR J PHARMACOL, V130, P105, DOI 10.1016/0014-2999(86)90188-3; LAPORTE JR, 1987, LANCET, V1, P809; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1995, CLIN PHARMACOKINET, V28, P216, DOI 10.2165/00003088-199528030-00004; Levy M, 1998, CLIN PHARMACOL THER, V64, P117, DOI 10.1016/S0009-9236(98)90029-7; LORENZETTI BB, 1985, EUR J PHARMACOL, V114, P375, DOI 10.1016/0014-2999(85)90383-8; Mazario J, 1999, NEUROSCI LETT, V274, P179, DOI 10.1016/S0304-3940(99)00721-1; MCCORMACK K, 1987, ARCH TOXICOL, V60, P261, DOI 10.1007/BF01234664; NEUGEBAUER V, 1994, AGENTS ACTIONS, V41, P62, DOI 10.1007/BF01986396; NODA A, 1976, CHEM PHARM BULL, V24, P1502; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Patrono C, 2001, CLIN EXP RHEUMATOL, V19, pS45; PESKAR BM, 1983, MED TOXICOL S1, V1, P39; Pigoso AA, 1998, INT J BIOCHEM CELL B, V30, P961, DOI 10.1016/S1357-2725(98)00030-2; Porro GB, 1996, DIGESTION, V57, P186; PRICE AH, 1990, DRUGS, V40, P1, DOI 10.2165/00003495-199000405-00003; Qin N, 2005, J PHARMACOL EXP THER, V315, P1298, DOI 10.1124/jpet.105.090944; REILLY IAG, 1987, BLOOD, V69, P180; Sanchez S, 2002, INFLAMM RES, V51, P385, DOI 10.1007/PL00000319; Sanchez S, 2002, DIGEST DIS SCI, V47, P1389, DOI 10.1023/A:1015395103160; Schwab JM, 2003, FASEB J, V17, P2174, DOI 10.1096/fj.03-0595lte; SHIMADA SG, 1994, AGENTS ACTIONS, V41, P188, DOI 10.1007/BF02001915; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Somasundaram S, 1997, GUT, V41, P344, DOI 10.1136/gut.41.3.344; TATSUO MAKF, 1994, INFLAMMATION, V18, P399, DOI 10.1007/BF01534437; TORTORICI V, 1995, EUR J NEUROSCI, V7, P1857, DOI 10.1111/j.1460-9568.1995.tb00706.x; VLAHOV V, 1990, EUR J CLIN PHARMACOL, V38, P61, DOI 10.1007/BF00314805; VOLZ M, 1980, BR J CLIN PHARM, V10, P299; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WEISS R, 1974, ARZNEIMITTEL-FORSCH, V24, P345; WEITHMANN KU, 1985, ARZNEIMITTEL-FORSCH, V35-1, P947; 1986, J AM MED ASS, V256, P1749	59	92	98	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2343	2351		10.1096/fj.06-8061com	http://dx.doi.org/10.1096/fj.06-8061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17435173				2022-12-25	WOS:000248454400009
J	Simard, CF; Bergeron, MJ; Frenette-Cotton, R; Carpentier, GA; Pelchat, ME; Caron, L; Isenring, P				Simard, Charles F.; Bergeron, Marc J.; Frenette-Cotton, Rachelle; Carpentier, Gabriel A.; Pelchat, Marie-Eve; Caron, Luc; Isenring, Paul			Homooligomeric and heterooligomeric associations between K+-Cl- cotransporter isoforms and between K+-Cl- and Na+-K+-Cl- cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; KCL COTRANSPORTER; STRUCTURAL UNIT; RABBIT KIDNEY; KCC4; LOCALIZATION; RAT; TRANSPORT; DEAFNESS	Little is known regarding the quaternary structure of cation-Cl- cotransporters (CCCs) except that the Na+-dependent CCCs can exist as homooligomeric units. Given that each of the CCCs exhibits unique functional properties and that several of these carriers coexist in various cell types, it would be of interest to determine whether the four K+-Cl- cotransporter (KCC) isoforms and their splice variants can also assemble into such units and, more importantly, whether they can form heterooligomers by interacting with each other or with the secretory Na+- K+-Cl- cotransporter (NKCC1). In the present work, we have addressed these questions by conducting two groups of analyses: 1) yeast two-hybrid and pull-down assays in which CCC-derived protein segments were used as both bait and prey and 2) coimmunoprecipitation and functional studies of intact CCCs coexpressed in Xenopus laevis oocytes. Through a combination of such analyses, we have found that KCC2 and KCC4 could adopt various oligomeric states (in the form of KCC2- KCC2, KCC4-KCC4, KCC2-KCC4, and even KCC4-NKCC1 complexes), that their carboxyl termini were probably involved in carrier assembly, and that the KCC4-NKCC1 oligomers, more specifically, could deploy unique functional features. Through additional coimmunoprecipitation studies, we have also found that KCC1 and KCC3 had the potential of assembling into various types of CCC-CCC oligomers as well, although the interactions uncovered were not characterized as extensively, and the protein segments involved were not identified in yeast two-hybrid assays. Taken together, these findings could change our views on how CCCs operate or are regulated in animal cells by suggesting, in particular, that cation-Cl- cotransport achieves higher levels of functional diversity than foreseen.	Univ Laval, Fac Med, Dept Med, Nephrol Res Grp,Hotel Dieu Quebec Res Inst, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hotel Dieu Quebec Inst, 10 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Bergeron MJ, 2006, J BIOL CHEM, V281, P15959, DOI 10.1074/jbc.M600015200; Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; Blaesse P, 2006, J NEUROSCI, V26, P10407, DOI 10.1523/JNEUROSCI.3257-06.2006; Boettger T, 2003, EMBO J, V22, P5422, DOI 10.1093/emboj/cdg519; Boettger T, 2002, NATURE, V416, P874, DOI 10.1038/416874a; Brunet GM, 2005, J GEN PHYSIOL, V126, P325, DOI 10.1085/jgp.200509334; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Crable SC, 2005, EXP HEMATOL, V33, P624, DOI 10.1016/j.exphem.2005.02.006; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Gagnon E, 2005, J BIOL CHEM, V280, P32555, DOI 10.1074/jbc.M505511200; Gagnon E, 2004, J BIOL CHEM, V279, P5648, DOI 10.1074/jbc.M311218200; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Ichinose Mayuri, 1999, Journal of the American Society of Nephrology, V10, p34A; Immink RGH, 2002, P NATL ACAD SCI USA, V99, P2416, DOI 10.1073/pnas.042677699; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Jansens Annemieke, 2003, Methods Mol Biol, V232, P133; Karadsheh MF, 2004, NEUROSCIENCE, V123, P381, DOI 10.1016/j.neuroscience.2003.10.004; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC299, DOI 10.1152/ajpcell.1998.274.2.C299; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Mercado A, 2005, AM J PHYSIOL-RENAL, V289, pF1246, DOI 10.1152/ajprenal.00464.2004; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Misri S, 2006, EXP EYE RES, V83, P1287, DOI 10.1016/j.exer.2006.07.006; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Parrish JR, 2006, CURR OPIN BIOTECH, V17, P387, DOI 10.1016/j.copbio.2006.06.006; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; Roussa E, 2002, HISTOCHEM CELL BIOL, V117, P335, DOI 10.1007/s00418-002-0393-3; Simard CF, 2004, J BIOL CHEM, V279, P40769, DOI 10.1074/jbc.M406458200; Song LY, 2002, MOL BRAIN RES, V103, P91, DOI 10.1016/S0169-328X(02)00190-0; Starremans PGJF, 2003, J AM SOC NEPHROL, V14, P3039, DOI 10.1097/01.ASN.0000097370.29737.5B; Velazquez H, 2003, AM J PHYSIOL-RENAL, V285, pF49, DOI 10.1152/ajprenal.00389.2002; Vu TQ, 2000, J NEUROSCI, V20, P1414; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	46	62	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18083	18093		10.1074/jbc.M607811200	http://dx.doi.org/10.1074/jbc.M607811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17462999	hybrid			2022-12-25	WOS:000247302000014
J	Zhang, DW; Lagace, TA; Garuti, R; Zhao, Z; McDonald, M; Horton, JD; Cohen, JC; Hobbs, HH				Zhang, Da-Wei; Lagace, Thomas A.; Garuti, Rita; Zhao, Zhenze; McDonald, Meghan; Horton, Jay D.; Cohen, Jonathan C.; Hobbs, Helen H.			Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; CALCIUM-BINDING; CYTOPLASMIC DOMAIN; DIFFERENT PROTEINS; HUMAN-FIBROBLASTS; FACTOR PRECURSOR; EGF DOMAINS; PCSK9 GENE	Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of hepatic low density lipoprotein receptors ( LDLR), the major route of clearance of circulating cholesterol. Gain-of-function mutations in PCSK9 cause hypercholesterolemia and premature atherosclerosis, whereas loss-of-function mutations result in hypocholesterolemia and protection from heart disease. Recombinant human PCSK9 binds the LDLR on the surface of cultured hepatocytes and promotes degradation of the receptor after internalization. Here we localized the site of binding of PCSK9 within the extracellular domain of the LDLR and determined the fate of the receptor after PCSK9 binding. Recombinant human PCSK9 interacted in a sequence-specific manner with the first epidermal growth factor-like repeat (EGF-A) in the EGF homology domain of the human LDLR. Similar binding specificity was observed between PCSK9 and purified EGF-A. Binding to EGF-A was calcium-dependent and increased dramatically with reduction in pH from 7 to 5.2. The addition of PCSK9, but not heat-inactivated PCSK9, to the medium of cultured hepatocytes resulted in redistribution of the receptor from the plasma membrane to lysosomes. These data are consistent with a model in which PCSK9 binding to EGF-A interferes with an acid-dependent conformational change required for receptor recycling. As a consequence, the LDLR is rerouted from the endosome to the lysosome where it is degraded.	SW Texas State Univ, Dept Mol Genet & Int Med, Dallas, TX 75390 USA; SW Texas State Univ, Donal W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; SW Texas State Univ, Howard Hughes Inst, Dallas, TX 75390 USA	Texas State University System; Texas State University San Marcos; Texas State University System; Texas State University San Marcos; Howard Hughes Medical Institute; Texas State University System; Texas State University San Marcos	Cohen, JC (corresponding author), SW Texas State Univ, Dept Mol Genet, 5323 Harry Hlines Blvd, Dallas, TX 75390 USA.	Jonathan.cohen@utsouthwestern.edu; Helen.hobbs@utsouthwestern.edu	Zhao, Zhenze/AAW-5870-2020; Zhang, Dawei/ABD-8990-2022	Zhang, Dawei/0000-0001-8279-8041	NHLBI NIH HHS [P01HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Beglova N, 2005, TRENDS BIOCHEM SCI, V30, P309, DOI 10.1016/j.tibs.2005.03.007; Beglova N, 2004, MOL CELL, V16, P281, DOI 10.1016/j.molcel.2004.09.038; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 2006, J BIOL CHEM, V281, P30561, DOI 10.1074/jbc.M606495200; Boswell EJ, 2004, J BIOL CHEM, V279, P30611, DOI 10.1074/jbc.M401412200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cameron J, 2006, HUM MOL GENET, V15, P1551, DOI 10.1093/hmg/ddl077; CASSIO D, 1991, J CELL BIOL, V115, P1397, DOI 10.1083/jcb.115.5.1397; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; ESSER V, 1988, J BIOL CHEM, V263, P13282; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Holla OL, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-9; Horton JD, 2007, TRENDS BIOCHEM SCI, V32, P71, DOI 10.1016/j.tibs.2006.12.008; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; Kotowski IK, 2006, AM J HUM GENET, V78, P410, DOI 10.1086/500615; Kurniawan ND, 2001, J MOL BIOL, V311, P341, DOI 10.1006/jmbi.2001.4867; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Leren TP, 2004, CLIN GENET, V65, P419, DOI 10.1111/j.0009-9163.2004.0238.x; Malby S, 2001, BIOCHEMISTRY-US, V40, P2555, DOI 10.1021/bi002322l; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; STENFLO J, 1988, J BIOL CHEM, V263, P21; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; Timms KM, 2004, HUM GENET, V114, P349, DOI 10.1007/s00439-003-1071-9; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; VANDERWESTHUYZEN DR, 1991, BIOCHEM J, V277, P677, DOI 10.1042/bj2770677; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Wouters MA, 2005, PROTEIN SCI, V14, P1091, DOI 10.1110/ps.041207005; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Zhang DW, 2006, J BIOL CHEM, V281, P4507, DOI 10.1074/jbc.M512277200; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	54	589	658	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18602	18612		10.1074/jbc.M702027200	http://dx.doi.org/10.1074/jbc.M702027200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452316	hybrid			2022-12-25	WOS:000247302000065
J	Tafesse, FG; Huitema, K; Hermansson, M; van der Poel, S; van den Dikkenberg, J; Uphoff, A; Somerharju, P; Holthuis, JCM				Tafesse, Fikadu Geta; Huitema, Klazien; Hermansson, Martin; van der Poel, Selene; van den Dikkenberg, Joep; Uphoff, Andreas; Somerharju, Pentti; Holthuis, Joost C. M.			Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; HAMSTER OVARY CELLS; GOLGI-APPARATUS; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; RAT-LIVER; SPHINGOLIPIDS; CERAMIDE; DIACYLGLYCEROL; BIOSYNTHESIS	Sphingomyelin ( SM) is a vital component of cellular membranes in organisms ranging from mammals to protozoa. Its production involves the transfer of phosphocholine from phosphatidylcholine to ceramide, yielding diacylglycerol in the process. The mammalian genome encodes two known SM synthase ( SMS) isoforms, SMS1 and SMS2. However, the relative contributions of these enzymes to SM production in mammalian cells remained to be established. Here we show that SMS1 and SMS2 are co-expressed in a variety of cell types and function as the key Golgi- and plasma membrane-associated SM synthases in human cervical carcinoma HeLa cells, respectively. RNA interference-mediated depletion of either SMS1 or SMS2 caused a substantial decrease in SM production levels, an accumulation of ceramides, and a block in cell growth. Although SMS-depleted cells displayed a reduced SM content, external addition of SM did not restore growth. These results indicate that the biological role of SM synthases goes beyond formation of SM.	Univ Utrecht, Dept Membrane Enzymol, Bijvoet Ctr, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CH Utrecht, Netherlands; Univ Helsinki, Inst Biomed, Dept Biochem, FIN-00014 Helsinki, Finland	Utrecht University; Utrecht University; Finland National Institute for Health & Welfare; University of Helsinki	Holthuis, JCM (corresponding author), Univ Utrecht, Dept Membrane Enzymol, Bijvoet Ctr, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.c.holthuis@chem.uu.nl	Hermansson, Martin/B-7854-2008; Holthuis, Joost/AAL-9157-2020	Hermansson, Martin/0000-0003-3387-8365; Tafesse, Fikadu/0000-0002-8575-4164; Holthuis, Joost/0000-0001-8912-1586				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; BARTLETT EM, 1970, ANAL BIOCHEM, V36, P159, DOI 10.1016/0003-2697(70)90343-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; CHAM BE, 1976, J LIPID RES, V17, P176; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FISHMAN JB, 1986, J BIOL CHEM, V261, P1896; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GAMBLE W, 1978, J LIPID RES, V19, P1068; Guillen N, 2007, GENE, V388, P117, DOI 10.1016/j.gene.2006.10.013; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hermansson M, 2005, J NEUROCHEM, V95, P609, DOI 10.1111/j.1471-4159.2005.03376.x; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Itoh M, 2003, CLIN CANCER RES, V9, P415; Lee NPY, 2007, J ENDOCRINOL, V192, P17, DOI 10.1677/JOE-06-0002; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MUEHLENBERG BA, 1972, CAN J BIOCHEM CELL B, V50, P166, DOI 10.1139/o72-022; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Riboni L, 2001, J BIOL CHEM, V276, P12797, DOI 10.1074/jbc.M011570200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tafesse FG, 2006, J BIOL CHEM, V281, P29421, DOI 10.1074/jbc.R600021200; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; van der Luit AH, 2007, BIOCHEM J, V401, P541, DOI 10.1042/BJ20061178; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090	39	156	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17537	17547		10.1074/jbc.M702423200	http://dx.doi.org/10.1074/jbc.M702423200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17449912	Green Published, hybrid			2022-12-25	WOS:000247084500024
J	Yamamoto, Y; Aoyama, Y; Shu, E; Tsunoda, K; Amagai, M; Kitajima, Y				Yamamoto, Yukari; Aoyama, Yumi; Shu, En; Tsunoda, Kazuyuki; Amagai, Masayuki; Kitajima, Yasuo			Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEMPHIGUS-VULGARIS ANTIGEN; DESMOGLEIN 3; CULTURED KERATINOCYTES; CELL-SURFACE; IGG; AUTOANTIBODIES; PROTEIN; FOLIACEUS; LOCALIZATION; DISSOCIATION	Pemphigus vulgaris (PV) is an autoimmune blistering disease, characterized by the loss of cell-cell adhesion between epidermal keratinocytes and the presence of autoantibody against desmoglein 3 (Dsg3), which provides adhesive integrity to desmosomes between adjacent keratinocytes. We have previously shown that PV-IgG purified from patients depletes desmosomes of Dsg3. However, PV-IgG contains not only antibodies against a variety of different epitopes of Dsg3 but also against other unknown antigens. Therefore, we examined whether the Dsg3-depleting activity of PV-IgG is generated specifically by antiDsg3 activity in a human squamous cell carcinoma cell line (DJM-1) and normal human keratinocytes by using four different pathogenic and nonpathogenic monoclonal antibodies against Dsg3. We demonstrate that these monoclonal antibodies deplete cells and desmosomes of Dsg3, as PV-IgG does. Individual monoclonal anti-Dsg3 antibodies display characteristic limits to their Dsg3-depleting activity, which correlates with their pathogenic activities. In combination, these antibodies exert a cumulative or synergistic effect, which may explain the potent Dsg3-depleting capability of PV-IgG, which is polyclonal. Finally, although Dsg3-depletion activity correlated with AK-monoclonal antibody pathogenicity in mouse models, the residual level of Dsg3, when below similar to 50%, does not correlate with the adhesive strength index in the present study. This may suggest that although the Dsg3 depletion is not indicative for adhesive strength, the level of Dsg3 can be used as a read-out of pathogenic changes within the cell and that the Dsg3 depletion from desmosomes plays an important role in skin fragility or susceptibility to blister formation in PV patients.	Gifu Univ, Sch Med, Dept Dermatol, Gifu 5011194, Japan; Keio Univ, Sch Med, Dept Dermatol, Keio, Tokyo 1608582, Japan	Gifu University; Keio University	Kitajima, Y (corresponding author), Yanagido 1-1, Gifu 5011194, Japan.	yaskitaj@gifu-u.ac.jp	Amagai, Masayuki/K-5325-2013; tsunoda, kazuyuki/GLR-8745-2022	Amagai, Masayuki/0000-0003-3314-7052; 				Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Amagai M, 2006, EXP DERMATOL, V15, P815, DOI 10.1111/j.1600-0625.2006.00499.x; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; ANDREW P, 1995, J INVEST DERMATOL, V105, P147; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Cirillo N, 2007, J CELL PHYSIOL, V210, P411, DOI 10.1002/jcp.20856; Cirlllo N, 2006, FEBS LETT, V580, P3276, DOI 10.1016/j.febslet.2006.04.089; ESAKI C, 1995, J INVEST DERMATOL, V105, P329, DOI 10.1111/1523-1747.ep12319948; EYRE RW, 1988, J CLIN INVEST, V81, P807, DOI 10.1172/JCI113387; Futei Y, 2003, J AM ACAD DERMATOL, V49, P1023, DOI 10.1016/S0190-9622(03)02160-1; HASHIMOTO T, 1990, J INVEST DERMATOL, V94, P327, DOI 10.1111/1523-1747.ep12874456; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 1997, J IMMUNOL, V159, P2010; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; IWATSUKI K, 1989, J AM ACAD DERMATOL, V20, P578, DOI 10.1016/S0190-9622(89)70066-9; Iwatsuki K, 1999, BRIT J DERMATOL, V140, P35; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; Kawasaki H, 2006, J INVEST DERMATOL, V126, P2621, DOI 10.1038/sj.jid.5700450; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; Kitajima Y, 2003, ARCH DERMATOL RES, V295, pS17, DOI 10.1007/s00403-002-0368-1; Kitajima Y, 2002, CLIN EXP DERMATOL, V27, P684, DOI 10.1046/j.1365-2230.2002.01116.x; KITAJIMA Y, 1987, J INVEST DERMATOL, V89, P167, DOI 10.1111/1523-1747.ep12470554; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MILNER Y, 1989, J CELL PHYSIOL, V139, P441, DOI 10.1002/jcp.1041390229; Muller R, 2006, EXP DERMATOL, V15, P606, DOI 10.1111/j.1600-0625.2006.00451.x; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Pelacho B, 2004, FEBS LETT, V566, P6, DOI 10.1016/j.febslet.2004.03.107; Puviani M, 2003, J INVEST DERMATOL, V120, P164, DOI 10.1046/j.1523-1747.2003.12014.x; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Seishima M, 1997, J INVEST DERMATOL, V109, P650, DOI 10.1111/1523-1747.ep12337662; Sekiguchi M, 2001, J IMMUNOL, V167, P5439, DOI 10.4049/jimmunol.167.9.5439; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Wang X, 2004, APOPTOSIS, V9, P131, DOI 10.1023/B:APPT.0000018795.05766.1f	44	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17866	17876		10.1074/jbc.M607963200	http://dx.doi.org/10.1074/jbc.M607963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428808	hybrid			2022-12-25	WOS:000247084500060
J	Fish, JE; Matouk, CC; Yeboah, E; Bevan, SC; Khan, M; Patil, K; Ohh, M; Marsden, PA				Fish, Jason E.; Matouk, Charles C.; Yeboah, Elizabeth; Bevan, Sian C.; Khan, Mukarram; Patil, Kedar; Ohh, Michael; Marsden, Philip A.			Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MESSENGER-RNA TRANSLATION; SMALL INTERFERING RNAS; HIPPEL-LINDAU PROTEIN; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; MEDIATED REGULATION; MAMMALIAN-CELLS; DOWN-REGULATION	The destabilization of endothelial nitric-oxide synthase (eNOS) mRNA in hypoxic endothelial cells may be important in the etiology of vascular diseases, such as pulmonary hypertension. Recently, an overlapping antisense transcript to eNOS/NOS3 was implicated in the post-transcriptional regulation of eNOS. We demonstrate here that expression of sONE, also known as eNOS antisense (NOS3AS) or autophagy 9-like 2 (APG9L2), is robustly induced by hypoxia or functional deficiency of von Hippel-Lindau protein. sONE is also up-regulated in the aortas of hypoxic rats. In hypoxic endothelial cells, sONE expression negatively correlates with eNOS expression. Blocking the hypoxic induction of sONE by RNA interference attenuates the fall in both eNOS RNA and protein. We provide evidence that the induction of sONE primarily involves transcript stabilization rather than increased transcriptional activity and is von Hippel-Lindau-but not hypoxia-inducible factor 2 alpha-dependent. We also demonstrate that sONE transcripts are enriched in the nucleus of normoxic cells and that hypoxia promotes an increase in the level of cytoplasmic and polyribosome-associated, sONE mRNA. The finding that eNOS expression can be regulated by an overlapping cis-antisense transcript in a stimulus-dependent fashion provides evidence that sense/antisense interactions may play a previously unappreciated role in vascular disease pathogenesis.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Div Renal, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, St Michaels Hosp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Matouk, Charles/AAF-7694-2019; Marsden, Philip A/B-1441-2012	Fish, Jason/0000-0003-0640-7277				Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; Aravin A, 2005, FEBS LETT, V579, P5830, DOI 10.1016/j.febslet.2005.08.009; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Berezhna SY, 2006, P NATL ACAD SCI USA, V103, P7682, DOI 10.1073/pnas.0600148103; Borsani O, 2005, CELL, V123, P1279, DOI 10.1016/j.cell.2005.11.035; Buhler M, 2002, EMBO REP, V3, P646, DOI 10.1093/embo-reports/kvf129; Calzada MJ, 2006, CANCER RES, V66, P1553, DOI 10.1158/0008-5472.CAN-05-3236; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Coudert AE, 2005, NUCLEIC ACIDS RES, V33, P5208, DOI 10.1093/nar/gki831; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Das R, 2006, GENE DEV, V20, P1100, DOI 10.1101/gad.1397406; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; de Miguel LS, 1999, J VASC RES, V36, P201, DOI 10.1159/000025643; DeCerbo J, 2005, CURR OPIN CELL BIOL, V17, P302, DOI 10.1016/j.ceb.2005.04.008; DECKER RS, 1980, AM J PATHOL, V98, P425; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Faghihi MA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r38; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kiyosawa H, 2005, GENOME RES, V15, P463, DOI 10.1101/gr.3155905; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozaki M, 2001, HYPERTENSION, V37, P322, DOI 10.1161/01.HYP.37.2.322; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; Shih SC, 1998, INT J EXP PATHOL, V79, P347, DOI 10.1046/j.1365-2613.1998.00088.x; SHWEIKI D, 1992, NATURE, V359, P845; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Steudel W, 1998, J CLIN INVEST, V101, P2468, DOI 10.1172/JCI2356; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Sun M, 2005, NUCLEIC ACIDS RES, V33, P5533, DOI 10.1093/nar/gki852; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Takemoto M, 2002, CIRCULATION, V106, P57, DOI 10.1161/01.CIR.0000020682.73694.AB; Toporsian M, 2000, CIRC RES, V86, P671, DOI 10.1161/01.RES.86.6.671; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; WANG GL, 1993, BLOOD, V82, P3610; Wang Y, 1997, J BIOL CHEM, V272, P11392; Ward ME, 2005, J CLIN INVEST, V115, P3128, DOI 10.1172/JCI20806; Weber M, 2005, CIRC RES, V96, P1161, DOI 10.1161/01.RES.0000170651.72198.fa; Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yamada T, 2005, J BIOL CHEM, V280, P18283, DOI 10.1074/jbc.M413957200; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	76	107	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15652	15666		10.1074/jbc.M608318200	http://dx.doi.org/10.1074/jbc.M608318200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403686	hybrid			2022-12-25	WOS:000246589600042
J	Isenberg, JS; Jia, YF; Fukuyama, J; Switzer, CH; Wink, DA; Roberts, DD				Isenberg, Jeff S.; Jia, Yifeng; Fukuyama, Julia; Switzer, Christopher H.; Wink, David A.; Roberts, David D.			Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RESPONSES; N-TERMINAL MYRISTOYLATION; PROTEIN-TYROSINE KINASES; CHAIN FATTY-ACIDS; METHIONINE AMINOPEPTIDASE-2; ANGIOGENESIS INHIBITOR; SELECTIVE REQUIREMENT; IN-VITRO; MEMBRANE; SYNTHASE	Although CD36 is generally recognized to be an inhibitory signaling receptor for thrombospondin- 1 (TSP1), the molecular mechanism for transduction of this signal remains unclear. Based on evidence that myristic acid and TSP1 each modulate endothelial cell nitric oxide signaling in a CD36-dependent manner, we examined the ability of TSP1 to modulate the fatty acid translocase activity of CD36. TSP1 and a CD36 antibody that mimics the activity of TSP1 inhibited myristate uptake. Recombinant TSP1 type 1 repeats were weakly inhibitory, but an anti-angiogenic peptide derived from this domain potently inhibited myristate uptake. This peptide also inhibited membrane translocation of the myristoylated CD36 signaling target Fyn and activation of Src family kinases. Myristate uptake stimulated cGMP synthesis via endothelial nitric-oxide synthase and soluble guanylyl cyclase. CD36 ligands blocked myristate-stimulated cGMP accumulation in proportion to their ability to inhibit myristate uptake. TSP1 also inhibited myristate-stimulated cGMP synthesis by engaging its receptor CD47. Myristate stimulated endothelial and vascular smooth muscle cell adhesion on type I collagen via the NO/cGMP pathway, and CD36 ligands that inhibit myristate uptake blocked this response. Therefore, the fatty acid translocase activity of CD36 elicits pro-angiogenic signaling in vascular cells, and TSP1 inhibits this response by simultaneously inhibiting fatty acid uptake via CD36 and downstream cGMP signaling via CD47.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008; Switzer, Christopher/D-9203-2013	Roberts, David D./0000-0002-2481-2981; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513	NATIONAL CANCER INSTITUTE [Z01SC009174, Z01SC009172, Z01SC007281] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 SC009172-04, Z01 SC009174-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; French KJ, 2004, J PHARMACOL EXP THER, V309, P340, DOI 10.1124/jpet.103.061572; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Haviv F, 2005, J MED CHEM, V48, P2838, DOI 10.1021/jm0401560; Hoekstra R, 2005, J CLIN ONCOL, V23, P5188, DOI 10.1200/JCO.2005.05.013; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Ignarro LJ, 2005, CURR TOP MED CHEM, V5, P595; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2006, CARDIOVASC RES, V71, P785, DOI 10.1016/j.cardiores.2006.05.024; Isenberg JS, 2006, J BIOL CHEM, V281, P26069, DOI 10.1074/jbc.M605040200; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kallander LS, 2005, J MED CHEM, V48, P5644, DOI 10.1021/jm050408c; Kanda S, 2005, J CELL SCI, V118, P961, DOI 10.1242/jcs.01686; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Koonen DPY, 2005, BBA-MOL CELL BIOL L, V1736, P163, DOI 10.1016/j.bbalip.2005.08.018; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Krotova K, 2006, BRIT J PHARMACOL, V148, P732, DOI 10.1038/sj.bjp.0706777; Lamalice L, 2006, J BIOL CHEM, V281, P34009, DOI 10.1074/jbc.M603928200; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; LIU JW, 1994, J BIOL CHEM, V269, P11691; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Maurer-Stroh S, 2002, J MOL BIOL, V317, P541, DOI 10.1006/jmbi.2002.5426; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; Milkiewicz M, 2005, AM J PHYSIOL-HEART C, V289, pH336, DOI 10.1152/ajpheart.01105.2004; Murad F, 2004, BIOSCIENCE REP, V24, P452, DOI 10.1007/s10540-005-2741-8; Murata R, 1997, INT J RADIAT ONCOL, V37, P1107, DOI 10.1016/S0360-3016(96)00628-1; Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427; Perrino BA, 2001, J BIOCHEM-TOKYO, V129, P835, DOI 10.1093/oxfordjournals.jbchem.a002927; Rioux V, 2002, J NUTR BIOCHEM, V13, P66, DOI 10.1016/S0955-2863(01)00196-6; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Rofstad EK, 2004, INT J RADIAT ONCOL, V58, P493, DOI 10.1016/j.ijrobp.2003.09.030; Sato Y, 2004, BIOL PHARM BULL, V27, P772, DOI 10.1248/bpb.27.772; Selvakumar P, 2006, BBA-REV CANCER, V1765, P148, DOI 10.1016/j.bbcan.2005.11.001; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; Shintani S, 2006, ORAL ONCOL, V42, P66, DOI 10.1016/j.oraloncology.2005.06.010; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; Thorne RF, 2006, BIOCHEM BIOPH RES CO, V351, P51, DOI 10.1016/j.bbrc.2006.09.156; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VOGEL T, 1993, ARCH BIOCHEM BIOPHYS, V300, P501, DOI 10.1006/abbi.1993.1068; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Werdich Xiang Q., 2005, Angiogenesis, V8, P315; Yap R, 2005, CLIN CANCER RES, V11, P6678, DOI 10.1158/1078-0432.CCR-05-0621; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Zhu WF, 2005, J BIOL CHEM, V280, P29543, DOI 10.1074/jbc.M501238200	66	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15404	15415		10.1074/jbc.M701638200	http://dx.doi.org/10.1074/jbc.M701638200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17416590	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000246589600016
J	Nikodemova, M; Watters, JJ; Jackson, SJ; Yang, SK; Duncan, ID				Nikodemova, Maria; Watters, Jyoti J.; Jackson, Samuel J.; Yang, Shaun K.; Duncan, Ian D.			Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)(alpha/beta II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE; TRANSACTIVATOR; ACTIVATION; RELEASE; CELLS; MODEL; CIITA	Experimental allergic encephalomyelitis, an autoimmune disorder mediated by T cells, results in demyelination, inflammation, and axonal loss in the central nervous system (CNS). Microglia play a critical role in major histocompatibility complex class II (MHC II)-dependent antigen presentation and in reactivation of CNS-infiltrated encephalitogenic T cells. Minocycline, a tetracycline antibiotic, has profound anti-inflammatory properties and is experimentally used for treatment of many CNS disorders; however, the mechanisms involved in minocycline effects remain unknown. We show that administration of minocycline for 2 weeks ameliorated clinical severity of experimental allergic encephalomyelitis, an effect that partially involves the down-regulation of MHC II proteins in the spinal cord. Therefore, we sought to elucidate the molecular mechanisms of minocycline inhibitory effects on MHC II expression in microglia. Although complex, the co-activator class II transactivator (CIITA) is a key regulator of MHC II expression. Here we show that minocycline inhibited interferon gamma(IFN gamma)induced CIITA and MHC II mRNA. Interestingly, however, it was without effect on STAT1 phosphorylation or IRF-1 expression, transcription factors that are activated by IFN gamma and necessary for CIITA expression. Further experiments revealed that MHC II expression is down-regulated in the presence of the PKC alpha inhibitor Go6976. Minocycline inhibited IFN gamma- induced PKC alpha/beta II phosphorylation and the nuclear translocation of both PKC alpha/beta II and IRF-1 that subsequently inhibits CIITA expression. Our present data delineate a molecular pathway of minocycline action that includes inhibitory effects on PKC alpha/beta II and transcription factors that regulate the expression of critical inflammatory genes such as MHC II. Such a fundamental mechanism may underlie the pleiotropic effects of minocycline in CNS inflammatory disorders.	Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nikodemova, M (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Med Sci, 2015 Linden Dr, Madison, WI 53706 USA.	nikodemova@svm.vetmed.wisc.edu			NINDS NIH HHS [R01 NS049033] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049033] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; de Graaf KL, 2004, J IMMUNOL, V173, P2792, DOI 10.4049/jimmunol.173.4.2792; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; El Behi M, 2005, IMMUNOL LETT, V96, P11, DOI 10.1016/j.imlet.2004.07.017; FONTANA A, 1987, IMMUNOL REV, V100, P185, DOI 10.1111/j.1600-065X.1987.tb00532.x; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Giroux M, 2003, J IMMUNOL, V171, P4187, DOI 10.4049/jimmunol.171.8.4187; Gunther E, 2001, IMMUNOGENETICS, V53, P520, DOI 10.1007/s002510100361; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Kim SS, 2004, ARCH PHARM RES, V27, P314, DOI 10.1007/BF02980066; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; McDole J, 2006, NEUROL RES, V28, P256, DOI 10.1179/016164106X98125; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; O'Keefe GM, 2002, J NEUROVIROL, V8, P496, DOI 10.1080/13550280290100941; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zika E, 2005, CURR OPIN IMMUNOL, V17, P58, DOI 10.1016/j.coi.2004.11.008	27	120	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15208	15216		10.1074/jbc.M611907200	http://dx.doi.org/10.1074/jbc.M611907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395590	hybrid			2022-12-25	WOS:000246589000060
J	Kallikourdis, M; Betz, AG				Kallikourdis, Marinos; Betz, Alexander G.			Periodic Accumulation of Regulatory T Cells in the Uterus: Preparation for the Implantation of a Semi-Allogeneic Fetus?	PLOS ONE			English	Article							HUMAN ENDOMETRIUM; ADOPTIVE TRANSFER; EXPRESSION; CHEMOKINE; CD4(+)CD25(+); RECRUITMENT; FRACTALKINE; RECEPTORS	Background. Naturally occurring Foxp3+ regulatory T cells play an important role in the inhibition of an immunological attack of the fetus. As implantation of the fetus poses an immediate antigenic challenge, the immune system has to prepare itself for this event prior to implantation. Methodology and Principal Findings. Here, we show using quantitative RT-PCR and flow cytometry that regulatory T cells accumulate in the uterus not only during pregnancy, but also every time the female becomes fertile. Their periodic accumulation is accompanied by matching fluctuations in uterine expression of several chemokines, which have been shown to play a role in the recruitment and retention of regulatory T cells. Conclusions/Significance. The data lead us to propose that every time a female approaches estrus, regulatory T cells start to accumulate in the uterus in preparation for a possible implantation event. Once pregnancy is established, those regulatory T cells that have seen alloantigen need to be retained at their site of action. Whilst several chemokines appear to be involved in the recruitment and/or retention of regulatory T cells during estrus, in pregnancy this role appears to be taken over by CCL4.	[Kallikourdis, Marinos; Betz, Alexander G.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Betz, AG (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	betz@mrc-lmb.cam.ac.uk	Kallikourdis, Marinos/AAA-5593-2019; Betz, Alexander/GQQ-2221-2022	Kallikourdis, Marinos/0000-0001-9318-3368; 	Medical Research Council UK; Arthritis Research Campaign [B0750]; Medical Research Council [MC_U105184296] Funding Source: researchfish; MRC [MC_U105184296] Funding Source: UKRI	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Arthritis Research Campaign(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council UK and a grant from the Arthritis Research Campaign (grant no: B0750).	Abrahams VM, 2005, PLACENTA, V26, P540, DOI 10.1016/j.placenta.2004.08.010; Akiyama M, 1999, BRIT J OBSTET GYNAEC, V106, P725, DOI 10.1111/j.1471-0528.1999.tb08374.x; Aluvihare VR, 2006, IMMUNOL REV, V212, P330, DOI 10.1111/j.0105-2896.2006.00408.x; Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Arruvito L, 2007, J IMMUNOL, V178, P2572, DOI 10.4049/jimmunol.178.4.2572; Caballero-Campo P, 2002, MOL HUM REPROD, V8, P375, DOI 10.1093/molehr/8.4.375; Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Itoh M, 1999, J IMMUNOL, V162, P5317; Jones RL, 2004, J CLIN ENDOCR METAB, V89, P6155, DOI 10.1210/jc.2004-0507; Kallikourdis M, 2007, P NATL ACAD SCI USA, V104, P594, DOI 10.1073/pnas.0604268104; Kitaya K, 2003, J CLIN ENDOCR METAB, V88, P1809, DOI 10.1210/jc.2002-020980; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T; Red-Horse K, 2001, AM J PATHOL, V159, P2199, DOI 10.1016/S0002-9440(10)63071-4; Rushbrook SM, 2005, J VIROL, V79, P7852, DOI 10.1128/JVI.79.12.7852-7859.2005; Salamonsen LA, 2002, J REPROD IMMUNOL, V57, P95, DOI 10.1016/S0165-0378(02)00011-6; Sasaki Y, 2004, MOL HUM REPROD, V10, P347, DOI 10.1093/molehr/gah044; SHORT DJ, 1969, IAT MANUAL LAB ANIMA, P342; Szanya V, 2002, J IMMUNOL, V169, P2461, DOI 10.4049/jimmunol.169.5.2461; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317; Watanabe M, 2006, INT J GYNECOL OBSTET, V92, P242, DOI 10.1016/j.ijgo.2005.12.012; Wysocki CA, 2005, BLOOD, V106, P3300, DOI 10.1182/blood-2005-04-1632; Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956; Zenclussen AC, 2004, EUR J IMMUNOL, V34, P377, DOI 10.1002/eji.200324469	28	80	85	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e382	10.1371/journal.pone.0000382	http://dx.doi.org/10.1371/journal.pone.0000382			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440618	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445500013
J	Plamondon, M; Labbe, AC; Frost, E; Deslandes, S; Alves, AC; Bastien, N; Pepin, J				Plamondon, Mireille; Labbe, Annie-Claude; Frost, Eric; Deslandes, Sylvie; Alves, Alfredo Claudino; Bastien, Nathalie; Pepin, Jacques			Hepatitis C Virus Infection in Guinea-Bissau: A Sexually Transmitted Genotype 2 with Parenteral Amplification?	PLOS ONE			English	Article							GENETIC DIVERSITY; HCV INFECTION; RISK-FACTORS; TRANSMISSION; ANTIBODIES; PREVALENCE; HETEROGENEITY; EPIDEMIOLOGY; HISTORY; WORKERS	Background. Sub-Saharan Africa is the continent with the highest prevalence of Hepatitis C virus (HCV) infection. Genotype 2 HCV is thought to have originated from West Africa several hundred years ago. Mechanisms of transmission remain poorly understood. Methodology/Principal Findings. To delineate mechanisms for HCV transmission in West Africa, we conducted a cross-sectional survey of individuals aged >= 50 years in Bissau, Guinea-Bissau. Dried blood spots were obtained for HCV serology and PCR amplification. Prevalence of HCV was 4.4% (47/1066) among women and 5.0% (27/544) among men. In multivariate analysis, the independent risk factors for HCV infection were age (baseline: 50-59 y; 60-69 y, adjusted odds ratio [AOR]: 1.67, 95% CI: 0.91-3.06; >= 70 y, AOR: 3.47, 95% CI: 1.89-6.39), belonging to the Papel, Mancanha, Balanta or Mandjako ethnic groups (AOR: 2.45, 95% CI: 1.32-4.53), originating from the Biombo, Cacheu or Oio regions north of Bissau (AOR: 4.16, 95% CI: 1.18-14.73) and having bought or sold sexual services (AOR: 3.60, 95% CI: 1.88-6.89). Of 57 isolates that could be genotyped, 56 were genotype 2. Conclusions. Our results suggest that transmission of HCV genotype 2 in West Africa occurs through sexual intercourse. In specific locations and subpopulations, medical interventions may have amplified transmission parenterally.	[Plamondon, Mireille; Frost, Eric; Deslandes, Sylvie; Pepin, Jacques] Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada; [Plamondon, Mireille; Frost, Eric; Deslandes, Sylvie; Pepin, Jacques] Univ Sherbrooke, Ctr Int Hlth, Sherbrooke, PQ J1K 2R1, Canada; [Labbe, Annie-Claude; Bastien, Nathalie] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada; [Alves, Alfredo Claudino] Hop Simao Mendes, Bissau, Guinea Bissau	University of Sherbrooke; University of Sherbrooke; Universite de Montreal	Pepin, J (corresponding author), Univ Sherbrooke, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1K 2R1, Canada.	jacques.pepin@usherbrooke.ca		Frost, Eric/0000-0001-8958-4388				Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Ayele W, 2002, J MED VIROL, V68, P12, DOI 10.1002/jmv.10164; Braga ACD, 2006, ACTA TROP, V97, P88, DOI 10.1016/j.actatropica.2005.09.003; Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007; Candotti D, 2003, J VIROL, V77, P7914, DOI 10.1128/JVI.77.14.7914-7923.2003; DACOSTA FMC, 1960, B CULTURAL GUINE POR, V15, P521; DENIS F, 1994, J MED VIROL, V43, P1, DOI 10.1002/jmv.1890430102; DEVELOUX M, 1994, T ROY SOC TROP MED H, V88, P536, DOI 10.1016/0035-9203(94)90151-1; Egawa K, 1996, J HEPATOL, V24, P397, DOI 10.1016/S0168-8278(96)80159-0; ELTIS D, 1999, TRANSATLANTIC SLAVE; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; FRETZ C, 1995, J MED VIROL, V47, P435, DOI 10.1002/jmv.1890470423; FROMMEL D, 1993, AM J TROP MED HYG, V49, P435, DOI 10.4269/ajtmh.1993.49.435; Jagger J, 2002, JAMA-J AM MED ASSOC, V288, P1469, DOI 10.1001/jama.288.12.1469; Jeannel D, 1998, J MED VIROL, V55, P92, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;92::AID-JMV2&gt;3.0.CO;2-I; Laurent C, 2001, INT J EPIDEMIOL, V30, P872, DOI 10.1093/ije/30.4.872; LECUONA MD, 1966, B CULTURAL GUINE POR, V21, P45; Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5; Martial J, 2004, J CLIN MICROBIOL, V42, P784, DOI 10.1128/JCM.42.2.784-791.2004; Mast EE, 2005, J INFECT DIS, V192, P1880, DOI 10.1086/497701; Memon MI, 2002, J VIRAL HEPATITIS, V9, P84, DOI 10.1046/j.1365-2893.2002.00329.x; Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606; Ndjomou J, 2003, J GEN VIROL, V84, P2333, DOI 10.1099/vir.0.19240-0; Pasquier C, 2005, J MED VIROL, V77, P390, DOI 10.1002/jmv.20468; Pepin J, 2006, AIDS, V20, P1303, DOI 10.1097/01.aids.0000232239.05545.33; Piazza M, 1997, ARCH INTERN MED, V157, P1537, DOI 10.1001/archinte.157.14.1537; PINTO A R, 1960, An Inst Med Trop (Lisb), V17, P817; PINTO AR, 1959, B CULTURAL GUINE POR, V14, P603; Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321; Ray SC, 2000, J INFECT DIS, V182, P698, DOI 10.1086/315786; Ruggieri A, 1996, J GEN VIROL, V77, P2073, DOI 10.1099/0022-1317-77-9-2073; SHEV S, 1995, SEX TRANSM DIS, V22, P210, DOI 10.1097/00007435-199507000-00002; Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0; Stark K, 2000, J MED VIROL, V62, P524, DOI 10.1002/1096-9071(200012)62:4&lt;524::AID-JMV19&gt;3.0.CO;2-N; Tovo PA, 2005, J INFECT DIS, V192, P1872, DOI 10.1086/497695; Vandelli C, 2004, AM J GASTROENTEROL, V99, P855, DOI 10.1111/j.1572-0241.2004.04150.x; Yazdanpanah Y, 2005, CLIN INFECT DIS, V41, P1423, DOI 10.1086/497131	37	30	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e372	10.1371/journal.pone.0000372	http://dx.doi.org/10.1371/journal.pone.0000372			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440608	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445500003
J	Mainguy, G; Koster, J; Woltering, J; Jansen, H; Durston, A				Mainguy, Gaell; Koster, Jan; Woltering, Joost; Jansen, Hans; Durston, Antony			Extensive Polycistronism and Antisense Transcription in the Mammalian Hox Clusters	PLOS ONE			English	Article								The Hox clusters play a crucial role in body patterning during animal development. They encode both Hox transcription factor and micro-RNA genes that are activated in a precise temporal and spatial sequence that follows their chromosomal order. These remarkable collinear properties confer functional unit status for Hox clusters. We developed the TranscriptView platform to establish high resolution transcriptional profiling and report here that transcription in the Hox clusters is far more complex than previously described in both human and mouse. Unannotated transcripts can represent up to 60% of the total transcriptional output of a cluster. In particular, we identified 14 non-coding Transcriptional Units antisense to Hox genes, 10 of which (70%) have a detectable mouse homolog. Most of these Transcriptional Units in both human and mouse present conserved sizeable sequences (. 40 bp) overlapping Hox transcripts, suggesting that these Hox antisense transcripts are functional. Hox clusters also display at least seven polycistronic clusters, i.e., different genes being co-transcribed on long isoforms (up to 30 kb). This work provides a reevaluated framework for understanding Hox gene function and dys-function. Such extensive transcriptions may provide a structural explanation for Hox clustering.	[Mainguy, Gaell; Woltering, Joost; Jansen, Hans; Durston, Antony] Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; [Koster, Jan] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Amsterdam; Academic Medical Center Amsterdam	Mainguy, G (corresponding author), Inst Veolia Environm, Paris, France.	gaell.mainguy@institut.veolia.org; A.J.Durston@biology.leidenuniv.nl	Koster, Jan/C-5934-2008	Koster, Jan/0000-0002-0890-7585; Woltering, Joost/0000-0002-2630-6572; Jansen, Hans/0000-0002-8563-4146	European Union; EMBO	European Union(European Commission); EMBO(European Molecular Biology Organization (EMBO))	This work was supported by the European Union FP5 Marie Curie and Biotech programmes, and also by an EMBO long term fellowship to GM and a Marie Curie individual fellowship to G. M. These sponsors supported all phases of this work up until the final writing phase.	Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Cook PR, 2003, J CELL SCI, V116, P4483, DOI 10.1242/jcs.00819; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Huang XQ, 1996, GENOMICS, V33, P21, DOI 10.1006/geno.1996.0155; Isono K, 2005, GENE DEV, V19, P536, DOI 10.1101/gad.1284605; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kosman D, 2004, SCIENCE, V305, P846, DOI 10.1126/science.1099247; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Nelson CE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r25; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Shiga Y, 2006, EVOL DEV, V8, P407, DOI 10.1111/j.1525-142X.2006.00114.x; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; Thanaraj TA, 2003, NUCLEIC ACIDS RES, V31, P2544, DOI 10.1093/nar/gkg355; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yousef GM, 2003, CLIN BIOCHEM, V36, P443, DOI 10.1016/S0009-9120(03)00055-9	26	69	72	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e356	10.1371/journal.pone.0000356	http://dx.doi.org/10.1371/journal.pone.0000356			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406680	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445300018
J	Jeng, YM; Cai-Ng, S; Li, A; Furuta, S; Chew, H; Chen, PL; Lee, EYH; Lee, WH				Jeng, Y-M; Cai-Ng, S.; Li, A.; Furuta, S.; Chew, H.; Chen, P-L; Lee, E-Y-H; Lee, W-H			Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation	ONCOGENE			English	Article						BRCA1; heterozygous mutant; ionizing radiation; ovarian tumor; haploinsufficiency	INDUCED MICRONUCLEUS FREQUENCIES; BREAST-CANCER RISK; MUTATION CARRIERS; SCREENING-TEST; EARLY-ONSET; DNA-REPAIR; GENE; LYMPHOCYTES; WOMEN; P53	BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5- fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploin sufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, Coll Med, 839 Med Sci Court,124 Sprague hall, Irvine, CA 92697 USA.	whlee@uci.edu	Chen, Phang-Lang/J-5031-2013; Furuta, Saori/P-9677-2018	Furuta, Saori/0000-0003-1121-0487; JENG, YUNG-MING/0000-0002-3878-4491	PHS HHS [R01 94170] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baeyens A, 2004, INT J RADIAT BIOL, V80, P745, DOI 10.1080/09553000400017937; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Baria K, 2001, CANCER RES, V61, P5948; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; EASTON DF, 1995, AM J HUM GENET, V56, P265; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Friedenson B, 2000, MedGenMed, V2, pE9; Goldfrank D, 2006, CANCER EPIDEM BIOMAR, V15, P2311, DOI 10.1158/1055-9965.EPI-06-0176; Goss PE, 1998, J CLIN ONCOL, V16, P338, DOI 10.1200/JCO.1998.16.1.338; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Kirova YM, 2005, CANCER-AM CANCER SOC, V104, P856, DOI 10.1002/cncr.21223; Kote-Jarai Z, 2006, BRIT J CANCER, V94, P308, DOI 10.1038/sj.bjc.6602912; Kotsopoulos J, 2007, BRIT J CANCER, V96, P118, DOI 10.1038/sj.bjc.6603528; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Metcalfe KA, 2005, GYNECOL ONCOL, V96, P222, DOI 10.1016/j.ygyno.2004.09.039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rothfuss A, 2000, CANCER RES, V60, P390; Salim EI, 2003, CARCINOGENESIS, V24, P335, DOI 10.1093/carcin/24.2.335; Schildkraut JM, 1997, JNCI-J NATL CANCER I, V89, P932, DOI 10.1093/jnci/89.13.932; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shanley S, 2006, CLIN CANCER RES, V12, P7025, DOI 10.1158/1078-0432.CCR-06-1244; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; WAGNER EH, 1998, EFFECTIVE CLIN PRACT, V1, P1; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	47	28	28	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6160	6166		10.1038/sj.onc.1210451	http://dx.doi.org/10.1038/sj.onc.1210451			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420720				2022-12-25	WOS:000249401300006
J	Zisman-Rozen, S; Fink, D; Ben-Izhak, O; Fuchs, Y; Brodski, A; Kraus, MH; Bejar, J; Ron, D				Zisman-Rozen, S.; Fink, D.; Ben-Izhak, O.; Fuchs, Y.; Brodski, A.; Kraus, M. H.; Bejar, J.; Ron, D.			Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas	ONCOGENE			English	Article						Sef; RTK; cancer	PROSTATE-CANCER; SPECIFICITY; EXPRESSION; PATHWAYS; ISOFORM; GRADE	Carcinomas are tumors of epithelial origin accounting for over 80% of all human malignancies. A substantial body of evidence implicates oncogenic signaling by receptor tyrosine kinases ( RTKs) in carcinoma development. Here we investigated the expression of Sef, a novel inhibitor of RTK signaling, in normal human epithelial tissues and derived malignancies. Human Sef ( hSef) was highly expressed in normal epithelial cells of breast, prostate, thyroid gland and the ovarian surface. By comparison, substantial downregulation of hSef expression was observed in the majority of tumors originating from these epithelia. Among 186 primary carcinomas surveyed by RNA in situ hybridization, hSef expression was undetectable in 116 cases including 72/99 ( 73%) breast, 11/ 16 ( 69%) thyroid, 16/ 31 ( 52%) prostate and 17/ 40 ( 43%) ovarian carcinomas. Moderate reduction of expression was observed in 17/ 186, and marked reduction in 40/ 186 tumors. Only 13/ 186 cases including 12 low- grade and one intermediate grade tumor retained high hSef expression. The association of hSef downregulation and tumor progression was statistically significant ( P<0.001). Functionally, ectopic expression of hSef suppressed proliferation of breast carcinoma cells, whereas inhibition of endogenous hSef expression accelerated fibroblast growth factor and epidermal growth factor- dependent proliferation of cervical carcinoma cells. The inhibitory effect of hSef on cell proliferation combined with consistent downregulation in human carcinoma indicates a tumor suppressor- like role for hSef, and implicates loss of hSef expression as a common mechanism in epithelial neoplasia.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Rambam Med Ctr, Dept Pathol, Haifa, Israel; Bnai Zion Med Ctr, Dept Gen Surg, Haifa, Israel; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Bnai Zion Med Ctr, Dept Pathol, Haifa, Israel	Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Bnai Zion Medical Center; University of Alabama System; University of Alabama Birmingham; Bnai Zion Medical Center	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@tx.technion.ac.il						Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Darby S, 2006, ONCOGENE, V25, P4122, DOI 10.1038/sj.onc.1209428; De Marzo AM, 1999, UROLOGY, V53, P29, DOI 10.1016/S0090-4295(98)00536-6; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Harduf H, 2005, DEV DYNAM, V233, P301, DOI 10.1002/dvdy.20364; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KOSARY CL, 1994, SEMIN SURG ONCOL, V10, P31, DOI 10.1002/ssu.2980100107; Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 2006, J BIOL CHEM, V281, P5178, DOI 10.1074/jbc.M509500200; TAVASSOLI FA, 2003, GENETICS TUMORS BREA, P18; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Ziv I, 2006, J BIOL CHEM, V281, P39225, DOI 10.1074/jbc.M607327200	22	39	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6093	6098		10.1038/sj.onc.1210424	http://dx.doi.org/10.1038/sj.onc.1210424			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420726				2022-12-25	WOS:000249277200012
J	Gungor, N; Godschalk, RWL; Pachen, DM; Van Schooten, FJ; Knaapen, AM				Gungor, Nejla; Godschalk, Roger W. L.; Pachen, Danielle M.; Van Schooten, Frederik J.; Knaapen, Ad M.			Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase	FASEB JOURNAL			English	Article						DNA adducts; DNA repair; inflammation; lung cancer	DNA ADDUCT LEVELS; HYPOCHLOROUS ACID; LUNG-CANCER; POTENT INHIBITOR; INFLAMMATION; OXIDATION; RISK; (+/-)-TRANS-7,8-DIHYDROXY-7,8-DIHYDROBENZO<A>PYRENE; SENSITIVITY; MUTAGENESIS	Neutrophils are thought to affect pulmonary carcinogenesis by promoting the metabolism of inhaled chemical carcinogens, causing enhanced formation of promutagenic DNA adducts. We hypothesized that neutrophils interfere with the removal of such DNA adducts by inhibiting nucleotide excision repair ( NER) in target cells. Human alveolar epithelial cells ( A549) were cocultured with activated neutrophils, and we observed a significant reduction of NER in the A549 cells, which was abrogated by addition of the myeloper-oxidase (MPO) inhibitor 4-aminobenzoic acid hydrazide. The inhibitory effect of neutrophils could be mimicked by the MPO product hypochlorous acid ( HOCl), which caused an acute, dose-dependent inhibition of NER in A549 cells. This was independent of cytotoxicity or ATP loss and persisted up to 24 h. These data were supported by showing that HOCl caused a delayed removal of DNA adducts in benzo[ a] pyrenediolepoxide-exposed A549 cells. The acute HOCl-induced inhibition of NER can only partly be explained by oxidative modification of repair proteins. To explain the more persistent effects of HOCl, we analyzed the expression of NER genes and found that HOCl significantly reduced XPC expression. In conclusion, these data indicate that neutrophils are potent inhibitors of nucleotide excision repair. This may provide a further biological explanation for the association between inflammation and lung cancer development.	Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Nutr & Toxicol Res Inst, NL-6200 MD Maastricht, Netherlands	Maastricht University	Knaapen, AM (corresponding author), Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Nutr & Toxicol Res Inst, POB 616, NL-6200 MD Maastricht, Netherlands.	a.knaapen@grat.unimaas.nl						Borm PJA, 1997, ENVIRON HEALTH PERSP, V105, P1089, DOI 10.2307/3433514; Buss IH, 2000, PEDIATR RES, V47, P640, DOI 10.1203/00006450-200005000-00014; Chien YH, 2004, FREE RADICAL BIO MED, V36, P1011, DOI 10.1016/j.freeradbiomed.2004.01.011; COCHRANE CG, 1991, AM J MED, V91, pS23, DOI 10.1016/0002-9343(91)90280-B; Collins AR, 2001, MUTAGENESIS, V16, P297, DOI 10.1093/mutage/16.4.297; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; DALLEGRI F, 1988, J LAB CLIN MED, V112, P765; Dally H, 2002, INT J CANCER, V102, P530, DOI 10.1002/ijc.10756; den Hartog GJM, 2002, TOXICOL APPL PHARM, V181, P228, DOI 10.1006/taap.2002.9419; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Feng ZH, 2004, P NATL ACAD SCI USA, V101, P8598, DOI 10.1073/pnas.0402794101; Feng ZH, 2006, MUTAT RES-FUND MOL M, V601, P125, DOI 10.1016/j.mrfmmm.2006.06.003; FLISS H, 1988, MOL CELL BIOCHEM, V84, P177, DOI 10.1007/BF00421053; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; HUNNINGHAKE GW, 1981, J CLIN INVEST, V68, P259, DOI 10.1172/JCI110242; Ide F, 2000, CARCINOGENESIS, V21, P1263, DOI 10.1093/carcin/21.6.1263; JANZ S, 1993, MUTAT RES, V293, P173, DOI 10.1016/0921-8777(93)90068-R; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Knaapen AM, 2006, MUTAGENESIS, V21, P225, DOI 10.1093/mutage/gel032; Knaapen AM, 2005, CARCINOGENESIS, V26, P1642, DOI 10.1093/carcin/bgi116; Knaapen AM, 2004, INT J CANCER, V109, P799, DOI 10.1002/ijc.11708; Knaapen AM, 1999, FREE RADICAL BIO MED, V27, P234, DOI 10.1016/S0891-5849(98)00285-8; Kulcharyk PA, 2001, BIOCHEMISTRY-US, V40, P3648, DOI 10.1021/bi001962l; Langie SAS, 2006, MUTAGENESIS, V21, P153, DOI 10.1093/mutage/gel013; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; Noguera A, 2001, THORAX, V56, P432, DOI 10.1136/thorax.56.6.432; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Pero RW, 1996, CARCINOGENESIS, V17, P13, DOI 10.1093/carcin/17.1.13; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Redaelli A, 1998, TERATOGEN CARCIN MUT, V18, P17, DOI 10.1002/(SICI)1520-6866(1998)18:1<17::AID-TCM3>3.0.CO;2-H; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Schottenfeld D, 2006, CA-CANCER J CLIN, V56, P69, DOI 10.3322/canjclin.56.2.69; Spencer JPE, 2000, FREE RADICAL BIO MED, V28, P1039, DOI 10.1016/S0891-5849(00)00190-8; van Haaften RIM, 2001, CHEM-BIOL INTERACT, V138, P77, DOI 10.1016/S0009-2797(01)00262-9; Van Schooten FJ, 2004, CANCER EPIDEM BIOMAR, V13, P828; VANRENSBURG CEJ, 1991, FREE RADICAL BIO MED, V11, P285, DOI 10.1016/0891-5849(91)90125-M; Whiteman M, 2002, P NATL ACAD SCI USA, V99, P12061, DOI 10.1073/pnas.152462399; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Wu XF, 2003, CARCINOGENESIS, V24, P505, DOI 10.1093/carcin/24.3.505; Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232	49	62	63	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2359	2367		10.1096/fj.07-8163com	http://dx.doi.org/10.1096/fj.07-8163com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17440118				2022-12-25	WOS:000248454400011
J	Rosenberger, P; Khoury, J; Kong, TQ; Weissmuller, T; Robinson, AM; Colgan, SP				Rosenberger, Peter; Khoury, Joseph; Kong, Tianqing; Weissmuller, Thomas; Robinson, Andreas M.; Colgan, Sean P.			Identification of vasodilator-stimulated phosphoprotein (VASP) as an HIF-regulated tissue permeability factor during hypoxia	FASEB JOURNAL			English	Article						barrier function; actin	INDUCIBLE FACTOR-I; ALVEOLAR EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; BARRIER FUNCTION; NITRIC-OXIDE; INDUCTION; SPECTRIN; GENE; EXPRESSION; ISCHEMIA	Increased tissue permeability is commonly associated with hypoxia of many origins. Since hypoxia-inducible factor (HIF) represents a predominant hypoxia signaling mechanism, we compared hypoxia-elicited changes in tissue barrier function in mice conditionally lacking intestinal epithelial hypoxia-inducible factor-1 alpha (hif1a). Somewhat surprisingly, these studies revealed that mutant hif1a mice were protected from hypoxia-induced increases in intestinal permeability in vivo. Guided by microarray analysis of tissues derived from these mutant hif1a mice, we identified HIF-1-dependent repression of vasodilator-stimulated phosphoprotein ( VASP), a molecule known to be important in the control of cytoskeletal dynamics, including barrier function. Studies at the mRNA and protein level confirmed hypoxia-elicited repression of VASP in murine tissue, cultured epithelia and endothelia, as well as human saphenous vein ex vivo. Targeted repression of VASP by siRNA recapitulated our findings with hypoxia and directed overexpression of VASP abolished hypoxia-induced barrier dysfunction. Studies in the cloned human VASP promoter revealed hypoxia-dependent transcriptional repression, and functional studies by chromatin immunoprecipitation (ChIP) and site-directed mutagenesis revealed hypoxia-dependent binding of HIF-1 alpha to the human VASP promoter. These studies identify HIF-1-dependent repression of VASP as a control point for hypoxia-regulated barrier dysfunction.	Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Denver, CO 80220 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Anesthesia & Perioperat Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Tubingen, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, 4200 E 9th Ave,Biochem Res Bldg,Rm 702, Denver, CO 80220 USA.	colgan@zeus.bwh.harvard.edu	Colgan, Sean P./B-4573-2009		NHLBI NIH HHS [R01 HL060569] Funding Source: Medline; NIDDK NIH HHS [R37 DK050189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bouvry D, 2006, AM J RESP CELL MOL, V35, P519, DOI 10.1165/rcmb.2005-0478OC; Cavanaugh KJ, 2001, AM J RESP CELL MOL, V25, P584, DOI 10.1165/ajrcmb.25.5.4486; Comerford KM, 2002, CANCER RES, V62, P3387; Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje; COMERFORD KM, 2002, FASEB J, V282, pC1235; DOCTOR RB, 1993, AM J PHYSIOL, V264, pC1003, DOI 10.1152/ajpcell.1993.264.4.C1003; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HU RJ, 1991, J BIOL CHEM, V266, P18200; Ibla JC, 2006, AM J PHYSIOL-CELL PH, V291, pC282, DOI 10.1152/ajpcell.00564.2005; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kwon O, 2002, AM J PHYSIOL-RENAL, V282, pF1012, DOI 10.1152/ajprenal.00294.2001; Laukoetter MG, 2006, CURR OPIN GASTROEN, V22, P85, DOI 10.1097/01.mog.0000203864.48255.4f; Lawrence DW, 2002, AM J PHYSIOL-CELL PH, V282, pC1235, DOI 10.1152/ajpcell.00288.2001; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; MANALO DJ, 2004, BLOOD, V16, P16; MIZUNOYAGYU Y, 1987, BIOCHEM PHARMACOL, V36, P3809; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; Molitoris BA, 1996, AM J PHYSIOL-RENAL, V271, pF790, DOI 10.1152/ajprenal.1996.271.4.F790; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Semenza GL, 2000, GENE DEV, V14, P1983; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wang FS, 2003, AM J RESP CELL MOL, V29, P62, DOI 10.1165/rcmb.2002-0180OC; Wojciak-Stothard B, 2006, AM J PHYSIOL-LUNG C, V290, pL1173, DOI 10.1152/ajplung.00309.2005; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Woroniecki R, 2003, AM J PHYSIOL-RENAL, V284, pF358, DOI 10.1152/ajprenal.00100.2002; WU NZ, 1992, AM J PHYSIOL, V262, pH1238; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129	44	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2613	2621		10.1096/fj.06-8004com	http://dx.doi.org/10.1096/fj.06-8004com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17412998	Green Accepted			2022-12-25	WOS:000248454400034
J	Wendeler, MW; Nufer, O; Hauri, HP				Wendeler, Markus W.; Nufer, Oliver; Hauri, Hans-Peter			Improved maturation of CFTR by an ER export signal	FASEB JOURNAL			English	Article						cystic fibrosis; membrane traffic; transport signal	TRANSMEMBRANE CONDUCTANCE REGULATOR; EARLY SECRETORY PATHWAY; COPII-DEPENDENT EXPORT; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; DELTA-F508 CFTR; PDZ DOMAINS; CHLORIDE CHANNEL; MOLECULAR-BASIS; GENE-THERAPY	The cystic fibrosis transmembrane conductance regulator ( CFTR) is a cAMP-regulated chloride channel in the plasma membrane of several epithelial cells. Maturation of CFTR is inefficient in most cells, with only a fraction of nascent chains being properly folded and transported to the cell surface. The most common mutation in CFTR, CFTR- Delta F508, leads to the genetic disease cystic fibrosis. CFTR- Delta F508 has a temperature-sensitive folding defect and is almost quantitatively degraded in the endoplasmic reticulum ( ER). Here we tested whether a strong ER export signal appended to CFTR improves its transport and surface expression. We show that a single valine ER export signal at the C terminus of the cytoplasmic tail of CFTR improves maturation of wild-type CFTR by 2-fold. This conservative mutation interfered with neither plasma membrane localization nor stability of mature CFTR. In contrast, the valine signal was unable to rescue CFTR- Delta F508 from ER-associated degradation. Our finding of improved maturation of CFTR mediated by a valine signal may be of potential use in gene therapy of cystic fibrosis. Moreover, failure of the valine signal to rescue CFTR- Delta F508 from ER degradation indicates that the inability of CFTR-Delta F508 to leave the ER is unlikely to be due to a malfunctioning ER export signal.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	hans-peter.hauri@unibas.ch						Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cyr DM, 2005, NAT STRUCT MOL BIOL, V12, P2, DOI 10.1038/nsmb0105-2; Davidson MH, 2006, ATHEROSCLEROSIS SUPP, V7, P1, DOI 10.1016/S1567-5688(06)80003-6; Davies JC, 2001, J GENE MED, V3, P409, DOI 10.1002/jgm.200; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Griesenbach U, 2002, GENE THER, V9, P1344, DOI 10.1038/sj.gt.3301791; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Liu SS, 2005, J PHARMACOL EXP THER, V314, P846, DOI 10.1124/jpet.105.083519; Liu XH, 2006, J BIOL CHEM, V281, P8275, DOI 10.1074/jbc.M512458200; Liu XM, 2002, NAT BIOTECHNOL, V20, P47, DOI 10.1038/nbt0102-47; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2003, J CELL SCI, V116, P4429, DOI 10.1242/jcs.00759; Nufer O, 2002, J CELL SCI, V115, P619; Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1; PIND S, 1994, J BIOL CHEM, V269, P12784; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; RIORDAN JR, 1989, SCIENCE, V245, P1066; Riordan JR, 1999, PEDIATR PULM, P83; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Sun WM, 2006, GENET MED, V8, P339, DOI 10.1097/01.gim.0000223549.57443.16; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; ZHAO W, 2006, J BIOL CHEM	55	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2352	2358		10.1096/fj.07-8128com	http://dx.doi.org/10.1096/fj.07-8128com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17392477				2022-12-25	WOS:000248454400010
J	Suemori, A; Iwakura, M				Suemori, Akio; Iwakura, Masahiro			A systematic and comprehensive combinatorial approach to simultaneously improve the activity, reaction specificity, and thermal stability of p-hydroxybenzoate hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SITE-DIRECTED MUTAGENESIS; AMINO-ACID OXIDASE; PROTOCATECHUATE 3,4-DIOXYGENASE; 4-HYDROXYBENZOATE HYDROXYLASE; PSEUDOMONAS-FLUORESCENS; HALOARCULA-MARISMORTUI; SUBSTRATE-SPECIFICITY; HALOPHILIC ARCHAEON; CRYSTAL-STRUCTURE	We have simultaneously improved the activity, reaction specificity, and thermal stability of p-hydroxybenzoate hydroxylase by means of systematic and comprehensive combinatorial mutagenesis starting from available single mutations. Introduction of random mutations at the positions of four cysteine and eight methionine residues provided 216 single mutants as stably expressed forms in Escherichia coli host cells. Four characteristics, hydroxylase activity toward p-hydroxybenzoate (main activity), protocatechuate-dependent NADPH oxidase activity (sub-activity), ratio of sub-activity to main activity (reaction specificity), and thermal stability, of the purified mutants were determined. To improve the above characteristics for diagnostic use of the enzyme, 11 single mutations (C152V, C211I, C332A, M52V, M52Q, M110L, M110I, M213G, M213L, M276Q, and M349A) were selected for further combinatorial mutagenesis. All possible combinations of the mutations provided 18 variants with double mutations and further combinatorial mutagenesis provided 6 variants with triple mutations and 9 variants with quadruple mutations with the simultaneously improved four properties.	Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Iwakura, M (corresponding author), Natl Inst Adv Ind Sci & Technol, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	masa-iwakura@aist.go.jp						ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ASHIHARA Y, 1983, J BIOCHEM-TOKYO, V94, P11, DOI 10.1093/oxfordjournals.jbchem.a134318; Baliga NS, 2004, GENOME RES, V14, P2221, DOI 10.1101/gr.2700304; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Bertani I, 2001, MICROBIOL-SGM, V147, P1611, DOI 10.1099/00221287-147-6-1611; Bornscheuer UT, 2001, CURR OPIN CHEM BIOL, V5, P137, DOI 10.1016/S1367-5931(00)00182-4; Buchan A, 2000, APPL ENVIRON MICROB, V66, P4662, DOI 10.1128/AEM.66.11.4662-4672.2000; Buchan A, 2004, APPL ENVIRON MICROB, V70, P1658, DOI 10.1128/AEM.70.3.1658-1668.2004; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; Campanella L, 2006, J PHARMACEUT BIOMED, V42, P94, DOI 10.1016/j.jpba.2006.03.020; Chelius D, 2000, BIOCHEMISTRY-US, V39, P9687, DOI 10.1021/bi000274z; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; Deka RC, 2003, COMB CHEM HIGH T SCR, V6, P1; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; EMERSON D, 1994, ARCH MICROBIOL, V161, P445, DOI 10.1007/s002030050081; Endelman JB, 2004, PROTEIN ENG DES SEL, V17, P589, DOI 10.1093/protein/gzh067; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; ENTSCH B, 1988, GENE, V71, P279, DOI 10.1016/0378-1119(88)90044-3; Fairley DJ, 2002, APPL ENVIRON MICROB, V68, P6246, DOI 10.1128/AEM.68.12.6246-6255.2002; Finan TM, 2001, P NATL ACAD SCI USA, V98, P9889, DOI 10.1073/pnas.161294698; Fu WJ, 1999, EXTREMOPHILES, V3, P45, DOI 10.1007/s007920050098; Garcia MT, 2005, FEMS MICROBIOL ECOL, V54, P97, DOI 10.1016/j.femsec.2005.03.009; Hamamatsu N, 2005, PROTEIN ENG DES SEL, V18, P265, DOI 10.1093/protein/gzi028; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; Harris JL, 1998, CURR OPIN CHEM BIOL, V2, P127, DOI 10.1016/S1367-5931(98)80044-6; HARTNETT C, 1990, J BACTERIOL, V172, P956, DOI 10.1128/jb.172.2.956-966.1990; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; Iwabata H, 2005, FEMS MICROBIOL LETT, V243, P393, DOI 10.1016/j.femsle.2004.12.030; Iwakura M, 2006, J BIOL CHEM, V281, P13234, DOI 10.1074/jbc.M508823200; Jestin JL, 2005, RES MICROBIOL, V156, P961, DOI 10.1016/j.resmic.2005.09.004; Ju SS, 2000, FEMS MICROBIOL LETT, V186, P215, DOI 10.1016/S0378-1097(00)00151-8; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kaneko T, 2002, DNA RES, V9, P189, DOI 10.1093/dnares/9.6.189; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Larsson AK, 2004, PROTEIN ENG DES SEL, V17, P49, DOI 10.1093/protein/gzh005; Li TP, 2003, PROTEIN ENG, V16, P323, DOI 10.1093/protein/gzg044; Mattevi A, 1998, BIOPHYS CHEM, V70, P217, DOI 10.1016/S0301-4622(97)00126-9; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603; Noivirt O, 2005, PROTEIN ENG DES SEL, V18, P247, DOI 10.1093/protein/gzi029; OREN A, 1990, INT J SYST BACTERIOL, V40, P209, DOI 10.1099/00207713-40-2-209; Overhage J, 1999, APPL ENVIRON MICROB, V65, P951; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; Quinn JA, 2001, GENE, V264, P77, DOI 10.1016/S0378-1119(00)00599-0; Sacchi S, 2004, PROTEIN ENG DES SEL, V17, P517, DOI 10.1093/protein/gzh064; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; Seibold B, 1996, EUR J BIOCHEM, V239, P469, DOI 10.1111/j.1432-1033.1996.0469u.x; SHUMAN B, 1993, J BIOL CHEM, V268, P17057; Slusarczyk H, 2000, EUR J BIOCHEM, V267, P1280, DOI 10.1046/j.1432-1327.2000.01123.x; Suemori A, 2001, BIOTECHNOL LETT, V23, P489, DOI 10.1023/A:1010345807073; Suen WC, 2004, PROTEIN ENG DES SEL, V17, P133, DOI 10.1093/protein/gzh017; Urgun-Demirtas M, 2006, CRIT REV BIOTECHNOL, V26, P145, DOI 10.1080/07388550600842794; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANDERBOLT FJT, 1994, PROTEIN ENG, V7, P801, DOI 10.1093/protein/7.6.801; Wattiau P, 2001, RES MICROBIOL, V152, P861, DOI 10.1016/S0923-2508(01)01269-4; WHITESTE.RH, 1970, BIOCHEM BIOPH RES CO, V38, P882, DOI 10.1016/0006-291X(70)90803-X; WONG CM, 1994, MICROBIOL-SGM, V140, P2775, DOI 10.1099/00221287-140-10-2775; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Zhao HM, 1997, CURR OPIN STRUC BIOL, V7, P480, DOI 10.1016/S0959-440X(97)80110-8	66	11	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19969	19978		10.1074/jbc.M610320200	http://dx.doi.org/10.1074/jbc.M610320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17462997	hybrid			2022-12-25	WOS:000247650600071
J	Zou, GZ; de Leeuw, E; Li, C; Pazgier, M; Li, CQ; Zeng, PY; Lu, WY; Lubkowski, J; Lu, WY				Zou, Guozhang; de Leeuw, Erik; Li, Chong; Pazgier, Marzena; Li, Changqing; Zeng, Pengyun; Lu, Wei-Yue; Lubkowski, Jacek; Lu, Wuyuan			Toward understanding the cationicity of defensins - Arg and Lys versus their noncoded analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-DEFENSINS; HUMAN BETA-DEFENSINS; ANTIMICROBIAL PEPTIDES; HUMAN BETA-DEFENSIN-3; HOST-DEFENSE; AMINO-ACIDS; ANTIBACTERIAL ACTIVITY; MAMMALIAN DEFENSINS; HUMAN-NEUTROPHILS; MESSENGER-RNA	Human defensins are a family of small antimicrobial proteins found predominantly in leukocytes and epithelial cells that play important roles in the innate and adaptive immune defense against microbial infection. The most distinct molecular feature of defensins is cationicity, manifested by abundant Arg and/or Lys residues in their sequences. Sequence analysis indicates that Arg is strongly selected over Lys in alpha-defensins but not in alpha-defensins. To understand this Arg/Lys disparity in defensins, we chemically synthesized human alpha-defensin 1 (HNP1) and several HNP1 analogs where three Arg residues were replaced by each of the following six alpha-amino acids: Lys, ornithine (Orn), diaminobutyric acid ( Dab), diaminopropionic acid (Dap), N, N-dimethyl-Lys ((diMe)Lys), and homo-Arg ((homo)Arg). In addition, we prepared human alpha-defensin 1 (hBD1) and (Lys3 -> Arg)hBD1 in which all four Lys residues were substituted for Arg. Bactericidal activity assays revealed the following. 1) Arg-containing HNP1 and (Lys3 -> Arg)hBD1 are functionally better than Lys-HNP1 and hBD1, respectively; the difference between Arg and Lys is more evident in the alpha-defensin than in the beta-defensin and is more evident at low salt concentrations than at high salt concentrations. 2) For HNP1, the Arg/Lys disparity is much more pronounced with Staphylococcus aureus than with Escherichia coli, and the Arg-rich HNP1 kills bacteria faster than its Lys-rich analog. 3) Arg and Lys appear to have optimal chain lengths for bacterial killing as shortening Lys or lengthening Arg in HNP1 invariably becomes functionally deleterious. Our findings provide insights into the Arg/Lys disparity in defensins, and shed light on the cationicity of defensins with respect to their antimicrobial activity and specificity.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; Fudan Univ, Sch Pharm, Fudan PharmCo Drug Target Res Ctr, Shanghai 200032, Peoples R China; NIH, NCI, Macromol Assembly Struct & Cell Signaling Sect, Frederick, MD 21702 USA	University System of Maryland; University of Maryland Baltimore; Fudan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lubkowski, J (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.	jacek@ncifcrf.gov; luw@umbi.umd.edu	Li, Chong/H-2515-2011; Lu, Wuyuan/J-8452-2017; Lu, Weiyue/E-7938-2010; Pazgier, Marzena/B-7295-2012; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; 	NATIONAL CANCER INSTITUTE [Z01SC010386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061482, R21AI056264] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI056264, AI061482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abiko Y, 2003, J DERMATOL SCI, V31, P225, DOI 10.1016/S0923-1811(03)00007-0; Alberts B., 1994, MOL BIOL CELL; Bateman A, 1996, J BIOL CHEM, V271, P10654, DOI 10.1074/jbc.271.18.10654; Baud F, 1999, P NATL ACAD SCI USA, V96, P12494, DOI 10.1073/pnas.96.22.12494; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Berezovsky IN, 2005, PLOS COMPUT BIOL, V1, P322, DOI 10.1371/journal.pcbi.0010047; Brock T.P., 1991, BIOL MICROORGANISMS, V340; Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.3.CO;2-B; Donald CD, 2003, LAB INVEST, V83, P501, DOI 10.1097/01.LAB.0000063929.61760.F6; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Ericksen B, 2005, ANTIMICROB AGENTS CH, V49, P269, DOI 10.1128/AAC.49.1.269-275.2005; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GILIS D, 2001, GENOME BIOL, V2; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; JUKES TH, 1975, SCIENCE, V189, P50, DOI 10.1126/science.237322; JUKES TH, 1974, BIOCHEM BIOPH RES CO, V58, P80, DOI 10.1016/0006-291X(74)90893-6; Karplus PA, 1997, PROTEIN SCI, V6, P1302; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Muhle SA, 2001, BIOCHEMISTRY-US, V40, P5777, DOI 10.1021/bi0100384; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Niyonsaba F, 2005, J IMMUNOL, V175, P1776, DOI 10.4049/jimmunol.175.3.1776; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pazgier M, 2006, CELL MOL LIFE SCI, V63, P1294, DOI 10.1007/s00018-005-5540-2; Pazgier M, 2007, J BIOL CHEM, V282, P1819, DOI 10.1074/jbc.M607210200; Raj PA, 2000, BIOCHEM J, V347, P633, DOI 10.1042/0264-6021:3470633; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; Szyk A, 2006, PROTEIN SCI, V15, P2749, DOI 10.1110/ps.062336606; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Tokunaga Y, 2001, J PEPT SCI, V7, P297, DOI 10.1002/psc.317; Varoga D, 2005, ARTHRITIS RHEUM-US, V52, P1736, DOI 10.1002/art.21090; WALLIS M, 1974, BIOCHEM BIOPH RES CO, V56, P711, DOI 10.1016/0006-291X(74)90663-9; WALSH CT, 2005, POSTTRANSLATIONAL MO, P121; WHITE SH, 1992, J MOL BIOL, V227, P991, DOI 10.1016/0022-2836(92)90515-L; WILDE CG, 1989, J BIOL CHEM, V264, P11200; Wu ER, 1998, PEPTIDES, V19, P793, DOI 10.1016/S0196-9781(98)00016-3; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Wu Z, 2004, J PEPT RES, V64, P118, DOI 10.1111/j.1399-3011.2004.00179.x; Wu Z, 2003, J PEPT RES, V62, P53, DOI 10.1034/j.1399-3011.2003.00068.x; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Wu ZB, 2005, J BIOL CHEM, V280, P43039, DOI 10.1074/jbc.M510562200; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Xie C, 2005, PEPTIDES, V26, P2377, DOI 10.1016/j.peptides.2005.06.002; Xie C, 2005, J BIOL CHEM, V280, P32921, DOI 10.1074/jbc.M503084200; Yang D, 2004, ARTHRITIS RHEUM, V50, P3401, DOI 10.1002/art.20604; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yang ST, 2003, FEBS LETT, V540, P229, DOI 10.1016/S0014-5793(03)00266-7; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200; Zhou CX, 2004, NAT CELL BIOL, V6, P458, DOI 10.1038/ncb1127	75	113	117	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19653	19665		10.1074/jbc.M611003200	http://dx.doi.org/10.1074/jbc.M611003200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17452329	hybrid			2022-12-25	WOS:000247650600040
J	Poulaki, V; Iliaki, E; Mitsiades, N; Mitsiades, CS; Paulus, YN; Bula, DV; Gragoudas, ES; Miller, JW				Poulaki, Vassiliki; Iliaki, Eirini; Mitsiades, Nicholas; Mitsiades, Constantine S.; Paulus, Yiannis N.; Bula, Deisy V.; Gragoudas, Evangelos S.; Miller, Joan W.			Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis	FASEB JOURNAL			English	Article						lipopolysaccharide; EIU; inflammatory eye disease	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; ALPHA MESSENGER-RNA; HEAT-SHOCK PROTEINS; NF-KAPPA-B; DIABETIC-RETINOPATHY; GENE-EXPRESSION; IN-VIVO	Heat shock protein (Hsp) 90 inhibitors, such as 17-allylamino-17-demethoxy-geldanamycin (17AAG), constitute promising novel therapeutic agents. We investigated the anti-inflammatory activity of 17AAG in endotoxin-induced uveitis (EIU) in rats. After the induction of EIU with a footpad injection of lipopolysaccharide (LPS), female Lewis rats received a single intraperitoneal. (i.p.) injection of 17-AAG or vehicle. Twenty-four hours later, the retinas were extracted and assayed for leukocyte adhesion; blood-retinal barrier breakdown; VEGF, TNF-alpha, IL-1 beta, and CD14 protein levels; NF-kappa B and HIF-1 alpha activity; hsp90 and 70 levels and expression and phosphorylation of the tight junction proteins ZO-1 and occludin. 17-AAG treatment significantly suppressed the LPS-induced increase in retinal leukocyte adhesion; vascular leakage; NF-kappa B, HIF-1 alpha, p38, and PI-3K activity; and VEGF, TNF-alpha, and IL-1 beta levels. 17-AAG also suppressed phosphorylation of ZO-1 and occludin by inhibiting their association with p38 and PI-3K. Although 17-AAG treatment did not reduce the LPS-induced increase in total CD14 levels in leukocytes, it significantly decreased membrane CD14 levels. These data suggest that Hsp90 inhibition suppresses several cardinal manifestations of endotoxin-induced uveitis in the rat. 17-AAG has demonstrated a favorable safety profile in clinical trials in cancer patients and represents a promising therapeutic agent for the treatment of inflammatory eye diseases.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Angiogenesis Laser Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Miller, JW (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Angiogenesis Laser Lab, 243 Charles St, Boston, MA 02114 USA.	jwmiller@meei.harvard.edu		Paulus, Yannis/0000-0002-0615-628X; Miller, Joan/0000-0003-2046-3996				Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Brito BE, 1999, INVEST OPHTH VIS SCI, V40, P2583; Bucci M, 2000, BRIT J PHARMACOL, V131, P13, DOI 10.1038/sj.bjp.0703549; Chavany C, 1996, J BIOL CHEM, V271, P4974; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Conde AG, 1997, J MOL CELL CARDIOL, V29, P1927, DOI 10.1006/jmcc.1997.0431; COUSINS SW, 1984, EXP EYE RES, V39, P665, DOI 10.1016/0014-4835(84)90065-4; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799; HOEKZEMA R, 1991, INVEST OPHTH VIS SCI, V32, P88; Hollander AP, 2001, ARTHRITIS RHEUM-US, V44, P1540, DOI 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7; Joly GA, 1997, FEBS LETT, V403, P40, DOI 10.1016/S0014-5793(97)00004-5; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kaarniranta K, 2005, MOL BRAIN RES, V137, P126, DOI 10.1016/j.molbrainres.2005.02.027; KONARI K, 1995, EXP EYE RES, V61, P99, DOI 10.1016/S0014-4835(95)80063-8; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; Malhotra V, 2001, AM J RESP CELL MOL, V25, P92, DOI 10.1165/ajrcmb.25.1.4384; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Mo JS, 1998, EXP EYE RES, V66, P547, DOI 10.1006/exer.1997.0451; Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277; NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Rao JN, 2000, AM J PHYSIOL-CELL PH, V279, pC1034, DOI 10.1152/ajpcell.2000.279.4.C1034; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Russ PK, 1998, INVEST OPHTH VIS SCI, V39, P2479; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHLETTER J, 1995, INFECT IMMUN, V63, P2576, DOI 10.1128/IAI.63.7.2576-2580.1995; Spek CA, 2003, J CLIN IMMUNOL, V23, P132, DOI 10.1023/A:1022528912387; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Verbon A, 2001, J IMMUNOL, V166, P3599, DOI 10.4049/jimmunol.166.5.3599; Wax S, 2003, ARTHRITIS RHEUM, V48, P541, DOI 10.1002/art.10780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; Xiao NQ, 1999, J NEUROCHEM, V72, P95, DOI 10.1046/j.1471-4159.1999.0720095.x; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5	56	70	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2113	2123		10.1096/fj.06-7637com	http://dx.doi.org/10.1096/fj.06-7637com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17400913				2022-12-25	WOS:000247500300021
J	Zhu, W; Boachie-Adjei, O; Rawlins, BA; Frenkel, B; Boskey, AL; Ivashkiv, LB; Blobel, CP				Zhu, Wei; Boachie-Adjei, Oheneba; Rawlins, Bernard A.; Frenkel, Baruch; Boskey, Adele L.; Ivashkiv, Lionel B.; Blobel, Carl P.			A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELLS; OSTEOBLASTIC DIFFERENTIATION; STEM/PROGENITOR CELLS; CHEMOKINE RECEPTORS; CANCER METASTASIS; SDF-1 CXCL12; HIV-1 ENTRY; MARROW; CXCR4; EXPRESSION	Stromal-derived factor 1 (SDF-1) is a chemokine with important functions in development and postnatal tissue homeostasis. SDF-1 signaling via the G-protein-coupled receptor CXCR4 regulates the recruitment of stem and precursor cells to support tissue-specific repair or regeneration. In this study we examined the contribution of SDF-1 signaling to osteogenic differentiation of mesenchymal C2C12 cells induced by bone morphogenic protein 2 (BMP2). Blocking SDF-1 signaling before BMP2 stimulation by treatment with siRNA, antibodies against SDF-1 or CXCR4, or the G-protein-coupled receptor inhibitor pertussis toxin strongly suppressed BMP2 induction of osteogenic differentiation in C2C12 cells, as evidenced by an early decrease in the expression of the myogenesis inhibitor Id1, the osteogenic master regulators Runx2 and Osx, the osteoblast-associated transcription factors JunB, Plzf, Msx2, and Dlx5, and later of the bone marker proteins osteocalcin and alkaline phosphatase. Similarly, blocking SDF-1/CXCR4 signaling strongly inhibited BMP2-induced osteogenic differentiation of ST2 bone marrow stromal cells. Moreover, we found that the interaction between SDF- 1 and BMP2 signaling was mediated via intracellular Smads and MAPK activation. Our data provide the first evidence for a co-requirement of the SDF-1/CXCR4 signaling axis in BMP2-induced osteogenic differentiation of C2C12 and ST2 cells and, thus, uncover a new potential target for modulation of osteogenesis.	Hosp Special Surg, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA; Hosp Special Surg, Dept Orthopaed Surg, Spinal Deform Serv, New York, NY 10021 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Hosp Special Surg, Musculoskeletal Integrit Program, New York, NY 10021 USA	University of Southern California	Zhu, W (corresponding author), Hosp Special Surg, Arthrit & Tissue Degenerat Program, Caspary Res Bldg,4th Floor,535 E 70th St, New York, NY 10021 USA.	ZhuW@HSS.EDU		Boskey, Adele/0000-0002-6181-2219				Ahn SE, 2006, BIOCHEM BIOPH RES CO, V340, P403, DOI 10.1016/j.bbrc.2005.12.020; Aiuti A, 1999, EUR J IMMUNOL, V29, P1823, DOI 10.1002/(SICI)1521-4141(199906)29:06<1823::AID-IMMU1823>3.0.CO;2-B; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cei S, 2006, J PERIODONTOL, V77, P699, DOI 10.1902/jop.2006.050155; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chen D, 2004, FRONT BIOSCI-LANDMRK, V9, P349, DOI 10.2741/1090; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Doitsidou M, 2002, CELL, V111, P647, DOI 10.1016/S0092-8674(02)01135-2; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5; Gu K, 2004, CELLS TISSUES ORGANS, V176, P28, DOI 10.1159/000075025; Gundberg CM, 2000, CLIN LAB MED, V20, P489; Hatch Heather M., 2002, Cloning and Stem Cells, V4, P339, DOI 10.1089/153623002321025014; Hatse S, 2005, BIOCHEM PHARMACOL, V70, P752, DOI 10.1016/j.bcp.2005.05.035; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Knippenberg M, 2006, BIOCHEM BIOPH RES CO, V342, P902, DOI 10.1016/j.bbrc.2006.02.052; Koike M, 2005, J BONE MINER METAB, V23, P219, DOI 10.1007/s00774-004-0587-y; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025; Kumar RB, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-25; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Papayannopoulou T, 2003, BLOOD, V101, P4739, DOI 10.1182/blood-2002-09-2741; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Sowa H, 2004, J BIOL CHEM, V279, P40267, DOI 10.1074/jbc.M401312200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; Taichman RS, 2002, CANCER RES, V62, P1832; Takagi M, 2004, J MOL HISTOL, V35, P81; Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yanai T, 2001, J BONE MINER METAB, V19, P345, DOI 10.1007/s007740170003; Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315; Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404; Zachos TA, 2006, J ORTHOP RES, V24, P1279, DOI 10.1002/jor.20068; Zhang L, 2005, J BIOL CHEM, V280, P37289, DOI 10.1074/jbc.M504260200; Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821; Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	67	87	93	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18676	18685		10.1074/jbc.M610232200	http://dx.doi.org/10.1074/jbc.M610232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17439946	hybrid			2022-12-25	WOS:000247475300005
J	Minami, Y; Ikeda, W; Kajita, M; Fujito, T; Amano, H; Tamaru, Y; Kuramitsu, K; Sakamoto, Y; Monden, M; Takai, Y				Minami, Yukiko; Ikeda, Wataru; Kajita, Mihoko; Fujito, Tsutomu; Amano, Hisayuki; Tamaru, Yoshiyuki; Kuramitsu, Kaori; Sakamoto, Yasuhisa; Monden, Morito; Takai, Yoshimi			Necl-5/poliovirus receptor interacts in cis with integrin alpha(v)beta(3) and regulates its clustering and focal complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES CELL-MIGRATION; SMALL G-PROTEINS; MALIGNANT GLIOMA; GROWTH-FACTOR; ADHESION; ACTIVATION; EXPRESSION; POLIOVIRUS; GENE; RAC	Integrin alpha(v)beta(3), which forms focal complexes at leading edges in moving cells, is up-regulated in cancer cells and so is implicated in their invasiveness. Necl-5, originally identified as a poliovirus receptor and also up-regulated in cancer cells, colocalizes with integrin alpha(v)beta(3) at leading edges in moving cells and enhances growth factor- induced cell movement. Here, we show that Necl-5 interacts directly, in cis, with integrin alpha(v)beta(3), and enhances integrin alpha(v)beta(3) clustering and focal complex formation at leading edges in NIH3T3 cells. The extracellular region of Necl-5, but not the cytoplasmic region, is necessary for its interaction with integrin alpha(v)beta(3); however, both regions are necessary for its action. An interaction between integrin alpha(v)beta(3) and vitronectin and PDGF-induced activation of Rac are also necessary for integrin alpha(v)beta(3) clustering. The interaction between Necl-5 and integrin alpha(v)beta(3) enhances PDGF-induced Rac activation, facilitating integrin alpha(v)beta(3) clustering presumably in a feedback amplification manner. Thus, Necl-5 has a critical role in integrin alpha(v)beta(3) clustering and focal complex formation.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Med, Dept Surg Clin Oncol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019; Amano, Hisayuki/AAE-6221-2022	Ikeda, Wataru/0000-0002-6907-9058; Sakamoto, Yasuhisa/0000-0003-1833-6197				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Chatterjee S, 2000, J NEURO-ONCOL, V46, P135, DOI 10.1023/A:1006444300504; CHIANG HS, 1994, BBA-MOL CELL RES, V1224, P506, DOI 10.1016/0167-4889(94)90288-7; Cram EJ, 2004, TRENDS CELL BIOL, V14, P55, DOI 10.1016/j.tcb.2003.12.009; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dogic D, 1998, J CELL SCI, V111, P793; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirota T, 2005, ONCOGENE, V24, P2229, DOI 10.1038/sj.onc.1208409; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Tran H, 2002, J CELL SCI, V115, P2031; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Woodard AS, 1998, J CELL SCI, V111, P469; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zamir E, 2001, J CELL SCI, V114, P3577	38	43	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18481	18496		10.1074/jbc.M611330200	http://dx.doi.org/10.1074/jbc.M611330200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17446174	hybrid			2022-12-25	WOS:000247302000054
J	Song, SH; Ozturk, N; Denaro, TR; Arat, NO; Kao, YT; Zhu, H; Zhong, D; Reppert, SM; Sancar, A				Song, Sang-Hun; Ozturk, Nuri; Denaro, Tracy R.; Arat, N. Ozlem; Kao, Ya-Ting; Zhu, Haisun; Zhong, Dongping; Reppert, Steven M.; Sancar, Aziz			Formation and function of flavin anion radical in cryptochrome 1 blue-light photoreceptor of monarch butterfly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PHOTOLYASE; ARABIDOPSIS CRYPTOCHROME-1; IN-VIVO; DROSOPHILA CRYPTOCHROME; SIGNAL-TRANSDUCTION; ELECTRON-TRANSFER; ACTION SPECTRUM; THALIANA; VITRO; GENE	The monarch butterfly ( Danaus plexippus) cryptochrome 1 ( DpCry1) belongs in the class of photosensitive insect cryptochromes. Here we purified DpCry1 expressed in a bacterial host and obtained the protein with a stoichiometric amount of the flavin cofactor in the two-electron oxidized, FAD(ox), form. Exposure of the purified protein to light converts the FAD(ox) to the FAD. flavin anion radical by intraprotein electron transfer from a Trp residue in the apoenzyme. To test whether this novel photoreduction reaction is part of the DpCry1 physiological photocycle, we mutated the Trp residue that acts as the ultimate electron donor in flavin photoreduction. The mutation, W328F, blocked the photoreduction entirely but had no measurable effect on the light-induced degradation of DpCry1 in vivo. In light of this finding and the recently published action spectrum of this class of Crys, we conclude that DpCry1 and similar insect cryptochromes do not contain flavin in the FAD(ox) form in vivo and that, most likely, the FAD(ox) ->(hv) FAD(center dot-) photoreduction reaction is not part of the insect cryptochrome photoreaction that results in proteolytic degradation of the photopigment.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Ohio State Univ, Dept Phys, Columbus, OH 43210 USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01650 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Massachusetts System; University of Massachusetts Worcester	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	Aziz_Sancar@med.unc.edu	Kao, Ya-Ting/AFR-9847-2022; Ozturk, Nuri/F-4140-2011; Zhong, Dongping/I-2444-2013	Kao, Ya-Ting/0000-0002-9245-6560; Ozturk, Nuri/0000-0001-5206-4127; Zhong, Dongping/0000-0001-9381-8992; Song, Sang-Hun/0000-0002-9609-3269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031082, R37GM031082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047141] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31082] Funding Source: Medline; NINDS NIH HHS [NS047141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Berndt A, 2007, J BIOL CHEM, V282, P13011, DOI 10.1074/jbc.M608872200; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; CHOONG YS, 1980, J BIOL CHEM, V255, P8672; DENARO TR, 2006, THESIS U N CAROLINA; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kavakli IH, 2004, BIOCHEMISTRY-US, V43, P15103, DOI 10.1021/bi0478796; Kottke T, 2006, BIOCHEMISTRY-US, V45, P2472, DOI 10.1021/bi051964b; LI YF, 1991, BIOCHEMISTRY-US, V30, P6322, DOI 10.1021/bi00239a034; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Ozgur S, 2006, BIOCHEMISTRY-US, V45, P13369, DOI 10.1021/bi061556n; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Partch CL, 2005, PHOTOCHEM PHOTOBIOL, V81, P1291, DOI 10.1562/2005-07-08-IR-607; Partch CL, 2005, BIOCHEMISTRY-US, V44, P3795, DOI 10.1021/bi047545g; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; vanVickle-Chavez SJ, 2007, J BIOL CHEM, V282, P10561, DOI 10.1074/jbc.M609314200; Yuan Q, 2007, MOL BIOL EVOL, V24, P948, DOI 10.1093/molbev/msm011; Zeugner A, 2005, J BIOL CHEM, V280, P19437, DOI 10.1074/jbc.C500077200; ZHONG D, 2007, CURR OPIN CHEM BIOL, V16, P722; Zhu HS, 2005, CURR BIOL, V15, pR953, DOI 10.1016/j.cub.2005.11.030	29	81	84	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17608	17612		10.1074/jbc.M702874200	http://dx.doi.org/10.1074/jbc.M702874200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17459876	Green Published, hybrid			2022-12-25	WOS:000247084500032
J	Costanzo, G; Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E				Costanzo, Giovanna; Saladino, Raffaele; Crestini, Claudia; Ciciriello, Fabiana; Di Mauro, Ernesto			Nucleoside phosphorylation by phosphate minerals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREBIOTIC SYNTHESIS; DIFFERENTIAL STABILITY; INFORMATIONAL POLYMERS; NUCLEIC-ACIDS; FORMAMIDE; ORIGIN; HYDROLYSIS; RNA; MONTMORILLONITE; KINETICS	In the presence of formamide, crystal phosphate minerals may act as phosphate donors to nucleosides, yielding both 5 '-and, to a lesser extent, 3 '-phosphorylated forms. With the mineral Libethenite the formation of 5 '-AMP can be as high as 6% of the adenosine input and last for at least 10(3) h. At high concentrations, soluble non-mineral phosphate donors (KH2PO4 or 5 '-CMP) afford 2 '- and 2 ': 3 '-cyclic AMP in addition to 5 '-and 3 '-AMP. The phosphate minerals analyzed were Herderite Ca[BePO4F], Hureaulite Mn2+ (5)(PO3(OH)(2)(PO4)(2)(H2O)(4), Libethenite Cu2+ (2)(PO4)(OH), Pyromorphite Pb-5(PO4)(3)Cl, Turquoise Cu2+ Al-6(PO4)(4)(OH)(8)(H2O)(4), Fluorapatite Ca-5(PO4)(3)F, Hydroxylapatite Ca-5(PO4)(3)OH, Vivianite Fe2+ (3)(PO4)(2)(H2O)(8), Cornetite Cu2+ (3)(PO4)(OH)(3), Pseudomalachite Cu2+ (5)(PO4)(2)(OH)(4), Reichenbachite Cu2+ (5)(PO4)(2)(OH)(4), and Ludjibaite Cu2+ (5)(PO4)(2)(OH)(4)). Based on their behavior in the formamide-driven nucleoside phosphorylation reaction, these minerals can be characterized as: 1) inactive, 2) low level phosphorylating agents, or 3) active phosphorylating agents. Instances were detected (Libethenite and Hydroxylapatite) in which phosphorylation occurs on the mineral surface, followed by release of the phosphorylated compounds. Libethenite and Cornetite markedly protect the beta-glycosidic bond. Thus, activated nucleic monomers can form in a liquid non-aqueous environment in conditions compatible with the thermodynamics of polymerization, providing a solution to the standard-state Gibbs free energy change (Delta G(o,)) problem, the major obstacle for polymerizations in the liquid phase in plausible prebiotic scenarios.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00133 Rome, Italy; Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; Tuscia University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Mauro, E (corresponding author), Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	Ernesto.dimauro@uniroma1.it	Crestini, Claudia/O-6781-2015; Ciciriello, Fabiana/AAA-8065-2020	Crestini, Claudia/0000-0001-9903-2675; Ciciriello, Fabiana/0000-0003-1493-9767				ACEVEDO OL, 1986, NATURE, V321, P790, DOI 10.1038/321790a0; Akhter MS, 2003, COLLOID SURFACE A, V219, P281, DOI 10.1016/S0927-7757(03)00055-4; ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; Bean HD, 2006, ORIGINS LIFE EVOL B, V36, P39, DOI 10.1007/s11084-005-2082-4; BECK A, 1967, SCIENCE, V157, P952, DOI 10.1126/science.157.3791.952; Benner SA, 2005, NAT REV GENET, V6, P533, DOI 10.1038/nrg1637; BRESLOW R, 1990, J AM CHEM SOC, V112, P9621, DOI 10.1021/ja00182a022; CAIRNSSMITH AG, 1966, J THEOR BIOL, V10, P53, DOI 10.1016/0022-5193(66)90178-0; CAIRNSSMITH AG, 1992, ORIGINS LIFE EVOL B, V22, P161, DOI 10.1007/BF01808023; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CORCORAN R, 1985, ANAL BIOCHEM, V144, P563, DOI 10.1016/0003-2697(85)90154-X; DeGraaf RM, 1997, J MOL EVOL, V44, P237, DOI 10.1007/PL00006140; Ertem G, 1998, ORIGINS LIFE EVOL B, V28, P485, DOI 10.1023/A:1006510228943; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; Franchi M, 2003, ORIGINS LIFE EVOL B, V33, P1, DOI 10.1023/A:1023982008714; GERLT JA, 1975, J BIOL CHEM, V250, P5059; Grenha R, 2005, ACTA CRYSTALLOGR F, V61, P459, DOI 10.1107/S174430910501095X; Hartman H, 1998, ORIGINS LIFE EVOL B, V28, P515, DOI 10.1023/A:1006548904157; Hazen RM, 2001, SCI AM, V284, P76, DOI 10.1038/scientificamerican0401-76; Huminicki DMC, 2002, REV MINERAL GEOCHEM, V48, P123, DOI 10.2138/rmg.2002.48.5; JARVINEN P, 1991, J ORG CHEM, V56, P5396, DOI 10.1021/jo00018a037; JONES NR, 1960, ANALYST, V85, P810, DOI 10.1039/an9608500810; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; LOHRMANN R, 1968, SCIENCE, V161, P64, DOI 10.1126/science.161.3836.64; LOHRMANN R, 1971, SCIENCE, V171, P490, DOI 10.1126/science.171.3970.490; Millar TJ, 2004, ASTROPHYS SPACE SC L, V305, P17; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; OIVANEN M, 1991, J ORG CHEM, V56, P3623, DOI 10.1021/jo00011a032; PITHA J, 1970, BIOCHIM BIOPHYS ACTA, V204, P39, DOI 10.1016/0005-2787(70)90488-0; Reimann R, 1999, ORIGINS LIFE EVOL B, V29, P229, DOI 10.1023/A:1006580009791; Saladino R, 2006, J BIOL CHEM, V281, P5790, DOI 10.1074/jbc.M512545200; Saladino R, 2005, J BIOL CHEM, V280, P35658, DOI 10.1074/jbc.M504537200; Saladino R, 2005, CHEMBIOCHEM, V6, P1368, DOI 10.1002/cbic.200500035; Saladino R, 2004, CHEMBIOCHEM, V5, P1558, DOI 10.1002/cbic.200400119; Saladino R, 2003, CHEMBIOCHEM, V4, P514, DOI 10.1002/cbic.200300567; Saladino R, 2001, BIOORGAN MED CHEM, V9, P1249, DOI 10.1016/S0968-0896(00)00340-0; Saladino R, 2006, CHEMBIOCHEM, V7, P1707, DOI 10.1002/cbic.200600139; SCHELLERKRATTIGER V, 1986, INORG CHEM, V25, P2628, DOI 10.1021/ic00235a028; SCHNEIDER KC, 1990, J AM CHEM SOC, V112, P453, DOI 10.1021/ja00157a073; SCHOFFSTALL AM, 1988, ORIGINS LIFE EVOL B, V18, P389, DOI 10.1007/BF01808217; SCHOFFSTALL AM, 1976, ORIGINS LIFE EVOL B, V7, P399, DOI 10.1007/BF00927935; SCHOFFSTALL AM, 1985, ORIGINS LIFE EVOL B, V15, P141, DOI 10.1007/BF01809496; SCHOFFSTALL AM, 1982, ORIGINS LIFE EVOL B, V12, P143, DOI 10.1007/BF00927141; Schwartz AW, 1997, ORIGINS LIFE EVOL B, V27, P505, DOI 10.1023/A:1006536817887; Shapiro R, 1999, P NATL ACAD SCI USA, V96, P4396, DOI 10.1073/pnas.96.8.4396; Shirota H, 2004, LANGMUIR, V20, P329, DOI 10.1021/la030161r; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; USHER DA, 1976, SCIENCE, V192, P53, DOI 10.1126/science.1257755; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; VANHOLDE K, 1980, ORIGINS LIFE EVOL B, P31; WESTHEIMER FH, 1968, ACCOUNTS CHEM RES, V1, P70, DOI 10.1021/ar50003a002; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WINTER D, 1995, ORIGINS LIFE EVOL B, V25, P61, DOI 10.1007/BF01581574; YAMAGATA Y, 1991, NATURE, V352, P516, DOI 10.1038/352516a0; Zubay G, 2001, ORIGINS LIFE EVOL B, V31, P87, DOI 10.1023/A:1006722423070	55	90	95	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16729	16735		10.1074/jbc.M611346200	http://dx.doi.org/10.1074/jbc.M611346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412692	Green Published, hybrid			2022-12-25	WOS:000246946500004
J	Saikia, S; Parker, EJ; Koulman, A; Scott, B				Saikia, Sanjay; Parker, Emily J.; Koulman, Albert; Scott, Barry			Defining paxilline biosynthesis in Penicillium paxilli - Functional characterization of two cytochrome p450 monooxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIBBERELLA-FUJIKUROI ENCODES; DITERPENE GENE-CLUSTER; INDOLE-DITERPENE; MOLECULAR-CLONING; TRANSFORMATION; REGULATOR; PASPALINE; ENDOPHYTE; PRODUCTS; OXIDASE	Indole diterpenes are a large, structurally and functionally diverse group of secondary metabolites produced by filamentous fungi. Biosynthetic schemes have been proposed for these metabolites but until recently none of the proposed steps had been validated by biochemical or genetic studies. Using Penicillium paxilli as a model experimental system to study indole diterpene biosynthesis we previously showed by deletion analysis that a cluster of seven genes is required for paxilline biosynthesis. Two of these pax genes, paxP and paxQ (encoding cytochrome P450 monooxygenases), are required in the later steps in this pathway. Here, we describe the function of paxP and paxQ gene products by feeding proposed paxilline intermediates to strains lacking the pax cluster but containing ectopically integrated copies of paxP or paxQ. Transformants containing paxP converted paspaline into 13-desoxypaxilline as the major product and beta-PC-M6 as the minor product. beta-PC-M6, but not alpha-PC-M6, was also a substrate for PaxP and was converted to 13-desoxypaxilline. paxQ-containing transformants converted 13-desoxypaxilline into paxilline. These results confirm that paspaline, beta-PC-M6, and 13-desoxypaxilline are paxilline intermediates and that paspaline and beta-PC-M6 are substrates for PaxP, and 13-desoxypaxilline is a substrate for PaxQ. PaxP and PaxQ also utilized beta-paxitriol and beta-PC-M6 as substrates converting them to paxilline and alpha-paxitriol, respectively. These findings have allowed us to delineate clearly the biosynthetic pathway for paxilline for the first time.	Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand; AgResearch, Grassland Res Ctr, Palmerston North, New Zealand	Massey University; Massey University; AgResearch - New Zealand	Scott, B (corresponding author), Massey Univ, Inst Mol Biosci, Private Bag 11222, Palmerston North, New Zealand.	d.b.scott@massey.ac.nz	Scott, David/J-3135-2013; Koulman, Albert/B-2967-2009	Koulman, Albert/0000-0001-9998-051X; Parker, Emily/0000-0002-9571-9987				ACKLIN W, 1977, CHIMIA, V31, P63; Bok JW, 2006, CHEM BIOL, V13, P31, DOI 10.1016/j.chembiol.2005.10.008; Bok JW, 2005, EUKARYOT CELL, V4, P1574, DOI 10.1128/EC.4.9.1574-1582.2005; Bok JW, 2004, EUKARYOT CELL, V3, P527, DOI 10.1128/EC.3.2.527-535.2004; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Byrne KM, 2002, J AM CHEM SOC, V124, P7055, DOI 10.1021/ja017183p; Chiou CH, 2002, APPL ENVIRON MICROB, V68, P306, DOI 10.1128/AEM.68.1.306-315.2002; DE JESUS AE, 1983, J CHEM SOC PERK T 1, P1863, DOI 10.1039/p19830001863; FISCHER RT, 1989, J LIPID RES, V30, P1621; Gatenby WA, 1999, J AGR FOOD CHEM, V47, P1092, DOI 10.1021/jf980767z; GLOER JB, 1995, ACCOUNTS CHEM RES, V28, P343, DOI 10.1021/ar00056a004; ITOH Y, 1994, CURR GENET, V25, P508, DOI 10.1007/BF00351670; Kawaide H, 2006, BIOSCI BIOTECH BIOCH, V70, P583, DOI 10.1271/bbb.70.583; Lamb DC, 1999, FEBS LETT, V462, P283, DOI 10.1016/S0014-5793(99)01548-3; LAWS I, 1989, J GEN MICROBIOL, V135, P2679; Malonek S, 2005, APPL ENVIRON MICROB, V71, P1462, DOI 10.1128/AEM.71.3.1462-1472.2005; MANTLE PG, 1994, PHYTOCHEMISTRY, V36, P1209, DOI 10.1016/S0031-9422(00)89639-9; McMillan LK, 2003, MOL GENET GENOMICS, V270, P9, DOI 10.1007/s00438-003-0887-2; Mihlan M, 2003, MOL MICROBIOL, V47, P975, DOI 10.1046/j.1365-2958.2003.03326.x; MILES CO, 1992, J AGR FOOD CHEM, V40, P234, DOI 10.1021/jf00014a013; MundayFinch SC, 1996, PHYTOCHEMISTRY, V41, P327, DOI 10.1016/0031-9422(95)00515-3; Namiki F, 2001, MOL PLANT MICROBE IN, V14, P580, DOI 10.1094/MPMI.2001.14.4.580; Parker EJ, 2005, MYCOLOGY S, V22, P405; PENN J, 1994, PHYTOCHEMISTRY, V35, P921, DOI 10.1016/S0031-9422(00)90639-3; Ro DK, 2005, P NATL ACAD SCI USA, V102, P8060, DOI 10.1073/pnas.0500825102; Rojas MC, 2001, P NATL ACAD SCI USA, V98, P5838, DOI 10.1073/pnas.091096298; Saikia S, 2006, FEBS LETT, V580, P1625, DOI 10.1016/j.febslet.2006.02.008; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT B, 2004, ADV FUNGAL BIOTECHNO, P163; Steyn P S, 1985, Fortschr Chem Org Naturst, V48, P1; SUZUKI K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P215, DOI 10.1016/0167-4838(93)90086-7; Tudzynski B, 2005, APPL MICROBIOL BIOT, V66, P597, DOI 10.1007/s00253-004-1805-1; Tudzynski B, 1999, MOL GEN GENET, V261, P106, DOI 10.1007/s004380050950; Tudzynski B, 2001, APPL ENVIRON MICROB, V67, P3514, DOI 10.1128/AEM.67.8.3514-3522.2001; Yoder OC, 1988, ADV PLANT PATHOL, P93, DOI 10.1016/B978-0-12-033706-4.50009-8; Young C, 1998, CURR GENET, V33, P368, DOI 10.1007/s002940050349; Young C, 2001, MOL MICROBIOL, V39, P754, DOI 10.1046/j.1365-2958.2001.02265.x; Young CA, 2005, MOL GENET GENOMICS, V274, P13, DOI 10.1007/s00438-005-1130-0; Young CA, 2006, FUNGAL GENET BIOL, V43, P679, DOI 10.1016/j.fgb.2006.04.004; Zhang S, 2004, APPL ENVIRON MICROB, V70, P6875, DOI 10.1128/AEM.70.11.6875-6883.2004	40	45	48	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16829	16837		10.1074/jbc.M701626200	http://dx.doi.org/10.1074/jbc.M701626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428785	hybrid			2022-12-25	WOS:000246946500015
J	DeFord-Watts, LM; Young, JA; Pitcher, LA; van Oers, NSC				DeFord-Watts, Laura M.; Young, Jennifer A.; Pitcher, Lisa A.; van Oers, Nicolai S. C.			The membrane-proximal portion of CD3 is an element of associates with the serine/threonine kinase GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; TCR-ZETA SUBUNIT; ANTIGEN RECEPTOR; TYROSINE KINASES; PROTEIN-KINASE; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; ACTIVATION; CD3-EPSILON; PHOSPHORYLATION	The activation of protein kinases is one of the primary mechanisms whereby T cell receptors (TCR) propagate intracellular signals. To date, the majority of kinases known to be involved in the early stages of TCR signaling are protein-tyrosine kinases such as Lck, Fyn, and ZAP-70. Here we report a constitutive association between the TCR and a serine/threonine kinase, which was mediated through the membrane-proximal portion of CD3 epsilon. Mass spectrometry analysis of CD3 epsilon-associated proteins identified G protein-coupled receptor kinase 2 (GRK2) as a candidate Ser/Thr kinase. Transient transfection assays and Western blot analysis verified the ability of GRK2 to interact with the cytoplasmic domain of CD3 epsilon within a cell. These findings are consistent with recent reports demonstrating the ability of certain G protein-coupled receptors (GPCR) and G proteins to physically associate with the alpha/beta TCR. Because GRK2 is primarily involved in arresting GPCR signals, its interaction with CD3 epsilon may provide a novel means whereby the TCR can negatively regulate signals generated through GPCRs.	Univ Texas, Dept Immunol, Southwestern Med Ctr, Dallas, TX 75390 USA; Univ Texas, Dept Microbiol, Southwestern Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	van Oers, NSC (corresponding author), Univ Texas, Dept Immunol, Southwestern Med Ctr, Dallas, TX 75390 USA.	nicolai.vanoers@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021	van Oers, Nicolai/0000-0002-6545-8405	NIAID NIH HHS [5T32AI005284] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI005284] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Call ME, 2005, ANNU REV IMMUNOL, V23, P101, DOI 10.1146/annurev.immunol.23.021704.115625; Cen O, 2003, J BIOL CHEM, V278, P8837, DOI 10.1074/jbc.M208261200; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Gil D, 2001, J BIOL CHEM, V276, P11174, DOI 10.1074/jbc.M010114200; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Lysechko TL, 2005, J IMMUNOL, V174, P7807, DOI 10.4049/jimmunol.174.12.7807; Malissen B, 2003, IMMUNOL REV, V191, P7, DOI 10.1034/j.1600-065X.2003.00016.x; Minguet S, 2007, IMMUNITY, V26, P43, DOI 10.1016/j.immuni.2006.10.019; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Peacock JW, 1999, J IMMUNOL, V162, P215; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SHINKAI Y, 1995, IMMUNITY, V2, P401; Sommers CL, 2000, J EXP MED, V192, P913, DOI 10.1084/jem.192.6.913; SONG WH, 1995, NUCLEIC ACIDS RES, V23, P3609, DOI 10.1093/nar/23.17.3609; Stanners J, 1995, J BIOL CHEM, V270, P30635, DOI 10.1074/jbc.270.51.30635; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Szymczak AL, 2005, J IMMUNOL, V175, P270, DOI 10.4049/jimmunol.175.1.270; Theilade J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P139, DOI 10.2174/1568008013341352; Tong A, 2005, J BIOL CHEM, V280, P38297, DOI 10.1074/jbc.M508123200; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang BH, 1998, PLANTA MED, V64, P195, DOI 10.1055/s-2006-957407; Yamazaki T, 1999, J BIOL CHEM, V274, P18173, DOI 10.1074/jbc.274.26.18173	51	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16126	16134		10.1074/jbc.M609418200	http://dx.doi.org/10.1074/jbc.M609418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420248	hybrid			2022-12-25	WOS:000246794300021
J	Kroh, HK; Tans, G; Nicolaes, GAF; Rosing, J; Bock, PE				Kroh, Heather K.; Tans, Guido; Nicolaes, Gerry A. F.; Rosing, Jan; Bock, Paul E.			Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-V ACTIVATION; MACROMOLECULAR SUBSTRATE RECOGNITION; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; FACTOR-XA; ACTIVE-SITE; NA+ BINDING; FLUORESCENCE PROBES; CRYSTAL-STRUCTURE; SERINE PROTEASES	The specificity of thrombin for procoagulant and anticoagulant substrates is regulated allosterically by Na+. Ordered cleavage of prothrombin (ProT) at Arg(320) by the prothrombinase complex generates proteolytically active, meizothrombin (MzT), followed by cleavage at Arg(271) to produce thrombin and fragment 1.2. The alternative pathway of initial cleavage at Arg271 produces the inactive zymogen form, the prethrombin 2 (Pre 2).fragment 1.2 complex, which is cleaved subsequently at Arg320. Cleavage at Arg320 of ProT or prethrombin 1 ( Pre 1) activates the catalytic site and the precursor form of exosite I (proexosite I). To determine the pathway of expression of Na+ (pro) exosite I linkage during ProT activation, the effects of Na+ on the affinity of fluorescein-labeled hirudin-(54-65) ([5F] Hir-(54-65)(SO3-)) for the zymogens, ProT, Pre 1, and Pre 2, and for the proteinases, MzT and MzT-desfragment 1 ( MzT(-F1)) were quantitated. The zymogens showed no significant linkage between proexosite I and Na+, whereas cleavage at Arg320 caused the affinities of MzT and MzT(-F1) for [5F] Hir-(54-65)(SO3-) to be enhanced by Na+ 8- to 10-fold and 5- to 6-fold, respectively. MzT and MzT-(F1) showed kinetically different mechanisms of Na+ enhancement of chromogenic substrate hydrolysis. The results demonstrate for the first time that MzT is regulated allosterically by Na+. The results suggest that the distinctive procoagulant substrate specificity of MzT, in activating factor V and factor VIII on membranes, and the anticoagulant, membrane-modulated activation of protein C by MzT bound to thrombomodulin are regulated by Na+- induced allosteric transition. Further, the Na+ enhancement in MzT activity and exosite I affinity may function in directing the sequential ProT activation pathway by accelerating thrombin formation from the MzT fast form.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Maastricht, Dept Biochem, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands	Vanderbilt University; Maastricht University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Nicolaes, Gerry A.F./A-8421-2016	Nicolaes, Gerry A.F./0000-0002-2482-0412	NHLBI NIH HHS [R01 HL038779-21, HL 07751, R01 HL038779, HL038779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779, T32HL007751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Arocas V, 1998, THROMB HAEMOSTASIS, V79, P1157, DOI 10.1055/s-0037-1615033; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bode W, 2005, J THROMB HAEMOST, V3, P2379, DOI 10.1111/j.1538-7836.2005.01356.x; Bode W, 2006, BLOOD CELL MOL DIS, V36, P122, DOI 10.1016/j.bcmd.2005.12.027; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Bukys MA, 2006, J BIOL CHEM, V281, P18569, DOI 10.1074/jbc.M600752200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1982, J BIOL CHEM, V257, P7944; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Petrovan RJ, 1998, BIOCHEMISTRY-US, V37, P1185, DOI 10.1021/bi971948h; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel I.H., 1993, ENZYME KINETICS, P227; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	61	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16095	16104		10.1074/jbc.M610577200	http://dx.doi.org/10.1074/jbc.M610577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430903	Green Accepted, hybrid			2022-12-25	WOS:000246794300018
J	Viana, R; Towler, MC; Pan, DA; Carling, D; Viollet, B; Hardie, DG; Sanz, P				Viana, Rosa; Towler, Mhairi C.; Pan, David A.; Carling, David; Viollet, Benoit; Hardie, D. Grahame; Sanz, Pascual			A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSON-WHITE-SYNDROME; SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-HYPERTROPHY; IN-VITRO; MUTATIONS; DISEASE; GLUCOSE; GLYCOGEN; SYSTEM	Mammalian AMP-activated protein kinase is a serine/threonine protein kinase that acts as a sensor of cellular energy status. AMP-activated protein kinase is a heterotrimer of three different subunits, i.e. alpha, beta and gamma, with alpha being the catalytic subunit and beta and gamma having regulatory roles. Although several studies have defined different domains in alpha and beta involved in the interaction with the other subunits of the complex, little is known about the regions of the gamma subunits involved in these interactions. To study this, we have made sequential deletions from the N termini of the gamma subunit isoforms and studied the interactions with alpha and beta subunits, both by two-hybrid analysis and by co-immunoprecipitation. Our results suggest that a conserved region of 20-25 amino acids in gamma 1, gamma 2, and gamma 3, immediately N-terminal to the Bateman domains, is required for the formation of a functional, active alpha beta gamma complex. This region is required for the interaction with the beta subunits. The interaction between the beta and gamma subunits does not require this region and occurs instead within the Bateman domains of the gamma subunit, although the beta-gamma interaction does appear to stabilize the beta-gamma interaction. In addition, sequential deletions from the C termini of the gamma subunits indicate that deletion of any of the CBS (cystathionine beta-synthase) motifs prevents the formation of a functional complex with the alpha and beta subunits.	Consejo Super Invest Cientificas, Inst Biomed Valencia, Valencia 46010, Spain; Inst Salud Carlos 3, Ctr Invest Biomed Red Enfermedades Raras, Valencia 46010, Spain; Hammersmith Hosp, Imp Coll, Med Res Ctr, Clin Sci Ctr,Cellular Stress Grp, London W12 0NN, England; Univ Dundee, Coll Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Imperial College London; University of Dundee; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Sanz, P (corresponding author), Consejo Super Invest Cientificas, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Carling, David/F-1943-2014; Viana, Rosa/L-1922-2014; Sanz, Pascual/K-2751-2014; Viollet, Benoit/N-2397-2019; Hardie, David/Z-1979-2019; Viollet, Benoit/O-6927-2017	Carling, David/0000-0002-2316-1830; Viana, Rosa/0000-0002-0036-0669; Sanz, Pascual/0000-0002-2399-4103; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Hardie, Grahame/0000-0002-8373-7379	Medical Research Council [MC_U120027537] Funding Source: Medline; Wellcome Trust [080982] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahmad F, 2005, ANNU REV GENOM HUM G, V6, P185, DOI 10.1146/annurev.genom.6.080604.162132; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Burwinkel B, 2005, AM J HUM GENET, V76, P1034, DOI 10.1086/430840; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; GOLEMIS EA, 1997, CURRENT PROTOCOLS MO, P201; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Leech A, 2003, EUKARYOT CELL, V2, P265, DOI 10.1128/EC.2.2.265-273.2003; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Polekhina G, 2005, STRUCTURE, V13, P1453, DOI 10.1016/j.str.2005.07.008; Rose MD., 1990, METHODS YEAST GENETI; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Wojtaszewski JFP, 2005, J PHYSIOL-LONDON, V564, P563, DOI 10.1113/jphysiol.2005.082669; Wong KA, 2006, J BIOL CHEM, V281, P36434, DOI 10.1074/jbc.M607410200; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4	41	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16117	16125		10.1074/jbc.M611804200	http://dx.doi.org/10.1074/jbc.M611804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403675	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000246794300020
J	Fujii, N; Hihara, S; Iriki, A				Fujii, Naotaka; Hihara, Sayaka; Iriki, Atsushi			Dynamic Social Adaptation of Motion-Related Neurons in Primate Parietal Cortex	PLOS ONE			English	Article								Social brain function, which allows us to adapt our behavior to social context, is poorly understood at the single-cell level due largely to technical limitations. But the questions involved are vital: How do neurons recognize and modulate their activity in response to social context? To probe the mechanisms involved, we developed a novel recording technique, called multi-dimensional recording, and applied it simultaneously in the left parietal cortices of two monkeys while they shared a common social space. When the monkeys sat near each other but did not interact, each monkey's parietal activity showed robust response preference to action by his own right arm and almost no response to action by the other's arm. But the preference was broken if social conflict emerged between the monkeys-specifically, if both were able to reach for the same food item placed on the table between them. Under these circumstances, parietal neurons started to show complex combinatorial responses to motion of self and other. Parietal cortex adapted its response properties in the social context by discarding and recruiting different neural populations. Our results suggest that parietal neurons can recognize social events in the environment linked with current social context and form part of a larger social brain network.	[Fujii, Naotaka; Hihara, Sayaka; Iriki, Atsushi] RIKEN Brain Sci Inst, Lab Symbol Cognit Dev, Wako, Saitama, Japan	RIKEN	Fujii, N (corresponding author), RIKEN Brain Sci Inst, Lab Symbol Cognit Dev, Wako, Saitama, Japan.	na@brain.riken.jp			MEXT of Japan [17021048, 18047029]; President's Discretionary Fund	MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); President's Discretionary Fund	This research was supported by Grant-in-Aid for Scientific Research on Priority Areas Integrative Brain Research from the MEXT of Japan (17021048), Grant-in-Aid for Scientific Research on Priority Areas Mobiligence from the MEXT of Japan (18047029) and 2006 Riken Strategic Programs for R&D (President's Discretionary Fund).	Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Barraclough NE, 2005, J COGNITIVE NEUROSCI, V17, P377, DOI 10.1162/0898929053279586; Beer JS, 2006, BRAIN RES, V1079, P1, DOI 10.1016/j.brainres.2006.02.001; Chambers CD, 2004, NAT NEUROSCI, V7, P217, DOI 10.1038/nn1203; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; Culham JC, 2006, CURR OPIN NEUROBIOL, V16, P205, DOI 10.1016/j.conb.2006.03.005; Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; FUJII N, 2006, 2006 ABSTRACT VIEWER; FUJII N, 2005, 2005 ABSTRACT VIEWER; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Goel V, 2004, BRAIN, V127, P783, DOI 10.1093/brain/awh086; Hietanen JK, 1999, NEUROREPORT, V10, P3443, DOI 10.1097/00001756-199911080-00033; HIHARA S, 2006, NEUROPSYCHOLOGIA; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Iriki A, 1996, NEUROREPORT, V7, P2325; Iriki A, 2001, NEUROSCI RES, V40, P163, DOI 10.1016/S0168-0102(01)00225-5; Iriki A, 2006, CURR OPIN NEUROBIOL, V16, P660, DOI 10.1016/j.conb.2006.10.008; Iwamura Y, 1998, CURR OPIN NEUROBIOL, V8, P522, DOI 10.1016/S0959-4388(98)80041-X; IWAMURA Y, 1994, NATURE, V369, P554, DOI 10.1038/369554a0; Jackson PL, 2004, CURR OPIN NEUROBIOL, V14, P259, DOI 10.1016/j.conb.2004.01.020; Jellema T, 2006, NEUROPSYCHOLOGIA, V44, P1535, DOI 10.1016/j.neuropsychologia.2006.01.020; Lotze M, 2006, NEUROPSYCHOLOGIA, V44, P1787, DOI 10.1016/j.neuropsychologia.2006.03.016; Maravita A, 2004, TRENDS COGN SCI, V8, P79, DOI 10.1016/j.tics.2003.12.008; Matsumoto K, 2004, CURR OPIN NEUROBIOL, V14, P178, DOI 10.1016/j.conb.2004.03.005; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Muhammad R, 2006, J COGNITIVE NEUROSCI, V18, P974, DOI 10.1162/jocn.2006.18.6.974; Obayashi S, 2000, NEUROREPORT, V11, P3499, DOI 10.1097/00001756-200011090-00020; Pelphrey KA, 2004, J COGNITIVE NEUROSCI, V16, P1706, DOI 10.1162/0898929042947900; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Saxe R, 2006, CEREB CORTEX, V16, P178, DOI 10.1093/cercor/bhi095; Schutz-Bosbach S, 2006, CURR BIOL, V16, P1830, DOI 10.1016/j.cub.2006.07.048; Shomstein S, 2006, J NEUROSCI, V26, P435, DOI 10.1523/JNEUROSCI.4408-05.2006	35	55	56	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2007	2	4							e397	10.1371/journal.pone.0000397	http://dx.doi.org/10.1371/journal.pone.0000397			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DV	17460764	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445600011
J	Chen, F; Mackey, AJ; Vermunt, JK; Roos, DS				Chen, Feng; Mackey, Aaron J.; Vermunt, Jeroen K.; Roos, David S.			Assessing Performance of Orthology Detection Strategies Applied to Eukaryotic Genomes	PLOS ONE			English	Article							COG DATABASE; CLASSIFICATION; IDENTIFICATION; ALGORITHM; PARALOGS; INFERENCE; PROTEINS; ORTHOMCL; DOMAINS; BLAST	Orthology detection is critically important for accurate functional annotation, and has been widely used to facilitate studies on comparative and evolutionary genomics. Although various methods are now available, there has been no comprehensive analysis of performance, due to the lack of a genomic-scale 'gold standard' orthology dataset. Even in the absence of such datasets, the comparison of results from alternative methodologies contains useful information, as agreement enhances confidence and disagreement indicates possible errors. Latent Class Analysis (LCA) is a statistical technique that can exploit this information to reasonably infer sensitivities and specificities, and is applied here to evaluate the performance of various orthology detection methods on a eukaryotic dataset. Overall, we observe a trade-off between sensitivity and specificity in orthology detection, with BLAST-based methods characterized by high sensitivity, and tree-based methods by high specificity. Two algorithms exhibit the best overall balance, with both sensitivity and specificity>80%: INPARANOID identifies orthologs across two species while OrthoMCL clusters orthologs from multiple species. Among methods that permit clustering of ortholog groups spanning multiple genomes, the (automated) OrthoMCL algorithm exhibits better within-group consistency with respect to protein function and domain architecture than the (manually curated) KOG database, and the homolog clustering algorithm TribeMCL as well. By way of using LCA, we are also able to comprehensively assess similarities and statistical dependence between various strategies, and evaluate the effects of parameter settings on performance. In summary, we present a comprehensive evaluation of orthology detection on a divergent set of eukaryotic genomes, thus providing insights and guides for method selection, tuning and development for different applications. Many biological questions have been addressed by multiple tests yielding binary (yes/no) outcomes but no clear definition of truth, making LCA an attractive approach for computational biology.	[Mackey, Aaron J.; Roos, David S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Chen, Feng] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Chen, Feng; Mackey, Aaron J.; Roos, David S.] Univ Penn, Genom Inst, Philadelphia, PA 19104 USA; [Vermunt, Jeroen K.] Tilburg Univ, Dept Methodol & Stat, Tilburg, Netherlands	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Tilburg University	Roos, DS (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu	Chen, Feng/A-4497-2011; vermunt, jeroen k/K-3680-2012	vermunt, jeroen k/0000-0001-9053-9330; Roos, David Siker/0000-0001-6725-4089	NIH; NIAID	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by grants from the NIH, and implementation by a Bioinformatics Resource Center contract from NIAID; DSR is a Senior Scholar in Global Infectious Diseases of the Ellison Medical Foundation.	Alexeyenko A, 2006, BIOINFORMATICS, V22, pE9, DOI 10.1093/bioinformatics/btl213; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bandyopadhyay S, 2006, GENOME RES, V16, P428, DOI 10.1101/gr.4526006; Chen F, 2006, NUCLEIC ACIDS RES, V34, pD363, DOI 10.1093/nar/gkj123; DeLuca TF, 2006, BIOINFORMATICS, V22, P2044, DOI 10.1093/bioinformatics/btl286; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Elsik CG, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r13; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Enright AJ, 2001, BIOINFORMATICS, V17, P853, DOI 10.1093/bioinformatics/17.9.853; Fitch WM, 2000, TRENDS GENET, V16, P227, DOI 10.1016/S0168-9525(00)02005-9; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gouzy J, 1999, COMPUT CHEM, V23, P333, DOI 10.1016/S0097-8485(99)00011-X; Hadgu A, 1998, J R STAT SOC C-APPL, V47, P603, DOI 10.1111/1467-9876.00131; Hegyi H, 2001, GENOME RES, V11, P1632, DOI 10.1101/gr. 183801; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Hui S L, 1998, Stat Methods Med Res, V7, P354, DOI 10.1191/096228098671192352; Hulsen T, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r31; Koonin EV, 2005, ANNU REV GENET, V39, P309, DOI 10.1146/annurev.genet.39.073003.114725; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; Koski LB, 2001, J MOL EVOL, V52, P540, DOI 10.1007/s002390010184; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Magidson J., 2004, SAGE HDB QUANTITATIV, P176, DOI [10.4135/9781412986311.n10, DOI 10.4135/9781412986311.N10]; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Qu YS, 1996, BIOMETRICS, V52, P797, DOI 10.2307/2533043; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Sonnhammer ELL, 2002, TRENDS GENET, V18, P619, DOI 10.1016/S0168-9525(02)02793-2; Storm CEV, 2003, GENOME RES, V13, P2353, DOI 10.1101/gr1305203; Storm CEV, 2002, BIOINFORMATICS, V18, P92, DOI 10.1093/bioinformatics/18.1.92; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Dongen SM, 2000, THESIS U UTRECHT NET; Vermunt J.K., 2005, LATENT GOLD 40 USERS; Vermunt J.K., 2016, TECHNICAL GUIDE LATE; Wall DP, 2003, BIOINFORMATICS, V19, P1710, DOI 10.1093/bioinformatics/btg213; Zmasek CM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-14; Zmasek CM, 2001, BIOINFORMATICS, V17, P821, DOI 10.1093/bioinformatics/17.9.821	40	289	302	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e383	10.1371/journal.pone.0000383	http://dx.doi.org/10.1371/journal.pone.0000383			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440619	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445500014
J	Kitazoe, Y; Kishino, H; Waddell, PJ; Nakajima, N; Okabayashi, T; Watabe, T; Okuhara, Y				Kitazoe, Yasuhiro; Kishino, Hirohisa; Waddell, Peter J.; Nakajima, Noriaki; Okabayashi, Takahisa; Watabe, Teruaki; Okuhara, Yoshiyasu			Robust Time Estimation Reconciles Views of the Antiquity of Placental Mammals	PLOS ONE			English	Article								Background. Molecular studies have reported divergence times of modern placental orders long before the Cretaceous-Tertiary boundary and far older than paleontological data. However, this discrepancy may not be real, but rather appear because of the violation of implicit assumptions in the estimation procedures, such as non-gradual change of evolutionary rate and failure to correct for convergent evolution. Methodology/Principal Findings. New procedures for divergence-time estimation robust to abrupt changes in the rate of molecular evolution are described. We used a variant of the multidimensional vector space (MVS) procedure to take account of possible convergent evolution. Numerical simulations of abrupt rate change and convergent evolution showed good performance of the new procedures in contrast to current methods. Application to complete mitochondrial genomes identified marked rate accelerations and decelerations, which are not obtained with current methods. The root of placental mammals is estimated to be similar to 18 million years more recent than when assuming a log Brownian motion model. Correcting the pairwise distances for convergent evolution using MVS lowers the age of the root about another 20 million years compared to using standard maximum likelihood tree branch lengths. These two procedures combined revise the root time of placental mammals from around 122 million years ago to close to 84 million years ago. As a result, the estimated distribution of molecular divergence times is broadly consistent with quantitative analysis of the North American fossil record and traditional morphological views. Conclusions/Significance. By including the dual effects of abrupt rate change and directly accounting for convergent evolution at the molecular level, these estimates provide congruence between the molecular results, paleontological analyses and morphological expectations. The programs developed here are provided along with sample data that reproduce the results of this study and are especially applicable studies using genome-scale sequence lengths.	[Kitazoe, Yasuhiro; Nakajima, Noriaki; Okabayashi, Takahisa; Watabe, Teruaki; Okuhara, Yoshiyasu] Kochi Med Sch, Ctr Med Informat, Nanko Ku, Kochi, Japan; [Kishino, Hirohisa; Waddell, Peter J.] Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo, Japan; [Waddell, Peter J.] Univ S Carolina, S Carolina Canc Ctr, Columbia, SC 29208 USA	Kochi University; University of Tokyo; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kitazoe, Y (corresponding author), Kochi Med Sch, Ctr Med Informat, Nanko Ku, Kochi, Japan.	kitazoey@kochi-u.ac.jp	Kishino, Hirohisa/U-9311-2019		Technology Agency (JST); Japan Society for the Promotion of Science (JSPS) [SR B-16300086]; NIH [5R01LM8626]; NATIONAL LIBRARY OF MEDICINE [R01LM008626] Funding Source: NIH RePORTER	Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported by the Technology Agency (JST) and the Japan Society for the Promotion of Science (JSPS grant SR B-16300086 to YK and HK). PJW acknowledges the JSPS Senior Fellowship Program and NIH grant 5R01LM8626 for support.	Alroy J, 1999, SYST BIOL, V48, P107, DOI 10.1080/106351599260472; Archibald J. David, 2001, Journal of Mammalian Evolution, V8, P107, DOI 10.1023/A:1011317930838; Arnason U, 2002, P NATL ACAD SCI USA, V99, P8151, DOI 10.1073/pnas.102164299; Benton MJ, 2003, SCIENCE, V300, P1698, DOI 10.1126/science.1077795; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Cao Y, 2000, GENE, V259, P149, DOI 10.1016/S0378-1119(00)00427-3; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Easteal S, 1999, BIOESSAYS, V21, P1052, DOI 10.1002/(SICI)1521-1878(199912)22:1<1052::AID-BIES9>3.0.CO;2-6; Hedges SB, 2004, TRENDS GENET, V20, P242, DOI 10.1016/j.tig.2004.03.004; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kitazoe Y, 2005, MOL BIOL EVOL, V22, P704, DOI 10.1093/molbev/msi051; Kitazoe Y, 2001, MOL BIOL EVOL, V18, P812, DOI 10.1093/oxfordjournals.molbev.a003863; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Misawa K, 2003, J MOL EVOL, V57, pS290, DOI 10.1007/s00239-003-0039-7; Mouchaty SK, 2000, MOL BIOL EVOL, V17, P60, DOI 10.1093/oxfordjournals.molbev.a026238; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Near TJ, 2004, PHILOS T R SOC B, V359, P1477, DOI 10.1098/rstb.2004.1523; Nikaido M, 2003, MOL PHYLOGENET EVOL, V28, P276, DOI 10.1016/S1055-7903(03)00120-9; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Okabayashi T, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-41; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Springer MS, 2004, TRENDS ECOL EVOL, V19, P430, DOI 10.1016/j.tree.2004.05.006; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Stein C., 1955, P 3 BERK S MATH STAT, V1, P197, DOI DOI 10.1525/9780520313880-018; Swofford D. L., 1996, MOL SYSTEMATICS, P450; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; Waddell P J, 2001, Genome Inform, V12, P141; Waddell PJ, 1999, SYST BIOL, V48, P119; Waddell PJ, 1999, SYST BIOL, V48, P31, DOI 10.1080/106351599260427; Waters PD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000158; Yang ZH, 2003, SYST BIOL, V52, P705, DOI 10.1080/10635150390235557; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yoder AD, 2000, MOL BIOL EVOL, V17, P1081, DOI 10.1093/oxfordjournals.molbev.a026389; Zhang JZ, 1997, MOL BIOL EVOL, V14, P527, DOI 10.1093/oxfordjournals.molbev.a025789; Zuckerkandl E., 1965, EVOLVING GENES PROTE; [No title captured]	42	54	56	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2007	2	4							e384	10.1371/journal.pone.0000384	http://dx.doi.org/10.1371/journal.pone.0000384			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DU	17440620	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445500015
J	Diretto, G; Al-Babili, S; Tavazza, R; Papacchioli, V; Beyer, P; Giuliano, G				Diretto, Gianfranco; Al-Babili, Salim; Tavazza, Raffaela; Papacchioli, Velia; Beyer, Peter; Giuliano, Giovanni			Metabolic Engineering of Potato Carotenoid Content through Tuber-Specific Overexpression of a Bacterial Mini-Pathway	PLOS ONE			English	Article								Background. Since the creation of "Golden Rice", biofortification of plant-derived foods is a promising strategy for the alleviation of nutritional deficiencies. Potato is the most important staple food for mankind after the cereals rice, wheat and maize, and is extremely poor in provitamin A carotenoids. Methodology. We transformed potato with a mini-pathway of bacterial origin, driving the synthesis of beta-carotene (Provitamin A) from geranylgeranyl diphosphate. Three genes, encoding phytoene synthase (CrtB), phytoene desaturase (CrtI) and lycopene beta-cyclase (CrtY) from Erwinia, under tuber-specific or constitutive promoter control, were used. 86 independent transgenic lines, containing six different promoter/gene combinations, were produced and analyzed. Extensive regulatory effects on the expression of endogenous genes for carotenoid biosynthesis are observed in transgenic lines. Constitutive expression of the CrtY and/or CrtI genes interferes with the establishment of transgenosis and with the accumulation of leaf carotenoids. Expression of all three genes, under tuber-specific promoter control, results in tubers with a deep yellow ("golden") phenotype without any adverse leaf phenotypes. In these tubers, carotenoids increase approx. 20-fold, to 114 mcg/g dry weight and beta-carotene 3600-fold, to 47 mcg/g dry weight. Conclusions. This is the highest carotenoid and beta-carotene content reported for biofortified potato as well as for any of the four major staple foods (the next best event being "Golden Rice 2", with 31 mcg/g dry weight beta-carotene). Assuming a beta-carotene to retinol conversion of 6: 1, this is sufficient to provide 50% of the Recommended Daily Allowance of Vitamin A with 250 gms (fresh weight) of "golden" potatoes.	[Diretto, Gianfranco; Tavazza, Raffaela; Papacchioli, Velia; Giuliano, Giovanni] Ente Nuove Tecnol Energia & Ambiente ENEA, Casaccia Res Ctr, Rome, Italy; [Al-Babili, Salim; Beyer, Peter] Univ Freiburg, Fac Biol, Freiburg, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; University of Freiburg	Giuliano, G (corresponding author), Ente Nuove Tecnol Energia & Ambiente ENEA, Casaccia Res Ctr, Rome, Italy.	giuliano@casaccia.enea.it	Diretto, Gianfranco/L-9279-2017; Giuliano, Giovanni/A-2701-2012	Diretto, Gianfranco/0000-0002-1441-0233; Giuliano, Giovanni/0000-0002-2486-0510; Al-Babili, Salim/0000-0003-4823-2882	EC; HarvestPlus; Italian Ministry of Research	EC(European CommissionEuropean Commission Joint Research Centre); HarvestPlus; Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR))	The work was supported by the EC projects ProVitA, EU-SOL and DeveloNutri, by the HarvestPlus (www.harvestplus.org) research consortium, and by the Italian Ministry of Research (FIRB project). None of the funding bodies took part in experiment planning, data analysis or in the writing of the paper.	Al-Babili S, 2006, J EXP BOT, V57, P1007, DOI 10.1093/jxb/erj086; Al-Babili S, 2005, TRENDS PLANT SCI, V10, P565, DOI 10.1016/j.tplants.2005.10.006; Diretto G, 2007, BMC PLANT BIOL, V7, DOI 10.1186/1471-2229-7-11; Diretto G, 2006, BMC PLANT BIOL, V6, DOI 10.1186/1471-2229-6-13; DUCKHAM SC, 1991, PLANT CELL ENVIRON, V14, P601, DOI 10.1111/j.1365-3040.1991.tb01531.x; Ducreux LJM, 2005, J EXP BOT, V56, P81, DOI 10.1093/jxb/eri016; Fiore A, 2006, FEBS LETT, V580, P4718, DOI 10.1016/j.febslet.2006.07.055; FRAY RG, 1995, PLANT J, V8, P693, DOI 10.1046/j.1365-313X.1995.08050693.x; Giuliano G, 2000, TRENDS PLANT SCI, V5, P406, DOI 10.1016/S1360-1385(00)01749-0; Griffiths DW, 2007, J AGR FOOD CHEM, V55, P379, DOI 10.1021/jf0620822; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hoa TTC, 2003, PLANT PHYSIOL, V133, P161, DOI 10.1104/pp.103.023457; Howe JA, 2006, J NUTR, V136, P2562, DOI 10.1093/jn/136.10.2562; Kim J, 2006, P NATL ACAD SCI USA, V103, P3474, DOI 10.1073/pnas.0511207103; Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S; Li L, 2006, PHYTOCHEMISTRY, V67, P1177, DOI 10.1016/j.phytochem.2006.05.013; LIU XY, 1991, PLANT MOL BIOL, V17, P1139, DOI 10.1007/BF00028731; Lu S, 2006, PLANT CELL, V18, P3594, DOI 10.1105/tpc.106.046417; MISAWA N, 1993, PLANT J, V4, P833, DOI 10.1046/j.1365-313X.1993.04050833.x; Morris WL, 2004, J EXP BOT, V55, P975, DOI 10.1093/jxb/erh121; Nesterenko S, 2003, HORTSCIENCE, V38, P1173, DOI 10.21273/HORTSCI.38.6.1173; Paine JA, 2005, NAT BIOTECHNOL, V23, P482, DOI 10.1038/nbt1082; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ravanello MP, 2003, METAB ENG, V5, P255, DOI 10.1016/j.ymben.2003.08.001; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; Romer S, 2002, METAB ENG, V4, P263, DOI 10.1006/mben.2002.0234; Romer S, 2000, NAT BIOTECHNOL, V18, P666, DOI 10.1038/76523; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaub P, 2005, PLANT PHYSIOL, V138, P441, DOI 10.1104/pp.104.057927; Shewmaker CK, 1999, PLANT J, V20, P401, DOI 10.1046/j.1365-313x.1999.00611.x; TAVAZZA R, 1989, PLANT SCI, V59, P175, DOI 10.1016/0168-9452(89)90135-0; Tian L, 2004, P NATL ACAD SCI USA, V101, P402, DOI 10.1073/pnas.2237237100; Tian L, 2003, PLANT CELL, V15, P1320, DOI 10.1105/tpc.011403; TO KY, 1994, MICROBIOL-SGM, V140, P331, DOI 10.1099/13500872-140-2-331; van Jaarsveld PJ, 2005, AM J CLIN NUTR, V81, P1080; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	37	213	225	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e350	10.1371/journal.pone.0000350	http://dx.doi.org/10.1371/journal.pone.0000350			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406674	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445300012
J	Landi, S; Cenni, MC; Maffei, L; Berardi, N				Landi, Silvia; Cenni, Maria Cristina; Maffei, Lamberto; Berardi, Nicoletta			Environmental Enrichment Effects on Development of Retinal Ganglion Cell Dendritic Stratification Require Retinal BDNF	PLOS ONE			English	Article								A well-known developmental event of retinal maturation is the progressive segregation of retinal ganglion cell (RGC) dendrites into a and b sublaminae of the inner plexiform layer (IPL), a morphological rearrangement crucial for the emergence of the ON and OFF pathways. The factors regulating this process are not known, although electrical activity has been demonstrated to play a role. Here we report that Environmental Enrichment (EE) accelerates the developmental segregation of RGC dendrites and prevents the effects exerted on it by dark rearing (DR). Development of RGC stratification was analyzed in a line of transgenic mice expressing plasma-membrane marker green fluorescent protein (GFP) under the control of Thy-1 promoter; we visualized the a and b sublaminae of the IPL by using an antibody selectively directed against a specific marker of cholinergic neurons. EE precociously increases Brain Derived Neurotrophic Factor (BDNF) in the retina, in parallel with the precocious segregation of RGC dendrites; in addition, EE counteracts retinal BDNF reduction in DR retinas and promotes a normal segregation of RGC dendrites. Blocking retinal BDNF by means of antisense oligos blocks EE effects on the maturation of RGC dendritic stratification. Thus, EE affects the development of RGC dendritic segregation and retinal BDNF is required for this effect to take place, suggesting that BDNF could play an important role in the emergence of the ON and OFF pathways.	[Landi, Silvia; Maffei, Lamberto] Scuola Normale Super Pisa, Pisa, Italy; [Cenni, Maria Cristina; Maffei, Lamberto; Berardi, Nicoletta] CNR, Ist Neurosci, I-56100 Pisa, Italy; [Berardi, Nicoletta] Univ Florence, Dipartimento Psicol, Florence, Italy	Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Florence	Landi, S (corresponding author), Scuola Normale Super Pisa, Pisa, Italy.	landi@in.cnr.it	Landi, Silvia/P-9418-2018	Landi, Silvia/0000-0001-7999-3452	MIUR COFIN	MIUR COFIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	This work was supported by MIUR COFIN to Lamberto Maffei.	Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; Bansal A, 2000, J NEUROSCI, V20, P7672; Bartoletti A, 2004, NAT NEUROSCI, V7, P215, DOI 10.1038/nn1201; Bloomfield SA, 2001, PROG RETIN EYE RES, V20, P351, DOI 10.1016/S1350-9462(00)00031-8; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; Bodnarenko SR, 1999, NEUROREPORT, V10, P2955, DOI 10.1097/00001756-199909290-00015; BODNARENKO SR, 1995, J NEUROSCI, V15, P7037; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Cellerino A, 1998, J NEUROSCI, V18, P3351; Cellerino A, 1997, J COMP NEUROL, V386, P149; Cohen-Cory S, 2004, INT J DEV BIOL, V48, P947, DOI 10.1387/ijdb.041883sc; De Paola V, 2003, NAT NEUROSCI, V6, P491, DOI 10.1038/nn1046; Deplano S, 2004, DEV NEUROSCI-BASEL, V26, P396, DOI 10.1159/000082282; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Galli-Resta L, 2000, EUR J NEUROSCI, V12, P3819, DOI 10.1046/j.1460-9568.2000.00280.x; Galli-Resta L, 2002, DEVELOPMENT, V129, P3803; Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197; Gunhan-Agar E, 2000, J NEUROSCI, V20, P306, DOI 10.1523/JNEUROSCI.20-01-00306.2000; KIRBY MA, 1991, VISUAL NEUROSCI, V7, P513, DOI 10.1017/S0952523800010324; Ladewig T, 2004, NEUROREPORT, V15, P2495, DOI 10.1097/00001756-200411150-00013; Landi S, 2007, FASEB J, V21, P130, DOI 10.1096/fj.06-6083com; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Lom B, 1999, J NEUROSCI, V19, P9928; Mandolesi G, 2005, CURR BIOL, V15, P2119, DOI 10.1016/j.cub.2005.10.045; MASLIM J, 1988, DEV BRAIN RES, V44, P87, DOI 10.1016/0165-3806(88)90120-4; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Menna E, 2003, MOL CELL NEUROSCI, V24, P972, DOI 10.1016/S1044-7431(03)00258-6; Miller ED, 1999, VISUAL NEUROSCI, V16, P1133, DOI 10.1017/S0952523899166136; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; PEREZ MTR, 1995, NEUROSCI LETT, V183, P96, DOI 10.1016/0304-3940(94)11123-Z; Pollock GS, 2001, J NEUROSCI, V21, P3923, DOI 10.1523/JNEUROSCI.21-11-03923.2001; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; Sale A, 2004, NEUROPHARMACOLOGY, V47, P649, DOI 10.1016/j.neuropharm.2004.07.008; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Sernagor E, 2001, J ANAT, V199, P375, DOI 10.1046/j.1469-7580.2001.19940375.x; Stacy RC, 2005, J NEUROSCI, V25, P9347, DOI 10.1523/JNEUROSCI.1800-05.2005; Stacy RC, 2003, J COMP NEUROL, V456, P154, DOI 10.1002/cne.10509; Thaler S, 2006, MOL VIS, V12, P100; Tian N, 2003, NEURON, V39, P85, DOI 10.1016/S0896-6273(03)00389-1; Vecino E, 2002, VISION RES, V42, P151, DOI 10.1016/S0042-6989(01)00251-6; Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615; Witkovsky P, 2004, DOC OPHTHALMOL, V108, P17, DOI 10.1023/B:DOOP.0000019487.88486.0a; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Zhang M, 2005, J COMP NEUROL, V484, P331, DOI 10.1002/cne.20470	47	59	61	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e346	10.1371/journal.pone.0000346	http://dx.doi.org/10.1371/journal.pone.0000346			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406670	Green Published, gold			2022-12-25	WOS:000207445300008
J	Swiatecka-Urban, A; Talebian, L; Kanno, E; Moreau-Marquis, S; Coutermarsh, B; Hansen, K; Karlson, KH; Barnaby, R; Cheney, RE; Langford, GM; Fukuda, M; Stanton, BA				Swiatecka-Urban, Agnieszka; Talebian, Laleh; Kanno, Eiko; Moreau-Marquis, Sophie; Coutermarsh, Bonita; Hansen, Karyn; Karlson, Katherine H.; Barnaby, Roxanna; Cheney, Richard E.; Langford, George M.; Fukuda, Mitsunori; Stanton, Bruce A.			Myosin vb is required for trafficking of the cystic fibrosis transmembrane conductance regulator in Rab11a-specific apical recycling endosomes in polarized human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; UNCONVENTIONAL MYOSIN; MOLECULAR MOTORS; INTRACELLULAR-TRANSPORT; INTERACTING PROTEIN-2; CFTR TRAFFICKING; ENDOCYTOSIS; RAB11A; RECEPTOR	Cystic fibrosis transmembrane conductance regulator ( CFTR)mediated Cl- secretion across fluid-transporting epithelia is regulated, in part, by modulating the number of CFTR Cl- channels in the plasma membrane by adjusting CFTR endocytosis and recycling. However, the mechanisms that regulate CFTR recycling in airway epithelial cells remain unknown, at least in part, because the recycling itineraries of CFTR in these cells are incompletely understood. In a previous study, we demonstrated that CFTR undergoes trafficking in Rab11a-specific apical recycling endosomes in human airway epithelial cells. Myosin Vb is a plus-end-directed, actin-based mechanoenzyme that facilitates protein trafficking in Rab11a-specific recycling vesicles in several cell model systems. There are no published studies examining the role of myosin Vb in airway epithelial cells. Thus, the goal of this study was to determine whether myosin Vb facilitates CFTR recycling in polarized human airway epithelial cells. Endogenous CFTR formed a complex with endogenous myosinVb and Rab11a. Silencing myosin Vb by RNA-mediated interference decreased the expression of wild-type CFTR and Delta F508-CFTR in the apical membrane and decreased CFTR-mediated Cl- secretion across polarized human airway epithelial cells. A recombinant tail domain fragment of myosin Vb attenuated the plasma membrane expression of CFTR by arresting CFTR recycling. The dominant-negative effect was dependent on the ability of the myosin Vb tail fragment to interact with Rab11a. Taken together, these data indicate that myosin Vb is required for CFTR recycling in Rab11a-specific apical recycling endosomes in polarized human airway epithelial cells.	Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Tohoku Univ, Grad Sch Life Sci, Lab Membrane Trafficking Mech, Dept Dev Biol & Neurosci,Aoba Ku, Sendai, Miyagi 9808578, Japan	Dartmouth College; Dartmouth College; RIKEN; University of North Carolina; University of North Carolina Chapel Hill; Tohoku University	Swiatecka-Urban, A (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA.	asurban@pitt.edu	Swiatecka-Urban, Agnieszka/AAP-6041-2020; Fukuda, MItsunori/I-1511-2015; SWIATECKA-URBAN, AGNIESZKA/H-6494-2015	Fukuda, MItsunori/0000-0002-8620-5853; SWIATECKA-URBAN, AGNIESZKA/0000-0002-6575-0334; Cheney, Richard/0000-0001-6565-7888; Langford, George/0000-0001-9737-2182	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003299] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR018787] Funding Source: Medline; NIDCD NIH HHS [R01 DC003299, R01-DC03299] Funding Source: Medline; NIDDK NIH HHS [R01-DK45811, R01-DK34533] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Batista DGJ, 2006, J HISTOCHEM CYTOCHEM, V54, P605, DOI 10.1369/jhc.5A6654.2005; Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Chang CW, 1997, J NEUROCHEM, V69, P859; Chung YJ, 2006, LEUKEMIA, V20, P1542, DOI 10.1038/sj.leu.2404310; Desrosiers RR, 1998, BIOCHEM CELL BIOL, V76, P63, DOI 10.1139/bcb-76-1-63; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; Elferink LA, 2005, METHOD ENZYMOL, V403, P732, DOI 10.1016/S0076-6879(05)03064-8; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Fukuda M, 2005, METHOD ENZYMOL, V403, P445, DOI 10.1016/S0076-6879(05)03039-9; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hamm-Alvarez SF, 1998, ADV DRUG DELIVER REV, V29, P229, DOI 10.1016/S0169-409X(97)00081-1; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Higuchi H, 2002, CURR OPIN CELL BIOL, V14, P50, DOI 10.1016/S0955-0674(01)00293-9; Hirosawa M, 1999, DNA Res, V6, P329, DOI 10.1093/dnares/6.5.329; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Kashina AS, 2004, CURR BIOL, V14, P1877, DOI 10.1016/j.cub.2004.10.003; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kues WA, 2000, BIOL REPROD, V62, P412, DOI 10.1095/biolreprod62.2.412; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lapierre LA, 2005, METHOD ENZYMOL, V403, P715, DOI 10.1016/S0076-6879(05)03062-4; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lehrich RW, 1998, J CLIN INVEST, V101, P737, DOI 10.1172/JCI803; Lise MF, 2006, J BIOL CHEM, V281, P3669, DOI 10.1074/jbc.M511725200; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Lukacs GL, 1997, BIOCHEM J, V328, P353; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Mueller J, 2000, Recent Results Cancer Res, V155, P29; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Rajan Sujatha, 2002, Semin Respir Infect, V17, P47, DOI 10.1053/srin.2002.31690; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez OC, 2002, J CELL SCI, V115, P991; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Swiatecka-Urban A, 2006, AM J PHYSIOL-CELL PH, V290, pC862, DOI 10.1152/ajpcell.00108.2005; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Swiatecka-Urban A, 2004, J BIOL CHEM, V279, P38025, DOI 10.1074/jbc.M403141200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; Tuma PL, 2002, MOL BIOL CELL, V13, P3400, DOI 10.1091/mbc.02-04-0054; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; van de Graaf SFJ, 2006, MOL CELL BIOL, V26, P303, DOI 10.1128/MCB.26.1.303-312.2006; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wakabayashi Y, 2005, P NATL ACAD SCI USA, V102, P15087, DOI 10.1073/pnas.0503702102; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Weixel Kelly, 2002, Methods Mol Med, V70, P323; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 2001, J CELL SCI, V114, P1091; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826; Zhu GY, 2004, NAT STRUCT MOL BIOL, V11, P975, DOI 10.1038/nsmb832	77	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23725	23736		10.1074/jbc.M608531200	http://dx.doi.org/10.1074/jbc.M608531200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17462998	hybrid, Green Published			2022-12-25	WOS:000248577500076
J	Lu, YS; Lv, YB; Ye, YH; Wang, YL; Hong, Y; Fortini, ME; Zhong, Y; Xie, ZP				Lu, Yisheng; Lv, Yubing; Ye, Yihong; Wang, Yalin; Hong, Yu; Fortini, Mark E.; Zhong, Yi; Xie, Zuoping			A role for presenilin in post-stress regulation: effects of presenilin mutations on Ca2+ currents in Drosophila	FASEB JOURNAL			English	Review						L-type Ca2+ channel; heat shock; Alzheimer's disease; synaptic function	VOLTAGE-DEPENDENT FACILITATION; SENSITIVE CALCIUM-CHANNELS; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; ENDOPLASMIC-RETICULUM; MUTANT PRESENILIN-1; SYNAPTIC PLASTICITY; WILD-TYPE; A-BETA; NEUROMUSCULAR-JUNCTION	It has been shown that presenilin is involved in maintaining Ca2+ homeostasis in neurons, including regulating endoplasmic reticulum ( ER) Ca2+ storage. From studies of primary cultures and cell lines, however, its role in stress- induced responses is still controversial. In the present study we analyzed the effects of presenilin mutations on membrane currents and synaptic functions in response to stress using an in vivo preparation. We examined voltage-gated K+ and Ca2+ currents at the Drosophila larval neuromuscular junction ( NMJ) with voltage-clamp recordings. Our data showed that both currents were generally unaffected by loss-of-function or Alzheimer's disease (AD)-associated presenilin mutations under normal or stress conditions induced by heat shock ( HS) or ER stress. In larvae expressing the mutant presenilins, prolonged Ca2+ tail current, reflecting slower deactivation kinetics of Ca2+ channels, was observed 1 day after stress treatments were terminated. It was further demonstrated that the L-type Ca2+ channel was specifically affected under these conditions. Moreover, synaptic plasticity at the NMJ was reduced in larvae expressing the mutant presenilins. At the behavioral level, memory in adult flies was impaired in the presenilin mutants 1 day after HS. The results show that presenilin function is important during the poststress period and its impairment contributes to memory dysfunction observed during adaptation to normal conditions after stress. Our findings suggest a new stress- related mechanism by which presenilin may be implicated in the neuropathology of AD.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Cold Spring Harbor Lab, Spring Harbor, NY 11724 USA; NIDDK, Lab Mol Biol, NIH, Bethesda, MD USA; NCI, Canc & Dev Biol Lab, Frederick, MD USA	Tsinghua University; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xie, ZP (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	zhongyi@cshl.edu; zuopingx@mail.tsinghua.edu.cn	Lu, Yubing/G-2644-2011; Wang, Yalin/C-8362-2011	Lu, Yubing/0000-0002-7715-9867; Zhong, Yi/0000-0002-7927-5976; Zhong, Yi/0000-0001-7810-9899	Intramural NIH HHS Funding Source: Medline; NIA NIH HHS [R01 AG14583] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010913, Z01BC010529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014583] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akaishi T, 2004, NEUROSCI LETT, V356, P25, DOI 10.1016/j.neulet.2003.11.012; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; Bhattacharya A, 1999, J NEUROBIOL, V39, P491, DOI 10.1002/(SICI)1097-4695(19990615)39:4<491::AID-NEU3>3.0.CO;2-6; Blatow M, 2003, NEURON, V38, P79, DOI 10.1016/S0896-6273(03)00196-X; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Brandt A, 2005, J NEUROSCI, V25, P11577, DOI 10.1523/JNEUROSCI.3411-05.2005; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cecchi C, 1999, NEUROSCI LETT, V275, P152, DOI 10.1016/S0304-3940(99)00751-X; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Chen L, 2005, J NEUROPHYSIOL, V94, P4131, DOI 10.1152/jn.00755.2004; De Sarno P, 2001, BRAIN RES, V903, P226, DOI 10.1016/S0006-8993(01)02428-3; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; Desmadryl G, 1998, EUR J NEUROSCI, V10, P545, DOI 10.1046/j.1460-9568.1998.00055.x; FORTI L, 1993, NEURON, V10, P437, DOI 10.1016/0896-6273(93)90332-L; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; FU WM, 1994, NEUROSCIENCE, V58, P131, DOI 10.1016/0306-4522(94)90160-0; Gamliel A, 2003, NEUROSCIENCE, V117, P19, DOI 10.1016/S0306-4522(02)00830-8; GIELOW ML, 1995, J NEUROSCI, V15, P6085; GORCZYCA MG, 1991, J MEMBRANE BIOL, V121, P237, DOI 10.1007/BF01951557; Gruol DL, 2006, CEREBELLUM, V5, P146, DOI 10.1080/14734220600719692; Gu GG, 1997, J NEUROBIOL, V33, P265, DOI 10.1002/(SICI)1097-4695(199709)33:3<265::AID-NEU5>3.0.CO;2-#; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Hong CS, 1997, NEUROREPORT, V8, P665, DOI 10.1097/00001756-199702100-00017; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Johnson BD, 1997, J NEUROSCI, V17, P1243; Jurkat-Rott K, 2004, J PHYSIOL-LONDON, V554, P609, DOI 10.1113/jphysiol.2003.052712; Kammermeier PJ, 1998, J NEUROPHYSIOL, V79, P410, DOI 10.1152/jn.1998.79.1.410; Karst H, 2002, EUR J NEUROSCI, V16, P1083, DOI 10.1046/j.1460-9568.2002.02172.x; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAVALALI ET, 1994, J PHYSIOL-LONDON, V480, P475, DOI 10.1113/jphysiol.1994.sp020376; Keller JN, 1998, J NEUROSCI, V18, P4439; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lleo A, 2004, AM J GERIAT PSYCHIAT, V12, P146, DOI 10.1176/appi.ajgp.12.2.146; Lleo A, 2002, MED CLIN-BARCELONA, V118, P698, DOI 10.1016/S0025-7753(02)72501-3; Lopera F, 1997, JAMA-J AM MED ASSOC, V277, P793, DOI 10.1001/jama.277.10.793; Lu FM, 2002, J NEUROPHYSIOL, V87, P1222, DOI 10.1152/jn.00323.2001; Lukinova NI, 1999, GENETICS, V153, P1789; MA J, 1992, BIOPHYS J, V63, P639, DOI 10.1016/S0006-3495(92)81634-X; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; Mejia S, 2003, INT PSYCHOGERIATR, V15, P337, DOI 10.1017/S1041610203009591; MENDELOWITZ D, 1995, J NEUROPHYSIOL, V73, P872, DOI 10.1152/jn.1995.73.2.872; Moerman AM, 1999, J NEUROSCI RES, V57, P962, DOI 10.1002/(SICI)1097-4547(19990915)57:6<962::AID-JNR22>3.3.CO;2-D; Moosmang S, 2005, J NEUROSCI, V25, P9883, DOI 10.1523/JNEUROSCI.1531-05.2005; Nakajima M, 2001, J NEUROCHEM, V78, P807, DOI 10.1046/j.1471-4159.2001.00478.x; Nakayama S, 2000, J PHYSIOL-LONDON, V526, P47, DOI 10.1111/j.1469-7793.2000.00047.x; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pamidimukkala J, 2006, BRAIN RES, V1078, P1, DOI 10.1016/j.brainres.2006.01.044; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Parri HR, 1996, J NEUROSCI, V16, P4890; PAULI D, 1992, EXPERIENTIA, V48, P623, DOI 10.1007/BF02118306; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2000, J NEUROSCI, V20, P8717; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Song WJ, 1996, J NEUROPHYSIOL, V76, P2290, DOI 10.1152/jn.1996.76.4.2290; Striessnig J, 2006, BIOCHEM SOC T, V34, P903, DOI 10.1042/BST0340903; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tandon A, 2002, GENOME BIOL, V3; Terro F, 2002, J NEUROSCI RES, V69, P530, DOI 10.1002/jnr.10312; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; van Gemert NG, 2006, J NEUROENDOCRINOL, V18, P732, DOI 10.1111/j.1365-2826.2006.01472.x; Vornanen M, 1998, J EXP BIOL, V201, P533; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; WU CF, 1985, J NEUROSCI, V5, P2626; Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	106	9	10	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2368	2378		10.1096/fj.06-6380com	http://dx.doi.org/10.1096/fj.06-6380com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17428965				2022-12-25	WOS:000248454400012
J	Parri, M; Buricchi, F; Giannoni, E; Grimaldi, G; Mello, T; Raugei, G; Ramponi, G; Chiarugi, P				Parri, Matteo; Buricchi, Francesca; Giannoni, Elisa; Grimaldi, Giovanna; Mello, Tommaso; Raugei, Giovanni; Ramponi, Giampietro; Chiarugi, Paola			EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to Rho-dependent actino/myosin contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; SRC FAMILY KINASES; DENDRITIC SPINE MORPHOGENESIS; RECEPTOR-TYROSINE KINASE; AXON GUIDANCE RECEPTORS; GROWTH CONE DYNAMICS; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS; CARCINOMA-CELLS; EPHA RECEPTORS	Eph receptors and ephrin ligands are widely expressed in epithelial cells and mediate cell repulsive motility through heterotypic cell-cell interactions. Several Ephs, including EphA2, are greatly overexpressed in certain tumors, in correlation with poor prognosis and high vascularity in cancer tissues. The ability of several Eph receptors to regulate cell migration and invasion likely contribute to tumor progression and metastasis. We report here that in prostatic carcinoma cells ephrinA1 elicits a repulsive response that is executed through a Rho-dependent actino/myosin contractility activation, ultimately leading to retraction of the cell body. This appears to occur through assembly of an EphA2-associated complex involving the two kinases Src and focal adhesion kinase (FAK). EphrinA1-mediated repulsion leads to the selective phosphorylation of Tyr-576/577 of FAK, enhancing FAK kinase activity. The repulsive response elicited by ephrinA1 in prostatic carcinoma cells is mainly driven by a Rho-mediated phosphorylation of myosin light chain II, in which Src and FAK activation are required steps. Consequently, Src and FAK are upstream regulators of the overall response induced by ephrinA1/EphA2, instructing cells to retract the cell body and to move away, probably facilitating dissemination and tissue invasion of ephrin-sensitive carcinomas.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Ctr Res Transfer & High Educ, I-50134 Florence, Italy; Farmacogenom Fdn FriorGen, I-50019 Florence, Italy	University of Florence	Chiarugi, P (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgani 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Chiarugi, Paola/CDD-7988-2022; Mello, Tommaso/I-4715-2012; Grimaldi, Giovanna/K-2678-2018; Giannoni, Elisa/AAE-2092-2020; Mello, Tommaso/AAO-7831-2021	Mello, Tommaso/0000-0002-6192-6902; Grimaldi, Giovanna/0000-0003-0134-7869; Mello, Tommaso/0000-0002-6192-6902; Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098; raugei, giovanni/0000-0003-1294-786X				Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Cooper HM, 2002, INT J DEV BIOL, V46, P621; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Fu WY, 2007, NAT NEUROSCI, V10, P67, DOI 10.1038/nn1811; Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112; Halford MM, 2003, DEV CELL, V5, P536, DOI 10.1016/S1534-5807(03)00299-5; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Irie F, 2005, NAT CELL BIOL, V7, P501, DOI 10.1038/ncb1252; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Klagsbrun M, 2005, CYTOKINE GROWTH F R, V16, P535, DOI 10.1016/j.cytogfr.2005.05.002; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Moeller ML, 2006, J BIOL CHEM, V281, P1587, DOI 10.1074/jbc.M511756200; Murai KK, 2005, NEURON, V46, P161, DOI 10.1016/j.neuron.2005.04.004; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nasertorabi F, 2006, J MOL RECOGNIT, V19, P30, DOI 10.1002/jmr.755; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; OWENS LV, 1995, CANCER RES, V55, P2752; Parri M, 2005, J BIOL CHEM, V280, P34008, DOI 10.1074/jbc.M502879200; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Santiago A, 2002, DEVELOPMENT, V129, P3621; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Zelinski DP, 2001, CANCER RES, V61, P2301; Zeng GY, 2003, AM J PATHOL, V163, P2271, DOI 10.1016/S0002-9440(10)63584-5; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200	58	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19619	19628		10.1074/jbc.M701319200	http://dx.doi.org/10.1074/jbc.M701319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17449913	hybrid			2022-12-25	WOS:000247650600036
J	Cuervo, A; Vaney, MC; Antson, AA; Tavares, P; Oliveira, L				Cuervo, Ana; Vaney, Marie-Christine; Antson, Alfred A.; Tavares, Paulo; Oliveira, Leonor			Structural rearrangements between portal protein subunits are essential for viral DNA translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE SPP1; MECHANISM; RESOLUTION; TERMINASE; ATPASE	Transport of DNA into preformed procapsids is a general strategy for genome packing inside virus particles. In most viruses, this task is accomplished by a complex of the viral packaging ATPase with the portal protein assembled at a specialized vertex of the procapsid. Such molecular motor translocates DNA through the central tunnel of the portal protein. A central question to understand this mechanism is whether the portal is a mere conduit for DNA or whether it participates actively on DNA translocation. The most constricted part of the bacteriophage SPP1 portal tunnel is formed by twelve loops, each contributed from one individual subunit. The position of each loop is stabilized by interactions with helix alpha-5, which extends into the portal putative ATPase docking interface. Here, we have engineered intersubunit disulfide bridges between alpha-5s of adjacent portal ring subunits. Such covalent constraint blocked DNA packaging, whereas reduction of the disulfide bridges restored normal packaging activity. DNA exit through the portal in SPP1 virions was unaffected. The data demonstrate that mobility between alpha-5 helices is essential for the mechanism of viral DNA translocation. We propose that the alpha-5 structural rearrangements serve to coordinate ATPase activity with the positions of portal tunnel loops relative to the DNA double helix.	CNRS, UMR 2472, Unite Virol Mol & Struct, UMR INRA 1157, F-91198 Gif Sur Yvette, France; Univ York, Dept Chem, York Struct Biol Lab, York Y010 5YW, N Yorkshire, England	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of York - UK	Tavares, P (corresponding author), CNRS, UMR 2472, Unite Virol Mol & Struct, UMR INRA 1157, Bat 14B Ave Terrasse, F-91198 Gif Sur Yvette, France.	tavares@vms.cnrs-gif.fr	Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816; Cuervo, Ana/0000-0001-9414-503X; Tavares, Paulo/0000-0002-2566-4546	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agirrezabala X, 2005, EMBO J, V24, P3820, DOI 10.1038/sj.emboj.7600840; Bath J, 2000, SCIENCE, V290, P995, DOI 10.1126/science.290.5493.995; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Calendar, 2006, BACTERIOPHAGES, P49; Camacho AG, 2003, J BIOL CHEM, V278, P23251, DOI 10.1074/jbc.M301805200; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Catalano Carlos Enrique, 2005, P1; CHAI S, 1992, J MOL BIOL, V224, P87, DOI 10.1016/0022-2836(92)90578-8; Chemla YR, 2005, CELL, V122, P683, DOI 10.1016/j.cell.2005.06.024; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; GUO PX, 1987, J MOL BIOL, V197, P219, DOI 10.1016/0022-2836(87)90120-3; Isidro A, 2004, VIROLOGY, V322, P253, DOI 10.1016/j.virol.2004.02.012; Isidro A, 2004, MOL MICROBIOL, V51, P949, DOI 10.1046/j.1365-2958.2003.03880.x; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Jiang W, 2006, NATURE, V439, P612, DOI 10.1038/nature04487; Lebedev AA, 2007, EMBO J, V26, P1984, DOI 10.1038/sj.emboj.7601643; Massey TH, 2006, MOL CELL, V23, P457, DOI 10.1016/j.molcel.2006.06.019; Morais MC, 2005, MOL CELL, V18, P149, DOI 10.1016/j.molcel.2005.03.013; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; Oliveira L, 2005, J MOL BIOL, V353, P529, DOI 10.1016/j.jmb.2005.08.063; Oliveira L, 2006, J BIOL CHEM, V281, P21914, DOI 10.1074/jbc.M603314200; Orlova EV, 2003, EMBO J, V22, P1255, DOI 10.1093/emboj/cdg123; Pease PJ, 2005, SCIENCE, V307, P586, DOI 10.1126/science.1104885; Petersen MTN, 1999, PROTEIN ENG, V12, P535, DOI 10.1093/protein/12.7.535; RAO VB, 1987, MOL BIOL, V200, P475; Saleh OA, 2004, EMBO J, V23, P2430, DOI 10.1038/sj.emboj.7600242; Sambook J., 1989, MOL CLONING LAB MANU, P743; Sao-Jose C, 2006, J BIOL CHEM, V281, P11464, DOI 10.1074/jbc.M513625200; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Tang L, 2005, EMBO J, V24, P2087, DOI 10.1038/sj.emboj.7600695; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Vinga I, 2006, MOL MICROBIOL, V61, P1609, DOI 10.1111/j.1365-2958.2006.05327.x; YEO A, 1995, J MOL BIOL, V245, P141, DOI 10.1006/jmbi.1994.0013	36	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18907	18913		10.1074/jbc.M701808200	http://dx.doi.org/10.1074/jbc.M701808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17446176	Green Published, hybrid			2022-12-25	WOS:000247475300031
J	Peixoto, PMV; Grana, F; Roy, TJ; Dunn, CD; Flores, M; Jensen, RE; Campo, ML				Peixoto, Pablo M. V.; Grana, Fernando; Roy, Teresa J.; Dunn, Cory D.; Flores, Montana; Jensen, Robert E.; Campo, Maria Luisa			Awaking TIM22, a dynamic ligand-gated channel for protein insertion in the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; OUTER-MEMBRANE; TOM CHANNEL; IMPORT; COMPONENT; COMPLEX; CARRIER; PERMEABILITY; MACHINERY; FORMS	Aqueous channels are at the core of the translocase of the outer membrane (TOM) and the translocase of the inner membrane for the transport of preproteins (TIM23), the translocases mediating the transport of proteins across the outer and inner mitochondrial membranes. Yet, the existence of a channel associated to the translocase of the inner membrane for the insertion of multitopic protein (TIM22) complex has been arguable, as its function relates to the insertion of multispanning proteins into the inner membrane. For the first time, we report conditions for detecting a channel activity associated to the TIM22 translocase in organelle, i.e. intact mitoplasts. An internal signal peptide in the intermembrane space of mitochondria is a requisite to inducing this channel, which is otherwise silent. The channel showed slightly cationic and high conductance activity of 1000 pS with a predominant half-open substate. Despite their different composition, the channels of the three mitochondrial translocases were thus remarkably similar, in agreement with their common task as pores transiently trapping proteins en route to their final destination. The opening of the TIM22 channel was a step-up process depending on the signal peptide concentration. Interestingly, low membrane potentials kept the channel fully open, providing a threshold level of the peptide is present. Our results portray TIM22 as a dynamic channel solely active in the presence of its cargo proteins. In its fully open conformation, favored by the combined action of internal signal peptide and low membrane potential, the channel could embrace the in-transit protein. As insertion progressed and initial interaction with the signal peptide faded, the channel would close, sustaining its role as a shunt that places trapped proteins into the membrane.	Univ Extremadura, Fac Vet Sci, Dept Biochem & Mol Biol, Caceres 10071, Spain; Univ Extremadura, Dept Biochem & Mol Biol, Caceres 10071, Spain; Univ Extremadura, Dept Anim Med, Caceres 10071, Spain; Johns Hopkins Univ, Dept Cell Biol, Baltimore, MD 21205 USA	Universidad de Extremadura; Universidad de Extremadura; Universidad de Extremadura; Johns Hopkins University	Campo, ML (corresponding author), Univ Extremadura, Fac Vet Sci, Dept Biochem & Mol Biol, Avda de la Univ S-N, Caceres 10071, Spain.	mlcampo@unex.es	Dunn, Cory/B-9611-2013; Peixoto, Pablo/G-3036-2010; Peixoto, Pablo/Y-8360-2019; Campo, Maria Luisa/L-5211-2014	Peixoto, Pablo/0000-0001-5953-6027; Dunn, Cory/0000-0003-2393-5944				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; Becker L, 2005, J MOL BIOL, V353, P1011, DOI 10.1016/j.jmb.2005.09.019; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; CAMPO ML, 1984, EUR J BIOCHEM, V141, P5, DOI 10.1111/j.1432-1033.1984.tb08147.x; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; Grigoriev SM, 2004, INT REV CYTOL, V238, P227, DOI 10.1016/S0074-7696(04)38005-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herrmann JM, 2005, TRENDS BIOCHEM SCI, V30, P205, DOI 10.1016/j.tibs.2005.02.005; HILLE B, 2002, IONIC CHANNELS EXCIT, P351; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; Martinez-Caballero S, 2007, J BIOL CHEM, V282, P3584, DOI 10.1074/jbc.M607551200; Martinez-Caballero S, 2007, ANAL BIOCHEM, V362, P76, DOI 10.1016/j.ab.2006.12.015; Meinecke M, 2006, SCIENCE, V312, P1523, DOI 10.1126/science.1127628; Milisav I, 2001, J BIOL CHEM, V276, P25856, DOI 10.1074/jbc.M102132200; Muro C, 2003, BIOPHYS J, V84, P2981, DOI 10.1016/S0006-3495(03)70024-1; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Peixoto PM, 2004, RECENT RES DEV BIOPH, V3, P413; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Reichert AS, 2004, TRENDS GENET, V20, P555, DOI 10.1016/j.tig.2004.08.012; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200	43	32	32	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18694	18701		10.1074/jbc.M700775200	http://dx.doi.org/10.1074/jbc.M700775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17462993	hybrid			2022-12-25	WOS:000247475300007
J	Kobayashi, S; Lee, SH; Meng, XW; Mott, JL; Bronk, SF; Werneburg, NW; Craig, RW; Kaufmann, SH; Gores, GJ				Kobayashi, Shogo; Lee, Sun-Hee; Meng, Xue W.; Mott, Justin L.; Bronk, Steven F.; Werneburg, Nathan W.; Craig, Ruth W.; Kaufmann, Scott H.; Gores, Gregory J.			Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; MEMBRANE PERMEABILIZATION; DEPENDENT DEGRADATION; CELL LEUKEMIA-1; BCL-2 PROTEINS; EXPRESSION; ACTIVATION; RESISTANCE; INHIBITION; SURVIVAL	Mcl-1 is an antiapoptotic Bcl-2 family member that is highly regulated and when dysregulated contributes to cancer. The Mcl-1 protein is phosphorylated at multiple sites in response to different signaling events. Phosphorylations at Thr(163) (by ERK) and Ser(159) (by glycogen-synthase kinase 3 beta) have recently been shown to slow and enhance, respectively, Mcl-1 protein turnover. Phosphorylation is also known to be stimulated at other, as-yet uncharacterized sites in the G(2)/M phase of the cell cycle. Using an S peptide-tagged Mcl-1 T163A mutant, Ser(64) was identified as a novel Mcl-1 phosphorylation site by mass spectrometry. Immunoblotting demonstrated that phosphorylation at this site was maximal in cells in G(2)/M phase, was enhanced by tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) treatment, was blocked by inhibitors of CDK (but not ERK or glycogen-synthase kinase 3 beta), and was stimulated in vitro by CDK1, CDK2, and JNK1. The half-life of a nonphosphorylatable S64A Mcl-1 mutant was indistinguishable from that of the wild type polypeptide. In contrast, this mutant failed to protect cells from TRAIL-mediated apoptosis, whereas reconstitution with the phosphomimetic S64E Mcl-1 mutant rendered cells TRAIL-resistant. This anti-apoptotic phenotype of the S64E Mcl-1 mutant was also associated with enhanced binding to the proapoptotic proteins Bim, Noxa, and Bak. A pharmacological CDK inhibitor that reduced Ser(64) phosphorylation also sensitized cells to TRAIL cytotoxicity. Collectively, these observations not only identify G(2)/M-associated phosphorylation at Ser(64) as a critical determinant of the antiapoptotic activity of Mcl-1 but also elucidate a novel mechanism by which CDK1/2 inhibitors can enhance the effectiveness of the cytotoxic cytokine TRAIL.	Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Cell & Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Oncol Res, Rochester, MN 55905 USA; Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Dartmouth College	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145; Mott, Justin/0000-0002-2927-6962	NCI NIH HHS [CA 57359, R01 CA069008, CA 69008, R01 CA057359] Funding Source: Medline; NIDDK NIH HHS [DK 59427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008, R01CA057359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059427, R56DK059427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Joo EK, 2004, STEM CELLS DEV, V13, P563, DOI 10.1089/scd.2004.13.563; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lam LT, 2001, GENOME BIOL, V2; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Moshinsky DJ, 2003, BIOCHEM BIOPH RES CO, V310, P1026, DOI 10.1016/j.bbrc.2003.09.114; MURAKAMI T, 1987, HEPATOLOGY, V7, P551, DOI 10.1002/hep.1840070322; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Rinkenberger JL, 2000, GENE DEV, V14, P23; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thallinger C, 2004, CLIN CANCER RES, V10, P4185, DOI 10.1158/1078-0432.CCR-03-0774; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	55	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18407	18417		10.1074/jbc.M610010200	http://dx.doi.org/10.1074/jbc.M610010200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17463001	hybrid			2022-12-25	WOS:000247302000047
J	Yang, LQ; Lin, CR; Zhao, SM; Wang, HZ; Liu, ZR				Yang, Liuqing; Lin, Chunru; Zhao, Shumin; Wang, Haizhen; Liu, Zhi-Ren			Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; ABL FAMILY KINASES; DEAD-BOX; BETA-CATENIN; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; PDGF RECEPTORS; GLIOMA-CELLS	p68 RNA helicase is a protypical member of DEAD box family RNA helicase. The protein plays an important role in the cell developmental program and organ maturation. We demonstrated previously that, in response to growth factor platelet-derived growth factor (PDGF)-BB stimulation, p68 is phosphorylated at Tyr(593), and the phosphorylation of p68 promotes epithelial-mesenchymal transition via promoting beta-catenin nuclear translocation (Yang, L., Lin, C., and Liu, Z. R. (2006) Cell 127, 139 -155). We show here that the tyrosine phosphorylation of p68 also mediates the effects of PDGF in stimulating cell proliferation. The phosphorylated p68 (referred to as phospho-p68) promotes cell proliferation by activating the transcription of cyclin D1 and c-Myc genes. We show that the ATPase/helicase activities of p68 are required for the activation of cyclin D1 transcription. The phospho-p68 participates in the complex assembled at the cyclin D1 and c-Myc promoters, which strongly suggests a direct role in transcriptional regulation. Furthermore, our data demonstrated that the phosphorylation of p68 at Tyr593 plays a role in mediating the autocrine loop effects of PDGF, suggesting an important role for p68 phosphorylation in cell proliferation.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Pl Atlanta, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		NIGMS NIH HHS [GM063874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; BENITO M, 1993, GROWTH REGULAT, V3, P172; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Buszczak M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chin LS, 1997, CLIN CANCER RES, V3, P771; CHUNG CK, 1992, CANCER RES, V52, P3453; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FELLSTROM B, 1989, KIDNEY INT, V36, P1099, DOI 10.1038/ki.1989.306; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; GUHA A, 1991, Pediatric Neurosurgery, V17, P14, DOI 10.1159/000120559; Heinlein UAO, 1998, J PATHOL, V184, P345, DOI 10.1002/(SICI)1096-9896(199804)184:4<345::AID-PATH1243>3.0.CO;2-6; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Katano M, 1998, ANN SURG, V227, P365, DOI 10.1097/00000658-199803000-00008; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lassman Andrew B, 2004, Curr Neurol Neurosci Rep, V4, P228, DOI 10.1007/s11910-004-0043-3; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Lin CR, 2005, MOL CELL BIOL, V25, P7484, DOI 10.1128/MCB.25.17.7484-7493.2005; Lokker NA, 2002, CANCER RES, V62, P3729; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Paques M, 1997, DIABETES METAB, V23, P125; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Perona Rosario, 2006, Clin Transl Oncol, V8, P77, DOI 10.1007/s12094-006-0162-1; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Rowlands TM, 2004, CELL CYCLE, V3, P145; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Stice LL, 1999, FRONT BIOSCI, V4, P72; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tumber A, 2000, J ENDOCRINOL, V167, P383, DOI 10.1677/joe.0.1670383; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Wei Y, 2001, Yi Chuan Xue Bao, V28, P991; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	75	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16811	16819		10.1074/jbc.M610488200	http://dx.doi.org/10.1074/jbc.M610488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412694	hybrid			2022-12-25	WOS:000246946500013
J	Sakamoto, Y; Watanabe, S; Ichimura, T; Kawasuji, M; Koseki, H; Baba, H; Nakao, M				Sakamoto, Yasuo; Watanabe, Sugiko; Ichimura, Takaya; Kawasuji, Michio; Koseki, Haruhiko; Baba, Hideo; Nakao, Mitsuyoshi			Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; HISTONE H3; DEVELOPMENTAL REGULATORS; COMPLEXES; INTERACTS; CHROMATIN; CANCER; MECHANISMS; MEMORY; MLL	Methylated DNA binding domain (MBD) proteins and Polycomb group ( PcG) proteins maintain epigenetic silencing of transcriptional activity. We report that the DNA methylation-mediated repressor MBD1 interacts with Ring1b and hPc2, the major components of Polycomb repressive complex 1. The cysteine-rich CXXC domains of MBD1 bound to Ring1b and the chromodomain of hPc2. Chromatin immunoprecipitation analysis revealed that MBD1 and hPc2 were present in silenced Homeobox A (HOXA) genes which could be reactivated by knockdown of either MBD1 or hPc2, suggesting that MBD1 and hPc2 cooperate for transcriptional repression of HOXA genes. In the nuclei of HeLa cells, MBD1 existed in close association with these PcG proteins in some heterochromatin foci, whereas an MBD1 mutant lacking the CXXC domains or an hPc2 mutant lacking the chromodomain lost this colocalization in foci. Use of the DNA demethylating agent 5-azadeoxycytidine abolished the formation of MBD1 foci but not PcG foci. Knockdown of MBD1 by small interfering RNAs did not affect the foci containing hPc2 and Ring1b, whereas the MBD1 foci were not influenced by knockdown of hPc2. These indicate that the heterochromatin foci showing MBD1 and hPc2 colocalization arise through the interaction of MBD1 and hPc2 and that the foci of MBD1 are separable from those of the PcG proteins per se. Our present findings suggest that MBD1 and PcG proteins have overlapping roles in epigenetic gene silencing and heterochromatin foci formation through their interactions.	Kumamoto Univ, Grad Sch Med Sci, Dept Regenerat Med, Inst Mol Embryol & Genet, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Surg, Kumamoto 860, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; RIKEN	Nakao, M (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Regenerat Med, Inst Mol Embryol & Genet, 2-2-1 Honjo, Kumamoto 860, Japan.	mnakao@gpo.kumamoto-u.ac.jp	Koseki, Haruhiko/I-3825-2014; Watanabe, Sugiko/Q-6201-2019	Koseki, Haruhiko/0000-0001-8424-5854; Watanabe, Sugiko/0000-0002-2120-9546				BAYLIN SB, 2005, HUM MOL GENET S1, V2, P4; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Damelin M, 2006, NAT STRUCT MOL BIOL, V13, P100, DOI 10.1038/nsmb0206-100; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Ichimura T, 2005, J BIOL CHEM, V280, P13928, DOI 10.1074/jbc.M413654200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Taghavi P, 2006, NATURE, V439, P794, DOI 10.1038/439794a; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Watanabe S, 2003, P NATL ACAD SCI USA, V100, P12859, DOI 10.1073/pnas.2131819100; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100	46	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16391	16400		10.1074/jbc.M700011200	http://dx.doi.org/10.1074/jbc.M700011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428788	hybrid			2022-12-25	WOS:000246794300047
J	Heo, K; Kim, B; Kim, K; Choi, J; Kim, H; Zhan, YX; Ranish, JA; An, W				Heo, Kyu; Kim, Bong; Kim, Kyunghwan; Choi, Jongkyu; Kim, Hyunjung; Zhan, Yuxia; Ranish, Jeffrey A.; An, Woojin			Isolation and characterization of proteins associated with histone H3 tails in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; FACILITATES TRANSCRIPTION; LYSINE METHYLATION; NUCLEAR RECEPTORS; CHROMATIN; NUCLEOSOME; BINDING; COMPLEX; CODE; ACETYLATION	The histoneH3amino-terminal tails play an important role in regulating chromatin transcription. Although the mechanisms by which the H3 tail modulates transcription are not well understood, recent discoveries of specific interactions of regulatory factors with H3 tails suggest that H3 tails are a key player in the precise regulation of transcription activity. To investigate the recruitment-based action of H3 tails in chromatin transcription, we purified H3 tail-associated proteins from HeLa cells that stably express epitope-tagged H3 tails. This approach resulted in the identification of multiple histone methyltransferase activities and transcription regulatory factors that are specifically associated with expressed H3 tail domains. Point mutations of Lys-9 and Lys-27 to block cellular modifications of the tail domains completely abolished the association of specific factors, including HP1 and several repressors. Importantly, our transcription analysis revealed that the purified factors can significantly stimulate p300-mediated transcription from chromatin templates. These results implicate that the H3 tail, when accessible in relaxed chromatin, acts as a transcriptional regulator by mediating recruitment of specific sets of cofactors.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Inst Syst Biol, Seattle, WA 98103 USA	University of Southern California; Institute for Systems Biology (ISB)	An, W (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,SRT-1014, Los Angeles, CA 90027 USA.	woojinan@usc.edu		Heo, Kyu/0000-0001-8833-4731				An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; An WJ, 2004, METHOD ENZYMOL, V377, P460; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Malik S, 2003, METHOD ENZYMOL, V364, P257; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Holde K.E., 1988, CHROMATIN; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303; Zlatanova J, 1998, BIOESSAYS, V20, P584, DOI 10.1002/(SICI)1521-1878(199807)20:7<584::AID-BIES10>3.0.CO;2-W	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15476	15483		10.1074/jbc.M610270200	http://dx.doi.org/10.1074/jbc.M610270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403666	hybrid			2022-12-25	WOS:000246589600023
J	Sehat, B; Andersson, S; Vasilcanu, R; Girnita, L; Larsson, O				Sehat, Bita; Andersson, Sandra; Vasilcanu, Radu; Girnita, Leonard; Larsson, Olle			Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation	PLOS ONE			English	Article							FACTOR-I RECEPTOR; GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; BETA-ARRESTIN; CANCER; CELLS; PROTEASOME; PATHWAY; PROTEIN	Background. The insulin-like growth factor 1 receptor (IGF-1R) plays numerous crucial roles in cancer biology. The majority of knowledge on IGF-1R signaling is concerned with its role in the activation of the canonical phosphatidyl inositol-3 kinase (PI3K)/Akt and MAPK/ERK pathways. However, the role of IGF-1R ubiquitination in modulating IGF-1R function is an area of current research. In light of this we sought to determine the relationship between IGF-1R phosphorylation, ubiquitination, and modulation of growth signals. Methodology. Wild type and mutant constructs of IGF-1R were transfected into IGF-1R null fibroblasts. IGF-1R autophosphorylation and ubiquitination were determined by immunoprecipitation and western blotting. IGF-1R degradation and stability was determined by cyclohexamide-chase assay in combination with lysosome and proteasome inhibitors. Principal Findings. IGF-1R autophosphorylation was found to be an absolute requirement for receptor ubiquitination. Deletion of C-terminal domain had minimal effect on IGF-1 induced receptor autophosphorylation, however, ubiquitination and ERK activation were completely abolished. Cells expressing kinase impaired IGF-1R, exhibited both receptor ubiquitination and ERK phosphorylation, however failed to activate Akt. While IGF-1R mutants with impaired PI3K/Akt signaling were degraded mainly by the proteasomes, the C-terminal truncated one was exclusively degraded through the lysosomal pathway. Conclusions. Our data suggest important roles of ubiquitination in mediating IGF-1R signaling and degradation. Ubiquitination of IGF-1R requires receptor tyrosine kinase activity, but is not involved in Akt activation. In addition we show that the C-terminal domain of IGF-1R is a necessary requisite for ubiquitination and ERK phosphorylation as well as for proteasomal degradation of the receptor.	[Larsson, Olle] Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, Stockholm, Sweden; Karolinska Univ Hosp Solna, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, Stockholm, Sweden.	olle.larsson@ki.se	Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500	Swedish Cancer Society; Cancer Society in Stockholm; Swedish Research Council; Swedish Children Cancer Society; Gustaf V Jubilee Foundation; Ingabritt and Arne Lundberg's research Foundation; Alex and Eva Wallstrom's Foundation; Karolinska Institute	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Children Cancer Society(Swedish Cancer Society); Gustaf V Jubilee Foundation; Ingabritt and Arne Lundberg's research Foundation; Alex and Eva Wallstrom's Foundation; Karolinska Institute(Karolinska Institutet)	The Swedish Cancer Society, the Cancer Society in Stockholm, the Swedish Research Council, the Swedish Children Cancer Society, The Gustaf V Jubilee Foundation, Ingabritt and Arne Lundberg's research Foundation, Alex and Eva Wallstrom's Foundation and the Karolinska Institute.	Alexander A, 1998, Front Biosci, V3, pd729; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, GROWTH HORM IGF RES, V10, pS43, DOI 10.1016/S1096-6374(00)90021-2; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Colombo MG, 2001, CARDIOVASC DRUG THER, V15, P25, DOI 10.1023/A:1011154616992; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; LI SW, 1994, J BIOL CHEM, V269, P32558; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Oli MW, 2006, EUKARYOT CELL, V5, P132, DOI 10.1128/EC.5.1.132-139.2006; Park DS, 2003, BIOCHEMISTRY-US, V42, P15124, DOI 10.1021/bi0356348; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu D, 2003, J BIOL CHEM, V278, P6702, DOI 10.1074/jbc.M209809200; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zaiss DMW, 2002, P NATL ACAD SCI USA, V99, P14344, DOI 10.1073/pnas.212257299; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	46	57	61	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e340	10.1371/journal.pone.0000340	http://dx.doi.org/10.1371/journal.pone.0000340			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406664	Green Published, gold			2022-12-25	WOS:000207445300002
J	Kucherlapati, M; Nguyen, A; Kuraguchi, M; Yang, K; Fan, K; Bronson, R; Wei, K; Lipkin, M; Edelmann, W; Kucherlapati, R				Kucherlapati, M.; Nguyen, A.; Kuraguchi, M.; Yang, K.; Fan, K.; Bronson, R.; Wei, K.; Lipkin, M.; Edelmann, W.; Kucherlapati, R.			Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies	ONCOGENE			English	Article						mouse; Apc(1638N); Exo1; Fen1	MISMATCH REPAIR PROTEINS; COLORECTAL-CANCER; GENE; EXONUCLEASE; MUTATIONS; MOUSE; INTERACTS; SYSTEM; MODEL; MSH6	Flap endonuclease 1 (Fen1) and exonuclease 1 (Exo1) have sequence homology and similar nuclease capabilities. Both function in multiple pathways of DNA metabolism, but appear to have distinct in vivo nucleic acid substrates, and therefore distinct metabolic roles. When combined with Apc(1638N), Fen1 promotes tumor progression. Because of functional similarity to Fen1, and because Exo1 is involved in DNA mismatch repair (MMR) by interaction with Msh2 and Mlh1, genes that cause hereditary nonpolyposis colorectal cancer ( HNPCC), we investigated the possibility that Exo1 might also act as a modi. er to Apc(1638N). We present evidence that mice with combined mutations in Apc(1638N) and Exo1 and Apc(1638N), Exo1 and Fen1 genes show moderate increased tumor incidence and multiplicity in comparison to Apc(1638N) siblings, implying a low penetrance role for Exo1 in early gastrointestinal (GI) tumorigenesis. Despite a decrease in median survival (10 months) in Apc(1638N) Exo1 mice, their tumors do not progress any more rapidly than those of Apc(1638N). Instead these animals die from infections that are the result of impaired immune response. Apc(1638N) Exo1 Fen1 mice survive longer (18 months), and therefore appear relatively immune competent. They die of invasive GI tumors that display microsatellite instability (MSI). Our results show that Exo1 has a modest tumor suppressor function.	Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Harvard University; Harvard Medical School; Rockefeller University; Harvard University; Harvard Medical School; Tufts University; Tufts University; Yeshiva University; Albert Einstein College of Medicine	Kucherlapati, R (corresponding author), Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, 77 Ave Louis Pasteur,NRB 160, Boston, MA 02115 USA.	mkucherlapati@rics.bwh.harvard.edu	Kucherlapati, Raju/ABC-8807-2021		NATIONAL CANCER INSTITUTE [U01CA084301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011040] Funding Source: NIH RePORTER; NCI NIH HHS [CA084301] Funding Source: Medline; NIEHS NIH HHS [ES011040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam NA, 2003, CANCER GENET CYTOGEN, V147, P121, DOI 10.1016/S0165-4608(03)00196-1; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Edelmann L, 2004, AM J MED GENET C, V129C, P91, DOI 10.1002/ajmg.c.30021; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 2000, CANCER RES, V60, P803; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Jagmohan-Changur S, 2003, CANCER RES, V63, P154; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rudolph C, 1998, CURR GENET, V34, P343, DOI 10.1007/s002940050405; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sokolsky T, 2000, GENETICS, V155, P589; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2004, DNA REPAIR, V3, P1549, DOI 10.1016/j.dnarep.2004.05.015; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117; Yamamoto H, 2005, CARCINOGENESIS, V26, P411, DOI 10.1093/carcin/bgh335	29	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6297	6306		10.1038/sj.onc.1210453	http://dx.doi.org/10.1038/sj.onc.1210453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452984				2022-12-25	WOS:000249583300006
J	Thakurdas, SM; Melicoff, E; Sansores-Garcia, L; Moreira, DC; Petrova, Y; Stevens, RL; Adachi, R				Thakurdas, Shakeel M.; Melicoff, Ernestina; Sansores-Garcia, Leticia; Moreira, Daniel C.; Petrova, Youlia; Stevens, Richard L.; Adachi, Roberto			The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; SUBSTRATE-SPECIFICITY; GRANULE PROTEASES; SERINE PROTEASES; MOUSE; EXPRESSION; MICE; TISSUE; GENE; TRANSCRIPTION	Although it has been shown that mast cell-deficient mice have diminished innate immune responses against bacteria, the most important immunoprotective factors secreted from activated mast cells have not been identified. Mouse mast cell protease 6 is a tetramer-forming tryptase. This serine protease is abundant in the secretory granules and is exocytosed upon bacterial challenge. Here we have described the generation of a mast cell protease-6-null mouse. Our discovery that mice lacking this neutral protease cannot efficiently clear Klebsiella pneumoniae from their peritoneal cavities reveals an essential role for this serine protease, and presumably its human ortholog, in innate immunity.	Univ Texas, MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA; Inst Biosci & Technol, Ctr Lung Inflammat & Infect, Houston, TX 77030 USA; Tecnol Monterrey Campus Monterrey, Sch Med, Monterrey 64710, Nuevo Leon, Mexico; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Tecnologico de Monterrey; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Adachi, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pulm Med, 2121 W Holcombe Blvd,Box 1100, Houston, TX 77030 USA.	radachi@mdanderson.org		Melicoff, Ernestina/0000-0001-5696-7112; Adachi, Roberto/0000-0002-0146-0768; Moreira, Daniel/0000-0003-4082-156X; Sansores-Garcia, Leticia/0000-0003-2510-225X	NCI NIH HHS [P30CA16672] Funding Source: Medline; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-54950] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannert N, 2001, J VIROL, V75, P10808, DOI 10.1128/JVI.75.22.10808-10814.2001; Clair JMS, 2004, J CLIN INVEST, V113, P628, DOI 10.1172/JCI200419062; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Hori Y, 2002, J IMMUNOL, V169, P1978, DOI 10.4049/jimmunol.169.4.1978; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; INAGAKI N, 1986, INT ARCH ALLER A IMM, V80, P285, DOI 10.1159/000234067; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Jippo T, 2003, J EXP MED, V197, P1417, DOI 10.1084/jem.20022157; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; Morii E, 2004, BLOOD, V104, P1656, DOI 10.1182/blood-2004-01-0247; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; ROYET JP, 1991, PROG NEUROBIOL, V37, P433, DOI 10.1016/0301-0082(91)90009-P; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Taub DD, 2004, CELL IMMUNOL, V230, P65, DOI 10.1016/j.cellimm.2004.09.005; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WEG VB, 1991, EUR J PHARMACOL, V204, P157, DOI 10.1016/0014-2999(91)90700-Z; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200; Wong GW, 2004, J BIOL CHEM, V279, P2438, DOI 10.1074/jbc.M308209200; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200	34	140	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20809	20815		10.1074/jbc.M611842200	http://dx.doi.org/10.1074/jbc.M611842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17456473	hybrid			2022-12-25	WOS:000248047500006
J	Bernstein, JR; Bulter, T; Shen, CR; Liao, JC				Bernstein, Jeffrey R.; Bulter, Thomas; Shen, Claire R.; Liao, James C.			Directed evolution of ribosomal protein S1 for enhanced translational efficiency of high GC Rhodopseudomonas palustris DNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; IN-VITRO; INITIATION; EXPRESSION; CLONING; GENES; REGION; STRATEGIES; SELECTION; SEQUENCE	The expression of foreign DNA in Escherichia coli is important in biotechnological applications. However, the translation of genes from GC-rich organisms is inefficient in E. coli. To overcome this problem, we applied directed evolution to E. coli ribosomal protein S1. Two selected mutants enabled 12- and 8-fold higher expression levels from GC-rich DNA targets. General improvements in translation efficiency over a range of genes from Rhodopseudomonas palustris and E. coli was achieved using an S1 mutant selected against multiple genes from R. palustris. This method opens new opportunities for the expression of GC-rich genes in E. coli.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Biomed Engn & Interdepartamental Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Liao, JC (corresponding author), 5531 Boelter Hall,420 Westwood Plaza, Los Angeles, CA 90095 USA.	liaoj@ucla.edu		Liao, James/0000-0002-4580-7276; Bulter, Thomas/0000-0002-7968-5844	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077625] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM077625-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVIDSON DN, 1991, BIOTECHNIQUES, V11, P733; Boni IV, 2000, J BACTERIOL, V182, P5872, DOI 10.1128/JB.182.20.5872-5879.2000; Brodersen DE, 2005, FEBS J, V272, P2098, DOI 10.1111/j.1742-4658.2005.04651.x; Bulter T, 2003, BIOTECHNOL BIOENG, V84, P815, DOI 10.1002/bit.10845; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Egland PG, 1999, J BACTERIOL, V181, P2102, DOI 10.1128/JB.181.7.2102-2109.1999; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Grill S, 2001, FEBS LETT, V495, P167, DOI 10.1016/S0014-5793(01)02378-X; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Heinz C, 2003, J CHROMATOGR B, V790, P337, DOI 10.1016/S1570-0232(03)00130-2; ISHIDA M, 1994, J BACTERIOL, V176, P2767, DOI 10.1128/JB.176.9.2767-2770.1994; Ishida M, 2002, J BIOCHEM, V132, P63, DOI 10.1093/oxfordjournals.jbchem.a003199; Itaya M, 2005, P NATL ACAD SCI USA, V102, P15971, DOI 10.1073/pnas.0503868102; Komarova AV, 2005, J BACTERIOL, V187, P1344, DOI 10.1128/JB.187.4.1344-1349.2005; Komarova AV, 2002, RNA, V8, P1137, DOI 10.1017/S1355838202029990; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Leem SH, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng029; Lessard IAD, 1998, CHEM BIOL, V5, P489, DOI 10.1016/S1074-5521(98)90005-9; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; McGinness KE, 2004, P NATL ACAD SCI USA, V101, P13454, DOI 10.1073/pnas.0405521101; MELANCON P, 1990, BIOCHEMISTRY-US, V29, P3402, DOI 10.1021/bi00465a037; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; POTAPOV AP, 1992, BIOCHEM INT, V27, P745; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Rohlin L, 2005, J BACTERIOL, V187, P6046, DOI 10.1128/JB.187.17.6046-6057.2005; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; Sukhodolets MV, 2006, RNA, V12, P1505, DOI 10.1261/rna.2321606; TONG IT, 1991, APPL ENVIRON MICROB, V57, P3541, DOI 10.1128/AEM.57.12.3541-3546.1991; TZAREVA NV, 1994, FEBS LETT, V337, P189, DOI 10.1016/0014-5793(94)80271-8; Voges D, 2004, BIOCHEM BIOPH RES CO, V318, P601, DOI 10.1016/j.bbrc.2004.04.064; Wang CW, 2000, BIOTECHNOL PROGR, V16, P922, DOI 10.1021/bp000124f	43	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18929	18936		10.1074/jbc.M701395200	http://dx.doi.org/10.1074/jbc.M701395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17412688	hybrid			2022-12-25	WOS:000247475300034
J	Lopez-Vinas, E; Bentebibel, A; Gurunathan, C; Morillas, M; de Arriaga, D; Serra, D; Asins, G; Hegardt, FG; Gomez-Puertas, P				Lopez-Vinas, Eduardo; Bentebibel, Assia; Gurunathan, Chandrashekaran; Morillas, Montserrat; de Arriaga, Dolores; Serra, Dolors; Asins, Guillermina; Hegardt, Fausto G.; Gomez-Puertas, Paulino			Definition by functional and structural analysis of two malonyl-CoA sites in carnitine palmitoyltransferase 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BROWN ADIPOSE-TISSUE; AMINO-ACID-RESIDUES; HIGH-AFFINITY; AUTOMATED DOCKING; CRYSTAL-STRUCTURE; SWISS-MODEL; CPT I; INTRAMOLECULAR INTERACTIONS; PROTEIN	Carnitine palmitoyltransferase 1 (CPT1) catalyzes the conversion of palmitoyl-CoA to palmitoylcarnitine in the presence of L-carnitine, thus facilitating the entry of fatty acids to mitochondria, in a process that is physiologically inhibited by malonyl-CoA. To examine the mechanism of CPT1 liver isoform (CPT1A) inhibition by malonyl-CoA, we constructed an in silico model of both its NH2- and COOH-terminal domains. Two malonyl-CoA binding sites were found. One of these, the "CoA site" or "A site," is involved in the interactions between NH2- and COOH-terminal domains and shares the acyl-CoA hemitunnel. The other, the "opposite-to-CoA site" or "O site," is on the opposite side of the enzyme, in the catalytic channel. The two sites share the carnitine-binding locus. To prevent the interaction between NH2- and COOH-terminal regions, we produced CPT1A E26K and K561E mutants. A double mutant E26K/K561E (swap), which was expected to conserve the interaction, was also produced. Inhibition assays showed a 12-fold decrease in the sensitivity (IC50) toward malonyl-CoA for CPT1A E26K and K561E single mutants, whereas swap mutant reverts to wild-type IC50 value. We conclude that structural interaction between both domains is critical for enzyme sensitivity to malonyl-CoA inhibition at the "A site." The location of the "O site" for malonyl-CoA binding was supported by inhibition assays of expressed R243T mutant. The model is also sustained by kinetic experiments that indicated linear mixed type malonyl-CoA inhibition for carnitine. Malonyl-CoA alters the affinity of carnitine, and there appears to be an exponential inverse relation between carnitine Km and malonyl-CoA IC50.	Univ Pompeu Fabra, Dept Ciencias Expt Salud, E-08003 Barcelona, Spain; Univ Autonoma Madrid, CSIC, Ctr Mol Biol Severo Ochoa, E-28049 Madrid, Spain; Univ Barcelona, Fac Farm, Dept Mol Biol, E-08028 Barcelona, Spain; Univ Leon, Dept Mol Biol, E-24071 Leon, Spain; Inst Salud Carlos III, CIBER, Inst Fisiopatol Obesidad & Nutr, E-28049 Madrid, Spain	Pompeu Fabra University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Barcelona; Universidad de Leon; CIBER - Centro de Investigacion Biomedica en Red; Instituto de Salud Carlos III	Hegardt, FG (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Diagonal 643, E-08028 Barcelona, Spain.	fgarciaheg@ub.edu	Morillas, Montserrat/G-6080-2015; López-Viñas, Eduardo/AAT-1124-2021; Gomez-Puertas, Paulino/G-8821-2014; Serra, Dolors/L-3657-2014	Gomez-Puertas, Paulino/0000-0003-3131-729X; Serra, Dolors/0000-0002-4936-4206; Morillas, Montserrat/0000-0001-7068-3167; de Arriaga Giner, Maria Dolores/0000-0003-4528-5815				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Bentebibel A, 2006, BIOCHEMISTRY-US, V45, P4339, DOI 10.1021/bi052186q; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIRD MI, 1985, BIOCHEM J, V230, P161, DOI 10.1042/bj2300161; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; Borthwick K, 2006, J BIOL CHEM, V281, P32946, DOI 10.1074/jbc.M600843200; Cha SH, 2006, P NATL ACAD SCI USA, V103, P15410, DOI 10.1073/pnas.0607334103; COOK GA, 1994, J BIOL CHEM, V269, P8803; Cordente AG, 2004, J BIOL CHEM, V279, P33899, DOI 10.1074/jbc.M402685200; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; Faye A, 2005, BIOCHEM J, V387, P67, DOI 10.1042/BJ20041533; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hsiao YS, 2006, BIOCHEM BIOPH RES CO, V346, P974, DOI 10.1016/j.bbrc.2006.06.006; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Jaroszewski L, 2000, PROTEIN SCI, V9, P1487, DOI 10.1110/ps.9.8.1487; Jogl G, 2005, J BIOL CHEM, V280, P738, DOI 10.1074/jbc.M409894200; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; Kashfi K, 1999, ADV EXP MED BIOL, V466, P27; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCGARRY JD, 1975, P NATL ACAD SCI USA, V72, P4385, DOI 10.1073/pnas.72.11.4385; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; Morillas M, 2004, BIOCHEM J, V379, P777, DOI 10.1042/BJ20031373; Morillas M, 2003, J BIOL CHEM, V278, P9058, DOI 10.1074/jbc.M209999200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nicot C, 2001, BIOCHEMISTRY-US, V40, P2260, DOI 10.1021/bi0024106; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Rufer AC, 2006, STRUCTURE, V14, P713, DOI 10.1016/j.str.2006.01.008; SAGGERSON ED, 1981, FEBS LETT, V129, P225, DOI 10.1016/0014-5793(81)80170-6; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SEGEL IH, 1993, ENZYME KINETICS, P170; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; Tress M, 2005, PROTEINS, V60, P275, DOI 10.1002/prot.20570; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335; ZAMMIT VA, 1984, BIOCHEM J, V218, P379, DOI 10.1042/bj2180379; ZAMMIT VA, 1985, BIOCHEM J, V231, P343, DOI 10.1042/bj2310343; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	58	38	38	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18212	18224		10.1074/jbc.M700885200	http://dx.doi.org/10.1074/jbc.M700885200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17452323	hybrid			2022-12-25	WOS:000247302000028
J	Voloshin, ON; Camerini-Otero, RD				Voloshin, Oleg N.; Camerini-Otero, R. Daniel			The DinG protein from Escherichia coli is a structure-specific helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK REVERSAL; DNA SUBSTRATE-SPECIFICITY; HOMOLOGOUS RECOMBINATION; XERODERMA-PIGMENTOSUM; GENE ENCODES; REPAIR; BINDING; BACH1; RECA; STRAND	The Escherichia coli DinG protein is a DNA damage-inducible member of the helicase superfamily 2. Using a panel of synthetic substrates, we have systematically investigated structural requirements for DNA unwinding by DinG. We have found that the helicase does not unwind blunt-ended DNAs or substrates with 3'-ss tails. On the other hand, the 5'-ss tails of 11-15 nucleotides are sufficient to initiate DNA duplex unwinding; bifurcated substrates further facilitate helicase activity. DinG is active on 5'-flap structures; however, it is unable to unwind 3'-flaps. Similarly to the homologous Saccharomyces cerevisiae Rad3 helicase, DinG unwinds DNA.RNA duplexes. DinG is active on synthetic D-loops and R-loops. The ability of the enzyme to unwind D-loops formed on superhelical plasmid DNA by the E. coli recombinase RecA suggests that D-loops may be natural substrates for DinG. Although the availability of 5'-ssDNA tails is a strict requirement for duplex unwinding by DinG, the unwinding of D-loops can be initiated on substrates without any ss tails. Since DinG is DNA damage-inducible and is active on D-loops and forked structures, which mimic intermediates of homologous recombination and replication, we conclude that this helicase may be involved in recombinational DNA repair and the resumption of replication after DNA damage.	NIDDK, NIH, Genet & Biochem Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Camerini-Otero, RD (corresponding author), Genet & Biochem Branch, 5 Mem Dr,Rm 201,MSC 0538, Bethesda, MD 20892 USA.	camerini@ncifcrf.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052032, Z01DK052033, ZIADK052033, ZIADK052032] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anand SP, 2004, NUCLEIC ACIDS RES, V32, P3190, DOI 10.1093/nar/gkh641; Baharoglu Z, 2006, EMBO J, V25, P596, DOI 10.1038/sj.emboj.7600941; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; Bartos JD, 2006, J BIOL CHEM, V281, P32227, DOI 10.1074/jbc.M606310200; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Cadman CJ, 2006, J MOL BIOL, V362, P18, DOI 10.1016/j.jmb.2006.06.032; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; Courcelle J, 2001, GENETICS, V158, P41; Courcelle J, 2003, ANNU REV GENET, V37, P611, DOI 10.1146/annurev.genet.37.110801.142616; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Flores MJ, 2004, EMBO REP, V5, P983, DOI 10.1038/sj.embor.7400262; Fujikane R, 2006, GENES CELLS, V11, P99, DOI 10.1111/j.1365-2443.2006.00925.x; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; Gupta R, 2005, J BIOL CHEM, V280, P25450, DOI 10.1074/jbc.M501995200; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Kanagaraj R, 2006, NUCLEIC ACIDS RES, V34, P5217, DOI 10.1093/nar/gkl677; Khil PP, 2002, MOL MICROBIOL, V44, P89, DOI 10.1046/j.1365-2958.2002.02878.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P1497, DOI 10.1093/nar/21.6.1497; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Kuusk S, 2005, J BIOL CHEM, V280, P24322, DOI 10.1074/jbc.M500354200; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LEWIS LK, 1992, J BACTERIOL, V174, P5110, DOI 10.1128/JB.174.15.5110-5116.1992; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Lukianova OA, 2005, CURR OPIN CHEM BIOL, V9, P145, DOI 10.1016/j.cbpa.2005.02.006; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Rudolf J, 2006, MOL CELL, V23, P801, DOI 10.1016/j.molcel.2006.07.019; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Van Dyk TK, 2001, J BACTERIOL, V183, P5496, DOI 10.1128/JB.183.19.5496-5505.2001; Voloshin ON, 2000, J MOL BIOL, V303, P709, DOI 10.1006/jmbi.2000.4163; Voloshin ON, 2003, J BIOL CHEM, V278, P28284, DOI 10.1074/jbc.M301188200; Warfield KL, 2006, CURR OPIN MOL THER, V8, P93; Weiss DS, 2004, MOL MICROBIOL, V54, P588, DOI 10.1111/j.1365-2958.2004.04283.x; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; Wu L, 2006, ANNU REV GENET, V40, P279, DOI 10.1146/annurev.genet.40.110405.090636	69	60	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18437	18447		10.1074/jbc.M700376200	http://dx.doi.org/10.1074/jbc.M700376200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17416902	hybrid			2022-12-25	WOS:000247302000050
J	Klutts, JS; Levery, SB; Doering, TL				Klutts, J. Stacey; Levery, Steven B.; Doering, Tamara L.			A beta-1,2-xylosyltransferase from Cryptococcus neoformans defines a new family of glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; CATALYTIC MECHANISM; VIRULENCE; YEAST; LAURENTII; PROTEIN; ALPHA-1,3-MANNOSYLTRANSFERASE; METHYLATION; REQUIRES; PATHWAY	Cryptococcus neoformans is an opportunistic fungal pathogen characterized by a prominent polysaccharide capsule that envelops the cell. Although this capsule is dispensable for in vitro growth, its presence is essential for virulence. The capsule is primarily made of two xylose-containing polysaccharides, glucuronoxylomannan and galactoxylomannan. There are likely to be multiple xylosyltransferases (XTs) involved in capsule synthesis, and the activities of these enzymes are potentially important for cryptococcal virulence. A beta-1,2-xylosyltransferase with specificity appropriate for capsule synthesis was purified similar to 3000-fold from C. neoformans, and the corresponding gene was identified and cloned. This sequence conferred XT activity when expressed in Saccharomyces cerevisiae, which lacks endogenous XT activity. The gene, termed CXT1 for cryptococcal xylosyltransferase 1, encodes a 79-kDa type II membrane protein with an N-linked glycosylation site and two DXD motifs. These latter motifs are believed to coordinate divalent cation binding in the activity of glycosyltransferases. Site-directed mutagenesis of one DXD motif abolished Cxt1p activity, even though this activity does not depend on the addition of a divalent cation. This may indicate a novel catalytic mechanism for glycosyl transfer. Five homologs of Cxt1p were found in the genome sequence of C. neoformans and 34 within the sequences of other fungi, although none were found in other organisms. Many of the homologous proteins are similar in size to Cxt1p, and all are conserved with respect to the essential DXD motif. These proteins represent a new family of glycosyltransferases, found exclusively within the fungal kingdom.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	Washington University (WUSTL); Washington University (WUSTL); University System Of New Hampshire; University of New Hampshire	Doering, TL (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	doering@wustl.edu		Klutts, James/0000-0003-3788-1940	NCRR NIH HHS [R21 RR20355] Funding Source: Medline; NIGMS NIH HHS [GM R01 071007, F32 GM072341, R01 GM071007, G32 GM 072341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR020355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071007, F32GM072341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2, P13; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; Barchiesi F, 2005, J INFECTION, V51, P10, DOI 10.1016/j.jinf.2004.07.013; Bencur P, 2005, BIOCHEM J, V388, P515, DOI 10.1042/BJ20042091; Bose I, 2003, EUKARYOT CELL, V2, P655, DOI 10.1128/EC.2.4.655-663.2003; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; Chang YC, 1998, INFECT IMMUN, V66, P2230, DOI 10.1128/IAI.66.5.2230-2236.1998; Chayakulkeeree M, 2006, INFECT DIS CLIN N AM, V20, P507, DOI 10.1016/j.idc.2006.07.001; Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146; Ciucanu I, 2003, J AM CHEM SOC, V125, P16213, DOI 10.1021/ja035660t; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Doering TL, 1999, J BACTERIOL, V181, P5482, DOI 10.1128/JB.181.17.5482-5488.1999; Fries BC, 1999, INFECT IMMUN, V67, P6076, DOI 10.1128/IAI.67.11.6076-6083.1999; Goldman DL, 1998, P NATL ACAD SCI USA, V95, P14967, DOI 10.1073/pnas.95.25.14967; Griffith CL, 2004, J BIOL CHEM, V279, P51669, DOI 10.1074/jbc.M408889200; Heise N, 2002, GLYCOBIOLOGY, V12, P409, DOI 10.1093/glycob/cwf053; HELLERQVIST CG, 1990, METHOD ENZYMOL, V193, P554, DOI 10.1016/0076-6879(90)93438-Q; HELLERQVIST CG, 1990, METHOD BIOCHEM ANAL, V34, P91; Hodson N, 2000, J BIOL CHEM, V275, P27311; Jain N, 2006, FEMS YEAST RES, V6, P480, DOI 10.1111/j.1567-1364.2006.00039.x; Janbon G, 2001, MOL MICROBIOL, V42, P453, DOI 10.1046/j.1365-2958.2001.02651.x; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Klutts JS, 2006, FEMS YEAST RES, V6, P499, DOI 10.1111/j.1567-1364.2006.00054.x; KWONCHUNG KJ, 1986, INFECT IMMUN, V51, P218, DOI 10.1128/IAI.51.1.218-223.1986; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; McFadden DC, 2006, J BIOL CHEM, V281, P1868, DOI 10.1074/jbc.M509465200; Moyrand F, 2004, EUKARYOT CELL, V3, P1513, DOI 10.1128/EC.3.6.1513-1524.2004; Moyrand F, 2002, MOL MICROBIOL, V45, P837, DOI 10.1046/j.1365-2958.2002.03059.x; Okabayashi K, 2007, MYCOPATHOLOGIA, V163, P1, DOI 10.1007/s11046-006-0083-0; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; RAIZADA MK, 1975, J BIOL CHEM, V250, P3310; Reese AJ, 2007, MOL MICROBIOL, V63, P1385, DOI 10.1111/j.1365-2958.2006.05551.x; SCHUTZBACH JS, 1974, J BIOL CHEM, V249, P2953; SCHUTZBACH JS, 1972, J BIOL CHEM, V247, P6574; Shibayama K, 1999, FEMS MICROBIOL LETT, V174, P105, DOI 10.1111/j.1574-6968.1999.tb13555.x; Sommer U, 2003, J BIOL CHEM, V278, P47724, DOI 10.1074/jbc.M307223200; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vaishnav VV, 1998, CARBOHYD RES, V306, P315, DOI 10.1016/S0008-6215(97)10058-1; Vecchiarelli A, 2005, CURR MOL MED, V5, P413, DOI 10.2174/1566524054022585; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WILSON DE, 1968, P SOC EXP BIOL MED, V127, P820, DOI 10.3181/00379727-127-32812; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	47	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17890	17899		10.1074/jbc.M701941200	http://dx.doi.org/10.1074/jbc.M701941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430900	hybrid			2022-12-25	WOS:000247084500062
J	Kok, KH; Ng, MHJ; Ching, YP; Jin, DY				Kok, Kin Hang; Ng, Ming-Him James; Ching, Yick-Pang; Jin, Dong-Yan			Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BINDING-PROTEIN; MICRORNA MATURATION; MAMMALIAN-CELLS; PKR; ACTIVATION; EXPRESSION; DROSOPHILA; PATHWAY; DSRNA	Mammalian Dicer interacts with double-stranded RNA-binding protein TRBP or PACT to mediate RNA interference and micro-RNA processing. TRBP and PACT are structurally related but exert opposite regulatory activities on PKR. It is not understood whether TRBP and PACT are simultaneously required for Dicer. Here we show that TRBP directly interacts with PACT in vitro and in mammalian cells. TRBP and PACT form a triple complex with Dicer and facilitate the production of small interfering RNA ( siRNA) by Dicer. Knockdown of both TRBP and PACT in cultured cells leads to significant inhibition of gene silencing mediated by short hairpin RNA but not by siRNA, suggesting that TRBP and PACT function primarily at the step of siRNA production. Taken together, these findings indicate that human TRBP and PACT directly interact with each other and associate with Dicer to stimulate the cleavage of double-stranded or short hairpin RNA to siRNA. Our work significantly alters the current model for the assembly and function of the Dicer-containing complex that generates siRNA and micro-RNA in human.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3-F Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk	Kok, Kin-Hang/C-4184-2009; Ching, Yick Pang/C-4244-2009	/0000-0003-3426-332X; CHING, Yick Pang/0000-0002-6461-8358				Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bennasser Y, 2006, J BIOL CHEM, V281, P27674, DOI 10.1074/jbc.C600072200; Bennett RL, 2006, BLOOD, V108, P821, DOI 10.1182/blood-2005-11-006817; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Chan CP, 2006, J VIROL, V80, P9279, DOI 10.1128/JVI.00659-06; Chen G, 2006, J BIOL CHEM, V281, P15909, DOI 10.1074/jbc.M600612200; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chin KT, 2007, CANCER RES, V67, P1072, DOI 10.1158/0008-5472.CAN-06-3053; Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gupta V, 2003, VIROLOGY, V315, P283, DOI 10.1016/S0042-6822(03)00589-0; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hitti EG, 2004, FEBS LETT, V574, P25, DOI 10.1016/j.febslet.2004.07.080; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Kok KH, 2006, J GEN VIROL, V87, P2639, DOI 10.1099/vir.0.81764-0; Lee JY, 2006, ONCOGENE, V25, P1143, DOI 10.1038/sj.onc.1209150; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Li SD, 2006, P NATL ACAD SCI USA, V103, P10005, DOI 10.1073/pnas.0602317103; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Liu X, 2006, RNA, V12, P1514, DOI 10.1261/rna.101606; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Margis R, 2006, FEBS LETT, V580, P2442, DOI 10.1016/j.febslet.2006.03.072; Ong CL, 2005, J VIROL, V79, P12763, DOI 10.1128/JVI.79.20.12763-12772.2005; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Park JK, 2007, CURR BIOL, V17, P533, DOI 10.1016/j.cub.2007.01.060; Parker GS, 2006, RNA, V12, P807, DOI 10.1261/rna.2338706; Parrish S, 2001, RNA, V7, P1397; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Rowe TM, 2006, P NATL ACAD SCI USA, V103, P5823, DOI 10.1073/pnas.0601287103; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Vaucheret H, 2006, GENE DEV, V20, P759, DOI 10.1101/gad.1410506; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; Zhou Y, 2002, NUCLEIC ACIDS RES, V30, P1664, DOI 10.1093/nar/30.7.1664	50	166	192	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17649	17657		10.1074/jbc.M611768200	http://dx.doi.org/10.1074/jbc.M611768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17452327	hybrid, Green Submitted			2022-12-25	WOS:000247084500037
J	Boggio, R; Passafaro, A; Chiocca, S				Boggio, Roberto; Passafaro, Alfonso; Chiocca, Susanna			Targeting SUMO E1 to ubiquitin ligases - A viral strategy to counteract sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SOCS-BOX; HISTONE DEACETYLASE-1; ADENOVIRUS; DEGRADATION; COMPLEX; IDENTIFICATION; ELONGATION; ACTIVATION; MECHANISM	SUMO-1 (small ubiquitin-related modifier-1) is a ubiquitin-like family member that is conjugated to its substrates through three discrete enzymatic steps, activation (involving the E1 enzyme (SAE1/SAE2)), conjugation (involving the E2 enzyme), and substrate modification (through the cooperation of the E2 and E3 protein ligases). The adenoviral protein Gam1 inactivates E1, both in vitro and in vivo, followed by SAE1/SAE2 degradation. We have shown here that Gam1 possesses a C-terminal SOCS domain that allows its interaction with two cellular cullin RING ( really interesting new gene) ubiquitin ligases. We demonstrate that Gam1 is necessary for the recruitment of SAE1/SAE2 into Cul2/5-EloB/C-Roc1 ubiquitin ligase complexes and for subsequent SAE1 ubiquitylation and degradation. The degradation of SAE2 is not tightly related to Gam1 but is a consequent effect of SAE1 disappearance. These results reveal the mechanism by which a viral protein inactivates and subsequently degrades an essential cellular enzyme, arresting a key regulatory pathway.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Chiocca, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	susanna.chiocca@ifom-ieo-campus.it	Chiocca, Susanna/AAC-8863-2019; Chiocca, Susanna/K-5233-2016	Chiocca, Susanna/0000-0002-9721-0850				Barry Michele, 2006, Sci STKE, V2006, ppe21; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Chiocca S, 2002, CURR BIOL, V12, P594, DOI 10.1016/S0960-9822(02)00720-0; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rose KM, 2004, TRENDS MOL MED, V10, P291, DOI 10.1016/j.molmed.2004.04.008; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204	22	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15376	15382		10.1074/jbc.M700889200	http://dx.doi.org/10.1074/jbc.M700889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17392274	hybrid			2022-12-25	WOS:000246589600013
J	Rosenbluh, J; Hayouka, Z; Loya, S; Levin, A; Armon-Omer, A; Britan, E; Hizi, A; Kotler, M; Friedler, A; Loyter, A				Rosenbluh, Joseph; Hayouka, Zvi; Loya, Shoshana; Levin, Aviad; Armon-Omer, Ayelet; Britan, Elena; Hizi, Amnon; Kotler, Moshe; Friedler, Assaf; Loyter, Abraham			Interaction between HIV-1 Rev and integrase proteins - A basis for the development of anti-HIV peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; REVERSE-TRANSCRIPTASE; TYPE-1 INTEGRASE; MAMMALIAN-CELLS; IN-VITRO; INHIBITORS; IMPORT; ASSAYS; MULTIMERIZATION	Human immunodeficiency virus 1 (HIV-1) Rev and integrase ( IN) proteins are required within the nuclei of infected cells in the late and early phases of the viral replication cycle, respectively. Here we show using various biochemical methods, that these two proteins interact with each other in vitro and in vivo. Peptide mapping and fluorescence anisotropy showed that IN binds residues 1-30 and 49-74 of Rev. Following this observation, we identified two short Rev-derived peptides that inhibit the 3'-end processing and strand-transfer enzymatic activities of IN in vitro. The peptides bound IN in vitro, penetrated into cultured cells, and significantly inhibited HIV-1 in multinuclear activation of a galactosidase indicator (MAGI) and lymphoid cultured cells. Real time PCR analysis revealed that the inhibition of HIV-1 multiplication is due to inhibition of the catalytic activity of the viral IN. The present work describes novel anti-HIV-1 lead peptides that inhibit viral replication in cultured cells by blocking DNA integration in vivo.	Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Organ Chem, Inst Chem, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	Loyter, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	loyter@mail.ls.huji.ac.il		Rosenbluh, Joseph/0000-0001-9815-8049				Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Cereseto A, 2005, EMBO J, V24, P3070, DOI 10.1038/sj.emboj.7600770; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Daelemans D, 2004, J BIOL CHEM, V279, P50167, DOI 10.1074/jbc.M407713200; de Soultrait VR, 2003, CURR MED CHEM, V10, P1765; de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5; Demart S, 2003, EXP CELL RES, V291, P484, DOI 10.1016/j.yexcr.2003.07.011; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Desjobert C, 2004, BIOCHEMISTRY-US, V43, P13097, DOI 10.1021/bi049385e; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; Gleenberg IO, 2005, J BIOL CHEM, V280, P21987, DOI 10.1074/jbc.M414679200; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Hoppe-Seyler F, 2004, CURR MOL MED, V4, P529, DOI 10.2174/1566524043360519; Hwang Y, 2000, NUCLEIC ACIDS RES, V28, P4884, DOI 10.1093/nar/28.24.4884; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Kass G, 2006, J GEN VIROL, V87, P2709, DOI 10.1099/vir.0.82021-0; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Li L, 2005, CELL RES, V15, P923, DOI 10.1038/sj.cr.7290370; LOYTER A, 1982, P NATL ACAD SCI-BIOL, V79, P422, DOI 10.1073/pnas.79.2.422; LUTZKE RAP, 1995, P NATL ACAD SCI USA, V92, P11456, DOI 10.1073/pnas.92.25.11456; Magliery TJ, 2005, J AM CHEM SOC, V127, P146, DOI 10.1021/ja046699g; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rosenbluh J, 2006, ANAL BIOCHEM, V352, P157, DOI 10.1016/j.ab.2006.03.002; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Van Maele B, 2005, AIDS REV, V7, P26; Watts NR, 1998, J STRUCT BIOL, V121, P41, DOI 10.1006/jsbi.1998.3964; Yamamoto N, 2006, VIRUS GENES, V32, P105, DOI 10.1007/s11262-005-5851-2	40	48	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15743	15753		10.1074/jbc.M609864200	http://dx.doi.org/10.1074/jbc.M609864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403681	hybrid			2022-12-25	WOS:000246589600050
J	Blethrow, JD; Tang, C; Deng, CH; Krutchinsky, AN				Blethrow, Justin D.; Tang, Chao; Deng, Changhui; Krutchinsky, Andrew N.			Modular Mass Spectrometric Tool for Analysis of Composition and Phosphorylation of Protein Complexes	PLOS ONE			English	Article								The combination of high accuracy, sensitivity and speed of single and multiple-stage mass spectrometric analyses enables the collection of comprehensive sets of data containing detailed information about complex biological samples. To achieve these properties, we combined two high-performance matrix-assisted laser desorption ionization mass analyzers in one modular mass spectrometric tool, and applied this tool for dissecting the composition and post-translational modifications of protein complexes. As an example of this approach, we here present studies of the Saccharomyces cerevisiae anaphase-promoting complexes (APC) and elucidation of phosphorylation sites on its components. In general, the modular concept we describe could be useful for assembling mass spectrometers operating with both matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) ion sources into powerful mass spectrometric tools for the comprehensive analysis of complex biological samples.	[Deng, Changhui; Krutchinsky, Andrew N.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Blethrow, Justin D.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Tang, Chao] XProteo Inc, New York, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Krutchinsky, AN (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	krutcha@picasso.ucsf.edu	Deng, Changhui/A-1010-2012		National Institute of Health; Sandler Family Fund	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Family Fund	This work was supported in part by funding from National Institute of Health and by the Sandler Family Fund. No sponsors or funders were involved in the design and conduct of the study.	Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; BASSMANN C, 2006, Patent No. 20060289; Chang EJ, 2004, ANAL CHEM, V76, P4472, DOI 10.1021/ac049637h; Chernushevich IV, 2001, J MASS SPECTROM, V36, P849, DOI 10.1002/jms.207; Cristea IM, 2005, MOL CELL PROTEOMICS, V4, P1933, DOI 10.1074/mcp.M500227-MCP200; de Godoy LMF, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-r50; Elias JE, 2005, NAT METHODS, V2, P667, DOI 10.1038/NMETH785; Ens W, 2005, METHOD ENZYMOL, V402, P49, DOI 10.1016/S0076-6879(05)02002-1; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Garrett TJ, 2006, ANAL CHEM, V78, P2465, DOI 10.1021/ac0522761; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hager JW, 2002, RAPID COMMUN MASS SP, V16, P512, DOI 10.1002/rcm.607; Hu QZ, 2005, J MASS SPECTROM, V40, P430, DOI 10.1002/jms.856; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Krutchinsky AN, 2000, J AM SOC MASS SPECTR, V11, P493, DOI 10.1016/S1044-0305(00)00114-8; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Loboda AV, 2003, RAPID COMMUN MASS SP, V17, P2508, DOI 10.1002/rcm.1241; Makarov A, 2006, ANAL CHEM, V78, P2113, DOI 10.1021/ac0518811; Martin RL, 2003, RAPID COMMUN MASS SP, V17, P1358, DOI 10.1002/rcm.1044; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Odegrip R, 2004, P NATL ACAD SCI USA, V101, P2806, DOI 10.1073/pnas.0400219101; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Purves RW, 1997, J AM SOC MASS SPECTR, V8, P1085, DOI 10.1016/S1044-0305(97)00146-3; Qin J, 1997, ANAL CHEM, V69, P4002, DOI 10.1021/ac970489n; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Sadygov RG, 2004, NAT METHODS, V1, P195, DOI 10.1038/NMETH725; Schroeder MJ, 2004, ANAL CHEM, V76, P3590, DOI 10.1021/ac0497104; Schwartz JC, 2002, J AM SOC MASS SPECTR, V13, P659, DOI 10.1016/S1044-0305(02)00384-7; Stafford G, 2002, J AM SOC MASS SPECTR, V13, P589, DOI 10.1016/S1044-0305(02)00385-9; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Tackett AJ, 2005, J PROTEOME RES, V4, P1752, DOI 10.1021/pr050225e; Vestal ML, 2005, METHOD ENZYMOL, V402, P79, DOI 10.1016/S0076-6879(05)02003-3; Wu JT, 1996, ANAL CHEM, V68, P3388, DOI 10.1021/ac960405v; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; YOST RA, 1978, J AM CHEM SOC, V100, P2274, DOI 10.1021/ja00475a072; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015	44	15	17	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2007	2	4							e358	10.1371/journal.pone.0000358	http://dx.doi.org/10.1371/journal.pone.0000358			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DS	17406682	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445300020
